The Federal Register is published daily, Monday through Friday, except official holidays, by the Office of the Federal Register, National Archives and Records Administration, Washington, DC 20408, under the Federal Register Act (44 U.S.C. Ch. 15) and the regulations of the Administrative Committee of the Federal Register (1 CFR Ch. I). The Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402 is the exclusive distributor of the official edition.

The Federal Register provides a uniform system for making available to the public regulations and legal notices issued by Federal agencies. These include Presidential proclamations and Executive Orders, Federal agency documents having general applicability and legal effect, documents required to be published by act of Congress, and other Federal agency documents of public interest.

Documents are on file for public inspection in the Office of the Federal Register the day before they are published, unless the issuing agency requests earlier filing. For a list of documents currently on file for public inspection, see http://www.nara.gov/. The Federal Register is published in paper and on 24x microfiche.

The seal of the National Archives and Records Administration authenticates the Federal Register as the official serial publication established under the Federal Register Act. Under 44 U.S.C. 1907, the contents of the Federal Register shall be judicially noticed.

The Federal Register is is published on GPO Access, a service of the U.S. Government Printing Office. The online edition of the Federal Register is issued under the authority of the Administrative Committee of the Federal Register as the official legal equivalent of the paper and microfiche editions (44 U.S.C. 4101 and 1 CFR 5.10). It is updated by 6 a.m. each day the Federal Register is published and it includes both text and graphics from Volume 59, Number 1 (January 2, 1994) forward. GPO Access users can choose to retrieve online Federal Register documents as TEXT (ASCII text, graphics omitted), PDF (Adobe Portable Document Format, including full text and all graphics), or SUMMARY (abbreviated text) files. Users should carefully check retrieved material to ensure that documents were properly downloaded.

On the World Wide Web, connect to the Federal Register at http://www.access.gpo.gov/nara. Those without World Wide Web access can also connect with a local WAIS client, by Telnet to swais.access.gpo.gov, or by dialing (202) 512-1661 with a computer and modem. When using Telnet or modem, type swais, then log in as guest with no password.

For more information about GPO Access, contact the GPO Access User Support Team by E-mail at gpoaccess@gpo.gov; by fax at (202) 512–1262; or call (202) 512–1530 or 1–888–293–6498 (toll free) between 7 a.m. and 5 p.m. Eastern time, Monday–Friday, except Federal holidays.

The annual subscription price for the Federal Register paper edition is $636, or $697 for a combined Federal Register, Federal Register Index and List of CFR Sections Affected (LSA) subscription; the microfiche edition of the Federal Register including the Federal Register Index and LSA is $233. Six month subscriptions are available for one-half the annual rate. The charge for individual copies in paper form is $9.00 for each issue, or $9.00 for each group of pages as actually bound; or $2.00 for each issue in microfiche form. All prices include regular domestic postage and handling. International customers please add 25% for foreign handling. Remit check or money order, made payable to the Superintendent of Documents, or charge to your GPO Deposit Account, VISA, MasterCard or Discover. Mail to: New Orders, Superintendent of Documents, P.O. Box 371954, Pittsburgh, PA 15250–7954.

There are no restrictions on the republication of material appearing in the Federal Register.

How To Cite This Publication: Use the volume number and the page number. Example: 65 FR 12345.
Agricultural Marketing Service

RULES
Cherries (tart) grown in—
Michigan et al., 82251–82254
Milk marketing orders:
Northeast et al., 82831–82842

Agriculture Department

See Agricultural Marketing Service
See Commodity Credit Corporation
See Cooperative State Research, Education, and Extension Service
See Food and Nutrition Service
See Foreign Agricultural Service
See Forest Service

NOTICES
Agency information collection activities:
Submission for OMB review; comment request, 82313–82314

Arts and Humanities, National Foundation

See National Foundation on the Arts and the Humanities

Children and Families Administration

NOTICES
Agency information collection activities:
Proposed collection; comment request, 82381–82382

Coast Guard

RULES
Drawbridge operations:
Louisiana, 82276
Ports and waterways safety:
Gulf of Mexico; shipping safety fairways and anchorage areas, 82276–82278
Safety zones and security zones, etc.; list of temporary rules, 82272–82276

PROPOSED RULES
Great Lakes pilotage regulations:
System safety, reliability, and efficiency; meeting, 82304–82305
Uninspected vessels:
Towing vessels; fire suppression systems and voyage planning
Meeting, 82303–82304

NOTICES
Agency information collection activities:
Submission for OMB review; comment request, 82445–82447
Aquatic Nuisance Species Task Force; recommendations:
Zebra mussels and other aquatic nuisance species; recreational activities to control spread; voluntary guidelines, 82447–82451
Committees; establishment, renewal, termination, etc.:
Cook Inlet and Prince William Sound Regional Citizen’s Advisory Councils; alternative voluntary advisory groups; recertification procedures, 82451–82453

Commerce Department

See Foreign-Trade Zones Board
See International Trade Administration
See National Institute of Standards and Technology

See National Oceanic and Atmospheric Administration
See Technology Administration

Committee for the Implementation of Textile Agreements

NOTICES
Special access and special regime programs:
Caribbean Basin countries; participating requirements; temporary amendments, 82327–82328
Textile and apparel categories:
Correlation with U.S. Harmonized Tariff Schedule, 82328

Commodity Credit Corporation

NOTICES
Grants and cooperative agreements; availability, etc.:
Foreign Market Development Cooperator Program, 82314–82315
Market Access Program, 82315–82317

Commodity Futures Trading Commission

RULES
Commodity Exchange Act:
Commodity interest transactions; intermediaries; regulatory framework
Customer funds investment; correction, 82270–82272
Multilateral transaction execution facilities, market intermediaries, and clearing organizations; commodity interest transactions, intermediaries; etc.
Partially withdrawn, 82272

Cooperative State Research, Education, and Extension Service

NOTICES
Reports and guidance documents; availability, etc.:
Agricultural research and extension formula funds; State work plans; guidelines, 82317

Defense Department

See Navy Department
See Uniformed Services University of the Health Sciences

PROPOSED RULES
Federal Acquisition Regulation (FAR):
High-technology workers; signing and retention, 82875–82876

NOTICES
Environmental statements; availability, etc.:
National Missile Defense Deployment; correction, 82460

Employment and Training Administration

NOTICES
Adjustment assistance:
Baxter Healthcare Corp. et al., 82391–82392
Dearborn Brass, 21st Century Companies, Inc., 82392
Guess?, Inc., 82392–82393
Johnson & Johnson Medical, Inc., 82393
Paris Accessories, Inc., 82393
Rugged Sportswear, 82393
STAEG Hamatech, Inc., 82393–82394
Staples Business Advantage, Staples, Inc., 82394
Agency information collection activities:
Proposed collection; comment request, 82394–82395
NAFTA transitional adjustment assistance:
Johnson & Johnson Medical, Inc., 82395
Rugged Sportswear, 82395
Samsonite Corp., 82395–82396
Stanley Door Systems, Stanley Works Co., et al., 82396–82400
Staples Business Advantage, Staples, Inc., 82400
United States Leather, Lackawanna Leather, 82400

Energy Department
See Federal Energy Regulatory Commission

NOTICES
Agency information collection activities:
Submission for OMB review; comment request, 82328–82329

Environmental Protection Agency

RULES
Air quality implementation plans; approval and promulgation; various States:
Missouri, 82285–82288
Pesticides; tolerances in food, animal feeds, and raw agricultural commodities:
Cyprodinil, 82288–82291
Desmedipham, 82291–82293

NOTICES
Pesticides, food, and feed additive petitions:
Interregional Research Project (No. 4) et al., 82349–82352
Pesticide registration, cancellation, etc.:
Kanoria Chemicals & Industries Ltd., 82346–82349
Pesticides; experimental use permits, etc.:
Monsanto Co., 82352–82353
Reports and guidance documents; availability, etc.:
Agency public involvement policy; review; comment request, 82335–82345
Pesticide registrants—Antimicrobial pesticides; treated articles exemption; applicability, 82345–82346
Superfund program:
Prospective purchaser agreements—Old Roosevelt Field Contaminated Groundwater Area Site, NY, 82877–82878

Federal Aviation Administration

RULES
Airworthiness directives:
Airbus, 82259–82263
Airworthiness standards:
Special conditions—Cessna Model 560, Citation V series airplanes, 82257–82259
Class E airspace, 82264–82266
Colored Federal Airways, 82263–82264
Standard instrument approach procedures, 82266–82269

PROPOSED RULES
Class E airspace, 82300–82301

NOTICES
Advisory circulars; availability, etc.:
Amateur-built aircraft; certification and operation, 82453
Agency information collection activities:
Proposed collection; comment request, 82453–82454
Meetings:
Aviation Rulemaking Advisory Committee, 82454–82455
RTCA, Inc., 82455–82456
Passenger facility charges; applications, etc.:
Pitt-Greenville Airport, NC, 82456

Federal Communications Commission

RULES
Common carrier services:
Commercial mobile radio services—Wireless services; TTY compatibility with enhanced 911 emergency dialing, 82293–82295
Radio stations; table of assignments:
Arizona, 82295
Oklahoma, 82296

PROPOSED RULES
Radio and television broadcasting:
Radio markets, defining and counting; compliance with multiple ownership rules, 82305–82310
Radio stations; table of assignments:
California, 82310

NOTICES
Agency information collection activities:
Submission for OMB review; comment request, 82353–82354

Federal Emergency Management Agency

NOTICES
Flood insurance program:
Insured structures; pilot inspection procedure—Florida, 82355

Federal Energy Regulatory Commission

NOTICES
Environmental statements; availability, etc.:
North Fork Hydroelectric Project et al., 82331–82332
Hydroelectric applications, 82332–82334
Applications, hearings, determinations, etc.:
ANR Pipeline Co., 82329
Columbia Gas Transmission Corp., 82329–82330
Kern River Gas Transmission Co., 82330
Northern Natural Gas Co., 82330–82331
Williams Gas Pipelines Central, Inc., 82331

Federal Highway Administration

PROPOSED RULES
Right-of-way and environment:
Highway traffic and construction noise abatement, 82301–82303

Federal Maritime Commission

NOTICES
Agreements filed, etc., 82355–82356
Ocean transportation intermediary licenses:
PVB Shipping USA Inc. et al., 82356

Federal Reserve System

NOTICES
Agency information collection activities:
Proposed collection; comment request, 82356–82359
Banks and bank holding companies:
Formations, acquisitions, and mergers, 82359–82360
Federal Reserve Bank services:
Private sector adjustment factor, 82360–82366
Meetings; Sunshine Act, 82366

Federal Trade Commission

RULES
Fur Products Labeling Act; implementation, 82269–82270

NOTICES
Premerger notification waiting periods; early terminations, 82366–82372
Prohibited trade practices:
Computer Sciences Corp. et al., 82372–82374
Financial Management Service
See Fiscal Service

Fiscal Service
NOTICES
Interest rates:
Renegotiation Board and prompt payment rates, 82456–82457

Fish and Wildlife Service
PROPOSED RULES
Endangered and threatened species:
Gunnison sage grouse; designation as candidate species, 82310–82312

Food and Nutrition Service
RULES
Child nutrition programs:
Summer food service program—Legislative reforms implementation, 82246–82251

Foreign Agricultural Service
NOTICES
Grants and cooperative agreements; availability, etc.:
Emerging Markets Program, 82317–82319

Foreign-Trade Zones Board
NOTICES
Applications, hearings, determinations, etc.:
California
Atlantic Richfield Products Co. (ARCO); oil refinery complex, 82320–82321
Texas
Caterpillar Inc.; construction equipment manufacturing facility, 82321
Phillips Petroleum Co.; oil refinery complex, 82322

Forest Service
NOTICES
Environmental statements; notice of intent:
Caribbean National Forest, PR, 82320

General Services Administration
PROPOSED RULES
Federal Acquisition Regulation (FAR):
High-technology workers; signing and retention, 82875–82876

Geological Survey
NOTICES
Grant and cooperative agreement awards:
Montgomery Watson Laboratories et al., 82385–82386

Health and Human Services Department
See Children and Families Administration
See Health Resources and Services Administration
See National Institutes of Health
RULES
Privacy Act; implementation
Individually identifiable health information; privacy standards, 82461–82829

NOTICES
Organization, functions, and authority delegations:
Civil Rights Office, Director, 82381

Health Resources and Services Administration
NOTICES
Meetings:
AIDS Advisory Committee, 82382

Immigration and Naturalization Service
RULES
Immigration:
Aliens—Parole authority; clarification, 82254–82256
Temporary protected status; employment authorization fee requirements, etc., 82256–82257

Interior Department
See Fish and Wildlife Service
See Geological Survey
See Land Management Bureau
See National Park Service

Internal Revenue Service
NOTICES
Agency information collection activities:
Proposed collection; comment request, 82457–82459

International Trade Administration
NOTICES
Antidumping:
Antifriction bearings (other than tapered roller bearings) and parts from—Japan, 82323–82324

Antidumping and countervailing duties:
Administrative review requests, 82322–82323
North American Free Trade Agreement (NAFTA); binational panel reviews:
Corrosion-resistant carbon steel flat products from—Canada, 82324–82325
Mexico, 82325
Gray portland cement and clinker from—Mexico, 82325–82326

Justice Department
See Immigration and Naturalization Service
NOTICES
Pollution control; consent judgments:
American Home Products, Corp., et al, 82389
Champion Chemical Co., Inc., et al., 82389–82390
Columbus McKinnon Corp., 82390
Hexagon Laboratories of New York, Inc., et al., 82390
Petroleum Specialties, Inc., et al., 82390–82391
Puerto Rico Aqueduct and Sewer Authority, 82391

Labor Department
See Employment and Training Administration
See Mine Safety and Health Administration

Land Management Bureau
NOTICES
Closure of public lands:
Idaho, 82386
Environmental statements; availability, etc.:
Red Rock Canyon National Conservation Area, NV, 82386–82387
Meetings:
Resource Advisory Councils—Southeast Oregon, 82387
Public land orders:
Colorado, 82387–82388
Washington, 82388
Realty actions; sales, leases, etc.:
Nevada; correction, 82388

Legal Services Corporation
NOTICES
Reports and guidance documents; availability, etc.:
State Planning and Performance Measures (Program Letter 2000-7), 82401–82404

Mine Safety and Health Administration
NOTICES
Mining products; testing, evaluation, and approval; user fee adjustments, 82400–82401

National Aeronautics and Space Administration
RULES
Acquisition regulations:
Miscellaneous amendments, 82296–82298

PROPOSED RULES
Federal Acquisition Regulation (FAR):
High-technology workers; signing and retention, 82875–82876

National Foundation on the Arts and the Humanities
NOTICES
Meetings:
Humanities Panel, 82404

National Institute of Standards and Technology
NOTICES
Meetings:
Manufacturing Extension Partnership National Advisory Board, 82326

National Institutes of Health
NOTICES
Agency information collection activities:
Proposed collection; comment request, 82382–82383
Inventions, Government-owned; availability for licensing, 82383–82384
Meetings:
National Heart, Lung, and Blood Institute, 82384
National Institute of Diabetes and Digestive and Kidney Diseases, 82385
National Institute of Neurological Disorders and Stroke, 82384–82385

National Oceanic and Atmospheric Administration
RULES
Fishery conservation and management:
Alaska; fisheries of Exclusive Economic Zone—Pacific cod; commercial fishing within Steller sea lions critical habitat; closure removed, 82298–82299

National Park Service
NOTICES
Meetings:
National Capital Memorial Commission, 82388–82389

Navy Department
NOTICES
Meetings:
Chief of Naval Operations Executive Panel, 82328

Nuclear Regulatory Commission
NOTICES
Meetings:
Nuclear Waste Advisory Committee, 82407–82408

Reactor Safeguards Advisory Committee, 82408–82410
Reactor Safeguards Advisory Committee et al., 82408–82409
Meetings; Sunshine Act, 82410–82411

Applications, hearings, determinations, etc.:
Carolina Power & Light Co., 82404–82405
Nuclear Management Co., LLC, 82405
PSEG Nuclear LLC et al., 82406–82407

Personnel Management Office
RULES
Employment:
Suitability for employment in competitive service positions and Senior Executive Service career appointments; determinations and procedures, 82239–82246

NOTICES
Agency information collection activities:
Proposed collection; comment request, 82411–82413
Meetings:
Federal Prevailing Rate Advisory Committee, 82413

Postal Service
RULES
International Mail Manual:
Global Express Guaranteed services; postal rate changes Correction, 82278–82285

Public Debt Bureau
See Fiscal Service

Public Health Service
See Health Resources and Services Administration
See National Institutes of Health

Securities and Exchange Commission
NOTICES
Self-regulatory organizations; proposed rule changes:
Chicago Board Options Exchange, Inc., 82413–82426
International Securities Exchange LLC, 82426–82428
National Association of Securities Dealers, Inc.; correction, 82428
New York Stock Exchange, Inc., 82428–82430
Options Clearing Corp., 82430–82432
Philadelphia Stock Exchange, Inc., 82432–82441

Small Business Administration
NOTICES
Agency information collection activities:
Submission for OMB review; comment request, 82441
Disaster loan areas:
Alabama, 82441
Arizona, 82441–82442

Social Security Administration
PROPOSED RULES
Ticket to Work and Self-Sufficiency Program; implementation, 82843–82874

NOTICES
Agency information collection activities:
Proposed collection and submission for OMB review; comment request, 82442–82443

State Department
NOTICES
Grants and cooperative agreements; availability, etc.:
Russian-U.S. Young Leadership Fellows for Public Service Program, 82443–82445
Technology Administration
NOTICES
Agency information collection activities:
  Proposed collection; comment request, 82326–82327

Textile Agreements Implementation Committee
See Committee for the Implementation of Textile Agreements

Transportation Department
See Coast Guard
See Federal Aviation Administration
See Federal Highway Administration

Treasury Department
See Fiscal Service
See Internal Revenue Service

Uniformed Services University of the Health Sciences
NOTICES
Meetings; Sunshine Act, 82328

Separate Parts In This Issue

Part II
Department of Health and Human Services, 82461–82829

Part III
Department of Agriculture, Agricultural Marketing Service, 82831–82842

Part IV
Social Security Administration, 82843–82874

Part V
Department of Defense, General Services Administration, National Aeronautics and Space Administration, 82875–82876

Part VI
Environmental Protection Agency, 82877–82878

Reader Aids
Consult the Reader Aids section at the end of this issue for phone numbers, online resources, finding aids, reminders, and notice of recently enacted public laws.
CFR PARTS AFFECTED IN THIS ISSUE

A cumulative list of the parts affected this month can be found in the Reader Aids section at the end of this issue.

5 CFR
731..................................82239

7 CFR
225..................................82246
930..................................82251
1000................................82832
1001................................82832
1005................................82832
1006................................82832
1007................................82832
1030................................82832
1032................................82832
1033................................82832
1124................................82832
1126................................82832
1131................................82832
1135................................82832

8 CFR
103..................................82254
208..................................82254
210..................................82254
212..................................82254
235..................................82254
241..................................82254
244..................................82256
245a..................................82254

14 CFR
25.....................................82257
39 (2 documents) ...............82259,
225, 82262
71 (3 documents) ...............82263,
82264, 82265
97 (2 documents) ...............82266,
82268

Proposed Rules:
71.....................................82300

16 CFR
301..................................82269

17 CFR
1 (2 documents) ...............82270,
82272
3.....................................82272
4.....................................82272
5.....................................82272
15..................................82272
35..................................82272
36..................................82272
37..................................82272
38..................................82272
39..................................82272
100................................82272
140................................82272
155................................82272
166................................82272
170................................82272
180................................82272

20 CFR
Proposed Rules:
411..................................82844

23 CFR
Proposed Rules:
772..................................82301

33 CFR
100..................................82272
117..................................82276
165..................................82272
166..................................82276

Proposed Rules:
164..................................82303
401..................................82304

39 CFR
20.....................................82278

52.....................................82285
180 (2 documents) ..........82288,
82290

45 CFR
160..................................82462
164..................................82462

46 CFR
Proposed Rules:
25.....................................82303
27.....................................82303

47 CFR
20.....................................82293
73 (2 documents) ...............82295

Proposed Rules:
73 (2 documents) ...............82305,
82310

48 CFR
1807.................................82296
1813.................................82296
1816.................................82296
1835.................................82296
1842.................................82296
1845.................................82296
1852.................................82296
1872.................................82296

Proposed Rules:
31.....................................82876

50 CFR
679..................................82297

Proposed Rules:
17.....................................82310
This section of the FEDERAL REGISTER contains regulatory documents having general applicability and legal effect, most of which are keyed to and codified in the Code of Federal Regulations, which is published under 50 titles pursuant to 44 U.S.C. 1510.

The Code of Federal Regulations is sold by the Superintendent of Documents. Prices of new books are listed in the first FEDERAL REGISTER issue of each week.

OFFICE OF PERSONNEL MANAGEMENT

5 CFR Part 731

RIN 3206-AC19

Suitability

AGENCY: Office of Personnel Management.

ACTION: Final rule.

SUMMARY: The Office of Personnel Management (OPM) is issuing final changes to the rule on personnel suitability which OPM previously issued as a proposed rule for comments. OPM received and considered public comments. This rule addresses the significant concerns expressed and incorporates some of the suggestions received.


FOR FURTHER INFORMATION CONTACT: Thomas DelPozzo, (724) 794-5612.

SUPPLEMENTARY INFORMATION: OPM promulgated the proposed final suitability regulations with a request for comments in Federal Register, Vol. 64, No. 18, p. 4336. Comments were received from 13 sources, including Federal agencies, individuals, and a labor organization. The following summarizes the principal comments and suggestions received and actions that were taken.

Part 731

Non-Specific General Comments

An agency suggested that OPM establish a time limit for investigation and/or adjudication of suitability cases to ensure completion a minimum of 90-120 days before expiration of the probationary period. Certain time frames to ensure timely processing are already in the regulations (for example, section 731.106 provides that investigations should be initiated before appointment or, at most, within 14 calendar days of placement in the position). The variances that are a natural part of investigation and adjudication make it difficult to require specific time limits. Agencies can manage adjudicative time frames in a number of ways, such as by dealing with applicant suitability issues prior to appointment; by investigating prior to appointment; by submitting required case papers for investigation, completed properly, within required time frames; by requesting the appropriate investigation service timeliness levels to ensure completion of the investigation in time to take the adjudicative action before the end of the probationary period; and by processing adjudicative actions more efficiently.

Section 731.101 Purpose

A commenter recommended that the definition of "material, intentional false statement" be altered to define the term "material" rather than the term "material, intentional false statement" since the proposed definition did not include definitions for "intentional" and "false." We agreed to the suggested wording with a slight modification.

One commenter suggested that the proposed definition of "material, intentional false statement" be excessively broad and vague in that virtually any statement would meet this definition. The commenter suggested that it was objectionable for OPM to apply a test for materiality that was not enunciated by the Supreme Court in other contexts. See e.g., United States v. Gaudin, 515 U.S. 506 (1995). Clearly, the Supreme Court did not create and apply a test for materiality that was unlawfully vague. Further, it is entirely appropriate that actions be taken against falsifiers whether or not they succeed in their attempts to deceive. OPM's suitability program seeks to deter applicants from falsifying statements to gain an advantage in the appointment process, as well as to detect applicants who falsify.

Section 731.102 Implementation

Two commenters suggested agencies be afforded up to one year to implement an adjudication program to reassess position designation, develop internal operating procedures, and undergo comprehensive training. We agreed to give agencies up to one year to modify their existing suitability adjudication program to accommodate the increased delegation of applicant suitability authority. Thus, although agencies must implement the new regulations now, OPM will continue to accept applicant suitability referrals, under our current procedures, for up to a year from the effective date of the new regulations. Additionally, OPM will provide supplemental guidance and suitability training to assist agencies.

Section 731.103 Delegation to Agencies

An agency asked whether agencies to which OPM previously had delegated authority will now be required to refer any cases involving falsification to OPM for adjudication. If so, the agency commented that this would be an additional burden. OPM's policy concerning material falsification cases has not changed. In supplemental guidance issued in 1991 with our current regulations, OPM policy stated, "OPM is responsible for adjudicating all cases (applicants, eligibles, appointees, and employees) involving material, intentional false statement, deception, or fraud in examination or appointment." Additionally, as stated in a 1995 Federal Investigations Notice (FIN 95-1), "All agencies, including those with delegated suitability adjudication authority, should refer any competitive service applicant situation where there is evidence of intentional false statement or deception or fraud in examination or appointment process, to the same office (OPM, Federal Investigations Processing Center, Suitability Adjudications Branch)."

In employee cases (a person who has completed the first year of a subject to investigation appointment), this policy applies only to fraud in the examination or appointment process for a "subject to investigation" appointment. Our basis for maintaining adjudicative control in

Rules and Regulations

Federal Register

Vol. 65, No. 250

Thursday, December 28, 2000
these cases is basically two-fold: (1) A violation of the merit system has occurred that affects the integrity of the competitive appointment process; and (2) OPM’s action can include debarment for up to three years.

A commenter objected to any use of confidential sources. The comment suggests that the proposed regulation would permit the unlimited use of corroborated confidential sources. The comment suggests that reliance on information provided by confidential sources would be contrary to due process principles.

The comment mischaracterized the intent and effect of the proposed regulations. Section 731.203(e) [now in 731.302(a) and 731.402] specifically provided that before a final suitability action is taken, an agency or OPM must provide for review, upon request, all materials relied upon in taking the action. Under the regulations, the deciding official, in taking his or her action, must consider all information made available to him or her except information furnished by confidential sources themselves. This satisfies all due process concerns. Any improperly-considered information will be subject to the statutory harmful error rule in any appeal challenging the action.

Of course, the deciding official may rely on any information, including similar or identical information, from any other source. This includes (a) non-confidential sources that are located through information provided by confidential sources or (b) information from a non-confidential source that corroborates information initially provided by a confidential source, as long as the material relied upon is made available under section available.

Upon reflection, we recognize that the reference in the last sentence of the regulation, which uses the phrase “such information,” is ambiguous and confusing. Inasmuch as this sentence was intended to summarize the entire regulation, we believe it to be redundant, and we are deleting it to eliminate any ambiguity.

A commenter believes delegation will have a workload impact on agencies, and supplemental guidance and training from OPM will be required. Although there will be an impact on agencies, we do not believe the impact will be that significant, since OPM will continue to adjudicate material, intentional falsification cases, and cases where a general extended debarment is warranted. The major agency impact occurs in the suitability examining process in application material and deciding the appropriate action to take. The actions most commonly taken would be to favorably adjudicate the applicant’s suitability, or refer to OPM for adjudication if warranted. OPM will also issue supplemental guidance, offer adjudicative products, provide assistance through training, and allow agencies up to a year to train personnel and develop processes to handle their new applicant suitability responsibilities.

An agency asked what skill level would be required for agency personnel assigned to adjudication responsibilities and whether the GS-1800 series was appropriate, as the agency was concerned about limited resources. OPM is not requiring a particular job series to handle this work; however, agencies will need to assess the inherent responsibilities associated with adjudication when determining who will do the work. They will have to ensure employees are properly trained and qualified to do the work.

731.104 Appointments Subject to Investigation and 731.105 Jurisdiction

One commenter suggested that OPM confused rather than clarified the length of time that employees, applicants, and appointees would be subject to investigation by deleting section 731.301(b). The commenter believes that the substitute language in sections 731.104 and 105 may accomplish the same purpose in a more complicated fashion—barring the removal of an employee as unsuitable after a year in the position based on information truthfully set forth in the application.

In the supplementary material accompanying the proposed regulations, we explained that the one-year period applies only to the time period during which OPM or an agency may take a suitability action against an applicant or appointee. It is not a time limitation on an OPM or an agency suitability investigation of an individual. However, our efforts to clarify and simplify the regulatory language have not succeeded. The text of the regulation, as opposed to the explanation in the supplementary material, remains somewhat unclear.

Therefore, we have again modified the language of section 731.104 to conform more clearly to the purpose we have articulated as follows:

- The right of OPM or an agency with delegated authority to conduct a suitability investigation has no time limit even though in some cases, enumerated in section 104, OPM or an agency with delegated authority is not required to conduct a suitability investigation.
- OPM’s authority to take a suitability action for fraud in examination or appointment also has no time limit.
- An agency with delegated suitability authority may not take a suitability action of any kind against an “employee” as defined in 5 CFR 731.101 of the regulations.

For suitability action purposes, an agency that has discerned evidence of material, intentional false statement or deception or fraud in examination or appointment may refer evidence to OPM for possible action.

We have also modified the title of section 731.105 to read “Authority to take suitability actions” instead of “Jurisdiction” to clarify that this regulation concerns only authority to take suitability actions and has nothing to do with an agency or OPM’s authority to conduct investigations.

Commenters felt this section needed clarification to eliminate the perception that if the investigation is not conducted within the first year, it can never be conducted. To address this concern we added language to 731.104(b) and also modified 731.106(c).

An agency requested further clarification of this section to avoid the interpretation that agencies are restricted from conducting investigations on transfers for individuals serving continuously for less than one year.

The agency misreads the regulation. A transfer is not subject to investigation unless investigation is required by a change in risk level or because an investigation required by law did not occur. Therefore, we have not changed the proposed regulation.

A commenter requested that we clarify whether investigation and negative suitability action are permitted when an individual moves from a position that is not subject to investigation to one with a higher risk designation. We revised 731.106(e) to require an investigation at the appropriate level when an individual moves to a position with a higher risk designation. We also added a new section, 731.106(f), to explain how these investigations are adjudicated depends on the person’s employment status.

Section 731.105 Jurisdiction

One commenter found the language in 731.105(d) regarding the authority for agency actions on employees unclear. Another suggested adding specific clarifying language, and that reference to “efficiency of the service” be deleted since all 752 actions, by definition, must promote the efficiency of the service.
investigative requirements should also vary commensurate with the risk level. Furthermore, public trust and national security need to be appropriately considered in tandem when evaluating position responsibilities and investigative levels. A national security case (SF–86) where an individual only needs a secret clearance (relatively low level of investigation) might also be a high risk public trust position (higher level of investigation). A person in a low risk public trust position (low level investigation) might require access to top secret information (high level investigation).

One commenter stated that the proposed regulations imply that where there is no existing authority for agencies to conduct periodic investigations of public trust employees, agencies may grant themselves this authority by promulgating their own regulations. The comment describes this as inconsistent with the position that OPM took in its 1996 proposed regulations, namely, that there was no indication that the provisions of any OPM regulation in order to place affected employees in the number of investigations conducted unless employees occupy positions affecting national security. The 1999 proposed regulations clarify that agencies may possess their own authority to require periodic reinvestigations for employees occupying certain public trust positions. These final regulations do not purport to create any additional authority for agencies to conduct this type of reinvestigation.

There is no inconsistency. Read in its entirety, the supplementary material accompanying the 1996 proposed regulations makes clear that OPM does not possess statutory authority to require that reinvestigations be conducted unless employees occupy positions affecting national security. The 1999 proposed regulations clarify that agencies may possess their own authority to require periodic reinvestigations for employees occupying certain public trust positions. These final regulations do not purport to create any additional authority for agencies to conduct this type of reinvestigation.

Two commenters found “731.106(e) Risk level changes” language confusing. We agreed and changed the wording.

Sections 731.201 Standard and 731.202 Criteria

One commenter suggested that the revised language in section 731.201 represents a significant change in the suitability standard and that the “integrity and efficiency” language was too vague and gave deciding officials too much discretion. The commenter suggested that deletion of language in section 731.202 would mean there is no limitation on criminal misconduct deemed to be unsuitable. The commenter suggested not revising the existing regulation.

The comment is not accepted. The revised regulation is designed primarily to be a rewording and reordering of the regulation in order to place affected applicants and employees on even clearer notice of the suitability standards.

The current efficiency of the service language might inadvertently lead some to believe that efficiency and effectiveness are limited to their dictionary definitions, namely, the capacity to produce desired results with a minimum expenditure of energy, time or money, or the ability to produce results. In fact, the efficiency of the service standard as used by OPM in a suitability context always has been a broader concept that involves, among other things, the integrity of the competitive examination system. To give one example, decisional law correctly recognizes when an applicant obtains an appointment through falsifying an application, he or she is unsuitable and may be removed from his or her position even if he or she efficiently carries out tasks in the job he or she has obtained. McCreary v. OPM, 27 M.S.P.R. 459 (1985); DeAngelis v. OPM, 28 M.S.P.R. 456 (1985). Adding the word integrity makes it even clearer that integrity and honest conduct always have been an important part of the existing efficiency of the service standard.

The revised standard is not vague. Indeed, it is somewhat more specific than the existing efficiency of the service standard. The courts have upheld similar language against legal challenges of constitutional vagueness, for example, in Arnett v. Kennedy, 416 U.S. 134 (1974); see also Meehan v. Macy, 392 F.2d 822 (D.C. Cir. 1968).

The suggestion that the revised regulations recognize no limit on the type of misconduct or criminal misconduct that will justify a suitability action is incorrect. The additional considerations set forth in section 731.202(c) make clear that a suitability determination may be made after considering the nature of the position, the nature and seriousness of the conduct and the circumstances surrounding the conduct, among other things.

An agency asked whether the specific factor at 731.201(b)(4) “Refusal to furnish testimony as required by § 5.4 of this chapter” referred to section 5.4 of 731. It does not. The proposed regulation as written was confusing. Federal regulations are organized by Title in the Code of Federal Regulation rather than by “chapters.”

Therefore, we have modified the proposed regulation by substituting the word “title” for “chapter” to clarify that this provision refers to section 5.4 of title 5, Code of Federal Regulations, one of the Civil Service Rules.
The same agency suggested that we add, in accordance with section 5.4, that this suitability factor also pertains to the requirement to provide forms, releases, answers to questions of investigators, and security adjudicators, among others. We have not adopted this suggestion. Although section 5.4 does list other requirements, the suitability factor is limited to the requirement in section 5.4 to provide testimony when required by OPM. We decline to expand the scope of the disqualifying factor.

Section 731.203 Actions by OPM and Other Agencies

One commenter suggested that there appeared to be a conflict between the procedures set forth in section 731.203(e) and those at subpart C of the regulations.

OPM did not intend a conflict between the two provisions. Section 203(e) was intended to provide general procedures for both agencies and OPM to follow when taking a suitability action. Subpart C was designed to provide the specific procedures OPM was to follow when taking an action.

We acknowledge this could cause some confusion. Therefore, we have eliminated the subsection on general procedures and have substituted a subsection that applies when agencies take an action.

Because we have expanded agencies’ authority in the areas of debarment and applicant adjudication, we decided to set forth several of the procedures applicable to them with greater specificity. We have modified both the regulatory provisions applying to OPM and agencies to make clear that whenever OPM or an agency takes an action, a written notice must be provided of the specific reasons for the action, a written response must be permitted, and notice must be provided of the time limit for the response and appeal rights.

Still, to give agencies a bit more flexibility, we have retained some differences in the provisions. We have not set forth a specific time limit for agency notice. Rather, we clarified that reasonable notice must be afforded. For OPM actions, we have retained a 30-day notice period. Of course, if an action is appealed, the harmful error rule at 5 U.S.C. § 7701(c)(2)(A) applies both to agency and OPM actions.

For clarity, we have added subsection 731.203(a) defining the term “action” for suitability purposes.

Two commenters questioned whether 731.203(f) [now 731.203(e)] represents an additional reporting requirement since agencies are already required to report actions on OPM investigations via INV form 79A, Report of Adjudicative Action on OPM Personnel Investigations. This section does contain a new reporting requirement. All negative adjudications based on delegated 5 CFR 731 authority must now be reported to OPM, even when those actions are not based on an OPM conducted investigation. This is necessary to permit OPM to adequately oversee the suitability adjudication responsibilities we have delegated to agencies. A new form is being created for this purpose, but agencies will not need to provide a duplicate report if the action is based on an OPM investigation and they are already reporting the action on the INV form 79A.

Section 731.204 Debarment by OPM

An agency requested that agencies be given the ability to appeal an OPM-imposed debarment when the position is critical and difficult to fill and there are no other suitable applicants. We made no change since agencies already have the right to respond to an OPM proposed action under section 731.303(b), and may provide evidence upon request in any MSPB appeal.

Section 731.205 Debarment by Agencies

An agency welcomed the opportunity to bar unsuitable employees. Another found the agency debarment language unclear. We believe the language satisfactory, and made no change. The language in this section states that agencies may impose a period of debarment of “no more than” one year, and that the agency has sole discretion to determine length of debarment “under this section.” It is within their discretion to determine the duration of the bar, up to the maximum period of one year.

Section 731.302 Notice of Proposed Action

A commenter objected to the provision “shall be entitled to be retained in a pay status during the notice period” because the individual may be involved in misconduct apart from the reasons for the suitability action which would warrant an agency action.

We have retained the proposed language. But, we emphasize that this provision does not preclude an agency from taking any other appropriate action during the suitability action notice period. Appropriate actions may include an adverse action under chapter 75 U.S. Code or a termination under part 315, title 5, Code of Federal Regulations.

Section 731.303 Answer

One commenter suggested the agency be permitted to determine the time and place of an oral response. Another suggested that reference to agency actions should be added to paragraph (a). No change was made since this section now only applies to OPM. Furthermore, only OPM, not agencies, may take action against “employees” under 731. The reference to the oral response here applies only to employees.

Section 731.304 Decision

A commenter felt the agency should have discretion to allow the employee to remain in an active duty status pending results of an appeal. We made no change for several reasons. OPM directs removal primarily in cases involving fraud in the application or appointment process, and an individual generally should not retain a position obtained fraudulently. Further, OPM gives agencies an opportunity to comment and express their views before OPM takes the action.

Section 731.401 Appeal to the Merit Systems Protection Board

One commenter stated that section 731.401 (now 731.501) should make clear that the Board lacks the authority to reverse a removal action, as well as lacking the authority to modify a debarment period, when it affirms a determination of unsuitability. It noted correctly that under OPM regulation, an agency could remove the employee and not impose a debarment. OPM has adopted this suggestion, which is entirely in keeping with OPM’s intent to clarify that once the Board has found that any of the charges of unsuitability is supported by preponderance of the evidence, it lacks authority to modify the action taken.

Another commenter took issue with OPM’s section 731.401 (now 731.501), asserting that, in the past, the courts have rejected OPM’s attempts to limit the Board’s authority to hear appeals. The comment does not acknowledge the difference between an appeal right to the Board granted by Congress, such as an adverse action appeal under Chapter 75, title 5, United States Code, which OPM may not limit, and one granted solely by OPM through regulation. The comment also does not recognize that when Congress or OPM authorizes the Board to hear a particular kind of appeal, the Board’s grant of authority is limited by the terms of the statute or OPM regulation and its underlying intent.

The Board’s authority to decide matters is strictly limited to those...
agency decisions placed within its jurisdiction by law or regulation. See, for example, King v. Jerome, 42 F.3d 1371 (Fed. Cir. 1994). An OPM suitability action is not taken under the same authority as an adverse action. Unlike adverse action appeals, suitability appeals to MSPB are not created by an act of Congress but by OPM regulations under substantive standards promulgated by OPM in Part 731. These standards need not be the same as those in Chapter 75, just as those contained in Chapter 43, title 5, United States Code pertaining to performance-based actions are not the same as those in Chapter 75. Lisiecki v. Merit Systems Protection Board, 769 F.2d 1588 (Fed. Cir. 1985).

The new regulation seeks to demarcate the differences between suitability actions and adverse actions so that no one will confuse them in the future. Specifically, the regulation is designed to clarify that the Board’s role in reviewing OPM or agency unsuitability decisions always has been a limited one. The Board may determine only whether a charge of unsuitability is sustained by a preponderance of evidence in accordance with the substantive standard set forth in section 731.202.

In addition, the proposed regulation provides OPM or the agency with an additional opportunity to amend the action taken if the Board sustains fewer than all of the suitability charges, something that the existing regulations do not provide for. Therefore, rather than limiting the Board’s authority, as the comment suggests, the new regulation allows the agency or OPM to review the action taken after taking into account only the charges that the Board sustained.

Regulatory Flexibility Act

I certify that this rule will not have significant economic impact on a substantial number of small entities because it affects only Federal applicants, employees and agencies.

List of Subjects in 5 CFR Part 731

Administrative practice and procedure, Government employees.
Office of Personnel Management.
Janice R. Lachance,
Director.

Accordingly, the Office of Personnel Management revises 5 CFR part 731 as follows:

PART 731—SUITABILITY

Subpart A—Scope

§731.101 Purpose.

§731.102 Implementation.

§731.103 Delegation to agencies.

§731.104 Appointments subject to investigation.

§731.105 Authority to take suitability actions.

§731.106 Designation of public trust positions and investigative requirements.

Subpart B—Suitability Determinations

§731.201 Standard.

§731.202 Criteria.

§731.203 Actions by OPM and other agencies.

§731.204 Debarment by OPM.

§731.205 Debarment by agencies.

Subpart C—OPM Suitability Action Procedures

§731.301 Scope.

§731.302 Notice of proposed action.

§731.303 Answer.

§731.304 Decision.

Subpart D—Agency Suitability Action Procedures

§731.401 Scope.

§731.402 Notice of proposed action.

§731.403 Answer.

§731.404 Decision.

Subpart E—Appeal to the Merit Systems Protection Board

§731.501 Appeal to the Merit Systems Protection Board.

Subpart F—Savings Provision

§731.601 Savings provision.


Subpart A—Scope

§731.101 Purpose.

(a) The purpose of this part is to establish criteria and procedures for making determinations of suitability for employment in positions in the competitive service and for career appointment in the Senior Executive Service (hereinafter in this part, “competitive service”) pursuant to 5 U.S.C. 3301 and Executive Order 10577 (3 CFR, 1954–1958 Comp., p. 218), Section 3301 of title 5, United States Code, directs consideration of “age, health, character, knowledge, and ability for the employment sought.” Executive Order 10577 directs OPM to examine “suitability” for competitive Federal employment. This part concerns only determinations of “suitability” based on an individual’s character or conduct that may have an impact on the integrity or efficiency of the service. Determinations made under this part are distinct from determinations of eligibility for assignment to, or retention in, sensitive national security positions made under Executive Order 10450 (3 CFR, 1949–1953 Comp., p. 936), Executive Order 12968, or similar authorities.

(b) Definitions. In this part:

Applicant. A person who has entered on duty and is in the first year of a subject to investigation appointment (as defined in §731.104).

Employee. A person who has completed the first year of a subject to investigation appointment.

Material. A “material” statement is one that is capable of influencing, or has a natural tendency to affect, an official decision.

§731.102 Implementation.

(a) An investigation conducted for the purpose of determining suitability under this part may not be used for any other purpose except as provided in a Privacy Act system of records notice published by the agency conducting the investigation.

(b) Under OMB Circular No. A–130 Revised, issued February 8, 1996, the Director of OPM is to establish policies for Federal personnel associated with the design, operation, or use of Federal automated information systems. Agencies are to implement and maintain a program to ensure that adequate protection is provided for all automated information systems. Agency programs should be consistent with government-wide policies and procedures issued by OPM. The Computer Security Act of 1987 (Public Law 100–225) provides additional requirements for Federal automated information systems.

(c) Policies, procedures, criteria, and guidance for the implementation of this part shall be set forth in OPM issuances. OPM may revoke an agency’s delegation to adjudicate suitability under this part if an agency fails to conform to OPM issuances.

§731.103 Delegation to agencies.

(a) OPM delegates to the heads of agencies limited authority for adjudicating suitability in cases involving applicants for and appointees to competitive service positions in the agency (including limited, agency-specific debarment authority under §731.205). OPM retains jurisdiction in all competitive service cases involving evidence of material, intentional false statement or deception or fraud in examination or appointment. Agencies must refer these cases to OPM for adjudication, or contact OPM for prior approval if the agency wants to take action under its own authority (5 CFR
(b) Any adjudication by an agency acting under delegated authority from OPM which indicates that an extended general, across agency lines, debarment by OPM under § 731.204(a) may be an appropriate action should be referred to OPM for debarment consideration if not favorably adjudicated by the agency. Referral should be made prior to any proposed action, but after sufficient resolution of the suitability issue(s) through subject contact or investigation to determine if an extended general debarment period appears warranted.

(c) Agencies exercising authority under this part by delegation from OPM must show by policies and records that reasonable methods are used to ensure adherence to regulations, standards, and quality control procedures established by OPM.

(d) Before making any applicant suitability determination, the agency should first ensure the applicant is eligible for the position, among the best qualified, and/or within reach of selection. Because suitability issues may not be disclosed until late in the application/appointment process, only the best qualified should require a suitability determination, with appropriate procedures followed and appeal rights provided, if suitability issues would form the only basis for elimination from further consideration.

(e) When an agency, exercising authority under this part by delegation from OPM, makes an adjudicative decision under this part, or changes a tentative favorable placement decision to an unfavorable decision, based on an OPM report of investigation or upon an investigation conducted pursuant to OPM-delegated authority, the agency should:

(1) Ensure that the records used in making the decision are accurate, relevant, timely, and complete to the extent reasonably necessary to ensure fairness to the individual in any determination;

(2) Ensure that all applicable administrative procedural requirements provided by law, the regulations in this part, and OPM policy guidance have been observed;

(3) Consider all available information in reaching its final decision, except information furnished by a non-corroborated confidential source. Information furnished by a non-corroborated confidential source can only be used for limited purposes, such as lead information or in interrogatories to a subject if the identity of the source is not compromised in any way; and

(4) Keep any record of the agency action as required by OPM in its supplemental guidance.

(f) Paragraph (a) of this section notwithstanding, OPM may exercise its jurisdiction under this part in any case when, in its discretion, deems necessary.

(g) Any applicant or appointee who is found unsuitable by an agency acting under delegated authority from OPM under this part may appeal the adverse suitability decision to the Merit Systems Protection Board under the Board's regulations.

§731.104 Appointments subject to investigation.

(a) To establish a person's suitability for employment, appointments to positions in the competitive service require the person to undergo an investigation by OPM or by an agency with delegated authority from OPM to conduct investigations. Certain appointments do not require investigation. Except when required because of risk level changes, a person in the competitive service who has undergone a suitability investigation need not undergo another one simply because the person has been:

(1) Promoted;

(2) Demoted;

(3) Reassigned;

(4) Converted from career-conditional to career tenure;

(5) Appointed or converted to an appointment if the person has been serving continuously with the agency for at least 1 year in one or more positions under an appointment subject to investigation; and

(6) Transferred, provided the individual has served continuously for at least 1 year in a position subject to investigation.

(b) OPM or an agency with delegated suitability authority may investigate and take a suitability action against an applicant, appointee, or employee in accordance with § 731.105. There is no time limit on the authority of OPM or an agency with delegated suitability authority to conduct an investigation of an applicant who has been appointed to a position.

(c) An employee does not have to serve a new probationary or trial period merely because his or her appointment is subject to investigation under this section. An employee’s probationary or trial period is not extended because his or her appointment is subject to investigation under this section.

(3) The subject to investigation condition also does not eliminate the need to conduct investigations required under §731.106 for public trust positions.

§731.105 Authority to take suitability actions.

(a) OPM may take a suitability action under this part against an applicant or appointee based on any of the criteria of §731.202;

(b) An agency, exercising delegated authority, may take a suitability action under this part against an applicant or appointee based on the criteria of §731.202 subject to the agency limitations prescribed in §731.103;

(c) OPM may take a suitability action under this part against an employee only in cases involving material, intentional false statement or deception or fraud in examination or appointment, or refusal to furnish testimony as required by §5.4 of this title, or statutory or regulatory bar. A statement may be a material statement even if an agency does not rely upon it.

(d) An agency may not take a suitability action against an employee under this part. Nothing in this part precludes, or is intended to preclude, an agency from taking an adverse action against an employee under the procedures and standards of part 752 of this title or terminating a probationary employee under the procedures of part 315 of this title.

§731.106 Designation of public trust positions and investigative requirements.

(a) Risk designation. Agency heads shall designate every competitive service position within the agency at a high, moderate, or low risk level as determined by the position's potential for adverse impact to the efficiency and integrity of the service. OPM will provide an example of a risk designation system for agency use in supplemental guidance.

(b) Public Trust positions. Positions at the high or moderate risk levels would normally be designated as “Public Trust” positions. Such positions may involve policy making, major program responsibilities, public safety and health, law enforcement duties, fiduciary responsibilities, or other duties demanding a significant degree of public trust; and positions involving access to or operation or control of financial records, with a significant risk
for causing damage or realizing personal gain.

(c) Investigative requirements. Persons receiving an appointment made subject to investigation under this part must undergo a background investigation. Minimum investigative requirements correlating to risk levels will be established in supplemental guidance provided by OPM. Investigations should be initiated before appointment or, at most, within 14 calendar days of placement in the position.

(d) Suitability reinvestigations. Agencies, relying on authorities such as the Computer Security Act of 1987 and OMB Circular No. A–130 Revised (issued February 8, 1996), may require incumbents of certain public trust positions to undergo periodic reinvestigations. The appropriate level of any reinvestigation will be determined by the agency, but may be based on supplemental guidance provided by OPM.

(e) Risk level changes. If an individual experiences a change in position risk level (moves to a higher risk level position, or the risk level of the position itself is changed) the individual may be held by, or leave in the position. Any upgrade investigation required for the new risk level should be initiated within 14 calendar days after the move or the new designation is final.

(f) Any suitability investigation completed by an agency under provisions of paragraphs (d) or (e) of this section must be adjudicated by the employing agency. The subject’s employment status will determine the applicable agency authority and procedures to be followed in any action taken.

Subpart B—Suitability Determinations

§ 731.201 Standard.

Subject to subpart A of this part, an applicant, appointee, or employee may be denied Federal employment or removed from a position only when the action will protect the integrity or promote the efficiency of the service.

§ 731.202 Criteria.

(a) General. In determining whether its action will protect the integrity or promote the efficiency of the service, OPM, or an agency to which OPM has delegated authority, shall make its determination on the basis of the specific factors in paragraph (b) of this section, with appropriate consideration given to the additional considerations outlined in paragraph (c) of this section.

(b) Specific factors. When making a determination under paragraph (a) of this section, the following may be considered a basis for finding an individual unsuitable:

1. Misconduct or negligence in employment;
2. Criminal or dishonest conduct;
3. Material, intentional false statement or deception or fraud in examination or appointment;
4. Refusal to furnish testimony as required by § 5.4 of this title;
5. Alcohol abuse of a nature and duration which suggests that the applicant or appointee would be prevented from performing the duties of the position in question, or would constitute a direct threat to the property or safety of others;
6. Illegal use of narcotics, drugs, or other controlled substances, without evidence of substantial rehabilitation;
7. Knowing and willful engagement in acts or activities designed to overthrow the U.S. Government by force;
8. Any statutory or regulatory bar which prevents the lawful employment of the person involved in the position in question.

(c) Additional considerations. In making a determination under paragraphs (a) and (b) of this section, OPM and agencies shall consider the following additional considerations to the extent they deem them pertinent to the individual case:

1. The nature of the position for which the person is applying or in which the person is employed;
2. The nature and seriousness of the conduct;
3. The circumstances surrounding the conduct;
4. The recency of the conduct;
5. The age of the person involved at the time of the conduct;
6. Contributing societal conditions; and
7. The absence or presence of rehabilitation or efforts toward rehabilitation.

§ 731.203 Actions by OPM and other agencies.

(a) List of actions. For purposes of this part, an action is one or more of the following:

1. Cancellation of eligibility;
2. Denial of appointment;
3. Removal;
4. Cancellation of reinstatement eligibility;
5. Debarment.

(b) An applicant’s eligibility may be cancelled, an applicant may be denied employment, or an appointee may be removed when OPM or an agency exercising delegated authority under this part finds that the applicant or appointee is unsuitable for the reasons cited in § 731.202 subject to the agency limitations of § 731.103(a).

(c) OPM may require that an employee be removed on the basis of a material, intentional false statement, or deception or fraud in examination or appointment; or refusal to furnish testimony; or a statutory or regulatory bar. OPM may also cancel any reinstatement eligibility obtained as a result of false statement, deception or fraud in the examination or appointment process.

(d) An action to remove an appointee or employee for suitability reasons under this part is not an action under parts 752 or 315 of this title. Where behavior covered by this part may also form the basis for a part 752 or 315 action, agencies may use parts 315 or 752, as appropriate, instead of this part.

(e) Agencies are required to report to OPM all unfavorable adjudicative actions taken under this part, and all actions based on an OPM investigation.

§ 731.204 Debarment by OPM.

(a) When OPM finds a person unsuitable for any reason listed in § 731.202, OPM, in its discretion, may deny that person examination for, and appointment to, a competitive service position for a period of not more than 3 years from the date of determination of unsuitability.

(b) On expiration of a period of debarment, OPM or an agency may redetermine a person’s suitability for appointment in accordance with the procedures of this part.

(c) OPM, in its sole discretion, determines the duration of any period of debarment imposed under this section.

§ 731.205 Debarment by agencies.

(a) Subject to the provisions of § 731.103, when an agency finds an applicant or appointee unsuitable for reasons listed in § 731.202, the agency may deny that person examination for, and appointment to, all, or specific, positions within the agency for a period of not more than 1 year from the date of determination of unsuitability.

(b) On expiration of a period of agency debarment, the agency may redetermine a person’s suitability for appointment by the agency, in accordance with the procedures of this part.

(c) The agency is responsible for enforcing the period of debarment and taking appropriate action should the individual apply or be inappropriately appointed during the debarment period. This does not limit OPM’s ability to exercise jurisdiction and take an action if it deems appropriate.
Subpart C—OPM Suitability Action Procedures

§ 731.301 Scope.

(a) Coverage. This subpart sets forth the procedures to be followed when OPM proposes to take, or instructs an agency to take, a final suitability action against an applicant, appointee or employee.

(b) Definition. In this subpart, days means calendar days.

§ 731.302 Notice of proposed action.

(a) OPM shall notify the applicant, appointee, or employee (hereafter, the “respondent”) in writing of the proposed action and of the charges against the respondent (including the availability for review, upon request, of the materials relied upon). The notice shall state the specific reasons for the proposed action and that the respondent has the right to answer the notice in writing. If the respondent is an employee, the notice shall further state that the employee may also make an oral answer, as specified in § 731.303(a). The notice shall further inform the respondent of the time limits for response as well as the address to which such response should be made.

(b) The notice of proposed action shall be served upon the respondent by such method as OPM deems appropriate, which may include mailing, hand delivery, personal service, or other methods authorized by law. To be timely, a response must be made within 30 days of the date of the notice.

(c) OPM shall send a copy of this notice to any employing agency that is involved.

§ 731.303 Answer.

(a) Respondent’s answer. A respondent may answer the charges in writing and furnish documentation and/or affidavits in support of the response. A respondent who is an employee may also answer orally. The respondent may be represented by a representative of the respondent’s choice, and such representative shall be designated in writing. To be timely, a written answer shall be made no more than 30 days after the date of the notice of proposed action. In the event an employing agency requests an oral answer, the request must be made within this 30 day time frame, and OPM shall determine the time and place thereof, and shall consider any answer the respondent makes in reaching a decision.

(b) Agency’s answer. An employing agency may also answer the notice of proposed action. The time limit for filing an answer is 30 days from the date of the notice. OPM shall consider any answer the agency makes in reaching a decision.

§ 731.304 Decision.

The decision shall be in writing, dated, and inform the respondent of the reasons for the decision. The employing agency shall remove the appointee or employee from the rolls within 5 work days of receipt of OPM’s final decision.

§ 731.401 Scope.

(a) Coverage. This subpart sets forth the procedures to be followed when an agency proposes to take a final suitability action against an applicant or appointee.

(b) Definition. In this subpart, days mean calendar days.

§ 731.402 Notice of proposed action.

The agency shall provide the applicant or appointee (hereinafter, the “respondent”) reasonable notice in writing of the proposed action and of the charges against the respondent (including the availability for review, upon request, of the materials relied upon). The notice shall state the specific reasons for the proposed action, and that the respondent has the right to answer the notice in writing. The notice shall inform the respondent of the time limits for response as well as the address to which such response should be made.

§ 731.403 Answer.

A respondent may answer the charges in writing and furnish documentation and/or affidavits in support of the response.

§ 731.404 Decision.

The decision shall be in writing, dated, and inform the respondent of the reasons for the decision. The respondent shall also be informed that an adverse decision can be appealed in accordance with subpart E of this part. The employing agency shall remove an appointee from the rolls within 5 work days of their final decision.

Subpart E—Appeal to the Merit Systems Protection Board

§ 731.501 Appeal to the Merit Systems Protection Board.

(a) Appeal to the Merit Systems Protection Board. An individual who has been found unsuitable for employment may appeal the determination to the Merit Systems Protection Board. If the Board finds that one or more charges are supported by a preponderance of the evidence, it shall affirm the determination. If the Board sustains fewer than all the charges, the Board shall remand the case to OPM or the agency to determine whether the action taken is appropriate based on the sustained charge(s). This determination of whether the action taken is appropriate shall be final without any further appeal to the Board.

(b) Appeal procedures. The procedures for filing an appeal with the Board are found at part 1201 of this chapter.

Subpart F—Savings Provision

§ 731.601 Savings provision.

No provision of the regulations in this part shall be applied in such a way as to affect any administrative proceeding pending on January 29, 2001. An administrative proceeding is deemed to be pending from the date of the agency or OPM “notice of proposed action” described in § 731.402.

DEPARTMENT OF AGRICULTURE

Food and Nutrition Service

7 CFR Part 225

RIN 0584–AC23

Summer Food Service Program Implementation of Legislative Reforms

AGENCY: Food and Nutrition Service, USDA.

ACTION: Final rule, with technical amendments.

SUMMARY: This rule makes final an interim rule published in the Federal Register on December 28, 1999. This final rule adopts the changes made to the Summer Food Service Program by the interim rule as mandated by three public laws—the Healthy Meals for
Healthy Americans Act of 1994, the Personal Responsibility and Work Opportunity Reconciliation Act of 1996, and the William F. Goodling Child Nutrition Reauthorization Act of 1998. Program changes include easing restrictions on participation by private nonprofit organizations and food service management companies, streamlining rules for schools to encourage Program sponsorship, and reducing paperwork burdens for State agencies. In addition, this rule makes minor technical changes to conform meal pattern requirements to the standards used in the National School Lunch Program and the School Breakfast Program, to correct errors in meal pattern charts and regional office addresses, and to conform application procedures to the Meal Benefit Form prototype. Finally, this rule restores and revises a paragraph that was inadvertently removed from program regulations by the interim rule.


FOR FURTHER INFORMATION CONTACT: Mr. Robert M. Eadie or Ms. Melissa Rothstein, 703–305–2620.

SUPPLEMENTARY INFORMATION:

I. Background and Discussion of the Final Rule

The Summer Food Service Program (SFSP) is authorized under section 13 of the Richard B. Russell National School Lunch Act (NSLA) (42 U.S.C. 1761). Its primary purpose is to provide nutritious meals to children from low-income areas during periods when schools are closed for vacation.

In 1994, 1996, and 1998, substantive changes to the SFSP were made with the enactment of three public laws. Readers can find information about these laws and details on the corresponding changes we made to the SFSP regulations in the interim rule (64 FR 72474) that was published on December 28, 1999, in the Federal Register.

The 180-day comment period on the interim rule ended June 25, 2000. One comment was received on the interim rule. The commenter supported the changes made to the SFSP regulations by the interim rulemaking and suggested that we continue the process of reducing paperwork burdens and streamlining requirements. This commenter provided a number of recommendations that we may consider in a future rulemaking. The specific comments made, however, did not apply directly to the language in the interim rulemaking.

We want to emphasize that the interim rule primarily brought the SFSP regulations up to date with the statutory requirements. Since these changes were implemented by State agencies based on Department guidance in a timely fashion after the enactment of each public law, there were essentially no new policy proposals in the rule to engender comments.

Following is a chart that lists by program area the provisions contained in the December 28, 1999, interim rule; we also provide regulatory citations in the chart for the reader’s convenience in locating the changes within the SFSP regulations at 7 CFR part 225.

BILLING CODE 3410–30–P
<table>
<thead>
<tr>
<th>Implementing Legislative Reforms in the SFSP – Final Rule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Provision</td>
</tr>
<tr>
<td>-----------</td>
</tr>
<tr>
<td>1. Private Nonprofit Organizations (PNOs):</td>
</tr>
<tr>
<td>• New sponsor selection priority system</td>
</tr>
<tr>
<td>• The one-year waiting period is eliminated for PNOs to serve an area previously served by a school food authority (SFA) or a government sponsor.</td>
</tr>
<tr>
<td>• Warnings only for PNOs printed on application materials are eliminated. At State option, all application materials may contain warning language. Upgraded maximum fine that can be levied to statutory limit of $25,000.</td>
</tr>
<tr>
<td>• Special training for PNOs is eliminated.</td>
</tr>
<tr>
<td>• Increase number of sites and children served at those sites by PNOs.</td>
</tr>
<tr>
<td>• PNOs can use commercial vendors.</td>
</tr>
<tr>
<td>• Eliminated the March 1 indication of interest requirement.</td>
</tr>
<tr>
<td>2. Paperwork Reductions:</td>
</tr>
<tr>
<td>• Eliminated criteria from the State’s Management and Administration Plans.</td>
</tr>
<tr>
<td>• Eliminated annual submission of free and reduced price policy statement for SFAs.</td>
</tr>
<tr>
<td>3. Food Service Management Companies (FSMC)</td>
</tr>
<tr>
<td>• Eliminated requirement that FSMCs must be registered by State agencies; it is now a State option. Conforming changes made to appeal procedures.</td>
</tr>
<tr>
<td>• Eliminated State agency reporting requirement on registration of FSMCs.</td>
</tr>
<tr>
<td>• Contracts with FSMCs must require mandatory periodic inspections of meals to determine if bacteria levels conform with local standards.</td>
</tr>
<tr>
<td>4. School Food Authorities (SFAs)</td>
</tr>
<tr>
<td>• SFAs don’t have to conduct training of site personnel</td>
</tr>
</tbody>
</table>
### Implementing Legislative Reforms in the SFSP – Final Rule

<table>
<thead>
<tr>
<th>Provision</th>
<th>Found In</th>
</tr>
</thead>
<tbody>
<tr>
<td>before getting their second advance operating payment.</td>
<td></td>
</tr>
<tr>
<td>• SFAs may utilize “offer versus serve” option at all sites.</td>
<td>§225.16(f)(1)(ii)</td>
</tr>
<tr>
<td>• SFAs must use a single permanent agreement and common claims form for all child nutrition programs.</td>
<td>§§225.6(e) and 225.9(d)</td>
</tr>
<tr>
<td>• SFAs with satisfactory reviews under the National School Lunch Program (NSLP) are exempt from SFSP review in the same year.</td>
<td>§225.7(d)(2)</td>
</tr>
</tbody>
</table>

### 5. Definition of Household Types and Clarifying Language on Application Procedures

All references to “AFDC” are removed and replaced with “TANF”.
“FDPIR household” is added as a definition and as a qualifying program for automatic eligibility for SFSP benefits.

§§225.2 definitions, 225.6(c)(4)(ii)(B), 225.15(e), and 225.15(f)(3),(4), and (5)

### 6. National Youth Sports Program (NYSP)

- Statutory authority for Academic-Year NYSP sites expired; all references to “academic-year NYSP” are removed.

§225.2 - definitions and throughout Part 225

- Definition of “NYSP feeding site” is revised to allow eligibility based on enrollment or area eligibility.

§§225.2

### 7. Consolidated Benefits for Homeless Children

- Administration and delivery of benefits to homeless children was consolidated under the Child and Adult Care Food Program. Homeless shelters may still operate SFSP as either open or enrolled sites.

References to homeless emergency shelters removed at: §§225.2, 225.6(c)(2), 225.6(d), 225.8(e), 225.14(c)(3), 225.14(d)(4), 225.15(a)(2), and 225.16(b)(2).

### 8. Number of Meals and Meal Pattern Requirements

- Reimbursable meals for camps and migrant sites were reduced from 4 to 3 (or 2 meals and 1 snack) per day per child.

 §§225.16(b)(1)(i) and 225.16(b)(4)

- The term “snack” replaced the term “supplement”.

Starting at §225.16(b)

- Equivalencies of egg to meat or meat alternatives are changed to conform to those used in the National School Lunch Program and School Breakfast Programs.

§225.16(d)

### 9. Program Payments

Reimbursement rates for Alaska and Hawaii were adjusted upward to reflect the higher cost of living in those States.

§225.9(d)(9)
Restoring a State Agency Reporting Requirement

Since 1990, FNS has played a special role in monitoring the participation of PNOs in the SFSP. Section 13(p)(1) of the NSLA, which was added by Pub. L. 101–147, the Child Nutrition and WIC Reauthorization Act of 1989, authorizes the Secretary to establish a system of compliance monitoring of PNOs. As mandated in section 13(p)(2), one half of one percent of each annual appropriation of the SFSP funds this monitoring system. FNS regional offices carry out this special monitoring effort by conducting reviews of PNOs in their States. In order to conduct these reviews, regional offices rely on receiving information on a timely basis from the State agencies about the PNOs that are approved each year to operate the Program. Because of the importance of these reviews, the SFSP regulations were amended on April 10, 1990, to require State agency submission of this information to FNS regional offices.

In the December 28, 1999 interim rule, paragraph (e) of §225.8 which contained this submission requirement was mistakenly removed. This paragraph required State agencies to submit to their FNS regional office a list of potential PNO sponsors and their addresses by May 1st each year. For each potential PNO sponsor, State agencies were required to estimate the number of sites, locations, dates of operation per site, and daily attendance per site. This paragraph also referenced the need to gather and analyze information on PNOs that was required in §225.6(a)(3). (The interim rule removed §225.6(a)(3) because the statutory requirement addressed in this paragraph was eliminated by Pub. L. 105–336, the William F. Goodling Child Nutrition Reauthorization Act of 1998). Additionally, State agencies were required to supply additional information and to update previously estimated information about each approved PNO within 5 working days of the approval.

To eliminate the potential for confusion about FNS’ need for this information, we are restoring this requirement in §225.8 in this rulemaking. The new paragraph contains similar language to the old paragraph, with some exceptions. The new paragraph does not require the analysis of information collected in accordance with §225.6(a)(3), since that analysis is no longer required. Similarly, we do not ask State agencies to report homeless sites, since sites are no longer categorized as specifically serving a homeless population.

Accordingly, a new paragraph (d) is added to §225.8 to require State agency submission of a list of potential PNO sponsors by May 1st of each year. New paragraph (d) will also require State agencies to submit additional detailed information of PNO sponsors within 5 days of their approval to participate in the Program.

Corrections

This rule corrects several errors in part 225. We are revising §225.15(f)(4)(vii) to specify that the penalties notice should appear immediately above the signature block on the application for free meals. This is consistent with the Meal Benefit Form prototype (free and reduced price meal application) that FNS revised in spring 2000. Another correction is to the breakfast meal pattern chart found in §225.16(d)(1). The minimum amount for cooked dry beans or peas under the meat and meat alternates component is shown as ½ cup. The correct amount should be ¼ cup. The SFSP meal pattern charts were most recently updated in a final rule entitled “Modification of the ‘Vegetable Protein Products’ Requirements for the National School Lunch Program, School Breakfast Program, Summer Food Service Program and Child and Adult Care Food Program,” which was published on March 9, 2000 (65 FR 12429). Lastly, we are correcting addresses for several FNS regional offices in various paragraphs of §225.19.

II. Procedural Matters

Executive Order 12866

This final rule has been determined to be not significant for purposes of Executive Order 12866, and therefore has not been reviewed by the Office of Management and Budget.

Public Law 104–4

Title II of the Unfunded Mandates Reform Act of 1995 (UMRA), Pub. L. 104–4, requires Federal agencies to assess the effects of their regulatory actions on State, local, and tribal governments and the private sector. Under section 202 of the UMRA, the Food and Nutrition Service generally must prepare a written statement, including a cost-benefit analysis, for proposed and final rules with Federal mandates that may result in expenditures to State, local, or tribal governments, in the aggregate, or to the private sector, of $100 million or more in any one year. When such a statement is needed for a rule, section 205 of the UMRA generally requires the Food and Nutrition Service to identify and consider a reasonable number of regulatory alternatives and adopt the least costly, more cost-effective or least burdensome alternative that achieves the objectives of the rule.

This rule contains no Federal mandates (under the regulatory provisions of Title II of the UMRA) for State, local and tribal governments or the private sector of $100 million or more in any one year. Thus, this rule is not subject to the requirements of sections 202 and 205 of the UMRA.

Executive Order 12372

The Summer Food Service Program is listed in the Catalog of Federal Domestic Assistance under No. 10.559. For the reasons set forth in the final rule in 7 CFR part 3015, subpart V, and related notices (48 FR 29114 and 49 FR 2276), this program is included in the scope of Executive Order 12372, which requires intergovernmental consultation with State and local officials.

Regulatory Flexibility Act

This final rule has been reviewed with regard to the requirements of the Regulatory Flexibility Act of 1980 (5 U.S.C. 601–612). Samuel Chambers, Jr., Administrator of the Food and Nutrition Service (FNS), has certified that this rule will not have a significant economic impact on a substantial number of small entities. Since the provisions contained in this rule were previously implemented, it will have no impact.

Executive Order 12988

This final rule has been reviewed under Executive Order 12988, Civil Justice Reform. This rule is intended to have preemptive effect with respect to any State or local laws, regulations or policies which conflict with its provisions or which would otherwise impede its full implementation. This rule is not intended to have retroactive effect unless so specified in the EFFECTIVE DATE section of the preamble of the rule. Prior to any judicial challenge to the provisions of this rule or the applications of its provisions, all applicable administrative procedures must be exhausted. This includes any administrative procedures available through State or local governments. SFSP administrative procedures are set forth at: (1) 7 CFR 225.13, which outlines appeals procedures for use by a sponsor or a food service management company; and (2) 7 CFR parts 3016 and 7 CFR, which address administrative appeal procedures for disputes involving...
procurement by State agencies and sponsors.

Paperwork Reduction Act

This final rule contains information collection requirements in §225.8(d) that have been approved by the Office of Management and Budget on February 28, 2000 (control number 0584–0280) under the Paperwork Reduction Act of 1995 (44 U.S.C. 3507).

List of Subjects in 7 CFR Part 225

Food and Nutrition Service, Food assistance programs, Grant programs—health, Infants and children, Labeling, Reporting and recordkeeping requirements.

Accordingly, the interim rule amending 7 CFR part 225, which was published at 64 FR 72474 on December 28, 1999, is adopted as a final rule with the following changes:

PART 225—SUMMER FOOD SERVICE PROGRAM

1. The authority citation for part 225 continues to read as follows:

Authority: Secs. 9, 13, and 14, National School Lunch Act, as amended (42 U.S.C. 1758, 1761, and 1762a).

2. In §225.8, add new paragraph (d) to read as follows:

§225.8 Records and reports.

(d)(1) By May 1 of each year, State agencies must submit to the appropriate FNSRO a list of potential private nonprofit organization sponsors. The list must include the following information for each applicant sponsor:

(i) Name and address;

(ii) Geographical area(s) proposed to be served;

(iii) Proposed number of sites; and

(iv) Any available details of each proposed site including address, dates of operation, and estimated daily attendance.

(2) State agencies must also notify the appropriate FNSRO within 5 working days after they approve each private nonprofit organization to participate as a SFSP sponsor. When State agencies notify the FNSRO of sponsor approval, they must provide the following information:

(i) Any changes to site locations, dates of operation, and estimated daily attendance that was previously provided;

(ii) The hours and type(s) of approved meal service at each site;

(iii) The type of site approval—open, restricted open, closed enrolled, or camp; and

(iv) Any other important details about each site that would help the FNSRO plan reviews, including whether the site is rural or urban, or vended or self-preparation.

3. In §225.15, revise paragraph (f)(4)(vii) to read as follows:

§225.15 Management responsibilities of sponsors.

* * * * *

(f) * * *

(4) * * *

(vii) A notice placed immediately above the signature block stating that the person signing the application certifies that all information provided is correct, that the household is applying for Federal benefits in the form of free Program meals, that Program officials may verify the information on the application, and that purposely provided untrue or misleading statements may result in prosecution under State or Federal criminal laws; and

* * * * *

4. In §225.16, revise the entry for “Cooked dry beans or peas” in the table under Meat and Meat Alternates (Optional) in paragraph (d)(1) to read as follows:

§225.16 Meal service requirements.

* * * * *

(d) * * *

(1) * * *

<table>
<thead>
<tr>
<th>Food components</th>
<th>Minimum amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>* * * * * *</td>
<td></td>
</tr>
<tr>
<td>Meat and Meat Alternates (Optional)</td>
<td>* * * *</td>
</tr>
<tr>
<td>Cooked dry beans or peas</td>
<td>1/4 cup.</td>
</tr>
<tr>
<td>* * * * * *</td>
<td></td>
</tr>
</tbody>
</table>

5. In §225.19, revise paragraphs (b), (c), (d), (e), (f) and (g) to read as follows:

§225.19 Regional office addresses.

* * * * *

(b) In the States of Delaware, District of Columbia, Maryland, New Jersey, Pennsylvania, Puerto Rico, Virginia, Virgin Islands, and West Virginia: Mid-Atlantic Regional Office, FNS, U.S. Department of Agriculture, Mercer Corporate Park, 300 Corporate Boulevard, Robbinsville, NJ 08691–1598.

(c) In the States of Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, and Tennessee: Southeast Regional Office, FNS, U.S. Department of Agriculture, 61 Forsyth Street, SW, Room 8T36, Atlanta, GA 30303–3415.

(d) In the States of Illinois, Indiana, Michigan, Minnesota, Ohio, and Wisconsin: Midwest Regional Office, FNS, U.S. Department of Agriculture, 77 West Jackson Boulevard, 20th Floor, Chicago, IL 60604–3507.

(e) In the States of Arkansas, Louisiana, New Mexico, Oklahoma and Texas: Southwest Regional Office, FNS, U.S. Department of Agriculture, 1100 Commerce Street, Room 5–C–30, Dallas, TX 75242–9980.


(g) In the States of Alaska, American Samoa, Arizona, California, Guam, Hawaii, Idaho, Nevada, Oregon, the Commonwealth of the Northern Mariana Islands, and Washington: Western Regional Office, FNS, U.S. Department of Agriculture, 550 Kearney Street, Room 400, San Francisco, CA 94108–2518.


George A. Braley,
Acting Administrator.

[FR Doc. 00–33095 Filed 12–27–00; 8:45 am]
BILLING CODE 3410–30–P

DEPARTMENT OF AGRICULTURE

Agricultural Marketing Service

7 CFR Part 930

[Docket No. FV00–930–4 FIR]

Tart Cherries Grown in the States of Michigan, et al.; Authorization of Japan as an Eligible Export Outlet for Diversion and Exemption Purposes

AGENCY: Agricultural Marketing Service, USDA.

ACTION: Final rule.

SUMMARY: The Department of Agriculture (Department) is adopting, as a final rule, without change, the provisions of an interim final rule which authorizes Japan as an eligible export market under the diversion and exemption provisions of the Federal tart cherry marketing order (order). Previously, shipments to Canada, Mexico, or Japan did not qualify for diversion credit and could not be approved as exempt uses. The Cherry Industry Administrative Board (Board) recommended allowing shipments to Japan to qualify as exempt use shipments and to be eligible for diversion credit. The order regulates the
handling of tart cherries grown in the States of Michigan, New York, Pennsylvania, Oregon, Utah, Washington, and Wisconsin and is administered locally by the Board.

**EFFECTIVE DATE:** January 29, 2001.

**FOR FURTHER INFORMATION CONTACT:** Patricia A. Petrella or Kenneth G. Johnson, Marketing Order Administration Branch, F&V, AMS, USDA, Suite 2A04, Unit 155, 4700 River Road, Riverdale, Maryland 20737, (301) 734–5243; Fax: (301) 734–5275, or George Kelhart, Technical Advisor, Marketing Order Administration Branch, Fruit and Vegetable Programs, AMS, USDA, room 2525–S, P.O. Box 96456, Washington, DC 20090–6456; telephone; (202) 720–2491, Fax: (202) 720–5608.

Small businesses may request information on complying with this regulation by contacting Jay Guerber, Marketing Order Administration Branch, Fruit and Vegetable Programs, AMS, USDA, P.O. Box 96456, room 2525–S, Washington, DC 20090–6456; telephone (202) 720–2491; Fax: (202) 720–5608, or E-mail: jay.guerber@usda.gov.

**SUPPLEMENTARY INFORMATION:** This rule is issued under Marketing Agreement and Order No. 930 (7 CFR part 930) regulating the handling of tart cherries grown in the States of Michigan, New York, Pennsylvania, Oregon, Utah, Washington, and Wisconsin, hereinafter referred to as the “order.” This order is effective under the Agricultural Marketing Agreement Act of 1937, as amended (7 U.S.C. 601–674), hereinafter referred to as the “Act.”

The Department of Agriculture (Department or USDA) is issuing this rule in conformance with Executive Order 12866. This rule has been reviewed under Executive Order 12988, Civil Justice Reform. This rule is not intended to have retroactive effect. This rule will not preempt any State or local laws, regulations, or policies, unless they present an irreconcilable conflict with this rule.

The Act provides that administrative proceedings must be exhausted before parties may file suit in court. Under section 608c(15)(A) of the Act, any handler subject to an order may file with the Secretary a petition stating that the order, any provision of the order, or any obligation imposed in connection with the order is not in accordance with law and request a modification of the order or to be exempted therefrom. A handler is provided the opportunity for a hearing on the petition. After the hearing the Secretary would rule on the

The Act provides that the district court of the United States in any district in which the handler is an inhabitant, or has his or her principal place of business, has jurisdiction to review the Secretary’s ruling on the petition, provided an action is filed not later than 20 days after the date of the entry of the ruling.

This rule continues to authorize shipments of tart cherries to Japan to qualify as exempt use shipments and to be eligible for diversion credit. Currently, exports to countries other than Canada or Mexico may receive diversion credit, and may qualify as exempt shipments. Prior to the issuance of the interim final rule published June 2, 2000 (65 FR 35265), Japan was not eligible for diversion and exemption in the past because, according to the Board, tart cherry markets were well established in that country. The Board, at its March 2, 2000, meeting, recommended allowing Japan to become an eligible export outlet for diversion credit and exempt uses in order to stimulate sales to that country. This was because exports to Japan have greatly decreased industry-wide.

The order authorizes the use of volume regulation. In years when volume regulation is implemented to stabilize supplies, a certain percentage of the cherry crop is required to be set aside as restricted tonnage, and the balance may be marketed freely as free tonnage. The restricted tonnage is required to be maintained in handler-owned inventory reserve pools. Handlers in volume regulated States may fulfill their restricted tonnage requirements with diversion credits earned by diverting cherries or cherry products. Handlers are permitted to divert (at plant or with grower-diversion certificates from growers choosing not to deliver their crop) as much of their restricted percentage (reserve pool) requirements as they deem appropriate. Handlers also may divert cherries by using cherries or cherry products for exempt purposes, including the development of export markets. Presently, these markets do not include Canada and Mexico.

Section 920.62 of the order (Exemptions) provides that cherries which are diverted in accordance with § 930.59, which are used for new product and new market development, which are used for experimental purposes, or which are used for any other purposes designated by the Board, including cherries processed into products for markets for which less than 5 percent of the 5-year average production of cherries was utilized, may be exempt from the assessment, quality control, volume regulation, and reserve provisions of the order.

Currently, § 930.162 of the rules and regulations under the order authorizes the sale of cherries and cherry products, including the development of sales for new and different tart cherry products or the expansion of sales for existing tart cherry products, to countries other than Canada and Mexico.

When the Board initially recommended regulations for exempt uses and handler diversion in 1997–98, exports to Japan were averaging about 3.0 million pounds per season. The industry considered Japan, as well as Canada and Mexico, to be a premium markets for tart cherries, not outlets for which exemptions and diversion credit should be given. With regard to Canada and Mexico, the industry also was concerned about transshipments of lower-priced cherries because of their close proximity to the primary domestic market. In 1996–99, sales to Japan fell to 1.6 million pounds, and in 1999–00 sales further dropped to 943,000 pounds. The Board, therefore, recommended that exports to Japan be eligible for diversion and exemption. This, in the Board’s opinion, would provide an incentive for handlers throughout the industry to make shipments to that country and stimulate activity.

The Regulatory Flexibility Act and Effects on Small Businesses

The Agricultural Marketing Service (AMS) has considered the economic impact of this action on small entities and has prepared this final regulatory flexibility analysis. The Regulatory Flexibility Act (RFA) will allow AMS to certify that regulations do not have a significant economic impact on a substantial number of small entities. However, as a matter of general policy, AMS’ Fruit and Vegetable Programs (Programs) no longer opt for such certification, but rather perform regulatory flexibility analyses for any rulemaking that would generate the interest of a significant number of small entities. Performing such analyses shifts the Programs’ efforts from determining whether regulatory flexibility analyses are required to the consideration of regulatory options and economic or regulatory impacts.

The purpose of the RFA is to fit regulatory actions to the scale of business subject to such actions in order that small businesses will not be unduly or disproportionately burdened. Marketing orders instituted pursuant to the Act, and rules thereunder, are unique in that they are brought about through
group action of essentially small entities acting on their own behalf. Thus, both statutes have small entity orientation and compatibility.

There are approximately 40 handlers of tart cherries who are subject to regulation under the order and approximately 900 producers of tart cherries in the regulated area. Small agricultural service firms, which include handlers, have been defined by the Small Business Administration (13 CFR 121.201) as those having annual receipts of less than $5,000,000, and small agricultural producers are defined as those having annual receipts of less than $500,000.

The principal demand for tart cherries is in the form of processed products. Tart cherries are dried, frozen, canned, juiced, and pureed. During the period 1995/96 through 1999/00, approximately 90 percent of the U.S. tart cherry crop, or 280.3 million pounds, was processed annually. Of the 280.3 million pounds of tart cherries processed, 29 percent were frozen, 29 percent canned and 8 percent utilized for juice. Exports to Japan in 1999–00 were 943,000 pounds.

This rule continues to authorize tart cherry shipments to Japan to qualify as exempt use shipments and to be eligible for diversion credit. The objective of this action is to stimulate and expand sales of tart cherries.

This rule is expected to benefit growers and handlers by assisting growers market a greater proportion of their crop to handlers having access to export markets. Handlers, instead of diverting at-plant or in-orchard or placing product in reserves, could ship product to Japan and receive diversion certificates that could be used to offset any restricted percentage obligations. Handlers also would benefit from this action as they would be able to process greater amounts of tart cherries, as a result of receiving more product from growers for shipment to Japan, through their facilities, thus spreading their operation costs and increasing returns to growers.

One alternative to this action considered by the Board was to disallow exemptions and diversion credit for shipments to Japan. However, this was not expected to be favorable to cherry growers and handlers throughout the production area because it might cause a further decline in the Japanese market, as occurred in 1999–00.

The Board's meetings were widely publicized throughout the tart cherry industry and all interested persons were invited to attend them and participate in Board deliberations. Like all Board meetings, the March 2000 meeting was a public meeting and all entities, both large and small, were able to express their views on these issues. The Board itself is composed of 18 members, of which 17 members are growers and handlers and one represents the public. Also, the Board has a number of appointed committees to review certain issues and make recommendations.

This rule will not impose any additional recordkeeping requirements on either small or large tart cherry handlers. As with all Federal marketing order programs, reports and forms are periodically reviewed to reduce information requirements and duplication by industry and public sectors. In addition, the Department has not identified any relevant Federal rules which duplicate, overlap or conflict with this rule.

In compliance with Office of Management and Budget (OMB) regulations (5 CFR part 1320) which implement the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35), the information and recordkeeping requirements imposed by this order have been previously approved by OMB and assigned OMB Number 0581–0177.

An interim final rule concerning this action was published in the Federal Register on June 2, 2000 (65 FR 35265). Copies of the rule were mailed by the Board's staff to all Board members and cherry handlers. In addition, the rule was made available through the Internet by the Office of the Federal Register. That rule provided a 60-day comment period which ended August 1, 2000. Two comments were received. One comment was received from the Oregon Farm Bureau and the other was received from a tart cherry grower and handler in Oregon.

The two commenters opposed making Japan an eligible export market under the diversion and exemption provisions of the order. Prior to the issuance of the interim final rule, shipments to Canada, Mexico, or Japan did not qualify for diversion credit and could not be approved as exempt uses. Japan was considered a premium market similar to the domestic market. The markets in Canada and Mexico also were considered similar to the domestic market. This was because these markets were in close proximity to the United States and the industry was concerned about transshipments of lower-priced cherries if shipments to these markets were eligible for diversion credit in meeting volume control obligations.

Under the volume control mechanism, the industry has established a price system with diversion credit shipments commanding lower prices than those shipped domestically. Handlers purchase the free percentage portion of the grower deliveries which can be marketed, and pay low prices for the excess cherries which are disposed of under the diversion and exemption provisions of the order. The cherries that are not disposed of in this manner are held in reserve. Some States in the production area, like Oregon, are not subject to volume regulation and handlers purchase all of the marketable production delivered by their growers. Generally, higher quality and condition cherries return more money to the grower.

Total U.S. exports to Japan have fallen from 3.2 million pounds in 1996–97 to 1.6 million pounds in 1998–99. During the 1999–00 crop year, total exports to Japan fell further to 943,000 pounds. This represents a 70 percent decrease in exports from 1996–97. Under the interim final rule, shipments to Japan qualify as exempt use shipments and are eligible for diversion credit. This is expected to stimulate shipments to Japan industry-wide.

Both commenters claim that Japan is a well-established and premium market which should not be eligible for diversion credit. The buyers in Japan are willing to pay a premium for cherries of the quality and condition they desire. One of the commenters, stated that its customers consistently pay top-dollar, and are rewarded with the very best his firm can offer. This commenter indicated that his firm has not experienced a comparable sense of “premium” in its exports to Canada. Nonetheless, the industry concerns on the transshipment of lower-priced cherries to the United States weigh heavily in considering Canada a primary market under the order. Oregon comprised about 1.4 percent of the domestic production during the last three shipping seasons (1997–1999).

Both commenters agree that exports to Japan have fluctuated over the years, but contend that the fluctuations are a function of the size of the Oregon crop and not a softening of the market. The goal of the Board in recommending this action was to stimulate shipments to Japan by providing growers and handlers from other parts of the production area with a means of competing in Japan. The intent of the action is not to negatively impact the Oregon growers and handlers shipping to Japanese markets, but to expand markets in Japan in the interest of the entire U.S. tart cherry industry.

Although the action is intended to enable firms from the other parts of the production area to gain a foothold in the
price conscious markets in Japan, it is not expected to prevent the firms in Oregon from supplying the needs of their quality conscious customers, willing to pay premium prices.

Shipments to markets under the diversion and exemption provisions of the order can be sold at lower prices than those shipped domestically because growers are paid less for the tart cherries subject to the diversion and exemption provisions. Because cherries produced in Oregon are not subject to volume regulation under the order, tart cherries are not subject to the diversion credit and exemption provisions of the order, and growers are paid for all of the cherries delivered.

The primary purpose of the order is to strengthen marketing conditions in the primary domestic market through volume regulation. In implementing volume controls and the related procedures, the Department’s goal is to apply the requirements uniformly in an equitable manner as possible, and to assure that any regulatory action is in the interest of the entire industry covered under the order, not just one segment or part of the industry.

Authorizing Japan as an eligible export market under the diversion and exemption provisions of the order is expected to help the industry further develop the Japanese market. This is in the long term interest of all growers and handlers of tart cherries covered under the order.

In view of this, these comments are denied.

A small business guide on complying with fruit, vegetable and specialty crop marketing agreements and orders may be viewed at: http://www.ams.usda.gov/fv/moab.html. Any questions about the compliance guide should be sent to Jay Guerber at the previously mentioned address in the FOR FURTHER INFORMATION CONTACT section.

After consideration of all relevant material presented, including the information and recommendation submitted by the Board and other available information, it is found that finalizing this interim final rule, without modifications, as published in the Federal Register (65 FR 35265), will tend to effectuate the declared policy of the Act.

List of Subjects in 7 CFR Part 930

Marketing agreements, Reporting and recordkeeping requirements, Tart cherries.

For the reasons set forth in the preamble, 7 CFR part 930 is amended as follows:

PART 930—TART CHERRIES GROWN IN THE STATES OF MICHIGAN, NEW YORK, PENNSYLVANIA, OREGON, UTAH, WASHINGTON, AND WISCONSIN

Accordingly, the interim final rule amending 7 CFR part 930 which was published at 65 FR 35265 on June 2, 2000, is adopted as a final rule without change.


Robert C. Keeney,
Deputy Administrator, Fruit and Vegetable Programs.

[FR Doc. 00–33142 Filed 12–27–00; 8:45 am]
BILLING CODE 3410–02–P

DEPARTMENT OF JUSTICE

Immigration and Naturalization Service

8 CFR Parts 103, 208, 210, 212, 235, 241, and 245a

[INS No. 2004–99]

RIN 1115–AF53

Clarification of Parole Authority

AGENCY: Immigration and Naturalization Service, Justice.

ACTION: Interim rule with request for comments.

SUMMARY: This rule amends the Immigration and Naturalization Service (Service) regulations concerning the authority to grant the parole of aliens from Service custody by specifically identifying the scope of that authority. This action is being taken to clarify which officials are authorized by the Attorney General, acting through the Commissioner, to grant parole from Service custody.

DATES: Effective Date: This interim rule is effective January 29, 2001.

Comment Date: Written comments must be submitted on or before February 26, 2001.

ADDRESSES: Please submit written comments, in triplicate, to the Director, Policy Directives and Instructions Branch, Immigration and Naturalization Service, 425 I Street NW, Room 4034, Washington, DC 20536. To ensure proper handling, please reference INS No. 2004–99 on your correspondence. Comments are available for public inspection at the above address by calling (202) 514–3048 to arrange for an appointment.

FOR FURTHER INFORMATION CONTACT: Yvette M. LaGonterie, Office of International Affairs, Parole Branch, 111 Massachusetts Avenue NW., ULLICO Building, third floor, Washington, DC 20001, telephone (202) 305–2670.

SUPPLEMENTARY INFORMATION:

How Does This Rule Amend the Existing Regulation?

Section 212(d)(5)(A) of the Immigration and Nationality Act (Act) gives the Attorney General discretion to parole into the United States, temporarily, for urgent humanitarian reasons or significant public benefit, any alien applying for admission to the United States. While the power to delegate this authority clearly flows from the Attorney General through the Commissioner to her designees, § 212.5 appears to delegate this parole authority solely to the district director (DD) and the chief patrol agent (CPA). This rule amends § 212.5 to bring it into conformity with the delegation of authority provisions contained in §§ 2.1 and 103.1. This rule adds a new paragraph (a) to § 212.5 which specifically states that the scope of the authority to grant parole flows from the Commissioner through her designees, so that the Deputy Commissioner, the Executive Associate Commissioner (EAC) for Field Operations, regional directors (RD) and other designees have the power to grant parole.

Why is This Rule Necessary?

This rule is intended to clarify the existing authority of Service officials to grant parole. Some have interpreted § 212.5 to mean that the authority to grant parole is limited to the DD and the CPA. This interpretation is erroneous. See Matter of ACCARDI, 14 I. & N. Dec. 367 (BIA 1973). Under section 212(d)(5) of the Act, parole authority is vested with the Attorney General. It is well established under both precedent decisions and § 2.1 that the Attorney General has delegated authority to the Commissioner to implement and enforce the provisions of the Act, but that the Attorney General retains that authority. Section 103.1 further establishes the power of the Commissioner to delegate her authority to subordinate officials, so that the authority to enforce the Act flows from the Commissioner to her designees, but without divesting the Commissioner or her subordinates of the delegated authority. The specific reference to the DD and the CPA in § 212.5 presumes a delegation of authority from the Commissioner through the chain of command set forth in § 103.1. To clarify this delegation of authority and to avoid an erroneous interpretation, § 212.5 will be amended to specifically recognize that authority. Therefore, the authority to parole aliens under § 212.5 is
clarified to include the Commissioner and officers within the Commissioner’s chain of command, including the Deputy Commissioner, the EAC for Field Operations, the RD, the DD and the CPA.

Exceptions to Notice and Comment

The Service’s implementation of this rule as an interim rule with provisions for post-promulgation public comment is based upon the exceptions to notice and comment found at 5 U.S.C. 553(a)(2) and 553(b)(A) for the following reason: this rule relates to agency management and the rules of agency organization. It does not create a new authority, but merely clarifies the delegation of an existing authority.

Regulatory Flexibility Act

The Commission of the Immigration and Naturalization Service, in accordance with 5 U.S.C. 605(b), has reviewed this regulation and, by approving it, certifies that this rule will not have a significant economic impact on a substantial number of small entities because this rule merely provides parole of aliens from Service custody. The aliens in Service custody are not considered small entities as that term is defined in 5 U.S.C. 601(6).

Unfunded Mandates Reform Act of 1995

This rule will not result in the expenditure by State, local and tribal governments in the aggregate, or by the private sector, of $100 million or more in any 1 year, and it will not significantly or uniquely affect small governments. Therefore, no actions were deemed necessary under the provisions of the Unfunded Mandates Reform Act of 1995.

Small Business Regulatory Enforcement Fairness Act of 1996

This rule is not a major rule as defined by section 804 of the Small Business Regulatory Enforcement Act of 1996. This rule will not result in an annual effect on the economy of $100 million or more; a major increase in costs or prices; or significant adverse effects on competition, employment, investment, productivity, innovation, or on the ability of United States-based companies to compete with foreign-based companies in domestic and export markets.

Executive Order 12866

This rule is not considered by the Department of Justice, Immigration and Naturalization Service, to be a “significant regulatory action” under Executive Order 12866, section 3(f), Regulatory Planning and Review, and the Office of Management and Budget has waived its review process under section 6(a)(3)(A).

Executive Order 13132

This rule will not have substantial direct effects on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government. Therefore, in accordance with section 6 of Executive Order 13132, it is determined that this rule does not have sufficient federalism implications to warrant the preparation of a federalism summary impact statement.

Executive Order 12988 Civil Justice Reform

This rule meets the applicable standards provided in section 3(a) and 3(b)(2) of Executive Order 12988.

List of Subjects

8 CFR Part 103
Authority delegations (Government agencies), Freedom of information, Privacy, Reporting and recordkeeping requirements, Surety bonds.

8 CFR Part 208
Administrative practice and procedure, Aliens, Immigration, Reporting and recordkeeping requirements.

8 CFR Part 210
Aliens, Migrant labor, Reporting and recordkeeping requirements.

8 CFR Part 212
Administrative practice and procedure, Aliens, Immigration, Passports and visas, Reporting and recordkeeping requirements.

8 CFR Part 235
Administrative practice and procedure, Aliens, Immigration, Reporting and recordkeeping requirements.

8 CFR Part 241
Aliens.

8 CFR Part 245a
Aliens, Immigration, Reporting and recordkeeping requirements.

Accordingly, chapter 1 of title 8 of the Code of Federal Regulations is amended as follows:

PART 103—POWERS AND DUTIES OF SERVICE OFFICERS; AVAILABILITY OF SERVICE RECORDS

1. The authority citation for part 103 continues to read as follows:


§ 103.12 [Amended]
2. Section 103.12 is amended by revising the reference to “212.5(a)(3)” to read “212.5(b)(3)” in paragraph (a)(3)(i).

PART 208—PROCEDURES FOR ASYLUM AND WITHHOLDING OF REMOVAL

3. The authority citation for part 208 continues to read as follows:


§ 208.8 [Amended]
4. Section 208.8 is amended by revising the reference to “212.5(e)” to read “212.5(f)” in paragraph (a) and (b).

PART 210—SPECIAL AGRICULTURAL WORKERS

5. The authority citation for part 210 continues to read as follows:


§ 210.4 [Amended]
6. Section 210.4 is amended by revising the reference to “212.5(e)” to read “212.5(f)” in the last sentence of paragraph (b)(2).

PART 212—DOCUMENTARY REQUIREMENTS; NONIMMIGRANTS; WAIVERS; ADMISSION OF CERTAIN INADMISSIBLE ALIENS; PAROLE

7. The authority citation for part 212 continues to read as follows:


§ 212.5 [Amended]
8. Section 212.5 is amended by:

a. Redesignating paragraphs (a) through (g) as paragraphs (b) through (h) respectively;
b. Adding a new paragraph (a);
c. Revising the reference to “[a](3)(i)” to read “(b)(3)(i)” in the introductory text in newly redesignated paragraph (b)(3);
d. Revising the reference to “paragraph (a)” to read “paragraph (b)” in the first sentence of newly redesignated paragraph (b)(3);
e. Revising the reference to “paragraph (c)” to read “paragraph (d)”
in the first sentence of newly redesignated paragraph (c);  

f. Revising the reference to “paragraph (e)” to read “paragraph (f)” in the second sentence of newly redesignated paragraph (c);  

g. Revising the reference to “paragraph (a) or (b)” to read “paragraph (b) or (c)” in the first sentence of the introductory text of newly redesignated paragraph (d);  

h. Revising the reference to “(d)(2)” to read “(e)(2)” in newly redesignated paragraph (e)(1);  

i. Revising the reference to “(d)(1)” to read “(e)(1)” in newly redesignated paragraph (e)(2)(i);  

j. Revising the reference to “212.5(d)(2)(i)” to read “212.5(e)(2)(i)” in the last sentence of newly redesignated paragraph (e)(2)(i);  

k. Revising the reference to “212.5(d)(5)(A)” to read “212.5(e)(5)(A)” of the Act shall be exercised by the district director or chief patrol agent, subject to the regional director, any of whom in the exercise of discretion may invoke this authority under section 212(d)(5)(A) of the Act.  

§ 212.5 Parole of aliens into the United States.  

(a) The authority of the Commissioner to continue an alien in custody or grant parole under section 212(d)(5)(A) of the Act shall be exercised by the district director or chief patrol agent, subject to the parole and detention authority of the Commissioner or her designees, which include the Deputy Commissioner, the Executive Associate Commissioner for Field Operations, and the regional director, any of whom in the exercise of discretion may invoke this authority under section 212(d)(5)(A) of the Act.  

PART 235—INSPECTION OF PERSONS APPLYING FOR ADMISSION  

9. The authority citation for part 235 continues to read as follows:  


§ 235.3 [Amended]  

10. Section 235.3 is amended by revising the reference to “212.5(a)” to read “212.5(b)” in the second sentence of paragraph (c).  

§ 235.4 [Amended]  

11. Section 235.4 is amended by revising the reference to “212.5(a)” to read “212.5(b)” in the last sentence.  

PART 241—APPREHENSION AND DETENTION OF ALIENS ORDERED REMOVED  

12. The authority citation for part 241 continues to read as follows:  


§ 241.33 [Amended]  

13. Section 241.33 is amended by revising the reference to “212.5(a)” to read “212.5(b)” in the introductory text of paragraph (a).  

PART 245a—ADJUSTMENT OF STATUS TO THAT OF PERSONS ADMITTED FOR LAWFUL TEMPORARY OR PERMANENT RESIDENT STATUS UNDER SECTION 245A OF THE IMMIGRATION AND NATIONAL ACTIVITY  

14. The authority citation for part 245a continues to read as follows:  

Authority: 8 U.S.C. 1101, 1103, 1255a and 1255a note.  

§ 245a.2 [Amended]  

15. Section 245a.2 is amended by revising the reference to “212.5(e)” to read “212.5(f)” in paragraph (m)(1), and in the last sentence of paragraph (n)(2)(i).  

§ 245a.4 [Amended]  

16. Section 245a.4 is amended by revising the reference to “212.5(e)” to read “212.5(f)” in paragraph (b)(13)(i), and in the last sentence of paragraph (b)(14)(i)(A).  


Mary Ann Wrysch,  
Acting Commissioner, Immigration and Naturalization Service.  

[FR Doc. 00–33133 Filed 12–27–00; 8:45 am]  
BILLING CODE 4410–10–M  

DEPARTMENT OF JUSTICE  
Immigration and Naturalization Service  

8 CFR Part 244  

INS No. 1972–99  
RIN 1115–AF01  

Temporary Protected Status: Amendments to the Requirements for Employment Authorization Fee, and Other Technical Amendments  

AGENCY: Immigration and Naturalization Service, Justice.  

ACTION: Final rule.  

SUMMARY: This rule adopts without change an interim rule published by the Immigration and Naturalization Service (Service) in the Federal Register on February 1, 1999. The interim rule amended the Service regulations by removing outdated language requiring that only certain El Salvadorans must pay a fee for Temporary Protected Status (TPS)-related employment authorization documents (EADs). Removing the language was necessary to make Service regulations conform to the requirement that instructs all applicants for TPS who desire employment to pay the fee.  

DATES: This final rule is effective January 29, 2001.  

FOR FURTHER INFORMATION CONTACT: Michael Valverde, Adjudications Officer, Office of Adjudications, Room 3040, 425 I Street NW., Washington, DC 20536, telephone: (202) 514–4754.  

SUPPLEMENTARY INFORMATION:  

What Did the February 1, 1999, Interim Rule Change?  

On February 1, 1999, the Service published an interim rule in the Federal Register at 64 FR 4780. The interim rule:  

(1) Amended § 244.6 to remove outdated language requiring that only certain El Salvadorans must pay a fee for TPS-related applications for EADs. Section 244.6 previously stated that “* * * the fee for Form I–765 will be charged only for those aliens who are nationals of El Salvador, and are between the ages of 14 and 65 (inclusive), and are requesting work authorization.” This language pertained to the statutory designation of El Salvador for TPS (under section 303 of the Immigration Act of 1990) that expired June 30, 1992. The El Salvador specific fee language was superseded by the fee requirements contained on the instructions to the Form I–765, Application for Employment Authorization. The Form I–765 instructs applicants filing for initial TPS to pay the fee if they wish to receive employment authorization. The Service generally charges fees for persons who apply for TPS on Form I–821, Application for Temporary Protected Status, and who want employment authorization regardless of nationality. Applicants also have the option of requesting a fee waiver for one or both of these fees in accordance with § 244.20. The Service does not charge a fee when a TPS applicant files the Form I–765 to comply with Service data collection purposes only and does not wish to receive employment authorization.  

(2) Amended 8 CFR part 244 to remove the word “district” when used in a reference to a “district director.” This change provides the Service with the flexibility to determine where an applicant should submit an application for TPS and which Service personnel will adjudicate the application.  

(3) Amended § 244.12 to allow the Service to issue EADs which are valid for a period of up to 18 months to be commensurate with the entire designation period of TPS. Under
section 244(b)(2) of the Act, the Attorney General can authorize an initial designation period for TPS from 6 to 18 months. Previously, § 244.12 limited the validity period of TPS-related EADs to 12 months.

Public Comment

The comment period expired April 2, 1999. The Service did not receive any comments regarding the promulgation of the interim rule. Since there were no comments relating to the interim rule, the Service is adopting the interim rule as a final rule without any changes.

Regulatory Flexibility Act

In accordance with 5 U.S.C. 605(b), the Commissioner certifies that this final rule does not have a significant economic impact on a substantial number of small entities. The factual basis for this certification is that this rule does not make any changes to the regulations. It merely adopts the interim rule, published on February 1, 1999, as final without change.

Unfunded Mandates Reform Act of 1995

This rule will not result in the expenditure by State, local, or tribal governments, in the aggregate, or by the private sector, of $100 million or more in any one year, and it will not significantly or uniquely affect small governments. Therefore, no actions were deemed necessary under the provisions of the Unfunded Mandates Reform Act of 1995.

Small Business Regulatory Enforcement Fairness Act of 1996

This rule is not a major rule as defined by section 804 of the Small Business Regulatory Enforcement Fairness Act of 1996. This rule will not result in an annual effect on the economy of $100 million or more; a major increase in costs or prices; or significant adverse effects on competition, employment, investment, productivity, innovation, or on the ability of United States-based companies to compete with foreign-based companies in domestic and export markets.

Executive Order 12866

This rule is not considered by the Department of Justice, Immigration and Naturalization Service, to be a “significant regulatory action” under Executive Order 12866, section 3(f), Regulatory Planning and Review, and the Office of Management and Budget has waived its review process under section 6(a)(3)(A).

Executive Order 13132

This regulation will not have substantial direct effects on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government. Therefore, in accordance with section 6 of Executive Order 13132, the Immigration and Naturalization Service has determined that this rule does not have sufficient federalism implications to warrant the preparation of a federalism summary impact statement.

Executive Order 12988 Civil Justice Reform

This rule meets the applicable standards set forth in sections 3(a) and 3(b)(2) of Executive Order 12988.

List of Subjects in 8 CFR Part 244

Aliens, Reporting and recordkeeping requirements.

Accordingly, the interim rule amending 8 CFR part 244, which was published in the Federal Register at 64 FR 4780 on February 1, 1999, is adopted as a final rule without change.


Mary Ann Wyrsch,
Acting Commissioner, Immigration and Naturalization Service.

[FR Doc. 00–33046 Filed 12–27–00; 8:45 am]

BILLING CODE 4410–10–M

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 25

[Docket No. NM180; Special Conditions No. 25–170–SC]

Special Conditions: Cessna Model 560, Citation V, Series Airplanes; High-Intensity Radiated Fields (HIRF)

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Final special conditions; request for comments.

SUMMARY: These special conditions are issued for Cessna Model 560, Citation V, series airplanes modified by Honeywell International Inc. These modified airplanes will have a novel and unusual design feature when compared to the state of technology envisioned in the airworthiness standards for transport category airplanes. The modification incorporates the installation of a new integrated electronic cockpit display system. The cockpit display system will utilize electrical and electronic systems that perform critical functions. The applicable airworthiness regulations do not contain adequate or appropriate safety standards for the protection of this system from the effects of high-intensity-radiated fields (HIRF). These special conditions contain the additional safety standards that the Administrator considers necessary to establish a level of safety equivalent to that established by the existing airworthiness standards.

DATES: The effective date of these special conditions is December 7, 2000. Comments must be received on or before January 29, 2001.

ADDRESSES: Comments on these special conditions may be mailed in duplicate to: Federal Aviation Administration, Transport Airplane Directorate, Attention: Rules Docket (ANM–114), Docket No. NM180, 1601 Lind Avenue SW., Renton, Washington 98055–4056; or delivered in duplicate to the Transport Airplane Directorate at the above address. All comments must be marked: Docket No. NM180. Comments may be inspected in the Rules Docket weekdays, except Federal holidays, between 7:30 a.m. and 4:00 p.m.


SUPPLEMENTARY INFORMATION:

Comments Invited

The FAA has determined that good cause exists for making these special conditions effective upon issuance; however, interested persons are invited to submit such written data, views, or arguments, as they may desire. Communications should identify the regulatory docket number and be submitted in duplicate to the address specified above. The Administrator will consider all communications received on or before the closing date for comments. These special conditions may be changed in light of the comments received. All comments received will be available in the Rules Docket for examination by interested persons, both before and after the closing date for comments. A report summarizing each substantive public contact with FAA personnel concerning this rulemaking will be filed in the docket. Commenters wishing the FAA to acknowledge receipt of their comments should submit such written data, views or arguments as they may desire. The docket Invited to the public comment process for this rulemaking contains general information on how to obtain public comment materials.
the following statement is made: “Comments to Docket No. NM180.” The postcard will be date stamped and returned to the commenter.

Background

On February 25, 2000, Honeywell International Inc., 21111 N. 19th Avenue, Phoenix, AZ 85027, applied for a Supplemental Type Certificate (STC) to modify the Cessna Model 560, Citation V, airplane approved under Type Certificate No. A22CE. The subject Cessna Model 560, Citation V, airplane is a straight wing, small transport category airplane. These airplanes, serial numbers 560–001 through 560–0259, are powered by two Pratt & Whitney JT15D–51 turbofans, with a maximum takeoff weight of 15,900 pounds. Serial numbers 560–0260 through 560–0538 are powered by two Pratt & Whitney JT15D–5D turbofans, with a maximum takeoff weight of 16,300 pounds. This series of airplanes operates with a 2-pilot crew and can hold up to 13 passengers.

The Model 560, Citation V, will incorporate integrated electronic PRIMUS EPIC Cockpit Display Systems (CDS), manufactured by Honeywell International Inc., which display altitude and heading information. The PRIMUS EPIC CDS performs a critical function associated with the display of altitude and heading information to the pilot, and must be designed and installed to ensure that its operation is not adversely affected by high intensity radiated fields (HIRF). This critical function can be susceptible to disruption of both command and response signals as a result of electrical and magnetic interference caused by HIRF external to the airplane. This disruption of signals could result in loss of critical flight displays and annunciators, or could present misleading information to the pilot.

Type Certification Basis

Under the provisions of 14 CFR 21.101, Honeywell International Inc. must show that the Cessna Model 560, Citation V, series airplanes, as changed, continue to meet the applicable provisions of the regulations incorporated by reference in Type Certificate No. A22CE, or the applicable regulations in effect on the date of application for the change. The regulations incorporated by reference in the type certificate are commonly referred to as the “original type certification basis.” The regulations included in the certification basis for the Cessna Model 560, Citation V, series airplanes include Title 14, Code of Federal Regulations (14 CFR) part 25, as amended by Amendments 25–1 through 25–8, plus additional requirements listed in the type certificate data sheet that are not relevant to these special conditions.

If the Administrator finds that the applicable airworthiness regulations (i.e., part 25, as amended) do not contain adequate or appropriate safety standards for the Cessna Model 560, Citation V, series airplanes because of a novel or unusual design feature, special conditions are prescribed under the provisions of §21.10.

In addition to the applicable airworthiness regulations and special conditions, the Cessna Model 560, Citation V, series airplanes must comply with the fuel vent and exhaust emission requirements of part 34 and the noise certification requirements of part 36.

Special conditions, as appropriate, are issued in accordance with §11.49, as required by §§11.28 and 11.29, and become part of the airplane’s type certification basis in accordance with §21.101(b)(2).

Special conditions are initially applicable to the model for which they are issued. Should the applicant apply for a supplemental type certificate to modify any other model included on the same type certificate to incorporate the same novel or unusual design features, these special conditions would also apply to the other model under the provisions of §21.101(a)(1).

Novel or Unusual Design Features

As stated earlier, the Cessna Model 560, Citation V, series airplanes modified by Honeywell International Inc. will incorporate the PRIMUS EPIC CDS, which performs critical functions. This system contains electronic equipment for which the current airworthiness standards of part 25 do not contain adequate or appropriate safety standards for the protection of this equipment from the adverse effects of HIRF. The CDS may be vulnerable to HIRF external to the airplane. Accordingly, this system is considered to be a novel or unusual design feature.

Discussion

There is no specific regulation that addresses the requirements for protection of electrical and electronic systems from HIRF. Increased power levels from ground-based radio transmitters and the growing use of sensitive electrical and electronic systems to command and control airplanes have made it necessary to provide adequate protection.

To ensure that a level of safety is achieved that is equivalent to that intended by the regulations incorporated by reference, special conditions are needed for the Cessna Model 560, Citation V, airplanes modified to include the PRIMUS EPIC CDS. These special conditions will require that this system, which performs critical functions, be designed and installed to preclude component damage and interruption of function due to both the direct and indirect effects of HIRF.

High-Intensity Radiated Fields (HIRF)

With the trend toward increased power levels from ground-based transmitters, plus the advent of space and satellite communications coupled with electronic command and control of the airplane, the immunity of critical digital avionics systems to HIRF must be established.

It is not possible to precisely define the HIRF to which the airplane will be exposed in service. There is also uncertainty concerning the effectiveness of airframe shielding for HIRF. Furthermore, coupling of electromagnetic energy to cockpit-installed equipment through the cockpit window apertures is undefined. Based on surveys and analysis of existing HIRF emitters, an adequate level of protection exists when compliance with the HIRF protection special condition is shown with either paragraph 1 OR 2 below:

1. A minimum threat of 100 volts rms per meter electric field strength from 10 kHz to 18 GHz.

   a. The threat must be applied to the system elements and their associated wiring harnesses without the benefit of airframe shielding.

   b. Demonstration of this level of protection is established through system tests and analysis.

2. A threat external to the airframe of the following field strengths for the frequency ranges indicated. Both peak and average field strength components from the Table are to be demonstrated.

<table>
<thead>
<tr>
<th>Frequency</th>
<th>Field strength (volts per meter)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Peak</td>
</tr>
<tr>
<td>10 kHz–100 kHz</td>
<td>50</td>
</tr>
<tr>
<td>100 kHz–500 kHz</td>
<td>50</td>
</tr>
<tr>
<td>500 kHz–2 MHz</td>
<td>50</td>
</tr>
<tr>
<td>2 MHz–30 MHz</td>
<td>100</td>
</tr>
<tr>
<td>30 MHz–70 MHz</td>
<td>50</td>
</tr>
<tr>
<td>70 MHz–100 MHz</td>
<td>50</td>
</tr>
<tr>
<td>100 MHz–200 MHz</td>
<td>100</td>
</tr>
<tr>
<td>200 MHz–400 MHz</td>
<td>100</td>
</tr>
<tr>
<td>400 MHz–700 MHz</td>
<td>700</td>
</tr>
<tr>
<td>700 MHz–1 GHz</td>
<td>700</td>
</tr>
<tr>
<td>1 GHz–2 GHz</td>
<td>2000</td>
</tr>
<tr>
<td>2 GHz–4 GHz</td>
<td>3000</td>
</tr>
<tr>
<td>4 GHz–6 GHz</td>
<td>3000</td>
</tr>
<tr>
<td>6 GHz–8 GHz</td>
<td>1000</td>
</tr>
<tr>
<td>8 GHz–12 GHz</td>
<td>3000</td>
</tr>
</tbody>
</table>
The field strengths are expressed in terms of peak of the root-mean-square (rms) over the complete modulation period.

The threat levels identified above are the result of a FAA review of existing studies on the subject of HIRF, in light of the ongoing work of the Electromagnetic Effects Harmonization Working Group of the Aviation Rulemaking Advisory Committee.

Applicability
As discussed above, these special conditions are applicable to Cessna Model 560, Citation V, series airplanes modified by Honeywell International Inc. to include the PRIMUS EPIC CDS. Should Honeywell International Inc. apply at a later date for a supplemental type certificate to modify any other model included on Type Certificate A22CE to incorporate the same novel or unusual design features, these special conditions would apply to that model as well under the provisions of § 21.101(a)(1).

Conclusion
This action affects only certain novel or unusual design features on the Cessna Model 560, Citation V, series airplanes modified by Honeywell International Inc. It is not a rule of general applicability and affects only the applicant who applied to the FAA for approval of these features on the airplanes.

The substance of the special conditions has been subjected to the notice and comment period in several prior instances and has been derived without substantive change from those previously issued. It is unlikely that prior public comment would result in a significant change from the substance contained herein. For this reason, and because a delay would significantly affect the certification of the airplane, which is imminent, the FAA has determined that prior public notice and comment are unnecessary and impracticable, and good cause exists for adopting these special conditions upon issuance. The FAA is requesting comments to allow interested persons to submit views that may not have been submitted in response to the prior opportunities for comment described above.

List of Subjects in 14 CFR Part 25
Aircraft, Aviation safety, Reporting and recordkeeping requirements.
Airbus AOT A330±71±3012.

The modification involves installing bolts and nuts made of MP159 material, to replace nuts and bolts made of the INCO718 material previously used. The Pratt & Whitney service bulletin, described previously, describes instructions for installing these parts, as referenced by Airbus Service Bulletin A330±71±3012.

Editorial Changes

Certain typographical errors were discovered in the version of AD 2000±25±53 that was sent previously to U.S. owners and operators of Airbus Model A320 series airplanes. Specifically, there were two notes identified as Note “2” and two notes identified as Note “3.” The notes have been correctly identified in this AD.

Interim Action

This is considered to be interim action. The manufacturer reports that further analysis is required to identify the root cause of the barrel nut failure. Continued inspections will provide better insight into the nature, cause, and prevalence of the cracking. If further action is identified to address the unsafe condition, the FAA may consider further rulemaking.

Determination of Rule’s Effective Date

Since it was found that immediate corrective action was required, notice and opportunity for prior public comment thereon were impracticable and contrary to the public interest, and good cause existed to make the AD effective immediately by individual notices issued on December 9, 2000, to all known U.S. owners and operators of Airbus Model A330 series airplanes. These conditions still exist, and the AD is hereby published in the Federal Register as an amendment to section 39.13 of the Federal Aviation Regulations (14 CFR 39.13) to make it effective as to all persons.

Comments Invited

Although this action is in the form of a final rule that involves requirements affecting flight safety and, thus, was not preceded by notice and an opportunity for public comment, comments are invited on this rule. Interested persons are invited to comment on this rule by submitting such written data, views, or arguments as they may desire. Communications shall identify the Rules Docket number and be submitted in triplicate to the address specified under the caption ADDRESSES. All communications received on or before the closing date for comments will be considered, and the rule may be amended in light of the comments received. Factual information that supports the commenter’s ideas and suggestions is extremely helpful in evaluating the effectiveness of the AD action and determining whether additional rulemaking action would be needed.

Comments are specifically invited on the overall regulatory, economic, environmental, and energy aspects of the rule that might suggest a need to modify the rule. All comments submitted will be available both before and after the closing date for comments, in the Rules Docket for examination by
§ 39.13 [Amended]

2. Section 39.13 is amended by adding the following new airworthiness directive:


Applicability: Model A330 series airplanes equipped with Pratt & Whitney 4000 series engines, certificated in any category; fitted with engine aft mount nuts and bolts installed in accordance with Airbus Modification 46948 (installed on-in-service airplanes per Airbus Service Bulletin A330±71±3012).

Note 1: This AD applies to each airplane identified in the preceding applicability provision, regardless of whether it has been modified, altered, or repaired in the area subject to the requirements of this AD. For airplanes that have been modified, altered, or repaired so that the performance of the requirements of this AD is affected, the owner/operator must request approval for an alternative method of compliance in accordance with paragraph (b) of this AD. The request should include an assessment of the effect of the modification, alteration, or repair on the unsafe condition addressed by this AD, and, if the unsafe condition has not been eliminated, the request should include specific proposed actions to address it.

Compliance: Required as indicated, unless accomplished previously.

To detect and correct cracking of the aft engine mount nut, which could result in reduced structural integrity of the engine-to- pylon aft mount assembly, or, in the case of multiple cracked nuts, possible loss of an engine, accomplish the following:

Inspection

(a) Before the next flight, perform either a detailed visual or borescopic inspection to detect cracking or other damage of all 4 barrel nuts of each engine aft mount, in accordance with paragraph 4.2.1 of Airbus All Operators Telex (AOT) A330±71A3014, dated December 8, 2000. This inspection should be accomplished before further flight, replace nuts and their associated bolts, as applicable, in accordance with paragraph 4.2.2 of the AOT. Repeat the inspection thereafter at least every 50 flight cycles.

Note 2: For the purposes of this AD, a detailed visual inspection is defined as: "An intensive visual examination of a specific structural area, system, installation, or assembly to detect damage, failure, or irregularity. Available lighting is normally supplemented with a direct source of good lighting at intensity deemed appropriate by the inspector. Inspection aids such as mirror, magnifying lenses, etc., may be used. Surface cleaning and elaborate access procedures may be required."

Note 3: Airbus AOT A330±71A3014, dated December 8, 2000, refers to Pratt & Whitney Service Bulletin PW4G±100±71±16, Revision 1, dated September 15, 1999, as an additional source of service information for replacing the nuts and bolts.

Alternative Methods of Compliance

(b) An alternative method of compliance or adjustment of the compliance time that provides an acceptable level of safety may be used if approved by the Manager, International Branch, ANM±116, Transport Airplane Directorate, FAA. Operators shall submit their requests through an appropriate FAA Principal Maintenance Inspector, who may add comments and then send it to the Manager, International Branch, ANM±116.

Note 4: Information concerning the existence of approved alternative methods of compliance with this AD, if any, may be obtained from the International Branch, ANM±116.

Special Flight Permits

(c) Special flight permits may be issued in accordance with sections 21.197 and 21.199 of the Federal Aviation Regulations (14 CFR 21.197 and 21.199) to operate the airplane to a location where the requirements of this AD can be accomplished.

Incorporation by Reference

(d) The actions shall be done in accordance with Airbus All Operators Telex A330±71A3014, dated December 8, 2000. This incorporation by reference was approved by the Director of the Federal Register in accordance with 5 U.S.C. 552(a) and 1 CFR part 51. Copies may be obtained from Airbus Industrie, 1 Rond Point Maurice Bellonte, 31707 Blagnac Cedex, France. Copies may be inspected at the FAA, Transport Airplane Directorate, 1601 Lind Avenue, SW., Renton, Washington; or at the Office of the Federal Register, 800 North Capitol Street, NW., suite 700, Washington, DC.

Note 5: The subject of this AD is addressed in French telegraphic airworthiness directive T2000±523±134(B), dated December 8, 2000.

Effective Date

(e) This amendment becomes effective on January 2, 2001, to all persons except those persons to whom it was made immediately effective by emergency AD 2000±25±53, issued December 9, 2000, which contained the requirements of this amendment.

Issued in Renton, Washington, on December 18, 2000.

Dorenda D. Baker,
Acting Manager, Transport Airplane Directorate, Aircraft Certification Service.
[FR Doc. 00±32763 Filed 12±27±00; 8:45 am]
BILLING CODE 4910±13±P
DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 39


RIN 2120–AA64

Airworthiness Directives; Airbus Model A300 B2 and B4 Series Airplanes, and Model A300 B4–600, A300 B4–600R, and A300 F4–600R (A300–600) Series Airplanes

AGENCY: Federal Aviation Administration, DOT.

ACTION: Final rule.

SUMMARY: This amendment supersedes an existing airworthiness directive (AD), applicable to certain Airbus Model A300 B2 and B4 and A300–600 series airplanes, that currently requires wiring modifications to the engine and auxiliary power unit (APU) fire detection system. This amendment requires new wiring modifications for the engine and APU fire detection system. This amendment is prompted by issuance of mandatory continuing airworthiness information by a foreign civil airworthiness authority. The actions specified by this AD are intended to prevent the fire warning from terminating prematurely, which could result in an unnoticed, uncontained engine/APU fire.


The incorporation by reference of certain publications listed in the regulations is approved by the Director of the Federal Register as of February 1, 2001.

ADDRESSES: The service information referenced in this AD may be obtained from Airbus Industrie, 1 Rond Point Maurice Bellonte, 31707 Blagnac Cedex, France. This information may be examined at the Federal Aviation Administration (FAA), Transport Airplane Directorate, Rules Docket, 1601 Lind Avenue, SW., Renton, Washington; or at the Office of the Federal Register, 800 North Capitol Street, NW., suite 700, Washington, DC.


SUPPLEMENTAL INFORMATION: A proposal to amend part 39 of the Federal Aviation Regulations (14 CFR part 39) by superseding AD 99–27–10, amendment 39–11491 (65 FR 204, January 4, 2000), which is applicable to certain Airbus Model A310 and A300–600 series airplanes, was published in the Federal Register on August 2, 2000 (65 FR 47356). The action proposed to require new wiring modifications to the engine and auxiliary power unit (APU) fire detection system.

Clarification of Model Designation

Since the issuance of the proposed AD, the FAA has changed the manner in which it identifies the airplane models referred to as “Airbus Model A300 and A300–600 series airplanes” to reflect the model designation specified on the type certificate data sheet. This final rule has been revised to show the appropriate model designations for those airplanes.

Comments

Interested persons have been afforded an opportunity to participate in the making of this amendment. No comments were submitted in response to the proposal or the FAA’s determination of the cost to the public.

Conclusion

The FAA has determined that air safety and the public interest require the adoption of the rule as proposed.

Cost Impact

There are approximately 113 Model A300 B2 and B4 and A300–600 series airplanes of U.S. registry that will be affected by this AD.

The actions required by this AD will take approximately 26 work hours per airplane to accomplish, at an average labor rate of $60 per work hour. Required parts will cost approximately $484 per airplane. Based on these figures, the cost impact of the requirements of this AD on U.S. operators is estimated to be $230,972, or $2,044 per airplane.

The cost impact figure discussed above is based on assumptions that no operator has yet accomplished any of the requirements of this AD action, and that no operator would accomplish those actions in the future if this AD were not adopted. The cost impact figures discussed in AD rulemaking actions represent only the time necessary to perform the specific actions actually required by the AD. These figures typically do not include incidental costs, such as the time required to gain access and close up, planning time, or time necessitated by other administrative actions.

Regulatory Impact

The regulations adopted herein will not have a substantial direct effect on the States, on the relationship between the national Government and the States, or on the distribution of power and responsibilities among the various levels of government. Therefore, it is determined that this final rule does not have federalism implications under Executive Order 13132.

For the reasons discussed above, I certify that this action (1) is not a “significant regulatory action” under Executive Order 12866; (2) is not a “significant rule” under DOT Regulatory Policies and Procedures (44 FR 11034, February 26, 1979); and (3) will not have a significant economic impact, positive or negative, on a substantial number of small entities under the criteria of the Regulatory Flexibility Act. A final evaluation has been prepared for this action and it is contained in the Rules Docket. A copy of it may be obtained from the Rules Docket at the location provided under the caption ADDRESSES.

List of Subjects in 14 CFR Part 39

Air transportation, Aircraft, Aviation safety. Incorporation by reference, Safety.

Adoption of the Amendment

Accordingly, pursuant to the authority delegated to me by the Administrator, the Federal Aviation Administration amends part 39 of the Federal Aviation Regulations (14 CFR part 39) as follows:

PART 39—AIRWORTHINESS DIRECTIVES

1. The authority citation for part 39 continues to read as follows:

Authority: 49 U.S.C. 106(g), 40113, 44701.

§ 39.13 [Amended]

2. Section 39.13 is amended by removing amendment 39–11491 (65 FR 204, January 4, 2000), and by adding a new airworthiness directive (AD), amendment 39–12052, to read as follows:


Applicability: Model A300 B2 and B4 series airplanes, and Model A300 B4–600, A300 B4–600R, and A300 F4–600R (A300–600) series airplanes, certificated in any category; except those on which Airbus Modifications 06267 and 07340 have been accomplished during production.

Note 1: This AD applies to each airplane identified in the preceding applicability provision, regardless of whether it has been otherwise modified, altered, or repaired in the area subject to the requirements of this AD. For airplanes that have been modified,
altered, or repaired so that the performance of the requirements of this AD is affected, the owner/operator must request approval for an alternative method of compliance in accordance with paragraph (b)(1) of this AD. The request should include an assessment of the effect of the modification, alteration, or repair on the unsafe condition addressed by this AD; and, if the unsafe condition has not been eliminated, the request should include specific proposed actions to address it.

Compliance: Required as indicated, unless accomplished previously.

To prevent the fire warning from terminating prematurely, which could result in an unnoticed, uncontained engine/auxiliary power unit (APU) fire, accomplish the following:

Modifications

(a) Within 12 months after the effective date of this AD, accomplish the wiring modifications for the engine and APU fire detection system in accordance with Airbus Service Bulletin A300–26–6038, Revision 03, dated March 30, 2000 (for Model A300–600 series airplanes); or A310–26–2024, Revision 06, dated March 31, 2000 (for Model A310–26–2024, Revision 06, dated March 31, 2000; as applicable). This incorporation by reference is amended as follows: 1 CFR part 51. Copies may be obtained from Airbus Industrie, 1 Rond Point Maurice Bellonte, 31707 Blagnac Cedex, France.

(b) The wiring modifications shall be done in accordance with Airbus Service Bulletin A300–26–6038, Revision 03, dated March 30, 2000; or Airbus Service Bulletin A310–26–2024, Revision 06, dated March 31, 2000; as applicable. This incorporation by reference was approved by the Director of the Federal Register in accordance with 5 U.S.C. 552(a) and 1 CFR part 51. Copies may be obtained from Airbus Industrie, 1 Rond Point Maurice Bellonte, 31707 Blagnac Cedex, France. Copies may be inspected at the FAA, Transport Airplane Directorate, 1601 Lind Avenue, SW., Renton, Washington; or at the Office of the Federal Register, 800 North Capitol Street, NW., suite 700, Washington, DC.

Note 4: The subject of this AD is addressed in French airworthiness directive 1999–238–286(B) R2, dated May 7, 2000.

Effective Date

(c) This amendment becomes effective on February 1, 2001.

Issued in Renton, Washington, on December 18, 2000.

Dorenda D. Baker,
 Acting Manager, Transport Airplane Directorate, Aircraft Certification Service.

[FR Doc. 00–32762 Filed 12–27–00; 8:45 am]
BILLING CODE 4910–13–P

DEPARTMENT OF TRANSPORTATION
Federal Aviation Administration

14 CFR Part 71

[Airspace Docket No. 00–AAL–16]

RIN 2120–AA66
Modification of Colored Federal Airways; AK

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Final Rule.

SUMMARY: This action modifies the description of two Colored Federal airways, Green 1 (G–1) and Red 2 (R–2), in Offshore Airspace Area 1234L, Alaska. The FAA is taking this action to create a uniform floor of Class E controlled airspace 2,000 feet above ground level (AGL) throughout Offshore Control Area 1234L.


FOR FURTHER INFORMATION CONTACT: Ken McElroy, Airways and Rules Division, 40103, Office of Air Traffic airspace Management, Federal Aviation Administration, 800 Independence Avenue, SW., Washington, DC 20591; telephone: (202) 267–8783.

SUPPLEMENTARY INFORMATION:

Background

The FAA is taking this action to create a uniform floor of Class E airspace. Colored Federal airways are published in paragraph 7400.9H dated September 1, 2000, and effective September 16, 2000, which is incorporated by reference in 14 CFR 71.1. The colored Federal airways listed in this document will be published subsequently in the order.

The Rule

This action amends title 14 CFR part 71 (part 71) by modifying the description of two Colored Federal airways, G–1 and R–2, in Offshore Airspace Area 1234L, Alaska. Specifically, this action adjusts the floor of G–1 and R–2 to be consistent with the 2,000-foot AGL floor of Offshore Control Area 1234L.

The FAA has determined that this regulation only involves an established body of technical regulations for which frequent and routine amendments are necessary to keep them operationally current. Therefore, this regulation: (1) Is not a “significant regulatory action” under Executive Order 12866; (2) is not a “significant rule” under DOT Regulatory Policies and Procedures (44 FR 11034; February 26, 1979); and (3) does not warrant preparation of a regulatory evaluation as the anticipated impact is so minimal. Since this is a routine matter that will only affect air traffic procedures and air navigation, it is certified that this rule, when promulgated, will not have a significant economic impact on a substantial number of small entities under the criteria of the Regulatory Flexibility Act.

List of Subjects in 14 CFR Part 71

Airspace, Incorporation by reference, Navigation (air).

Adoption of the Amendment

In consideration of the foregoing, the Federal Aviation Administration amends 14 CFR part 71 as follows:

PART 71—DESIGNATION OF CLASS A, CLASS B, CLASS C, CLASS D, AND CLASS E AIRSPACE AREAS; AIRWAYS; ROUTES; AND REPORTING POINTS

1. The authority citation for part 71 continues to read as follows:


§71.1 [Amended]

2. The incorporation by reference in 14 CFR 71.1 of the Federal Aviation Administration Order 7400.9H, Airspace Designations and Reporting Points, dated September 1, 2000, and effective September 16, 2000, is amended as follows:
Paragraph 6009(a)—Green Federal Airways

From Mt. Moffett, AK, NDB 20 AGL; INT Elfee, AK, NDB 253° and Dutch Harbor, AK, NDB 360° 20 AGL; INT Elfee, AK, NDB 253° and Cold Bay VORTAC 82 DME 20 AGL; to Elfee, AK, NDB.

Paragraph 6009(b)—Red Federal Airways

From Elfee, AK, NDB 20 AGL; to Port Heiden, AK, NDB.

Issued in Washington, DC, on December 21, 2000.

Reginald C. Matthews,
Manager, Airspace and Rules Division.

[FR Doc. 00–33180 Filed 12–27–00; 8:45 am]
BILLING CODE 4910–13–P

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 71

[Airspace Docket No. 00–AAL–17]

Revision of Class E Airspace; Iliamna, AK

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Final rule.

SUMMARY: This action revises Class E airspace at Iliamna, AK. The establishment of four new Area Navigation (RNAV) instrument approaches to runway (RWY) 7, RWY 25, RWY 17 and RWY 35 at Iliamna Airport, Iliamna, AK, made this action necessary. This rule provides adequate controlled airspace for aircraft flying Instrument Flight Rules (IFR) operations at Iliamna, AK.


FOR FURTHER INFORMATION CONTACT: Robert van Haastert, Operations Branch, Federal Aviation Administration, 222 West 7th Avenue, Box 14, Anchorage, AK 99513–7587; telephone number (907) 271–5863; fax: (907) 271–2850; email: Robert.ctr.van-Haastert@faa.gov. Internet address: http://www.alaska.faa.gov/at.

SUPPLEMENTARY INFORMATION:

History

On October 25, 2000, a proposal to amend part 71 of the Federal Aviation Regulations (14 CFR part 71) to revise the Class E airspace at Iliamna, AK, was published in the Federal Register (65 FR 63821). The proposal was necessary due to the establishment of four new RNAV instrument approaches to RWY 7, RWY 25, RWY 17, and RWY 35 at Iliamna, AK.

Interested parties were invited to participate in this rulemaking proceeding by submitting written comments on the proposal to the FAA. No public comments to the proposal were received, thus, the rule is adopted as written.

The area will be depicted on aeronautical charts for pilot reference. The coordinates for this airspace docket are based on North American Datum 83. The Class E airspace areas designated as surface areas are published in paragraph 6002 and the Class E airspace areas designated as 700/1200 foot transition areas are published in paragraph 6005 in FAA Order 7400.9H, Airspace Designations and Reporting Points, dated September 1, 2000, and effective September 16, 2000, which is incorporated by reference in 14 CFR 71.1. The Class E airspace designations listed in this document will be published subsequently in the Order.

The Rule

This amendment to 14 CFR part 71 revises the Class E airspace at Iliamna, AK, through the establishment of four new RNAV instrument approaches to RWY 7, RWY 25, RWY 17, and RWY 35 at Iliamna, AK. The intended effect of this proposal is to provide adequate controlled airspace for IFR operations at Iliamna, AK.

The FAA has determined that this proposed regulation only involves an established body of technical regulations for which frequent and routine amendments are necessary to keep them operationally current. It, therefore—(1) is not a "significant regulatory action" under Executive Order 12866; (2) is not a "significant rule" under DOT Regulatory Policies and Procedures (44 FR 11034; February 26, 1979); and (3) does not warrant preparation of a regulatory evaluation as the anticipated impact is so minimal. Since this is a routine matter that will only affect air traffic procedures and air navigation, it is certified that this rule will not have a significant economic impact on a substantial number of small entities under the criteria of the Regulatory Flexibility Act.

List of Subjects in 14 CFR Part 71

Airspace, Incorporation by reference, Navigation (air).

The Proposed Amendment

In consideration of the foregoing, the Federal Aviation Administration amends 14 CFR part 71 as follows:

PART 71—DESIGNATION OF CLASS A, CLASS B, CLASS C, CLASS D, AND CLASS E AIRSPACE AREAS; AIRWAYS; ROUTES; AND REPORTING POINTS

1. The authority citation for 14 CFR part 71 continues to read as follows:


§ 71.1 [Amended]

2. The incorporation by reference in 14 CFR 71.1 of Federal Aviation Administration Order 7400.9H, Airspace Designations and Reporting Points, dated September 1, 2000, and effective September 16, 2000, is amended as follows:

Paragraph 6002 Class E airspace designated as surface areas.

AAL AK E2 Iliamna, AK [Revised]

Iliamna Airport, AK

(Lat. 59° 45′ 16″ N, long. 154° 54′ 39″ W)

Iliamna NDB

(Lat. 59° 44′ 53″ N, long. 154° 54′ 35″ W)

Within a 4-mile radius of the Iliamna Airport and within 2.5 miles east of the 189° bearing and 2.5 miles west of the 200° bearing from the Iliamna NDB extending from the 4-mile radius to 7.4 miles south of the airport. This Class E airspace area is effective during specific dates and times established in advance by a Notice to Airmen. The effective date and time will thereafter be continuously published in the Supplement Alaska (Airport/Facility Directory).

Paragraph 6005 Class E airspace extending upward from 700 feet or more above the surface of the earth.
153° 00' 00" W, lat. 59° 28' 00" N long. 154° 13' 00" W, lat. 59° 18' 00" N long. 154° 04' 00" W, lat. 59° 11' 00" N long. 155° 17' 00" W, lat. 59° 32' 00" N long. 155° 31' 00" W, lat. 59° 41' 00" N long. 156° 35' 00" W, to the point of beginning.

Issued in Anchorage, AK, on December 19, 2000.

Anthony M. Wylie,
Acting Manager, Air Traffic Division, Alaskan Region.

[FR Doc. 00-33178 Filed 12-27-00; 8:45 am]
BILLING CODE 4910-13-P

DEPARTMENT OF TRANSPORTATION
Federal Aviation Administration

14 CFR Part 71
[Airspace Docket No. 00–AAL–5]

Revision of Class E Airspace; Gulkana, AK

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Final rule.

SUMMARY: This action amends 14 CFR part 71 to revise the Class E airspace at Gulkana, AK, to establish new RNAV instrument approach procedures to RWY 14 and RWY 32 at Gulkana, AK.Interested parties were invited to participate in this rulemaking proceeding by submitting written comments on the proposal to the FAA. No public comments to the proposal were received, thus, the rule is adopted as written.

The area will be depicted on aeronautical charts for pilot reference. The coordinates for this airspace docket are based on North American Datum 83. The Class E airspace areas designated as surface areas are published in paragraph 6002 and the Class E airspace areas designated as 700/1200 foot transition areas are published in paragraph 6005 in FAA Order 7400.9H, Airspace Designations and Reporting Points, dated September 1, 2000 and, effective September 16, 2000, which is incorporated by reference in 14 CFR 71.1. The Class E airspace designations listed in this document will be published subsequently in the Order.

The Rule

This amendment to 14 CFR part 71 revises the Class E airspace at Gulkana, AK, through the establishment of two new RNAV instrument approaches and revision of the VOR and NDB instrument approach procedures to RWY 14 and RWY 32 at Gulkana, AK. The intended effect of this proposal is to provide adequate controlled airspace for IFR operations at Gulkana, AK.

The FAA has determined that this proposed regulation only involves an established body of technical regulations for which frequent and routine amendments are necessary to keep them operationally current. It, therefore—(1) is not a “significant regulatory action” under Executive Order 12866; (2) is not a “significant rule” under DOT Regulatory Policies and Procedures (44 FR 11034; February 26, 1979); and (3) does not warrant preparation of a regulatory evaluation as the anticipated impact is so minimal. Since this is a routine matter that will only affect air traffic procedures and air navigation, it is certified that this rule will not have a significant economic impact on a substantial number of small entities under the criteria of the Regulatory Flexibility Act.

List of Subjects in 14 CFR Part 71

Airspace, Incorporation by reference, Navigation (air).

The Proposed Amendment

In consideration of the foregoing, the Federal Aviation Administration amends 14 CFR part 71 as follows:

PART 71—DESIGNATION OF CLASS A, CLASS B, CLASS C, CLASS D, AND CLASS E AIRSPACE AREAS; AIRWAYS; ROUTES; AND REPORTING POINTS

1. The authority citation for 14 CFR part 71 continues to read as follows:


§ 71.1 [Amended]

2. The incorporation by reference in 14 CFR 71.1 of Federal Aviation Administration Order 7400.9H, Airspace Designations and Reporting Points, dated September 1, 2000, and effective September 16, 2000, is amended as follows:

AAL AK E2 — Gulkana, AK [Revised]

Gulkana Airport, AK
(Lat. 62° 09' 18" N., long. 145° 27' 24" W.)
Gulkana VORTAC
(Lat. 62° 09' 08" N., long. 145° 27' 01" W.)

Glenallen NDB
(Lat. 62° 11' 43" N., long. 145° 28' 05" W.)
That airspace extending upward from the surface to and including 4,100 feet MSL within a 4 mile radius of the Gulkana Airport, and within 2.8 miles west of the Gulkana VORTAC 344° radial clockwise to 2.8 miles east of the 352° radial extending from the Gulkana airport to 9.4 miles north of the airport, and within 2.5 miles east of the Gulkana VORTAC 172° radial clockwise to 2.5 miles west of the Gulkana 180° radial extending from the Gulkana airport to 7 miles south of the Gulkana airport. This airspace is effective during specific dates and times established in advance by Notice to Airmen. The effective dates and times will thereafter be continuously published in the Airport/Facility Directory.

Paragraph 6005 — Class E airspace designated as surface areas.

AAL AK E5 — Gulkana, AK [Revised]

Gulkana Airport, AK
(Lat. 62° 09' 18" N., long. 145° 27' 24" W.)
Gulkana VORTAC
(Lat. 62° 09' 08" N., long. 145° 27' 01" W.)

Glenallen NDB
(Lat. 62° 11' 43" N., long. 145° 28' 05" W.)
That airspace extending upward from 700 feet or more above the surface of the earth.

List of Subjects in 14 CFR Part 71

Airspace, Incorporation by reference, Navigation (air).
miles south of the Gulkana airport; and that airspace extending upward from 1,200 feet above the surface within an area bounded by lat. 62°35′00″ N long. 145°39′30″ W, counter clockwise to lat. 62°02′00″ N long. 146°30′00″ W, to lat 61°41′30″ N long. 145°13′00″ W, to lat. 62°22′30″ N long. 144°27′00″W, to the point of beginning.

Issued in Anchorage, AK, on December 19, 2000. 

Anthony M. Wylie, Acting Manager, Air Traffic Division, Alaskan Region.

[FR Doc. 00–33177 Filed 12–27–00; 8:45 am]

BILLING CODE 4910–13–P

DEPARTMENT OF TRANSPORTATION
Federal Aviation Administration
14 CFR Part 97
[Docket No. 30223; Amdt. No. 2029]

Standard Instrument Approach Procedures; Miscellaneous Amendments

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Final rule.

SUMMARY: This amendment establishes, amends, suspends, or revokes Standard Instrument Approach Procedures (SIAPs) for operations at certain airports. These regulatory actions are needed because of changes occurring in the National Airspace System, such as the commissioning of new navigational facilities, addition of new obstacles, or changes in air traffic requirements. These changes are designed to provide safe and efficient use of the navigable airspace and to promote safe flight operations under instrument flight rules at the affected airports.

DATES: An effective date for each SIAP is specified in the amendatory provisions.

Incorporation by reference-approved by the Director of the Federal Register on December 31, 1980, and reapproved as of January 1, 1982.

ADDRESSES: Availability of matter incorporated by reference in the amendment is as follows:

For Examination—
1. FAA Rules Docket, FAA Headquarters Building, 800 Independence Avenue, SW., Washington, DC 20591;
2. The FAA Regional Office of the region in which affected airport is located; or
3. The Flight Inspection Area Office which originated the SIAP.

For Purchase—Individual SIAP copies may be obtained from:

1. FAA Public Inquiry Center (APA–200), FAA Headquarters Building, 800 Independence Avenue, SW., Washington, DC 20591; or
2. The FAA Regional Office of the region in which the affected airport is located.

By Subscription—Copies of all SIAPs, mailed once every 2 weeks, are for sale by the Superintendent of Documents, US Government Printing Office, Washington, DC 20402.

FOR FURTHER INFORMATION CONTACT: Donald P. Pate, Flight Procedure Standards Branch (AMCAFS–420), Flight Technologies and Programs Division, Flight Standards Service, Federal Aviation Administration, Mike Monroney Aeronautical Center, 6500 South MacArthur Blvd., Oklahoma City, OK 73169 (Mail Address: P.O. Box 25082 Oklahoma City, OK 73125) telephone: (405) 954–4164.

SUPPLEMENTARY INFORMATION: This amendment to part 97 of the Federal Aviation Regulations (14 CFR part 97) establishes, amends, suspends, or revokes Standard Instrument Approach Procedures (SIAPs). The complete regulatory description on each SIAP is contained in the appropriate FAA Form 8260 and the National Flight Data Center (FDC)/Permanent (P) Notices to Airmen (NOTAM) which incorporate by reference the amendment under 5 U.S.C. § 552(a), 1 CFR part 51, and § 97.20 of the Federal Aviation’s Regulations (FAR). Materials incorporated by reference are available for examination or purchase as stated above.

The large number of SIAPs, their complex nature, and the need for a special format make their verbatim publication in the Federal Register expensive and impractical. Further, airmen do not use the regulatory text of the regulatory text of the SIAPs, but refer to their graphic depiction of charts printed by publishers of aeronautical materials. Thus, the advantages of incorporation by reference are realized and publication of the complete description of each SIAP contained in FAA form documents is unnecessary. The provisions of this amendment state the affected CFR (and FAR) sections, with the types and effective dates of the SIAPs. This amendment also identifies the airport, its location, the procedure identification and the amendment number.

The Rule

This amendment to part 97 of the Federal Aviation Regulations (14 CFR part 97) establishes, amends, suspends, or revokes SIAPs. For safety and timeliness of change considerations, this amendment incorporates only specific changes contained in the content of the following FDC/P NOTAMs for each SIAP. The SIAP information in some previously designated FDC/Temporary (FDC/T) NOTAMs is of such duration as to be permanent. With conversion to FDC/P NOTAMs, the respective FDC/T NOTAMs have been canceled.

The FDC/P NOTAMs for the SIAPs contained in this amendment are based on the criteria contained in the U.S. Standard for Terminal Instrument Procedures (TERPS). In developing these chart changes to SIAPs by FDC/T NOTAMs, the TERPS criteria were applied to only these specific conditions existing at the affected airports. All SIAP amendments in this rule have been previously issued by the FAA in a National Flight Data Center (FDC) Notice to Airmen (NOTAM) as an emergency action of immediate flight safety relating directly to published aeronautical charts. the circumstances which created the need for all these SIAP amendments requires making them effective in less than 30 days.

Further, the SIAPs contained in this amendment are based on the criteria contained in the TERPS. Because of the close and immediate relationship between these SIAPs and safety in air commerce, I find that notice and public procedure before adopting these SIAPs is impracticable and contrary to the public interest and, where applicable, that good cause exists for making these SIAPs effective in less than 30 days.

Conclusion

The FAA has determined that this regulation only involves an established body of technical regulations for which frequent and routine amendments are necessary to keep them operationally current. It, therefore—(1) is not a “significant regulatory action” under Executive Order 12866; (2) is not a “significant rule” under DOT Regulatory Policies and Procedures (44 FR 11034; February 26, 1979); and (3) does not warrant preparation of a regulatory evaluation as the anticipated impact is so minimal. For the same reason, the FAA certifies that this amendment will not have a significant economic impact on a substantial number of small entities under the criteria of the Regulatory Flexibility Act.

List of Subjects in 14 CFR Part 97

Air Traffic Control, Airports, Navigation (air).
Issued in Washington, DC on December 22, 2000.
L. Nicholas Lacey,
Director, Flight Standards Service.

Adoption of the Amendment

Accordingly, pursuant to the authority delegated to me, part 97 of the Federal Aviation Regulations (14 CFR part 97) is amended by establishing, amending, suspending, or revoking Standard Instrument Approach Procedures, effective at 0901 UTC on the dates specified, as follows:

### PART 97—STANDARD INSTRUMENT APPROACH PROCEDURES

1. The authority citation for part 97 is revised to read as follows:

   Authority: 49 U.S.C. 40103, 40113, 40120, 44701; 49 U.S.C. 106(g); and 14 CFR 11.49(b)(2).

2. Part 97 is amended to read as follows:

   Effective Upon Publication

<table>
<thead>
<tr>
<th>FDC date</th>
<th>State</th>
<th>City</th>
<th>Airport</th>
<th>FDC number</th>
<th>SIAP</th>
</tr>
</thead>
<tbody>
<tr>
<td>12/19/00</td>
<td>MS</td>
<td>Oxford</td>
<td>University-Oxford</td>
<td>FDC 0/5323</td>
<td>VOR/DME RNAV Rwy 27 AMDT 2</td>
</tr>
<tr>
<td>12/10/00</td>
<td>MS</td>
<td>Oxford</td>
<td>University-Oxford</td>
<td>FDC 0/5322</td>
<td>VOR/DME RNAV Rwy 9 AMDT 2</td>
</tr>
<tr>
<td>12/19/00</td>
<td>IL</td>
<td>Lincoln</td>
<td>Logan County</td>
<td>FDC 0/5362</td>
<td>NDB OR GPS Rwy 21 AMDT 1</td>
</tr>
<tr>
<td>12/18/00</td>
<td>FL</td>
<td>Miami</td>
<td>Miami Intl</td>
<td>FDC 0/5293</td>
<td>ILS Rwy 27R AMDT 14</td>
</tr>
<tr>
<td>12/18/00</td>
<td>FL</td>
<td>Miami</td>
<td>Miami Intl</td>
<td>FDC 0/5292</td>
<td>GPS Rwy 27R ORIG-A</td>
</tr>
<tr>
<td>12/18/00</td>
<td>IN</td>
<td>Indianapolis</td>
<td>Indianapolis Intl</td>
<td>FDC 0/5306</td>
<td>ILS Rwy 5L AMDT 1B</td>
</tr>
<tr>
<td>12/18/00</td>
<td>WA</td>
<td>Bellingham</td>
<td>Bellingham Intl</td>
<td>FDC 0/5172</td>
<td>ILS Rwy 16 AMDT 3</td>
</tr>
<tr>
<td>12/14/00</td>
<td>WA</td>
<td>Bellingham</td>
<td>Bellingham Intl</td>
<td>FDC 0/5171</td>
<td>REPLACES 0/4728</td>
</tr>
<tr>
<td>12/14/00</td>
<td>WA</td>
<td>Bellingham</td>
<td>Bellingham Intl</td>
<td>FDC 0/5170</td>
<td>GPS Rwy 16 ORIG-A</td>
</tr>
<tr>
<td>12/15/00</td>
<td>TX</td>
<td>Bridgeport</td>
<td>Bridgeport Muni</td>
<td>FDC 0/5241</td>
<td>REPLACES 0/4725</td>
</tr>
<tr>
<td>12/07/00</td>
<td>NY</td>
<td>Monticello</td>
<td>Sullivan County Intl</td>
<td>FDC 0/4954</td>
<td>NDB Rwy 16 ORIG-B</td>
</tr>
<tr>
<td>12/05/00</td>
<td>CA</td>
<td>Riverside</td>
<td>Riverside Muni</td>
<td>FDC 0/4857</td>
<td>LOC Rwy 22 AMDT 1C</td>
</tr>
<tr>
<td>12/01/00</td>
<td>NJ</td>
<td>Caldwell</td>
<td>Essex County</td>
<td>FDC 0/4794</td>
<td>ORIG-B</td>
</tr>
<tr>
<td>12/01/00</td>
<td>MA</td>
<td>Orange</td>
<td>Orange Muni</td>
<td>FDC 0/4788</td>
<td>VOR/DME RNAV Rwy 25 AMDT 9</td>
</tr>
<tr>
<td>12/01/00</td>
<td>CA</td>
<td>Oxnard</td>
<td>Oxnard</td>
<td>FDC 0/4785</td>
<td>GPS Rwy 25L AMDT 4C</td>
</tr>
<tr>
<td>12/01/00</td>
<td>NV</td>
<td>Las Vegas</td>
<td>McCarran Intl</td>
<td>FDC 0/4796</td>
<td>VOR/DME RNAV Rwy 15 ORIG-A</td>
</tr>
<tr>
<td>12/14/00</td>
<td>MD</td>
<td>College Park</td>
<td>College Park</td>
<td>FDC 0/5201</td>
<td>GPS Rwy 15 AMDT 4C</td>
</tr>
<tr>
<td>11/08/00</td>
<td>NV</td>
<td>Elko</td>
<td>Elko Regional</td>
<td>FDC 0/3923</td>
<td>VOR/DME OR GPS-B AMDT 3A</td>
</tr>
<tr>
<td>12/15/00</td>
<td>AR</td>
<td>Pine Bluff</td>
<td>Grider Field</td>
<td>FDC 0/5215</td>
<td>ILS Rwy 17 AMDT 3B</td>
</tr>
<tr>
<td>12/14/00</td>
<td>AR</td>
<td>Pine Bluff</td>
<td>Grider Field</td>
<td>FDC 0/5197</td>
<td>VOR OR GPS Rwy 17 AMDT 12</td>
</tr>
<tr>
<td>12/12/00</td>
<td>MO</td>
<td>St. Joseph</td>
<td>Rosecrans Memorial</td>
<td>FDC 0/5093</td>
<td>ILS Rwy 35 AMDT 30A</td>
</tr>
<tr>
<td>12/12/00</td>
<td>MO</td>
<td>St. Joseph</td>
<td>Rosecrans Memorial</td>
<td>FDC 0/5092</td>
<td>VOR/DME RNAV OR GPS Rwy 17 AMDT 30A</td>
</tr>
<tr>
<td>12/12/00</td>
<td>MO</td>
<td>St. Joseph</td>
<td>Rosecrans Memorial</td>
<td>FDC 0/5091</td>
<td>NDB Rwy 17 AMDT 8D</td>
</tr>
<tr>
<td>12/12/00</td>
<td>MO</td>
<td>St. Joseph</td>
<td>Rosecrans Memorial</td>
<td>FDC 0/5090</td>
<td>NDB Rwy 35 AMDT 28D</td>
</tr>
<tr>
<td>12/12/00</td>
<td>MS</td>
<td>Hattiesburg/Laurel</td>
<td>Hattiesburg/Laurel Regional</td>
<td>FDC 0/5059</td>
<td>VOR-A ORIG</td>
</tr>
<tr>
<td>12/12/00</td>
<td>FL</td>
<td>West Palm Beach</td>
<td>Palm Beach Airport</td>
<td>FDC 0/5119</td>
<td>VOR OR GPS Rwy 15 AMDT 2A</td>
</tr>
<tr>
<td>12/12/00</td>
<td>FL</td>
<td>Tampa</td>
<td>Tampa Intl</td>
<td>FDC 0/5117</td>
<td>RADAR-1 AMDT 12</td>
</tr>
<tr>
<td>12/12/00</td>
<td>FL</td>
<td>Tampa</td>
<td>Tampa Intl</td>
<td>FDC 0/5115</td>
<td>ILS Rwy 18R AMDT 3A</td>
</tr>
<tr>
<td>12/12/00</td>
<td>ND</td>
<td>Fargo</td>
<td>Hector Intl</td>
<td>FDC 0/5102</td>
<td>ILS Rwy 17 AMDT 4C</td>
</tr>
<tr>
<td>12/12/00</td>
<td>ND</td>
<td>Fargo</td>
<td>Hector Intl</td>
<td>FDC 0/5103</td>
<td>ILS Rwy 35 AMDT 32D</td>
</tr>
<tr>
<td>12/12/00</td>
<td>FL</td>
<td>Miami</td>
<td>Miami Intl</td>
<td>FDC 0/5051</td>
<td>NDB Rwy 12 AMDT 4B</td>
</tr>
<tr>
<td>12/11/00</td>
<td>MO</td>
<td>Sedalia</td>
<td>Sedalia Memorial</td>
<td>FDC 0/5041</td>
<td>NDB Rwy 36 AMDT 8B</td>
</tr>
<tr>
<td>12/08/00</td>
<td>SC</td>
<td>Winnsboro</td>
<td>Fairfield County</td>
<td>FDC 0/4991</td>
<td>GPS Rwy 22 ORIG-A</td>
</tr>
</tbody>
</table>
Amendments Procedures; Miscellaneous Standard Instrument Approach

Summary: This amendment establishes, amends, suspends, or revokes Standard Instrument Approach Procedures (SIAPs) for operations at certain airports. These regulatory actions are needed because of the adoption of new or revised criteria, or because of changes occurring in the National Airspace System, such as the commissioning of new navigational facilities, addition of new obstacles, or changes in air traffic requirements. These changes are designed to provide safe and efficient use of the navigable airspace and to promote safe flight operations under instrument flight rules at the affected airports.

Dates: An effective date for each SIAP is specified in the amendatory provisions.

Incorporation by reference-approved by the Director of the Federal Register on December 31, 1980, and reapproved as of January 1, 1982.

Addresses: Availability of matters incorporated by reference in the amendment is as follows:

For Examination—
1. FAA Rules Docket, FAA Headquarters Building, 800 Independence Avenue, SW., Washington, DC 20591;
2. The FAA Regional Office of the region in which the affected airport is located; or
3. The Flight Inspection Area Office which originated the SIAP.

For Purchase—Individual SIAP copies may be obtained from:
1. FAA Public Inquiry Center (APA-200), FAA Headquarters Building, 800 Independence Avenue, SW., Washington, DC 20591; or
2. The FAA Regional Office of the region in which the affected airport is located.

By Subscription—Copies of all SIAPs, mailed once every 2 weeks, are for sale by the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402.

For Further Information Contact: Donald P. Pate, Flight Procedure Standards Branch (AMCAFS-420), Flight Technologies and Programs Division, Flight Standards Service, Federal Aviation Administration, Mike Monroney Aeronautical Center, 6500 South MacArthur Blvd, Oklahoma City, OK 73169 (Mail Address: P.O. Box 25082 Oklahoma City, OK 73125) telephone: (405) 954–4164.

Supplementary Information: This amendment to part 97 of the Federal Aviation Regulations (14 CFR part 97) establishes, amends, suspends, or revokes Standard Instrument Approach Procedures (SIAPs). The complete regulatory description of each SIAP is contained in official FAA form documents which are incorporated by reference in this amendment under 5 U.S.C. 522(a), 1 CFR part 51, and § 97.20 of the Federal Aviation Regulations (FAR). The applicable FAA Forms are identified as FAA Forms 8260–3, 8260–4, and 8260–5. Materials incorporated by reference are available for examination or purchase as stated above.

The large number of SIAPs, their complex nature, and the need for a special format make their verbatim publication in the Federal Register expensive and impractical. Further, airmen do not use the regulatory text of the SIAPs, but refer to their graphic depiction on charts printed by publishers of aeronautical materials. Thus, the advantages of incorporation by reference are realized and publication of the complete description of each SIAP contained in FAA form documents is unnecessary. The provisions of this amendment state the affected CFR and FAR sections, with the types and effective dates of the SIAPs. This amendment also identifies

<table>
<thead>
<tr>
<th>FDC date</th>
<th>State</th>
<th>City</th>
<th>Airport</th>
<th>FDC number</th>
<th>SIAP</th>
</tr>
</thead>
<tbody>
<tr>
<td>12/08/00</td>
<td>SC</td>
<td>Charleston</td>
<td>Charleston AFB/Intl</td>
<td>FDC 0/4992</td>
<td>VOR/DME OR TACAN OR GPS Rwy 33 AMDT 12</td>
</tr>
<tr>
<td>12/08/00</td>
<td>GA</td>
<td>Macon</td>
<td>Herbert Smart Downtown</td>
<td>FDC 0/5000</td>
<td>VOR OR GPS–A AMDT 5A</td>
</tr>
<tr>
<td>12/08/00</td>
<td>FL</td>
<td>Miami</td>
<td>Miami Intl</td>
<td>FDC 0/4981</td>
<td>GPS Rwy 9R ORIG–C</td>
</tr>
<tr>
<td>12/08/00</td>
<td>FL</td>
<td>Miami</td>
<td>Miami Intl</td>
<td>FDC 0/4980</td>
<td>LOC Rwy 30 AMDT 6</td>
</tr>
<tr>
<td>12/08/00</td>
<td>FL</td>
<td>Miami</td>
<td>Miami Intl</td>
<td>FDC 0/4979</td>
<td>ILS Rwy 271 AMDT 23</td>
</tr>
<tr>
<td>12/08/00</td>
<td>AR</td>
<td>Little Rock</td>
<td>Adams Field</td>
<td>FDC 0/4977</td>
<td>ILS Rwy 41 AMDT 25</td>
</tr>
<tr>
<td>12/07/00</td>
<td>TX</td>
<td>Leilelland</td>
<td>Leilelland Muni</td>
<td>FDC 0/4946</td>
<td>NB D 35 AMDT 18</td>
</tr>
<tr>
<td>12/07/00</td>
<td>MO</td>
<td>Boonville</td>
<td>Jesse Viertel Memorial</td>
<td>FDC 0/4941</td>
<td>GPS Rwy 36 ORIG–A</td>
</tr>
<tr>
<td>12/07/00</td>
<td>MO</td>
<td>Boonville</td>
<td>Jesse Viertel Memorial</td>
<td>FDC 0/4940</td>
<td>GPS Rwy 18 AMDT 10A</td>
</tr>
<tr>
<td>12/07/00</td>
<td>MO</td>
<td>Boonville</td>
<td>Jesse Viertel Memorial</td>
<td>FDC 0/4937</td>
<td>GPS Rwy 18 AMDT 7C</td>
</tr>
<tr>
<td>12/07/00</td>
<td>MO</td>
<td>Sedalia</td>
<td>Sedalia Memorial</td>
<td>FDC 0/4938</td>
<td>GPS Rwy 18 ORIG–B</td>
</tr>
<tr>
<td>12/07/00</td>
<td>MO</td>
<td>Sedalia</td>
<td>Sedalia Memorial</td>
<td>FDC 0/4935</td>
<td>GPS Rwy 18 AMDT 7C</td>
</tr>
<tr>
<td>12/07/00</td>
<td>NC</td>
<td>Wilson</td>
<td>Wilson Industrial Air Center</td>
<td>FDC 0/4933</td>
<td>GPS Rwy 36 ORIG–B</td>
</tr>
<tr>
<td>12/07/00</td>
<td>MO</td>
<td>Marshall</td>
<td>Marshall Memorial Muni</td>
<td>FDC 0/4909</td>
<td>NB OR GPS Rwy 21 AMDT 1A</td>
</tr>
<tr>
<td>12/06/00</td>
<td>TX</td>
<td>Baytown</td>
<td>RWJ Airpark</td>
<td>FDC 0/4904</td>
<td>RNAV Rwy 36 ORIG–B</td>
</tr>
<tr>
<td>12/06/00</td>
<td>TX</td>
<td>Crosbyton</td>
<td>Crosbyton Muni</td>
<td>FDC 0/4915</td>
<td>GPS Rwy 35 ORIG</td>
</tr>
<tr>
<td>12/06/00</td>
<td>TX</td>
<td>Crosbyton</td>
<td>Crosbyton Muni</td>
<td>FDC 0/4916</td>
<td>NB D 35 ORIG</td>
</tr>
<tr>
<td>12/07/00</td>
<td>TN</td>
<td>Millington</td>
<td>Charles W. Baker</td>
<td>FDC 0/4956</td>
<td>GPS Rwy 35 ORIG</td>
</tr>
</tbody>
</table>
the airport, its location, the procedure identification and the amendment number.

The Rule

This amendment to part 97 is effective upon publication of each separate SIAP as contained in the transmittal. Some SIAP amendments may have been previously issued by the FAA in a National Flight Data Center (NFDC) Notice to Airmen (NOTAM) as an emergency action of immediate flight safety relating directly to published aeronautical charts. The circumstances which created the need for some SIAP amendments may require making them effective in less than 30 days. For the remaining SIAPs, an effective date at least 30 days after publication is provided.

Further, the SIAPs contained in this amendment are based on the criteria contained in the U.S. Standard for Terminal Instrument Procedures (TERPS). In developing these SIAPs, the TERPS criteria were applied to the conditions existing or anticipated at the affected airports. Because of the close and immediate relationship between these SIAPs and safety in air commerce, I find that notice and public procedure before adopting these SIAPs are impracticable and contrary to the public interest and, where applicable, that good cause exists for making some SIAPs effective in less than 30 days.

Conclusion

The FAA has determined that this regulation only involves an established body of technical regulations for which frequent and routine amendments are necessary to keep them operationally current. It, therefore—(1) is not a "significant regulatory action" under Executive Order 12866; (2) is not a "significant rule" under DOT Regulatory Policies and Procedures (44 FR 11034; February 26, 1979); and (3) does not warrant preparation of a regulatory evaluation as the anticipated impact is so minimal. For the same reason, the FAA certifies that this amendment will not have a significant economic impact on a substantial number of small entities under the criteria of the Regulatory Flexibility Act.

List of Subjects in 14 CFR Part 97

Air Traffic Control, Airports, Navigation (Air).

Issued in Washington, DC on December 22, 2000.

L. Nicholas Lacey,
Director, Flight Standards Service.

Adoption of the Amendment

Accordingly, pursuant to the authority delegated to me, part 97 of the Federal Aviation Regulations (14 CFR part 97) is amended by establishing, amending, suspending, or revoking Standard Instrument Approach Procedures, effective at 0901 UTC on the dates specified, as follows:

PART 97—STANDARD INSTRUMENT APPROACH PROCEDURES

1. The authority citation for part 97 is revised to read as follows:

Authority: 49 U.S.C. 106(g), 40103, 40113, 40120, 44701; and 14 CFR 11.49(b)(2).

2. Part 97 is amended to read as follows:

§§ 97.23, 97.25, 97.27, § 97.29, § 97.31, § 97.33, and § 97.35 [Amended]

By amending: § 97.23 VOR, VOR/DME, VOR or TACAN, and VOR/DME or TACAN; § 97.25 LOC, LOC/DME, LDA, LDA/DME, SDF, SDF/DME; § 97.27 NDB, NDB/DME, SDF, SDF/DME; § 97.29 ILS, ILS/DME, ILS/MLS, MLS, MLS/DME, MLS/RNAV; § 97.31 RADAR SIAPs; § 97.33 RNAV SIAPs; and § 97.35 COPTER SIAPs, identified as follows:

* * * Effective January 25, 2001

Crestview, FL, Bob Sikes, NDB OR GPS RWY 17, Amdt 2C

Daytona Beach, FL, Daytona Beach Intl, LOC BC RWY 25R, Amdt 14C

Daytona Beach, FL, Daytona Beach Intl, NDB OR GPS RWY 7L, Amdt 25A

Dunnellon, FL, Dunnellon/Marion Co & Park of Commerce, VOR/DME RWY 23, Amdt 1A

Dunnellon, FL, Dunnellon/Marion Co & Park of Commerce, GPS RWY 23, Orig-A

Melbourne, FL, Melbourne International, NDB OR GPS RWY 9R, Amdt 14D

Lamoni, IA, Lamoni Muni, RNAV (GPS) RWY 17, Orig

Lamoni, IA, Lamoni Muni, RNAV (GPS) RWY 35, Orig

Ogallala, NE, Searle Field, VOR/DME RWY 8, Orig

Ogallala, NE, Searle Field, VOR RWY 8, Amdt 5

Ogallala, NE, Searle Field, VOR/DME RWY 26, Orig

Ogallala, NE, Searle Field, VOR RWY 26, Amdt 5

Ogallala, NE, Searle Field, GPS RWY 26, Orig (CANCELLLED)

Ogallala, NE, Searle Field, RNAV (GPS) RWY 8, Orig

Ogallala, NE, Searle Field, RNAV (GPS) RWY 26, Orig

Fremont, OH, Sandusky County Regional, VOR/DME RWY 24, Orig

Emporia, VA, Emporia-Greensville Regional, LOC RWY 33, Orig

Emporia, VA, Emporia-Greensville Regional, NDB OR GPS RWY 33, Amdt 6, CANCELLED

Newport News, VA, Newport News/Williamsburg Intl, RNAV (GPS) RWY 7, Orig

Newport News, VA, Newport News/Williamsburg Intl, RNAV (GPS) RWY 25, Orig

* * * February 22, 2001

Grand Island, NE, Central Nebraska Regional, VOR RWY 13, Amdt 19

Grand Island, NE, Central Nebraska Regional, VOR RWY 17, Amdt 24

Grand Island, NE, Central Nebraska Regional, VOR/DME RWY 31, Amdt 7

Grand Island, NE, Central Nebraska Regional, VOR/DME RWY 35, Amdt 15

Grand Island, NE, Central Nebraska Regional, NDB RWY 35, Amdt 8

Gallup, NM, Gallup Municipal, VOR RWY 6, Amdt 8

Pulaski, TN, Abernathy Field, VOR/DME RWY 33, Amdt 1

* * * March 22, 2001

Mason City, IA, Mason City Muni, VOR/DME RWY 17, Amdt 4

Mason City, IA, Mason City Muni, VOR RWY 35, Amdt 6

Mason City, IA, Mason City Muni, LOC BC RWY 17, Amdt 6

Mason City, IA, Mason City Muni, NDB RWY 35, Amdt 5

Bardstown, KY, Samuels Field, NDB OR GPS-A, Amdt 5A, CANCELLED

Norfolk, NE, Karl Stefan Memorial, VOR RWY 1, Amdt 8

Norfolk, NE, Karl Stefan Memorial, VOR RWY 13, Amdt 7

Norfolk, NE, Karl Stefan Memorial, VOR RWY 19, Amdt 8

Norfolk, NE, Karl Stefan Memorial, VOR RWY 31, Amdt 7

Abilene, TX, Abilene Regional, RADAR-1, Amdt 9

[FR Doc. 00–33181 Filed 12–27–00; 8:45 am]

BILLING CODE 4910–13–M

FEDERAL TRADE COMMISSION

16 CFR Part 301

Rules and Regulations Under the Fur Products Labeling Act

AGENCY: Federal Trade Commission.

ACTION: Final rule.

SUMMARY: The Federal Trade Commission (FTC or Commission) amends the Rules and Regulations under the Fur Products Labeling Act (Fur Rules) pursuant to the Dog and Cat Protection Act of 2000. That Act prohibits importing, exporting, manufacturing, selling, advertising, transporting, or distributing any dog or cat fur product. The Dog and Cat Protection Act also amends the Fur Act to exclude dog and cat fur products from items the Commission may exempt
from Fur Act requirements because they contain only a small amount of fur. The amendments announced herein concern the Fur Rules to the amended Fur Act by making clear that the exemption from the Fur Act does not apply to dog and cat fur products. Because the amendments are technical in nature and merely incorporate the statutory change, the Commission finds that notice and comment are not required. See 5 U.S.C. 553(b). For this reason, the requirements of the Regulatory Flexibility Act also do not apply. See 5 U.S.C. 603, 604.

**EFFECTIVE DATE:** The amended Rules are effective January 29, 2001.

**ADDRESSES:** Requests for copies of the amended Rules should be sent to the Consumer Response Center, Room 202, Federal Trade Commission, 600 Pennsylvania Avenue, NW, Washington, DC 20580. The notice announcing the amendments is available on the Internet at the Commission’s website: http://www.ftc.gov.

**FOR FURTHER INFORMATION CONTACT:** Carol Jennings, Attorney, (202) 326–3010, cjennings@ftc.gov, or Stephen Ecklund, Senior Investigator, (202) 326–2841, secklund@ftc.gov, Division of Enforcement, Bureau of Consumer Protection, Federal Trade Commission, 600 Pennsylvania Avenue NW, Washington, DC 20580.

**SUPPLEMENTARY INFORMATION:** The Fur Products Labeling Act (Fur Act), 15 U.S.C. 69, and Commission rules pursuant to the Act, 16 CFR Part 301, require that sellers of covered fur products mark each product to show: (1) The name of the animal that produced the fur; (2) that the fur product contains or is composed of used fur, if such is the fact; (3) that the fur product contains or is composed of artificially colored fur, if such is the fact; (4) that the fur product is composed in whole or in substantial part of paws, tails, bellies, or waste fur, if such is the fact; (5) the name under which the manufacturer or other responsible company does business, or in lieu thereof, the RN issued to the company by the Commission; and (6) the country of origin of imported furs. The statute and rules also include advertising and recordkeeping requirements. The Fur Act authorizes the Commission to exempt products containing a relatively small amount of fur, and the rule amendments continue to make clear that the exemptions are available in lieu thereof, the RN issued to the company by the Commission, or the country of origin of imported furs. The Commission is also making certain technical corrections to the rule amendments.

The Dog and Cat Protection Act of 2000, Pub. L. 106–476, prohibits importing, exporting, manufacturing, selling, advertising, transporting, or distributing any dog or cat fur product. Violations may result in the imposition of civil penalties ranging from $3,000 to $10,000 for each separate violation; forfeiture of the illegal products; and debarment from importing, exporting, manufacturing, transporting, distributing, or selling any fur product in the U.S.

In addition, the Dog and Cat Protection Act amends the Fur Act, 16 U.S.C. 69(d), to exclude dog and cat fur products from those items the Commission is authorized to exempt from the labeling and other requirements of the Fur Act and implementing regulations. The amendments to the Fur Rules announced herein implement this amendment to the Fur Act.

**List of Subjects in 16 CFR Part 301**

Furs, Labeling, Trade Practices.

For the reasons set forth above, the Commission amends 16 CFR Part 301 as follows:

**PART 301—RULES AND REGULATIONS UNDER THE FUR PRODUCTS LABELING ACT**

1. The authority citation for Part 301 continues to read as follows:


2. Section 301.1(a) is amended by adding paragraphs (6), (7), and (8) to read as follows:

   § 301.1 Terms defined.

   (a) * * *

   (6) The term cat fur means the pelt or skin of any animal of the species Felis catus.

   (7) The term dog fur means the pelt or skin of any animal of the species Canis familiaris.

   (8) The term dog or cat fur product means any item of merchandise which consists, or is composed in whole or in part, of any dog fur, cat fur, or both.

   3. In § 301.39, the second sentence of paragraph (a) is revised to read as follows:

   § 301.39 Exempted fur products.

   (a) * * *

   The exemption provided for herein shall not be applicable: (1) to any dog or cat fur product; (2) if any false, deceptive, or misleading representations as to the fur contained in the fur product are made; or (3) if any representations as to the fur are made in labeling, invoicing, or advertising without disclosing: (i) in the case of labels, the information required to be disclosed under section 4(2)(A), (C), and (D) of the Act; (ii) in the case of advertising, the information required to be disclosed under section 5(a)(1), (3), and (4) of the Act; and (iii) in the case of invoicing, the information required to be disclosed under section 5(b)(1)(A), (C), and (D) of the Act.

   By direction of the Commission.

   Donald S. Clark.
   Secretary.

   [FR Doc. 00–33026 Filed 12–27–00; 8:45 am]
   BILLING CODE 6750–01–M

**COMMODITY FUTURES TRADING COMMISSION**

17 CFR Part 1

RIN 3038–AB56

Investment of Customer Funds

**AGENCY:** Commodity Futures Trading Commission.

**ACTION:** Final rules; change of effective date.

**SUMMARY:** The Commodity Futures Trading Commission (Commission) is moving forward the effective date of its recent rule amendments concerning the investment of customer funds by futures commission merchants (FCMs) and clearing organizations to permit FCMs and clearing organizations to engage in the expanded investment activity at an earlier date. The Commission is also making certain technical corrections to the rule amendments.

**DATES:** The revision of § 1.25 published on December 13, 2000 (65 FR 77993) as amended by this rule is effective December 28, 2000. The revision of § 1.26 and the amendments to §§ 1.20, 1.27, 1.28 and 1.29 published on December 13, 2000 (65 FR 77993) are effective December 28, 2000.

**FOR FURTHER INFORMATION CONTACT:** Lawrence B. Patent, Associate Chief Counsel, Paul H. Bjarnason, Jr., Special Advisory for Accounting Policy, or Ky Tran-Trong, Attorney-Advisor, Division of Trading and Markets, Commodity Futures Trading Commission, Three Lafayette Centre, 1155 21st Street, NW., Washington, DC 20581. Telephone: (202) 418–5450.

**SUPPLEMENTARY INFORMATION:**
I. Background

On December 13, 2000, the Commission published final rules and rule amendments in the Federal Register revising its rules relating to intermediation of commodity futures and commodity options (commodity interest) transactions. As part of the new rules and rule amendments, the Commission has amended Rule 1.25 to expand the range of instruments in which FCMs and clearing organizations may invest customer funds to include such highly liquid and readily marketable instruments as certain sovereign debt, agency debt, money market mutual funds, and corporate notes (permitted investments). Additional provisions to minimize credit, volatility and liquidity risk have also been adopted. Previously, investments of customer funds had been limited to U.S. government securities, municipal securities, and instruments fully guaranteed as to principal and interest by the U.S. government. When the Commission proposed the amendments to Rule 1.25, it stated that “an expanded list of permitted investments could enhance the yield available to FCMs, clearing organizations and their customers without compromising the safety of customer funds.”

As provided in the adopting release, the new rules and rule amendments relating to intermediaries, including the changes to Rule 1.25, are to become effective on February 12, 2001. The Commission established an effective date 60 days following publication in the Federal Register for the new rules and rule amendments relating to intermediaries, as well as for the other elements of regulatory reform adopted simultaneously by the Commission, to allow time for entities affected by the rule changes to make the necessary adjustments to their operations. The Commission has been apprised by the futures industry, however, that the implementation of new Rule 1.25 does not require such a lengthy delay, and that it may be more efficient if FCMs are permitted to implement the rule revisions relating to Rule 1.25 on an earlier date. The Commission agrees with the industry request and has determined to move forward the effective date for the amendments to Rule 1.25 to December 28, 2000. The Commission has further determined to move forward the effective date of related amendments to Rules 1.20 and 1.26–1.29.

II. Technical Corrections

Paragraph (a) of Rule 1.25 sets forth the types of permissible investments of customer funds, e.g., U.S. Treasury obligations, commercial paper, corporate notes. Each type of investment must meet certain quality requirements, including requirements for marketability, credit ratings, restrictive features and concentration limitations. Currently, these quality requirements are all contained in separate provisions of paragraph (b) of the rule, except for the requirements regarding sovereign debt, which are contained in paragraph (a)(1)(vii). The Commission believes that this placement could be confusing. Therefore, in order to clarify Rule 1.25, the requirements for all types of permitted investments are now placed together, in the same paragraphs, as follows: (i) the requirement that foreign sovereign debt be rated in the highest category by at least one nationally recognized statistical rating organization has been moved from paragraph (a)(1)(vii) to paragraph (b)(2)(i)(D) and, concurrently, the reference to permit sovereign debt contained in paragraph (b)(2)(i)(A) is no longer necessary and, therefore, has been deleted; and (ii) the requirement that investments in a particular country’s sovereign debt be limited to amounts owed in that currency has been moved from paragraph (a)(1)(vii) to paragraph (b)(4)(i)(D).

III. Other Matters

The Commission has determined that there is good cause to move forward the effective date of the amendments to Rule 1.25, as well as the amendments to Rules 1.20 and 1.26–1.29, and to make the clarifying revisions discussed above to Rule 1.25 because it is not contrary to the public interest to permit FCMs and clearing organizations to invest customer funds in an expanded range of permissible investments. Such investments could potentially provide a higher yield to those FCMs and clearing organizations without compromising the safety of customer funds. The Commission has further determined that these rules may be made effective less than 30 days following their date of publication in the Federal Register because these are substantive rules that relieve a restriction on those FCMs and clearing organizations seeking to invest customer funds in a wider range of financial instruments.

List of Subjects in 17 CFR Part 1

Brokers, Commodity futures, Consumer protection, Reporting and recordkeeping requirements.

In consideration of the foregoing, and pursuant to the authority contained in the Commodity Exchange Act, and in particular, Sections 4(c), 4d(2) and 8a(5) thereof, 7 U.S.C. 6(c), 6d(2) and 12a(5), the Commission hereby makes the amendments to rules 1.20 and 1.25 through 1.29 that were published on December 13, 2000 at 65 FR 77993, 78009–13 as further amended in this release, effective December 28, 2000.

PART 1—GENERAL REGULATIONS UNDER THE COMMODITY EXCHANGE ACT

1. The authority citation for Part 1 continues to read as follows:

Authority: 7 U.S.C. 1a, 2, 2a, 4, 4a, 6, 6a, 6b, 6c, 6d, 6e, 6f, 6g, 6h, 6i, 6j, 6k, 6l, 6m, 6n, 6o, 6p, 7, 7a, 7b, 8, 9, 12, 12a, 12c, 13a, 13a–1, 16, 16a, 19, 21, 23 and 24.

2. Section 1.25 is amended by revising paragraphs (a)(1)(vii), (b)(2)(i)(A) and (b)(2)(i)(C), by redesignating paragraph (b)(2)(i)(D) as paragraph (b)(2)(i)(E), by adding a new paragraph (b)(2)(i)(D), by adding a new paragraph (b)(4)(i)(A) and by adding a new paragraph (b)(4)(i)(D). For the convenience of the reader, printed below is revised paragraph (a)(1)(vii) as well as the complete paragraphs (b)(2)(i) and (b)(4)(i) as revised:

§ 1.25 Investment of customer funds.

(a) * * *

(1) * * *

(vii) General obligations of a sovereign nation; and

* * * * *

(b) * * *

(2) Ratings. (i) Initial requirement. Instruments that are required to be rated by this section must be rated by a nationally recognized statistical rating organization.

7 5 U.S.C. 553(d) generally provides that the publication or service of a substantive rule shall not be made less than 30 days before its effective date, except for: (1) a substantive rule which grants or recognizes an exemption or relieves a restriction; (2) interpretative rules and statements of policy; or (3) as otherwise provided by the agency for good cause found and published with the rule.
organization (NRSRO), as that term is defined in § 270.2a-7 of this title. For an investment to qualify as a permitted investment, ratings are required as follows:

(A) U.S. government securities need not be rated;

(B) Municipal securities, government sponsored agency securities, certificates of deposit, commercial paper, and corporate notes, except notes that are asset-backed, must have the highest short-term rating of an NRSRO or one of the two highest long-term ratings of an NRSRO;

(C) Corporate notes that are asset-backed must have the highest ratings of an NRSRO;

(D) Sovereign debt must be rated in the highest category by at least one NRSRO; and

(E) Money market mutual funds that are rated by an NRSRO must be rated at the highest rating of an NRSRO.

* * * * *

(4) Concentration and other limitations. (i) Direct investments. (A) U.S. government securities and money market mutual funds shall not be subject to a concentration limit or other limitation.

(B) Securities of any single issuer of government sponsored agency securities held by a futures commission merchant or clearing organization may not exceed 25 percent of total assets held in segregation by the futures commission merchant or clearing organization.

(C) Securities of any single issuer of municipal securities, certificates of deposit, commercial paper, or corporate notes held by a futures commission merchant or clearing organization may not exceed 5 percent of total assets held in segregation by the futures commission merchant or clearing organization.

(D) Sovereign debt is subject to the following limits: a futures commission merchant may invest in the sovereign debt of a country to the extent it has balances in segregated accounts owed to its customers denominated in that country’s currency; a clearing organization may invest in the sovereign debt of a country to the extent it has balances in segregated accounts owed to its clearing member futures commission merchants denominated in that country’s currency.

* * * * *

Issued in Washington, DC on December 21, 2000 by the Commission.

Jean A. Webb,
Secretary of the Commission.

[FR Doc. 00–32976 Filed 12–27–00; 8:45 am]

BILLING CODE 6351–01–M

DEPARTMENT OF TRANSPORTATION

Coast Guard

33 CFR Parts 100 and 165

[USCG–2000–8541]

Safety Zones, Security Zones, and Special Local Regulations

AGENCY: Coast Guard, DOT.

ACTION: Notice of temporary rules issued.

SUMMARY: This document provides required notice of substantive rules adopted by the Coast Guard and temporarily effective between July 1, 2000 and September 30, 2000 which were not published in the Federal Register. This notice also contains 9 temporary final rules issued during the period of April 1, 2000, thru June 30, 2000, that were not included in the docket USCG 2000–7757. This quarterly notice lists temporary local regulations, security zones, and safety zones of limited duration and for which timely publication in the Federal Register was not possible.

DATES: This notice lists temporary Coast Guard regulations that became effective and were terminated between April 1, 2000, and September 30, 2000.

ADDRESSES: The Docket Management Facility maintains the public docket for this notice. Documents indicated in this notice will be available for inspection or copying at the Docket Management Facility, U.S. Department of Transportation, Room PL–401, 400 Seventh Street SW., Washington, DC 20593–0001 between 9 a.m. and 5 p.m., Monday through Friday, except Federal Holidays. You may electronically access the public docket for this notice on the Internet at http://dms.dot.gov.

FOR FURTHER INFORMATION CONTACT: For questions on this notice, contact Lieutenant Bruce Walker, Office of Regulations and Administrative Law, telephone (202) 267–6233. For questions on viewing, or on submitting material to the docket, contact Dorothy Beard, Chief, Dockets, Department of Transportation (202) 866–9329.

SUPPLEMENTARY INFORMATION: District Commanders and Captains of the Port (COTP) must be immediately responsive to the safety needs of the waters within...
their jurisdiction; therefore, District Commanders and COTP's have been delegated the authority to issue certain local regulations. Safety zones may be established for safety or environmental purposes. A safety zone may be stationary and described by fixed limits or it may be described as a zone around a vessel in motion. Security zones limit access to vessels, ports, or waterfront facilities to prevent injury or damage. Special local regulations are issued to enhance the safety of participants and spectators at regattas and other marine events. Timely publication of these regulations in the Federal Register is often precluded when a regulation responds to an emergency, or when an event occurs without sufficient advance notice. However, the affected public is informed of these regulations through Local Notices to Mariners, press releases, and other means. Moreover, actual notification is provided by Coast Guard patrol vessels enforcing the restrictions imposed by the regulation. Because mariners are notified by Coast Guard officials on-scene prior to enforcement action, Federal Register notice is not required to place the special local regulation, security zone, or safety zone in effect. However, the Coast Guard, by law, must publish in the Federal Register notice of substantive rules adopted. To meet this obligation without imposing undue expense on the public, the Coast Guard periodically publishes a list of these temporary special local regulations, security zones, and safety zones.

Permanent regulations are not included in this list because they are published in their entirety in the Federal Register. Temporary regulations may also be published in their entirety if sufficient time is available to do so before they are placed in effect or terminated. The safety zones, special local regulations and security zones listed in this notice have been exempted from review under Executive Order 12866 because of their emergency nature, or limited scope and temporary effectiveness.

The following regulations were placed in effect temporarily during the period April 1, 2000 and September 30, 2000, unless otherwise indicated.

S.G. Venckus,
Chief, Office of Regulations and Administrative Law.

### COTP QUARTERLY REPORT

<table>
<thead>
<tr>
<th>COTP docket</th>
<th>Location</th>
<th>Type</th>
<th>Effective date</th>
</tr>
</thead>
<tbody>
<tr>
<td>HOUSTON-GALVESTON 00–004</td>
<td>HOUSTON SHIP CHANNEL, HOUSTON, TX</td>
<td>SAFETY ZONE</td>
<td>07/17/2000</td>
</tr>
<tr>
<td>HOUSTON-GALVESTON 00–008</td>
<td>FREEPORT CHANNEL</td>
<td>SAFETY ZONE</td>
<td>08/20/2000</td>
</tr>
<tr>
<td>HOUSTON-GALVESTON 00–009</td>
<td>DEEPWATER BERTHING OLD BRAZOS RIVER</td>
<td>SAFETY ZONE</td>
<td>08/23/2000</td>
</tr>
<tr>
<td>HOUSTON-GALVESTON 00–010</td>
<td>GULF INTRACOASTAL WATERWAY, M 357 TO 359</td>
<td>SAFETY ZONE</td>
<td>08/25/2000</td>
</tr>
<tr>
<td>HOUSTON-GALVESTON 00–011</td>
<td>GULF OF MEXICO 3.1 MILES S. OF GALVESTON, TX</td>
<td>SAFETY ZONE</td>
<td>09/12/2000</td>
</tr>
<tr>
<td>HUNTINGTON 00–003</td>
<td>KANAWHA RIVER, M. 54.5 TO 55.8</td>
<td>SAFETY ZONE</td>
<td>08/14/2000</td>
</tr>
<tr>
<td>JACKSONVILLE 00–067</td>
<td>INDIAN RIVER, TITUSVILLE, FL</td>
<td>SAFETY ZONE</td>
<td>07/04/2000</td>
</tr>
<tr>
<td>JACKSONVILLE 00–068</td>
<td>INTERCOASTAL WATERWAY, ORMOND BEACH, FL</td>
<td>SAFETY ZONE</td>
<td>07/04/2000</td>
</tr>
<tr>
<td>JACKSONVILLE 00–069</td>
<td>INDIAN RIVER, COCOA BEACH, FL</td>
<td>SAFETY ZONE</td>
<td>07/04/2000</td>
</tr>
<tr>
<td>JACKSONVILLE 00–070</td>
<td>ATLANTIC OCEAN, DAYTONA BEACH, FL</td>
<td>SAFETY ZONE</td>
<td>07/04/2000</td>
</tr>
<tr>
<td>JACKSONVILLE 00–071</td>
<td>INTERCOASTAL WATERWAY, MELBOURNE, FL</td>
<td>SAFETY ZONE</td>
<td>07/04/2000</td>
</tr>
<tr>
<td>JACKSONVILLE 00–072</td>
<td>ST. JOHNS RIVER, JACKSONVILLE, FL</td>
<td>SAFETY ZONE</td>
<td>07/04/2000</td>
</tr>
<tr>
<td>JACKSONVILLE 00–074</td>
<td>ST. JOHNS RIVER, ORANGE PARK, FL</td>
<td>SAFETY ZONE</td>
<td>07/04/2000</td>
</tr>
<tr>
<td>JACKSONVILLE 00–075</td>
<td>ATLANTIC OCEAN, COCOA BEACH, FL</td>
<td>SAFETY ZONE</td>
<td>07/04/2000</td>
</tr>
<tr>
<td>LAS/LE 00–005</td>
<td>HUNTINGTON BEACH, CA</td>
<td>SAFETY ZONE</td>
<td>08/20/2000</td>
</tr>
<tr>
<td>LAS/LE 00–006</td>
<td>LONG BEACH, CA</td>
<td>SAFETY ZONE</td>
<td>08/13/2000</td>
</tr>
<tr>
<td>LOUISVILLE 00–017</td>
<td>OHIO RIVER, M. 428.6 TO 428.5</td>
<td>SAFETY ZONE</td>
<td>08/05/2000</td>
</tr>
<tr>
<td>LOUISVILLE 00–018</td>
<td>OHIO RIVER, M. 470 TO 471.1</td>
<td>SAFETY ZONE</td>
<td>08/19/2000</td>
</tr>
<tr>
<td>LOUISVILLE 00–019</td>
<td>NEW ALBANY, IA</td>
<td>SAFETY ZONE</td>
<td>09/09/2000</td>
</tr>
<tr>
<td>LOUISVILLE 00–020</td>
<td>LOUISVILLE, KY</td>
<td>SAFETY ZONE</td>
<td>09/03/2000</td>
</tr>
<tr>
<td>LOUISVILLE 00–022</td>
<td>OHIO RIVER, M. 470</td>
<td>SAFETY ZONE</td>
<td>09/26/2000</td>
</tr>
<tr>
<td>LOUISVILLE 00–025</td>
<td>BLUEGRASS IN THE PARK FIREWORKS DISPLAY</td>
<td>SAFETY ZONE</td>
<td>08/11/2000</td>
</tr>
<tr>
<td>LOUISVILLE 00–026</td>
<td>LOUISVILLE, KY</td>
<td>SAFETY ZONE</td>
<td>09/09/2000</td>
</tr>
<tr>
<td>MEMPHIS 00–015</td>
<td>MISSISSIPPI RIVER, M. 850.7 TO 852.7</td>
<td>SAFETY ZONE</td>
<td>08/01/2000</td>
</tr>
<tr>
<td>MEMPHIS 00–016</td>
<td>MISSISSIPPI RIVER, M. 852 TO 845</td>
<td>SAFETY ZONE</td>
<td>08/02/2000</td>
</tr>
<tr>
<td>MEMPHIS 00–017</td>
<td>MISSISSIPPI RIVER, M. 740 TO 744</td>
<td>SAFETY ZONE</td>
<td>09/12/2000</td>
</tr>
<tr>
<td>MEMPHIS 00–018</td>
<td>MISSISSIPPI RIVER, M. 771 TO 773</td>
<td>SAFETY ZONE</td>
<td>09/16/2000</td>
</tr>
<tr>
<td>MIAMI 00–008</td>
<td>FT. LAUDERDALE, FLORIDA</td>
<td>SAFETY ZONE</td>
<td>09/01/2000</td>
</tr>
<tr>
<td>NEW ORLEANS 00–016</td>
<td>LWR MISSISSIPPI RIVER, M. 120 TO 122</td>
<td>SAFETY ZONE</td>
<td>07/03/2000</td>
</tr>
<tr>
<td>NEW ORLEANS 00–017</td>
<td>LWR MISSISSIPPI RIVER, M. 137 TO 139</td>
<td>SAFETY ZONE</td>
<td>07/03/2000</td>
</tr>
<tr>
<td>NEW ORLEANS 00–020</td>
<td>LWR MISSISSIPPI RIVER, M. 174 TO 177</td>
<td>SAFETY ZONE</td>
<td>07/03/2000</td>
</tr>
<tr>
<td>NEW ORLEANS 00–021</td>
<td>LWR MISSISSIPPI RIVER, M. 228 TO 231</td>
<td>SAFETY ZONE</td>
<td>07/04/2000</td>
</tr>
<tr>
<td>NEW ORLEANS 00–022</td>
<td>LWR MISSISSIPPI RIVER, M. 362 TO 364</td>
<td>SAFETY ZONE</td>
<td>07/04/2000</td>
</tr>
<tr>
<td>NEW ORLEANS 00–023</td>
<td>J. BENNETT JOHNSTON WATERWAY, M. 58.5 TO 60.5</td>
<td>SAFETY ZONE</td>
<td>07/06/2000</td>
</tr>
<tr>
<td>NEW ORLEANS 00–024</td>
<td>J. BENNETT JOHNSTON WATERWAY, M. 58.5 TO 60.5</td>
<td>SAFETY ZONE</td>
<td>07/13/2000</td>
</tr>
<tr>
<td>NEW ORLEANS 00–025</td>
<td>LWR MISSISSIPPI RIVER, M. 438 TO 436</td>
<td>SAFETY ZONE</td>
<td>09/14/2000</td>
</tr>
<tr>
<td>NEW ORLEANS 00–026</td>
<td>INNER HARBOR NAVIGATION CANAL, MORRISON PIER</td>
<td>SAFETY ZONE</td>
<td>08/05/2000</td>
</tr>
<tr>
<td>NEW ORLEANS 00–027</td>
<td>LWR MISSISSIPPI RIVER, M. 165 TO M. 167</td>
<td>SAFETY ZONE</td>
<td>08/30/2000</td>
</tr>
<tr>
<td>NEW ORLEANS 00–028</td>
<td>LWR MISSISSIPPI RIVER, M. 436 TO 438</td>
<td>SAFETY ZONE</td>
<td>09/19/2000</td>
</tr>
<tr>
<td>NEW ORLEANS 00–029</td>
<td>LWR MISSISSIPPI RIVER, M. 348 TO 351</td>
<td>SAFETY ZONE</td>
<td>09/29/2000</td>
</tr>
<tr>
<td>PADUCAH 00–007</td>
<td>CLINCE RIVER, M. 1, KINGSTON, TN</td>
<td>SAFETY ZONE</td>
<td>07/04/2000</td>
</tr>
</tbody>
</table>
### COTP Quarterly Report—Continued

<table>
<thead>
<tr>
<th>COTP docket</th>
<th>Location</th>
<th>Type</th>
<th>Effective date</th>
</tr>
</thead>
<tbody>
<tr>
<td>PADUCAH 00–008</td>
<td>TENNESSEE RIVER, M. 646.5 TO 647.5</td>
<td>SAFETY ZONE</td>
<td>07/04/2000</td>
</tr>
<tr>
<td>PADUCAH 00–009</td>
<td>TENNESSEE RIVER, M. 647.4 TO 648</td>
<td>SAFETY ZONE</td>
<td>07/02/2000</td>
</tr>
<tr>
<td>PADUCAH 00–011</td>
<td>CUMBERLAND RIVER, M. 125 TO 126</td>
<td>SAFETY ZONE</td>
<td>07/25/2000</td>
</tr>
<tr>
<td>PADUCAH 00–012</td>
<td>CUMBERLAND RIVER, M. 125 TO 126</td>
<td>SAFETY ZONE</td>
<td>09/09/2000</td>
</tr>
<tr>
<td>PADUCAH 00–013</td>
<td>CUMBERLAND RIVER, M. 126.5 TO 128.5</td>
<td>SAFETY ZONE</td>
<td>09/10/2000</td>
</tr>
<tr>
<td>PADUCAH 00–014</td>
<td>OHIO RIVER M. 975 TO 978</td>
<td>SAFETY ZONE</td>
<td>09/08/2000</td>
</tr>
<tr>
<td>PADUCAH 00–015</td>
<td>LWR MISSISSIPPI RIVER, M. 921</td>
<td>SAFETY ZONE</td>
<td>09/12/2000</td>
</tr>
<tr>
<td>PORT ARTHUR 00–004</td>
<td>SABINE-NECHES CANAL, PORT ARTHUR, TX</td>
<td>SAFETY ZONE</td>
<td>07/04/2000</td>
</tr>
<tr>
<td>SAN DIEGO 00–008</td>
<td>LAKE HAVasu, COLORADO RIVER, AZ</td>
<td>SAFETY ZONE</td>
<td>09/30/2000</td>
</tr>
<tr>
<td>SAN FRANCISCO BAY 00–004</td>
<td>SAN FRANCISCO BAY, SAN FRANCISCO, CA</td>
<td>SAFETY ZONE</td>
<td>07/04/2000</td>
</tr>
<tr>
<td>SAN FRANCISCO BAY 00–005</td>
<td>OAKLAND INNER HARBOR, OAKLAND, CA</td>
<td>SAFETY ZONE</td>
<td>07/04/2000</td>
</tr>
<tr>
<td>SAN FRANCISCO BAY 00–006</td>
<td>SAN FRANCISCO BAY, SAN FRANCISCO, CA</td>
<td>SAFETY ZONE</td>
<td>07/04/2000</td>
</tr>
<tr>
<td>SAN JUAN 00–087</td>
<td>PUERTO RICO AND THE VIRGIN ISLANDS</td>
<td>SAFETY ZONE</td>
<td>08/22/2000</td>
</tr>
<tr>
<td>SAVANNAH 00–089</td>
<td>SAVANNAH, GA</td>
<td>SAFETY ZONE</td>
<td>09/18/2000</td>
</tr>
<tr>
<td>SOUTHEAST ALASKA 00–009</td>
<td>SITKA CHANNEL, SITKA, AK</td>
<td>SAFETY ZONE</td>
<td>07/03/2000</td>
</tr>
<tr>
<td>SOUTHEAST ALASKA 00–014</td>
<td>TONGASS NARROWS, KETCHikan, AK</td>
<td>SAFETY ZONE</td>
<td>08/25/2000</td>
</tr>
<tr>
<td>TAMPA 00–081</td>
<td>TAMPA BAY, FL</td>
<td>SAFETY ZONE</td>
<td>07/26/2000</td>
</tr>
<tr>
<td>TAMPA 00–093</td>
<td>TAMPA BAY, FL</td>
<td>SAFETY ZONE</td>
<td>09/16/2000</td>
</tr>
</tbody>
</table>

### District Quarterly Report

<table>
<thead>
<tr>
<th>District docket</th>
<th>Location</th>
<th>Type</th>
<th>Effective date</th>
</tr>
</thead>
<tbody>
<tr>
<td>01–00–149</td>
<td>FIREWORKS DISPLAY, LARCHMONT HARBOR, NY</td>
<td>SAFETY ZONE</td>
<td>07/07/2000</td>
</tr>
<tr>
<td>01–00–151</td>
<td>WESTHAVEN, CT</td>
<td>SAFETY ZONE</td>
<td>07/03/2000</td>
</tr>
<tr>
<td>01–00–153</td>
<td>HARTFORD, CT</td>
<td>SAFETY ZONE</td>
<td>07/01/2000</td>
</tr>
<tr>
<td>01–00–156</td>
<td>LYNN, MA</td>
<td>SAFETY ZONE</td>
<td>07/01/2000</td>
</tr>
<tr>
<td>01–00–230</td>
<td>DUXBURY, MA</td>
<td>SAFETY ZONE</td>
<td>07/02/2000</td>
</tr>
<tr>
<td>01–00–161</td>
<td>KINGSTON FIREWORKS, RONDOUT CREEK, NY</td>
<td>SAFETY ZONE</td>
<td>07/02/2000</td>
</tr>
<tr>
<td>01–00–162</td>
<td>ROCKAWAY INLET, NY</td>
<td>SAFETY ZONE</td>
<td>07/02/2000</td>
</tr>
<tr>
<td>01–00–164</td>
<td>MADISON, CT</td>
<td>SAFETY ZONE</td>
<td>07/02/2000</td>
</tr>
<tr>
<td>01–00–165</td>
<td>NEW HAVEN, CT</td>
<td>SAFETY ZONE</td>
<td>07/04/2000</td>
</tr>
<tr>
<td>01–00–168</td>
<td>FENWICH PIER, OLD SAYBROOK, CT</td>
<td>SAFETY ZONE</td>
<td>07/01/2000</td>
</tr>
<tr>
<td>01–00–171</td>
<td>GREENWICH, CT</td>
<td>SAFETY ZONE</td>
<td>07/02/2000</td>
</tr>
<tr>
<td>01–00–172</td>
<td>BAYLEY BEACH, ROWAYTON, CT</td>
<td>SAFETY ZONE</td>
<td>07/02/2000</td>
</tr>
<tr>
<td>01–00–175</td>
<td>FIRE ISLAND PINES, NY</td>
<td>SAFETY ZONE</td>
<td>07/01/2000</td>
</tr>
<tr>
<td>01–00–176</td>
<td>COLD SPRING HARBOR, COVE NECK, NY</td>
<td>SAFETY ZONE</td>
<td>07/04/2000</td>
</tr>
<tr>
<td>01–00–178</td>
<td>SUNKEN VESSEL JESSICA ANN, CAPE ELIZABETH, ME</td>
<td>SAFETY ZONE</td>
<td>07/01/2000</td>
</tr>
<tr>
<td>01–00–179</td>
<td>NICOLL BAY, SAYVILLE, NY</td>
<td>SAFETY ZONE</td>
<td>07/22/2000</td>
</tr>
<tr>
<td>01–00–180</td>
<td>BATH IRON WORKS, KENNEBEC RIVER, BATH, ME</td>
<td>SAFETY ZONE</td>
<td>07/02/2000</td>
</tr>
<tr>
<td>01–00–197</td>
<td>SALEM, MA</td>
<td>SAFETY ZONE</td>
<td>08/19/2000</td>
</tr>
<tr>
<td>01–00–198</td>
<td>NEWBURYPORT, MA</td>
<td>SAFETY ZONE</td>
<td>08/05/2000</td>
</tr>
<tr>
<td>01–00–199</td>
<td>GLOUCESTER, MA</td>
<td>SAFETY ZONE</td>
<td>08/05/2000</td>
</tr>
<tr>
<td>01–00–200</td>
<td>TAUNTON RIVER, FALL RIVER, MA</td>
<td>SAFETY ZONE</td>
<td>08/12/2000</td>
</tr>
<tr>
<td>01–00–202</td>
<td>BEVERLY, MA</td>
<td>SAFETY ZONE</td>
<td>08/06/2000</td>
</tr>
<tr>
<td>01–00–207</td>
<td>NEWPORT, RI</td>
<td>SAFETY ZONE</td>
<td>08/19/2000</td>
</tr>
<tr>
<td>01–00–210</td>
<td>BEVERLY, MA</td>
<td>SAFETY ZONE</td>
<td>09/02/2000</td>
</tr>
<tr>
<td>01–00–211</td>
<td>GLOUCESTER, MA</td>
<td>SAFETY ZONE</td>
<td>09/02/2000</td>
</tr>
<tr>
<td>01–00–212</td>
<td>BOSTON, MA</td>
<td>SAFETY ZONE</td>
<td>09/03/2000</td>
</tr>
<tr>
<td>01–00–219</td>
<td>VIKING SHIP SAIL 2000, NEW HAVEN, CT</td>
<td>SAFETY ZONE</td>
<td>09/28/2000</td>
</tr>
<tr>
<td>01–00–226</td>
<td>BOSTON, MA</td>
<td>SECURITY ZONE</td>
<td>09/28/2000</td>
</tr>
<tr>
<td>01–00–230</td>
<td>OIL SPILL RECOVERY, LOWER NEW YORK</td>
<td>SAFETY ZONE</td>
<td>09/15/2000</td>
</tr>
<tr>
<td>01–00–250</td>
<td>MIDDLETOWN, RI</td>
<td>SAFETY ZONE</td>
<td>07/07/2000</td>
</tr>
<tr>
<td>05–00–025</td>
<td>PATAPSCO RIVER, BALTIMORE MD</td>
<td>SAFETY ZONE</td>
<td>05/05/2000</td>
</tr>
<tr>
<td>05–00–026</td>
<td>CHESTER RIVER, KENT ISLAND NARROWS, MD</td>
<td>SPECIAL LOCAL</td>
<td>07/02/2000</td>
</tr>
<tr>
<td>05–00–029</td>
<td>DELAWARE RIVER, PHILADELPHIA, PA</td>
<td>SAFETY ZONE</td>
<td>07/30/2000</td>
</tr>
<tr>
<td>05–00–034</td>
<td>DELAWARE RIVER, PHILADELPHIA, PA</td>
<td>SAFETY ZONE</td>
<td>07/27/2000</td>
</tr>
<tr>
<td>05–00–037</td>
<td>DELAWARE RIVER, PHILADELPHIA, PA AND CAMDEN</td>
<td>SAFETY ZONE</td>
<td>08/15/2000</td>
</tr>
<tr>
<td>05–00–040</td>
<td>CHESTER RIVER, KENT ISLAND NARROWS, MD</td>
<td>SPECIAL LOCAL</td>
<td>09/03/2000</td>
</tr>
<tr>
<td>07–00–057</td>
<td>NEW HALLANDALE BEACH BLVD. (SR824 BRIDGE)</td>
<td>DRAWBRIDGE</td>
<td>07/13/2000</td>
</tr>
<tr>
<td>07–00–063</td>
<td>HILSSBORO BOULEVARD BRIDGE, M 1050</td>
<td>DRAWBRIDGE</td>
<td>07/16/2000</td>
</tr>
<tr>
<td>09–00–041</td>
<td>GILLS ROCK, WI</td>
<td>SAFETY ZONE</td>
<td>07/04/2000</td>
</tr>
<tr>
<td>09–00–042</td>
<td>KEWAUNEE, WI</td>
<td>SAFETY ZONE</td>
<td>07/14/2000</td>
</tr>
</tbody>
</table>
## DISTRICT QUARTERLY REPORT—Continued

<table>
<thead>
<tr>
<th>District docket</th>
<th>Location</th>
<th>Type</th>
<th>Effective date</th>
</tr>
</thead>
<tbody>
<tr>
<td>09-00-047</td>
<td>LAKE MICHIGAN, CHICAGO, IL</td>
<td>SAFETY ZONE</td>
<td>07/03/2000</td>
</tr>
<tr>
<td>09-00-048</td>
<td>LAKE KALAMAZOO, SAUGATUCK, MI</td>
<td>SAFETY ZONE</td>
<td>07/04/2000</td>
</tr>
<tr>
<td>09-00-049</td>
<td>LAKE MICHIGAN, PENTWATER, MI</td>
<td>SAFETY ZONE</td>
<td>07/03/2000</td>
</tr>
<tr>
<td>09-00-051</td>
<td>LAKE MICHIGAN, FRANKFORT, MI</td>
<td>SAFETY ZONE</td>
<td>07/04/2000</td>
</tr>
<tr>
<td>09-00-052</td>
<td>WHITE LAKE WHITE HALL, MI</td>
<td>SAFETY ZONE</td>
<td>07/04/2000</td>
</tr>
<tr>
<td>09-00-053</td>
<td>MILWAUKEE, WI</td>
<td>SAFETY ZONE</td>
<td>07/03/2000</td>
</tr>
<tr>
<td>09-00-054</td>
<td>LAKE ERIE, PUT-IN-BAY, OHIO</td>
<td>SAFETY ZONE</td>
<td>07/04/2000</td>
</tr>
<tr>
<td>09-00-056</td>
<td>LAKE MICHIGAN, MANISTEE, MI</td>
<td>SAFETY ZONE</td>
<td>07/03/2000</td>
</tr>
<tr>
<td>09-00-057</td>
<td>FOX RIVER, GREEN BAY, WI</td>
<td>SAFETY ZONE</td>
<td>07/04/2000</td>
</tr>
<tr>
<td>09-00-058</td>
<td>MILWAUKEE, WI</td>
<td>SAFETY ZONE</td>
<td>07/04/2000</td>
</tr>
<tr>
<td>09-00-059</td>
<td>KENOSHA, WI</td>
<td>SAFETY ZONE</td>
<td>07/04/2000</td>
</tr>
<tr>
<td>09-00-061</td>
<td>LAKE MICHIGAN, KENILWORTH, IL</td>
<td>SAFETY ZONE</td>
<td>07/04/2000</td>
</tr>
<tr>
<td>09-00-062</td>
<td>LAKE MICHIGAN, MICHIGAN CITY, IN</td>
<td>SAFETY ZONE</td>
<td>07/09/2000</td>
</tr>
<tr>
<td>09-00-063</td>
<td>WASHINGTON PARK, MICHIGAN CITY, MI</td>
<td>SAFETY ZONE</td>
<td>07/09/2000</td>
</tr>
<tr>
<td>09-00-064</td>
<td>MILWAUKEE, WI</td>
<td>SAFETY ZONE</td>
<td>07/20/2000</td>
</tr>
<tr>
<td>09-00-066</td>
<td>BAYVIEW, WI</td>
<td>SAFETY ZONE</td>
<td>07/14/2000</td>
</tr>
<tr>
<td>09-00-067</td>
<td>PORT WASHINGTON, WI</td>
<td>SAFETY ZONE</td>
<td>07/15/2000</td>
</tr>
<tr>
<td>09-00-068</td>
<td>SHEDD AQUARIUM, CHICAGO, IL</td>
<td>SAFETY ZONE</td>
<td>07/16/2000</td>
</tr>
<tr>
<td>09-00-069</td>
<td>LAKE MICHIGAN, ST. JOSEPH, MI</td>
<td>SAFETY ZONE</td>
<td>07/15/2000</td>
</tr>
<tr>
<td>09-00-070</td>
<td>MILWAUKEE, WI</td>
<td>SAFETY ZONE</td>
<td>07/28/2000</td>
</tr>
<tr>
<td>09-00-071</td>
<td>LAKE MICHIGAN, CHICAGO, IL</td>
<td>SAFETY ZONE</td>
<td>07/29/2000</td>
</tr>
<tr>
<td>09-00-072</td>
<td>LAKE OKAMAZOE, SAUGATUCK, MI</td>
<td>SAFETY ZONE</td>
<td>07/29/2000</td>
</tr>
<tr>
<td>09-00-073</td>
<td>LAKE MICHIGAN, FERRYSBURG, MI</td>
<td>SAFETY ZONE</td>
<td>07/22/2000</td>
</tr>
<tr>
<td>09-00-074</td>
<td>LAKE MICHIGAN, CHICAGO, IL</td>
<td>SAFETY ZONE</td>
<td>07/22/2000</td>
</tr>
<tr>
<td>09-00-076</td>
<td>MILWAUKEE, WI</td>
<td>SAFETY ZONE</td>
<td>08/16/2000</td>
</tr>
<tr>
<td>09-00-077</td>
<td>MILWAUKEE, WI</td>
<td>SAFETY ZONE</td>
<td>08/18/2000</td>
</tr>
<tr>
<td>09-00-078</td>
<td>MILWAUKEE, WI</td>
<td>SAFETY ZONE</td>
<td>08/25/2000</td>
</tr>
<tr>
<td>09-00-081</td>
<td>CLEVELAND HARBOR, CLEVELAND, OH</td>
<td>SAFETY ZONE</td>
<td>07/30/2000</td>
</tr>
<tr>
<td>09-00-082</td>
<td>NEW BUFFALO, MI</td>
<td>SAFETY ZONE</td>
<td>08/05/2000</td>
</tr>
<tr>
<td>09-00-084</td>
<td>LAKE MICHIGAN, PENTWATER, MI</td>
<td>SAFETY ZONE</td>
<td>08/10/2000</td>
</tr>
<tr>
<td>09-00-085</td>
<td>HAMMOOD, IN</td>
<td>SAFETY ZONE</td>
<td>08/05/2000</td>
</tr>
<tr>
<td>09-00-086</td>
<td>GRAND HAVEN, MI</td>
<td>SAFETY ZONE</td>
<td>08/31/2000</td>
</tr>
<tr>
<td>09-00-088</td>
<td>GRAND HAVEN, MI</td>
<td>SAFETY ZONE</td>
<td>08/24/2000</td>
</tr>
<tr>
<td>09-00-089</td>
<td>ALGOMA, WI</td>
<td>SAFETY ZONE</td>
<td>08/31/2000</td>
</tr>
<tr>
<td>09-00-090</td>
<td>OSHIKOSHI, WI</td>
<td>SAFETY ZONE</td>
<td>09/02/2000</td>
</tr>
<tr>
<td>09-00-092</td>
<td>MILWAUKEE, WI</td>
<td>SAFETY ZONE</td>
<td>09/08/2000</td>
</tr>
<tr>
<td>09-00-096</td>
<td>MUSKEGON LAKE MUSKEGON, MI</td>
<td>SAFETY ZONE</td>
<td>08/18/2000</td>
</tr>
<tr>
<td>09-00-097</td>
<td>CHICAGO, IL</td>
<td>SAFETY ZONE</td>
<td>08/31/2000</td>
</tr>
<tr>
<td>09-00-098</td>
<td>NAVY PIER, LAKE MICHIGAN, CHICAGO HARBOUR, IL</td>
<td>SAFETY ZONE</td>
<td>08/31/2000</td>
</tr>
<tr>
<td>09-00-102</td>
<td>NAVY PIER, LAKE MICHIGAN, CHICAGO HARBOUR, IL</td>
<td>SAFETY ZONE</td>
<td>09/08/2000</td>
</tr>
<tr>
<td>09-00-103</td>
<td>CHICAGO, IL</td>
<td>SAFETY ZONE</td>
<td>09/14/2000</td>
</tr>
<tr>
<td>09-00-104</td>
<td>AIR AND WATER SHOW, GARY, IN</td>
<td>SAFETY ZONE</td>
<td>09/16/2000</td>
</tr>
<tr>
<td>09-00-105</td>
<td>CHICAGO, IL</td>
<td>SAFETY ZONE</td>
<td>09/16/2000</td>
</tr>
<tr>
<td>09-00-107</td>
<td>MILWAUKEE, WI</td>
<td>SAFETY ZONE</td>
<td>09/15/2000</td>
</tr>
<tr>
<td>09-00-109</td>
<td>MILWAUKEE, WI</td>
<td>SAFETY ZONE</td>
<td>09/19/2000</td>
</tr>
<tr>
<td>09-00-111</td>
<td>GRAYS HARBOR, WESTPORT, WA</td>
<td>SAFETY ZONE</td>
<td>07/04/2000</td>
</tr>
<tr>
<td>13-00-011</td>
<td>COLUMBIA RIVER, VANCOUVER, WA</td>
<td>SAFETY ZONE</td>
<td>07/04/2000</td>
</tr>
<tr>
<td>13-00-012</td>
<td>COLUMBIA RIVER, ST. HELENS, OR</td>
<td>SAFETY ZONE</td>
<td>07/04/2000</td>
</tr>
<tr>
<td>13-00-013</td>
<td>WILLAMETTE RIVER, PORTLAND, OR</td>
<td>SAFETY ZONE</td>
<td>07/04/2000</td>
</tr>
<tr>
<td>13-00-014</td>
<td>COLUMBIA RIVER, KENNEWICK, WA</td>
<td>SAFETY ZONE</td>
<td>07/04/2000</td>
</tr>
<tr>
<td>13-00-015</td>
<td>COLUMBIA RIVER, CASCADE LOCKS, OR</td>
<td>SAFETY ZONE</td>
<td>07/04/2000</td>
</tr>
<tr>
<td>13-00-017</td>
<td>COLUMBIA RIVER, ARLINGTON, OR</td>
<td>SAFETY ZONE</td>
<td>07/03/2000</td>
</tr>
<tr>
<td>13-00-018</td>
<td>CHEHALIS RIVER ABERDEEN, WA</td>
<td>SAFETY ZONE</td>
<td>07/04/2000</td>
</tr>
<tr>
<td>13-00-019</td>
<td>COLUMBIA RIVER, HOOD RIVER, OR</td>
<td>SAFETY ZONE</td>
<td>07/04/2000</td>
</tr>
<tr>
<td>13-00-020</td>
<td>COLUMBIA RIVER, GRESHAM, OR</td>
<td>SAFETY ZONE</td>
<td>07/04/2000</td>
</tr>
<tr>
<td>13-00-021</td>
<td>WILLAMETTE RIVER, GLADSTONE, OR</td>
<td>SAFETY ZONE</td>
<td>07/04/2000</td>
</tr>
<tr>
<td>13-00-023</td>
<td>COLUMBIA RIVER, RAINIER, OR</td>
<td>SAFETY ZONE</td>
<td>07/08/2000</td>
</tr>
<tr>
<td>13-00-025</td>
<td>FREEDOM FAIR AIRSHOW, COMMENCEMENT BAY, WA</td>
<td>SAFETY ZONE</td>
<td>07/04/2000</td>
</tr>
<tr>
<td>13-00-026</td>
<td>CLEFT OF SEATTLE, SEATTLE, WA</td>
<td>SECURITY ZONE</td>
<td>08/02/2000</td>
</tr>
<tr>
<td>13-00-027</td>
<td>LAKE WASHINGTON, WA</td>
<td>SAFETY ZONE</td>
<td>07/20/2000</td>
</tr>
<tr>
<td>13-00-033</td>
<td>COMMENCEMENT BAY, TACOMA, WA</td>
<td>SAFETY ZONE</td>
<td>09/17/2000</td>
</tr>
</tbody>
</table>

## REGULATIONS NOT ON APR–JUN 00 QUARTERLY REPORT

<table>
<thead>
<tr>
<th>District/COTP</th>
<th>Location</th>
<th>Type</th>
<th>Effective date</th>
</tr>
</thead>
<tbody>
<tr>
<td>09-00-016</td>
<td>MILWAUKEE, WI</td>
<td>SAFETY ZONE</td>
<td>06/02/00</td>
</tr>
<tr>
<td>09-00-018</td>
<td>MILWAUKEE, WI</td>
<td>SAFETY ZONE</td>
<td>05/30/00</td>
</tr>
<tr>
<td>09-00-019</td>
<td>MILWAUKEE, WI</td>
<td>SAFETY ZONE</td>
<td>06/10/00</td>
</tr>
<tr>
<td>09-00-040</td>
<td>KEWAUNEE, WI</td>
<td>SAFETY ZONE</td>
<td>06/24/00</td>
</tr>
</tbody>
</table>
DEPARTMENT OF TRANSPORTATION

Coast Guard

33 CFR Part 117

[CGD08–00–032]

Supplementary Information: The LA 77 bridge across the Lower Grand River, mile 47.0 (Alternate Route) at Grosse Tete, Iberville Parish, Louisiana, has a vertical clearance of 2 feet above high water in the closed-to-navigation position and unlimited clearance in the open-to-navigation position. Navigation on the waterway consists mainly of tows with barges and some recreational craft. The Louisiana Department of Transportation and Development requested a temporary deviation from the normal operation of the bridge in order to accommodate the final repairs to the bridge caused by an allision in June of 2000.

This deviation allows the draw of the LA 77 pontoon drawbridge across the Lower Grand River, mile 47.0 (Alternate Route) at Grosse Tete, Iberville Parish, Louisiana, to remain in the closed-to-navigation position from 6 a.m. until 11 a.m. and from 1 p.m. to 6 p.m., Monday through Friday, from January 8, 2001 until January 26, 2001. Presently, the draw of the LA 77 bridge, mile 47.0 (Alternate Route) at Grosse Tete, shall open on signal at any time for an emergency aboard a vessel.


Paul J. Pluta,
U.S. Coast Guard, Commander, Eighth Coast Guard District.

ACTION: Final rule.

SUMMARY: The Coast Guard is creating a new anchorage area on the eastern side of the Sabine Pass Safety Fairway, opposite the Sabine Bank Offshore (North) Anchorage area in the Gulf of Mexico south of Sabine Pass. This will help alleviate the need for in-bound deep draft vessels to cross the Sabine Pass Safety Fairway and navigate around a charted shallow area just to the southeast of the North anchorage. This rule allows deep draft vessels to enter and depart Sabine Bank anchorages on a safer, lower risk course.

DATES: This final rule is effective January 29, 2001.

ADDRESSES: Comments and material received from the public, as well as documents mentioned in this preamble as being available in the docket, are part of docket CGD 08–00–012 and are available for inspection or copying at the Coast Guard Marine Safety Office, Federal Building, 2875 Jimmy Johnson Blvd., Port Arthur, TX 77640–2099 between 8 a.m. and 4 p.m., Monday through Friday, except Federal holidays.

FOR FURTHER INFORMATION CONTACT: If you have questions on this rule or on viewing the docket, call Lieutenant Lamont Bazemore, Waterways Management, Coast Guard Marine Safety Office Port Arthur, telephone 409–723–6509 ext. 243.

SUPPLEMENTARY INFORMATION:

Regulatory History

On June 21, 2000, we published a notice of proposed rulemaking entitled “Anchorage Regulation; Sabine Pass, TX, Gulf of Mexico” in the Federal Register (65 FR 38474). We received no letters commenting on the proposed rule. No public hearing was requested and none was held. For the Semi-Annual Agenda, we changed the RIN and title of this rule to “Shipping Safety Fairways and Anchorage Areas, Gulf of Mexico, 2115–AG02”, to correctly reflect the CFR part that we are affecting.

Background and Purpose

In 1997, the in-bound tank vessel CROSBY ran aground just outside the
Sabine Bank Offshore (North) Anchorage area located in the Gulf of Mexico, approximately 13 miles south of Sabine Pass, TX. This vessel was carrying over 650,000 barrels of crude oil. Although no oil was spilled, the result could have been disastrous.

The subsequent investigation revealed that the vessel’s master crossed the safety fairway and attempted to navigate into the North anchorage. However, a strong westerly current pushed the CROSBY toward the shallow area southeast of the anchorage area. The master was unable to maneuver away from the shallows and the vessel grounded. Four tugboats took 15 hours to refloat the CROSBY.

In-bound petroleum laden deep draft vessels invariably have a need to anchor and wait for daylight transit. The new anchorage east of the Sabine Bank Offshore (North) Anchorage eliminates the need for these vessels to cross the safety fairway and navigate the surrounding shallow areas to reach anchorage. The new anchorage is also free of shallow areas immediately surrounding it. This significantly reduces navigational risks to in-bound deep draft vessels.

Discussion of Comments and Changes

No comments were received regarding the notice of proposed rulemaking and no changes were made.

Regulatory Evaluation

This rule is not a “significant regulatory action” under section 3(f) of Executive Order 12866, Regulatory Planning and Review, and does not require an assessment of potential costs and benefits under section 6(a)(3) of that Order. The Office of Management and Budget has not reviewed it under that Order. It is not “significant” under the regulatory policies and procedures of the Department of Transportation (DOT) (44 FR 11040, February 26, 1979). We expect the economic impact of this rule to be so minimal that a full Regulatory Evaluation under paragraph 10e of the regulatory policies and procedures of DOT is unnecessary.

There are no fees, permits, or specialized requirements for the maritime industry to utilize this anchorage area. Use of the Sabine Bank Offshore (East) Anchorage Area is voluntary. This regulation is solely for the purpose of advancing safety of maritime commerce.

Small Entities

Under the Regulatory Flexibility Act (5 U.S.C. 601–612), we considered whether this rule would have a significant economic impact on a substantial number of small entities. The term “small entities” comprises small businesses, not-for-profit organizations that are independently owned and operated and are not dominant in their fields, and governmental jurisdictions with populations of less than 50,000.

Since there are no fees, permits, or specialized requirements for the maritime industry to utilize this anchorage, and the use of the anchorage is voluntary, the Coast Guard certifies under 5 U.S.C. 605(b) that this final rule will not have a significant economic impact on a substantial number of small entities.

Assistance for Small Entities

Under section 213(a) of the Small Business Regulatory Enforcement Fairness Act of 1996 (Public Law 104–121), we offered to assist small entities in understanding the rule so that they could better evaluate its effects on them and participate in the rulemaking. No assistance was requested or provided.

Collection of Information

This rule calls for no new collection of information under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501–3520).

Federalism

We have analyzed this rule under Executive Order 13132, Federalism, and have determined that it does not have implications for federalism under that Order.

Unfunded Mandates Reform Act

The Unfunded Mandates Reform Act of 1995 (2 U.S.C. 1531–1538) requires Federal agencies to assess the effects of their regulatory actions not specifically required by law. In particular, the Act addresses actions that may result in the expenditure by a State, local, or tribal government, in the aggregate, or by the private sector of $100,000,000 or more in any one year. Though this rule will not result in such an expenditure, we do discuss the effects of this rule elsewhere in this preamble.

Taking of Private Property

This rule will not effect a taking of private property or otherwise have taking implications under Executive Order 12630, Governmental Actions and Interference with Constitutionally Protected Property Rights.

Civil Justice Reform

This rule meets applicable standards in sections 3(a) and 3(b)(2) of Executive Order 12988, Civil Justice Reform, to minimize litigation, eliminate ambiguity, and reduce burden.

Protection of Children

We have analyzed this rule under Executive Order 13045, Protection of Children from Environmental Health Risks and Safety Risks. This rule is not an economically significant rule and does not concern an environmental risk to health or risk to safety that may disproportionately affect children.

Environment

We considered the environmental impact of this rule and concluded that, under figure 2–1, paragraph (34)(f), of Commandant Instruction M16475.1C, this rule is categorically excluded from further environmental documentation. Implementation of this action will not result in any—

• Significant cumulative impacts on the human environment;
• Substantial controversy or substantial change to existing environmental conditions;
• Impacts which are more than minimal on properties protected under 4(f) of the DOT Act as superceded by Public Law 97–449, and Section 106 of the National Historic Preservation Act; and
• Inconsistencies with any Federal, State, or local laws or administrative determinations relating to the environment.

A “Categorical Exclusion Determination” is available in the docket where indicated under ADDRESSES.

List of Subjects in 33 CFR Part 166

Anchorage grounds, Marine Safety, Navigation (water), Waterways.

For the reasons discussed in the preamble, the Coast Guard amends 33 CFR part 166 as follows:

PART 166—SHIPPING SAFETY FAIRWAYS

1. The authority citation for part 166 continues to read as follows:

Authority: 33 U.S.C. 1223; 49 CFR 1.46.

2. In §166.200, add paragraph (d)(13)(iv) to read as follows:

§166.200 Shipping safety fairways and anchorage areas, Gulf of Mexico.

* * * * *

(d) * * *

(13) * * *

(iv) Sabine Bank Offshore (East) Anchorage Area. The area enclosed by rhumb lines joining points at:

<table>
<thead>
<tr>
<th>Latitude</th>
<th>Longitude</th>
</tr>
</thead>
<tbody>
<tr>
<td>29°26′06″ N</td>
<td>93°38′52″ W</td>
</tr>
</tbody>
</table>
POSTAL SERVICE

39 CFR Part 20

Global Express Guaranteed: Changes in Postal Rates

AGENCY: Postal Service.

ACTION: Amendment to interim rule.

SUMMARY: On December 11, 2000, a Federal Register notice (65 FR 77302) was published with correct new rates but erroneously omitted the revised country group listing. In addition, the rate groups were listed with an alpha-character designation, when in fact the rate groups have numeric designations. This amendment publishes the rate charts and the revised country group listing.

EFFECTIVE DATE: The effective date is concurrent with the effective date for the new domestic rates, January 7, 2001. Comments on the amendment to the interim rule must be received on or before January 6, 2001.

ADDRESSES: Written comments should be mailed or delivered to Business

<table>
<thead>
<tr>
<th>Country</th>
<th>Document service rate group</th>
<th>Non-document service rate group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Afghanistan</td>
<td>No Service</td>
<td>No Service</td>
</tr>
<tr>
<td>Albania</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Algeria</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Andorra</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>Angola</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Anguilla</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Antigua &amp; Barbuda</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Argentina</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Armenia</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Aruba</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Ascension</td>
<td>No Service</td>
<td>No Service</td>
</tr>
<tr>
<td>Australia</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Austria</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>Azerbaijan</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Bahamas</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Bahrain</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>Bangladesh</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>Barbados</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Belarus</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Belgium</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Belize</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Benin</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Country</td>
<td>Document service rate group</td>
<td>Non-document service group</td>
</tr>
<tr>
<td>--------------------------------------</td>
<td>-----------------------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td>Bermuda</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Bhutan</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Bolivia</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Bosnia-Herzegovina</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Botswana</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Brazil</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>British Virgin Islands</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Brunei Darussalam</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Bulgaria</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Burkina Faso</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Burma (Myanmar)</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Burundi</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Cambodia</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Cameroon</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Canada</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Cape Verde</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Cayman Islands</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Central African Republic</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Chad</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Chile</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>China</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Colombia</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Comoros</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Congo, Democratic Republic of the</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Congo, Republic of the (Brazzaville)</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Costa Rica</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Cote d’Ivoire (Ivory Coast)</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Croatia</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Cuba</td>
<td>8</td>
<td>No Service</td>
</tr>
<tr>
<td>Cyprus</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>Czech Republic</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Denmark</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Djibouti</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Dominica</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Dominican Republic</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Ecuador</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Egypt</td>
<td>7</td>
<td>No Service</td>
</tr>
<tr>
<td>El Salvador</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Equatorial Guinea</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Eritrea</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Estonia</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Ethiopia</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Falkland Islands</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Faroe Islands</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>Fiji</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Finland</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>France</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>French Guiana</td>
<td>5</td>
<td>No Service</td>
</tr>
<tr>
<td>French Polynesia</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Gabon</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Gambia</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Georgia, Republic of</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Germany</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Ghana</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Gibraltar</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>Great Britain &amp; Northern Ireland</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Greece</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>Greenland</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>Grenada</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Guadeloupe</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Guatemala</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Guinea</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Guinea-Bissau</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Guyana</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Haiti</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Honduras</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Hong Kong</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Hungary</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Iceland</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>India</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>Indonesia</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Country</td>
<td>Document service rate</td>
<td>Non-document service rate</td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>-----------------------</td>
<td>---------------------------</td>
</tr>
<tr>
<td>Iran</td>
<td>7</td>
<td>No Service</td>
</tr>
<tr>
<td>Iraq</td>
<td>3</td>
<td>No Service</td>
</tr>
<tr>
<td>Ireland (Eire)</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>Israel</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>Italy</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Jamaica</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Japan</td>
<td>No Service</td>
<td>No Service</td>
</tr>
<tr>
<td>Jordan</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>Kazakhstan</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Kenya</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Kiribati</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Korea, Democratic People’s Rep. of (North)</td>
<td>No Service</td>
<td>No Service</td>
</tr>
<tr>
<td>Korea, Republic of (South)</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Kuwait</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>Kyrgyzstan</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Laos</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Latvia</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Lebanon</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>Lesotho</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Liberia</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Libya</td>
<td>No Service</td>
<td>No Service</td>
</tr>
<tr>
<td>Liechtenstein</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>Lithuania</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Luxembourg</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Macao</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Macedonia, Republic of</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Madagascar</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Malawi</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Malaysia</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Maldives</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Mali</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Malta</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>Martinique</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Mauritania</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Mauritius</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Mexico</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Moldova</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Mongolia</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Montserrat</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Morocco</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Mozambique</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Namibia</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Nauru</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Nepal</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Netherlands</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Netherlands Antilles</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>New Caledonia</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>New Zealand</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Nicaragua</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Niger</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Nigeria</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Norway</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>Oman</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>Pakistan</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>Panama</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Papua New Guinea</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Paraguay</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Peru</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Philippines</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Pitcairn Island</td>
<td>No Service</td>
<td>No Service</td>
</tr>
<tr>
<td>Poland</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Portugal</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>Qatar</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>Reunion</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Romania</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Russia</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Rwanda</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>St. Christopher (St. Kitts) &amp; Nevis</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Saint Helena</td>
<td>No Service</td>
<td>No Service</td>
</tr>
<tr>
<td>Saint Lucia</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Saint Pierre &amp; Miquelon</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Country</td>
<td>Document service rate group</td>
<td>Non-document service group</td>
</tr>
<tr>
<td>--------------------------------------------------------------</td>
<td>----------------------------</td>
<td>----------------------------</td>
</tr>
<tr>
<td>Saint Vincent &amp; Grenadines</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>San Marino</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Sao Tome &amp; Principe</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Saudi Arabia</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>Senegal</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Serbia-Montenegro (Yugoslavia)</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Seychelles</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Sierra Leone</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Singapore</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Slovak Republic (Slovakia)</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Slovenia</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Solomon Islands</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Somalia</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>South Africa</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Spain</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>Sri Lanka</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>Sudan</td>
<td>No Service</td>
<td>No Service</td>
</tr>
<tr>
<td>Suriname</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Swaziland</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>Sweden</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>Switzerland</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>Syrian Arab Republic (Syria)</td>
<td>7</td>
<td>No Service</td>
</tr>
<tr>
<td>Taiwan</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Tajikistan</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Tanzania</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Thailand</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Togo</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Tonga</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Trinidad &amp; Tobago</td>
<td>No Service</td>
<td>No Service</td>
</tr>
<tr>
<td>Tristan da Cunha</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Tunisia</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Turkey</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>Turkmenistan</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Turks &amp; Caicos Islands</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Tuvalu</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Uganda</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Ukraine</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>United Arab Emirates</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Uruguay</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>Uzbekistan</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Vanuatu</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Vatican City</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Venezuela</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Vietnam</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Wallis &amp; Futuna Islands</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Western Samoa</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Yemen</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>Zambia</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Zimbabwe</td>
<td>8</td>
<td>8</td>
</tr>
</tbody>
</table>

GXG service is available to all locations that are referenced in the Individual Country Listings except for the following:

Afghanistan
Ascension
Iraq
Japan
Korea, Democratic People’s Republic of (North)

Libya
Pitcairn Island
Saint Helena
Sudan
Tristan da Cunha

The following countries are limited to GXG Document service only:

Cuba
Egypt
French Guiana

Iran
Syrian Arab Republic (Syria)

* * * * *

216 Postage

216.1 Document Service Rates/Groups

BILLING CODE 7710-12-P
<table>
<thead>
<tr>
<th>Weight not over (lbs.)</th>
<th>Rate Group 1</th>
<th>Rate Group 2</th>
<th>Rate Group 3</th>
<th>Rate Group 4</th>
<th>Rate Group 5</th>
<th>Rate Group 6</th>
<th>Rate Group 7</th>
<th>Rate Group 8</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.5</td>
<td>$24.00</td>
<td>$25.00</td>
<td>$32.00</td>
<td>$32.00</td>
<td>$45.00</td>
<td>$33.00</td>
<td>$34.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>1</td>
<td>33.00</td>
<td>34.00</td>
<td>39.00</td>
<td>45.00</td>
<td>52.00</td>
<td>47.00</td>
<td>46.00</td>
<td>75.00</td>
</tr>
<tr>
<td>2</td>
<td>38.00</td>
<td>40.00</td>
<td>46.00</td>
<td>52.00</td>
<td>65.00</td>
<td>55.00</td>
<td>52.00</td>
<td>89.00</td>
</tr>
<tr>
<td>3</td>
<td>40.00</td>
<td>46.00</td>
<td>53.00</td>
<td>59.00</td>
<td>79.00</td>
<td>62.00</td>
<td>60.00</td>
<td>101.00</td>
</tr>
<tr>
<td>4</td>
<td>43.00</td>
<td>50.00</td>
<td>60.00</td>
<td>66.00</td>
<td>93.00</td>
<td>68.00</td>
<td>68.00</td>
<td>112.00</td>
</tr>
<tr>
<td>5</td>
<td>46.00</td>
<td>55.00</td>
<td>67.00</td>
<td>73.00</td>
<td>106.00</td>
<td>75.00</td>
<td>75.00</td>
<td>124.00</td>
</tr>
<tr>
<td>6</td>
<td>48.00</td>
<td>58.00</td>
<td>72.00</td>
<td>80.00</td>
<td>119.00</td>
<td>80.00</td>
<td>82.00</td>
<td>136.00</td>
</tr>
<tr>
<td>7</td>
<td>51.00</td>
<td>61.00</td>
<td>76.00</td>
<td>86.00</td>
<td>131.00</td>
<td>86.00</td>
<td>89.00</td>
<td>148.00</td>
</tr>
<tr>
<td>8</td>
<td>53.00</td>
<td>65.00</td>
<td>80.00</td>
<td>93.00</td>
<td>143.00</td>
<td>91.00</td>
<td>96.00</td>
<td>160.00</td>
</tr>
<tr>
<td>9</td>
<td>55.00</td>
<td>68.00</td>
<td>85.00</td>
<td>100.00</td>
<td>156.00</td>
<td>96.00</td>
<td>103.00</td>
<td>172.00</td>
</tr>
<tr>
<td>10</td>
<td>58.00</td>
<td>70.00</td>
<td>89.00</td>
<td>104.00</td>
<td>165.00</td>
<td>102.00</td>
<td>110.00</td>
<td>180.00</td>
</tr>
<tr>
<td>11</td>
<td>60.00</td>
<td>73.00</td>
<td>92.00</td>
<td>109.00</td>
<td>175.00</td>
<td>105.00</td>
<td>116.00</td>
<td>191.00</td>
</tr>
<tr>
<td>12</td>
<td>62.00</td>
<td>76.00</td>
<td>96.00</td>
<td>115.00</td>
<td>185.00</td>
<td>109.00</td>
<td>122.00</td>
<td>203.00</td>
</tr>
<tr>
<td>13</td>
<td>65.00</td>
<td>79.00</td>
<td>99.00</td>
<td>120.00</td>
<td>195.00</td>
<td>113.00</td>
<td>127.00</td>
<td>215.00</td>
</tr>
<tr>
<td>14</td>
<td>67.00</td>
<td>81.00</td>
<td>103.00</td>
<td>125.00</td>
<td>205.00</td>
<td>117.00</td>
<td>132.00</td>
<td>226.00</td>
</tr>
<tr>
<td>15</td>
<td>69.00</td>
<td>84.00</td>
<td>106.00</td>
<td>130.00</td>
<td>214.00</td>
<td>121.00</td>
<td>137.00</td>
<td>238.00</td>
</tr>
<tr>
<td>16</td>
<td>72.00</td>
<td>87.00</td>
<td>109.00</td>
<td>136.00</td>
<td>223.00</td>
<td>125.00</td>
<td>142.00</td>
<td>249.00</td>
</tr>
<tr>
<td>17</td>
<td>74.00</td>
<td>89.00</td>
<td>113.00</td>
<td>141.00</td>
<td>231.00</td>
<td>129.00</td>
<td>147.00</td>
<td>260.00</td>
</tr>
<tr>
<td>18</td>
<td>76.00</td>
<td>92.00</td>
<td>116.00</td>
<td>146.00</td>
<td>238.00</td>
<td>133.00</td>
<td>153.00</td>
<td>271.00</td>
</tr>
<tr>
<td>19</td>
<td>79.00</td>
<td>95.00</td>
<td>120.00</td>
<td>151.00</td>
<td>246.00</td>
<td>137.00</td>
<td>159.00</td>
<td>282.00</td>
</tr>
<tr>
<td>20</td>
<td>81.00</td>
<td>97.00</td>
<td>123.00</td>
<td>156.00</td>
<td>253.00</td>
<td>141.00</td>
<td>165.00</td>
<td>293.00</td>
</tr>
<tr>
<td>21</td>
<td>83.00</td>
<td>100.00</td>
<td>126.00</td>
<td>161.00</td>
<td>260.00</td>
<td>144.00</td>
<td>171.00</td>
<td>302.00</td>
</tr>
<tr>
<td>22</td>
<td>85.00</td>
<td>102.00</td>
<td>130.00</td>
<td>166.00</td>
<td>268.00</td>
<td>148.00</td>
<td>176.00</td>
<td>311.00</td>
</tr>
<tr>
<td>23</td>
<td>87.00</td>
<td>105.00</td>
<td>133.00</td>
<td>171.00</td>
<td>275.00</td>
<td>152.00</td>
<td>181.00</td>
<td>318.00</td>
</tr>
</tbody>
</table>
82284


VerDate 11<MAY>2000

19:22 Dec 27, 2000

Jkt 194001

PO 00000

Frm 00046

Fmt 4700

Sfmt 4725

E:\FR\FM\28DER1.SGM

pfrm10

PsN: 28DER1


ENvironmental Protection AGENCY

40 CFR Part 52

[Region 7 Tracking No. 113–1113a; FRL–6923–2]

Approval and Promulgation of Implementation Plans; State of Missouri

AGENCY: Environmental Protection Agency (EPA).

ACTION: Final rule.

SUMMARY: EPA is announcing final approval of a statewide NO\textsubscript{X} rule to reduce the emissions of nitrogen oxides (NO\textsubscript{X}) and establish a NO\textsubscript{X} emissions trading program for the state of Missouri. This rule is a critical element in the state’s plan to attain the ozone standard in the St. Louis ozone nonattainment area.

DATES: This rule is effective on January 29, 2001.

ADDRESSES: Copies of the state submittals are available at the following address for inspection during normal business hours: Environmental Protection Agency, Air Planning and Development Branch, 901 North 5th Street, Kansas City, Kansas 66101.

FOR FURTHER INFORMATION CONTACT: Kim Johnson at (913) 551–7975.

SUPPLEMENTARY INFORMATION:

Throughout this document whenever “we, us, or our” is used, we mean EPA. This section provides additional information by addressing the following questions:

What is a SIP?

What is the Federal approval process for a SIP?

What does Federal approval of a state regulation mean to me?

What is being addressed in this action?

Have the requirements for approval of a SIP revision been met?

What action is EPA taking?

What is a SIP?

Section 110 of the Clean Air Act (CAA) requires states to develop air pollution regulations and control strategies to ensure that state air quality meets the national ambient air quality standards established by EPA. These ambient standards are established under section 109 of the CAA, and they currently address six criteria pollutants. These pollutants are: carbon monoxide, nitrogen dioxide, ozone, lead, particulate matter, and sulfur dioxide.

Each state must submit these regulations and control strategies to EPA for approval and incorporation into the Federally enforceable SIP.

Each Federally approved SIP protects air quality primarily by addressing air pollution at its point of origin. These SIPs can be extensive, containing state regulations or other enforceable documents and supporting information such as emission inventories, monitoring networks, and modeling demonstrations.

What is the Federal Approval Process for a SIP

In order for state regulations to be incorporated into the Federally enforceable SIP...
enforceable SIP, states must formally adopt the regulations and control strategies consistent with state and Federal requirements. This process generally includes a public notice, public hearing, public comment period, and a formal adoption by a state-authorized rulemaking body.

Once a state rule, regulation, or control strategy is adopted, the state submits it to us for inclusion into the SIP. We must provide public notice and seek additional public comment regarding the proposed Federal action on the state submission. If adverse comments are received, they must be addressed prior to any final Federal action by us.

All state regulations and supporting information approved by EPA under section 110 of the CAA are incorporated into the Federally approved SIP. Records of such SIP actions are maintained in the Code of Federal Regulations (CFR) at Title 40, Part 52, entitled “Approval and Promulgation of Implementation Plans.” The actual state regulations which are approved are not reproduced in their entirety in the CFR but are “incorporated by reference,” which means that we have approved a given state regulation with a specific effective date.

What Does Federal Approval of a State Regulation Mean to Me?

Enforcement of the state regulation before and after it is incorporated into the Federally approved SIP is primarily a state responsibility. However, after the regulation is Federally approved, we are authorized to take enforcement action against violators. Citizens are also offered legal recourse to address violations as described in section 304 of the CAA.

What is Being Addressed in This Document?

We are taking final action to approve, as an amendment to Missouri’s SIP, rule 10 CSR 10–6.350, “Emissions Limitations and Emissions Trading of Oxides of Nitrogen,” submitted to us on November 15, 2000. The Missouri rule was adopted by the Missouri Air Conservation Commission on May 25, 2000, and submitted to EPA for parallel processing on June 29, 2000. The rule became effective under state law on August 30, 2000. The Missouri Air Conservation Commission on May 25, 2000, and submitted to EPA for parallel processing on June 29, 2000. The rule became effective under state law on August 30, 2000. The November 15, 2000, submittal included the adopted rule, the comments on the rule during the state’s adoption process, and the state’s response to comments, and other information necessary to meet EPA’s completeness criteria. For additional information on the completeness criteria and on parallel processing, the reader should refer to EPA’s August 24, 2000, proposal, 65 FR 51564, and to 40 CFR Part 51, Appendix V.

The rule requires reductions in NOX emissions by establishing NOX emissions limitations for large electric generating units (EGU) which includes any EGU with a nameplate capacity greater than 25 megawatts across the state, beginning May 1, 2003. EGUs located in the eastern third of the state are limited to an emission rate of 0.25 lbs. NOX per million British thermal units per hour (mmBtu/hr) of heat input during the control period. The EGUs located in the western two-thirds of the state are limited to the less stringent rate of 0.35 lbs. NOX mmBtu/hr of heat input during the control period. The control period begins on May 1 and ends on September 30 of the same calendar year, which is when ozone formation is most likely to occur at unhealthful levels.

This rule is a critical element in the state’s plan to attain the ozone standard in the St. Louis area. The state of Missouri has assessed the statewide impacts of NOX emissions and has imposed the reductions specified in this rule to demonstrate attainment of the ozone NAAQS in the St. Louis nonattainment area. The state of Missouri has assessed the statewide impacts of NOX emissions and has imposed the reductions specified in this rule to demonstrate attainment of the ozone standard in the St. Louis area.

As also explained in the proposal, our evaluation of the statewide NOX rule is not related to the obligations which Missouri may subsequently have under EPA’s regional NOX reduction rule (the NOX SIP call). That rule requires that certain states develop regional NOX controls to address contributions to downwind nonattainment of the ozone standard in the eastern portion of the country. In response to a recent judicial remand of the SIP call as it relates to Missouri, EPA intends to undertake rulemaking to establish regional NOX requirements for a portion of Missouri. When that rulemaking is completed, we anticipate that it will establish separate NOX reduction requirements to address contributions by Missouri sources to ozone nonattainment in other areas. The state would then be required to take subsequent action, pursuant to the NOX SIP call, to ensure NOX emissions address long-range transport, and we would then take separate rulemaking action on Missouri’s response to the NOX SIP call.

Have the Requirements for Approval of a SIP Revision Been Met?

The state submittal has met the public notice requirements for SIP submissions in accordance with 40 CFR 51.102. The submittal also satisfied the completeness criteria of 40 CFR Part 51, Appendix V. In addition, as explained above and in more detail in the technical support document which is part of this document, the revision meets the substantive SIP requirements of the CAA, including section 110 and implementing regulations.

What Action is EPA Taking?

We are taking final action to approve as an amendment to the Missouri SIP rule 10 CSR 10–6.350, “Emissions Limitations and Emissions Trading of Oxides of Nitrogen,” submitted to us on November 15, 2000. This rule is a critical element in the state’s plan to attain the ozone standard in the St. Louis ozone nonattainment area.

Administrative Requirements

Under Executive Order 12866 (58 FR 51735, October 4, 1993), this action is not a “significant regulatory action” and therefore is not subject to review by the Office of Management and Budget. This action merely approves state law as meeting Federal requirements and imposes no additional requirements beyond those imposed by state law. Accordingly, the Administrator certifies that this rule will not have a significant economic impact on a substantial number of small entities under the Regulatory Flexibility Act (5 U.S.C. 601
et seq.). Because this rule approves preexisting requirements under state law and does not impose any additional enforceable duty beyond that required by state law, it does not contain any unfunded mandate or significantly or uniquely affect small governments, as described in the Unfunded Mandates Reform Act of 1995 (Public Law 104–4). For the same reason, this rule also does not significantly or uniquely affect the communities of tribal governments, as specified by Executive Order 13084 (63 FR 27655, May 10, 1998). This rule will not have substantial direct effects on the states, on the relationship between the national government and the states, or on the distribution of power and responsibilities among the various levels of government, as specified in Executive Order 13132 (64 FR 43255, August 10, 1999), because it merely approves a state rule implementing a Federal standard, and does not alter the relationship or the distribution of power and responsibilities established in the CAA. This rule also is not subject to Executive Order 13045 (62 FR 19885, April 23, 1997), because it is not economically significant.

In reviewing SIP submissions, our role is to approve state choices, provided that they meet the criteria of the CAA. In this context, in the absence of a prior existing requirement for the state to use voluntary consensus standards (VCS), we have no authority to disapprove a SIP submission for failure to use VCS. It would thus be inconsistent with applicable law for EPA, when it reviews a SIP submission, to use VCS in place of a SIP submission that otherwise satisfies the provisions of the CAA. Thus, the requirements of section 12(d) of the National Technology Transfer and Advancement Act of 1995 (15 U.S.C. 272 note) do not apply. As required by section 3 of Executive Order 12988 (61 FR 4729, February 7, 1996), in issuing this rule, we have taken the necessary steps to eliminate drafting errors and ambiguity, minimize potential litigation, and provide a clear legal standard for affected conduct. EPA has complied with Executive Order 12630 (53 FR 8859, March 15, 1988) by examining the takings’’ implications of the rule in accordance with the “Attorney General’s Supplemental Guidelines for the Evaluation of Risk and Avoidance of Unanticipated Takings” issued under the Executive Order. This rule does not impose an information collection burden under the provisions of the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 et seq.).

The Congressional Review Act, 5 U.S.C. 801 et seq., as added by the Small Business Regulatory Enforcement Fairness Act of 1996, generally provides that before a rule may take effect, the agency promulgating the rule must submit a rule report, which includes a copy of the rule, to each House of the Congress and to the Comptroller General of the United States. We will submit a report containing this rule and other required information to the United States Senate, the United States House of Representatives, and the Comptroller General of the United States prior to publication of the rule in the Federal Register. A major rule cannot take effect until 60 days after it is published in the Federal Register. This action is not a “major rule” as defined by 5 U.S.C. 804(2).

Under section 307(b)(1) of the CAA, petitions for judicial review of this action must be filed in the United States Court of Appeals for the appropriate circuit by February 26, 2001. Filing a petition for reconsideration by the Administrator of this final rule does not affect the finality of this rule for the purposes of judicial review nor does it extend the time within which a petition for judicial review may be filed, and shall not postpone the effectiveness of such rule or action. This action may not be challenged later in proceedings to enforce its requirements. (See section 307(b)(2).

List of Subjects 40 CFR Part 52

Environmental protection, Air pollution control, Carbon monoxide, Hydrocarbons, Incorporation by reference, Intergovernmental relations, Lead, Nitrogen dioxide, Ozone, Particulate matter, Reporting and recordkeeping requirements, Sulfur oxides.


Thomas F. Hogan,
Acting Regional Administrator, Region 7.
Chapter I, title 40 of the Code of Federal Regulations is amended as follows:

PART 52—[AMENDED]

1. The authority citation for part 52 continues to read as follows:

Authority: 42 U.S.C. 7401 et seq.

Subpart AA—Missouri

2. Section 52.1320 is amended:

a. In the table to paragraph (c) by adding in numerical order an entry “10–6.350”; and

b. In the table to paragraph (e) by adding to the end of that table a new entry.

The additions read as follows:

EPA-APPROVED MISSOURI REGULATIONS

<table>
<thead>
<tr>
<th>Missouri citation</th>
<th>Title</th>
<th>State effective date</th>
<th>EPA approval date</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chapter 6—Air Quality Standards, Definitions, Sampling and Reference Methods, and Air Pollution Control Regulations for the State of Missouri</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>10–6.350 .................</td>
<td>Emissions Limitations and Emissions Trading of Oxides of Nitrogen.</td>
<td>8/30/00</td>
<td>12/28/00</td>
<td>[insert FR cite]</td>
</tr>
</tbody>
</table>

EPA-APPROVED MISSOURI NONREGULATORY SIP PROVISIONS

<table>
<thead>
<tr>
<th>Name of nonregulatory SIP provision</th>
<th>Applicable geographic or nonattainment area</th>
<th>State submittal date</th>
<th>EPA approval date</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Commitments with respect to implemen-tation of rule 10 CSR 10–6.350, Emissions Limitations and Emissions Trading of Oxides of Nitrogen.</td>
<td>Statewide ....................................</td>
<td>8/8/00</td>
<td>12/28/00</td>
<td>[insert FR cite]</td>
</tr>
</tbody>
</table>

[FR Doc. 00–32947 Filed 12–27–00; 8:45 am]
BILLING CODE 6560–50–P

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 180

[OPP–301089; FRL–6756–4]

RIN 2070–AB78

Cyprodinil; Extension of Tolerance for Emergency Exemptions

AGENCY: Environmental Protection Agency (EPA).

ACTION: Final rule.

SUMMARY: This regulation extends a time-limited tolerance for residues of the fungicide cyprodinil in or on canebberries at 10 parts per million (ppm) for an additional 1-year period. This tolerance will expire and is revoked on December 31, 2001. This action is in response to EPA’s granting of emergency exemptions under section 18 of the Federal Insecticide, Fungicide, and Rodenticide Act authorizing use of the pesticide on canebberries. Section 408(l)(6) of the Federal Food, Drug, and Cosmetic Act requires EPA to establish a time-limited tolerance or exemption from the requirement for a tolerance for pesticide chemical residues in food that will result from the use of a pesticide under an emergency exemption granted by EPA under section 18 of the Federal Insecticide, Fungicide, and Rodenticide Act.

DATES: This regulation is effective December 28, 2000. Objections and requests for hearings, identified by docket control number OPP–301089, must be received by EPA on or before February 26, 2001.

ADDRESSES: Written objections and hearing requests may be submitted by mail, in person, or by courier. Please follow the detailed instructions for each method as provided in Unit III. of the SUPPLEMENTARY INFORMATION. To ensure proper receipt by EPA, your objections and hearing requests must identify docket control number OPP–301089 in the subject line on the first page of your response.

FOR FURTHER INFORMATION CONTACT: By mail: Stephen Schaible, Registration Division (7505C), Office of Pesticide Programs, Environmental Protection Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460; telephone number: 703–308–9362; and e-mail address: schaible.stephen@epa.gov.

SUPPLEMENTARY INFORMATION:

I. General Information

A. Does this Action Apply to Me?

You may be affected by this action if you are an agricultural producer, food manufacturer, or pesticide manufacturer. Potentially affected
categories and entities may include, but are not limited to:

<table>
<thead>
<tr>
<th>Categories</th>
<th>NAICS codes</th>
<th>Examples of potentially affected entities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Industry</td>
<td>111 112 311 32532</td>
<td>Crop production Animal production Food manufacturing Pesticide manufacturing</td>
</tr>
</tbody>
</table>

This listing is not intended to be exhaustive, but rather provides a guide for readers regarding entities likely to be affected by this action. Other types of entities not listed in the table could also be affected. The North American Industrial Classification System (NAICS) codes have been provided to assist you and others in determining whether or not this action might apply to certain entities. If you have questions regarding the applicability of this action to a particular entity, consult the person listed under FOR FURTHER INFORMATION CONTACT.

B. How Can I Get Additional Information, Including Copies of this Document and Other Related Documents?

1. Electronically. You may obtain electronic copies of this document, and certain other related documents that might be available electronically, from the EPA Internet Home Page at http://www.epa.gov/. To access this document, on the Home Page select “Laws and Regulations,” “Regulations and Proposed Rules,” and then look up the entry for this document under the “Federal Register—Environmental Documents.” You can also go directly to the Federal Register listings at http://www.epa.gov/fedrgstr/.

2. In person. The Agency has established an official record for this action under docket control number OPP–301089. The official record consists of the documents specifically referenced in this action, and other information related to this action, including any information claimed as Confidential Business Information (CBI). This official record includes the documents that are physically located in the docket, as well as the documents that are referenced in those documents. The public version of the official record does not include any information claimed as CBI. The public version of the official record, which includes printed, paper versions of any electronic comments submitted during an applicable comment period is available for inspection in the Public Information and Records Integrity Branch (PIRIB), Rm. 119, Crystal Mall #2, 1921 Jefferson Davis Hwy., Arlington, VA, from 8:30 a.m. to 4 p.m., Monday through Friday, excluding legal holidays. The PIRIB telephone number is (703) 305–5805.

II. Background and Statutory Findings

EPA issued a final rule, published in the Federal Register of June 30, 1999 (64 FR 35032) (FRL–6086–3), which announced that on its own initiative under section 408 of the Federal Food, Drug, and Cosmetic Act (FFDCA), 21 U.S.C. 346a, as amended by the Food Quality Protection Act of 1996 (FQPA) (Public Law 104–170) it established a time-limited tolerance for the residues of cyprodinil in or on caneberries at 10 ppb, with an expiration date of December 31, 2000. EPA established the tolerance because section 408(l)(6) of the FFDCA requires EPA to establish a time-limited tolerance or exemption from the requirement for a tolerance for pesticide chemical residues in food that will result from the use of a pesticide under an emergency exemption granted by EPA under section 18 of the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Such tolerances can be established without providing notice or period for public comment.

EPA received a request to extend the use of cyprodinil on caneberries for this year's growing season due to the widespread development of pest resistance to previously-used standard fungicides benomyl, iprodione and vinclozolin; no currently available alternatives appear to provide suitable disease control and significant economic losses are expected with moderate to severe disease pressure. After having reviewed the submission, EPA concurs that emergency conditions exist. EPA has authorized under FIFRA section 18 the use of cyprodinil on caneberries for control of gray mold in Oregon and Washington.

EPA assessed the potential risks presented by residues of cyprodinil in or on caneberries. In doing so, EPA considered the safety standard in FFDCA section 408(b)(2), and decided that the necessary tolerance under FFDCA section 408(l)(6) would be consistent with the safety standard and with FIFRA section 18. The data and other relevant material have been evaluated and discussed in the final rule of June 30, 1999 (64 FR 35032) (FRL–6086–3). Based on that data and information considered, the Agency reaffirms that extension of the time-limited tolerance will continue to meet the requirements of section 408(l)(6).

Therefore, the time-limited tolerance is extended for an additional 1-year period. EPA will publish a document in the Federal Register to remove the revoked tolerance from the Code of Federal Regulations (CFR). Although this tolerance will expire and is revoked on December 31, 2001, under FFDCA section 408(l)(5), residues of the pesticide not in excess of the amounts specified in the tolerance remaining in or on caneberreries after that date will not be unlawful, provided the pesticide is applied in a manner that was lawful under FIFRA and the application occurred prior to the revocation of the tolerance. EPA will take action to revoke this tolerance earlier if any experience with, scientific data on, or other relevant information on this pesticide indicate that the residues are not safe.

III. Objections and Hearing Requests

Under section 408(g) of the FFDCA, as amended by the FQPA, any person may file an objection to any aspect of this regulation and may also request a hearing on those objections. The EPA procedural regulations which govern the submission of objections and requests for hearings appear in 40 CFR part 178. Although the procedures in those regulations require some modification to reflect the amendments made to the FFDCA by the FQPA of 1996, EPA will continue to use those procedures, with appropriate adjustments, until the necessary modifications can be made. The new section 408(g) provides essentially the same process for persons to “object” to a regulation for an exemption from the requirement of a tolerance issued by EPA under new section 408(d), as was provided in the old FFDCA sections 408 and 409. However, the period for filing objections is now 60 days, rather than 30 days.

A. What Do I Need to Do to File an Objection or Request a Hearing?

You must file your objection or request a hearing on this regulation in accordance with the instructions provided in this unit and in 40 CFR part 178. To ensure proper receipt by EPA, you must identify docket control number OPP–301089 in the subject line on the first page of your submission. All requests must be in writing, and must be mailed or delivered to the Hearing Clerk on or before February 26, 2001.

1. Filing the request. Your objection must specify the specific provisions in the regulation that you object to, and the grounds for the objections (40 CFR 178.25). If a hearing is requested, the objections must include a statement of the factual issues(s) on which a hearing is requested, the requestor’s contentions on such issues, and a summary of any evidence relied upon by the objector (40 CFR 178.27). Information submitted in connection with an objection or hearing
request may be claimed confidential by marking any part or all of that information as CBI. Information so marked will not be disclosed except in accordance with procedures set forth in 40 CFR part 2. A copy of the information that does not contain CBI must be submitted for inclusion in the public record. Information not marked confidential may be disclosed publicly by EPA without prior notice.

Mail your written request to: Office of the Hearing Clerk (1900), Environmental Protection Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460. You may also deliver your request to the Office of the Hearing Clerk in Rm. C400, Waterside Mall, 401 M St., SW., Washington, DC 20460. The Office of the Hearing Clerk is open from 8 a.m. to 4 p.m., Monday through Friday, excluding legal holidays. The telephone number for the Office of the Hearing Clerk is (202) 260–4865.

2. Tolerance fee payment. If you file an objection or a request, you must pay the fee prescribed by 40 CFR 180.33(i) or request a waiver of that fee pursuant to 40 CFR 180.33(m). You must mail the fee to: EPA Headquarters Accounting Operations Branch, Office of Pesticide Programs, P.O. Box 360277M, Pittsburgh, PA 15251. Please identify the fee submission by labeling it “Tolerance Petition Fees.”

EPA is authorized to waive any fee requirement “when in the judgement of the Administrator such a waiver or refund is equitable and not contrary to the purpose of this subsection.” For additional information regarding the waiver of these fees, you may contact James Tompkins by phone at (703) 305–5697, by e-mail at tompkins.jim@epa.gov, or by mailing a request for information to Mr. Tompkins at Registration Division (7505C), Office of Pesticide Programs, Environmental Protection Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460.

If you would like to request a waiver of the tolerance objection fees, you must mail your request for such a waiver to: James Hollins, Information Resources and Services Division (7502C), Office of Pesticide Programs, Environmental Protection Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460.

3. Copies for the Docket. In addition to filing an objection or hearing request with the Hearing Clerk as described in Unit III.A., you should also send a copy of your request to the PIRIB for its inclusion in the official record that is described in Unit I.B.2. Mail your copies, identified by docket control number, to: Public Information and Records Integrity Branch, Information Resources and Services Division (7502C), Office of Pesticide Programs, Environmental Protection Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460. In person or by courier, bring a copy to the location of the PIRIB described in Unit I.B.2. You may also send an electronic copy of your request via e-mail to: opp-docket@epa.gov. Please use an ASCII file format and avoid the use of special characters and any form of encryption. Copies of electronic objections and hearing requests will also be accepted on disks in WordPerfect 6.1/8.0 file format or ASCII file format. Do not include any CBI in your electronic copy. You may also submit an electronic copy of your request at many Federal Depository Libraries.

B. When Will the Agency Grant a Request for a Hearing?

A request for a hearing will be granted if the Administrator determines that the material submitted shows the following: There is a genuine and substantial issue of disputed fact; there is a reasonable possibility that available evidence identified by the requestor would, if established resolve one or more of such issues in favor of the requestor, taking into account uncontested claims or facts to the contrary; and resolution of the factual issue(s) in the manner sought by the requestor would be adequate to justify the action requested (40 CFR 178.32).

IV. Regulatory Assessment Requirements

This final rule extends the expiration date of a time-limited tolerance under FFDCA section 408. The Office of Management and Budget (OMB) has exempted these types of actions from review under Executive Order 12866, entitled Regulatory Planning and Review (58 FR 51735, October 4, 1993). This final rule does not contain any information collections subject to OMB approval under the Paperwork Reduction Act (PRA), 44 U.S.C. 3501 et seq., or impose any enforceable duty or contain any unfunded mandate as described under Title II of the Unfunded Mandates Reform Act of 1995 (UMRA) (Public Law 104–4). Nor does it require any prior consultation as specified by Executive Order 13041, entitled Consultation and Coordination with Indian Tribal Governments (63 FR 27655, May 19, 1998). Special considerations as required by Executive Order 13272, entitled Federal Actions to Address Environmental Justice in Minority Populations and Low-Income Populations (59 FR 7629, February 16, 1994); or require OMB review for any Agency action under Executive Order 13045, entitled Protection of Children from Environmental Health Risks and Safety Risks (62 FR 19985, April 23, 1997). This action does not involve any technical standards that would require Agency consideration of voluntary consensus standards pursuant to section 12(d) of the National Technology Transfer and Advancement Act of 1995 (NTTAA), Public Law 104–113, section 12(d) (15 U.S.C. 272 note). Since tolerances and exemptions that are established on the basis of a FIFRA section 18 petition under FFDCA section 408, such as the tolerance in this final rule, do not require the issuance of a proposed rule, the requirements of the Regulatory Flexibility Act (RFA) (5 U.S.C. 601 et seq.) do not apply. In addition, the Agency has determined that this action will not have a substantial direct effect on States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government, as specified in Executive Order 13132, entitled Federalism (64 FR 43235, August 10, 1999). Executive Order 13132 requires EPA to develop an accountable process to ensure “meaningful and timely input by State and local officials in the development of regulatory policies that have federalism implications.” “Policies that have federalism implications” is defined in the Executive Order to include regulations that have “substantial direct effects on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government.” This final rule directly regulates growers, food processors, food handlers and food retailers, not States. This action does not alter the relationships or distribution of power and responsibilities established by Congress in the preemption provisions of FFDCA section 408(n)(4).

V. Submission to Congress and the Comptroller General

The Congressional Review Act, 5 U.S.C. 801 et seq., as added by the Small Business Regulatory Enforcement Fairness Act of 1996, generally provides that before a rule may take effect, the agency promulgating the rule must submit a rule report, which includes a copy of the rule, to each House of the Congress and to the Comptroller General of the United States. EPA will submit a report containing this rule and other required information to the U.S. Senate, the U.S. House of Representatives, and the Comptroller General of the United States prior to publication of this final rule in the Federal Register.
rule is not a “major rule” as defined by 5 U.S.C. 804(2).

List of Subjects in 40 CFR Part 180

Environmental protection, Administrative practice and procedure, Agricultural commodities, Pesticides and pests, Reporting and recordkeeping requirements.


James Jones,
Director, Registration Division, Office of Pesticide Programs.

Therefore, 40 CFR chapter I is amended as follows:

PART 180—[AMENDED]

1. The authority citation for part 180 continues to read as follows:

Authority: 21 U.S.C. 321(q), (346a) and 371.

§ 180.532 Amended

2. In § 180.532, by amending the table in paragraph (b), by revising the expiration/revocation date for Canberries from “12/31/00” to read “12/31/01”.

[FR Doc. 00–33169 Filed 12–27–00; 8:45 am]
BILLING CODE 6560–50–S

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 180

[OPP–301090; FRL–6756–5]

RIN 2070–AB78

Desmedipham; Extension of Tolerances for Emergency Exemption

AGENCY: Environmental Protection Agency (EPA).

ACTION: Final rule.

SUMMARY: This regulation extends time-limited tolerances for residues of the herbicide desmedipham in or on red beet roots at 0.2 part per million (ppm) and red beet tops at 15 ppm for an additional 1–year period. These tolerances will expire and are revoked on December 31, 2001. This action is in response to EPA’s granting of an emergency exemption under section 18 of the Federal Insecticide, Fungicide, and Rodenticide Act authorizing use of the pesticide on garden (red) beets.

Section 408(l)(6) of the Federal Food, Drug, and Cosmetic Act requires EPA to establish a time-limited tolerance or exemption from the requirement for a tolerance for pesticide chemical residues in food that will result from the use of a pesticide under an emergency exemption granted by EPA under section 18 of the Federal Insecticide, Fungicide, and Rodenticide Act.

DATES: This regulation is effective December 28, 2000. Objections and requests for hearings, identified by docket control number OPP–301090, must be received by EPA on or before February 26, 2001.

ADDRESSES: Written objections and hearing requests may be submitted by mail, in person, or by courier. Please follow the detailed instructions for each method as provided in Unit III. of the SUPPLEMENTARY INFORMATION. To ensure proper receipt by EPA, your objections and hearing requests must identify docket control number OPP–301090 in the subject line on the first page of your response.

FOR FURTHER INFORMATION CONTACT: By mail: Stephen Schaible, Registration Division, Office of Pesticide Programs, Environmental Protection Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460; telephone number: 703–308–9362; and e-mail address: schaible.stephen@epa.gov.

SUPPLEMENTARY INFORMATION:

I. General Information

A. Does this Action Apply to Me?

You may be affected by this action if you are an agricultural producer, food manufacturer, or pesticide manufacturer. Potentially affected categories and entities may include, but are not limited to:

<table>
<thead>
<tr>
<th>Categories</th>
<th>NAICS codes</th>
<th>Examples of potentially affected entities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Industry</td>
<td></td>
<td></td>
</tr>
<tr>
<td>111</td>
<td>Crop production</td>
<td></td>
</tr>
<tr>
<td>112</td>
<td>Animal production</td>
<td></td>
</tr>
<tr>
<td>311</td>
<td>Food manufacturing</td>
<td></td>
</tr>
<tr>
<td>32532</td>
<td>Pesticide manufacturing</td>
<td></td>
</tr>
</tbody>
</table>

This listing is not intended to be exhaustive, but rather provides a guide for readers regarding entities likely to be affected by this action. Other types of entities not listed in the table could also be affected. The North American Industrial Classification System (NAICS) codes have been provided to assist you and others in determining whether or not this action might apply to certain entities. If you have questions regarding the applicability of this action to a particular entity, consult the person listed under FOR FURTHER INFORMATION CONTACT.

B. How Can I Get Additional Information, Including Copies of this Document and Other Related Documents?

1. Electronically. You may obtain electronic copies of this document, and certain other related documents that might be available electronically, from the EPA Internet Home Page at http://www.epa.gov/. To access this document, on the Home Page select “Laws and Regulations,” “Regulations and Proposed Rules,” and then look up the entry for this document under the “Federal Register—Environmental Documents.” You can also go directly to the Federal Register listings at http://www.epa.gov/fedregstr/.

2. In person. The Agency has established an official record for this action under docket control number OPP–301090. The official record consists of the documents specifically referenced in this action, and other information related to this action, including any information claimed as Confidential Business Information (CBI). This official record includes the documents that are physically located in the docket, as well as the documents that are referenced in those documents. The public version of the official record does not include any information claimed as CBI. The public version of the official record, which includes printed, paper versions of any electronic comments submitted during an applicable comment period is available for inspection in the Public Information and Records Integrity Branch (PIRIB), Rm. 119, Crystal Mall #2, 1921 Jefferson Davis Hwy., Arlington, VA, from 8:30 a.m. to 4 p.m., Monday through Friday, excluding legal holidays. The PIRIB telephone number is (703) 305–5805.

II. Background and Statutory Findings

EPA issued a final rule, published in the Federal Register of August 29, 1997 (62 FR 45741) [FRL–5738–5], which announced that it was taking its own initiative under section 408 of the Federal Food, Drug, and Cosmetic Act (FFDCA), 21 U.S.C. 346a, as amended by the Food Quality Protection Act of 1996 (FQPA) (Public Law 104–170) it established time-limited tolerances for the residues of desmedipham in or on red beet roots at 0.2 ppm and red beet tops at 15 ppm, with an expiration date of August 31, 1998. EPA extended this expiration date to December 31, 2000 in a final rule published in the Federal Register of August 25, 1999. EPA established these tolerances because section 408(l)(6) of the FFDCA requires EPA to establish a time-limited tolerance or exemption from the requirement for a tolerance for
pesticide chemical residues in food that will result from the use of a pesticide under an emergency exemption granted by EPA under section 18 of the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Such tolerances can be established without providing notice or period for public comment.

EPA received a request to extend the use of desmedipham on red beets for this year's growing season due to the continued non-routine situation facing red beet growers in New York; the voluntary cancellation of diethylthiocarbamate in 1993 has left growers with no registered alternatives which provide adequate or dependable weed control. After having reviewed the submission, EPA concurs that emergency conditions exist. EPA has authorized under FIFRA section 18 the use of desmedipham on red beets for control of broadleaf weeds in New York.

EPA assessed the potential risks presented by residues of desmedipham in or on red beets. In doing so, EPA considered standards in FFDCA section 408(b)(2), and decided that the necessary tolerances under FFDCA section 408(l)(6) would be consistent with the safety standard and with FIFRA section 18. The data and other relevant material have been evaluated and discussed in the final rule of August 29, 1997 (62 FR 45741) (FRL–5738–5). Based on that data and information considered, the Agency reaffirms that extension of the time-limited tolerances will continue to meet the requirements of section 408(l)(6). Therefore, the time-limited tolerances are extended for an additional 1-year period. EPA will publish a document in the Federal Register to remove the revoked tolerances from the Code of Federal Regulations (CFR). Although these tolerances will expire and are revoked on December 31, 2001, under FFDCA section 408(l)(5), residues of the pesticide not in excess of the amounts specified in the tolerances remaining in or on red beet roots or tops after that date will not be unlawful, provided the pesticide is applied in a manner that was lawful under FIFRA and the application occurred prior to the revocation of the tolerances. EPA will take action to revoke these tolerances earlier if any experience with, scientific data on, or other relevant information on this pesticide indicate that the residues are not safe.

III. Objections and Hearing Requests

Under section 408(g) of the FFDCA, as amended by the FQPA, any person may file an objection to any aspect of this regulation and may also request a hearing on those objections. The EPA procedural regulations which govern the submission of objections and requests for hearings appear in 40 CFR part 178. Although the procedures in these regulations require some modification to reflect the amendments made to the FFDCA by the FQPA of 1996, EPA will continue to use those procedures, with appropriate adjustments, until the necessary modifications can be made. The new section 408(g) provides essentially the same process for persons to "object" to a regulation for an exemption from the requirement of a tolerance issued by EPA under new section 408(d), as was provided in the old FFDCA sections 408 and 409. However, the period for filing objections is now 60 days, rather than 30 days.

A. What Do I Need to Do to File an Objection or Request a Hearing?

You must file your objection or request a hearing on this regulation in accordance with the instructions provided in this unit and in 40 CFR part 178. To object or request a hearing by EPA, you must identify docket control number OPP–301090 in the subject line on the first page of your submission. All requests must be in writing, and must be mailed or delivered to the Hearing Clerk on or before February 26, 2001.

1. Filing the request. Your objection must specify the specific provisions in the regulation that you object to, and the grounds for the objections (40 CFR 178.25). If a hearing is requested, the objections must include a statement of the factual issue(s) on which a hearing is requested, the requestor's contentions on such issues, and a summary of any evidence relied upon by the objector (40 CFR 178.27). Information submitted in connection with an objection or hearing request may be claimed confidential by marking any part or all of that information as CBI. Information so marked will not be disclosed except in accordance with procedures set forth in 40 CFR part 2. A copy of the information that does not contain CBI must be submitted for inclusion in the public record. Information not marked confidential may be disclosed publicly by EPA without prior notice.

Mail your written request to: Office of the Hearing Clerk (1900), Environmental Protection Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460. You may also deliver your request to the Office of the Hearing Clerk in Rm. C400, Waterside Mall, 401 M St., SW., Washington, DC 20460. The telephone number for the Office of the Hearing Clerk is (202) 260–4865.

2. Tolerance fee payment. If you file an objection or request a hearing, you must also pay the fee prescribed by 40 CFR 180.33(i) or request a waiver of that fee pursuant to 40 CFR 180.33(m). You must mail the fee to: EPA Headquarters Accounting Operations Branch, Office of Pesticide Programs, P.O. Box 360277M, Pittsburgh, PA 15251. Please identify the fee submission by labeling it "Tolerance Petition Fees."

EPA is authorized to waive any fee requirement "when in the judgement of the Administrator such a waiver or refund is equitable and not contrary to the purpose of this subsection." For additional information regarding the waiver of these fees, you may contact James Tompkins by phone at (703) 305–5697, by e-mail at tompkins.jim@epa.gov, or by mailing a request for information to Mr. Tompkins at Registration Division (7505C), Office of Pesticide Programs, Environmental Protection Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460.

If you file a request for a waiver of the tolerance objection fees, you must mail your request for such a waiver to: James Hollins, Information Resources and Services Division (7502C), Office of Pesticide Programs, Environmental Protection Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460.

3. Copies for the Docket. In addition to filing an objection or hearing request with the Hearing Clerk as described in Unit III.A., you should also send a copy of your request to the PIRIB for its inclusion in the official record that is described in Unit I.B.2. Mail your copies, identified by docket control number OPP–301090, to: Public Information and Records Integrity Branch, Information Resources and Services Division (7502C), Office of Pesticide Programs, Environmental Protection Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460. In person or by courier, bring a copy to the location of the PIRIB described in Unit I.B.2. You may also send an electronic copy of your request via e-mail to: opp-docket@epa.gov. Please use an ASCII file format and avoid the use of special characters and any form of encryption. Copies of electronic objections and hearing requests will also be accepted on disks in WordPerfect 6.1/8.0 file format or ASCII file format. Do not include any CBI in your electronic copy. You may also submit an electronic copy of your request at many Federal Depository Libraries.

B. When Will the Agency Grant a Request for a Hearing?

A request for a hearing will be granted if the Administrator determines that the
material submitted shows the following: There is a genuine and substantial issue of fact; there is a reasonable possibility that available evidence identified by the requestor would, if established resolve one or more of such issues in favor of the requestor, taking into account uncontested claims or facts to the contrary; and resolution of the factual issues(s) in the manner sought by the requestor would be adequate to justify the action requested (40 CFR 178.32).

IV. Regulatory Assessment Requirements

This final rule extends the expiration date of time-limited tolerances under FFDCA section 408. The Office of Management and Budget (OMB) has exempted these types of actions from review under Executive Order 12866, entitled Regulatory Planning and Review (58 FR 51735, October 4, 1993). This final rule does not contain any information collections subject to OMB approval under the Paperwork Reduction Act (PRA), 44 U.S.C. 3501 et seq., or impose any enforceable duty or contain any unfunded mandate as described under Title II of the Unfunded Mandates Reform Act of 1995 (UMRA) (Public Law 104-4). Nor does it require any prior consultation as specified by Executive Order 13084, entitled Consultation and Coordination with Indian Tribal Governments (63 FR 27655, May 19, 1998); special considerations as required by Executive Order 12898, entitled Federal Actions to Address Environmental Justice in Minority Populations and Low-Income Populations (59 FR 7629, February 16, 1994); or require OMB review or any Agency action under Executive Order 13045, entitled Protection of Children from Environmental Health Risks and Safety Risks (62 FR 19885, April 23, 1997). This action does not involve any technical standards that would require Agency consideration of voluntary consensus standards pursuant to section 12(d) of the National Technology Transfer and Advancement Act of 1995 (NTTAA), Public Law 104-113, section 12(d) (15 U.S.C. 272 note). Since tolerances and exemptions that are established on the basis of a FIFRA section 18 petition under FFDCA section 408, such as the tolerances in this final rule, do not require the issuance of a proposed rule, the requirements of the Regulatory Flexibility Act (RFA) (5 U.S.C. 601 et seq.) do not apply. In addition, the Agency has determined that this action will not have a substantial direct effect on States, or on the distribution of power and responsibilities among the various levels of government, as specified in Executive Order 13132, entitled Federalism (64 FR 43255, August 10, 1999). Executive Order 13132 requires EPA to develop an accountable process to ensure “meaningful and timely input by State and local officials in the development of regulatory policies that have federalism implications.” “Policies that have federalism implications” is defined in the Executive Order to include regulations that have “substantial direct effects on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government.” This final rule directly regulates growers, food processors, food handlers and food retailers, not States. This action does not alter the relationships or distribution of power and responsibilities established by Congress in the preemption provisions of FFDCA section 408(n)(4).

V. Submission to Congress and the Comptroller General

The Congressional Review Act, 5 U.S.C. 801 et seq., as added by the Small Business Regulatory Enforcement Fairness Act of 1996, generally provides that before a rule may take effect, the agency promulgating the rule must submit a rule report, which includes a copy of the rule, to each House of Congress and to the Comptroller General of the United States. EPA will submit a report containing this rule and other required information to the U.S. Senate, the U.S. House of Representatives, and the Comptroller General of the United States prior to publication of this final rule in the Federal Register. This final rule is not a “major rule” as defined by 5 U.S.C. 804(2).

List of Subjects in 40 CFR Part 180

Environmental protection, Administrative practice and procedure, Agricultural commodities, Pesticides and pests, Reporting and recordkeeping requirements.


James Jones,
Director, Registration Division, Office of Pesticide Programs.

Therefore, 40 CFR chapter I is amended as follows:

PART 180—AMENDED

1. The authority citation for part 180 continues to read as follows: Authority: 21 U.S.C. 321(q), (346a) and 371.

§180.353 [Amended]

2. In §180.353, by amending the table in paragraph (b), by revising the expiration/revocation date from “12/31/00” to read “12/31/01” wherever it appears.

[F.R. Doc. 00-33171 Filed 12-27-00; 8:45 a.m.]

BILLING CODE 6560-50-S

FEDERAL COMMUNICATIONS COMMISSION

47 CFR Part 20

[CC Docket No. 94-102; FCC 00-436]

Wireless Radio Services; Compatibility with Enhanced 911 Emergency Calling Systems

AGENCY: Federal Communications Commission.

ACTION: Final rule.

SUMMARY: In this document the Commission takes steps to ensure that persons with hearing and speech disabilities using text telephone (TTY) devices will be able to make 911 emergency calls over digital wireless systems. With this in mind, the Commission establishes June 30, 2002, as the deadline by which digital wireless service providers must be capable of transmitting 911 calls made using TTY devices. The Commission also imposes a reporting requirement on carriers, which may be fulfilled through an industry forum that has been actively involved in resolving TTY/digital compatibility problems.

DATES: The amendment to 47 CFR part 20 is effective February 26, 2001.

ADDRESSES: A copy of any comments on the information collection contained herein should be submitted to Judy Boley, Federal Communications Commission, Room 1–C804, 445 12th Street, SW., Washington, D.C. 20554, or via the Internet to jboley@fcc.gov.


SUPPLEMENTARY INFORMATION: This is a summary of the Commission’s Fourth Report and Order (Fourth R&O) in CC Docket No. 94–102; FCC 00–436, adopted December 11, 2000, and released December 14, 2000. The
complete text of this Fourth R&O is available for inspection and copying during normal business hours in the FCC Reference Information Center, Courtyard Level, 445 12th Street, SW., Washington, DC, and also may be purchased from the Commission’s copy contractor, International Transcription Services (ITS, Inc.), CY–B400, 445 12th Street, SW., Washington, DC.

Synopsis of the Fourth Report and Order

1. In this Fourth Report and Order (Fourth R&O), the Commission takes steps to ensure that persons with hearing and speech disabilities using text telephone (TTY) devices will be able to make 911 emergency calls over digital wireless systems. In light of recent technological advances related to TTY/digital compatibility, the Commission establishes June 30, 2002, as the deadline by which digital wireless service providers must be capable of transmitting 911 calls made using TTY devices. In order to monitor the development and implementation of this capability within carrier networks, the Commission imposes a reporting requirement on carriers, which may be fulfilled by reporting through an industry forum that has been actively involved in resolving TTY/digital compatibility problems.

2. As indicated in paragraphs 8, 9, and 10 of the full text of the Fourth R&O, the Commission establishes December 31, 2001, as the deadline for carriers operating digital wireless systems to have obtained all software upgrades and equipment necessary to make their systems capable of transmitting 911 calls from TTY devices. However, the Commission allows carriers an additional six-month period, until June 30, 2002, to integrate, test, and deploy the technology in their systems in conjunction with the public safety community.

3. In addition to amending the Commission’s rules to reflect the modified implementation deadline for digital wireless systems to be capable of transmitting 911 calls using TTY devices, the Fourth R&O also addresses pending petitions seeking waiver of the TTY regulations of 47 CFR 20.18(c). As indicated in paragraph 11 of the Fourth R&O, the majority of these petitions were filed on or before December 4, 1998, and, due to technological advances that have occurred since that time, and the revised implementation schedule adopted in the Fourth R&O, the Commission finds that these waiver petitions are moot and thus dismisses them.

4. Paragraphs 12 through 18 of the Fourth R&O considers methods that the Commission could use to monitor the carriers’ progress toward attaining digital TTY accessibility, as well as the progress of technological developments and the adoption of standards. The Fourth R&O, in response to this need, adopts a requirement that carriers submit quarterly reports, but to allow them to fulfill this requirement by reporting through the TTY Forum. As detailed in paragraph 14 of the Fourth R&O, wireless carriers formed the TTY Forum for the purpose of sharing information and developing solutions to the TTY/digital incompatibility problem. The TTY Forum has done an excellent job of helping carriers move toward the goal of making digital wireless systems widely accessible to TTY devices. Most carrier and equipment manufacturer commenters agree that reports by the TTY Forum should be required in lieu of individual reports by carriers. The Commission finds that providing carriers with the flexibility to either file an individual quarterly report or to fulfill this requirement by reporting through the TTY Forum. The quarterly reports must be filed either by the individual carrier or by the carrier through the TTY Forum 15 days after the end of each quarter, beginning on April 15, 2001, with a report for the quarter ending March 31, 2001, and continuing through the implementation deadline of June 30, 2002. This requirement contains information collection requirements that are not effective until approved by the Office of Management and Budget. The FCC will publish a document in the Federal Register announcing the effective date for this requirement. Public comment on the information collection is due February 26, 2001.

5. The quarterly reports should contain updates on the status of the various solutions and should distinguish between different air interfaces. The reports should provide information concerning deployment “milestones” and issues as detailed in paragraph 17 of the Fourth R&O. Paragraph 18 of the Fourth R&O provides information on how and where to file the quarterly reports.

6. The Fourth R&O, in paragraphs 20 through 32, notes several additional consumer issues related to the solutions, including the effect of the solutions on TTYs with proprietary enhanced protocols, the support of voice carry over in the solutions, and concerns about the capability of certain handsets to allow for simultaneous connections to the audio jack and the power cord input. With respect to these issues, the Commission encourages handset and TTY manufacturers and carriers to work toward resolution of these issues. In response to consumer concerns about the availability and cost of analog wireless services, the Commission encourages carriers to work with TTY users to provide an analog service plan comparable to what is offered to digital customers.

Regulatory Flexibility Act

7. The Commission hereby certifies pursuant to section 605(b) of the Regulatory Flexibility Act (RFA), 5 U.S.C. 605(b), that the progress monitoring reporting requirement adopted in this Fourth R&O will not have a significant economic impact on a substantial number of small entities. The report is much like the reporting requirements the Commission previously adopted in the E911 proceeding. The Commission is only requiring the filing of these reports for a limited period of time. Finally, the Commission has adopted (at the suggestion of the industry) a mechanism for filing the reports that minimizes any burdens on small entities. The Commission therefore concludes that there will not be a significant economic impact as a result of this reporting requirement.

8. Report to Congress: The Commission will send a copy of the Fourth R&O, including the Final Regulatory Flexibility Act Certification, in a report to Congress pursuant to the Congressional Review Act, see 5 U.S.C. 801(a)(1)(A). In addition, the Commission will send a copy of the Fourth R&O, including the Final Regulatory Flexibility Act Certification, to the Chief Counsel for Advocacy of the Small Business Administration.

Ordering Clauses:

9. Part 20 of the Commission’s Rules is amended as set forth in the Rule Changes section of this summary. The rule amendments made by this Fourth R&O shall become effective February 26, 2001.

10. The information collections contained in this order will become effective following approval by the Office of Management and Budget. The Commission will publish a document in the Federal Register at a later date establishing the effective date for these collections.

11. All petitions for waiver of section 20.18(c) of the Commission’s rules are dismissed as moot in light of the rule changes adopted in this Fourth R&O.

12. The Commission’s Consumer Information Bureau, Reference Information Center shall send a copy of this Fourth R&O, including the Final
Regulatory Flexibility Certification, to
the Chief Counsel for Advocacy of the
Small Business Administration.

**Paperwork Reduction Act**

1. This Fourth R&O contains a new
information collection. As part of the
Commission’s continuing effort to
reduce paperwork burdens, the
Commission invites the general public
and the Office of Management and
Budget to take this opportunity to
comment on the information collections
contained in this Fourth R&O, as
required by the Paperwork Reduction
and agency comments are due February
26, 2001. Comments should address: (a)
Whether the new collection of
information is necessary for the proper
performance of the functions of the
Commission, including whether the
information shall have practical utility;
(b) the accuracy of the Commission’s
burden estimates; (3) ways to enhance
the quality, utility, and clarity of the
information collected; and (4) ways to
minimize the burden of the collection of
information on the respondents,
including the use of automated
collection techniques or other forms of
information technology.

**OMB Approval Number:** N.A.

**Title:** Revision of the Commission’s
Rules To Ensure Compatibility with
Enhanced 911 Emergency Calling
Systems, Fourth R&O.

**Form No.** N.A.

**Type of Review:** New information
collection.

**Respondents:** Business or other for
profit.

**Number of Respondents:** 4,000.

**Estimated Time Per Response:** 2
Hours.

**Total Annual Burden:** 32,000 Hours.

**Cost to Respondents:** $0.

**Needs and Uses:** The information
submitted in the quarterly reports will
be used by the Commission to keep
track of the carriers’ progress in
complying with E911 TTY requirements
and also to monitor the progress
technology is making towards
compatibility with TTY devices.

**List of Subjects in 47 CFR Part 20**

Communications common carrier,
Communications equipment, Radio.

Federal Communications Commission.

Magalie Roman Salas,
Secretary.

**Rule Changes**

For the reasons discussed in the
preamble, The Federal Communications
Commission amends 47 CFR part 20 as
follows:

**PART 20—COMMERCIAL MOBILE
RADIO SERVICES**

1. The authority citation for part 20
continues to read as follows:

*Authority:* 47 U.S.C. 154, 160, 251–254,
303, and 332 unless otherwise noted.

2. In §20.18, is amended by revising
the note to paragraph (c) to read as
follows:

**§20.18 911 Service.

* * * * *

(c) * * *

Note to Paragraph (c): Operators of
digital wireless systems must begin
complying with the provisions of this
paragraph on or before June 30, 2002.

* * * * *

[FR Doc. 00–33025 Filed 12–27–00; 8:45 am]

BILLING CODE 6712–01–U

**FEDERAL COMMUNICATIONS
COMMISSION**

47 CFR Part 73

[DA 00–2887; MM Docket Nos. 00–189, 00–
190, 00–191, 00–192; RM–9984, RM–9985,
RM–9986, RM–9987]

**Radio Broadcasting Services (Heber,
Snowflake, Overgaard, and Taylor,
Arizona)**

**AGENCY:** Federal Communications
Commission.

**ACTION:** Final rule.

**SUMMARY:** The Commission, at the
request of New Directions Media, Inc.,
allots Channel 288C2 at Heber, Arizona,
Channel 258C2 at Snowflake, Arizona,
Channel 232C3 at Overgaard, Arizona,
and Channel 278C3 at Taylor, Arizona
as each community’s first local aural
service. See 65 FR 64924 (October 31,
2000). Channel 288C2 can be allotted to
Heber in compliance with the
Commission’s minimum distance
separation requirements, with respect to
domestic allotments, without the
imposition of a site restriction at
coordinates 34–27–54 NL and 110–05–
26 WL. A filing window for Channel
288C2 at Heber, Arizona, Channel
258C2 at Snowflake, Arizona, Channel
232C3 at Overgaard, Arizona, and
Channel 278C3 at Taylor will not be
opened at this time. Instead, the issue of
opening a filing window for each
channel will be addressed by the
Commission in a subsequent order.

**DATES:** Effective February 5, 2001.

**FOR FURTHER INFORMATION CONTACT:**
Victoria M. McCauley, Mass Media
Bureau, (202) 418–2180.

**SUPPLEMENTARY INFORMATION:** This is a
synopsis of the Commission’s Report
and Order, MM Docket No., adopted
December 13, 2000, and released
December 22, 2000. The full text of this
Commission decision is available for
inspection and copying during normal
business hours in the FCC Reference
Center (Room 239), 445 12th Street,
SW., Washington, DC. The complete
text of this decision may also be
purchased from the Commission’s copy
contractor, International Transcription
Services, Inc., (202) 857–3800, 1231
20th Street, NW., Washington, DC
20036.

List of Subjects in 47 CFR Part 73

Radio broadcasting.

Part 73 of Title 47 of the Code of
Federal Regulations is amended as follows:

**PART 73—RADIO BROADCAST SERVICES**

1. The authority citation for Part 73
continues to read as follows:


**§73.202 [Amended]**

2. Section 73.202(b), the Table of FM
Allotments under Arizona is amended by
adding Heber, Channel 288C2;
Snowflake, Channel 258C2; Overgaard,
Channel 232C3; and Taylor, Channel
278C3.

Federal Communications Commission.

John A. Karousos,
Chief, Allocations Branch, Policy and Rules
Division, Mass Media Bureau.

[FR Doc. 00–33211 Filed 12–27–00; 8:45 am]

BILLING CODE 6712–01–U
FEDERAL COMMUNICATIONS
COMMISSION

47 CFR Part 73

[DA 00–2885; MM Docket No. 98–155; RM–9082; RM–9133]

Radio Broadcasting Services; Alva, Mooreland, Tishomingo, Tuttle and Woodward, OK

AGENCY: Federal Communications Commission.

ACTION: Final rule.

SUMMARY: The Commission, at the request of FM 92 Broadcasters, Inc., allocates Channel 283C1 to Mooreland, OK, as the community’s first local aural service. This action also denies the request of Ralph Tyler to reallocate Channel 259C3 from Tishomingo, OK, to Mooreland, OK, as its first local aural service. This action also denies the request of FM 92 Broadcasters, Inc., to reallocate Channel 283C1 from Tishomingo, OK, to Mooreland, OK, as the community’s first local aural service. The FCC Reference Center (Room 239), 445 12th Street, SW, Washington, DC 20546, telephone: (202) 358–1645; email: cdalton@hq.nasa.gov.


FOR FURTHER INFORMATION CONTACT: Leslie K. Shapiro, Mass Media Bureau, (202) 418–2180.

SUPPLEMENTARY INFORMATION: This is a final rule amending the NASA FAR Supplement (NFS) to make miscellaneous administrative and editorial changes.

SUMMARY: This is a final rule amending the NASA FAR Supplement (NFS) to make miscellaneous administrative and editorial changes.

PART 73—RADIO BROADCAST SERVICES

1. The authority citation for Part 73 continues to read as follows:


§ 73.202 [Amended]

2. Section 73.202(b), the Table of FM Allotments under Oklahoma, is amended by adding Mooreland, Channel 283C1.

Federal Communications Commission.

John A. Karousos,
Chief, Allocations Branch, Policy and Rules Division, Mass Media Bureau.

BILLING CODE 6712–01–P

NATIONAL AERONAUTICS AND SPACE ADMINISTRATION

48 CFR Parts 1807, 1813, 1816, 1835, 1842, 1845, 1852, and 1872

Acquisition Regulations;

Miscellaneous Changes

AGENCY: National Aeronautics and Space Administration (NASA).

ACTION: Final rule.

SUMMARY: This is a final rule amending the NASA FAR Supplement (NFS) to make miscellaneous administrative and editorial changes.


PART 1807—ACQUISITION PLANNING

1807.105 [Amended]

2. Remove paragraph (b)(1) in section 1807.105.

PART 1813—SIMPLIFIED ACQUISITION PROCEDURES

3. Add section 1813.301–71 to read as follows:

1813.301–71 Training.

All cardholders and approving officials must complete training prior to receiving a purchase card. Training will address the responsibilities of the cardholder and approving official, prohibited purchases, purchase limitations, and sources of supply.

PART 1816—TYPES OF CONTRACTS

4. In section 1816.203–4, revise paragraph (a) to read as follows:

1816.203–4 Contract clauses.

(a) In addition to the approval requirements in the prescriptions at FAR 52.216–2 through 52.216–4, the contracting officer shall coordinate with the installation’s Deputy Chief Financial Officer (Finance) before exceeding the ten-percent limit in paragraph (c)(1) of the clauses at FAR 52.216–2 and 52.216–3 and paragraph (c)(4) of the clause at 52.216–4.

C. Paperwork Reduction Act

The Paperwork Reduction Act does not apply because the changes to the NFS do not impose any recordkeeping or information collection requirements that require the approval of the Office of Management and Budget under 44 U.S.C. 3501, et seq.

List of Subjects in 48 CFR Parts 1807, 1813, 1816, 1835, 1842, 1845, 1852, and 1872

Government procurement.

Tom Luedtke,
Associate Administrator for Procurement.

Accordingly, 48 CFR Parts 1807, 1813, 1816, 1835, 1842, 1845, 1852, and 1872 are amended as follows:

1. The authority citation for 48 CFR Parts 1807, 1813, 1816, 1835, 1842, 1845, 1852, and 1872 continues to read as follows:

Authority: 42 U.S.C. 2473(c)(1)

Bill to

1807.105 [Amended]

2. Remove paragraph (b)(1) in section 1807.105.

PART 1813—SIMPLIFIED ACQUISITION PROCEDURES

3. Add section 1813.301–71 to read as follows:

1813.301–71 Training.

All cardholders and approving officials must complete training prior to receiving a purchase card. Training will address the responsibilities of the cardholder and approving official, prohibited purchases, purchase limitations, and sources of supply.

PART 1816—TYPES OF CONTRACTS

4. In section 1816.203–4, revise paragraph (a) to read as follows:

1816.203–4 Contract clauses.

(a) In addition to the approval requirements in the prescriptions at FAR 52.216–2 through 52.216–4, the contracting officer shall coordinate with the installation’s Deputy Chief Financial Officer (Finance) before exceeding the ten-percent limit in paragraph (c)(1) of the clauses at FAR 52.216–2 and 52.216–3 and paragraph (c)(4) of the clause at 52.216–4.

* * * * *

PART 1807—ACQUISITION PLANNING

1807.105 [Amended]

2. Remove paragraph (b)(1) in section 1807.105.

PART 1813—SIMPLIFIED ACQUISITION PROCEDURES

3. Add section 1813.301–71 to read as follows:

1813.301–71 Training.

All cardholders and approving officials must complete training prior to receiving a purchase card. Training will address the responsibilities of the cardholder and approving official, prohibited purchases, purchase limitations, and sources of supply.

PART 1816—TYPES OF CONTRACTS

4. In section 1816.203–4, revise paragraph (a) to read as follows:

1816.203–4 Contract clauses.

(a) In addition to the approval requirements in the prescriptions at FAR 52.216–2 through 52.216–4, the contracting officer shall coordinate with the installation’s Deputy Chief Financial Officer (Finance) before exceeding the ten-percent limit in paragraph (c)(1) of the clauses at FAR 52.216–2 and 52.216–3 and paragraph (c)(4) of the clause at 52.216–4.

* * * * *

PART 1807—ACQUISITION PLANNING

1807.105 [Amended]

2. Remove paragraph (b)(1) in section 1807.105.

PART 1813—SIMPLIFIED ACQUISITION PROCEDURES

3. Add section 1813.301–71 to read as follows:

1813.301–71 Training.

All cardholders and approving officials must complete training prior to receiving a purchase card. Training will address the responsibilities of the cardholder and approving official, prohibited purchases, purchase limitations, and sources of supply.
PART 1835—RESEARCH AND DEVELOPMENT CONTRACTING

1835.017–71 [Amended]

5. In section 1835.016–71, amend the first sentence of paragraph (b)(2) by removing “and 1805.201”.

PART 1842—CONTRACT ADMINISTRATION AND AUDIT SERVICES

6. Revise section 1842.1501 to read as follows:

1842.1501 General.

Communications with contractors are vital to improved performance and this is NASA’s primary objective in evaluating past performance. Other objectives include providing data for future source selections. While the evaluations must reflect both shortcomings and achievements during performance, they should also elicit from the contractors their views on impediments to improved performance emanating from the Government or other sources.

7. Revise section 1842.7301 to read as follows:

1842.7301 NASA external audit follow-up system.

(a) This section implements OMB Circular No. A–50 and NASA Policy Directive (NPD) 1200.10 “Internal Management Controls and Audit Liaison and Followup”, which provide more detailed guidance. Recommendations from external audits (OMB Circular No. A–133, Audits of States, Local Governments, and Non-Profit Institutions) shall be resolved by formal review and approval procedures analogous to those at 1815.406–171.

(b) The external audit followup system tracks all contract and OMB Circular No. A–133 audits where NASA has resolution and disposition authority. The objective of the tracking system is to ensure that audit recommendations are resolved within 6 months after receipt of the audit report and corrected as expeditiously as possible.

(c)(1) The identification and tracking of contract audit reports under NASA cognizance are accomplished in cooperation with the DCAA.

(2) Identification and tracking of OMB Circular No. A–133 audit reports are accomplished in cooperation with the NASA Office of the Inspector General (OIG).

(d)(1) All reportable contract audit reports as defined by Chapter 15, Section 6, of the DCAA Contract Audit Manual (CAM) shall be reported quarterly to the Headquarters Office of Procurement (Code HK); and

(2) Only OMB Circular No. A–133 audit reports involving the following shall be reported quarterly to Code HK:

(i) A significant management control issue; or

(ii) Questioned costs of $10,000 or more due to an audit finding (see Subpart E–Auditor, paragraph 510 of OMB Circular No. A–133).

(3) NASA contracting officers will maintain a dialogue with DOD Administrative Contracting Officers (ACO) who have been delegated activities on NASA contracts. A review will be conducted no less frequently than semiannually, and the status and disposition of significant audit findings will be documented in the contract file. During this review, NASA contracting officers should discuss with the ACO both prime and subcontract audit reports that have been delegated to DOD. Should these reports contain any findings or recommendations, the NASA contracting officer should obtain their status and document the contract file accordingly.

(e)(1) The terms “resolution” and “disposition” are defined in as follows:

(i) Resolution—The point at which the IG and Management agree on the action to be taken on audit report findings and recommendations.

(ii) Corrective action—Management action responsive to an agreed upon audit recommendation.

(2) The resolution and disposition of OMB Circular No. A–133 audits are handled as follows:

(i) Audit findings pertaining to an individual NASA award are the responsibility of the procurement officer administering that award.

(ii) Audit findings having a Governmentwide impact are the responsibility of the cognizant Federal agency responsible for oversight. For organizations subject to OMB Circular No. A–133, there is either a cognizant agency or an oversight agency. The cognizant agency is the Federal agency that provides the predominant amount of direct funding to the recipient organization unless OMB makes a specific cognizant agency for audit assignment. To provide for the continuity of cognizance, the determination of the predominant amount of direct funding will be based on the direct Federal awards expended in the recipient’s fiscal years ending in 1995, 2000, 2005, and every fifth year thereafter. When there is no direct funding, the Federal agency with the predominant indirect funding is to assume the oversight responsibilities. In cases where NASA is the cognizant or oversight Federal agency, audit resolution and disposition is the responsibility of the procurement officer for the Center having the largest amount of direct funding, or, if there is no direct funding, the largest amount of indirect funding for the audited period. A copy of the memorandum dispositioning the findings shall be provided by each Center having resolution responsibility for the particular report to the Headquarters OIG office and Code HK.

PART 1845—GOVERNMENT PROPERTY

8. In section 1845.7101–1, revise paragraph (c) to read as follows:

1845.7101–1 Property classification.

(c) Buildings. Includes costs of buildings, improvements to buildings, and fixed equipment required for the operation of a building which is permanently attached to and a part of the building and cannot be removed without cutting into the walls, ceilings, or floors. Contractors shall report buildings with a unit acquisition cost of $100,000 or more. Examples of fixed equipment required for functioning of a building include plumbing, heating and lighting equipment, elevators, central air conditioning systems, and built-in safes and vaults.

PART 1852—SOLICITATION PROVISIONS AND CONTRACT CLAUSES

1852.247–73 Shipment by Government Bills of Lading.

9. Amend the date of the clause at section 1852.247–73 by removing “(MARCH 1997)” and adding “(OCTOBER 2000)” in its place.

PART 1872—ACQUISITIONS OF INVESTIGATIONS

1872.305 [Amended]

10. Amend section 1872.305 by removing “Appendix A” in paragraph (b).

1872.306 [Amended]

11. Amend section 1872.306 by removing “Appendix B” and adding “1872.705–2” in its place.

12. Revise section 1872.307 to read as follows:


While not all of the guidelines outlined in 1872.705–2 will be applicable in response to every AO, the investigator should be informed of the
relevant information required. The proposal may be submitted on a form supplied by the Program Office. However, the proposal should be submitted in at least two sections: (a) Investigation and Technical Plan; and (b) Management and Cost Plan as described in 1872.705–2.

1872.705 [Amended] 13. Amend Part VI of section 1872.705 by removing “Appendix C” in paragraph (b)(5) and adding “Appendix B” in its place and removing “General Instructions and Provisions” in paragraphs (d) and (e) and adding “Guidelines for Proposal Preparation” in its place.

[FR Doc. 00–32962 Filed 12–27–00; 8:45 am]
BILLING CODE 7510–01–P

DEPARTMENT OF COMMERCE
National Oceanic and Atmospheric Administration

50 CFR Part 679
[Docket No. 001213348–0366–02; I.D. 121100A]
RIN 0648-AO44

Fisheries of the Exclusive Economic Zone Off Alaska; Removal of Groundfish Closure

AGENCY: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.

ACTION: Final rule.

SUMMARY: NMFS revises an existing closure to commercial fishing for Pacific cod within critical habitat designated for Steller sea lions in the exclusive economic zone (EEZ) off Alaska west of 144° W. long. through December 31, 2000. The revision of the existing closure is necessary to permit relatively small-scale, fixed-gear fisheries for Pacific cod to continue for a limited period of time. The revised closure is intended to ensure that Steller sea lions are adequately protected based on conclusions in a biological opinion issued November 30, 2000, while mitigating short-term social and economic effects on fixed-gear fisheries for Pacific cod.


FOR FURTHER INFORMATION CONTACT: Jay Ginter, 907–586–7228 or jay.ginter@noaa.gov.

SUPPLEMENTARY INFORMATION: NMFS manages the U.S. groundfish fisheries in the EEZ of the Bering Sea and Aleutian Islands Management Area (BSAI) and Gulf of Alaska (GOA) under the fishery management plans (FMPs) for groundfish in the respective areas. The North Pacific Fishery Management Council (Council) prepared, and NMFS approved, the FMPs under the authority of the Magnuson-Stevens Fishery Conservation and Management Act (Magnuson-Stevens Act), 16 U.S.C. 1801 et seq. Regulations implementing the FMPs appear at 50 CFR part 679. General regulations governing U.S. fisheries appear at 50 CFR part 600.

NMFS also has statutory authority to promulgate regulations governing the groundfish fisheries under the Endangered Species Act (ESA), 16 U.S.C. 1531 et seq. The ESA requires that each Federal agency ensure that any action authorized, funded, or carried out by such agency is not likely to jeopardize the continued existence of any endangered or threatened species or result in the destruction or adverse modification of critical habitat of such species.

On August 7, 2000, the United States District Court for the Western District of Washington issued an order dissolving the injunction issued on August 7, 2000. Based on that Order, NMFS issued a final rule on December 14, 2000 (65 FR 79784, December 20, 2000) revoking the closure of all groundfish trawl fishing in designated critical habitat that was published on August 15, 2000 (65 FR 49766). However, because the BiOp concluded that the fisheries for Pacific cod, along with pollock and Atka mackerel, as currently prosecuted, jeopardize the continued existence of the western population of Steller sea lions and adversely modify their critical habitat, NMFS reached this conclusion based on information that the pollock, Pacific cod, and Atka mackerel fisheries and the Steller sea lions compete for the same species, that this competition causes reduced availability of prey for the Steller sea lions, that reduced availability of prey leads to nutritional stress, and that nutritional stress, especially of juveniles and to a lesser extent adult females, is the leading hypothesis to explain the continued decline of the western population of Steller sea lions.

On December 5, 2000, the United States District Court for the Western District of Washington issued an order dissolving the injunction issued on August 7, 2000. Based on that Order, NMFS issued a final rule on December 14, 2000 (65 FR 79784, December 20, 2000) revoking the closure of all groundfish trawl fishing in designated critical habitat that was published on August 15, 2000 (65 FR 49766). However, because the BiOp concluded that the fisheries for Pacific cod, along with pollock and Atka mackerel, as currently prosecuted, jeopardize the continued existence of the western population of Steller sea lions and adversely modify their critical habitat, and because only Pacific cod was still available for harvest in certain fisheries, the December 20, 2000, final rule prohibited commercial fishing for Pacific cod in designated critical habitat through December 31, 2000. Commercial fisheries for pollock and Atka mackerel were not included in the final rule because fisheries for those species already were prohibited through...
December 31, 2000, pursuant to other regulatory requirements.

This final rule revises the December 14, 2000, final rule by permitting directed fishing for Pacific cod by vessels using non-trawl gear and continuing the prohibition on directed fishing for Pacific cod by vessels using trawl gear in designated critical habitat. This action is being taken to allow three previously authorized fisheries for Pacific cod with non-trawl gear to continue through the end of the fishing year (i.e., December 31, 2000) or until otherwise closed sooner due to attainment of catch or bycatch limits. The three previously authorized Pacific cod fisheries include: (1) fishing in the BSAI under the Community Development Quota (CDQ) Program, (2) fishing in the BSAI by vessels less than 60 ft (18.3 m) length overall (LOA), and (3) fishing in the GOA by vessels using pot gear for processing by the offshore component.

The number of vessels that were participating in these three fisheries and the remaining catch quota of Pacific cod to be harvested is small relative to the BSAI and GOA groundfish fisheries generally. Based on current participation and harvest information, the CDQ fishery could have about 10 vessels using hook-and-line gear to harvest a remaining quota of 1,800 mt of Pacific cod in critical habitat in the BSAI. The under 60 ft (18.3 m) LOA fishery could have about 4 vessels using non-trawl gear to harvest a remaining quota of 1,200 mt of Pacific cod in critical habitat in the BSAI. Through December 15, 2000, this fishery harvested only 62 mt of this quota and, based on previous harvest rates, NMFS anticipates that another 33 mt will be harvested before January 1, 2001. No vessels were operating in the GOA “offshore” fishery for Pacific cod as of December 15, 2000. Only vessels using pot gear can operate in this fishery because restrictions on Pacific halibut bycatch prevent vessels using hook-and-line gear from participating in the GOA “offshore” fishery for Pacific cod through December 31, 2000. Hence, these are relatively small-scale fisheries and NMFS has determined that allowing them to continue within designated critical habitat would not contravene the Reasonable and Prudent Alternative described in Section 9 of the BiOp. In addition, this action expires on December 31, 2000, thereby severely limiting the potential effect of this action on Steller sea lions.

Classification

The Assistant Administrator for Fisheries, NOAA (AA), has determined that this final rule is consistent with the Court’s Order and is authorized by the ESA.

Because prior notice and opportunity for public comment are not required for this final rule by 5 U.S.C. 553, or any other law, the analytical requirements of the Regulatory Flexibility Act, 5 U.S.C. 601 et seq., do not apply to this action. This final rule has been determined to be not significant under section 3(f)(1) of E.O. 12866.

The AA, under 5 U.S.C. 553(b)(B), finds there is good cause to waive providing prior notice and an opportunity for public comment for the partial removal of the existing closure. This removal stems from a United States District Court Order dissolving, as of December 5, 2000, the injunction requiring the closure. Delaying this action to provide prior notice and opportunity for comment would cause unnecessary economic harm to the affected fishermen and thus would be contrary to the public interest. Because this action relieves a restriction, under 5 U.S.C. 553(d)(1) it is not subject to a 30-day delay in the effective date.

List of Subjects in 50 CFR Part 679

Alaska, Fisheries, Recordkeeping and reporting requirements.


Penelope D. Dalton
Assistant Administrator for Fisheries, National Marine Fisheries Service.

For reasons set forth in the preamble, 50 CFR part 679 is amended as follows:

PART 679—FISHERIES OF THE EXCLUSIVE ECONOMIC ZONE OFF ALASKA

1. The authority citation for 50 CFR part 679 continues to read as follows:


2. In § 679.22, paragraph (k) is removed and reserved and paragraph (l) is added, effective through December 31, 2000, to read as follows:

§ 679.22 Closures.

(k) Closure of critical habitat.

(Applicable through December 31, 2000.) Vessels using trawl gear within Steller sea lion critical habitat within the EEZ and west of 144° W. long., as such critical habitat is defined by regulations codified at 50 CFR 226.202 and Tables 1 and 2 to 50 CFR part 226, must not retain at any time amounts of Pacific cod that exceed the maximum retainable bycatch amounts at § 679.20(e) and (f).

[FR Doc. 00-33162 Filed 12-22-00; 3:10 pm]
This section of the FEDERAL REGISTER contains notices to the public of the proposed issuance of rules and regulations. The purpose of these notices is to give interested persons an opportunity to participate in the rule making prior to the adoption of the final rules.

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 71

[Airspace Docket No. 00–AAL–21]

Proposed Establishment of Class E Airspace; Egegik, AK

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Notice of proposed rulemaking.

SUMMARY: This action establishes Class E airspace at Egegik, AK. The establishment of Area Navigation (RNAV) instrument approaches at the Egegik Airport has made this action necessary. The Egegik Airport status will change from Visual Flight Rules (VFR) to Instrument Flight Rules (IFR). Adoption of this proposal would result in adequate controlled airspace for IFR operations at Egegik, AK.

DATES: Comments must be received on or before February 12, 2001.

ADDRESSES: Send comments on the proposal in triplicate to: Manager, Operations Branch, AAL–530, Docket No. 00–AAL–21, Federal Aviation Administration, 222 West 7th Avenue, Box 14, Anchorage, AK 99513–7587.

The official docket may be examined in the Office of the Regional Counsel for the Alaskan Region at the same address.

An informal docket may also be examined during normal business hours in the Office of the Manager, Operations Branch, Air Traffic Division, at the address shown above and on the Internet at Alaskan Region’s homepage at http://www.alaska.faa.gov/at or at address http://162.58.28.41/at.

FOR FURTHER INFORMATION CONTACT: Robert Durand, Operations Branch, AAL–531, Federal Aviation Administration, 222 West 7th Avenue, Box 14, Anchorage, AK 99513–7587; telephone number (907) 271–5988; fax: (907) 271–2850; email: Bob.Durand@faa.gov. Internet address: http://www.alaska.faa.gov/at.

SUPPLEMENTARY INFORMATION:

Comments Invited

Interested parties are invited to participate in this proposed rulemaking by submitting such written data, views, or arguments as they may desire. Comments that provide the factual basis supporting the views and suggestions presented are particularly helpful in developing reasoned regulatory decisions on the proposal. Comments are specifically invited on the overall regulatory, aeronautical, economic, environmental, and energy-related aspects of the proposal. Communications should identify the airspace number and be submitted in triplicate to the address listed above. Commenters wishing the FAA to acknowledge receipt of their comments on this notice must submit with those comments a self-addressed, stamped postcard on which the following statement is made: “Comments to Airspace Docket No. 00–AAL–21.” The postcard will be date/time stamped and returned to the commenter. All communications received on or before the specified closing date for comments will be considered before taking action on the proposed rule. The proposal contained in this notice may be changed in light of comments received. All comments submitted will be available for examination in the Operations Branch, Air Traffic Division, Federal Aviation Administration, 222 West 7th Avenue, Box 14, Anchorage, AK, both before and after the closing date for comments. A report summarizing each substantive public contact with FAA personnel concerned with this rulemaking will be filed in the docket.

Availability of Notice of Proposed Rulemaking’s (NPRM’s)

An electronic copy of this document may be downloaded, using a modem and suitable communications software, from the FAA regulations section of the Fedworld electronic bulletin board service (telephone: 703–321–3339) or the Federal Register’s electronic bulletin board service (telephone: 202–512–1661).

Internet users may reach the Federal Register’s web page for access to recently published rulemaking documents at http://www.access.gpo.gov/su_docs/aces/aces140.html.

Any person may obtain a copy of this NPRM by submitting a request to the Operations Branch, AAL–530, Federal Aviation Administration, 222 West 7th Avenue, Box 14, Anchorage, AK 99513–7587. Communications must identify the notice number of this NPRM. Persons interested in being placed on a mailing list for future NPRM’s should contact the individual(s) identified in the FOR FURTHER INFORMATION CONTACT section.

The Proposal

The FAA proposes to amend 14 CFR part 71 by establishing Class E airspace at Egegik, AK, to create controlled airspace for the RNAV instrument approaches to RWY 12 and RWY 30. The Egegik Airport status will be upgraded from VFR to IFR. The intended effect of this proposal is to provide adequate controlled airspace for IFR operations at Egegik, AK.

The area would be depicted on aeronautical charts for pilot reference. The coordinates for this airspace docket are based on North American Datum 83. The Class E airspace areas designated as 700/1200 foot transition areas are published in paragraph 6005 in FAA Order 7400.9H, Airspace Designations and Reporting Points, dated September 1, 2000, and effective September 16, 2000, which is incorporated by reference in 14 CFR 71.1. The Class E airspace designations listed in this document would be published subsequently in the Order.

The FAA has determined that this proposed regulation only involves an established body of technical regulations for which frequent and routine amendments are necessary to keep them operationally current. It, therefore—(1) is not a “significant regulatory action” under Executive Order 12866; (2) is not a “significant rule” under DOT Regulatory Policies and Procedures (44 FR 11034; February 26, 1979); and (3) does not warrant preparation of a regulatory evaluation as the anticipated impact is so minimal. Since this is a routine matter that will only affect air traffic procedures and air navigation, it is certified that this rule, when promulgated, will not have a significant economic impact on a substantial number of small entities under the criteria of the Regulatory Flexibility Act.
List of Subjects in 14 CFR Part 71
Airspace, Incorporation by reference, Navigation (air).

The Proposed Amendment
In consideration of the foregoing, the Federal Aviation Administration proposes to amend 14 CFR part 71 as follows:

PART 71—DESIGNATION OF CLASS A, CLASS B, CLASS C, CLASS D, AND CLASS E AIRSPACE AREAS; AIRWAYS; ROUTES; AND REPORTING POINTS

1. The authority citation for 14 CFR part 71 continues to read as follows:

§ 71.1 [Amended]
2. The incorporation by reference in 14 CFR 71.1 of Federal Aviation Administration Order 7400.9H, Airspace Designations and Reporting Points, dated September 1, 2000, and effective September 16, 2000, is to be amended as follows:

Paragraph 6005 Class E airspace extending upward from 700 feet or more above the surface of the earth.

AAL AK E5 Egegik, AK [New]
Egegik Airport, AK
That airspace extending upward from 700 feet above the surface within a 6.3 mile radius of the Egegik Airport.

Issued in Anchorage, AK, on December 19, 2000.

Anthony M. Wylie,
Acting Manager, Air Traffic Division, Alaskan Region.

[Docket No. 2000–8056]

Federal Highway Administration

23 CFR Part 772

For Abatement of Highway Traffic Noise and Construction Noise

AGENCY: Federal Highway Administration (FHWA), DOT.

ACTION: Advance notice of proposed rulemaking (ANPRM); request for comments.

SUMMARY: The FHWA is requesting comments on whether its regulations on noise insulation of private residences should be revised to allow Federal participation when a traffic noise impact occurs, i.e., when predicted traffic noise levels substantially exceed the existing noise levels. Currently, Federal participation in the noise insulation of private residences is allowable only in situations where: Severe traffic noise impacts exist or are expected, and normal abatement measures are physically infeasible or economically unreasonable. In these instances, the FHWA may approve a State’s request for unusual or extraordinary abatement measures on a case-by-case basis. When considering extraordinary abatement measures, the State must demonstrate that the affected activities experience traffic noise impacts to a far greater degree than other similar activities adjacent to highway facilities. For example, residential areas experience absolute noise levels of at least 75 decibels or residential areas experience noise level increases of at least 30 decibels over existing noise levels. The noise insulation of private residences is an example of an extraordinary abatement measure.

DATES: Comments must be received on or before February 26, 2001.

ADDRESSES: Mail or hand deliver comments to the U.S. Department of Transportation, Dockets Management Facility, Room PL–401, 400 Seventh Street, SW., Washington, DC 20590, or submit electronically at http://dmses.dot.gov/submit. All comments received will be available for examination and copying at the above address from 9 a.m. to 5 p.m., e.t., Monday through Friday, except Federal holidays. Those desiring notification of receipt of comments must include a self-addressed, stamped postcard or you may print the acknowledgment page that appears after submitting comments electronically.

FOR FURTHER INFORMATION CONTACT: Mr. Robert Armstrong, Office of Natural Environment, HEPN–20, (202) 366–2073, or Mr. Robert Black, Office of the Chief Counsel, HCC–30, (202) 366–1359, Federal Highway Administration, 400 Seventh Street, SW., Washington, DC 20590–0001. Office hours are from 7:45 a.m. to 4:15 p.m., e.t., Monday through Friday, except Federal holidays.

SUPPLEMENTARY INFORMATION: Electronic Access and Filing
You may submit or retrieve comments online through the Document Management System (DMS) at: http://dmses.dot.gov/submit. Acceptable formats include: MS Word (versions 95 to 97), MS Word for Mac (versions 6 to 8), Rich Text File (RTF), American Standard Code Information Interchange (ASCII) (TXT), Portable Document Format (PDF), and Wordperfect (versions 7 to 8). The DMS is available 24 hours each day, 365 days each year. Electronic submission and retrieval help and guidelines are available under the help section of the web site.


Background
The FHWA noise regulations were developed as a result of the Federal-Aid Highway Act of 1970 (Public Law 91–605, 84 Stat. 1713) and apply to projects where a State department of transportation has requested Federal funding for participation in the project. Under FHWA noise requirements found at 23 CFR part 772, the State transportation department must determine if there will be traffic noise impacts in areas adjacent to federally-aided highways when a project is proposed for the construction of a highway on a new location or the reconstruction of an existing highway to either significantly change the horizontal or vertical alignment or increase the number of through-traffic lanes. Such a project is termed a “Type I” project. If the State transportation department identifies potential traffic noise impacts, it must consider noise abatement measures and implement the measures when they are determined to be reasonable and feasible.

Federal law and FHWA regulations do not require the State departments of transportation to implement noise abatement along existing highways. However, they may voluntarily initiate this type of abatement, termed a “Type II” project, but they are solely responsible for making this decision. Federal participation in the funding of such projects is limited to those that propose abatement measures along lands that were developed or were under substantial construction before approval of the acquisition of the right-of-way for, or construction of, the existing highway.
Noise abatement measure which may be incorporated in “Type I” and “Type II” projects include the following: (1) Traffic management measures (e.g., traffic control devices and signing for prohibition of certain vehicle types, time-use restrictions for certain vehicle types, modified speed limits and exclusive land designations); (2) alteration of horizontal and vertical alignments; (3) acquisition of property rights (either in fee or lesser interest) for construction of noise barriers; (4) construction of noise barriers (including landscaping for aesthetic purposes), whether within or outside the highway right-of-way; (5) acquisition of real property or interests therein (predominantly unimproved property) to serve as a buffer zone to preempt development which would be adversely impacted by traffic noise (this measure may be included in “Type I” projects only); and (6) noise insulation of public use or nonprofit institutional structures.

In establishing the noise regulations, the FHWA limited routine noise insulation to public use or nonprofit institutional structures.

1. Should the FHWA revise its noise regulation to routinely allow Federal participation in the noise insulation of private residences whenever a traffic noise impact occurs, not only when a severe traffic noise impact occurs?

2. Should the FHWA revise its noise regulation to routinely allow Federal participation in the noise insulation of private residences, i.e., add it to the listing of abatement measures which may be included in “Type I” and “Type II” projects, or should Federal participation in the noise insulation of private residences be allowed only after all the other listed abatement measures have been determined not to be reasonable and feasible?

3. Should the FHWA revise its noise regulation to address the noise insulation of private residences in a manner which is different from that discussed in the first two questions?

Rulemaking Analyses and Notices

All comments received before the close of business on the comment closing date indicated above will be considered and will be available for examination using the docket number appearing at the top of this document in the docket room at the above address or via the electronic addresses provided above. The FHWA will file comments received after the comment closing date in the docket and will consider late comments to the extent practicable. In addition to late comments, the FHWA will also continue to file in the docket relevant information becoming available after the comment closing date, and interested persons should continue to examine the docket for new material. An NPRM may be issued at any time after close of the comment period.

Executive Order 12866 (Regulatory Planning and Review) and DOT Regulatory Policies and Procedures

The FHWA has determined that this action is not a significant regulatory action within the meaning of Executive Order 12866, nor would it be a significant regulatory action within the Department of Transportation’s regulatory policies and procedures. Due to the preliminary nature of this document and lack of necessary information on costs and benefits, the FHWA is unable to evaluate the impact of potential changes to the regulatory requirements concerning the noise insulation of private residences.

Comments, information, and data are solicited on the economic and other related costs and/or possible benefits of the potential changes. Based on the information received in response to this notice, the FHWA intends to carefully consider the costs and benefits associated with various alternative requirements.

Regulatory Flexibility Act

In compliance with the Regulatory Flexibility Act (5 U.S.C. 601–612), the FHWA has determined that the potential regulatory changes will have no economic impacts on small entities. This action would merely seek information concerning the noise insulation of private residences. Based on this evaluation, the FHWA certifies that this action would not have a significant economic impact on a substantial number of small entities.

National Environmental Policy Act

The FHWA will analyze any actions that might be proposed in response to comments received here for the purpose of the National Environmental Policy Act of 1969 (42 U.S.C. 4321 et seq.) to assess whether there would be any effect on the quality of the environment.

Unfunded Mandates Reform Act of 1995

Due to the preliminary nature of this document and lack of necessary information on costs, the FHWA is unable to evaluate the effects of the potential regulatory changes in regards to imposing a Federal mandate involving the expenditure by State, local, and tribal governments, in the aggregate, or by the private sector, of $100 million or more in any one year (2 U.S.C. 1532). Nevertheless, the FHWA will evaluate any regulatory action that might be proposed in subsequent stages of this rulemaking to assess the effects on State, local, and tribal governments and the private sector.

Executive Order 12988 (Civil Justice Reform)

The FHWA will evaluate any action that may be proposed in response to comments received here to ensure that such action meets applicable standards in sections 3(a) and 3(b)(2) of Executive Order 12988, Civil Justice Reform, to minimize litigation, eliminate ambiguity, and reduce burden.
Executive Order 13045 (Protection of Children)

The FHWA will evaluate any rule that may be proposed in response to comments received here under Executive Order 13045, Protection of Children from Environmental Health Risks and Safety Risks. We do not, however, anticipate that any such rule would be economically significant or would present an environmental risk to health or safety that may disproportionately affect children.

Executive Order 12630 (Takings of Private Property)

The FHWA will evaluate any rule that may be proposed in response to comments received here to ensure that any such rule will not effect a taking of private property or otherwise have taking implications under Executive Order 12630, Governmental Actions and Interference with Constitutionally Protected Property Rights.

Executive Order 13132 (Federalism)

Any action that may be initiated in response to comments received here will be analyzed in accordance with the principles and criteria contained in Executive Order 13132, dated August 4, 1999. The FHWA anticipates that such action would not have a substantial direct effect or sufficient Federalism implications on States that would limit the policymaking discretion of the States. Nor do we anticipate that such action would directly preempt any State law or regulation.

Executive Order 12372 (Intergovernmental Review)

Catalog of Federal Domestic Assistance Program Number 20.205 Highway Planning and Construction. The regulations implementing Executive Order 12372 regarding intergovernmental consultation on Federal programs and activities apply to this program.

Paperwork Reduction Act of 1995


Regulation Identification Number

A regulation identification number (RIN) is assigned to each regulatory action listed in the Unified Agenda of Federal Regulations. The Regulatory Information Service Center publishes the Unified Agenda in April and October of each year. The RIN contained in the heading of this document can be used to cross reference this action with the Unified Agenda.

List of Subjects in 23 CFR Part 772

Grant programs-transportation, Highways and roads, Noise control.

Authority: 23 U.S.C. 109(h) and (i); 42 U.S.C. 4331, 4332; and 49 CFR 1.48(b).


Kenneth R. Wykle,
Federal Highway Administrator.

[FR Doc. 00–33195 Filed 12–27–00; 8:45 am] BILLING CODE 4910–22–M

DEPARTMENT OF TRANSPORTATION

Coast Guard

33 CFR Part 164

46 CFR Parts 25 and 27

[USCG–2000–6931]

Fire-Suppression Systems and Voyage Planning for Towing Vessels

AGENCY: Coast Guard, DOT.

ACTION: Notice of meeting; request for comments.

SUMMARY: The Coast Guard will hold a public meeting to discuss proposed rules for improving the safety of towing vessels. A supplemental notice of proposed rulemaking published on November 8, 2000, would require the installation of fixed fire-extinguishing systems in towing vessels’ engine rooms, and it would require owners or operators, and masters, to ensure that voyage plans are complete before their towing vessels commence trips with any barge in tow. These rules would reduce the number of uncontrolled fires in engine rooms, and other fire-related or operational mishaps on towing vessels; as a result, they would save lives, diminish property damage, and reduce the associated threats to the environment and maritime commerce.

The Coast Guard encourages interested parties to attend the meeting and submit comments for discussion during the meeting. In addition, the Coast Guard seeks written comments from any party who is unable to attend the meeting.

DATES: The Coast Guard will hold this public meeting on February 8, 2001, from 1 p.m. to 5 p.m. This meeting may close early if all business is finished. Written material for discussion during the meeting should reach the Docket Management Facility on or before February 2, 2001. Other written comments must reach the Docket Management Facility on or before March 8, 2001.

ADDRESSES: The Coast Guard will hold this public meeting at the U.S. Department of Transportation, Nassif Building, rooms 2230 and 2232, 400 Seventh Street SW., Washington, DC 20590–0001. The telephone number is 202–267–1181. You may mail your comments to the Docket Management Facility [USCG–2000–6931], U.S. Department of Transportation, room PL–401, 400 Seventh Street SW., Washington, DC 20590–0001, or deliver them to room PL–401 on the Plaza level of the Nassif Building at the same address between 9 a.m. and 5 p.m., Monday through Friday, except for Federal holidays. The telephone number is 202–366–9329.

The Docket Management Facility maintains the public docket for this notice. Comments, and documents as indicated in this notice, will become part of this docket and will be available for inspection or copying at room PL–401, on the Plaza level of the Nassif Building at the same address between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays. You may also access this docket on the Internet at http://dms.dot.gov.

FOR FURTHER INFORMATION CONTACT: For questions on this notice, contact Randall Eberly, P.E., Project Manager, Lifesaving and Fire Safety Division of the Office of Design and Engineering Standards (G–MSE–4), Coast Guard, telephone 202–267–1861. For questions on viewing, or submitting material to the docket, contact Dorothy Beard, Chief, Dockets, Department of Transportation, telephone 202–366–9329.

SUPPLEMENTARY INFORMATION:

Requests for Comments

The Coast Guard encourages interested persons to submit written data, views, or arguments. Persons submitting comments should include their names and addresses, identify this notice [USCG–2000–6931], and give the reason for each comment. Please submit all comments and attachments in an unbound format, no larger than 8 1/2 by 11 inches, suitable for copying and electronic filing to the Docket Management Facility at the address under ADDRESSES. Persons wanting acknowledgement of receipt of comments should enclose stamped, self-addressed postcards or envelopes.

The Coast Guard will consider all comments received during the comment period.

Information on Service for Individuals With Disabilities

For information on facilities or services for individuals with disabilities
The spill led Congress to amend the law of its contents into the coastal waters. The incident on January 19, 1996, off the coast of Rhode Island when the tugboat SCANDIA, with the tank barge NORTH CAPE in tow, caught fire five miles off the coast. The spill led Congress to amend the law to permit the Secretary of Transportation—“in consultation with the Towing Safety Advisory Committee” (TSAC)—to require fire-suppression and other measures on all towing vessels. The measures outlined in the SNPRM would likely decrease the number and severity of injuries to crews, prevent damage to vessels, structures and other property, and protect the environment.

**Public Meeting**

This meeting is open to the public. Please note that the meeting may close early if all business is finished. Members of the public make oral presentations during the meeting. If you would like to make an oral presentation at the meeting, please notify the Coast Guard point of contact listed under FOR FURTHER INFORMATION CONTACT no later than February 2, 2001.


Joseph J. Angelo,
Director of Standards, Marine Safety and Environmental Protection.

[FR Doc. 00–33079 Filed 12–27–00; 8:45 am]

**BILLING CODE 4910–15–P**

**DEPARTMENT OF TRANSPORTATION**

**Coast Guard**

**33 CFR Part 401**

[USCG–2000–8569]

**Great Lakes Pilotage Regulations**

**AGENCY:** Coast Guard, DOT.

**ACTION:** Notice of meeting; request for comments.

**SUMMARY:** The Coast Guard’s Office of Great Lakes Pilotage will hold a public meeting. This meeting is in response to the marine industry’s request for a comprehensive review of the Great Lakes Pilotage System. The purpose of the meeting is to discuss options for improving the safety, reliability, and efficiency of the Great Lakes Pilotage System. We encourage interested parties to attend the meeting and submit comments for discussion during the meeting. We also seek written comments from any party who is unable to attend the meeting.

**DATES:** Public Meeting: We will hold the meeting on January 30, 2001, from 10 a.m. to 4 p.m.

**ADDRESSES:** Public Meeting: We will hold the meeting in room B1, The Federal Building, 1240 East 9th Street, Cleveland, Ohio 44199.

Written Comments: The Docket Management Facility must receive your comments on or before January 22, 2001.

For information concerning this notice or the public meeting, contact Tom Lawler, Chief Economist, Office of Great Lakes Pilotage (G–MW), U.S. Coast Guard Headquarters, 2100 Second Street, SW., Washington, DC 20590, telephone 202–267–6164. For questions on viewing or submitting material to the docket contact Dorothy Beard, Chief, Dockets, Department of Transportation, telephone 202–366–9329.

**FOR FURTHER INFORMATION CONTACT:** For information concerning this notice or the public meeting, contact Tom Lawler, Chief Economist, Office of Great Lakes Pilotage (G–MW), U.S. Coast Guard Headquarters, 2100 Second Street, SW., Washington, DC 20590, telephone 202–267–6164. For questions on viewing or submitting material to the docket contact Dorothy Beard, Chief, Dockets, Department of Transportation, telephone 202–366–9329.

**SUPPLEMENTARY INFORMATION:**

How Do I Participate in This Action?

The Coast Guard encourages you to participate by submitting comments and related material, and by attending the public meeting. If you submit written comments, please include—

• Your name and address;

• The docket number for this notice (USCG–2000–8569);

• The specific section of this notice to which each comment applies; and

• The reason for each comment.

You may mail, deliver, fax, or electronically submit your comments and attachments to the Docket Management Facility, using an address or fax number listed in the ADDRESSES section of this notice. Please do not submit the same comment or attachment by more than one method. If you mail or deliver your comments, they must be on 8½ by 11 inch paper and the quality of the copy should be clear enough for copying and scanning. If you mail your comments, and you would like to know if the Docket Management Facility received them, please enclose a stamped, self-addressed postcard or envelope. We will consider all
comments and material received during the comment period.

How Can I Get Additional Information, Including Copies of This Notice or Other Related Documents?

The Docket Management Facility maintains the public dockets for this notice. The docket number for this notice is USCG–2000–8569. Comments, and other documents related to this notice will become part of this docket and will be available for inspection or copying as follows:

- **In person:** You may access the docket in room PL–401, on the Plaza Level of the Nassif Building at the same address, between 9 a.m. and 5 p.m., Monday through Friday. The facility is closed on Federal holidays.

- **Electronically:** You may access the docket on the Internet at [http://dms.dot.gov](http://dms.dot.gov).

Where Can I Get Information on Service for Individuals With Disabilities?

To obtain information on facilities or services for individuals with disabilities or to request that we provide special assistance at the public meeting, please contact Mr. Tom Lawler as soon as possible. You will find his address and phone number in the **FOR FURTHER INFORMATION CONTACT** section of this notice.

Why Is the Coast Guard Holding This Public Meeting?

This meeting is in response to requests for a comprehensive review to improve the safety, reliability, and efficiency of the Great Lakes pilotage system. The requests came from all facets of the marine industry operating on the Great Lakes. We are holding the meeting to discuss ways to design a safer, more reliable and efficient pilotage system for the Great Lakes.

What Issues Should I Discuss at the Meeting or Address in Written Comments?

The public meeting on January 30, 2001 will provide a forum for members of the public to discuss ways to improve the safety, reliability and efficiency of the Great Lakes Pilotage System. You can discuss or comment on any ideas you have for improving the safety, reliability, and efficiency of the Great Lakes pilotage system. Interested parties are strongly encouraged to submit issues for discussion at the public meeting to the docket prior to January 22, 2001.

**What Is the Agenda for the Public Meeting?**

**Agenda**

The agenda for the meeting on January 30, 2001 is as follows:

- **Session I—Introduction and Overview.**
- **Session II—Presentation and discussion of Concept Papers on centralized dispatch, centralized billing, and the possible advantages and disadvantages of combining the existing three pilotage Districts into one District or one Pilots’ Association.**
- **Session III—Discussion of issues submitted to the docket.**


**Joseph J. Angelo,**

**Acting Assistant Commandant for Marine Safety and Environmental Protection.**

[FR Doc. 00–33077 Filed 12–27–00; 8:45 am]

**BILLING CODE 4910–15–U**

---

**FEDERAL COMMUNICATIONS COMMISSION**

**47 CFR Part 73**

**[MM Docket No. 00–244; FCC 00–427]**

**Broadcast Services; Radio Stations, Television Stations**

**AGENCY:** Federal Communications Commission.

**ACTION:** Proposed rule.

**SUMMARY:** This document proposes to revise the Commission’s methodologies for defining radio markets, counting the number of stations in a radio market, and determining the number of stations that a party owns in a radio market for the purposes of determining compliance with its multiple ownership rules. Experience in applying those methodologies since the enactment of the Telecommunications Act of 1996, has indicated that the Commission’s current framework may be having results that may frustrate the structure of the Telecommunications Act and that are not in the public interest.

**DATES:** Comments are due by January 26, 2001; reply comments are due by February 12, 2001.

**ADDRESSES:** Federal Communications Commission, 445 12th Street, SW., Washington, DC 20554.

**FOR FURTHER INFORMATION CONTACT:**


**SUPPLEMENTARY INFORMATION:** This is a synopsis of the Notice of Proposed Rule Making (“NPRM”) in MM Docket No. 00–244, FCC 00–427, adopted December 6, 2000, and released December 13, 2000. The complete text of this NPRM is available for inspection and copying during normal business hours in the FCC Reference Center, Room CY–A257, 445 12th Street, SW., Washington, DC and may also be purchased from the Commission’s copy contractor, International Transcription Service (202) 857–3800, 445 12th Street, SW., Room CY–B402, Washington, DC. The NPRM is also available on the Internet at the Commission’s website: [http://www.fcc.gov](http://www.fcc.gov).

**Synopsis of Notice of Proposed Rule Making**

1. We are adopting this NPRM to seek comment on whether and how we should modify the way in which we determine the dimensions of radio markets and count the number of stations in them. We are also seeking comment on whether and how we should amend the method by which we determine the number of radio stations owned by a party in a radio market for the purpose of applying our multiple ownership rules.

**Overview**

2. In 1991, we commenced a proceeding to relax our local and national radio ownership rules. We ultimately established two market sizes that would determine the number of radio stations in which an entity could have an attributable interest in a local area. One tier included markets with 15 or more commercial radio stations. The other market tier consisted of markets with fewer than 15 stations. A party could have attributable interests in a different number of stations depending on the tier into which its market fell. This decision required that we establish both how we would define a market and, because of the different treatment of markets with less than 15 stations and those with 15 or more, how we would count the number of stations in a market. We determined that:

- we will define the radio market as that area encompassed by the principal community contours (i.e., predicted or measured 5 mV/m for AM stations and predicted 3.16 mV/m for FM stations) of the mutually overlapping stations proposing to have common ownership.

With regard to how we would count the number of stations in a market, we stated: [the number of stations in the market will be determined based on the principal community contours of all commercial stations whose principal community contours overlap or intersect the principal...](/28DEP1.SGM)
community contours of the commonly-owned stations.

In section 202(b)(1) of the Telecommunications Act of 1996 (Public Law 104–104, 110 Stat. 56 (1996) ("1996 Act")), Congress directed the Commission to increase the number of stations in a market in which a party could have a cognizable ownership interest, providing that in the largest markets a single entity could own up to eight stations. The number of stations in which it could have such an interest would depend upon the number of commercial stations in the market. Our methods of defining a radio market and determining the number of stations in a market, however, were not altered by the 1996 Act or by our Orders implementing that statute.

3. Using this methodology, we evaluate whether a proposed transaction complies with our ownership rules by first determining the boundaries of each market created by the transaction. Thus, we look to all stations that will be commonly owned after the proposed transaction is consummated and group these stations into “markets” based on which stations have mutually overlapping signal contours. A market is defined as the area within the combined contours of the stations to be commonly owned that have a common overlap. For example, suppose an applicant proposes to own stations A, B, C, and D. The contours of stations A, B, and C each overlap the contours of the other two stations—that is, there is some area which the contours of all three stations have in common. Station D, on the other hand, overlaps the principal community contour of station A, but not those of stations B or C. Under our current definitions, the area encompassed by the combined contours of stations A, B, and C form one “market” and the area within the combined contours of stations A and D form another market.

4. To determine the total number of stations “in the market,” as defined above, we count all stations whose principal community contours overlap the principal community contour of any one or more of the stations whose contours define the market. Thus, in the market formed by the contours of stations A, B, and C, any station whose contour overlapped the contour of A, B or C would be counted as “in the market.” We use a different methodology, however, to determine the number of stations that any single entity is deemed to own in a given market. For this purpose, we only count those stations having principal community contours overlap the common overlap area of all of the stations whose contours define the market. Thus, a station owned by the applicant that is counted as being “in the market” because its contour overlaps the contour of at least one of the stations that create the market will not be counted as a station owned by the applicant in the market unless its contour overlaps the area which the contours of all of the stations that define the market have in common. Referring to our example of the market formed by the contours of stations A, B, and C, station D would be counted as “in the market” because its contour overlaps the contour of station A. But, station D would not be counted as a station owned by the applicant in the ABC market because station D’s contour does not also overlap the contours of stations B and C. In short, the applicant’s ownership of station D would not be counted against it in determining compliance with the ownership cap in the ABC market.

5. Our experience has led us to conclude that this framework may be having results that may frustrate the structure of the statute and that are not in the public interest. For example, under the existing policies and rules, the Commission’s Mass Media Bureau recently determined that Wichita, KS, is a market containing 52 stations and granted the assignment application for station KOEZ(FM) from Kansas Radio Assets to Journal Broadcasting Corporation, giving Journal six stations, including 5 FM stations, in the Wichita market. This is well within the eight stations that a single owner would be permitted to own in a market with more than 45 stations under our rules implementing the 1996 Act. Yet Arbitron, which defines radio markets for commercial purposes, classifies Wichita as a 24-station market in which, under these rules, a single entity could only have an interest in six radio stations, no more than 4 of which could be in the same service. Similarly, under the existing policies and rules, BIA data show that one party seeks to own nine stations in Youngstown, OH. (Appendix B describes how our radio definitions and counting methodologies may be applied in Youngstown.) Yet Arbitron data show only 23 commercial radio stations in the Youngstown metropolitan area. In another transaction, using the Commission’s methodology, an applicant was able to show that Ithaca, NY, was a market with at least 32 commercial radio stations. Yet Arbitron data show only 9 commercial radio stations in the Ithaca metropolitan area.

6. Given such results, we question whether the use of overlapping signal contours is an appropriate means of defining market boundaries and counting the number of stations in a market. Our methodology sometimes leads to results that are completely at odds with commercial market definitions and economic reality, and may undermine the structure of the statute to allow levels of ownership that increase commensurately with the size of the market. Additionally, our methodology may encourage applicants to structure transactions to fragment what are commercially considered single markets into a number of smaller markets. While a licensee may be within our ownership limit as to each of these fragmented markets, in the aggregate it owns more stations than our rules would permit were these markets considered to be a single market, as they are by commercial rating services and would be under any economically meaningful market definition.

7. The Commission has used this methodology for defining markets and counting stations in markets since 1992. While the methodology has produced some odd results since its inception, it was not until the ownership limits were substantially increased in 1996 that the methodology’s potential to cause results at odds with economic reality became clearly discernible. Until then, the number of problems and their impact were constrained, by the more modest numerical ownership limits and by a 25 percent audience share cap in markets with 15 or more stations.

8. Another problem with this methodology was highlighted in the Commission’s recent Pine Bluff decision. (In re Application of Pine Bluff Radio, Inc., 14 FCC Rcd 6594 (1999).) In that case, Seark Radio, Inc., sought to purchase one AM and two FM stations in Pine Bluff, Arkansas. Seark already had direct or attributable interests in three other stations in Pine Bluff and environs. A petitioner (Bayou Broadcasting, Inc.) filed a Petition to Deny claiming, in part, that the relevant market contained 11 stations and that grant of the subject application would give Seark direct or attributable interests in 6 of those stations. Were this the case, it would have caused Seark to exceed the “cap” that one party can have in an 11-station market because it would give it interests in more than 5 of the stations in the market. In a decision which we recently reaffirmed on review, the Mass Media Bureau determined that, under the Commission’s method for defining markets and counting the number of stations in a market, the stations involved actually formed three separate markets. Market 7 was formed by two mutually overlapping stations attributable to Seark. Two other stations...
were determined to contribute to this market. One of those two stations was owned by Seark. However, because this station’s principal community contour did not overlap the principal community contours of both of the stations whose overlapping principal community contours established the market, it was not counted as an attributable interest of Seark’s in this market. Thus, application of our existing methodologies led to the determination that this Seark station would be counted as being “in the market” for purposes of determining the base number of stations in that market. But, the same station would not be considered to be “in the market” for the purposes of determining how many stations in the market were and would be owned by Seark, and thus whether Seark complied with the numerical station caps. Seark could not have owned three stations in this market because that would have given it an attributable interest in more than half of the four stations considered to be in Market 3. Section 73.3555(a)(1)(iv) allows a party to own, operate, or control up to 5 commercial stations in markets with 14 or fewer stations provided that “a party may not own, operate, or control more than 50 percent of the stations in such market.” Accordingly, strict compliance with our precedents in this area led to the conclusion that Seark had an attributable interest in only two of the four stations in this market, notwithstanding its attributable interest in a third station which counted as a station for the purpose of determining the total number of stations in the market. (We recognized that this appeared to be an anomalous result but pointed out that it was produced by methodology that had been consistently used since 1992 and that subsequent events in the market had rendered harmless the impact of this anomaly in that case.)

**Options**

9. Several options or approaches present themselves as possible means of addressing the definitional issues raised in the preceding discussion. With respect to the counting consistency issue exemplified by the Pine Bluff case, the most direct solution might be simply to alter our counting methodology and count against an applicant’s ownership allowance in a given market any station that it owned and that was included in determining how many stations were “in the market” for purposes of assessing compliance with the local radio ownership rules. Under this proposed approach, the applicant in the Pine Bluff case would have been charged with ownership of three stations in a four-station market, rather than two, and the transaction would not have complied with the numerical limits in our rules. This would clearly and logically resolve the inconsistency in our present approach and produce more rational results. Moreover, this approach may better reflect the statute’s structure, and lend consistency and predictability to the commercial marketplace. We invite comment on this approach. Alternatively, we could exclude from the count of the number of stations in a market, any stations owned by the applicant, except the commonly owned stations that form the market. We seek comment on this approach.

10. Another, broader approach might address both the counting anomaly and the discontinuity between the Commission’s and commercial rating services’ definition of radio markets generally. Under this approach, we would eliminate our current market definition and, instead, rely on commercially determined market definitions. For example, we could adopt Arbitron radio metro market definitions and simply rely on these commercial delineations to determine the total number of stations in any given market and how many stations an applicant would control in that market. Arbitron-defined markets have the advantage that they attempt to reflect accurately the location of a station’s listeners and the identity of stations that are actually perceived by advertisers to be in a market. Additionally, the Department of Justice utilizes Arbitron markets in its competition analysis of radio station mergers. However, the use of Arbitron markets has the disadvantage that many radio stations are not in an Arbitron market. Out of 3100 counties in the United States, slightly less than 850 (containing, however, nearly 80 percent of the nation’s population) are in Arbitron markets. Arbitron defines a geographic area based on county lines. We recognize that Arbitron metros do not encompass all the counties that can receive some of the radio signals of the metro radio stations. However, the radio stations included in the Arbitron metro do a significant portion of their business in the counties that are included in the Arbitron metro.

11. In our 1992 decision (on reconsideration) concerning radio markets we decided not to utilize Arbitron markets to define radio markets. The Commission accepted petitioners’ arguments that Arbitron markets change regularly, the number of rated stations continually fluctuate and that Arbitron tends to undercount the number of stations in a market because it has minimum reporting standards or overcount them because it counts out-of-market stations with reportable shares in the market. See Memorandum Opinion and Order and Further Notice of Proposed Rule Making in MM Docket No. 91–140, supra at 6394–95, 57 FR 42701 (September 16, 1972). We do not believe these to be insurmountable problems and, for the reasons discussed above, we believe the use of Arbitron markets or equivalent commercial markets may result in more accurate measures of the number of stations in a market than do our current methodologies.

12. We seek comment on whether we should use Arbitron or other commercially defined markets. How should we determine the dimensions of a market when the stations involved are not located in a commercially defined market? If we use Arbitron or another commercially defined market, what should we do when a market changes? For example, population growth might result in a county that was in a single market to later be split between two markets. This could cause the number of stations in the market to drop, placing some existing ownership combinations above the local ownership limits. One approach to such changes would be to disregard them (effectively grandfathering existing combinations) until such time as a relevant application is filed, at which point we would apply the market definition in effect at the time of the application’s filing or grant. We seek comment on these and on alternative proposals.

13. Alternatively, should we determine the number of stations in a market using a different contour overlap standard? For example, we could count as being in a market only those stations whose principal community contours overlap or intersect the overlap area of the principal city contours of the stations whose ownership is to be merged. This might provide a superior gauge relative to the area with which we are most concerned in merger situations with respect to both competition and diversity. However, this standard might be too restrictive and thus inappropriately thwart the relaxation of the ownership rules that the 1996 Act contemplated. Is there some other overlap standard that might more accurately provide a count of the number of stations in a market? Perhaps counting only those stations that overlap a certain percentage of the contour of one or more of the mutually overlapping stations would provide
accurate results. What percentage would be appropriate? Another option would be simply to count only those stations that are actually heard in a market. What methodology should we use in the event we adopt this option? We invite comment on all of these alternatives.

**Procedural Matters**

14. We do not propose that any rules and policies we adopt herein should be applied retroactively to existing ownership arrangements. Those ownership arrangements were granted as being in the public interest and in accordance with applicable Commission rules and policies. There is no reason to disturb these ownership combinations. If multiple docket or rulemaking numbers appear in the caption of this proceeding, commenters must submit two additional copies for each additional docket or rulemaking number. All filings must be sent to the Commission’s Secretary, Magalie Roman Salas, Office of the Secretary, Federal Communications Commission, 445 Twelfth Street, SW., TW—A325, Washington, DC 20554.

15. Merger applications now pending or filed after the adoption of this NPRM but before our final decision in this proceeding present another case. As a general matter, we will continue to process applications under the existing standards, unless and until they are changed in this proceeding. In cases raising concerns about how we count the number of stations a party owns in a market, however, we will defer decision pending resolution of that issue in this proceeding. As we concluded in the 1998 Biennial Review Report, the “shifting market definition” in our counting methodology “appears illogical and contrary to Congress’ intent.” Given this conclusion, it would be inappropriate to continue to apply this standard to pending and newly filed applications. We believe that the harm caused by application of this standard would not harm caused by the deferment of decision on these applications. We intend to act expeditiously in this proceeding to ensure that any such deferments are few in number and short in duration.

**Administrative Matters**


17. Comments filed through the ECFS can be sent as an electronic file via the Internet to <http://www.fcc.gov/e-file/ecfs.html>. Generally, only one copy of an electronic submission must be filed. If multiple docket or rulemaking numbers appear in the caption of this proceeding, commenters must transmit one electronic copy of the comments to each docket or rulemaking number referenced in the caption. In completing the transmittal screen, commenters should include their full name, Postal Service mailing address, and the applicable docket or rulemaking number. Parties may also submit an electronic comment by Internet e-mail. To get filing instructions for e-mail comments, commenters should send an e-mail to ecf@fcc.gov, and should include the following words in the body of the message, “get form <your e-mail address>.” A sample form and directions will be sent in reply. Parties who choose to file by paper must file an original and four copies of each filing. If more than one docket or rulemaking number appear in the caption of this proceeding, commenters must submit two additional copies for each additional docket or rulemaking number. All filings must be sent to the Commission’s Secretary, Magalie Roman Salas, Office of the Secretary, Federal Communications Commission, 445 Twelfth Street, SW., TW—A325, Washington, DC 20554.

18. Parties who choose to file by paper should also submit their comments on diskette. Diskettes should be submitted to: Wanda Hardy, 445 Twelfth Street, SW., Room, 2—C207, Washington, DC 20554. Such a submission should be on a 3.5 inch diskette formatted in an IBM compatible format using MS Word 97 for Windows or compatible software. The diskette should be accompanied by a cover letter and should be submitted in “read only” mode. The diskette should be clearly labeled with the commenter’s name, proceeding (including the docket number in this case, MM Docket No. 00—244, type of pleading (comment or reply comment), date of submission, and the name of the electronic file on the diskette. The label should also include the following phrase “Disk Copy—Not an Original.” Each diskette should contain only one party’s pleadings, preferably in a single electronic file. In addition, commenters must send diskette copies to the Commission’s copy contractor, International Transcription Service, Inc., 445 Twelfth Street, SW., CY—B402, Washington, DC 20554.

19. Comments and reply comments will be available for public inspection during regular business hours in the FCC Reference Center, Federal Communications Commission, 445 Twelfth Street, SW., CY—A257, Washington, DC 20554. Persons with disabilities who need assistance in the FCC Reference Center may contact Bill Cline at (202) 418—0270, (202) 418—2555 TTY. Comments and reply comments will also be available electronically at the Commission’s


20. This document is available in alternative formats (computer diskette, large print, audio cassette, and Braille). Persons who need documents in such formats may contact Martha Conteet at (202) 4810—0260, TTY (202) 418—2555, or mconteet@fcc.gov.

21. **Ex Parte Rules.** This is a permissive but-disclose notice and comment rulemaking proceeding. Ex parte presentations are permitted except during the Sunshine Agenda period, provided they are disclosed as provided in the Commission’s Rules. See generally 47 CFR 1.1202, 1.1203, and 1.1206(a).

22. **Initial Regulatory Flexibility Analysis.** As required by Section 603 of the Regulatory Flexibility Act, the Commission has prepared the following IRFA of the possible significant economic impact on small entities of the proposals contained in this NPRM. Written public comments are requested on the IRFA. In order to fulfill the mandate of the Contract with America Advancement Act of 1996 regarding the Final Regulatory Flexibility Analysis, we ask a number of questions in our IRFA regarding the prevalence of small businesses in the radio broadcasting industry. Comments on the IRFA must be filed in accordance with the same filing deadlines as comments on the NPRM, but they must have a distinct heading designating them as responses to the IRFA.

23. As required by the Regulatory Flexibility Act (RFA), the Commission has prepared this present Initial Regulatory Flexibility Analysis (IRFA) of the possible significant economic impact on small entities by the policies and rules proposed in this NPRM. Written public comments are requested on this IRFA. Comments must be identified as responses to the IRFA and must be filed by the deadlines for comments on the NPRM provided above in paragraph 16. The Commission will send a copy of the NPRM, including this IRFA, to the Chief Counsel for Advocacy of the Small Business Administration (SBA). See 5 U.S.C. 603(a). In addition, the NPRM and the IRFA (or summaries thereof) will be published in the Federal Register.

A. **Need for, and Objectives of, the Proposed Rules**

24. Section 202(h) of the Telecommunications Act of 1996 (1996 Act) requires the Commission to review all of its broadcast ownership rules
every two years commencing in 1998, and to determine whether any of these rules are necessary in the public interest as the result of competition. The 1996 Act also requires the Commission to repeal or modify any regulation it determines to be no longer in the public interest. The Commission adopted a Notice of Inquiry (63 FR 15353, March 31, 1998) in 1998 in compliance with this requirement. The Commission believes that its present method of determining the dimensions of radio markets and/or of counting the stations available in those markets may be having results that do not reflect the structure of the Telecommunications Act with regard to local radio station ownership and are not in the public interest. Present methodology may result in radio markets whose dimensions do not reflect actual listening patterns or availability, artificially enhance the number of stations in those markets or artificially fragment what may be single individual markets into several independent smaller markets, thereby allowing a single owner to own a number of stations in a market in excess of what Congress intended. Our methodology sometimes leads to results that are completely at odds with commercial market definitions and economic reality, and thus does not advance the statute structure which allows levels of ownership that increase commensurately with the size of the market. Additionally, the Commission determined in its biennial review proceeding (MM Docket No. 98–35) that it appears that the way in which it determines the number of radio stations that a party owns in a market may have lead to unintended results. This NPRM is designed to solicit comment on proposals to assure that our definitions and methodologies more closely reflect commercial realities and the intent of Congress. Because Section 202(h) of the 1996 Act directs the Commission to repeal or modify any broadcast ownership regulation it finds no longer in the public interest the Commission has adopted this NPRM to solicit comment on the modification of the subject policies and rules. 

B. Legal Basis

25. This NPRM is adopted pursuant to sections 1, 2(a), 4(i), 303, 307, 309, 310, of the Communications Act of 1934, as amended, 47 U.S.C. 151, 152(a), 154(i), 303, 307, 309, 310, and Section 202(h) of the Telecommunications Act of 1996.

C. Description and Estimate of the Number of Small Entities to Which the Proposed Rules Will Apply

26. The RFA directs agencies to provide a description of, and, where feasible, an estimate of the number of small entities that may be affected by the proposed rules, if adopted. The RFA defines the term “small entity” as having the same meaning as the terms “small business,” “small organization,” and “small governmental jurisdiction.” In addition, the term “small business” has the same meaning as the term “small business concern” under the Small Business Act. A small business concern is one which: (1) Is independently owned and operated; (2) is not dominant in its field of operation; and (3) satisfies any additional criteria established by the SBA.

27. The SBA defines a radio broadcasting station that has $5 million or less in annual receipts as a small business. A radio broadcasting station is an establishment primarily engaged in broadcasting aural programs by radio to the public. Included in this industry are commercial, religious, educational, and other radio stations. The 1992 Census indicates that 96 percent of radio station establishments produced less than $5 million in revenue in 1992. Official Commission records indicate that 11,334 individual radio stations were operating in 1992. As of September 30, 2000, Commission records indicate that 12,717 radio stations (both commercial and noncommercial) were operating of which 2,140 were noncommercial educational FM radio stations. (Our multiple ownership rules, however, do not apply to noncommercial educational radio stations.) Applying the 1992 percentage of station establishments producing less than $5 million in revenue (i.e., 96 percent) to the number of commercial radio stations in operation, (i.e., 10,577) indicates that 10,154 of these radio stations would be considered “small businesses” or “small organizations.”

D. Description of Projected Reporting, Recordkeeping, and Other Compliance Requirements

28. There currently are no recordkeeping or other compliance requirements associated with the subject rule and policies. The NPRM proposes no new recordkeeping or other compliance requirements.

E. Steps Taken To Minimize Significant Impact on Small Entities, and Significant Alternatives Considered

29. The RFA requires an agency to describe any significant alternatives that it has considered in reaching its proposed approach, which may include the following four alternatives (among others): (1) The establishment of differing compliance or reporting requirements or timetables that take into account the resources available to small entities; (2) the clarification, consolidation, or simplification of compliance or reporting requirements under the rule for small entities; (3) the use of performance, rather than design, standards; and (4) an exemption from coverage of the rule, or any part thereof, for small entities.

30. In fashioning its Report in the Commission’s Biennial Review Proceeding (MM Docket No. 98–35) the Commission considered a number of alternatives to the subject counting methodology policy. These alternatives were: (1) Retention of the existing radio market definition policy; (2) modification of the existing radio market definition policy; (3) retention of the existing rule (47 CFR 73.3555(a)(3)(iii)) concerning counting the number of stations in the radio market; (4) modification of the existing rule concerning counting the number of stations in the radio market; (5) retention of the existing policy for counting the number of stations a party owns in a radio market; and (6) modification of the existing policy for counting the number of stations a party owns in a radio market. The Biennial Review Report tentatively concluded that the existing policy for determining radio markets and counting methodology rule and policy should be modified. An alternative considered in this item is to maintain the status quo. However, the NPRM does propose to modify the current method of defining radio markets and to modify our station-counting methodologies. Alternatives (2), (4), and (6) may have a beneficial effect on small entities. A more accurate and predictable definition of radio markets, and improved counting methodologies may more precisely determine the size of markets and the number of stations in them and allow the Commission to achieve the results intended by Congress in passing the 1996 Act. This could result in some small radio stations facing competition from commonly owned local station groups that are more of the size Congress intended than is the case under current Commission rules and policies. Any significant alternatives presented in the comments received in response to the instant NPRM will certainly be considered.
SUPPLEMENTARY INFORMATION: This is a synopsis of the Commission’s Report and Order, MM Docket No. 99–352, adopted December 13, 2000, and released December 22, 2000. The full text of this Commission decision is available for inspection and copying during normal business hours in the FCC’s Reference Information Center (Room CY–A257), 445 Twelfth Street, SW., Washington, DC.

The complete text of this decision may also be purchased from the Commission’s copy contractor, International Transcription Service, Inc., 1231 20th Street, NW., Washington, DC 20036, (202) 857–3800.

Federal Communications Commission.

John A. Karousos,
Chief, Allocations Branch, Policy and Rules Division, Mass Media Bureau.

[FR Doc. 00–33213 Filed 12–27–00; 8:45 am] BILLING CODE 6712–01–P

DEPARTMENT OF THE INTERIOR
Fish and Wildlife Service

50 CFR Part 17

Endangered and Threatened Wildlife

Endangered and Threatened Wildlife and Plants; Notice of Designation of the Gunnison Sage Grouse as a Candidate Species

AGENCY: Fish and Wildlife Service, Interior.

ACTION: Notice of designation of a candidate species.

SUMMARY: In this document, we present information on the recent addition of the Gunnison sage grouse (Centrocercus minimus) found in Colorado and Utah to the list of candidates for listing under the Endangered Species Act of 1973, as amended. Identification of candidate taxa can assist environmental planning efforts by providing advance notice of potential listings, allowing resource managers to alleviate threats and, thereby, possibly remove the need to list taxa as endangered or threatened. Even if we subsequently list this candidate species, the early notice provided here could result in fewer restrictions on activities by prompting candidate conservation measures to alleviate threats to this species.

We also announce the availability of the candidate and listing priority assignment form for this candidate species. This document describes the status and threats that we evaluated to determine that Gunnison sage grouse warrants consideration for listing, and to assign a listing priority to this species.

We request additional status information that may be available for the Gunnison sage grouse. We will consider this information in evaluating, monitoring, and developing conservation strategies for this species.

DATES: We will accept comments on this document at any time.

ADDRESSES: Submit written comments and data regarding the Gunnison sage grouse to the U.S. Fish and Wildlife Service, Western Colorado Field Office, 764 Horizon Drive, South Annex A, Grand Junction, Colorado 81506–3946.

FOR FURTHER INFORMATION CONTACT: Terry Ireland, at the above address, e-mail <terry_ireland@fws.gov>, or telephone (970) 243–2778.

SUPPLEMENTARY INFORMATION: Background

The Endangered Species Act of 1973, as amended (Act) (16 U.S.C. 1531 et seq.), requires that we list taxa of wildlife and plants that are endangered or threatened, based on the best available scientific and commercial information. As part of this program, we also identify taxa that we regard as candidates for listing. Candidate taxa are those taxa for which we have on file sufficient information to support issuance of a proposed rule to list under the Act. In addition to our annual review of all candidate taxa (64 FR 57534; October 25, 1999), we have an on-going review process, particularly to update taxa whose status may have changed markedly.

Section 3 of the Act generally defines an endangered species as any species which is in danger of extinction throughout all or a significant portion of its range, and a threatened species as any species which is likely to become an endangered species within the foreseeable future throughout all or a significant portion of its range. A species may be determined to be an endangered or threatened species due to one or more of the five factors described in section 4(a)(1) of the Act.

(A) The present or threatened destruction, modification, or curtailment of the species’ habitat or range;

(B) Overutilization of the species for commercial, recreational, scientific, or educational purposes;

(C) Disease or predation affecting the species;

(D) The inadequacy of existing regulatory mechanisms to protect the species; and

(E) Other natural or manmade factors affecting the species’ continued existence.

We are required to make the listing determination “solely on the basis of the
that either positively or negatively affect other specific conservation measures, regulations, ordinances, programs, or us to consider any State or local laws, Sections 4(a)(1) and 4(b)(1)(A) and our predator control, protection of habitat subdivision of a State or foreign nation, State or foreign nation, or any political efforts that create, exacerbate, reduce, or remove threats identified through the section 4(a)(1) analysis.

We maintain the list of candidate species for a variety of reasons, including—to provide advance knowledge of potential listings that could affect decisions of environmental planners and developers; to solicit input from interested parties to identify those candidate taxa that may not require protection under the Act or additional taxa that may require the Act’s protections; and to solicit information needed to prioritize the order in which we will propose taxa for listing. We encourage consideration of candidate taxa in environmental planning, such as in environmental impact analysis under the National Environmental Policy Act of 1969 (implemented at 40 CFR parts 1500–1508) and in local and Statewide land use planning.

According to our 1983 Listing Priority System (48 FR 43098; September 21, 1983), all species that are candidates for listing are assigned a listing priority number. This system ranks species according to—(1) the magnitude of threats they face, (2) the immediacy of these threats, and (3) the taxonomic distinctiveness of the entity that may be listed. Listing priority numbers range from 1 (highest priority) to 12 (lowest priority). We will complete proposals to list candidate species, based on their listing priority, to the extent that our resources for listing activities and our workload for other listing activities will allow.

This document provides specific explanation for the classification of Gunnison sage grouse as a candidate. It is important to note that candidate assessment is an ongoing function and changes in status should be expected. If we remove taxa from the candidate list, they may be restored to candidate status if additional information supporting such listing becomes available to us. We issue requests for such information in a Candidate Notice of Review published in the Federal Register every year.

Findings

In 1977, Dr. Clait Braun, formerly with the Colorado Division of Wildlife, noticed that sage grouse (Centrocercus sp.) wings collected in the Gunnison Basin of southwestern Colorado were smaller than sage grouse wings collected in northern Colorado. Over the 2 decades since then, Dr. Braun and others have been studying the morphological (Hupp and Braun 1991), behavioral (Young et al. 1994, Braun and Young 1995) and genetic differences (Quinn et al. 1997, Kahn et al. 1999, Oyler-McCance 1999) between the sage grouse. The differences are great enough that the American Ornithologists’ Union has determined that the sage grouse in southwestern Colorado are a distinct species, the Gunnison sage grouse (C. minimus). The American Ornithologists’ Union included a footnote about the Gunnison sage grouse potentially becoming a distinct species in their latest list of bird species. The July 2000 issue of Auk is planned to contain the American Ornithologists’ Union’s next list of bird species that will formally include the Gunnison sage grouse as a distinct species (Dr. Richard Banks, National Museum of Natural History, pers. comm. 2000).

Through museum specimens or written accounts, Braun (1995) determined that the Gunnison sage grouse’s historic range occurred in southwestern Colorado, southwestern Kansas, northwestern Oklahoma, northern New Mexico, northeastern Arizona, and southeastern Utah. There are currently believed to be seven population areas in Colorado and one population in Utah. The Gunnison Basin breeding population is the largest with up to 3,000 birds. The other 6 populations in Colorado only have 6 to 300 breeding birds, and the Monticello, Utah, population also is only around 120 birds for a total breeding population around 4,000. Long-term trends since at least the 1970s have shown steady declines in the number of males/lek, and one area, Sims Mesa, may have recently been extirpated. The overall population numbers have increased the last 2 to 3 years in the Gunnison Basin; however, this may be attributed to increased survey efforts. The number of males/lek in the Crawford Area population has increased since 1993, though the overall population estimate is not greater than 320. Other populations appear to be stable in the last 3 to 4 years but remain small.

The Gunnison sage grouse uses a variety of habitats throughout the year but the primary component necessary is species of Artemisia spp. (sagebrush) (Braun 1995). The most important sagebrushes are subspecies of A. tridentata (big sagebrush). Sagebrush is used for hiding and thermal cover as well as a major source of food in the winter (Hupp and Braun 1989). From mid-March to early June males will display on leks (strutting grounds) that are open areas with good visibility (for predator detection) and acoustics (for transmission of male display sounds). After mating, females will select nest sites, typically in relatively tall and dense stands of sagebrush from 200 yards (183 meters) to 5 miles (8 kilometers) away from the leks. Nest sites selected have residual grass and forbs that provide additional hiding cover. Hens with chicks remain in sagebrush uplands if hiding cover is adequate and if food consisting of succulent forbs and insects are available. As chicks mature and vegetation in the uplands desiccates, hens will move their broods to wet meadow areas that retain succulent forbs and insects through the summer (Klebenow 1969, Wallestad 1971). Preferred wet meadow areas also contain tall grasses for hiding and at least 165-yard (150-meter) wide sagebrush stands (Dunn and Braun 1986) along the periphery for hiding and foraging areas. From mid-September into November all sage grouse will use upland areas with 20 percent or greater sagebrush cover and some green forbs. As winter progresses and snow cover is extensive (greater than 80 percent) and deep (greater than 12 inches (30 centimeters)), sage grouse forage in tall sagebrush (greater than 16 inches (41 centimeters)) in valleys and lower flat areas (Hupp and Braun 1989) and roost in shorter sagebrush along ridge tops. Roosting and foraging is typically restricted to south or west facing slopes where snow is often shallower and less extensive (Hupp and Braun 1989). Small foraging areas that have 30–40 percent big sagebrush canopy cover also are important.

Potential threats include reduction in habitat by direct habitat loss, fragmentation, and degradation from building development, road and utility corridors, fences, energy development, conversion of native habitat to hay or other crop fields, alteration or destruction of wetland and riparian areas, inappropriate livestock management, competition for winter range by big game, and creation of large reservoirs.
Other factors affecting the Gunnison sage grouse include fire suppression allowing encroachment of its habitat by *Pinus edulis* (pinyon) and *Juniperus* spp. (juniper) invasion, fire suppression resulting in decadent stands of the sagebrush community, overgrazing by elk (*Cervus elaphus*) and deer (*Odocoileus hemionus*), drought, disturbance or death by off-highway-vehicles, disturbance by construction projects, harassment from people and pets, continuous noise that impairs acoustical quality of leks, genetic depression, herbicides, pesticides, pollution, and competition for habitat from other species.

Despite development of the Conservation Plans and numerous actions implemented under those Plans to date, all of the threats to the Gunnison sage grouse, under the five listing factors, should be considered non-imminent threat with a high magnitude of occurring, or have potential to occur. In addition, the reduction of about 75 percent of the range and uncertain continued existence of the small, disjunct, populations outside of the Gunnison Basin population, leads us to believe that listing the Gunnison sage grouse as threatened is warranted. Therefore, we have assigned the Gunnison sage grouse a listing a priority of five under our Listing Priority System.

**Request for Information**

We request you submit any further information on the Gunnison sage grouse as soon as possible or whenever it becomes available. We are seeking the following types of information:

1. Biological, commercial trade, or other relevant data concerning any threat (or lack thereof) to the Gunnison sage grouse;
2. Reasons why any habitat of this species should or should not be determined to be critical habitat pursuant to section 4 of the Act;
3. Additional information concerning the range, distribution, and population size of this species; and,
4. Current or planned activities in the subject area and their possible impacts on this species.

Information regarding the range, status, habitat needs, and listing priority assignment for the Gunnison sage grouse is available for review by contacting the Service as specified in the **ADDRESSES** section.

Our practice is to make comments, including names and home addresses of respondents, available for public review during regular business hours. Individual respondents may request that we withhold their home address from the rulemaking record, which we will honor to the extent allowable by law. In certain circumstances, we would withhold from the rulemaking record a respondent’s identity, as allowable by law. If you wish for us to withhold your name and/or address, you must state this request prominently at the beginning of your comment. However, we will not consider anonymous comments. We will make all submissions from organizations or businesses, and from individuals identifying themselves as representatives or officials of organizations or businesses, available for public inspection in their entirety.

**References Cited**

A complete list of all references cited herein, as well as others, is available upon request from the Marine Mammals Management Office (see **ADDRESSES** section).

**References Cited**


**Author**

The author of this notice is Terry Ireland (see **ADDRESSES** section).

**Authority**

The authority for this action is the Endangered Species Act of 1973, as amended, 16 U.S.C. 1531 et seq.


**John A. Blankenship,**

Deputy Regional Director, U.S. Fish and Wildlife Service.

[FR Doc. 00–33089 Filed 12–27–00; 8:45 am]
This section of the FEDERAL REGISTER contains documents other than rules or proposed rules that are applicable to the public. Notices of hearings and investigations, committee meetings, agency decisions and rulings, delegations of authority, filing of petitions and applications and agency statements of organization and functions are examples of documents appearing in this section.

DEPARTMENT OF AGRICULTURE

Submission for OMB Review; Comment Request


The Department of Agriculture has submitted the following information collection requirement(s) to OMB for review and clearance under the Paperwork Reduction Act of 1995, Public Law 104–13. Comments regarding (a) whether the collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (b) the accuracy of the agency’s estimate of burden including the validity of the methodology and assumptions used; (c) ways to enhance the quality, utility and clarity of the information to be collected; (d) ways to minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology should be addressed to: Desk Officer for Agriculture, Office of Information and Regulatory Affairs, Office of Management and Budget (OMB), Washington, DC 20503 and to Departmental Clearance Office, USDA, OCIO, Mail Stop 7602, Washington, DC 20250–7602. Comments regarding these information collections are best assured of having their full effect if received within 30 days of this notification. Copies of the submission(s) may be obtained by calling (202) 720–6746.

An Agency may not conduct or sponsor a collection of information unless the collection of information displays a currently valid OMB control number.

Cooperative State Research, Education, and Extension Service

Title: Grant Application Forms for Higher Education Programs.

OMB Control Number: 0524–0030.

Summary of Collection: The Cooperative State Research, Education, and Extension Service (CSREES), Science and Education Resources Development (SERD) division, though its Higher Education Program (HEP) office, administers several competitive peer-reviewed research and teaching programs under which grants of a high-priority nature are awarded. These programs are authorized pursuant to the authorities contained in the National Agricultural Research, Extension, and Teaching Policy Act of 1977, as amended (7 U.S.C. 3101), section 1417(b)(1) for the Challenge Grants Program (7 U.S.C. 3152), section 1417(b)(4) for the 1890 Institution Capacity Building Grants Program (7 U.S.C. 3152), section 1455 for the Hispanic-Serving Institutions Education Grants Program (7 U.S.C. 301 et seq.) for the Tribal Colleges Education Equity Grants Program. Before grants can be awarded, certain information is required from applicants as part of the overall package. CSREES will collect the information using several forms.

Need and Use of the Information: CSREES will collect information to evaluate proposals. The information collected will reduce the potential for errors or omissions of important data essential in the proposal review and award process.

Description of Respondents: Not-for-profit institutions; State, Local or Tribal Government.

Number of Respondents: 450.

Frequency of Responses: Recordkeeping; Reporting; On occasion.

Total Burden Hours: 5,376.

Cooperative State Research, Education, and Extension Service

Title: Application Kit for Research and Extension Programs.

OMB Control Number: 0524–NEW.

Summary of Collection: The United States Department of Agriculture (USDA), Cooperative State Research, Education, and Extension Service (CSREES) administers several competitive, peer-reviewed research and extension programs, under which awards of a high-priority nature are made. These programs are authorized pursuant to the authorities contained in the National Agricultural Research, Extension, and Teaching Policy Act of 1977, as amended (7 U.S.C. 3101), the Smith-Lever Act, and a variety of other legislative authorities. Before grants can be awarded, certain information is required from applicants as part of an overall package. Because the proposals submitted are competitive in nature and necessitate review by peer panelists, it is particularly important that applicants provide the information in a standardized fashion to ensure equitable treatment for all. CSREES will collect information using forms CSREES 2002, 2003, 2004, 2005, 2006, 2007, and 2008.

Need and Use of the Information: CSREES will collect the following information: Program Summary and Narrative, Credentials, Budget, Identification of Conflicts of Interest, Narrative, Budget, need and Use of the Information: CSREES will collect information to evaluate proposals. The information collected will reduce the potential for errors or omissions of important data essential in the proposal review and award process.

Description of Respondents: Not-for-profit institutions; State or Local; Federal Government; Tribes or Tribal Government.

Number of Respondents: 8,900.

Frequency of Responses: Reporting: Annually.

Total Burden Hours: 144,700.

Rural Housing Service

Title: 7 CFR 1927–B, “Real Estate Title Clearance and Loan Closing”.

OMB Control Number: 0575–0147.

Summary of Collection: Rural Development and the Farm Service Agency are the credit agencies for the Department of Agriculture. They offer a supervised credit program to build family farms, modest housing, sanitary water and sewer systems, essential community facilities, businesses and industries in rural areas. Section 501 of Title V of the Housing Act of 1949, as amended, authorizes the Secretary of Agriculture to extend financial assistance to construct, improve, alter, repair, replace or rehabilitate dwellings, farm buildings and or related facilities to provide decent, safe, and sanitary

Federal Register

Vol. 65, No. 250

Thursday, December 28, 2000

82313
living conditions and adequate farm buildings and other structures in rural areas. Title clearance is required to assure the agency(s) that the loan is legally secured and has the required lien priority.

Need and Use of the Information: Forms and/or guidelines are provided to assist in the collection and submission of information. The agency personnel use the required information to verify that the required lien position has been obtained. The information is collected at the field office responsible for processing a loan application through loan closing and is also used to insure the program is administered in a manner consistent with legislative and administrative requirements. If the information were not collected, the agency would be unable to determine if the loan is adequately and legally secured.

Description of Respondents: Individuals or households; Business or other for-profit; Not-for-profit institutions; Farms.

Number of Respondents: 32,000.

Frequency of Responses: Reporting:
On occasion.

Total Burden Hours: 41,296.

Food and Nutrition Service

Title: Evaluation of the School Breakfast Pilot Project.

OMB Control Number: 0584–NEW.

Summary of Collection: Section 109(b) of the William F. Goodling Child Nutrition Act of 1998 (Pub. L. 105–336) amended Section 18 of the Richard B. Russell National School Lunch Act (42 U.S.C. 1769) to authorize a pilot study that provides free school breakfast to all students regardless of family income in up to six school districts. The evaluation will rigorously assess the impact of this universal-free school breakfast program on program participation and a board range of student outcomes, including academic achievement, school attendance and tardiness, classroom behavior and attentiveness, and dietary status.

Need and Use of the Information: The Food and Nutrition Service (FNS) will collect information from school district personnel to examine how school districts and schools administer the universal-free breakfast program and the impact it has on their costs and administrative duties. FNS will also collect information from students, parents, teachers, and school records to determine effects on students.

Description of Respondents: Not-for-profit institutions; Individual or households.

Number of Respondents: 9,792.

Frequency of Responses: Reporting:
On occasion.

Total Burden Hours: 7,817.

Sondra Blakey,
Departmental Clearance Officer.
[FR Doc. 00–33137 Filed 12–27–00; 8:45 am]

DEPARTMENT OF AGRICULTURE

Commodity Credit Corporation

Announcement of the Foreign Market Development Cooperator Program for Fiscal Year 2002

AGENCY: Commodity Credit Corporation, USDA.

ACTION: Notice.

SUMMARY: This notice announces the application period for the Fiscal Year 2002 Foreign Market Development Cooperator (Cooperator) Program.

DATES: All applications must be received by 5 p.m. Eastern Standard Time, March 12, 2001.


SUPPLEMENTARY INFORMATION:

Introduction

The Commodity Credit Corporation (CCC) announces that applications are being accepted for participation in the Fiscal Year 2002 Cooperator program. The program is designed to create, expand, and maintain foreign markets for United States agricultural commodities and products through cost-share assistance. Financial assistance under the Cooperator program will be made available on a competitive basis and applications will be reviewed against the evaluation criteria contained herein. The Cooperator program is administered by personnel of the Foreign Agricultural Service (FAS).

Under the Cooperator program, CCC enters into agreements with nonprofit U.S. trade organizations that have the broadest possible producer representation of the commodity being promoted and gives priority to those organizations that are nationwide in membership and scope. Cooperators may only receive assistance for the promotion of generic activities that do not involve promotions targeted directly at consumers. The program generally operates on a reimbursement basis.

Authority


Eligible Applicants

To participate in the Cooperator program, an applicant must be a nonprofit U.S. agricultural trade organization.

Application Process

To be considered for the Cooperator program, an applicant must submit to FAS information required by the Cooperator program regulations set forth in 7 CFR part 1484. Incomplete applications and applications that do not otherwise conform to this announcement will not be accepted for review.

We also point out that FAS administers various other agricultural export assistance programs, including the Market Access Program (MAP), Cochran Fellowships, the Emerging Markets Program, the Quality Samples Program, Section 108 foreign currency guarantee programs, and several Export Credit Guarantee programs. Organizations which are interested in applying for Cooperator program funds are encouraged to submit their requests using the Unified Export Strategy (UES) format. The UES format allows interested entities to submit a consolidated and strategically coordinated single proposal that incorporates requests for funding and recommendations for virtually all FAS marketing programs, financial assistance programs, and market access programs. The suggested UES format encourages applicants to examine the constraints or barriers to trade they face, identify activities which would help overcome such impediments, consider the entire pool of complementary marketing tools and program resources, and establish realistic export goals.

Applicants are not required, however, to use the UES format. Organizations can submit applications in the UES format by two methods. The first allows an applicant to submit information directly to FAS through the UES application Internet site. FAS highly recommends applying via the Internet, as this format virtually eliminates paperwork and expedites the FAS processing and review cycle. Applicants also have the option of submitting electronic versions (along with two paper copies) of their applications to FAS on diskette.

Applicants planning to sue the Internet-based system must contact the
Marketing Operations Staff of FAS at (202) 720–4327 to obtain site access information. The Internet-based application, including step-by-step instructions for its use, is located at the following URL address: http://www.fas.usda.gov/cooperators.html.

Applicants who choose to submit applications on diskette can download the UES handbook, including the suggested application format and instructions, from the following URL address: http://www.fas.usda.gov/mos/ues/unified.html. A UES handbook may also be obtained by contacting the Marketing Operations Staff at (202) 720–4327.

All Cooperator program applicants, whether applying via the Internet or diskette, must also submit by March 12, 2001, via hand delivery or U.S. mail, an original signed certification statement as specified in 7 CFR section 1484.20(a)(14). The UES handbook contains an acceptable certification format.

Any organization which is not interested in applying for the Cooperator program but would like to request assistance through one of the other programs mentioned, should contact the Marketing Operations Staff at (202) 720–4327.

Review Process and Allocation Criteria

FAS allocates funds in a manner that effectively supports the strategic decision-making initiatives of the Government Performance and Results Act (GPRA) of 1993. In deciding whether a proposed project will contribute to the effective creation, expansion, or maintenance of foreign markets, FAS seeks to identify a clear, long-term agricultural trade strategy and a program effectiveness time line against which results can be measured at specific intervals using quantifiable product or country goals. These performance indicators are part of FAS’ resource allocation strategy to fund applicants which can demonstrate performance based on a long-term strategic plan and address the performance measurement objectives of the GPRA.

Following is a description of the FAS process for reviewing applications and the criteria for allocating available Cooperator program funds.

1) Phase 1—Sufficiency Committee and FAS Divisional Review

Application received by the closing date will be reviewed by FAS to determine the eligibility of the applicants and the completeness of the applications. These requirements appear at § 1484.14 and § 1484.20 of the Cooperator program regulations. Applications which meet the application requirements will then be further evaluated by the applicable FAS Commodity Division. The Divisions will review each application against the criteria listed in § 1484.21 and § 1484.22 of the Cooperator program regulations. The purpose of this review is to identify meritorious proposals and to recommend an appropriate funding level for each application based upon these criteria.

(a) Contribution Level

• The applicant’s 6-year average share (1997–2002) of all contributions (contributions may include cash and goods and services provided by U.S. entities in support of foreign market development activities) compared to
• The applicant’s 6-year average share (1997–2002 of all Cooperator marketing plan budgets.

(b) Past Export Performance

• The 6-year average share (1996–2001) of the value of exports promoted by the applicant compared to
• The applicant’s 6-year average share (1996–2001 of all Cooperator marketing plan budgets plus a 6-year average share (1995–2000) of MAP program ceiling levels and a 6-year average share (1995–2000) of foreign overhead provided for co-location within a U.S. agricultural trade office.

(c) Past Demand Expansion Performance

• The 6-year average share (1996–2001) of the total value of world trade of the commodities promoted by the applicant compared to
• The applicant’s 6-year average share (1996–2001 of all Cooperator marketing plan budgets plus a 6-year average share (1995–2000) of MAP program ceiling levels and a 6-year average share (1995–2000) of foreign overhead provided for co-location within a U.S. agricultural trade office.

(d) Future Demand expansion Goals

• The projected total dollar value of world trade of the commodities being promoted by the applicant for the year 2007 compared to
• The applicant’s requested funding level.

(e) Accuracy of Past Demand expansion Projections

• The actual dollar value share of world trade of the commodities being promoted by the applicant for the year 2000 compared to
• The applicant’s past projected share of world trade of the commodities being promoted by the applicant for the year 2000, as specified in the 2000 Cooperator program application.

The Commodity Divisions’ recommended funding level for each applicant is converted to a percentage of the total Cooperator program funds available and multiplied by the total weight factor to determine the amount of funds allocated to each applicant.

Closing Date for Applications

All Internet-based applications must be properly submitted by 5:00 p.m. Eastern Standard Time, March 12, 2001. Signed certification statements also must be received by that time at one of the addresses listed below.

All applications on diskette (with two accompanying paper copies and a signed certification statement) and any other applications must be received by 5:00 p.m. Eastern Standard Time, March 12, 2001, at one of the following addresses:

Hand Delivery (including FedEx, DHL, UPS, etc.): U.S. Department of Agriculture, Foreign Agricultural Service, Marketing Operations Staff, Room 4932–S, 1400 Independence Avenue, SW., Washington, DC 20250–1042.


Timothy J. Galvin, Administrator, Foreign Agricultural Service, and Vice President, Commodity Credit Corporation.

[FR Doc. 00–33138 Filed 12–27–00; 8:45 am]

BILLING CODE 3410–10–M

DEPARTMENT OF AGRICULTURE

Commodity Credit Corporation

Announcement of the Market Access Program for Fiscal Year 2001

AGENCY: Commodity Credit Corporation, USDA.

ACTION: Notice.
SUMMARY: This notice announces the application period for the Fiscal Year 2001 Market Access Program (MAP).

DATES: All applications must be received by 5 p.m. Eastern Standard Time, March 12, 2001.


SUPPLEMENTARY INFORMATION:

Introduction

The Commodity Credit Corporation (CCC) announces that applications are being accepted for participation in the Fiscal Year 2001 MAP. The MAP is designed to create, expand, and maintain foreign markets for United States agricultural commodities and products through cost-share assistance. Financial assistance under the MAP will be made available on a competitive basis and applications will be reviewed against the evaluation criteria contained herein. The MAP is administered by personnel of the Foreign Agricultural Service (FAS).

Under the MAP, CCC enters into agreements with eligible participants to share the costs of certain overseas marketing and promotion activities. MAP participants may receive assistance for either generic or brand promotion activities. The program generally operates on a reimbursement basis.

Authority

The MAP is authorized under section 203 of the Agricultural Trade Act of 1978, as amended, and MAP regulations appear at 7 CFR part 1483.

Eligible Applicants

To participate in the MAP, an applicant must be: A nonprofit U.S. agricultural trade organization, a nonprofit state regional trade group (i.e., an association of State Departments of Agriculture), a U.S. agricultural cooperative, a State agency, or a small-sized U.S. commercial entity (other than a cooperative or producer association).

Available Funds

$90 million of cost-share assistance may be obligated under this announcement to eligible MAP applicants.

Application Process

To be considered for the MAP, an applicant must submit to FAS information required by the MAP regulations set forth in 7 CFR part 1485. Incomplete applications and applications that do not otherwise conform to this announcement will not be accepted for review. We also point out that FAS administers various other agricultural export assistance programs, including the Foreign Market Development Cooperator (Cooperator) program, Cochran Fellowships, the Emerging Markets Program, the Quality Samples Program, the Section 108 foreign currency program, and several Export Credit Guarantee programs.

Organizations which are interested in applying for MAP funds are encouraged to submit their requests using the Unified Export Strategy (UES) format. The UES allows interested entities to submit a consolidated and strategically coordinated single proposal that incorporates requests for funding and recommendations for virtually all FAS marketing programs, financial assistance programs, and market access programs. The suggested UES format encourages applicants to examine the constraints or barriers to trade they face, identify activities which would help overcome such impediments, consider the entire pool of complementary marketing tools and program resources, and establish realistic export goals. Applicants are not required, however, to use the UES format.

Organizations can submit applications in the UES format by two methods. The first allows an applicant to submit information directly to FAS through the UES application Internet site. FAS highly recommends applying via the Internet, as this format virtually eliminates paperwork and expedites the FAS processing and review cycle. Applicants also have the option of submitting electronic versions (along with two paper copies) of their applications to FAS on diskette.

Applicants planning to use the Internet-based system must contact the Marketing Operations Staff of FAS at (202) 720–4327 to obtain site access information. The Internet-based application, including step-by-step instructions for its use, is located at the following URL address: http://www.fas.usda.gov/cooperators.html. Applicants who choose to submit applications on diskette can download the UES handbook, including the suggested application format and instructions, from the following URL address: http://www.fas.usda.gov/mos/ues/unified.html. A UES handbook may also be obtained by contacting the Marketing Operations Staff at (202) 720–4327.

All MAP applicants, whether applying via the Internet or diskette, must also submit by March 12, 2001, via hand delivery or U.S. mail, an original signed certification statement as specified in 7 CFR 1485.13(a)(2)(i)(G). The UES handbook contains an acceptable certification format.

Any organization which is not interested in applying for the MAP but would like to request assistance through one of the other programs mentioned, should contact the Marketing Operations Staff at (202) 720–4327.

Review Process and Allocation Criteria

FAS allocates funds in a manner that effectively supports the strategic decision-making initiatives of the Government Performance and Results Act (GPRA) of 1993. In deciding whether a proposed project will contribute to the effective creation, expansion, or maintenance of foreign markets, FAS seeks to identify a clear, long-term agricultural trade strategy and a program effectiveness time line against which results can be measured at specific intervals using quantifiable product or country goals. These performance indicators are part of FAS’ resource allocation strategy to fund applicants which can demonstrate performance based on a long-term strategic plan and address the performance measurement objectives of the GPRA.

Following is a description of the FAS process for reviewing applications and the criteria for allocating available MAP funds.

(1) Phase 1—Sufficiency Committee and FAS Divisional Review

Applications received by the closing date will be reviewed by FAS to determine the eligibility of the applicants and the completeness of the applications. These requirements appear at § 1485.12 and § 1485.13 of the MAP regulations. Applications which meet the application requirements will then be further evaluated by the applicable FAS Commodity Division. The Divisions will review each application against the criteria listed in § 1485.14 of the MAP regulations. The purpose of this review is to identify meritorious proposals and to recommend an appropriate funding level for each application based upon these criteria.

(2) Phase 2—Competitive Review

Meritorious applications will then be passed on to the Office of the Deputy Administrator, Commodity and Marketing Programs, for the purpose of allocating available funds among the applicants. Applications which pass the Divisional Review will compete for funds on the basis of the following allocation criteria (the number in
Department of Agriculture and Extension Service

The Commodity Divisions’ recommended funding level for each applicant is converted to a percentage of the total MAP funds available and multiplied by the total weight factor as described above to determine the amount of funds allocated to each applicant.

Closing Date for Applications

All Internet-based applications must be properly submitted by 5 p.m. Eastern Standard Time, March 12, 2001. Signed certification statements also must be received by that time at one of the addresses listed below.

All applications on diskette (with two accompanying paper copies and a signed certification statement) and any other applications must be received by 5 p.m. Eastern Standard Time, March 12, 2001, at one of the following addresses:


Timothy J. Galvin, Administrator, Foreign Agricultural Service, and Vice President, Commodity Credit Corporation.

[FR Doc. 00–33141 Filed 12–27–00; 8:45 am]
BILLING CODE 3410–10–P

DEPARTMENT OF AGRICULTURE

Cooperative State Research, Education, and Extension Service Guidelines for State Plans of Work for the Agricultural Research and Extension Formula Funds

AGENCY: Cooperative State Research, Education, and Extension Service.

ACTION: Final notice.

SUMMARY: The Cooperative State Research, Education, and Extension Service (CSREES) published Guidelines for the State Plans of Work for Agricultural Research and Extension Formula Funds on July 1, 1999 [64 FR 35910–35919]. The guidelines describe the procedures to be followed by the eligible institutions receiving Federal agricultural research and extension formula funds under the Hatch Act of 1887, as amended (7 U.S.C. 361a et seq.); sections 3(b)(1) and (c) of the Smith-Lever Act of 1914, as amended (7 U.S.C. 343(b)(1) and (c)); and sections 1444 and 1445 of the National Agricultural Research, Extension, and Teaching Policy Act of 1977, as amended (7 U.S.C. 3221 and 3222). The recipients of these funds are commonly referred to as the 1862 land-grant institutions and the 1890 land-grant institutions, including Tuskegee University. CSREES is publishing this notice to inform these institutions that the due date for the Annual Report of Accomplishments and Results is changed from December 31 to March 1.

FOR FURTHER INFORMATION CONTACT: Dr. George Cooper; Deputy Administrator, Partnerships; Cooperative State Research, Education, and Extension Service; U.S. Department of Agriculture; Washington, DC 20250; at 202–720–5285 or 202–720–5369, 202–720–4924 (fax); or via electronic mail at bhewitt@ree.usda.gov.

SUPPLEMENTARY INFORMATION: The guidelines for State Plans of Work provide guidance for the submission of a 5-Year Plan of Work for the use of the agricultural research and extension formula funds described above. The first 5-Year Plan of Work was due July 15, 1999, for the period covering October 1, 1999, through September 30, 2004. In addition, the Guidelines prescribe procedures for updating the 5-Year Plan of Work, if necessary, and for reporting annually on the accomplishments and results of the plan. The latter report is referred to as the Annual Report of Accomplishments and Results. CSREES has decided, in consultation with the land-grant institutions, to change the due date for the Annual Report of Accomplishments and Results from December 31 to March 1. Therefore, the first report will be due March 1, 2001, and not December 31, 2000. It is anticipated that the additional two months will provide the institutions more time each year to report on their accomplishments and results for the fiscal year ending September 30.

Done at Washington, DC, this 21st day of December 2000.

Colien Hefferan, Administrator, Cooperative State Research, Education, and Extension Service.

[FR Doc. 00–33208 Filed 12–27–00; 8:45 am]
BILLING CODE 3410–22–P

DEPARTMENT OF AGRICULTURE

Foreign Agricultural Service

Announcement of the Emerging Markets Program for Fiscal Year 2001

AGENCY: Foreign Agricultural Service, USDA.

ACTION: Notice.

SUMMARY: This notice announces the application period for the Fiscal Year 2001 Emerging Markets Program.

DATES: All proposals must be received by 5 p.m. Eastern Standard Time, March 12, 2001.


SUPPLEMENTARY INFORMATION: Authority

The Emerging Markets Program is authorized by Section 1542(d)(1)(D) of the Food, Agriculture, Conservation, and Trade Act of 1990, as amended (the Act). Up to $10 million is available to fund the program each fiscal year.
Introduction

The Foreign Agricultural Service (FAS) announces that proposals are being accepted for participation in the Fiscal Year 2001 Emerging Markets Program (EMP). The purpose of the EMP is to assist U.S. organizations, public and private, to improve market access and develop and promote U.S. agricultural products in emerging markets by providing, or paying the costs of, approved technical assistance activities. The EMP generally operates on a reimbursement basis.

The Act defines an emerging market as any country that the Secretary of Agriculture determines:

1. Is taking steps toward a market-oriented economy through the food, agriculture, or rural business sectors of the economy of the country; and
2. Has the potential to provide a viable and significant market for United States agricultural commodities or products of United States agricultural commodities. Because funds are limited and the range of potential emerging market countries is worldwide, proposals for funding technical assistance activities ("proposals") will be considered which target those countries with (1) per capita income less than $9,360 (the ceiling on upper middle income economies as determined by the World Bank [World Development Indicators 2000]); and (2) population greater than 1 million. Proposals may address suitable regional groupings, e.g., the islands of the Caribbean Basin.

Eligible Applicants, Commodities, and Activities

Any United States agricultural or agribusiness organization, university, or state department of agriculture is eligible to participate in the EMP. Activities may seek to develop, maintain, or expand markets for any agricultural commodities or products except tobacco. Proposals will be considered under this announcement from any U.S. private agricultural or agribusiness organization, with certain restrictions as indicated below. Proposals from research and consulting organizations will be considered if they provide evidence of substantial participation by the U.S. industry. Proposals may include multiple commodities.

Only technical assistance activities are eligible for reimbursement. Following are examples of the types of activities that may be funded:

- Projects designed specifically to improve market access in emerging foreign markets. **Examples:** activities intended to mitigate the impact of sudden political events or economic and currency crises in order to maintain U.S. market share; responses to time-sensitive market opportunities;
- Marketing and distribution of more value-added products, including new products or uses. **Examples:** food service development; market research on potential for consumer-ready foods or new uses of a product;
- Studies of food distribution channels in emerging markets, including infrastructural impediments to U.S. exports; such studies may include cross-commodity activities which focus on problems, e.g., distribution, which affect more than one industry. **Examples:** grain storage handling and inventory systems development; distribution infrastructure development;
- Projects that specifically address various constraints to U.S. exports, including sanitary and phytosanitary issues and other non-tariff barriers. **Examples:** seminars on U.S. food safety standards and regulations; assessing and addressing pest and disease problems that inhibit U.S. product exports;
- Assessments and follow up activities designed to improve country-wide food and business systems, to reduce trade barriers, to increase prospects for U.S. trade and investment in emerging markets, and to determine the potential use for general export credit guarantees, including especially the Facilities Guarantee Program, for commodities, facilities and services. **Examples:** product needs assessments and market analysis; assessments for using facilities credits to address infrastructural impediments;
- Projects that help foreign governments collect and use market information and develop free trade policies that benefit American exporters as well as the target country or countries. **Examples:** agricultural statistical analysis; development of market information systems; policy analysis;
- Short-term training in broad aspects of agriculture and agribusiness trade that will benefit U.S. exporters, including seminars and training at trade shows designed to expand the potential for U.S. agricultural exports by focusing on the trading system. **Examples:** retail training; marketing seminars; transportation seminars; training keying to opening new or expanding existing markets. Ineligible activities include restaurant promotions; branded product promotions (including labeling and supplementing normal company sales activities intended to increase awareness and stimulate sales of branded products); advertising; administrative and operational expenses for trade shows; and the preparation and printing of brochures, flyers, posters, etc., except in connection with specific technical assistance activities such as training seminars. Other items excluded from funding are detailed in the FY 2001 EMP Guidelines.

Project Suitability and Allocation of Funds

The underlying premise of the EMP is that there are distinctive characteristics of emerging agricultural markets that necessitate or benefit significantly from U.S. governmental assistance before the private sector moves to develop these markets through normal corporate or trade promotional activities. The emphasis is on marketing opportunities where there are risks that the private sector would not normally undertake alone, with funding provided for successful activities on a project-by-project basis. The EMP complements the efforts of other FAS marketing programs. Once a market access issue has been addressed by the EMP, further market development activities may be considered under other programs such as GSM–102 or GSM–103 credit guarantee programs, the Facilities Guarantee Program, the Suppliers’ Guarantee Program, the MAP, or the Cooperator Program.

In general, priority consideration will be given to proposals that identify and seek to address specific problems or constraints in rural business systems or food and agribusiness systems in emerging markets through technical assistance to expand or maintain U.S. agricultural exports. Priority will also be given to those proposals that include the willingness of the applicant to commit its own funds, or those of the U.S. industry, to seek export opportunities in an emerging market. The EMP is intended to supplement, not supplant, the efforts of the U.S. private sector. The percentage of private funding proposed for a project will therefore be a critical factor in determining which proposals are funded under the EMP. Proposals will also be judged on their ability to provide benefits to the organization receiving EMP funds and to the broader industry which that organization represents.

The following marketing criteria will be used to determine the suitability of projects for funding by the EMP:

1. Low U.S. market share and significant market potential;
Quick Response Market Fund. More details concerning these specialty funds are contained in the EMP Guidelines.

Application Process
This notice is complemented by concurrent notices announcing other foreign market development programs administered by FAS including the Market Access Program (MAP), the Foreign Market Development Cooperator (Cooperator) Program, the Section 108 Program, and the Quality Samples Program (QSP). The MAP and Cooperator Program notices detail a Unified Export Strategy (UES) application process which provides a means for interested applicants to submit a consolidated and strategically coordinated single proposal that incorporates funding requests for any or all of these programs. Some applicants to the EMP, particularly those who are applying for funding under more than one program, may wish to use the UES application procedure. The Internet-based UES application, including step-by-step instructions for its use, is located at the following URL address: http://www.fas.usda.gov/cooperators.html. Other applicants, particularly those who are applying for funding only under the EMP, should follow the application procedures contained in this notice. Interested applicants that are unsure of which application is appropriate are urged to contact the Marketing Operations Staff at the address above. The deadline for all applications to the EMP, regardless of format, is 5 p.m. Eastern Standard Time, March 12, 2001. FAS recommends that applications not be longer than ten (10) pages.

It is strongly recommended that applicants obtain a copy of the 2001 EMP Guidelines prior to submitting an application. Requests for the 2001 EMP Guidelines and additional information may be obtained from the Marketing Operations Staff at the address above. The Guidelines are also available at the following URL address: http://www.fas.usda.gov/excredits/em-markets/em-markets.html.

Application Information
To assist FAS in making determinations regarding funding, FAS recommends that proposals contain the following information: (1) Name and address of person/organization submitting proposal; (2) organization qualifications (this may be submitted as an attachment to the application); (3) telephone and fax numbers; (4) Federal tax ID number of the responsible organization; (5) full title of proposal; (6) projected starting date for the proposal and time line(s) for project implementation; (7) precis of the proposal, including objectives, summary of proposed activities, targeted country/countries for proposed activities, and funding amount requested; (8) statement of problem (specific trade constraint) to be addressed through the proposed project; (9) supporting market analysis of the targeted market(s)—brief economic analysis for each commodity and country, including current market conditions, relevant trade data, existing percentage of U.S. export market share, and the basis or source(s) for this data; (10) benefits to U.S. agricultural exports as a result of the proposed project, including specific performance measures; (11) detailed description of proposed activities and budgets, including other sources of funding for the project and contributions from participating organizations (refer to the EMP Guidelines for additional details); (12) information on whether similar activities are or have previously been funded in targeted country/countries (e.g., under other Federal assistance programs); (13) and a clearly stated justification as to why participating organization(s) are unlikely to carry out the proposed activities without EMP funding.

Reporting Requirement
A performance report detailing the results of each project supported with EMP funds must be submitted to the Marketing Operations Staff at the address above. Because public funds are used to support EMP projects, these reports will be made available to the public.

Closing Date for Applications
All Internet-based applications, plus the supplemental information, must be properly submitted by 5 p.m. Eastern Standard Time, March 12, 2001. All applications on diskette (with two accompanying paper copies) must be received by 5 p.m. Eastern Standard Time, March 12, 2001, at one of the following addresses:

Hand Delivery (including FedEx, DHL, UPS, etc.): U.S. Department of Agriculture, Foreign Agricultural Service, Marketing Operations Staff, Room 4932-S, 1400 Independence Avenue, SW., Washington, DC 20250–1042.


Timothy J. Galvin,
Administrator, Foreign Agricultural Service.

[FR Doc. 00–33139 Filed 12–27–00; 8:45 am]
DEPARTMENT OF AGRICULTURE

Forest Service

Rio Sabana Day Use Picnic Area, Caribbean National Forest, Naguabo, Puerto Rico; Revised Notice of Intent To Prepare an Environmental Impact Statement

AGENCY: Forest Service, USDA.

ACTION: Revised notice.

SUMMARY: This notice is to announce that the Caribbean National Forest is revising the date for filing a Draft Environmental Impact Statement (DEIS) for the Rio Sabana Day Use Picnic Area; and that the USDA Forest Service and the Puerto Rico Department of Transportation and Public works have agreed to act as joint lead agencies in the preparation of the EIS. This revises the notice of intent for this project, originally published in the Federal Register on Friday, September 18, 1998, Vol. 63, No. 181, pp. 49894-49895, and revised notices of intent published December 21, 1998, Vol. 63, No. 244, pp. 70385–70386; and December 28, 1998, Vol. 63, No. 248, pp. 71441–71442. The agency expects to file a DEIS with the Environmental Protection Agency (EPA) and make it available for public comment March 2001.

DATES: Comments on the DEIS, to be considered in preparation of the Final Environmental Impact Statement (FEIS), must be received 45 days following the publication of notice of availability of the DEIS.

ADRESSES: Send written comments to Ricardo Garcia, Forest Planner; Caribbean National Forest, P.O. Box 490, Palmer, Puerto Rico 00721.

FOR FURTHER INFORMATION CONTACT: Ricardo Garcia, Forest Planner, 787–888–5640.

SUPPLEMENTARY INFORMATION: The Caribbean National Forest is proposing to develop a day use picnic area located in the vicinity of the Rio Sabana Bridge, on Highway PR 191 at Km. 20.0, in the Cubuy Sector of the Municipality of Naguabo, and to reconstruct the Rio Sabana Trail (approximately 2.5 miles). In order to provide vehicular access to the proposed picnic area, the Puerto Rico Department of Transportation and Public Works is proposing to reconstruct the section of Highway PR 191 from Km. 21.3 to Km. 20.0 (approximately 0.8 miles), that is currently closed to public traffic.

Scoping actions which have been completed to date include: (1) a field trip to the site with local residents, elected officials, and agency representatives (2/4/98); (2) a meeting with interested parties at a local residence (2/23/98); (3) a meeting with Rep. Robert Baez, Puerto Rico House of Representatives (8/28/98); and (4) mailing of scoping letters to approximately 75 potentially interested individuals, organizations and government agencies (12/98).

The following preliminary issues have been identified through scoping; (1) lack of developed recreation sites and trails on the south side of the Forest; (2) inadequate budget for operation and maintenance of additional recreation facilities on the Forest; (3) possible adverse impacts on wilderness values; (4) possible adverse impacts on primary forest and endangered, threatened or sensitive plants or animals; (5) potential for increased soil erosion and stream sedimentation; (6) possible improvement in water quality due to providing toilets at the site which is receiving heavy recreation use; (7) potential adverse impacts on cultural resources; (8) potential for increased traffic congestion on Highway PR 191; and (9) potential to increase law enforcement and public safety problems.

A DEIS is expected to be available for public review, beginning about March 2001. The comment period on the DEIS will be 45 days from the date the EPA publishes the notice of availability in the Federal Register.

The Forest Service believes, at this early stage it is important to give reviewers notice of several court rulings related to public participation in the environmental review process. First, reviewers of DEIS, must structure their participation in the environmental review of the proposal so that it is meaningful and alerts an agency to the reviewer’s position and contentions.

Vermont Yankee Nuclear Power Corp. v. NRDC, 435 U.S. 519, (1978). Also, environmental objections that could be raised at the DEIS stage, but that are not raised until after completion of the FEIS, may be waived or dismissed by the courts. City of Angoon v. Hodel, 803 F.2d 1016, 1022 (9th Cir. 1986) and Wisconsin Heritage, Inc. v. Harris, 490 F. Supp. 1334, 1338 (E.D. Wis. 1980). Because of these court rulings, it is very important that those interested in this proposed action participate by the close of the comment period (45 days after publication in the Federal Register of the notice of availability of the DEIS, estimated to be March 2001) so that substantive comments and objections are made available to the Forest Service at a time when it can meaningfully consider them and respond to them in the FEIS.

To assist the Forest Service in identifying and considering issues and concerns on the proposed action, comments on the DEIS should be as specific as possible. It is also helpful if comments refer to specific pages or chapters of the draft statement. Comments may also address the adequacy of the DEIS or the merits of the alternatives formulated and discussed in the statement. Reviewers may wish to refer to the Council on Environmental Quality Regulations for implementing the procedural provisions of the National Environmental Policy Act at 40 CFR 1503.3 in addressing these points.

After the comment period on the DEIS ends, the comments will be analyzed, considered, and responded to by the Forest Service in preparing the FEIS. The Responsible Official will consider the comments, responses, environmental consequences discussed in the FEIS, and applicable laws, regulations, and policies in making a decision. The Responsible Official will document the decision and rationale for the decision in a Record of Decision.

The decision will be subject to appeal in accordance with 36 CFR Part 215. The Responsible Official is: Pablo Cruz, Forest Supervisor, Caribbean National Forest, P.O. Box 490, Palmer, Puerto Rico 00721.

Dated: December 1, 2000.

Pablo Cruz,
Forest Supervisor.

BILING CODE 3410–11–M

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

(Docket 71–2000)

Foreign-Trade Zone 50, Long Beach, CA; Proposed Foreign-Trade Subzone; ARCO Products Company, (Oil Refinery Complex); Long Beach, CA, Area

An application has been submitted to the Foreign-Trade Zones Board (the Board) by the Board of Harbor Commissioners of the City of Long Beach, grantee of FTZ 50, requesting special-purpose subzone status for the oil refinery complex of Atlantic Richfield Company (ARCO), a wholly-owned subsidiary of BP America, located in the Long Beach, California, area. The application was submitted pursuant to the provisions of the Foreign-Trade Zones Act, as amended (19 U.S.C. 81a-81u), and the regulations
of the Board (15 CFR part 400). It was formally filed on December 14, 2000.

The ARCO refinery complex (854 acres) is located at 7 sites in the Long Beach area (Los Angeles County). California: Site 1 (268,000 BPD capacity, 6.7 million barrel capacity, 646.5 acres)—main refinery complex, located at 1801 East Sepulveda Blvd., some 25 miles south of downtown Los Angeles; Site 2 (5.5 acres)—Berth 121 of Terminal 1, Long Beach Harbor, for receiving crude oil; Site 3 (24 tanks, 1.7 million barrel capacity, 19 acres)—Terminal 2, Long Beach Harbor, crude oil and product storage; Site 4 (27 tanks, 2.1 million barrel capacity, 73 acres)—Hynes facility for crude and product storage, located at 5900 Cherry Avenue, Long Beach, some 4 miles northwest of the refinery; Site 5 (4 tanks, 1.2 million barrel capacity, 15 acres)—“Southern California Edison-Long Beach” leased storage facility, located at 2665 Seaside Blvd., Long Beach, some 6 miles south of the refinery; Site 6 (12 tanks, 3.6 million barrel capacity, 75 acres)”—“Southern California Edison-Dominguez” leased storage facility, 2500 East Victoria, Compton, some 5 miles northeast of the refinery; and Site 7 (20 tanks, 1 million barrel capacity, 20 acres)—Hathaway terminal, 2350 Hathaway Drive, Signal Hill, some 5 miles east of the refinery.

The refinery (920 employees) is used to produce fuels and petrochemical feedstocks. Fuel products include gasoline, jet fuel, distillates, residual fuels, naphthas and motor fuel blendstocks. Petrochemical feedstocks and refinery by-products include methane, ethane, propane, propylene, butane, petroleum coke and sulfur.

Some 15 percent of the crude oil (91 percent of inputs) is sourced abroad. The application also indicates that the company may in the future import under FTZ procedures some naphthas, virgin gas oil, natural gas condensate, and motor fuel blendstocks.

Zone procedures would exempt the refinery from Customs duty payments on the foreign products used in its exports. On domestic sales, the company would be able to choose the duty rate that applies to certain imported components currently range from 2.5 to 4.0 percent. Caterpillar also indicates that other components will be purchased from abroad as the company progresses with its planned transfer of additional production stages to the Waco site.

This application requests authority to allow Caterpillar to conduct the activity under FTZ procedures, which would exempt the company from Customs duty payments on the foreign components used in export activity. On its domestic sales, the company would be able to choose the duty rate that applies to finished dump trucks (duty free) for foreign components, such as those noted above. The company would also be exempt from duty payments on foreign merchandise that becomes scrap/waste.

In accordance with the Board’s regulations, a member of the FTZ Staff has been designated examiner to investigate the application and report to the Board.

The company indicates that the following foreign components will be admitted initially under FTZ procedures: cabs, axles, radial tires, and dump bodies (duty rates on these imported components currently range from 2.5 to 4.0 percent). Caterpillar also indicates that other components will be purchased from abroad as the company progresses with its planned transfer of additional production stages to the Waco site.

In accordance with the Board’s regulations, a member of the FTZ Staff has been designated examiner to investigate the application and report to the Board.

Public comment is invited from interested parties. Submissions (original and 3 copies) shall be addressed to the Board’s Executive Secretary at the address below.

The closing period for their receipt is February 26, 2001. Rebuttal comments in response to material submitted during the foregoing period may be submitted during the subsequent 15-day period (to March 13, 2001).

A copy of the application and accompanying exhibits will be available for public inspection at each of the following locations:

U.S. Department of Commerce, Export Assistance Center, One World Trade Center, Suite 1670, Long Beach, CA 90831;
Office of the Executive Secretary, Foreign-Trade Zones Board, Room 4008, U.S. Department of Commerce, 14th & Pennsylvania Avenue, NW, Washington, DC 20230.


Dennis Puccinelli,
Executive Secretary.

[FR Doc. 00–33201 Filed 12–27–00; 8:45 am]
BILLING CODE 3510–DS–P

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[Docket 69–2000]

Request for Manufacturing Authority within Proposed Foreign-Trade Zone, Caterpillar Inc. (Construction Equipment), Waco, Texas

An application has been submitted to the Foreign-Trade Zones Board (the Board) by the City of Waco (Texas), which has an application pending for Foreign-Trade Zone status, requesting authority on behalf of Caterpillar Inc. (Caterpillar) for the manufacture/processing of off-road articulated dump trucks under FTZ procedures within Site 2 of the proposed FTZ. The application was submitted pursuant to the provisions of the Foreign-Trade Zones Act, as amended (19 U.S.C. 81a–81u), and the regulations of the Board (15 CFR part 400). It was formally filed on December 12, 2000.

Caterpillar operates a 103-acre facility (110 employees projected) within the proposed foreign-trade zone for the manufacture/processing of off-road articulated dump trucks (imported duty-free under HTSUS heading 8704.10.50). Currently, components purchased from foreign sources comprise up to 48 percent of the finished product’s value.

In accordance with the Board’s regulations, a member of the FTZ Staff has been designated examiner to investigate the application and report to the Board.

Public comment is invited from interested parties. Submissions (original and 3 copies) shall be addressed to the Board’s Executive Secretary at the address below. The closing period for their receipt is February 26, 2001. Rebuttal comments in response to material submitted during the foregoing period may be submitted during the subsequent 15-day period to March 13, 2001.

A copy of the application and the accompanying exhibits will be available for public inspection at each of the following locations:

Office of the Executive Secretary, Foreign-Trade Zones Board, U.S. Department of Commerce, Room 4008, 14th and Pennsylvania Avenue, NW, Washington, DC 20230;
Greater Waco Chamber of Commerce, 101 South University Parks Drive, Waco, TX 76701.


Dennis Puccinelli,
Executive Secretary.

[FR Doc. 00–33200 Filed 12–27–00; 8:45 am]
BILLING CODE 3510–DS–P
The People’s Republic of China: Fresh Garlic,* A–570–831 ....................................................................... ........................... 11/1/99±10/31/00
SeAH Steel Corporation
Shinho Steel Co.
Hyundai Pipe Co., Ltd.

Antidumping Duty Proceedings

<table>
<thead>
<tr>
<th>Country/Region</th>
<th>Description</th>
<th>Period to be reviewed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hyundai Pipe Co., Ltd.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shinho Steel Co.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SeAH Steel Corporation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The People’s Republic of China</td>
<td>Fresh Garlic,* A–570–831</td>
<td>11/1/99–10/31/00</td>
</tr>
</tbody>
</table>
During any administrative review covering all or part of a period falling between the first and second or third and fourth anniversary of the publication of an antidumping duty order under section 351.211 or a determination under section 351.218(f)(4) to continue an order or suspended investigation (after sunset review), the Secretary, if requested by a domestic interested party within 30 days of the date of publication of the notice of initiation of the review, will determine whether antidumping duties have been absorbed by an exporter or producer subject to the review if the subject merchandise is sold in the United States through an importer that is affiliated with such exporter or producer. The request must include the name(s) of the exporter or producer for which the inquiry is requested.

Interested parties must submit applications for disclosure under administrative protective orders in accordance with 19 CFR 351.305.

These initiations and this notice are the result of investigations of (1994-1995) procedures and based on information received in the reviews of the antidumping duty orders on antifriction bearings (other than tapered roller bearings) and parts thereof from Japan. On February 28, 1995, the Department published its final results of administrative reviews of the antidumping duty orders on antifriction bearings and parts thereof from Japan, Germany, Italy, Japan, Singapore, Sweden, and the United Kingdom, covering the period May 1, 1992, through April 30, 1993 (60 FR 10900). The classes or kinds of merchandise covered by these reviews are ball bearings and parts thereof, cylindrical roller bearings and parts thereof, and spherical plain bearings and parts thereof. The period of review is May 1, 1992, through April 30, 1993. As there is now a final and conclusive court decision in this action, we are amending our final results of reviews, as appropriate, and we will subsequently instruct the U.S. Customs Service to liquidate entries subject to these reviews.

**SUMMARY:** The United States Court of International Trade and the United States Court of Appeals for the Federal Circuit have affirmed the Department of Commerce’s final remand results affecting final assessment rates for the administrative reviews of the antidumping duty orders on antifriction bearings (other than tapered roller bearings) and parts thereof from Japan with regard to NTN Corporation, Koyo Seiko Co., Ltd., and Honda Motor Company Limited. The classes or kinds of merchandise covered by these reviews are ball bearings and parts thereof, cylindrical roller bearings and parts thereof, and spherical plain bearings and parts thereof. The period of review is May 1, 1992, through April 30, 1993 (60 FR 10900) (AFBs 4). The classes or kinds of merchandise covered by these reviews are ball bearings and parts thereof (BBs), cylindrical roller bearings and parts thereof (CRBs), and spherical plain bearings and parts thereof (SPBs). Subsequently, one domestic producer (The Torrington Company), NSK Ltd., NTN Corporation (NTN), and Koyo Seiko Co., Ltd. (Koyo), filed lawsuits with the U.S. Court of International Trade (CIT) challenging the final results. These lawsuits were consolidated and litigated at the CIT and the United States Court of Appeals for the Federal Circuit (CAFC). The CIT and CAFC affirmed the Department’s final remand results for AFBs 4 with respect to all companies except NTN, Koyo, and Honda Motor Company Limited (Honda) in the proceedings concerning antifriction bearings from Japan. On
September 13, 1999, the Department published its amended final results of administrative reviews of the antidumping duty orders on antifriction bearings (other than tapered roller bearings) and parts thereof, from France, Germany, Italy, Japan, Singapore, Sweden, and the United Kingdom, covering the period May 1, 1992, through April 30, 1993, with respect to all companies except NTN, Koyo, and Honda [64 FR 49442].

The CIT and CAFC have affirmed the Department’s original determination in AFBs 4 with respect to Honda. Therefore, since neither court remanded the determination with respect to Honda to the Department, the Department has not changed its final results of review with respect to Honda and no amendment to AFBs 4 is necessary with respect to this company.

However, the Department received remand instructions during the litigation pertaining to NTN and Koyo. The CIT and CAFC issued a number of orders and opinions of which the following have resulted in changes to the antidumping margins we had calculated for NTN and Koyo in AFBs 4:

- NTN—(1) apply a tax-neutral methodology in computing the value-added tax adjustment, (2) deny the adjustment to foreign market value (FMV) for home-market discounts, (3) deny the adjustments to FMV for billing adjustments that were not made solely to in-scope merchandise, (4) exclude sample sales from the home-market database for which NTN received no consideration, (5) allow the adjustment to U.S. indirect selling expenses for interest expense incurred in financing antidumping duty cash deposits, (6) recalculate the cost of production and constructed value without resort to best information available, and (7) correct a clerical error; Koyo—(1) apply a tax-neutral methodology in computing the value-added tax adjustment, (2) reopen the record to allow Koyo to submit documentation showing the nature of the expenses it characterized as non-operating expenses and subsequently exclude certain items from general expenses for purposes of calculating cost of production and constructed value, (3) re-examine the acceptance of the allocation of air-freight expenses, (4) explain further the basis for accepting Koyo’s efficiency variance without adjustment, and (5) correct a clerical error.

The CIT and CAFC have affirmed the Department’s final remand results affecting final assessment rates for these reviews of NTN and Koyo. As there are now final and conclusive court decisions in these actions, we are amending our final results of review in these matters and we will subsequently instruct the U.S. Customs Service to liquidate entries subject to these reviews.

Amendment to Final Results

Pursuant to section 516A(e) of the Tariff Act, we are now amending the final results of administrative reviews of the antidumping duty orders on antifriction bearings (other than tapered roller bearings) and parts thereof from Japan and the period May 1, 1992, through April 30, 1993, with respect to NTN and Koyo. The revised weighted-average margins are as follows:

<table>
<thead>
<tr>
<th>Company</th>
<th>BBs</th>
<th>CRBs</th>
<th>SPBs</th>
</tr>
</thead>
<tbody>
<tr>
<td>NTN</td>
<td>14.90</td>
<td>6.53</td>
<td>(1)</td>
</tr>
<tr>
<td>NTN Seiko</td>
<td>9.25</td>
<td>7.99</td>
<td>0.43</td>
</tr>
</tbody>
</table>

(1) No shipments or sales subject to this review.

Accordingly, the Department will determine and the U.S. Customs Service will assess appropriate antidumping duties on entries of the subject merchandise made by firms covered by these reviews. Individual differences between United States price and FMV may vary from the percentages listed above. The Department has already issued appraisement instructions to the Customs Service for certain companies whose margins have not changed from those announced in AFBs 4 and the September 13, 1999, amendment. The Department will issue appraisement instructions to the U.S. Customs Service for NTN, Koyo, and Honda after publication of these amended final results of reviews.

This notice is published pursuant to section 751(a) of the Tariff Act.


Troy H. Cribb, Assistant Secretary for Import Administration.

[FR Doc. 00–33203 Filed 12–27–00; 8:45 am]
BILLING CODE 3510–05–P

DEPARTMENT OF COMMERCE

International Trade Administration


AGENCY: NAFTA Secretariat, United States Section, International Trade Administration, Department of Commerce.

ACTION: Notice of consent motion to terminate the panel review of the final antidumping duty administrative review made by the International Trade Administration, respecting certain corrosion resistant carbon steel flat products from Canada (Secretariat File No. USA–CDA–99–1904–01).

SUMMARY: Pursuant to the Notice of Consent Motion to Terminate the Panel Review by the complainants, the panel review is terminated as of December 15, 2000. No panel has been appointed to this panel review. Pursuant to Rule 71(2) of the Rules of Procedure for Article 1904 Binational Panel Review, this panel review is terminated.

FOR FURTHER INFORMATION CONTACT: Caratina L. Alston, United States Secretary, NAFTA Secretariat, Suite 2061, 14th and Constitution Avenue, Washington, DC 20230, (202) 482–5438.

SUPPLEMENTARY INFORMATION: Chapter 19 of the North American Free-Trade Agreement ("Agreement") establishes a mechanism to replace domestic judicial review of final determinations in antidumping and countervailing duty cases involving imports from a NAFTA country with review by independent binational panels. When a Request for
Panel Review is filed, a panel is established to act in place of national courts to review expeditiously the final determination to determine whether it conforms with the antidumping or countervailing duty law of the country that made the determination.

Under Article 1904 of the Agreement, which came into force on January 1, 1994, the Government of the United States, the Government of Canada and the Government of Mexico established Rules of Procedure for Article 1904 Binational Panel Reviews ("Rules"). These Rules were published in the Federal Register on February 23, 1994 (59 FR 8686). The panel review in this matter was requested and terminated pursuant to these Rules.


Caratina L. Alston,
United States Secretary, NAFTA Secretariat.

[FR Doc. 00–33051 Filed 12–27–00; 8:45 am]
BILLING CODE 3510–GT–U

DEPARTMENT OF COMMERCE
International Trade Administration
[North American Free Trade Agreement (NAFTA), Article 1904]

Binational Panel Reviews: Notice of Termination of Panel Review

AGENCY: NAFTA Secretariat, United States Section, International Trade Administration, Department of Commerce.

ACTION: Notice of consent motion to terminate the panel review of the final antidumping duty administrative review made by the International Trade Administration, respecting certain corrosion resistant carbon steel flat products from Canada (Secretariat File No. USA–CDA–00–1904–02).

SUMMARY: Pursuant to the Notice of Consent Motion to Terminate the Panel Review by the complainants, the panel review is terminated as of December 15, 2000. No panel has been appointed to this panel review. Pursuant to Rule 71(2) of the Rules of Procedure for Article 1904 Binational Panel Review, this panel review is terminated.

FOR FURTHER INFORMATION CONTACT: Caratina L. Alston, United States Secretary, NAFTA Secretariat, Suite 2061, 14th and Constitution Avenue, Washington, DC 20230, (202) 482–5438.

SUPPLEMENTARY INFORMATION: Chapter 19 of the North American Free-Trade Agreement ("Agreement") establishes a mechanism to replace domestic judicial review of final determinations in antidumping and countervailing duty cases involving imports from a NAFTA country with review by independent binational panels. When a Request for Panel Review is filed, a panel is established to act in place of national courts to review expeditiously the final determination to determine whether it conforms with the antidumping or countervailing duty law of the country that made the determination.

Under Article 1904 of the Agreement, which came into force on January 1, 1994, the Government of the United States, the Government of Canada and the Government of Mexico established Rules of Procedure for Article 1904 Binational Panel Reviews ("Rules"). These Rules were published in the Federal Register on February 23, 1994 (59 FR 8686). The panel review in this matter was requested and terminated pursuant to these Rules.


Caratina L. Alston,
United States Secretary, NAFTA Secretariat.

[FR Doc. 00–33052 Filed 12–27–00; 8:45 am]
BILLING CODE 3510–GT–U

DEPARTMENT OF COMMERCE
International Trade Administration
[North American Free Trade Agreement (NAFTA), Article 1904]

Binational Panel Reviews: Notice of Termination of Panel Review

AGENCY: NAFTA Secretariat, United States Section, International Trade Administration, Department of Commerce.

ACTION: Notice of Consent Motion to Terminate the Panel Review of the final antidumping duty administrative review made by the International Trade Administration, respecting certain corrosion resistant carbon steel flat products from Mexico (Secretariat File No. USA–CDA–00–1904–08).

SUMMARY: Pursuant to the Notice of Consent Motion to Terminate the Panel Review by the complainants, the panel review is terminated as of December 1, 2000. A panel has not been appointed to this panel review. Pursuant to Rule 71(2) of the Rules of Procedure for Article 1904 Binational Panel Review, this panel review is terminated.

FOR FURTHER INFORMATION CONTACT: Caratina L. Alston, United States Secretary, NAFTA Secretariat, Suite 2061, 14th and Constitution Avenue, Washington, DC 20230, (202) 482–5438.

SUPPLEMENTARY INFORMATION: Chapter 19 of the North American Free-Trade Agreement ("Agreement") establishes a mechanism to replace domestic judicial review of final determinations in antidumping and countervailing duty cases involving imports from a NAFTA country with review by independent binational panels. When a Request for Panel Review is filed, a panel is established to act in place of national courts to review expeditiously the final determination to determine whether it conforms with the antidumping or countervailing duty law of the country that made the determination.

Under Article 1904 of the Agreement, which came into force on January 1, 1994, the Government of the United States, the Government of Canada and the Government of Mexico established Rules of Procedure for Article 1904 Binational Panel Reviews ("Rules"). These Rules were published in the Federal Register on February 23, 1994 (59 FR 8686). The panel review in this matter was requested and terminated pursuant to these Rules.

Dated: December 5, 2000.

Caratina L. Alston,
United States Secretary, NAFTA Secretariat.

[FR Doc. 00–33241 Filed 12–27–00; 8:45 am]
BILLING CODE 3510–GT–P

DEPARTMENT OF COMMERCE
International Trade Administration
[North American Free-Trade Agreement, Article 1904]

NAFTA Panel Reviews; Request for Panel Review

AGENCY: NAFTA Secretariat, United States Section, International Trade Administration, Department of Commerce.

ACTION: Notice of first request for panel review.

SUMMARY: On November 21, 2000, CEMEX, S.A. de C.V. ("CEMEX") filed a First Request for Panel Review with the United States Section of the NAFTA Secretariat pursuant to Article 1904 of the North American Free Trade Agreement. On November 22, 2000 a second request for panel review was filed by Cementos de Chihuahua, S.A. de C.V. Panel review was requested of the five-year sunset review of the antidumping duty order made by the International Trade Commission, respecting Gray Portland Cement and Clinker from Mexico. This determination was published in the Federal Register (65 FR 65527) on November 1, 2000. The NAFTA Secretariat has assigned Case Number USA–MEX–00–1904–10 to these requests.
review.

review and the procedural and investigating authority, that are set out to the allegations of error of fact or law, for filing a Notice of Appearance in accordance with Rule 40 the panel review by filing a Notice of support of any reviewable portion of the Complaint but that intends to appear in a Complaint is December 21, 2000); for Panel Review (the deadline for filing days after the filing of the first Request in accordance with Rule 39 within 30 whole or in part by filing a Complaint challenge the final determination in above.

Article 1904 of the Agreement, on the NAFTA Secretariat, pursuant to Rules of Procedure for Article 1904 Binational Panel Reviews (“Rules”). These Rules were published in the Federal Register on February 23, 1994 (59 FR 8686).

A first Request for Panel Review was filed with the United States Section of the NAFTA Secretariat, pursuant to Article 1904 of the Agreement, on November 21, 2000, requesting panel review of the five-year sunset review of the antidumping countervailing duty order described above.

The Rules provide that:

(a) A Party or interested person may challenge the final determination in whole or in part by filing a Complaint in accordance with Rule 39 within 30 days after the filing of the first Request for Panel Review (the deadline for filing a Complaint is December 21, 2000);

(b) A Party, investigating authority or interested person that does not file a Complaint but that intends to appear in support of any reviewable portion of the final determination may participate in the panel review by filing a Notice of Appearance in accordance with Rule 40 within 45 days after the filing of the first Request for Panel Review (the deadline for filing a Notice of Appearance is January 5, 2001); and

(c) the panel review shall be limited to the allegations of error of fact or law, including the jurisdiction of the investigating authority, that are set out in the Complaints filed in the panel review and the procedural and substantive defenses raised in the panel review.

Dated: December 5, 2000.

Caratina L. Alston,
United States Secretary, NAFTA Secretariat.

DEPARTMENT OF COMMERCE
National Institute of Standards and Technology
Manufacturing Extension Partnership National Advisory Board

AGENCY: National Institute of Standards and Technology, Department of Commerce.

ACTION: Notice of partially closed meeting.

SUMMARY: Pursuant to the Federal Advisory Committee Act, 5 U.S.C. app. 2, notice is hereby given that the Manufacturing Extension Partnership National Advisory Board (MEPNAB), National Institute of Standards and Technology (NIST), will meet Thursday, January 18, 2001 from 8 a.m. to 3:30 p.m. The MEPNAB is composed of eight members appointed by the Director of NIST who were selected for their expertise in the area of industrial extension and their work on behalf of smaller manufacturers. The Board was established to fill a need for outside input on MEP. MEP is a unique program consisting of centers in all 50 states and Puerto Rico. The centers have been created by state, federal, and local partnerships. The Board works closely with MEP to provide input and advice on MEP’s programs, plans, and policies. The agenda will include a review by program managers of their programs for 2000 with updates and accomplishments in the areas of center management, tool and product development and national marketing activities, and a discussion of program goals and strategies for 2001. The portion of the meeting which involves personnel and proprietary budget information will be closed to the general public. All other portions of the meeting will be open to the public.

DATES: The meeting will convene January 18, 2001 at 8 a.m. and will adjourn at 3:30 p.m. on January 18, 2001.

ADDRESSES: The meeting will be held in the Tenth Floor Conference Room, Administration Building, at NIST, Gaithersburg, Maryland.

FOR FURTHER INFORMATION CONTACT: Linda Acierio, Senior Policy Advisor, Manufacturing Extension Partnership, National Institute of Standards and Technology, Gaithersburg, MD 20899–4800, telephone number (301) 975–5033.

SUPPLEMENTARY INFORMATION: The Assistant Secretary for Administration with the concurrence of the General Counsel formally determined on December 18, 2000, that portions of the meeting which involve discussion of proposed funding of the MEP may be closed in accordance with 5 U.S.C. 552b(c)(9)(B), because that portion will divulge matters the premature disclosure of which would be likely to significantly frustrate implementation of proposed agency actions; and that portions of the meeting which involve discussion of the staffing of positions in MEP may be closed in accordance with 5 U.S.C. 552b(c)(6), because divulging information discussed in that portion of the meeting is likely to reveal information of a personal nature, where disclosure would constitute a clearly unwarranted invasion of personal privacy.


Raymond G. Kammer, Director.

FOR FURTHER INFORMATION CONTACT: Madeleine Clayton, Departmental Forms Clearance Officer, Department of Commerce, Room 6086, 14th and Constitution Avenue, NW., Washington, DC 20230 or via the Internet (MClayton@doc.gov).

DEPARTMENT OF COMMERCE
Technology Administration
National Medal of Technology

ACTION: Proposed collection; Comment request.

SUMMARY: The Department of Commerce (DOC), as part of its continuing effort to reduce paperwork and respondent burden, invites the general public and other Federal agencies to comment on the continuing and proposed information collection, as required by the Paperwork Reduction Act of 1995, Public Law 104–13 (44 U.S.C. 3506(c)(2)(A))

DATES: Written comments must be submitted on or before February 26, 2001.

ADDRESSES: Direct all written comments to Madeleine Clayton, Departmental Forms Clearance Officer, Department of Commerce, Room 6086, 1401 Constitution Avenue, NW., Washington, DC 20230 or via the Internet (MClayton@doc.gov).

FOR FURTHER INFORMATION CONTACT: Requests for additional information should be directed to the attention of Mildred Porter, Director, National Medal of Technology Program, Technology Administration, 1401
Constitution Avenue, NW., Room 4226, Washington, DC 20230. In addition, written comments may be sent via fax, (202) 501–8153, and e-mail to mporter@ita.doc.gov.

SUPPLEMENTARY INFORMATION:

I. Abstract

This information collection is critical for the Nomination Evaluation Committee to determine selection eligibility and merit according to specified criteria or the annual selection of the Nation’s leading technological innovators honored by the President of the United States. The information is needed in order to comply with P.L. 96–480 and P.L. 105.309. Comparable information is not available on a standardized basis.

II. Method of Collection

By mail, but the nomination forms and instructions are electronically posted on the National Medal of Technology web site so interested parties can review criteria and informational requirements at their convenience.

III. Data

OMB Number: 0692–0001.

Type of Review: Revision of a currently approved collection.

Affected Public: Individuals or households; business or other for-profit organizations; not-for-profit institutions; and, Federal Government.

Estimated Number of Respondents: 102.

Estimated Time Per Response: 25 hours.

Estimated Total Annual Respondent Burden Hours: 2550.

Estimated Total Annual Respondent Cost Burden: None.

IV. Requests for Comments

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (b) the accuracy of the agency’s estimate of the burden (including hours and cost) of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, e.g., the use of automated collection techniques or other forms of information technology.

Comments submitted in response to this notice should summarize or be included in the request for OMB approval of this information collection; it will also become a matter of public record.


Madeleine Clayton,

Departmental Forms Clearance Officer, Office of the Chief Information Officer.

[FR Doc. 00–33240 Filed 12–27–00; 8:45 am]

BILLING CODE 3510–18–P

COMMITTEE FOR THE IMPLEMENTATION OF TEXTILE AGREEMENTS

                                                                                       Extension of Temporary Amendment to the Requirements for Participating in the Special Access Program for Caribbean Basin Countries


AGENCY: Committee for the Implementation of Textile Agreements (CITA).

ACTION: Issuing a directive to the Commissioner of Customs extending amendments of requirements for participation in the Special Access Program for a temporary period.


SUPPLEMENTARY INFORMATION:

Authority: Section 204 of the Agricultural Act of 1956, as amended (7 U.S.C. 1854); Executive Order 11651 of March 3, 1972, as amended.

A notice published in the Federal Register on December 18, 1998 (63 FR 70112), amended on December 24, 1998 (64 FR 149, published on January 4, 1999), extended the exemption period for women’s and girls’ and men’s and boys’ chest type plate, “hymo” piece or “sleeve header” of woven or felt-inserted warp knit construction of coarse animal hair or man-made filaments used in the manufacture of tailored suit jackets and suit-type jackets in Categories 433, 435, 443, 444, 633, 635, 643 and 644, which are entered under the Special Access Program, for the periods December 23, 1998 through December 31, 2000 for women’s and girls’ “hymo” type interlinings and September 23, 1998 through December 31, 2000 for men’s and boys’ “hymo” type interlinings. See also directive dated September 16, 1996 (61 FR 49439), as amended.

Effective on January 1, 2001, by date of export, you are directed to extend through December 31, 2002, the amendment to treat non-U.S. formed, U.S.-cut interlinings for chest type plate, “hymo” piece or “sleeve header” of woven or felt-inserted warp knit construction of coarse animal hair or man-made filaments used in the manufacture of tailored suit jackets and suit-type jackets in Categories 433, 443, 633 and 643 as qualifying for exception for findings and trimmings, including elastic strips less than one inch in width, created under the Special Access Program effective September 1, 1986 (see 51 FR 21208). In the aggregate, such interlinings, findings and trimmings must not exceed 25 percent of the cost of the components of the assembled article. Non-U.S. formed, U.S.-cut interlinings may be used in imports of women’s and girls’ and men’s and boys’ suit jackets and suit-type jackets entered under the Special Access Program (9802.00.8015) provided they are cut in the United States and of a type described above.
The Committee for the Implementation of Textile Agreements has determined that this action falls within the foreign affairs exception of the rulemaking provisions of 5 U.S.C. 553(a)(1).

Sincerely,
Richard B. Steinkamp,
Chairman, Committee for the Implementation of Textile Agreements.

[FR Doc. 00–33050 Filed 12–27–00; 8:45 am]
BILLING CODE 3510–DR–F

COMMITTEE FOR THE IMPLEMENTATION OF TEXTILE AGREEMENTS

Availability of the Correlation: Textile and Apparel Categories With the Harmonized Tariff Schedule of the United States for 2001


AGENCY: Committee for the Implementation of Textile Agreements (CITA).

ACTION: Notice.


SUPPLEMENTARY INFORMATION: The Committee for the Implementation of Textile Agreements (CITA) announces that the 2001 Correlation, based on the Harmonized Tariff Schedule of the United States, will be available in January 2001 as part of the Office of Textiles and Apparel (OTEXA) CD-Rom publications.

The CD-Rom may be purchased from the U.S. Department of Commerce, Office of Textiles and Apparel, 14th and Constitution Avenue, NW., room H3100, Washington, DC 20230, ATTN: Barbara Anderson, at a cost of $25. Checks or money orders should be made payable to the U.S. Department of Commerce.

The Correlation is also available on the OTEXA website at http://otexa.ita.doc.gov.

Richard B. Steinkamp,
Chairman, Committee for the Implementation of Textile Agreements.

[FR Doc. 00–33053 Filed 12–27–00; 8:45 am]
BILLING CODE 3510–DR–F

DEPARTMENT OF DEFENSE

Department of the Navy

Meeting of the Chief of Naval Operations (CNO) Executive Panel

AGENCY: Department of the Navy, DOD.

ACTION: Notice of closed meeting of the CNO Executive Panel.

SUMMARY: The CNO Executive Panel is to conduct the final briefing of the Expeditionary Sensors Task Force to the Chief of Naval Operations. This meeting will consist of discussions relating to how to best bring a robust sensor system with supporting networks into being.

DATES: The meeting will be held on January 19, 2001 from 9:30 to 11 a.m.

ADDRESSES: The meeting will be held at the office of the Chief of Naval Operations, 2000 Navy Pentagon, Washington, DC 20350–2000.

FOR FURTHER INFORMATION CONCERNING THIS MEETING CONTACT: Commander Christopher Agan, CNO Executive Panel, 4825 Mark Center Drive, Alexandria, Virginia 22311, (703) 681–6205.

SUPPLEMENTARY INFORMATION: Pursuant to the provisions of the Federal Advisory Committee Act (5 U.S.C. App. 2), these matters constitute classified information that is specifically authorized by Executive Order to be kept secret in the interest of national defense and are, in fact, properly classified pursuant to such Executive Order. Accordingly, the Secretary of the Navy has determined in writing that the public interest requires that all sessions of the meeting be closed to the public because they will be concerned with matters listed in section 552(b)(1) of title 5, United States Code.


James L. Roth,
Lieutenant Commander, United States Navy, Judge Advocate General’s Corps, Federal Register Liaison Officer.

[FR Doc. 00–33053 Filed 12–27–00; 8:45 am]
BILLING CODE 3810–FF–P

UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES

Sunshine Act Meeting

AGENCY HOLDING THE MEETING: Uniformed Services University of the Health Sciences.

TIME AND DATE: 8:00 a.m. to 4:00 p.m., February 6, 2001.

PLACE: Uniformed Services University of the Health Sciences, Board of Regents Conference Room (D3001), 4301 Jones Bridge Road, Bethesda, MD 20814–4799.

STATUS: Open—under “Government in the Sunshine Act” (5 U.S.C. 552b(e)(3)).

MATTERS TO BE CONSIDERED:

8:30 a.m. Meeting—Board of Regents

(1) Approval of Minutes—November 20, 2000

(2) Faculty Matters

(3) Departmental Reports

(4) Financial Reports

(5) Report—President, USUHS

(6) Report—Dean, School of Medicine

(7) Report—Dean, Graduate School of Nursing

(8) Comments—Chairman, Board of Regents

(9) New Business

CONTACT PERSON FOR MORE INFORMATION: Mr. Bobby D. Anderson, Executive Secretary, Board of Regents, (301) 295–3116.


Patricia L. Toppings,
Alternate OSD Federal Register Liaison Officer, Department of Defense.

[FR Doc. 00–33268 Filed 12–26–00; 10:57 am]
BILLING CODE 5001–01–M

DEPARTMENT OF ENERGY

Agency Information Collection Under Review by the Office of Management and Budget

AGENCY: Department of Energy.

ACTION: Submission for OMB review; comment request.

SUMMARY: The Department of Energy (DOE) has submitted renewals for an additional three years for the information collection(s) listed at the end of this notice to the Office of Management and Budget (OMB) for review under sections 3507(h)(1) of the Paperwork Reduction Act of 1995 (Pub. L. 104–13) (44 U.S.C. 3501 et seq).

Each entry contains the following information: (1) The collection number and title; (2) a summary of the collection of information, type of request (new, revision, extension, or reinstatement), response obligation (mandatory, voluntary, or required to obtain or retain benefits); (3) a description of the need and proposed use of the information; (4) a description of the likely respondents; and (5) an estimate of the total annual reporting burden (i.e., the estimated number of likely respondents times the proposed frequency of response per year times the average hours per response).

DATES: Comments must be filed by January 29, 2001. If you anticipate that you will be submitting comments but find it difficult to do so within the time allowed by this notice, you should advise the OMB DOE Desk Officer listed below of your intention to do so, as soon as possible. The OMB Desk Officer may be telephoned at (202) 395–7318. (Also, please notify the DOE contact listed below.)

ADDRESSES: Address comments to the Department of Energy Desk Officer,
Office of Information and Regulatory Affairs, Office of Management and Budget, 725 17th Street, NW, Washington, DC 20503. (Comments should also be addressed to the Records Management Division, Office of the Chief Information Officer, at the address below.)

FOR FURTHER INFORMATION, CONTACT: Requests for additional information should be directed to Susan L. Frey, Director, Records Management Division, Office of Records and Business Management (SO–312), U.S. Department of Energy, Germantown, MD 20874–1290. Ms. Frey can be contacted by telephone at (301) 903–3666, or e-mail at Susan.Frey@hq.doe.gov

SUPPLEMENTARY INFORMATION: The information collections submitted to OMB for review were: 1. Current OMB No.: 1910–0400. Package Title: Financial Assistance. Summary: A three-year extension is requested, which includes both mandatory and response to obtain or retain benefits. Purpose: This information is required by the Department to manage all phases of the process of awarding, administering, and closing out financial assistance awards. The package contains 58 information and/or recordkeeping requirements. Type of Respondents: DOE management and operating contractors and offsite contractors. Estimated Number of Burden Hours: 664,673.

2. Current OMB No.: 1910–1000. Package Title: Personal Property. Summary: A three-year extension is requested for these mandatory response obligations. Purpose: This provides the Department with the information necessary for the management, control, reutilization, and disposal of government personal property. The package contains 29 information and/or recordkeeping requirements. Type of Respondents: DOE management and operating contractors and offsite contractors. Estimated Number of Responses: 3,857. Estimated Total Burden Hours: 247,374.

3. Current OMB No.: 1910–1800. Package Title: Safeguards and Security. Summary: A three-year extension is requested for these mandatory response obligations. Purpose: This information is required by the Department for guard service contracts, security classified records, facility security, nuclear facility safety, and nuclear facility security. The package contains information and/or recordkeeping requirements. Type of Respondents: DOE management and operating contractors and offsite contractors. Estimated Total Burden Hours: 612,985.


Susan L. Frey, Director, Records Management Division, Office of Records and Business Management, Office of the Chief Information Officer.

BILLING CODE 6450–01–P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[DOCKET NO. RP01–166–001]

ANR Pipeline Company: Notice of Proposed Changes in FERC Gas Tariff


Take notice that on December 15, 2000, ANR Pipeline Company (ANR) tendered for filing as part of its FERC Gas Tariff, Original Volume No. 2, the following revised tariff sheets, to be effective January 1, 2001:

Substitute Fifteenth Revised Sheet No. 570
Substitute Second Revised Sheet No. 573

ANR states that the above-referenced tariff sheets are being filed to correct a clerical error in ANR’s December 1, 2000 filing in the captioned proceeding, which sought a continuance of the suspension of ANR’s tariff provisions regarding the requirement to annually redetermine the monthly charge for services provided to High Island Offshore System under ANR’s Rate Schedule X–64. The December 1st filing did not reflect that (a) the proposed charge was an annual fee, and (b) the term extension commences on January 1, 2001 and expires December 31, 2015.

Any person desiring to protest said filing should file a protest with the Federal Energy Regulatory Commission, 888 First Street, NE, Washington, DC 20426, in accordance with section 385.211 of the Commission’s Rules and Regulations. All such protests must be filed in accordance with section 154.210 of the Commission’s Regulations. Protests will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protesters parties to the proceedings. Copies of this filing are on file with the Commission and are available for public inspection in the Public Reference Room. This filing may be viewed on the web at http://www.ferc.fed.us/online/rims.htm (call 202–208–2222 for assistance). Comments and protests may be filed electronically via the internet in lieu of paper. See, 18 CFR 385.2001(a)(9)(iii) and the instructions on the Commission’s web site at http://www.ferc.fed.us/efi/doorbell.htm.

Linwood A. Watson, Jr., Acting Secretary.

[FR Doc. 00–33096 Filed 12–27–00; 8:45 am] BILLING CODE 6717–01–M

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[DOCKET NO. RP01–192–000]

Columbia Gas Transmission Corporation; Notice of Proposed Changes in FERC Gas Tariff


Take notice that on December 15, 2000, Columbia Gas Transmission Corporation (Columbia) tendered for filing as part of its FERC Gas Tariff, Second Revised Volume No. 1, the following revised tariff sheets, bearing a proposed effective date of January 1, 2001:

Forty-seventh Revised Sheet No. 25
Forty-seventh Revised Sheet No. 26
Forty-seventh Revised Sheet No. 27
Twenty-first Revised Sheet No. 30A

Columbia states that this filing is being submitted pursuant to Stipulation I, Article I, Section E, True-up Mechanism, of the Settlement (Settlement) in Docket No. RP05–408 et al., approved by the Commission on April 17, 1997 (79 FERC ¶ 61,044 (1997)). Under the approved section of the Settlement, Columbia is required to true-up its collections pursuant to the Settlement Component for 12-month periods commencing November 1, 1996 and ending October 31, 2004. The fourth 12-month Period (Period IV) ended October 31, 2000. Columbia is making this true-up filing in compliance with the Settlement to return a net over-recovery of $2,130,235 for Period IV, which includes interest and the true-up of the Period III Settlement Component adjustment, through an adjustment to the Settlement Component of the base rates for the period January 1, 2001 through October 31, 2001.

Columbia states that copies of its filing have been mailed to all firm customers, interruptible customers, and affected state commissions. Any person desiring to be heard or to protest said filing should file a motion to intervene or a protest with the Federal Energy Regulatory Commission, 888 First Street, NE, Washington, DC 20426, in accordance with sections 385.214 or 385.211 of the Commission’s
Rules and Regulations. All such motions or protests must be filed in accordance with section 154.210 of the Commission’s Regulations. Protests will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceedings. Any person wishing to become a party must file a motion to intervene. Copies of this filing are on file with the Commission and are available for public inspection in the Public Reference Room. This filing may be viewed on the web at http://www.ferc.fed.us/efi/doorbell.htm. Comments and protests may be filed electronically via the internet in lieu of paper. See, 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission’s web site at http://www.ferc.fed.us/efi/doorbell.htm.

Linwood A. Watson, Jr., Acting Secretary.

[FR Doc. 00–33098 Filed 12–27–00; 8:45 am]
BILLING CODE 6717–01–M

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. RP95–408–038]

Columbia Gas Transmission Corporation; Notice of Compliance Filing


Take notice that on December 15, 2000, Columbia Gas Transmission Corporation (Columbia) tendered a filing in compliance with Stipulation II, Article III, Section F, of the settlement filed in Docket No. RP95–408 et al. approved on April 17, 1997 (79 FERC ¶ 61.044 (1997)) [Settlement].

In accordance with this provision, Columbia is required to share with its customers the gain or loss on the sale of certain gathering and products extraction facilities. On December 15, 1999, Columbia shared the initial gain on the disposition of its stranded gathering and products extraction facilities. In the instant filing, Columbia is filing to share an additional excess of $0.676. Columbia is also filing a report on its plan to dispose of its remaining gathering facilities as required under the terms of Stipulation II, Article III, Section F of the Settlement.

Columbia states further that copies of this filing have been mailed to all of its customers and affected state regulatory commissions.

Any person desiring to protest said filing should file a protest with the Federal Energy Regulatory Commission, 888 First Street, N.E., Washington, DC 20426, in accordance with section 385.211 of the Commission’s Rules and Regulations. All such protests must be filed in accordance with section 154.210 of the Commission’s Regulations. Protests will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceedings. Copies of this filing are on file with the Commission and are available for public inspection in the Public Reference Room. This filing maybe viewed on the web at http://www.ferc.fed.us/efi/doorbell.htm. Comments and protests may be filed electronically via the internet in lieu of paper. See, 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission’s web site at http://www.ferc.fed.us/efi/doorbell.htm.

Linwood A. Watson, Jr., Acting Secretary.

[FR Doc. 00–33101 Filed 12–27–00; 8:45 am]
BILLING CODE 6717–01–M

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. RP01–190–000]

Kern River Gas Transmission Company; Notice of Filing of Pro Forma Tariff Sheets


Take notice that on December 15, 2000, Kern River Gas Transmission Company (Kern River) tendered for filing as part of its FERC Gas Tariff, Second Revised Volume No. 1, the pro forma tariff sheets listed in Appendix A to the filing.

Kern River states that the purpose of the filing is to establish in Kern River’s tariff a mechanism for converting the maximum daily quantities (MDQs) stated in transportation service agreements that were executed on a volumetric (i.e., Mcf) basis to demand maximum daily quantities (DMDQs), transportation maximum daily quantities (TMDQs), and receipt and delivery point entitlements, all on a thermal (i.e., Dth) basis, and all as more fully described in the filing.

Kern River states that it has served a copy of this filing upon its customers and interested state regulatory commissions.

Any person desiring to be heard or to protest said filing should file a motion to intervene or a protest with the Federal Energy Regulatory Commission, 888 First Street, N.E., Washington, DC 20426, in accordance with sections 385.214 or 385.211 of the Commission’s Rules and Regulations. All such motions or protests must be filed on or before December 27, 2000. Protests will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceedings. Any person wishing to become a party must file a motion to intervene. Copies of this filing are on file with the Commission and are available for public inspection in the Public Reference Room. This filing may be viewed on the web at http://www.ferc.fed.us/efi/doorbell.htm. Comments and protests may be filed electronically via the internet in lieu of paper. See, 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission’s web site at http://www.ferc.fed.us/efi/doorbell.htm.

Linwood A. Watson, Jr., Acting Secretary.

[FR Doc. 00–33099 Filed 12–27–00; 8:45 am]
BILLING CODE 6717–01–M

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. RP96–272–022]

Northern Natural Gas Company; Notice of Proposed Changes in FERC Gas Tariff


Take notice that on December 18, 2000, Northern Natural Gas Company (Northern) tendered for filing to become part of Northern’s FERC Gas Tariff, Fifth Revised Volume No. 1, the following tariff sheet, proposed to become effective on December 19, 2000.

Third Revised Sheet No. 66A

Northern states that the above sheet is being filed to amend the negotiated rate transaction with OGE Energy Resources, Inc. filed on December 12, 2000 in accordance with the Commission’s Policy Statement on Alternatives to Traditional cost-of-Service Ratemaking for Natural Gas Pipelines. Specifically, the amendment sets forth the MDQ that the negotiated rate applies to through the end of December, 2000.

Northern further states that copies of the filing have been mailed to each of its customers and interested State Commissions.

Any person desiring to protest said filing should file a protest with the
Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, in accordance with section 385.211 of the Commission’s Rules and Regulations. All such protests must be filed in accordance with section 154.210 of the Commission’s Regulations. Protests will be considered by the commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceedings. Copies of this filing are on file with the Commission and are available for public inspection in the Public Reference Room. This filing may be viewed on the web at http://www.ferc.fed.us/efi/doorbell.htm (call 202-208–2222 for assistance). Comments and protests may be filed electronically via the internet in lieu of paper. See, 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission’s web site at http://www.ferc.fed.us/efi/doorbell.htm.

Linwood A. Watson, Jr., Acting Secretary.

[FR Doc. 00–33100 Filed 12–27–00; 8:45 am] BILLING CODE 6717–01–M

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. RP96–272–021]

Northern Natural Gas Company; Notice of Compliance Filing


Take notice that on December 15, 2000, Northern Natural Gas Company (Northern), tendered for filing in its FERC Gas Tariff, Fifth Revised Volume No. 1, the following tariff sheet proposed to be effective November 1, 2000:

Substitute Eleventh Revised Sheet No. 66

Northern states that the purpose of this filing is to comply with the Commission’s Order issued on November 30, 2000 in Docket No. RP96–272–019. Northern is filing the revised tariff sheet to specify separately the components of the negotiated rate between the transmission component and the construction cost reimbursement component in Footnote 7 which details the negotiated rate agreement with Midwest Natural Gas, Inc.

Northern further states that copies of the filing have been mailed to each of its customers and interested State Commissions.

Any person desiring to be heard or to protest said filing should file a motion to intervene or a protest with the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, in accordance with sections 385.214 or 385.211 of the Commission’s Rules and Regulations. All such motions or protests must be filed in accordance with section 154.210 of the Commission’s Regulations. Protests will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceedings.

Protests will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceedings. Copies of this filing are on file with the Commission and are available for public inspection in the Public Reference Room. This filing may be viewed on the web at http://www.ferc.fed.us/efi/doorbell.htm (call 202–208–2222 for assistance).

Northern further states that copies of the purpose of this filing is to comply with the Commission’s Order issued on November 30, 2000 in Docket No. RP96–272–019. Northern is filing the revised tariff sheet to specify separately the components of the negotiated rate between the transmission component and the construction cost reimbursement component in Footnote 7 which details the negotiated rate agreement with Midwest Natural Gas, Inc.

Northern further states that copies of the filing have been mailed to each of its customers and interested State Commissions.

Any person desiring to be heard or to protest said filing should file a motion to intervene or a protest with the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, in accordance with section 385.211 of the Commission’s Rules and Regulations. All such protests must be filed in accordance with section 154.210 of the Commission’s Regulations. Protests will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceedings. Copies of this filing are on file with the Commission and are available for public inspection in the Public Reference Room. This filing may be viewed on the web at http://www.ferc.fed.us/efi/doorbell.htm (call 202–208–2222 for assistance). Comments and protests may be filed electronically via the internet in lieu of paper. See, 18 CFR 385.2001(a)(ii) and the instructions on the Commission’s web site at http://www.ferc.fed.us/efi/doorbell.htm.

Linwood A. Watson, Jr., Acting Secretary.

[FR Doc. 00–33100 Filed 12–27–00; 8:45 am] BILLING CODE 6717–01–M

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. RP95–136–016]

Williams Gas Pipelines Central, Inc.; Notice of Refund Report


Take notice that on December 18, 2000 Williams Gas Pipeline Central, Inc. (Williams) tendered for filing its interruptible excess refund report for the twelve-month period ended September 2000.

Williams stated that a copy of its filing was served on all participants listed on the service list maintained by the Commission in the docket referenced above and on all of Williams’ jurisdictional customers and interested state commissions.

Any person desiring to protest said filing should file a protest with the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, in accordance with section 385.211 of the Commission’s Rules and Regulations. All such protests must be filed on or before December 28, 2000. Protests will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceedings. Copies of this filing are on file with the Commission and are available for public inspection in the Public Reference Room. This filing may be viewed on the web at http://www.ferc.fed.us/efi/doorbell.htm (call 202–208–2222 for assistance). Comments and protests may be filed electronically via the internet in lieu of paper. See, 18 CFR 385.2001(a)(ii) and the instructions on the Commission’s web site at http://www.ferc.fed.us/efi/doorbell.htm.

Linwood A. Watson, Jr., Acting Secretary.

[FR Doc. 00–33100 Filed 12–27–00; 8:45 am] BILLING CODE 6717–01–M

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Project No. 2194; Project No. 135]

North Fork Hydroelectric Project, Oak Grove Hydroelectric Project, Portland General Electric Company, Portland, Oregon; Notice of Intent To Conduct Public Scoping Meetings


The Federal Energy Regulatory Commission (Commission or FERC) allows an applicant in the relicensing of a hydroelectric project, the option of filing a Third Party Contractor prepared Environmental Impact Statement (EIS) in lieu of Exhibit E of the license application. Portland General Electric (PGE—Applicant) has requested, and the Commission has approved this alternative procedure for the relicensing of the North Fork Hydroelectric Project No. 2195 and the Oak Grove Hydroelectric Project No. 135. The 121-megawatt North Fork project is located on the Clackamas River, Oregon and the 44-megawatt Oak Grove Project is located on the Oak Grove Fork of the Clackamas River. Public and agency scoping meetings will be held on February 6, 2001, for preparation of a preliminary Environmental Impact Statement.

Scoping Meetings

FERC staff will conduct one agency scoping meeting and one public meeting. The agency scoping meeting will focus on resource agency and non-governmental organization (NGO) concerns, while the public scoping meeting is primarily for public input. All interested individuals, organizations, and agencies are invited to attend one or both of the meetings, and to assist the staff in identifying the scope of the environmental issues that
should be analyzed in the EIS. The times and locations of these meetings are as follows:

Agency Scoping Meeting

Date: February 6, 2001.
Time: 9:00 a.m.–noon.
Place: Two World Trade Center (Mezzanine).
Address: 121 SW Salmon Street, Portland, Oregon.

Public Scoping Meeting

Date: February 6, 2001.
Time: 7:00 p.m.–9:00 p.m.
Place: Mt. Hood National Forest, Clackamas River Ranger District Office.
Address: 595 N.W. Industrial Way, Estacada, Oregon.

The Ranger District Office is located off of Highway 224, one-half mile west of the town of Estacada. Industrial Way runs parallel to Hwy. 224 and is one block south. There is a sign for the office on Hwy. 224.

To help focus discussions, we will distribute a Scoping Document (SD1) outlining the subject areas to be addressed at the meeting to the parties on the Commission’s mailing list. Copies of the SD1 also will be available at the scoping meetings.

Objectives

At the scoping meetings, the staff will: (1) Summarize the environmental issues tentatively identified for analysis in the EIS; (2) solicit from the meeting participants all available information, especially quantifiable data, on the resources at issue; (3) encourage statements from experts and the public on issues that should be analyzed in the EIS, including viewpoints in opposition to, or in support of, the staff’s preliminary views; (4) determine the relative depth of analysis for issues to be addressed in the EIS; and (5) identify resource issues that are of lesser importance, and, therefore, do not require detailed analysis.

Procedures

The meetings will be recorded by a stenographer and will become part of the formal record of the Commission proceeding on the project. Individuals presenting statements at the meetings will be asked to sign in before the meeting starts and to clearly identify themselves for the record. Speaking time for attendees at the meetings will be determined before the meeting, based on the number of persons wishing to speak and the approximate amount of time available for the session. All speakers will be provided at least 5 minutes to present their views.

Individuals, organizations, and agencies with environmental expertise and concerns are encouraged to attend the meetings and to assist the staff in defining and clarifying the issues to be addressed in the EIS.

Submitting Comments

Persons choosing not to speak at the meetings, but who have views on the issues, may submit written statements for inclusion in the public record at the meeting, or mail their comments to: Mr. David Heintzman, Portland General Electric (3 WTC–BRHL), 121 SW Salmon Street, Portland, OR 97204, (503) 464–8162.

All correspondence must identify the projects on the first page as: Clackamas River Hydroelectric Relicensing, Oak Grove Project—FERC No. 135 and North Fork Project—FERC No. 2195. All correspondence should be postmarked no later than March 7, 2001.

For further information, please contact David Heintzman, FGE, (503) 464–8162 or John Blair, FERC, (202) 219–2845.

Linwood A. Watson, Jr.,
Acting Secretary.
[FR Doc. 00–33103 Filed 12–27–00; 8:45 am]
BILLING CODE 6717–01–M

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

Notice of Intent To Prepare an Environmental Assessment and Solicit Written Scoping Comments


Take notice that the following hydroelectric application has been filed with Commission and is available for public inspection:

a. Type of Application: Subsequent License.

b. Project No.: 2103–002.

c. Date filed: June 29, 2000.

d. Applicant: Cominco American Incorporated.

e. Name of Project: Cedar Creek.

f. Location: On Cedar Creek, a tributary of the Pend Oreille River, in Stevens County, Washington. The Project occupies 2.058 acres of land managed by the Bureau of Land Management, 0.298 acre of International Boundary Reserve land controlled by the International Joint Commission, and 0.44 acre of private land.

g. Filed Pursuant to: Federal Power Act, 16 U.S.C. 791(a)–825(r).

h. Applicant Contact: Bruce DiLuzio, Cominco American Incorporated, 15918 E. Euclid Avenue, Spokane, WA, 99216, (509) 747–6111.

i. FERC Contact: Brandi Bradford, (202) 219–2789, brandi.bradford@ferc.fed.us.


All documents (original and eight copies) should be filed with: David P. Boegers, Secretary, Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426.

The Commission’s Rules of Practice and Procedure require all intervenors filing documents with the Commission to serve a copy of that document on each person on the official service list for the project. Further, if an intervenor files comments or documents with the Commission relating to the merits of an issue that may affect the responsibilities of a particular resource agency, they must also serve a copy of the document on that resource agency.

Scoping comments may be filed electronically via the internet in lieu of paper. See 18 CFR 385.001(a)(iii) and the instructions on the Commission’s web site at http://www.ferc.gov.

k. This application is not ready for environmental analysis at this time.

l. The existing Cedar Creek Project consists of 2.4 acres of land periodically inundated by operation of the Waneta Project located in British Columbia, Canada. The Cedar Creek Project area is located in the United States. All Waneta Project facilities, including the dam and power generation facilities, are located in Canada and are outside FERC jurisdiction. Within the confines of the Cedar Creek Project, the maximum pool is EL 1517.8 (Canadian Geodetic Survey of Canada Datum) and minimum pool is EL 1502. Cominco American Incorporated currently has flowage rights to lands in the Cedar Creek Project boundary up to EL 1521.

m. A copy of the application is available for inspection and reproduction at the Commission’s Public Reference Room, located at 888 First Street, NE., Room 2A, Washington, DC 20426, or by calling (202) 208–1371. The application may be viewed on http://www.ferc.gov (call (202) 208–2222 for assistance). A copy is also available for inspection and reproduction at the address in item h above.

n. Scoping Process.

The Commission intends to prepare an Environmental Assessment (EA) on the project in accordance with the National Environmental Policy Act. The EA will consider both site-specific and cumulative environmental impacts and reasonable alternatives to the proposed action.
We are asking agencies, Native American tribes, non-governmental organizations, and individuals to help us identify the scope of environmental issues that should be analyzed in the EA, and to provide us with information that may be useful in preparing the EA by submitting written scoping comments.

To help focus comments on the environmental issues, a Scoping Document 1 that outlines subject areas to be addressed in the EA will soon be mailed to those on the mailing list for the project. The Scoping Document 1 will also be available from the address and website listed in item m above. For further information, please contact Brandi Bradford at (202) 219–2789.

Linwood A. Watson, Jr.,
Acting Secretary.

[FR Doc. 00–33104 Filed 12–27–00; 8:45 am]
BILLING CODE 6717–01–M

DEPARTMENT OF ENERGY
Federal Energy Regulatory Commission

Notice of Settlement Agreement and Soliciting Comments


Take notice the following Settlement Agreement has been filed with the Commission and is available for public inspection:

a. Type of Application: Settlement on New Minor License Application.

b. Project No.: 2694–002, Project Name: Queens Creek, Applicant: Nantahala Power and Light, a Division of Duke Engineering Corporation.

c. Date Settlement Agreement Filed: October 30, 2000.

d. Location: On Queens Creek, near the town of Topton, in Macon County, North Carolina. The project would not utilize federal lands.

 e. Filed Pursuant to: Federal Power Act, 16 U.S.C. 791(a)–825(r).

 f. Applicant Contact: John Wishon; 301 NP&L Loop Road; Franklin, NC 28734; (828) 369–4604.

 g. FERC Contact: Kevin Whalen [202] 219–2790.


i. All documents (original and eight copies) should be filed with: David P. Boergers, Secretary; Federal Energy Regulatory Commission; 888 First Street, NE; Washington, DC 20426.

The Commission’s Rules of Practice and Procedure require all intervenors filing documents with the Commission to serve a copy of that document on each person whose name appears on the official service list for the project. Further, if an intervenor files comments or documents with the Commission relating to the merits of an issue that may affect the responsibilities of a particular resource agency, they must also serve a copy of the document on that resource agency.

Protests, comments on filings, comments on environmental assessments and environmental impact statements, and reply comments may be filed electronically via the internet in lieu of paper. See 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission’s web site at http://www.ferc.fed.us/efi/doorbell.htm.

A Settlement Agreement was filed with the Commission on October 30, 2000. The agreement is the final, executed Queens Creek Settlement Agreement for Project No. 2694. The purpose of the agreement is to resolve among the signatory parties issues related to reservoir operating limits, recreational facility improvements, and minimum flows in the bypass reach, as well as other resolved subjects. Comments and reply comments on the Settlement Agreement are due as indicated in item h. above.

1. A copy of the offer of settlement is available for inspection and reproduction at the Commission’s Public Reference Room, located at 888 First Street, NE, Room 2A, Washington, DC 20424, or by calling (202) 208–1371. The Settlement Agreement may be viewed on the web at http://www.ferc.fed.us/online/rims.htm (call (202) 208–2222 for assistance). A copy is also available for inspection and reproduction at the address in item f above.

Linwood A. Watson, Jr.,
Acting Secretary.

[FR Doc. 00–33105 Filed 12–27–00; 8:45 am]
BILLING CODE 6717–01–M


<table>
<thead>
<tr>
<th>Subdocket No.</th>
<th>Buyer’s name</th>
<th>Size in acres +/-</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>–329</td>
<td>Hamm Estate</td>
<td>4.57</td>
<td>Off Macedonia Church Road, Newberry County.</td>
</tr>
<tr>
<td>–331</td>
<td>Kenneth Chapman</td>
<td>5.0</td>
<td>Off Wildwood Road, Saluda County.</td>
</tr>
<tr>
<td>–332</td>
<td>Nick Leventis</td>
<td>5.0</td>
<td>Off Road S–41–89, Saluda County.</td>
</tr>
<tr>
<td>–333</td>
<td>Brent Richardson</td>
<td>1.61</td>
<td>Off Dreher Island Rd., Lexington County.</td>
</tr>
</tbody>
</table>
DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

Notice of Application Accepted for Filing and Soliciting Motions To Intervene and Protests


Take notice that the following hydroelectric application has been filed with the Commission and is available for public inspection:

a. Type of Application: New Major License.


d. Applicant: Reliant Energy Mid-Atlantic Power Holdings, LLC.

e. Name of Project: Piney Hydroelectric Project.

f. Location: On the Clarion River in Clarion County, Pennsylvania. The project would not utilize any federal lands or facilities.

g. Filed Pursuant to: Federal Power Act, 16 U.S.C. 791(a)–825(r).

h. Applicant Contact: Mr. Thomas Teitt; Reliant Energy Mid-Atlantic Power Holdings, LLC; 1001 Broad Street; Johnstown, Pennsylvania 15905–1050; (814) 533–8028.

i. FERC Contact: Kevin Whalen (202) 219–2790.

j. Deadline for filing interventions and protests: 60 days from the issuance date of this notice.

All documents (original and eight copies) should be filed with: David P. Boergers, Secretary, Federal Energy Regulatory Commission, 888 First Street, NE, Washington, DC 20426.

The Commission’s Rules of Practice and Procedure require all intervenors filing documents with the Commission to serve a copy of that document on each person whose name appears on the official service list for the project. Further, if an intervenor files comments or documents with the Commission relating to the merits of an issue that may affect the responsibilities of a particular resource agency, they must also serve a copy of the document on that resource agency.

Protests, comments on filings, comments on environmental assessments and environmental impact statements, and reply comments may be filed electronically via the internet in lieu of paper. See 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission’s web site at http://www.ferc.fed.us/efi/doorbell.htm.

k. Status of environmental analysis: This application is not ready for environmental analysis at this time.

1. Description of the Project: The project consists of the following: (1) the 427-foot-long and 139-foot-high concrete arch dam with crest elevation at 1,075 feet msl, and 84-foot-long left non-overflow wall, and a 200-foot-long right non-overflow wall; (2) and 800-acre surface area reservoir; (3) an 84-foot-wide integral intake; (4) three 230-foot-long, 14-foot-diameter penstocks; (5) a powerhouse with 3 generating units totaling 28,300 kilowatts; (6) a 250-foot-long tailrace; (7) 700-foot-long and 900-foot-long transmission lines; and (8) appurtenant facilities.

m. Locations of the application: A copy of the application is available for inspection and reproduction at the Commission’s Public Reference Room, located at 888 First Street, NE, Room 2A, Washington, DC 20426, or by calling (202) 208–1371. The application may be viewed on the web at www.frc.fed.us/onlineirms.htm (call (202) 208–2222 for assistance). A copy is also available for inspection and reproduction at the addresses in time h above.

m. Comments, Protests, or Motions to Intervene—Anyone may submit comments, a protest, or a motion to intervene in accordance with the requirements of Rules of Practice and Procedure, 18 CFR 385.210, .211, .214. In determining the appropriate action to take, the Commission will consider all protests or other comments filed, but only those who file a motion to intervene in accordance with the Commission’s Rules may become a party to the proceeding. Any comments, protests, or motions to intervene must be received on or before the specified comment date for the particular application.

n. Filing and Service of Responsive Documents—Any filings must bear in all capital letters the title “COMMENTS”, “NOTICE OF INTENT TO FILE COMPETING APPLICATION”, “COMPETING APPLICATION”, “PROTEST”, “MOTION TO INTERVENE”, as applicable, and the Project Number of the particular application to which the filing refers. An additional copy must be sent to Director, Division of Hydropower Administration and Compliance, Federal Energy Regulatory Commission, at the above-mentioned address. A copy of any notice of intent, competing application or motion to intervene must also be served upon each representative of the Applicant specified in the particular application.

o. Agency Comments—Federal, state, and local agencies are invited to file comments on the described application. A copy of the application may be obtained by agencies directly from the Applicant. If an agency does not file comments within the time specified for filing comments, it will be presumed to have no comments. One copy of an agency’s comments must also be sent to the Applicant’s representatives.

Linwood A. Watson, Jr.,
Acting Secretary.

ENVIRONMENTAL PROTECTION AGENCY

[FRL–6923–9]

Draft Public Involvement Policy

AGENCY: Environmental Protection Agency.

ACTION: Proposed policy.

SUMMARY: The Environmental Protection Agency is revising its 1981 Public Participation Policy. The revised policy is being issued as the Draft 2000 Public Involvement Policy for 120-day public comment. The Draft Policy was updated to reflect changes over the past nineteen years such as additional Agency responsibilities, new regulations, expanded public involvement techniques, and the changed nature of public access due to the Internet. The Policy will provide guidance and direction to EPA officials on reasonable and effective means to involve the public in its regulatory and program decisions.

DATES: Comments will be accepted until April 27, 2001.

ADDRESSES: Submit comments to Patricia A. Bonner, United States Environmental Protection Agency, Office of Policy, Economics and Innovation (MC 1802), 1200 Pennsylvania Ave, NW, Washington, DC 20460, by facsimile at 202–260–4903 or by electronic mail to bonner.patricia@epa.gov.

FOR FURTHER INFORMATION CONTACT: Patricia Bonner at 202–260–0599. In addition to sending comments by mail, interested parties may file comments electronically to: stakeholders@epa.gov.

The Draft Public Involvement Policy may be downloaded from http://www.epa.gov/stakeholders. Any additional opportunities for public involvement on the Draft Policy will also be posted on the same web site.

EPA particularly seeks comments on how the Agency can improve involvement opportunities for minority, low-income and underserved populations and how it can encourage involvement opportunities in programs delegated or authorized to states, tribes and local governments.

SUPPLEMENTARY INFORMATION:

Background

On January 19, 1981, the EPA published its first Agency-wide Public Participation Policy “to ensure that managers plan in advance needed public involvement in their programs, that they consult with the public on issues where public comment can be truly helpful, that they use methods of consultation that will be effective both for program purposes and for the members of the public who take part, and finally that they are able to apply what they have learned from the public in their final program decisions.” (46 FR 5736, Jan. 19, 1981)

The 1981 Policy complemented regulations on “Public Participation in Programs Under the Resource Conservation and Recovery Act, the Safe Drinking Water Act, and the Clean Water Act,” 40 CFR Part 25 (2000) which EPA promulgated in 1979. Part 25 covers procedures that the Agency (or state, tribe, etc.) should or must follow. Like the 1981 Policy, these procedures include matters associated with information, notification, consultation responsibilities, public hearings, public meetings, advisory committees, responsiveness summaries, permit enforcement, rulemakings, and work elements in financial assistance agreements.

In the nearly two decades following issuance of the 1981 Policy, Congress and three Presidents added to EPA’s responsibilities, EPA promulgated many new regulations, public involvement techniques expanded, and the Internet revolutionized the nature of public access. EPA also developed and extended its methods of ensuring compliance with environmental regulations through partnerships, technical assistance, information and data access, and public involvement under the laws it implements. Legislation and executive orders established new government-wide administrative procedures and public involvement requirements. Since many EPA programs are authorized or delegated to the states, tribes and in some instances, local governments, many of these organizations developed their own public policies and procedures for public involvement.

Most importantly, EPA itself made public involvement an increasingly important part of its decision-making at all levels, ranging from advisory committees for national rules to local involvement in permitting, cleanups, and a host of other initiatives. Further, the Agency developed tools to assist EPA staff and regulatory partners to conduct public involvement and consultation, such as the “RCRA Public Involvement Manual” (EPA530-R–96–007, September 1996), “Public Involvement in Environmental Permits: A Reference Guide (EPA599-R00–007, August 2000), the Model Plan for Public Participation” (EPA300–K–96–003, November 1996), “Environmental Justice in the Permitting Process” (EPA/300-R-00–004, December 1999), and the Office of Pesticide Program’s “How to Participate in EPA Decision-making” (63 FR 58038, October, 1998).

It was in that context that EPA stated in its July 1999 publication “Aiming for Excellence: Actions to Encourage Stewardship and Accelerate Environmental Progress” (EPA 100-R–99–006) that the Agency would evaluate and update EPA’s public involvement requirements and assess how well its regulations and policies ensure public involvement in decision-making. In November 1999 the Agency sought the public’s opinion on whether the 1981 Policy needed to be revised and updated (64 FR 66906, November 30, 1999). EPA collected, analyzed, and posted public comments on the Internet http://www.epa.gov/stakeholders.

Based on the comments received, EPA believes that, while the 1981 Policy required updating, it is basically sound and workable. Therefore, EPA is issuing today this Draft 2000 Public Involvement Policy (hereinafter called the Draft Policy) which updates and strengthens (but does not fundamentally change) the 1981 Policy. It incorporates many comments submitted in response to the 1999 Federal Register notice. After comments are received on this Draft Policy, EPA will issue a Final Public Involvement Policy.

Many of the 1999 comments can be grouped into several themes which are reflected in this Draft Policy. They suggest that the Agency should:

(a) increase efforts to identify groups or individuals interested in or affected by an issue and who represent a balance of views;

(b) provide notices and outreach materials in “plain English,” and in other languages when appropriate;

(c) listen to, seek to understand, and involve stakeholders in issues of critical importance to them;

(d) select the most appropriate level of effort and mechanisms for public involvement in any specific circumstance;

(e) incorporate Environmental Justice considerations;

(f) inform and involve the public earlier; and

(g) evaluate EPA public involvement policies and practices.

Certain other suggestions were not fully reflected in this Draft Policy, for the following reasons:

(a) Expand the length of public comment periods.

The Agency’s response: Some comment periods are set in regulations and statutes, and Executive Orders in some instances. EPA managers already choose the length of a specific comment period based on the complexity and
other aspects of the rule or other proposed actions. Because the Draft Policy is meant to enhance public involvement, its implementation should ensure better planning and enable managers to engage the public in discussions during the development of proposals, prior to opening a formal comment period on proposals, and to set the length of comment periods that give the public adequate time to develop comments.

The Agency's response: Implementing this suggestion would create unnecessary barriers rather than expand public access to staff and managers. Its effect would be to lessen public involvement in Agency activities and to greatly expand the administrative procedures and costs. The public would be overwhelmed with notices to review and receive information. If every such session were subject to public notice, the administrative burdens created would interfere with the environmental protection and public health functions of the Agency, and the public would not be well served.

(c) Think broadly about the environmental issues in an area (e.g., a watershed) and how all stakeholders can work together to identify: (1) Their information needs and how they prefer to obtain information; (2) issues that concern them; and (3) reach joint solutions, whenever possible; and (d) Advance the concept of stewardship.

The Agency's response on (c) and (d): EPA's environmental education programs, community based and watershed focused activities, pollution prevention activities, and related outreach and public access activities are attempting to promote and provide opportunities for holistic approaches to environmental problems. Though the stewardship philosophy is not stated in the Draft Policy, the Agency strongly supports such efforts. EPA has encouraged and actively participated in several industry stewardship programs and sustainability efforts, and in June 2000, EPA launched the National Environmental Performance Track. This new program rewards facilities that do more to protect the environment than they are legally required to do, and motivates them to become environmental stewards. Program participants are also required to share environmental information with their communities and involve them in relevant decisions.

In requesting public input on today's Draft Policy, EPA is particularly interested in comment on the following topics:

What EPA can do to encourage, promote and ensure effective public involvement in programs that have been delegated to states, tribes and local governments;

How EPA can improve involvement opportunities for minority, low-income and underserved populations; and

How EPA can more fully address the comments received earlier regarding place-based approaches.

The Draft 2000 Public Involvement Policy builds upon the 1981 Policy on Public Participation, not fundamentally changing its message. The strongest advice we received in response to the 1999 Federal Register notice was not to make major changes, but to place a high priority on carrying out the Draft Policy consistently at EPA national and regional levels. Therefore, the Administrator is directing that EPA staff and managers implement the Draft Policy while the Agency receives and considers public comments, and that they continue to implement other statutory and regulatory public involvement requirements. This directive is appropriate because in most respects this Draft Policy simply formalizes what has been the Agency's intent and widespread practice in recent years.

The Administrator also is charging the Agency's Reinvention Action Council, through a cross-Agency work group for public involvement, with developing a Draft Strategic Plan for Public Involvement during 2001. This group will design the plan to: Ensure full implementation of the Final Policy (when released); enhance Agency-wide public involvement; increase access to environmental information and involvement processes for under-served communities; and track and report progress on efforts to improve public involvement to the Agency and to the public. EPA will solicit input on the Plan from stakeholders and request public comments. The workgroup will also review EPA's Part 25 regulations and, if necessary, other regulations relating to public participation, to ensure consistency with Part 25.

The Administrator is further directing the Agency to develop the means to measure progress in implementing public involvement, evaluate the effectiveness of their involvement activities, and encourage our regulatory partners to implement the intent of this Draft Policy and other statutory and regulatory public involvement requirements.


EPA Draft Agency-wide 2000 Public Involvement Policy

Introduction

This Draft 2000 Public Involvement Policy (hereinafter called the Draft Policy) addresses public involvement in all of the Environmental Protection Agency's (EPA) decision-making, rulemaking, and program implementation activities. The fundamental premise of this Draft Policy is that, in all its programs, EPA should provide for meaningful public involvement. This requires that everyone at EPA remain open to receive all points of view and extend every effort to solicit input from those who will be affected by decisions. This openness to the public furthers our mission to protect public health and safeguard the natural environment by increasing our credibility and improving our decision-making. Our willingness to remain open to new ideas from our constituents, and to incorporate them where appropriate, is absolutely essential to the execution of our mission. At the same time, we should not accord privileged status to any special interest, nor accept any recommendation or proposal without careful, critical examination.

Definitions

The term "the public" is used in the Draft Policy in the broadest sense, meaning the general population of the United States. Many segments of the public may have a particular interest or may be affected by Agency programs and decisions. In addition to private individuals, "the public" includes, but is not limited to, representatives of consumer, environmental and other advocacy groups; environmental justice groups; indigenous people; minority and ethnic groups; business and industrial interests, including small businesses; elected and appointed public officials; the media; trade, industrial, agricultural, and labor organizations; public health, scientific, and professional representatives and societies; civic and community associations; faith-based organizations; research, university, education, and governmental organizations and associations, and governments and agencies at all levels. Public agencies that serve as co-regulators may have a dual role; they can be beneficiaries of
public involvement in their decision-making processes as well as stakeholders who provide input into EPA’s decisions.

The term public involvement is used in this document to encompass the full range of actions and processes that EPA uses to engage the public in the Agency’s work, and means that the Agency considers public concerns, values, and preferences when making decisions. Public involvement enables the public to work with the Agency and hold it accountable for its decisions. Though every person living in the United States is an ultimate beneficiary of EPA actions to protect public health and the environment, a relatively small number of individuals directly participate in Agency activities. Individuals and organizations who have a strong interest in the Agency’s work and policies are referred to as stakeholders. Stakeholders also may interact with EPA on behalf of another person or group that seeks to influence the Agency’s future direction. Some stakeholders are, or believe they are, affected parties, that is, individuals or groups who will be impacted by EPA policies or decisions.

What Are the Purposes, Goals and Objectives of This Draft Policy?

The purposes of this Draft Policy are to:

• Reaffirm EPA’s commitment to early and meaningful public involvement;
• Ensure that environmental decisions are made with an understanding of the interests and concerns of affected people and entities;
• Promote the use of a wide variety of techniques to create early and, when appropriate, continuing opportunity for public involvement in Agency decisions; and
• Establish clear and effective procedures for conducting public involvement activities in EPA’s decision-making processes.

Implementing a strong policy and consistent procedures will make it easier for the public to become involved and to affect the Agency’s decisions. This in turn will assist the EPA in carrying out its mission by providing the Agency with a better understanding of the public’s viewpoints, concerns, and preferences. Full implementation of this Draft Policy also should build public trust and make the Agency’s decisions more likely to be accepted and implemented by those who are most concerned with and affected by them.

Finally, implementing this policy will support EPA in meeting statutory requirements regarding public participation, particularly in environmental permitting programs and enforcement activities.

Decision makers are sometimes concerned about delays associated with public involvement. In some circumstances, a compelling need for immediate action may make it appropriate to limit public involvement. However, issues that are not resolved to the satisfaction of the concerned public may ultimately face time-consuming review. Achievement of EPA’s public involvement objectives may reduce delays caused by litigation or other adversarial activities.

EPA has the following goals for public involvement processes:

• To foster a spirit of mutual trust, confidence, and openness between the Agency and the public;
• To fulfill legal requirements imposed by various environmental statutes;
• To ensure that the Agency consults with interested or affected segments of the public and takes public viewpoints into consideration when making decisions;
• To ensure that the Agency provides the public with information at a time and in a form that it needs to participate in a meaningful way;
• To ensure that the public understands official programs and the implications of potential alternative courses of action;
• To learn from the public the information it is uniquely able to provide (community values, concerns, practices, local norms, and relevant history, such as locations of past contaminant sources, or potential impacts on small businesses, etc.);
• To solicit assistance from the public in understanding potential consequences of technical issues, identifying alternatives to be studied, and selecting among the alternatives considered;
• To keep the public informed about significant issues and changes in proposed programs or projects;
• To foster, to the extent possible, equal and open access to the regulatory process for all interested and affected parties;
• To ensure that the government understands public goals and concerns, and is responsive to them;
• To anticipate conflicts and encourage early discussions of differences among affected parties;
• To promote the public’s involvement in implementing environmental protection laws; and
• To ensure that the Agency communicates to the public how its input affected the Agency’s decision.

To achieve the purposes and goals, while also recognizing resource constraints, Agency officials will strive to provide for, encourage, and assist public involvement in the following ways:

• Beginning public involvement early in the decision-making process and continuing it throughout the process as necessary to provide the best information possible;
• Striving to identify, communicate with and listen to all affected sectors of the public. The role of Agency officials is to plan and conduct public involvement activities that provide equal opportunity for all individuals and groups to be heard. Where appropriate, implementation of this Draft Policy will require Agency officials to give extra encouragement and consider providing assistance to some sectors, such as minorities and low-income populations, or small businesses, which may have fewer opportunities or resources to participate;
• Involving members of the public in developing options and alternatives (when possible) and, before making decisions, seeking the public’s opinion on options or alternatives. Agency officials must avoid advocacy and pre-commitment to any particular alternative or option prior to decision-making, unless statutory or regulatory requirements dictate otherwise (e.g. when EPA proposes a Plan for a Superfund site);
• Actively developing options that address the conflicts in underlying issues expressed by disagreeing stakeholders, thereby seeking to facilitate discussion; and
• Making every effort to match the design of public involvement programs with the complexity and potential for controversy surrounding the issue being addressed, the segments of the public affected, the time frame for decision-making, and the overall desired outcome of the public involvement process.

When Does This Draft Policy Apply?

This Draft Policy applies to all EPA programs conducted under the laws and Executive Orders that EPA implements. Appendix 1 contains a list of these laws and orders.

The activities covered by this Draft Policy include:

• EPA rulemaking, when the regulations are classified as significant (under the terms of Executive Order 12866);
• The issuance or significant modification of permits or licenses;
Meaningful Public Involvement?

What Should EPA Do to Ensure Full and Meaningful Public Involvement?

Each Assistant Administrator, Associate Administrator, Office Director, or Regional Administrator should ensure that the Agency fully carries out this Draft Policy and all public involvement provisions of the laws that they are responsible for implementing. They should ensure that, to the greatest extent possible, authorized and delegated program partners provide opportunities for the public to participate in decision-making related to implementing their EPA-related programs. EPA officials are responsible for determining forthcoming decisions or activities to which this Draft Policy and applicable laws and Executive Orders should be applied, and taking the steps needed to ensure that applicable public involvement processes are developed and implemented.

This Draft Policy identifies six key functions that should be considered when planning for public involvement. Agency officials must exercise judgment and take into consideration the particular circumstances of each situation in determining how those functions will be carried out. Agency employees should strive to provide the most meaningful public involvement opportunities appropriate to each situation. The issues, locations, potential environmental and public health consequences of the activities, potential for controversy, specific needs of the public and the Agency, and other circumstances will influence the design of public involvement processes. The Draft Policy recognizes the Agency’s need to set priorities for its use of resources. It also emphasizes involvement by the public in decisions where options are available and alternatives must be weighed, or where EPA is seeking substantial agreement from the public to carry out a program.

The six basic functions for effective public involvement in any decision or activity are:

1. Plan and budget for public involvement activities;
2. Identify the interested and affected public;
3. Consider providing technical or financial assistance to the public to facilitate involvement;
4. Provide information and outreach to the public;
5. Conduct public consultation and involvement activities; and
6. Assist in information and provide feedback to the public.

The goals(s) and recommended actions for each of these functions are described below.

1. Plan and budget for public involvement activities

Goal: To ensure effective public involvement processes through advance planning, early notice to stakeholders, adequate time and resources, and evaluation.

a. Recommended actions: When preparing budgetary documents for programs affecting the public, Agency officials should include resources for conducting and evaluating public involvement activities. These may be included as an element of regulatory development plans, analytic blueprints, program plans, or EPA’s plans for complying with the Government Performance and Results Act. Programs also should plan for complying with the Unfunded Mandates Reform Act, the Regulatory Flexibility Act, as amended by the Small Business Regulatory Enforcement Fairness Act, Executive
Order 13132 (Federism), and Executive Order 13175 (Consultation and Coordination with Indian Tribal Governments).

Such planning documents should set forth, at a minimum:
- Key decisions subject to public involvement;
- Staff contacts and budget resources to be allocated to public involvement;
- Segments of the public targeted for involvement and plans for identifying organizations and individuals, consistent with the Paperwork Reduction Act if the plans involve the collection of information;
- Proposed schedule for public involvement activities consistent with the Federal Advisory Committee Act;
- Mechanisms to apply the six basic functions—Planning and Budgeting, Identification, Providing Assistance, Information and Outreach, Public Consultation and Involvement, and Assimilation and Feedback—outlined above; and
- Measures or methods to evaluate the effectiveness of public involvement.

When identified in an approved grant work plan, grant funds may be used, subject to any statutory or regulatory limitations, to support reasonable costs of public involvement incurred by assisted agencies, including advisory group expenses.

Assistant Administrators, Associate Administrators and Regional Administrators should ensure that program and activity planning documents include public involvement activities and that they are developed in a timely manner for use in the annual budget planning process.

2. Identify the interested and affected public

Goal: To identify groups or members of the public who may have expressed an interest in, or may by the nature of their location, purposes or activities be affected by or have an interest in an upcoming activity or action.

a. Recommended actions: The responsible official should develop a contact list for each program, activity or project, and add to the list those members of the public who request to be added. Each list should be updated frequently, and will be most useful if subdivided by category of interest or geographic area. The nature and intensity of the involvement activities will drive the updating frequency. Pro-active efforts should be made to ensure that all points of view are represented on the lists. The contact lists should be used for announcements of involvement opportunities; notices of meetings, hearings, field trips, and other events; notices of available information, reports and documents; and to identify members of the public who may be considered for advisory group membership and other activities. Where circumstances ("lesser actions" such as minor program guidance or minor amendments to a permit) do not warrant identifying individual interested parties to this extent, Agency officials should, at a minimum, be aware of who the interested parties are and how best to provide them notice.

b. Methods: Construction of this list of contacts may be accomplished by any number of activities, including, but not limited to the following (Note: Where the above activities involve the collection of information from non-agency parties, they may be subject to the Paperwork Reduction Act (PRA). For advice, staff should consult with the Office of General Counsel):

- Requesting the names of interested and affected individuals from others in the Agency; from facilities/companies; state, tribal, regional and local governments; or from key non-governmental for-profit and not-for-profit groups;
- Using questionnaires or surveys to find out levels of awareness;
- Reviewing dockets, depositories, research papers or other publications for previous similar or related activities;
- Including an EPA point of contact on EPA documents (fact sheets, public notices, sign-up sheets at meetings, etc.) so that individuals may ask to be placed on lists;
- Soliciting interest through notices in the Federal Register; trade and trade association publications; local print, radio, cable and television outlets; not-for-profit secular and religious publications; or through the Internet or other electronic means;
- Asking those who attend events what, if any, interests or key individuals are missing; and
- By using other comprehensive or creative means that consider the community structure, languages spoken, local communications preferences and the locations (such as libraries and other centers) where the community regularly congregates.

3. Consider Providing Technical or Financial Assistance to the Public to Facilitate Involvement

Goal: To assist stakeholder groups and members of the public who may not have resources to obtain the technical assistance or funding that would enable them to contribute effectively and in a timely manner.

a. Recommended actions: EPA recognizes that responsible involvement by the various elements of the public in some of the highly technical and complex issues addressed by the Agency requires substantial commitments of time, study, research, analysis, and discussion. Where it is possible to provide technical or financial assistance, doing so can improve the quality of public involvement.

In some circumstances, direct financial assistance may be available. For example, depending on annual budget authorizations, Assistant and Associate Administrators, Regional Administrators and Office Directors may have authority to provide funds to outside organizations and individuals for public involvement activities associated with rules under development that they, as EPA managers, deem appropriate and essential for achieving program goals. However, funds for such purposes are generally very limited. When funding is provided, the primary purpose must be consistent with the Federal Grant and Cooperative Agreement Act and appropriate authority for the funded activities must be provided in one or more of EPA's statutes. In other cases, assistance in forms other than direct financial support can be provided. Examples of such assistance are provided below.

b. Methods: There are numerous ways to provide assistance to members of the public who lack the ability to participate in an effective or timely manner in Agency public consultation or involvement activities. Agency managers should consult with knowledgeable staff to determine the most feasible and legal methods to follow. Methods may include staff resources or funding for:

- Access to Agency experts or contractors to obtain information and analyses as resources allow;
- Access to technical personnel through grants to universities (e.g.: The Superfund Program’s Technical Outreach Services to Communities project has provided independent university-based scientific and engineering expertise to 115 communities dealing with hazardous substance contamination questions);
- Travel and per diem to consult and provide advice directly to Agency officials;
- Compensation for time spent on Federal Advisory Committee meetings;
- Technical Assistance Grants (TAGs) under Section 117 of CERCLA awarded to groups of individuals who may be affected by a release or a threatened release at Superfund sites to obtain assistance in interpreting and
To ensure that the public understands the legal requirements for Agency action and the significance of the related technical data so that the public can provide meaningful comments that assist the Agency in its decision-making.

a. Recommended actions: Agency officials should:

1. Ensure that adequate, timely information concerning a forthcoming action or decision reaches the public;
2. Provide policy, program, and technical information to the affected public and interested parties at the earliest practicable times, to enable those potentially affected or interested persons to make informed and constructive contributions to decision-making;
3. Ensure that information is provided at places easily accessible to interested and affected persons and organizations;
4. Fully implement the goals of the Agency’s Public Access Strategy when released (to provide the public with integrated, online, user-friendly access to environmental data and information) and, to the extent practicable, enable communities, including minority, low-income, and underserved populations, to have access to relevant data and information;
5. To the extent practicable, direct that information and educational programs be developed so that all levels of government and the public have an opportunity to become familiar with the issues and the technical data from which they emerge;
6. Ensure that informational materials clearly identify the role of the public in the specific decisions to be made;
7. Highlight significant issues that will be the subject of decision-making;
8. Make special efforts to summarize complex technical materials for the public;
9. Write documents in plain language that the public will easily understand; and
10. Consider whether EPA should provide documents in languages in addition to English in order to reach the affected public or interested parties.

b. Methods: Information and outreach programs require the use of appropriate communication tools, and should be tailored to accommodate the public’s level of familiarity with the subject. The following, among many other approaches, may be used for this purpose:

1. Publications, fact sheets, technical summaries, bibliographies, resource guides and other printed materials which may be made available through the mail and at information depositories (e.g., EPA regional and field offices, federal repository libraries and local public libraries, and state/tribal/local agencies);
2. Videos and CD ROMs;
3. Questionnaires, surveys, and interviews, subject to approval by the Office of Management and Budget under the Paperwork Reduction Act;
4. Public service announcements and news releases;
5. Educational publications, programs or activities;
6. Electronic communications such as Web pages, chat rooms, on-line dialogues, and list servers;
7. Participation in conferences, workshops, or meetings;
8. Telephone communications such as hotlines, clearinghouses and toll-free comment lines;
9. Video conferences and satellite downlinks; and
10. Participation at public events, such as fairs and festivals.

c. Content: Outreach materials may include:

- Background information (e.g., statutory basis, rationale, specific goal(s) of involvement activities, or the triggering event of the action);
- A timetable of proposed actions;
- Summaries of lengthy documents or technical material if relevant;
- A delineation of issues and the interests that they may affect;
- Alternative courses of action or tentative determinations that the Agency may have made;
- Information on whether an Environmental Impact Statement or Environmental Assessment is, or will be, available;
- Specific encouragement to stimulate active involvement by the public, including describing the nature of its influence, roles, and potential impact on the decisions;
- The name and contact information (address, e-mail address, telephone and telefax numbers) to reach an individual for further information;
- Whenever possible, the social, economic, and environmental consequences of proposed decisions and alternatives; and
- Technical evidence and research methodology explained in non-technical language. (Summaries of technical documents should be footnoted to refer to the original data.)

Fact sheets, news releases, summaries, and similar publications in print and on the Internet may be used to provide notice of availability of materials and to facilitate public understanding of more complex documents, but should not be a substitute for public access to the complete documents. When practicable,
information should be provided in formats and locations that match the public's needs. Some information (e.g., Confidential Business Information) is not available for public review and the Agency cannot release it.

d. Notification. Responsible officials should seek to ensure that parties on the contact list and the media are aware of the outreach materials available and that they have adequate time and opportunity to receive and review the information before any additional public involvement activities are conducted. Notices should include information about the repository (address, hours of operation, etc.) or other information relating to access to all documents referred to in the notice, including the name of a contact person when appropriate.

e. Timing. To enable effective and meaningful public involvement, outreach materials that make the public aware of the planned activity and that outline the issue(s) should be distributed as early as such information is available. The more complex the issue and greater the potential for controversy or misunderstanding, the earlier the materials should be distributed. When the Agency holds a formal public comment process, notification should take place as soon as possible when the Agency takes an action to permit the public to obtain and review the materials, and prepare responses in a timely and meaningful way. Minimum public comment periods are often specified in statutes or rules. Generally, materials for public comment should be provided as soon as they are available and should allow for not less than 30 days for the public review and comment (or longer, as specified in program-specific requirements), or 45 days in the case of public hearings.

When unusually complex issues or lengthy documents are presented for public review this period generally should be no less than 60 days. (For Superfund actions, regardless of complexity, the public is provided 30 days to submit comments on proposed remedies. Upon a timely request, the public comment period can be extended by a minimum of 30 additional days.)

1. Fees for Copying: Whenever possible, the Agency should provide copies of relevant documents, free of charge. Free copies may be reserved for private citizens, public interest organizations, or small businesses with limited funds. Any charges must be consistent with requirements under the Freedom of Information Act as set forth in 40 CFR Part 2.

g. Depositions or docketing: The Agency should provide one or more central collections of documents, reports, studies, plans, etc., relating to controversial issues or significant decisions in a location or locations convenient to the public. Suitable locations will depend on the nature of the action; for national rules a single central docket is generally appropriate whereas local repositories may be preferable when decisions relate to individual facilities or sites. RCRA authorizes EPA to require a facility to set up and maintain a repository. In all other instances, for actions at local facilities or sites, Agency officials should work with community representatives and the facility to determine the most accessible repository site(s) within the community. Consideration should be given to accessibility, travel time, parking, transit, and availability during off-work hours. Copying facilities, at reasonable charges, should be available at depositories. Agency officials are encouraged to determine the accessibility to the interested public and feasibility of electronic depositories that take advantage of the Internet to reach directly into homes, libraries and other facilities throughout a community and across the nation. If the public has reasonably convenient, well advertised electronic repositories, this can achieve significantly enhanced accessibility at a very modest cost.

5. Conduct public consultation and involvement activities.

Goals: To understand the interests and needs of the affected public. To provide for the exchange of information and views and open exploration of issues, alternatives and consequences between interested and affected members of the public and officials responsible for the forthcoming action or decision.

a. Recommended actions: Agency officials should:

• Ensure that public consultation and involvement are preceded by timely outreach activities, including timely distribution of information;

• Notify the public of potential consultation and involvement activities early enough to ensure that the public has adequate time to obtain and evaluate information; conduct any additional data gathering; consult experts and formulate their opinions, options, and suggestions prior to Agency action;

• Conduct public consultation and involvement activities at times and places which, to the maximum extent feasible, facilitate attendance or involvement by the affected public. Whenever possible, public meetings concerning local facilities or sites should be held during non-work hours, such as evenings or weekends, and at locations accessible to public transportation:

• Identify and select the public consultation or involvement process appropriate to the decision being made, and the time frame and resources available. When possible, consult or involve the affected public in identifying and selecting appropriate public involvement processes. This ensures that the approaches selected consider and, if appropriate, accommodate the potentially affected parties' needs, preferences, schedules and resources, as well as the Agency's needs;

• Provide guidance, resources, training, and professional assistance to Agency staff, interested delegated program partners, and the public to assist them in conducting or participating in public consultation and involvement activities in an effective and credible manner. Consider comments on how best this can be accomplished, particularly with respect to including those from minority, low-income, and other underserved communities;

• Consider the appropriate use of third parties in the development and implementation of programs, projects and activities; and

• Be knowledgeable of and comply with provisions of open meetings laws and regulations, such as the Federal Advisory Committee Act, whenever they apply to the public involvement process being conducted.

b. Methods: Consultation and involvement processes may take a variety of forms, depending upon the issues to be addressed, the timing of the decision-making action, and the needs and resources of the public whose involvement is sought. Public hearings and public meetings are two familiar forms of consultation and often are legally required, but their use should not serve as the only forum for citizen input. When required, public hearings and meetings should be held at the end of a process that has previously given the public more informal and interactive opportunities for becoming informed and involved. Alternative Dispute Resolution (ADR) is another tool that the Agency uses to consider and seek to resolve differences among various stakeholders. ADR is a consensual resolution of disputes and issues in controversy. ADR allows EPA to obtain the services of neutral parties on an expedited basis to manage a public dialogue in which neighbors, business interests, environmental groups, and
other interested parties have an opportunity to raise concerns to the parties involved in the enforcement action or other controversy. EPA and other public agencies employ a wide variety of consultation techniques that can be divided into three categories based upon the outcomes of the process:

(1) Information Exchange;
(2) Recommendations; and
(3) Agreements.

Information exchange involves EPA staff and management sharing data, options, issues, and ideas with the public in a way that encourages dialogue. Information exchange activities include workshops, forums, joint fact finding, interactive public meetings, focus groups, surveys (subject to provisions of the Paperwork Reduction Act), roundtables, and informal consultation such as meetings with interest groups, attendance at conferences, and other opportunities for informal dialogue. These activities are not meant to reach agreement or consensus on future action. Their purpose is to compile a mutually developed knowledge base of everyone’s interests, ideas, and needs. Though not a fully interactive method, the notice and comment process also serves as a limited form of information exchange. Recommendations activities involve a number of stakeholder representatives collaborating with each other and with Agency staff to develop recommendations. The Agency may accord significant deference to the recommendations, but is generally not bound to implement the recommendations, nor are the parties bound to accept them. (See Appendix 2 for FACA requirements.) Examples of recommendations activities include FACA committees established by EPA, external technical committees (such as those conducted with the American Society for Testing and Materials), peer review panels, and various technical advisory groups, citizens advisory groups, or panels.

Agreement activities involve EPA management and representatives of stakeholders who reach an agreement by consensus. Agreement activities include negotiated rulemaking committees and other mediated agreements. If the agreement activity used does not produce a legally binding agreement, the desired outcome of such an activity is a commitment on the part of the participants to full implementation.

The list above is not exhaustive but it indicates the need for program officials to be flexible and choose the right techniques for the right occasion. These activities are not mutually exclusive; they form a progression. They can and should be used as part of a thorough, well-planned system of consultation and public involvement. Successful agreement or recommendation processes occur only with significant information exchange and outreach. However, progressing to a recommendation process or agreement process is not necessary, practical or affordable in all decision-making processes.

c. Content—Agency officials should clearly identify issues to be discussed, negotiated or decided prior to and throughout the engagement process so that the public understands which decisions are subject to its input. The type of process to be conducted, the schedule, and the assumptions and expectations for the outcomes of the process should also be clearly stated so that the public and its representatives understand whether they are being invited to an information exchange or a negotiation and can set their expectations accordingly. If possible, the public should be involved in determining the design of the processes. The Agency will comply with all applicable open meeting requirements, such as FACA and all information gathering requirements, such as the Paperwork Reduction Act, in the design of its public outreach processes.

d. Notification—The Agency should ensure that all parties on the contact list and the media are notified of opportunities to participate and provided with appropriate information. Agency officials should not assume that the general public reads printed legal notices or Federal Register notices which are often required by statute or regulation. Although these methods serve as legal notice to the public, they can be augmented by broader notice to the media or interested persons on the contact list, and other tailored notifications. Notification should give the time, date and location of the consultation process, a general description of the topics or agenda, a contact person and contact information, and a general description of the nature of the process to be conducted, as well as the role of the public. Agency officials should consider the use of multilingual notices of upcoming activities and/or translator services, when appropriate.

e. Timing—Agency officials should provide early advance notice of public involvement processes so that the public can obtain background information, obtain and evaluate additional data, formulate their needs and interests, and obtain expert assistance, if necessary. Generally, notice should be given not less than 15 days in advance of an impending meeting or consultation process. If the issues are unusually complex or involve review of lengthy documents this period generally should be no less than 60 days. Program specific notice requirements should be consulted; for example, for Superfund actions, regardless of complexity, the public is provided 30 days to submit comments on proposed remedies. Upon a timely request, the public comment period can be extended by a minimum of 30 additional days.

f. Summaries: Detailed summaries of advisory committee meetings under FACA are required by law. [Appendix 2 contains requirements for formation and use of EPA advisory committees.] In addition, some statutes also require minutes of public meetings. Even when not required, when possible and appropriate, Agency officials should make summaries of public hearings and public meetings available to participants and other interested parties. When possible and appropriate, Agency officials should be open to participants’ comments that might correct or add to the summary. In rulemaking proceedings under the Administrative Procedure Act, a memorandum summarizing any significant new factual data or information likely to affect the final decision received during an informal meeting or other conversations should be placed in the public docket for the rule. In other situations, it may be helpful to document discussions that contribute information useful to decision-making and make that information available to participants and interested parties.

6. Assimilate information and provide feedback to the public.

Goal: To consistently earn and retain the public’s trust and credibility for EPA consultation processes, by examining and assimilating public viewpoints and preferences into final decisions, where appropriate and possible, and communicating to the public the decisions made and how their input affected those decisions.

Assimilating public viewpoints and preferences into decisions and final actions involves examining and analyzing public input, considering if and how to incorporate that input into final program decisions, and making or modifying decisions according to carefully considered public views. The Agency should demonstrate, in its decisions and actions, that it has understood and fully considered public concerns. Finally, the Agency should communicate the decision and discuss
the influence of the public’s input in the final decision.

a. Recommended actions:
   (1) Assimilate the information:
      Agency officials should briefly and clearly document consideration of the public’s views in Responsiveness Summaries, regulatory preambles, ELIs or other appropriate forms. This should be done at key decision points. Each Responsiveness Summary (or similar document) should:
      - Include a statement of the action that was taken;
      - Explain briefly the type of public involvement activity that was conducted;
      - Identify or summarize those who participated and their affiliation;
      - Describe the matters on which the public was consulted;
      - Summarize the public’s views, important comments, criticisms and suggestions;
      - Disclose the Agency’s logic in developing decisions;
      - Indicate the effect the public’s comments had on that action; and
      - Discuss the Agency’s specific responses to significant issues, in terms of modifying the proposed action, or explaining why the Agency rejected proposals made by the public.
   (2) Provide feedback to the public: For all major actions and whenever practical for lesser actions, the Agency should provide feedback to participants and interested parties concerning the outcome of the public’s involvement. The Agency should publish, post on a web site or in public places, distribute, mail, or e-mail a Responsiveness Summary or similar document for those who participated in or observed the public involvement processes, those who provided public comments and to those on the contact list. In addition, where circumstances and resources permit, or where the number of participants was small, feedback may be in the form of personal letters. Feedback provided in meetings or through other means should be documented.

Who is responsible for ensuring that this Draft Policy is applied appropriately?

Public involvement is an integral part of any program. It should routinely be included in decision-making and not be treated as an independent or secondary function. Managers should ensure that personnel are properly trained, supported and counseled, and that adequate funding needs are incorporated in their specific budgets. Under the overall direction of the Administrator, the Assistant, Associate, and Regional Administrators are responsible and accountable for the adequacy of public involvement programs. They are ultimately responsible for making certain that, for the activities under their jurisdiction, all Agency staff implement the purpose of this Draft Policy. They are responsible for ensuring that the level of effort in public involvement is commensurate with the potential impact of the upcoming action or decision. The Regional, Assistant, or Associate Administrators will make certain that concerns about the adequacy of public involvement are heard and, where necessary, acted upon as resources allow. Citizens who have questions or objections about the substance of this Draft Policy or the appropriateness of applying it in a particular case should raise that issue with the Agency officials involved.

Although this Draft Policy is not binding on states, tribes and local governments, EPA encourages these entities to adopt similar policies where they administer federal programs authorized, approved or delegated by EPA. The Agency intends to include public involvement among the issues discussed during the annual reviews of state, tribal or local program(s), and during any other program audit or review.

1. The Administrator maintains overall direction and responsibility for the Agency’s public involvement activities. Specifically, the Administrator will:
   a. Establish policy direction and guidance for all EPA public involvement programs;
   b. Provide incentives to Agency personnel to ensure commitment to and competence in implementing this Draft policy; and
   c. Evaluate the adequacy of public involvement activities conducted under this Draft Policy, the appropriateness and results of public involvement expenditures, and the effectiveness of this Draft Policy.

2. Assistant Administrators and Associate Administrators have the following responsibilities:
   a. Identify and address those activities and major decisions where application of this Draft Policy is appropriate;
   b. Ensure that plans developed for these programs or activities include and provide adequate time and resources for effective public involvement;
   c. Consider providing guidance and assistance to support regional office public involvement activities at the request of Regional Administrators;
   d. Implement the public information and public involvement portions of approved plans;
   e. Evaluate the effectiveness and appropriateness of public involvement expenditures and activities under their jurisdiction, revising and improving them as necessary;
   f. Encourage coordination of public involvement activities;
   g. Ensure that, as regulations for the programs cited in Appendix 1 of the Draft Policy are amended, they incorporate the Draft Policy’s provisions;
   h. Consider funding authorized pilot and/or innovative demonstration projects;
   i. Consider measures to ensure Draft Policy implementation in appropriate managers’ performance standards;
   j. Provide financial assistance, as appropriate and available, for authorized public involvement activities at the national level;
   k. Coordinate public involvement funding to outside groups to ensure the most economical expenditures;
   l. Provide guidance and technical assistance and training as appropriate to support authorized and delegated program activities of state, tribal, regional and local entities;
   m. Develop guidance and training needed to ensure that program personnel are equipped to implement the Draft Policy;
   n. Provide incentives to Agency staff to ensure commitment to and competence in implementing this Draft Policy;
   o. Seek public involvement in decisions to modify or develop major national policies, at their discretion; and
   p. Ensure that applicable legal requirements associated with public involvement are adhered to, such as the Federal Advisory Committee Act and the Paperwork Reduction Act.

3. Regional Administrators have the following responsibilities:
   a. Identify and address those EPA activities, policies, and programs where this Draft Policy should be applied;
   b. Ensure that plans developed by the programs for activities, programs and policies subject to this Draft Policy provide for adequate public involvement;
   c. Implement the public information and public involvement portions of approved Agency plans;
   d. Provide information and technical assistance to staff and participants in delegated programs on the conduct of public involvement activities;
   e. Discuss with state, tribal, regional and local entities the effectiveness and appropriateness of their public involvement activities during periodic meetings;
   f. Encourage coordination of public involvement activities;


This Draft Policy also applies to EPA activities under the following Executive Orders:

- E.O. 12580—Superfund Implementation
- E.O. 12856—Federal Compliance with Right-to-Know Laws and Pollution Prevention Requirements
- E.O. 12866—Regulatory Planning and Review
- E.O. 13132 Federalism (which replaced E.O. 12875—Enhancing the Intergovernmental Partnerships)
- E.O. 12898—Federal Actions to Address Environmental Justice in Minority Populations and Low IncomePopulations
- E.O. 13045—Protection of Children from Environmental Health Risks and Safety Risks
- E.O. 13007—Indian Sacred Sites
- E.O. 13175—Consultation and Coordination with Indian Tribal Governments
- E.O. 11988—Floodplain Management
- E.O. 13166—Improving Access to Services for Persons with Limited English Proficiency

In addition, this Draft Policy is effective for EPA activities conducted under the following statutes for which other agencies have primary responsibility:


Implementing public involvement activities may also involve complying with the following Acts, Executive Orders, Executive Memoranda, and Regulation:

- Negotiated Rulemaking Act 5 U.S.C. 561–570a
- E.O. 12862—Setting Customer Service Standards
- E.O. 12999—Educational Technology Ensuring Opportunity for all Children in the Next Century
- E.O. 11593—Protection of and Enhancement of the Cultural Environment
- E.O. 11990—Protection of Wetlands
- Presidential Memorandum on Plain Language in Government Writing (June 1, 1998)
- Presidential Memorandum on Electronic Government (December 17, 1999)
- Presidential Memorandum on Government-to-Government Relations with Native American Tribal Governments (April 29, 1994)
- Minority Business Enterprise and Women’s Business Enterprise Program, contained in portions of 40 CFR Parts 30, 31, 35 and 40

Appendix 2: Advisory Committees

To gain advice from a representative group of stakeholders or experts, one of the methods that the Agency may choose is forming an advisory committee. These committees are usually subject to the
chartering, balanced membership, and open meeting requirements of the Federal Advisory Committee Act (FACA). The Office of General Counsel or the Regional Counsel should be consulted to determine whether FACA applies to a particular group.

In general, the Agency forms a group of non-federal people to provide EPA with collective advice, the requirements of the Federal Advisory Committee Act (FACA) may apply. Such groups shall not meet until the requirements of FACA are met. Staff may contact the Office of Cooperative Environmental Management for advice on complying with these requirements, and to learn about the exceptions to FACA.

The primary function of an advisory group is to assist elected or appointed officials by making recommendations to them on issues that the decision-making body considers relevant. These issues may include policy development, project alternatives, financial assistance applications, work plans, major contracts, interagency agreements, and budget submissions, among others. Advisory groups can provide a forum for addressing issues, promote constructive dialogue among the various interests represented on the group, and enhance community understanding of the Agency’s action.


These requirements are:
- The development of a Charter that has been approved by the General Services Administration and Office of Management and Budget. It must contain the committee’s objectives and the scope of its activities, the period of time necessary for the committee to carry out its objectives, the agency responsible for providing the necessary support for the committee, and a description of the duties for which the committee is responsible. The Charter must be renewed every two years. 5 U.S.C. App. 2, sec. 9.
- The Establishment Federal Register Notice. At least 15 days before the charter is filed for a new committee, EPA is required to publish an establishment notice in the Federal Register. Such notice describes the nature and purpose of the committee, the agency’s plan to attain fairly balanced membership, and a statement that the committee is necessary and in the public interest. 5 U.S.C. App. 2, sec. 9.
- Balanced Membership. Advisory committees must be “fairly balanced” in points of view represented. 5 U.S.C. App. 2, sec. 5.
- The Meeting Federal Register Notice. Each advisory committee meeting must be noticed in the Federal Register at least 15 days prior to the meeting. 5 U.S.C. App. 2, sec. 10.
- To close a meeting to the public, you must obtain the approval of both the Administrator and the General Counsel. 5 U.S.C. App. 2, sec. 10.

Detailed minutes must be kept of all advisory committee meetings. 5 U.S.C. App. 2, sec. 10.

- Open Meetings. Interested persons may file written statements with any advisory committee, attend any advisory committee meeting (unless properly closed), and appear before any advisory committee. 5 U.S.C. App. 2, sec. 10.
- DFO Attendance. Each meeting must be attended by a Designated Federal Official (DFO), a full-time federal employee who is authorized to adjourn the meeting and approve the agenda. 5 U.S.C. App. 2, sec. 10.
- Documents Available to the Public. All advisory committee documents (including drafts) shall be available to the public upon request. 5 U.S.C. App. 2, sec. 10.
- B. State and Local Advisory Committees: In instances where regulations, program guidance, or the public involvement plans of state, substate, or local agencies, call for advisory groups, they should follow applicable state and local laws.

Note: Find information about EPA's FACA committees at http://www.epa.gov/ocem/websites.htm#faca

[FR Doc. 00–33157 Filed 12–27–00; 8:45 am]
BILLING CODE 6560–50–P

ENVIRONMENTAL PROTECTION AGENCY

[OPP–00693; FRL–6762–2]

Pesticides; Final Guidance for Pesticide Registrants on Applicability of the Treated Articles Exemption to Antimicrobial Pesticides

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice of availability.

SUMMARY: The Agency is issuing PR Notice 2000–10 which extends the effective date of when it will begin to rely upon PR Notice 2000–1 (issued March 6, 2000). PR Notice 2000–1 provides guidance on the applicability of the “treated articles exemption” in 40 CFR 152.25(a) to antimicrobial pesticide products.

FOR FURTHER INFORMATION CONTACT: Jeff Kempter (75110C), Environmental Protection Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460; telephone number: (703) 305–5448; fax number: (703) 308–6467; e-mail address: kempter.carlton@epa.gov.

SUPPLEMENTARY INFORMATION:

I. General Information

A. Does this Action Apply to Me?

This action is directed to the public in general. This action may be of particular interest to those persons who produce pesticides or who produce articles treated with pesticides. Since other entities may also be interested, the Agency has not attempted to describe all the specific entities that may be affected by this action. If you have any questions regarding the information in this notice, consult the person listed under FOR FURTHER INFORMATION CONTACT.

B. How Can I Get Additional Information, Including Copies of this Document and Other Related Documents?

1. Electronically. You may obtain electronic copies of this document and the PR Notice from the Office of Pesticide Programs' Home Page at http://www.epa.gov/pesticides/. You can also go directly to the listings from the EPA Internet Home Page at http://www.epa.gov/. To access this document, on the Home Page select “Laws and Regulations,” “Regulations and Proposed Rules,” and then look up the entry for this document under the “Federal Register—Environmental Documents.” You can also go directly to the Federal Register listings at http://www.epa.gov/fedregstr/.

2. In person. The Agency has established an official record for this action under docket control number OPP–00693. The official record consists of the documents specifically referenced in this action, any public comments received during an applicable comment period, and other information related to this action, including any information claimed as confidential business information (CBI). This official record includes the documents that are physically located in the docket, as well as the documents that are referenced in those documents. The public version of the official record does not include any information claimed as CBI. The public version of the official record, which includes printed, paper versions of any electronic comments submitted during an applicable comment period, is available for inspection in the Public Information and Records Integrity Branch (PIRIB), Rm. 119, Crystal Mall #2, 1921 Jefferson Davis Highway, Arlington, VA, from 8:30 a.m. to 4 p.m., Monday through Friday, excluding legal holidays. The PIRIB telephone number is (703) 305–5805.

II. Background

A. What Guidance Does this PR Notice Provide?

On March 6, 2000, the Agency issued PR Notice 2000–1 concerning the applicability of the “treated articles exemption” in 40 CFR 152.25(a) to antimicrobial pesticide products. The intent of that notice was to clarify current Agency policy with respect to the scope of the treated articles exemption. Specifically, the notice addressed the types of claims which are or are not permitted on treated articles,
and explained the requirement that the pesticide in a treated article be "registered for such use."

Section VI of PR Notice 2000–1, titled “Effective Date and Procedures,” encouraged producers, distributors, and other persons selling or distributing pesticide-treated articles and substances to bring their products into compliance with 40 CFR 152.25(a). That section also indicated that the Agency would begin to rely on the guidance provided in that notice on February 11, 2001, and that products in commerce after that date which make statements or claims that do not reflect the clarifications offered in that notice, would risk being considered out of compliance with 40 CFR 152.25(a).

The Agency has since learned that certain segments of the industry which produce treated articles will not be able to meet the February 11, 2001 date, both in production of treated articles and in their sale and distribution in commerce. Further, the Agency is concerned that some distributors of treated articles may not be aware that their products are subject to PR Notice 2000–1 due to the fact that the notice was sent primarily to registrants and not generally to the distributors of treated articles. Finally, the Agency is concerned that the current date of February 11, 2001, and the inclusion of all treated articles in commerce could have an unintended adverse economic impact on affected companies.

For these reasons, the Agency is extending the effective date of when it will begin to rely upon PR Notice 2000–1 from February 11, 2001 to April 30, 2001. In addition, the Agency is changing the guidance in that notice such that treated articles produced on or before April 30, 2001, may continue to be sold or distributed by anyone through commerce without being subject to the clarifying guidance in PR Notice 2000–1. Thus, only treated articles produced after April 30, 2001, which make statements or claims that do not reflect the clarifications offered in that notice, would risk being out of compliance with 40 CFR 152.25(a). Producers of treated articles produced on or before April 30, 2001, would need to be able to provide adequate documentation of the production date of such articles found in commerce. All other elements of PR Notice 2000–1, as well as the current enforcement approach, will remain as stated or referenced in that notice.

B. PR Notices are Guidance Documents

The PR Notice discussed in this notice is intended to provide guidance to EPA personnel, the public, pesticide registrants, and producers of pesticide-treated articles. This notice is not binding on EPA, pesticide registrants, or treated article producers, and EPA may depart from the guidance where circumstances warrant and without prior notice. Likewise, pesticide registrants and treated article producers may assert that the guidance is not appropriate generally or not applicable to a specific pesticide, treated article, or situation.

List of Subjects

Environmental protection, Administrative practice and procedure, Agricultural commodities, Pesticides, Antimicrobials, and pests.


Marcia E. Mulkey,
Director, Office of Pesticide Programs.

Federal Register Volume 65, Number 250 / Thursday, December 28, 2000 / Notices
Section 3(c)(2)(B)(iv) of FIFRA provides that any hearing may be held and a determination issued within 75 days after receipt of a hearing request. This 75-day period may not be extended unless all parties in the proceeding stipulate to such an extension. If a hearing is requested and the Agency will issue a final order at the conclusion of the hearing governing the suspension of your product(s).

A request for a hearing pursuant to this Notice must 1) include specific objections to the basis of any of the issues which may be heard at the hearing, 2) identify the registrations for which a hearing is requested, and 3) set forth all necessary supporting facts pertaining to any of the objections which you have identified in your request for a hearing. If a hearing is requested by any person other than the registrant, that person must also state specifically why he asserts that he would be adversely affected by the suspension action described in this Notice. Three copies of the request must be submitted to:

Hearing Clerk
U.S. Environmental Protection Agency
1200 Pennsylvania Avenue, NW
Washington, DC 20460

and an additional copy should be sent to the signatory listed below. The request must be received by the Hearing Clerk by the 30th day from your receipt of this Notice in order to be legally effective. The 30-day time limit is established by FIFRA and cannot be extended for any reason. Failure to meet the 30-day time limit will result in automatic suspension of your registration(s) if operated in violation of FIFRA.

The suspension of the registration of each product listed in Attachment I will become final unless at least one of the following actions is completed:

1. You may avoid suspension under this Notice if you or another person adversely affected by this Notice properly request a hearing within 30 days of your receipt of this Notice. If you request a hearing, it will be conducted in accordance with the requirements of section 6(d) of FIFRA and the Agency’s Procedures for Procedural Regulations in 40 CFR Part 164.

Section 3(c)(2)(B), however, provides that the only allowable issues which may be addressed at the hearing are whether you have failed to comply with the terms of the 3(c)(2)(B) Data Call-In Notice. The specific basis for issuance of this Notice is stated in the Explanatory Appendix (Attachment III) to this Notice. The affected product(s) and the requirement(s) which you failed to satisfy are listed and described in the following three attachments:

Attachment I Suspension Report—Product List
Attachment II Suspension Report—Requirement List
Attachment III Suspension Report—Explanatory Appendix

The suspension of the registration of each product listed in Attachment I will become final unless at least one of the following actions is completed:

1. You may avoid suspension under this Notice if you or another person adversely affected by this Notice properly request a hearing within 30 days of your receipt of this Notice. If you request a hearing, it will be conducted in accordance with the requirements of section 6(d) of FIFRA and the Agency’s Procedures for Procedural Regulations in 40 CFR Part 164.

The Agency’s Rules of Practice at 40 CFR 164.7 forbid anyone who may take part in the proceeding from discussing the merits of the proceeding in any manner which would have been unlawful prior to the suspension.

The suspension of the registration(s) of your product(s) described in this Notice is ineffective if you or another person, by showing cause, can demonstrate that:

1. The suspension of your product(s) is inconsistent with the public interest.
2. The suspension of your product(s) is not in accordance with law.
3. The suspension of your product(s) is not in accordance with the terms of the 3(c)(2)(B) Data Call-In Notice.

The suspension of the registration(s) of your product(s) is effective until such time as the suspension is rescinded.

The suspension of the registration(s) of your product(s) is based on your failure to comply with the registration requirements that are the bases of this Notice.

Persons other than the registrant subject to this Notice, including all supplemental registrants of product(s) listed in Attachment I, may not legally distribute, sell, use, offer for sale, hold for sale, ship, deliver or receive and (having so received) deliver or offer to deliver, to any person, the product(s) listed in Attachment I.

Nothing in this Notice authorizes any person to distribute, sell, use, offer for sale, hold for sale, ship, deliver for shipment, or receive and (having so received) deliver or offer to deliver, to any person, the product(s) listed in Attachment I.

The suspension of the registration(s) of your product(s) is effective as of the date of this Notice.

The suspension of the registration(s) of your product(s) is suspended when the Agency determines you have complied fully with the requirements which were the bases of this Notice. Such compliance may only be achieved by submission of the data/information described in the attachments to the signatory listed below.

Your product will remain suspended, however, until the Agency determines you are in compliance with the requirements which are the bases of this Notice and so informs you in writing.

After the suspension becomes final and effective, the registrant subject to this Notice, including all supplemental registrants of product(s) listed in Attachment I, may not legally distribute, sell, use, offer for sale, hold for sale, ship, deliver for shipment, or receive and (having so received) deliver or offer to deliver, to any person, the product(s) listed in Attachment I.

Nothing in this Notice authorizes any person to distribute, sell, use, offer for sale, hold for sale, ship, deliver for shipment, or receive and (having so received) deliver or offer to deliver, to any person, the product(s) listed in Attachment I.

The suspension of the registration(s) of your product(s) is suspended as of the date of this Notice.

The suspension of the registration(s) of your product(s) is suspended when the Agency determines you have complied fully with the requirements which were the bases of this Notice. Such compliance may only be achieved by submission of the data/information described in the attachments to the signatory listed below.

Your product will remain suspended, however, until the Agency determines you are in compliance with the requirements which are the bases of this Notice and so informs you in writing.

After the suspension becomes final and effective, the registrant subject to this Notice, including all supplemental registrants of product(s) listed in Attachment I, may not legally distribute, sell, use, offer for sale, hold for sale, ship, deliver for shipment, or receive and (having so received) deliver or offer to deliver, to any person, the product(s) listed in Attachment I.

Nothing in this Notice authorizes any person to distribute, sell, use, offer for sale, hold for sale, ship, deliver for shipment, or receive and (having so received) deliver or offer to deliver, to any person, the product(s) listed in Attachment I.

The suspension of the registration(s) of your product(s) is suspended as of the date of this Notice.

The suspension of the registration(s) of your product(s) is suspended when the Agency determines you have complied fully with the requirements which were the bases of this Notice. Such compliance may only be achieved by submission of the data/information described in the attachments to the signatory listed below.

Your product will remain suspended, however, until the Agency determines you are in compliance with the requirements which are the bases of this Notice and so informs you in writing.

After the suspension becomes final and effective, the registrant subject to this Notice, including all supplemental registrants of product(s) listed in Attachment I, may not legally distribute, sell, use, offer for sale, hold for sale, ship, deliver for shipment, or receive and (having so received) deliver or offer to deliver, to any person, the product(s) listed in Attachment I.

Nothing in this Notice authorizes any person to distribute, sell, use, offer for sale, hold for sale, ship, deliver for shipment, or receive and (having so received) deliver or offer to deliver, to any person, the product(s) listed in Attachment I.
all supplementary registered distributors of your basic registered product that this suspension action also applies to their supplementary registered products and that you may be held liable for violations committed by your distributors.

If you have any questions about the requirements and procedures set forth in this suspension notice or in the subject section

3(c)(2)(B) Data Call-In Notice, please contact Frances Liem at (202) 564–2365.

Sincerely yours,
Rick Colbert, Director
Agriculture and Ecosystems Division
Office of Compliance

Attachments: Attachment I—Product List
Attachment II—Requirement List

### Attachment III—Explanatory Appendix

#### III. Registrants Receiving and Affected by Notices of Intent to Suspend: Date of Issuance, Active Ingredient, and Products Affected

The following is a list of products for which a letter of notification has been sent:

<table>
<thead>
<tr>
<th>Registrant affected</th>
<th>EPA registration no.</th>
<th>Active ingredient</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kanoria</td>
<td>66951–1</td>
<td>Lindane</td>
</tr>
<tr>
<td>Kanoria</td>
<td>66951–2</td>
<td>Lindane</td>
</tr>
</tbody>
</table>

### IV. Basis for Issuance of Notice of Intent: Requirement List

The following companies failed to submit the following requirement data or information.

<table>
<thead>
<tr>
<th>Active ingredient</th>
<th>Registrant affected</th>
<th>Guideline no.</th>
<th>Requirement name</th>
<th>Due date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lindane</td>
<td>Kanoria</td>
<td>870–6300</td>
<td>Developmental Neurotoxicity Study</td>
<td>February, 1999</td>
</tr>
<tr>
<td></td>
<td></td>
<td>870–4200</td>
<td>Oncogenicity Study-Mouse</td>
<td>December, 2000</td>
</tr>
</tbody>
</table>

* The arbitrator's award and decision regarding KCIL's default did not specify any apportionment of over-due costs among subject study requirements.

### V. Attachment III Suspension Report—Explanatory Appendix

A discussion of the basis for the Notices of Intent to Suspend follows:

#### Lindane

On September 30, 1985, EPA issued a Registration Standard for Lindane (gamma isomer of hexachlorocyclohexane, CAS Registry No. 58–89–9). The Registration Standard imposed certain data requirements to maintain the registration of pesticide products containing Lindane. Subsequent data requirements pertaining to Lindane were required in Data Call-In ("DCI") Notices on September 30, 1991, March 3, 1995, October, 1995 and March 31, 1997. Kanoria Chemicals & Industries Limited ("KCIL") registered two technical Lindane products on May 1, 1995, for use in the United States. KCIL became a member of the Centre International D'Etudes du Lindane ("CIEL"), which was conducting studies intended to satisfy EPA's data requirements. On June 9, 1997, KCIL notified EPA it was terminating its membership in CIEL, that it had made a written offer to compensate CIEL and/or to share in the cost of developing data required by the March 31, 1997, DCI, and that it agreed to be bound by an arbitration decision under FIFRA section 3(c)(2)(B)(iii) if the parties failed to reach agreement on terms of the cost sharing.

Following earlier employment of the American Arbitration Association to assist the parties' efforts to reach a cost-sharing agreement, on December 10, 1998, CIEL and KCIL notified the arbitrator that they had reached an agreement to share the costs of producing data in support of registration of pesticides containing lindane required under the September 30, 1985, Registration Standard and the four Data Call-In Notices issued by the Agency on September 30, 1991, March 3, 1995, October, 1995 and March 31, 1997. The arbitrator overseeing the negotiations leading to this agreement entered the cost-sharing agreement as an arbitral Award on January 11, 1999.

In January 2000, KCIL was presented with invoices for DCI cost-sharing expenses by CIEL, and KCIL refused to pay its share of certain costs related to the DCIs. Pursuant to the dispute resolution procedures of the January 11, 1999, Award, CIEL referred this non-payment to the arbitrator and KCIL cross-claimed. After reviewing the claims of both parties, the arbitrator issued an Order dated May 12, 2000, finding CIEL entitled to reimbursement of the disputed monies and interest from KCIL, and declaring KCIL in default of the cost-sharing agreement. The arbitrator reaffirmed KCIL's default in a July 20, 2000, ruling.

On May 19, 2000, CIEL requested EPA to issue a Notice of Intent to Suspend KCIL's lindane product registrations pursuant to FIFRA section 3(c)(2)(B)(iv), and to prohibit sale of existing stocks. EPA has reviewed materials provided by both CIEL and KCIL and has determined that KCIL has failed to "comply with the terms of an agreement or arbitration decision concerning a joint data development arrangement" under FIFRA section 3(C)(2)(B). Accordingly, at this time, EPA is issuing this Notice of Intent to Suspend KCIL's registrations for pesticides containing lindane due to non-compliance with the March 31, 1997, DCI.

### VI. Conclusions

EPA has issued a Notice if Intent to Suspend on the dates indicated. Any further information regarding these notices may be obtained from the contact person above.

#### List of Subjects

Environmental protection.

Richard Colbert,
Director, Agriculture and Ecosystems Division, Office of Compliance.

[FR Doc. 00–33173 Filed 12–27–00; 8:45 am] BILLING CODE 6560–50–S

ENGLISH PROTECTION AGENCY

[PF–990; FRL–6761–6]

Notice of Filing a Pesticide Petition to Establish a Tolerance for a Certain Pesticide Chemical in or on Food

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice.

SUMMARY: This notice announces the initial filing of a pesticide petition proposing the establishment of regulations for residues of a certain pesticide chemical in or on various food commodities.

DATES: Comments, identified by docket control number PF–990, must be received on or before January 29, 2001.

ADDRESSES: Comments may be submitted by mail, electronically, or in person. Please follow the detailed instructions for each method as provided in Unit I.C. of the SUPPLEMENTARY INFORMATION. To ensure proper receipt by EPA, it is imperative that you identify docket control number PF–990 in the subject line on the first page of your response.

FOR FURTHER INFORMATION CONTACT: By mail: Shaja R. Brothers, Registration Programs, Environmental Protection Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460; telephone number: (703) 308–3194; e-mail address: brothers.shaja@epa.gov.

SUPPLEMENTARY INFORMATION:

I. General Information

A. Does this Action Apply to Me?

You may be affected by this action if you are an agricultural producer, food manufacturer or pesticide manufacturer. Potentially affected categories and entities may include, but are not limited to:

<table>
<thead>
<tr>
<th>Categories</th>
<th>NAICS codes</th>
<th>Examples of potentially affected entities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Industry</td>
<td></td>
<td></td>
</tr>
<tr>
<td>111</td>
<td>Crop production</td>
<td></td>
</tr>
<tr>
<td>112</td>
<td>Animal production</td>
<td></td>
</tr>
<tr>
<td>311</td>
<td>Food manufacturing</td>
<td></td>
</tr>
</tbody>
</table>

This listing is not intended to be exhaustive, but rather provides a guide for readers regarding entities likely to be affected by this action. Other types of entities not listed in the table could also be affected. The North American Industrial Classification System (NAICS) codes have been provided to assist you and others in determining whether or not this action might apply to certain entities. If you have questions regarding the applicability of this action to a particular entity, consult the person listed under FOR FURTHER INFORMATION CONTACT.

B. How Can I Get Additional Information, Including Copies of this Document and Other Related Documents?

1. Electronically. You may obtain electronic copies of this document, and certain other related documents that might be available electronically, from the EPA Internet Home Page at http://www.epa.gov/. To access this document, on the Home Page select “Laws and Regulations,” “Regulations and Proposed Rules,” and then look up the entry for this document under the “Federal Register—Environmental Documents.” You can also go directly to the Federal Register listings at http://www.epa.gov/fedreg/. You may submit comments electronically by e-mail to: opp-docket@epa.gov, or you can submit a computer disk as described above. Do not submit any information electronically that you consider to be CBI. Avoid the use of special characters and any form of encryption. Electronic submissions will be accepted in Wordperfect 6.1/8.0 or ASCII file format. All comments in electronic form must be identified by docket control number PF–990. Electronic comments may also be filed online at many Federal Depository Libraries.

D. How Should I Handle CBI That I Want to Submit to the Agency?

Do not submit any information electronically that you consider to be CBI. You may claim information that you submit to EPA in response to this document as CBI by marking any part or all of that information as CBI. Information so marked will not be disclosed except in accordance with procedures set forth in 40 CFR part 2. In addition to one complete version of the comment that includes any information claimed as CBI, a copy of the comment that does not contain the information claimed as CBI must be submitted for inclusion in the public version of the official record. Information marked confidential will be included in the public version of the comment received during an applicable comment period, and other information related to this action, including any information claimed as confidential business information (CBI). This official record includes the documents that are physically located in the docket, as well as the documents that are referenced in those documents. The public version of the official record does not include any information claimed as CBI. The public version of the official record, which includes printed, paper versions of any electronic comments submitted during an applicable comment period, is available for inspection in the Public Information and Records Integrity Branch (PIRIB), Rm. 119, Crystal Mall #2, 1921 Jefferson Davis Highway, Arlington, VA, from 8:30 a.m. to 4 p.m., Monday through Friday, excluding legal holidays. The PIRIB telephone number is (703) 305–5805.

C. How and to Whom Do I Submit Comments?

You may submit comments through the mail, in person, or electronically. To ensure proper receipt by EPA, it is imperative that you identify docket control number PF–990 in the subject line on the first page of your response.

1. By mail. Submit your comments to: Public Information and Records Integrity Branch (PIRIB), Information Resources and Services Division (7502C), Office of Pesticide Programs (OPP), Environmental Protection Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460.

2. In person or by courier. Deliver your comments to: Public Information and Records Integrity Branch (PIRIB), Information Resources and Services Division (7502C), Office of Pesticide Programs (OPP), Environmental Protection Agency, Rm. 119, Crystal Mall #2, 1921 Jefferson Davis Highway, Arlington, VA. The PIRIB is open from 8:30 a.m. to 4 p.m., Monday through Friday, excluding legal holidays. The PIRIB telephone number is (703) 305–5805.

3. Electronically. You may submit your comments electronically by e-mail to: opp-docket@epa.gov, or you can submit a computer disk as described above. Do not submit any information electronically that you consider to be CBI. Avoid the use of special characters and any form of encryption. Electronic submissions will be accepted in Wordperfect 6.1/8.0 or ASCII file format. All comments in electronic form must be identified by docket control number PF–990. Electronic comments may also be filed online at many Federal Depository Libraries.
of the official record without prior notice. If you have any questions about CBI or the procedures for claiming CBI, please consult the person identified under FOR FURTHER INFORMATION CONTACT.

E. What Should I Consider as I Prepare My Comments for EPA?

You may find the following suggestions helpful for preparing your comments:

1. Explain your views as clearly as possible.
2. Describe any assumptions that you used.
3. Provide copies of any technical information and/or data you used that support your views.
4. If you estimate potential burden or costs, explain how you arrived at the estimate that you provide.
5. Provide specific examples to illustrate your concerns.
6. Make sure to submit your comments by the deadline in this notice.
7. To ensure proper receipt by EPA, be sure to identify the docket control number assigned to this action in the subject line on the first page of your response. You may also provide the name, date, and Federal Register citation.

II. What Action is the Agency Taking?

EPA has received a pesticide petition as follows proposing the establishment and/or amendment of regulations for residues of a certain pesticide chemical in or on various food commodities under section 408 of the Federal Food, Drug, and Cosmetic Act (FFDCA), 21 U.S.C. 346a. EPA has determined that this petition contains data or information regarding the elements set forth in section 408(d); however, EPA has not fully evaluated the sufficiency of the submitted data at this time or whether the data support granting of the petition. Additional data may be needed before EPA rules on the petition.

List of Subjects

Environmental protection, Agricultural commodities, Food additives, Food additives, Pesticides and pests, Reporting and recordkeeping requirements.


James Jones,
Director, Registration Division, Office of Pesticide Programs.

Summary of Petition

The petitioner summary of the pesticide petition is printed below as required by section 408(d)(3) of the FFDCA. The summary of the petition was prepared by the petitioner and represents the view of the petitioners. EPA is publishing the petition summary verbatim without editing it in any way. The petition summary announces the availability of a description of the analytical methods available to EPA for the detection and measurement of the pesticide chemical residues or an explanation of why no such method is needed.

Research Project Number 4 and Gowana Company

0E6198 and 0E6215

EPA has received pesticide petitions (0E6198 and 0E6215) from the Interregional Research Project Number 4 (IR-4), Technology Centre of New Jersey, 681 U.S. Highway #1 South, North Brunswick, New Jersey 08902-3390 proposing, pursuant to section 408(d) of the FFDCA, 21 U.S.C. 346a(d), to amend 40 CFR part 180 by establishing tolerances for residues of the miticide, heptythiazox, trans-5-(4-chlorophenyl)-N-cyclohexyl-4-methyl-2-oxothiazolidine-3-carboxamide and its metabolites containing the (4-chlorophenyl)-methyl-2-oxo-3-thiazolidine moiety (expressed as parts per million (ppm) of the parent compound in or on the following raw agricultural commodities (RAC) at the tolerance levels listed:

- PP 0E6198 proposes the establishment of a tolerance for mint at 0.0 ppm.
- PP 0E6215 proposes the establishment of a tolerance for the caneberry subgroup at 1.0 ppm.

EPA has determined that the petitions contain data or information regarding the elements set forth in section 408(d)(2) of the FFDCA; however, EPA has not fully evaluated the sufficiency of the submitted data at this time or whether the data support granting of the petitions. Additional data may be needed before EPA rules on these petitions. This notice includes a summary of the petitions prepared by Gowana Company, POB 5569, Yuma AZ 85366-5569.

A. Residue Chemistry

1. Plant metabolism. The metabolism of heptythiazox as well as the nature of the residues in plants is adequately understood for purposes of these tolerances. Metabolism studies were conducted in four crops, viz.: pears, grapes, citrus, and apples. The major residue component is unmetabolized parent. The metabolites are hydroxyhexthiazox and ketocyclohexyl analogs of heptythiazox, and the amide formed by loss of the cyclohexyl ring.

Parent heptythiazox and its metabolites are converted to a common moiety for residue analysis.

2. Analytical method. A practical analytical method, high pressure liquid chromatography with a ultraviolet ray (UV) detector which detects and measures residues of heptythiazox and its metabolites as a common moiety, is available for enforcement purposes with a limit of detection that allows monitoring of food with residues at or above the levels set in these tolerances.

B. Toxicological Profile

1. Acute toxicity. A battery of acute toxicity studies places technical grade heptythiazox in toxicity category IV for acute oral lethal dose LD₅₀ (LD₅₀ >5,000 milligrams/kilogram (mg/kg)), category III for dermal LD₅₀ (LD₅₀ >5,000 mg/kg), category III for inhalation lethal concentration (LC₅₀ >2.0 mg/L), category III for primary eye irritation (showed mild irritation (reddened conjunctival), and category IV for dermal irritation (non irritant). Heptythiazox is a non-sensitizer. Acute toxicological studies place technical grade heptythiazox in toxicology category III.

2. Genotoxicity. The following genotoxicity studies were all negative: Ames gene mutation, Chinese hamster ovary (CHO) gene mutation, chromosome aberration, mouse micronucleus, and rat hepatocyte unscheduled DNA synthesis.

3. Reproductive and developmental toxicity. In a developmental toxicity study in rats, the maternal no observed adverse effect level (NOAEL) was 240 mg/kg/day and the maternal lowest observed adverse effect level (LOAEL) was 720 mg/kg/day based on increased ovarian weights and decreased bone ossification.

In a developmental toxicity study in rabbits, the maternal NOAEL was 1,080 mg/kg/day highest dose tested (HDT); the maternal LOAEL was not determined. In a 2-generation reproduction study in rats, the parental...
NOAEL was 35 mg/kg/day and the parental LOAEL was 200 mg/kg/day based on decreased body weight (bw) gain, decreased food consumption and efficiency, and increased liver, kidney and ovarian weights. The reproductive NOAEL was 35 mg/kg/day and the reproductive LOAEL was 200 mg/kg/day based on decreased pup bw during lactation, delayed hair growth and eye opening.

4. Subchronic toxicity. In a 1–month feeding study in dogs, the NOAEL was 1.75 mg/kg/day and the LOAEL was 12.5 mg/kg/day, based on increased liver, and adrenal weights.

5. Chronic toxicity. In a 1-year feeding study in dogs, the NOAEL was 2.5 mg/kg/day and the LOAEL was 12.5 mg/kg/day, based on increased alkaline phosphatase, increased adrenal, and liver weights, liver, and adrenal lesions. In a carcinogenicity study in mice, the NOAEL was 36 mg/kg/day and the LOAEL was 215 mg/kg/day. Effects were decreased bw in males and increased hepatocellular adenomas and combined adenoma/carcinomas.

In a chronic feeding/carcinogenicity study in rats, the NOAEL (systemic) was 26 mg/kg/day and the LOAEL (systemic) was 180 mg/kg/day based on decreased bw gain, and increased liver weights in both sexes.

The chronic reference dose (RFD) for hexythiazox is based on the 1-year dog feeding study with a NOAEL of 2.5 mg/kg/day and an uncertainty factor of 100. The Agency has classified hexythiazox as a category C (possible human) carcinogen based on an increased incidence of hepatocellular carcinomas (p = 0.028) and combined adenomas/carcinomas (p = 0.024) in female mice at the HDT (1500 ppm) when compared to the controls as well as a significantly increased (p<0.001) incidence of pre-neoplastic hepatic nodules in both males and females at the HDT. The decision supporting a category C classification was based primarily on the fact that only one species was affected and mutagenicity studies were negative. In classifying hexythiazox as a category C carcinogen, the Agency concluded that a quantitative estimate of the carcinogenic potential for humans should be calculated because of the increased incidence of liver tumors in the female mouse. A Q^2 of 0.022 (mg/kg/day)^2 in human equivalents was published in the Federal Register, October 16, 1998, 63FR 55540 (FRL-6035-2).

6. Animal metabolism. The metabolism of hexythiazox has been studied in rats, hens, and rats. Metabolic pathways in the animal are similar to those in plants.

7. Metabolite toxicology. There are no metabolites of toxicological concern based on a differential metabolism between plants and animals.

8. Endocrine disruption. No specific tests have been conducted with hexythiazox to determine whether the chemical may have an effect in humans that is similar to an effect produced by a naturally occurring estrogen or other endocrine effects. However, there were no significant findings in other relevant toxicity tests, i.e., developmental and multi-generation reproduction studies, which would suggest that hexythiazox produces effects characteristic of the disruption of the estrogenic hormone.

C. Aggregate Exposure

1. Dietary exposure—i. Food. Tolerances have been established (40 CFR 180.479) for residues of hexythiazox trans-5-[4-(chlorophenyl)-N-cyclohexyl-4-methyl-2-oxothiazolidine-3-carboxamide] and its metabolites containing the (4-chlorophenyl)-4-methyl-2-oxo-3-thiazolidine moiety in or on apples at 0.02 ppm, pears at 0.3 ppm, and hops (imported) at 2 ppm. Additional tolerances are pending for a variety of plant and animal RACs and process fractions including apple pomace at 0.7 ppm, apples at 0.4 ppm, almond hulls at 10 ppm, cattle fat at 0.05, cattle meat at 0.05 ppm, cattle MBTP at 0.01 ppm, cotton gin by-products at 3 ppm (California), cottonseed at 0.2 ppm (California), milk at 0.05 ppm, prunes at 5 ppm, raisins at 10 ppm, stone fruit at 1 ppm, strawberries at 3 ppm, and tree nuts (crop group 14) at 0.2 ppm. Additional tolerances are being requested in this petition by IR-4 for mint at 2.0 ppm, and caneberrys at 1.0 ppm.

Chronic exposure. A chronic dietary exposure analysis for existing and pending proposed uses was conducted for the general U.S. population and 26 population subgroups. Mint and caneberry did not contribute to dietary exposure. In this analysis it was assumed that 100% of crops were treated for both crops. Chronic exposures of 0.000172 mg/kg/day and 0.000203 mg/kg/day were calculated for mint and caneberry respectively for the average U.S. population. Non-nursing infants, the most heavily exposed subgroup, had a calculated exposure of 0.000972 mg/kg/day and 0.001080 mg/kg/day respectively for mint and caneberry. Actual exposures would be much lower, however, because far less than 100% of crops would be treated. The Agency has not conducted a detailed analysis of potential exposure to hexythiazox via drinking water or outdoor ornamental plants from existing or pending proposed uses.

However, it is believed that chronic exposure from these sources is very small.

Acute exposure. No developmental, reproductive or mutagenic effects have been observed with hexythiazox. Therefore, an analysis of acute exposure has not been conducted.

ii. Drinking water. The environmental fate of hexythiazox has been evaluated, and Gowan Company believes that the compound is not expected to contaminate groundwater or surface water to any measurable extent.

2. Non-dietary exposure. Hexythiazox is also registered for use on outdoor ornamental plants by commercial applicators only. It is believed that non-occupational exposure from this use is very low. Hexythiazox is not registered for greenhouse, lawn, garden, or residential use.

D. Cumulative Effects

Gowan Company does not have, at this time, available data to determine whether hexythiazox has a common mechanism of toxicity with other substances or how to include this pesticide in a cumulative risk assessment. Unlike other pesticides for which EPA has followed a cumulative risk approach based on a common mechanism of toxicity, hexythiazox does not appear to produce a toxic metabolite produced by other substances. For purposes of these petitions only, the potential risks of hexythiazox in its aggregate exposure will be considered.

E. Safety Determination

1. U.S. population—i. Chronic risk. Chronic risk was calculated using anticipated residue concentrations from all current and proposed uses of hexythiazox and assuming that 100% of each crop is treated. Dietary exposure of the general U.S. population was equivalent to 0.7% of the RFD. Exposure of the most heavily exposed subgroup, non-nursing infants, was equivalent to 3.9% of the RFD.

ii. Carcinogenic risk. Carcinogenic risk was evaluated using anticipated residue concentrations and taking into account the percent of crop known or expected to be treated. Lifetime carcinogenic risk for the U.S. population was calculated, to be 4.5 X 10^-7.

iii. Acute risk. An estimate of acute risk with this compound has not been conducted since no acute reproductive
or developmental effects have been observed.

2. Infants and children. In assessing the potential for additional sensitivity of infants and children to residues of hexythiazox, EPA considered data from developmental toxicity studies in the rat and rabbit, and a 2-generation study in the rat. The developmental toxicity studies are designed to evaluate adverse effects on the developing organism resulting from pesticide exposure during prenatal development to 1 or both parents. Reproduction studies provide information relating to effects from exposure to the pesticide on the reproductive capability of mating animals and data on systemic toxicity.

No developmental or reproductive effects have been observed in any study with hexythiazox. The lowest acute NOAEL was 2,400 ppm in the diet (200 mg/kg/day), HDT, in the 2-generation rat reproduction study. In the rat developmental study, the maternal and fetotoxic NOAEL was 240 mg/kg/day and the developmental NOAEL was 2,160 mg/kg/day, HDT. In the rabbit developmental study, the maternal and developmental NOAEL was 1,080 mg/kg/day, HDT.

Taking into account current toxicological data requirements, the data base for hexythiazox relative to prenatal and postnatal effects is complete. In the rat developmental study, the NOAELs for maternal toxicity and fetotoxicity were the same, which suggests that there is no special prenatal sensitivity in the absence of maternal toxicity. Furthermore, the lowest developmental or reproductive NOAEL is 2 orders of magnitude higher than the chronic NOAEL on which the RfD is based. It is concluded that there is a reasonable certainty of no harm to infants and children from aggregate exposure to hexythiazox residues.

F. International Tolerances

Codex MRLs for 12 commodities, not including mint, have been established. A MRL for blackberries at 0.2 ppm has been established in the Netherlands. There are no Canadian or Mexican MRLs for hexythiazox.

ENVIRONMENTAL PROTECTION AGENCY
[OPP–50875; FRL–6757–3]

Experimental Use Permit; Receipt of Application of a Transgenic Plant-Pesticide

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice.

SUMMARY: This notice announces receipt of an application to amend/extend 524–EUP–93 from Monsanto Company, requesting an experimental use permit (EUP) for the plant-pesticide Bacillus thuringiensis Cry3Bb protein and the genetic material necessary for its production (Vector ZMIR13L) in corn plants. The Agency has determined that the application may be of regional and national significance. Therefore, in accordance with 40 CFR 172.11(a), the Agency is soliciting comments on this application.

DATES: Comments, identified by docket control number OPP–50875, must be received on or before January 29, 2001.

ADDRESSES: Comments and data may be submitted by mail, electronically, or in person. Please follow the detailed instructions for each method as provided in Unit I. of the SUPPLEMENTARY INFORMATION. To ensure proper receipt by EPA, it is imperative that you identify docket control number OPP–50875 in the subject line on the first page of your response.

SUPPLEMENTARY INFORMATION:

I. General Information

A. Does this Action Apply to Me?

This action is directed to the public in general. This action may, however, be of interest to those persons who are interested in agricultural biotechnology or may be required to conduct testing of chemical substances under the Federal Food, Drug and Cosmetic Act (FFDCA), or the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Since other entities may also be interested, the Agency has not attempted to describe all the specific entities that may be affected by this action. If you have any questions regarding the applicability of this action to a particular entity, consult the person listed under FOR FURTHER INFORMATION CONTACT.

B. How Can I Get Additional Information, Including Copies of this Document and Other Related Documents?

1. Electronically. You may obtain electronic copies of this document, and certain other related documents that might be available electronically, from the EPA Internet Home Page at http://www.epa.gov/. To access this document, on the Home Page select “Laws and Regulations,” “Regulations and Proposed Rules,” and then look up the entry for this document under the “Federal Register—Environmental Documents.” You can also go directly to the Federal Register listings at http://www.epa.gov/fedrgstr/.

2. In person. The Agency has established an official record for this action under docket control number OPP–50875. The official record consists of the documents specifically referenced in this action, and other information related to this action, including any information claimed as Confidential Business Information (CBI). This official record includes the documents that are physically located in the docket, as well as the documents that are referenced in those documents. The public version of the official record does not include any information claimed as CBI. The public version of the official record, which includes printed, paper versions of any electronic comments submitted during an applicable comment period is available for inspection in the Public Information and Records Integrity Branch (PIRIB), Rm. 119, Crystal Mall #2, 1921 Jefferson Davis Hwy., Arlington, VA, from 8:30 a.m. to 4 p.m., Monday through Friday, excluding legal holidays. The PIRIB telephone number is (703) 305–5805.

C. How and to Whom Do I Submit Comments?

You may submit comments through the mail, in person, or electronically. To ensure proper receipt by EPA, it is imperative that you identify docket control number OPP–50875 in the subject line on the first page of your response.

1. By mail. Submit your comments to: Public Information and Records Integrity Branch (PIRIB), Information Resources and Services Division (7502C), Office of Pesticide Programs (OPP), Environmental Protection Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460.

2. In person. Submit your comments to: Public Information and Records Integrity Branch (PIRIB),
Information Resources and Services Division (7502C), Office of Pesticide Programs (OPP), Environmental Protection Agency, Rm. 119, Crystal Mall #2, 1921 Jefferson Davis Hwy., Arlington, VA. The PIRIB is open from 8:30 a.m. to 4 p.m., Monday through Friday, excluding legal holidays. The PIRIB telephone number is (703) 305–5805.

3. Electronically. You may submit your comments electronically by e-mail to: opp-docket@epa.gov, or you can submit a computer disk as described above. Do not submit any information electronically that you consider to be CBI. Avoid the use of special characters and any form of encryption. Electronic submissions will be accepted in WordPerfect 6.1/8.0 or ASCII file format. All comments in electronic form must be identified by docket control number OPP–50875. Electronic comments may also be filed online at many Federal Depository Libraries.

D. How Should I Handle CBI That I Want to Submit to the Agency?

Do not submit any information electronically that you consider to be CBI. You may claim information that you submit to EPA in response to this document as CBI by marking any part or all of that information as CBI. Information so marked will not be disclosed except in accordance with procedures set forth in 40 CFR part 2. In addition to one complete version of the comment that includes any information claimed as CBI, a copy of the comment that does not contain the information claimed as CBI must be submitted for inclusion in the public version of the official record.

Information not marked confidential will be included in the public version of the official record without prior notice. If you have any questions about CBI or the procedures for claiming CBI, please consult the person listed under FOR FURTHER INFORMATION CONTACT.

E. What Should I Consider as I Prepare My Comments for EPA?

You may find the following suggestions helpful for preparing your comments:

1. Explain your views as clearly as possible.
2. Describe any assumptions that you used.
3. Provide copies of any technical information and/or data you used that support your views.
4. If you estimate potential burden or costs, explain how you arrived at the estimate that you provide.
5. Provide specific examples to illustrate your concerns.

6. Offer alternative ways to improve the notice.

7. Make sure to submit your comments by the deadline in this document.

8. To ensure proper receipt by EPA, be sure to identify the docket control number assigned to this action in the subject line on the first page of your response. You may also provide the name, date, and Federal Register citation.

II. Background

Monsanto Company has applied for an amendment of Experimental Use Permit No. 524–EUP–93 to continue testing and evaluation from 2/1/2001 until 2/28/2002 of genetically modified corn that has been developed to resist damage from corn rootworm (Diabrotica spp.) larval feeding. The experimental program will include: (1) breeding and observation trials; (2) inbred seed increase trials; (3) agronomic performance trials; (4) efficacy trials; (5) product characterization, performance and labeling trials; (6) insect resistance management trials; (7) non-target organism trials; and (8) seed treatment trials. Monsanto proposes to plant 4,000 acres in Alabama, Arkansas, California, Colorado, Delaware, Florida, Georgia, Hawaii, Iowa, Idaho, Illinois, Indiana, Kansas, Kentucky, Louisiana, Maryland, Michigan, Minnesota, Missouri, Mississippi, Montana, North Carolina, North Dakota, Nebraska, New Mexico, New York, Ohio, Oklahoma, Pennsylvania, Puerto Rico, South Dakota, Tennessee, Texas, Utah, Virginia, and Wisconsin. All plantings of corn containing the Bacillus thuringiensis Cry3Bb protein under these experimental programs will be contained. No portion of the crops will be used as food or feed.

III. What Action is the Agency Taking?

Following the review of the Monsanto Company application and any comments and data received in response to this notice, EPA will decide whether to issue or deny the EUP request for this EUP program, and if issued, the conditions under which it is to be conducted. Any issuance of an EUP will be announced in the Federal Register.

IV. What is the Agency’s Authority for Taking this Action?

40 CFR Part 172.

List of Subjects

Environmental protection, Experimental use permits.


Janet L. Anderson, Director, Biotechnology and Pollution Prevention Division, Office of Pesticide Programs.

[FR Doc. 00–33167 Filed 12–27–00; 8:45 am]

BILLING CODE 6560–50–S

FEDERAL COMMUNICATIONS COMMISSION

Notice of Public Information Collection(s) Being Submitted to OMB for Review and Approval


SUMMARY: The Federal Communications Commission, as part of its continuing effort to reduce paperwork burden invites the general public and other Federal agencies to take this opportunity to comment on the following information collection, as required by the Paperwork Reduction Act of 1995, Public Law 104–13. An agency may not conduct or sponsor a collection of information unless it displays a currently valid control number. No person shall be subject to any penalty for failing to comply with a collection of information subject to the Paperwork Reduction Act (PRA) that does not display a valid control number. Comments are requested concerning (a) whether the proposed collection of information is necessary for the proper performance of the functions of the Commission, including whether the information shall have practical utility; (b) the accuracy of the Commission’s burden estimate; (c) ways to enhance the quality, utility, and clarity of the information collected; and (d) ways to minimize the burden of the collection of information on the respondents, including the use of automated collection techniques or other forms of information technology.

DATES: Written comments should be submitted on or before January 29, 2001. If you anticipate that you will be submitting comments, but find it difficult to do so within the period of time allowed by this notice, you should advise the contact listed below as soon as possible.

ADDRESSES: Direct all comments to Les Smith, Federal Communications Commission, Room 1–A804, 445 12th Street, SW., Washington, DC 20554 or via the Internet to lessmith@fcc.gov.

FOR FURTHER INFORMATION CONTACT: For additional information or copies of the information collections contact Les Smith at (202) 418–0217 or via the Internet at lessmith@fcc.gov.

SUPPLEMENTARY INFORMATION:
OMB Control Number: 3060–0929.
Title: Application for Multipoint Distribution Service or Instructional Television Fixed Service Modification to Main Station, Booster Station, Response Station Hub, or 125 KHz (I Channels) Point to Multipoint Transmissions.

Form Number: FCC 331.
Type of Review: Extension of a currently approved collection.
Number of Respondents: 4,000.
Estimate Time Per Response: 2 hours.
Frequency of Response: On occasion and “open window” reporting requirements.

Total Annual Burden: 8,000 hours.
Total Annual Costs: $19,465.

Needs and Uses:
On September 17, 1998, the FCC adopted a Report and Order (R&O) in MM Docket No. 97–217. The rule changes in this R&O enhance the flexibility of MDS and ITFS operations through facilitated use of response stations, use of cellular configurations, use of signal booster stations with program origination capability, and use of variable bandwidth (subchanneling or superchanneling). Thus, MDS and ITFS frequencies in the 2 GHz band may be used by licensees, or leased to operators, for broadband data, video, or voice transmissions to and/or from subscribers’ premises, promoting the competitive position of the relevant industry, augmenting the educational uses of these frequencies by ITFS entities, and increasing services to consumers. The FCC has adopted an initial one-week filing window, in which it will accept FCC Form 331 applications from MDS and ITFS licensees. Following this initial filing window, the FCC will accept FCC Form 331 applications via a rolling, one-day filing window. FCC Form 331 may be used by licensees of MDS, MMDS, ITFS, or Commercial ITFS to apply for modification to main station, response station hub, high-power signal booster station, notification of low-power signal booster station, or 125 KHz (I channel(s)) point to multipoint transmitters.

OMB Control Number: 3060–XXXX.
Title: Section 79.2, Accessibility of Programming Providing Emergency Information.
Form Number: N/A.
Type of Review: New collection.
Number of Respondents: 200.
Estimate Time Per Response: 1 to 2 hours.

Frequency of Response: On occasion reporting requirements.

Total Annual Burden: 275 hours.
Total Annual Costs: $5,400.

Needs and Uses: On July 21, 2000, the FCC adopted a Report and Order (R&O), MM Docket No. 99–339, that adopted video description rules to make television more accessible to persons with visual disabilities. Among other things, the R&O requires any broadcast station or multiple video programming distributor (MVPD) that provides local emergency information as part of a regularly scheduled newscast, or as part of a newscast that interrupts regularly scheduled programming, to make the critical details of the information accessible to persons with visual disabilities in the affected local area. Any broadcast station or MVPD that provides emergency information through a crawl or scroll must also accompany that information with an aural tone to alert persons with disabilities that the station or MVPD is providing this information. In addition, 47 CFR Section 79(c) contains a complaint procedure—a complaint alleging a violation of this section may be transmitted to the FCC. The FCC then will notify the video programming distributor of the complaint, giving the distributor 30 days to reply to the complaint.

Federal Communications Commission.
Magalie Roman Salas,
Secretary.

FEDERAL COMMUNICATIONS COMMISSION
Notice of Public Information Collection(s) Being Submitted to OMB for Review and Approval

December 12, 2000.

SUMMARY: The Federal Communications Commission, as part of its continuing effort to reduce paperwork burden invites the general public and other Federal agencies to take this opportunity to comment on the following information collection, as required by the Paperwork Reduction Act of 1995, Public Law 104–13. An agency may not conduct or sponsor a collection of information unless it displays a currently valid control number. No person shall be subject to any penalty for failing to comply with a collection of information subject to the Paperwork Reduction Act (PRA) that does not display a valid control number. Comments are requested concerning (a) whether the proposed collection of information is necessary for the proper performance of the functions of the Commission, including whether the information shall have practical utility; (b) the accuracy of the Commission’s burden estimate; (c) ways to enhance the quality, utility, and clarity of the information collected; and (d) ways to minimize the burden of the collection of information on the respondents, including the use of automated collection techniques or other forms of information technology.

DATES: Written comments should be submitted on or before January 29, 2001. If you anticipate that you will be submitting comments, but find it difficult to do so within the period of time allowed by this notice, you should advise the contact listed below as soon as possible.

ADDRESSES: Direct all comments to Les Smith, Federal Communications Commission, Room 1–A804, 445 12th Street, SW., Washington, DC 20554 or via the Internet to lesmith@fcc.gov.

FOR FURTHER INFORMATION CONTACT: For additional information or copies of the information collections contact Les Smith at (202) 418–0217 or via the Internet at lesmith@fcc.gov.

SUPPLEMENTARY INFORMATION:

OMB Control Number: 3060–0963.
Title: Sections 101.527, Construction Requirements for 24 GHz Operations, and 101.529, Renewal Expectancy Criteria for 24 GHz Licensees.
Form Number: N/A.
Type of Review: New collection.
Respondents: Business and other for-profit entities.
Number of Respondents: 952.
Estimate Time Per Response: 30 mins. to 20 hrs.
Frequency of Response: Once every 10 years reporting requirement.

Total Annual Burden: 14,399 hours.
Total Annual Costs: $952,000.

Needs and Uses: The information required by 47 CFR Sections 101.527 and 101.529 is used to determine whether a renewal applicant of a 24 GHz Service system has complied with the requirement to provide substantial service by the end of the ten-year initial license term. The FCC uses this information to determine whether an applicant’s license will be renewed at the end of the license period.

Federal Communications Commission.
Magalie Roman Salas,
Secretary.

BILLING CODE 6712–01–U
Notice of Intent To Implement a Pilot Inspection Procedure of Insured Structures Under the National Flood Insurance Program

AGENCY: Federal Emergency Management Agency (FEMA).

ACTION: Notice of intent.

SUMMARY: We, FEMA, give notice that we will implement the pilot inspection procedure for Monroe County, Florida, and the Village of Islamorada, located in Monroe County, under the National Flood Insurance Program (NFIP). We established the pilot inspection procedure and the criteria for implementing the procedure by a rule published on June 27, 2000 in the Federal Register.

DATES: The starting date for the inspection procedure is January 1, 2001 for Monroe County and the Village of Islamorada. The termination date for Monroe County is December 31, 2007. The termination date for the Village of Islamorada is January 1, 2004.


SUPPLEMENTARY INFORMATION: We established the pilot inspection procedure and the criteria to implement it under 44 CFR 59.30 in a final rule published in the Federal Register on June 27, 2000, 65 FR 39726. We established the procedure: (1) To help the communities of Monroe County and the Village of Islamorada verify that structures comply with the community’s floodplain management ordinance; and (2) to ensure that property owners pay flood insurance premiums to the NFIP commensurate with their flood risk. The inspection procedure requires owners of insured buildings to obtain an inspection from community officials and to submit a Community Inspection Report as a condition of renewing the Standard Flood Insurance Policy on the building.

The community inspection procedure applies only to insured post-FIRM (Flood Insurance Rate Map) buildings located in the Special Flood Hazard Areas of the communities participating in the inspection procedure.

The final rule requires the Associate Director for Mitigation and the Federal Insurance Administrator to establish the starting and termination dates for the pilot inspection procedure based on the recommendation of the Regional Director. The Regional Director has consulted with each community. The final rule further requires that before the inspection procedure starts the Associate Director and the Federal Insurance Administrator must publish a notice in the Federal Register that the communities will undertake the inspection procedure, stating the purpose and effective time that the pilot inspection procedure will cover. Each community must also publish a similar notice in a prominent local newspaper and publish other notices as appropriate.

The starting date for the inspection procedure for Monroe County and the Village of Islamorada is January 1, 2001. For Monroe County, the termination date is December 31, 2007 and for the Village of Islamorada, the termination date is January 1, 2004.

After the starting date, the insurers will send endorsements to the Standard Flood Insurance Policy to policyholders notifying all policyholders in the two communities that we may require them to obtain a community inspection as a condition of renewing the Standard Flood Insurance Policy. All new and renewed policies effective February 15, 2001 and thereafter must contain the endorsement, which we established in the final rule.

For insured buildings that the community identifies as possible violations of the community’s floodplain management ordinance, the insurer will send a subsequent notice to the policyholder six months before the flood insurance policy renewal date. We anticipate that the insurers will start sending the six-month notice August 15, 2001 and thereafter must contain the endorsement, which we established in the final rule.

For insured buildings that the community identifies as possible violations of the community’s floodplain management ordinance, the insurer will send a subsequent notice to the policyholder six months before the flood insurance policy renewal date. We anticipate that the insurers will start sending the six-month notice August 15, 2001 and thereafter must contain the endorsement, which we established in the final rule.

For insured post-FIRM buildings that the community inspects and determines to violate the community’s floodplain management regulations, the community must demonstrate that it is undertaking measures to remedy the violation to the maximum extent possible.

A major goal of the NFIP is to reduce flood losses by implementing floodplain management regulations that protect new and substantially improved construction in flood prone areas from flood damages. Community adoption and enforcement of a floodplain management ordinance is critical in protecting a building from future flood damages, in reducing taxpayer funded disaster assistance, and in keeping flood insurance rates affordable.


James L. Witt,
Director.

[FR Doc. 00–33175 Filed 12–27–00; 8:45 am]

FEDERAL MARITIME COMMISSION

Notice of Agreement(s) Filed

The Commission hereby gives notice of the filing of the following agreement(s) under the Shipping Act of 1984. Interested parties can review or obtain copies of agreements at the Washington, DC offices of the Commission, 800 North Capitol Street, NW., Room 940. Interested parties may submit comments on an agreement to the Secretary, Federal Maritime Commission, Washington, DC 20573, by January 8, 2001.

Agreement No.: 011528–017.
Title: Japan–United States Eastbound Freight Conference Agreement.
Synopsis: The amendment restates the extension of the suspension of the agreement through July 31, 2001.

Agreement No.: 011649–003.
Title: Joint Operating Agreement Between Interoceran Lines, Inc. and Trinity Shipping Lines, S.A.
Parties: Interoceran Lines, Inc. Trinity Shipping Line, S.A.
Synopsis: The modification restates the agreement to specify that the vessels will be committed to the service; exclude revenue sharing and otherwise narrow the terms of the agreement to
those required of a vessel sharing arrangement; extend the term of the agreement through January 31, 2003, with automatic yearly renewal; and specify ports served in the trade between South Florida and Pananma, Ecuador, Peru, and Colombia.

**Agreement No.:** 011739.  
**Title:** YML/HJS U.S. East and Gulf Coast Slot Charter Agreement.  
**Parties:** Yangming Marine Transport Corp., Hanjin Shipping Co., Ltd.  
**Synopsis:** The slot charter agreement permits Yangming to charter space to Hanjin in the trade between the U.S. East and Gulf Coast and Europe.

**Agreement No.:** 011740.  
**Title:** Maersk Sealand/Nordana/CGM Antilles/Gyuane/Marfret, Mediterranean/Caribbean Sea Vessel Sharing Agreement.  
**Parties:** A.P. Moller-Maersk Sealand, CGM Antilles Gyuane, Compagnie Maritime Marfret, S.A., Nordana Line AS.  
**Synopsis:** The proposed agreement authorizes a vessel sharing arrangement among the parties for the purpose of operating of a new direct weekly service between Puerto Rico and the Virgin Islands and the Mediterranean and other Caribbean points.

**Agreement No.:** 011741.  
**Title:** U.S. Pacific Coast-Oceania Agreement.  
**Parties:** P&O Nedlloyd Limited/P&O Nedlloyd B.V., Australia New Zealand Direct Line, Hamburg-Dampfschiffahrtsgesellschaft KG (Columbus Line), Fesco Ocean Management Ltd.  
**Synopsis:** The proposed agreement authorizes the parties to discuss and agree on the number of vessels deployed and to charter space to/from one another in the trades between the U.S. Pacific Coast and Australia, New Zealand, and the Pacific Islands, and between the U.S. Pacific Coast and Canada and Mexico. It also authorizes the parties to engage in limited related cooperative activities.

By Order of the Federal Maritime Commission  
Bryant L. VanBrakle, Secretary.

[FR Doc. 00–33075 Filed 12–27–00; 8:45 am]
BILLING CODE 6730–01–P

**FEDERAL RESERVE SYSTEM**

**Agency Information Collection Activities: Proposed Collection; Comment Request**

**AGENCY:** Board of Governors of the Federal Reserve System (Board).

**ACTION:** Notice and request for comment.

**SUMMARY:** In accordance with the requirements of the Paperwork Reduction Act of 1995 (44 U.S.C. chapter 35), the Board, the Federal Deposit Insurance Corporation (FDIC), and the Office of the Comptroller of the Currency (OCC) (the “agencies”) may not conduct or sponsor, and the respondent is not required to respond to, an information collection unless it displays a currently valid Office of Management and Budget (OMB) control number. The Federal Financial Institutions Examination Council (FFIEC), of which the agencies are members, has approved for public comment proposed revisions to the Report of Assets and Liabilities of U.S. Branches and Agencies of Foreign Banks (FFIEC 002). The Board is publishing the proposed revisions on behalf of the agencies. At the end of the comment period, the comments and recommendations received will be analyzed to determine the extent to which the FFIEC should modify the proposed revisions prior to giving its final approval. The Board will then submit the revisions to OMB for review and approval.

**DATES:** Comments must be submitted on or before February 26, 2001.

**ADDRESSES:** Interested parties are invited to submit written comments to the agency listed below. All comments, which should refer to the OMB control number, will be shared among the agencies.

Written comments should be addressed to Jennifer J. Johnson,
Secretary, Board of Governors of the Federal Reserve System, 20th and C Streets, NW., Washington, DC 20551, submitted by electronic mail to regs.comments@federalreserve.gov, or delivered to the Board’s mail room between 8:45 a.m. and 5:15 p.m., and to the security control room outside of those hours. Both the mail room and the security control room are accessible from the courtyard entrance on 20th Street between Constitution Avenue and C Street, NW. Comments received may be inspected in room M–P–500 between 9:00 a.m. and 5:00 p.m., except as provided in section 261.12 of the Board’s Rules Regarding Availability of Information, 12 CFR 261.12(a).

A copy of the comments may also be submitted to the OMB desk officer for the Board: Alexander T. Hunt, Office of Information and Regulatory Affairs, Office of Management and Budget, New Executive Office Building, Room 3208, Washington, DC 20503.

FOR FURTHER INFORMATION CONTACT: A draft copy of the proposed FFIEC 002 reporting form may be obtained at the FFIEC’s web site (www.ffiec.gov). A copy of the proposed revisions to the collection of information may also be requested from Mary M. West, Federal Reserve Board Clearance Officer, (202) 452–3544, Board of Governors of the Federal Reserve System, 20th and C Streets, NW., Washington, DC 20551. Telecommunications Device for the Deaf (TDD) users may contact Diane Jenkins, (202) 452–3544, Board of Governors of the Federal Reserve System, 20th and C Streets, NW., Washington, DC 20551.

SUPPLEMENTARY INFORMATION: Proposal to revise the following currently approved collection of information:


Form Number: FFIEC 002.

OMB Number: 7100–0032.

Frequency of Response: Quarterly.

Affected Public: U.S. branches and agencies of foreign banks.

Estimated Number of Respondents: 354.

Estimated Total Annual Responses: 1,416.

Estimated Time per Response: 2.25 burden hours.

Estimated Total Annual Burden: 31,860 burden hours.

General Description of Report

This information collection is mandatory: 12 U.S.C. 3105(b)(2), 1817(c)(1), 121 (3), and 3102(b). Except for select sensitive items, this information collection is not given confidential treatment (5 U.S.C. 552(b)(8)). Small businesses (that is, small U.S. branches and agencies of foreign banks) are affected.

Abstract

On a quarterly basis, all U.S. branches and agencies of foreign banks (U.S. branches) are required to file detailed schedules of assets and liabilities in the form of a condition report and a variety of supporting schedules. This information is used to fulfill the supervisory and regulatory requirements of the International Banking Act of 1978. The data are also used to augment the bank credit, loan, and deposit information needed for monetary policy and other public policy purposes. The Federal Reserve System collects and processes this report on behalf of all three agencies.

Current Actions

The agencies propose to implement a number of revisions to streamline the existing reporting requirements of the Report of Assets and Liabilities of U.S. Branches and Agencies of Foreign Banks (FFIEC 002), consistent with eliminations and reductions in detail proposed to the Reports of Condition and Income (Call Report) (proposed FFIEC 031 and 041) filed by insured commercial banks and FDIC-supervised savings banks. The agencies are also endeavoring to improve the relevance of the FFIEC 002 by identifying new types of information necessary to monitor new activities and other recent developments that may expose institutions to new or different types of risk.

The proposed revisions to the FFIEC 002 summarized below have been approved for publication by the FFIEC. The agencies would implement these proposed changes, except for new information proposed on fiduciary and related services, as of the June 30, 2001, reporting date. Proposed new information on fiduciary and related services would be effective with the December 31, 2001, reporting date.

A. Specific Proposed Deletions, Reductions in Detail, and Redefinitions

Schedule RAL—Assets and Liabilities


3. Memorandum item 9, “Mutual fund and annuity sales during the quarter,” would be redefined as “Assets under the reporting branch or agency’s management in proprietary mutual funds and annuities.” For branches and agencies with proprietary mutual funds and annuities, reporting the amount of assets under management should be significantly less burdensome than reporting the quarterly sales volume of both proprietary products and nonproprietary products. Branches and agencies without proprietary mutual funds and annuities will no longer need to report any information on their involvement with these products.

4. Memorandum item 12, “Amount of assets netted against liabilities to nonrelated parties (excluding deposits in insured branches) on the balance sheet in accordance with generally accepted accounting principles,” would be eliminated.

5. Statutory or Regulatory Requirement item S.3.a, “FDIC asset maintenance requirement (for FDIC-insured branches only): Average liabilities,” currently collects average liabilities for the quarter ending on the report date. The agencies propose to redefine this item to collect average liabilities for the calendar quarter preceding the quarter ending on the report date. This redefinition would ensure that, as of a given report date, the asset maintenance requirement calculation for FDIC-insured branches in Section 347.211 of the FDIC’s regulations can be accomplished by using only data filed on the current FFIEC 002 report. For example, using the FFIEC 002 report for the third quarter, eligible assets on the last day of the third quarter (reported in item S.3.b) would be divided by average liabilities for the second quarter (reported in item S.3.a).

Schedule A—Cash and Balances Due from Depository Institutions

Memorandum item 1, “Noninterest-bearing balances due from commercial banks in the U.S. (including their IBFs),” would be deleted.

Schedule C—Loans

The separate loan categories for “Loans to depository institutions” and “Acceptances of other banks” (items 2 and 5, respectively) would be combined.

Schedule E—Deposit Liabilities and Credit Balances

1. The reporting of demand deposits by category of depositor in column B of
the body of the deposits schedule would be eliminated, with branches and agencies reporting instead only the total amount of their demand deposits in this column. Branches and agencies would continue to provide a category-by-category breakdown of their total transaction accounts in column A, which includes their demand deposits, but the current duplicate reporting of demand deposits by category in both columns A and B would end.

2. Item 6, “Certified and official checks,” would be combined with deposits of “Individuals, partnerships, and corporations” (item 1).

Schedule L—Derivatives and Off-Balance-Sheet Items

1. Item 6, “Participations in acceptances acquired from the reporting (non-accepting) branch or agency,” would be deleted.

2. Item 11.b for the gross notional amount of derivative contracts held for purposes other than trading that are not marked to market would be deleted. All derivative contracts, including those held for purposes other than trading, will be marked to market once a branch or agency adopts FASB Statement No. 133, Accounting for Derivative Instruments and Hedging Activities, which is effective for fiscal years beginning after June 15, 2000. Thus, item 11.b will no longer have any relevance in 2001.

3. For branches and agencies with $100 million or more in total assets: Items 12.c.(1) and (2) for the gross positive and gross negative fair values of derivatives held for purposes other than trading that are not marked to market would be deleted because of the effect of FASB Statement No. 133.

Schedule N—Past Due, Nonaccrual, and Restructured Loans

Memorandum item 2.b, “Replacement cost of [past due derivative] contracts with a positive replacement cost,” would be deleted. Once branches and agencies adopt FASB Statement No. 133, Accounting for Derivative Instruments and Hedging Activities, all of their derivative contracts will be carried on the balance sheet at fair value. Since the replacement cost of a derivative contract is its fair value and its book value will also be its fair value, Memorandum items 2.a, “Book value of amounts carried as assets,” and 2.b would duplicate each other. The caption for Memorandum item 2.a would be revised to read “Fair value of amounts carried as assets.”

B. Proposed New Information

Securitization and Asset Sale Activities

The agencies propose to revise and expand the information collected in the FFIEC 002 report to facilitate more effective analysis of the impact of securitization and asset sale activities on credit exposures. In this regard, the agencies are proposing to introduce a separate new schedule (Schedule S) that would comprehensively capture information related to securitization and asset sale activities.

Under this proposal, branches and agencies involved in securitization and asset sale activities would report quarter-end data for seven loan and lease categories. These data would cover 1–4 family residential loans, home equity lines, credit card receivables, auto loans, other consumer loans, commercial and industrial loans, and all other loans and all leases. For each loan category, branches and agencies would report: (1) The outstanding principal balance of assets sold and securitized with servicing retained or with recourse or seller-provided credit enhancements, (2) the maximum amount of credit exposure arising from recourse or credit enhancements to securitization structures (separately for those sponsored by the reporting branch or agency and those sponsored by other institutions), (3) the past due amounts on the underlying securitized assets, (4) the amount of any commitments to provide liquidity to the securitization structures, (5) the outstanding principal balance of assets sold with servicing retained or with recourse or seller-provided credit enhancements that have not been securitized, and (6) the maximum amount of credit exposure arising from assets sold with recourse or seller-provided credit enhancements that have not been securitized.

A limited amount of information would also be collected on credit exposures to asset-backed commercial paper conduits. For the home equity line, credit card receivable, and the commercial and industrial loan categories, branches and agencies would also report the amount of any ownership (or seller’s) interests in securitizations that are carried as securities and as loans and the past due amounts on the assets underlying the seller’s interests carried as securities.

Although the proposed new schedule would collect a considerable amount of information on these securitization and asset sale activities, most branches and agencies will not be affected by Schedule S and the increase in reporting burden associated with the schedule’s new information will be confined to a relatively small segment of the industry.

On a related matter, the agencies also propose to collect information to facilitate more effective assessments of credit and other exposures related to branch and agency portfolios of asset-backed securities. Currently all asset-backed securities are reported in Schedule RAL, item 1.b, “U.S. Government securities,” or item 1.c, “Other bonds, notes, debentures, and corporate stock (including state and local securities),” depending on the issuer or guarantor. The agencies propose to add two new items on Schedule RAL to segregate branch and agency holdings of mortgage-backed securities and other asset-backed securities. Collection of this information would promote risk-focused supervision by enhancing the agencies’ ability to assess credit exposures and asset concentrations.

Reporting of Trust Data

The agencies propose to change the manner in which branches and agencies report information on their trust activities. Branches and agencies that file the existing Annual Report of Trust Assets (FFIEC 001) would instead file a new Fiduciary and Related Services Schedule (Fiduciary Schedule) (Schedule T) as part of the FFIEC 002. Under this proposal, branches and agencies that have fiduciary or related activity would be required to report
certain trust information in Schedule T annually as of December 31. This information includes the number of accounts and the market value of trust assets for eight categories of fiduciary activities. These institutions would also report data on corporate trust activities, collective investment funds and common trust funds, and types of managed assets held in personal trust and agency accounts.

In creating proposed Schedule T, modifications have been made to some of the existing items currently reported on the FFIEC 001 to improve their value and usefulness. However, the total number of separately reportable data items in the proposed Fiduciary Schedule represents a decrease of more than 60 percent in the number of reportable items in the FFIEC 001. Thus, the agencies believe this proposal would not produce an increase in reporting burden for trust institutions.

The agencies are proposing to add the new Fiduciary Schedule to the FFIEC 002 instead of retaining separate trust reports in order to facilitate the timely collection and processing of the information. Institutions filing the current annual trust reports generally must submit their reports within 45 days after year-end. Electronically submitted annual trust reports, first allowed for year-end 1998 reporting, have a 75-day filing deadline. By moving the reporting of fiduciary information into the FFIEC 002, the submission deadline for the FFIEC 002 would apply to this reporting requirement. The length of time that trust institutions would have for completing the Fiduciary Schedule would be reduced from 45 days to 30 days for most institutions and from 75 days to 30 days for institutions that file electronically. The proposed implementation of this Fiduciary Schedule and the modification of the submission deadline for this reporting requirement is consistent with the reporting treatment currently proposed for insured commercial banks and FDIC-supervised savings banks.

C. Other Issue for Which Public Comment Is Requested

Eliminating Confidential Treatment for Certain Past Due and Nonaccrual Data

An important public policy issue for the agencies has been how to use market discipline to complement supervisory resources. Market discipline relies on market participants having information about the risks and financial condition of banking organizations. Disclosure that increases transparency should lead to more accurate market assessments of risk and value. This, in turn, should result in more effective market discipline on banking organizations.

Despite this emphasis on market discipline, the FFIEC and the agencies currently accord confidential treatment to the information branches and agencies report in Schedule N of the FFIEC 002 report on the amounts of their loans, leases, and other assets that are past due, in nonaccrual status, or restructured and in compliance with modified terms. In order to give the public, including branches and agencies, more complete information on the level of and trends in asset quality at individual institutions, the agencies are proposing to eliminate the confidential treatment currently provided for this information beginning with the amounts reported as of June 30, 2001.

Some financial institutions have held that information on loans, leases, and other assets that are past due 30 through 89 days is not a reliable indicator of future loan losses or of general asset quality. They further note that market discipline would be reduced, rather than enhanced, by the release of information that is highly susceptible to misinterpretation to the extent that it could cause an unjustifiable loss of funding to the industry. However, banking supervisors have consistently found information on loans and leases past due 30 through 89 days to be helpful in identifying financial institutions with emerging asset quality problems. Therefore, the agencies believe that such information is a useful indicator of general asset quality and would not represent misleading information to the public.

Currently the agencies publicly disclose information reported by insured commercial banks, FDIC-supervised savings banks, and bank holding companies on loans and leases that are past due 90 days or more and still accruing, in nonaccrual status, or restructured and in compliance with modified terms. The agencies have proposed to publicly disclose reported information on loans and leases that are past due 30 through 89 days and still accruing for these institutions effective as of March 31, 2001. Disclosing the information reported on Schedule N of the FFIEC 002 would also provide for a consistent reporting treatment with other U.S. banking institutions.

Request for Comment

Comments submitted in response to this Notice will be shared among the agencies and will be summarized or included in the Board’s request for OMB approval. All comments will become a matter of public record. Written comments should address the accuracy of the burden estimates and ways to minimize burden as well as other relevant aspects of the information collection requests. Comments are invited on:

(a) Whether the proposed collection of information is necessary for the proper performance of the agencies’ functions, including whether the information has practical utility;
(b) The accuracy of the agencies’ estimate of the burden of the information collection, including the validity of the methodology and assumptions used;
(c) Ways to enhance the quality, utility, and clarity of the information to be collected;
(d) Ways to minimize the burden of the information collection on respondents, including through the use of automated collection techniques or other forms of information technology; and
(e) Estimates of capital or start up costs and costs of operation, maintenance, and purchase of services to provide information.


Jennifer J. Johnson,
Secretary of the Board.

[Fed. Reg. 00-33206 Filed 12-27-00; 8:45 am]

BILLING CODE 6210-01-P

FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 et seq.) (BHC Act), Regulation Y (12 CFR Part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The application also will be
available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States. Additional information on all bank holding companies may be obtained from the National Information Center website at www.ffiec.gov/nic/.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than January 22, 2000.

A. Federal Reserve Bank of Richmond (A. Linwood Gill, III, Vice President) 701 East Byrd Street, Richmond, Virginia 23261–4528:


B. Federal Reserve Bank of Chicago (Phillip Jackson, Applications Officer) 230 South LaSalle Street, Chicago, Illinois 60690–1414:

1. First BancTrust Corporation, Paris, Illinois; to become a bank holding company by acquiring 100 percent of the voting shares of First Bank & Trust, S.B., Paris, Illinois (upon the bank’s conversion to stock form).


Jennifer J. Johnson
Secretary of the Board.

[FR Doc. 00–33207 Filed 12–27–00; 8:45 am]

BILLING CODE 6210–01–S

FEDERAL RESERVE SYSTEM

[Docket No. R–1095]

Federal Reserve Bank Services; Private Sector Adjustment Factor

AGENCY: Board of Governors of the Federal Reserve System.

ACTION: Notice with request for comments.

SUMMARY: The Board requests comment on a proposal to modify the method for calculating the private sector adjustment factor (PSAF). The PSAF imputes the costs that would have been incurred and profits that would have been earned had the Federal Reserve Banks’ priced services been provided by a private firm. The Monetary Control Act of 1980 (MCA) requires that the Federal Reserve set fees for its services to recover, over the long term, its actual costs of providing the services, as well as these imputed costs and profits. The Board reviews its method for calculating the PSAF periodically to assess whether it is still appropriate in light of the changing environment.

Specifically, the Board requests comment on a proposal to modify the current method for imputing debt and equity, to enhance the method for determining the target rate of return on equity, and to continue using the fifty largest bank holding companies’ financial data as a proxy for Federal Reserve priced-services activities. If adopted, the changes would be effective for the 2002 PSAF and fees for Federal Reserve priced services.

DATES: Comments must be submitted on or before April 6, 2001.

ADDRESSES: Comments, which should refer to Docket No. R–1095, may be mailed to Ms. Jennifer J. Johnson, Secretary, Board of Governors of the Federal Reserve System, 20th and C Streets, NW, Washington, DC 20551 or mailed electronically to: regs.comments@federalreserve.gov. Comments addressed to Ms. Johnson also may be delivered to the Board’s mail room between 8:45 a.m. and 5:15 p.m. and to the security control room outside of those hours. Both the mail room and the security control room are accessible from the courtyard entrance on 20th Street between Constitution Avenue and C Street, NW. Comments may be inspected in Room MP–500 between 9 a.m. and 5 p.m. weekdays, pursuant to §261.12, except as provided in §261.14 of the Board’s Rules Regarding Availability of Information, 12 CFR 261.12 and 261.14.

FOR FURTHER INFORMATION CONTACT: Gregory L. Evans, Manager (202/452–3945); Brenda Richards, Sr. Financial Analyst (202/452–2753); or Rebecca Kenyon, Financial Analyst (202/452–2974), Division of Reserve Bank Operations and Payment Systems. For users of Telecommunication Device for the Deaf (TDD) only, please contact Janice Simms, (202/872–4984). Copies of a research paper describing the theoretical basis and detailed application of each of the proposed models (“The Federal Reserve Banks’ Imputed Cost of Equity Capital”) may be obtained from the Board through the Freedom of Information Office (202/452–3684) or at the Board’s web site at www.federalreserve.gov by accessing the press release for this proposal.

SUPPLEMENTARY INFORMATION:

I. Background

The current method for calculating the PSAF involves determining the value of Federal Reserve assets to be used in providing priced services during the coming year, the financing mix used to fund them, and the rates used to impute financing costs. Assets are determined using Reserve Bank information on actual assets and projected disposals and acquisitions. The priced-services portion of mixed-use assets is determined based on the allocation of related depreciation expense. Historically, short-term assets are assumed to be financed with short-term liabilities and long-term assets are assumed to be financed with a combination of long-term debt and equity. The financing rates and the combination of financing types are based on data developed from the “bank holding company (BHC) model,” a model that contains consolidated financial data for the nation’s fifty largest (asset size) BHCs.

Imputed taxes are captured using a pre-tax return on equity (ROE). The use of the pre-tax ROE assumes that a 100 percent recovery of expenses, including the targeted ROE, will be achieved. Should the pre-tax earnings be more or less than the targeted ROE, the PSAF is adjusted (“variable PSAF”) for the tax expense or savings associated with the adjusted recovery. The variable PSAF tax rate is the median of the rates paid by the BHCs over the past five years.
adjusted to the extent that the BHCs are invested in municipal bonds.

In addition, the PSAF includes the estimated priced-services expenses of the Board of Governors, imputed sales taxes, and an assessment for FDIC insurance, imputed based on current FDIC rates and projected clearing balances (deposits) held with the Reserve Banks.

B. Net Income on Clearing Balances (NICB)

Depository institutions may hold both reserve and clearing balances with the Federal Reserve Banks. Reserve balances are held pursuant to a regulatory requirement and are separate from the Reserve Banks’ priced-services activities. Clearing balances, based on contractual agreements with Reserve Banks, are held to settle transactions arising from use of Federal Reserve priced services. In some cases, depository institutions hold clearing balances in excess of the contractual agreements. The NICB calculation assumes that the Reserve Banks invest the clearing balances net of imputed reserves, and imputes an equal investment in three-month Treasury bills. The calculation also determines the actual priced-services cost of earnings credits (amounts available to offset future service fees) on contracted clearing balances held, net of expired earnings credits, based on the federal funds rate. Because they are held for clearing priced-services transactions, clearing balances are directly related to priced services. Therefore, the net earnings or expense attributable to the imputed Treasury-bill investments and clearing balances are considered income or expense for priced-services activities.

II. Proposed Methodology Changes

Since the adoption of the PSAF and NICB framework, certain finance theories have gained industry acceptance and the levels of clearing balances held by depository institutions with the Reserve Banks have increased significantly. In addition, mergers, acquisitions, and the expansion of allowable BHC activities may alter the comparability of the top fifty BHCs to the Reserve Bank priced-services activities. The criteria used for evaluating alternatives proposed for various components of the calculation were based on the conceptual framework of the PSAF and its relationship to private-sector practice.

As a result, the Board requests comment on a proposal that seeks to create a priced-services balance sheet that resembles that of a private business firm, using real assets and liabilities, imputing liabilities and equity only to the extent necessary, and more appropriately reflecting the risk inherent in priced-service activity.

A. Imputed Debt and Equity

The current method for computing the PSAF and NICB unnecessarily imputes larger amounts of certain assets and liabilities and the related income and expenses to priced services. Considering the growth in the size of clearing balances since the inception of the NICB and the stable nature of the majority of the balances, it is likely that rather than incur additional debt costs, a private business firm would use a portion of these balances to finance its capital needs. Assuming a sensible business use of clearing balances is necessary to provide an appropriate cost comparison between Reserve Banks and private-sector service providers. For the Federal Reserve, such an assumption requires the integration of the PSAF and NICB computations to effectively eliminate imputed debt and reduce imputed investments in Treasury securities. Essentially, the Reserve Bank priced-services activity will forgo earnings at the Treasury-bill rate to reduce long-term and short-term debt expenses. Under the proposal, a portion of the contracts clearing balances would be considered “core deposits,” that is, deposits that will remain stable without regard to the magnitude of actual clearing balances. This use is consistent with a banking organization’s use of deposits. Banking and regulatory practice recognizes that core deposits, while technically short-term, are largely stable over time. This stability provides confidence that a substantial portion of the balances can appropriately be used to fund longer-term assets.

1. Imputed Debt

When the PSAF methodology was established, clearing balances were new, quite small, and did not offer a significant source of funding. Since 1992 the balances have not fallen below $4 billion. This proposal recommends that $4 billion of clearing balances (out of more than $7 billion clearing balances currently maintained) could initially be considered available to finance long-term assets. The Board considers this a conservative level of core balances. Based on the current level of priced services, an insubstantial part of these balances would actually be used for financing. The Board expects that the definition of core deposits may be adjusted over time to consider clearing balance trends.

The Board requests comment on the benefits and drawbacks of using core clearing balances as a source of financing long-term assets. The Board is also interested in commenters’ opinions on whether establishing an initial level of core balances of $4 billion is reasonable. If commenters have an opinion on how the core balance should be determined, the Board would be interested in learning the details of that method.

2. Imputed Equity

Another important aspect of the PSAF calculation is determining an appropriate level of equity from which to impute a target ROE. The proposal’s use of clearing balances to determine the appropriate amount of imputed debt, rather than using a debt-to-equity ratio from the BHC model, requires a new method of imputing equity.2 A private business firm would generally maintain equity, an expensive financing source, at the minimum level necessary to finance assets, to manage risk, and to meet regulatory requirements. The current PSAF method for imputing equity is not based on these considerations and imputed equity has historically been either more or less than regulatory requirements, depending on the BHC model debt-to-equity ratio. The Board proposes targeting an equity level sufficient to satisfy the FDIC requirement for a well-capitalized institution, which is currently 5 percent of total assets and 10 percent of risk-weighted assets.3 This proposal is consistent with how the Board believes rational bank management would target its equity level. The Board requests comment on whether basing priced-services equity on regulatory requirements is a reasonable method.

B. Imputed Return on Equity

The Board proposes that the target ROE used for the PSAF be calculated using a combination of the current comparable accounting earnings model.

---

1 Clearing balances, unless otherwise indicated, refer to contracted and excess clearing balances held by depository institutions with the Federal Reserve Banks.

2 The BHC model debt-to-equity ratio is currently used to determine imputed debt and equity necessary to finance long-term priced-services assets.

3 The FDIC requirements for a well-capitalized financial institution are (1) a ratio of total capital to risk-weighted assets of 10 percent or greater; and (2) a ratio of Tier 1 capital to risk-weighted assets of 6 percent or greater; and (3) a leverage ratio of Tier 1 capital to total assets of 5 percent or greater. The Federal Reserve priced-services balance sheet total capital has no components of tier 1 or total capital other than equity; therefore, requirements 1 and 2 are essentially the same measurement.
and two additional economic models, a capital asset pricing model and a discounted cash flow model.4

1. Current Method

The target return on equity for Reserve Bank priced services is calculated using BHC data from publicly available audited financial statements. The PSAF BHC equity cost of capital, or ROE, is calculated as an average of the ratios of the BHCs' net income and average book value of equity. An example of a comparable accounting earnings (CAE) model, the BHC model can be duplicated and is readily accepted in industry practice. Its shortcomings are that it uses historical data from the two to seven years before the target year to predict future earnings and is based on book rather than market values.5

2. Capital Asset Pricing Model (CAPM)

The CAPM approach estimates the imputed BHC ROE from the return on a stock portfolio of the fifty largest (asset size) BHCs over a one-year period. The ROE estimated using this approach is the sum of a measure of the one-year risk-free rate and an equity risk premium for the BHC sample. This risk premium is the product of the sensitivity of the specified portfolio of BHC sample stocks to the overall stock market (the portfolio’s beta) plus a historical measure of the one-year stock market return relative to the risk-free rate. As proposed, the portfolio weights are based on BHC equity market capitalization. This model provides a strong theoretical framework for addressing risk and its effect on the required rate of return. The CAPM requires judgment in determining the risk-free rate, the average risk premium for the market, and the data used for measuring beta. The Board proposes using the three-month Treasury-bill rate as the risk-free rate and a standard data series on returns for the stock market from 1927 (earliest available data) forward using a rolling ten-year period to determine the average risk premium for the market. The proposed beta compares the returns based on BHC data with the stock market as a whole.

The Board requests comment on whether the three-month Treasury-bill rate is an appropriate Treasury maturity for use as the risk-free rate in the CAPM, if stock market activity since 1927 is an appropriate source for data in determining the average risk premium for the market, and whether using a rolling ten-year average of BHC data provides a reasonable beta.

3. Discounted Cash Flow Model (DCF)

The DCF model assumes that a firm’s stock price is equal to the present discounted value of all expected future dividends. If the price and expected future dividends are known, the implied discount rate for the firm can be calculated and is considered to be the firm’s equity cost of capital. The DCF approach requires as inputs the BHC stock prices as well as forecasts of their future dividends and long-term dividend growth rates. As proposed, consensus forecasts of future dividends and long-term growth rates would be transformed into earnings forecasts by multiplying them by the BHC’s dividend pay-out ratios. The equity costs of capital for the individual BHCs are then combined into a single measure using a weighted average, in which the weights are proposed to be based on the BHC equity market capitalization. The Board proposes using commercially available consensus forecasts, such as those published by Institutional Brokers Estimate System (I/B/E/S). Academic studies have found consensus forecasts to be more accurate than individual forecasts.

The Board requests comment on whether commercially available consensus forecasts are an appropriate measure of future dividends and long-term growth rates.

4. Combining the Models

Unlike the CAE, the CAPM and DCF use data that predict future earnings and reflect current academic practice. All three models are widely used in industry and in regulatory consideration of an appropriate rate of return. For example, for several years the New York State Public Service Commission has used a weighted average of different ROEs in determining its allowed cost of equity capital for the utilities it regulates.

Academic studies have demonstrated that use of multiple models can improve estimation techniques when each model provides new information. The CAE, CAPM, and DCF models each use different data and examine different factors. The Board proposes to calculate the target ROE for Reserve Bank priced services as a weighted average of the results from the three models. This combination will incorporate additional data and conceptual frameworks into the current practice and will minimize the impact of outlying observations to provide a more predictable series over time.

The Board requests comment on the economic models and whether the three economic models are theoretically sound and should be used to calculate the PSAF. The Board also requests comment on the appropriateness of using a simple average of the three models.

5. Weighting the Data

Currently, the PSAF ROE is calculated by taking an equally-weighted average of the BHC ROEs from the CAE. The weighting used in the CAE model has the practical benefit of avoiding illogical results such as a negative target ROE in a year when a large bank holding company encounters financial difficulties. How observations are weighted in the models is relevant because the bank holding companies in the peer group are imperfect proxies, that is, they engage in a wider spectrum of activities than the range of Reserve Bank payment services for which the PSAF methodology is used to estimate an appropriate cost of equity capital.

Alternative weighting schemes can be constructed. One alternative would be to take a value-weighted average of the ROEs by multiplying each BHC’s ROE by that company’s market valuation and then dividing the sum of these weighted returns by the total market valuation of the fifty BHCs. Such market weighting places more emphasis on large BHCs and reflects current academic and industry practice when applying it to the CAPM and DCF models. The Board proposes to use a market capitalization weight to determine the CAPM and DCF ROEs while retaining the commonly used equal weighting of BHC ROEs under the CAE. The Board requests comment on the appropriateness of this proposal.

Other methods for weighting BHC data in the three models were considered, such as weighting based on balances due to depository institutions. Such weighting attempts to measure the significance of a BHC’s correspondent banking activities to the total bank holding company activities and as a result, gives BHCs with the largest correspondent-banking business lines greater weight. Deposits due to depository institutions are not typically reported separately in BHC annual reports but are reported at the commercial bank level in publicly available Call Report data. The Board requests comment on BHC weighting.

4. A research paper (“The Federal Reserve Banks’ Imputed Cost of Equity Capital”) describing the theoretical basis and detailed application of each of the models is available at the Board’s web site at www.federalreserve.gov by accessing the press release for this proposal.

5. The target ROE for 2001, for example, is calculated using data from BHC financial statements for the years 1995 to 1999.
based on due-to balances to determine the ROEs.

C. Peer Group

The Board considered whether organizations other than the top fifty BHCs would provide a better basis for imputing the costs that would have been incurred and the profits that would have been earned had the Reserve Banks’ priced-services activities been provided by a private-sector firm. Specifically, the consideration included whether segment data from BHC financial reports could be used to match more closely the BHC capital structure to the System’s priced-services activity, or whether service bureaus should be used as proxy for private-sector firms engaged in priced-services activity.

Bank holding company activities are far more diverse than Reserve Bank priced-services activities and payment services are generally a small segment of BHC activities. For this reason, BHCs are not a precise counterpart, but they do provide the most reasonable alternative available as a peer group given the similarity of services provided, the competition between BHCs and the Reserve Banks, and the availability of useful financial data.

Service bureaus are also diverse; they do not provide settlement or other services comparable to those of Reserve Banks, and they do not generally view the Reserve Banks as primary competitors. Therefore, the Board does not believe service bureaus to be a preferred substitute for the BHCs in the PSAF model. Maintaining the BHC sample size at fifty encompasses the majority of banking assets nationwide and minimizes the effects of any one BHC’s financial performance on the data.

The Board considered using BHC segment data in order to exclude the effect of BHC non-comparable activities on the PSAF. Although these data increasingly are included in financial reports, the Board identified several obstacles to using segment data. There is no standard definition of “segment” for use in financial reporting. Segments may be reported based on any combination of customer type, product, or service provided and compilation of specific segment data may reflect a total return on equity that is greater or less than the return on equity for the entity as a whole. It is often impossible, with the data available, to determine in which BHC segments activities comparable to priced-services activities are included to ensure inclusion of those that are related to Reserve Bank priced services and exclusion of those that are not. As a result, information is not reliable, complete, or consistent across BHCs or even within one BHC over time.

The Board requests comment on whether the fifty largest (in asset size) bank holding companies continue to be a reasonable data peer group for Reserve Bank priced-services activities. Further, the Board would like commenters’ views on whether there are ways to adjust BHC data to resemble more closely the Federal Reserve Banks’ priced-services activities.

D. Pension Financing Costs

The Board considered the current treatment for pension accounting, financing the pension assets net of the retirement liabilities, and concluded that it is consistent with that at BHCs and other firms, follows current rules for recognizing increases in pension assets, and is theoretically sound.

E. Priced-Services Balance Sheet

Table 1 represents the elements of the priced-services balance sheet and how they will be derived under the proposal. All actual assets and liabilities presented on the priced-services balance sheet are based on projected average daily balances.

<table>
<thead>
<tr>
<th>Assets</th>
<th>Type</th>
<th>Description</th>
<th>Method for computing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Required reserves</td>
<td>Imputed</td>
<td>Intended to simulate commercial bank reserve requirements</td>
<td>10 percent of total clearing balances.</td>
</tr>
<tr>
<td>U.S. Treasury securities</td>
<td>Imputed</td>
<td>Represents the portion of clearing balances not required for reserves or to finance other actual or imputed priced-service assets.</td>
<td>Total liabilities plus equity less other assets.</td>
</tr>
<tr>
<td>Short-term assets</td>
<td>Actual</td>
<td>Receivables, prepaid expenses, materials and supplies reported on the Federal Reserve Banks’ balance sheets that are attributed to priced services.</td>
<td></td>
</tr>
<tr>
<td>Cash items in process of collection</td>
<td>Actual</td>
<td>Transactions credited to the accounts of depository institutions but not yet collected by the Federal Reserve Banks that are attributed to priced services.</td>
<td></td>
</tr>
<tr>
<td>Pension assets</td>
<td>Actual</td>
<td>The amount of prepaid pension costs reported on the Federal Reserve Banks’ balance sheets that are attributed to priced services.</td>
<td></td>
</tr>
<tr>
<td>Long-term assets</td>
<td>Actual</td>
<td>The amount of premises, furniture and equipment, leases, and leasehold improvements that are reported on the Federal Reserve Banks’ and Board of Governors balance sheets that are attributed to priced services.</td>
<td>Estimated amount of actual contracted clearing balances that have historically been stable. Initially set at $4 billion.</td>
</tr>
<tr>
<td>Core clearing balances</td>
<td>Actual</td>
<td>The portion of clearing balances considered stable and available to finance long-term priced-service assets.</td>
<td>Equal to total clearing balances less core clearing balances.</td>
</tr>
<tr>
<td>Non-core clearing balances</td>
<td>Actual</td>
<td>Deposits of financial institutions maintained at Federal Reserve Banks for clearing transactions. Available to finance short-term priced service assets.</td>
<td></td>
</tr>
<tr>
<td>Short-term payables</td>
<td>Actual</td>
<td>The portion of sundry items payable, earnings credits due depository institutions and accrued expenses unpaid reported on the Federal Reserve Banks’ balance sheets that is attributed to priced services.</td>
<td></td>
</tr>
<tr>
<td>Deferred credits</td>
<td>Actual</td>
<td>The value of checks deposited with the Federal Reserve Banks but not yet credited to the accounts of the Reserve Banks’ depositors.</td>
<td></td>
</tr>
<tr>
<td>Postemployment/postretirement liability</td>
<td>Actual</td>
<td>The portion of post-retirement benefits due reported on the Federal Reserve Banks’ balance sheets that is attributed to priced services.</td>
<td></td>
</tr>
</tbody>
</table>
TABLE 1.—PRICED-SERVICES BALANCE SHEET—Continued

<table>
<thead>
<tr>
<th>Assets</th>
<th>Type</th>
<th>Description</th>
<th>Method for computing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Long-term debt ...</td>
<td>Imputed</td>
<td>An amount imputed when equity and core clearing balances are not sufficient to finance long-term priced-services assets.</td>
<td>Equal to the larger of zero or long-term and pension assets less postemployment/postretirement liability, core clearing balances, and equity. The greater of five percent of total assets or 10 percent of risk-weighted assets.</td>
</tr>
<tr>
<td>Equity .......................</td>
<td>Imputed</td>
<td>The minimum amount of equity necessary to meet FDIC requirements for a well-capitalized institution.</td>
<td></td>
</tr>
</tbody>
</table>

F. Effects of Proposal

The combination of the current equally-weighted CAE and the proposed market-weighted DCF and CAPM models produces the following pre-tax ROE based on the BHC performance data used for the 2001 PSAF:

<table>
<thead>
<tr>
<th>CAE</th>
<th>DCF</th>
<th>CAPM</th>
<th>Combined</th>
</tr>
</thead>
<tbody>
<tr>
<td>24.0</td>
<td>21.6</td>
<td>23.7</td>
<td>23.1</td>
</tr>
</tbody>
</table>

From year to year, the proposed combined model for calculating ROE can yield a target ROE that is higher or lower than the current method. On the average during the period from 1983 to 2001, the combined model yielded a pre-tax ROE that is 230 basis points higher than the current method.

Using core clearing balances as a source of financing for actual priced-services assets reduces imputed short- and long-term debt and imputed investments in marketable securities. As a result, the income and expenses associated with these imputed elements is reduced as well. Establishing equity at the level required by FDIC requirements for a well-capitalized bank results in setting equity equal to five percent of total assets, which is a slight reduction from the level planned in 2001 under the current methodology (5.3 percent). Applying the proposed changes to the 2001 priced-services balance sheet would reduce PSAF costs $33.8 million or 90 percent. This result is a net reduction of costs to priced services of $19.5 million or slightly more than 2 percent of total actual and imputed costs, including the target ROE of $138.2 million. Table 3 illustrates the effects of the proposal on the various elements of the PSAF and NICB calculations.

TABLE 2.—PRE-TAX RETURN ON EQUITY

<table>
<thead>
<tr>
<th></th>
<th>CAE</th>
<th>DCF</th>
<th>CAPM</th>
<th>Combined</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>24.0</td>
<td>21.6</td>
<td>23.7</td>
<td>23.1</td>
</tr>
</tbody>
</table>

TABLE 3.—2001 COMPARISON DATA

[Dollars in millions]

<table>
<thead>
<tr>
<th>Balance Sheet</th>
<th>Current</th>
<th>Proposed</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Required Reserves .........................................</td>
<td>$742.4</td>
<td>$742.4</td>
<td>$0.0</td>
</tr>
<tr>
<td>U.S. Treasury Securities ..................................</td>
<td>6,681.9</td>
<td>6,117.8</td>
<td>(564.1)</td>
</tr>
<tr>
<td>Short Term Assets .........................................</td>
<td>104.3</td>
<td>104.3</td>
<td>0.0</td>
</tr>
<tr>
<td>CIPC ...................................................................</td>
<td>3,606.7</td>
<td>3,606.7</td>
<td>0.0</td>
</tr>
<tr>
<td>Pension Assets .............................................</td>
<td>718.5</td>
<td>718.5</td>
<td>0.0</td>
</tr>
<tr>
<td>Long Term Assets ..........................................</td>
<td>676.9</td>
<td>676.9</td>
<td>0.0</td>
</tr>
<tr>
<td>Total Assets ................................................</td>
<td>$12,530.7</td>
<td>$11,966.6</td>
<td>($564.1)</td>
</tr>
<tr>
<td>Clearing Balances .........................................</td>
<td>$7,424.3</td>
<td>$7,424.3</td>
<td>0.0</td>
</tr>
<tr>
<td>Short-Term Payables .......................................</td>
<td>85.4</td>
<td>85.4</td>
<td>0.0</td>
</tr>
<tr>
<td>Short-Term Liabilities ....................................</td>
<td>18.9</td>
<td>0.0</td>
<td>(18.9)</td>
</tr>
<tr>
<td>Deferred Credits ..........................................</td>
<td>3,606.7</td>
<td>3,606.7</td>
<td>0.0</td>
</tr>
<tr>
<td>Postemployment/postretirement Liability ...............</td>
<td>251.9</td>
<td>251.9</td>
<td>0.0</td>
</tr>
<tr>
<td>Long-Term Liabilities .....................................</td>
<td>479.1</td>
<td>0.0</td>
<td>(479.1)</td>
</tr>
<tr>
<td>Equity ..................................................................</td>
<td>664.4</td>
<td>598.3</td>
<td>(66.1)</td>
</tr>
<tr>
<td>Total Liabilities &amp; Equity ...............................</td>
<td>$12,530.7</td>
<td>$11,966.6</td>
<td>($564.1)</td>
</tr>
<tr>
<td>Capital to Risk-weighted Assets .........................</td>
<td>30.8%</td>
<td>27.7%</td>
<td></td>
</tr>
<tr>
<td>Capital to Total Assets ....................................</td>
<td>5.3%</td>
<td>5.0%</td>
<td></td>
</tr>
</tbody>
</table>

PSAF

| Target Pre-Tax ROE ........................................ | 24.0%   | 23.1%    | −0.9%    |

6 Under this proposal, priced-services revenue would be $944.7 million and expenses would be $951.5 million, resulting in cost recovery of 99.3 percent as compared to 98 percent under the 2001 prices.
TABLE 3.—2001 COMPARISON DATA—Continued

[Dollars in millions]

<table>
<thead>
<tr>
<th>Cost of:</th>
<th>Current</th>
<th>Proposed</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Equity</td>
<td>$159.5</td>
<td>$138.2</td>
<td>($21.3)</td>
</tr>
<tr>
<td>Long-term Debt</td>
<td>31.1</td>
<td>0.0</td>
<td>(31.1)</td>
</tr>
<tr>
<td>Short-term Debt</td>
<td>0.9</td>
<td>0.0</td>
<td>(0.9)</td>
</tr>
<tr>
<td>FDIC Insurance</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>Sales Taxes</td>
<td>10.5</td>
<td>10.5</td>
<td>0.0</td>
</tr>
<tr>
<td>BOG Oversight</td>
<td>4.9</td>
<td>4.9</td>
<td>0.0</td>
</tr>
<tr>
<td>Total PSAF</td>
<td>$206.9</td>
<td>$153.6</td>
<td>($53.3)</td>
</tr>
</tbody>
</table>

NicB

<table>
<thead>
<tr>
<th>Return on Investment</th>
<th>$399.6</th>
<th>$365.8</th>
<th>($33.8)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cost of Earning Credits</td>
<td>(361.9)</td>
<td>(361.9)</td>
<td>0.0</td>
</tr>
<tr>
<td>NicB</td>
<td>$37.7</td>
<td>$3.9</td>
<td>($33.8)</td>
</tr>
</tbody>
</table>

Net Effect of New Methodology

<table>
<thead>
<tr>
<th>PSAF</th>
<th>$206.9</th>
<th>$153.6</th>
<th>($53.3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NicB</td>
<td>$37.7</td>
<td>$3.9</td>
<td>($33.8)</td>
</tr>
<tr>
<td>Net Cost</td>
<td>$169.2</td>
<td>$149.7</td>
<td>($19.5)</td>
</tr>
</tbody>
</table>

Details may not add to totals due to rounding.

III. Competitive Impact Analysis

All operational and legal changes considered by the Board and the changes to payment system participants are subject to competitive impact analysis described in the March 1990 policy statement “The Federal Reserve in the Payments System.” Under this policy, the Board assesses whether the change would have a direct and material adverse effect on the ability of other service providers to compete effectively with the Federal Reserve in providing similar services because of differing legal powers or constraints or because of a dominant market position of the Federal Reserve deriving from such legal differences. If the fees or fee structures create such an effect, the Board must further evaluate the changes to assess whether their benefits—such as contributions to payment system efficiency, payment system integrity, or other Board objectives—can be retained while reducing the hindrances to competition.

Because the PSAF includes costs that must be recovered through fees for priced services, changes made to the PSAF may have an effect on fees. This proposal is intended to refine the PSAF to more closely mirror the costs and profits of other service providers as required by the MCA. By mirroring these costs and profits, the fees adopted by the Reserve Banks should be based on the types of costs and expected profits that are more comparable to those of other providers. Accordingly, the Board believes this proposal will not have a direct and material adverse effect on the ability of other service providers to compete effectively with the Federal Reserve in providing similar services.

IV. Summary of Comments Requested

The Board believes the proposed changes to the PSAF methodology are consistent with the requirements of the MCA. The Board evaluated each alternative proposed for various components of the PSAF calculation based on the following framework principles: (1) To provide a conceptually sound basis for economically efficient pricing in the market for payments processing and collection services; (2) to maintain consistency with actual Reserve Bank financial information and practice; (3) to maintain consistency with private-sector practice; and (4) to use data in the public domain so others could replicate the PSAF calculation.

To assist commenters in the preparation of their responses to this notice, the Board requests comment on the following questions:

A. Overall Proposal

1. Are the CAE, DCF, and CAPM economic models theoretically sound and should they be used to calculate the PSAF?

2. Is an initial core clearing balance of $4 billion reasonable? If not, what would be a reasonable amount and what would be the best method for determining it?

3. Is basing priced-services equity on regulatory requirements a reasonable method?

C. Imputed Return on Equity

1. Are the CAE, DCF, and CAPM economic models theoretically sound and should they be used to calculate the PSAF?

2. Is the three-month Treasury-bill rate an appropriate Treasury maturity for use as the risk-free rate in the CAPM?

3. In determining the average risk premium for the market in the CAPM model, is stock market activity since 1927 an appropriate source for data?

4. Does using a rolling ten-year average of bank holding company data provide a reasonable beta for use in the CAPM?

5. Are commercially available consensus forecasts an appropriate measure of future dividends and long-term growth rates for use in the DCF economic model?

6. Does a simple average of the results of the three economic models provide an appropriate ROE?
FEDERAL RESERVE SYSTEM

Sunshine Act Meeting

AGENCY HOLDING THE MEETING: Board of Governors of the Federal Reserve System

TIME AND DATE: 11:00 a.m., Tuesday, January 2, 2001.
PLACE: Marriner S. Eccles Federal Reserve Board Building, 20th and C Streets, NW., Washington, DC 20551.
STATUS: Closed.

MATTERS TO BE CONSIDERED:
1. Personnel actions (appointments, promotions, assignments, reassignments, and salary actions) involving individual Federal Reserve System employees.
2. Any items carried forward from a previously announced meeting.

CONTACT PERSON FOR MORE INFORMATION:
Lynn S. Fox, Assistant to the Board; 202–452–3204.

SUPPLEMENTARY INFORMATION: You may call 202–452–3206 beginning at approximately 5 p.m. two business days before the meeting for a recorded announcement of bank and bank holding company applications scheduled for the meeting; or you may contact the Board’s Web site at http://www.federalreserve.gov for an electronic announcement that not only lists applications, but also indicates procedural and other information about the meeting.


Jennifer J. Johnson, Secretary of the Board.

BILLING CODE 6210–01–P
<table>
<thead>
<tr>
<th>Acquiring</th>
<th>Acquired</th>
<th>Entitles</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hoak Communications Partners, L.P.</td>
<td>TeleCorp-Tritel Holding Company.</td>
<td>TeleCorp-Tritel Holding Company.</td>
</tr>
<tr>
<td>William M. Mounger, II</td>
<td>TeleCorp-Tritel Holding Company.</td>
<td>TeleCorp-Tritel Holding Company.</td>
</tr>
<tr>
<td>Orica Limited</td>
<td>LaRoche Industries Inc</td>
<td>LaRoche Industries Inc.</td>
</tr>
<tr>
<td>Exodus Communications, Inc.</td>
<td>Global Crossing Ltd</td>
<td>Global Center Holding Co.</td>
</tr>
<tr>
<td>Global Crossing Ltd</td>
<td>Exoduc Communications, Inc.</td>
<td>Exoduc Communications, Inc.</td>
</tr>
<tr>
<td>Hans Georg Nader</td>
<td>Hanger Orthopedic Group, Inc.</td>
<td>Seattle Orthopedic Group, Inc.</td>
</tr>
<tr>
<td>Kenneth R. Thomson</td>
<td>Thyssen-Bornemisza Continuity Trust.</td>
<td>IHS EEO Management Systems Inc.; IHS Environmental Products Inc.; and IHS HR Products Inc.</td>
</tr>
<tr>
<td>Hicks, Muse, Tate &amp; Furst Equity Fund V, L.P.</td>
<td>J.D. Power Clubs, Inc</td>
<td>J.D. Power Clubs, Inc.</td>
</tr>
<tr>
<td>Broadbase Software, Inc</td>
<td>Servicesoft, Inc</td>
<td>Servicesoft, Inc.</td>
</tr>
<tr>
<td>Sigma Partners IV, L.P.</td>
<td>Broadbase Software, Inc</td>
<td>Broadbase Software, Inc</td>
</tr>
<tr>
<td>ABRY Broadcast Partners III, L.P.</td>
<td>John D. Engelbrecht</td>
<td>South Central Communications Corporation.</td>
</tr>
<tr>
<td>Broadcom Corporation</td>
<td>Allayer Communications</td>
<td>Allayer Communications.</td>
</tr>
<tr>
<td>SCF–IV, L.P.</td>
<td>HORNBECK–LEEVAC Marine Services, Inc.</td>
<td>HORNBECK–LEEVAC Marine Services, Inc.</td>
</tr>
<tr>
<td>Patrick J. Purcell</td>
<td>Galveston-Houston Company</td>
<td>Community News, LLC.</td>
</tr>
<tr>
<td>Komatsu Ltd</td>
<td>Network Two Communications Group, Inc.</td>
<td>Hensley Industries, Inc.</td>
</tr>
<tr>
<td>Peter Munk</td>
<td>Simpson Industries, Inc</td>
<td>NetworkTwo Communications Group, Inc.</td>
</tr>
<tr>
<td>Heartland Industrial Partners, L.P.</td>
<td>InterPacket Networks, Inc</td>
<td>Simpson Industries, Inc</td>
</tr>
<tr>
<td>American Tower Corporation</td>
<td>InterPacket Networks, Inc</td>
<td>InterPacket Networks, Inc</td>
</tr>
<tr>
<td>Citigroup Inc</td>
<td>Geneva Group, Inc</td>
<td>Geneva Group, Inc</td>
</tr>
<tr>
<td>Caisse Nationale de Credit Agricole.</td>
<td>CPR</td>
<td>CPR</td>
</tr>
<tr>
<td>General Electric Company</td>
<td>Columbia New Media Investors, L.P.</td>
<td>SpaceWorks, Inc.</td>
</tr>
<tr>
<td>Warburg, Pincus Equity Partners, L.P.</td>
<td>Novo Nordisk A/S</td>
<td>ZymoGenetics, Inc.</td>
</tr>
<tr>
<td>APAX Excelsior VI, L.P.</td>
<td>Novo Nordisk stA/S</td>
<td>ZymoGenetics, Inc.</td>
</tr>
<tr>
<td>Grant Prideco, Inc.</td>
<td>Seam-Mac Tube, Inc</td>
<td>Seam-Mac Tube, Ltd.</td>
</tr>
<tr>
<td>NOVA Chemicals Corporation.</td>
<td>The Dow Chemical Company</td>
<td>Midland Pipeline Corp.</td>
</tr>
<tr>
<td>Carrols Holding Corporation</td>
<td>Taco Cabana, Inc</td>
<td>Taco Cabana, Inc.</td>
</tr>
<tr>
<td>Thoma Cressey Fund VI, L.P.</td>
<td>Arvind Goel</td>
<td>Unixpros, Inc.</td>
</tr>
<tr>
<td>O. Bruton Smith</td>
<td>Eddie W. Philpott</td>
<td>Philpott Motors, Ltd.</td>
</tr>
<tr>
<td>Andreas Strungmann</td>
<td>Teva Pharmaceutical Industries Limited.</td>
<td>Teva Pharmaceutical Industries Limited.</td>
</tr>
</tbody>
</table>

**TRANSACTIONS GRANTED EARLY TERMINATION—10/31/2000**
<table>
<thead>
<tr>
<th>Trans No.</th>
<th>Acquiring</th>
<th>Acquired</th>
<th>Entities</th>
</tr>
</thead>
<tbody>
<tr>
<td>20010013</td>
<td>Siemens AG</td>
<td>Acuson Corporation</td>
<td>Acuson Corporation.</td>
</tr>
<tr>
<td>20010057</td>
<td>David Smith</td>
<td>GOCOM Holdings, LLC</td>
<td>GOCOM Corporation.</td>
</tr>
<tr>
<td>20010079</td>
<td>ABRY Broadcast Partners II, L.P.</td>
<td>CareFirst, Inc</td>
<td>Preferred Health Network of Maryland, Inc.</td>
</tr>
<tr>
<td>20010088</td>
<td></td>
<td>Preferred Health Network of Maryland, Inc.</td>
<td>Preferred Health Network of Maryland, Inc.</td>
</tr>
<tr>
<td>20010121</td>
<td>Sun Microsystems, Inc</td>
<td>Cobalt Networks, Inc</td>
<td>Cobalt Networks, Inc</td>
</tr>
<tr>
<td>20010131</td>
<td>Xenogen Corporation</td>
<td>Xenogen Corporation</td>
<td>Xenogen Corporation</td>
</tr>
<tr>
<td>20010132</td>
<td>MDS Inc</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20010064</td>
<td>ASM Lithophathy Holding N.V.</td>
<td>Silicon Valley Group, Inc</td>
<td>Silicon Valley Group, Inc</td>
</tr>
<tr>
<td>20010256</td>
<td>Tom Brown, Inc</td>
<td>Kinder Morgan, Inc</td>
<td>Wildhorse Energy Partners, LLC.</td>
</tr>
<tr>
<td>2005134</td>
<td>E M. TV &amp; Merchandising AG.</td>
<td>Voting Trust, 12/4/68, for the v.s. of Hallmark Cards Inc.</td>
<td>Crown Media Holdings, Inc.</td>
</tr>
<tr>
<td>20010011</td>
<td>AT&amp;T Corporation</td>
<td>VoiceStream Wireless Corporation.</td>
<td>Omnipoint Holdings, Inc.; Omnipoint MI-Indiana DE License, LLC; Omnipoint St. Louis Area DE License, LLC; and VoiceStream PCS BTA I License Corporation.</td>
</tr>
<tr>
<td>20010018</td>
<td>John H. Harland Company</td>
<td>Netzee, Inc</td>
<td>Netzee, Inc.</td>
</tr>
<tr>
<td>20010128</td>
<td>UnitedHealth Group Incorporated.</td>
<td>Lifemark Corporation</td>
<td>Lifemark Corporation</td>
</tr>
<tr>
<td>20010148</td>
<td>Ronald W. Burkle</td>
<td>Kmart Corporation</td>
<td>Kmart Corporation</td>
</tr>
<tr>
<td>20010179</td>
<td>Baker Communications Fund II (QP), L.P.</td>
<td>Traffic.com, Inc</td>
<td>Traffic.com, Inc</td>
</tr>
<tr>
<td>20010182</td>
<td>LSI Industries, Inc</td>
<td>Eugene Littman</td>
<td>Lightron of Cornwall, Inc.</td>
</tr>
<tr>
<td>20010197</td>
<td>HWH Capital Partners, L.P.</td>
<td>Mei Harris</td>
<td>Preferred Healthcare Staffing, Inc.</td>
</tr>
<tr>
<td>20010215</td>
<td>De Sammensluttede Vognmaend af 13-7 1976 A/S.</td>
<td>The J. Lauritzen Foundation</td>
<td>DFS Dan Transport Group A/S</td>
</tr>
<tr>
<td>20010288</td>
<td>Pechiney</td>
<td>JPS Packaging Company</td>
<td>JPS Packaging Company</td>
</tr>
<tr>
<td>20010312</td>
<td>UBS Capital Americas II, LLC.</td>
<td>TCA Acquisition Corp</td>
<td>TCA Acquisition Corp</td>
</tr>
<tr>
<td>20010312</td>
<td>UBS Capital Americas II, LLC.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20010257</td>
<td>Hicks, Muse, Tate &amp; Furst Equity Fund III, L.P.</td>
<td>Laughlin-Wilt Group, Inc</td>
<td>Laughlin-Wilt Group, Inc</td>
</tr>
<tr>
<td>20010272</td>
<td>The Dow Chemical Company.</td>
<td>The Collaborative Group, Ltd.</td>
<td>Collaborative Bioalliance, Inc.; and Collaborative Smithfield Corp.</td>
</tr>
<tr>
<td>20010281</td>
<td>Jackpot Enterprises, Inc</td>
<td>InterWorld Corporation</td>
<td>InterWorld Corporation</td>
</tr>
<tr>
<td>20010310</td>
<td>Tyco International Ltd</td>
<td>Perseus Fisk, L.L.C.</td>
<td>Fisk Corporation.</td>
</tr>
<tr>
<td>20010328</td>
<td>Cisco Systems, Inc</td>
<td>CAIS Internet</td>
<td>CAIS Software Solutions, Inc., CAIS, Inc.</td>
</tr>
<tr>
<td>Trans No.</td>
<td>Acquiring</td>
<td>Acquired</td>
<td>Entities</td>
</tr>
<tr>
<td>-----------</td>
<td>-----------</td>
<td>----------</td>
<td>----------</td>
</tr>
<tr>
<td>20010335</td>
<td>United News &amp; Media plc</td>
<td>Creative Planet, Inc</td>
<td>Creative Planet, Inc</td>
</tr>
</tbody>
</table>

**TRANSACTIONS GRANTED EARLY TERMINATION—11/08/2000**

<table>
<thead>
<tr>
<th>Trans No.</th>
<th>Acquiring</th>
<th>Acquired</th>
<th>Entities</th>
</tr>
</thead>
<tbody>
<tr>
<td>20010097</td>
<td>USX Corporation</td>
<td>The LTV Corporation</td>
<td>LTV Steel Company, Inc</td>
</tr>
<tr>
<td>20010165</td>
<td>DoubleClick Inc</td>
<td>Haven Bancorp, Inc</td>
<td>Haven Bancorp, Inc</td>
</tr>
<tr>
<td>20010185</td>
<td>Queens County Bancorp, Inc</td>
<td>Potomac Electric Power Company</td>
<td>Potomac Electric Power Company</td>
</tr>
<tr>
<td>20010198</td>
<td>The Southern Company</td>
<td>NetCreations, Inc</td>
<td>NetCreations, Inc</td>
</tr>
<tr>
<td>20010228</td>
<td>DoubleClick Inc</td>
<td>JWGenesis Financial Corp</td>
<td>JWGenesis Financial Corp</td>
</tr>
<tr>
<td>20010230</td>
<td>First Union Corporation</td>
<td>Rapid Communications, Partners, L.P</td>
<td>Rapid Communications, Partners, L.P</td>
</tr>
<tr>
<td>20010269</td>
<td>Brian L. Roberts</td>
<td>Z=Tel Technologies, Inc</td>
<td>Z=Tel Technologies, Inc</td>
</tr>
<tr>
<td>20010285</td>
<td>The 1818 Fund III, L.P</td>
<td>ADAC Laboratories, Inc</td>
<td>ADAC health Care Information Systems Inc</td>
</tr>
<tr>
<td>20010294</td>
<td>Cerner Corporation</td>
<td>E'Town Corporation</td>
<td>E'Town Corporation</td>
</tr>
<tr>
<td>20010317</td>
<td>RWE Aktiengellschaft</td>
<td>Panasonic Energy Company</td>
<td>Panasonic Energy Company</td>
</tr>
</tbody>
</table>

**TRANSACTIONS GRANTED EARLY TERMINATION—11/09/2000**

<table>
<thead>
<tr>
<th>Trans No.</th>
<th>Acquiring</th>
<th>Acquired</th>
<th>Entities</th>
</tr>
</thead>
<tbody>
<tr>
<td>20003866</td>
<td>Oak Hill Capital Partners, L.P</td>
<td>TCA Acquisition Corporation</td>
<td>TCA Acquisition Corporation</td>
</tr>
<tr>
<td>20010113</td>
<td>Egide S.A</td>
<td>Industrial Growth Partners, L.P</td>
<td>Industrial Growth Partners, L.P</td>
</tr>
<tr>
<td>20010178</td>
<td>C-MAC Industries Inc</td>
<td>Fred Kavli</td>
<td>Kavilco Corporation</td>
</tr>
<tr>
<td>20010195</td>
<td>GS Capital Partners II Offshore, L.P</td>
<td>PNY Technologies, Inc</td>
<td>PNY Technologies, Inc</td>
</tr>
<tr>
<td>20010196</td>
<td>GS Capital Partners II, L.P</td>
<td>PNY Technologies, Inc</td>
<td>PNY Technologies, Inc</td>
</tr>
<tr>
<td>20010218</td>
<td>Hicks, Muse, Tate &amp; Furst Equity Fund V, L.P</td>
<td>Vetrivex Business Solutions, Inc</td>
<td>Vetrivex Business Solutions, Inc</td>
</tr>
<tr>
<td>20010234</td>
<td>Cinergy</td>
<td>Albert E. Cinelli</td>
<td>Q-Comm Corporation</td>
</tr>
<tr>
<td>20010235</td>
<td>Albert E. Cinelli</td>
<td>Cinergy Corporation</td>
<td>Cinergy Telecommunications Networks Holdings, Inc</td>
</tr>
<tr>
<td>20010237</td>
<td>Bank One Corporation</td>
<td>Linc.net, Inc</td>
<td>Linc.net, Inc</td>
</tr>
<tr>
<td>20010238</td>
<td>Granada Compass, plc</td>
<td>ABP Acquisition Holdings Corporation</td>
<td>ABP Acquisition Holdings Corporation</td>
</tr>
<tr>
<td>20010253</td>
<td>The SKM Equity Fund II, L.P</td>
<td>Lin.net, Inc</td>
<td>Lin.net, Inc</td>
</tr>
<tr>
<td>20010262</td>
<td>Medallion Financial Corp</td>
<td>The Royal Bank of Scotland Group plc</td>
<td>Firestone Financial Canada, Ltd</td>
</tr>
<tr>
<td>20010276</td>
<td>Thomas Shrugmann</td>
<td>Teva Pharmaceutical Industries Limited</td>
<td>Teva Pharmaceutical Industries Limited</td>
</tr>
<tr>
<td>20010277</td>
<td>Eon Labs, Inc</td>
<td>Teva Pharmaceutical Industries Limited</td>
<td>Teva Pharmaceutical Industries Limited</td>
</tr>
<tr>
<td>20010300</td>
<td>C-MAC Industries, Inc</td>
<td>DY 4 Systems Inc</td>
<td>DY 4 Systems Inc</td>
</tr>
<tr>
<td>20010301</td>
<td>Olympus Growth Fund III, L.P</td>
<td>TCA Acquisition Corporation</td>
<td>TCA Acquisition Corporation</td>
</tr>
<tr>
<td>20010313</td>
<td>David Lee</td>
<td>CIDCO Incorporated</td>
<td>CIDCO Incorporated</td>
</tr>
<tr>
<td>20010346</td>
<td>Exelon Corporation</td>
<td>David J. Brule, Sr</td>
<td>NEWCO</td>
</tr>
</tbody>
</table>

**TRANSACTIONS GRANTED EARLY TERMINATION—11/09/2000**

<table>
<thead>
<tr>
<th>Trans No.</th>
<th>Acquiring</th>
<th>Acquired</th>
<th>Entities</th>
</tr>
</thead>
<tbody>
<tr>
<td>20010138</td>
<td>Genzyme Corporation</td>
<td>GelTex Pharmaceuticals, Inc</td>
<td>GelTex Pharmaceuticals, Inc</td>
</tr>
<tr>
<td>20010204</td>
<td>School Speciality, Inc</td>
<td>J. L. Hammett Company</td>
<td>J. L. Hammett Company</td>
</tr>
<tr>
<td>20010241</td>
<td>Huhtamaki Lan Leer Oy</td>
<td>Howard P. Hooper</td>
<td>Packaging Resources Group, Inc</td>
</tr>
<tr>
<td>20010243</td>
<td>V. Prem Watsa</td>
<td>PXRE Group Ltd</td>
<td>Transnational Insurance Company</td>
</tr>
<tr>
<td>20010254</td>
<td>Kinder Morgan Energy Partners, L.P</td>
<td>Gavin J. Parfit</td>
<td>Delta Terminal Services, Inc</td>
</tr>
<tr>
<td>20010260</td>
<td>Melton Financial Corporation</td>
<td>The Chase Manhattan Corporation</td>
<td>ChaseMellon Financial Group, LLC</td>
</tr>
<tr>
<td>20010264</td>
<td>Community Health Systems, Inc</td>
<td>Northeast Regional Medical Center, Inc</td>
<td>Northeast Regional Medical Center, Inc</td>
</tr>
<tr>
<td>20010273</td>
<td>Seminole Transportation and Trading, Inc</td>
<td>Petro Source Investments, Inc</td>
<td>Petro Source Investments, Inc</td>
</tr>
<tr>
<td>20010279</td>
<td>Morgenthaler Partners VI, L.P</td>
<td>Peregrine Semiconductor Corporation</td>
<td>Peregrine Semiconductor Corporation</td>
</tr>
</tbody>
</table>
### TRANSACTIONS GRANTED EARLY TERMINATION—11/14/2000

<table>
<thead>
<tr>
<th>Trans No.</th>
<th>Acquiring Acquired Entities</th>
</tr>
</thead>
<tbody>
<tr>
<td>20010116</td>
<td>Exelon Corporation</td>
</tr>
<tr>
<td>20010199</td>
<td>Bayer AG</td>
</tr>
<tr>
<td>20010274</td>
<td>Toshiba Corporation</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>20010280</td>
<td>Novartis AG</td>
</tr>
<tr>
<td>20010283</td>
<td>Stanley E. Fulton</td>
</tr>
<tr>
<td>20010315</td>
<td>Kenneth R. Thomson</td>
</tr>
<tr>
<td>20010319</td>
<td>Bank of America Corporation.</td>
</tr>
<tr>
<td>20010322</td>
<td>Imison Investments N.V.</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>20010324</td>
<td>Deere &amp; Company</td>
</tr>
<tr>
<td>20010325</td>
<td>West Fraser Timber Co. Ltd.</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>20010327</td>
<td>Robert Alpert</td>
</tr>
<tr>
<td>20010332</td>
<td>Computer Associates Interna-</td>
</tr>
<tr>
<td></td>
<td>tional, Inc.</td>
</tr>
<tr>
<td>20010338</td>
<td>Audax Private Equity Fund,</td>
</tr>
<tr>
<td></td>
<td>L.P.</td>
</tr>
<tr>
<td>20010342</td>
<td>Steven B. Kalafer</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>20010347</td>
<td>Outokumpu Oyj</td>
</tr>
<tr>
<td>20010349</td>
<td>John Robert McCaig and M.</td>
</tr>
<tr>
<td></td>
<td>Ann McCaig.</td>
</tr>
<tr>
<td>20010369</td>
<td>Schlumberger Limited</td>
</tr>
<tr>
<td>20010411</td>
<td>Performance Food Group Company</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### TRANSACTIONS GRANTED EARLY TERMINATION—11/16/2000

<table>
<thead>
<tr>
<th>Trans No.</th>
<th>Acquiring Acquired Entities</th>
</tr>
</thead>
<tbody>
<tr>
<td>20010229</td>
<td>Calpine Corporation</td>
</tr>
<tr>
<td>20010361</td>
<td>SAirGroup AG</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>20010367</td>
<td>Berkshire Hathaway Inc</td>
</tr>
<tr>
<td>20010378</td>
<td>Hewlett-Packard Company</td>
</tr>
<tr>
<td>20010379</td>
<td>John and Patricia MacFarlane.</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### TRANSACTIONS GRANTED EARLY TERMINATION—11/17/2000

<table>
<thead>
<tr>
<th>Trans No.</th>
<th>Acquiring Acquired Entities</th>
</tr>
</thead>
<tbody>
<tr>
<td>20010244</td>
<td>Marc Ladreit de Lacharriere</td>
</tr>
<tr>
<td>20010248</td>
<td>SmithKline Beecham plc</td>
</tr>
<tr>
<td>20010306</td>
<td>CacheFlow, Inc</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### TRANSACTIONS GRANTED EARLY TERMINATION—11/20/2000

<table>
<thead>
<tr>
<th>Trans No.</th>
<th>Acquiring Entities</th>
<th>Acquired Entities</th>
<th>Entities Acquired by Acquiring Entities</th>
</tr>
</thead>
<tbody>
<tr>
<td>20010137</td>
<td>Tyco International Ltd</td>
<td>InnerDyne Inc</td>
<td>InnerDyne Inc</td>
</tr>
<tr>
<td>20010139</td>
<td>Baird Electric Company</td>
<td>Thomas J. McGuire</td>
<td>Pow'R Gard Generator Corporation</td>
</tr>
<tr>
<td>20010138</td>
<td>Illinois Tool Works Inc</td>
<td>David A. Williams</td>
<td>Aervoe Pacific Company, Inc.</td>
</tr>
<tr>
<td>20010371</td>
<td>Protocol Communications, Inc.</td>
<td>CPU, Inc</td>
<td>CPU, Inc</td>
</tr>
<tr>
<td>20010392</td>
<td>College Enterprises, Inc</td>
<td>AT&amp;T Corp</td>
<td>AT&amp;T CampusWide Access Solutions, Inc.</td>
</tr>
<tr>
<td>20010395</td>
<td>Occidental Petroleum Corporation</td>
<td>BP Amoco p.l.c</td>
<td>Amoco Este Pipeline Company; and Bravo pipeline Company, Amoco Pipeline Asset Company.</td>
</tr>
<tr>
<td>20010397</td>
<td>Vectren Corporation</td>
<td>NiSource Inc</td>
<td>NiSource Inc</td>
</tr>
<tr>
<td>20010398</td>
<td>Cinergy Corporation</td>
<td>NiSource Inc</td>
<td>Miller Pipeline Corporation</td>
</tr>
<tr>
<td>20010402</td>
<td>Quanex Corporation</td>
<td>Temroc Metals, Inc</td>
<td>Temroc Metals, Inc.</td>
</tr>
<tr>
<td>20010403</td>
<td>George A. Steiner Trust</td>
<td>Michael C. Carlos</td>
<td>Servitex, Inc.</td>
</tr>
<tr>
<td>20010404</td>
<td>George A. Steiner Trust</td>
<td>Jay M. Davis</td>
<td>Servitex, Inc.</td>
</tr>
<tr>
<td>20010405</td>
<td>Teleogic AB</td>
<td>Continuus Software Corporation</td>
<td>Continuus Software Corporation.</td>
</tr>
<tr>
<td>20010406</td>
<td>NCO, Inc</td>
<td>Credittrust Corporation</td>
<td>Credittrust Corporation</td>
</tr>
<tr>
<td>20010410</td>
<td>Marriott International, Inc</td>
<td>H Group Holding, Inc</td>
<td>Rosemont Purchasing, Inc.</td>
</tr>
<tr>
<td>20010413</td>
<td>Wells Fargo &amp; Co</td>
<td>eFORCE, Inc</td>
<td>eFORCE, Inc.</td>
</tr>
<tr>
<td>20010414</td>
<td>J. Brent &amp; Katherin Wood</td>
<td>Aviation Sales Company</td>
<td>Aviation Sales Company.</td>
</tr>
<tr>
<td>20010419</td>
<td>Bernhard Fritsch</td>
<td>Applied Digital Solutions, Inc.</td>
<td>Applied Digital Solutions, Inc.</td>
</tr>
<tr>
<td>20010420</td>
<td>Applied Digital Solutions, Inc.</td>
<td>Bernhard Fritsch</td>
<td>MCO.com, Inc.</td>
</tr>
<tr>
<td>20010421</td>
<td>Cherokee Investment Partners II, L.P.</td>
<td>Royal Dutch Petroleum</td>
<td>Royal Dutch Petroleum Company.</td>
</tr>
<tr>
<td>20010422</td>
<td>Rail Van, Inc.</td>
<td>Rail Van, Inc</td>
<td>Rail Van LLC.</td>
</tr>
<tr>
<td>Trans No.</td>
<td>Acquiring</td>
<td>Acquired</td>
<td>Entities</td>
</tr>
<tr>
<td>----------</td>
<td>-----------</td>
<td>----------</td>
<td>----------</td>
</tr>
<tr>
<td>20010424</td>
<td>Flextronics International Ltd</td>
<td>Silver Lake Partners, L.P.</td>
<td>SubmitOrder.com, Inc.</td>
</tr>
<tr>
<td>20010425</td>
<td>Sanyo Company Limited ...</td>
<td>Pfizer Inc</td>
<td>Sanyo/Parke Davis.</td>
</tr>
<tr>
<td>20010427</td>
<td>Arrow Electronics, Inc .......</td>
<td>eChips, Inc.</td>
<td>eChips, Inc.</td>
</tr>
<tr>
<td>20010428</td>
<td>The TriZetto Group, Inc .......</td>
<td>Thomas H. Heimsoth</td>
<td>Resource Information Management Systems, Inc.</td>
</tr>
<tr>
<td>20010429</td>
<td>The TriZetto Group, Inc .......</td>
<td>Terry L. Kirch</td>
<td>Resource Information Management Systems, Inc.</td>
</tr>
<tr>
<td>20010434</td>
<td>Avnet, Inc</td>
<td>eChips, Inc</td>
<td>eChips, Inc.</td>
</tr>
<tr>
<td>20010438</td>
<td>International Rectifier Corporation.</td>
<td>Smiths Industries plc</td>
<td>Lambda Advanced Analog Inc.</td>
</tr>
<tr>
<td>20010442</td>
<td>Microchip Technologies, Inc</td>
<td>TelCom Semiconductor, Inc</td>
<td>TelCom Semiconductor, Inc.</td>
</tr>
<tr>
<td>20010449</td>
<td>Henry L. Hillman</td>
<td>Henry L. Hillman</td>
<td>Fluid Power Holdings, LLC.</td>
</tr>
<tr>
<td>20010450</td>
<td>Associated Healthcare Systems, Inc.</td>
<td>A.H. Belo Corporation</td>
<td>CHK, Inc.</td>
</tr>
<tr>
<td>20010453</td>
<td>Berkshire Hathaway Inc</td>
<td>Shaw Industries, Inc</td>
<td>Shaw Industries, Inc.</td>
</tr>
<tr>
<td>20010456</td>
<td>OAO Oil Company Lukoil ....</td>
<td>Getty Petroleum Marketing Inc.</td>
<td>Getty Petroleum Marketing Inc.</td>
</tr>
<tr>
<td>20010459</td>
<td>Seaman Furniture Company, Inc.</td>
<td>Levitz Furniture Incorporated.</td>
<td>Levitz Furniture Incorporated.</td>
</tr>
<tr>
<td>20010460</td>
<td>M.D. Sass Corporate Resurgence Partners, LP.</td>
<td>Levitz Home Furnishings, Inc.</td>
<td>Levitz Home Furnishings, Inc.</td>
</tr>
<tr>
<td>20010461</td>
<td>M.D. Sass Re/Enterprise Partners, LP.</td>
<td>Levitz Home Furnishings, Inc.</td>
<td>Levitz Home Furnishings, Inc.</td>
</tr>
<tr>
<td>20010462</td>
<td>Trust “O” for a portion of the Assets of the Kodak.</td>
<td>Levitz Home Furnishings, Inc.</td>
<td>Levitz Home Furnishings, Inc.</td>
</tr>
<tr>
<td>20010463</td>
<td>M.D. Sass Corporate Resurgence International, Ltd.</td>
<td>Levitz Home Furnishings, Inc.</td>
<td>Levitz Home Furnishings, Inc.</td>
</tr>
<tr>
<td>20010464</td>
<td>M.D. Sass Corporate Resurgence Partners II, LP.</td>
<td>Levitz Home Furnishings, Inc.</td>
<td>Levitz Home Furnishings, Inc.</td>
</tr>
<tr>
<td>20010465</td>
<td>AutoNation, Inc</td>
<td>MoBex Communications, Inc.</td>
<td>Nissan of Brandon, Inc.</td>
</tr>
<tr>
<td>20010466</td>
<td>Nextel Communications, Inc</td>
<td>MoBex License Company.</td>
<td>MoBex License Company.</td>
</tr>
<tr>
<td>20010467</td>
<td>The AES Corporation</td>
<td>Gener S.A</td>
<td>Associated Packaging Enterprises, Inc.</td>
</tr>
<tr>
<td>20010471</td>
<td>Castle Harlan Partners III, LP.</td>
<td>Jon C. Buff</td>
<td>Associated Packaging Enterprises, Inc.</td>
</tr>
<tr>
<td>20010474</td>
<td>Gannett Co, Inc</td>
<td>space.com, Inc</td>
<td>space.com, Inc.</td>
</tr>
<tr>
<td>20010476</td>
<td>Tyco International Ltd</td>
<td>Frank Hsing</td>
<td>FAI Technology (Holding) Inc.</td>
</tr>
<tr>
<td>20010487</td>
<td>AES Corporation</td>
<td>IPALCO Enterprises, Inc</td>
<td>IAPLCO Enterprises, Inc.</td>
</tr>
<tr>
<td>20010491</td>
<td>Intracom S.A. Hellenic Telecommunications &amp; Electronics Ind.</td>
<td>Charles and Mable E. Conklin</td>
<td>Conklin Corporation.</td>
</tr>
<tr>
<td>20010493</td>
<td>Siemens Aktiengesellschaft</td>
<td>Quintus Corporation</td>
<td>Quintus Corporation.</td>
</tr>
<tr>
<td>20010495</td>
<td>SBC Communications Inc ...</td>
<td>SBC Communications Inc</td>
<td>Springwich Cellular Limited Partnership.</td>
</tr>
</tbody>
</table>

**TRANSACTIONS GRANTED EARLY TERMINATION—11/22/2000**

<table>
<thead>
<tr>
<th>Trans No.</th>
<th>Acquiring</th>
<th>Acquired</th>
<th>Entities</th>
</tr>
</thead>
<tbody>
<tr>
<td>20010302</td>
<td>Smiths Industries plc</td>
<td>TI Group plc</td>
<td>TI Group plc.</td>
</tr>
<tr>
<td>20010501</td>
<td>PRIMEO Inc</td>
<td>About.com, Inc</td>
<td>About.com, Inc.</td>
</tr>
<tr>
<td>20010525</td>
<td>Sonera Corporation</td>
<td>Metro One Telecommunications, Inc.</td>
<td>Metro One Telecommunications, Inc.</td>
</tr>
</tbody>
</table>

By Direction of the Commission, Donald S. Clark, Secretary.

[FR Doc. 00–33030 Filed 12–27–00 8:45 am]
BILLING CODE 6750–01–M

FEDERAL TRADE COMMISSION

[File No. 001–0181; Docket No. C–3991]

Computer Sciences Corporation and Mynd Corporation; Analysis To Aid Public Comment

AGENCY: Federal Trade Commission.

ACTION: Proposed Consent Agreement.

SUMMARY: The consent agreement in this matter settles alleged violations of federal law prohibiting unfair or deceptive acts or practices or unfair methods of competition. The attached consent agreement, and the terms of the consent agreement, and the methods of competition. The attached consent agreement and the terms of the consent order—embodied in the consent agreement—that would settle these allegations.

DATES: Comments must be received on or before January 19, 2001.

ADDRESSES: Comments should be directed to: FTC/Office of the Secretary, Room H–159, 600 Pennsylvania Avenue, NW., Washington, DC 20580.


SUPPLEMENTARY INFORMATION: Pursuant to section 6(f) of the Federal Trade Commission Act, 38 Stat. 721, 15 U.S.C. 46, and section 2.34 of the Commission’s Rules of Practice (16 CFR 2.34), notice is hereby given that the above-captioned consent agreement containing a consent order to cease and desist, having been filed with and accepted, subject to final approval, by the Commission, has been placed on the public record for a period of thirty (30) days. The following Analysis to Aid Public Comment describes the terms of the consent agreement, and the allegations in the complaint. An electronic copy of the full text to the consent agreement package can be obtained from the FTC Home Page (for December 20, 2000), on the World Wide Web, at “http://www.ftc.gov/os/2000/12/index.htm.” A paper copy can be obtained from the FTC Public Reference Room, Room H–130, 600 Pennsylvania Avenue, NW., Washington, DC 20580, either in person or by calling (202) 326–3267.

Public comment is invited. Comments should be directed to: FTC/Office of the Secretary, Room H–159 600 Pennsylvania Avenue, NW., Washington, DC 20580. Two paper copies of each comment should be filed, and should be accompanied, if possible, by a 3½ inch diskette containing an electronic copy of the comment. Such comments or views will be considered by the Commission and will be available for inspection and copying at its principal office in accordance with section 4.9(b)(6)(ii) of the Commission’s Rules of Practice (16 CFR 4.9(b)(6)(ii)).

Analysis of the Complaint and Proposed Consent Order To Aid Public Comment

I. Introduction

The Federal Trade Commission (the “Commission”) has accepted, subject to final approval, a proposed Decision and Order (the “Order”) that would require CSC to divest Mynd’s claims assessment systems business to Insurance Services Office, Incorporated ("ISO"). Mynd develops and sells a claims assessment system known as COA, and CSC develops and sells a claims assessment system known as Colossus. The Consent Agreement also includes an Order to Maintain Assets that requires respondents to preserve the assets they are required to divest as a viable, competitive, and ongoing operation until the divestiture is achieved.

The Order, if finally issued by the Commission, would settle charges that CSC’s proposed acquisition of Mynd may have substantially lessened competition in the United States market for claims assessment systems. The Consent Agreement includes an Order to Maintain Assets that requires respondents to preserve the assets they are required to divest as a viable, competitive, and ongoing operation until the divestiture is achieved.

II. Description of the Parties and the Proposed Merger

CSC, headquartered in El Segundo, California, is a large computer-services provider, which also sells vertical software applications in the financial services industries. CSC’s Financial Services Group (“FSG”), headquartered in Austin, Texas, provides consulting and support services along with application software to insurance companies, banking, consumer finance companies, and investment companies.

Mynd, headquartered in Columbia, South Carolina, provides consulting and services and packaged software solutions to the insurance and other financial services industries.

Pursuant to an agreement, CSC will make a $16 per share cash tender offer for outstanding Mynd shares. Mynd will then become a wholly-owned subsidiary of CSC.

III. The Proposed Complaint

According to the Commission’s proposed complaint, the relevant line of commerce in which to analyze the effects of CSC’s proposed acquisition of Mynd is the provision of claims assessment systems, and the relevant geographic market is the United States. Claims assessment systems are computer software and other intellectual property used by insurance companies and others to evaluate appropriate payments for claims for bodily injury or to evaluate return-to-work plans in workers compensation claims. Claims assessment systems are designed to aid claims adjusters by providing a consistent methodology for analyzing information that an adjuster would take into account in assessing the appropriate settlement values for claims. Mynd sells the claims assessment system known as COA, and CSC sells the claims assessment system known as Colossus. The proposed complaint alleges that the market for claims assessment systems in the United States is highly concentrated and that CSC and Mynd are the only significant competitors in the provision of claims assessment systems. The proposed complaint also alleges that entry into the relevant market would not be timely, likely, or sufficient to deter or offset adverse effects of the acquisition on competition. Entry is difficult in this market because the time expense necessary to develop software systems such as these are great. Claims
assessment systems involve the use of expert-system technology, which is a set of computerized methods for exploiting information drawn from relevant knowledge domains through rules or algorithms so as to assist in the solution of realworld problems, such as claims assessment. Entry is difficult in this market because of the time and expense necessary for finding and choosing the appropriate domain information, choosing or developing the appropriate rules or algorithms, and integrating the expert-system technology into a computing platform that is sufficiently robust, scalable, and stable while incorporating a domain-appropriate user interface.

The proposed complaint alleges that CSC's proposed acquisition of Mynd would eliminate actual, direct, and substantial competition between CSC and Mynd. Elimination of this competition would likely result in increased prices for claims assessment systems and reduced innovation as a result of delayed or reduced product development.

IV. Terms of the Agreement Containing Consent Order

The proposed Order is designed to remedy the anticompetitive effects of the acquisition in the United States market for claims assessment systems, as alleged in the complaint, by requiring the divestiture to ISO of Mynd's claims assessment business. The Order would also require respondents to dismiss with prejudice all of CSC's intellectual-property litigation claims against Neuronworks, the original developers of COA, so as to enable Neuronworks to perform COA-related consulting or other work in conjunction with ISO or another acquirer. Further, the Order would require respondents to release, hold harmless, and indemnify ISO or other acquirer from liability for any past, current, or future claims arising out of Mynd's and Neuronworks's acts prior to the divestiture date related to COA. The purpose of these provisions is to allow the acquiring to compete in the market by selling COA free from claims by CSC of intellectual property infringement. The proposed Order would also require respondents to divest other assets related to Mynd's claims assessment systems business, including customer lists, contracts, intellectual property, and other intangible assets so as to put ISO or another acquirer into a position to compete as soon as possible following the divestiture.

ISO, based in New York City, is a leading vendor of statistical, actuarial, and underwriting information for and about the property and casualty insurance industry. ISO uses these statistics to develop advisory prospective loss costs—projections of average future claim payments and loss adjustment expenses, for various lines of insurance and classifications of policy holders. Insurance companies use these loss costs to develop their own independent rates for their insurance policies. ISO also provides aggregate insurance statistics to state regulators.

If the Commission, at the time that it accepts the proposed Order for public comment, notifies respondents that it does not approve of the proposed divestiture to ISO, or the manner of the divestiture, the proposed Order provides that respondents would have three months to divest Mynd's claims assessment business to a different Commission-approved acquirer. If respondents did not complete the divestiture in that period, a trustee would be appointed who, upon Commission approval, would have the authority to divest Mynd's claims assessment business to a Commission-approved acquirer.

The proposed Order to Maintain Assets that is also included in the Consent Agreement requires that respondents preserve the Mynd assets they are required to divest as a viable and competitive operation and conduct the Mynd claims assessment business in the ordinary course of business until those Mynd assets are transferred to the Commission-approved acquirer.

The Consent Agreement requires respondents to provide the Commission with an initial report setting forth in detail the manner in which respondents will comply with the provisions relating to the divestiture of assets. The proposed Order further requires respondents to provide the Commission with a report of compliance with the Order within thirty (30) days following the date the Order becomes final and every thirty (30) days thereafter until they have complied with the terms of the Order.

V. Opportunity for Public Comment

The proposed Order has been placed on the public record for thirty days for receipt of comments by interested persons. Comments received during this period will become part of the public record. After thirty days, the Commission will again review the proposed Order and the comments received and will decide whether it should withdraw from the proposed Order or make it final. By accepting the proposed Order for final approval, the Commission anticipates that the competitive problems alleged in the proposed complaint will be resolved. The purpose of this analysis is to invite public comment on the proposed Order, including the proposed divestiture, to aid the Commission in its determination of whether to make the proposed Order final. This analysis is not intended to constitute an official interpretation of the proposed Order, nor is it intended to modify the terms of the proposed Order in any way.

By direction of the Commission.

Donald S. Clark,
Secretary.

AGENCY: Federal Trade Commission.
ACTION: Proposed Consent Agreement.

SUMMARY: The consent agreement in this matter settles alleged violations of federal law prohibiting unfair or deceptive acts or practices or unfair methods of competition. The attached Analysis to Aid Public Comment describes both the allegations in the draft complaint that accompanies the consent agreement and the terms of the consent order embodied in the consent agreement—that would settle these allegations.

DATES: Comments must be received on or before January 17, 2001.

ADDRESSES: Comments should be directed to: FTC/Office of the Secretary, Room H-159, 600 Pennsylvania Avenue, NW., Washington, DC 20580.

FOR FURTHER INFORMATION CONTACT: Molly S. Boast or Jacqueline K. Mendel, FTC/H-374, 600 Pennsylvania Avenue, NW., Washington, DC 20580, (202) 326-2039 or 326-2603.

SUPPLEMENTARY INFORMATION: Pursuant to section 6(f) of the Federal Trade Commission Act, 38 Stat. 721, 15 U.S.C. 46, and section 2.34 of the Commission's Rules of Practice (16 CFR 2.34), notice is hereby given that the above-captioned consent agreement containing a consent order to cease and desist, having been filed with and accepted, subject to final approval, by the Commission, has been placed on the public record for a period of thirty (30) days. The following Analysis to Aid Public Comment describes the terms of the consent agreement, and the allegations in the complaint. An
electronic copy of the full text of the consent agreement package can be obtained from the FTC Home Page (for December 18, 2000), on the World Wide Web, at “http://www.ftc.gov/os/2000/12/index.htm.” A paper copy can be obtained from the FTC Public Reference Room, Room H–130, 600 Pennsylvania Avenue, NW., Washington, DC 20580, either in person or by calling (202) 326–3627.

Public comment is invited. Comments should be directed to: FTC/Office of the Secretary, Room H–159, 600 Pennsylvania Avenue, NW., Washington, DC 20580. Two paper copies of each comment should be filed, and should be accompanied, if possible, by a 3½ inch diskette containing an electronic copy of the comment. Such comments or views will be considered by the Commission and will be available for inspection and copying at its principal office in accordance with section 4.9(b)(i) of the Commission’s Rules of Practice (16 CFR 4.9(b)(i)).

Analysis of Proposed Consent Order To Aid Public Comment

The Federal Trade Commission (“Commission”) has accepted, subject to final approval, an agreement containing a proposed Consent Order from Glaxo Wellcome plc (“Glaxo”) and SmithKline Beecham plc. (“SB”) which is designed to remedy the anticompetitive effects of the merger of Glaxo and SB. Under the terms of the agreement, the companies would be required to: (1) Divest all of SB’s worldwide rights and intellectual property relating to its antiemetic drug, Kytril, to F. Hoffman-LaRoche; (2) divest SB’s intellectual property rights to manufacture and market ceftazidime to Abbott Laboratories; (3) divest SB’s worldwide rights and intellectual property relating to its antiviral drugs, Famvir and Denavir, including the rights to the base active ingredients, penciclovir and famciclovir, to Novartis Pharm AG and Novartis Pharmaceuticals Corporation; (4) return to Cantab Pharmaceuticals plc all rights to use Cantab’s DISC technology for the development of a prophylactic herpes vaccine; (5) divest Glaxo’s U.S. and Canadian Zantac trademark rights to Pfizer (formerly Warner-Lambert) and thereby remove restrictions on the ability of Pfizer’s Zantac 75 to compete in the over-the-counter (“OTC”) H–2 blocker acid relief market; (6) assign all of SB’s relevant intellectual property rights and relinquish all options to the drug renzapride, a drug to treat irritable bowel syndrome, to Alizyme plc; (7) assign all of SB’s relevant intellectual property rights and relinquish all of Glaxo’s reversionary rights to GI147211C, a topoisomerase I inhibitor to treat certain types of cancer, to Gilead Sciences, Inc.; and (8) assign all of SB’s relevant intellectual property rights and relinquish all options to regain control over frovatriptan, a drug to treat migraine headaches, to Vernalis Ltd.

The proposed Consent Order has been placed on the public record for thirty (30) days for receipt of comments by interested persons. Comments received during this period will become part of the public record. After thirty (30) days, the Commission will again review the agreement and the comments received, and will decide whether it should withdraw from the agreement or make final the agreement’s proposed Consent Order.

Pursuant to a scheme of arrangement announced on January 17, 2000, Glaxo and SB propose to combine their two companies in a transaction valued at approximately $182 billion. Thereafter, the merged entity will be renamed Glaxo SmithKline plc. The proposed Consent Order requires the proposed merger, if consummated, would constitute a violation of Section 7 of the Clayton Act, as amended, 15 U.S.C. 18, and section 5 of the FTC Act, as amended, 15 U.S.C. 45, in the markets for the research, development, manufacture and sale of: (1) 5HT–3 antiemetic drugs; (2) ceftazidime; (3) second generation oral and intravenous antiviral drugs for the treatment of herpes virus infections; (4) prescription topical antiviral cremes for herpes labialis or oral herpes, commonly referred to as cold sores; (5) prophylactic herpes vaccines; (6) OTC H–2 blockers; (7) topoisomerase I inhibitors marketed or in development for the treatment of ovarian, non-small cell lung, colorectal and other solid tumor cancers; (8) drugs for the treatment of irritable bowel syndrome (“IBS”); and (9) triptan drugs for the treatment of migraine headaches. The proposed Consent Order would remedy the alleged violations by replacing the lost competition that would result from the merger in each of these markets.

5HT–3 Antiemetic Drugs

Antiemetic drugs are administered to cancer patients undergoing chemotherapy and radiation therapy to prevent or lessen the nausea and vomiting associated with those medical procedures. 5HT–3 antiemetic products have revolutionized the treatment of patients with cancer because they are more effective than any of the older antiemetic products. Today, oncologists can pursue more aggressive chemotherapy and radiation regimens because patients are much less likely to experience debilitating nausea and vomiting, side effects that can curtail aggressive cancer treatment.

The United States market for 5HT–3 antiemetic drugs is highly concentrated. In the $778 million dollar 5HT–3 antiemetic market, Glaxo markets Zofran and SB markets Kytril, which together represent approximately 90% of the market. Only one other firm, Aventis, markets a 5HT–3 antiemetic product, called Anzemet.

Entry into the manufacture and sale of prescription pharmaceutical drugs is difficult, expensive, and time-consuming. De novo entry for pharmaceutical products has been estimated to take between 12 and 24 years and cost upwards of $359 million. No other pharmaceutical company is expected to enter the United States market with a 5HT–3 antiemetic product in the foreseeable future.

The merger of SB and Glaxo would reduce the number of 5HT–3 antiemetic competitors from three to two; create a dominant firm with a greater than 90%, share of the overall market; and leave Anzemet as the only remaining competitor against the combined Glaxo SmithKline. Currently, health care provider customers benefit enormously by competing Zofran and Kytril against one another to achieve favorable pricing.

The Consent Agreement effectively remedies the anticompetitive effects in the market for 5HT–3 antiemetic drugs by requiring that: (1) SB divest all of its worldwide rights and intellectual property relating to Kytril (granisetron) to F. Hoffman-LaRoche Ltd. (“Roche”); (2) SB submit all confidential information and know-how regarding Kytril to Roche; (3) the former SB sales force and management who participated in the marketing of Kytril maintain the confidentiality of this information; and (4) the former SB sales and marketing personnel be prohibited from selling products that compete with Kytril, i.e., Zofran, for a period of six to twelve months (depending on the status of the employee).

The Consent Agreement also requires SB to contract manufacture Kytril for Roche until Roche obtains approval from the U.S. Food and Drug Administration (“FDA”) to manufacture Kytril for itself.

Second Generation Oral and Intravenous Antiviral Drugs for the Treatment of Herpes

SB manufactures and markets Famvir, and Glaxo manufactures and markets Valtrex, the only two second generation oral and intravenous antiviral prescription drugs for the treatment of
herpes infections. Due to their greater bioavailability, superior efficacy, and requirements for less frequent dosing, Famvir and Valtrex have a significant advantage in treating herpes simplex virus Type 1 ("HSV–1"), herpes simplex virus Type 2 ("HSV–2") and the herpes varicella zoster virus ("herpes zoster") over the first-generation drug acyclovir.

New entry into the manufacture and sale of second generation antiviral drugs for the treatment of HSV–1, HSV–2 and herpes zoster infections is difficult, time-consuming, and expensive. SB and Glaxo are the only firms that have introduced second generation products to the market, and no other companies are developing drugs for these indications. Thus, given the amount of time it would take for a new product to obtain regulatory approval, entry cannot occur in a timely fashion to counter the anticipated anticompetitive effects of the proposed merger.

The proposed merger of SB and Glaxo would eliminate the only competition that exists in the $500 million market for second generation prescription oral and intravenous antiviral drugs for the treatment of HSV–1, HSV–2, and herpes zoster. As a result of the proposed merger, American consumers are likely to pay higher prices for Valtrex and Famvir, and because SB and Glaxo offer the only second generation drugs available to treat HSV–1, HSV–2, and herpes zoster infections, the merger will result in a monopoly for an extended period, as there are no other drugs in research or development for these indications.

The proposed divestiture to Novartis remedies the anticompetitive effects of the merger in both the oral and intravenous antiviral herpes infection treatment market as well as those in the topical oral herpes prescription creme market, which is discussed below. In the oral and intravenous herpes antiviral market, the divestiture resolves the anticompetitive effects of the proposed merger by requiring that: (1) SB divest all of its worldwide rights and intellectual property relating to Famvir, including rights to the base active ingredient famciclovir, to Novartis; (2) SB submit all confidential information and know-how regarding Famvir to Novartis; (3) the former SB sales force and management who participated in the marketing of Famvir maintain the confidentiality of this information; and (4) the former SB sales and marketing personnel be prohibited from selling products that compete with Famvir, i.e., Valtrex for a period of six to twelve months (depending on the status of the employee).

The Consent Agreement also requires SB to contract manufacture Famvir for Novartis until Novartis obtains FDA approval to manufacture Famvir for itself.

**Prescription Topical Antiviral Cremes for Oral Herpes**

SB's Denavir is currently the only prescription topical antiviral medication approved by the FDA for the treatment of oral herpes infections, commonly called cold sores. Meanwhile, Glaxo's Zovirex creme is the dominant prescription cold sore product in much of Europe. Glaxo was in the final stages of seeking FDA approval to market its creme formulation of Zovirex for the treatment of oral cold sores in the United States. But, in April of 2000, after the announcement of its proposed merger with SB, Glaxo withdrew the Zovirex creme application then pending at the FDA, but without prejudice to refiling. At the time, Glaxo was little more than six months from bringing its Zovirex creme to the U.S. market to compete against Denavir.

*De novo* entry into prescription topical antiviral cremes for the treatment of oral herpes is difficult, time-consuming, and expensive. No other companies are currently developing prescription topical medications for the treatment of cold sores.

The proposed merger eliminates the only potential entrant into the market for prescription topical antiviral medications for the treatment of cold sores—the Zovirex creme which Glaxo was close to bringing to market. If SB and Glaxo merge, it is highly unlikely that the merged firm would bring the Zovirex creme to market to compete against Denavir.

As noted above, the proposed divestiture to Novartis remedies the anticompetitive effects of the merger in both the oral and intravenous antiviral herpes infection treatment market as well as those in the prescription topical oral herpes antiviral market. In the prescription topical oral herpes antiviral market, the divestiture resolves the anticompetitive effects of the proposed merger by requiring that: (1) SB divest all of its worldwide rights and intellectual property relating to Denavir, including rights to the base active ingredient penciclovir, to Novartis; (2) SB submit all confidential information and know-how regarding Denavir to Novartis; (3) the former SB sales force and management who participated in the marketing of Denavir maintain the confidentiality of this information; and (4) the former SB sales and marketing of Denavir maintain the confidentiality of this information; and (4) the former SB sales and marketing personnel be prohibited from selling products that compete with Denavir, i.e., topical Zovirex creme, for a period of six to twelve months (depending on the status of the employee).

The Consent Agreement also requires SB to contract manufacture Denavir for Novartis until Novartis obtains FDA approval to manufacture Denavir for itself.

**Ceftazidime**

Ceftazidime is an injectable antibiotic administered to hospitalized patients who are critically ill and at risk of contracting, and possible dying from, pseudomonas infection, a serious hospital-borne infection. Ceftazidime is considered the "gold standard" for treating patients who are either at risk of contracting pseudomonas or who have such infections. Ceftazidime is a third-generation of a class of antibiotics called cephalosporins and is considered a "broad spectrum" antibiotic effective at treating a broad range of hospital-borne infection. Nearly all hospitals in the U.S. have ceftazidime on their formularies for use in combating pseudomonas infections.

Last year, sales of all ceftazidime products were approximately $82 million dollars in the U.S. Currently, only two firms, SB and Glaxo, manufacture ceftazidime. Three firms market ceftazidime products: Glaxo manufactures and markets Fortaz and Ceptaz; Lilly markets Tazidime, which is manufactured by SB; and Abbott Labs markets SB’s Tazicef brand in the U.S. In 1999, sales of Glaxo’s Fortaz and Ceptaz and of SB’s Tazicef amounted to 85% of the market.

There are significant barriers to entry into the manufacture and sale of ceftazidime. The production of ceftazidime requires an aseptic facility for both the manufacture and sterile filling processes, greatly increasing the costs and complexities of manufacturing the product. Building and obtaining FDA approval for this type of facility takes much longer than two years, and patents covering the manufacture of ceftazidime that do not expire for a number of years prevent generic production of ceftazidime at this time.

The proposed merger of Glaxo and SB would create a monopoly in the manufacture of ceftazidime and would reduce the number of firms marketing ceftazidime from three to two. Glaxo SmithKline would not likely continue its relationship with Abbott as a marketer, removing a competing marketer of branded ceftazidime. Lilly, the only other competitor to Glaxo
SmithKline, would be dependent on Glaxo SmithKline for its supply. The presence of three ceftazidime competitors in the market allows customers to negotiate more favorable pricing than would be possible with only two firms. Consequently, after the merger, customers’ ability to negotiate lower prices for ceftazidime would diminish, likely resulting in higher prices.

The Consent Agreement effectively remedies the anticompetitive effects in the market for ceftazidime by requiring: (1) SB to provide all necessary intellectual property rights to manufacture and market ceftazidime to Abbott Laboratories; and (2) the creation of a new stream of supply for ceftazidime to Abbott that is independent of SB. Thereby, the Consent Agreement replaces SB’s manufacturing and marketing rights and capabilities in the United States ceftazidime market.

**Prophylactic Herpes Vaccines**

The evidence shows that the development of prophylactic vaccines to prevent infection by HSV–1 and HSV–2 is a relevant product market. Currently, no vaccines exist for the prevention of HSV–1 and HSV–2 infection, but SB and Glaxo are two of very firms developing prophylactic vaccines to prevent herpes infections. SB is one of the world’s three leading vaccine suppliers, and currently, SB has the most advanced development effort toward a prophylactic herpes vaccine. Glaxo is relatively new in the vaccine area, but has a significant effort underway to develop vaccines against genital herpess. Glaxo has been developing a vaccine for genital HSV infection using the Disabled Infectious Single Cycle (“DISC”) technology developed by Cantab Pharmaceuticals. With Cantab, Glaxo is currently pursuing a therapeutic indication, and had planned to begin work with Cantab designing Phase III clinical trials on a prophylactic indication this year, exercising its option to do so pursuant to its contract with Cantab.

New entry into the research, development, manufacture and sale of vaccines to prevent HSV–1 and HSV–2 infection is extremely difficult, time-consuming, and expensive. Development of vaccines for other diseases have generally taken more than a decade and the time frames for vaccine development tend to be longer than those for prescription drugs. Other firms that have undertaken efforts to develop a prophylactic herpes vaccine either have failed in their efforts or are far behind and Glaxo/Cantab.

The merger is likely to chill innovations in a very complex area as a combined Glaxo SmithKline would potentially forego the development efforts of one of the firms. Even if both products were developed, the merger would eliminate future price competition between the two prophylactic vaccines.

The Consent Agreement effectively remedies the anticompetitive effects in the market for prophylactic vaccines for the prevention of infection by HSV–1 and HSV–2 by requiring Glaxo to return to Cantab all rights and information and results from clinical trials that are necessary for Cantab to develop a prophylactic herpes vaccine. This will permit Cantab to pursue a prophylactic indication for the vaccine developed by the joint venture, and, should that effort be unsuccessful, to develop a different prophylactic herpes vaccine using its DISC technology.

**OTC H–2 Blockers**

Histamine-2 blockers, more commonly known as “H–2 blockers,” are a class of drugs available over-the-counter (“OTC”) for acide relief. H–2 blocker products originated as prescription products and were later approved by the FDA for OTC sale. As their name implies, H–2 blockers work by blocking histamine (acid) production, acting in essence like corks to prevent the release of stomach acid.

Today, the $502 million OTC H–2 blocker market is comprised of four branded products—SB’s Tagamet, Glaxo’s Zantac 75 (marketed by Pfizer, formerly Warner-Lambert), Johnson & Johnson’s Pepcid AC and Whitehall-Robin’s Axid, along with private label equivalents of Tagamet, Zantac 75, and Pepcid AC. SB’s Tagamet and Glaxo’s Zantac 75 have a combined market share of approximately 41%.

Entry into the OTC H–2 blocker acid relief market is time-consuming, difficult, and expensive. New products take several years to develop; each must be approved by the FDA for OTC sale, or alternatively, approved to switch from prescription to OTC status; and furthermore, expensive advertising and promotion is required to establish a brand name in the OTC market. Currently, no additional H–2 blockers are expected to enter the OTC market.

The merger of SB and Glaxo is likely to lessen the competitiveness of Zantac 75 in the OTC market where it is marketed by Pfizer. Currently, the trademark license under which Pfizer sells Zantac 75 requires the approval of Glaxo to make any changes or improvements. Prior to the merger, as licensor to Pfizer, Glaxo had the incentive to approve changes or improvements that would enhance the competitiveness of Zantac 75 in the OTC H–2 blocker market. But after the merger, it is likely that Glaxo SmithKline will be less inclined to approve changes to enhance the competitiveness of Zantac 75, an OTC H–2 rival to its Tagamet. Furthermore, Pfizer would be in the difficult position of having to ask its close rival for permission to make product improvements, thereby exposing its future competitive strategy, which the rival might preemptively counter. Such a situation could prevent or discourage Pfizer from pursuing such competitive product improvements, as Glaxo SmithKline would be provided with direct access to competitive intelligence on a product that competes directly against its own.

The Consent Agreement effectively remedies the anticompetitive effects in the market for OTC H–2 blockers by: (1) Requiring Glaxo to divest all of its U.S. and Canadian trademark rights to Zantac to Pfizer; (2) removing all requirements on Pfizer to seek prior approval from Glaxo for any product line extensions; (3) removing all restrictions on Pfizer’s ability to seek FDA approval of higher OTC dosage strengths for Zantac; (4) reducing the cost to Pfizer if a higher dosage strength is approved by the FDA for the OTC market to a payment not to exceed $3 million; and (5) allowing Pfizer to use any FDA approved form of the base active, ranitidine, in Zantac products. In the United States and Canada, Glaxo only retains the exclusive use of the Zantac name for prescription products that contains ranitidine. This gives Pfizer the unrestricted ability to market the OTC Zantac products, improve those products, and use the Zantac trademarks unfettered, which will allow Pfizer to compete vigorously and effectively in the OTC H–2 blocker market.

**Topoisomerase I Inhibitors for the Treatment of Ovarian, non-SCLC, Colorectal, and Other Solid Tumor Cancers**

zSB’s drug Hycamptin is currently a leading therapy for ovarian and non-small cell lung cancer (“non-SCLC”), and SB is pursuing indications for these cancers as well as a second-line indication for treating colorectal and other solid-tumor cancers. Gilead Sciences, in conjunction with Glaxo, is developing a topoisomerase I inhibitor, G14722C, that is being developed for ovarian, breast, non-SCLC, and other solid-tumor indications, including colorectal cancer. The only other topoisomerase I inhibitor on the market...
is Pharmacia’s Camptosar, which is indicated as a second-line treatment for colorectal cancer, and is being tested for non-SCLC.

The proposed merger is likely to create anticompetitive effects in the topoisomerase I inhibitor market by potentially eliminating one of the few research and development efforts in this area. As a result of the merger, the combined entity could unilaterally delay, terminate or otherwise fail to develop the GI147211C topoisomerase I inhibitor, resulting in less product innovation, fewer choices, and higher prices for consumers.

The Consent Agreement effectively remedies the anticompetitive effects in the market for topoisomerase I inhibitors for the treatment of certain cancers by requiring Glaxo to assign all relevant GI147211C intellectual property to Gilead and to relinquish its reversionary rights to Gilead’s drug. Thus, the Consent Agreement eliminates Glaxo’s ability to regain control over GI147211C, a drug likely to compete against SB’s Hycamptin in combating ovarian, non-SCLC, colorectal, and other solid tumor cancers.

**Drugs for the Treatment of Irritable Bowel Syndrome**

Irritable bowel syndrome (“IBS”) is not well understood and often has been labeled as several different conditions, including irritable colon and spastic colon. People with IBS experience varying symptoms, with some sufferers experiencing symptoms of diarrhea, others constipation, and still others a mix of both. The symptoms of IBS may include cramping, abdominal pain and other forms of abdominal discomfort. Seventy percent of IBS sufferers are women. IBS is estimated to affect up to 15% of the U.S. population.

Glaxo currently owns a drug called Lotronex for the treatment of IBS. Though effective in treating IBS sufferers, Lotronex was recently taken off the market by Glaxo because of concerns about serious side effects in some patients, but Glaxo continues to conduct clinical trials for Lotronex. Lotronex is the only FDA-approved drug for the treatment of IBS. SB currently does not have a drug in this market, but has an option to acquire and market renzapride, a drug being developed by Alizyme Therapeutics plc for the treatment of IBS. Alizyme’s renzapride drug is about 2–3 years from being on the market. In addition to the Alizyme/SB renzapride development effort, only two other IBS drugs are in clinical development; thus, timely entry will not occur to deter or counteract the likely anticompetitive effects of the proposed merger.

The proposed merger likely would eliminate one of the few research and development efforts on drugs to treat IBS. As a result of the merger, Glaxo SmithKline would likely delay, terminate or otherwise fail to develop renzapride which would compete against Lotronex, resulting in less product innovation, and consequently, fewer product choices, and higher prices for consumers.

The Consent Agreement effectively remedies the anticompetitive effects in the market for drugs to treat IBS by requiring SB to assign all relevant intellectual property rights to Alizyme and to relinquish all options in renzapride, thus removing any possible influence over Alizyme’s development of an IBS drug that is likely to compete directly against Glaxo’s Lotronex.

**Triptan Drugs for the Treatment of Migraine Headaches**

Glaxo is the leading seller of triptan drugs for the treatment of migraine headaches with its two triptan migraine drugs—Immitrex (sumatriptan succinate) and Amerge (naratriptan hydrochloride). SB has a reversionary interest in another triptan drug for migraines—SB209509 (frovatriptan)—which is being developed by Vernalis Ltd. The only other approved migraine drugs in the triptan class are Maxalt (rizatriptan benzoate) from Merck and Zomig (zolmitriptan) from Astra Zeneca. Vernalis expects to submit final data to the FDA by the end of 2000, and hopes to launch its frovatriptan drug in the second half of 2001.

In addition to the SB/Vernalis frovatriptan effort, only two other triptan drugs for migraine are in clinical development and are well behind the SB/Vernalis efforts. Thus, timely entry will not occur to deter or counteract the likely anticompetitive effects of the proposed merger.

The proposed merger likely would eliminate one of the few research and development efforts on triptan drugs to treat migraines. As a result of the merger, Glaxo SmithKline would likely delay, terminate or otherwise fail to develop frovatriptan which would compete against Glaxo’s Immitrex and Amerge, resulting in less product innovation, and consequently, fewer product choices and higher prices for consumers.

To resolve the merger’s anticompetitive effects in this market, SB renegotiated its agreement with Vernalis. SB will assign all relevant intellectual property to Vernalis and relinquishing its options in frovatriptan, which likely will compete directly against Glaxo’s Immitrex and Amerge. The Consent Agreement also allows the Commission to appoint a Monitor Trustee to ensure Glaxo SmithKline’s compliance with all of the requirements of the Order. In addition, the Commission may appoint a Divestiture Trustee in the event that Glaxo SmithKline fails to divest all of the assets required to be divested. Finally, the Consent Agreement imposes reporting requirements on Glaxo SmithKline until such time as it has fully complied with all of the provisions of the Order.

The purpose of this analysis is to facilitate public comment on the proposed Consent Order, and it is not intended to constitute an official interpretation of the proposed Consent Order or to modify its terms in any way.

By direction of the Commission.

Donald S. Clark,
Secretary.

[FR Doc. 00–33029 Filed 12–27–00; 8:45 am]

**FEDERAL TRADE COMMISSION**

[File No. 001 0215; Docket No. C–3987]

Philip Morris Companies, Inc., and Nabisco Holdings Corp.; Analysis To Aid Public Comment

**AGENCY:** Federal Trade Commission.

**ACTION:** Proposed consent agreement.

**SUMMARY:** The consent agreement in this matter settles alleged violations of federal law prohibiting unfair or deceptive acts or practices or unfair methods of competition. The attached Analysis To Aid Public Comment describes both the allegations in the draft complaint that accompanies the consent agreement and the terms of the consent order—embodied in the consent agreement—that would settle these allegations.

**DATES:** Comments must be received on or before January 8, 2001.

**ADDRESSES:** Comments should be directed to: FTC/Office of the Secretary, Room H–159, 600 Pennsylvania Avenue, NW., Washington, DC 20580.

**FOR FURTHER INFORMATION CONTACT:** Richard Parker or Joseph Brownman, FTC/H–374, 600 Pennsylvania Avenue, NW., Washington DC 20580.

notice is hereby given that the above-captioned consent agreement containing a consent order to cease and desist, having been filed with and accepted, subject to final approval, by the Commission, has been placed on the public record for a period of thirty (30) days. The following Analysis to Aid Public Comment describes the terms of the consent agreement, and the allegations in the complaint. An electronic copy of the full text of the consent agreement package can be obtained from the FTC Home Page (for December 7, 2000), on the World Wide Web, at “http://www.ftc.gov/os/2000/12/index.htm.” A paper copy can be obtained from the FTC Public Reference Room, Room H-130, 600 Pennsylvania Avenue, NW., Washington, DC 20580, either in person or by calling (202) 326-3627.

Public comment is invited. Comments should be directed to: FTC/Office of the Secretary, Room 159, 600 Pennsylvania Avenue, NW., Washington, DC 20580. Two paper copies of each comment should be filed, and should be accompanied, if possible, by a 3½ inch diskette containing an electronic copy of the comment. Such comments or views will be considered by the Commission and will be available for inspection and copying at its principal office in accordance with Section 4.9(b)(6)(ii) of the Commission’s Rules of Practice (16 CFR 4.9(b)(6)(ii)).

Analysis To Aid Public Comment on the Provisionally Accepted Consent Order

I. Introduction

The Federal Trade Commission (“Commission”) has accepted for public comment from Philip Morris Companies, Inc. (“Philip Morris”) and Nabisco Holdings Corp. (“Nabisco”) an Agreement Containing Consent Orders (“Provisionally Accepted Consent Order”). Philip Morris and Nabisco (“Proposed Respondents”) have also reviewed a Draft Complaint that the Commission contemplates issuing. The Commission and the Proposed Respondents have also agreed to an Order to Maintain Assets that requires the Proposed Respondents to maintain the competitive viability of certain assets pending divestiture. The Proposed Consent Order will remedy the likely anticompetitive effects in five relevant product markets arising from the proposed acquisition by Philip Morris of Nabisco.

II. Parties and Transaction

Proposed Respondent Philip Morris is a Virginia corporation with its headquarters and principal place of business at 120 Park Avenue, New York, New York 10017-5592. In 1999, Philip Morris had total worldwide sales of approximately $79 billion, and total United States sales of approximately $48 billion. Philip Morris, through its Kraft Foods Inc. subsidiary, is the nation’s largest food and beverage company.

Proposed Respondent Nabisco is a Delaware corporation with its headquarters and principal place of business located at 7 Campus Drive, Parsippany, New Jersey 07054-0311. In 1999, Nabisco had total worldwide sales of approximately $8.3 billion, and total United States sales of approximately $5.9 billion. Nabisco is the nation’s seventh largest food and beverage company.

On June 25, 2000, Philip Morris and Nabisco entered into an agreement for Philip Morris to acquire Nabisco. The value of the transaction is approximately $19.4 billion.

III. Proposed Complaint

According to the Draft Complaint that the Commission intends to issue, Philip Morris, through its Kraft Foods subsidiary, and Nabisco compete in the United States to market and distribute (a) dry-mix gelatin, (b) dry-mix pudding, (c) no-bake desserts, (d) baking powder, and (e) intense mints.

The Commission is concerned that the proposed acquisition would eliminate substantial competition between Philip Morris and Nabisco, and increase concentration substantially, in each relevant market, and result in higher prices. The Commission stated it has reason to believe that the proposed acquisition would have anticompetitive effects and violate Section 7 of the Clayton Act and Section 5 of the Federal Trade Commission Act.

IV. Competitive Concerns

A. Dry-Mix Gelatin Market

Total United States sales of all dry-mix gelatin dessert products are about $212 million. In this market, Philip Morris, through its Jell-O brand, is the largest competitor with about an 86% share, and Nabisco, through its Royal and My-T-Fine brands, has about a 9% share. After the acquisition, Philip Morris will control approximately 91% of all dry-mix pudding sales. The proposed acquisition will increase the HHI by more than 1400 points and result in a market concentration of over 8300 points.

B. Dry-Mix Pudding Market

Total United States sales of all dry-mix pudding dessert products are about $202 million. In this market, Philip Morris, through its Jell-O brand, is the largest competitor with about an 82% share, and Nabisco, through its Royal and My-T-Fine brands, has about a 9% share. After the acquisition, Philip Morris will control approximately 91% of all dry-mix pudding sales. The proposed acquisition will increase the HHI by more than 1400 points and result in a market concentration of over 8300 points.

V. The Consent Order

The Proposed Consent Order, if finally issued by the Commission, would settle all of the charges alleged in the Commission’s Draft Complaint. Under the terms of the Proposed Consent Order, Philip Morris and Nabisco will be required to divest the...
Nabisco dry-mix desserts and baking powder businesses to The Jel Sert Company and the intense mints business, together with related Ice Breakers gum and Breath Savers mint businesses, to Hershey Foods Corporation.

Philip Morris and Nabisco will be required to complete the required divestitures within ten (10) business days from the date they consummate their proposed acquisition. In the event Philip Morris and Nabisco do not complete the required divestitures in the time allowed, procedures for the appointment of a trustee to sell the assets have been agreed to and will be triggered. The Proposed Consent Order empowers the trustee to sell such additional ancillary assets as may be necessary to assure the marketability, viability, and competitiveness of the businesses that are required to be divested.

Accompanying the Proposed Consent Order is an Order to Maintain Assets. This order requires Philip Morris and Nabisco to preserve and maintain the competitive viability of all of the assets required to be divested in order to insure that the competitive value of these assets will be maintained after the merger but before the assets are actually divested.

VI. Opportunity for Public Comment

This Proposed Consent Order has been placed on the public record for thirty (30) days for receipt of comments from interested persons. Comments received during this period will become part of the public record. After the thirty (30) days, the Commission will again review the Proposed Consent Order and the comments received, and will decide whether it should withdraw from the agreement or make final the Consent Order in the agreement.

By accepting the Proposed Consent Order subject to final approval, the Commission anticipates that the competitive problems alleged in the Draft Complaint will be resolved. The purpose of this analysis is to invite and facilitate public comment concerning the Proposed Consent Order. It is not intended to constitute an official interpretation of the Proposed Consent Order, nor is it intended to modify the terms of the orders in any way.

By direction of the Commission.

Donald S. Clark,
Secretary.

[FDoc. 00–33197 Filed 12–27–00; 8:45 am]

FEDERAL TRADE COMMISSION

[File No. 001–0197]

The Valspar Corporation; Analysis to Aid Public Comment

AGENCY: Federal Trade Commission.

ACTION: Proposed consent agreement.

SUMMARY: The consent agreement in this matter settles alleged violations of federal law prohibiting unfair or deceptive acts or practices or unfair methods of competition. The attached Analysis to Aid Public Comment describes both the allegations in the draft complaint that accompanies the consent agreement and the terms of the consent order—embodied in the consent agreement—that would settle these allegations.

DATES: Comments must be received on or before January 18, 2001.

ADDRESSES: Comments should be directed to: FTC/Office of the Secretary, Room H–159, 600 Pennsylvania Avenue, NW., Washington, DC 20580.

FOR FURTHER INFORMATION CONTACT: Christina R. Perez, FTC/H–374, 600 Pennsylvania Avenue, NW., Washington, DC 20580. (202) 326–2048.

SUPPLEMENTARY INFORMATION: Pursuant to section 6(f) of the Federal Trade Commission Act, 38 Stat. 721, 15 U.S.C. 46, and section 2.34 of the Commission’s Rules of Practice (16 CFR 2.34), notice is hereby given that the above-captioned consent agreement containing a consent order to cease and desist, having been filed with and accepted, subject to final approval, by the Commission, has been placed on the public record for a period of thirty (30) days. The following Analysis to Aid Public Comment describes the terms of the consent agreement, and the allegations in the complaint. An electronic copy of the full text of the consent agreement package can be obtained from the FTC's Web site at “http://www.ftc.gov/os/2000/12/index.htm.” A paper copy can be obtained from the FTC’s Public Reference Room, Room H–130, 600 Pennsylvania Avenue, NW., Washington, DC 20580, either in person or by calling (202) 326–3627.

Public comment is invited. Comments should be directed to: FTC/Office of the Secretary, Room H–159, 600 Pennsylvania Avenue, NW., Washington, DC 20580. Two paper copies of each comment should be filed, and should be accompanied, if possible, by a 31⁄2 inch diskette containing an electronic copy of the comment. Such comments or views will be considered by the Commission and will be available for inspection and copying at its principal office in accordance with section 4.9(b)(6)(ii) of the Commission’s Rules of Practice (16 CFR 4.9(b)(6)(ii)).

Analysis of Agreement Containing Consent Order To Aid Public Comment

The Federal Trade Commission ("Commission") has accepted, subject to final approval, an Agreement Containing Consent Order ("Consent Agreement") from Valspar Corporation ("Valspar"), which is designed to remedy the anticompetitive effects resulting from Valspar’s acquisition of Lilly Industries, Inc. ("Lilly"). Under the terms of the agreement, within ten days of the date the Consent Agreement is placed on the public record, Valspar will be required to divest its mirror coatings business, which is comprised of silver, tin and copper solutions, mirror backing paint, and any other coating researched, developed, manufactured or sold by Valspar that is used in the production of a mirror, to Spraylat Corporation. Should Valspar fail to do so, the Commission may appoint a trustee to divest the mirror coatings business.

The proposed Consent Agreement has been placed on the public record for thirty (30) days for reception of comments by interested persons. Comments received during this period will become part of the public record. After thirty (30) days, the Commission will again review the proposed Consent Agreement and the comments received, and will decide whether it should withdraw from the proposed Consent Agreement or make final the Decision & Order.


Valspar and Lilly are the two leading suppliers of silver, tin and copper solutions (“mirror solutions”) in the United States and two of three suppliers of mirror backing paint in the United States. Five basic inputs are needed to make a mirror: glass, a tin solution, a silver solution, a copper solution, and mirror backing paint. Most mirrors are made by placing clean pieces of glass flat on a conveyor belt, which moves the glass through the various stations where the solutions and paint are applied to
the back of each piece of glass. The first layer applied to the glass is a tin solution, which is an adhesion promoter so that the silver will bond to the glass. After the tin solution, a silver solution is applied, which creates a metal film on the glass surface, giving the mirror its reflective surface. The third step is to apply a copper solution, which helps keep the silver from oxidizing and creates a surface to which the mirror backing paint will adhere. Finally, the mirror backing paint is applied. This adds a hard coating that protects the solutions from becoming scratched or damaged and further protects the silver solution from corrosion.

Both Lilly and Valspar produce all of the components, other than glass, necessary to make a mirror. The United States mirror solutions and mirror backing paint markets are highly concentrated, and the proposed acquisition would produce a firm controlling over 90% of the mirror solutions markets and over 60% of the mirror backing paint market. Both companies have frequently competed against each other for customers. By eliminating competition between the two most significant competitors in these highly concentrated markets, the proposed acquisition would allow the combined firm to exercise market power unilaterally, thereby increasing the likelihood that purchasers of mirror solutions as well as mirror backing paint would be forced to pay higher prices and that innovation and service levels in these markets would decrease.

Significant impediments to new entry exist in the mirror solutions and mirror backing paint markets. A new entrant into any of these markets would need to undertake the difficult, expensive and time-consuming process of developing a competitive product, establishing reliable U.S. distribution and technical support, and developing a reputation among mirror manufacturers for consistently producing a high-quality product. Because of the difficulty of accomplishing these tasks, new entry into either the mirror solutions markets or the mirror backing paint market could not be accomplished in a timely manner. Additionally, new entry into any one of these markets is made more unlikely because of the limited sales opportunities available to new entrants.

The Consent Agreement effectively remedies the acquisition’s anticompetitive effects in the United States mirror solutions and mirror backing paint markets by requiring Valspar to divest its mirror coatings business. Pursuant to the Consent Agreement, Valspar is required to divest its mirror coatings business to Spraylat Corporation within ten days of the date the Commission places the Order on the public record. Should Valspar fail to do so, the Commission may appoint a trustee to divest the business.

The Commission’s goal in evaluating possible purchasers of divested assets is to maintain the competitive environment that existed prior to the acquisition. A proposed buyer of divested assets must not itself present competitive problems. The Commission is satisfied that Spraylat is a well-qualified acquirer of the divested assets. Based in Mount Vernon, New York, Spraylat is a family owned company that manufactures and sells specialty paints and coatings for industrial uses. Spraylat possesses the necessary industry expertise to replace the competition that existed prior to the proposed acquisition. Furthermore, Spraylat poses no separate competitive issues as the acquirer of the divested assets.

The Consent Agreement includes a number of provisions that are designed to ensure that the transfer of Valspar’s mirror coatings business to the acquirer is successful. The Consent Agreement requires Valspar to provide incentives to certain key employees to accept employment, and remain employed, by the acquirer. Valspar is also prohibited from inducing key customers from terminating their contracts with the acquirer for a period of one year. Finally, Valspar employees involved with its mirror coating business are prohibited from disclosing any confidential information to employees involved with the Lilly business.

In order to ensure that the Commission remains informed about the status of the Valspar mirror coatings business pending divestiture, and about efforts being made to accomplish the divestiture, the Consent Agreement requires Valspar to report to the Commission within 30 days, and every thirty days thereafter until the divestiture is accomplished. In addition, Valspar is required to report to the Commission every 60 days regarding its obligations to provide transitional services and facilities management.

The purpose of this analysis is to facilitate public comment on the Consent Agreement, and it is not intended to constitute an official interpretation of the Consent Agreement or to modify in any way its terms.

By direction of the Commission.

Donald S. Clark,
Secretary.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Office for Civil Rights; Statement of Delegation of Authority

Notice is hereby given that I have delegated to the Director, Office for Civil Rights (OCR), with authority to redelegate, the following authorities vested in the Secretary of Health and Human Services:

1. The authority under section 262 of the Health Insurance Portability and Accountability Act of 1996 (HIPAA), Public Law 104–191, as amended, to the extent that these actions pertain to the Standards for the Privacy of Individually Identifiable Health Information, to:

   A. impose civil monetary penalties, under section 1176 of the Social Security Act, for a covered entity’s failure to comply with certain requirements and standards;

   B. make exception determinations, under section 1178(a)(2)(A) of the Social Security Act, concerning when provisions of State laws that are contrary to the federal standards are not preempted by the federal provisions; and

2. The authority under section 264 of HIPAA, as amended, to administer the regulations, “Standards for the Privacy of Individually Identifiable Health Information,” 45 CFR Part 164, and General Administrative Requirements, 45 CFR Part 160, as these requirements pertain to Part 164, and to make decisions regarding the interpretation, implementation and enforcement of these Standards and General Administrative Requirements.

I hereby affirm and ratify any actions taken by the Director of OCR, or any subordinates, involving the exercise of the authorities delegated herein prior to the effective date of this delegation. This Delegation of Authority is effective concurrent with the effective date of the regulations, 45 CFR Parts 160 through 164.

Donna E. Shalala,
Secretary.

BILLING CODE 4153–01–M
Department of Health and Human Services
Administration for Children and Families

Proposed Information Collection Activity; Comment Request

Proposed Projects:
About: Runaway and Homeless Youth Management Information System (RHYMIS).
OMB No. 0970–0123.
Description: In the Runaway and Homeless Youth Act (42 U.S.C. 5701 et seq.) Congress mandated that the
Department of Health and Human Services (HHS) report regularly on the status of HHS-funded programs serving
runaway and homeless youth in Basic Center programs (BC), Transitional Living programs (TLP) and Street
Outreach programs. Organizations funded under the Runaway and Homeless Youth program are required by statute (42 U.S.C. 5712, 42 U.S.C. 5714–2) to meet several data collection and reporting requirements, including maintaining client statistical records and submitting annual program reports regarding the profile of the youth and families served and the services
provided to them. The RHYMIS data supports these organizations as they carry out a variety of integrated, ongoing
responsibilities and projects, including legislative reporting requirements, planning and public policy
development for runaway and homeless youth programs, accountability monitoring, program management,
research, and evaluation. RHYMIS has been redesigned and streamlined to reduce the collection burden upon
respondents and to capture key information previously not requested.
Respondents: Not-for-profit
institutions.

ANNUAL BURDEN ESTIMATES

<table>
<thead>
<tr>
<th>Instrument</th>
<th>Number of respondents</th>
<th>Number of responses per respondent</th>
<th>Average burden hours per response</th>
<th>Total burden hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>BC/TLP Youth Profile</td>
<td>400</td>
<td>185</td>
<td>.75</td>
<td>55,500</td>
</tr>
<tr>
<td>Street Outreach Report</td>
<td>140</td>
<td>2</td>
<td>.40</td>
<td>112</td>
</tr>
<tr>
<td>BC/TLP Brief Contacts</td>
<td>400</td>
<td>100</td>
<td>.10</td>
<td>4,000</td>
</tr>
<tr>
<td>BC/TLP Turnaways</td>
<td>400</td>
<td>50</td>
<td>.10</td>
<td>2,000</td>
</tr>
<tr>
<td>Date Transfer</td>
<td>400</td>
<td>2</td>
<td>.50</td>
<td>400</td>
</tr>
</tbody>
</table>

Estimated Total Annual Burden Hours: 62,012

In compliance with the requirements of section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995, the Administration for Children
and Families is soliciting public comment on the specific aspects of
the information collection described above. Copies of the proposed
collection of information can be obtained and
comments may be forwarded by writing to the Administration for Children
and Families, Office of Information Services, 370 L’Enfant Promenade, SW.,
Washington, DC 20447, Attn: ACF
Reports Clearance Officer. All requests should be identified by the title of the
information collection.

The Department specifically requests comments on: (a) whether the proposed
collection of information is necessary for the proper performance of the
functions of the agency, including whether the information shall have
practical utility; (b) the accuracy of the agency’s estimate of the burden of the
proposed collection of information; (c) the quality, utility, and clarity of the
information to be collected; and (d) ways to minimize the burden of the
collection of information on respondents, including through the use
of automated collection techniques or other forms of information technology.
Consideration will be given to
comments and suggestions submitted
within 60 days of this publication.

Bob Sargis,
Reports Clearance Officer.
[FR Doc. 00–33038 Filed 12–27–00; 8:45 am]
BILLING CODE 4184–01–M

DEPARTMENT OF HEALTH AND
HUMAN SERVICES

Health Resources and Services
Administration

HRSA AIDS Advisory Committee;
Notice of Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Public Law 92–463), announcement is
made of the following National Advisory body scheduled to meet during the month of February 2001.

Name: HRSA AIDS Advisory Committee (HAAC).
Date and Time: February 8, 2001; 8:30 a.m.—5:00 p.m., February 9, 2001; 8:30 a.m.—1:30 p.m.
Place: Four Points Sheraton Bethesda, 8400 Wisconsin Avenue, Bethesda, Maryland 20814, Telephone: (301) 941–2704.
The meeting is open to the public.
Agenda: Agenda items for the meeting include: implementation update of the Ryan White CARE Act, program
updates, and discussion of HIV prevention and care linkages.
Anyone requiring further information should contact Joan Holloway, HIV/AIDS
Bureau, Parklawn Building, Room 7–13, 5600 Fishers Lane, Rockville, Maryland 20857, telephone (301) 443–5761.
Jane Harrison,
Director, Division of Policy Review and Coordination.
[FR Doc. 00–33088 Filed 12–27–00; 8:45 am]
BILLING CODE 4160–15–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES

National Institutes of Health

Proposed Collection; Comment Request; Case-Control Study of Cancer and Related Disorders Among Benzene-Exposed Workers in China
SUMMARY: In compliance with the requirement of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995, for opportunity for public comment on
proposed data collection projects, the National Cancer Institute (NCI), the
National Institutes of Health (NIH) will publish periodic summaries of proposed
projects to be submitted to the Office of Management and Budget (OMB) for
review and approval.
Proposed Collection: Title: Case-Control Study of Cancer and Related Disorders Among Benzene-Exposed Workers in China. Type of Information
Collection Request: Extension. (OMB No. 0925–0454 expires 3/31/01) Need
and Use of Information Collection: A case-control study will examine the relationship between exposure to benzene and the risk of lymphohematopoietic malignancies and related disorders and lung cancer in Chinese workers. Cases and controls will be selected from participants in a recent cohort study of benzene-exposed workers in China. The data will be used by the NCI to examine risk among workers exposed to low levels of benzene, and to characterize the dose and time-specific relationship between benzene exposure and disease risk. Frequency of Response: One-time study. Affected Public: Individuals or households. Type of Respondents: Workers. The annual reporting burden is as follows: Estimated Number of Respondents: 1,545; Estimated Number of Responses per Respondent: One; Average Burden Hours per Response: 0.75; and Estimated Total Annual Burden Hours Requested: 386.

There are no Capital Costs, Operating Costs, and/or Maintenance Costs to report.

Request for Comments: Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points: (1) Whether the proposed collection or information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) The accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Ways to enhance the quality, utility, and clarity of the information to be collected; and (4) Ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

FOR FURTHER INFORMATION: To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact Dr. Richard Hayes, Project Officer, National Cancer Institute, Executive Plaza South, Room 8114, Rockville, Maryland 20852, telephone: 301/402-0220, or fax: 301/402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

Transcranial Magnetic Stimulation Coil for Specific Non-Invasive Deep Brain Stimulation

The invention is a magnetic stimulator that is placed in contact with the head of a subject to magnetically stimulate the brain. The invention has applications in the treatment of neurophysiological or cardiovascular conditions, and may be of particular utility in the treatment of disorders associated with deep regions of the brain, such as drug addiction and depression. The unique coil shape of the stimulator is designed to target deep brain regions like the nucleus accumbens, which are associated with the biological mechanism underlying drug abuse. Deep regions of the brain are also implicated in depressive disorders, and this coil is likely to offer an improvement in the transcranial magnetic stimulation therapy currently being tested for treatment of depression.

Peroxynitrite Generators, Compositions Comprising Same, and Methods for Treating Biological Disorders Using Same

Challice L. Bonifant, Joseph E. Saavedra and Larry K. Keefer (NCI)

DHHS Reference No. E–175–00/0 filed 02 June 2000
Diazoniumdiolates are a class of compounds which release nitric oxide (NO) under physiological conditions. Nitric oxide performs a number of regulatory functions in vivo such as controlling vascular tone and platelet function, but it can also combine with superoxide ion to produce peroxynitrite ion, as especially reactive species. Peroxynitrite-mediated cellular toxicity may have several therapeutic applications. Because of the relatively low amounts of superoxide ion present in some cells, the peroxynitrite mechanism of diazoniumdiolate toxicity is not uniformly available. In order to generate peroxynitrite ions in tissues or other media lacking adequate levels of superoxide ion, this invention provides a new class of compounds which release NO and superoxide ion simultaneously to generate peroxynitrite ions.

Molecules of this invention can be designed to generate peroxynitrite ion at specific biochemical targets. For one type of targeting, the release of NO is designed to be triggered by nucleophilic attack on the diazoniumdiolate drug while superoxide generation is simultaneously occurring at a quinone moiety elsewhere in the molecule. If the required nucleophilic attack is designed to be specifically catalyzed in the active site of glutathione S-transferase-pi, a cytoprotective enzyme overexpressed by certain tumors to render them drug-resistant, compounds of this invention could restore the susceptibility of tumor cells to chemotherapy by knocking out the excess enzyme, thereby preventing the tumor cells from inactivating the chemotherapeutic agents. Attachment of the compounds to polymeric compositions would physically localize the peroxynitrite activity. Physical localization in vivo may have utility against the recently recognized chronic infections caused by biofilms, and generation of peroxynitrite ions in vitro may have utility against infectious biofilms on medical devices.


Jack Spiegel,
Director, Division of Technology, Development and Transfer, Office of Technology Transfer, National Institutes of Health.

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2); notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel Program Project Reviews.
Date: January 12, 2001.
Time: 8 AM to 2 PM.
Agenda: To review and evaluate grant applications.
Place: Sheraton Columbia Hotel, 10207 Wincopin Circle, Columbia, MD 21044.
Contact Person: Jeffrey H. Hurst, PhD, Health Scientist Administrator, 6701 Rockledge Drive, Room 7208, Bethesda, MD 20892, 301-435-0303.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 33.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)

LaVerne Y. Stringfield,
Director, Office of Federal Advisory Committee Policy.

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Neurological Disorders and Stroke; Notice of Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Board of Scientific Counselors, National Institute of Neurological Disorders and Stroke.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public as indicated below in accordance with the provisions set forth in section 552b(c)(6), Title 5 U.S.C., as amended for the review, discussion, and evaluation of individual intramural programs and projects conducted by the National Institute of Neurological Disorders and Stroke, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Board of Scientific Counselors, National Institute of Neurological Disorders and Stroke
Date: February 4–6, 2001.
Closed: February 4, 2001, 7:00 PM to 10:00 PM.
Agenda: To review and evaluate personal qualifications and performance, and competence of individual investigators.
Place: Bethesda Marriott Hotel, 5151 Pooks Hill Road, Bethesda, MD 20814.
Open: February 5, 2001, 8:15 AM to 11:10 AM.
Agenda: To discuss program planning and project accomplishments.
Place: National Institutes of Health, Natcher Building, Conference Room F-½, Bethesda, MD 20892.
Closed: February 5, 2001, 11:10 AM to 1:15 PM.
Agenda: To review and evaluate personal qualifications and performance, and competence of individual investigators.
Place: National Institutes of Health, Natcher Building, Conference Room F-½, Bethesda, MD 20892.
Open: February 5, 2001, 1:15 PM to 4:15 PM.
Agenda: To discuss program planning and program accomplishments.
Place: National Institutes of Health, Natcher Building, Conference Room F-½, Bethesda, MD 20892.
Closed: February 5, 2001, 4:15 PM to 5:15 PM.
Agenda: To review and evaluate personal qualifications and performance, and competence of individual investigators.
Place: National Institutes of Health, Natcher Building, Conference Room F-½, Bethesda, MD 20892.
Closed: February 5, 2001, 6:00 PM to 10:00 PM.

BILLING CODE 4140–01–M

Licensing Contact: Norbert Pontzer; 301/496–7735, ext. 284; e-mail: pontzern@od.nih.gov
DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.


Date: January 29, 2001.

Time: 8 AM to 4 PM.

Agenda: To review and evaluate contract proposals.

Place: Doubletree Hotel, 1750 Rockville Pike, Rockville, MD 20852.

Contact Person: John S. Young, PhD, Scientific Review Administrator, Review Branch, DEA, NIDDK, Room 503, 550 G Street, N.W., Surgeon General Building 36, Room 5A05, Bethesda, MD 20892, (301) 480-7797.

(Catalogue of Federal Domestic Assistance Program Nos. 93.147, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS)


LaVerne Y. Stringfield, Director, Office of Federal Advisory Committee Policy.

[FR Doc. 00-33083 Filed 12-27-00; 8:45 am]
BILLING CODE 4140-01-M

DEPARTMENT OF THE INTERIOR

Geological Survey

Technology Transfer Act of 1986


ACTION: Notice of proposed Cooperative Research and Development Agreement (CRADA) negotiations.

SUMMARY: The United States Geological Survey (USGS) is contemplating entering into a Cooperative Research and Development Agreement (CRADA) with Montgomery Watson Laboratories (“MWL”), a division of Montgomery Watson Americas, a Colorado Company, which has its principal place of business at 533 E. Walnut, Pasadena, CA 91101; Hach Company (“Hach”), a Colorado Company, which has its principal place of business at P.O. Box 389, Loveland, Colorado 80539–0389; Office of Water (“OW”), Office of Groundwater and Drinking Water, Technical Support Center (“TSC”), of the U.S. Environmental Protection Agency (“EPA”); Regions 2’s Division of Environmental Science and Assessment (“DESA”), of the U.S. Environmental Protection Agency (“EPA”); Region 3’s Environmental Science Center, of the U.S. Environmental Protection Agency (“EPA”); Unified Sewerage Agency (“USA”), a XXX of the State of Oregon, located at 155 N. First Avenue, Suite 270, Hillsboro, OR 97124, Hampton Roads Sanitation District (“HRSD”), a XXX of the State of Virginia, located at 1432 Air Rail Avenue, Virginia Beach, Virginia 23471; Oregon Department of Environmental Quality (“OREDEQ”) Laboratory Division, a Department of the State of Oregon, located at 1712 SW 11th Avenue, Portland, OR 97201; Demonstrate the validity of the Performance Based System (PBMS) by establishing a pilot study to verify a non-USEPA approved method for the measurement of Chemical Oxygen Demand (COD). The currently approved method for COD requires mercury, a
hazardous and potentially carcinogenic metal, which results in high disposal and recycling costs and potentially hazardous exposure to analysts. The new method is potentially advantageous because hazardous or carcinogenic reagents are not used, making this procedure a more environmentally sound practice. This new analytical method, as with all other methods, is only approved after validation. This CRADA deals with an approach to validate new analytical methodology.

**ADDRESSES:** Inquiries may be addressed to the National Water Quality Laboratory, U.S. Geological Survey, P.O. Box 25046, Denver Federal Center, Building 95, MS 407, Denver, CO 80225–0046; Telephone (303) 236–3501, facsimile (303) 236–0499; Internet mshockey@usgs.gov.

**FOR FURTHER INFORMATION CONTACT:** Merle W. Shockey, address above.

**SUPPLEMENTARY INFORMATION:** This notice is to meet the USGS requirement stipulated in Survey Manual 8341.2. The vehicle closure is required to validate new analytical methodology.

**DEPARTMENT OF THE INTERIOR**

Bureau of Land Management

**[ID–075–2822 JL F604]**

Notice of Emergency Closure

**AGENCY:** Bureau of Land Management, Interior.

**ACTION:** Notice of emergency closure.

**SUMMARY:** Notice is hereby given that effective immediately, certain public lands in Oneida County, Idaho shall be closed to all vehicle traffic to prevent erosion and allow vegetation to recover from the Taylor Mountain wildfire. The restriction will remain in effect until March 1, 2003.

The fire burned approximately 8,197 acres of public land within portions of each of the following sections: From Boise Meridian; T. 16S., R. 33E., sections: 2, 3, 4, 5, 6, 8, 9, 10, 11, 12, 14, 15 and T. 15S., R. 33E., sections: 15, 22, 25, 26, 27, 28, 32, 33, 34, 35.

**SUPPLEMENTARY INFORMATION:** The closure is in conformance with principles established by the Federal Land Policy and Management Act of 1976 and in accordance with 43 CFR 8341.2. The vehicle closure is required to prevent environmental damage by motorized vehicles to soils, vegetation, wildlife values, and associated resources. This closure does not apply to Bureau of Land Management personnel, or an authorized representative of the Bureau of Land Management, or Idaho Department of Fish & Game personnel.

**FOR FURTHER INFORMATION CONTACT:** Jeff Steele, Field Office Manager, Pocatello Field Office, Bureau of Land Management—1111 N 8th Ave, Pocatello, ID (208)–478–6340. Maps of the closed areas are available in the Pocatello Field office and the Malad Field Station—138 So. Main St., Malad City, ID (208)–766–4866.


Jeff S. Steele, Pocatello Field Office Manager.

[FR Doc. 00–33034 Filed 12–27–00; 8:45 am]

**BILLING CODE 4310–GG–P**

**DEPARTMENT OF THE INTERIOR**

Bureau of Land Management

**[ID–075–2822 JL F604]**

Notice of Closure to Livestock Grazing Use and Notice of Intent To Impound

**AGENCY:** Bureau of Land Management, Interior.

**ACTION:** Notice of closure to livestock grazing use and notice of intent to impound.

**SUMMARY:** Effective immediately, the entire East Holbrook allotment, #06361, is closed to livestock grazing, as well as the burned portions of the following areas: Hansel Mountain allotment, #06365, referred to as the Hansel Mountain pasture; Ridgedale allotment, #06360; and Grandine pasture of the Curlew allotment, #16001. This closure will remain in effect until March 1, 2003; or until such time as the authorized officer of the Bureau of Land Management (BLM) Pocatello Field Office determines the closure may be lifted.

This closure is a direct result of a wildland fire which burned this area in September of 2000 and of the subsequent rehabilitation efforts of the BLM. The closure will promote the reestablishment of vegetation on this site and improve the potential for recovery of wildlife and livestock forage.

This notice is also to inform the public/permittees that any unauthorized livestock grazing upon public land or other lands under the BLM’s control is in violation of 4140.1(b)(1) and may be impounded. The unauthorized livestock may be impounded after 5 days from delivery of this notice or any time after 5 days from publishing and posting this notice. Unauthorized livestock within the entire East Holbrook allotment, #06361 as well as those portions of the other allotments listed above may be impounded without further notice any time in the 12 month period beginning 5 days from receipt of this notice as authorized by 43 CFR 4150.4–2. This notice is issued in accordance with 43 CFR 4150.4–1(a) and (b); any impoundment of unauthorized livestock in connection with this notice will be done in accordance with 43 CFR 4150.4–2. Pursuant to 43 CFR 4150.4–4, any owner or his agent, or both, or lien-holder of record of the impounded livestock may redeem them under these regulations or, if a suitable agreement is in effect, in accordance with State law, prior to the time of sale upon settlement with the United States under Sec. 4150.3 or adequate showing that there has been no violation.

**SUPPLEMENTARY INFORMATION:** The area of closure and impoundment affected by this notice is specifically the following allotments within the Upper Snake River Districts: East Holbrook, Hansel Mountain, Ridgedale, and Curlew, and is more specifically described wholly or partially: From Boise Meridian, T. 15 S., R. 33 E., secs. 1, 2, 10, 11, 15, 22, 23, 27, 32, 33, 34; and T. 16 S., R. 33 E., secs. 2, 3, 4, 5, 6, 9, 10, 14, and 15. Detailed maps of the area closed to livestock grazing are available at the Malad Field Station, Malad, Idaho.

**FOR FURTHER INFORMATION CONTACT:** The BLM Malad Field Station, 138 S. Main, Malad, ID 83252 or the BLM Pocatello Field Office, 1111 N. 8th Avenue, Pocatello, ID 83201.


Jeff S. Steele, Pocatello Field Manager.

[FR Doc. 00–33035 Filed 12–27–00; 8:45 am]

**BILLING CODE 4310–GG–P**

**DEPARTMENT OF THE INTERIOR**

Bureau of Land Management

**[NV–058–01–1610–DG]**

Red Rock Canyon National Conservation Area, Las Vegas, NV

**AGENCY:** Bureau of Land Management; Interior

**ACTION:** Notice of availability.

**SUMMARY:** Pursuant to Public Law 103–621 (11/2/94) which expanded the boundaries of RRCNCA as designated in the Red Rock Canyon National Conservation Establishment Act (Public
Law 101-421 11/16/90) and amends portions of the Act, the Las Vegas Field Office, BLM, has completed the Proposed General Management Plan/ Final Environmental Impact Statement (GMP/FEIS) for Red Rock Canyon National Conservation Area.

The Proposed Plan and FEIS is available to the public for a 30-day protest period. The Proposed Plan may be protested by any person who participated in the planning process and who has an interest which is or may be adversely affected by the approval of the Proposed Plan. A protest may raise only those issues which were submitted for the record during the planning process (see 43 CFR 1610.5-2).

All protests must be written and must be postmarked on or before February 28, 2001 and shall contain the following information:

The name, mailing address, telephone number and interest of the person filing the protest.

A statement of the issue or issues being protested.

A statement of the part or parts of the part or parts of the document being protested.

A copy of all documents addressing the issue or issues previously submitted during the planning process by the protesting party, or an indication of the date the issue or issues were discussed for the record.

A concise statement explaining precisely why the Bureau of Land Management, Nevada State Director’s decision is wrong.

Upon resolution of any protests, an Approved Plan and record of Decision will be issued. The approved Plan/Record of Decision will be mailed to all those issues which were submitted for the record during the planning process.

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[OR-020-1020-PG; G 01-0060]

Southeast Oregon Resource Advisory Council Meeting

AGENCY: Bureau of Land Management (BLM), Burns District, Interior.

ACTION: Meeting notice for the Southeast Oregon Resource Advisory Council.

SUMMARY: The Southeast Oregon Resource Advisory Council (SEORAC) will meet at the Shilo Inn, Klamath Falls Suites Hotel and Conference Center, 2500 Almond Street, Klamath Falls, Oregon 97601, 8 a.m. to 5 p.m., Pacific Standard Time (PST), on Monday, January 22, and conduct a field tour to view baid eagles, Tuesday, January 23, 2001. The tour will begin early Tuesday morning and should last approximately 2 hours. Contact the BLM office listed below for exact time as the tour date approaches.

The meeting will resume after the tour and should adjourn by 2 p.m., PST, Tuesday, January 23, 2001. Topics to be discussed by the Council include the Forest Service (FS) Roads Restoration Program, the FS Roadless Final Environmental Impact Statement, BLM off-highway vehicle strategy update, a report from the Lakeview Resource Management Plan subcommittee, update on the Malheur Landscape Area Management Plan, a presentation on minerals in the southeast Oregon area, Klamath Falls water issues update, Pelican Butte ski area update, Federal officials’ update, reports on FS/BLM fire program expansion, County payment program, and such other matters as may reasonably come before the Council.

The entire meeting is open to the public. Information to be distributed to the Council members is requested in written format 10 days prior to the start of the Council meeting. Public comments is scheduled for 11 a.m. to 11:30 a.m., PST, on January 22, 2001.

FOR FURTHER INFORMATION CONTACT:

Gene Arnesen, GMP Team Leader, at BLM’s Las Vegas Field Office listed above or telephone (702) 647-5068.


Mark T. Morse,
Las Vegas Field Office Manager.
[FR Doc. 00-33244 Filed 12-27-00; 8:45 am]

BILLING CODE 4310-HC-M

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[CO-930-1430-ET; COC-28257]

Public Land Order No. 7476; Revocation of Bureau of Land Management Order dated December 22, 1949; Colorado

AGENCY: Bureau of Land Management, Interior.

ACTION: Public land order.

SUMMARY: This order revokes, in its entirety, a Bureau of Land Management order as to the remaining 328.13 acres of public lands withdrawn for the Bureau of Reclamation’s Missouri Basin Project, Bijou No. 2 Reservoir. The lands are no longer needed for reclamation purposes.


FOR FURTHER INFORMATION CONTACT:

Doris Chelius, BLM Colorado State Office, 2850 Youngfield Street, Lakewood, Colorado 80215-7093, 303-239-3706.

By virtue of the authority vested in the Secretary of the Interior by Section 204 of the Federal Land Policy and Management Act of 1976, 43 U.S.C. 1714 (1994), it is ordered as follows:

1. The Bureau of Land Management Order dated December 22, 1949, which withdrew the following described lands for the Bureau of Reclamation’s Missouri Basin Project, Bijou No. 2 Reservoir, is hereby revoked in its entirety:

Sixth Principal Meridian

T. 4 N., R. 59 W.,
Sec. 6, lot 4; Sec. 21, SE1/4; Sec. 22, SW1/4; Sec. 27, NW1/4; E1/2SW1/4, and W1/2SE1/4.

The areas described aggregate 328.13 acres in Morgan County.

2. At 9 a.m. on January 29, 2001, the lands will be opened to the operation of the public land laws generally, subject to valid existing rights, the provisions of existing withdrawals, other segregations of record, and the requirements of applicable law. All valid applications received at or prior to 9 a.m. on January 29, 2001, shall be considered as...
3. At 9 a.m. on January 29, 2001, the lands will be opened to location and entry under the United States mining laws subject to valid existing rights, the provisions of existing withdrawals, other segregations of record, and the requirements of applicable law. Appropriation of any of the lands described in this order under the general mining laws prior to the date and time of restoration is unauthorized.

Any such attempted appropriation, including attempted adverse possession under 30 U.S.C. 38 (1994), shall vest no rights against the United States. Acts required to establish a location and to initiate a right of possession are governed by State law where not in conflict with Federal law. The Bureau of Land Management will not intervene in disputes between rival locators over possessory rights since Congress has provided for such determination in local courts.


Sylvia V. Baca,
Assistant Secretary of the Interior.

[FR Doc. 00–33245 Filed 12–27–00; 8:45 am]
BILLING CODE 4310–J8–P

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[OR–955–1430–ET; HAG01–0025; WA–19679]

Public Land Order No. 7475; Partial Revocation of the Geological Survey; Order Dated July 25, 1952; Washington

AGENCY: Bureau of Land Management, Interior.

ACTION: Public land order.

SUMMARY: This order partially revokes a Geological Survey order insofar as it affects 1,159.54 acres of lands withdrawn for Bureau of Land Management Power Site Classification No. 426. The lands are no longer needed for the purpose for which they were withdrawn. This action will open 56.22 acres to surface entry. These lands have been and will remain open to mining and mineral leasing. The remaining 1,103.32 acres of lands are included in overlapping withdrawals or have been conveyed out of Federal ownership, and will remain closed to surface entry and mining.


By virtue of the authority vested in the Secretary of the Interior by Section 204 of the Federal Land Policy and Management Act of 1976, 43 U.S.C. 1714 (1994), it is ordered as follows:

1. The Geological Survey Order dated July 25, 1952, which established Power Site Classification No. 426, is hereby revoked insofar as it affects the following described lands:

**Willamette Meridian**

T. 3 N., R. 18 E., Sec. 22, NW1/4NE1/4 and SE1/4NE1/4.

T. 4 N., R. 22 E., Sec. 23, SE1/4SW1/4; Sec. 24, NE1/4NW1/4; Sec. 28, SE1/4NE1/4, NE1/4SW1/4, and NW1/4SE1/4.

T. 4 N., R. 23 E., Sec. 12, SE1/4NE1/4; Sec. 18, SE1/4NE1/4 and NE1/4SW1/4.

T. 5 N., R. 24 E., Sec. 32, SW1/4NE1/4SW1/4 and S1/2N1/2SE1/4; sec. 34, S1/2S1/2SW1/4SW1/4; Sec. 35, S1/2SW1/4; Sec. 36, S1/2NE1/4, SE1/4NW1/4, and S1/2.

T. 5 N., R. 25 E., Sec. 12, lot 2; Sec. 13, lot 5; Sec. 14, lots 3, 4, 6, 7, 8, and 9; Sec. 22, lot 9.

T. 5 N., R. 26 E., Sec. 12, W1/2SW1/4SE1/4NW1/4, SE1/4SW1/4SE1/4NW1/4, W1/2SW1/4NE1/4SE1/4, SE1/4SW1/4NE1/4SE1/4, and SW1/4SE1/4NE1/4SE1/4.

The areas described aggregate 1,159.54 acres in Benton and Wallowa Counties.

2. At 8:30 a.m., on January 12, 2001, the following described lands, which are included in paragraph 1, will be opened to the operation of the public land laws generally, subject to valid and existing rights, other segregations of record, and the requirements of applicable law.

**Willamette Meridian**

T. 4 N., R. 23 E., Sec. 12, NW1/4NW1/4 SE1/4NE1/4; Sec. 18, N1/2SE1/4NE1/4 and N1/2SW1/4SE1/4.

T. 5 N., R. 25 E., Sec. 14, lots 6 and 8.

The areas described aggregate 56.22 acres in Benton and Klickitat Counties.

3. The lands described in paragraph 1, excluding those described in paragraph 2, are within the John Day Lock and Dam Project, the Umatilla National Wildlife Refuge, or have been conveyed out of Federal ownership, and will remain closed to surface entry and mining.


Sylvia V. Baca,
Assistant Secretary of the Interior.

[FR Doc. 00–33246 Filed 12–27–00; 8:45 am]
BILLING CODE 4310–33–P

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[NV–056–1430–ES; N–41566–38]

Notice of Realty Action: Correction

AGENCY: Bureau of Land Management, Interior.

ACTION: Correction to Notice of Realty Action.

SUMMARY: On December 6, 2000, a Notice of Realty Action (NORA) was published in the Federal Register for the title transfer of Recreation & Public Purposes Patent #827–96–0002. The NORA incorrectly cited the authority for the transfer as the Federal Land Policy and Management Act. The authority for this transfer is the Recreation & Public Purposes Act.

Dated: December 14, 2000

Rex Wells,
Assistant Field Manager, Las Vegas, NV.

[FR Doc. 00–33037 Filed 12–27–00; 8:45 am]
BILLING CODE 4510–HC–P

DEPARTMENT OF THE INTERIOR

National Park Service

National Capital Memorial Commission; Notice of Public Meeting

Notice is hereby given in accordance with the Federal Advisory Committee Act that a meeting of the National Capital Memorial Commission (the Commission) will be held at 1 p.m. on Tuesday, January 16, at the National Building Museum, Room 312, 5th and F Streets, NW., Washington, DC.

The purpose of the meeting will be to discuss currently authorized and proposed memorials in the District of Columbia and environs. In addition to discussing general matters and routine business, the Commission will consider:

Action Item

Consideration of a recommendation relative to placement, within Area I as established by the Commemorative Works Act of 1986, of the Memorial of Honor Veterans Who Become Disabled While Serving in the Armed Forces of the United States of America.

The Commission was established by Public Law 99–652, the Commemorative...
Works Act, to advise the Secretary and the Administrator, General Services Administration, (the Administrator) on policy and procedures for establishment of (and proposals to establish) commemorative works in the District of Columbia and its environs, as well as such other matters as it may deem appropriate concerning commemorative works.

The Commission examines each memorial proposal for conformance to the Commemorative Works Act, and makes recommendations to the Secretary and the Administrator and to Members and Committees of Congress. The Commission also serves as a source of information for persons seeking to establish memorials in Washington, DC, and its environs.

The members of the Commission are as follows: Director, National Park Service; Chairman, National Capital Planning Commission; Architect of the Capitol; Chairman, American Battle Monuments Commission; Chairman, Commission of Fine Arts; Mayor of the District of Columbia; Administrator, General Services Administration; and Secretary of Defense.

The meeting will be open to the public. Any person may file with the Commission a written statement concerning the matters to be discussed. Persons who wish to file a written statement or testify at the meeting or who want further information concerning the meeting may contact Ms. Nancy Young, Executive Secretary to the Commission, at (202) 619–7097.


Joseph M. Lawler,
Regional Director, National Capital Region.

DEPARTMENT OF JUSTICE

Notice of Lodging of Consent Decree Pursuant to the Comprehensive Environmental Response, Compensation, and Liability Act

Notice is hereby given that a proposed Consent Decree in United States v. American Home Products, Corp., et al., Civil Action No. C00–4173MWB, was lodged on December 8, 2000, with the United States District Court for the Northern District of Iowa.

In this action the United States sought to recover, pursuant to Section 107 of the Comprehensive Environmental Response, Compensation, and Liability Act (“CERCLA”), 42 U.S.C. 9607, response costs incurred and to be incurred by the U.S. Environmental Protection Agency (“EPA”) in response to the release of hazardous substances into the environment at or from the InterChem Superfund Site (hereinafter “the Site”) located in Alton, Iowa.

The proposed Consent Decree embodies an agreement with four potentially responsible parties (“PRPs”) pursuant to Section 107 of CERCLA, 42 U.S.C. 9607, to pay $212,400 in past response costs for EPA’s unreimbursed oversight costs. The PRPs, American Home Products, Corp., American Cyanamid Company, Solvay America, Inc., and Salsbury Chemicals, Inc., are successors to Salsbury Laboratories, Inc. (“SLI”). SLI had sent raw pesticide ingredients including malathion, which is a hazardous substance, to the Site for formulation, which was then returned to SLI as finished pesticide products. A removal action at the Site to remove hazardous substances, including malathion, was undertaken by other PRPs with EPA oversight and was completed in 1996. The defendants are paying $212,400 which is proportionate to the costs incurred by the other PRPs who undertook the prior removal. This payment leaves EPA’s outstanding unreimbursed response costs at less than $25,000, at a Site where the total response action expenditures, including expenditures by PRPs, were over $1.5 million.

The Department of Justice will receive, for a period of thirty (30) days from the date of this publication, comments relating to the proposed Consent Decree. Comments should be addressed to the Assistant Attorney General for the Environmental and Natural Resources Division, Department of Justice, P.O. Box 7611, Washington, DC 20044–7611, and should refer to United States v. American Home Products, Corp., et al., DOJ Ref. No. 90–11–3–06738.

The proposed Consent Decree may be examined at the Office of the United States Attorney, Northern District of Iowa, Hach Building, Suite 400, 401 1st Street, SE., Cedar Rapids, Iowa 52401, and the Region VII Office of the Environmental Protection Agency, Region VII Records Center, 901 N. 5th St., Kansas City, KS 66101. A copy of the proposed Consent Decree may be obtained by mail from the Consent Library, U.S. Department of Justice, Environmental Enforcement Section, Post Office Box 7611, Washington, DC 20044. In requesting a copy, please refer to the referenced case and enclose a check in the amount of $5.50 (25 cents per page reproduction costs), payable to the Consent Decree Library.

Bruce Gelber,
Chief, Environmental Enforcement Section
Environment and Natural Resources Division.

DEPARTMENT OF JUSTICE

Notice of Consent Judgment Pursuant to the Comprehensive Environmental Response, Compensation and Liability Act

In accordance with Departmental Policy, 28 CFR 50.7, 38 Fed. Reg. 19029, and 42 U.S.C. 9622(d), notice is hereby given that two proposed consent decrees in United States v. Champion Chemical Company, Inc., Imperial Oil Company, Inc., Emil Stevens and June Stevens, DOJ # 90–11–2–946, Civ. No. 96–1521 (AET), were lodged in the United States District Court for the District of New Jersey on December 7, 2000. The consent decrees resolve or partially resolve the liability of defendants Champion Chemical Company, Inc., Imperial Oil Company, Inc., Emil Stevens, and June Stevens under Sections 107(a) and 106(b) of the Comprehensive Environmental Response, Compensation and Liability Act (“CERCLA”), 42 U.S.C. 9607(a) and 9606(b), relating to the Imperial Oil Company, Inc./Champion Chemical Superfund Site located in Marlboro Township, Monmouth County, New Jersey (the “Imperial Site”). The consent decrees also resolve the liability of these settling defendants under Section 107(a) of CERCLA, 42 U.S.C. 9607(a), for the Burnt Fly Bog Superfund Site located within Marlboro Township and Old Bridge Township, New Jersey (the “Burnt Fly Bog Site”).

Under the proposed consent decree between the United States, Champion Chemical Company, Inc. (“Champion”), Imperial Oil Company, Inc. (“Imperial”), and the State of New Jersey, settling defendants Champion and Imperial, based on their representations of a limited ability to pay, will make payments toward reimbursement of the United States’ response costs for the Imperial Site and the Burnt Fly Bog Site. These payments, totaling at least $1.375 million (additional amounts are owed as a percentage of profits), will be deposited into site special accounts for the Imperial Site and the Burnt Fly Bog Site to fund future response actions. Settling defendants will also reimburse the United States and/or to the State of New Jersey a portion of their insurance recoveries.
related to the sites and proceeds from the sale of property at the Imperial Site. Additionally, Champion and Imperial will jointly pay the sum of $75,000 as a civil penalty for violations of EPA’s unilateral administrative orders for the Imperial Site. In return, the United States and the State will provide to Champion and Imperial covenants not to sue as to (a) past response costs incurred in connection with the Imperial Site and (b) past and future response costs incurred in connection with the Burnt Fly Bog Site.

Under the proposed consent decree between the United States, Emil Stevens and June Stevens, the settling defendants agree to pay to the United States $300,000 toward the Imperial Site and $100,000 toward the Burnt Fly Bog Site in reimbursement of response costs incurred in connection with the two sites. These amounts will be deposited into site specific accounts for the Imperial Site and the Burnt Fly Bog Site to fund future response actions. The settling defendants also agree to limit their future involvement with, and income, from Champion and Imperial. In return, the United States will provide to Emil and June Stevens covenants not to sue as to past and future response costs incurred in connection with the Imperial Site and the Burnt Fly Bog Site.

The Department of Justice will receive, for a period of thirty (30) days from the date of this publication, written comments relating to the proposed consent decrees. Comments should be addressed to the Assistant Attorney General for the Environment and Natural Resources Division, Department of Justice, Washington, DC 20530, and should refer to United States v. Champion Chemical Company, Inc., et al., DOJ # 90–11–2–946. The proposed consent decrees may be examined at the Office of the United States Attorney, District of New Jersey, 402 East State Street, Room 502, Trenton, New Jersey 08608; and at the Region II Office of the U.S. Environmental Protection Agency, 200 Broadway, New York, New York 10278. Copies of the Consent Decree may be obtained by mail from the Consent Decree Library, United States Department of Justice, P.O. Box 7611, Ben Franklin Station, Washington, DC 20044. In requesting a copy of the consent decree between the United States, Emil Stevens, and June Stevens, please enclose a check in the amount of $11.00 (25 cents per page reproduction costs) payable to the Consent Decree Library.

Bruce Gelber,
Chief, Environmental Enforcement Section, Environment and Natural Resources Division.

[FR Doc. 00–33056 Filed 12–27–00; 8:45 am]
BILLING CODE 4410–15–M

DEPARTMENT OF JUSTICE
Notice of Lodging of Consent Decree for Payment of Civil Penalty for Violations of the Clean Air Act

Under 28 CFR 50.7, notice is hereby given that on December 4, 2000, a proposed Consent Decree in United States v. Columbus McKinnon Corporation, Civil Action No. C00–3096MWB, was filed with the United States District Court for the Northern District of Iowa.

In this action, the United States seeks civil penalties for Columbus McKinnon Corporation’s (“Columbus”) violations of Section 112 of the Clean Air Act, 42 U.S.C. 7412, and of the National Emission Standards for Hazardous Air Pollutants for Chromium Emissions from Hard and Decorative Chromium Electroplating and Chromium Anodizing Tanks, codified at 40 CFR part 63, subpart N. The allegations occurred at a facility located in Laurens, Iowa, which is owned by Columbus McKinnon Corporation, and concern the failure to comply with the Chromium emission limitations, untimely submission of initial notification, and conducting an untimely performance test. Under the Consent Decree, Columbus will pay a civil penalty of $60,000.

The Department of Justice will receive, for a period of thirty (30) days from the date of this publication, comments relating to the Consent Decree. Comments should be addressed to the Assistant Attorney General for the Environment and Natural Resources Division, Department of Justice, Washington, DC 20530, and should refer to United States v. Columbus McKinnon Corporation, DOJ #90–5–2–1–06754.

The Consent Decree may be examined at the Office of the United States Attorney, 401 1st St. SE, Cedar Rapids, Iowa, 52401; at EPA Region VII, 901 N. 5th Street, Kansas City, KS, 66101; or can be obtained by mail from the Consent Decree Library, P.O. Box 7611, United States Department of Justice, Washington, DC 20044–7611. In requesting a copy, please enclose a check of $5.25 (25 cents per page reproduction cost) payable to the Consent Decree Library.

Stephen J. Rapp,
United States Attorney, Northern District Iowa.

[FR Doc. 00–33248 Filed 12–27–00; 8:45 am]
BILLING CODE 4410–15–M

DEPARTMENT OF JUSTICE
Notice of Lodging of Consent Decrees Pursuant to the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as Amended

Notice is hereby given that on December 18, 2000, a proposed consent decree in United States v. Hexagon Laboratories of New York, Inc., et al., Civil Action No. 96 Civ. 2911 (DAB), was lodged with the United States District Court for the Southern District of New York.

In this action, the United States sought the recovery of response costs incurred by the United States with respect to the Hexagon laboratories Superfund Site (the “Site”) in the Bronx, New York. The proposed consent decree resolves the United States’ claims under the Comprehensive Environmental Response, Compensation, and Liability Act (“CERCLA”), 42 U.S.C. 9601 et seq., against defendant Louis P. Wiener relating to the Site. Under the terms of the proposed consent decree, Mr. Wiener will pay $110,000, in installments, in satisfaction of the United States’ claims.

The Department of Justice will receive, for a period of thirty (30) days from the date of this publication, comments relating to the proposed consent decree. Comments should be addressed to the Assistant Attorney General of the Environment and Natural Resources Division, Department of Justice, Washington, DC 20530, and should refer to United States v. Hexagon Laboratories of New York, Inc., et al., Civil Action No. 96 Civ. 2911 (DAB), D.J. Ref. 90–11–3–1662.

The proposed consent decree may be examined at the Office of the United States Attorney, Southern District of New York, 100 Church Street, New York, New York 10007, and at U.S. EPA Region II, 290 Broadway, New York, New York 10007. A copy of the proposed consent decree may be obtained by mail from the Consent Decree Library, P.O. Box 7611, Washington, DC 20044–7611. In requesting a copy, please enclose a
check in the amount of $5.00 (25 cents per page reproduction cost).

Bruce Gelber,
Chief, Environmental Enforcement Section, Environmental and Natural Resources Division.

[FR Doc. 00–33057 Filed 12–27–00; 8:45 am] BILLING CODE 4410±15±M

DEPARTMENT OF JUSTICE

Notice of Lodging of Consent Decree Pursuant to the Comprehensive Environmental Response, Compensation and Liability Act and the Oil Pollution Act

In accordance with Departmental policy, 28 CFR 50.7, the Department of Justice gives notice that a proposed consent decree, in United States v. Petroleum Specialties, Inc., et al., Civil No. 99–72421 (E.D. Mich.), was lodged with the United States District Court for the Eastern District of Michigan on December 7, 2000, pertaining to the Petroleum Specialties, Inc. Site (the “Site”), located in Flat Rock, Wayne County, Michigan. The proposed consent decree would resolve the United States’ civil claims against Petroleum Specialties, Inc. (“PSI”) and Marvin Fleischman (collectively, the “Settling Defendants”), under Sections 107(a) and 113(g) of the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (“CERCLA”), 42 U.S.C. §§ 9607(a) and 9613(g), and against PSI under Sections 1002, 1015 and 1017 of the Oil Pollution Act of 1990 (“OPA”), 33 U.S.C. §§ 2702, 2715 and 2717, in connection with the Site.

Under the proposed consent decree, PSI stipulates to entry of a judgment against itself in the amount of $6 million for federal Response Costs and Removal Costs incurred at the Site. In addition, the proposed consent decree requires Marvin Fleischman to make payments totaling $150,000 to the United States for federal Response Costs and Removal Costs incurred at the Site following entry of the proposed consent decree. The consent decree includes, inter alia, a covenant not to sue by the United States under Sections 106 and 107 of CERCLA, 42 U.S.C. §§ 9606 and 9607, and under Section 1002(b)(1) of OPA, 33 U.S.C. § 2702(b)(1), and provisions relating to Settling Defendants’ receipt of insurance proceeds for the Site.

The Department of Justice will receive, for a period of thirty (30) days from the date of this publication, comments relating to the proposed consent decree. Comments should be addressed to the Assistant Attorney General, Environmental and Natural Resources Division, United States Department of Justice, Washington, DC 20530, and should refer to United States v. Petroleum Specialties, Inc., et al., Civil No. 99–72421 (E.D. Mich.), and DOJ Reference Nos. 90–11–2–1374 and 90–5–1–1–4530.

The proposed consent decree may be examined at: (1) The Office of the United States Attorney for the Eastern District of Michigan, Suite 2001, 211 West Fort Street, Detroit, Michigan 48226–3211 (313–226–9700); and (2) the United States Environmental Protection Agency (Region 5), 77 West Jackson Boulevard, Chicago, Illinois 60604–3590 (contact: Diana Embil (312–886–7899)). A copy of the proposed consent decree may be obtained by mail from the Consent Decree Library, U.S. Department of Justice, P.O. Box 7611, Washington, DC 20044–7611. In requesting a copy, please refer to the referenced case and DOJ Reference Numbers and enclose a check in the amount of $5.00 (25 cents per page reproduction costs), made payable to the Consent Decree Library.

Bruce S. Gelber,
Chief, Environmental Enforcement Section, Environmental and Natural Resources Division.

[FR Doc. 00–33249 Filed 12–27–00; 8:45 am] BILLING CODE 4410±15±M

DEPARTMENT OF JUSTICE

Notice of Lodging of Consent Decree Pursuant to the Clean Water Act and the Safe Drinking Water Act

In accordance with 28 CFR 50.7, 38 Fed. Reg. 19029, notice is hereby given that on December 8, 2000, a proposed consent decree in United States v. Puerto Rico Aqueduct and Sewer Authority, Civil Action No. 00–2554 (JAF), was lodged with the United States District Court for the District of Puerto Rico. The complaint in this action alleged that the Puerto Rico Aqueduct & Sewer Authority (“PRASA”) has been violating the Clean Water Act (“CWA”), 33 U.S.C. 1251, et seq., by discharging wastewater from 23 of its drinking water treatment plants in excess of the effluent limitations in the applicable National Pollutant Discharge Elimination System (“NPDES”) permits or without possessing such permits. The complaint also alleged that PRASA failed or is failing to provide filtration of the surface waters it uses to supply drinking water to 20 of its public water systems in violation of the Surface Water Treatment Rule (“SWTR”), 40 CFR 141.70, et seq., and the Safe Drinking Water Act (“SDWA”), 42 U.S.C. 300f, et seq. The complaint sought injunctive relief and civil penalties.

The Consent Decree requires PRASA to pay a total cash penalty of $550,000 to settle these violations of the CWA and the SDWA, as well as to implement two supplemental environmental projects (“SEPs”). The two SEPs involve the connection of two non-PRASA drinking water systems, which currently do not have filtered water, to one of PRASA’s public water systems that receives filtered drinking water. The estimated cost of these two SEPs is $490,600.

With regard to the PRASA drinking water treatment plants violating the CWA, the Consent Decree requires PRASA to achieve compliance in accordance with schedules for individual plants which vary from two to four years in duration. As to the PRASA public water systems that have not achieved compliance with the SWTR, the Consent Decree requires PRASA to remedy its noncompliance by constructing filtration facilities, connecting public water systems to other PRASA public water systems that have filtration plants, or installing groundwater well systems in lieu of the use of unfiltered surface water supplies. The completion dates in the SDWA compliance schedules for individual public water systems are in 2000–2002.

The Department of Justice will receive comments relating to the proposed consent decree for a period of thirty (30) days from the date of this publication. Comments should be addressed to the Assistant Attorney General, Environment and Natural Resources Division, Department of Justice, P.O. Box 7611, Washington, DC 20044, and should refer to United States v. Puerto Rico Aqueduct and Sewer Authority, D.J. Ref. 90–5–1–1–06179, 90–5–1–1–06475.

The proposed consent decree may be examined at the office of the United States Attorney, Federal Office Building, Rm. 101, Carlos E. Chardon Avenue, Hato Rey, Puerto Rico 00918 and at the Region II office of the Environmental Protection Agency, 290 Broadway, New York, New York 10007. A copy of the proposed consent decree may also be obtained by mail from the Department of Justice Consent Decree Library, P.O. Box 7611, Washington, DC 20044. In requesting a copy, please enclose a check (there is a 25 cent per page reproduction cost) in the amount of...
DEPARTMENT OF LABOR

Employment and Training Administration

Investigations Regarding Certifications of Eligibility To Apply for Worker Adjustment Assistance

Petitions have been filed with the Secretary of Labor under section 221(a) of the Trade Act of 1974 ("the Act") and are identified in the Appendix to this notice. Upon receipt of these petitions, the Director of the Division of Trade Adjustment Assistance, Employment and Training Administration, has instituted investigations pursuant to section 221(a) of the Act.

The purpose of each of the investigations is to determine whether the workers are eligible to apply for adjustment assistance under title II, chapter 2, of the Act. The investigations will further relate, as appropriate, to the determination of the date on which total or partial separations began or threatened to begin and the subdivision of the firm involved.

The petitioners or any other persons showing a substantial interest in the subject matter of the investigations may request a public hearing, provided such request is filed in writing with the Director, Division of Trade Adjustment Assistance, at the address shown below, not later than January 8, 2001.

Interested persons are invited to submit written comments regarding the subject matter of the investigations to the Director, Division of Trade Adjustment Assistance, at the address shown below, not later than January 8, 2001.

The petitions filed in this case are available for inspection at the Office of the Director, Division of Trade Adjustment Assistance, Employment and Training Administration, U.S. Department of Labor, Room C-5311, 200 Constitution Avenue, NW., Washington, DC 20210.

Dated: Signed at Washington, DC this 11th day of December, 2000.

Edward A. Tomchick.
Trade Adjustment Assistance.

Appendix

PETITIONS INSTITUTED ON 12/11/2000

<table>
<thead>
<tr>
<th>TA–W</th>
<th>Subject firm (petitioners)</th>
<th>Location</th>
<th>Date of petition</th>
<th>Product(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>38,402</td>
<td>Comp Air (Wrks)</td>
<td>Sidney, OH</td>
<td>11/15/2000</td>
<td>Air compressors and parts.</td>
</tr>
<tr>
<td>38,405</td>
<td>Cabot Performance (Wrks)</td>
<td>Boyertown, PA</td>
<td>12/01/2000</td>
<td>Tanalum wire.</td>
</tr>
<tr>
<td>38,409</td>
<td>Money’s Foods US, Inc. (Comp)</td>
<td>Blandon, PA</td>
<td>12/01/2000</td>
<td>Grocery store.</td>
</tr>
<tr>
<td>38,412</td>
<td>Columbia Falls Aluminum (Comp)</td>
<td>Columbia Falls, MT</td>
<td>11/21/2000</td>
<td>Aluminum ingot.</td>
</tr>
<tr>
<td>38,414</td>
<td>Villazon and Co., Inc. (Comp)</td>
<td>Tampa, FL</td>
<td>12/04/2000</td>
<td>Cigars—machine made.</td>
</tr>
<tr>
<td>38,416</td>
<td>Willamette Electric (Comp)</td>
<td>Portland, OR</td>
<td>11/22/2000</td>
<td>Automotive starters, alternators.</td>
</tr>
<tr>
<td>38,418</td>
<td>Harbor Industries (Comp)</td>
<td>Traverse City, MI</td>
<td>11/25/2000</td>
<td>Point of purchase displays.</td>
</tr>
<tr>
<td>38,422</td>
<td>LTV Steel Corp. (USWA)</td>
<td>Aliquippa, PA</td>
<td>11/22/2000</td>
<td>Flat rolled coated products.</td>
</tr>
</tbody>
</table>
DEPARTMENT OF LABOR
Employment and Training Administration
[TA-W-38,377]

Dearborn Brass, 21st Century Companies, Inc., Media, PA; Notice of Termination of Investigation

Pursuant to section 221 of the Trade Act of 1974, an investigation was initiated on October 4, 2000 in response to a petition filed on behalf of workers at Dearborn Brass, 21st Century Companies, Inc., Media, Pennsylvania.

The petition verification stage of the investigation revealed the petitioning group of workers are actually located in Tyler, Texas. The worker group is subject to an ongoing investigation for which a determination has not yet been issued (TA-W-38,349). Consequently, further investigation in this case would serve no purpose, and the investigation has been terminated.

Signed in Washington, DC this 12th day of December, 2000.
Linda G. Poole,
Certifying Officer, Division Trade Adjustment Assistance.

DEPARTMENT OF LABOR
Employment and Training Administration
[TA-W-37,919]

Guess?, Inc., Los Angeles, California; Notice of Negative Determination Regarding Application for Reconsideration

By application dated December 1, 2000, the petitioners request administrative reconsideration of the Department’s negative determination regarding eligibility to apply for Trade Adjustment Assistance (TAA), applicable to workers and former workers of the subject firm. The denial notice was signed on November 3, 2000, and published in the Federal Register on December 6, 2000.

Pursuant to 29 CFR 90.18(c) reconsideration may be granted under the following circumstances:
(1) If it appears on the basis of facts not previously considered that the determination complained of was erroneous;
(2) if it appears that the determination complained of was based on a mistake in the determination of facts not previously considered; or
(3) if in the opinion of the Certifying Officer, a mis-interpretation of facts or of the law justified reconsideration of the decision.

The November 3, 2000, denial of TAA for workers of Guess?, Inc., was based on the finding the workers separated from employment at the subject firm in Los Angeles, California, were engaged in distribution of apparel and not in the production of an article as required in the group eligibility requirements of the Trade Act of 1974.

The petitioners, in the application for reconsideration, state that some of the distribution workers were formerly employed in production operations (cutting, samples and embroidery). Workers were transferred to distribution before being separated from employment.

Although not elaborated on in the negative determination, sales and production at Guess?, Inc., Los Angeles, California, increased in the relevant time period. Consequently, there was no basis for further investigation.

Conclusion

After review of the application and investigative findings, I conclude that there has been no error or misinterpretation of the law or of the facts which would justify reconsideration of the Department of Labor’s prior decision. Accordingly, the application is denied.

Signed at Washington, DC this 18th day of December 2000.
Linda G. Poole,
Certifying Officer, Division Trade Adjustment Assistance.

DEPARTMENT OF LABOR
Employment and Training Administration
[TA-W-38,364]

Johnson and Johnson Medical, Inc., El Paso, TX; Notice of Termination of Investigation

Pursuant of section 221 of the Trade Act of 1974, an investigation was initiated on November 27, 2000 in response to a petition which was filed by a company official on behalf of workers at Johnson and Johnson Medical, Inc. in El Paso, Texas.

The petitioner has requested that the petition be withdrawn. Consequently, further investigation in this case would serve no purpose, and the investigation has been terminated.

Linda Poole,
Certifying Officer, Division of Trade Adjustment Assistance.

DEPARTMENT OF LABOR
Employment and Training Administration
[TA-W-38,077]

Paris Accessories, Inc. Belt Division, Allentown, Pennsylvania; Dismissal of Application for Reconsideration

Pursuant to 29 CFR 90.18(c) an application for administrative reconsideration was filed with the Director of the Division of Trade Adjustment Assistance for workers at Paris Accessories, Inc., Belt Division, Allentown, Pennsylvania. The application contained no new substantial information which would bear importantly on the Department’s determination. Therefore, dismissal of the application was issued.

TA-W-38,077; Paris Accessories, Inc., Belt Division Allentown, Pennsylvania (December 12, 2000)

Signed at Washington, DC this 13th day of December, 2000.
Edward A. Tomchick,
Director, Division of Trade Adjustment Assistance.

DEPARTMENT OF LABOR
Employment and Training Administration
[TA-W-37,571 and TA-W-37,517A]

Rugged Sportswear, Siler City, NC and Walstonburg, NC; Amended Certification Regarding Eligibility To Apply for Worker Adjustment Assistance

In accordance with section 223 of the Trade Act of 1974 (19 U.S.C. 2273) the Department of Labor issued a Certification of Eligibility to Apply for Worker Adjustment Assistance on May 30, 2000, applicable to workers of Rugged Sportswear, Siler City, North Carolina. The notice was published in
the Federal Register on June 29, 2000 (65 FR 40134).

At the request of the company, the Department reviewed the certification for workers of the subject firm. New findings show that worker separations occurred at subject firms’ Walstonburg, North Carolina facility when it closed in October, 2000. The workers were engaged in the production of sweat shirts, sweat pants and sweat shorts.

Accordingly, the Department is amending the certification to include the workers at the Walstonburg, North Carolina location of Rugged Sportswear. The intent of the Department’s certification is to include 11 workers of Rugged Sportswear who were adversely affected by increased imports.

The amended notice applicable to TA–W–37,571 is hereby issued as follows:

All workers of Rugged Sportswear, Siler City, North Carolina (TA–W–37,571) and Walstonburg, North Carolina (TA–W–37,571A) who became totally or partially separated from employment on or after March 31, 1999 through May 30, 2002 are eligible to apply for adjustment assistance under Section 223 of the Trade Act of 1974.

Signed in Washington DC this 15th day of December, 2000.

Linda G. Poole,
Certifying Officer, Division of Trade Adjustment Assistance.

[FR Doc. 00–33063 Filed 12–27–00; 8:45 am]
BILLING CODE 4510–30–M

DEPARTMENT OF LABOR

Employment and Training Administration

[TA–W–38,328]

Staples Business Advantage, Staples, Inc. Canton, MI; Notice of Termination of Investigation

Pursuant to Section 221 of the Trade Act of 1974, an investigation was initiated on November 20, 2000 in response to a worker petition which was filed on behalf of workers at Staples Business Advantage, Staples Inc., Canton, Michigan.

The petitioner has requested that the petition be withdrawn. Consequently, further investigation in this case would serve no purpose, and the investigation has been terminated.

Dated: Signed in Washington, DC this 18th day of December, 2000.

Linda G. Poole,
Certifying Officer, Division of Trade Adjustment Assistance.

[FR Doc. 00–33063 Filed 12–27–00; 8:45 am]
BILLING CODE 4510–30–M

DEPARTMENT OF LABOR

Employment and Training Administration

[TA–W–38,237]

STAEG Hamatech, Inc., Saco, ME; Notice of Termination of Investigation

Pursuant to section 221 of the Trade Act of 1974, an investigation was initiated on October 23, 2000 in response to a worker petition which was filed by a company official on October 17, 2000 on behalf of workers at STAEG Hamatech, Inc., Saco, Maine.

The petitioner has requested that the petition be withdrawn. Consequently, further investigation in this case would serve no purpose, and the investigation has been terminated.

Signed in Washington, D.C., this 14th day of December, 2000.

Linda G. Poole,
Certifying Officer, Division of Trade Adjustment Assistance.

[FR Doc. 00–33062 Filed 12–27–00; 8:45 am]
BILLING CODE 4510–30–M

DEPARTMENT OF LABOR

Employment and Training Administration

[TA–W–37,571]

STAEG Hamatech, Inc., Saco, ME; Notice of Termination of Investigation

Pursuant to Section 221 of the Trade Act of 1974, an investigation was initiated on October 23, 2000 in response to a worker petition which was filed on behalf of workers at STAEG Hamatech, Inc., Saco, Maine.

The petitioner has requested that the petition be withdrawn. Consequently, further investigation in this case would serve no purpose, and the investigation has been terminated.

Dated: Signed in Washington, DC this 18th day of December, 2000.

Linda G. Poole,
Certifying Officer, Division of Trade Adjustment Assistance.

[FR Doc. 00–33063 Filed 12–27–00; 8:45 am]
BILLING CODE 4510–30–M

DEPARTMENT OF LABOR

Employment and Training Administration

[TA–W–38,328]

Staples Business Advantage, Staples, Inc. Canton, MI; Notice of Termination of Investigation

Pursuant to Section 221 of the Trade Act of 1974, an investigation was initiated on November 20, 2000 in response to a worker petition which was filed on behalf of workers at Staples Business Advantage, Staples Inc., Canton, Michigan.

The petitioner has requested that the petition be withdrawn. Consequently, further investigation in this case would serve no purpose, and the investigation has been terminated.

Dated: Signed in Washington, DC this 18th day of December, 2000.

Linda G. Poole,
Certifying Officer, Division of Trade Adjustment Assistance.

[FR Doc. 00–33063 Filed 12–27–00; 8:45 am]
BILLING CODE 4510–30–M

DEPARTMENT OF LABOR

Employment and Training Administration

[TA–W–38,237]

STAEG Hamatech, Inc., Saco, ME; Notice of Termination of Investigation

Pursuant to section 221 of the Trade Act of 1974, an investigation was initiated on October 23, 2000 in response to a worker petition which was filed by a company official on October 17, 2000 on behalf of workers at STAEG Hamatech, Inc., Saco, Maine.

The petitioner has requested that the petition be withdrawn. Consequently, further investigation in this case would serve no purpose, and the investigation has been terminated.

Signed in Washington, D.C., this 14th day of December, 2000.

Linda G. Poole,
Certifying Officer, Division of Trade Adjustment Assistance.

[FR Doc. 00–33062 Filed 12–27–00; 8:45 am]
BILLING CODE 4510–30–M

DEPARTMENT OF LABOR

Employment and Training Administration

[TA–W–37,571]

STAEG Hamatech, Inc., Saco, ME; Notice of Termination of Investigation

Pursuant to Section 221 of the Trade Act of 1974, an investigation was initiated on October 23, 2000 in response to a worker petition which was filed on behalf of workers at STAEG Hamatech, Inc., Saco, Maine.

The petitioner has requested that the petition be withdrawn. Consequently, further investigation in this case would serve no purpose, and the investigation has been terminated.

Dated: Signed in Washington, DC this 18th day of December, 2000.

Linda G. Poole,
Certifying Officer, Division of Trade Adjustment Assistance.

[FR Doc. 00–33063 Filed 12–27–00; 8:45 am]
BILLING CODE 4510–30–M

DEPARTMENT OF LABOR

Employment and Training Administration

[TA–W–38,328]

Staples Business Advantage, Staples, Inc. Canton, MI; Notice of Termination of Investigation

Pursuant to Section 221 of the Trade Act of 1974, an investigation was initiated on November 20, 2000 in response to a worker petition which was filed on behalf of workers at Staples Business Advantage, Staples Inc., Canton, Michigan.

The petitioner has requested that the petition be withdrawn. Consequently, further investigation in this case would serve no purpose, and the investigation has been terminated.

Dated: Signed in Washington, DC this 18th day of December, 2000.

Linda G. Poole,
Certifying Officer, Division of Trade Adjustment Assistance.

[FR Doc. 00–33063 Filed 12–27–00; 8:45 am]
BILLING CODE 4510–30–M
• Enhance the quality, utility, and clarity of the information to be collected; and
• Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms technology, e.g., permitting electronic submissions of responses.

III. Current Actions

The proposed collection of information must be approved so that the Department can effectively manage and evaluate the WIA National Farmworker Jobs Program authorized under Title I section 167 of the Act in compliance with the requirements set forth in Public Law 105–220 and 20 CFR 652 et al., Workforce Investment Act; Final Rules, dated August 11, 2000.

Type of Review: New.
Agency: Employment and Training Administration.
Title: Workforce Investment Act (WIA), Employment and Training Administration, Financial Reporting Requirements for National Farmworker Jobs Program.

OMB Number: 1205–0NEW.
Agency Numbers: ETA 9092.
Frequency: Quarterly.
Affected Public: State agencies; private, non-profit corporations; and consortia of any and/or all of the above.

Reporting Burden: See the following Reporting Burden Table for NFJP grantees to report requested WIA financial data electronically on form at ETA 9092.

### DOL–ETA Reporting Burden for WIA Title I—NFJP Grantees

<table>
<thead>
<tr>
<th>Requirements</th>
<th>PY 1999</th>
<th>PY 2000</th>
<th>PY 2001</th>
<th>PY 2002</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Reports Per Entity Per Quarter</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Total Number of Reports Per Entity Per Year</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
</tr>
<tr>
<td>Number of Hours Required Per Report</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Total Number of Hours Required Per Report Per Year</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
</tr>
<tr>
<td>Number of Entities Reporting</td>
<td>53</td>
<td>53</td>
<td>53</td>
<td>53</td>
</tr>
<tr>
<td>Total Number of Hours Required for Reporting Per Year</td>
<td>636</td>
<td>636</td>
<td>636</td>
<td>636</td>
</tr>
<tr>
<td>Total Burden Cost @ $25.00 per hour*</td>
<td>$15,900</td>
<td>$15,900</td>
<td>$15,900</td>
<td>$15,900</td>
</tr>
</tbody>
</table>

* $25.00 per hour is based on a GS 12 Step 1 salary.

Note: Number of reports required per entity per quarter/year is impacted by the 3 year life of each year of appropriated funds, i.e., PY 1997 and 1998 funds are available for expenditure in PY 1999, thus 3 reports reflect 3 available funding years.

Comments submitted in response to this comment request will be summarized and/or included in the request for Office of Management and Budget approval of the information collection request; they will also become a matter of public record.


Bryan T. Keilty,
Director, Office of Financial and Administrative Management.
[FR Doc. 00–33074 Filed 12–27–00; 8:45 am]
BILLING CODE 4510–30–M

DEPARTMENT OF LABOR

Employment and Training Administration

[NAFTA 04302]

Johnson and Johnson Medical, Inc., El Paso, Texas; Notice of Termination of Investigation

Pursuant to title V of the North American Free Trade Agreement Implementation Act (Pub. L. 103–182) concerning transitional adjustment assistance, hereinafter called NAFTA–TAA and in accordance with section 250(a), subchapter D, chapter 2, title II, of the Trade Act of 1974, as amended (19 USC 2331), an investigation was initiated on November 14, 2000, in response to a petition filed by a company official on behalf of workers at Johnson and Johnson Medical, Inc.

The petitioner has requested that the petition be withdrawn. Consequently, further investigation in this case would serve no purpose, and the investigation has been terminated.

Signed in Washington, DC this 12th day of December, 2000.

Linda Poole,
Certifying Officer, Division of Trade Adjustment Assistance.
[FR Doc. 00–33068 Filed 12–27–00; 8:45 am]
BILLING CODE 4510–30–M

DEPARTMENT OF LABOR

Employment and Training Administration

[NAFTA–03838 and NAFTA–03838A]

Rugged Sportswear, Siler City, NC; Rugged Sportswear Walstonburg, NC; Amended Certification Regarding Eligibility to Apply for NAFTA Transitional Adjustment Assistance

In accordance with section 250(a), Subchapter 2, Title II, of the Trade Act of 1974, as amended (19 U.S.C. 2273), the Department of Labor issued a Certification of Eligibility to Apply for NAFTA Adjustment Assistance on May 30, 2000, applicable to workers of Rugged Sportswear, Siler City, North Carolina. The notice was published in the Federal Register on June 8, 2000 (65 FR 36470).

At the request of the company, the Department reviewed the certification for workers of the subject firm. New information shows that worker separations occurred at the subject firms’ Walstonburg, North Carolina facility when it closed in October, 2000. The workers were engaged in the production of sweat shirts, sweat pants and sweat shorts.

Accordingly, the Department is amending the certification to include the workers at the Walstonburg, North Carolina location of Rugged Sportswear.

The intent of the Department’s certification is to include all workers of Rugged Sportswear who were adversely affected by a shift of production to Mexico.

The amended notice applicable to NAFTA–03838 is hereby issued as follows:

All workers of Rugged Sportswear, Siler City, North Carolina (NAFTA–03838) and Walstonburg, North Carolina (NAFTA–03838A) who becomes totally or partially separated from employment on or after March 31, 1999 through May 30, 2002 are eligible to apply for NAFTA–TAA under Section 250 of the Trade Act of 1974.

Signed at Washington, DC this 15th day of December, 2000.

Linda G. Poole,
Certifying Officer, Division of Trade Adjustment Assistance.
[FR Doc. 00–33065 Filed 12–27–00; 8:45 am]
BILLING CODE 4510–30–M
DEPARTMENT OF LABOR
Employment and Training Administration
[NAFTA–4202]

Samsonite Corporation, Tucson, AZ; Amended Notice of Revised Determination on Reconsideration

In accordance with section 250(a), subchapter D, chapter 2, title II, of the Trade Act of 1974, as amended (19 USC 2273), the Department of Labor issued a Notice of Revised Determination on Reconsideration regarding eligibility to apply for NAFTA Transitional Adjustment Assistance, on December 8, 2000, applicable to workers of Samsonite Corporation, Tucson, Arizona. The notice will soon be published in the Federal Register.

At the request of the State agency, the Department reviewed the decision for workers of the subject firm. The State pointed out that workers of the subject firm were covered under a previous certification, NAFTA–2263, which expired on April 20, 2000. Based on this information, to avoid overlap in worker coverage, the Department is amending the September 29, 1999, impact date set in the revised determination for NAFTA–4202, to April 21, 2000.

The amended notice applicable to NAFTA–4202 is hereby issued as follows:

- All workers of Samsonite Corporation, Tucson, Arizona, who became totally or partially separated from employment on or after April 21, 2000, through December 8, 2002, are eligible to apply for NAFTA–TAA under Section 250 of the Trade Act of 1974.

Signed in Washington, DC this 15th day of December 2000.
Linda G. Poole,
Certifying Officer, Division of Trade Adjustment Assistance.

BILLING CODE 4510–30–M

DEPARTMENT OF LABOR
Employment and Training Administration

Investigations Regarding Certifications of Eligibility to Apply for NAFTA Transitional Adjustment Assistance

Petitions for transitional adjustment assistance under the North American Free Trade Agreement–Transitional Adjustment Assistance Implementation Act (Pub. L. 103–182), hereinafter called (NAFTA–TAA), have been filed with State governors under section 250(b)(1) of subchapter D, Chapter 2, title II, of the Trade Act of 1974, as amended, are identified in the Appendix to this notice. Upon notice from a Governor that a NAFTA–TAA petition has been received, the Director of the Division of Trade Adjustment Assistance (DTAA), Employment and Training Administration (ETA), Department of Labor (DOL), announces the filing of the petition and takes action pursuant to paragraphs (c) and (e) of section 250 of the Trade Act.

The purpose of the Governor’s actions and the Labor Department’s investigations are to determine whether the workers separated from employment on or after December 8, 1993 (date of enactment of Pub. L. 103–182) are eligible to apply for NAFTA–TAA under Subchapter D of the Trade Act because of increased imports from or the shift in production to Mexico or Canada.

The petitioners or any other persons showing a substantial interest in the subject matter of the investigations may request a public hearing with the Director of DTAA at the U.S. Department of Labor (DOL) in Washington, DC provided such request if filed in writing with the Director of DTAA not later than January 8, 2001.

Also, interested persons are invited to submit written comments regarding the subject matter of the petitions to the Director of DTAA at the address shown below not later than January 8, 2001.

Petitions filed with the Governors are available for inspection at the Office of the Director, DTAA, ETA, DOL, Room C–5311, 200 Constitution Avenue, NW., Washington, D.C. 20210.

Signed at Washington, DC this 19th day of December, 2000.
Edward A. Tomchick,
Director, Division of Trade Adjustment Assistance.

Appendix

<table>
<thead>
<tr>
<th>Subject firm</th>
<th>Location</th>
<th>Date received at Governor’s office</th>
<th>Petition No.</th>
<th>Articles produced</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stanley Door Systems, Stanley Works (Co.)</td>
<td>San Dimas, CA</td>
<td>10/16/2000</td>
<td>NAFTA–4,215 ...</td>
<td>hardware components for doors</td>
</tr>
<tr>
<td>Ashby Industries (Co.)</td>
<td>Martinsville, VA</td>
<td>10/30/2000</td>
<td>NAFTA–4,216 ...</td>
<td>textile machinery</td>
</tr>
<tr>
<td>Leapwood Apparel (Co.)</td>
<td>Adamsville, TN</td>
<td>10/16/2000</td>
<td>NAFTA–4,217 ...</td>
<td>bleach range</td>
</tr>
<tr>
<td>Designer Hearths (Wkrs)</td>
<td>Missoula, MT</td>
<td>10/06/2000</td>
<td>NAFTA–4,218 ...</td>
<td>men’s &amp; women’s knit shirts</td>
</tr>
<tr>
<td>Colortex International (Wkrs)</td>
<td>Salisbury, NC</td>
<td>10/11/2000</td>
<td>NAFTA–4,219 ...</td>
<td>dyed &amp; finished woven cloth</td>
</tr>
<tr>
<td>Stimson Lumber (LPIW)</td>
<td>Bonner, MT</td>
<td>10/06/2000</td>
<td>NAFTA–4,220 ...</td>
<td>plywood &amp; veneer products</td>
</tr>
<tr>
<td>Key Circuit (Wkrs)</td>
<td>Fountain Valley, CA</td>
<td>10/10/2000</td>
<td>NAFTA–4,221 ...</td>
<td>printed circuit boards</td>
</tr>
<tr>
<td>Norton Company (PACE)</td>
<td>Watervliet, NY</td>
<td>10/10/2000</td>
<td>NAFTA–4,222 ...</td>
<td>Sandpaper</td>
</tr>
<tr>
<td>Amscan (Wkrs)</td>
<td>Brooklyn, NY</td>
<td>10/11/2000</td>
<td>NAFTA–4,223 ...</td>
<td>wedding accessories</td>
</tr>
<tr>
<td>Northside Manufacturing (Co.)</td>
<td>Philipsburg, PA</td>
<td>10/11/2000</td>
<td>NAFTA–4,224 ...</td>
<td>men’s suits</td>
</tr>
<tr>
<td>Streamline Fashions (Co.)</td>
<td>Philipsburg, PA</td>
<td>10/11/2000</td>
<td>NAFTA–4,224 ...</td>
<td>electromagnetic lighting ballasts</td>
</tr>
<tr>
<td>Advance Transformer (Wkrs)</td>
<td>Monroe, WI</td>
<td>09/25/2000</td>
<td>NAFTA–4,225 ...</td>
<td>heating, ventilating &amp; A/C systems</td>
</tr>
<tr>
<td>Airtherm Products (USWA)</td>
<td>Forrest City, AR</td>
<td>10/11/2000</td>
<td>NAFTA–4,226 ...</td>
<td>cotton yarn</td>
</tr>
<tr>
<td>Harriet and Henderson Yarns (Co.)</td>
<td>Summerville, GA</td>
<td>10/16/2000</td>
<td>NAFTA–4,227 ...</td>
<td>disposable medical electrodes</td>
</tr>
<tr>
<td>Contour Medical Technology (Wkrs)</td>
<td>LaVergne, TN</td>
<td>10/13/2000</td>
<td>NAFTA–4,228 ...</td>
<td>medical dental gloves</td>
</tr>
<tr>
<td>Maxim Medical (Wkrs)</td>
<td>Clearwater, FL</td>
<td>10/04/2000</td>
<td>NAFTA–4,229 ...</td>
<td>medical dental gloves</td>
</tr>
<tr>
<td>Subject firm</td>
<td>Location</td>
<td>Date received at Governor's office</td>
<td>Petition No.</td>
<td>Articles produced</td>
</tr>
<tr>
<td>-------------------------------------------</td>
<td>---------------------------------</td>
<td>-----------------------------------</td>
<td>--------------</td>
<td>--------------------------------------------------------</td>
</tr>
<tr>
<td>General Electric (IBEW)</td>
<td>Bloomington, IN</td>
<td>10/16/2000</td>
<td>NAFTA-4,230</td>
<td>side by side refrigerators</td>
</tr>
<tr>
<td>Talon (Co.)</td>
<td>Lake City, SC</td>
<td>10/19/2000</td>
<td>NAFTA-4,231</td>
<td>parts for zippers</td>
</tr>
<tr>
<td>Talon (Co.)</td>
<td>Stanley, NC</td>
<td>10/19/2000</td>
<td>NAFTA-4,231</td>
<td>parts for zippers</td>
</tr>
<tr>
<td>California Direct Service (Wkrs)</td>
<td>San Diego, CA</td>
<td>09/19/2000</td>
<td>NAFTA-4,232</td>
<td>mails direct mail</td>
</tr>
<tr>
<td>Wundies Santony Wear (Wkrs)</td>
<td>Rockingham, NC</td>
<td>10/20/2000</td>
<td>NAFTA-4,233</td>
<td>ladies underwearments</td>
</tr>
<tr>
<td>Parana Supplies (Co.)</td>
<td>El Paso, TX</td>
<td>10/19/2000</td>
<td>NAFTA-4,234</td>
<td>dot matrix ribbon cartridges for printer</td>
</tr>
<tr>
<td>Precision Interconnect (Wkrs)</td>
<td>Waupin, WI</td>
<td>10/17/2000</td>
<td>NAFTA-4,235</td>
<td>interface cables</td>
</tr>
<tr>
<td>John Crane, Inc. (Co.)</td>
<td>Morton Grove, IL</td>
<td>10/19/2000</td>
<td>NAFTA-4,236</td>
<td>water pump seals</td>
</tr>
<tr>
<td>Middleby Marshall (Wkrs)</td>
<td>Fuquay Varina, NC</td>
<td>10/18/2000</td>
<td>NAFTA-4,237</td>
<td>fryers, stoves and steamers</td>
</tr>
<tr>
<td>Dekko Automotive Technologies (Co.)</td>
<td>Mt. Ayr, IA</td>
<td>10/13/2000</td>
<td>NAFTA-4,238</td>
<td>wiring harness assemblies</td>
</tr>
<tr>
<td>DR Rent (Co.)</td>
<td>Klamath Falls, OR</td>
<td>10/18/2000</td>
<td>NAFTA-4,239</td>
<td>hauling freight &amp; logs</td>
</tr>
<tr>
<td>Schlage Lock—Ingersoll Rand (Co.)</td>
<td>San Jose, CA</td>
<td>10/17/2000</td>
<td>NAFTA-4,240</td>
<td>door cylinders &amp; hardware</td>
</tr>
<tr>
<td>Tower Automotive (Wkrs)</td>
<td>Kalamazo, MI</td>
<td>10/17/2000</td>
<td>NAFTA-4,241</td>
<td>automotive parts</td>
</tr>
<tr>
<td>Hi Line Storage Systems (Wkrs)</td>
<td>Perkasie, PA</td>
<td>10/17/2000</td>
<td>NAFTA-4,242</td>
<td>storage rack</td>
</tr>
<tr>
<td>Pronov Ship Management (Wkrs)</td>
<td>Greenwich, CT</td>
<td>09/19/2000</td>
<td>NAFTA-4,243</td>
<td>crew members for vessels</td>
</tr>
<tr>
<td>Robert Helmick (Co.)</td>
<td>Kingston, ID</td>
<td>09/29/2000</td>
<td>NAFTA-4,244</td>
<td>vessel sailing</td>
</tr>
<tr>
<td>Still Man Heating Products (Co.)</td>
<td>Cookeville, TN</td>
<td>10/23/2000</td>
<td>NAFTA-4,245</td>
<td>logging roads</td>
</tr>
<tr>
<td>National Mills (Wkrs)</td>
<td>Pittsburg, KS</td>
<td>10/19/2000</td>
<td>NAFTA-4,246</td>
<td>heating elements</td>
</tr>
<tr>
<td>Union Pacific Resources (Co.)</td>
<td>Fort Worth, TX</td>
<td>10/23/2000</td>
<td>NAFTA-4,248</td>
<td>sweaters</td>
</tr>
<tr>
<td>Union Pacific Resources (Co.)</td>
<td>Operating in the State of CO.</td>
<td>10/23/2000</td>
<td>NAFTA-4,248</td>
<td>crude oil and natural gas</td>
</tr>
<tr>
<td>Union Pacific Resources (Co.)</td>
<td>Operating in the State of OK.</td>
<td>10/23/2000</td>
<td>NAFTA-4,248</td>
<td>crude oil and natural gas</td>
</tr>
<tr>
<td>Union Pacific Resources (Co.)</td>
<td>Operating in the State of KS.</td>
<td>10/23/2000</td>
<td>NAFTA-4,248</td>
<td>crude oil and natural gas</td>
</tr>
<tr>
<td>Union Pacific Resources (Co.)</td>
<td>Operating in the State of LA.</td>
<td>10/23/2000</td>
<td>NAFTA-4,248</td>
<td>crude oil and natural gas</td>
</tr>
<tr>
<td>Union Pacific Resources (Co.)</td>
<td>Operating in the State of UT.</td>
<td>10/23/2000</td>
<td>NAFTA-4,248</td>
<td>crude oil and natural gas</td>
</tr>
<tr>
<td>Union Pacific Resources (Co.)</td>
<td>Operating in the State of TX.</td>
<td>10/23/2000</td>
<td>NAFTA-4,248</td>
<td>crude oil and natural gas</td>
</tr>
<tr>
<td>Autoliv ASP (Co.)</td>
<td>Ogden, UT</td>
<td>10/24/2000</td>
<td>NAFTA-4,249</td>
<td>filter &amp; leadwire assemblies</td>
</tr>
<tr>
<td>Poland Springs Bottling (UFCW)</td>
<td>Poland Springs, ME</td>
<td>10/18/2000</td>
<td>NAFTA-4,250</td>
<td>bottle water</td>
</tr>
<tr>
<td>Authentic Fitness (Wkrs)</td>
<td>Bell, CA</td>
<td>9/16/2000</td>
<td>NAFTA-4,251</td>
<td>trivets</td>
</tr>
<tr>
<td>Tri County Blue Print (Wkrs)</td>
<td>Ventura, CA</td>
<td>10/30/2000</td>
<td>NAFTA-4,252</td>
<td>reprographic/microfilm services</td>
</tr>
<tr>
<td>Homestake Mining (USWA)</td>
<td>Lead, SD</td>
<td>10/23/2000</td>
<td>NAFTA-4,253</td>
<td>gold</td>
</tr>
<tr>
<td>Jakel (Wkrs)</td>
<td>East Prairie, MO</td>
<td>10/25/2000</td>
<td>NAFTA-4,254</td>
<td>electrical motors</td>
</tr>
<tr>
<td>Exide Technologies (Wkrs)</td>
<td>Farmes Branch, TX</td>
<td>10/25/2000</td>
<td>NAFTA-4,255</td>
<td>automobiles lead acid batteries</td>
</tr>
<tr>
<td>Fairfield Manufacturing (UAW)</td>
<td>Lafayette, IN</td>
<td>10/19/2000</td>
<td>NAFTA-4,256</td>
<td>custom gears &amp; planetary devices</td>
</tr>
<tr>
<td>A.O. Smith Electrical Products (Co.)</td>
<td>Paoi, IN</td>
<td>10/23/2000</td>
<td>NAFTA-4,257</td>
<td>subfractional horsepower electric motors</td>
</tr>
<tr>
<td>U.S. Label Artistic (Wkrs)</td>
<td>Clinton, NC</td>
<td>10/26/2000</td>
<td>NAFTA-4,258</td>
<td>printed labels</td>
</tr>
<tr>
<td>Facemate Corporation (Co.)</td>
<td>N. Somersworth, NH</td>
<td>10/24/2000</td>
<td>NAFTA-4,259</td>
<td>flannels</td>
</tr>
<tr>
<td>3M Company (Co.)</td>
<td>Boise, ID</td>
<td>10/26/2000</td>
<td>NAFTA-4,260</td>
<td>fly rod cases</td>
</tr>
<tr>
<td>Grant Western Lumber (Wkrs)</td>
<td>John Day, OR</td>
<td>10/30/2000</td>
<td>NAFTA-4,261</td>
<td>dimension lumber</td>
</tr>
<tr>
<td>ABC–NACO (IBM)</td>
<td>Ashland, WI</td>
<td>10/26/2000</td>
<td>NAFTA-4,262</td>
<td>railrack switch</td>
</tr>
<tr>
<td>Carolina Mills (Co.)</td>
<td>St. Pauls, NC</td>
<td>10/30/2000</td>
<td>NAFTA-4,263</td>
<td>textile yarns</td>
</tr>
<tr>
<td>Austin Apparel (Co.)</td>
<td>Lascaster, KY</td>
<td>10/31/2000</td>
<td>NAFTA-4,264</td>
<td>apparel</td>
</tr>
<tr>
<td>Tingley Rubber (USWA)</td>
<td>South Plainfield, NJ</td>
<td>11/01/2000</td>
<td>NAFTA-4,265</td>
<td>Rubberized Clothing Goods</td>
</tr>
<tr>
<td>Originals Bi-Judi, Inc. (Co.)</td>
<td>Tolleson, AZ</td>
<td>10/31/2000</td>
<td>NAFTA-4,266</td>
<td>Baby Comforters</td>
</tr>
<tr>
<td>Alcoa Fujikura Ltd (Co.)</td>
<td>Shelbyville, KY</td>
<td>10/19/2000</td>
<td>NAFTA-4,267</td>
<td>Wiring Harnesses</td>
</tr>
<tr>
<td>Utica Cutlery Co (Co.)</td>
<td>Utica, NY</td>
<td>10/30/2000</td>
<td>NAFTA-4,268</td>
<td>Flatware</td>
</tr>
<tr>
<td>Snyder Walls Industries (Co.)</td>
<td>Snyder, TX</td>
<td>10/26/2000</td>
<td>NAFTA-4,269</td>
<td>six pocket pants</td>
</tr>
<tr>
<td>Elmer’s Products, Inc</td>
<td>Bainbridge, NY</td>
<td>10/30/2000</td>
<td>NAFTA-4,270</td>
<td>Wood Fillers, Caulk, Spackling</td>
</tr>
<tr>
<td>Subject firm</td>
<td>Location</td>
<td>Date received at Governor’s office</td>
<td>Petition No.</td>
<td>Articles produced</td>
</tr>
<tr>
<td>--------------------------------------------------</td>
<td>---------------------------</td>
<td>-----------------------------------</td>
<td>--------------</td>
<td>----------------------------------------</td>
</tr>
<tr>
<td>American Baseball Cap (Wkrs)</td>
<td>Freidens, PA</td>
<td>11/01/2000</td>
<td>NAFTA-4,271</td>
<td>batting helmets</td>
</tr>
<tr>
<td>Pyramid Mountain Lumber, Inc (Co.)</td>
<td>Sayle Lake, MT</td>
<td>11/01/2000</td>
<td>NAFTA-4,272</td>
<td>children’s Pajamas</td>
</tr>
<tr>
<td>Hit Apparel (Wkr)</td>
<td>Athens, TN</td>
<td>11/06/2000</td>
<td>NAFTA-4,273</td>
<td>aluminum</td>
</tr>
<tr>
<td>Vanalco (Wkr)</td>
<td>Vancouver, WA</td>
<td>11/06/2000</td>
<td>NAFTA-4,274</td>
<td>Passenger Airbag</td>
</tr>
<tr>
<td>Autoliv ASP (Wkrs)</td>
<td>Ogden, UT</td>
<td>11/06/2000</td>
<td>NAFTA-4,275</td>
<td>Cushions</td>
</tr>
<tr>
<td>Stora Enso North America (Co.)</td>
<td>Wisconsin Rapids, WI</td>
<td>11/01/2000</td>
<td>NAFTA-4,276</td>
<td>Paper</td>
</tr>
<tr>
<td>NRB Industries, Inc. (Co.)</td>
<td>Radford, VA</td>
<td>11/06/2000</td>
<td>NAFTA-4,277</td>
<td>Broadwoven Fabrics</td>
</tr>
<tr>
<td>Encore Textiles, Inc (Co.)</td>
<td>Monroe, NC</td>
<td>11/07/2000</td>
<td>NAFTA-4,278</td>
<td>Tee Shirts</td>
</tr>
<tr>
<td>Alstom Power (Co.)</td>
<td>Kings Mountain, NC</td>
<td>11/07/2000</td>
<td>NAFTA-4,279</td>
<td>heat recovery steam generators</td>
</tr>
<tr>
<td>Caffall Brothers (Co.)</td>
<td>Wilsonville, OR</td>
<td>11/09/2000</td>
<td>NAFTA-4,280</td>
<td>cedar fencing</td>
</tr>
<tr>
<td>Greenwood Mills (Co.)</td>
<td>Greenwood, SC</td>
<td>11/08/2000</td>
<td>NAFTA-4,281</td>
<td>lightweight textiles</td>
</tr>
<tr>
<td>Norman Barnes &amp; Company (Co.)</td>
<td>Arlington, WA</td>
<td>11/03/2000</td>
<td>NAFTA-4,282</td>
<td>logs</td>
</tr>
<tr>
<td>Rockwell Automotive (UE)</td>
<td>Milwaukee, WI</td>
<td>11/07/2000</td>
<td>NAFTA-4,283</td>
<td>industrial controls</td>
</tr>
<tr>
<td>Lending Textile (Co.)</td>
<td>Hackettstown, NJ</td>
<td>11/02/2000</td>
<td>NAFTA-4,284</td>
<td>toner bottles &amp; cartridge</td>
</tr>
<tr>
<td>Astron Johnson (Co.)</td>
<td>Walterboro, SC</td>
<td>11/08/2000</td>
<td>NAFTA-4,285</td>
<td>specialty fabrics</td>
</tr>
<tr>
<td>Poli One (Co.)</td>
<td>Denver, CO</td>
<td>11/08/2000</td>
<td>NAFTA-4,286</td>
<td>polyethylene pellets</td>
</tr>
<tr>
<td>ABB Westinghouse (Wkrs)</td>
<td>Festus, MO</td>
<td>10/26/2000</td>
<td>NAFTA-4,287</td>
<td>nuclear fuel</td>
</tr>
<tr>
<td>Posies (Co.)</td>
<td>Rockpoint, ME</td>
<td>11/13/2000</td>
<td>NAFTA-4,288</td>
<td>dresses</td>
</tr>
<tr>
<td>Staples (Wkrs)</td>
<td>Canton, MI</td>
<td>11/02/2000</td>
<td>NAFTA-4,289</td>
<td>office products</td>
</tr>
<tr>
<td>Central Industries of Indiana (Co.)</td>
<td>Greenwood, AR</td>
<td>11/07/2000</td>
<td>NAFTA-4,290</td>
<td>electrical wiring harnesses</td>
</tr>
<tr>
<td>American Garment Finishers (Co.)</td>
<td>El Paso, TX</td>
<td>11/01/2000</td>
<td>NAFTA-4,291</td>
<td>garment finishing</td>
</tr>
<tr>
<td>Artex International (Co.)</td>
<td>St. George, UT</td>
<td>10/26/2000</td>
<td>NAFTA-4,293</td>
<td>linens &amp; aprons</td>
</tr>
<tr>
<td>Rich and Me (Wkrs)</td>
<td>Vernon, CA</td>
<td>11/13/2000</td>
<td>NAFTA-4,294</td>
<td>apparel</td>
</tr>
<tr>
<td>Jeld Wen Lumber Company</td>
<td>Bend, OR</td>
<td>11/07/2000</td>
<td>NAFTA-4,295</td>
<td>wood mouldings &amp; millwork</td>
</tr>
<tr>
<td>Mulox (Co.)</td>
<td>Macon, GA</td>
<td>9/01/2000</td>
<td>NAFTA-4,296</td>
<td>flexible bulk containers</td>
</tr>
<tr>
<td>AAVID Thermalloy (Wkrs.)</td>
<td>Santa Ana, CA</td>
<td>11/03/2000</td>
<td>NAFTA-4,297</td>
<td>digital assembly</td>
</tr>
<tr>
<td>Cottrell International (Co.)</td>
<td>Englewood, CO</td>
<td>11/14/2000</td>
<td>NAFTA-4,298</td>
<td>dental &amp; medical pouches</td>
</tr>
<tr>
<td>Smith and Nephew (Co.)</td>
<td>Charlotte, NC</td>
<td>11/13/2000</td>
<td>NAFTA-4,299</td>
<td>ortho glass</td>
</tr>
<tr>
<td>Sasib (USWA)</td>
<td>Depere, WI</td>
<td>11/16/2000</td>
<td>NAFTA-4,300</td>
<td>paper industries machinery</td>
</tr>
<tr>
<td>HoltraChem Manufacturing (Co.)</td>
<td>Riegelwood, NC</td>
<td>11/16/2000</td>
<td>NAFTA-4,301</td>
<td>chlorine, caustic soda</td>
</tr>
<tr>
<td>Johnson and Johnson Medical (Co.)</td>
<td>El Paso, TX</td>
<td>11/14/2000</td>
<td>NAFTA-4,302</td>
<td>disposable surgical gowns, drapes etc.</td>
</tr>
<tr>
<td>Dearborn Brass (GMPPA)</td>
<td>Tyler, TX</td>
<td>11/16/2000</td>
<td>NAFTA-4,303</td>
<td>metal traps</td>
</tr>
<tr>
<td>Flowserve Corporation (Wkrs)</td>
<td>Temecula, CA</td>
<td>11/16/2000</td>
<td>NAFTA-4,304</td>
<td>shaft seals</td>
</tr>
<tr>
<td>Berg Lumber Company (Wkrs)</td>
<td>Lewiston, MT</td>
<td>11/14/2000</td>
<td>NAFTA-4,305</td>
<td>lumber</td>
</tr>
<tr>
<td>Parker Hannifin (USWA)</td>
<td>Lebanon, IN</td>
<td>11/13/2000</td>
<td>NAFTA-4,306</td>
<td>printer cartridges</td>
</tr>
<tr>
<td>Light—SPX Corp. (Co.)</td>
<td>Wytheville, VA</td>
<td>11/15/2000</td>
<td>NAFTA-4,307</td>
<td>parts for heavy duty trucks</td>
</tr>
<tr>
<td>Spreckels Sugar (UFCW)</td>
<td>Woodland, CA</td>
<td>11/13/2000</td>
<td>NAFTA-4,308</td>
<td>sugar</td>
</tr>
<tr>
<td>Kojo Worldwide (Wkrs)</td>
<td>Huntington Beach, CA</td>
<td>11/06/2000</td>
<td>NAFTA-4,309</td>
<td>pillows, bedsprads and drapery</td>
</tr>
<tr>
<td>Cooper Standard Automotive (Wkrs)</td>
<td>Mio, MI</td>
<td>11/14/2000</td>
<td>NAFTA-4,311</td>
<td>automotive metal tubing</td>
</tr>
<tr>
<td>Trumark Industries (Wkrs)</td>
<td>Spokane, WA</td>
<td>11/17/2000</td>
<td>NAFTA-4,312</td>
<td>fingertip studs</td>
</tr>
<tr>
<td>AgriLink Foods (Wkrs)</td>
<td>Alamo, TX</td>
<td>11/20/2000</td>
<td>NAFTA-4,313</td>
<td>okra</td>
</tr>
<tr>
<td>Lexmark International (Wkrs)</td>
<td>Lexington, KY</td>
<td>11/20/2000</td>
<td>NAFTA-4,314</td>
<td>personal printers &amp; printer cartridges</td>
</tr>
<tr>
<td>Consolidated Metco (Wkrs)</td>
<td>Portland, OR</td>
<td>11/17/2000</td>
<td>NAFTA-4,315</td>
<td>parts for heavy duty trucks</td>
</tr>
<tr>
<td>Hatfield Trousers (UNITE)</td>
<td>Hatfield, PA</td>
<td>11/20/2000</td>
<td>NAFTA-4,316</td>
<td>men’s pants</td>
</tr>
<tr>
<td>Don Shapiro—Action West (Wkrs)</td>
<td>El Paso, TX</td>
<td>11/21/2000</td>
<td>NAFTA-4,318</td>
<td>woman’s apparel</td>
</tr>
<tr>
<td>Lending Textile (Co.)</td>
<td>Montgomery, PA</td>
<td>11/21/2000</td>
<td>NAFTA-4,320</td>
<td>decorative textile trims</td>
</tr>
<tr>
<td>Atlas Bag (Co.)</td>
<td>Des Plaines, IL</td>
<td>11/13/2000</td>
<td>NAFTA-4,321</td>
<td>flexible bbl containers</td>
</tr>
<tr>
<td>Owens Brockway (GMP)</td>
<td>Brockway, PA</td>
<td>11/21/2000</td>
<td>NAFTA-4,323</td>
<td>glass containers</td>
</tr>
<tr>
<td>Johns Manville (GMP)</td>
<td>Corona, CA</td>
<td>11/22/2000</td>
<td>NAFTA-4,324</td>
<td>fiberglass</td>
</tr>
<tr>
<td>Maytag (Co.)</td>
<td>Jefferson City, MO</td>
<td>11/22/2000</td>
<td>NAFTA-4,325</td>
<td>wire harness</td>
</tr>
<tr>
<td>Subject firm</td>
<td>Location</td>
<td>Date received at Governor's office</td>
<td>Petition No.</td>
<td>Articles produced</td>
</tr>
<tr>
<td>--------------------------------------</td>
<td>-------------------</td>
<td>-----------------------------------</td>
<td>--------------</td>
<td>----------------------------------------</td>
</tr>
<tr>
<td>Tyco Electronics (Wkrs)</td>
<td>Sanford, ME</td>
<td>11/22/2000</td>
<td>NAFTA±4,326</td>
<td>terminal blocks</td>
</tr>
<tr>
<td>Hagale Industries (Wkrs)</td>
<td></td>
<td></td>
<td></td>
<td>motorbearers</td>
</tr>
<tr>
<td>Velvac (Wkrs)</td>
<td></td>
<td></td>
<td></td>
<td>components for heavy trucks</td>
</tr>
<tr>
<td>Tyco Electronics (Co.)</td>
<td>Chesterfield, MI</td>
<td>11/27/2000</td>
<td>NAFTA±4,331</td>
<td>electrical connectors</td>
</tr>
<tr>
<td>Litton Network Access Systems (Co.)</td>
<td>St. Louis, MO</td>
<td>12/28/2000</td>
<td>NAFTA±4,332</td>
<td>network access</td>
</tr>
<tr>
<td>Karmazin Products (Co.)</td>
<td>Wyandotte, MI</td>
<td>11/28/2000</td>
<td>NAFTA±4,333</td>
<td>truck parts</td>
</tr>
<tr>
<td>Cherokee Finishing (Co.)</td>
<td>Gaffney, SC</td>
<td>11/27/2000</td>
<td>NAFTA±4,334</td>
<td>printed fabrics</td>
</tr>
<tr>
<td>Mediacyo (Co.)</td>
<td>San Leandro, CA</td>
<td>11/28/2000</td>
<td>NAFTA±4,335</td>
<td>video cassettes</td>
</tr>
<tr>
<td>Philips Display Components (Wkrs)</td>
<td>Ottawa, OH</td>
<td>11/28/2000</td>
<td>NAFTA±4,336</td>
<td>TV picture tubes</td>
</tr>
<tr>
<td>Wiscasset Mills (Co.)</td>
<td>Kannapolis, NC</td>
<td>11/29/2000</td>
<td>NAFTA±4,338</td>
<td>yarns</td>
</tr>
<tr>
<td>Tower Automotive Products (USWA)</td>
<td>Milwaukee, WI</td>
<td>11/29/2000</td>
<td>NAFTA±4,339</td>
<td>truck frames</td>
</tr>
<tr>
<td>Walls Industries (Co.)</td>
<td>Boaz, AL</td>
<td>11/29/2000</td>
<td>NAFTA±4,341</td>
<td>toolboxes and running boards</td>
</tr>
<tr>
<td>Dawus Manufacturing (Wkrs)</td>
<td>Pensacola, FL</td>
<td>11/20/2000</td>
<td>NAFTA±4,342</td>
<td>controls</td>
</tr>
<tr>
<td>Johnson Controls (Co.)</td>
<td>Poteau, OK</td>
<td>11/29/2000</td>
<td>NAFTA±4,343</td>
<td>alternator rotors</td>
</tr>
<tr>
<td>A and B Group (Wkrs)</td>
<td>Shubuta, MS</td>
<td>11/14/2000</td>
<td>NAFTA±4,344</td>
<td></td>
</tr>
<tr>
<td>Hutchinson Moving &amp; Storage (Co.)</td>
<td>Chief Rivers Falls, MN</td>
<td>10/19/2000</td>
<td>NAFTA±4,345</td>
<td>trucking service</td>
</tr>
<tr>
<td>Williamette Electric Products (Co.)</td>
<td>Portland, OR</td>
<td>12/01/2000</td>
<td>NAFTA±4,346</td>
<td></td>
</tr>
<tr>
<td>Owens Brockway (GMPPA)</td>
<td>Lakeland, FL</td>
<td>12/01/2000</td>
<td>NAFTA±4,347</td>
<td></td>
</tr>
<tr>
<td>John Campbell (Wkrs)</td>
<td>Perkasie City, PA</td>
<td>12/04/2000</td>
<td>NAFTA±4,348</td>
<td></td>
</tr>
<tr>
<td>Enterprise Lumber—Miller Shingle (Co.)</td>
<td>Arlington, WA</td>
<td>12/04/2000</td>
<td>NAFTA±4,349</td>
<td></td>
</tr>
<tr>
<td>State Coat Front (Co.)</td>
<td>Boston, MA</td>
<td>12/01/2000</td>
<td>NAFTA±4,350</td>
<td></td>
</tr>
<tr>
<td>G.F. Wright Steel &amp; Wire (USWA)</td>
<td>Worcester, MA</td>
<td>12/01/2000</td>
<td>NAFTA±4,351</td>
<td></td>
</tr>
<tr>
<td>LTV Steel—Alqiqua Works (USWA)</td>
<td>Aliquippa, PA</td>
<td>12/01/2000</td>
<td>NAFTA±4,352</td>
<td></td>
</tr>
<tr>
<td>Centec Roll (Co.)</td>
<td>Bethlehem, PA</td>
<td>12/04/2000</td>
<td>NAFTA±4,353</td>
<td></td>
</tr>
<tr>
<td>Akzo Nobel—Transportation Coatings (Co.)</td>
<td>Brownsville, TX</td>
<td>12/04/2000</td>
<td>NAFTA±4,354</td>
<td></td>
</tr>
<tr>
<td>AWC Crestline (Co.)</td>
<td>Commerce, TX</td>
<td>12/06/2000</td>
<td>NAFTA±4,355</td>
<td></td>
</tr>
<tr>
<td>Ameripol SYNpol (PACE)</td>
<td>Port Neches, TX</td>
<td>12/06/2000</td>
<td>NAFTA±4,356</td>
<td></td>
</tr>
<tr>
<td>Oxford Automotive (UAW)</td>
<td>Arooga, IN</td>
<td>12/06/2000</td>
<td>NAFTA±4,357</td>
<td></td>
</tr>
<tr>
<td>Warm Springs Forest Products Industries (Co.)</td>
<td>Warm Springs, OR</td>
<td>12/06/2000</td>
<td>NAFTA±4,358</td>
<td></td>
</tr>
<tr>
<td>G and P Cutting Contractors (Wkrs)</td>
<td>Parkdale, OR</td>
<td>12/06/2000</td>
<td>NAFTA±4,359</td>
<td></td>
</tr>
<tr>
<td>Phelps Trucking (Wkrs)</td>
<td>Hood River, OR</td>
<td>12/06/2000</td>
<td>NAFTA±4,360</td>
<td></td>
</tr>
<tr>
<td>Money’s Foods (Co.)</td>
<td>Bladford, PA</td>
<td>12/06/2000</td>
<td>NAFTA±4,361</td>
<td></td>
</tr>
<tr>
<td>Carolina Imprints (Co.)</td>
<td>Medford, OR</td>
<td>12/06/2000</td>
<td>NAFTA±4,362</td>
<td></td>
</tr>
<tr>
<td>Condor DC Power Supplies (Co.)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sola Optical USA (Wkrs)</td>
<td>Miami, FL</td>
<td>12/06/2000</td>
<td>NAFTA±4,363</td>
<td></td>
</tr>
<tr>
<td>New Venture Gear (UAW)</td>
<td>East Syracuse, NY</td>
<td>12/06/2000</td>
<td>NAFTA±4,364</td>
<td></td>
</tr>
<tr>
<td>Eastern Fine Paper (Co.)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bynnum Concepts (Wkrs)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carolina Imprints (Co.)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Condor DC Power Supplies (Co.)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sola Optical USA (Wkrs)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Langstown Corporation (Wkrs)</td>
<td>Cherry Hill, NJ</td>
<td>12/08/2000</td>
<td>NAFTA±4,370</td>
<td></td>
</tr>
<tr>
<td>Columbia Falls Aluminum (Co.)</td>
<td>Columbia Falls, MT</td>
<td>12/05/2000</td>
<td>NAFTA±4,371</td>
<td></td>
</tr>
<tr>
<td>Bermo (IUE)</td>
<td>Sank Rapids, MN</td>
<td>12/11/2000</td>
<td>NAFTA±4,372</td>
<td></td>
</tr>
<tr>
<td>Country Roads (Co.)</td>
<td>Greeneville, MI</td>
<td>12/11/2000</td>
<td>NAFTA±4,373</td>
<td></td>
</tr>
<tr>
<td>NTN—BCA Corp. (Wkrs)</td>
<td>Lillie, PA</td>
<td>12/11/2000</td>
<td>NAFTA±4,375</td>
<td></td>
</tr>
<tr>
<td>Amtex (Co.)</td>
<td>Pilot Mountain, NC</td>
<td>12/12/2000</td>
<td>NAFTA±4,376</td>
<td></td>
</tr>
<tr>
<td>Editorial America (Wkrs)</td>
<td>Miami, FL</td>
<td>12/12/2000</td>
<td>NAFTA±4,377</td>
<td></td>
</tr>
<tr>
<td>Eaton Corporation (Wkrs)</td>
<td>Carol Stream, IL</td>
<td>12/12/2000</td>
<td>NAFTA±4,378</td>
<td></td>
</tr>
<tr>
<td>ABC NACO (UAW)</td>
<td>Melrose Park, IL</td>
<td>12/13/2000</td>
<td>NAFTA±4,379</td>
<td></td>
</tr>
<tr>
<td>Wind Industries (Wkrs)</td>
<td>Mt. Pleasant, TX</td>
<td>12/13/2000</td>
<td>NAFTA±4,380</td>
<td></td>
</tr>
<tr>
<td>Warren Logging (Co.)</td>
<td>Gold Hill, OR</td>
<td>12/14/2000</td>
<td>NAFTA±4,381</td>
<td></td>
</tr>
<tr>
<td>Comp X—Chicago Lock (Wkrs)</td>
<td>Pleasant Prairie, WI</td>
<td>12/07/2000</td>
<td>NAFTA±4,382</td>
<td></td>
</tr>
<tr>
<td>Saputo Cheese (IBS)</td>
<td>Monroe, WI</td>
<td>12/13/2000</td>
<td>NAFTA±4,383</td>
<td></td>
</tr>
<tr>
<td>Saputo Cheese (IBS)</td>
<td>Thorp, WI</td>
<td>12/13/2000</td>
<td>NAFTA±4,384</td>
<td></td>
</tr>
</tbody>
</table>
DEPARTMENT OF LABOR
Employment and Training Administration

[NAFTA—04106]

United States Leather, Lackawanna Leather, Including Leased Workers of Snelling Personnel Services Employed at United States Leather, Lackawanna Leather, El Paso, TX; Amended Certification Regarding Eligibility To Apply for NAFTA-Transitional Adjustment Assistance

In accordance with Section 250(A), Subchapter D, Chapter 2, Title II, of the Trade Act of 1974 (19 USC 2273), the Department of Labor issued a Certification for NAFTA Transitional Adjustment Assistance on October 6, 2000, applicable to workers of United States Leather, Lackawanna Leather, El Paso, Texas. The notice was published in the Federal Register on November 1, 2000 (65 FR 65331).

At the request of the State agency, the Department reviewed the certification for workers of the subject firm. New information shows that some workers of United States Leather, Lackawanna Leather were leased from Snelling Personnel Services to produce leather hides used for the production of car seats at the El Paso, Texas facility. Information also shows that workers separated from employment at the subject firm had their wages reported under a separate unemployment insurance (UI) tax account for Snelling Personnel Services.

Based on these findings, the Department is amending the certification to include workers of Snelling Personnel Services leased to United States Leather, Lackawanna Leather, El Paso, Texas.

The intent of the Department’s certification is to include all workers of United States Leather, Lackawanna Leather adversely affected by imports from Mexico.

The amended notice applicable to NAFTA—04106 is hereby issued as follows:

All workers of United States Leather, Lackawanna Leather, El Paso, Texas and leased workers of Snelling Personnel Services, El Paso, Texas engaged in employment related to the production of leather hides used for the production of car seats for United States Leather, Lackawanna Leather, El Paso, Texas who became totally or partially separated from employment on or after August 14, 1999 through October 6, 2002 are eligible to apply for NAFTA-TAA under Section 250 of the Trade Act of 1974.

Signed at Washington, DC this 19th day of December, 2000.

Linda G. Poole,
Certifying Officer, Division of Trade Adjustment Assistance.

[FR Doc. 00–33066 Filed 12–27–00; 8:45 am]

BILLING CODE 4510–30–M

DEPARTMENT OF LABOR
Mine Safety and Health Administration

Fee Adjustments for Testing, Evaluation, and Approval of Mining Products

AGENCY: Mine Safety and Health Administration (MSHA), Labor.

ACTION: Notice of fee adjustments.

SUMMARY: This notice revises our (MSHA Approval and Certification Center (A&CC)) user fees. Fees compensate us for the costs that we incur for testing, evaluating, and approving certain products for use in underground mines. We based the 2001 fees on our actual expenses for fiscal year 2000. The fees reflect changes both in our approval processing operations and in our costs to process approval actions.

[FR Doc. 00–33060 Filed 12–27–00; 8:45 am]

BILLING CODE 4510–30–M
DATES: These fee schedules are effective from January 1, 2001 through December 31, 2001.

FOR FURTHER INFORMATION CONTACT:
Steven J. Luzik, Chief, Approval and Certification Center (A&CC), 304–547–2029 or 304–547–0400.

SUPPLEMENTARY INFORMATION:

Background

On May 8, 1987 (52 FR 17506), we published a final rule, 30 CFR part 5—Fees for Testing, Evaluation, and Approval of Mining Products. The rule established specific procedures for calculating, administering, and revising user fees. We have revised our fee schedule for 2001 in accordance with the procedures of that rule and include this new fee schedule below. For approval applications postmarked before January 1, 2001, we will continue to calculate fees under the previous (2000) fee schedule, published on December 28, 1999.

Fee Computation

In general, we computed the 2001 fees based on fiscal year 2000 data. We calculated a weighted-average, direct cost for all the services that we provided during fiscal year 2000 in the processing of requests for testing, evaluation, and approval of certain products for use in underground mines. From this cost, we calculated a single hourly rate to apply uniformly across all of the product approval categories during 2001.


J. Davitt McAteer, Assistant Secretary for Mine Safety and Health.

<table>
<thead>
<tr>
<th>FEE SCHEDULE EFFECTIVE JANUARY 1, 2001</th>
</tr>
</thead>
<tbody>
<tr>
<td>[Based on FY 2000 data]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Action title</th>
<th>Hourly rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fees for Testing, Evaluation, and Approval of all Mining Products ¹</td>
<td>$58</td>
</tr>
<tr>
<td>Retesting for Approval as a Result of Post-Approval Product Audit ²</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>30 CFR PART 15—EXPLOSIVES TESTING</th>
</tr>
</thead>
<tbody>
<tr>
<td>Permissibility Tests for Explosives:</td>
</tr>
<tr>
<td>Weigh-in</td>
</tr>
<tr>
<td>Physical Exam: First size</td>
</tr>
<tr>
<td>Chemical Analysis</td>
</tr>
<tr>
<td>Air Gap—Minimum Product Firing Temperature</td>
</tr>
<tr>
<td>Air Gap—Room Temperature</td>
</tr>
<tr>
<td>Pendulum Friction Test</td>
</tr>
<tr>
<td>Detonation Rate</td>
</tr>
<tr>
<td>Gallery Test 7</td>
</tr>
<tr>
<td>Gallery Test 8</td>
</tr>
<tr>
<td>Toxic Gases (Large Chamber)</td>
</tr>
<tr>
<td>Permissibility Tests for Sheathed Explosives:</td>
</tr>
<tr>
<td>Physical Examination</td>
</tr>
<tr>
<td>Gallery Test 9</td>
</tr>
<tr>
<td>Gallery Test 10</td>
</tr>
<tr>
<td>Gallery Test 11</td>
</tr>
<tr>
<td>Gallery Test 12</td>
</tr>
<tr>
<td>Drop Test</td>
</tr>
<tr>
<td>Temperature Effects/Detonation</td>
</tr>
<tr>
<td>Toxic Gases</td>
</tr>
</tbody>
</table>

¹ Full approval fee consists of evaluation cost plus applicable test costs.

² Fee based upon the approval schedule in effect at the time of retest.

Note: When the nature of the product requires that we test and evaluate it at a location other than our premises, you must reimburse us for the traveling, subsistence, and incidental expenses of our representative in accordance with standardized government travel regulations. This reimbursement is in addition to the fees charged for evaluation and testing.

[FR Doc. 00–33132 Filed 12–27–00; 8:45 am]
BILLING CODE 4510–43–P

LEGAL SERVICES CORPORATION

Program Letter 2000–7—State Planning and Performance Measures

AGENCY: Legal Services Corporation.


SUMMARY: This Notice sets forth the text of Program Letter 2000–7—State Planning and Performance Measures. The program letter announces three strategies to advance LSC’s efforts to create comprehensive integrated, coordinated, client-centered state justice communities in each state:

1. The creation of a team within LSC specifically assigned responsibility for state planning;

2. A period of self-evaluation by and in each state justice community, with an evaluation report to be issued to LSC at the end of the evaluation period; and

3. The linking of state planning with the development of new performance measurement tools.

This Program Letter has been sent to each LSC grant recipient and is also posted to the LSC website at www.lsc.gov.

FURTHER INFORMATION CONTACT:
Randi Youells, Vice President for Programs, Legal Services Corporation, 750 First Street, NE, Washington, DC 20002–4250; 202/336–7269 (phone); youellsr@lsc.gov.

SUPPLEMENTARY INFORMATION:

Program Letter 2000–7

To: All LSC Program Directors.

From: Randi Youells, Vice President for Programs.
Date: December 13, 2000.


Program Letters 98–1 and 98–6 launched LSC’s most recent state planning activities approximately three years ago. Pressured by funding shortfalls and the changing needs of clients and concerned with enhancing system efficiency, effectiveness and the ability to meet clients’ legal needs, legal services programs throughout the United States were challenged by these two program letters to become actively engaged in a process of reassessing their delivery policies and programs, restructuring their legal services delivery systems and reallocating their legal services dollars. Essentially, LSC Program Letters 98–1 and 98–6 asked grantees to look at their roles in a new way—to expand their horizons from what’s best for the clients in my service area to what is best for clients throughout the state. Using this new lens, programs were asked to report on how they would coordinate and integrate their work in seven important areas—enhancing client access, efficiently delivering high quality legal assistance, using technology to expand access to legal services, improving client self-help and preventive legal education and advice, coordinating legal work and training staff, coordinating and collaborating with the private bar; developing additional resources to support legal services delivery; and designing a legal services delivery configuration that enhanced client services, reduced barriers and operated efficiently and effectively.

On January 28, 2000, the LSC Board of Directors approved LSC’s 5-year Strategic Direction Plan. This document commits LSC to dramatically enhance the impact of Legal Services programs throughout the nation by improving access to legal services among eligible persons while enhancing the quality of the services delivered. The Plan highlighted LSC’s State Planning Initiative as the primary strategy for expanding access to and availability of services throughout the United States.

Over the course of the last three years, many states have begun to develop comprehensive and integrated legal services delivery systems that:

1. (1) recognize that state justice communities must be broader than just LSC-funded grantees to include both LSC-funded and non-LSC funded sectors of the legal services delivery system, and
   (2) provide a continuum of services that encompasses individual representation, extended representation, advice, pro se advocacy, preventative education, community involvement and support, and the use of technology to expand essential services to all low-income persons within a state.

   These are exciting developments. However, it continues to be apparent that in many states and territories, the legal services delivery system remains a fragmented set of disconnected services. In many states we continue to find a wide divergence in the availability of services, client access capabilities and civil equal justice resources. This stands in stark contrast to our expectation that the statewide delivery system be constructed and maintained to provide:
   (a) Relative equity of client access to the civil legal services delivery system throughout the state; and
   (b) relative equity in the availability of the full range of client service capacities necessary to meet the full continuum of client legal needs regardless of where in the state clients live;
   (c) relative equity in the capacity to serve client communities in all of their diversity; and
   (d) relative equity in the investment of civil equal justice resources (federal, state, private, and in-kind/pro bono) throughout the state.

   A hallmark of an integrated delivery system is its flexibility to deploy resources in geographic or substantive areas so that quality of services is improved, funds are increased and outcomes for clients are expanded in areas where they are weak. In this context, then, relative equity considers the system’s various capacities throughout the state, from region to region, and directs necessary resources to locales where improvement of any sort is required to assure that all low-income people in the state have similar degrees of access to the full spectrum of equal justice services.

   In this program letter we are announcing three strategies to advance LSC’s efforts to create comprehensive, integrated, coordinated, client-centered state justice communities in each state:
   (1) The creation of a team within LSC specifically assigned responsibility for state planning;
   (2) A period of self-evaluation by and in each state justice community, with an evaluation report to be issued to LSC at the end of the evaluation period; and
   (3) The linking of state planning with the development of new performance measurement tools.

   The information received from the field on the State Planning Process and Program Letters 98–1 and 98–6 after publication of these two documents in the Federal Register and input derived from more than two years of on-site engagement by LSC staff and consultants in the field were instrumental in the development of these strategies.

   The Creation of a State Planning Team within LSC

   LSC’s Strategic Plan emphasizes that LSC’s State Planning Initiative is our primary strategy for expanding access to and availability of services throughout the United States. To stress the importance of this effort and to facilitate the development of state justice communities, LSC will create a planning team to coordinate our state planning activities. This team will be directly attached to and supervised by the LSC Vice-President for Programs.

   A Period of Self-Evaluation by and in Each State Justice Community

   We are in a period of significant transition moving from an LSC-centric legal services model to comprehensive, integrated and client-centered state justice communities. We acknowledge that the journey is not over and that significant effort remains to ensure that comprehensive justice communities exist and function within every state and territory. As we move forward with our efforts, we must remain conscious of the need to address several questions of fundamental relevance. These include:

   (1) To what extent has a comprehensive, integrated client-centered legal services delivery system been achieved in a particular state?
   (2) To what extent have intended outcomes of a comprehensive, integrated and client-centered legal service delivery system been achieved including but not limited to service effectiveness/quality; equity in terms of client access; greater involvement by members of the private bar in the legal lives of clients; and client-community empowerment?
   (3) Are the best organizational and human resource management configurations and approaches being used?

   We believe that the next several months are an appropriate time to try to begin to answer these questions. We have been involved in state planning activities for approximately three years, and LSC believes that states need a period of introspection about where

   1To download a copy, go to http://www.lsc.gov/press/pr_pi_pl.htm.
they have been and where they are going. Moreover, we can all acknowledge that self-evaluation is a worthwhile and important part of our planning for the creation of comprehensive, integrated, client-centered legal services delivery systems within each state. We are, accordingly, requiring our grantees and requesting that other state planners begin a period of evaluation of their planning efforts and activities over the last three years using the above questions as a framework for the evaluation report. These self-evaluations will inform each state justice community and LSC of what has worked, what has not worked and why, what obstacles stand in planners path, and what steps and support might assist each state to better achieve a comprehensive, integrated, client-centered delivery system that delivers upon the promise of equal justice for all.

Evaluations can be performed by state planners themselves or by outside consultants hired to perform this task. We ask that a single evaluation report for each state be submitted to LSC on or before July 1, 2001 unless LSC has granted your state an extension of time in which to file the report. Please submit your extension requests no later than May 15, 2001, to Robert Gross, Senior Program Counsel for State Planning at LSC. Reports should be no longer than 30 pages (not more than 10 pages single-spaced for each area of inquiry) and should contain the name and telephone number of a contact person(s). Attachments will be accepted as long as they provide additional information that clarifies a particular issue or area of inquiry as identified in the body of the report. The report should assume that the effort to create state justice communities is ongoing and that we do not expect that you have completed your work. Self-evaluation reports should be a candid and honest assessment of the progress that each state has made in creating a comprehensive, integrated and client-centered delivery system as well as of the work that remains to be done. Reports should address the following issues in the order presented:

To what extent has a comprehensive, integrated and client-centered legal services delivery system been achieved in a particular state?

Areas of exploration include:

(1) What are the important issues that impact upon low income people within your state? How is your state responding to these issues?
(2) What are the components of the delivery system?
(3) Has this system created mechanisms to assess its performance in relationship to commonly-accepted external guides such as the ABA Standards for Providers of Civil Legal Services to the Poor, the LSC Performance Criteria or some other set of objective criteria? What is the protocol for undertaking system performance review and when was a review last undertaken?
(4) Does your statewide system work to ensure the availability of equitable legal assistance capacities to clients—regardless of who the clients are, where they reside or the languages they speak? How does your system ensure that clients have equitable access to necessary assistance including self-help, legal education, advice, brief service, and representation in all relevant forums? Please describe what steps you anticipate taking to ensure equitable access in the coming years.
(5) How does the legal service delivery system employ technology to provide critical legal services to low-income clients including hard to reach groups such as migrant farmworkers, Native Americans, the elderly, those with physical or mental disabilities, those confined to institutions, immigrants and the rural poor?
(6) Has the legal service delivery system expanded its resources to provide critical legal services to low-income clients including hard to reach groups such as migrant farmworkers, Native Americans, the elderly, those with physical or mental disabilities, those confined to institutions, immigrants and the rural poor?
(7) What steps have been implemented within the legal service delivery system and among client communities to identify and nurture new leaders? Do the existing leaders reflect the diversity within the state and within client communities that your delivery system serves? Do your state’s equal justice leaders reflect the gender, race, ethnic and economic concerns of important but sometimes overlooked groups within your state? Does the leadership provide opportunities for innovation and experimentation; does it support creative solutions to meet changing needs; are new ideas welcomed; are clients nurtured as leaders? Has the leadership been given sufficient authority and resources to implement needed changes?
(8) What do you envision will be your next steps to achieve a client-centered integrated and comprehensive delivery system within your state or territory? How will clients be actively involved in the determination of these next steps?
(9) What has been the greatest obstacle to achieving a statewide, integrated, client-centered delivery system and how was that obstacle overcome or, alternatively, how do you plan to overcome that obstacle?
(10) Has any benefit-to-cost analysis been made in terms of creating a comprehensive, integrated and client-centered legal services delivery system in your state? If yes, what does your analysis show?
(11) What resources, technical assistance and support would help you meet your goals?
To what extent have intended outcomes of a comprehensive, integrated client-centered legal service delivery system been achieved including but not limited to service effectiveness/quality; efficiency; equity in terms of client access; greater involvement by members of the private bar in the legal lives of clients, and client-community empowerment?

Areas of exploration include:

(1) In terms of the issues impacting upon low-income persons within your state, what strategies have you designed to address these issues and how do you plan to measure your future success in addressing your objectives?
(2) Has the legal services delivery system expanded access and services through coordination with providers throughout the state? Can this be quantified?
(3) Has the quality of services provided by the legal services delivery system improved. How?
(4) Since 1998, has there been improvement in the relative equity of client access throughout the state for all low income clients regardless of who they are, where in the state they reside, what languages they speak, their race/ gender/national origin, or the existence of other access barriers? How is this equity achieved?
(5) Since 1998, has there been improvement in the relative equity in terms of the availability of the full range of civil equal justice delivery capacities throughout the state? What mechanisms have been developed to ensure such relative equity is achieved and maintained? Since 1998, has there been improvement in the relative equity in the development and distribution of civil equal justice resources throughout the state? Are there areas of the state that suffer from a disproportionate lack of resources (funding as well as in-kind/ pro bono)? If so, is there a strategy to overcome such inequities?
(6) Does this legal services delivery system operate efficiently? Are there areas of duplication?
(7) Has the system expanded the way it involves private lawyers in the
delivery of essential services to low-income persons? Does the system effectively and efficiently use the private bar to deliver essential services to low income people?

Are the best organizational and human resource management configurations and approaches being used?

Areas of exploration include:
(1) For calendar year 2001, what is the current configuration of programs (LSC and non-LSC) that deliver services to low income clients—i.e., what are the components (size, areas of responsibility, governance) of the delivery system? What are the funding sources and levels for each of these components of the delivery system?
(2) Since October 1998, what other configurations and/or approaches have been seriously explored? Were any adopted? Were any rejected? Are any changes contemplated in the coming year?
(3) Is there any identifiable duplication in capacities or services in the state? How many duplicative systems—accounting systems, human resources management systems, case management systems, etc.—currently exist? Does the service delivery system now in use minimize or eliminate duplications that existed prior to October 1, 1998?
(4) Since October 1998, what innovative service delivery systems/mechanisms/initiatives have been adopted in the state? Have any been explored and then rejected?

**Linking State Planning with the Development of New Performance Measurement Tools**

Simultaneously with these self-evaluations, LSC will proceed to contract with a private research firm to formally evaluate legal services delivery systems in a selected number of states. LSC plans to select several states that we believe are at important stages of the planning-implementation process for an outside evaluation. If your state is chosen, you will not have to do the self-evaluation discussed in this program letter. Moreover, LSC will provide discretionary grants and/or technical assistance to assist with and help defray any in-kind program costs associated with this project.

The purpose of these evaluations will be to determine whether or not the delivery model in use in the state has effectively implemented the concepts and principles of a comprehensive, integrated and client-centered legal services delivery system. LSC will study the relationship between the structure of the delivery system and desired outcomes as articulated by the selected states in prior planning documents. The findings of these formal evaluations—together with the material presented in the self-evaluations—will assist LSC and other interested stakeholders in understanding how best to conceptualize, design and deliver comprehensive, integrated and client-centered legal services. We will use this information to begin to develop new performance measurement tools.

**Victor M. Fortuno,**
**General Counsel and Vice President for Legal Affairs.**

[FR Doc. 00–33143 Filed 12–27–00; 8:45 am]

**BILLING CODE 7050–01–P**

### NATIONAL FOUNDATION ON THE ARTS AND THE HUMANITIES

#### Meetings of the Humanities Panel

**AGENCY:** The National Endowment for the Humanities.

**ACTION:** Notice of meetings.

**SUMMARY:** Pursuant to the provisions of the Federal Advisory Committee Act (Public Law 92–463, as amended) notice is hereby given that the following meetings of the Humanities Panel will be held at the Old Post Office, 1100 Pennsylvania Avenue, NW., Washington, DC 20506.

##### FOR FURTHER INFORMATION CONTACT:
Lauras S. Nelson, Advisory Committee Management Officer, National Endowment for the Humanities, Washington, DC 20506; telephone (202) 606–8322. Hearing-impaired individuals are advised that information on this matter may be obtained by contacting the Endowment’s TDD terminal on (202) 606–8282.

##### SUPPLEMENTARY INFORMATION:
The proposed meetings are for the purpose of panel review, discussion, evaluation and recommendation on applications for financial assistance under the National Foundation on the Arts and the Humanities Act of 1965, as amended, including discussion of information given in confidence to the agency by the grant applicants. Because the proposed meetings will consider information that is likely to disclose trade secrets and commercial or financial information obtained from a person and privileged or confidential and/or information of a personal nature the disclosure of which would constitute a clearly unwarranted invasion of personal privacy, pursuant to authority granted me by the Chairman’s Delegation of Authority to Close Advisory Committee meetings, dated July 19, 1993, I have determined that these meetings will be closed to the public pursuant to subsections (c)(4), (6) of section 552b of Title 5, United States Code.

1. **Date:** January 5, 2001.
   **Time:** 8:30 a.m. to 5:00 p.m.
   **Room:** 315.

   **Program:** This meeting will review applications for Asia and Africa in Collaborative Research, submitted to the Division of Research Programs at the September 1, 2000 deadline.

2. **Date:** January 8, 2001.
   **Time:** 8:30 a.m. to 5:00 p.m.
   **Room:** 315.

   **Program:** This meeting will review applications for American Studies II in Collaborative Research, submitted to the Division of Research Programs at the September 1, 2000 deadline.

3. **Date:** January 9, 2001.
   **Time:** 8:30 a.m. to 5:00 p.m.
   **Room:** 415.

   **Program:** This meeting will review applications for a New Millennium, submitted to the Division of Education Programs at the October 1, 2000 deadline.

4. **Date:** January 9, 2001.
   **Time:** 8:30 a.m. to 5:00 p.m.
   **Room:** 315.

   **Program:** This meeting will review applications for European Studies in Collaborative Research, submitted to the Division of Research Programs at the September 1, 2000 deadline.

5. **Date:** January 10, 2001.
   **Time:** 8:30 a.m. to 5:00 p.m.
   **Room:** 415.

   **Program:** This meeting will review applications for National Education Projects, submitted to the Division of Education at the October 15, 2000 deadline.

6. **Date:** January 11, 2001.
   **Time:** 9:00 a.m. to 5:00 p.m.
   **Room:** 315.

   **Program:** This meeting will review applications for Ancient and Medieval Studies in Collaborative Research, submitted to the Division of Research Programs at the September 1, 2000 deadline.

7. **Date:** January 11, 2001.
   **Time:** 8:30 a.m. to 5:00 p.m.
   **Room:** 415.

   **Program:** This meeting will review applications for Schools for a New Millennium, submitted to the Division of Education Programs at the October 1, 2000 deadline.

8. **Date:** January 12, 2001.
   **Time:** 8:30 a.m. to 5:00 p.m.
   **Room:** 415.

   **Program:** This meeting will review applications for National Education Programs at the September 1, 2000 deadline.

This meeting will review applications for National Education Programs at the September 1, 2000 deadline.
NUCLEAR REGULATORY COMMISSION

[Docket No. 50–400]

Carolina Power & Light Company; Notice of Issuance of Amendment to Facility Operating License and Final Determination of No Significant Hazards Consideration

The U.S. Nuclear Regulatory Commission (Commission) has issued Amendment No. 103 to Facility Operating License No. NPF–63 issued to Carolina Power & Light Company (CP&L, the licensee), which revised the Technical Specifications (TS) for operation of the Shearon Harris Nuclear Power Plant, Unit 1 (HNP), located in Wake and Chatham Counties, North Carolina. The amendment is effective as of the date of issuance.

The amendment modified the TS to support a modification to HNP to increase the spent fuel storage capacity by adding rack modules to spent fuel pools (SFPs) C and D and placing the pools in service. Specifically, the amendment consists of: (1) A revision to TS 5.6 to identify pressurized water reactor fuel burnup restrictions, boiling water reactor fuel enrichment limits, pool capacities, heat load limitations, and nominal center-to-center distances between fuel assemblies in the racks to be installed in SFPs C and D; (2) an alternative plan in accordance with the requirements of 10 CFR 50.55a to demonstrate an acceptable level of quality and safety in completion of the component cooling water (CCW) and SFPs C and D cooling and cleanup system piping; and (3) an unreviewed safety question for additional heat load on the CCW system.

The application for the amendment complies with the standards and requirements of the Atomic Energy Act of 1954, as amended (the Act), and the Commission’s rules and regulations. The Commission has made appropriate findings as required by the Act and the Commission’s rules and regulations in 10 CFR Chapter I, which are set forth in the license amendment. Notice of Consideration of Issuance of Amendment to Facility Operating License and Opportunity for a Hearing in connection with this action was published in the Federal Register on January 13, 1999 (64 FR 2237). A request for a hearing was filed on February 12, 1999, by the Board of Commissioners of Orange County, North Carolina (BCOC).

On July 12, 1999, the Atomic Safety and Licensing Board (ASLB) ruled that BCOC had standing and had submitted two admissible contentions. The two contentions related to (1) whether General Design Criterion 62 allows the use of administrative controls to prevent criticality (TC–2); and (2) the adequacy of the licensee’s proposed alternative plan for the cooling system piping (TC–3). On July 29, 1999, the ASLB granted CP&L’s request to hold the hearing in accordance with the hybrid hearing procedures of 10 CFR Part 2, Subpart K. On January 4, 2000, all parties filed written summaries and on January 21, 2000, the ASLB heard oral arguments related to the two admitted contentions. On May 5, 2000, the ASLB issued a decision in favor of CP&L, stating that “(1) there is no genuine and substantial dispute of fact or law that can only be resolved with sufficient accuracy by the introduction of evidence in an evidentiary hearing; and (2) contentions TC–2 and TC–3 are disposed of as being resolved in favor of CP&L.”

On January 31, 2000, BCOC filed four late-filed environmental contentions that challenged the adequacy of the staff’s December 21, 1999, environmental assessment related to CP&L’s amendment request. On March 3, 2000, the NRC and CP&L responded to the late-filed contentions, and on March 13, 2000, BCOC submitted its reply to the responses. On August 7, 2000, the ASLB issued its Ruling on Late-filed Environmental Contentions. In its ruling, the ASLB admitted one environmental contention (EC–6) regarding the probability of occurrence of BCOC’s postulated accident scenario. On November 20, 2000, all parties filed written summaries and on December 7, 2000, the ASLB heard oral arguments related to EC–6.

Under its regulations, the Commission may issue and make an amendment immediately effective, notwithstanding the pendency before it of a request for a hearing from any person, in advance of the holding or completion of any request for hearing. Where it has determined that no significant hazards considerations are involved.

The Commission has applied the standards of 10 CFR 50.92 and has made a final determination that the amendment involves no significant hazards considerations. The basis for this determination is contained in the Safety Evaluation related to this action. Accordingly, as described above, the amendment has been issued and made immediately effective and any hearing will be held after issuance.

The Commission has prepared an Environmental Assessment related to the action and has determined not to prepare an environmental impact statement. Based upon the environmental assessment, the Commission has concluded that the issuance of the amendment will not have a significant effect on the quality of the human environment (64 FR 71514).

For further details with respect to the action see (1) the application for amendment dated December 23, 1998, as supplemented on March 15, April 5, April 30, June 14, July 23, September 3, October 15, and October 29, 1999, and April 14, and July 19, 2000, (2) Amendment No. 103 to License No. NPF–63, (3) the Commission’s related Safety Evaluation, and (4) the Commission’s Environmental Assessment. All of these items are available for public inspection at the Commission’s Public Document Room, located at One White Flint North, 11555 Rockville Pike (first floor), Rockville, Maryland, and accessible electronically through the ADAMS Public Electronic Reading Room link at the NRC Web site (http://www.nrc.gov).

Dated at Rockville, Maryland, this 21st day of December 2000.

For the Nuclear Regulatory Commission.

Richard P. Correia,
Chief, Section 2, Project Directorate II, Division of Licensing Project Management, Office of Nuclear Reactor Regulation.

[FR Doc. 00–33152 Filed 12–27–00; 8:45 am]

BILLING CODE 7590–01–P

NUCLEAR REGULATORY COMMISSION

[Docket No. 50–305]

Nuclear Management Company, LLC; Notice of Withdrawal of Application for Amendment to Facility Operating License

The U.S. Nuclear Regulatory Commission (the Commission) has granted the request of Nuclear Management Company, LLC (the licensee) to withdraw the June 7, 1999, as supplemented February 4, and
September 26, 2000, application for proposed amendment to Facility Operating License No. DPR–43 for the Kewaunee Nuclear Power Plant, located in Kewaunee County, Wisconsin.

The proposed amendment would have revised the Kewaunee Nuclear Power Plant Technical Specifications for the facility’s reactor pressure vessel Pressure-Temperature limit curves.

The Commission had previously issued a Notice of Consideration of Issuance of Amendment published in the Federal Register on November 15, 2000 (65 FR 69061). However, by letter dated December 18, 2000, the licensee withdrew the proposed amendment change, but the licensee did not withdraw the exemption requests in the submittals dated June 7, 1999, as supplemented February 4, September 26, and December 18, 2000. The exemption requests are being processed separately.

For further details with respect to this action, see the application for amendment dated June 7, 1999, as supplemented February 4, and September 26, 2000, and the licensee’s letter dated December 18, 2000, which withdrew the application for license amendment. Documents may be examined, and/or copied for a fee, at the NRC’s Public Document Room, located at One White Flint North, 11555 Rockville Pike (first floor), Rockville, Maryland, and accessible electronically through the ADAMS Public Electronic Reading Room link at the NRC Web site (http://www.nrc.gov).

Dated at Rockville, Maryland, this 21st day of December 2000.

For the Nuclear Regulatory Commission.

John G. Lamb,
Project Manager, Section 1, Project Directorate III, Division of Licensing Project Management, Office of Nuclear Reactor Regulation...

[FR Doc. 00–33151 Filed 12–27–00; 8:45 am]

BILLING CODE 7590–01–P

NUCLEAR REGULATORY COMMISSION

[Docket Nos. 50–272 and 50–311]

In the Matter of PSEG Nuclear LLC, Philadelphia Electric Company, (PESCO Energy Company), Delmarva Power and Light Company, Atlantic City Electric Company, (Salem Nuclear Generating Station, Units 1 and 2);

Supplemental Order Regarding Approval of Transfer of Licenses and Conforming Amendments

I

PSEG Nuclear LLC, Philadelphia Electric Company (PESCO Energy Company), Delmarva Power and Light Company (DP&L), and Atlantic City Electric Company (ACE) are the joint owners of the Salem Nuclear Generating Station, Unit Nos. 1 and 2 (Salem), located in Salem County, New Jersey. They hold Facility Operating Licenses Nos. DPR–70 and DPR–75, issued by the U.S. Nuclear Regulatory Commission (NRC or Commission) on August 13, 1976, and May 20, 1981, respectively, pursuant to Part 50 of Title 10 of the Code of Federal Regulations (10 CFR Part 50). Under these licenses, PSEG Nuclear LLC (currently owner of 42.59 percent of each Salem unit) is authorized to possess, use, and operate the Salem units. The current combined nonoperating ownership interests of DP&L and ACE are 14.82 percent of each Salem unit. They own 7.41 percent of each Salem unit individually.

II

By an application dated December 20, 1999, as supplemented February 11, and February 25, 2000, PSEG Nuclear LLC, DP&L, and ACE requested approval by the NRC of the transfer to PSEG Nuclear LLC of the Salem licenses, to the extent held by DP&L and ACE, in conjunction with the proposed acquisition of DP&L’s and ACE’s combined ownership interests in the Salem units by PSEG Nuclear LLC. DP&L and ACE are both subsidiaries of Conectiv. In response to that request, the NRC staff published a notice of the license transfer application, the related conforming amendment request included in the application, and an opportunity for a hearing in the Federal Register on February 18, 2000 (65 FR 8452). No hearing requests were filed. The NRC approved the transfer request by an Order dated April 21, 2000. That Order, which contained several conditions of approval, was based in part on the premise that the DP&L and ACE interests would be transferred concurrently as a combined interest. In a supplemental application dated October 10, 2000, DP&L and ACE indicated that due to certain delays in receiving other necessary regulatory approvals, their interests in the Salem licenses need to be transferred independently in two phases to PSEG Nuclear LLC, namely the DP&L interest would be transferred first, followed by the transfer of the ACE interest. They asked that the effectiveness of the Order approving the license transfers be extended until December 31, 2001, due to the delays in receiving the other regulatory approvals, and that any necessary actions be taken to allow the transfers to occur in two phases.

PSEG Nuclear LLC also requested approval of conforming license amendments, modified from the amendments previously approved to reflect the transfers as they may occur in two phases. The amendments would still delete references to DP&L and ACE to reflect the transfer of each of their interests, as they occur, in the licenses to PSEG Nuclear LLC.

Approval of the transfers, as they may now occur in two phases, and corresponding modified conforming license amendments was requested pursuant to 10 CFR 50.80 and 50.90. The NRC staff determined that the supplemental application dated October 10, 2000, related only to schedular matters and did not involve any material changes to the underlying basis for the transfer approval Order dated April 21, 2000. Therefore, the supplemental application was within the scope of the PSEG Nuclear LLC Order dated April 18, 2000, Federal Register notice and did not require remoting or a new opportunity for a hearing.

Pursuant to 10 CFR 50.80, no license, or any right thereunder, shall be transferred, directly or indirectly, through transfer of control of the license, unless the Commission shall give its consent in writing. After reviewing the information submitted in the October 10, 2000, submittal and other information before the Commission, the NRC staff has determined that its previous findings set forth in the Order dated April 21, 2000, remain valid notwithstanding the transfers occurring in two phases, namely, PSEG Nuclear LLC is qualified to hold the license for each Salem unit to the same extent the licenses are now held by DP&L and ACE, and that the transfer of the licenses, as previously described herein, is otherwise consistent with applicable provisions of law, regulations, and orders issued by the Commission subject to the conditions described herein. The NRC staff has further found that the...
supplemental application for the proposed license amendments to reflect the transfers occurring in two phases complies with the standards and requirements of the Atomic Energy Act of 1954, as amended (the Act), and the Commission’s rules and regulations set forth in 10 CFR Chapter I; the facility will operate in conformity with the application, the provisions of the Act, and the rules and regulations of the Commission; there is reasonable assurance that the activities authorized by the proposed license amendments can be conducted without endangering the health and safety of the public and that such activities will be conducted in compliance with the Commission’s regulations; the issuance of the proposed license amendments will not be inimical to the common defense and security or to the health and safety of the public; and the issuance of the proposed license amendments will be in accordance with 10 CFR Part 51 of the Commission’s regulations and all applicable requirements have been satisfied. These findings are supported by a safety evaluation dated December 21, 2000.

III

Accordingly, pursuant to Sections 161b, 161i, and 184 of the Atomic Energy Act of 1954, as amended, 42 U.S.C. §§ 2201(b), 2201(i), and 2234, and 10 CFR 50.80, It Is Hereby Ordered that the effectiveness of the Order dated April 21, 2000, is extended to December 31, 2001. Any concurrent transfer of the DP&L and ACE interests to PSEG Nuclear LLC shall remain subject to the terms and conditions of the April 21, 2000, Order.

It Is Further Ordered that the license transfers from DP&L and ACE to PSEG Nuclear LLC may occur in two phases, as described above, subject to the following conditions:

1. DP&L shall transfer to the PSEG Nuclear LLC decommissioning trusts for Salem at the time its interests in the Salem licenses are transferred to PSEG Nuclear LLC, all of ACE’s accumulated decommissioning trust funds for Salem Unit Nos. 1 and 2. Immediately following such transfer, the amounts in the PSEG Nuclear LLC decommissioning trusts must, with respect to the interests in Salem Unit Nos. 1 and 2 PSEG Nuclear LLC would then hold, be at a level no less than the formula amounts under 10 CFR Section 50.75.

2. ACE shall transfer to the PSEG Nuclear LLC decommissioning trusts for Salem at the time its interests in the Salem licenses are transferred to PSEG Nuclear LLC, all of ACE’s accumulated decommissioning trust funds for Salem Unit Nos. 1 and 2. Immediately following such transfer, the amounts in the PSEG Nuclear LLC decommissioning trusts must, with respect to the interests in Salem Unit Nos. 1 and 2 PSEG Nuclear LLC would then hold, be at a level no less than the formula amounts under 10 CFR Section 50.75.

3. Conditions 3.a. through 3.e. of the April 21, 2000, Order, which have now been incorporated into the Salem licenses by a separate licensing action, shall remain applicable to the PSEG Nuclear LLC decommissioning trust agreements for Salem Unit Nos. 1 and 2. The citation in the foregoing condition 3.e. is corrected to read “10 CFR 35.32(a)(3)”.

4. PSEG Nuclear LLC shall inform the Director, Office of Nuclear Reactor Regulation, in writing, of the date of closing of each subject transfer no later than 2 business days before the date of each closing. If the transfer of the DP&L or ACE interests is not completed by December 31, 2001, this Order shall become null and void with respect to any such transfer not yet completed; however, on application and for good cause shown, such date may be extended.

It Is Further Ordered that, consistent with 10 CFR 2.1315(b), license amendments that make changes, as indicated in Enclosure 2 to the cover letter forwarding this Order, to conform each Salem license to reflect each subject license transfer are approved. To the extent the license pages in Enclosure 2 reflect intervening events and completed licensing actions that have occurred since the issuance of the April 21, 2000, Order, and therefore are inconsistent with the license pages referenced in that Order showing the changes to the licenses approved by that Order, the amendment pages approved by this Order supersede the previously approved license pages. Those amendments approved by this Order appropriate to the particular license transfers in fact occurring shall be issued and made effective at the time the corresponding license transfers are completed.

This Order is effective upon issuance. For further details with respect to this Order, see the submittal dated October 10, 2000, the previous related application dated December 20, 1999, and supplements thereto dated February 11, and February 23, 2000, which may be examined, and/or copied for a fee, at the NRC’s Public Document Room, located at 11555 Rockville Pike (first floor), Rockville, MD, and are accessible electronically through the ADAMS Public Electronic Reading Room link at the NRC Web site http://www.nrc.gov.

Dated at Rockville, Maryland, this 21st day of December 2000.

For the Nuclear Regulatory Commission.

Samuel J. Collins,
Director, Office of Nuclear Reactor Regulation.

[FR Doc. 00–33150 Filed 12–27–00; 8:45 am]

BILLING CODE 7590–01–P

NUCLEAR REGULATORY COMMISSION

Advisory Committee on Nuclear Waste; Notice of Meeting

The Advisory Committee on Nuclear Waste (ACNW) will hold its 124th meeting on January 16–18, 2001, at 11545 Rockville Pike, Rockville, Maryland, Room T–2B3. The entire meeting will be open to public attendance.

The schedule for this meeting is as follows:

Tuesday, January 16, 2001

A. 8:30–10:00 A.M.: Opening Statement/Planning and Procedures (Open)—The Chairman will open the meeting with brief opening remarks. The Committee will then review items under consideration at this meeting and consider topics proposed for future consideration by the full Committee.

B. 10:15–12:00 Noon: Progress on ACNW’s Sufficiency Review Application Task Action Plan (TAP) (Open)—The Committee will discuss the ACNW’s TAP, its approach to conducting a sufficiency review and its progress on proposed vertical slices.

C. 1:00–2:00 P.M.: Entombment Option for Decommissioning Power Reactors (Open)—The Committee will discuss with cognizant NMSS staff selected issues related to this topic.

D. 2:00–7:00 P.M.: Discussion of Proposed ACNW Reports (Open)—The ACNW Chairman will make opening remarks regarding the conduct of the meeting.

Wednesday, January 17, 2001

E. 8:30–8:40 A.M.: Opening Remarks by the ACNW Chairman (Open)—The ACNW Chairman will make opening remarks regarding the conduct of the meeting.

F. 8:40–9:40 A.M.: Institutional Control Status (Open)—The Committee will discuss and hear a presentation
from the NRC staff on the status of considerations regarding long-term custodial responsibilities for sites whose license is terminated under restricted release conditions.


H. 11:00–12:30 P.M.: Meeting with the Director, Office of Nuclear Material Safety and Safeguards, (NMSS) (Open)—The Committee will meet with the Director, NMSS to discuss items of mutual interest.


Thursday, January 18, 2001

1. 8:30–8:35 A.M.: Opening Remarks by the ACNW Chairman (Open)—The ACNW Chairman will make opening remarks regarding the conduct of the meeting.

K. 8:35–11:30 A.M.: Preparation for Meeting with the NRC Commissioners (Open)—The next meeting with the Commissioners is scheduled to be held in the Commission Conference Room in One White Flint North on March 22, 2001. The Committee will review its proposed presentations.

L. 12:30–5:00 P.M.: Discussion of Proposed ACNW Reports (Open)—The Committee will continue its discussion of proposed ACNW reports.

M. 5:00–5:30 P.M.: Miscellaneous (Open)—The Committee will discuss matters related to the conduct of Committee activities and matters and specific issues that were not completed during previous meetings, as time and availability of information permit.

Procedures for the conduct of and participation in ACNW meetings were published in the Federal Register on October 11, 2000 (65 FR 60475). In accordance with these procedures, oral or written statements may be presented by members of the public, electronic recordings will be permitted only during those portions of the meeting that are open to the public, and questions may be asked only by members of the Committee, its consultants, and staff. Persons desiring to make oral statements should notify Howard J. Larson, ACNW, as far in advance as practicable so that appropriate arrangements can be made to schedule the necessary time during the meeting for such statements. Use of still, motion picture, and television cameras during this meeting will be limited to selected portions of the meeting as determined by the ACNW Chairman. Information regarding the time to be set aside for taking pictures may be obtained by contacting the ACNW office, prior to the meeting. In view of the possibility that the schedule for ACNW meetings may be adjusted by the Chairman as necessary to facilitate the conduct of the meeting, persons planning to attend should notify Mr. Larson as to their particular needs.

Further information regarding topics to be discussed, whether the meeting has been canceled or rescheduled, the Chairman’s ruling on requests for the opportunity to present oral statements and the time allotted therefore can be obtained by contacting Mr. Howard J. Larson, ACNW (Telephone 301/415–6805), between 8:00 A.M. and 5:00 P.M. EST.

ACNW meeting notices, meeting transcripts, and letter reports are now available for downloading or viewing on the internet at http://www.nrc.gov/ACRS/ACNW.

Videoteleconferencing service is available for observing open sessions of ACNW meetings. Those wishing to use this service for observing ACNW meetings should contact Mr. Theron Brown, ACNW Audiovisual Technician (301/415–8066), between 7:30 a.m. and 3:45 p.m. EST at least 10 days before the meeting to ensure the availability of this service. Individuals or organizations requesting this service will be responsible for telephone line charges and for providing the equipment and facilities that they use to establish the videoteleconferencing link. The availability of videoteleconferencing services is not guaranteed.


Annette Vietti-Cook,
Acting Advisory Committee Management Officer.

[FR Doc. 00–33144 Filed 12–27–00; 8:45 am]
BILLING CODE 7590–01–P

NUCLEAR REGULATORY COMMISSION

Advisory Committee on Reactor Safeguards Subcommittee Meeting on Planning and Procedures Notice of Meeting

The ACRS Subcommittee on Planning and Procedures will hold a meeting on January 22–24, 2001, in Room T–2B3, 11545 Rockville Pike, Rockville, Maryland.

The entire meeting will be open to public attendance, with the exception of a portion that may be closed pursuant to 5 U.S.C. 552(b)(2) and (6) to discuss organizational and personnel matters that relate solely to internal personnel rules and practices of ACRS, and information the release of which would constitute a clearly unwarranted invasion of personal privacy.

The agenda for the subject meeting shall be as follows:

Monday, January 22, 2001—8:30 a.m. until the close of business: The Subcommittee will discuss stakeholder views of ACRS activities, self-assessment of ACRS performance in CY 2000, potential operational areas for improved effectiveness, and other activities related to the conduct of ACRS business. It will also discuss identification and quantification of design margins, adequacy of PRA models and codes, risk-informed regulation, AP1000 review issues, and potential future ACRS activities.

Tuesday, January 23, 2001—8:30 a.m. until the conclusion of business: The Subcommittee will continue to discuss self-assessment of ACRS performance in CY 2000, potential operational areas for improved effectiveness, and other activities related to the conduct of ACRS business. It will also continue the discussion on the identification and quantification of design margins, adequacy of PRA models and codes, risk-informed regulation, AP1000 review issues, and potential future ACRS activities.

Wednesday, January 24, 2001—8:30 a.m.–1:00 p.m.: The Subcommittee will discuss the annual ACRS report to the Commission on the NRC Safety Research Program and potential future ACRS activities.

The purpose of this meeting is to gather information, analyze relevant issues and facts, and to formulate proposed positions and actions, as appropriate, for deliberation by the full Committee.

Oral statements may be presented by members of the public with the concurrence of the Subcommittee Chairman; written statements will be accepted and made available to the Committee. Electronic recordings will be permitted only during those portions of the meeting that are open to the public, and questions may be asked only by members of the Subcommittee, its consultants, and staff. Persons desiring to make oral statements should notify the cognizant ACRS staff person named below five days prior to the meeting, if possible, so that appropriate arrangements can be made.
Further information regarding topics to be discussed, the scheduling of sessions open to the public, whether the meeting has been canceled or rescheduled, the Chairman’s ruling on requests for the opportunity to present oral statements, and the time allotted therefor can be obtained by contacting the cognizant ACRS staff person, Dr. John T. Larks (telephone: 301/415–7360) between 7:30 a.m. and 4:15 p.m. (EST). Persons planning to attend this meeting are urged to contact the above-named individual one or two working days prior to the meeting to be advised of any changes in schedule, etc., that may have occurred.


James E. Lyons,
Associate Director for Technical Support, ACRS/ACNW.

[FR Doc. 00–33145 Filed 12–27–00; 8:45 am] BILLING CODE 7590–01–P

NUCLEAR REGULATORY COMMISSION

Advisory Committee on Reactor Safeguards and Advisory Committee on Nuclear Waste Joint Subcommittee Meeting; Notice of Meeting

The Advisory Committee on Reactor Safeguards (ACRS) and the Advisory Committee on Nuclear Waste (ACNW) Joint Subcommittee will hold a meeting on January 19, 2001, Room T–2B3, 11545 Rockville Pike, Rockville, Maryland.

The meeting will be open to public attendance.

The agenda for the subject meeting shall be as follows: Friday, January 19, 2001—8:30 a.m. until the conclusion of business: The ACRS and ACNW Joint Subcommittee will discuss risk assessment methods associated with Integrated Safety Analysis (ISA) and the status of risk-informed activities in the Office of Nuclear Material Safety and Safeguards.

The Joint Subcommittee will also discuss risk analysis methods and applications associated with the Department of Energy (DOE) Integrated Safety Management (ISM) program. The purpose of this meeting is to gather information, analyze relevant issues and facts, and formulate proposed positions and actions, as appropriate, for deliberation by the ACRS and ACNW full Committees.

Oral statements may be presented by members of the public with the concurrence of the Subcommittee Chairman. Written statements will be accepted and made available to the ACRS and ACNW full Committees.

Electronic recordings will be permitted only during those portions of the meeting that are open to the public, and questions may be asked only by members of the Subcommittee, its consultants, and staff. Persons desiring to make oral statements should notify the cognizant ACRS/ACNW staff member named below five days prior to the meeting, if possible, so that appropriate arrangements can be made.

During the initial portion of the meeting, the Subcommittee, along with any consultants who may be present, may exchange preliminary views regarding matters to be considered during the balance of the meeting. The Subcommittee will then hear presentations by and hold discussions with representatives of the NRC staff, its consultants, and other interested persons regarding these matters.

Further information regarding topics to be discussed, whether the meeting has been canceled or rescheduled, the Subcommittee’s ruling on requests for the opportunity to present oral statements and the time allotted therefor can be obtained by contacting the cognizant senior staff engineer, Michael T. Markley (telephone 301/415–6885) between 7:30 a.m. and 4:15 p.m. (EST) or by e-mail MTM@NRC.gov. Persons planning to attend this meeting are urged to contact the above-named individual one to two working days prior to the meeting to be advised of any potential changes in the proposed agenda, etc., that may have occurred.


James E. Lyons,
Associate Director for Technical Support, ACRS/ACNW.

[FR Doc. 00–33146 Filed 12–27–00; 8:45 am] BILLING CODE 7590–01–P

NUCLEAR REGULATORY COMMISSION

Advisory Committee on Reactor Safeguards Meeting of the ACRS Joint Subcommittees on Materials and Metallurgy and on Thermal-Hydraulic Phenomena; Notice of Meeting

The ACRS Subcommittees on Materials and Metallurgy and on Thermal-Hydraulic Phenomena will hold a joint meeting on January 18, 2001, Room T–2B1, 11545 Rockville Pike, Rockville, Maryland.

The entire meeting will be open to public attendance.

The agenda for the subject meeting shall be as follows: Thursday, January 18, 2001—8:30 a.m. until the conclusion of business: The Subcommittees will discuss the treatment of uncertainties in both the FAVOR Probabilistic Fracture Mechanics Code, and the associated thermal-hydraulic analyses which are being developed as part of the Pressurized Thermal Shock (PTS) Technical Basis Reevaluation Project. The purpose of this meeting is to gather information, analyze relevant issues and facts, and to formulate proposed positions and actions, as appropriate, for deliberation by the full Committee.

Oral statements may be presented by members of the public with the concurrence of the Subcommittee Chairman. Written statements will be accepted and made available to the Committee. Electronic recordings will be permitted only during those portions of the meeting that are open to the public, and questions may be asked only by members of the Subcommittees, their consultants, and staff. Persons desiring to make oral statements should notify the cognizant ACRS staff engineer named below five days prior to the meeting, if possible, so that appropriate arrangements can be made.

During the initial portion of the meeting, the Subcommittees, along with any of their consultants who may be present, may exchange preliminary views regarding matters to be considered during the balance of the meeting.

The Subcommittees will then hear presentations by and hold discussions with representatives of the NRC staff and other interested persons regarding this review.

Further information regarding topics to be discussed, whether the meeting has been canceled or rescheduled, and the Chairman’s ruling on requests for the opportunity to present oral statements and the time allotted therefor, can be obtained by contacting the cognizant ACRS staff engineer, Mr. Paul A. Boehnert (telephone 301/415–8065) between 7:30 a.m. and 4:15 p.m. (EST). Persons planning to attend this meeting are urged to contact the above-named individual one to two working days prior to the meeting to be advised of any potential changes to the agenda, etc., that may have occurred.


James E. Lyons,
Associate Director for Technical Support, ACRS/ACNW.

[FR Doc. 00–33147 Filed 12–27–00; 8:45 am] BILLING CODE 7590–01–P

NUCLEAR REGULATORY COMMISSION

Advisory Committee on Reactor Safeguards and Advisory Committee on Nuclear Waste Joint Subcommittee Meeting; Notice of Meeting

The Advisory Committee on Reactor Safeguards (ACRS) and the Advisory Committee on Nuclear Waste (ACNW) Joint Subcommittee will hold a meeting on January 19, 2001, Room T–2B3, 11545 Rockville Pike, Rockville, Maryland.

The meeting will be open to public attendance.

The agenda for the subject meeting shall be as follows: Friday, January 19, 2001—8:30 a.m. until the conclusion of business: The ACRS and ACNW Joint Subcommittee will discuss risk assessment methods associated with Integrated Safety Analysis (ISA) and the status of risk-informed activities in the Office of Nuclear Material Safety and Safeguards.

The Joint Subcommittee will also discuss risk analysis methods and applications associated with the Department of Energy (DOE) Integrated Safety Management (ISM) program. The purpose of this meeting is to gather information, analyze relevant issues and facts, and formulate proposed positions and actions, as appropriate, for deliberation by the ACRS and ACNW full Committees.

Oral statements may be presented by members of the public with the concurrence of the Subcommittee Chairman. Written statements will be accepted and made available to the ACRS and ACNW full Committees.

Electronic recordings will be permitted only during those portions of the meeting that are open to the public, and questions may be asked only by members of the Subcommittee, its consultants, and staff. Persons desiring to make oral statements should notify the cognizant ACRS/ACNW staff member named below five days prior to the meeting, if possible, so that appropriate arrangements can be made.

During the initial portion of the meeting, the Subcommittee, along with any of their consultants who may be present, may exchange preliminary views regarding matters to be considered during the balance of the meeting.

The Subcommittee will then hear presentations by and hold discussions with representatives of the NRC staff, its consultants, and other interested persons regarding these matters.

Further information regarding topics to be discussed, whether the meeting has been canceled or rescheduled, the Subcommittee’s ruling on requests for the opportunity to present oral statements and the time allotted therefor can be obtained by contacting the cognizant senior staff engineer, Michael T. Markley (telephone 301/415–6885) between 7:30 a.m. and 4:15 p.m. (EST) or by e-mail MTM@NRC.gov. Persons planning to attend this meeting are urged to contact the above-named individual one to two working days prior to the meeting to be advised of any potential changes in the proposed agenda, etc., that may have occurred.


James E. Lyons,
Associate Director for Technical Support, ACRS/ACNW.

[FR Doc. 00–33145 Filed 12–27–00; 8:45 am] BILLING CODE 7590–01–P

NUCLEAR REGULATORY COMMISSION

Advisory Committee on Reactor Safeguards Meeting of the ACRS Joint Subcommittees on Materials and Metallurgy and on Thermal-Hydraulic Phenomena; Notice of Meeting

The ACRS Subcommittees on Materials and Metallurgy and on Thermal-Hydraulic Phenomena will hold a joint meeting on January 18, 2001, Room T–2B1, 11545 Rockville Pike, Rockville, Maryland.

The entire meeting will be open to public attendance.

The agenda for the subject meeting shall be as follows: Thursday, January 18, 2001—8:30 a.m. until the conclusion of business: The Subcommittees will discuss the treatment of uncertainties in both the FAVOR Probabilistic Fracture Mechanics Code, and the associated thermal-hydraulic analyses which are being developed as part of the Pressurized Thermal Shock (PTS) Technical Basis Reevaluation Project. The purpose of this meeting is to gather information, analyze relevant issues and facts, and to formulate proposed positions and actions, as appropriate, for deliberation by the full Committee.

Oral statements may be presented by members of the public with the concurrence of the Subcommittee Chairman. Written statements will be accepted and made available to the Committee. Electronic recordings will be permitted only during those portions of the meeting that are open to the public, and questions may be asked only by members of the Subcommittees, their consultants, and staff. Persons desiring to make oral statements should notify the cognizant ACRS staff engineer named below five days prior to the meeting, if possible, so that appropriate arrangements can be made.

During the initial portion of the meeting, the Subcommittees, along with any of their consultants who may be present, may exchange preliminary views regarding matters to be considered during the balance of the meeting.

The Subcommittees will then hear presentations by and hold discussions with representatives of the NRC staff and other interested persons regarding this review.

Further information regarding topics to be discussed, whether the meeting has been canceled or rescheduled, and the Chairman’s ruling on requests for the opportunity to present oral statements and the time allotted therefor, can be obtained by contacting the cognizant ACRS staff engineer, Mr. Paul A. Boehnert (telephone 301/415–8065) between 7:30 a.m. and 4:15 p.m. (EST). Persons planning to attend this meeting are urged to contact the above-named individual one to two working days prior to the meeting to be advised of any potential changes to the agenda, etc., that may have occurred.


James E. Lyons,
Associate Director for Technical Support, ACRS/ACNW.

[FR Doc. 00–33147 Filed 12–27–00; 8:45 am] BILLING CODE 7590–01–P
NUCLEAR REGULATORY COMMISSION

Advisory Committee on Reactor Safeguards Subcommittee Meeting on Planning and Procedures; Notice of Meeting

The ACRS Subcommittee on Planning and Procedures will hold a meeting on January 31, 2001, Room T–2B1, 11545 Rockville Pike, Rockville, Maryland.

The entire meeting will be open to public attendance, with the exception of a portion that may be closed pursuant to 5 U.S.C. 552b(c) (2) and (6) to discuss organizational and personnel matters that relate solely to internal personnel rules and practices of ACRS, and information the release of which would constitute a clearly unwarranted invasion of personal privacy.

The agenda for the subject meeting shall be as follows:

Wednesday, January 31, 2001—1:00 p.m. until the conclusion of business: The Subcommittee will discuss proposed ACRS activities and related matters. The purpose of this meeting is to gather information, analyze relevant issues and facts, and to formulate proposed positions and actions, as appropriate, for deliberation by the full Committee.

Oral statements may be presented by members of the public with the concurrence of the Subcommittee Chairman; written statements will be accepted and made available to the Committee. Electronic recordings will be permitted only during those portions of the meeting that are open to the public, and questions may be asked only by members of the Subcommittee, its consultants, and staff. Persons desiring to make oral statements should notify the cognizant ACRS staff person named below five days prior to the meeting, if possible, so that appropriate arrangements can be made.

Further information regarding topics to be discussed, the scheduling of sessions open to the public, and procedures will be available from the Secretariat, ACRS/ACNW.

James E. Lyons, Associate Director for Technical Support ACRS/ACNW.

BILLING CODE 7590±01±P

NUCLEAR REGULATORY COMMISSION

Advisory Committee on Reactor Safeguards Subcommittee Meeting on Thermal-Hydraulic Phenomena; Notice of Meeting

The ACRS Subcommittee on Thermal-Hydraulic Phenomena will hold a meeting on January 16–17, 2000, Room T–2B1, 11545 Rockville Pike, Rockville, Maryland.

A portion of the January 17 meeting session may be closed to public attendance to discuss proprietary information per 5 U.S.C. 552b(c)(4) pertinent to the Siemens Power Corporation.

The agenda for the subject meeting shall be as follows: Tuesday, January 16, 2001—8:30 a.m. until the conclusion of business.

Wednesday, January 17, 2001—8:30 a.m. until the conclusion of business.

The Subcommittee will continue its review of the: (1) Revised Electric Power Research Institute Report, TR–113594, “Resolution of Generic Letter 96–06 Waterhammer issues”, (2) Siemens Power Corporation S–RELAP5 thermal-hydraulic code and its application to small-break LOCA analyses. The purpose of this meeting is to gather information, analyze relevant issues and facts, and to formulate proposed positions and actions, as appropriate, for deliberation by the full Committee.

Oral statements may be presented by members of the public with the concurrence of the Subcommittee Chairman. Written statements will be accepted and made available to the Committee. Electronic recordings will be permitted only during those portions of the meeting that are open to the public, and questions may be asked only by members of the Subcommittee, its consultants, and staff. Persons desiring to make oral statements should notify the cognizant ACRS staff engineer named below five days prior to the meeting, if possible, so that appropriate arrangements can be made.

During the initial portion of the meeting, the Subcommittee, along with any of its consultants who may be present, may exchange preliminary views regarding matters to be considered during the balance of the meeting.

James E. Lyons, Associate Director for Technical Support ACRS/ACNW.

BILLING CODE 7590±01±P

NUCLEAR REGULATORY COMMISSION

Sunshine Act Meeting

AGENCY HOLDING THE MEETING: Nuclear Regulatory Commission

DATES: Weeks of December 25, 2000, January 1, 8, 15, 22, and 29 2001

PLACE: Commissioners’ Conference Room, 11555 Rockville Pike, Rockville, Maryland

STATUS: Public and closed

MATTERS TO BE CONSIDERED:

Week of December 25
There are no meetings scheduled for the Week of December 25.

Week of January 1, 2001—Tentative
There are no meetings scheduled for the Week of January 1, 2001.

Week of January 8, 2001—Tentative

Tuesday, January 9, 2001
9:30 a.m.
Briefing on EEO Program (Public Meeting) (Contact: Irene Little, 301–415–7380)

Wednesday, January 10, 2001
9:25 a.m.
Affirmation Session (Public Meeting) (If needed)
9:30 a.m.
Briefing on Status of Nuclear Materials Safety (Public Meeting) (Contact: Claudia Seelig, 301–415–7243)

This meeting will be webcast live at the Web address—www.nrc.gov/live.html
Week of January 15, 2001—Tentative

Wednesday, January 17, 2001

9:25 a.m.
Affirmation Session (Public meeting) (if needed)

9:30 a.m.
Briefing on Status of Nuclear Reactor Safety (Public Meeting) (Contact: Mike Case, 301–415–1134)

This meeting will be webcast live at the Web address—www.nrc.gov/live.html

Week of January 22—Tentative

There are no meetings scheduled for the Week of January 22.

Week of January 29—Tentative

Tuesday, January 30, 2001

9:30 a.m.
Briefing on Status of Nuclear Waste Safety (Public Meeting) (Contact: Claudia Seelig, 301–415–7243)

This meeting will be webcast live at the Web address—www.nrc.gov/live.html

Wednesday, January 31, 2001

9:25 a.m.
Affirmation Session (Public Meeting) (if needed)

9:30 a.m.
Briefing on Status of OCIO Programs, Performance, and Plans (Public Meeting) (Contact: Donnie Grimley, 301–415–8702)

This meeting will be webcast live at the Web address—www.nrc.gov/live.html

Thursday, February 1, 2001

9:30 a.m.
Briefing on Status of OCFO Programs, Performance and Plans (Public Meeting) (Contact: Lars Solander, 301–415–6080)

This meeting will be webcast live at the Web address—www.nrc.gov/live.html

The Schedule for Commission meetings is subject to change on short notice. To verify the status of meetings call (recording)—(301) 415–1292.

CONTACT PERSON FOR MORE INFORMATION:
Bill Hill (301) 415–1661.

* * * * *

ADDITIONAL INFORMATION:

By a vote of 5–0 on December 20, the Commission determined pursuant to U.S.C. 552(b)(6) and § 9.107(a) of the Commission’s rules that “Affirmation of Use of Potassium iodide (KI) for the General Public After a Severe Accident at a Nuclear Power Plant” be held on December 22, and on less than one week’s notice to the public.

By a vote of 5–0 on December 21, the Commission determined pursuant to U.S.C. 552(b)(6) and § 9.107(a) of the Commission’s rules that “Affirmation of Final Amendments to 10 CFR 50.47; Thereby Granting in Part Two Petitions for Rulemaking (50–63 and 50–63A); Relating to a Reevaluation of Policy on the Use of Potassium iodide (KI) for the General Public After a Severe Accident at a Nuclear Power Plant” be held on December 22, and on less than one week’s notice to the public.

* * * * *

The NRC Commission Meeting Schedule can be found on the Internet at: http://www.nrc.gov/SECY/smai/schedule.htm

* * * * *

This notice is distributed by mail to several hundred subscribers: if you no longer wish to receive it, or would like to be added to it, please contact the Office of the Secretary, Attn: Operations Branch, Washington, DC 20555 9301–415–1661). In addition, distribution of this meeting notice over the Internet system is available. If you are interested in receiving this Commission meeting schedule electronically, please send an electronic message to wmh@nrc.gov or dkw@nrc.gov.


William M. Hill, Jr.,
SECY Tracking Officer, Office of the Secretary.

[FR Doc. 00–33289 Filed 12–26–00; 12:48 pm]

BILLING CODE 7590–01–M

OFFICE OF PERSONNEL MANAGEMENT

Proposed Collection; Comment Request for Review of an Expiring Information Collection: OPM FORM 1644

AGENCY: Office of Personnel Management.

ACTION: Notice.

SUMMARY: In accordance with the Paperwork Reduction Act of 1995 (Public Law 104–13, May 22, 1995), this notice announces that the Office of Personnel Management (OPM) intends to submit to the Office of Management and Budget a request for review of an expiring information collection. OPM Form 1644, Child Care Provider Information: Child Care Tuition Assistance Program for Federal Employees, is used to verify that child care providers are licensed and/or regulated by local and/or State authorities. Agencies need to know that child care providers to whom they make disbursements in the form of tuition assistance subsidies, are licensed and/or regulated by local and/or State authorities.

Pub. L. 106–58, passed by Congress on September 29, 1999, permits Federal agencies to use appropriated funds to help their lower income employees with their costs for child care. It is up to the agencies to decide on whether to implement this law. This is a new law and the extent to which it will be implemented, including the number of providers that will be involved, cannot be easily predicted. We estimate approximately 3000–5000 OPM 1644 forms will be completed annually. The form will take approximately 10 minutes to complete by each provider.

The annual estimated burden is 83.5 hours.

Comments are particularly invited on:
• Whether the form adequately captures the information needed to verify child care provider State and/or local licensure and regulation;
• Whether our estimate of the public burden of this collection is accurate, and based on valid assumptions and methodology; and
• Ways in which we can minimize the burden of the collection of information on those who are to respond, through use of the appropriate technological collection techniques or other information collection strategies.

For copies of this proposal, contact Mary Beth Smith-Toomey on (202) 606–8358, or E-mail to mbtoomey@opm.gov.

DATES: Comments on this proposal should be received on or before February 26, 2001.

ADDRESSES: Send or deliver comments to: Patricia F. Kinney, Director, Office of Work/Life Programs, U.S. Office of Personnel Management, 1900 E St., NW., Washington, DC 20415.


Office of Personnel Management.

Janice R. Lachance,
Director.

[FR Doc. 00–33112 Filed 12–27–00; 8:45 am]
OFFICE OF PERSONNEL MANAGEMENT

Proposed Collection; Comment Request for Review of an Expiring Information Collection: OPM 1536

AGENCY: Office of Personnel Management.

ACTION: Notice.

SUMMARY: In accordance with the Paperwork Reduction Act of 1995 (Public Law 104–13, May 22, 1995), this notice announces that the Office of Personnel Management (OPM) intends to submit to the Office of Management and Budget a request for review of an expiring information collection. OPM 1536, Application for Survivor Annuity Under the Civil Service Retirement System, is designed for use by former spouses of Federal employees and annuitants who are applying for a monthly Civil Service Retirement System benefit. The application collects information about whether the applicant is covered by the Federal Employees Health Benefits Program and about any court order which awards the applicant retirement benefits.

Comments are particularly invited on: Whether this information is necessary for the proper performance of functions of OPM, and whether it will have practical utility; whether our estimate of the public burden of this collection of information is accurate, and based on valid assumptions and methodology; and ways in which we can minimize the burden of the collection of information on those who are to respond, through the use of appropriate technological collection techniques or other forms of information technology.

Approximately 500 OPM Forms 1536 will be completed annually. The form takes approximately 45 minutes to complete. The annual burden is 375 hours.

For copies of this proposal, contact Mary Beth Smith-Toomey on (202) 606–8358, or E-mail to mbtoomey@opm.gov.

DATES: Comments on this proposal should be received on or before February 26, 2001.


OFFICE OF PERSONNEL MANAGEMENT

Proposed Collection; Comment Request for Revision of an Information Collection: RI 30–31

AGENCY: Office of Personnel Management.

ACTION: Notice.

SUMMARY: In accordance with the Paperwork Reduction Act of 1995 (Public Law 104–13, May 22, 1995), this notice announces that the Office of Personnel Management (OPM) intends to submit to the Office of Management and Budget (OMB) a request for revision of an information collection. RI 30–31, Request for Information About Your Disability Annuity and Employment, is used by persons who are not yet age 60 and who are receiving disability annuity and are subject to inquiry as to their medical condition as OPM deems reasonably necessary. RI 30–1 collects information as to whether the disabling condition has changed.

Approximately 8,000 RI 30–1 forms will be completed annually. We estimate it takes approximately 60 minutes to complete the form. The annual burden is 8,000 hours.

Comments are particularly invited on:
—Whether this collection of information is necessary for the proper performance of functions of the Office of Personnel Management, and whether it will have practical utility;
—Whether our estimate of the public burden of this collection is accurate and based on valid assumptions and methodology; and
—Ways in which we can minimize the burden of the collection of information on those who are to respond, through use of the appropriate technological collection techniques or other forms of information technology.

For copies of this proposal, contact Mary Beth Smith-Toomey on (202) 606–2150, or E-mail to mbtoomey@opm.gov.

DATES: Comments on this proposal should be received on or before February 26, 2001.


and based on valid assumptions and methodology; and
—Ways in which we can minimize the burden of the collection of information on those who are to respond, through use of the appropriate technological collection techniques or other forms of information technology.

For copies of this proposal, contact Mary Beth Smith-Toomey on (202) 606–8358, or E-mail to mbtoomey@opm.gov.

DATES: Comments on this proposal should be received within 60 calendar days from the date of this publication.


Janice R. Lachance,

Director.

[FR Doc. 00–33116 Filed 12–27–00; 8:45 am]

BILLING CODE 6325–01–P

OFFICE OF PERSONNEL MANAGEMENT

Proposed Collection; Emergency Request for Review of an Information Collection: OPM Form 1644

AGENCY: Office of Personnel Management.

ACTION: Notice.

SUMMARY: In accordance with the Paperwork Reduction Act of 1995 (Pub. L. 104–13, May 22, 1995), this notice announces that the Office of Personnel Management (OPM) will submit to the Office of Management and Budget an emergency request for review of an expiring information collection, OPM Form 1644, Child Care Provider Information: Child Care Tuition Assistance Program for Federal Employees, is used to verify that child care providers are licensed and/or regulated by local and/or State authorities. Agencies need to know that child care providers to whom they make disbursements in the form of tuition assistance subsidies are licensed and/or regulated by local and/or State authorities.

Pub. L. 106–58, passed by Congress on September 29, 1999, permits Federal agencies to use appropriated funds to help their lower income employees with their costs for child care. It is up to the agencies to decide on whether to implement this law. This is a new law and the extent to which it will be implemented, including the number of providers that will be involved, cannot be easily predicted. We estimate approximately 5000 OPM 1644 forms will be completed annually.

The form will take approximately 10 minutes to complete by each provider. The annual estimated burden is 835 hours.

Comments are particularly invited on:
—Whether the form adequately captures the information needed to verify child care provider State and/or local licensure and regulation;
—Whether our estimate of the public burden of this collection is accurate, and based on valid assumptions and methodology; and
—Ways in which we can minimize the burden of the collection of information on those who are to respond, through use of the appropriate technological collection techniques or other information collection strategies.

For copies of this proposal, contact Mary Beth Smith-Toomey on (202) 606–8358, or E-mail to mbtoomey@opm.gov.

DATES: Comments on this proposal should be received on or before January 8, 2001.

ADDRESSES: Send or deliver comments to:
Patricia F. Kinney, Director, Office of Work/Life Programs, U.S. Office of Personnel Management, 1900 E St., NW, Washington, DC 20415

Joseph Lackey, Agency Desk Officer, Office of Management and Budget, 725 17th St., NW Room 10235, Washington, DC 20503


Janice R. Lachance,

Director.

[FR Doc. 00–33270 Filed 12–27–00; 8:45 am]

BILLING CODE 6325–01–P

OFFICE OF PERSONNEL MANAGEMENT

Federal Prevailing Rate Advisory Committee; Meeting

AGENCY: Office of Personnel Management.

ACTION: Notice of meeting.

TIME AND DATE: 11:00 a.m., January 2, 2001.

PLACE: OPM Executive Conference Room 5A06A, Theodore Roosevelt Building, 1900 E Street, NW., Washington, DC 20415–0001

STATUS: This meeting will be open to the public at 11:00 am.

MATTERS TO BE CONSIDERED: This meeting is called by the Office of the Chair with less than 15 days public notice so the Committee can complete its current agenda. The meeting is open to the public.

CONTACT PERSON FOR MORE INFORMATION:
Geri Coates, Recording Secretary, Office of Personnel Management, Theodore Roosevelt Building, 1900 E Street, NW., Room 5538, Washington, DC 20415–1600, (202) 606–1500.

John F. Leyden, Chairman, Federal Prevailing Rate, Advisory Committee.

[FR Doc. 00–33117 Filed 12–27–00; 8:45 am]

BILLING CODE 6325–01–P

SECURITIES AND EXCHANGE COMMISSION


Self-Regulatory Organizations; Chicago Board Options Exchange, Inc.; Order Approving and Notice of Filing and Order Granting Accelerated Approval of Amendment Nos. 1, 2, 3, 4, 5, 6, and 7 to the Proposed Rule Change Relating to the Evaluation of Trading Crowd Performance


I. Introduction

On October 23, 1998, the Chicago Board Options Exchange, Inc. ("CBOE" or "Exchange") filed with the Securities and Exchange Commission ("Commission"), pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 ("Act")¹ and Rule 19e–4 thereunder,² a proposed rule change to amend CBOE Rule 8.60, Evaluation of Trading Crowd Performance, to provide limited remedial actions for Designated Primary Market Makers ("DPMs"), market makers, and other members and trading crowds (collectively referred to as "Market Participants") who have failed to satisfy their market responsibilities. The proposed rule change was published for comment in the Federal Register on December 10,

the proposal. On April 12, 1999, CBOE filed Amendment No. 2 to the proposal. On June 17, 1999, CBOE filed Amendment No. 3 to the proposal. On October 23, 2000, CBOE filed Amendment No. 4 to the proposal. On November 13, 2000, the Commission received a faxed copy of CBOE's Amendment No. 5 to the proposal. On December 4, 2000, CBOE filed Amendment No. 6 to the proposal. On December 19, 2000, the CBOE filed Amendment No. 7 to the proposal. The Commission received one comment regarding the proposal. The Commission is approving the proposed rule change, as amended, and publishing this notice to solicit comments on Amendment Nos. 1, 2, 3, 4, 5, 6, and 7. The Commission is also approving Amendment Nos. 1, 2, 3, 4, 5, 6, and 7 on an accelerated basis.

II. Description of the Proposal

The Exchange proposes to modify CBOE Rule 8.60 to clarify and improve the market performance evaluation of Market Participants on the Exchange.

The proposed rule change should provide the appropriate Market Performance Committee ("Committee") greater procedural flexibility in addressing the performance of Market Participants, while clarifying the due process safeguards that apply to the exercise of the Committee's authority.

The purpose of CBOE Rule 8.60 is to provide the appropriate Committee with a means to work with Market Participants to improve market quality and competition. The market performance evaluation process is designed to assist the appropriate Committee in working with Market Participants to improve their market performance. Currently, under CBOE Rule 8.60, the Committee must hold a formal hearing to impose serious sanctions such as: (1) Suspension, termination, or restriction of registration of a market maker; (2) suspension, termination or restriction of an appointment to one or more option classes; (3) restriction of appointments to additional option classes; (4) relocation of option classes; and (5) prohibiting a member from trading at a particular trading station. However, under the current Rule, the appropriate Committee does not have explicit authority to take limited remedial actions. Under the proposed rule change, the Committee would be able to take certain limited remedial actions after an informal meeting with Market Participants who have been identified through the evaluation process.

The proposed rule would amend CBOE Rule 8.60(a) to indicate that the Committee in evaluating whether a Market Participant is satisfying its market responsibilities may consider: (1) Quality of markets; (2) extent of competition in the crowd; (3) due diligence in representing orders as agent; (4) adherence to ethical standards; (5) carrying out administrative responsibilities; and (6) other matters as the Exchange may deem relevant. Under the proposal, in addition to the survey, the Committee may also consider any other relevant information including, but not limited to, statistical measures of performance and such other factors and data as the Committee may determine to be pertinent to the evaluation of Market

See letter from Andrew D. Spiwak, Managing Director, Legal Department, Office of Enforcement, CBOE, to Marc McKayle, Attorney, Division, dated April 8, 1999 ("Amendment No. 2"). In Amendment No. 2, CBOE clarified that there is no automatic stay of an action during the appeal of a remedial sanction, but that a Market Participant could request a stay of action during an appeal. CBOE also reorganized the primary difference between the sanctions that presently exist under the Rule and the limited remedial actions introduced by this proposal is the severity of the sanctions. The Exchange registered pursuant to CBOE Rule 19.1, Interpretations and Policies .01, a Market Participant would be considered aggrieved in an economic sense if sanctioned under the proposed revisions to CBOE Rule 8.60, and thus entitled to appeal any action taken by a Market Performance Committee under the rule. The Exchange also noted that, pursuant to Rule 19.5, any decision of the Appeals Committee is subject to review by the Exchange's Board of Directors. The Exchange also explained that limited remedial actions taken under the proposal by the appropriate Market Performance Committee would not constitute a disciplinary action, and thus Exchange reporting requirements under Rule 19d—1(e) of the Act, 17 CFR 240.19d—1(e), would not be triggered. Finally, the Exchange assured the Commission that the three Market Performance Committees have exclusive, non-overlapping jurisdiction, and thus Market Participants would not be subject to duplicative sanctions stemming from one course of conduct.

See letter from Andrew D. Spiwak, Managing Director, Legal Department, Office of Enforcement, CBOE, to Nancy Sanow, Assistant Director, Division, dated November 13, 2000 ("Amendment No. 5"). Amendment No. 5 was replaced in its entirety by Amendment No. 6.

See letter from Andrew D. Spiwak, Managing Director, Legal Department, Office of Enforcement, CBOE, to Nancy Sanow, Assistant Director, Division, dated November 27, 2000 ("Amendment No. 6"). Amendment No. 6, in addition to technical changes, amended CBOE Rule 8.60(d) to require the Committee to provide the appropriate Market Performance Committee with a report of its findings and recommendations. This change, the Committee's recommendation of suggested actions, and such other factors and data as the Committee may determine to be pertinent to the evaluation of Market

See letter from Andrew D. Spiwak, Managing Director, Legal Department, Office of Enforcement, CBOE, to Nancy Sanow, Assistant Director, Division, dated December 12, 2000 ("Amendment No. 7"). Amendment No. 7, proposed CBOE Rule 8.60(g) was amended to specify that the Committee's recommendation of suggested actions, and such other factors and data as the Committee may determine to be pertinent to the evaluation of Market
Participants. CBOE Rule 8.60(a) is also being amended to clarify that the Rule pertains to DPMs (both market-making and agency responsibilities), market makers, and other members (individually or collectively as trading crowds).

Under the proposal, CBOE Rule 8.60(b) would be amended to indicate that the Committee may find that a Market Participant has failed to satisfy its market responsibilities, if the evaluation of the Market Participant results in a ranking that is one or more standard deviations from the mean score of all Market Participants within the Committee’s jurisdiction, or if such a finding may reasonably be supported by any other relevant information known to the Committee. Currently, under CBOE Rule 8.60(b), the Committee must presume a failure to meet minimum performance standards exists for all members of a trading crowd, if the trading crowd is ranked in the bottom 10% of trading crowds in the aggregate results of the Crowd Evaluation Questionnaire.

Under the proposal, the rule language in current CBOE Rule 8.60(a) listing the sanctions for a market-maker’s failure to meet minimum performance standards would be moved to paragraph (c) of the proposed rule. In addition to the more serious sanctions that are currently listed in the Rule, the proposal would amend CBOE Rule 8.60(c), to clarify that the Committee has the authority to take limited remedial actions if a Market Participant fails to satisfy its market responsibilities. Thus, under the proposed CBOE Rule 8.60(c) the Committee may take one or more of the following actions, if it finds that a Market Participant has failed to satisfy its market responsibilities:

1. Suspension, termination, or restriction of registration of a Market Participant (which may also include the termination of a DPM appointment);
2. Suspension, termination or restriction of an appointment to one or more option classes or other securities;
3. Relocation or reallocation of option classes or other securities to other trading crowds;
4. Prohibiting a Market Participant from trading at a particular trading station;
5. Requiring the Market Participant to submit a business plan to the Committee detailing those steps that the Market Participant intends to take to improve its performance;
6. Requiring that one or more Market Participants in a crowd execute 100% of their opening transactions in that crowd in person;
7. Restricting the ability of Market Participants to participate in the Exchange’s Retail Automatic Execution System (“RAES”);
8. Restricting the eligibility of a crowd to be allocated new option classes or other securities;
9. Requiring that one or more Market Participants attend a meeting or series of meetings as the Committee shall require for the purpose of education or improving their performance as Market Participants;
10. Requiring that all bookable orders be booked if not executed immediately upon presentation in the crowd; and
11. Restricting the ability of Market Participants to participate in ROS.

The Exchange has indicated that it may in the future add comparable limited remedial sanctions to the Rule by filing a proposed rule change with the Commission pursuant to 19(b)(3)(A) of the Act. CBOE Rule 8.60(c) is also being amended to delete language pertaining to the distribution of a crowd evaluation questionnaire on a six-month periodic basis. Under the proposal, the Exchange will conduct market performance evaluations twice a year as it deems necessary, but generally on a six-month periodic basis.

The proposed rule change would amend CBOE Rule 8.60(d) to include the Rule’s formal hearing and informal meeting procedures. Under the proposal, before taking any remedial action, the Committee would be required to give written notice to the Market Participant to indicate that the Committee is considering taking action and the basis for the action, and that the Market Participant is entitled to an opportunity to appear before the Committee (or a panel thereof). If the Committee contemplates taking any of the actions listed in proposed CBOE Rule 8.60(c)(1) through (4), a formal hearing with a verbatim record would be required, although the Committee would have the authority to take any action listed in CBOE Rule 8.60(c) after a formal hearing. If the Committee contemplates taking any of the actions listed in proposed CBOE Rule 8.60(c)(5) through (11) that will not be imposed for a period longer than one year, an informal meeting without the requirement of a verbatim record would be permitted. In addition, under proposed CBOE Rule 8.60(d), a Market Participant receiving written notice of potential Committee action would be required to appear at the formal hearing or informal meeting, as applicable, and could also submit a written statement to the Committee in addition to an appearance. At such a hearing or meeting, the formal rules of evidence would not apply and the Committee would decide all questions of procedure and admissibility of evidence. If after the hearing or meeting the Committee determined that the Market Participant failed to satisfy its market responsibilities, the Committee would give written notice to all affected Market Participants reflecting the sanction ordered, the length of the sanction, and the basis for the Committee’s findings and conclusions.

The proposed rule change would also amend CBOE Rule 8.60(e) to provide the Committee with the authority to impose any sanction under CBOE Rule 8.60(c) if the Market Participant failed to appear before or meet with the Committee pursuant to proposed CBOE Rule 8.60(d) and did not have a reasonable justification or excuse. CBOE Rule 8.60(e) would also be amended to indicate that a Market Participant’s unexcused absence before the Committee could result in a referral to the Business Conduct Committee.

The proposal also amends CBOE Rules 8.60(f) and (g) to specify the process for taking appeals from a Committee action. Under proposed CBOE Rule 8.60(f), consistent with the current Rule, Committee actions taken after a formal hearing may be appealed directly to the Board of Directors. Proposed CBOE Rule 8.60(g) specifies any action taken by the Committee after an informal meeting in accordance with CBOE Rule 8.60(c)(5) through (11) may be appealed pursuant to Chapter XIX of the Exchange Rules. CBOE believes that Chapter XIX appeals would be procedurally duplicative for Committee actions taken after a formal hearing where a verbatim record is kept.

Finally, the proposal amends Interpretation and Policy .01 under CBOE Rule 8.60 to provide the Committee discretion in defining whether a market maker is a member of a trading crowd.

III. Comments

The Commission received one comment letter on the proposal. The commenter inquired: (1) Whether the proposed restriction of RAES participation as a limited remedial
sanction would supercede the remedial actions in CBOE Rule 8.16.\(^{18}\) (2) whether appealing parties must be aggrieved in an economic sense when appealing pursuant to Chapter XIX of the Exchange Rules; and (3) whether inequitable results would occur because of overlapping jurisdictions of the Market Performance Committees.\(^{19}\) In Amendment No. 1, the Exchange stated that the proposed limited remedial sanction restricting RAES participation would not supercede remedial actions under CBOE Rule 8.16. The Exchange explained that CBOE Rule 8.16 and CBOE Rule 8.60, as proposed, are not facially inconsistent with each other and may co-exist within the CBOE regulatory framework because action may be taken under one rule without implicating the other. The Exchange also explained its view that, despite the separate and distinct jurisdictions of the three Market Performance Committees, a Market Participant could not be sanctioned by more than one Committee for a single course of conduct. The Exchange also clarified that if a Market Participant received a limited remedial sanction under the proposal, it would be considered to have been aggrieved in an economic sense, and thus the sanction would be appealable pursuant to Section 6(b)(5) of the Exchange Rules.\(^{20}\)

**IV. Discussion**

The Commission finds that the proposed rule change is consistent with the Act\(^{21}\) and, in particular, with section 6(b) of the Act.\(^{22}\) Specifically, the Commission believes that the proposal is consistent with the sections 6(b)(5), (b)(6), and (b)(7) of the Act.\(^{23}\) Section 6(b)(5) of the Act\(^{24}\) requires that rules of an exchange be designed to promote just and equitable principles of trade, perfect the mechanism of a free and open market, prevent fraudulent and manipulative acts, and, in general, protect investors and the public interest.

Section 6(b)(6) of the Act\(^{25}\) requires an exchange to provide rules to appropriately discipline its members for violation of the provisions of the Act, the rules or regulations thereunder, or the rules of the exchange, by expulsion, suspension, limitation of activities, functions, and operations, fine, censure, being suspended or barred from being associated with a member, or any other fitting sanction. Section 6(b)(7) of the Act\(^{26}\) requires the rules of an exchange generally to provide a fair procedure for the disciplining of members.

The Commission finds that proposed CBOE Rule 8.60(a) is consistent with Section 6(b)(5)\(^{27}\) because it is designed to help the Exchange maintain market quality and integrity by providing the appropriate Market Performance Committee with a means to identify Market Participants that fail to satisfy their market responsibilities. The proposed rule change amends CBOE Rule 8.60(a) to enumerate, and add, factors that the Committee may consider in evaluating whether a Market Participant satisfactorily meets its market responsibilities. The proposed rule change also amends CBOE Rule 8.60(a) to specify that the Rule pertains to DPMs, market makers, and other members (individually or collectively as trading crowds). The Commission believes that the ability of the Committee to evaluate the market performance of Market Participants should be enhanced by the addition of new factors and clarification of existing factors to be contained in the survey of members that is a part of the market performance evaluation. The proposal should also provide the Committee and Market Participants with appropriate guidance on how the Exchange evaluates the market performance of its members. The Commission notes that CBOE Rule 8.60(a) is also being amended to enable the Committee to consider any other relevant information that the Committee determines is pertinent to the evaluation of Market Participants. In such instances, where non-enumerated factors have been included in a Market Participant’s evaluation, the Exchange has represented that the factors beyond those explicitly mentioned in the Rule’s text would be detailed in the written notice of a Market Participant’s potential failure to satisfy its market responsibilities, as required by CBOE Rule 8.60(d).\(^{28}\) Further, the Commission notes that in order to provide appropriate guidance in the future, the Exchange should inform Market Participants of any additional factors determined to be pertinent in evaluating whether a Market Participant has satisfied its market responsibilities.

The Commission finds that proposed CBOE Rule 8.60(b) is consistent with the Act,\(^{29}\) including section 6(b)(6),\(^{30}\) because the Rule is part of the scheme that provides the Exchange with a means to appropriately discipline its members. The proposed rule change would amend CBOE rule 8.60(b) to indicate that the Committee may determine that a Market Participant has failed to satisfy its market responsibilities if the Market Participant evaluation results in a ranking that is one or more standard deviations from the mean score of all Market participants within the Committee’s jurisdiction, or if such a finding may reasonably be supported by any other relevant information known to the Committee. The Commission believes that it is reasonable for the Committee to find that a Market Participant has failed to satisfy its market responsibilities if the Market Participant evaluation results in a ranking that is one or more standard deviations below the mean score of all Market Participants within the Committee’s jurisdiction. Moreover, this evaluation should provide an objective measure as to whether Market Participants have failed to satisfy their market responsibilities.

The Exchange has represented that each Committee has exclusive jurisdiction over discrete market performance issues, and that such specialization provides the separate Committees added competence to review certain market performance matters. The Commission believes that the structure of the Exchange’s market performance evaluation should permit the appropriate Committee to properly evaluate whether satisfactory market performance has been achieved by Market Participants based on the factors set forth in revised CBOE Rule 8.60(a). As indicated above, the Commission considers it essential that a Market Price Participant be fully cognizant of the factors that may bear upon the Committee’s evaluation, particularly if that evaluation could result in remedial action by the Committee. Thus, the Commission expects that the Exchange
will fully apprise Market Participants of any other relevant information known to the Committee that influences a Committee finding that a Market Participant has failed to meet his market responsibility.

The Commission also finds that proposed CBOE Rule 8.60(c) is consistent with the Act, particularly Section 6(b)(6).\(^31\) CBOE Rule 8.60(c) will be amended to include the more serious sanctions found in current CBOE Rule 8.60(a), and to clarify that the Committee also has the authority to take more remedial actions if a Market Participant fails to satisfy its market responsibilities. The Commission believes that the proposed rule change should enhance the flexibility of the Exchange’s market performance evaluation. Presently, the Exchange does not have an express mechanism to address market performance matters that may warrant remedial action, but are not serious enough to warrant suspension, termination, or restriction of a market-maker’s registration under the current Rule. The proposed rule change should permit the CBOE to implement appropriate, limited remedial sanctions that will permit the Committee to take corrective measures to enhance the performance of Market Participants before more serious sanctions, such as suspension or termination, are warranted. The Commission believes that the proposed rule change should enhance the performance of Market Participants before more serious sanctions, such as suspension or termination, are warranted. The Commission finds that the proposed rule change should enhance the flexibility of the Exchange’s market performance evaluation.

Further, the Commission believes that amended CBOE Rule 8.60(d) should provide Market Participants with adequate procedural safeguards under the Rule. For instance, before any action is taken, the Committee would be required to give written notice to the Market Participant to indicate that the Committee is considering taking action and the basis for the action, and that the Market Participant is entitled to an opportunity to appear before the Committee (or a panel thereof). The Commission believes that Market Participants should be provided with reasonable due process safeguards and that CBOE Rule 8.60(d), as amended, should provide a fair procedure for disciplining members, and thus is consistent with Section 6(b)(7) of the Act.\(^34\)

The Commission also finds that proposed CBOE Rule 8.60(e) is consistent with Section 6(b)(6) of the Act.\(^35\) The proposed rule change amends CBOE Rule 8.60(e) to authorize the Committee to impose any sanction listed under CBOE Rule 8.60(c) if a Market Participant fails to appear before the Committee, without reasonable justification or excuse, as required by proposed CBOE Rule 8.60(d). CBOE Rule 8.60(e) would also be amended to indicate that a Market Participant’s unexcused absence before the Committee could result in a referral to the Business Conduct Committee. The Commission believes that CBOE Rule 8.60(e) provides appropriate discipline for violation of the provisions found in amended CBOE Rule 8.60(d), and thus is consistent with section 6(b)(6) of the Act.\(^36\)

The Commission finds that proposed CBOE Rules 8.60(f) and (g) are consistent with Section 6(b)(7) of the Act.\(^37\) The proposal amends CBOE Rule 8.60(f) to specify that Market Participants may appeal Committee action taken after a formal hearing directly to the Board of Directors. The proposal also amends CBOE Rule 8.60(g) to specify that after an informal meeting, a Market Participant may appeal a Committee action imposed under CBOE Rule 8.60(c)(5) through (11) to an Appeals Committee in accordance with Chapter XIX of the Exchange Rules. The Commission believes that direct appeals to the Board of Directors for Committee action taken after a formal hearing with a verbatim record should provide Market Participants with adequate procedural protections. The Commission also believes that CBOE Rule 8.60(g), which allows Market Participants to appeal in accordance with Chapter XIX of the Exchange Rules any Committee action pursuant to CBOE Rule 8.60(c)(5) through 11 after an informal meeting, should provide adequate procedural safeguards. The Commission therefore finds that CBOE Rules 8.60(f) and (g) are consistent with Section 6(b)(7) of the Act because they provide fair procedures for the disciplining of Exchange members.\(^38\)

V. Commission’s Findings and Order Granting Accelerated Approval of Proposed Rule Change

For the reasons discussed below, the Commission finds good cause for approving Amendment Nos. 1 through 7 to the proposed rule change prior to the thirtieth day after the date of publication of notice thereof in the Federal Register.

In Amendment No. 1, as outlined above, CBOE responded to various issues raised by a commenter. In Amendment No. 2, CBOE explained and clarified the procedural impact of the proposal. Specifically, Amendment Nos. 1 and 2 were of a technical, non-substantive nature, and did not significantly alter the original proposal, which was subject to a full notice and comment period. Thus, the Commission finds that granting accelerated approval to Amendment Nos. 1 and 2 is appropriate and consistent with section 19(b)(2) of the Act.\(^39\)

In Amendment No. 3, CBOE amended Rule 8.60 to restrict a member’s ability to participate in the ROS as a limited remedial sanction. CBOE also deleted language from the Rule’s text that would have given the appropriate Market Performance Committee discretion to “take any other limited remedial action.” CBOE also indicated that any additional comparable limited remedial sanctions would be added to the Rule by a proposed rule change filed with the Commission pursuant to section 19(b)(3)(A) of the Act.\(^40\) The changes in proposed Amendment No. 3 should help to ensure that Market Participants are fully notified to the types of limited remedial sanctions that may be imposed under Rule 8.60. Amendment No. 3 also set forth how additional limited remedial sanctions may be added to Rule 8.60 in future. The Commission finds that Amendment No. 3 strengthens and clarifies Rule 8.60 from a procedural perspective. Thus, the Commission finds that granting

accelerated approval to Amendment No. 3 is appropriate and consistent with section 19(b)(2) of the Act.41

In Amendment No. 4, CBOE reorganized the text of Rule 8.60 and consolidated all remedial actions and hearing procedures into paragraphs (c) and (d), respectively, of the Rule, as amended. In addition, CBOE added language to specify that Rule 8.60 pertained to DPMs, market makers, and other members (individually or collectively as trading crowds) and not just market makers. The CBOE also amended the Rule to refer to the “market responsibilities” of market participants instead of “performance standards.” The Exchange also revised the Rule’s text to indicate that the appropriate Market Performance Committee can find a Market Participant has failed to satisfy its market responsibilities if the Market Participant is ranked one or more standard deviations from the mean score of all trading crowds in a periodic examination. The Commission finds that the proposed changes in Amendment No. 4 serve to clarify the intent and application of the proposal. Thus, the Commission finds that granting accelerated approval to Amendment No. 4 is appropriate and consistent with Section 19(b)(2) of the Act.42

In Amendment No. 6,43 in addition to technical changes, CBOE Rule 8.60(d) was amended to clarify that the Committee may take any action listed in CBOE Rule 8.60(c) after a formal hearing, and may take any of the actions listed in CBOE Rule 8.60(c)(5) through (11) after an informal meeting. In addition, a conforming change was made in CBOE Rule 8.60(f) to clarify that a Market Participant may appeal any Committee action taken after a formal hearing directly to the Board of Directors.44 The Commission finds that the proposed changes in Amendment No. 6 serve to clarify the intent and application of the proposal. Thus, the Commission finds that granting accelerated approval to Amendment No. 6 is appropriate and consistent with Section 19(b)(2) of the Act.45

In Amendment No. 7, proposed CBOE Rule 8.60(g) was amended to clarify that Committee actions taken after an informal meeting in accordance with CBOE Rule 8.60(c)(5) through (11) may be appealed in accordance with Chapter XIX of the Exchange Rules. The Commission finds that the proposed change in Amendment No. 7 serves to clarify the intent and application of the proposal. Thus, the Commission finds that granting accelerated approval to Amendment No. 7 is appropriate and consistent with section 19(b)(2) of the Act.46

VI. Solicitation of Comments

Interested persons are invited to submit written data, views and arguments concerning Amendment Nos. 1, 2, 3, 4, 5, 6, and 7, including whether the proposed amendments are consistent with the Act. Persons making written submissions should file six copies thereof with the Secretary, Securities and Exchange Commission, 450 Fifth Street NW., Washington DC, 20549–0609. Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for inspection and copying in the Commission’s Public Reference Room. Copies of such filing will also be available for inspection and copying at the principal office of the CBOE. All submissions should refer to File No. SR–CBOE–98–46 and should be submitted by January 21, 2001.

VII. Conclusion

It is therefore ordered, pursuant to Section 19(b)(2) of the Act,47 that the proposed rule change, as amended, (SR–CBOE–98–46) is approved.

For the Commission, by the Division of Market Regulation, pursuant to delegated authority. 

Margaret H. McFarland, 
Deputy Secretary.

[FR Doc. 00–33118 Filed 12–27–00; 8:45 am]

BILLING CODE 8010–01–M

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34–43745; File No. SR–CBOE–00–58]

Self-Regulatory Organizations; Notice of Filing of Proposed Rule Change by the Chicago Board Options Exchange, Inc. Relating to an Interim Intermarket Linkage


Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 (“Act”) 1 and Rule 19b–4 thereunder, 2 notice is hereby given that on November 15, 2000, the Chicago Board Options Exchange, Inc. (“CBOE” or “Exchange”) filed with the Securities and Exchange Commission (“SEC” or “Commission”) the proposed rule change as described in Items I, II, and III below, which Items have been prepared by the CBOE. On December 13, 2000, the Exchange submitted Amendment No. 1 to the proposed rule change.3 The Commission is publishing this notice to solicit comments on the proposed rule change from interested persons.

I. Self-Regulatory Organization’s Statement of the Terms of Substance of the Proposed Rule Change

The Exchange is proposing to adopt a rule providing for the implementation of “interim linkages” with the other option exchanges. Below is the text of the proposed rule change. Additions are italicized.

CHAPTER VIII

Section B: Trading Crowds

Pilot Program for Away Market Maker Access

Rule 8.52

(1) Definitions. For the purposes of this Rule, the terms below have the following definitions.

(1) “Corresponding Rule” means a rule of a Participating Exchange that is substantially identical to this Rule 8.52.

(2) “Customer Size” means the lesser of (i) the number of option contracts that the Participating Exchange sending the order guarantees it will automatically execute at its disseminated quotation in an Eligible Option Class for Public Customer Orders and (ii) the number of option contracts that the Participating Exchange receiving the order expiring on January 31, 2002.

3 In Amendment No. 1, the Exchange made technical changes to the proposed rule text and specified that the proposed interim intermarket linkage would be effective for a pilot period expiring on January 31, 2002. See letter from Timothy Thompson, Assistant General Counsel, Legal Department, CBOE, to Nancy Sanow, Assistant Director, Division of Market Regulation, Commission, dated December 12, 2000 (“Amendment No. 1”).
guarantees it will automatically execute at its disseminated quotation in an Eligible Option Class for Public Customer Orders. This number shall be no fewer than 10.

(3) “Eligible Away Market-Maker” (“EAMM”) means, with respect to an Eligible Option Class, a market-maker, as that term is defined in Section 3(a)(22) of the Exchange Act, on a Participating Exchange: (A) is assigned to, and is providing two-sided quotations in the Eligible Option Class; and

(B) that is participating in its market’s automatic execution system in such Eligible Option Class.

(4) “Eligible Away Designated Primary Market-Maker” (“EADPM”) means: with respect to the American Stock Exchange and the Philadelphia Stock Exchange, a Specialist in an Eligible Option Class; with respect to the International Securities Exchange, a Primary Market Maker in an Eligible Option Class; and with respect to the Pacific Exchange, a Lead Market Maker in an Eligible Option Class.

(5) “Eligible Option Class” means all option series underlying a security, including both put and call options, which class is traded by the Exchange and at least one other Participating Exchange, to the extent that such Participating Exchanges have mutually agreed to include the option class in the Pilot Program.

(6) “Eligible Order” means an order for the account of a Designated Primary Market Maker or an Eligible Away Market Maker that can be sent to a Participating Exchange marked as a Public Customer Order pursuant to provisions of paragraphs (b), (c), and (d) of this Rule.

(7) “Participating Exchange” means (i) the Exchange, the Membership of the Exchange, a Designated Primary Market-Maker or an EADPM that complies with the following conditions: (1) the order is an immediate-or-cancel order; (2) the price of the order is equal to the bid (offer) disseminated by the Participating Exchange at the time the market-maker sends an order to sell (buy), and such bid (offer) is equal to the national best bid (offer) in that series of an Eligible Option Class, as calculated by the Exchange; (3) the Exchange’s bid (offer) at the time market-maker sends the order to sell (buy) is not then equal to the national highest bid (offer) in that series of an Eligible Option Class, as calculated by the Exchange; (4) the order is no larger than the Principal Size; and

(5) except with respect to orders a Designated Primary Market-Maker is sending pursuant to paragraph (c) below, the market-maker has not received an execution of another such order in the same series of an Eligible Option Class on the same Participating Exchange pursuant to the Pilot Program in the previous one minute period.

(c) Additional Access to Other Participating Exchanges. In addition to the access to other Participating Exchanges provided in paragraph (b) above, a Designated Primary Market-Maker participating in the Pilot Program may send an order to another Participating Exchange for execution as a Public Customer if:

(1) the Designated Primary Market-Makers complies with subparagraphs (1) through (3) of paragraph (b) above;

(2) the order reflects the same terms as an Underlying Customer Order the Designated Primary Market-Maker is holding; and

(3) the order is no larger than the Customer Size.

(d) Access to the Exchange by Eligible Market-Makers on Other Participating Exchanges. Notwithstanding any other Rule of the Exchange, a Member may send to the Exchange for execution as a Public Customer Order an order for an account of an EAMM or an EADPM that complies with the Governing Rule of the EAMM’s or EADPM’s Participating Exchange.

(e) Order Not Be in Writing. Notwithstanding the terms of Rule 6.24, an Eligible Order need not be in writing.

(f) Implementation of the Pilot Program. The President, or his designee, may implement the Pilot Program, in whole or in part, with respect to specific Participating Exchanges, to the extent that any such Participating Exchange has agreed to implement corresponding aspects of the Pilot Program. Designated Primary Market-Maker participation in the Pilot Program shall be voluntary.

(g) This Rule will be in effect on a pilot basis until January 31, 2002.

II. Self-Regulatory Organization’s Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

In its filing with the Commission, the CBOT included statements concerning the purpose of and basis for the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item IV below. The CBOT has prepared summaries, set forth in Sections A, B, and C below, of the most significant aspects of such statements.

A. Self-Regulatory Organization’s Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

1. Purpose

The purpose of this proposed rule change is to implement certain aspects of an intermarket options linkage on an “interim” basis. This interim linkage would utilize existing systems to facilitate the sending and receiving of order flow between CBOE market makers and their counterparts on the other option exchanges as an interim step towards development of a “permanent” linkage.

The Commission has approved a linkage plan that now includes all five option exchanges. The option exchanges continue to work towards implementation of this linkage. However, because the implementation may take a significant amount of time, the option exchanges have discussed implementing an “interim” linkage. Such a linkage would use the existing market infrastructure to route orders between market-makers on the participating exchanges in a more efficient manner.

The key component of the interim linkage would be for the participating exchanges to open their automated customer execution systems, on a limited basis, to market-maker orders. Specifically, market-makers would be able to designate certain orders as “customer” orders, and thus would receive automatic execution of those orders on participating exchanges.

This proposed rule would authorize the CBOT to implement bilateral or multilateral interim arrangements with the other exchanges to provide for equal access between market makers on our respective exchanges. The Exchange currently anticipates that the initial arrangements would allow CBOT Designated Primary Market-Makers (“DPMs”) and their equivalents on the other exchanges, when they are holding customer orders, to effectively send those orders to the other market for execution when the other market has a better quote. Such orders would be limited in size to the lesser of the size

4 Under the proposal, the interim linkage would be for a pilot period expiring on January 31, 2002.

of the two markets’ automatic execution size for customer orders. The Exchange expects that the interim linkage may expand to include limited access for pure principal orders, for orders of no more than 10 contracts.

All interim linkage orders must be “immediate or cancel” (that is, they cannot be placed on an exchange’s limit order book), and a market-maker may send a linkage order only when the other (receiving) market is displaying the best national bid or offer and the sending market is displaying an inferior price. This will allow a market-maker to access the better price for its customer. In addition, if the interim linkage includes principal orders, it would allow market-makers to attempt to “clear” another market displaying a superior quote. Any exchange participating in the interim linkage will implement heightened surveillance procedures to help ensure that their market-makers send only properly-qualified orders through the linkage.

DPM participation in the interim linkage will be voluntary. Only when a DPM and its equivalent on another exchange believe that this form of mutual access would be advantageous will the exchanges employ the interim linkage procedures. The CBOE believes that the interim linkage will benefit investors and will provide useful experience that will help the exchanges in implementing the full linkage.

2. Statutory Basis

The proposed rule change meets the requirement of Section 6(b)(5) under the Act in that it is designed to prevent fraudulent and manipulative acts and practices, to promote just and equitable principles of trade, to foster cooperation and coordination with persons engaged in regulating, clearing, settling, processing information with respect to, and facilitating transactions in securities, to remove impediments to and perfect the mechanism for a free and open market and a national market system, and, in general, to protect investors and the public interest.

B. Self-Regulatory Organization’s Statement on Burden on Competition

The CBOE does not believe that the proposed rule change will impose any burden on competition.

C. Self-Regulatory Organization’s Statement on Comments on the Proposed Rule Change Received From Members, Participants, or Others

No written comments were solicited or received with respect to the proposed rule change.

III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action

Within 35 days of the date of publication of this notice in the Federal Register or within such longer period (I) as the Commission may designate up to 90 days of such date if it finds such longer period to be appropriate and publishes its reasons for so finding or (ii) as to which the self-regulatory organization consents, the Commission will:

(A) by order approve such proposed rule change, or
(B) institute proceedings to determine whether the proposed rule change should be disappproved.

IV. Solicitation of Comments

Interested persons are invited to submit written data, views, and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Persons making written submissions should file six copies thereof with the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW., Washington, DC 20549–0609. Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for inspection and copying in the Commission’s Public Reference Room. Copies of such filing also will be available for inspection and copying at the principal office of the CBOE. All submissions should refer to File No. SR–CBOE–00–58 and should be submitted by January 18, 2001.

For the Commission, by the Division of Market Regulation, pursuant to delegated authority.

Margaret H. McFarland,
Deputy Secretary.
[FR Doc. 00–33119 Filed 12–27–00; 8:45 am]

BILLING CODE 8010–01–M

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34–43750; File No. SR–CBOE–00–52]

Self-Regulatory Organizations; Notice of Filing and Immediate Effectiveness of Proposed Rule Change by the Chicago Board Options Exchange, Inc., Relating to Participation Entitlements of Designated Primary Market Makers and Time and Priority Rules


Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 (“Act”), and Rule 19b–4 thereunder, notice is hereby given that on November 7, 2000, the Chicago Board Options Exchange, Inc. (“CBOE” or “Exchange”), filed with the Securities and Exchange Commission (“Commission”) the proposed rule change as described in Items I, II, and III below, which Items have been prepared by the Exchange. The proposed rule change has been filed by the CBOE as a “non-controversial” rule change pursuant to Rule 19b–4(f)(6) under the Act. The Commission is publishing this notice to solicit comments on the proposed rule change from interested persons.

I. Self-Regulatory Organization’s Statement of the Terms of Substance of the Proposed Rule Change

The CBOE is proposing to increase the participation entitlements of Designated Primary Market Makers (“DPMs”) when only one or two market makers are at parity with the DPM, and to clarify the operation of various CBOE rules concerning participation entitlements, time and priority rules, and orders represented by a DPM as agent. The text of the proposed rule change is available at the Office of the Secretary, CBOE, and at the Commission.

II. Self-Regulatory Organization’s Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

In its filing with the Commission, the CBOE included statements concerning the purpose of and basis for the proposed rule change and discussed any comments it received on the proposed rule change. The text these statements may be examined at the places specified in Item IV below. The CBOE has prepared summaries, set forth in

---

The CBOE’s current DPM participation entitlement is 30% for all transactions occurring at the DPM’s previously established bid or offer. The 30% entitlement is a flat rate and applies regardless of the volume in a particular class and the number of market makers present in the trading crowd, and regardless of whether the class if multiplied list. The CBOE is proposing to increase its DPM participation entitlements when there are one or two market makers at parity with the DPM 4 as follows:

- 50% when there is one market maker bidding (offering) at the DPM’s previously established bid (offer); and
- 40% when there are two market makers at parity with the DPM.

When there are three or more market makers at parity with the DPM, the DPM’s participation entitlement will remain unchanged at 30%. Accordingly, the changes would only occur in those limited instances where there are just one or two market makers at parity with the DPM, as the case may be. As discussed in more detail below, the CBOE proposes to issue a regulatory circular (“Regulatory Circular”) to establish these changes.

The proposed changes will enable the CBOE to conform its participation entitlement percentages to the entitlements established by the rules and/or practices of the other exchanges. For example, on the Philadelphia Stock Exchange (“Phlx”), a specialist is currently allocated 60% of an order when one “controlled account” is on parity, 40% when two are on parity, and 30% when three or more are on parity. Similarly, on the International Securities Exchange (“ISE”), after all public customer orders have been filled, a Primary Market Maker (“PMM”) is allocated 60% of an order if only one other participant is quoting at the best price, 40% if two other participants are at the best price, and 30% if more than two other participants are at the best price. The American Stock Exchange (“Amex”) and Pacific Exchange (“PCX”) have similar practices and provisions.

The primary purpose of the DPM participation right is to provide Exchange members with an incentive to become and remain DPMs and to assume the additional affirmative obligations imposed on DPMs that other members do not have. These obligations include the obligation to be present at the trading post throughout every business day, the obligation to participate at all times in automated execution and order handling systems such as the Exchange’s Retail Automatic Execution System (RAES), the obligation to act as an Order Book Official and to maintain the public order book, and the obligation to provide high quality markets and services and to promote the Exchange as a marketplace to customers and other market participants.

In this respect, lower DPM participation entitlements on the CBOE make it more difficult to attract and retain qualified DPMs. This puts the CBOE at a competitive disadvantage to those exchanges that provide for higher guarantees. Thus, the Exchange believes that increasing the DPM participation entitlements are necessary to promote the CBOE’s competitiveness within the exchange-traded options marketplace.

The CBOE notes that the proposed changes will not affect the priority currently afforded to public customers in the execution of their option orders. The Exchange will continue to apply the DPM participation entitlement only to that portion of the order that remains

---

4 Certain exceptions apply, as provided in Rule 6.45.
5 Similarly, by the principles set forth in Rule 6.45, if a market maker is first to respond with the best bid (offer) in response to a request for a market, the market maker is entitled to participate up to 100% in any resulting transaction. However, this entitlement applies only if the market maker’s bid (offer) is better than the DPM’s previously established principal bid (offer). If the DPM had previously established its principal bid (offer) at the price at which the transaction is to take place, the DPM entitlement provisions of CBOE Rule 6.87 apply, as explained below. It should be noted further that, by the terms of Rule 6.45, if the best bid (offer) is also represented by an order in the customer limit order book, that order will have priority over any other bid (offer) at the trading post.
6 As specified in rule 8.87, the extent of the entitlement is subject to the review of the CBOE Board of Directors.
7 On the other hand, when a DPM and one or more market makers all announce bids (offers) that establish the best bid (offer) at a price at which the DPM was not previously bidding, the priority rules apply as set forth in Rule 6.45. As such, the member who was first to respond at the best price (be it the DPM, market maker, or a floor broker) is entitled to participate up to the full amount of the order. As further provided by Rule 6.45, after the member with time priority has been satisfied, all other members bidding (offering) at the best price are entitled to participate based upon the sequence of their bids (offers). Concerning the application of the DPM entitlement when a customer order is at the best bid (offer), see further below.
8 According to the CBOE, market makers are deemed to be “at parity” with the DPM when they are bidding or offering at the DPM’s previously established bid or offer; and “at parity” with each other when it is impossible to determine, in the open outcry of the auction floor, which market maker responds first with the best bid (offer) in response to the request for a market. Telephone conversation between Arthur B. Reinstein and Steve Youn, CBOE, and Ira L. Brandriss, Division of Market Regulation, Commission, on December 4, 2000.
9 See Phlx Rule 1014(g)(ii). A “controlled account,” for the purposes of the referenced rule, includes any account controlled by an individual or accounts under common control with a member broker-dealer of the Phlx.
10 The Phlx also discussed Rule 1014(g)(ii), which incorporates additional provisions for situations when a customer order is on parity.
after all public customer orders have been filled. This applies to customer orders in the book as well as those represented in the crowd. Thus, CBOE’s DPM participation entitlement will continue to benefit customers by allowing them to receive full executions of their orders before a DPM can assert its participation entitlement.

As mentioned above, to effect the changes to the DPM participation entitlement level, the CBOE proposes to issue a new regulatory circular. The CBOE further believes that it would be beneficial to its membership if, for ease of access, the Exchange were to combine a discussion of the provisions referencing priority and DPM participation entitlements into one circular. Currently, in order to determine whether and to what extent a DPM is entitled to participate in a transaction, market participants must first reference Rule 6.45 and the corresponding, previously issued circulars to determine whether these entitlements apply and at what level. By combining the relevant provisions of these previously issued circulars and the new changes into one comprehensive circular, CBOE believes that its membership will be in a better position to access this important information more quickly and efficiently.

The first section of the Regulatory Circular, “Price and Time Priority,” contains a brief summary of the price and time priority principles contained in CBOE Rule 6.45. The second section of the Regulatory Circular, “DPM Participation Right,” establishes and describes the participation percentages discussed in this proposal. As such, it explains when a DPM is entitled to a participation entitlement and, if so entitled, under what circumstances a 30%, 40%, or 50% participation entitlement is appropriate.

This section further clarifies a long-held CBOE interpretation that a DPM’s participation entitlement is applicable to all securities traded by a DPM, which includes options as well as non-option securities traded pursuant to Chapter XXX of CBOE’s Rules. Rule 8.87(b) states that, with respect to the DPM entitlement, a DPM has the right to participate for its own account “in securities allocated to the DPM.” The circular makes clear that the term “securities” is restricted to options only and, therefore, that the participation entitlement extends to non-option securities traded on the CBOE.

The third section of Regulatory Circular, “Agency Orders,” is an amplification of the principle that public customer orders, whether in the book or in the trading crowd, take priority over a DPM’s participation right. As such, this section clearly states that a DPM’s participation right is applicable only to that portion of an order that remains after public customer orders have been filled. The proposed circular also contains an example illustrating these principles:

Assume there is an order in the book to buy 150 contracts at $3, a price that represents the national best bid. The DPM’s previously established principal bid is $3 and there are two market makers in the crowd each bidding at $3. If a floor broker enters the crowd with a market order to sell 300 contracts, the order in the book receives full execution of 150 contracts at $3. Thereafter, because the market makers’ bids are at parity with the DPM’s previously established principal bid, the DPM is entitled to a participation right of 40% with respect to the remaining 150 contracts of the market order. Therefore, the DPM receives 40% of the remaining 150 contracts at $3, or 60 contracts. The two market makers in the crowd each receive 45 contracts at $3.

The fourth section of the Regulatory Circular, “Orders in the Order Book,” is primarily a restatement of time priority principles contained in CBOE Rule 6.45 as applied to the Order Book. The first sentence clarifies that because a DPM’s previously established principal bid (offer) could not have been equal to the book, a DPM cannot participate with a market maker that was first to buy the book offer (sell to the book bid). The next sentence explains the operation of this principle in the context of crossed orders. Currently, when the AutoQuote system bid or offer would cross a booked order, AutoQuote will not adjust until the booked order trades. Thus, when a market maker trades with the booked order in this instance, a DPM is not entitled to participate because its previously established best bid or offer could not have matched the book. This section clarifies that this is the case even if the operation of AutoQuote may have prevented the DPM’s quote from automatically adjusting to match the book offer (bid).

The last section of the Regulatory Circular, “Orders Represented by a DPM as Agent,” establishes that, because of its knowledge of orders it represents as agent, a DPM Designee acting on behalf of the DPM’s market maker account cannot be deemed first to respond to the request for a market from another person acting on behalf of the DPM in performing the DPM’s agency function. This is designed to prevent a DPM from using knowledge of orders it represents as agent in order to trade ahead of other market participants. This section clarifies that other market participants must have the opportunity to act upon the order represented by the DPM as agent before the DPM’s principal account can transact with that agency order.

However, a DPM Designee acting on behalf of the DPM’s principal trading account may be the first to make a bid (offer) at a particular price with respect to a previously displayed resting order in the book or a previously represented resting order held by a DPM Designee acting as floor broker.

2. Statutory Basis

The CBOE believes that the proposed rule change will improve the operation of the DPM trading system by making the DPM participation entitlement more equitable for members while retaining the incentive for members to become and remain DPMs. Accordingly, the Exchange believes that the proposed rule change is consistent with Section 6(b) of the Act,14 in general, and furthers the objectives of Section 6(b)(5) of the Act,15 in particular, in that it is designed to remove impediments to and perfect the mechanism of a free and open market.

B. Self-Regulatory Organization’s Statement on Burden on Competition

The CBOE does not believe that the proposed rule change will impose any burden on competition not necessary or appropriate in furtherance of the purposes of the Act.

C. Self-Regulatory Organization’s Statement on Comments on the Proposed Rule Change Received From Members, Participants, or Others

No written comments were solicited or received with respect to the proposed rule change.

III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action

The foregoing proposed rule change has become effective pursuant to Section 19(b)(3)(A) of the Act16 and Rule 19b–4(f)(6) thereunder17 because the proposed rule change (1) does not significantly affect the protection of

---

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34–43746; File No. SR–CBOE–00–62]

Self-Regulatory Organizations; Notice of Filing of Proposed Rule Change by the Chicago Board Options Exchange, Incorporated to Limit the Meaning of “Public Customer” for Purposes of Determining Who May Use RAES


Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 (“Act”) 1 and Rule 19b–4 2 thereunder, notice is hereby given that on November 28, 2000, the Chicago Board Options Exchange, Incorporated (“CBOE” or “Exchange”) filed with the Securities and Exchange Commission (“Commission”) the proposed rule change as described in Items I, II, and III below, which Items have been prepared by the Exchange. The Commission is publishing this notice to solicit comments on the proposed rule change from interested persons.

I. Self-Regulatory Organization’s Statement of the Terms of Substance of the Proposed Rule Change

The Exchange proposes to amend the provisions of CBOE Rule 6.8 (RAES Operations) that govern the eligibility of the owners of certain types of accounts to submit orders through the Exchange’s Retail Automatic Execution System (“RAES”). 3 The text of the proposed rule change is set forth below. Deleted text is in brackets; new text is in italics.

Rule 6.8 RAES Operations

(a)(i) Firms on the Exchange’s Order Routing System (“ORS”) will automatically be on the Exchange’s Retail Automatic Execution System (“RAES”) for purposes of routing small public customer market or marketable limit orders into the RAES system. Those orders which are eligible for routing to RAES may be subject to such contingencies as the appropriate Floor Procedure Committee (“FPC”) shall approve. Public customer orders are orders for accounts other than accounts in which a member, non-member participant in a joint-venture with a member, or foreign broker-dealer, or member of a futures or securities exchange has an interest. The appropriate Floor

Procedures Committee (“FPC”) shall determine the size of orders eligible for entry into RAES in accordance with paragraph (e) of this Rule. For purposes of determining what a small customer order is, a customer’s order cannot be split up such that its parts are eligible for entry into RAES. Firms on ORS have the ability to go on and off ORS at will. Firms not on ORS that wish to participate will be given access to RAES from terminals at their booths on the floor.

* * * * *

Interpretations and Policies

* * * * *

.12 For purposes of this rule (or Rule 6.8(a)(i)), members, non-member participants in a joint venture with a member, non-member broker dealers, and members of a futures or securities exchange are deemed to have an interest in accounts held by the following:

1. Spouses of, or family members living in the same household with: CBOE members, non-member participants in a joint venture with a member, non-member broker dealers, or members of futures or securities exchange.

2. (a) An affiliate that holds a 5% or more interest in the CBOE member, non-member participant in a joint venture with a member, non-member broker-dealer, or member of a futures or securities exchange; (b) Spouses of, or family members living in the same household with, any affiliate as defined in this rule.

II. Self-Regulatory Organization’s Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

In its filing with the Commission, CBOE included statements concerning the purpose of and basis for the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item IV below. CBOE has prepared summaries, set forth in Sections A, B, and C below, of the most significant aspects of such statements.

A. Self-Regulatory Organization’s Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

1. Purpose

CBOE proposes to amend its rule governing the eligibility of the owners of certain types of accounts to submit orders through the Exchange’s RAES system by: (i) interpreting the term

---

3 RAES is the Exchange’s automatic execution system for public customer market or marketable limit orders of less than a certain size.


Margaret H. McFarland,
Deputy Secretary.

[FR Doc. 00–33123 Filed 12–27–00; 8:45 am]
BILLING CODE 3010–01–M
“interest,” and (ii) providing that members of futures exchanges are not considered “public customers” for purposes of the rule.

CBOE has stated that the RAES system provides a mechanism whereby public customers can receive automatic execution of their small market or marketable limit orders 4 at the National Best Bid or Offer (“NBBO”). 5 For the purposes of determining who is eligible to submit orders through RAES, Rule 6.8(a)[i] defines “public customer orders” as: Orders for accounts other than accounts in which a member, non-member participant in a joint-venture with a member, or any non-member broker-dealer (including a foreign broker-dealer as defined in Rule 1.1(xx)) has an interest.

Accordingly, any account in which a CBOE member or non-member participant in a joint venture with a CBOE member, or any non-member broker-dealer has an interest would not be deemed to be an eligible account for purposes of submitting RAES orders. A problem arises, however, in trying to determine what constitutes an “interest.” The Exchange has received numerous requests to provide interpretive advice with respect to whether certain individuals, who by nature of their relationship to persons who clearly are not public customers, are permitted to trade on RAES. For instance, there have been several inquiries as to whether the spouse or a relative of a CBOE member can trade for his or her own account through RAES. The Exchange notes that there is a strong interrelationship between the futures and securities markets. Futures, futures options, and stock options overlie many of the same indices and, in fact, may be used to hedge each other or to exploit an arbitrage opportunity. Given the specialized knowledge of the member of the futures exchange, CBOE does not believe it would be reasonable to classify this entity as a “public customer.” For purposes of this rule, CBOE proposes to define “affiliate” as a person or entity that holds a 5 percent or more interest in the member of the futures exchange.

Next, the Exchange proposes to add new Interpretation .12 6 to enumerate two categories of accounts in which CBOE members are deemed to have an interest. 7 The first category addresses the status of relatives of CBOE members. The proposal would clarify that a CBOE member is deemed to have an interest in any account maintained by the spouse of, or family members living in the same household with, that CBOE member. The Exchange notes that this prohibition is designed to prevent a CBOE member from trading on RAES by opening an account for a family member and submitting orders through that account. This prohibition applies regardless of whether the account is jointly or individually titled or owned. In this instance, because the parties share the same household and are ostensibly one economic unit, it can reasonably be inferred that the proceeds from the trading account would inure to all individuals in the household.

Furthermore, without this prohibition, it would be easy for a CBOE member to frustrate the purpose of the prohibition. For these reasons, the Exchange believes it is reasonable to impose a RAES-access trading restriction on relatives of CBOE members.

The second category applies to affiliates of CBOE members. Specifically, CBOE members are deemed to have an interest in any account maintained by an affiliate of a CBOE member. The Exchange believes it is necessary to place a restriction on affiliates by virtue of their relationship to CBOE members. In many instances, the affiliate will be an entity that either owns, or is owned by, the CBOE member. Given the relationship of the two entities and the fact that one may exert control over the other, CBOE believes it is proper to impose a prohibition on RAES trading by the affiliate of the CBOE member. In other instances, the affiliate may be a business partner of the CBOE member. In those situations, the two parties will share a common economic bond with respect to the operation of their business venture. Accordingly, CBOE believes it is reasonable to prevent the affiliate from trading on RAES. If the affiliate is an individual, the Exchange notes that the prohibition against RAES trading also extends to spouses and/or family members living in the same household as the affiliate. For purposes of this rule, the exchange defines an affiliate as a person or entity that holds a 5 percent or more interest in the CBOE member, non-member participant in a joint venture with a member, non-member broker-dealer, or member of a futures or securities exchange.

CBOE has asserted that the rules of all of the floor-based options exchanges, which have been approved by the Commission, limit access to their automatic execution systems either to the accounts of public customers or to non-broker-dealer accounts. 8 Given this limitation, the Exchange finds it necessary to provide interpretive guidance to clarify the types of accounts that it does not believe are eligible to submit orders through RAES. The clarifications provided in this proposed

---

4 Currently, RAES permits orders for up to 75 contracts (in all classes for which a greater maximum is not expressly provided for in the rules). Options subject to the 75-contract maximum include all classes of equity options and all classes of sector index options on the S&P 500 Index, the Nasdaq 100 Index, the Dow Jones Industrial Average, and the High Yield Select Ten, as well as interest rate options, currently are subject to a 100-contract limit.

5 The Commission notes, however, that a consolidated NBBO does not currently exist for the options markets. Instead, each options exchange separately calculates the best bid or offer for each multiply traded options class. See Securities Exchange Act Release No. 43086 (July 28, 2000), 65 FR 48023, 48024 n.22 (August 4, 2000).

6 This proposal also excludes members of any securities exchange from trading on RAES. This exclusion is intended to apply specifically to those individuals or entities that have a securities exchange membership but who are not registered as broker-dealers.

7 The text of the notice prepared by the Exchange inadvertently referred to the proposed interpretation here as Interpretation .11. If approved by the Commission, the proposed Interpretation would be in Interpretaion .12. Telephone conversation between Steve Youhn, Attorney, CBOE, and Michael Gaw, Attorney-Advisor, Division of Market Regulation, Commission, on November 30, 2000.

8 For simplification, the Exchange uses the term “CBOE member” to refer to CBOE members, non-member participants in a joint venture with a member, non-member broker dealers, and members of a futures or securities exchange.

9 See, e.g., PCX Rule 6.87(a) (only non-broker-dealer customer orders are eligible for execution on exchange’s Automatic Execution System); Amex Rule 933(a) (same).
rule change serve to ensure that RAES will continue to be for use by public
customers for the automatic execution of their small market or marketable limit
orders. The proposal also makes clear that certain other types of accounts will not be eligible to submit trades through
RAES. The Exchange notes, however, that nothing would prevent the owners
of these accounts from sending their orders to the floor for manual execution
where they would receive firm quote treatment and execution at the NBBO.

2. Statutory Basis

The Exchange believes the proposed rule change is consistent with the Act
and the rules and regulations under the Act applicable to a national securities
exchange and, in particular, the requirements of Section 6(b) of the Act. Specifically, the Exchange believes the proposed rule change is consistent with the Section 6(b)(5) requirements that the rules of an
exchange be designed to promote just and equitable principles of trade, to
prevent fraudulent and manipulative
acts, and in general to protect investors and the public interest.

B. Self-Regulatory Organization’s
Statement and Burden on Competition

The CBOE does not believe that the proposed rule change would impose any
burden on competition not necessary or appropriate in furtherance of the
purposes of the Act.

C. Self-Regulation Organization’s
Statement on Comments on the
Proposed Rule Change Received From
Members, Participants, or Others

No written comments were solicited
or received with respect to the proposed
rule change.

III. Date of Effectiveness of the
Proposed Rule Change and Timing for
Commission Action

Within 35 days of the date of
publication of this notice in the Federal
Register or with such longer period (i) as the Commission may designate up to
90 days of such date if it finds such longer period to be appropriate and
publishes its reasons for so finding, or (ii) as to which the Exchange consents, the Commission will:

(A) By order approve such proposed
rule change; or
(B) institute proceedings to determine
whether the proposed rule change should be disapproved.

IV. Solicitation of Comments

Interested persons are invited to
submit written data, views, and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Persons making written submissions should file six copies thereof with the Secretary, Securities and Exchange Commission, 450 Fifth Street NW, Washington DC 20549–0609. Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for inspection and copying in the Commission’s Public Reference Room. Copies of such filings will also be available for inspection and copying at the principal office of the CBOE. All submissions should refer to File No. SR–CBOE–00–62 and should be submitted by January 18, 2001.

For the Commission, by the Division of
Market Regulation, pursuant to delegated
authority.
Margaret H. McFarland, Deputy Secretary.

[Bills Doc. 00–33125 Filed 12–27–00; 8:45 am]
BILLING CODE 8010–01–M

SECURITIES AND EXCHANGE
COMMISSION

[Release No. 34–43744; File No. SR–CBOE–
00–64]

Self-Regulatory Organizations; Notice of
Filing and Immediate Effectiveness of
Proposed Rule Change by the
Chicago Board Options Exchange,
Inc., Relating to Exchange Fees


Pursuant to Section 19(b)(1) of the
Securities Exchange Act of 1934 ("Act") and
Rule 19b–4 thereunder, notice is hereby given that on December 1,
2000, the Chicago Board Options Exchange, Inc. ("CBOE" or "Exchange") filed with the Securities and Exchange Commission ("Commission") the
proposed rule change as described in Items I, II, and III below, which Items
have been prepared by the Exchange. The Commission is publishing this notice to solicit comments on the

proposed rule change from interested
persons.

I. Self-Regulatory Organization’s
Statement of the Terms of Substance of
the Proposed Rule Change

The CBOE proposes to make a change
to its fee schedule related to options on the
CBOE Mini-NDX. The test of the
proposed rule change is available at the
CBOE and the Commission.

II. Self-Regulatory Organization’s
Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule
Change

In its filing with the Commission, the
CBOE included statements concerning
the purpose of and basis for the
proposed rule change and discussed any
comments it received on the proposed
rule change. The text of these statements
may be examined at the places specified in
Item IV below. The CBOE has prepared summaries, set forth in
Sections A, B, and C below, of the most
significant aspects of such statements.

A. Self-Regulatory Organization’s
Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule
Change

1. Purpose

On August 29, 2000, the Commission
approved the Exchange’s proposed rule
change to waive all customer fees for options on the CBOE Mini-NDX
("MNXSM"). The Exchange decided to waive these customer fees to promote
the launch of the MNX product, which
started trading on August 14, 2000. The
purpose of the proposed rule change is
to reinstate all customer fees relating to
public customer MNX options orders
effective on December 1, 2000.

Specifically, the Exchange proposes to
reinstate the transaction fee, trade match
fee, floor brokerage fee and RAES fee for
public customer MNX options orders.
These customer fees will revert to the
standard rates that currently apply to
public customer orders for all other
Exchange index options. The Exchange
believes the customer fee waiver served
the purpose of promoting a successful
launch of the MNX product while
generating significant savings for its

(August 29, 2000), 65 FR 54333 (September 7, 2000). The Commission approved the trading of
options on the CBOE Mini-NDX on June 30, 2000. See

4 These “customer fees” are actually those fees
assessed on Exchange members relating to public
customer MNX options orders executed by such
members. Telephone conversation between Jamie
Galvan, Attorney, CBOE, and Geoffrey Pembie,
Attorney, Division of Market Regulation, Commission, on December 19, 2000.

customers. The Exchange now proposes to charge customer fees for MX options orders as it does for any other index product.

2. Statutory Basis
   The CBOE believes that the proposed rule change is consistent with Section 6(b) of the Exchange Act (“Act”), 6 in general, and furthers the objectives of Section 6(b)(4) of the Act, 7 in particular, in that it is designed to provide for the equitable allocation of reasonable dues, fees, and other changes among CBOE members.

B. Self-Regulatory Organization’s Statement on Burden on Competition
   The Exchange does not believe that the proposed rule change will impose any burden on competition.

C. Self-Regulatory Organization’s Statement on Comments on the Proposed Rule Change Received From Members, Participants, or Others
   Written comments were neither solicited nor received.

III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action
   Because the foregoing rule change establishes or changes a due, fee or other charge imposed by the Exchange, it has become effective pursuant to Section 19(b)(3)(A)(ii) 7 of the Act and subappropiate (f)(2) of Rule 19b-4 thereunder. 8 At any time within 60 days of the filing of the proposed rule change, the Commission may summarily abrogate such rule change if it appears to the Commission that such action is necessary or appropriate in the public interest, for the protection of investors, or otherwise in furtherance of the purposes of the Act.

IV. Solicitation of Comments
   Interested persons are invited to submit written data, views, and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Persons making written submissions should file six copies thereof with the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW., Washington, DC 20549–0609. Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for inspection and copying at the Commission’s Public Reference Room. Copies of such filing will also be available for inspection and copying at the principal office of the Exchange. All submissions should refer to the File No. SR-CBOE–00–64 and should be submitted by January 18, 2001.

For the Commission, by the Division of Market Regulation, pursuant to delegated authority. 9
Margaret H. McFarland,
Deputy Secretary.

SECURITIES AND EXCHANGE COMMISSION


Self-Regulatory Organizations; Notice of Filing of Proposed Rule Change by the International Securities Exchange, LLC Relating to an Interim Intermarket Linkage


Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 (“Act”) 1 and Rule 19b–4 thereunder, 2 notice is hereby given that on November 15, 2000, the International Securities Exchange LLC (“ISE” or “Exchange”) filed with the Securities and Exchange Commission (“SEC” or “Commission”) the proposed rule change as described in Items I, II, and III below, which Items have been prepared by the ISE. On December 13, 2000, the Exchange submitted Amendment No. 1 to the proposed rule change. 3 The Commission is publishing this notice to solicit comments on the proposed rule change from interested persons.

I. Self-Regulatory Organization’s Statement of the Terms of Substance of the Proposed Rule Change
   The Exchange is proposing a rule authorizing implementation of “interim linkages” with the other options exchanges. The interim linkage will permit qualified market makers on participating exchanges to send specified types of principal orders to other participating exchanges for automatic execution as if such orders were customer orders. Below is the text of the proposed rule change. Proposed new language is italicized.

   Rule 721. Pilot Program for Away Market Maker Access
   (a) Definitions. Solely for the purpose of this Rule:

   (1) “Corresponding Rule” means a rule of a Participating Exchange that is substantially identical to this Rule 721.

   (2) “Customer Size” means the lesser of (i) the number of option contracts that the Participating Exchange receiving the order guarantees it will automatically execute at its disseminated quotation in an Eligible Option Class for Public Customer Orders or (ii) the number of option contracts that the Participating Exchange sending the order guarantees sending the order guarantees it will automatically execute at its disseminated quotation in an Eligible Option Class for Public Customer Orders. This number shall be no fewer than 10.

   (3) “Eligible Away Market Maker” (“EAMM”) means, with respect to an Eligible Option Class, a market maker, as that term is defined in Section 3(a)(22) of the Exchange Act, on a Participating Exchange that:

   (i) is assigned to, and is providing two-sided quotations in the Eligible Option Class; and

   (ii) that is participating in its market’s automatic execution system in such Eligible Option Class.

   (4) “Eligible Away Principal Market Maker” (“EAPMM”) means: with respect to the American Stock Exchange and the Philadelphia Stock Exchange, a Specialist in an Eligible Option Class; with respect to the Chicago Board Options Exchange, a Designated Primary Maker in an Eligible Option Class; and with respect to the Pacific Exchange, a Lead Maker in an Eligible Option Class.

   (5) “Eligible Option Class” means all option series overlying a security, including both put and call options, which class is traded by the Exchange and at least one other Participating Exchange, to the extent that such Participating Exchanges have mutually agreed to include the option class in the Pilot Program.

   (6) “Eligible Order” means an order for the account of a market maker, an EAMM or an EAPMM that can be sent to a Participating Exchange marked as a Public Customer Order pursuant to

---

13 In Amendment No. 1, the Exchange specified that the proposed interim linkage would be for a pilot period expiring on January 31, 2002. See letter from Michael Simon, Senior Vice President and General Counsel, ISE, to Nancy Sanow, Assistant Director, Division of Market Regulation, Commission, dated December 11, 2000 (“Amendment No. 1”).
provisions of paragraphs (b), (c), and (d) of this Rule.

(7) “Participating Exchange” means (i) the Exchange and (ii) one or more of the American Stock Exchange, the Chicago Board Options Exchange, the Pacific Exchange, and the Philadelphia Stock Exchange, as the President of the Exchange, or his designee, has designated from time to time as having adopted a Corresponding Rule.

(8) “Pilot Program” means the program established by this Rule and the Corresponding Rules of the other Participating Exchanges.

(9) “Principal Size” means the number of option contracts that two or more Participating Exchanges mutually agree that they will automatically execute during the Pilot Program at their disseminated quotation for orders sent for the principal account of a market maker, an EAMM or an EAPMM that does not correspond to a Underlying Customer Order. This number shall be no fewer than 10.

(10) “Underlying Customer Order” means an associated Public Customer Order for which a Primary Market Maker or EAPMM is acting as agent and which underlies an Eligible Order.

(b) Access to Other Participating Exchanges by Market Makers. Pursuant to the Pilot Program, a market maker participating in the program may send an order to another Participating Exchange for execution as a Public Customer if:

(1) the Primary Market Maker complies with subparagraphs (1) through (3) of paragraph (b), above:

(2) the order reflects the same terms and conditions:

(3) the order is no larger than the Principal Size.

(d) Access to the Exchange by Eligible Market Makers on other Participating Exchanges. Notwithstanding any other Rule of the Exchange, an Electronic Access Member may send to the Exchange for execution as a Public Customer Order an order for the account of an EAMM or an EAPMM that complies with the Corresponding Rule of the EAMM’s or EAPMM’s Participating Exchange.

(e) Implementation of the Pilot Program. The President, or his designee, may implement the Pilot Program, in whole or in part, with respect to specific Participating Exchanges, to the extent that any such Participating Exchange has agreed to implement corresponding aspects of the Pilot Program. Primary Market Maker participation in the Pilot Program shall be voluntary.

II. Self-Regulatory Organization’s Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

In its filing with the Commission, the ISE included statements concerning the purpose of and basis for the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item IV below. The ISE has prepared summaries, set forth in Sections A, B, and C below, of the most significant aspects of such statements.

A. Self-Regulatory Organization’s Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

1. Purpose

The purpose of the proposed rule change is to implement certain aspects of an intermarket options linkage on an “interim” basis. This interim linkage would utilize existing order types to facilitate the sending and receiving of order flow between ISE market makers and their counterparts on the other options exchanges as an interim step towards development of a “permanent” linkage.

By way of background, the Commission has approved a linkage plan that now includes all five options exchanges. The options exchanges continue to work towards implementation of this linkage, which likely will include contracting with a third party to build a linkage infrastructure. Since this will take a significant amount of time, the options exchanges have discussed implementing an “interim” linkage. Such a linkage would use the existing market infrastructure to route orders between market makers on the participating exchanges in a more efficient manner.

The key component of the interim linkage would be for the participating exchanges to open their automated customer execution systems, on a limited basis, to market maker orders. Specifically, market makers would be able to designate certain orders as “customer” orders, and thus would receive automatic execution of those orders on participating exchanges.

This proposed rule would authorize the ISE to implement bilateral or multilateral interim arrangements with the other exchanges to provide for equal access between market makers on our respective exchanges. The Exchange currently anticipates that the initial arrangements would allow ISE Primary Market Makers (“PMMs”) and their equivalents on the other exchanges, when they are holding customer orders, to send orders reflecting the customer orders to the other market for execution when the other market has a better quote. Such orders would be limited in size to the lesser of the size of the two markets’ “firm” quotes for customer orders. The Exchange expects that the interim linkage may expand to include limited access for pure principal orders, for orders of no more than 10 contracts.

All interim linkage orders must be “immediate or cancel” (that is, they cannot be placed on an exchange’s limit order book), and a market maker can send a linkage order only when the other (receiving) market is displaying the best national bid or offer and the sending market is an inferior price. This will allow a market maker to access the better price for its customer. In addition, if the interim linkage includes principal orders, it would allow market makers to attempt to “clear” another market.

Under the proposal, the interim linkage would be for a pilot period expiring on January 31, 2002. See Amendment No. 1, supra note 3.

5 Under the proposal, the interim linkage would be for a pilot period expiring on January 31, 2002. See Amendment No. 1, supra note 3.
displaying a superior quote. Any exchange participating in the interim linkage will implement heightened surveillance procedures to help ensure that their market makers send only properly-qualified orders through the linkage.

PMM participation in the interim linkage will be voluntary. Only when a PMM and its equivalent on another exchange believe that this form of mutual access would be advantageous will the exchanges employ the interim linkage procedures. The ISE believes that the interim linkage will benefit investors and will provide useful experience that will help the exchanges in implementing the full linkage.

2. Statutory Basis

The ISE believes that the basis under the Act for this proposed rule change is the requirement under Section 6(b)(5) of the Act, that an exchange have rules that are designed to prevent fraudulent and manipulative acts and practices, to promote just and equitable principles of trade, to foster cooperation and coordination with persons engaged in regulating, clearing, settling, processing information with respect to, and facilitating transaction in securities, to remove impediments to and perfect the mechanism for a free and open market and a national market system, and, in general, to protect investors and the public interest.

B. Self-Regulatory Organization’s Statement on Burden on Competition

The CBOE does not believe that the proposed rule change will impose any burden on competition.

C. Self-Regulatory Organization’s Statement on Comments on the Proposed Rule Change Received From Members, Participants, or Others

No written comments were solicited or received with respect to the proposed rule change.

III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action

Within 35 days of the date of publication of this notice in the Federal Register or within such longer period (i) as the Commission may designate up to 90 days of such date if it finds such longer period to be appropriate and publishes its reasons for so finding or (ii) as to which the self-regulatory organization consents, the Commission will:

(A) By order approve such proposed rule change, or

(B) Institute proceedings to determine whether the proposed rule change should be disapproved.

IV. Solicitation of Comments

Interested persons are invited to submit written data, views, and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Persons making written submissions should file six copies thereof with the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW., Washington, DC 20549–0609. Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for inspection and copying in the Commission’s Public Reference Room. Copies of such filing also will be available for inspection and copying at the principal office of the ISE. All submissions should refer to File No. SR–ISE–00–15 and should be submitted by January 18, 2001.

For the Commission, by the Division of Market Regulation, pursuant to delegated authority.

Margaret H. McFarland,
Deputy Secretary.

SECURITIES AND EXCHANGE COMMISSION

BILLING CODE 8010–01–M

The correction to the original document is being published simultaneously elsewhere in today’s issue of the Federal Register.

For the Commission, by the Division of Market Regulation, pursuant to delegated authority.

Margaret H. McFarland,
Deputy Secretary.

[FR Doc. 00–31303 Filed 12–27–00; 8:45 am]

BILLING CODE 8010–01–M

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34–43726; File No. SR–NYSE–00–57]

Self-Regulatory Organizations; Notice of Filing and Immediate Effectiveness of Proposed Rule Change by the New York Stock Exchange, Inc. to Implement a New Trading Floor Regulatory Fee


Pursuant to section 19(b)(1) of the Securities Exchange Act of 1934 (“Act”) and Rule 19b–4 thereunder, notice hereby is given that on December 13, 2000, the New York Stock Exchange, Inc. (“NYSE” or “Exchange”) filed with the Securities and Exchange Commission (“Commission”) the proposed rule change as described in Items I, II, and III below, which Items have been prepared by the Exchange. The Commission is publishing this notice to solicit comments on the proposed rule change from interested persons.

I. Self-Regulatory Organization’s Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

The NYSE proposes to implement a new Trading Floor Regulatory Fee to be charged to members doing business on the trading floor. Each specialist firm would contribute according to the number of memberships associated with the firm. Other floor members would be assessed an annual fee, subject to a maximum fee per firm. The proposed rule change is available at the principal office of the NYSE and at the Commission’s Public Reference Room.

II. Self-Regulatory Organization’s Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

In its filing with the Commission, the NYSE included statements concerning the purpose of and basis for the


proposed rule change and discussed any comments it received regarding the proposed rule change. The text of these statements may be examined at the places specified in Item IV below. The NYSE has prepared summaries, set forth in Sections A, B, and C below, of the most significant aspects of such statements.

A. Self-Regulatory Organization’s Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

1. Purpose

The NYSE’s Market Surveillance Division monitors all trading activity on the trading floor on a real-time basis. This surveillance applies to all members doing business on the trading floor. Market Surveillance has become increasingly important, visible, and costly over recent years. The proposed rule change is the requirement under section 19(B)(3)(A)(ii) of the Act and subparagraph (f)(2) of Rule 19b–4 thereunder. At any time within 60 days of the filing of such proposed rule change, the Commission may summarily abrogate such rule change if it appears to the Commission that such action is necessary or appropriate in the public interest, for the protection of investors, or otherwise in furtherance of the purposes of the Act.

B. Self-Regulatory Organization’s Statement of Burden on Competition

The NYSE does not believe that the proposed rule change would impose any burden on competition that is not necessary or appropriate in furtherance of the purpose of the Act.

C. Self-Regulatory Organization’s Statement on Comments on the Proposed Rule Change Received From Members, Participants, or Others

The NYSE has neither solicited nor received written comments on the proposed rule change.

III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action

The foregoing rule change establishes or changes a due, fee, or other charge imposed by the Exchange and therefore has become effective pursuant to section 19(B)(3)(A)(ii) of the Act and subparagraph (f)(2) of Rule 19b–4 thereunder. At any time within 60 days of the filing of such proposed rule change, the Commission may summarily abrogate such rule change if it appears to the Commission that such action is necessary or appropriate in the public interest, for the protection of investors, or otherwise in furtherance of the purposes of the Act.

IV. Solicitation of Comments

Interested persons are invited to submit written data, views, and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Persons making written submissions should file six copies thereof with the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW., Washington, DC 20549–0609. Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for inspection and copying at the Commission’s Public Reference Room. Copies of such filing will also be available for inspection and copying at the principal office of the Exchange. All submissions should refer to File No. SR–NYSE–00–57 and should be submitted by January 18, 2001.

For the Commission, by the Division of Market Regulation, pursuant to delegated authority.

Margaret H. McFarland,
Deputy Secretary.

[FR Doc. 00–33121 Filed 12–27–00; 8:45 am]

BILLING CODE 8010–01–M

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34–43741; File No. SR–NYSE–00–47]

Self-Regulatory Organizations; Notice of Filing and Order Granting Accelerated Approval of Proposed Rule Change by the New York Stock Exchange, Inc. Relating to Listed Company Fees


Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 (“Act”) and Rule 19b–4 thereunder, notice is hereby given that on November 29, 2000, the New York Stock Exchange, Inc. (“NYSE” or “Exchange”) filed with the Securities and Exchange Commission (“SEC” or “Commission”) the proposed rule change as described in Items I and II below, which Items have been prepared by the Exchange. The Commission is publishing this notice to solicit comments on the proposed rule change from interested persons and to approve the proposal on an accelerated basis.

I. Self-Regulatory Organization’s Statement of the Terms of Substance of the Proposed Rule Change

The NYSE proposes to amend Paragraphs 902.02 through .04 of the Exchange’s Listed Company Manual (the “Manual”), concerning the minimum original listing fee for overseas companies to that applied to domestic companies earlier this year, increasing the minimum continuing listing fee applicable to domestic companies, and adopting a specific schedule for closed-end funds. The text of the proposed rule change is available at the Office of the Secretary, the NYSE, and at the Commission.

II. Self-Regulatory Organization’s Statements of the Purpose of, and Statutory Basis for, the Proposed Rule Change

In its filing with the Commission, the Exchange included statements concerning the purpose of and basis for the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item III below. The Exchange has prepared summaries, set forth in sections A, B, and C below, of the most significant aspects of such statements.
A. Self-Regulatory Organization’s Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

1. Purpose

Earlier this year the Exchange amended its listing fee schedule to implement a minimum original listing fee for each domestic issuer (excluding closed-end funds).\(^3\) Having had a positive experience with this matter, and to achieve greater consistency in the minimum fee applicable to domestic and overseas companies, the Exchange proposes to raise the minimum original listing fee for overseas companies to $150,000 as well, from its present level of $100,000.

The Exchange also imposes on listed companies continuing annual fees, generally based on the number of shares listed on the Exchange. Currently the Exchange imposes a minimum continuing fee for overseas companies of $35,000, while the minimum for domestic companies is $16,170. Again, having had a positive experience with the minimum continuing annual fee applicable to overseas companies, the Exchange proposes to raise the minimum continuing annual fee for domestic companies to the same level, $35,000. Companies with more than one class of common stock where both issues are below the new minimum fee would incur an increased fee only on the issue with the most shares outstanding. The other class would be charged at the per share and minimum rate in effect today. In addition, companies that listed during 2000 will be billed for the year 2001 only at the per share and minimum rate in effect today, moving to the new schedule in 2002.

The minimum continuing fee for closed-end funds would be $25,000 for funds with ten million shares or less; those with greater than ten million shares would pay a minimum of $35,000. Families of funds with from five to fifteen funds outstanding would receive a discount of 5%, while those with greater than fifteen funds listed on the Exchange would receive a 10% discount on the continuing annual fee applied to each fund.

The Exchange has a separate schedule of fees for “short-term securities,” which are securities having a term of seven years or less (e.g., index warrants, foreign currency warrants, contingent value rights, etc.). The minimum continuing annual fee for short-term securities is being raised to $17,500, in line with the increase discussed above for regular common stock.

Finally, the Exchange considers it appropriate to specify a separate annual continuing fee minimum of $3,600 for other equity issues as specified in Section 902.02 of the Manual.

The Exchange proposes to implement all the foregoing changes as of January 1, 2001.

2. Statutory Basis

The Exchange believes the proposed rule change is consistent with Section 6(b) of the Act \(^4\) in general, and further the objectives of Section 6(b)(4) of the Act \(^5\) in particular, in that it provides for the equitable allocation of reasonable dues, fees, and other charges among its members and issuers and other persons using its facilities.

B. Self-Regulatory Organization’s Statement on Burden on Competition

The Exchange believes that the proposed fee change will not impose any burden on competition that is not necessary or appropriate in the furtherance of the purposes of the Act.

C. Self-Regulatory Organization’s Statement on Comments on the Proposed Rule Change Received From Members, Participants or Others

The Exchange neither solicited nor received any written comments on the proposed rule change.

III. Solicitation of Comments

Interested persons are invited to submit written data, views and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Persons making written submissions should file six copies thereof with the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW, Washington, DC 20549–0609. Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for inspection and copying in the Commission’s Public Reference Room. Copies of such filing will also be available for inspection and copying at the principal office of the NYSE. All submissions should refer to File No. SR–NYSE–00–47 and should be submitted by January 18, 2001.

IV. Commission’s Findings and Order

The Commission finds that the proposed rule change is consistent with the requirements of the Act and the rules and regulations thereunder applicable to a national securities exchange. In particular, the Commission finds that the proposed rule change is consistent with Section 6(b)(4) of the Act, which provides for the equitable allocation of reasonable dues, fees, and other charges among an exchange’s members and issuers and other persons using its facilities.\(^6\) The Commission believes that the Exchange’s changes to its listing fees are not unreasonable.

Finally, the Commission, pursuant to Section 19(b)(2) of the Act,\(^7\) finds good cause for approving the proposed rule change prior to the thirtieth day after the date of publication of notice thereof in the Federal Register.\(^8\) The Commission notes that granting accelerated approval to this proposal will allow the NYSE to implement the fee changes by January 1, 2001. Accordingly, the Commission finds that there is good cause, consistent with Section 19(b)(2) of the Act,\(^9\) to approve the proposal on an accelerated basis.

V. Conclusion

It is therefore ordered, pursuant to Section 19(b)(2) of the Act,\(^10\) that the proposed rule change (SR–NYSE–00–47) is hereby approved on an accelerated basis.

For the Commission, by the Division of Market Regulation, pursuant to delegated authority.\(^11\)

Margaret H. McFarland,
Deputy Secretary.

[FR Doc. 00–33127 Filed 12–27–00; 8:45 am]
BILLING CODE 8010–01–M


\(^6\) In approving this proposal, the Commission has considered its impact on efficiency, competition, and capital formation. 15 U.S.C. 78f(f).


\(^9\) Id.

\(^10\) Id.

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-43755; File No. SR–OCC–00–00–12]

Self-Regulatory Organizations; The Options Clearing Corporation; Notice of Filing of Proposed Rule Change Relating to The Creation of a Program to Relieve Strains on Clearing Members’ Liquidity in Connection With Settlements


Pursuant to 19(b)(1) of the Securities Exchange Act of 1934 ("Act") 1 notice is hereby given that on November 27, 2000, The Options Clearing Corporation ("OCC") filed with the Securities and Exchange Commission ("Commission") the proposed rule change as described in Items I, II, and III below, which items have been prepared primarily by OCC. The Commission is publishing this notice to solicit comments on the proposed rule change from interested parties.

I. Self-Regulatory Organizations

Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

The proposed rule change proposes a program to relieve strains on clearing members’ liquidity in heavy expiration months by reducing inefficiencies in the exercise settlement process. 2

II. Self-Regulatory Organization’s Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

In its filing with the Commission, OCC included statements concerning the purpose of and basis for the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item IV below. OCC has prepared summaries, set forth in sections (A), (B), and (C) below, of the most significant aspects of these statements. 3

(A) Self-Regulatory Organization’s Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

1. Background

Under the Third Amended and Restated Options Exercise Settlement Agreement (the “Accord”) dated February 16, 1995, between OCC and National Securities Clearing Corporation (“NSCC”), OCC and NSCC each guarantee that if the other sustains a loss on liquidity of a common member 4 with pending settlement activity at NSCC resulting option exercises and assignments, it will make a payment to the other in an amount (which may be zero) determined by a formula set forth in the Accord. 5

Under the Accord, NSCC has until 6:00 a.m. Central Time on the day after an option exercise settlement date (E+4) to notify OCC that it has ceased to act or may cease to act for a common member. If NSCC fails to give such notice by that time, OCC is released from its guarantee obligation with respect to transactions for which E+3 was the settlement date. Because OCC is not released from its guarantee obligation until the morning of E+4, it must continue to hold margin on assignments settling on E+3 until E+4. This means that assets that a clearing member has deposited with OCC as margin for pending assignments cannot be used to settle or to finance settlement of those assignments. Instead, the clearing member must find other sources of financing and that can strain some clearing members’ liquidity in months with heavy exercise and assignment activity.

2. The Proposed Rule Change

In an effort to reduce the strains on liquidity resulting from the after-the-fact release of margin on pending assignments, OCC, in conjunction with NSCC and The Depository Trust Company ("DTC"), has worked out a program to allow OCC clearing member to withdraw equity securities 6 deposited with OCC as margin and pledge them to DTC participant banks as collateral for loans. The proceeds of such loans would be disbursed by the bank directly to OCC and used to discharge settlement obligations of the clearing member at NSCC that were guaranteed by OCC. OCC’s liability exposure to NSCC under the Accord would be correspondingly reduced as would OCC’s need to continue to hold margin until E+4.

The program would work as follows:

- On the morning of E+3, a clearing member would determine from OCC the amount of the loan that it could collateralize with securities held by OCC as a margin. That amount would be no less than the value assigned by OCC to such securities for margin purposes 7 and would be no more than the lesser of (i) the margin requirement for the account from which the securities were to be withdrawn 8 and (ii) the amount of OCC’s guarantee exposure to NSCC (assuming that the clearing member’s NSCC positions liquidated to a deficit). 9
- The clearing member would then contact its bank and arrange for the loan. When the terms of the loan were agreed upon, the clearing member would use a new Participant Terminal System screen developed by DTC to confirm both to the bank and to OCC the amount of the loan and the quantity and description of the securities to be withdrawn from OCC and pledged to the bank as collateral. The bank and OCC would use that information to validate the loan request.
- The date of both the bank and OCC approved the loan, DTC would transfer the securities from a “pledged to OCC” field in the clearing member’s DTC account to a special OCC account at DTC. From that account, the securities would be pledged to the bank against receipt of the loan proceeds. The proceeds would thus be paid directly to OCC without passing through the hands of the clearing member.
- Upon receipt in the special OCC account, the loan proceeds would automatically be paid over to NSCC for the benefit of the clearing member resulting in a corresponding reduction in OCC’s guarantee exposure to NSCC under the Accord.

3. Summary of Comments Received

The text of these statements and the purpose for, and basis of, the proposed rule change, as well as the comments it received on the proposed rule change are published in SECURITIES AND EXCHANGE COMMISSION, Notice of Proposed Rule Change—OCC—The Options Clearing Corporation: Notice of Proposed Rule Change—A Program to Relieve Strains on Clearing Members’ Liquidity in Connection With Settlements, 65 FR 51731 (September 26, 1996), and the public comments thereon are available at the Commission’s Public Reference Section or through OCC.

4. Conclusion

For example, if the clearing member had equity securities with a market value of $10 million on deposit in an account with OCC as margin (which OCC would value at $7 million for margin purposes), the amount of the bank loan collateralized by those securities would have to be no less than $7 million. If the loan amount were, for example, $6 million, OCC would be exchanging $7 million worth of margin for a reduction of only $6 million in its guarantee exposure to NSCC.

5. For example, if, in the preceding example, the margin requirement in the relevant account were only $6 million, the loan would be limited to that amount and OCC would only release equity securities with a market value of $8.57 million ($6 million in margin value). The remaining $1.43 million of securities would be excess margin, which the clearing member would be free to withdraw and pledge separately.

6. If, in the preceding examples, OCC’s guarantee exposure to NSCC were only $5 million, the loan would be limited to that amount and OCC would only release equity securities with a value of $7.14 million ($5 million in margin value). If the loan amount were in excess of $5 million, OCC would be releasing margin worth more than $5 million for a reduction of only $5 million in its guaranteed exposure.
• At the end of the day, DTC would automatically transfer the securities from a “pledged to bank” field in the special OCC account to a “pledged to bank” field in the clearing member’s DTC account, leaving the clearing member in the same position as if it had been able to pledge the securities to the bank without OCC’s intermediation.

Upon allowing securities to be withdrawn and pledged under the program, OCC would reduce its margin requirement in the account from which the securities were withdrawn by an amount equal to the value assigned to the securities for margin purposes. The account would, however, be required to be fully margined the next morning.

Initially, clearing members will be permitted to withdraw and pledge securities held by OCC as margin only on settlement dates for exercises of expiring equity options. OCC may at a future date decide to make it available on other exercise settlement dates as well.

3. Timing

Historically, the heaviest volume of option expirations, and hence exercises, occurs in January. In January 2000, 26,099,346 option contracts expired, accounting for 41.9% of total open interest. Open interest as of November 21, 2000, included 26,378,070 contracts expiring in January 2001 (43.2% of total open interest). OCC believes that it is important to have the new program in place in time for the January 2001 expiration to help relieve potential strains on liquidity resulting from the large volume of exercise activity expected to occur at that time.

The proposed rule change is consistent with the requirements of section 17A of the Act and the rules and regulations thereunder applicable to OCC because it would reduce inefficiencies in the exercise settlement process and relieve strains on clearing members’ liquidity in heavy expiration months thereby promoting the safeguarding of securities and funds.

(B) Self-Regulatory Organization’s Statement on Burden on Competition

OCC does not believe that the proposed rule change would impose any burden on competition.

(C) Self-Regulatory Organization’s Statement on Comments on the Proposed Rule Change Received From Members, Participants or Others

Written comments were not and are not intended to be solicited with respect to the proposed rule change and none have been received.

III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action

Within thirty-five days of the date of publication of this notice in the Federal Register or within such longer period as the Commission may designate up to ninety days of such date if it finds such longer period to be appropriate and publishes its reasons for so finding or (ii) as to which the self-regulatory organization consents, the Commission will:

(A) by order approve such proposed rule change or

(B) institute proceedings to determine whether the proposed rule change should be disapproved.

IV. Solicitation of Comments

Interested persons are invited to submit written data, views, and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Persons making written submissions should file six copies thereof with the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW., Washington, DC 20549–0609. Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for inspection and copying in the Commission’s Public Reference Section 450 Fifth Street, NW., Washington, DC 20549. Copies of such filing also will be available for inspection and copying at the principal office of OCC. All submissions should refer to File No. SR–OCC–00–12 and should be submitted by January 18, 2001.

For the Commission by the Division of Market Regulation, pursuant to delegated authority.11

Margaret H. McFarland,
Deputy Secretary.

[FR Doc. 00–33120 Filed 12–27–00; 8:45 am]
BILLING CODE 8010–01–M


SECURITIES AND EXCHANGE COMMISSION

[Release No. 34–43757; File No. SR–Phlx–00–13]

Self-Regulatory Organizations; Notice of Filing of Proposed Rule Change, as Amended, by the Philadelphia Stock Exchange, Inc. Relating to Timing Guidelines for Application in Disciplinary Hearings


Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 (“Act”) and Rule 19b–4 thereunder, notice is hereby given that on July 13, 2000, the Philadelphia Stock Exchange, Inc. (“Phlx” or “Exchange”) filed with the Securities and Exchange Commission (“SEC” or “Commission”) the proposed rule change as described in Items I, II, and III below, which Items have been prepared by the Exchange. On August 23, 2000, the Phlx filed Amendment No. 1 to the proposed rule change. On November 9, 2000, the Phlx filed Amendment No. 2 to the proposed rule change. On November 22, 2000, the Phlx filed Amendment No. 3 to the proposed rule change. On December 13, 2000, the Phlx filed Amendment No. 4 to the proposed rule change. The Commission is publishing this notice to solicit comments on the proposed rule change.
change, as amended, from interested persons.

I. Self-Regulatory Organization’s Statement of the Terms of Substance of the Proposed Rule Change

The Phlx proposes to amend Phlx Rule 960.5(a), (b), (c), and (d) to provide timing guidelines for certain procedures conducted pursuant to Phlx Rule 960.5. Revised Rule 960.5 proposes to adopt a timing guideline of 120 days after the filing of a written Answer by a Respondent to a Statement of Charges, within which time a hearing is requested, for the scheduling of a hearing date.\(^7\) Also proposed is a five business day timing guideline\(^8\) for the Chair of the Committee, or its designee, after receiving a request from Counsel for the Exchange, to schedule a hearing date and name a Hearing Panel. Further, it is proposed that, should the request for a hearing come from the Respondent, Counsel for the Exchange must request that a hearing date be set and a Hearing Panel be named ten business days of receiving Respondent’s request.\(^9\) An exchange of evidence and witness lists between the parties, as well as providing same to the members of the Hearing Panel, is to be completed not less than eight business days prior to the scheduled hearing date.\(^10\) The proposed amendments require that a transcript of the hearing be provided to the Hearing Panel members and the Respondent within five business days of receipt of the transcript by Counsel for the Exchange. The Respondent, along with being provided a copy of the transcript, will be issued a bill for its portion of the costs of the transcript.\(^11\) The costs of the transcript, and producing copies, will be borne equally by the Exchange and by Respondent.\(^12\) The Hearing Panel, upon receipt of the transcript, would then have forty-five days to produce a hearing report.\(^13\) Finally, the proposed amendments establish formal procedures for the requesting and granting of adjournments of the hearing date. Such requests are to be presented in writing to the presiding person of the Hearing Panel, and will be considered for just cause.\(^14\)

The proposed amendments also allow the Chair of the Committee to name a designee.\(^15\) This is proposed for administrative purposes, such as the Chair’s unavailability due to illness, the need for recusal, or other circumstances which may arise.

Below is the text of the proposed rule change. Proposed new language is italicized, and proposed deletions are in brackets.

**Rule 960.5. Hearing**

(a) Participants and Selection of Hearing Panels

1. Request for a Hearing—A hearing on the Statement of Charges shall, at the request of Respondent in his answer, or upon motion of the Business Conduct Committee, be held before a Hearing Panel composed of three persons to be appointed by the Chairman of the Business Conduct Committee or their designee. Should the hearing be at the request of the Respondent, counsel for the Exchange must provide notice to the Chairman of the Business Conduct Committee or their designee which requests the naming of a hearing panel within 10 business days of receiving Respondents request for a hearing.

2. Selection of Hearing Panel—The Chairman of the Business Conduct Committee or their designee shall name a Hearing Panel within 5 business days of either (i) receipt of notice from counsel for the Exchange which requests the naming of a Hearing Panel, or (ii) upon motion of the Business Conduct Committee for naming of a Hearing Panel. The Chairman of the Business Conduct Committee or their designee shall then promptly notify counsel for the Exchange and Respondent of the names of the members of the Hearing Panel. The presiding person of each Hearing Panel shall be a member of the Business Conduct Committee. The other persons on the Hearing Panel shall be members of the Exchange, or general partners or officers of member organizations, or such other persons whom the Chairman of the Business Conduct Committee or their designee considers to be qualified. The Chairman of the Business Conduct Committee or their designee shall select these two other persons from those persons who shall have been designated by the Chairman of the Board of Governors to serve on such hearing panels. In making such selections the Chairman or their designee shall, to the extent practicable, choose individuals whose background, experience and training qualify them to consider and make determinations regarding the subject matter to be presented to the Hearing Panel. He shall also consider such factors as the availability of individual hearing officers, the extent of their prior service on Hearing Panels and any relationship between such persons and a respondent which might make it inappropriate for such person to serve on the Hearing Panel.

3. Notice—Promptly after the selection of the panelists, the Chairman of the Business Conduct Committee or their designee shall cause written notice thereof to be given to the accused. If any person involved in the disciplinary proceeding shall have knowledge of a relationship between himself and any person selected for service on the Hearing Panel which might result in such panelist being unable to render a fair and impartial decision, he shall give prompt written notice thereof to the Chairman of the Business Conduct Committee or their designee, specifying the nature of such relationship and the grounds for contesting the qualification of such person to serve on the Hearing Panel. The decision of the Committee or their designee shall be final and conclusive with respect to the qualification of any person to serve on the Hearing Panel.

(b) Notice of Hearing and Pre-Hearing Procedures

1. Scheduling of a Hearing Date—A hearing on the Statement of Charges shall be scheduled for no later than 120 days after the filing of a written Answer by the Respondent wherein a hearing is requested. Should the hearing be at the request of the Respondent, counsel for the Exchange must provide notice to the Chairman of the Business Conduct Committee or their designee which requests the setting of a hearing date within 10 business days of receiving Respondents request for a hearing. The request for a hearing date shall be made in writing to the Chairman of the Business Conduct Committee or their designee by (i) counsel for the Exchange, or (ii) upon motion of the Business Conduct Committee.

2. Notice—The Respondent shall be given at least 15 business days notice of the time and place of the hearing.

---

\(^7\) See also Chicago Board Options Exchange, Rule 17.8. Offers of Settlement, Interpretations and Policies. 02 (discussing a similar timing guideline for scheduling a hearing date).

\(^8\) See Amendment No. 2, supra note 4; see also Amendment No. 3, supra note 5. The Phlx confirmed that Amendment No. 3 incorrectly indicates that the time periods for filing the hearing date and for providing a transcript of the hearing to the Hearing Panel members and the Respondent was initially ten days and later amended to five days. However, these time periods have, and will remain, five days throughout the filing. Telephone conversation with Les Falgie, Director of Enforcement/Counsel, Phlx, and Sapna C. Panel, Law Clerk, Division, Commission (Nov. 27, 2000).

\(^9\) See Amendment No. 2, supra note 4; see also Amendment No. 3, supra note 5.

\(^10\) See also Cincinnati Stock Exchange, Rule 8.6. Hearings, Sub-Paragraph (b) Notice and List of Documents (discussing a similar time frame for parties to exchange evidence and witness lists).

\(^11\) See Amendment No. 1, supra note 3.

\(^12\) See Amendment No. 1, supra note 3.

\(^13\) See also Pacific Exchange, Rule 10.7. Notice—(discussing a similar time frame after receipt of the transcript in which to produce a report); see also Amendment No. 2, supra note 4; see also Amendment No. 3, supra note 5.

\(^14\) See Amendment No. 1, supra note 3.

\(^15\) See Amendment No. 1, supra note 3.
3. Requests for Adjournments—A request for an adjournment of the hearing date shall be in writing and will be considered for just cause. If the request is made by the Respondent, said request shall be presented to the presiding person of the Hearing Panel with a copy to counsel for the Exchange, who shall enter the request into the Respondent’s file. If the request is made by counsel for the Exchange, said request shall be presented to the presiding person of the Hearing Panel, with a copy to the Respondent, and in Respondent’s file. The presiding person of the Hearing Panel shall promptly consider the request for an adjournment for just cause, rule on the request and inform the parties, in writing if time permits, as to whether the request was, or was not, granted. In the event that the request for an adjournment for just cause is granted, the presiding person of the Hearing Panel shall, at that time, schedule a new hearing date and so inform the parties of the new date.

4. Exchange of Evidence—The Exchange and the Respondent shall, not less than 8 business days in advance of the scheduled hearing date, furnish to the members of the Hearing Panel and to each other (i) copies of all documentary evidence each intends to present at the hearing, and (ii) a list of witnesses, including names, addresses and telephone numbers, that each intends to call at the Hearing.

5. Pre-Hearing Conferences—Where appropriate, the presiding person of the Hearing Panel, where appropriate, shall schedule a pre-hearing conference to be held not less than 8 business days in advance of the scheduled hearing date, to be attended by representatives of the Exchange, each of the Respondents and a member of the Hearing Panel. The pre-hearing conference shall be held for the purpose of clarifying and simplifying issues and otherwise expediting the proceeding. At such conference, and if they have not been done so previously, the Exchange and the Respondents shall furnish to the Hearing Panel and to each other (i) copies of all documentary evidence each intends to present at the Hearing, and (ii) a list of witnesses, including names, addresses and telephone numbers, that each intends to call at the Hearing.

The Exchange and Respondent shall also attempt to stipulate to the authenticity of documents and to facts issues not in dispute, and any other items which will serve to expedite the hearing of the matter.

Section IV. Conduct of Hearing, Rules for the Hearing Panel

(c) Conduct of Hearing. The Hearing Panel shall determine all questions concerning the admissibility of evidence and shall otherwise regulate the conduct of the hearing. Formal rules of evidence shall not apply. The charges shall be present by a representative of the Exchange who, along with Respondent, may present evidence and produce witnesses who shall testify under oath and shall be subject to cross examination. The Hearing Panel may, on its own motion, request the production of documentary evidence and witnesses and may also question witnesses. A transcript of the hearing shall be made and shall become a part of the record. The costs of the making of such a transcript, including, but not limited to, the costs for the court reporter, reproduction of the transcript and producing copies thereof, shall be equally borne by the Exchange and by Respondent. Counsel for the Exchange shall provide a copy of the transcript of the hearing to each member of the Hearing Panel within 5 business days of receiving the transcript. The Respondent shall be issued a bill for its portion of the costs along with its copy of the transcript.

(d) Recommendation of Hearing Panel. Based on its review of the entire record of the proceeding, the Hearing Panel shall submit a written hearing report to the Business Conduct Committee containing: (i) Proposed findings of fact concerning the allegations in the statement of charges; (ii) conclusions as to whether a violation within the disciplinary jurisdiction of the Exchange has occurred and an enumeration of such violations; and (iii) recommendations as to appropriate sanctions. The Hearing Panel shall complete such a hearing report no later than 45 days after counsel for the Exchange has served the members of the Hearing Panel with a copy of the transcript of the hearing. The hearing report shall be presented to the Business Conduct Committee at the next Business Conduct Committee meeting after the report is completed.

Interpretation and Policies

.01 Intervention. Any person not otherwise a party may intervene as a party to the hearing upon demonstrating to the satisfaction of the Hearing Panel that he has an interest in the subject of hearing and that the disposition of the matter, may, as a practical matter, impair or impede his ability to protect that interest. Also, the Hearing Panel may in its discretion permit a person to intervene as a party to the hearing when the person’s claim or defense and the main action have questions of law or fact in common. Any person wishing to intervene as a party to a hearing shall file with the Hearing Panel a notice requesting the right to intervene, stating the grounds therefor, and setting forth the claim or defense for which intervention is sought.

.02 The Hearing Panel, in exercising its discretion concerning intervention, shall take into consideration whether the intervention will unduly delay or prejudice the adjudication of the rights of the original parties.

* * *

II. Self-Regulatory Organization’s Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

In its filing with the Commission, the Exchange included statements concerning the purpose of and basis for the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item IV below. The Exchange has prepared summaries, set forth in Sections A, B, and C below, of the most significant aspects of such statements.

A. Self-Regulatory Organization’s Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

1. Purpose

The Exchange is proposing to implement certain timing guidelines to promote efficient handling of enforcement matters during the hearing process. Although the Exchange currently utilizes these guidelines as Exchange procedure, the Exchange believes that incorporating them expressly into Exchange rules may promote more effective implementation and monitoring of the timing guidelines, as well as fairness and due process both for respondents to a Statement of Charges authorized by the Committee, and to the Exchange and its Committees.

The Exchange believes that the proposed revisions promote notions of fairness, due process and consistency for the members of the Exchange and its disciplinary arm, the Committee, as they are intended to prevent undue delay, as well alleviate the vexation that such delays may cause.
2. Statutory Basis
The Exchange believes the proposed rule change is consistent with Section 6(b)(7) of the Act in general, and furthers the objectives of Sections 6(b)(6) and 6(b)(7) of the Act in particular, in that it is designed to ensure that Exchange members, and persons associated with members, are appropriately disciplined for violations of the provisions of the Act, the rules and regulations thereunder, or the rules of the Exchange, as well as providing a fair procedure for the disciplining of Exchange members, and persons associated with members, by fostering a prompt, efficient disciplinary process.

B. Self-Regulatory Organization’s Statement on Burden on Competition
The Phlx does not believe that the proposed rule change, as amended, will impose any burden on competition.

C. Self-Regulatory Organization’s Statement on Comments on the Proposed Rule Change Received From Members, Participants or Others
The Exchange has neither solicited nor received written comments on the proposed rule change.

III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action
Within 35 days of the date of publication of this notice in the Federal Register or within such longer period (i) as the Commission may designate up to 90 days of such date if it finds such longer period to be appropriate and publishes its reasons for so finding or (ii) as to which the Exchange consents, the Commission will:

(A) by order approve such proposed rule change, or

(B) institute proceedings to determine whether the proposed rule change should be disapproved.

IV. Solicitation of Comments
Interested persons are invited to submit written data, views and arguments concerning the foregoing, including whether the proposed rule change, as amended, is consistent with the Act. Persons making written submissions should file six copies thereof with the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW, Washington, DC 20549–0609. Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for inspection and copying in the Commission’s Public Reference Room. Copies of such filing will also be available for inspection and copying at the principal office of the Phlx. All submissions should refer to File No. SR–Phlx–00–13 and should be submitted by January 18, 2001.

For the Commission by the Division of Market Regulation, pursuant to delegated authority.
Margaret H. McFarland,
Deputy Secretary.

BILLING CODE 8010–01–M

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34–43747; File No. SR–Phlx–00–62]

Self-Regulatory Organizations; Order Granting Approval to Proposed Rule Change by the Philadelphia Stock Exchange, Inc. Relating to Mandatory Auto-Quote Settings to Update Quotations Based on a Certain Minimum Movement in the Underlying Security


I. Introduction
On August 1, 2000, the Philadelphia Stock Exchange, Inc. (“Phlx” or “Exchange”) filed with the Securities and Exchange Commission (“Commission”), pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 (“Act”) and Rule 19b–4 thereunder, a proposal to grant the Chairman of the Exchange’s Board of Governors (or his designee) the authority to mandate that the Exchange’s Auto-Quote System (“Auto-Quote”) be set to update options quotations based on a certain minimum movement in the underlying security.

On September 14, 2000, the Commission published the proposed rule change in the Federal Register. The Commission received no comments on the proposal. This order approves the proposed rule change.

II. Description of the Proposal
Phlx has proposed to amend Commentary .01 to Exchange Rule 1080, “Philadelphia Stock Exchange Automated Options Market (AUTOM) and Automatic Execution System (AUTO–X),” to allow the Chairman of the Exchange’s Board of Governors (or his designee) (“Chairman”) to increase the increment by which the price of the underlying security would have to change before Auto-Quote would generate new quotes for the overlying options.

Outbound options quotations are forwarded electronically by the Exchange to the Options Price Reporting Authority (“OPRA”), which, in turn, disseminates them to vendors. Recently, due to increased overall options volume and significant increases in the number of quotations generated, OPRA has, at times, been unable to disseminate quotation traffic on a timely basis. To address the capacity constraints, the Commission recently adopted a formula to allocate among the options exchanges a specific allotment of bandwidth capacity for messages transmitted to, and received from, OPRA during peak usage periods.

The proposed rule is intended to enhance the Exchange’s ability to manage quote traffic while various solutions to quote capacity issues are being implemented. Currently, one longstanding method the Exchange has used to manage quote traffic is “throttling,” or capping outbound quote message traffic to OPRA. For many years, the Exchange’s options trading systems have had the ability to throttle outbound message traffic to OPRA by limiting the amount of messages sent to OPRA in a given second. This is accomplished by withholding some Auto-Quote generated messages from dissemination each second until the next second. Throttling may result in some quotations being overridden by subsequent quotations and, thus, prevent older quotations-in-waiting from ever being disseminated.

The proposed rule will allow the Chairman, if the Exchange’s options trading systems throttle quotations for at least three minutes, to mandate that Auto-Quote be set to update quotations based on a certain minimum movement


4 Auto-Quote is the Exchange’s electronic options pricing system that enables specialists to automatically monitor and instantly update quotations, based on incremental changes in the price of the security underlying the option.

in the underlying security. For example, Auto-Quote may be set to update options quotations based on a price change in the underlying security of an eighth of $1.00. Thus, each time the price of the underlying security increased or decreased by an eighth or more, Auto-Quote would update the quotation on the overlying option to reflect such a change. The proposed rule will allow the Chairman to mandate that Auto-Quote be set to update options quotations based on, for example, a price change of a quarter of $1.00 in the underlying security, meaning that Auto-Quote would not update quotations on the overlying option until the price of the underlying security increases or decreases by a quarter. Increasing the incremental price change in the underlying security required for an Auto-Quote update would result in fewer quotes generated and, thus, fewer messages queuing to be sent to OPRA.

The Chairman could exercise the authority described in the proposed rule change with respect to certain securities but not others, or cause Auto-Quote to raise the threshold to different amounts for different underlying securities (e.g., one quarter for Stock A and one half for Stock B). The Commission has determined that the proposed rule change is consistent with the Act and the rules and regulations thereunder applicable to a national securities exchange. In particular, the Commission believes that the proposal is consistent with Sections 6(b)(5) and 6(b)(8) of the Act. Section 6(b)(5) requires, among other things, that the rules of an exchange be designed to promote just and equitable principles of trade, to facilitate transactions in securities, to remove impediments to and perfect the mechanisms of a free and open market and a national market system, and, in general, to protect investors and the public interest. Section 6(b)(5) also requires that those rules not be designed to permit unfair discrimination between customers, issuers, brokers, or dealers. Finally, Section 6(b)(8) of the Act requires that the rules of an exchange not impose any burden on competition not necessary or appropriate in furtherance of the purposes of the Act.

As the Commission has previously noted, the amount of market data generated by the options markets has, at times, exceeded OPRA’s capacity to disseminate it publicly on a real-time basis. When this occurs, the only market participants with up-to-date quote and trade information are those present on the floor of an exchange. Market participants not physically present on the floor are at an informational disadvantage, which reduces market transparency, impedes efficient pride discovery, and is inconsistent with the goal of fair competition.

As discussed above, because OPRA has not been able to increase its systems capacity in the short-term sufficiently and because the participants in OPRA have not been able to agree to how to allocate existing capacity amongst themselves, the Commission recently adopted certain amendments to the OPRA Plan to allocate among the options exchanges OPRA’s peak-period message handling capacity. In its Order, the Commission asserted its expectation that the options exchanges would continue to “consider and implement other quote message mitigation strategies as both long-term and short-term solutions.” The Commission also noted that “the allocation formula should encourage each individual exchange to establish and utilize quote reduction methods based on the amount of message capacity it has been allocated, thereby promoting efficiency of the market data dissemination process.” Phlx’s proposed rule change is one such quote reduction method. Upon implementation of the new rule, the Chairman of the Exchange’s Board of Directors (or his designee) could require Auto-Quote to be set to update options quotations only if the price of the underlying security were to move more than a designated amount. If Auto-Quote were set in this manner, the options prices determined by Auto-Quote would remain static if the price of the underlying security moved by less than the designated increment. The result of Auto-Quote’s reduced sensitivity to changes in the price of the underlying security would be fewer new quotations generated by Auto-Quote and, consequently, fewer quote messages to be sent to OPRA.

The Commission recognizes that the proposal could affect price competition because, as a result of the restrictions to Auto-Quote, the options prices generated may not reflect the price that otherwise would be dictated by the pricing model used by a Phlx specialist or a specialist or market-maker on another options exchange. As a result, the proposed rule change may increase the likelihood that the prices offered by Phlx specialists—as displayed on OPRA—will differ from those displayed on other options exchanges. These disparities could result in an increased occurrence of locked and crossed markets across the options markets. However, the Commission believes that this minimal impact on competition is necessary and appropriate in furtherance of the purposes of the Act and, thus, is consistent with Section 6(b)(8) of the Act.

In approving this rule, the Commission has considered the proposed rule’s impact on efficiency, competition, and capital formation. See 15 U.S.C. 78f(c)(1). Thus, a price change in the underlying security would not result in a shift to the spread for the overlying option unless that price change triggered a shift in that option’s spread of one eighth or greater (assuming the option was trading over $3.00). The proposed rule will merely give the Chairman the authority to raise the threshold.

9 Telephone conversation between Richard S. Rudolph, Counsel, Phlx, and Michael Gaw, Attorney-Adviser, Division, Commission, on December 18, 2000.

10 In its Order, the Commission asserted its expectation that the options exchanges would continue to “consider and implement other quote message mitigation strategies as both long-term and short-term solutions.” The Commission also noted that “the allocation formula should encourage each individual exchange to establish and utilize quote reduction methods based on the amount of message capacity it has been allocated, thereby promoting efficiency of the market data dissemination process.” Phlx’s proposed rule change is one such quote reduction method. Upon implementation of the new rule, the Chairman of the Exchange’s Board of Directors (or his designee) could require Auto-Quote to be set to update options quotations only if the price of the underlying security were to move more than a designated amount. If Auto-Quote were set in this manner, the options prices determined by Auto-Quote would remain static if the price of the underlying security moved by less than the designated increment. The result of Auto-Quote’s reduced sensitivity to changes in the price of the underlying security would be fewer new quotations generated by Auto-Quote and, consequently, fewer quote messages to be sent to OPRA.

The Commission recognizes that the proposal could affect price competition because, as a result of the restrictions to Auto-Quote, the options prices generated may not reflect the price that otherwise would be dictated by the pricing model used by a Phlx specialist or a specialist or market-maker on another options exchange. As a result, the proposed rule change may increase the likelihood that the prices offered by Phlx specialists—as displayed on OPRA—will differ from those displayed on other options exchanges. These disparities could result in an increased occurrence of locked and crossed markets across the options markets. However, the Commission believes that this minimal impact on competition is necessary and appropriate in furtherance of the purposes of the Act and, thus, is consistent with Section 6(b)(8) of the Act. Given that the Exchange is allocated only a defined percentage of OPRA’s capacity during peak usage periods, it must take steps to ensure that the message traffic it generates does not exceed that allocation.

To address this problem,
the Exchange for many years has had the ability to “throttle” outgoing message traffic by preventing the dissemination to OPRA of certain quotes that have been generated by Auto-Quote. The current proposal takes a slightly different tack by restricting the generation of new quotes rather than “throttling” the transmission to OPRA of new quotes that have been generated. On the whole, the Commission believes that both are reasonable means by which to address the problem of the limited capacity of the OPRA system and, as such, are consistent with the Act.

The Commission believes, though, that the proposed rule change may offer a more effective tool to restrain message traffic than throttling and, thus, may have a more minimal effect on competition. Presently, the throttling function is applied indiscriminately to all quotes generated by Auto-Quote. The approach described in the proposed rule change, however, may be used selectively. Thus, Phlx could choose to continue updating quotes for certain options classes continuously while restraining the generation of new quotes in other options classes. As a result, Phlx would be able to determine—based on competitive factors—which options classes should have a greater share during peak usage periods of the bandwith allocated to it by OPRA. Therefore, the Commission believes the proposal promotes just and equitable transactions in securities, and removes any impediments to a free and open market, consistent with Section 6(b)(5) of the Act.18

IV. Conclusion

It Is Therefore Ordered, pursuant to Section 19(b)(2) of the Act,19 that the proposed rule change (SR–Phlx–00–62) is approved.

For the Commission, by the Division of Market Regulation, pursuant to delegated authority.20

Margaret H. McFarland,
Deputy Secretary.

[FR Doc. 00–33124 Filed 12–27–00; 8:45 am]

BILLING CODE 8010–01–M

SECURITIES AND EXCHANGE COMMISSION

[Release No. 43740; File No. SR–Phlx–00–48]

Self-Regulatory Organizations; Notice of Filing of Proposed Rule Change by the Philadelphia Stock Exchange, Inc. Relating to Telephone Use on the Options Floor


Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 (“Act”)1 and Rule 19b–4 thereunder,2 notice is hereby given that on June 16, 2000, the Philadelphia Stock Exchange, Inc. (“Phlx” or “Exchange”) filed with the Securities and Exchange Commission (“Commission”) the proposed rule change described in Items I, II, and III below, which Items have been prepared by the Exchange. The Exchange filed Amendment No. 1 to the proposed rule change on December 1, 2000.3 The Commission is publishing this notice to solicit comments on the proposed rule change from interested persons.

I. Self-Regulatory Organization’s Statement of the Terms of Substance of the Proposed Rule Change

The Phlx proposes to amend Exchange Rule 606 and to create new Options Floor Procedure Advice (“OFPA”) F–31 to establish rules and procedures for telephone use on the Phlx’s options floor. The text of the proposed rule change is set forth below. All text is being added.

Wire and Other Connections

Communications and Equipment

Rule 606

(e)(1) Registration. Members and member organizations must register, prior to use, any new telephone to be used on the Options Floor. Each phone registered with the Exchange must be registered by category of user. If there is a change in the category of any user, the phone must be re-registered with the Exchange. At the time of registration, members and member firm representatives must sign a statement that they are aware of and understand the rules and procedures governing the use of telephones on the Options Floor.

(2) Capacity and Functionality. No wireless telephone used on the Options Floor may have an output greater than one watt. No person on the Options Floor may use any device for the purpose of maintaining an open line of continuous communication whereby a person not located in the trading crowd may continuously monitor the activities in the trading crowd. This prohibition covers intercoms, walkie-talkies and any similar devices. Speed-dialing features are permitted on any member telephone.

(3) Specialist and Registered Options Traders.

(a) Specialists and Registered Options Traders (“ROTs”) may use their own cellular and cordless phones to place calls to any person at any location (whether on or off the Options Floor).

(b) ROTs located off the Options Floor may not place an order by calling a Floor Broker who is present in a trading crowd. ROTs located off the Options Floor may not otherwise place an order by calling the specialist phone in the trading crowd. Any telephonic order entered from off the Options Floor must be placed with a person located in a member firm booth.

(4) Floor Brokers.

(a) Floor Brokers may use cellular and cordless telephones, but only to communicate with persons located on the Options Floor. These telephones may not include a call forwarding feature. Headsets are permitted for Floor Brokers, but if the Exchange determines that a Floor Broker is maintaining a continuous open line through the use of a headset, the Floor Broker will be prohibited from further use of any headset for a length of time to be determined by the Exchange.

(b) All orders phoned to the Floor Brokers must be received initially at the Floor Broker’s booth. Floor Brokers may not receive telephonic orders while in the trading crowd except from their booth. Any telephonic order entered from off the Options Floor must be placed with a person located in a member firm booth.

(5) Clerks.

(a) Floor Broker clerks are subject to the same terms and conditions on telephone use as Floor Brokers.

(b) Stock Execution clerks are subject to the same terms and conditions on telephone use as Floor Brokers.

(c) The Options Committee reserves the right to prohibit clerks from using cellular or cordless phones on the floor at any time that it is necessary due to electronic interference problems or capacity problems resulting from the number of such phones then in use on the Options Floor. In such circumstances, the Committee will first consider restricting the use of such phones by Stock Execution Clerks, and then by Floor Broker Clerks.

(6) General Access In-House Phones. The general access in-house telephones located outside of the trading post areas may be used by any member, clerk or floor broker to communicate with persons located on the Options Floor or within the Exchange Complex.

3 The Exchange submitted a new Form 19b–4, which replaces and supersedes the original filing (“Amendment No. 1”). Amendment No. 1 amends the purpose section of the proposed rule change to provide a description of provisions governing floor brokers, registered options traders, general access phones, and exchange liability. Amendment No. 1 also clarifies that registration and maintenance of registration records is handled through the Exchange’s Membership Services Department. Finally Amendment No. 1 amends proposed Phlx Rule 606(e)(3) to include specialists.
(7) Telephone Records. Members must maintain their cellular or cordless telephone records, including logs of calls placed, for a period of not less than one year. The Exchange reserves the right to inspect and/or examine such telephone records.

(8) Exchange Liability. The Exchange assumes no liability to members or member organizations due to conflicts between telephones in use on the Options Floor or due to electronic interference problems resulting from the use of telephones on the trading floor.

Options Floor Procedure Advice F±31
Communications and Equipment

(1) Registration. Members and member organizations must register, prior to use, any new telephone to be used on the Options Floor. Each phone registered with the Exchange must be registered by category of user. If there is a change in the category of any user, the phone must be re-registered with the Exchange. At the time of registration, members and member firm representatives must sign a statement that they are aware of and understand the rules and procedures governing the use of telephones on the Options Floor.

(2) Capacity and Functionality. No wireless telephone used on the Options Floor may have an output greater than one watt. No person on the Options Floor may use any device for the purpose of maintaining an open line of continuous communication whereby a person not located in the trading crowd may continuously monitor the activities in the trading crowd. This prohibition covers intercoms, walkie-talkies and any similar devices. Speed-dialing features are permitted on any member telephone.

(3) Specialists and Registered Options Traders. (a) Specialists and Registered Options Traders (“ROTs”) may use their own cellular and cordless phones to place calls to any person at any location (whether on or off the Options Floor).
(b) ROTs located off the Options Floor may not place an order by calling a Floor Broker who is present in a trading crowd. ROTs located off the Options Floor may not otherwise place an order by calling the specialist phone in the trading crowd. Any telephonic order entered from off the Options Floor must be placed with a person located in a member firm booth.

(4) Floor Brokers. (a) Floor Brokers may use cellular and cordless telephones, but only to communicate with persons located on the Options Floor. These telephones may not include a call forwarding feature. Headsets are permitted for Floor Brokers, but if the Exchange determines that a Floor Broker is maintaining a continuous open line through the use of a headset, the Floor Broker will be prohibited from future use of any headset for a length of time to be determined by the Exchange.
(b) All orders phoned to Floor Brokers must be received initially at the Floor Broker's booth. Floor Brokers may not receive telephonic orders while in the trading crowd except from their booths. Any telephonic order entered from off the Options Floor must be placed with a person located in a member firm booth.

(5) Clerks. (a) Floor Broker clerks are subject to the same terms and conditions on telephone use as Floor Brokers.
(b) Stock Execution clerks are subject to the same terms and conditions on telephone use as Floor Brokers.
(c) The Options Committee reserves the right to prohibit clerks from using cellular or cordless phones on the floor at any time that it is necessary due to electronic interference problems or capacity problems resulting from the number of such telephones in use on the Options Floor. In such circumstances, the Committee will first consider restricting the use of such phones by Stock Execution Clerks, and then by Floor Broker Clerks.

(6) General Access In-House Phones. The general access in-house telephones located outside of the trading post areas may be used by any member, clerk or floor broker to communicate with persons located on the Options Floor or within the Exchange complex.

(7) Telephone Records. Members must maintain their cellular or cordless telephone records, including logs of calls placed, for a period of not less than one year. The Exchange reserves the right to inspect and/or examine such telephone records.

(8) Exchange Liability. The Exchange assumes no liability to members or member organizations due to conflicts between telephones in use on the Options Floor or due to electronic interference problems resulting from the use of telephones on the trading floor.

FINE SCHEDULE (implemented on a three year running calendar basis)

<table>
<thead>
<tr>
<th>Occurrence</th>
<th>Fine</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st Occurrence</td>
<td>$250.00</td>
</tr>
<tr>
<td>2nd Occurrence</td>
<td>$500.00</td>
</tr>
<tr>
<td>3rd Occurrence</td>
<td>$1,000.00</td>
</tr>
<tr>
<td>4th and thereafter</td>
<td>Sanction is discretionary with Business Conduct Committee</td>
</tr>
</tbody>
</table>

II. Self-Regulatory Organization’s Statements Regarding the Proposed Rule Change

In its filing with the Commission, the Phlx included statements concerning the purpose of, and basis for, the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item IV below. The Phlx has prepared summaries, set forth in sections A, B and C below, of the most significant aspects of such statements.

A. Self-Regulatory Organization’s Statement of the Purpose of, and the Statutory Basis for, the Proposed Rule Change

1. Purpose

The purpose of the proposed rule change is to establish rules and procedures for telephone use on the options floor. Proposed Phlx Rule 606(e) and OFPA F±31 would set forth procedures and restrictions regarding telephone use on the options floor. The proposed rule contemplates that certain types of telephones (i.e., cellular phones) may be used for personal purposes. The proposed rule would limit the use of telephones on the options floor for business purposes, depending on the category of user (specialist, registered options trader (“ROT”), floor broker, or clerk).

The proposed rule change would require members and member organizations to register by category of user, any new telephone to be used on the options floor, prior to use. Registration and maintenance of registration records would be handled through the Exchange’s Membership Services Department. If there is a change in the category of user, the telephone must be re-registered with the Exchange. At the time of registration, the user must sign a statement that the user is aware of and understands the rules governing the use of telephones on the options floor. The Exchange believes that this should facilitate record keeping and should also enhance the ability of the Exchange’s Market Surveillance Department to investigate potential violations of the rule.

The proposed rule would also provide that no person on the options floor may use any device, including, but not limited to, intercoms, walkie-talkies, and similar devices, for the purpose of maintaining an open line of communication whereby a person located in a trading crowd may continuously monitor the activities of that crowd.

Capacity and Functionality: The proposed rule specifies the capacity and functionality permitted for use of telephones on the options floor. Specifically, proposed Phlx Rule 606(e)(2) provides that no wireless telephone on the options floor may have an output of more than one watt. The purpose of this provision is to minimize...
the possibility of radio frequency or other interference with the systems of the Exchange or those of other members. The proposed rule would also state that no person on the options floor may use any device for the purpose of maintaining an open line of continuous communication whereby a person not located in the trading crowd may continuously monitor the activities in the trading crowd. This prohibition covers intercoms, walkie-talkies, and any similar devices.

Members and Member Firm Employees. The proposed rule sets forth specific guidelines for each category of user on the options floor, as follows:

Specialists and ROTs. Proposed Phlx Rule 606(e)(3) would provide that specialists and ROTs may use their own cellular and cordless phones to place calls to any person at any location (whether on or off the options floor). The proposal would also provide that specialists and ROTs located off the options floor may not place an order by calling a floor broker located in a trading crowd or directly to the specialist phone. Any telephonic order entered from off the options floor must be placed with a person located in a floor broker booth. The Exchange believes that this should facilitate adequate surveillance of telephonic orders and ensure that there is a record of the order in the event that a problem arises in connection with the order.

Floor Brokers. Proposed Phlx Rule 606(e)(4) would allow floor brokers to use cellular and cordless phones, but only to communicate with persons located on the options floor. The proposed rule would prohibit floor brokers from receiving telephonic orders while in the trading crowd. Orders phoned to floor brokers must be received at the floor broker’s booth.

This should facilitate the adequate surveillance of telephonic orders and should ensure that there is a record of each telephonic order in the event of a trading problem or dispute relating to an order. Moreover, the Phlx believes the prohibition against floor brokers receiving telephonic orders in the trading crowd is consistent with Exchange procedures that require floor brokers to time stamp tickets for each order at the time of receipt of the order, prior to representing the order in the crowd for execution.

Clerks. Proposed Phlx Rule 606(e)(5) would provide that floor broker clerks and stock execution clerks are subject to the same terms and conditions on telephone use as floor brokers. The proposal also states that the Options Committee reserves the right to prohibit clerks from using cellular or cordless phones on the floor at any time that it is necessary due to electronic interference problems.

In such circumstances, the Options Committee would first consider restricting the use of phones by ROT clerks, then by stock execution clerks, and then finally, by floor broker clerks.

General Access In-House Phones, Telephone Records, and Exchange Liability. Proposed Phlx Rule 606(e)(6) states that the general access in-house telephones located outside of the trading post areas may be used by any member, clerk or floor broker to communicate with persons located on the options floor or within the Exchange complex.

Proposed Phlx Rule 606(e)(7) would require members to maintain all cellular or cordless telephone records for at least one year, and provides the Exchange the right to inspect and/or examine these records. The Exchange believes that this requirement should facilitate the review by the Exchange’s Examinations Department of the records of members for whom the Exchange is the Designated Examining Authority, and should allow for investigations and possible enforcement action by the Exchange’s Market Surveillance Department in the event of allegations of violations of the proposed rules.

Finally, Proposed Phlx Rule 606(e)(8) states that the Exchange assumes no liability to members or member organizations due to conflicts between telephones in use on the options floor or due to electronic interference problems resulting from the use of telephones on the trading floor.

Proposed OFPA F–31 contains the same provisions as proposed Rule Phlx 606(e) in order to facilitate on-floor reference to the Exchange’s regulations regarding on-floor communications devices. If a violation of OFPA F–31 is deemed to be minor pursuant to the Exchange’s Minor Rule Plan, a fine schedule, implemented on a three year running calendar basis, would be implemented as follows:

<table>
<thead>
<tr>
<th>Occurrence</th>
<th>Fine</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st Occurrence</td>
<td>$250.00</td>
</tr>
<tr>
<td>2nd Occurrence</td>
<td>$500.00</td>
</tr>
<tr>
<td>3rd Occurrence</td>
<td>$1,000.00</td>
</tr>
<tr>
<td>4th and thereafter</td>
<td>Sanction is discretionary with Business Conduct Committee</td>
</tr>
</tbody>
</table>

The three year running calendar would begin on the date of the first infraction.

2. Statutory Basis

The Exchange believes that the proposed rule change, as amended, is consistent with section 6(b) of the Act in general, and further the objectives of section 6(b)(5) in particular, in that it is designed to remove impediments to and perfect the mechanism of a free and open market and a national market system and, in general, to protect investors and the public interest, by regulating communications to and from the Exchange’s options floor.

B. Self-Regulatory Organization’s Statement on Burden on Competition

The Phlx does not believe that the proposed rule change, as amended, will impose any inappropriate burden on competition.

C. Self-Regulatory Organization’s Statement on Comments on the Proposed Rule Change Received From Members, Participants, or Others

The Exchange did not solicit or receive written comments on the proposed rule change.

III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action

Within 35 days of the date of publication of this notice in the Federal Register or within such longer period (i) as the Commission may designate up to 90 days or such date if it finds such...
later period to be appropriate and publishes its reasons for so finding or (ii) as to which the Phlx consents, the Commission will:

(A) By order approve such proposed rule change, or

(B) institute proceedings to determine whether the proposed rule change should be disapproved.

IV. Solicitation of Comments

Interested persons are invited to submit written data, views, and arguments concerning the foregoing, including whether the proposed rule change, as amended, is consistent with the Act. Persons making written submission should file six copies thereof with the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW., Washington, DC 20549–0609. Copies of the submission, all subsequent amendments, all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for inspection and copying in the Commission’s Public Reference Room. Copies of such filing will also be available for inspection and copying at the principal office of the Phlx. All submissions should refer to the File No. SR–Phlx–00–48 and should be submitted by January 18, 2001.

For the Commission, by the Division of Market Regulation, pursuant to delegated authority.13

Margaret H. McFarland,
Deputy Secretary.

[FR Doc. 00–33126 Filed 12–27–00; 8:45 am]
rules.4 The Phlx notes that the language of new Commentary .01, however, is not intended to require a ROT to trade with another ROT at a price at which the ROT is unwilling to trade, unless otherwise required by Phlx rule(s).

The Phlx believes that the conduct prohibited in proposed new Commentary .01 to Rule 707 is fundamentally inconsistent with the obligations of members to their customers and each other, and is contrary to the public interest in fair and efficient options markets.5

2. Statutory Basis

The Exchange believes that the proposed rule change is consistent with Section 6(b)(5) of the Act 6 in general, and furthers the objectives of Section 6(b)(5) 7 in particular, in that it is designed to prevent fraudulent and manipulative acts and practices and to promote just and equitable principles of trade by prohibiting members, member organizations, or persons associated with or employed by members or member organizations from engaging in harassment and other improper behavior because of listing or competitive practices.

B. Self-Regulatory Organization’s Statement on Burden on Competition

The Exchange does not believe that the proposed rule change will impose any inappropriate burden on competition.

C. Self-Regulatory Organization’s Statement on Comments on the Proposed Rule Change Received From Members, Participants or Others

Written comments were neither solicited nor received.

III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action

Within 35 days of the date of publication of this notice in the Federal Register or within such longer period (i) as the Commission may designate up to 90 days of such date if it finds such longer period to be appropriate and publishes it reasons for so finding or (ii) as to which the self-regulatory organization consents, the Commission will:

A. by order approve the proposed rule change, or

B. institute proceedings to determine whether the proposed rule change should be disapproved.

IV. Solicitation of Comments

Interested persons are invited to submit written data, views, and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Persons making written submissions should file six copies thereof with the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW., Washington, DC 20549–0609. Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for inspection and copying at the Commission’s Public Reference Room. Copies of such filing will also be available for inspection and copying at the principal office of the Exchange. All submissions should refer to File No. SR–Phlx–00–94 and should be submitted by January 18, 2001.

For the Commission, by the Division of Market Regulation, pursuant to delegated authority.8

Margaret H. McFarland,

Deputy Secretary.

[FR Doc. 00–33128 Filed 12–27–00; 8:45 am]

BILLING CODE 8010–01–M

SMALL BUSINESS ADMINISTRATION
[Declaration of Disaster #3310]

State of Alabama

As a result of the President’s major disaster declaration on December 18, 2000, I find that the following Counties in the State of Alabama constitute a disaster area due to damages caused by severe storms and tornadoes that occurred beginning on December 16, 2000 and continuing: Dale, Etowah, Geneva, Henry, Houston, Limestone, Macon, St. Clair and Tuscaloosa Counties. Applications for loans for physical damage as a result of this disaster may be filed until the close of business on February 16, 2001 and for economic injury until the close of business on September 18, 2001 at the address listed below or other locally announced locations: U.S. Small
Business Administration, Disaster Area 2 Office, One Baltimore Place, Suite 300, Atlanta, GA 30308.

In addition, applications for economic injury loans from small businesses located in the following contiguous counties may be filed until the specified date at the above location: Barbour, Bibb, Blount, Bullock, Calhoun, Cherokee, Coffee, Covington, De Kalb, Elmore, Fayette, Greene, Hale, Jefferson, Lauderdale, Lawrence, Lee, Madison, Marshall, Montgomery, Morgan, Pickens, Pike, Russell, Shelby, Talladega, Tallapoosa, and Walker Counties in Alabama; Holmes, Jackson, and Walton Counties in Florida; Clay, Early, Quitman, and Seminole Counties in Georgia; and Lincoln and Giles Counties in Tennessee.

The interest rates are:

<table>
<thead>
<tr>
<th>For Physical Damage:</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Homeowners with credit available elsewhere</td>
<td>7.00%</td>
</tr>
<tr>
<td>Homeowners without credit available elsewhere</td>
<td>3.50%</td>
</tr>
<tr>
<td>Businesses with credit available elsewhere</td>
<td>8.00%</td>
</tr>
<tr>
<td>Businesses and non-profit organizations without credit available elsewhere</td>
<td>4.00%</td>
</tr>
<tr>
<td>Others (Including non-profit organizations) with credit available elsewhere</td>
<td>7.00%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>For Economic Injury:</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Businesses and small agricultural cooperatives without credit available elsewhere</td>
<td>4.00%</td>
</tr>
</tbody>
</table>

The number assigned to this disaster for physical damage is 331012. For economic injury, the numbers are 9K0200 for Alabama, 9K0300 for Florida, 9K0400 for Georgia, and 9K0500 for Tennessee.

(Catalog of Federal Domestic Assistance Program Nos. 59002 and 59008)


Herbert L. Mitchell,
Acting Associate Administrator for Disaster Assistance.

[FR Doc. 00–33032 Filed 12–27–00; 8:45 am]

BILLING CODE 8025–01–P

SOCIAL SECURITY ADMINISTRATION

Agency Information Collection Activities: Proposed Request and Comment Request

The Social Security Administration (SSA) publishes a list of information collection packages that will require clearance by the Office of Management and Budget (OMB) in compliance with Pub. L. 104–13 effective October 1, 1995. The Paperwork Reduction Act of 1995. SSA is soliciting comments on the accuracy of the agency’s burden estimate; the need for the information; its practical utility; ways to enhance its quality, utility and clarity; and on ways to minimize burden on respondents, including the use of automated collection techniques or other forms of information technology.

Written comments and recommendations regarding the information collection(s) should be submitted to the SSA Reports Clearance Officer and to the OMB Desk Officer at the following addresses:


I. The information collections listed below will be submitted to OMB within 60 days from the date of this notice. Your comments should be submitted to SSA within 60 days from the date of this publication. You can obtain a copy of the collection instruments by calling the SSA Reports Clearance Officer at 410–965–4145, or by writing to him at the address listed above.

1. Pre-1957 Military Service Federal Benefit Questionnaire—0960–0120. Form SSA–2512 collects data used in the claims adjudication process to grant gratuitous military wage credits, when applicable, and solicits sufficient information to make a determination of eligibility. The respondents are individuals who are applying for Social Security benefits on the record of a wage earner with pre-1957 military service.

Number of Respondents: 12,000.

Frequency of Response: 1.

Average Burden Per Response: 10 minutes.

Estimated Annual Burden: 2,000 hours.

2. Application for a Social Security Card—0960–0066. The information collected on form SS–5 is needed to assign a Social Security Number (SSN) and issue a card. SSA screens its records to make sure applicants for original SSN cards don’t already have SSNs before assigning an original number. SSA also uses the information from the SS–5 to insure that replacement SSN cards are issued to the correct number holder. Use of SSNs enables SSA to keep an accurate record of each individual’s earnings for the payment of benefits and for administrative purposes as an identifier for health-maintenance and income-maintenance programs, such as the Retirement, Survivors and Disability Insurance programs, the SSI program and other programs administered by the Federal government including Black Lung, Medicare and veterans compensation and pension programs.

The Internal Revenue Service uses the SSN as a taxpayer identification number for those individuals who are eligible to be assigned an SSN. The respondents are applicants for original, duplicate or corrected Social Security cards.

Number of Respondents: 17.6 million.

Frequency of Response: 1.

Average Burden Per Response: 8½–9 minutes.

Estimated Annual Burden: 2,501,667 hours.

3. Certificate of Responsibility for Welfare and Care of Child Not in Applicant’s Custody—0960–0019. SSA uses the information collected on form SSA–781 to decide if “in care” requirements are met by non-custodial parent(s), who is filing for benefits based on having a child in care. The respondents are non-custodial wage earners whose entitlement to benefits depends upon having an entitled child in care.

Number of Respondents: 14,000.

Frequency of Response: 1.

Average Burden Per Response: 10 minutes.

Estimated Annual Burden: 2,333 hours.

4. Questionnaire for Children Claiming SSI Benefits—0960–0499. The information collected on form SSA–3881 is used by SSA to evaluate disability in children who apply for...
Supplemental Security Income (SSI) payments. The respondents are individuals who apply for SSI benefits for a disabled child.

**Number of Respondents:** 272,000.
**Frequency of Response:** 1.
**Average Burden Per Response:** 30 minutes.
**Estimated Annual Burden:** 136,000 hours.

II. The information collections listed below have been submitted to OMB for clearance. Your comments on the information collections would be most useful if received by OMB and SSA within 30 days from the date of this notice. You can obtain a copy of the OMB clearance packages by calling the SSA Reports Clearance Officer on (410) 965-4145, or by writing to him at the address listed above.

**Number of Respondents** | **Frequency of Response** | **Average Burden Per Response (minute)** | **Estimated Annual Burden (hours)** |
---|---|---|---|
SSA-512 | SSA-513 | SSA-512 | SSA-513 |
---|---|---|---|
200,000 | 350,000 | 1 | 1 | 2 | 2 | 6,667 | 11,667 |

3. Affective Disorder Treatment Demonstration Project—0960–NEW

**Background**

There is substantial research evidence that affective disorders (i.e., mental disorders that affect a person’s mood, such as depression and bipolar disorder) usually respond to treatment; there is also evidence that many individuals with affective disorders do not receive effective treatment. The cost of care is one of the reasons for the low treatment rates of individuals with affective disorder. This may be true for many beneficiaries, particularly those in the Medicare waiting period. Therefore, SSA will test the hypothesis that providing access to treatment will result in improved health status of Disability Insurance (DI) beneficiaries with affective disorders, which might, in turn, lead to increased labor force participation and self-sufficiency. This outcome would benefit both participants and taxpayers.

**The Demonstration Project**

SSA plans to implement a 5-year demonstration project that will test the effectiveness of providing better access to quality affective disorders treatments for DI beneficiaries who have an affective disorder as their primary reason for disability. Several forms and survey instruments will be used during the demonstration to collect information for screening program participants, beneficiary protection, and program evaluation. Some of the data will be collected from beneficiaries, and other data will be collected from the medical service providers who treat beneficiaries during the study.

The respondents to this collection will be randomly selected DI beneficiaries with an affective disorder and their health care providers.

<table>
<thead>
<tr>
<th>Beneficiary:</th>
<th>Annual number of respondents</th>
<th>Frequency of response</th>
<th>Average burden per response</th>
<th>Estimated annual burden</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beneficiary telephone screening</td>
<td>1,068</td>
<td>1</td>
<td>16</td>
<td>285</td>
</tr>
<tr>
<td>Authorization for release of medical information</td>
<td>855</td>
<td>1</td>
<td>5</td>
<td>71</td>
</tr>
<tr>
<td>Baseline survey</td>
<td>400</td>
<td>1</td>
<td>35</td>
<td>233</td>
</tr>
<tr>
<td>8-Month follow-up survey</td>
<td>380</td>
<td>1</td>
<td>32</td>
<td>203</td>
</tr>
<tr>
<td>16-Month follow-up survey</td>
<td>361</td>
<td>1</td>
<td>32</td>
<td>193</td>
</tr>
<tr>
<td>24-Month follow-up survey</td>
<td>343</td>
<td>1</td>
<td>32</td>
<td>183</td>
</tr>
<tr>
<td>32-Month follow-up survey</td>
<td>326</td>
<td>1</td>
<td>35</td>
<td>190</td>
</tr>
<tr>
<td>Health Provider:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Copy medical records</td>
<td>667</td>
<td>1</td>
<td>20</td>
<td>222</td>
</tr>
<tr>
<td>Medical records questionnaire</td>
<td>667</td>
<td>1</td>
<td>10</td>
<td>111</td>
</tr>
<tr>
<td>Treatment participation screen</td>
<td>200</td>
<td>1</td>
<td>15</td>
<td>50</td>
</tr>
<tr>
<td>Provider credentialing questionnaire</td>
<td>150</td>
<td>1</td>
<td>15</td>
<td>38</td>
</tr>
<tr>
<td>Initial treatment plan</td>
<td>150</td>
<td>1</td>
<td>30</td>
<td>75</td>
</tr>
<tr>
<td>Quarterly progress report</td>
<td>143</td>
<td>8</td>
<td>30</td>
<td>572</td>
</tr>
<tr>
<td>Total Respondents</td>
<td>5,708</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total Annual Burden Hrs</td>
<td></td>
<td></td>
<td></td>
<td>2,426</td>
</tr>
</tbody>
</table>
DEPARTMENT OF STATE

Bureau of Educational and Cultural Affairs Request for Grant Proposals: Russian-U.S. Young Leadership Fellows for Public Service Program

SUMMARY: The Office of Academic Exchange Programs of the Bureau of Educational and Cultural Affairs announces an open competition for administration of the Russian-U.S. Young Leadership Fellows for Public Service Program for the academic year 2002–2003. Public and private non-profit organizations meeting the provisions described in IRS regulation 26 CFR 1.501(c) may submit proposals to administer recruitment, selection, placement, monitoring, evaluation and follow-on activities. Organizations with less than four years of experience in conducting international exchange are not eligible for this competition.

Program Information

The Russian-U.S. Young Leadership Fellows for Public Service Program began in 1999 as an initiative to provide practical experience in developing personal leadership skills and promoting the importance of community responsibility for young Russian and American students. Under the auspices of the FREEDOM Support Act, the program will enrich the experience and education of young people who show the promise of contributing to the betterment of their own countries and to the increased mutual understanding between the two countries.

The educational exchange program combines academic course-work with complementary community service and an internship, and targets Russian and American college graduates who have demonstrated leadership skills and an interest in public service. The program provides full scholarships for one year of non-degree study in the United States or Russia at qualified universities and colleges. The Russian and American students have different but complementary program designs. Russian students select a concentration in either Community Affairs, Governmental Affairs, or Corporate Affairs. American students focus on Russian Studies.

ECA will award one grant for this program. Should an applicant organization wish to work with other organizations in the implementation of this program, a subgrant agreement must be arranged. Programs and projects must conform with Bureau requirements and guidelines outlined in the Solicitation Package. ECA programs are subject to the availability of funds. Programs must comply with J–1 visa regulations. Please refer to Solicitation Package for further information.

Budget Guidelines

Applicants must submit a comprehensive budget for the entire program. Awards may not exceed $1,700,000. There must be a summary budget as well as breakdowns reflecting both administrative and program budgets. Applicants may provide separate sub-budgets for each program component, phase, location, or activity to provide clarification. Please refer to the Solicitation Package for complete budget guidelines and formatting instructions.

Announcement Title and Number

All correspondence with the Bureau concerning this RFGP should reference the above title and number ECA/A/E/EUR–02–01.

FOR FURTHER INFORMATION CONTACT: The Office of Academic Exchange Programs, ECA/A/E/EUR, Room 246, U.S. Department of State, 301 4th Street, SW., Washington, DC 20547, Phone: 202–205–0525; Fax: 202–260–7985, sgovatsk@pd.state.gov to request a Solicitation Package. The Solicitation Package contains detailed award criteria, required application forms, specific budget instructions, and standard guidelines for proposal preparation. Please specify Bureau Program Manager Sondra Govatski on all other inquiries and correspondence. Please send the complete Federal Register announcement before sending inquiries or submitting proposals. Once the RFGP deadline has passed, Bureau staff may not discuss this competition with applicants until the proposal review process has been completed.

To Download A Solicitation Package via Internet

The entire Solicitation Package may be downloaded from the Bureau’s website: http://exchanges.state.gov/education/RFGPs. Please read all information before downloading.

Deadline for Proposals

All proposal copies must be received at the Bureau of Educational and Cultural Affairs by 5 p.m. Washington, DC time on Friday, March 2, 2001. Faxed documents will not be accepted at any time. Documents postmarked the due date but received on a later date will not be accepted. Each applicant must ensure that the proposals are received by the above deadline.

Applicants must follow all instructions in the Solicitation Package. The original and eight copies of the application should be sent to: U.S. Department of State, SA–44, Bureau of Educational and Cultural Affairs, Ref.: ECA/ A/E/EUR–02–01, Program Management, ECA/EX/PM, Room 534, 301 4th Street, SW., Washington, DC 20547.

Applicants must also submit the “Executive Summary” and “Proposal Narrative” sections of the proposal on a 3.5” diskette, formatted for DOS. These documents must be provided in ASCII text (DOS) format with a maximum line length of 65 characters. The Bureau will transmit these files electronically to the Public Affairs section at the US Embassy for its review, with the goal of reducing the time it takes to get embassy comments for the Bureau’s grants review process.

Diversity, Freedom and Democracy Guidelines

Pursuant to the Bureau's authorizing legislation, programs must maintain a non-political character and should be balanced and representative of the diversity of American political, social, and cultural life. “Diversity” should be interpreted in the broadest sense and encompass differences including, but not limited to ethnicity, race, gender, religion, geographic location, socio-economic status, and physical challenges. Applicants are strongly encouraged to adhere to the advancement of this principle both in program administration and in program content. Please refer to the review criteria under the “Support for Diversity” section for specific suggestions on incorporating diversity into the total proposal. Public Law 104–319 provides that “in carrying out programs of educational and cultural exchange in countries whose people do not fully enjoy freedom and democracy”, the Bureau “shall take appropriate steps to provide opportunities for participation in such programs to human rights and democracy leaders of such countries.” Public Law 106–113 requires that the governments of the countries described above do not have inappropriate influence in the selection process. Proposals should reflect advancement of these goals in their program content, to the fullest extent deemed feasible.
Review Process

The Bureau will acknowledge receipt of all proposals and will review them for technical eligibility. Proposals will be deemed ineligible if they do not fully adhere to the guidelines stated herein and in the Solicitation Package. All eligible proposals will be reviewed by the program office, as well as the Public Diplomacy section overseas, where appropriate. Eligible proposals will be forwarded to panels of Bureau officers for advisory review. Proposals may also be reviewed by the Office of the Legal Adviser or by other Department elements. Final funding decisions are at the discretion of the Department of State’s Assistant Secretary for Educational and Cultural Affairs. Final technical authority for assistance awards (grants or cooperative agreements) resides with the Bureau’s Grants Officer.

Review Criteria

Technically eligible applications will be competitively reviewed according to the criteria stated below. These criteria are not rank ordered and all carry equal weight in the proposal evaluation:

1. Quality of the program idea: Proposals should exhibit originality, substance, precision, and relevance to the Bureau’s mission.

2. Program planning and ability to achieve program objectives: Detailed agenda and relevant work plan should demonstrate substantive undertakings and logistical capacity. Agenda and plan should adhere to the program overview and guidelines described above. Objectives should be reasonable, feasible, and flexible. Proposals should clearly demonstrate how the institution will meet the program’s objectives and plan.

3. Multiplier effect/impact: Proposed programs should strengthen long-term mutual understanding, including maximum sharing of information and establishment of long-term institutional and individual linkages.

4. Support of Diversity: Proposals should demonstrate substantive support of the Bureau’s policy on diversity. Achievable and relevant features should be cited in both program administration (selection of participants, program venue and program evaluation) and program content (orientation and wrap-up sessions, program meetings, resource materials and follow-up activities).

5. Institutional Capacity: Proposed personnel and institutional resources should be adequate and appropriate to achieve the program or project’s goals. Proposals should demonstrate an institutional record of successful exchange programs, including responsible fiscal management and full compliance with all reporting requirements for past Bureau grants as determined by Bureau Grant Staff. The Bureau will consider the past performance of prior recipients and the demonstrated potential of new applicants.

6. Follow-on Activities: Proposals should provide a plan for continued follow-on activity (without Bureau support) ensuring that Bureau supported programs are not isolated events.

7. Project Evaluation: Proposals should include a plan to evaluate the activity’s success, both as the activities unfold and at the end of the program. A draft survey questionnaire or other technique plus description of a methodology to use to link outcomes to original project objectives is recommended. Successful applicants will be expected to submit intermediate reports after each project component is concluded or quarterly, whichever is less frequent.

8. Cost-effectiveness: The overhead and administrative components of the proposal, including salaries and honoraria, should be kept as low as possible. All other items should be necessary and appropriate. Proposals should maximize cost-sharing through other private sector support as well as institutional direct funding contributions.

Authority

Overall grant making authority for this program is contained in the Mutual Educational and Cultural Exchange Act of 1961, Public Law 87–256, as amended, also known as the Fulbright-Hays Act. The purpose of the Act is “to enable the Government of the United States to increase mutual understanding between the people of the United States and the people of other countries * * *; to strengthen the ties which unite us with other nations by demonstrating the educational and cultural interests, developments, and achievements of the people of the United States and other nations * * * and thus to assist in the development of friendly, sympathetic and peaceful relations between the United States and the other countries of the world.” The funding authority for the program cited above is provided through the FREEDOM Support Act.

Notice

The terms and conditions published in this RFGP are binding and may not be modified by any Bureau representative. Explanatory information provided by the Bureau that contradicts published language will not be binding. Issuance of the RFGP does not constitute an award commitment on the part of the Government. The Bureau reserves the right to reduce, revise, or increase proposal budgets in accordance with the needs of the program and the availability of funds. Awards made will be subject to periodic reporting and evaluation requirements.

Notification

Final awards cannot be made until funds have been appropriated by Congress, allocated and committed through internal Bureau procedures.


William B. Bader,
Assistant Secretary for Educational and Cultural Affairs, U.S. Department of State.

[FR Doc. 00–33204 Filed 12–27–00; 8:45 am]
BILLING CODE 4710–05–P
inspection and printing on the internet at http://dms.dot.gov; and for inspection from the Commandant (G–CIM–2), U.S. Coast Guard, room 6106, 2100 Second Street SW., Washington, DC, between 10 a.m. and 4 p.m., Monday through Friday, except Federal holidays.

FOR FURTHER INFORMATION CONTACT: Barbara Davis, Office of Information Management, 202–267–2326, for questions on this document; Dorothy Beard, Chief, Documentary Services Division, U.S. Department of Transportation, 202–366–9330, for questions on the docket.

SUPPLEMENTARY INFORMATION:

Regulatory History

This request constitutes the 30-day notice required by OMB. The Coast Guard has already published [65 FR 59884 (October 6, 2000)] the 60-day notice required by OMB. That request elicited no comments.

Request for Comments

The Coast Guard invites comments on the proposed collections of information to determine whether the collections are necessary for the proper performance of the functions of the Department. In particular, the Coast Guard would appreciate comments addressing: (1) The practical utility of the collections; (2) the accuracy of the Department’s estimated burden of the collections; (3) ways to enhance the quality, utility, and clarity of the information that is the subject of the collections; and (4) ways to minimize the burden of collections on respondents, including the use of automated collection techniques or other forms of information technology. Comments, to DMS or OIRA, must contain the OMB Control Numbers of all ICRs addressed. Comments to DMS must contain the docket number of this request, USCG 2000–0832. Comments to OIRA are best assured of having their full effect if OIRA receives them within 30 days or less after the publication of this request.

Information Collection Requests

1. Title: Direct Users’ Fees for Inspection or Examination of U.S. and Foreign Commercial Vessels.

OMB Control Number: 2115–0016.

Type of Request: Extension of a currently approved collection.

Affected Public: Manufacturers of chemicals.

Forms: CG–4355.

Abstract: The Coast Guard requires manufacturers of new chemicals to submit data on the chemicals. From these data, the Coast Guard determines the appropriate precautions to take.

Annual Estimated Burden Hours: The estimated burden is 129 hours a year.


V.S. Crea,
Director of Information and Technology.
FR Doc. 00–33190 Filed 12–27–00; 8:45 am]
BILLING CODE 4910–15–P

DEPARTMENT OF TRANSPORTATION

Coast Guard

[USCG 2000–7933]


AGENCY: Coast Guard, DOT.

ACTION: Request for comments.

SUMMARY: In compliance with the Paperwork Reduction Act of 1995, this request for comments announces that the Coast Guard has forwarded the five Information Collection Requests (ICRs) abstracted below to OMB for review and comment. These ICRs describe the information we seek to collect from the public. Review and comment by OMB ensure that we impose only paperwork burdens commensurate with our performance of duties.

DATES: Please submit comments on or before January 29, 2001.

ADDRESSES: Please send comments to (1) the Docket Management System (DMS), U.S. Department of Transportation (DOT), room PL–401, 400 Seventh Street SW., Washington, DC 20590–0001; and (2) the Office of Information and Regulatory Affairs (OIRA), Office of Management and Budget (OMB), 725 17th Street NW., Washington, DC 20503, to the attention of the Desk Officer for the USCG.

Copies of the complete ICRs are available for inspection and copying in public docket USCG 2000–7933 of the Docket Management Facility between 10 a.m. and 5 p.m., Monday through Friday, except Federal holidays; for inspection and printing on the internet at http://dms.dot.gov; and for inspection from the Commandant (G–CIM–2), U.S. Coast Guard, room 6106, 2100 Second Street SW., Washington, DC, between 10 a.m. and 4 p.m., Monday through Friday, except Federal holidays.

FOR FURTHER INFORMATION CONTACT: Barbara Davis, Office of Information Management, 202–267–2326, for questions on this document; Dorothy Beard, Chief, Documentary Services Division, U.S. Department of Transportation, 202–366–9330, for questions on the docket.

SUPPLEMENTARY INFORMATION:

Regulatory History

This request constitutes the 30-day notice required by OMB. That request elicited no comments.

Request for Comments

The Coast Guard invites comments on the proposed collections of information to determine whether the collections are necessary for the proper performance of the functions of the Department. In particular, the Coast Guard would appreciate comments addressing: (1) the practical utility of the collections; (2) the accuracy of the Department’s estimated burden of the collections; (3) ways to enhance the quality, utility, and clarity of the information that is the subject of the collections; and (4) ways to minimize the burden of collections on respondents, including the use of automated collection techniques or other forms of information technology.

Comments, to DMS or OIRA, must contain the OMB Control Numbers of all ICRs addressed. Comments to DMS must contain the docket number of this request, USCG 2000–7933. Comments to OIRA are best assured of having their full effect if OIRA receives them within 30 days or less after the publication of this request.

Information Collection Requests

1. Title: Alternative Provisions for Reinspection of Offshore Supply Vessels (OSVs) in Foreign Ports.

OMB Control Number: 2115–0571.

Type of Request: Extension of a currently approved collection.

Affected Public: Owners and operators of vessels.

Form(s): This collection of information provides a mechanism for
owners and operators of OSVs based overseas to submit certified examination reports and statements to the Coast Guard as alternatives to reinspection by the Coast Guard.

Annual Estimated Burden Hours: The estimated burden is 143 hours a year.

2. Title: Waterfront Facilities Handling Liquefied Natural Gas (LNG) and Liquefied Hazardous Gas (LHG). OMB Control Number: 2115–0532.

Type of Request: Extension of a currently approved collection.

Affected Public: Owners and operators of waterfront facilities that transfer LNG or LHG.

Forms: This collection of information does not require the public to fill out Coast Guard forms, but an operator of a waterfront facility must submit all requests in writing to the Coast Guard when handling and transferring LNG or LHG in bulk.

Abstract: LNGs and LHGs present a risk to the public when handled at waterfront facilities. These rules should either prevent accidental releases at waterfront facilities or mitigate their results. They are necessary to promote and verify compliance with safety standards.

Annual Estimated Burden Hours: The estimated burden is 3,372 hours a year.


Type of Request: Extension of a currently approved collection.

Affected Public: Owners and operators of self-propelled hopper dredges who request working freeboards.

Forms: This collection of information does not require the public to fill out Coast Guard forms. Owners or operators must submit to the Coast Guard calculations showing that their dredges meet certain structural and stability standards for working freeboards.

Abstract: This collection of information provides a mechanism for owners and operators of self-propelled hopper dredges to request working freeboards.

Annual Estimated Burden Hours: The estimated burden is 46 hours a year.

4. Title: Approval of Plans and Records for Subdivision and Stability. OMB Control Number: 2115–0589.

Type of Request: Extension of a currently approved collection.

Affected Public: Owners, operators, or masters of vessels.

Forms: This collection of information does not require the public to fill out Coast Guard forms. Owners or operators must submit to the Coast Guard plans, technical information, or operating instructions before building or altering vessels.

Abstract: This collection of information requires owners, operators, or masters of certain inspected vessels to obtain or post various documents as part of the program of the Coast Guard for the safety of commercial vessels.

Annual Estimated Burden Hours: The estimated burden is 10,003 hours a year.

5. Title: Discharge of Refuse from Ships. OMB Control Number: 2115–0613.

Type of Request: Extension of a currently approved collection.

Affected Public: Owners, operators, masters, and persons-in-charge of vessels.

Forms: This collection of information does not require the public to fill out Coast Guard forms. Operators of U.S. oceangoing ships must maintain refuse- record books.

Abstract: The Marine Plastic Pollution Research and Control Act of 1987 requires the keeping of records on the discharge of refuse by oceangoing commercial vessels that are 40 feet in length or more. The rules appear in 33 CFR 151.55.

Annual Estimated Burden Hours: The estimated burden is 523,302 hours a year.


V.S. Crea,
Director of Information and Technology.

[FR Doc. 00–33191 Filed 12–27–00; 8:45 am]

BILLING CODE 4910–15–P

DEPARTMENT OF TRANSPORTATION

Coast Guard
[USCG–2000–7206]

Voluntary Guidelines on Recreational Activities To Control the Spread of Zebra Mussels and Other Aquatic Nuisance Species

AGENCY: Coast Guard, DOT.

ACTION: Notice of issuance.

SUMMARY: The Coast Guard makes available this final version of the voluntary guidelines for persons engaged in water-related recreational activities (e.g., boating and fishing) to help control the spread of aquatic nuisance species (ANS). The Coast Guard must issue these guidelines per the recommendations prepared by the Aquatic Nuisance Species Task Force.

DATES: These voluntary guidelines are effective January 29, 2001.

ADDRESSES: The Docket Management Facility maintains the public docket for this notice. Comments and material received from the public are a part of this docket and are available for inspection or copying at room PL–401, on the Plaza level of the Nassif Building, 400 Seventh Street SW., Washington, DC, between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays. You may also find this docket on the Internet at http://dms.dot.gov.

FOR FURTHER INFORMATION CONTACT: For questions on this notice or associated guidelines, call Lieutenant junior grade JoAnne Hanson, Project Manager, Office of Operating and Environmental Standards (G–MSO), Coast Guard, telephone, 202–267–2079. For questions on viewing materials in the docket, call Dorothy Beard, Chief, Dockets, Department of Transportation, telephone 202–366–9329.

SUPPLEMENTARY INFORMATION:

What Is the Regulatory History of the Voluntary Guidelines?

On April 13, 2000, we published a notice and request for comments entitled “Voluntary Guidelines on Recreational Activities to Control the Spread of Zebra Mussels and Other Aquatic Nuisance Species” in the Federal Register (65 FR 9953). We received four comment letters. On May 4, 2000, we published a correction notice in the Federal Register (65 FR 25980) citing minor editorial corrections to the notice and request for comments. No public hearing was requested and none was held.

What Comments Did the Coast Guard Receive in Response to Its Notice and Request for Comments and What Changes, if Any, Were Made to the Voluntary Guidelines as a Result of These Comments?

We received four comment letters in response to the notice and request for comments. Each of the four comment letters expresses support for the proposed guidelines, including the distribution of educational and outreach materials.

One comment proposes that the Coast Guard work with associations, educational institutions, or agencies that conduct education and outreach on recreational activities as part of their overall mission.

As a member of the Aquatic Nuisance Species Task Force (ANSTF), the Coast Guard is represented on the Task Force’s Communication, Education and Outreach Committee. This committee was established to provide the Task Force with a way to support the congressional mandates through outreach campaigns. The committee is currently working on creating a National Aquatic Nuisance Species Campaign and these voluntary guidelines will play
an important role in that effort. The Coast Guard will also rely on the Coast Guard Auxiliary to promote these guidelines to the boating public through their boating safety courses.

One comment suggests clarifying the term "natural resource managers and others" used in the guidelines under the heading "What activities do the voluntary guidelines address and what are the recommended procedures?"

The Coast Guard intends for the various county, regional, and State agencies to use the voluntary guidelines as basic guidelines to incorporate into their own aquatic nuisance species materials, which they can distribute in their areas, including specific points of contact.

One comment suggests that the Coast Guard purchase public service television spots to televise the educational videos. The comment also suggests that we make the guidelines available on the Coast Guard's web page.

As noted previously, as a member of the ANSTF's Communication, Education, and Outreach Committee, the Coast Guard is involved in the development of a national campaign to highlight these voluntary guidelines. A variety of outreach materials are being developed to publicize the guidelines. We expect televised publicity to be considered as well. The guidelines are currently available on the Coast Guard's web page.

One comment suggests using a species other than the spiny water flea to illustrate the efficacy of drying because the spiny water flea's resting stage eggs, which it produces seasonally, can dry out. The comment notes that the adult female cannot.

In response to this comment, the ANSTF Recreational Activities Committee (RAC) has recommended that we change the wording at the end of paragraph [e], entitled "Boating," under the "Pathway-Specific Guidelines" heading to read as follows: "* * * reduce the risk * * *" instead of "* * * prevent the transport * * *". We have made this wording change.

One comment suggests that, in the first bullet under "Never do the following," under "Generic Guidelines," we remove the word "from" and add the words "to or from." The sentence would then read as follows: "Never transport plants, animals, mud, or water to or from lakes, rivers, wetlands, and coastal waters."

We have revised the wording under the "Generic Guidelines" based on this suggestion.

**Why Is the Coast Guard Issuing Voluntary Guidelines?**

To comply with the National Invasive Species Act of 1996 (NISA), we are issuing voluntary guidelines for recreational activities to control the spread of zebra mussels and other Aquatic Nuisance Species (ANS). These guidelines will be explained in pamphlets, videos, and other types of outreach materials.

The voluntary guidelines in this notice are based on the ones drafted and recommended by the RAC. The guidelines developed by the Committee are available in the docket and may be accessed on the Internet at http://dms.dot.gov.

**What Are Aquatic Nuisance Species (ANS)?**

ANS are organisms introduced into non-native habitats and are often freed from the natural predators, parasites, pathogens, and competitors that have kept them in check. Once established, these organisms can displace native species; they can impede municipal, industrial, and private water intake systems; and they can degrade aquatic ecosystems.

The introduction of most ANS is the work of humans. In some cases, this is intentional, but, in many, it is accidental. In addition to overland transport of boats, which has long been identified as a key dispersal pathway, there are many others. The other human activities that can disperse ANS include angling, scuba diving, and waterfowl hunting.

Establishing these final voluntary guidelines will help to promote good habits that will control the spread of ANS. Surveys have shown that participants in recreational activities will take necessary precautions if they know what to do. Conversely, they will not take precautions unless they know what to do.

**What Is the Purpose of the Voluntary Guidelines?**

The voluntary guidelines will give the public clear, concise information on how to avoid the transport of ANS. These voluntary guidelines provide specific procedures that individuals engaged in the corresponding recreational activity can follow so they will not accidentally transport ANS.

**What Activities Do the Voluntary Guidelines Address and What Are the Recommended Procedures?**

These voluntary guidelines address the following water-related recreational activities: Scuba diving; waterfowl hunting; harvesting of bait by recreational anglers; angling; boating; operating seaplanes; and operating personal watercraft. These voluntary guidelines are intended to assist natural resource managers and others involved in educating individuals who participate in these recreational activities about the problems associated with the spread of ANS in the United States.

**Voluntary Guidelines for Recreational Activities To Control the Spread of Zebra Mussels and Other Aquatic Nuisance Species**

**Generic Guidelines**

Some guidelines are appropriate for any recreational activity associated with water. The generic preventive-guidelines that follow apply to most recreational activities occurring in marine and inland waters. In addition to these guidelines, States and provinces may include specific laws and guidelines for their areas.

Always do the following:

- Always inspect equipment (in the broadest sense, e.g., boats, planes, trailers, decoy anchors, SCUBA gear, and lures) for visible plants and animals before transporting.
- Always remove visible plants and animals from equipment (expel plants, animals, and water from internal parts).
- Always drain water from equipment before transporting.
- Always clean equipment that has been in infested waters before placing it in other waters (see the "Pathway-specific guidelines" section for specific methods).
- Always report questionable species to your resource agency for identification. Information is available from many sources about identification of ANS; however, specimens are needed to confirm sightings. Many jurisdictions have different rules regarding possession and transport. Always ask your local natural resources management agency for instructions.
- Avoid the following: Transporting plants, animals, mud, or water to or from lakes, rivers, wetlands, and coastal waters.
- Releasing animals or plants (e.g., aquarium species, bait, or water garden plants) into the wild unless you release them into the same waterbody or location where the species came from.

**Pathway-Specific Guidelines**

These guidelines cover recreational activities that are potential pathways for transferring ANS. Individuals engaged in these activities should follow these guidelines to help prevent the spread of ANS. You should note that States and
it is possible to inadvertently spread ANS from one lake or wetland to another via boats, motors, trailers, and decoys. Waterfowlers should assume that any fragments of aquatic plants could be potentially harmful and should not be transported from one wetland, lake, river, or coastal area to another. In addition, zebra mussels and their microscopic larvae can attach to aquatic plants. If fragments of these plants are transported, they can inadvertently transport zebra mussels to other waters. By following the guidelines on recreational activities, you can help prevent the spread of ANS via waterfowl hunting. Guidelines:

Before the hunting season—

• Switch to elliptical, bulb-shaped, or strap anchors on decoys, which avoid collecting submerged and floating aquatic plants; or

• If boats are moored in waters infested with zebra mussels, use the following tips to remove or kill zebra mussels or other aquatic animals and plants that might be in or on your boat:
  (1) Remove any visible zebra mussels from the boat and wash and rinse the boat with hot water; or
  (2) Spray the boat with high-pressure water; or
  (3) Dry all parts of the boat for at least 5 days before placing it into another waterbody.

After hunting—

• Inspect waders or hip boots; remove aquatic plants; and, where possible, rinse mud from them before leaving the waters; or

• Remove aquatic plants, animals, and mud that are attached to decoy lines or anchors; and

• Drain the water from boats before transporting to other waters. Between hunting trips—

• Inspect equipment for any aquatic plants, animals, and mud not removed after hunting; remove and dispose of them on land away from the waters; and

• Follow the guidelines for boaters in paragraph (e).

(c) Recreational Anglers’ Harvest of Live Bait (Non-Commercial Harvest)

The guidelines that follow apply to the non-commercial harvesting of live bait by recreational anglers. Nonindigenous species can lodge in nets and other equipment used to harvest baitfish and can be unintentionally transported into non-infested waters. Some species can survive up to 2 weeks out of water and remain viable when dislodged into another waterbody. Non-target species like ruffe and round gobies, as well as fragments of aquatic nuisance plants, such as hydrilla or Eurasian water milfoil, can be harvested along with target baitfish species. If such species are transferred to non-infested waters, they can have harmful effects on native fish populations. To help prevent the transfer of these species, you should conduct the procedures that follow or after the harvest of live bait for personal use.

Guidelines:

• Inspect harvested live bait for non-target species, and remove them where harvested.

• Always dispose of unwanted live bait on land (away from contact with waters) before leaving the waters. Never release live bait into another body of water or move aquatic plants or animals from one waterbody into a different waterbody.

• Remove all aquatic plants from boats, trailers, nets, or other equipment while on shore before leaving the waterbody access.

• Before reusing nets, roll out, hand clean, and dry them.

• Drain water from boats (cooling stem of motors) and equipment (bilge pump, tubs, live wells, etc.) before leaving any waterbody access.

• Never use water from infested waters to transport live bait to other waters. In many States and provinces, live bait harvested from designated infested waters is illegal. Check with your local State natural resource agency before you collect live bait.

• In areas where harvest of bait from infested waters is legal, avoid using the same equipment in infested and non-infested waters. Some aquatic nuisance species once removed from infested waters can survive up to two weeks in a moist environment. By drying surfaces where they can be lodged or attached, you can substantially reduce the risk of transporting them in boats and equipment.

• Rinse all equipment, including boats and trailers, with tap water and dry them for as long as possible, but for at least 5 days before re-use, especially in other waters. Before re-use, you should roll out nets, hand clean them, and dry them for a minimum of 10 days, or freeze them for 2 days.

• The following applies to disinfection, specific to zebra mussels, of equipment that is difficult to treat with drying and washing methods (use these methods away from the waterbody):

  (1) As an added equipment treatment, a dip of 100 percent vinegar for 20 minutes can kill small zebra mussels and may be effective against other ANS.

  (2) Treatment with other chemicals such as a 1-percent solution of table salt
for 24 hours can be as effective as a dip of vinegar.

The recipes provided in the following table are for a 1-percent solution of table salt (sodium chloride) treatment in water.¹

<table>
<thead>
<tr>
<th>Gallons of water</th>
<th>Cups of salt</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>2 1/2</td>
</tr>
<tr>
<td>10</td>
<td>1 1/4</td>
</tr>
<tr>
<td>25</td>
<td>3</td>
</tr>
<tr>
<td>50</td>
<td>6 1/4</td>
</tr>
<tr>
<td>100</td>
<td>12 1/2</td>
</tr>
</tbody>
</table>

¹ Based on 312 g per cup.

(d) Angling

The introduction of ANS can cause significant changes in freshwater and marine ecosystems. Populations of prey and game fish can be significantly harmed by the presence of species such as the sea lamprey, Asian swamp eel, Chinese carp, and zebra mussel. Some aquatic nuisance plants (e.g., hydrilla, Eurasian water milfoil, and water hyacinth) may limit the viable fishing area of inland waters. You can help prevent the transfer of ANS by following the guidelines in this section whenever you engage in angling.

Guidelines

- Dispose of unwanted live bait on land before leaving the waterbody.
- Never release live bait into a different body of water or move aquatic plants or animals from one waterbody to another.
- Wash and dry your boat, tackle, downriggers, float tube, waders, and other equipment to remove or kill harmful species that were not visible at the boat launch.
- Inspect all fish caught using seines, dipnets, or other types of netting; remove and properly discard all non-target species.

(e) Boating

ANS, such as the zebra mussel, spiny water flea, and Eurasian water milfoil, can be unintentionally transported through water-related recreation activities because some ANS can survive many days out of water. If you are a water recreationalist (watercraft users), there are some important actions you can take to reduce the risk of transport of ANS from one waterbody to another.

Guidelines

- Before leaving all waters, inspect your boat (sailboats check centerboard and bilgeboard wells, and keel boats check the rudder-post area), trailer (check axles, runners, lights, and rollers), and other boating equipment (check anchors, water-skis, or other tow lines), and remove any plants, animals, or mud that are visible (see diagram 1).
- Drain water from the motor, livewell, bilge, and transoms while on land and before leaving all waters.
- Wash and dry your boat, tackle, fishing lines, downriggers, trailer, and other boating equipment to kill harmful species that were not visible at the boat launch. You can do this on your way home or once you arrive home.
- Before you transport to other waters, do one of the following:
  1. Rinse your boat and boating equipment with hot (greater than 40 °C or 104 °F) tap water.
  2. Spray your boat and trailer with high-pressure water.
  3. Dry your boat and equipment for at least 5 days.

For your information, the U.S. Fish and Wildlife Service, in conjunction with Canadian officials and other partners, are implementing the 100th Meridian Initiative, which focuses on preventing the westward spread of zebra mussels and other ANS by boat inspections and by dissemination of posters, brochures, and other information about ANS. There are many other State and Federal initiatives focusing on controlling the spread of ANS. Consult your local Fish and Wildlife Service facility or other appropriate State or Federal natural resource management agency for additional information.

(f) Seaplanes

Many ANS, such as the zebra mussel and Eurasian water milfoil, can be unintentionally transported from one waterbody to another on the floats of seaplanes. Therefore, it is important to clean the aircraft to remove ANS before traveling, rather than after landing at new locations. In addition, it is important for you to incorporate the procedures listed here into the operation of your seaplane. However, plane safety is the first priority when considering and following these guidelines.

Guidelines:

Before entering the aircraft—

- Inspect and remove aquatic plants from the floats, wires or cables, and water rudders;
- Pump floats, which may contain infested water; and
- If moored in waters infested by zebra mussels for extended periods, check the transom, chine, bottom, wheel wells, and step area of floats (see diagram 2). If zebra mussels are present on the floats, you can use (any) one of the following methods to remove or kill them:
  1. Wash the floats with hot water.
  2. Spray the floats with high-pressure water.
  3. Dry all parts of the floats for at least 5 days. Before takeoff—

Diagram (1)

American Fisheries Society, 1991, by Doug Jensen, University of Minnesota Sea Grant Program.
(g) Personal Watercraft

Personal watercraft that have jet-drive systems require some extra precautions to avoid ANS. A pump pulls water in through an opening under the craft, and the impeller (an internal propeller) forces water out, moving the craft forward. ANS can easily get lodged in the jet-drive system and get transported if the watercraft is taken from one waterbody to another. A small piece of Eurasian water milfoil, or other ANS, caught in the impellers can infest a new lake or river. Zebra mussels can survive in excess water in the jet drive and spread to other waters. By applying the following guidelines, you can help prevent the transfer of ANS via your personal watercraft.

Guidelines:

In the water—
- Avoid running the engine through aquatic plants near the boat access; and
- Push or winch the watercraft up on the trailer without running the engine.

On the trailer—
- After you pull the watercraft from the water, start the engine for 5 to 10 seconds to blow out any excess water and vegetation. (The dark, damp, enclosed area of the impeller provides an ideal environment for aquatic nuisance plants to survive.); and
- After the engine stops, pull plants out of the steering nozzle. Inspect your trailer and any other sporting equipment for fragments of aquatic plants, and remove them before you leave the access area.

After trailering and before re-use—
- Wash and dry your watercraft and equipment to kill or remove harmful species that you did not see at the boat launch. You can do this on your way home or once you arrive home. Choose one of the following methods of disinfection before transporting to another waterbody:
  1. Rinse your watercraft and other equipment with hot (greater than 40 °C or 104 °F) tap water.
  2. Spray your watercraft and trailer with high-pressure water.
  3. Dry your watercraft and equipment for at least 5 days.


R.C. North,

U.S. Coast Guard, Assistant Commandant for Marine, Safety and Environmental Protection.

[FR Doc. 00–33076 Filed 12–27–00; 8:45 am]

BILLING CODE 4910–15–P

DEPARTMENT OF TRANSPORTATION

Coast Guard

[USCG–2000–8568]

Revised Recertification Procedure for Alternative Voluntary Advisory Groups in Lieu of Councils, Prince William Sound and Cook Inlet, AK

AGENCY: Coast Guard, DOT.

ACTION: Notice of proposal to change procedure; request for comments.

SUMMARY: Under the Oil Terminal and Oil Tanker Environmental Oversight and Monitoring Act of 1990, the Coast Guard may certify, on an annual basis, alternative voluntary advisory groups in lieu of a Regional Citizen’s Advisory Council for Cook Inlet and Prince William Sound regions of Alaska. The purpose of this notice is to inform the public that the Coast Guard intends to revise the procedure by which the alternative voluntary advisory groups undergo annual recertification with the objective of streamlining the administrative burden to the advisory groups, the Coast Guard and other involved parties.

DATES: Comments must reach the Document Management Facility on or before February 12, 2001.

ADDRESSES: To make sure your written comments and related material are not entered more than once in the docket,
please submit them by only one of the following means:


(2) By hand delivery to room PL–401 on the Plaza level of the Nassif Building, 400 Seventh Street SW., Washington, DC 20590–0001, between 9 a.m. and 5 p.m., Monday through Friday, except holidays. The telephone number is 202–366–9329.

(3) By fax to the Docket Management Facility at 202–493–2251.


The Docket Management Facility maintains the public docket for this notice. Comments will become part of this docket and will be available for inspection or copying at room PL–401, located on the Plaza Level of the Nassif Building at the above address between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays. You may electronically access the public docket for this notice on the Internet at http://dms.dot.gov.

FOR FURTHER INFORMATION CONTACT: For questions on viewing or submitting material to the docket, contact Dorothy Beard, Chief, Dockets, Department of Transportation, telephone 202–366–9329; for questions on this notice, contact LT Mark Tennyson, Coast Guard, telephone 202–267–0486.

SUPPLEMENTARY INFORMATION:

Request for Comments:

We encourage you to submit comments and related material on this notice. If you do so, please include your name and address, identify the docket number for this notice (USCG–2000–8568), and give the reasons for each comment. You may submit your comments and material by mail, hand delivery, fax, or electronic means to the Document Management Facility at the address under ADDRESSES; but please submit your comments and material by only one means. If you submit them by mail or hand delivery, submit them in an unbound format, no larger than 8½×11 inches, suitable for copying and electronic filing. If you want acknowledgment of receipt of your comments, enclose a stamped, self-addressed post card or envelope. We will consider all comments and materials received during the comment period. We intend to finalize any procedural changes in time for the 2001 certification season. A notice will be published in a later Federal Register.

Public Meeting:

We do not now plan to hold a public meeting. You may submit a request for a public hearing by writing to Director (G–MW), Commandant, 2100 Second Street SW., Washington, DC 20593–0001. You may also deliver them to the same address in room 1408. The request should include reasons why a hearing would be beneficial. If there is sufficient evidence to determine that oral presentations will aid this process, we will hold a public hearing at a time and place announced by a later notice in the Federal Register.

Background and Purpose:

As part of the Oil Pollution Act of 1990, Congress passed the Oil Terminal and Oil Tanker Environmental Oversight and Monitoring Act of 1990 (33 U.S.C. 2732) (the Act) to foster the long-term partnership among industry, government, and local communities in overseeing compliance with environmental concerns in the operation of crude oil terminals and oil tankers.

Paragraph (o) of the Act permits an alternative voluntary advisory group to represent the communities and interests in the vicinity of the oil terminal facilities in Cook Inlet and Prince William Sound regions of Alaska in lieu of a Council of the type specified in 33 U.S.C. 2732(d), if certain conditions are met. The Act requires that each group enter into a contract to ensure annual funding and receive annual certification from the President that it fosters the general goals and purposes of the Act and is broadly representative of the community and interests in the vicinity of the terminal facilities. Accordingly, in 1991, the President granted certification to both the Cook Inlet Regional Citizen’s Advisory Council (RCAC) and the Prince William Sound RCAC alternative voluntary advisory groups (advisory groups). The authority to certify advisory groups was subsequently delegated to the Commandant of the Coast Guard and redelegated to the Chief, Office of Marine Safety, Security and Environmental Protection. In February 1999, the authority to certify these advisory groups was redelegated to the Command, Seventeenth Coast Guard District in Juneau, Alaska.

The Coast Guard published guidelines on December 31, 1992 (57 FR 62600), to assist groups seeking recertification under the Act. We issued a policy statement on July 7, 1993 (58 FR 36504), to clarify the factors that we would be considering in making our determination as to whether advisory groups should be certified in accordance with the Act; and the procedures which we would follow in meeting our certification responsibilities under the Act. Since then, both the Prince William Sound and Cook Inlet advisory groups have been recertified annually. Based on the experiences of the recertification processes conducted from 1993 to 2000, as well as the evolution of the advisory groups from new, untested organizations to stable, functioning organizations, the Coast Guard believes the recertification procedure should be streamlined, reducing the substantial annual administrative burden placed on the advisory groups, the Coast Guard and the public.

Proposed Action:

This notice proposes two changes to the guidelines available to assist advisory groups seeking recertification under the Act. First, we propose to amend the application procedure. Second, we propose to amend the public review procedure (i.e., the notice and comment period provided under the current procedure).

Under the current guidelines, when an advisory group applies or re-applies for annual certification, it should submit the information relevant to the general criteria set forth in section 2732 (c) through (l) of the Act and, subsequently, in the July 7, 1993 Federal Register (58 FR 36504). This information enables us to review the advisory group’s activities over the past year, as well as future planned activities, including projects, studies, plans, permits, regulations, procedures, membership policies, public accessibility of the advisory group and its work, use of finances, and the establishment of a funding contract with designated industry members.

We now propose that an applicant for recertification should provide us with this comprehensive information once every 3 years (triennially). For each of the 2 years between the triennial application procedure, applicants should submit a letter requesting recertification and describe any substantive changes to the information provided at the last triennial recertification. A copy of the previous year’s annual report, annual financial statement, and Budget and Spending Plan for the coming year should also be included.

Although we will continue to evaluate an advisory group’s request for recertification every year, we believe that an annual collection of information is redundant and unnecessary. Experience gathered from 1993 to present has shown us that the majority of information submitted by advisory
groups seeking recertification remains unchanged year-to-year and both the government and the public would benefit from a streamlined administrative procedure.

The second proposed change pertains to the solicitation of public comments through Federal Register publication. The current guidelines provide that upon receipt of an application for recertification as an alternative advisory group, we will solicit comments from the public by publishing a notice and request for comments in the Federal Register. After a 45 day comment period, we will review the application and all comments received within the comment period and make a determination. The public will then be notified of the decision by Federal Register publication.

We now propose to solicit public comments every three years by publishing a notice and request for comments in the Federal Register. We believe that the public will benefit from a triennial public comment period. The majority of recent comments have expressed general agreement that the advisory groups have fulfilled their role as mandated by the Oil Pollution Act of 1990. Therefore, interested individuals and groups will be able to engage in a more substantial and meaningful dialogue if the comment period is opened triennially rather than annually. This streamlining provision would also reduce the administrative burden to both the government and the public.

This notice proposes to change the procedure for certification only during the 2 intervening years. First, a previously-certified advisory group will not have to re-submit a full application for recertification every year. Instead, an advisory group certified in the triennial certification year will, in the intervening 2 years, only have to submit updates or changes from the previous year’s application. Second, we will only solicit comments from the public during the triennial certification year. We propose that this procedure commences with the 2001 certification season, meaning that applicants seeking recertification in 2001 need only submit the streamlined application and that we will not solicit public comments prior to recertification during 2001. The triennial review process will take place in 2003. However, we will continue to recertify advisory groups annually. We will continue to use our established criteria to evaluate an advisory group’s application for recertification. Finally, we will advise the public of any recertification granted each year, by Federal Register notice.


Joseph J. Angelo,
Acting Assistant Commandant, for Marine Safety and Environmental Protection.

[FR Doc. 00–33192 Filed 12–27–00; 8:45 am]
BILLING CODE 4910–15–P

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

Proposed Advisory Circular 20–27E, Certification and Operation of Amateur-Built Aircraft

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Notice.

SUMMARY: This notice announces the availability of proposed Advisory Circular (AC) 20–27E, Certification and Operation of Amateur-Built Aircraft for review and comment. The proposal Advisory Circular 20–27E provides information and guidance concerning an acceptable means, but not the only means, of demonstrating compliance with the requirements of Title 14, Code of Federal Regulations, part 21, Certification Procedures for Products and Parts, regarding Certification and Operation of Amateur-Built Aircraft.

DATES: Comments submitted must identify the proposed AC 20–27E and be received by February 22, 2001.

ADDRESSES: Copies of the proposed AC 20–27E can be obtained from and comments may be returned to the aforementioned.

FOR FURTHER INFORMATION CONTACT: Rodney Watson, Airworthiness Certification Branch, AIR–210, Production and Airworthiness Division, 800 Independence Avenue, SW., Washington, DC 20591.

SUMMARY: In compliance with the Paperwork Reduction Act (44 U.S.C. 3501 et seq.), the FAA invites public comment on a new public information collection which will be submitted to OMB for approval.

DATES: Comments must be submitted on or before February 26, 2001.

ADDRESSES: Comments may be mailed or delivered to FAA, at the following address: Ms. Judith Street, Room 613, Federal Aviation Administration, Standards and Information Division, APF–100, 800 Independence Avenue, SW., Washington, DC 20591.

FOR FURTHER INFORMATION CONTACT: Ms. Judith Street, at the above address or on (202) 267–8995.

SUPPLEMENTARY INFORMATION: The FAA solicits comments on the following new collection of information in order to evaluate the necessity of the collection, the accuracy of the agency’s estimate of burden, the quality, utility, and clarity of the information to be collected, and possible ways to minimize the burden of collection. The following is a synopsis of the information collection activity which will be submitted to OMB for review and approval:
The FAA published Advisory Circulars (AC) 36±1G, Noise Levels for U.S. Certificated and Foreign Aircraft,” and 36±3G, Estimated Airplane Noise Levels in A-Weighted Decibels in August 1997 and April 1996 respectively. AC 36±1G contains a list of the aircraft noise certification levels. As this AC represents the only publicly available compilation of certificated aircraft noise levels, AC 36±1G is widely used within the aviation industry for various purposes, including determination of compliance with local airport noise restrictions and for various aircraft noise related studies. AC 36±3G contains a list of estimated airplane noise levels in units of a-weighted sound level in decibels (dBA). The users of AC 36±3G include several airport authorities, e.g., Ronald Reagan Washington National Airport, the utilize the noise level information in AC 36±3G to determine compliance with local airport noise restrictions.

The FAA proposes to collect current data from aircraft manufacturer’s (or modifiers) to update the two AC’s. The following will be the method used. First, a draft revision to AC 36±1G and AC 36±3G containing information that resides within the FAA will be produced. The draft AC’s will then be sent to each aircraft manufacturer and modifier advising them that the Advisory Circulars are being updated and asking them to (1) review the draft AC’s for consistency with the aircraft manufacturer’s (or modifier’s) records, and (2) provide any additions or corrections to the information in the draft AC’s.

If the collection were not conducted, the revised Advisory Circulars would be published using only the noise level information that the FAA has on hand. This would leave the possibility that a manufacturer(s) may find inconsistencies (including additional aircraft not in the revised AC’s) between its data and the published revisions to AC 36±1G and AC 36±3G.

The respondents and burden estimate are as follows: We estimate 50 respondents including U.S. and non-U.S. aircraft manufacturers/modifiers. Out of the 50, 5 respondents will take approximately 40 hours each to provide the information. The remaining 45 respondents will take approximately 15 hours. The difference in burden is due to the different number of airplane models manufactured by the various respondents. Our estimated total burden is 875 hours.

It is also noted that an agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. When assigned by OMB, the respondents will be notified of the control number.

Issued in Washington, DC on December 21, 2000.

Steve Hopkins, Manager, Standards and Information Division, APF–100.

[FR Doc. 00–33183 Filed 12–27–00; 8:45 am]
BILLING CODE 4910–13–M

DEPARTMENT OF TRANSPORTATION
Federal Aviation Administration

Notice of Intent To Request Renewal From the Office of Management and Budget (OMB) of Four Current Public Collections of Information

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Notice.

SUMMARY: In compliance with the Paperwork Reduction Act (44 U.S.C. 3501 et seq.), the FAA invites public comment on four currently approved public information collections which will be submitted to OMB for renewal.

DATES: Comments must be received on or before February 26, 2001.

ADDRESSES: Comments may be mailed or delivered to the FAA at the following address: Ms. Judy Street, Room 613, Federal Aviation Administration, Standards and Information Division, APF–100, 800 Independence Ave., SW., Washington, DC 20591.

FOR FURTHER INFORMATION CONTACT: Ms. Judy Street at the above address or on (202) 267–9895.

SUPPLEMENTARY INFORMATION: The FAA solicits comments on the following four current collections of information in order to evaluate the necessity of the collection, the accuracy of the agency’s estimate of the burden, the quality, utility, and clarity of the information to be collected, and possible ways to minimize the burden of the collection. Following are short synopses of the information collection activities which will be submitted to OMB for review and renewal:

1. 2120–0075, Airport Security—14 CFR part 107. 14 CFR part 107, Airport Security, implements the provisions of the Public Law 103–272 and the Aviation Security Improvement Act that relate to security of persons and property at airports operating in commercial air transportation. Airport security programs, training records, screenings, bomb threats, and arrest reports are needed to ensure protection of persons and property in air transportation against acts of criminal violence to ensure passenger screening procedures are effective and that information is available to comply with congressional reporting requirements. Currently, we estimate 465 respondents with a burden of approximately 75,500 hours annually.

2. 2120–0085, Certifications and Operations: 14 CFR part 125. Part A of Subtitle VII of the Revised Title 49 USC authorizes the issuance of regulations governing the use of navigable airspace. 14 CFR 125 will prescribe requirements for leased aircraft, Aviation Service Firms and Air Travel Clubs. Information collected shows compliance and the applicant’s eligibility. The current number of respondents is 57 part 125 operators. The current burden is 29,445 hours annually.

3. 2120–0568, Federal Aviation Administration, Flight standards Customer Satisfaction Survey. The Flight Standards Service wishes to continue to survey customers in keeping with its strategic initiative to improve the quality of its service by anticipating customers needs and responding to the public interest. The FAA Flight Standards Offices proposes to continue with follow-up surveys based on information provided in the first phases of the surveys. In the past surveys, the respondents have been an estimated 63,700 Flight Standards customers from the categories of air operators, air agencies and airmen, resulting in a burden of 12,740 hours.

4. 2120–0623, Office of Rulemaking Request for Evaluation of Customer Standards Survey. The FAA Office of Rulemaking proposes to survey exemption customers on customer standards that were developed and published. The data collected will be analyzed by the Office of Rulemaking (ARM) to determine the quality of services provided by ARM to its exemption customers, and make any changes or improvements to the exemption process. In the past survey, the number surveyed was 325 for an estimated burden on 81 hours.

Issued in Washington, DC, on December 21, 2000.

Steve Hopkins, Manager, Standards and Information Division, APF–100.

[FR Doc. 00–33188 Filed 12–27–00; 8:45 am]
BILLING CODE 4910–13–M
DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

Aviation Rulemaking Advisory Committee Air Carrier Operations Issues—New Task

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Notice of new task assignment for the Aviation Rulemaking Advisory Committee (ARAC).

SUMMARY: Notice is given of a new task assigned to and accepted by the Aviation Rulemaking Advisory Committee (ARAC). This notice informs the public of the activities of ARAC.

FOR FURTHER INFORMATION CONTACT: Linda Williams, 800 Independence Ave., SW., Washington, DC 20591, 202–267–9685, linda.williams@faa.gov.

SUPPLEMENTARY INFORMATION:

Background

The FAA has established an Aviation Rulemaking Advisory Committee to provide advice and recommendations to the FAA Administrator, through the Associate Administrator for Regulation and Certification, on the full range of the FAA’s rulemaking activities with respect to aviation-related issues.

The Task

This notice is to inform the public that the FAA has asked ARAC to provide advice and recommendations on the following task:

Task: Review Advisory Circular 120–29A Criteria for Approval of Nonprecision, Category I, and Category II Weather Minima for Takeoff, Approach and Landing, dated September 13–22, 2000, all associated comments received in docket FAA–2000–8080, and other documents as necessary to resolve any issues that would cause negative impact to operators. The FAA, JAA, and industry would provide resources necessary to accomplish this task. The end product would be a proposed AC recommended for signature, that reflects the best consensus of the issues related to AC 120–29A. If consensus cannot be reached on any issue, the lack of consensus should be documented and all minority positions should be presented in a letter transmitting the recommendations.

Schedule: The final ARAC recommendations will be provided to the FAA by March 30, 2001.

ARAC Acceptance of Tasks

ARAC has accepted the task and has chosen to assign the task to the All Weather Operations Harmonization Working Group, Air Carrier Operations Issues. The working group will serve as staff to ARAC. Working group recommendations must be reviewed and approved by ARAC. If ARAC accepts the working group’s recommendations, it forwards them to the FAA as ARAC recommendations.

Working Group Activity

The All Weather Operations Harmonization Working Group is expected to comply with the procedures adopted by ARAC. As part of the procedures, the working group is expected to:

1. Recommend a work plan for completion of the task, including the rationale supporting such a plan, for consideration of the ARAC Air Carrier Operations Issues.
2. Give a detailed conceptual presentation of the proposed recommendations.
3. Draft the appropriate documents and required analyses.
4. Provide a status report at each meeting of the ARAC held to consider Air Carrier Operations Issues.

Participation in the working Group

The All Weather Operations Harmonization Working Group is composed of technical experts having an interest in the assigned task. A working group member need not be a representative of a member of the full committee.

An individual who has expertise in the subject matter and wishes to become a member of the working group should write to the person listed under the caption FOR FURTHER INFORMATION CONTACT expressing that desire, describing his or her interest in the task and stating the expertise he or she would bring to the working group. All requests to participate must be received no later than January 12, 2001. The requests will be reviewed by the assistant chair, the assistant executive director, and the working group chair, and the individuals will be advised whether or not the request can be accommodated.

Individuals chosen for membership on the working group will be expected to represent their aviation community segment and participate actively in the working group (e.g., attend all meetings, provide written comments when requested to do so, etc.). They also will be expected to devote the resources necessary to support the ability of the working group in meeting any assigned deadline(s). Members are expected to keep their management chain and those they may represent advised of working group activities and decisions to ensure that the agreed technical solutions do not conflict with their sponsoring organization’s position when the subject being negotiated is presented to ARAC for approval.

The Secretary of Transportation has determined that the formation and use of the ARAC is necessary and in the public interest in connection with the performance of duties imposed on the FAA by law.

Meetings of the ARAC will be open to the public. Meetings of the All Weather Operations Harmonization Working Group will not be open to the public, except to the extent that individuals with an interest and expertise are selected to participate. No public announcement of working group meetings will be made.

Issued in Washington, DC, on December 19, 2000.

Anthony F. Fazio,
Executive Director, Aviation Rulemaking Advisory Committee.

[FR Doc. 00–33184 Filed 12–27–00; 8:45 am]

BILLING CODE 4910–13–M

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

RTCA; Joint RTCA Special Committee 181/EUROCAE Working Group 13 Standards of Navigation Performance

Pursuant to section 10(a) (2) of the Federal Advisory Committee Act (Pub. L. 92–463, 5 U.S.C., Appendix 2), notice is hereby given for a joint Special Committee 181/EUROCAE Working Group 13 meeting to be held January 22–25, 2001, starting at 9:00 a.m. The meeting will be held at Honeywell International Inc., Phoenix AZ 85036.

The agenda will include the following: January 22, 24, 25: (1) Working Groups [WG] 1 and 4 to meet separately, January 23: 9:00 a.m.–12:00 a.m. (2) Plenary Session; (3) Introductory Remarks; (4) Working Group Reports; (5) Plenary Review: (a) Expanding the Scope of WG–4; (b) Possible new Terms of Reference; (6) New Business; (7) Date and Location of Next Meeting; (8) Closing.

Attendance is open to the interested public but limited to space availability. With the approval of the chairman, members of the public may present oral statements at the meeting. Persons
wishing to present statements or obtain information should contact the RTCA Secretariat, 1140 Connecticut Avenue, NW., Suite 1020, Washington, DC 20036; (202) 833–9339 (phone); (202) 833–9434 (fax); or http://www.rtca.org (web site); or the on-site contact, Mr. Mike Adams, at (602) 436–2995 (phone), michael.adams@honeywell.com (email). Members of the public may present a written statement to the committee at any time.

Issued in Washington, DC, on December 21, 2000.

Janice L. Peters,
Designated Official.

[FR Doc. 00–33186 Filed 12–27–00; 8:45 am]
BILLING CODE 4910–13–M

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

RTCA Special Committee 159;
Minimum Operational Performance Standards for Airborne Navigation Equipment Using Global Positioning System (GPS)

Pursuant to section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463, 5 U.S.C., Appendix 2), notice is hereby given for a Special Committee 159 meeting to be held January 29–February 2, 2001, starting at 9 a.m. each day unless stated otherwise. The meeting will be held at RTCA, 1140 Connecticut Avenue, NW., Washington, DC 20026.

The agenda will include: Specific Working Group Sessions—January 29: Working Group (WG)–2C, GPS/Inertial; January 30: WG–2, GPS/WAAS; WG–4, Precision Landing Guidance (GPS/LAAS); WG–6, GPS/Interference; January 31: WG–2, GPS/WAAS; WG–4, Precision Landing Guidance (GPS/LAAS); WG–6, GPS/Interference; February 1: (1:30–4:30) WG–1, 3RD Civil Frequency; (5:00–8:00) Precision Landing Guidance (GPS/LAAS) (Editors Only); (9:00–11:30) WG–5, Surface Surveillance; (12:00–2:30) Ad Hoc Working Group, JHU/APL Report Response; February 2: Plenary Session: (1) Introductory Remarks; (2) Approve Summary of Previous Meeting; (3) Review Working Group (WG) Progress and Identify Issues for Resolution: (a) GPS/3RD Civil Frequency (WG–1); (b) GPS/WAAS (WG–2); (c) GPS/GLONASS (WG–2A); (d) GPS/Inertial (WG–2C); (e) GPS/Precision Landing Guidance (WG–4); (f) GPS/Airport Surface surveillance (WG–5); (g) GPS/Interference (WG–6); (h) SC–159 Ad Hoc; (4) Review of EUROCAE Activities; (5) Review/Approve Final Draft, revisions to RTCA DO–229B—Minimum Operational Performance Standards for Global Positioning System/Wide Area Augmentation System Airborne Equipment, RTCA Paper No. 407–00/SC159–883. (6) Assignment/Review of Future Work; (7) Other Business; (8) Date and Location of Next Meeting; (9) Closing.

Attendance is open to the interested public but limited to space availability. With the approval of the chairman, members of the public may present oral statements at the meeting. Persons wishing to present statements or obtain information should contact the RTCA Secretariat, at (202) 833–9339 (phone), (202) 833–9434 (fax). Members of the public may present a written statement to the committee at any time.

Issued in Washington, DC, on December 21, 2000.

Janice L. Peters,
Designated Official.

[FR Doc. 00–33187 Filed 12–27–00; 8:45 am]
BILLING CODE 4910–13–M

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

Notice of Intent To Rule on Application To Impose and Use the Revenue From a Passenger Facility Charge (PFC) at Pitt-Greenville Airport, Greenville, NC

AGENCY: Federal Aviation Administration (FAA), DOT.
ACTION: Notice of intent to rule on application.

On December 19, the FAA determined that the application to impose and use the revenue from a PFC submitted by Pitt Company—City of Greenville Airport Authority was substantially complete within the requirements of section 158.25 of Part 158. The FAA will approve or disapprove the application, in whole or in part, no later than March 30, 2001.

The following is a brief overview of the application.

PFC Application No.: 01–02–C–00–PGV.
Level of the proposed PFC: $4.50
Proposed charge effective date: July 1, 2001
Proposed charge expiration date: May 1, 2009
Total estimated net PFC revenue: $1,480,404
Brief description of proposed project(s):
Impose and Use:
Environmental Assessment
Extend Runway 19 (500 ft. to 6,000 ft.)
Update Airport Layout Plan
Taxiway A Extension
Design Rehab/Relocation of Taxiways A & B, and Air Carrier Apron
Disaster Recovery—ARFF Building Rehab
Disaster Recovery—Rehab Runways
Disaster Recovery—Airfield Lighting Rehab
Disaster Recovery—Install Instrument Approach Aids
Disaster Recovery—Rehab Terminal Building
Prepare PFC Application
Runway 2 Safety Area Improvements
Taxiway A Relocation
Air Carrier Apron Rehab
Taxiway B Rehab
Fiscal Service, Treasury. 2001 the prompt payment interest rate January 1, 2001 and ending on June 30, 2001 period. FOR FURTHER INFORMATION CONTACT: In addition, any person may, upon request, inspect the application, notice and other documents germane to the application in person at the Pitt County—City of Greenville Airport Authority. Dated: Issued in Atlanta, GA on December 12, 2000. Rans D. Black, Acting Manager, Atlanta Airports District Office, Southern Region. [FR Doc. 00–33189 Filed 12–27–00; 8:45 am] BILLING CODE 4910–13–M

DEPARTMENT OF THE TREASURY
Fiscal Service

Renegotiation Board Interest Rate; Prompt Payment Interest Rate; Contract Disputes Act

AGENCY: Bureau of the Public Debt, Fiscal Service, Treasury.

ACTION: Notice.

SUMMARY: For the period beginning January 1, 2001 and ending on June 30, 2001 the prompt payment interest rate is 6.375 per centum per annum. ADDRESSES: Comments or inquiries may be mailed to Eleanor Farrar, Team Leader, Debt Accounting Branch, Office of Public Debt Accounting, Bureau of the Public Debt, Parkersburg, West Virginia 26106–1328. A copy of this Notice will be available to download from the http://www.publicdebt.treas.gov.

DATES: This notice announces the applicable interest rate for the January 1, 2001 to June 30, 2001 period.


SUPPLEMENTARY INFORMATION: Although the Renegotiation Board is no longer in existence, other Federal Agencies are required to use interest rates computed under the criteria established by the Renegotiation Act of 1971 Sec. 2, Pub. L. 92–41, 85 Stat. 97. For example, the Contract Disputes Act of 1978 Sec. 12, Pub. L. 95–563, 92 Stat. 2389 and the Prompt Payment Act of 1982 Sec. 2, Pub. L. 97–177, 96 Stat. 85, provide for the calculation of interest due on claims at a rate established by the Secretary of the Treasury pursuant to 31 U.S.C. § 3902(a). Therefore, notice is given that the Secretary of the Treasury has determined that the rate of interest applicable, for the period beginning January 1, 2001 and ending on June 30, 2001, is 6.375 per centum per annum. This rate is determined pursuant to the above mentioned sections for the purpose of said sections.

Dated: December 22, 2000. Donald V. Hammond, Fiscal Assistant Secretary. [FR Doc. 00–33205 Filed 12–27–00; 8:45 am] BILLING CODE 4810–39–M

DEPARTMENT OF THE TREASURY
Internal Revenue Service

[REG–103330–97]

Proposed Collection; Comment Request for Regulation Project

AGENCY: Internal Revenue Service (IRS), Treasury.

ACTION: Notice and request for comments.

SUMMARY: The Department of the Treasury, as part of its continuing effort to reduce paperwork and respondent burden, invites the general public and other Federal agencies to take this opportunity to comment on proposed and/or continuing information collections, as required by the Paperwork Reduction Act of 1995, Public Law 104–13 (44 U.S.C. 3506(c)(2)(A)). Currently, the IRS is soliciting comments concerning an existing final regulation, REG–103330–97 (TD 8893), IRS Adoption Taxpayer Identification Numbers ($ 301.6109–3).

DATES: Written comments should be received on or before February 26, 2001 to be assured of consideration.

ADDRESSES: Direct all written comments to Garrick R. Shear, Internal Revenue Service, room 5244, 1111 Constitution Avenue NW., Washington, DC 20224.

FOR FURTHER INFORMATION CONTACT: Requests for additional information or copies of the regulation should be directed to Carol Savage, (202) 622–3945, Internal Revenue Service, room 5242, 1111 Constitution Avenue NW., Washington, DC 20224.

SUPPLEMENTARY INFORMATION:

Title: IRS Adoption Taxpayer Identification Numbers.

OMB Number: 1545–1564.


Abstract: The regulations provide rules for obtaining IRS adoption taxpayer identification numbers (ATINs), which are used to identify children placed for adoption. To obtain an ATIN, a prospective adoptive parent must file Form W–7A. The regulations assist prospective adoptive parents in claiming tax benefits with respect to these children.

Current Actions: There is no change to this existing regulation.

Type of Review: Extension of a currently approved collection.

The burden for the collection of information is reflected in the burden for Form W–7A.

The following paragraph applies to all of the collections of information covered by this notice: An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless the collection of information displays a valid OMB control number. Books or records relating to a collection of information must be retained as long as their contents may become material in the administration of any internal revenue law. Generally, tax returns and tax return information are confidential, as required by 26 U.S.C. 6103.

Request for Comments: Comments submitted in response to this notice will be summarized and/or included in the request for OMB approval. All comments will become a matter of public record. Comments are invited on: (a) Whether the collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency’s estimate of the burden of the collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology; and (e) estimates of capital or start-up costs and costs of operation, maintenance, and purchase of services to provide information.
The following paragraph applies to all of the collections of information covered by this notice:

An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless the collection of information displays a valid OMB control number. Books or records relating to a collection of information must be retained as long as their contents may become material in the administration of any internal revenue law. Generally, tax returns and tax return information are confidential, as required by 26 U.S.C. 6103.

Comments are invited on: (a) Whether the collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency’s estimate of the burden of the collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology; and (e) estimates of capital or start-up costs and costs of operation, maintenance, and purchase of services to provide information.


Garrick R. Shear,
IRS Reports Clearance Officer.

[FR Doc. 00–33042 Filed 12–27–00; 8:45 am]
BILLING CODE 4830–01–U

DEPARTMENT OF THE TREASURY
Internal Revenue Service

Proposed Collection; Comment Request for Revenue Procedure 2001–XX

AGENCY: Internal Revenue Service (IRS), Treasury.

ACTION: Notice and request for comments.

SUMMARY: The Department of the Treasury, as part of its continuing effort to reduce paperwork and respondent burden, invites the general public and other Federal agencies to take this opportunity to comment on proposed and/or continuing information collections, as required by the Paperwork Reduction Act of 1995, Public Law 104–13 (44 U.S.C. 3506(c)(2)(A)). Currently, the IRS is soliciting comments concerning an existing final regulation, LR–189–80 (T.D. 7927), Amortization of Reforestation Expenditures (§§ 1.194–2 and 1.194–4). Comments are invited on: (a) Whether the collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency’s estimate of the burden of the collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology; and (e) estimates of capital or start-up costs and costs of operation, maintenance, and purchase of services to provide information.


Garrick R. Shear,
IRS Reports Clearance Officer.

[FR Doc. 00–33042 Filed 12–27–00; 8:45 am]
BILLING CODE 4830–01–U

DEPARTMENT OF THE TREASURY
Internal Revenue Service

[LR–189–80]

Proposed Collection; Comment Request for Regulation Project

AGENCY: Internal Revenue Service (IRS), Treasury.

ACTION: Notice and request for comments.

SUMMARY: The Department of the Treasury, as part of its continuing effort to reduce paperwork and respondent burden, invites the general public and other Federal agencies to take this opportunity to comment on proposed and/or continuing information collections, as required by the Paperwork Reduction Act of 1995, Public Law 104–13 (44 U.S.C. 3506(c)(2)(A)). Currently, the IRS is soliciting comments concerning an existing final regulation, LR–189–80 (T.D. 7927), Amortization of Reforestation Expenditures (§§ 1.194–2 and 1.194–4). Comments are invited on: (a) Whether the collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency’s estimate of the burden of the collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology; and (e) estimates of capital or start-up costs and costs of operation, maintenance, and purchase of services to provide information.


Garrick R. Shear,
IRS Reports Clearance Officer.
revenue law. Generally, tax returns and tax return information are confidential, as required by 26 U.S.C. 6103.

Request for Comments: Comments submitted in response to this notice will be summarized and/or included in the request for OMB approval. All comments will become a matter of public record. Comments are invited on: (a) Whether the collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology; and (e) estimates of capital or start-up costs and costs of operation, maintenance, and purchase of services to provide information.

Garrick R. Shear,
IRS Reports Clearance Officer.

[FR Doc. 00–33045 Filed 12–27–00; 8:45 am]
BILLING CODE 4830–01–U

DEPARTMENT OF THE TREASURY
Internal Revenue Service
[FI–46–89]

Proposed Collection; Comment Request for Regulation Project

AGENCY: Internal Revenue Service (IRS), Treasury.

ACTION: Notice and request for comments.

SUMMARY: The Department of the Treasury, as part of its continuing effort to reduce paperwork and respondent burden, invites the general public and other Federal agencies to take this opportunity to comment on proposed and/or continuing information collections, as required by the Paperwork Reduction Act of 1995, Public Law 104–13 (44 U.S.C. 3506(c)(2)(A)). Currently, the IRS is soliciting comments concerning an existing final regulation, FI–46–89 (T. D. 8641), Treatment of Acquisition of Certain Financial Institutions; Certain Tax Consequences of Federal Financial Assistance to Financial Institutions (§§ 1.597–2 and 1.597–4, 1.597–6 and 1.597–7).

DATES: Written comments should be received on or before February 26, 2001 to be assured of consideration.

ADDRESSES: Direct all written comments to Garrick R. Shear, Internal Revenue Service, room 5244, 1111 Constitution Avenue NW., Washington, DC 20224.

FOR FURTHER INFORMATION CONTACT: Requests for additional information or copies of the information collection should be directed to Larnice Mack, (202) 622–3179, Internal Revenue Service, room 5244, 1111 Constitution Avenue NW., Washington, DC 20224.

Title: Treatment of Acquisition of Certain Financial Institutions; Certain Tax Consequences of Federal Financial Assistance to Financial Institutions.

OMB Number: 1545–1300.

Regulation Project Number: FI–46–89.

Abstract: Recipients of Federal financial assistance (FFA) must maintain an account of FFA that is deferred from inclusion in gross income and subsequently recaptured. This information is used to determine the recipient’s tax liability. Also, tax not subject to collection must be reported and information must be provided if certain elections are made.

Current Actions: There is no change to this existing regulation.

Type of Review: Extension of a currently approved collection.

Affected Public: Business or other for-profit organizations, and the Federal Government.

Estimated Number of Respondents: 500.

Estimated Time Per Respondent: 4 hr., 24 min.

Estimated Total Annual Burden Hours: 2,200.

The following paragraph applies to all of the collections of information covered by this notice:

An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless the collection of information displays a valid OMB control number. Books or records relating to a collection of information must be retained as long as their contents may become material in the administration of any internal revenue law. Generally, tax returns and tax return information are confidential, as required by 26 U.S.C. 6103.

REQUEST FOR COMMENTS: Comments submitted in response to this notice will be summarized and/or included in the request for OMB approval. All comments will become a matter of public record.

Comments are invited on: (a) Whether the collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency’s estimate of the burden of the collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology; and (e) estimates of capital or start-up costs and costs of operation, maintenance, and purchase of services to provide information.


Garrick R. Shear,
IRS Reports Clearance Officer.

[FR Doc. 00–33045 Filed 12–27–00; 8:45 am]
BILLING CODE 4830–01–U
Corrections

This section of the FEDERAL REGISTER contains editorial corrections of previously published Presidential, Rule, Proposed Rule, and Notice documents. These corrections are prepared by the Office of the Federal Register. Agency prepared corrections are issued as signed documents and appear in the appropriate document categories elsewhere in the issue.

DEPARTMENT OF DEFENSE
Office of the Secretary

Notice of Availability of The National Missile Defense Deployment Final Environmental Impact Statement

Correction

In notice document 00–32046, on page 78475 in the issue of Friday, December 15, 2000, make the following correction:

On page 78475, in the third column, at the end of the first full paragraph, the internet site should read "www.acq.osd.mil/bmdo/bmdolink/html/nmd.html.".

[FR Doc. C0–32046 Filed 12–27–00; 8:45 am]
BILLING CODE 1505–01–D

SECURITIES AND EXCHANGE COMMISSION


Self-Regulatory Organizations; Notice of Filing of Proposed Rule Change and Amendment Nos. 1, 2, and 3 by the National Association of Securities Dealers, Inc. Concerning Related Performance Information

Correction

In notice document 00–28653 beginning on page 67025 in the issue of Wednesday, November 8, 2000, make the following correction:

On page 67025, in the third column, in paragraph (1), beginning on the 13th line, remove the sentence that begins with "However" and add the following sentence in its place: "[However, communications may not include the performance of an existing fund for the purposes of promoting investment in a similar, but new investment option (i.e., clone fund or model fund) available in a variable contract.]"

[FR Doc. C0–28653 Filed 12–27–00; 8:45 am]
BILLING CODE 1505–01–D
Thursday,
December 28, 2000

Part II

Department of Health and Human Services

Office of the Secretary

45 CFR Parts 160 and 164
Standards for Privacy of Individually Identifiable Health Information; Final Rule
The use of these standards will improve the efficiency and effectiveness of public and private health programs and health care services by providing enhanced protections for individually identifiable health information. These protections will begin to address growing public concerns that advances in electronic technology and evolution in the health care industry are resulting, or may result, in a substantial erosion of the privacy surrounding individually identifiable health information maintained by health care providers, health plans and their administrative contractors. This rule implements the privacy requirements of the Administrative Simplification subtitle of the Health Insurance Portability and Accountability Act of 1996.

DATES: The final rule is effective on February 26, 2001.


SUPPLEMENTARY INFORMATION:

Availability of copies, and electronic access.
Copies: To order copies of the Federal Register containing this document, send your request to: New Orders, Superintendent of Documents, P.O. Box 371954, Pittsburgh, PA 15250–7954. Specify the date of the issue requested and enclose a check or money order payable to the Superintendent of Documents, or enclose your Visa or Master Card number and expiration date. Credit card orders can also be placed by calling the order desk at (202) 512–1800 or by fax to (202) 512–2250. The cost for each copy is $8.00. As an alternative, you can view and photocopy the Federal Register document at most libraries designated as Federal Depository Libraries and at many other public and academic libraries throughout the country that receive the Federal Register.

(i) Standard: uses and disclosures for research purposes.

(j) Standard: uses and disclosures to avert a serious threat to health or safety.

(k) Standard: uses and disclosures for specialized government functions.


164.514 Other requirements relating to uses and disclosures of protected health information.

(a) Standard: de-identification of protected health information.

(b) Implementation specifications: requirements for de-identification of protected health information.

(c) Implementation specifications: re-identification.

(d) Standard: minimum necessary requirements.

(e) Standard: uses and disclosures of protected health information for marketing.

(f) Standard: uses and disclosures for fundraising.

(g) Standard: uses and disclosures for underwriting and related purposes.

(h) Standard: verification requirements

164.520 Notice of privacy practices for protected health information.

(a) Standard: notice of privacy practices.

(b) Implementation specifications: content of notice.

(c) Implementation specifications: provision of notice.

(d) Implementation specifications: joint notice by separate covered entities.

(e) Implementation specifications: documentation.

164.522 Rights to request privacy protection for protected health information.

(a) Standard: right of an individual to request restriction of uses and disclosures.

(b) Standard: confidential communications requirements.

164.524 Access of individuals to protected health information.

(a) Standard: access to protected health information.

(b) Implementation specifications: requests for access and timely action.

(c) Implementation specifications: provision of access.

(d) Implementation specifications: denial of access.

(e) Implementation specification: documentation.

164.526 Amendment of protected health information.

(a) Standard: right to amend.

(b) Implementation specifications: requests for amendment and timely action.

(c) Implementation specifications: accepting the amendment.

(d) Implementation specifications: denying the amendment.

(e) Implementation specification: actions on notices of amendment.

(f) Implementation specification: documentation.

164.528 Accounting of disclosures of protected health information.

(a) Standard: right to an accounting of disclosures of protected health information.

(b) Implementation specifications: content of the accounting.

(c) Implementation specifications: provision of the accounting.

(d) Implementation specification: documentation.

164.530 Administrative requirements.

(a) Standard: personnel designations.

(b) Standard: training.

(c) Standard: safeguards.

(d) Standard: complaints to the covered entity.

(e) Standard: sanctions.

(f) Standard: mitigation.

(g) Standard: refraining from intimidating or retaliatory acts.

(h) Standard: waiver of rights.

(i) Standard: policies and procedures.

(j) Standard: documentation.

(k) Standard: group health plans.

164.532 Transition provisions.

(a) Standard: effect of prior consents and authorizations.

(b) Implementation specification: requirements for retaining effectiveness of prior consents and authorizations.

164.534 Compliance dates for initial implementation of the privacy standards.

(a) Health care providers.

(b) Health plans.

(c) Health care clearinghouses.

Purpose of the Administrative Simplification Regulations

This regulation has three major purposes: (1) To protect and enhance the rights of consumers by providing them access to their health information and controlling the inappropriate use of that information; (2) to improve the quality of health care in the U.S. by restoring trust in the health care system among consumers, health care professionals, and the multitude of organizations and individuals committed to the delivery of care; and (3) to improve the efficiency and effectiveness of health care delivery by creating a national framework for health privacy protection that builds on efforts by states, health systems, and individual organizations and individuals.

This regulation is the second final rule to be issued in the package of rules mandated under title II subtitle F section 261–264 of the Health Insurance Portability and Accountability Act of 1996 (HIPAA), Public Law 104–191, titled “Administrative Simplification.” Congress called for steps to improve “the efficiency and effectiveness of the health care system by encouraging the development of a health information system through the establishment of standards and requirements for the electronic transmission of certain health information.” To achieve that end, Congress required the Department to promulgate a set of interlocking regulations, establishing standards and protections for health information systems. The first regulation in this set, Standards for Electronic Transactions 65 FR 50312, was published on August 17, 2000 (the “Transactions Rule”). This regulation establishing Standards for Privacy of Individually Identifiable Health Information is the second final rule in the package. A rule establishing a unique identifier for employers to use in electronic health care transactions, a rule establishing a unique identifier for providers for such transactions, and a rule establishing standards for the security of electronic information systems have been proposed. See 63 FR 25272 and 25320 (May 7, 1998); 63 FR 32784 (June 16, 1998); 63 FR 43242 (August 12, 1998). Still to be proposed are rules establishing a unique identifier for health plans for electronic transactions, standards for claims attachments, and standards for transferring among health plans appropriate standard data elements needed for coordination of benefits. (See section C, below, for a more detailed explanation of the statutory mandate for these regulations.)

In enacting HIPAA, Congress recognized the fact that administrative simplification cannot succeed if we do not also protect the privacy and confidentiality of personal health information. The provision of high-quality health care requires the exchange of personal, often-sensitive information between an individual and a skilled practitioner. Vital to that interaction is the patient’s ability to trust that the information shared will be protected and kept confidential. Yet many patients are concerned that their information is not protected. Among the factors adding to this concern are the growth of the number of organizations involved in the provision of care and the processing of claims, the growing use of electronic information technology, increased efforts to market health care and other products to consumers, and the increasing ability to collect highly sensitive information about a person’s current and future health status as a result of advances in scientific research.

Rules requiring the protection of health privacy in the United States have been enacted primarily by the states. While virtually every state has enacted one or more laws to safeguard privacy, these laws vary significantly from state to state and typically apply to only part of the health care system. Many states have adopted laws that protect the health information relating to certain health conditions such as mental illness, communicable diseases, cancer, HIV/AIDS, and other stigmatized conditions. An examination of state health privacy laws and regulations,
however, found that “state laws, with a few notable exceptions, do not extend comprehensive protections to people’s medical records.” Many state rules fail to provide such basic protections as ensuring a patient’s legal right to see a copy of his or her medical record. See Health Privacy Project, “The State of Health Privacy: An Uneven Terrain,” Institute for Health Care Research and Policy, Georgetown University (July 1999) (http://www.healthprivacy.org) (the “Georgetown Study”).

Until now, virtually no federal rules existed to protect the privacy of health information and guarantee patient access to such information. This final rule establishes, for the first time, a set of basic national privacy standards and fair information practices that provides all Americans with a basic level of protection and peace of mind that is essential to their full participation in their care. The rule sets a floor of ground rules for health care providers, health plans, and health care clearinghouses to follow, in order to protect patients and encourage them to seek needed care. The rule seeks to balance the needs of the individual with the needs of the society. It creates a framework of protection that can be strengthened by both the federal government and by states as health information systems continue to evolve.

Need for a National Health Privacy Framework

The Importance of Privacy

Privacy is a fundamental right. As such, it must be viewed differently than any ordinary economic good. The costs and benefits of a regulation must, of course, be considered as a means of identifying and weighing options. At the same time, it is important not to lose sight of the inherent meaning of privacy: it speaks to our individual and collective freedom.

A right to privacy in personal information has historically found expression in American law. All fifty states today recognize in tort law a common law or statutory right to privacy. Many states specifically provide a remedy for public revelation of private facts. Some states, such as California and Tennessee, have a right to privacy as a matter of state constitutional law. The multiple historical sources for legal rights to privacy are traced in many places, including Chapter 13 of Alan Westin’s Privacy and Freedom and in Ellen Alderman & Caroline Kennedy, The Right to Privacy (1965).

Throughout our nation’s history, we have placed the rights of the individual at the forefront of our democracy. In the Declaration of Independence, we asserted the “unalienable right” to “life, liberty and the pursuit of happiness.” Many of the most basic protections in the Constitution of the United States are imbued with an attempt to protect individual privacy while balancing it against the larger social purposes of the nation.

To take but one example, the Fourth Amendment to the United States Constitution guarantees that “the right of the people to be secure in their persons, houses, papers and effects, against unreasonable searches and seizures, shall not be violated.” By referring to the need for security of “persons” as well as “papers and effects” the Fourth Amendment suggests enduring values in American law that relate to privacy. The need for security of “persons” is consistent with obtaining patient consent before performing invasive medical procedures. The need for security in “papers and effects” underscores the importance of protecting information about the person, contained in sources such as personal diaries, medical records, or elsewhere. As is generally true for the right of privacy in information, the right is not absolute. The test instead is what constitutes an “unreasonable” search of the papers and effects.

The United States Supreme Court has upheld the constitutional protection of personal health information. In Whalen v. Roe, 429 U.S. 589 (1977), the Court analyzed a New York statute that created a database of persons who obtained drugs for which there was both a lawful and unlawful market. The Court, in upholding the statute, recognized at least two different kinds of interests within the constitutionally protected “zone of privacy.” “One is the individual interest in avoiding disclosure of personal matters,” such as this regulation principally addresses. This interest in avoiding disclosure, discussed in Whalen in the context of medical information, was found to be distinct from a different line of cases concerning “the interest in independence in making certain kinds of important decisions.”

Individuals’ right to privacy in information about themselves is not absolute. It does not, for instance, prevent reporting of public health information on communicable diseases or stop law enforcement from getting information when due process has been observed. But many people believe that individuals have some right to control personal and sensitive information about themselves. Among different sorts of personal information, health information is among the most sensitive. Many people believe that details about their physical self should not generally be put on display for neighbors, employers, and government officials to see. Informed consent laws place limits on the ability of other persons to intrude physically on a person’s body. Similar concerns apply to intrusions on information about the person.

Moving beyond these facts of physical treatment, there is also significant intrusion when records reveal details about a person’s mental state, such as during treatment for mental health. If, in Justice Brandeis’ words, the “right to be let alone” means anything, then it likely applies to having outsiders have access to one’s intimate thoughts, words, and emotions. In the recent case of Jaffee v. Redmond, 116 S.Ct. 1923 (1996), the Supreme Court held that statements made to a therapist during a counseling session were protected against civil discovery under the Federal Rules of Evidence. The Court noted that all fifty states have adopted some form of the psychotherapist-patient privilege. In upholding the federal privilege, the Supreme Court stated that it “serves the public interest by facilitating the appropriate treatment for individuals suffering the effects of a mental or emotional problem. The mental health of our citizenry, no less than its physical health, is a public good of transcendent importance.”

Many writers have urged a philosophical or common-sense right to privacy in one’s personal information. Examples include Alan Westin, Privacy and Freedom (1967) and Janna Malamud Smith, Private Matters: In Defense of the Personal Life (1997). These writings emphasize the link between privacy and freedom and privacy and the “personal life,” or the ability to develop one’s own personality and self-expression. Smith, for instance, states:

The bottom line is clear. If we continually, gratuitously, reveal other people’s privacies, we harm them and ourselves, we undermine the richness of the personal life, and we fuel a social atmosphere of mutual exploitation. Let me put it another way: Little in life is as precious as the freedom to say and do things with people you love that you would not say or do if someone else were present. And few experiences are as fundamental to liberty and autonomy as maintaining control over when, how, to whom, and where you disclose personal material. Id. at 240–241.

In 1980, Louis D. Brandeis and Samuel D. Warren defined the right to privacy as “the right to be let alone.” See L. Brandeis, S. Warren, “The Right
To Privacy,” 4 Harv. L.Rev. 193. More than a century later, privacy continues to play an important role in Americans’ lives. In their book, The Right to Privacy, (Alfred A. Knopf, New York, 1995) Ellen Alderman and Caroline Kennedy describe the importance of privacy in this way:

Privacy covers many things. It protects the solitude necessary for creative thought. It allows us the independence that is part of raising a family. It protects our right to be secure in our own homes and possessions, assured that the government cannot come barging in. Privacy also encompasses our right to self-determination and to define who we are. Although we live in a world of noisy self-confession, privacy allows us to keep certain facts to ourselves if we so choose. The right to privacy, it seems, is what makes us civilized.

Or, as Cavoukian and Tapsott observed the right of privacy is: “the claim of individuals, groups, or institutions to determine for themselves when, how, and to what extent information about them is communicated.” See A. Cavoukian, D. Tapsott, “Who Knows: Safeguarding Your Privacy in a Networked World,” Random House (1995).

Increasing Public Concern About Loss of Privacy

Today, it is virtually impossible for any person to be truly “let alone.” The average American is inundated with requests for information from potential employers, retail shops, telephone marketing firms, electronic marketers, banks, insurance companies, hospitals, physicians, health plans, and others. In a 1998 national survey, 88 percent of consumers said they were “concerned” by the amount of information being requested, including 55 percent who said they were “very concerned.” See Privacy and American Business, 1998 Privacy Concerns & Consumer Choice Survey (http://www.pandab.org). These worries are not just theoretical. Consumers who use the Internet to make purchases or request “free” information often are asked for personal and financial information. Companies making such requests routinely promise to protect the confidentiality of that information. Yet several firms have tried to sell this information to other companies even after promising not to do so.

Americans’ concern about the privacy of their health information is part of a broader anxiety about their lack of privacy in an array of areas. A series of national public opinion polls conducted by Louis Harris & Associates documents a rising level of public concern about privacy, growing from 64 percent in 1978 to 82 percent in 1995. Over 80 percent of persons surveyed in 1999 agreed with the statement that they had “lost all control over their personal information.” See Harris Equifax, Health Information Privacy Study (1993) (http://www.epic.org/privacy/medical/polls.html). A Wall Street Journal/ABC poll on September 16, 1999 asked Americans what concerned them most in the coming century. “Loss of personal privacy” was the first or second concern of 29 percent of respondents. All other issues, such a terrorism, world war, and global warming had scores of 23 percent or less.

This growing concern stems from several trends, including the growing use of interconnected electronic media for business and personal activities, our increasing ability to know an individual’s genetic make-up, and, in health care, the increasing complexity of the system. Each of these trends brings the potential for tremendous benefits to individuals and society generally. At the same time, each also brings new potential for invasions of our privacy.

Increasing Use of Interconnected Electronic Information Systems

Until recently, health information was recorded and maintained on paper and stored in the offices of community-based physicians, nurses, hospitals, and other health care professionals and institutions. In some ways, this imperfect system of record keeping created a false sense of privacy among patients, providers, and others. Patients’ health information has never remained completely confidential. Until recently, however, a breach of confidentiality involved a physical exchange of paper records or a verbal exchange of information. Today, however, more and more health care providers, plans, and others are utilizing electronic means of storing and transmitting health information. In 1996, the health care industry invested an estimated $10 billion to $15 billion on information technology. See National Research Council, Computer Science and Telecommunications Board, “For the Record: Protecting Electronic Health Information,” (1997). The electronic information revolution is transforming the recording of health information so that the disclosure of information may require only a push of a button. In a matter of seconds, a person’s most profoundly private information can be shared with hundreds, thousands, even millions of individuals and organizations without our knowledge or consent. While the majority of medical records still are in paper form, information from those records is often copied and transmitted through electronic means.

This ease of information collection, organization, retention, and exchange made possible by the advances in computer and other electronic technology affords many benefits to individuals and to the health care industry. Use of electronic information has helped to speed the delivery of effective care and the processing of billions of dollars worth of health care claims. Greater use of electronic data has also increased our ability to identify and treat those who are at risk for disease, conduct vital research, detect fraud and abuse, and measure and improve the quality of care delivered in the U.S. The National Research Council recently reported that “the Internet has great potential to improve Americans’ health by enhancing communications and improving access to information for care providers, patients, health plan administrators, public health officials, biomedical researchers, and other health professionals.” See “Networking Health: Prescriptions for the Internet,” National Academy of Sciences (2000).

At the same time, these advances have reduced or eliminated many of the financial and logistical obstacles that previously served to protect the confidentiality of health information and the privacy interests of individuals. And they have made our information available to many more people. The shift from paper to electronic records, with the accompanying greater flows of sensitive health information, thus strengthens the argument for giving legal protection to the right to privacy in health information. In an earlier period where it was far more expensive to access and use medical records, the risk of harm to individuals was relatively low. In the potential near future, when technology makes it almost free to send lifetime medical records over the Internet, the risks may grow rapidly. It may become cost-effective, for instance, for companies to offer services that allow purchasers to obtain details of a person’s physical and mental treatments. In addition to legitimate possible uses for such services, malicious or inquisitive persons may download medical records for purposes ranging from identity theft to embarrassment to prurient interest in the life of a celebrity or neighbor. The comments to the proposed privacy rule indicate that many persons believe that they have a right to live in society without having these details of their lives laid open to unknown and possibly hostile eyes. These technological changes, in short, may provide a reason for institutionalizing
privacy protections in situations where the risk of harm did not previously justify writing such protections into law.

The growing level of trepidation about privacy in general, noted above, has tracked the rise in electronic information technology. Americans have embraced the use of the Internet and other forms of electronic information as a way to provide greater access to information, save time, and save money. For example, 60 percent of Americans surveyed in 1999 reported that they have a computer at home; 82 percent reported that they have used a computer; 64 percent say they have used the Internet; and 58 percent have sent an e-mail. Among those who are under the age of 60, these percentages are even higher. See “National Survey of Adults on Technology,” Henry J. Kaiser Family Foundation (February, 2000). But 59 percent of Americans reported that they worry that an unauthorized person will gain access to their information. A recent survey suggests that 75 percent of consumers seeking health information on the Internet are concerned or very concerned about the health sites they visit sharing their personal health information with a third party without their permission. Ethics Survey of Consumer Attitudes about Health Web Sites, California Health Care Foundation, at 3 (January, 2000).

Unless public fears are allayed, we will be unable to obtain the full benefits of electronic technologies. The absence of national standards for the confidentiality of health information has made the health care industry and the population in general uncomfortable about this primarily financially-driven expansion in the use of electronic data. Many plans, providers, and clearinghouses have taken steps to safeguard the privacy of individually identifiable health information. Yet they must currently rely on a patchwork of State laws and regulations that are incomplete and, at times, inconsistent. States have, to varying degrees, attempted to enhance confidentiality by establishing laws governing at least some aspects of medical record privacy. This approach, though a step in the right direction, is inadequate. These laws fail to provide a consistent or comprehensive legal foundation of health information privacy. For example, there is considerable variation among the states in the type of information protected and the scope of the protections provided. See Georgopoulos, supra. See also Executive Summary; Lawrence O. Gostin, Zita Lazzarini, Kathleen M. Flaherty, Legislative Survey of State Confidentiality Laws, with Specific Emphasis on HIV and Immunization, Report to Centers for Disease Control, Council of State and Territorial Epidemiologists, and Task Force for Child Survival and Development, Carter Presidential Center (1996) (Gostin Study).

Moreover, electronic health data is becoming increasingly “national”; as more information becomes available in electronic form, it can have value far beyond the immediate community where the patient resides. Neither private action nor state laws provide a sufficiently comprehensive and rigorous legal structure to allay public concerns, protect the right to privacy, and correct the market failures caused by the absence of privacy protections (see discussion below of market failure under section V.C). Hence, a national policy with consistent rules is necessary to encourage the increased and proper use of electronic information while also protecting the very real needs of patients to safeguard their privacy.

Advances in Genetic Sciences

Recently, scientists completed nearly a decade of work unlocking the mysteries of the human genome, creating tremendous new opportunities to identify and prevent many of the leading causes of death and disability in this country and around the world. Yet the absence of privacy protections for health information endanger these efforts by creating a barrier of distrust and suspicion among consumers. A 1995 national poll found that more than 85 percent of those surveyed were either “very concerned” or “somewhat concerned” that insurers and employers might gain access to and use genetic information. See Harris Poll, 1995 #34. Sixty-three percent of the 1,000 participants in a 1997 national survey said they would not take genetic tests if insurers and employers could gain access to the results. See “Genetic Information and the Workplace,” Department of Labor, Department of Health and Human Services, Equal Employment Opportunity Commission, January 20, 1998. “In genetic testing studies at the National Institutes of Health, thirty-two percent of eligible people who were offered a test for breast cancer risk declined to take it, citing concerns about loss of privacy and the potential for discrimination in health insurance.” Sen. Leahy’s comments for March 10, 1999 Introduction of the Medical Information Privacy and Security Act.

The Changing Health Care System

The number of entities who are maintaining and transmitting individually identifiable health information has increased significantly over the last 10 years. In addition, the rapid growth of integrated health care delivery systems requires greater use of integrated health information systems. The health care industry has been transformed from one that relied primarily on one-on-one interactions between patients and clinicians to a system of integrated health care delivery networks and managed care providers. Such a system requires the processing and collection of information about patients and plan enrollees (for example, in claims files or enrollment records), resulting in the creation of databases that can be easily transmitted. This dramatic change in the practice of medicine brings with it important prospects for the improvement of the quality of care and reducing the cost of that care. It also, however, means that increasing numbers of people have access to health information. And, as health plan functions are increasingly outsourced, a growing number of organizations not affiliated with our physicians or health plans also have access to health information.

According to the American Health Information Management Association (AHIMA), an average of 150 people “from nursing staff to x-ray technicians, to billing clerks” have access to a patient’s medical records during the course of a typical hospitalization. While many of these individuals have a legitimate need to see all or part of a patient’s records, no laws govern who those people are, what information they are able to see, and what they are and are not allowed to do with that information once they have access to it. According to the National Research Council, individually identifiable health information frequently is shared with:

- Consulting physicians;
- Managed care organizations;
- Health insurance companies;
- Life insurance companies;
- Self-insured employers;
- Pharmacies;
- Pharmacy benefit managers;
- Clinical laboratories;
- Accrediting organizations;
- State and Federal statistical agencies; and
- Medical information bureaus.

Much of this sharing of information is done without the knowledge of the patient involved. While many of these functions are important for smooth functioning of the health care system, there are no rules governing how that
information is used by secondary and tertiary users. For example, a pharmacy benefit manager could receive information to determine whether an insurance plan or HMO should cover a prescription, but then use the information to market other products to the same patient. Similarly, many of us obtain health insurance coverage though our employer and, in some instances, the employer itself acts as the insurer. In these cases, the employer will obtain identifiable health information about its employees as part of the legitimate health insurance functions such as claims processing, quality improvement, and fraud detection activities. At the same time, there is no comprehensive protection prohibiting the employer from using that information to make decisions about promotions or job retention.

Public concerns reflect these developments. A 1993 Lou Harris poll found that 75 percent of those surveyed worry that medical information from a computerized national health information system will be used for many non-health reasons, and 38 percent are very concerned. This poll, taken during the health reform efforts of 1993, showed that 85 percent of respondents believed that protecting the confidentiality of medical records is “absolutely essential” or “very essential” in health care reform. An ACLU Poll in 1994 also found that 75 percent of those surveyed are concerned about their personal information being put into a computer information bank to which others have access. Harris Equifax, Health Information Privacy Study 2,33 (1993) http://www.epic.org/privacy/medical/poll.html. Another survey found that 35 percent of Fortune 500 companies look at people’s medical records before making hiring and promotion decisions. Starr, Paul, “Health and the Right to Privacy,” American Journal of Law and Medicine, 1999, Vol. 25, pp. 193–201.

Concerns about the lack of attention to information privacy in the health care industry are not merely theoretical. In the absence of a national legal framework of health privacy protections, consumers are increasingly vulnerable to the exposure of their personal health information. Disclosure of individually identifiable information can occur deliberately or accidentally and can occur within an organization or be the result of an external breach of security. Examples of recent privacy breaches include:

• A Michigan-based health system accidentally posted the medical records of thousands of patients on the Internet (The Ann Arbor News, February 10, 1999).
• A Utah-based pharmaceutical benefits management firm used patient data to solicit business for its owner, a drug store (Kiplingers, February 2000).
• An employee of the Tampa, Florida, health department took a computer disk containing the names of 4,000 people who had tested positive for HIV, the virus that causes AIDS (USA Today, October 10, 1996).
• The health insurance claims forms of thousands of patients blew out of a truck on its way to a recycling center in East Hartford, Connecticut (The Hartford Courant, May 14, 1999).
• A patient in a Boston-area hospital discovered that her medical record had been read by more than 200 of the hospital’s employees (The Boston Globe, August 1, 2000).
• A Nevada woman who purchased a used computer discovered that the computer still contained the prescription records of the customers of the pharmacy that had previously owned the computer. The pharmacy data base included names, addresses, social security numbers, and a list of all the medicines the customers had purchased. (The New York Times, April 4, 1997 and April 12, 1997).
• A speculator bid $4000 for the patient records of a family practice in South Carolina. Among the business man’s uses of the purchased records was selling them back to the former patients. (New York Times, August 14, 1991).
• In 1993, the Boston Globe reported that Johnson and Johnson marketed a list of 5 million names and addresses of elderly incontinent women. (ACLU Legislative Update, April 1998).
• A few weeks after an Orlando woman had her doctor perform some routine tests, she received a letter from a drug company promoting a treatment for her high cholesterol. (Orlando Sentinel, November 30, 1997).

No matter how or why a disclosure of personal information is made, the harm to the individual is the same. In the face of industry evolution, the potential benefits of our changing health care system, and the real risks and occurrences of harm, protection of privacy must be built into the routine operations of our health care system.

Privacy Is Necessary To Secure Effective, High Quality Health Care

While privacy is one of the key values on which our society is built, it is more than an end in itself. It is also necessary for the effective delivery of health care, both to individuals and to populations. The market failures caused by the lack of effective privacy protections for health information are discussed below (see section V.C below). Here, we discuss how privacy is a necessary foundation for delivery of high quality health care. In short, the entire health care system is built upon the willingness of individuals to share the most intimate details of their lives with their health care providers.

The need for privacy of health information, in particular, has long been recognized as critical to the delivery of needed medical care. More than anything else, the relationship between a patient and a clinician is based on trust. The clinician must trust the patient to give full and truthful information about their health, symptoms, and medical history. The patient must trust the clinician to use that information to improve his or her health and to respect the need to keep such information private. In order to receive accurate and reliable diagnosis and treatment, patients must provide health care professionals with accurate, detailed information about their personal health, behavior, and other aspects of their lives. The provision of health information assists in the diagnosis of an illness or condition, in the development of a treatment plan, and in the evaluation of the effectiveness of that treatment. In the absence of full and accurate information, there is a serious risk that the treatment plan will be inappropriate to the patient’s situation.

Patients also benefit from the disclosure of such information to the health plans that pay for and can help them gain access to needed care. Health plans and health care clearinghouses rely on the provision of such information to accurately and promptly process claims for payment and for other administrative functions that directly affect a patient’s ability to receive needed care, the quality of that care, and the efficiency with which it is delivered.

Accurate medical records assist communities in identifying troubling public health trends and in evaluating the effectiveness of various public health efforts. Accurate information helps public and private payers make correct payments for care received and lower costs by identifying fraud. Accurate information provides scientists with data they need to conduct research. We cannot improve the quality of health care without information about which treatments work, and which do not.

Individuals cannot be expected to share the most intimate details of their lives unless they have confidence that such information will not be used or
shaped inappropriately. Privacy violations reduce consumers’ trust in the health care system and institutions that serve them. Such a loss of faith can impede the quality of the health care they receive, and can harm the financial health of health care institutions.

Patients who are worried about the possible misuse of their information often take steps to protect their privacy. Recent studies show that a person who does not believe his privacy will be protected is much less likely to participate fully in the diagnosis and treatment of his medical condition. A national survey conducted in January 1999 found that one in five Americans believe their health information is being used inappropriately. See California HealthCare Foundation, “National Survey: Confidentiality of Medical Records” (January, 1999) (http://www.chcf.org). More troubling is the fact that one in six Americans reported that they have taken some sort of evasive action to avoid the inappropriate use of their information by providing inaccurate information to a health care provider, changing physicians, or avoiding care altogether. Similarly, in its comments on our proposed rule, the Association of American Physicians and Surgeons reported 78 percent of its members reported withholding information from a patient’s record due to privacy concerns and another 87 percent reported having had a patient request to withhold information from their records. For an example of this phenomenon in a particular demographic group, see Drs. Bearman, Ford, and Moody, “Foregone Health Care among Adolescents,” JAMA, vol. 282, no. 23 (1999); Cheng, T.L., et al., “Confidentiality in Health Care: A Survey of Knowledge, Perceptions, and Attitudes among High School Students,” JAMA, vol. 269, no. 11 (1993), at 1404–1407.

The absence of strong national standards for medical privacy has widespread consequences. Health care professionals who lose the trust of their patients cannot deliver high-quality care. In 1999, a coalition of organizations representing various stakeholders including health plans, physicians, nurses, employers, disability and mental health advocates, accreditation organizations as well as experts in public health, medical ethics, information systems, and health policy adopted a set of “best principles” for health care privacy that are consistent with the law laid out here. (See the Health Privacy Working Group, “Best Principles for Health Privacy” (July, 1999) (Best Principles Study). The Best Principles Study states that—

To protect their privacy and avoid embarrassment, discrimination, some people withhold information from their health care providers, provide inaccurate information, doctor-hop to avoid a consolidated medical record, pay out-of-pocket for care that is covered by insurance, and—in some cases—avoid care altogether. Best Principles Study, at 9. In their comments on our proposed rule, numerous organizations representing health plans, health providers, employers, and others acknowledged the value of a set of national privacy standards to the efficient operation of their practices and businesses.

Breaches of Health Privacy Harm More Than Our Health Status

A breach of a person’s health privacy can have significant implications well beyond the physical health of that person, including the loss of a job, alienation of family and friends, the loss of health insurance, and public humiliation. For example:

- A banker who also sat on a county health board gained access to patients’ records and identified several people with cancer and called in their mortgages. See the National Law Journal, May 30, 1994.
- A physician was diagnosed with AIDS at the hospital in which he practiced medicine. His surgical privileges were suspended. See Estate of Behringer v. Medical Center at Princeton, 249 N.J. Super. 597.
- A candidate for Congress nearly saw her campaign derailed when newspapers published the fact that she had sought psychiatric treatment after a suicide attempt. See New York Times, October 10, 1992, Section 1, page 25.

The answer to these concerns is not for consumers to withdraw from society and the health care system, but for society to establish a clear national legal framework for privacy. By spelling out what is and what is not an allowable use of a person’s identifiable health information, such standards can help to restore and preserve trust in the health care system and the individuals and institutions that comprise that system. As medical historian Paul Starr wrote: “Patients have a strong interest in preserving the privacy of their personal health information but they also have an interest in medical research and other efforts by health care organizations to improve the medical care they receive. As members of the wider community, they have an interest in public health measures that require the collection of personal data.” (P. Starr, “Health and the Right to Privacy.” American Journal of Law & Medicine, 25, nos. 2&3 (1999) 193–201). The task of society and its government is to create a balance in which the individual’s needs and rights are balanced against the needs and rights of society as a whole.

National standards for medical privacy must recognize the sometimes competing goals of improving individual and public health and advancing scientific knowledge, enforcing the laws of the land, and processing and paying claims for health care services. This need for balance has been recognized by many of the experts in this field. Cavoukian and Tapscott described it this way: “An individual’s right to privacy may conflict with the collective rights of the public * * *. We do not suggest that privacy is an absolute right that reigns supreme over all other rights. It does not. However, the case for privacy will depend on a number of factors that can influence the balance—the level of harm to the individual involved versus the needs of the public.”

The Federal Response

There have been numerous federal initiatives aimed at protecting the privacy of especially sensitive personal information over the past several years—and several decades. While the rules below are likely the largest single federal initiative to protect privacy, they are by no means alone in the field. Rather, the rules arrive in the context of recent legislative activity to grapple with advances in technology, in addition to an already established body of law granting federal protections for personal privacy.

In 1965, the House of Representatives created a Special Subcommittee on Invasion of Privacy. In 1973, this Department’s predecessor agency, the Department of Health, Education and Welfare issued The Code of Fair Information Practice Principles establishing an important baseline for
information privacy in the U.S. These principles formed the basis for the federal Privacy Act of 1974, which regulates the government’s use of personal information by limiting the disclosure of personally-identifiable information, allows consumers access to information about them, requires federal agencies to specify the purposes for collecting personal information, and provides civil and criminal penalties for misuse of information.

In the last several years, with the rapid expansion in electronic technology—and accompanying concerns about individual privacy—laws, regulations, and legislative proposals have been developed in areas ranging from financial privacy to genetic privacy to the safeguarding of children on-line. For example, the Children’s Online Privacy Protection Act was enacted in 1998, providing protection for children when interacting at websites. In February, 2000, President Clinton signed Executive Order 13145, banning the use of genetic information in federal hiring and promotion decisions. The landmark financial modernization bill, signed by the President in November, 1999, likewise contained financial privacy protections for consumers. There also has been recent legislative activity on establishing legal safeguards for the privacy of individuals’ Social Security numbers, and calls for regulation of on-line privacy in general.

These most recent laws, regulations, and legislative proposals come against the backdrop of decades of privacy-enhancing statutes passed at the federal level to enact safeguards in fields ranging from government data files to video rental records. In the 1970s, individual privacy was paramount in the passage of the Fair Credit Reporting Act (1970), the Privacy Act (1974), the Family Educational Rights and Privacy Act (1974), and the Right to Financial Privacy Act (1978). These key laws were followed in the next decade by another series of statutes, including the Privacy Protection Act (1980), the Electronic Communications Privacy Act (1986), the Video Privacy Protection Act (1988), and the Employee Polygraph Protection Act (1988). In the last ten years, Congress and the President have passed additional legal privacy protection through, among others, the Telephone Consumer Protection Act (1991), the Driver’s Privacy Protection Act (1994), the Telecommunications Act (1996), the Children’s Online Privacy Protection Act (1998), the Identity Theft and Assumption Deterrence Act (1998), and Title V of the Gramm-Leach-Bliley Act (1999) governing financial privacy.

In 1997, a Presidential advisory commission, the Advisory Commission on Consumer Protection and Quality in the Health Care Industry, recognized the need for patient privacy protection in its recommendations for a Consumer Bill of Rights and Responsibilities (November 1997). In 1997, Congress enacted the Balanced Budget Act (Public Law 105–34), which added language to the Social Security Act (18 U.S.C. 1852) to require Medicare+Choice organizations to establish safeguards for the privacy of individually identifiable patient information. Similarly, the Veterans Benefits section of the U.S. Code provides for confidentiality of medical records in cases involving drug abuse, alcoholism or alcohol abuse, HIV infection, or sickle cell anemia (38 U.S.C. 7332).

As described in more detail in the next section, Congress recognized the importance of protecting the privacy of health information by enacting the Health Insurance Portability and Accountability Act of 1996. The Act called on Congress to enact a medical privacy statute and asked the Secretary of Health and Human Services to provide Congress with recommendations for protecting the confidentiality of health care information. The Congress further recognized the importance of such standards by providing the Secretary with authority to promulgate regulations on health care privacy in the event that lawmakers were unable to act within the allotted three years.

Finally, it also is important for the U.S. to join the rest of the developed world in establishing basic medical privacy protections. In 1995, the European Union (EU) adopted a Data Privacy Directive requiring its 15 member states to adopt consistent privacy laws by October 1998. The EU urged all other nations to do the same or face the potential loss of access to information from EU countries.

Statutory Background

History of the Privacy Component of the Administrative Simplification Provisions

The Congress addressed the opportunities and challenges presented by the rapid evolution of health information systems in the Health Insurance Portability and Accountability Act of 1996 (HIPAA), Public Law 104–191, which was enacted on August 21, 1996. Sections 261 through 264 of HIPAA are known as the Administrative Simplification provisions. The major part of these Administrative Simplification provisions are found at section 262 of HIPAA, which enacted a new part C of title XI of the Social Security Act (hereinafter we refer to the Social Security Act as the “Act” and we refer to all other laws cited in this document by their names).

In section 262, Congress primarily sought to facilitate the efficiencies and cost savings for the health care industry that the increasing use of electronic technology affords. Thus, section 262 directs HHS to issue standards to facilitate the electronic exchange of information with respect to financial and administrative transactions carried out by health plans, health care clearinghouses, and health care providers who transmit information electronically in connection with such transactions.

At the same time, Congress recognized the challenges to the confidentiality of health information presented by the increasing complexity of the health care industry, and by advances in health information systems technology and communications. Section 262 thus also directs HHS to develop standards to protect the security, including the confidentiality and integrity, of health information.

Congress has long recognized the need for protection of health information privacy generally, as well as the privacy implications of electronic data interchange and the increased ease of transmitting and sharing individually identifiable health information.

Congress has been working on broad health privacy legislation for many years and, as evidenced by the self-imposed three year deadline included in the HIPAA, discussed below, believes it can and should enact such legislation. A significant portion of the first Administrative Simplification section debated on the floor of the Senate in 1994 (as part of the Health Security Act) consisted of privacy provisions. In the version of the HIPAA passed by the House of Representatives in 1996, the requirement for the issuance of privacy standards was located in the same section of the bill (section 1173) as the requirements for issuance of the other HIPAA Administrative Simplification standards. In conference, the requirement for privacy standards was moved to a separate section in the same part of HIPAA, section 264, so that Congress could link the Privacy standards to Congressional action.

Section 264(b) requires the Secretary of HHS to develop and submit to the Congress recommendations for:

The rights that an individual who is a subject of individually identifiable health information should have.
• The procedures that should be established for the exercise of such rights.
• The uses and disclosures of such information that should be authorized or required.

The Secretary’s Recommendations were submitted to the Congress on September 11, 1997. Section 264(c)(1) provides that:

If legislation governing standards with respect to the privacy of individually identifiable health information transmitted in connection with the transactions described in section 1173(a) of the Social Security Act (as added by section 262) is not enacted by [August 21, 1999], the Secretary of Health and Human Services shall promulgate final regulations containing such standards not later than [February 21, 2000]. Such regulations shall address at least the subjects described in subsection (b).

As the Congress did not enact legislation regarding the privacy of individually identifiable health information prior to August 21, 1999, HHS published proposed rules setting forth such standards on November 3, 1999. 64 FR 59918, and is now publishing the mandated final regulation.

These privacy standards have been, and continue to be, an integral part of the suite of Administrative Simplification standards intended to simplify and improve the efficiency of the administration of our health care system.

The Administrative Simplification Provisions, and Regulatory Actions to Date

Part C of title XI consists of sections 1171 through 1179 of the Act. These sections define various terms and impose several requirements on HHS, health plans, health care clearinghouses, and health care providers who conduct the identified transactions electronically.

The first section, section 1171 of the Act, establishes definitions for purposes of part C of title XI for the following terms: code set, health care clearinghouse, health care provider, health information, health plan, individually identifiable health information, standard, and standard setting organization.

Section 1172 of the Act makes the standard adopted under part C applicable to: (1) Health plans, (2) health care clearinghouses, and (3) health care providers who transmit health information in electronic form in connection with transactions referred to in section 1173(a)(1) of the Act (hereinafter referred to as the “covered entities”). Section 1172 also contains procedural requirements concerning the adoption of standards, including the role of standard setting organizations and required consultations, summarized in subsection F and section VI, below.

Section 1173 of the Act requires the Secretary to adopt standards for transactions, and data elements for such transactions, to enable health information to be exchanged electronically. Section 1173(a)(1) describes the transactions to be promulgated, which include the nine transactions listed in section 1173(a)(2) and other transactions determined appropriate by the Secretary. The remainder of section 1173 sets out requirements for the specific standards the Secretary is to adopt: Unique health identifiers, code sets, security standards, electronic signatures, and transfer of information among health plans. Of particular relevance to this proposed rule is section 1173(d), the security standard provision. The security standard authority applies to both the transmission and the maintenance of health information, and requires the entities described in section 1172(a) to maintain reasonable and appropriate safeguards to ensure the integrity and confidentiality of the information, protect against reasonably anticipated threats or hazards to the security or integrity of the information or unauthorized uses or disclosures of the information, and to ensure compliance with part C by the entity’s officers and employees.

In section 1174 of the Act, the Secretary is required to establish standards for all of the above transactions, except claims attachments, by February 21, 1998. The statutory deadline for the claims attachment standard is February 21, 1999.

As noted above, a proposed rule for most of the transactions was published on May 7, 1998, and the final Transactions Rule was promulgated on August 17, 2000. The delay was caused by the deliberate consensus building process, working with industry, and the large number of comments received (about 17,000). In addition, in a series of Notices of Proposed Rulemakings, HHS published other proposed standards, as described above. Each of these steps was taken in concert with the affected professions and industries, to ensure rapid adoption and compliance.

Generally, after a standard is established, it may not be changed during the first year after adoption except for changes that are necessary to permit compliance with the standard. Modifications to any of these standards may be made after the first year, but not more frequently than once every 12 months. The Secretary also must ensure that procedures exist for the routine maintenance, testing, enhancement, and expansion of code sets and that there are crosswalks from prior versions.

Section 1175 of the Act prohibits health plans from refusing to process, or from delaying processing of, a transaction that is presented in standard format. It also establishes a timetable for compliance: each person to whom a standard or implementation specification applies is required to comply with the standard within 24 months (or 36 months for small health plans) of its adoption. A health plan or other entity may, of course, comply voluntarily before the effective date. The section also provides that compliance with modifications to standards or implementation specifications must be accomplished by a date designated by the Secretary, which date may not be earlier than 180 days from the notice of change.

Section 1176 of the Act establishes civil monetary penalties for violation of the provisions in part C of title XI of the Act, subject to several limitations. Penalties may not be more than $100 per person per violation and not more than $25,000 per person for violations of a single standard for a calendar year. The procedural provisions of section 1128A of the Act apply to actions taken to obtain civil monetary penalties under this section.

Section 1177 establishes penalties for any person that knowingly uses a unique health identifier, or obtains or discloses individually identifiable health information in violation of the part. The penalties include: (1) A fine of not more than $50,000 and/or imprisonment of not more than 1 year; (2) if the offense is “under false pretenses,” a fine of not more than $100,000 and/or imprisonment of not more than 5 years; and (3) if the offense is with intent to sell, transfer, or use individually identifiable health information for commercial advantage, personal gain, or malicious harm, a fine of not more than $250,000 and/or imprisonment of not more than 10 years.

Under section 1178 of the Act, the requirements of part C, as well as any standards or implementation specifications adopted thereunder, preempt contrary state law. There are three exceptions to this general rule of preemption: State laws that the Secretary determines are necessary for certain purposes set forth in the statute; the laws that the Secretary determines address controlled substances; and state laws relating to the privacy of
individually identifiable health information that are contrary to and more stringent than the federal requirements. There also are certain areas of state law (generally relating to public health and oversight of health plans) that are explicitly carved out of the general rule of preemption and addressed separately.

Section 1179 of the Act makes the above provisions inapplicable to financial institutions (as defined by section 1101 of the Right to Financial Privacy Act of 1978) or anyone acting on behalf of a financial institution when “authorizing, processing, clearing, settling, billing, transferring, reconciling, or collecting payments for a financial institution.”

Finally, as explained above, section 264 requires the Secretary to issue standards with respect to the privacy of individually identifiable health information. Section 264 also contains a preemption provision that provides that contrary provisions of state laws that are more stringent than the federal standards, requirements, or implementation specifications will not be preempted.

**Our Approach to This Regulation**

**Balance**

A number of facts informed our approach to this regulation. Determining the best approach to protecting privacy depends on where we start, both with respect to existing legal expectations and also with respect to the expectations of individuals, health care providers, payers and other stakeholders. From the comments we received on the proposed rule, and from the extensive fact-finding in which we engaged, a confused picture developed. We learned that stakeholders in the system have very different ideas about the extent and nature of the privacy protections that exist today, and very different ideas about appropriate uses of health information. This leads us to seek to balance the views of the different stakeholders, weighing the varying interests on each particular issue with a view to creating balance in the regulation as a whole.

For example, we received hundreds of comments explaining the legitimacy of various uses and disclosure of health information. We agree that many uses and disclosures of health information are “legitimate,” but that is not the end of the inquiry. Neither privacy, nor the important social goals described by the commenters, are absolutes. In this regulation, we are asking health providers and institutions to add privacy into the balance, and we are asking individuals to add social goals into the balance.

The vast difference among regulated entities also informed our approach in significant ways. This regulation applies to solo practitioners, and multi-national health plans. It applies to pharmacies and information clearinghouses. These entities differ not only in the nature and scope of their businesses, but also in the degree of sophistication of their information systems and information needs. We therefore designed the core requirements of this regulation to be flexible and “scalable.” This is reflected throughout the rule, particularly in the implementation specifications for making the minimum necessary uses and disclosures, and in the administrative policies and procedures requirements.

We also are informed by the rapid evolution in industry organization and practice. Our goal is to enhance privacy protections in ways that do not impede this evolution. For example, we received many comments asking us to assign a status under this regulation based on a label or title. For example, many commenters asked whether “disease management” is a “health care operation,” or whether a “pharmacy benefits manager” is a covered entity. From the comments and our fact-finding, however, we learned that these terms do not have consistent meanings today; rather, they encompass diverse activities and information practices.

Further, the statutory definitions of key terms such as health care provider and health care clearinghouse describe functions, not specific types of persons or entities. To respect both the Congressional approach and industry evolution, we designed the rule to follow activities and functions, not titles and labels.

Similarly, many commenters asked whether a particular person would be a “business associate” under the rule, based on the nature of the person’s business. Whether a business associate arrangement must exist under the rule, however, depends on the relationship between the entities and the services being performed, not on the type of persons or companies involved.

Our approach is also significantly informed by the limited jurisdiction conferred by HIPAA. In large part, we have the authority to regulate those who create and disclose health information, but not many key stakeholders who receive that health information from a covered entity. Again, this led us to look to the balance between the burden on covered entities and need to protect privacy in determining our approach to such disclosures. In some instances, we approach this dilemma by requiring covered entities to obtain a representation or documentation of purpose from the person requesting information. While there would be advantages to legislation regulating such third persons directly, we cannot justify abandoning any effort to enhance privacy.

It also became clear from the comments and our fact-finding that we have expectations as a society that conflict with individuals’ views about the privacy of health information. We expect the health care industry to develop treatment protocols for the delivery of high quality health care. We expect insurers and the government to reduce fraud in the health care system. We expect to be protected from epidemics, and we expect medical research to produce miracles. We expect the police to apprehend suspects, and we expect to pay for our care by credit card. All of these activities involve disclosure of health information to someone other than our physician.

While most commenters support the concept of health privacy in general, many go on to describe activities that depend on the disclosure of health information and urge us to protect those information flows. Section III, in which we respond to the comments, describes our approach to balancing these conflicting expectations.

Finally, we note that many commenters were concerned that this regulation would lessen current privacy protections. It is important to understand this regulation as a new federal floor of privacy protections that does not disturb more protective rules or practices. Nor do we intend this regulation to describe a set of “best practices.” Rather, this regulation describes a set of basic consumer protections and a series of regulatory permissions for use and disclosure of health information. The protections are a mandatory floor, which other governments and any covered entity may exceed. The permissions are just that, permissive—the only disclosures of health information required under this rule are to the individual who is the subject of the information or to the Secretary for enforcement of this rule. We expect covered entities to rely on their professional ethics and use their own best judgements in deciding which of these permissions they will use.

**Combining Workability With New Protections**

This rule establishes national minimum standards to protect the privacy of individually identifiable health information in prescribed
settings. The standards address the many varied uses and disclosures of individually identifiable health information by health plans, certain health care providers and health care clearinghouses. The complexity of the standards reflects the complexity of the health care marketplace to which they apply and the variety of subjects that must be addressed. The rule applies not only to the core health care functions relating to treating patients and reimbursing health care providers, but also to activities that range from when individually identifiable health information should be available for research without authorization to whether a health care provider may release protected health information about a patient for law enforcement purposes. The number of discrete provisions, and the number of commenters requesting that the rule recognize particular activities, is evidence of the significant role that individually identifiable health information plays in many vital public and private concerns.

At the same time, the large number of comments from individuals and groups representing individuals demonstrate the deep public concern about the need to protect the privacy of individually identifiable health information. The discussion above is rich with evidence about the importance of protecting privacy and the potential adverse consequences to individuals and their health if such protections are not extended.

The need to balance these competing interests—the necessity of protecting privacy and the public interest in using identifiable health information for vital public and private purposes—in a way that is also workable for the varied stakeholders causes much of the complexity in the rule. Achieving workability without sacrificing protection means some level of complexity, because the rule must track current practices and current practices are complex. We believe that the complexity entered in reflecting those practices is better public policy than a perhaps simpler rule that disturbed important information flows.

Although the rule taken as a whole is complicated, we believe that the standards are much less complex as they apply to particular actors. What a health plan or covered health care provider must do to comply with the rule is clear, and the two-year delayed implementation provides a substantial period for trade and professional associations, working with their members, to assess the effects of the standards and develop policies and procedures to come into compliance with them. For individuals, the system may look substantially more complicated because, for the first time, we are ensuring that individuals will receive detailed information about how their individually identifiable health information may be used and disclosed. We also provide individuals with additional tools to exercise some control over those uses and disclosures. The additional complexity for individuals is the price of expanding their understanding and their rights.

The Department will work actively with members of the health care industry, representatives of individuals and others during the implementation of this rule. As stated elsewhere, our focus is to develop broader understanding of how the standards work and to facilitate compliance. We intend to provide guidance and check lists as appropriate, particularly to small businesses affected by the rule. We also will work with trade and professional associations to develop guidance and provide technical assistance so that they can help their members understand and comply with these new standards. If this effort is to succeed, the various public and private participants inside and outside of the health care system will need to work together to assure that the competing interests described above remain in balance and that an ethic that recognizes their importance is established.

**Enforcement**

The Secretary has decided to delegate her responsibility under this regulation to the Department's Office for Civil Rights (OCR). OCR will be responsible for enforcement of this regulation. Enforcement activities will include working with covered entities to ensure voluntary compliance through the provision of technical assistance and other means; responding to questions regarding the regulation and providing interpretations and guidance; responding to state requests for exception determinations; investigating complaints and conducting compliance reviews; and, where voluntary compliance cannot be achieved, seeking civil monetary penalties and making referrals for criminal prosecution.

**Consent**

**Current Law and Practice**

The issue that drew the most comments overall is the question of when individuals’ permission should be obtained prior to use or disclosure of their health information. We learned that individuals’ views and the legal view of “consent” for use and disclosure of health information are different and in many ways incompatible. Comments from individuals revealed a common belief that, today, people must be asked permission for each and every release of their health information. Many believe that they “own” the health records about them. However, current law and practice do not support this view.

Current privacy protection practices are determined in part by the standards and practices that the professional associations have adopted for their members. Professional codes of conduct for ethical behavior generally can be found as opinions and guidelines developed by organizations such as the American Medical Association, American Nurses’ Association, the American Hospital Association, the American Psychiatric Association, and the American Dental Association. These are generally issued though an organization’s governing body. The codes do not have the force of law, but providers often recognize them as binding rules.

Our review of professional codes of ethics revealed partial, but loose, support for individuals’ expectations of privacy. For example, the American Medical Association’s Code of Ethics recognizes both the right to privacy and the need to balance it against societal needs. It reads in part: “conflicts between a patient’s right to privacy and a third party’s need to know should be resolved in favor of the patient, except where that would result in serious health hazard or harm to the patient or others.” AMA Policy No 140.989. See also, Mass. Med. Society, Patient Privacy and Confidentiality (1996), at 14:

Patients enter treatment with the expectation that the information they share will be used exclusively for their clinical care. Protection of our patients’ confidences is an integral part of our ethical training.

These codes, however, do not apply to many who obtain information from providers. For example, the National Association of Insurance Commissioners model code, “Health Information Privacy Model Act” (1998), applies to insurers but has not been widely adopted. Codes of ethics are also often written in general terms that do not provide guidance to providers and plans confronted with specific questions about protecting health information.

State laws are a crucial means of protecting health information, and today state laws vary dramatically. Some states reflect the precedents of conduct, others provide general guidelines for privacy protection, and
others provide detailed requirements relating to the protection of information relating to specific diseases or to entire classes of information. Cf., D.C. Code Ann. § 2–3305.14(16) and Haw. Rev. Stat. 323C, et seq. In general, state statutes and case law addressing consent to use of health information do not support the public’s strong expectations regarding consent for use and disclosure of health information. Only about half of the states have a general law that prohibits disclosure of health information without patient authorization and some of these are limited to hospital medical records. Even when a state has a law limiting disclosure of health information, the law typically exempts many types of disclosure from the authorization requirement. Georgetown Study, Key Findings; Lisa Dahm, “50-State Survey on Patient Health Care Record Confidentiality,” American Health Lawyers Association (1999). One of the most common exemptions from a consent requirement is disclosure of health information for treatment and related purposes. See, e.g., Wis.Stat. § 164.82; Cal. Civ. Code 56:10; National Conference of Commissioners on Uniform State Laws, Uniform Health-Care Information Act, Minneapolis, MN, August 9, 1985. Some states include utilization review and similar activities in the exemption. See, e.g., Ariz. Rev. Stat. § 12–2294. Another common exemption from consent is disclosure of health information for purposes of obtaining payment. See, e.g., Fla. Stat. Ann. § 455.667; Tex. Rev. Civ. Stat. Art. 4495, § 5.08(b); 410 Ill. Comp. Stat. 50/3(d). Other common exemptions include disclosures for emergency care, and for disclosures to government authorities (such as a department of public health). See Gostin Study, at 1–2; 48–51. Some states also exempt disclosure to law enforcement officials (e.g., Massachusetts, Ch. 254 of the Acts of 2000), coroners (Wis. Stat. § 146.82), and for such purposes as business operations, oversight, research, and for directory information. Under these exceptions providers can disclose health information without any consent or authorization from the patient. When states require specific, written authorization for disclosure of health information, the authorizations are usually only required for certain types of disclosures or certain types of information, and one authorization can suffice for multiple disclosures over time.

The states that do not have laws prohibiting disclosure of health information impose no specific requirements for consent or authorization prior to release of health information. There may, however, be other controls on release of health information. For instance, most health care professional licensure laws include general prohibitions against “breaches of confidentiality.” In some states, patients can hold providers accountable for some unauthorized disclosures of health information about them under various tort theories, such as invasion of privacy and breach of a confidential relationship. While these controls may affect certain disclosure practices, they do not amount to a requirement that a provider obtain authorization for each and every disclosure of health information.

Further, patients are typically not given a choice; they must sign the “consent” in order to receive care. As the Georgetown Study points out, “In effect, the authorization may function more as a waiver of consent—the patient may not have an opportunity to object to any disclosures.” Georgetown Study, Key Findings.

In the many cases where neither state law nor professional ethical standards exist, the only privacy protection individuals have is limited to the policies and procedures that the health care entity adopts. Corporate privacy policies are often proprietary. While several professional associations attached their privacy principles to their comments, health care entities did not. One study we found indicates that these policies are not adequate to provide appropriate privacy protections and alleviate public concern. The Committee on Maintaining Privacy and Security in Health Care Applications of the National Information Infrastructure made multiple findings highlighting the need for heightened privacy and security, including:

Finding 5: The greatest concerns regarding the privacy of health information derive from widespread sharing of patient information throughout the health care industry and the inadequate federal and state regulatory framework for systematic protection of health information.


Consent Under This Rule

In the NPRM, we expressed concern about the coercive nature of consents currently obtained by providers and plans relating to the use and disclosure of health information. We also expressed concern about the lack of information available to the patient during the consent process. The fact that patients often were not even presented with a copy of the consent that they have signed. These and other concerns led us to propose that covered entities be permitted to use and disclose protected health information for treatment, payment and health care operations without the express consent of the subject individual.

In the final rule, we alter our proposed approach and require, in most instances, that health care providers who have a direct treatment relationship with their patients obtain the consent of their patients to use and disclose protected health information for treatment, payment and health care operations. While our concern about the coercive nature of these consents remains, many comments that we received from individuals, health care professionals, and organizations that represent them indicated that both patients and practitioners believe that patient consent is an important part of the current health care system and should be retained.

Providing and obtaining consent clearly has meaning for patients and practitioners. Patient advocates argued that the act of signing focuses the patient’s attention on the substance of the transaction and provides an opportunity for the patient to ask questions about or seek modifications in the provider’s practices. Many health care practitioners and their representatives argued that seeking a patient’s consent to disclose confidential information is an ethical requirement that strengthens the physician-patient relationship. Both practitioners and patients argued that the approach proposed in the NPRM actually reduced patient protections by eliminating the opportunity for patients to agree to how their confidential information would be used and disclosed.

While we believe that the provisions in the NPRM that provided for detailed notice to the patient and the right to request restrictions would have provided an opportunity for patients and providers to discuss and negotiate over information practices, it is clear from the comments that many practitioners and patients believe the approach proposed in the NPRM is not an acceptable replacement for the patient providing consent.

To encourage a more informed interaction between the patient and the provider during the consent process, the final rule requires that the consent form that is presented to the patient be accompanied by a notice that contains a detailed discussion of the provider’s health information practices. The consent form must reference the notice and also must inform the patient that he
or she has the right to ask the health care provider to request certain restrictions as to how the information of the patient will be used or disclosed. Our goal is to provide an opportunity for and to encourage more informed discussions between patients and providers about how protected health information will be used and disclosed within the health care system.

We considered and rejected other approaches to consent, including those that involved individuals providing a global consent to uses and disclosures when they sign up for insurance. While such approaches do require the patient to provide consent, it is not really an informed one or a voluntary one. It is also unclear how a consent obtained at the enrollment stage would be meaningfully communicated to the many providers who create the health information in the first instance. The ability to negotiate restrictions or otherwise have a meaningful discussion with the front-line provider would be independent of, and potentially in conflict with, the consent obtained at the enrollment stage. In addition, employers today are moving toward simplified enrollment forms, using check-off boxes and similar devices. The opportunity for any meaningful consideration or interaction at that point is slight. For these and other reasons, we decided that, to the extent a consent can accomplish the goal sought by individuals and providers, it must be focused on the direct interaction between an individual and provider.

The comments and fact-finding indicate that our approach will not significantly change the administrative aspect of consent as it exists today. Most direct treatment providers today obtain some type of consent for some uses and disclosures of health information. Our regulation will ensure that those consents cover the routine uses and disclosures of health information, and provide an opportunity for individuals to obtain further information and have further discussion, should they so desire.

Administrative Costs

Section 1172(b) of the Act provides that “[a]ny standard adopted under this part [part C of title XI of the Act] shall be consistent with the objective of reducing the administrative costs of providing and paying for health care.” The privacy and security standards are the platform on which the remaining standards rest; indeed, the design of part C of title XI makes clear that the various standards are intended to function together. Thus, the costs of privacy and security are properly attributable to the suite of administrative simplification regulations as a whole, and the cost savings realized should likewise be calculated on an aggregated basis, as is done below. Because the privacy standards are an integral and necessary part of the suite of Administrative Simplification standards, and because that suite of standards will result in substantial administrative cost savings, the privacy standards are “consistent with the objective of reducing the administrative costs of providing and paying for health care.” As more fully discussed in the Regulatory Impact and Regulatory Flexibility analyses below, we recognize that these privacy standards will entail substantial initial and ongoing administrative costs for entities subject to the rules. It is also the case that the privacy standards, like the security standards authorized by section 1173(d) of the Act, are necessitated by the technological advances in information exchange that the remaining Administrative Simplification standards facilitate for the health care industry. The same technological advances that make possible enormous administrative cost savings for the industry as a whole have also made it possible to breach the security and privacy of health information on a scale that was previously inconceivable. The Congress recognized that adequate protection of the security and privacy of health information is a sine qua non of the increased efficiency of information exchange brought about by the electronic revolution by enacting the security and privacy provisions of the law. Thus, as a matter of policy as well as law, the administrative standards should be viewed as a whole in determining whether they are “consistent with” the objective of reducing administrative costs.

Consultations

The Congress required the Secretary to consult with specified groups in developing the standards under sections 262 and 264. Section 264(d) of HIPAA specifically requires the Secretary to consult with the National Committee on Vital and Health Statistics (NCVHS) and the Attorney General in carrying out her responsibilities under the section. Section 1172(b)(3) of the Act, which was enacted by section 262, requires that, in developing a standard under section 1172 for which no standard setting organization has already developed a standard, the Secretary must, before adopting the standard, consult with the National Uniform Claim Committee (NUCC), the National Uniform Claim Committee, the Workgroup for Electronic Data Interchange (WEDI), and the American Dental Association (ADA). Section 1172(f) also requires the Secretary to rely on the recommendations of the NCVHS and consult with other appropriate federal and state agencies and private organizations.

We engaged in the required consultations including the Attorney General, NUBC, NUCC, WEDI and the ADA. We consulted with the NCVHS in developing the Recommendations, upon which this proposed rule is based. We continued to consult with this committee by requesting the committee to review the proposed rule and provide comments prior to its publication, and by reviewing transcripts of its public meeting on privacy and related topics. We consulted with representatives of the National Congress of American Indians, the National Indian Health Board, and the self governance tribes. We also met with representatives of the National Governors’ Association, the National Conference of State Legislatures, the National Association of Public Health Statistics and Information Systems, and a number of other state organizations to discuss the framework for the proposed rule, issues of special interests to the states, and the process for providing comments on the proposed rule.

Many of these groups submitted comments to the proposed rule, and those were taken into account in developing the final regulation.

In addition to the required consultations, we met with numerous individuals, entities, and agencies regarding the regulation, with the goal of making these standards as compatible as possible with current business practices, while still enhancing privacy protection. During the open comment period, we met with dozens of groups.

Relevant federal agencies participated in the interagency working groups that developed the NPRM and the final regulation, with additional representatives from all operating divisions and many staff offices of HHS. The following federal agencies and offices were represented on the interagency working groups: the Department of Justice, the Department of Commerce, the Social Security Administration, the Department of Defense, the Department of Veterans Affairs, the Department of Labor, the Office of Personnel Management, and the Office of Management and Budget.
II. Section-by-Section Description of Rule Provisions

Part 160—Subpart A—General Provisions

Part 160 applies to all the administrative simplification regulations. We include the entire regulation text in this rule, not just those provisions relevant to this Privacy regulation. For example, the term “trading partner” is defined here, for use in the Health Insurance Reform: Standards for Electronic Transactions regulation, published at 65 FR 50312, August 17, 2000 (the “Transactions Rule”). It does not appear in the remainder of this Privacy rule.

Sections 160.101 and 160.104 of Subpart A of part 160 were promulgated in the Transactions Rule, and we do not change them here. We do, however, make changes and additions to § 160.103, the definitions section of Subpart A. The definitions that were promulgated in the Transactions Rule and that remain unchanged here are: Act, ANSI, covered entity, compliance date, group health plan, HCFA, HHS, health care provider, health information, health insurance issuer, health maintenance organization, modify or modification, Secretary, small health plan, standard setting organization, and trading partner agreement. Of these terms, we discuss further in this preamble only covered entity and health care provider.

Section 160.102—Applicability

The proposed rule stated that the subchapter (Parts 160, 162, and 164) applies to the entities set out at section 1172(a) of the Act: Health plans, health care clearinghouses, and health care providers who transmit any health information in electronic form in connection with a transaction covered by the subchapter. The final rule adds a provision (§ 160.102(b)) clarifying that to the extent required under section 201(a)(5) of HIPAA, nothing in the subchapter is to be construed to diminish the authority of any Inspector General. This was done in response to comment, to clarify that the administrative simplification rules, including the rules below, do not conflict with the cited provision of HIPAA.

Section 160.103—Definitions

Business Associate

We proposed to define the term “business partner” to mean, with respect to a covered entity, a person to whom the covered entity discloses protected health information so that the person can carry out, assist with the performance of, or perform on behalf of, a function or activity for the covered entity. “Business partner” would have included contractors or other persons who receive protected health information from the covered entity (or from another business partner of the covered entity) for the purposes described in the previous sentence, including lawyers, auditors, consultants, third-party administrators, health care clearinghouses, data processing firms, billing firms, and other covered entities. “Business partner” would have excluded persons who are within the covered entity’s workforce, as defined in this section.

This rule reflects the change in the name from “business partner” to “business associate,” included in the Transactions Rule.

In the final rule, we change the definition of “business associate” to clarify the circumstances in which a person is acting as a business associate of a covered entity. The changes clarify that the business association occurs when the right to use or disclose the protected health information belongs to the covered entity, and another person is using or disclosing the protected health information (or creating, obtaining and using the protected health information) to perform a function or activity on behalf of the covered entity. We also clarify that providing specified services to a covered entity creates a business associate relationship if the provision of the service involves the disclosure of protected health information to an act service provider. In the proposed rule, we had included a list of persons that were considered to be business partners of the covered entity. However, it is not always clear whether the provision of certain services to a covered entity is “for” the covered entity or whether the service provider is acting “on behalf of” the covered entity. For example, a person providing management consulting services may need protected health information to perform those services, but may not be acting “on behalf of” the covered entity. This we believe led to some general confusion among the commenters as to whether certain arrangements fell within the definition of a business partner under the proposed rule. The construction of the final rule clarifies that the provision of the specified services gives rise to a business associate relationship if the performance of the service involves disclosure of protected health information by the covered entity to the business associate. The specified services are legal, actuarial, accounting, consulting, management, administrative accreditation, data aggregation, and financial services. The list is intended to include the types of services commonly provided to covered entities where the disclosure of protected health information is routine to the performance of the service, but when the person providing the service may not always be acting “on behalf of” the covered entity.

In the final rule, we reorganize the list of examples of the functions or activities that may be conducted by business associates. We place a part of the proposed list in the portion of the definition that addresses when a person is providing functions or activities for or on behalf of a covered entity. We place other parts of the list in the portion of the definition that specifies the services that give rise to a business associate relationship, as discussed above. We also have expanded the examples to provide additional guidance and in response to questions from commenters.

We have added data aggregation to the list of services that give rise to a business associate relationship. Data aggregation, as discussed below, is where a business associate in its capacity as the business associate of one covered entity combines the protected health information of such covered entity with protected health information received by the business associate in its capacity as a business associate of another covered entity in order to permit the creation of data for analyses that relate to the health care operations of the respective covered entities. Adding this service to the business associate definition clarifies the ability of covered entities to contract with business associates to undertake quality assurance and comparative analyses that involve the protected health information of more than one contracting covered entity. For example, a state hospital association could act as a business associate of its member hospitals and could combine data provided to it to assist the hospitals in evaluating their relative performance in areas such as quality, efficiency and other patient care issues. As discussed below, however, the business associate contracts of each of the hospitals would have to permit the activity, and the protected health information of one hospital could not be disclosed to another hospital unless the disclosure is otherwise permitted by the rule.

The definition also states that a business associate may be a covered entity, and that business associate excludes a person who is part of the covered entity’s workforce.

We also clarify in the final rule that a business association arises with
respect to a covered entity when a person performs functions or activities on behalf of, or provides the specified services to or for, an organized health care health care arrangement in which the covered entity participates. This change recognizes that where covered entities participate in certain joint arrangements for the financing or delivery of health care, they often contract with persons to perform functions or to provide services for the joint arrangement. This change is consistent with changes made in the final rule to the definition of health care operations, which permits covered entities to use or disclose protected health information not only for their own health care operations, but also for the operations of an organized health care arrangement in which the covered entity participates. By making these changes, we avoid the confusion that could arise in trying to determine whether a function or activity is being provided on behalf of (or if a specified service is being provided to or for) a covered entity or on behalf of or for a joint enterprise involving the covered entity. The change clarifies that in either instance the person performing the function or activity (or providing the specified service) is a business associate.

We also add language to the final rule that clarifies that the mere fact that two covered entities participate in an organized health care arrangement does not make either of the covered entities a business associate of the other covered entity. The fact that the entities participate in joint health care operations or other joint activities, or pursue common goals through a joint activity, does not mean that one party is performing a function or activity on behalf of the other party (or is providing a specified services to or for the other party).

In general under this provision, actions relating to the protected health information of an individual undertaken by a business associate are considered, for the purposes of this rule, to be actions of the covered entity, although the covered entity is subject to sanctions under this rule only if it has knowledge of the wrongful activity and fails to take the required actions to address the wrongdoing. For example, if a business associate maintains the medical records or manages the claims system of a covered entity, the covered entity is considered to have protected health information and the covered entity must ensure that individuals who are the subject of the information can have access to it pursuant to § 164.524.

The business associate relationship does not describe all relationships between covered entities and other persons or organizations. While we permit uses or disclosures of protected health information for a variety of purposes, business associate contracts or other arrangements are only required for those cases in which the covered entity is disclosing information to someone or some organization that will use the information on behalf of the covered entity, when the other person will be creating or obtaining protected health information on behalf of the covered entity, or when the business associate is providing the specified services to the covered entity and the provision of those services involves the disclosure of protected health information by the covered entity to the business associate. For example, when a health care provider discloses protected health information to health plans for payment purposes, no business associate relationship is established. While the covered provider may have an agreement to accept discounted fees as reimbursement for services provided to health plan members, neither entity is acting on behalf of or providing a service to the other.

Similarly, where a physician or other provider has staff privileges at an institution, neither party to the relationship is a business associate based solely on the staff privileges because neither party is providing functions or activities on behalf of the other. However, if a party provides services to or for the other, such as where a hospital provides billing services for physicians with staff privileges, a business associate relationship may arise with respect to those services. Likewise, where a group health plan purchases insurance or coverage from a health insurance issuer or HMO, the provision of insurance by the health insurance issuer or HMO to the group health plan does not make the issuer a business associate. In such case, the activities of the health insurance issuer or HMO are on their own behalf and not on the behalf of the group health plan. We note that where a group health plan contracts with a health insurance issuer or HMO to perform functions or activities or to provide services that are in addition to or not directly related to the provision of insurance, the health insurance issuer or HMO may be a business associate with respect to those additional functions, activities or services. We also note that covered entities are permitted to disclose protected health information to oversight agencies that act to provide oversight of federal programs and the health care system. These oversight agencies are not performing services for or on behalf of the covered entities and so are not business associates of the covered entities. Therefore HCFA, the federal agency that administers Medicare, is not required to enter into a business associate contract in order to disclose protected health information to the Department’s Office of Inspector General.

We do not require a covered entity to enter into a business associate contract with a person or organization that acts merely as a conduit for protected health information (e.g., the US Postal Service, certain private couriers and their electronic equivalents). A conduit transports information but does not access it other than on a random or infrequent basis as may be necessary for the performance of the transportation service, or as required by law. Since no disclosure is intended by the covered entity and the probability of exposure of any particular protected health information to a conduit is very small, we do not consider a conduit to be a business associate of the covered entity.

We do not consider a financial institution to be acting on behalf of a covered entity, and therefore no business associate contract is required, when it processes consumer-conducted financial transactions by debit, credit or other payment card, clears checks, initiates or processes electronic funds transfers, or conducts any other activity that directly facilitates or effects the transfer of funds for compensation for health care. A typical consumer-conducted payment transaction is when a consumer pays for health care or health insurance premiums using a check or credit card. In these cases the identity of the consumer is always included and some health information (e.g., diagnosis or procedure) may be implied through the name of the health care provider or health plan being paid. Covered entities that initiate such payment activities must meet the minimum necessary disclosure requirements described in the preamble to § 164.514.

Covered Entity

We provided this definition in the NPRM for convenience of reference and proposed it to mean the entities to which part C of title XI of the Act applies. These are the entities described in section 1172(a)(1): Health Plans, health care clearinghouses, and health care providers who transmit any health information in electronic form in connection with a transaction referred
to in section 1173(a)(1) of the Act (a "standard transaction").

We note that health care providers who do not submit HIPAA transactions in standard form become covered by this rule when other entities, such as a billing service or a hospital, transmit standard electronic transactions on their behalf. A provider could not circumvent these requirements by assigning the task to its business associate since the business associate would be considered to be acting on behalf of the provider. See the definition of "business associate."

Where a public agency is required or authorized by law to administer a health plan jointly with another entity, we consider each agency to be a covered entity with respect to the health plan functions it performs. Unlike private sector health plans, public plans are often required by or expressly authorized by law to jointly administer health programs that meet the definition of "health plan" under this regulation. In some instances the public entity is required or authorized to administer the program with another public agency. In other instances, the public entity is required or authorized to administer the program with a private entity. In either circumstance, we note that joint administration does not meet the definition of "business associate" in §164.501. Examples of joint administration include state and federal administration of the Medicaid and SCHIP program, or joint administration of a Medicare+Choice plan by the Health Care Financing Administration and the issuer offering the plan.

Health Care

We proposed to define "health care" to mean the provision of care, services, or supplies to a patient and to include any: (1) Preventive, diagnostic, therapeutic, rehabilitative, maintenance, or palliative care, counseling, service, assessment, or procedure with respect to the physical or mental condition, or functional status, of an individual or that affects the structure or function of the body; and (2) Sale or dispensing of a drug, device, equipment, or other item in accordance with a prescription.

We delete the term "providing" from the definition to delineate more clearly the relationship between "treatment," as the term is defined in §164.501, and "health care." Other key revisions include adding the term "assessment" in subparagraph (1) and deleting proposed subparagraph (3) from the rule. Therefore the procurement or banking of organs, blood (including autologous blood), sperm, eyes or any other tissue or human product is not considered to be health care under this rule and the organizations that perform such activities would not be considered health care providers when conducting these functions. As described in §164.512(b), covered entities are permitted to disclose protected health information without individual authorization, consent, or agreement (see below for explanation of authorizations, consents, and agreements) as necessary to facilitate cadaveric donation.

Health Care Clearinghouse

In the NPRM, we defined "health care clearinghouse" as a public or private entity that processes or facilitates the processing of nonstandard data elements of health information into standard data elements. The entity receives health care transactions from health care providers or other entities, translates the data from a given format into one acceptable to the intended payor or payors, and forwards the processed transaction to appropriate payors and clearinghouses. Billing services, repricing companies, community health management information systems, and "value-added" networks and switches would have been considered to be health care clearinghouses for purposes of this part, if they perform the functions of health care clearinghouses as described in the preceding sentences.

In the final regulation, we modify the definition of health care clearinghouse to reflect changes in the definition published in the Transactions Rule. The definition in the final rule is:

Health care clearinghouse means a public or private entity, including billing services, repricing companies, community health management information systems or community health information systems, and "value-added" networks and switches, that does either of the following functions:

(1) Processes or facilitates the processing of health information received from another entity in a nonstandard format or containing nonstandard data content into standard data elements or a standard transaction.

(2) Receives a standard transaction from another entity and processes or facilitates the processing of health information into nonstandard format or nonstandard data content for the receiving entity.

We note here that the term health care clearinghouse may have other meanings and connotations in other contexts, but the regulation defines it specifically, and an entity is considered a health care clearinghouse only if it meets the criteria in this definition. Telecommunications entities that provide connectivity or mechanisms to convey information, such as telephone companies and Internet Service Providers, are not health care clearinghouses as defined in the rule unless they actually carry out the functions outlined in our definition. Value added networks and switches are not health care clearinghouses unless they carry out the functions outlined in the definition. The examples of entities in our proposed definition we continue to consider to be health care clearinghouses, as well as any other entities that meet that definition, to the extent that they perform the functions in the definition.

In order to fall within this definition of clearinghouse, the covered entity must perform the clearinghouse function on health information received from some other entity. A department or component of a health plan or health care provider that transforms nonstandard information into standard data elements or standard transactions (or vice versa) is not a clearinghouse for purposes of this rule, unless it also performs these functions for another entity. As described in more detail in §164.504(d), we allow affiliates to perform clearinghouse functions for each other without triggering the definition of "clearinghouse" if the conditions in §164.504(d) are met.

Health Care Provider

We proposed to define health care provider to mean a provider of services as defined in section 1861(s) of the Act, a provider of medical or health services as defined in section 1861(s) of the Act, and any other person or organization who furnishes, bills, or is paid for health care services or supplies in the normal course of business.
In the final rule, we delete the term "services and supplies," in order to eliminate redundancy within the definition. The definition also reflects the addition of the applicable U.S.C. citations (42 U.S.C. 1395x(u) and 42 U.S.C. 1395x(s), respectively) for the referenced provisions of the Act that were promulgated in the Transactions Rule.

To assist the reader, we also provide here excerpts from the relevant sections of the Act. (Refer to the U.S.C. sections cited above for complete definitions in sections 1861(u) and 1861(s).) Section 1861(u) of the Act defines a "provider of services," to include, for example, a hospital, critical access hospital, skilled nursing facility, comprehensive outpatient rehabilitation facility, home health agency, hospice program, or, for purposes of section 1814(g) (42 U.S.C. 1395f(g)) and section 1835(e) (42 U.S.C. 1395n(e), a fund."

Section 1861(s) of the Act defines the term "medical and other health services," and includes a list of covered items or services, as illustrated by the following excerpt:

The term "medical and other health services" means any of the following items or services:

(1) Physicians' services;
(2) Services and supplies furnished as an incident to a physician's professional service, or kinds which are commonly furnished in physicians' offices and are commonly either rendered without charge or included in the physicians' bills;
(3) Durable medical equipment;
(4) Surgical dressings and splints, casts, and other devices used for reduction of fractures and dislocations;
(5) X-ray, radium, and radioactive isotope therapy, including materials and services of technicians;
(6) Surgical dressings, and splints, casts, and other devices used for reduction of fractures and dislocations;
(7) Ambulance service where the use of other methods of transportation is contraindicated by the individual's condition;
(8) Prosthetic devices (other than dental) which replace all or part of an internal body organ (including colostomy bags and supplies directly related to colostomy care), including items and services paid for as part of an anti-cancer chemotherapy regimen;
(9) Leg, arm, back, and neck braces, and artificial legs, arms, and eyes, including replacements if required;
(10) A pneumococcal vaccine and its administration;
(11) A hepatitis B vaccine and its administration;
(12) Extra-depth shoes with inserts or custom molded shoes with inserts for an individual with diabetes;
(13) Screening mammography;
(14) Screening pap smear and screening pelvic exam; and
(15) Bone mass measurement.

Health Plan

We proposed to define "health plan" essentially as section 1171(S) of the Act defines it. Section 1171 of the Act refers to several definitions in section 2791 of the Public Health Service Act, 42 U.S.C. 300gg-91, as added by Public Law 104-191.

As defined in section 1171(S), a "health plan" is an individual plan or group health plan that provides, or pays the cost of, medical care. We proposed that this definition include, but not be limited to the 15 types of plans (e.g., group health plan, health insurance issuer, health maintenance organization) listed in the statute, as well as any combination of them. Such term would have included, when applied to public benefit programs, the component of the government agency that administers the program. Church plans and government plans would have been included to the extent that they fall into one or more of the listed categories.

In the proposed rule, "health plan" included the following, singly or in combination:

(1) A group health plan, defined as an employee welfare benefit plan (as currently defined in section 3(1) of the Employee Retirement Income and Security Act of 1974, 29 U.S.C. 1002(1)), including insured and self-insured plans, to the extent that the plan provides medical care (as defined in section 2791(a)(2) of the Public Health Service Act, 42 U.S.C. 300gg-91(a)(2)), including items and services paid for as medical care, to employees or their dependents directly or through insurance or otherwise, that:

(i) Has 50 or more participants; or
(ii) Is administered by an entity other than the employer that established and maintains the plan.

(2) A health insurance issuer, defined as an insurance company, insurance service, or insurance organization that is licensed to engage in the business of insurance in a state and is subject to state or other law that regulates insurance.

(3) A health maintenance organization, defined as a federally qualified health maintenance organization, an organization recognized as a health maintenance organization under state law, or a similar organization regulated for solvency under state law in the same manner and to the same extent as such a health maintenance organization.

(4) Part A or Part B of the Medicare program under title XVIII of the Act.

(5) The Medicaid program under title XIX of the Act.
(6) A Medicare supplemental policy (as defined in section 1882(g)(1) of the Act, 42 U.S.C. 1395ss).
(7) A long-term care policy, including a nursing home fixed-indemnity policy.
(8) An employee welfare benefit plan or any other arrangement that is established or maintained for the purpose of offering or providing health benefits to the employees of two or more employers.
(9) The health care program for active military personnel under title 10 of the United States Code.
(11) The Civilian Health and Medical Program of the Uniformed Services (CHAMPUS), as defined in 10 U.S.C. 1072(4).
(12) The Indian Health Service program under the Indian Health Care Improvement Act (25 U.S.C. 1601, et seq.).
(14) An approved state child health plan for child health assistance that meets the requirements of section 2103 of the Act.
(15) A Medicare Plus Choice organization as defined in 42 CFR 422.2, with a contract under 42 CFR part 422, subpart K.

In addition to the 15 specific categories, we proposed that the list include any other individual plan or group health plan, or combination thereof, that provides or pays for the cost of medical care. The Secretary would determine which plans that meet these criteria would be considered health plans for the purposes of this rule.

Consistent with the other titles of HIPAA, our proposed definition did not include certain types of insurance entities, such as workers’ compensation and automobile insurance carriers, other property and casualty insurers, and certain forms of limited benefit coverage, even when such arrangements provide coverage for health care services.

In the final rule, we add two provisions to clarify the types of policies or programs that we do not consider to be a health plan. First, the rule excepts any policy, plan or program to the extent that it provides, or pays for the cost of, excepted benefits, as defined in section 2791(c)(1) of the PHS Act, 42 U.S.C. 300gg–91(c)(1). We note that, while coverage for on-site medical clinics is excluded from definition of “health plan,” such clinics may meet the definition of “health care provider” and persons who work in the clinic may also meet the definition of health care provider.” Second, many commenters were confused by the statutory inclusion as a health plan of any “other individual or group plan that provides or pays the cost of medical care;” they questioned how the provision applied to many government programs. We therefore clarify that while many government programs (other than the programs specified in the statute) provide or pay the cost of medical care, we do not consider them to be individual or group plans and therefore, do not consider them to be health plans. Government funded programs that do not have as their principal purpose the provision of, or payment for, the cost of health care but which do incidentally provide such services are not health plans (for example, programs such as the Special Supplemental Nutrition Program for Women, Infants and Children (WIC) and the Food Stamp Program, which provide or pay for nutritional services, are not considered to be health plans). Government funded programs that have as their principal purpose the provision of health care, either directly or by grant, are also not considered to be health plans. Examples include the Ryan White Comprehensive AIDS Resources Emergency Act, government funded health centers and immunization programs. We note that some of these may meet the rule’s definition of health care provider.

We note that in certain instances eligibility for or enrollment in a health plan that is a government program providing public benefits, such as Medicaid or SCHIP, is determined by an agency other than the agency that administers the program, or individually identifiable health information used to determine enrollment or eligibility in such a health plan is collected by an agency other than the agency that administers the health plan. In these cases, we do not consider an agency that is not otherwise a covered entity, such as a local welfare agency, to be a covered entity because it determines eligibility or enrollment or collects enrollment information as authorized by law. We also do not consider the agency to be a business associate when conducting these functions, as we describe further in the business associate discussion above.

The definition in the final rule also reflects the following changes promulgated in the Transactions Rule:
(1) Exclusion of nursing home fixed-indemnity policies
(2) Addition of the word “issuer” to Medicare supplemental policy, and long-term care policy;
(3) Addition or revision of the relevant statutory cites where appropriate;
(4) Deletion of the term “or assisted” when referring to government programs;
(5) Replacement of the word “organization” with “program” when referring to Medicare + Choice;
(6) Deletion of the term “health” when referring to a group plan in subparagraph (xvi);
(7) Extraction of the definitions of “group health plan,” “health insurance issuer,” and “health maintenance organization” into Part 160 as distinct definitions;
(8) In the definition of “group health plan,” deletion of the term “currently” from the reference to the statutory cite of ERISA, addition of the relevant statutory cite for the term “participant,” and addition of the term “reimbursement;”
(9) In the definition of “health insurance issuer,” addition of the relevant statutory cite, deletion of the term “or other law” after “state law,” addition of health maintenance organizations for consistency with the statute, and clarification that the term does not include a group health plan; and
(10) In the definition of “health maintenance organization,” addition of the relevant statutory cite.

Finally, we add to this definition a high risk pool that is a mechanism established under state law to provide health insurance coverage or comparable coverage to eligible individuals. High risk pools are designed mainly to provide health insurance coverage for individuals who, due to health status or pre-existing conditions, cannot obtain insurance through the individual market or who can do so only at very high premiums. Some states use their high risk pool as an alternative mechanism under section 2744 of HIPAA. We do not reference the definition of “qualified high risk pool” in HIPAA because that definition includes the requirements for a state to use its risk pool as its alternative mechanism under HIPAA. Some states may have high risk pools, but do not use them as their alternative mechanism and therefore may not meet the definition in HIPAA. We want to make clear that state high risk pools are covered entities under this rule whether or not they meet the definition of a qualified high risk pool under section 2744. High risk pools, as described in this rule, do not include any program established under state law solely to provide excepted benefits. For example, a state program established to provide workers’ compensation coverage is not
considered to be a high risk pool under the rule.

Implementation Specification

This definition was adopted in the Transactions Rule and is minimally revised here. We add the words “requirements or” before the word “instructions.” The word “instructions” is appropriate in the context of the implementation specifications adopted in the Transactions Rule, which are generally a series of instructions as to how to use particular electronic forms. However, that word is not apropos in the context of the rules below. In the rules below, the implementation specifications are specific requirements for how to comply with a given standard. The change to this definition thus ties in to this regulatory framework.

Standard

This definition was adopted in the Transactions Rule and we have modified it to make it clearer. We also add language reflecting section 264 of the statute, to clarify that the standards adopted by this rule meet this definition.

State

We modify the definition of state as adopted in the Transactions Rule to clarify that this term refers to any of the several states.

Transaction

We change the term “exchange” to the term “transmission” in the definition of Transaction to clarify that these transactions may be one-way communications.

Workforce

We proposed in the NPRM to define workforce to mean employees, volunteers, trainees, and other persons under the direct control of a covered entity, including persons providing labor on an unpaid basis.

The definition in the final rule reflects one revision established in the Transactions Rule, which replaces the term “including persons providing labor on an unpaid basis” with the term “whether or not they are paid by the covered entity.” In addition, we clarify that if the assigned work station of persons under contract is on the covered entity’s premises and such persons perform a substantial proportion of their activities at that location, the covered entity may choose to treat them either as business associates or as part of the workforce, as explained in the discussion of the definition of business associate. If there is no business associate contract, we assume the person is a member of the covered entity’s workforce. We note that independent contractors may or may not be workforce members. However, for compliance purposes we will assume that such personnel are members of the workforce if no business associate contract exists.

Part 160—Subpart B—Preemption of State Laws

Statutory Background

Section 1178 of the Act establishes a “general rule” that state law provisions that are contrary to the provisions or requirements of part C of title XI or the standards or implementation specifications adopted or established thereunder are preempted by the federal requirements. The statute provides three exceptions to this general rule: (1) In section 1178(a)(2)(A)(i), for state laws that the Secretary determines are necessary to prevent fraud and abuse, ensure appropriate state regulation of insurance and health plans, for state reporting on health care delivery, and other purposes; (2) in section 1178(a)(2)(A)(ii), for state laws that address controlled substances; and (3) in section 1178(a)(2)(B), for state laws relating to the privacy of individually identifiable health information that as provided for by the related provision of section 264(c)(2) of HIPAA, are contrary to and more stringent than the federal requirements. Section 1178 also carves out, in sections 1178(b) and 1178(c), certain areas of state authority that are not limited or invalidated by the provisions of part C of title XI: these areas relate to public health and state regulation of health plans.

The NPRM proposed a new Subpart B of the proposed part 160. The new Subpart B, which would apply to all standards, implementation specifications, and requirements adopted under HIPAA, would consist of four sections. Proposed § 160.201 provided that the provisions of Subpart B applied to exception determinations and advisory opinions issued by the Secretary under section 1178. Proposed § 160.202 set out proposed definitions for four terms: (1) “Contrary,” (2) “more stringent,” (3) “relates to the privacy of individually identifiable health information,” and (4) “state law.” The definition of “contrary” was drawn from case law concerning preemption. A seven-part set of specific criteria, drawn from fair information principles, was proposed for the definition of “more stringent.” The definition of “relates to the privacy of individually identifiable health information” was also based on case law. The definition of “state law” was drawn from the statutory definition of this term elsewhere in HIPAA. We note that state action having the force and effect of law may include common law. We eliminate the term “decision” from the proposed rule because it is redundant.

Proposed § 160.203 proposed a general rule reflecting the statutory general rule and exceptions that generally mirrored the statutory language of the exceptions. The one substantive addition to the statutory exception language was with respect to the statutory exception, “for other purposes.” The following language was added: “for other purposes related to improving the Medicare program, the Medicaid program, or the efficiency and effectiveness of the health care system.”

Proposed § 160.204 proposed two processes, one for the making of exception determinations, relating to determinations under section 1178(a)(2)(A) of the Act, the other for the rendering of advisory opinions, with respect to section 1178(a)(2)(B) of the Act. The processes proposed were similar in the following respects: (1) Only the state could request an exception determination or advisory opinion, as applicable; (2) both required the request to contain the same information, except that a request for an exception determination also had to set out the length of time the requested exception would be in effect, if less than three years; (3) both sets of requirements provided that requests had to be submitted to the Secretary as required by the Secretary, and until the Secretary’s determination was made, the federal standard, requirement or implementation specification remained in effect; (4) both sets of requirements provided that the Secretary’s decision would be effective intrastate only; (5) both sets of requirements provided that any change to either the federal or state basis for the Secretary’s decision would require a new request, and the federal standard, implementation specification, or requirement would remain in effect until the Secretary acted favorably on the new request; (6) both sets of requirements provided that the Secretary could seek changes to the federal rules or urge states or other organizations to seek changes; and (7) both sets of requirements provided for annual publication of Secretarial decisions. In addition, the process for exception determinations provided for a maximum effective period of three years for such determinations.

The following changes have been made to subpart B in the final rules. First, § 160.201 now expressly...
Implied Repeal Analysis

When faced with the need to determine how different federal laws interact with one another, we turn to the judiciary’s approach. Courts apply the implied repeal analysis to resolve tensions that appear to exist between two or more statutes. While the implication of a regulation-on-regulation conflict is unclear, courts agree that administrative rules and regulations that do not conflict with express statutory provisions have the force and effect of law. Thus, we believe courts would apply the standard rules of interpretation that apply to statutes to address questions of interpretation with regard to regulatory conflicts.

When faced with two potentially conflicting statutes, courts attempt to construe them so that both are given effect. If this construction is not possible, courts will look for express language in the later statute, or an intent in its legislative history, indicating that Congress intended the later statute to repeal the earlier one. If there is no expressed intent to repeal the earlier statute, courts will characterize the statutes as either general or specific. Ordinarily, later, general statutes will not repeal the special provisions of an earlier, specific statute. In some cases, when a later, general statute creates an irreconcilable conflict or is manifestly inconsistent with the earlier, specific statute in a manner that indicates a clear and manifest Congressional intent to repeal the earlier statute, courts will find that the later statute repeals the earlier statute by implication. In these cases, the latest legislative action may prevail and repeal the prior law, but only to the extent of the conflict.

There should be few instances in which conflicts exist between a statute or regulation and the rules below. For example, if a statute permits a covered entity to disclose protected health information and the rules below prohibit the use or dissemination of that information, courts would attempt to resolve it so that both laws applied. For example, if a statute or regulation permits dissemination of protected health information, but the rules below prohibit the use or disclosure without an authorization, we believe a covered entity would be able to comply with both because it could obtain an authorization under § 164.508 before disseminating the information under the other law.

Many apparent conflicts will not be true conflicts. For example, if a conflict
appears to exist because a previous statute or regulation requires a specific use or disclosure of protected health information that the rules below appear to prohibit, the use or disclosure pursuant to that statute or regulation would not be a violation of the privacy regulation because § 164.512(a) permits covered entities to use or disclose protected health information as required by law.

If a statute or regulation prohibits dissemination of protected health information, but the privacy regulation requires that an individual have access to that information, the earlier, more specific statute would apply. The interaction between the Clinical Laboratory Improvement Amendments regulation is an example of this type of conflict. From our review of several federal laws, it appears that Congress did not intend for the privacy regulation to override existing statutory requirements in these instances.

Examples of Interaction

We have summarized how certain federal laws interact with the privacy regulation to provide specific guidance in areas deserving special attention and to serve as examples of the analysis involved. In the Response to Comment section, we have provided our responses to specific questions raised during the comment period.

The Privacy Act

The Privacy Act of 1974, 5 U.S.C. 552a, prohibits disclosures of records contained in a system of records maintained by a federal agency (or its contractors) without the written request or consent of the individual to whom the record pertains. This general rule is subject to various statutory exceptions. In addition to the disclosures explicitly permitted in the statute, the Privacy Act permits agencies to disclose information for other purposes compatible with the purpose for which the information was collected by identifying the disclosure as a “routine use” and publishing notice of it in the Federal Register. The Act applies to all federal agencies and certain federal contractors who operate Privacy Act systems of records on behalf of federal agencies.

Some federal agencies and contractors of federal agencies that are covered entities under the privacy rules are subject to the Privacy Act. These entities must comply with all applicable federal statutes and regulations. For example, if the privacy regulation permits a disclosure, but the disclosure is not permitted by the Privacy Act, the federal agency may not make the disclosure. If, however, the Privacy Act allows a federal agency the discretion to make a routine use disclosure, but the privacy regulation prohibits the disclosure, the federal agency will have to apply its discretion in a way that complies with the regulation. This means not making the particular disclosure.

The Freedom of Information Act

FOIA, 5 U.S.C. 552, provides for public disclosure, upon the request of any person, of many types of information in the possession of the federal government, subject to nine exemptions and three exclusions. For example, Exemption 6 permits federal agencies to withhold “personnel and medical files and similar files the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.” 5 U.S.C. 552(b)(6).

Uses and disclosures required by FOIA come within § 164.512(a) of the privacy regulation that permits uses or disclosures made by law if the uses or disclosures meet the relevant requirements of the law. Thus, a federal agency must determine whether it may apply an exemption or exclusion to redact the protected health information when responding to a FOIA request. When a FOIA request asks for documents that include protected health information, we believe the agency, when appropriate, must apply Exemption 6 to preclude the release of medical files or otherwise redact identifying details before disclosing the remaining information.

We offer the following analysis for federal agencies and federal contractors who operate Privacy Act systems of records on behalf of federal agencies and must comply with FOIA and the privacy regulation. If presented with a FOIA request that would result in the disclosure of protected health information, a federal agency must first determine if FOIA requires the disclosure or if an exemption or exclusion would be appropriate. We believe that generally a disclosure of protected health information, when requested under FOIA, would come within FOIA Exemption 6. We recognize, however, that the application of this exemption to information about deceased individuals requires a different analysis than that applicable to living individuals because, as a general rule, under the Privacy Act, privacy rights are extinguished at death. However, under FOIA, it is entirely appropriate to consider the privacy interests of a decedent’s survivors under Exemption 6. See Department of Justice FOIA Guide 2000, Exemption 6: Privacy Considerations. Covered entities subject to FOIA must evaluate each disclosure on a case-by-case basis, as they do now under current FOIA procedures.

Federal Substance Abuse Confidentiality Requirements

The federal confidentiality of substance abuse patient records statute, section 543 of the Public Health Service Act, 42 U.S.C. 290dd-2, and its implementing regulation, 42 CFR part 2, establish confidentiality requirements for patient records that are maintained in connection with the performance of any federally-assisted specialized alcohol or drug abuse program. Substance abuse programs are generally programs or personnel that provide alcohol or drug abuse treatment, diagnosis, or referral for treatment. The term “federally-assisted” is broadly defined and includes federally conducted or funded programs, federally licensed or certified programs, and programs that are tax exempt.

Certain exceptions apply to information held by the Veterans Administration and the Armed Forces.

There are a number of health care providers that are subject to both these rules and the substance abuse statute and regulations. In most cases, a conflict will not exist between these rules. These privacy rules permit a health care provider to disclose information in a number of situations that are not permitted under the substance abuse regulation. For example, disclosures allowed, without patient authorization, under the privacy rule for law enforcement, judicial and administrative proceedings, public health, health oversight, directory assistance, and as required by other laws would generally be prohibited under the substance abuse statute and regulation. However, because these disclosures are permissive and not mandatory, there is no conflict. An entity would not be in violation of the privacy rules for failing to make these disclosures.

Similarly, provisions in the substance abuse regulation provide for permissive disclosures in case of medical emergencies, to the FDA, for research activities, for audit and evaluation activities, and in response to certain court orders. Because these are permissive disclosures, programs subject to both the privacy rules and the substance abuse rule are able to comply with both rules even if the privacy rules restrict these types of disclosures. In addition, the privacy rules generally require that an individual be given access to his or her own health information. Under the substance abuse
regulation, programs may provide such access, so there is no conflict.

The substance abuse regulation requires notice to patients of the substance abuse confidentiality requirements and provides for written consent for disclosure. While the privacy rules have requirements that are somewhat different, the program may use notice and authorization forms that include all the elements required by both regulations. The substance abuse rule provides a sample notice and a sample authorization form and states that the use of these forms would be sufficient. While these forms do not satisfy all of the requirements of the privacy regulation, there is no conflict because the substance abuse regulation does not mandate the use of these forms.

Employee Retirement Income Security Act of 1974

ERISA was enacted in 1974 to regulate pension and welfare benefit plans established by private sector employers, unions, or both, to provide benefits to their workers and dependents. Under ERISA, plans that provide “through the purchase of insurance or otherwise * * * medical, surgical, or hospital care or benefits, or benefits in the event of sickness, accident, disability, [or] death” are defined as employee welfare benefit plans. 29 U.S.C. 1002(1). In 1996, HIPAA amended ERISA to require portability, nondiscrimination, and renewability of health benefits provided by group health plans and group health insurance issuers. Numerous, although not all, ERISA plans are covered under the rules proposed below as “health plans.”

Section 514(a) of ERISA, 29 U.S.C. 1144(a), preempts all state laws that “relate to” any employee benefit plan. However, section 514(b) of ERISA, 29 U.S.C. 1144(b)(2)(A), expressly saves from preemption state laws that regulate insurance. Section 514(b)(2)(B) of ERISA, 29 U.S.C. 1144(b)(2)(B), provides that an ERISA plan is deemed not to be an insurer for the purpose of regulating the plan under the state insurance laws. Thus, under the deemer clause, states may not treat ERISA plans as insurers subject to direct regulation by state law. Finally, section 514(d) of ERISA, 29 U.S.C. 1144(d), provides that ERISA does not “alter, amend, modify, invalidate, impair, or supersede any law of the United States.”

We considered whether the preemption provision of section 264(c)(2) of HIPAA would give effect to state laws that ERISA otherwise be preempted by section 514(a) of ERISA. As discussed above, our reading of the statutes together is that the effect of section 264(c)(2) is only to leave in place state privacy protections that would otherwise apply and that are more stringent than the federal privacy protections.

Many health plans covered by the privacy regulation are also subject to ERISA requirements. Our discussions and consultations have not uncovered any particular ERISA requirements that would conflict with the rules.

The Family Educational Rights and Privacy Act

FERPA, as amended, 20 U.S.C. 1232g, provides parents of students and eligible students (students who are 18 or older) with privacy protections and rights for the records of students maintained by federally funded educational agencies or institutions or persons acting for these agencies or institutions. We have excluded education records covered by FERPA, including those education records designated as education records under Parts B, C, and D of the Individuals with Disabilities Education Act Amendments of 1997, from the definition of protected health information. For example, individually identifiable health information of students under the age of 18 created by a nurse in a primary or secondary school that receives federal funds and that is subject to FERPA is an education record, but not protected health information. Therefore, the privacy regulation does not apply. We followed this course because Congress specifically addressed how information in education records should be protected in FERPA.

We have also excluded certain records, those described at 20 U.S.C. 1232g(a)(4)(B)(iv), from the definition of protected health information because FERPA also provided a specific structure for the maintenance of these records. These are records (1) of students who are 18 years or older or are attending post-secondary educational institutions, (2) maintained by a physician, psychiatrist, psychologist, or recognized professional or paraprofessional acting or assisting in that capacity, (3) that are made, maintained, or used only in connection with the provision of treatment to the student, and (4) that are not available to anyone, except a physician or appropriate professional reviewing the record as designated by the student. Because FERPA excludes these records from its protections only to the extent they are not available to anyone other than persons providing treatment to students, any use or disclosure of the record for other purposes, including providing access to the individual student who is the subject of the information, would turn the record into an education record. As education records, they would be subject to the protections of FERPA.

These exclusions are not applicable to all schools, however. If a school does not receive federal funds, it is not an educational agency or institution as defined by FERPA. Therefore, its records that contain individually identifiable health information are not education records. These records may be protected health information. The educational institution or agency that employs a school nurse is subject to our regulation as a health care provider if the school nurse or the school engages in a HIPAA transaction.

While we strongly believe every individual should have the same level of privacy protection for his/her individually identifiable health information, we did not provide Congress with authority to disturb the scheme it had devised for records maintained by educational institutions and agencies under FERPA. We do not believe Congress intended to amend or preempt FERPA when it enacted HIPAA.

With regard to the records described at 20 U.S.C. 1232g(a)(4)(B)(iv), we considered requiring health care providers engaged in HIPAA transactions to comply with the privacy regulation up to the point those records were used or disclosed for purposes other than treatment. At that point, the records would be converted from protected health information into education records. This conversion would occur any time a student sought to exercise his/her access rights. The provider, then, would need to treat the record in accordance with FERPA’s requirements and be relieved from its obligations under the privacy regulation. We chose not to adopt this approach because it would be unduly burdensome to require providers to comply with two different, yet similar, sets of regulations and inconsistent with the policy in FERPA that these records be exempt from regulation to the extent the records were used only to treat the student.

Gramm-Leach-Bliley

In 1999, Congress passed Gramm-Leach-Bliley (GLB), Pub. L. 106–102, which included provisions, section 501 et seq., that limit the ability of financial institutions to disclose “nonpublic personal information” about consumers to non-affiliated third parties and require financial institutions to provide customers with their privacy policies and practices with respect to nonpublic
personal information. In addition, Congress required seven agencies with jurisdiction over financial institutions to promulgate regulations as necessary to implement these provisions. GLB and its accompanying regulations define “financial institutions” as including institutions engaged in the financial activities of bank holding companies, which may include the business of insuring. See 15 U.S.C. 6809(3); 12 U.S.C. 1843(k). However, Congress did not provide the designated federal agencies with the authority to regulate health insurers. Instead, it provided states with an incentive to adopt and have their state insurance authorities enforce these rules. See 15 U.S.C. 6805. If a state were to adopt laws consistent with GLB, health insurers would have to determine how to comply with both sets of rules.

Thus, GLB has caused concern and confusion among health plans that are subject to our privacy regulation. Although Congress remained silent as to its understanding of the interaction of GLB and HIPAA’s privacy provisions, the Federal Trade Commission and other agencies implementing the GLB privacy provisions noted in the preamble to their GLB regulations that they “would consult with HHS to avoid the imposition of duplicative or inconsistent requirements.” 65 Fed. Reg. 33646, 33648 (2000). Additionally, the FTC also noted that “persons engaged in providing insurance” would be within the jurisdiction of state insurance authorities and not within the jurisdiction of the FTC. Id.

Because the FTC has clearly stated that it will not enforce the GLB privacy provisions against persons engaged in providing insurance, health plans will not be subject to dual federal agency jurisdiction for information that is both nonpublic personal information and protected health information. If states choose to adopt GLB-like laws or regulations, which may or may not track the federal rules completely, health plans would need to evaluate these laws under the preemption analysis described in subpart B of Part 160.

Federally Funded Health Programs

These rules will affect various federal programs, some of which may have requirements that are, or appear to be, inconsistent with the requirements of these regulations. This programs include those operated directly by the federal government (such as health programs for military personnel and veterans) as well as programs in which health services or benefits are provided by the private sector or by state or local governments, but which are governed by various federal laws (such as Medicare, Medicaid, and ERISA).

Congress explicitly included some of these programs in HIPAA, subjecting them directly to the privacy regulation. Section 1171 of the Act defines the term “health plan” to include the following federally conducted, regulated, or funded programs: Group plans under ERISA that either have 50 or more participants or are administered by an entity other than the employer who established and maintains the plan; federally qualified health maintenance organizations; Medicare; Medicaid; Medicare supplemental policies; the health care program for active military personnel; the health care program for veterans; the Civilian Health and Medical Program of the Uniformed Services (CHAMPUS); the Indian health service program under the Indian Health Care Improvement Act, 25 U.S.C. 1601, et seq.; and the Federal Employees Health Benefits Program. There also are many other federally conducted, regulated, or funded programs in which individually identifiable health information is created or maintained, but which do not come within the statutory definition of “health plan.” While these latter types of federally conducted, regulated, or assisted programs are not explicitly covered by part C of title XI in the same way that the programs listed in the statutory definition of “health plan” are covered, the statute may nonetheless apply to transactions and other activities conducted under such programs. This is likely to be the case when the federal entity or federally regulated or funded entity provides health services; the requirements of part C may apply to such an entity as a “health care provider.” Thus, the issue of how different federal requirements apply is likely to arise in numerous contexts.

There are a number of authorities under the Public Health Service Act and other legislation that contain explicit confidentiality requirements, either in the enabling legislation or in implementing regulations. Many of these are so general that there would appear to be no problem of inconsistency, in that nothing in those laws or regulations would appear to restrict the provider’s ability to comply with the privacy regulation’s requirements.

There may, however, be authorities under which either the requirements of the enabling legislation or of the program regulations would impose requirements that differ from these rules.

For example, regulations applicable to the substance abuse block grant program funded under section 1943(b) of the Public Health Service Act require compliance with 42 CFR part 2, and, thus, raise the issues identified above in the substance abuse confidentiality regulations discussion. There are a number of federal programs which, either by statute or by regulation, restrict the disclosure of patient information to, with minor exceptions, disclosures “required by law.” See, for example, the program of projects for prevention and control of sexually transmitted diseases funded under section 318(e)(5) of the Public Health Service Act (42 CFR 51b.404); the regulations implementing the community health center program funded under section 330 of the Public Health Service Act (42 CFR 51c.110); the regulations implementing the program of grants for family planning services under title X of the Public Health Service Act (42 CFR 59.13); the regulations implementing the program of grants for black lung clinics funded under 30 U.S.C. 437(a) (42 CFR 55a.104); the regulations implementing the program of maternal and child health projects funded under section 501 of the Act (42 CFR 51a.6); the regulations implementing the program of medical examinations of coal miners (42 CFR 37.80(a)). These legal requirements would restrict the grantees or other entities providing services under the programs involved from making many of the disclosures that §§164.510 or 164.512 would permit. In some cases, permissive disclosures for treatment, payment, or health care operations would also be limited. Because §§164.510 and 164.512 are merely permissive, there would not be a conflict between the program requirements, because it would be possible to comply with both. However, entities subject to both sets of requirements would not have the total range of discretion that they would have if they were subject only to this regulation.

Food, Drug, and Cosmetic Act

The Food, Drug, and Cosmetic Act, 21 U.S.C. 301, et seq., and its accompanying regulations outline the responsibilities of the Food and Drug Administration with regard to monitoring the safety and effectiveness of drugs and devices. Part of the agency’s responsibility is to obtain reports about adverse events, track medical devices, and engage in other types of post marketing surveillance. Because many of these reports contain protected health information, the information within them may come within the purview of the privacy rules.
Although some of these reports are required by the Food, Drug, and Cosmetic Act or its accompanying regulations, other types of reporting are voluntary. We believe that these reports, while not mandated, play a critical role in ensuring that individuals receive safe and effective drugs and devices.

Therefore, in §164.512(b)(1)(iii), we have provided that covered entities may disclose protected health information to a person subject to the jurisdiction of the Food and Drug Administration for specified purposes, such as reporting adverse events, tracking medical devices, or engaging in other postmarketing surveillance. We describe the scope and conditions of such disclosures in more detail in §164.512(b).

**Clinical Laboratory Improvement Amendments**

CLIA, 42 U.S.C. 263a, and the accompanying regulations, 42 CFR part 493, require clinical laboratories to comply with standards regarding the testing of human specimens. This law requires clinical laboratories to disclose test results or reports only to authorized persons, as defined by state law. If a state does not define the term, the federal law defines it as the person who orders the test.

We realize that the person ordering the test is most likely a health care provider and not the individual who is the subject of the protected health information included within the result or report. Under this requirement, therefore, a clinical laboratory may be prohibited by law from providing the individual who is the subject of the test result or report with access to this information.

Although we believe individuals should be able to have access to their individually identifiable health information, we recognize that in the specific area of clinical laboratory testing and reporting, the Health Care Financing Administration, through regulation, has provided that access may be more limited. To accommodate this requirement, we have provided at §164.524(1)(iii) that covered entities maintaining protected health information that is subject to the CLIA requirements do not have to provide individuals with a right of access to or a right to inspect and obtain a copy of this information if the disclosure of the information to the individual would be prohibited by CLIA.

Not all clinical laboratories, however, will be exempted from providing individuals with these rights. If a clinical laboratory operates in a state in which the term “authorized person” is defined to include the individual, the clinical laboratory would have to provide the individual with these rights. Similarly, if the individual was the person who ordered the test and an authorized person included such a person, the laboratory would be required to provide the individual with these rights.

Additionally, CLIA regulations exempt the components or functions of “research laboratories that test human specimens but do not report patient specific results for the diagnosis, prevention or treatment of any disease or impairment of, or the assessment of the health of individual patients” from the CLIA regulatory scheme. 42 CFR 493.5(a)(2). If subject to the access requirements of this regulation, such entities would be forced to meet the requirements of CLIA from which they are currently exempt. To eliminate this additional regulatory burden, we have also excluded covered entities that are exempt from CLIA under that rule from the access requirement of this regulation.

Although we are concerned about the lack of immediate access by the individual, we believe that, in most cases, individuals who receive clinical tests will be able to receive their test results or reports through the health care provider who ordered the test for them. The provider will receive the information from the clinical laboratory. Assuming that the provider is a covered entity, the individual will have the right of access and right to inspect and copy this protected health information through his or her provider.

**Other Mandatory Federal or State Laws**

Many federal laws require covered entities to provide specific information to specific entities in specific circumstances. If a federal law requires a covered entity to disclose a specific type of information, the covered entity would not need an authorization under §164.508 to make the disclosure because the final rule permits covered entities to make disclosures that are required by law under §164.512(a).

Other laws, such as the Social Security Act (including its Medicare and Medicaid provisions), the Family and Medical Leave Act, the Public Health Service Act, Department of Transportation regulations, the Environmental Protection Act and its accompanying regulations, the National Labor Relations Act, the Federal Aviation Administration, and the Federal Aviation Administration rules, may also contain provisions that require covered entities or others to use or disclose protected health information for specific purposes.

When a covered entity is faced with a question as to whether the privacy regulation would prohibit the disclosure of protected health information that it seeks to disclose pursuant to a federal law, the covered entity should determine if the disclosure is required by that law. In other words, it must determine if the disclosure is mandatory rather than merely permissible. If it is mandatory, a covered entity may disclose the protected health information pursuant to §164.512(a), which permits covered entities to disclose protected health information without an authorization when the disclosure is required by law. If the disclosure is not required (but only permitted) by the federal law, the covered entity must determine if the disclosure comes within one of the other permissible disclosures. If the disclosure does not come within one of the provisions for permissible disclosures, the covered entity must obtain an authorization from the individual who is the subject of the information or de-identify the information before disclosing it.

If another federal law prohibits a covered entity from using or disclosing information that is also protected health information, but the privacy regulation permits the use or disclosure, a covered entity will need to comply with the other federal law and not use or disclose the information.

**Federal Disability Nondiscrimination Laws**

The federal laws barring discrimination on the basis of disability protect the confidentiality of certain medical information. The information protected by these laws falls within the larger definition of “health information” under this privacy regulation. The two primary disability nondiscrimination laws are the Americans with Disabilities Act (ADA), 42 U.S.C. 12101 et seq., and the Rehabilitation Act of 1973, as amended, 29 U.S.C. 701 et seq., although other laws barring discrimination on the basis of disability (such as the nondiscrimination provisions of the Workforce Investment Act of 1988, 29 U.S.C. 2938) may also apply. Federal disability nondiscrimination laws cover two general categories of entities relevant to this discussion: employers and entities that receive federal financial assistance.

Employers are not covered entities under the privacy regulation. Many employers, however, are subject to the federal disability nondiscrimination laws and, therefore, must protect the
confidentiality of all medical information concerning their applicants and employees.

The employment provisions of the ADA, 42 U.S.C. 12111 et seq., expressly cover employers of 15 or more employees, employment agencies, labor organizations, and joint labor-management committees. Since 1992, employment discrimination complaints arising under sections 501, 503, and 504 of the Rehabilitation Act also have been subject to the ADA’s employment nondiscrimination standards. See “Rehabilitation Act Amendments,” Pub. L. No. 102–569, 106 Stat. 4344. Employers subject to ADA nondiscrimination standards have confidentiality obligations regarding applicant and employee medical information. Employers must treat such medical information, including medical information from voluntary health or wellness programs and any medical information that is voluntarily disclosed as a confidential medical record, subject to limited exceptions.

Transmission of health information by an employer to a covered entity, such as a group health plan, is governed by the ADA confidentiality restrictions. The ADA, however, has been interpreted to permit an employer to use medical information for insurance purposes. See 29 CFR part 1630 App. at §1630.14(b) (describing such use with reference to 29 CFR 1630.16(f), which in turn explains that the ADA regulation “is not intended to disrupt the current regulatory structure for self-insured employers.”) Of current industry practices in sales, underwriting, pricing, administrative and other services, claims and similar insurance related activities based on classification of risks as regulated by the states”). See also, “Enforcement Guidance on Disability-Related Inquiries and Medical Examinations of Employees under the Americans with Disabilities Act,” 4, n.10 (July 26, 2000), FEP Manual (BNA) (“Enforcement Guidance on Disability-Related Questions and Medical Examinations”) (October 10, 1995), 8 FEP Manual (BNA) 405:7191 (1995) (also available at http://www.eeoc.gov). Thus, use of medical information for insurance purposes may include transmission of health information to a covered entity.

If an employer-sponsored group health plan is closely linked to an employer, the group health plan may be subject to ADA confidentiality restrictions as well as this privacy regulation. See Carparts Distribution Center, Inc. v. Automotive Wholesaler’s Association of New England, Inc., 37 F.3d 12 (1st Cir. 1994)(setting forth three bases for ADA Title I jurisdiction over an employer-provided medical reimbursement plan, in a discrimination challenge to the plan’s HIV/AIDS cap). Transmission of applicant or employee health information by the employer’s management to the group health plan may be permitted under the ADA standards as the use of medical information for insurance purposes. Similarly, disclosure of such medical information by the group health plan, under the limited circumstances permitted by this privacy regulation, may involve use of the information for insurance purposes as broadly described in the ADA discussion above.

Entities that receive federal financial assistance, which may also be covered entities under the privacy regulation, are subject to section 504 of the Rehabilitation Act (29 U.S.C. 794) and its implementing regulations. Each federal agency has promulgated such regulations that apply to entities that receive financial assistance from that agency (“recipients”). These regulations may limit the disclosure of medical information about persons who apply to or participate in a federal financially assisted program or activity. For example, the Department of Labor’s section 504 regulation (found at 29 CFR part 32), consistent with the ADA standards, requires recipients that conduct employment-related programs, including employment training programs, to maintain confidentiality regarding any information about the medical condition or history of applicants to or participants in the program or activity. Such information must be kept separate from other information about the applicant or participant and may be provided to certain specified individuals and entities, but only under certain limited circumstances described in the regulation. See 29 CFR 32.15(d). Apart from those circumstances, the information must be afforded the same confidential treatment as medical records. A recipient of federal financial assistance from the Department of Health and Human Services, such as hospitals, are subject to the ADA’s employment nondiscrimination standards. They must, accordingly, maintain confidentiality regarding the medical condition or history of applicants for employment and employees.

The statutes and implementing regulations under which the federal financial assistance is provided may contain additional provisions regulating collection and disclosure of medical, health, and disability-related information. See, e.g., section 188 of the Workforce Investment Act of 1988 (29 U.S.C. 2938) and 29 CFR 37.3(b). Thus, covered entities that are subject to this privacy regulation, may also be subject to the restrictions in these laws as well.

U.S. Safe Harbor Privacy Principles (European Union Directive on Data Protection)

The U.S. Directive became effective in October 1998 and prohibits European Union Countries from permitting the transfer of personal data to another country without ensuring that an “adequate level of protection,” as determined by the European Commission, exists in the other country or pursuant to one of the Directive’s derogations of this rule, such as pursuant to unambiguous consent or to fulfill a contract with the individual. In July 2000, the European Commission concluded that the U.S. Safe Harbor Privacy Principles 1 constituted “adequate protection.” Adoption of the Principles is voluntary. Organizations wishing to engage in the exchange of personal data with E.U. countries may assert compliance with the Principles as one means of obtaining data from E.U. countries.

The Department of Commerce, which negotiated these Principles with the European Commission, has provided guidance for U.S. organizations seeking to adhere to the guidelines and comply with U.S. law. We believe this guidance addresses the concerns covered entities seeking to transfer personal data from E.U. countries may have. When “U.S. law imposes a conflicting obligation, U.S. organizations whether in the safe harbor or not must comply with the law.” An organization does not need to comply with the Principles if a conflicting U.S. law “explicitly authorizes” the particular conduct. The organization’s non-compliance is “limited to the extent necessary to meet the overriding legitimate interests further[ed] by such authorization.” However, if only a difference exists such that an “option is allowable under the Principles and/or U.S. law, organizations are expected to opt for the higher protection where possible.” Questions regarding compliance and interpretation will be decided based on U.S. law. See Department of Commerce, Memorandum on Damages for Breaches

1 The Principles are: (1) Notice; (2) Choice (i.e., consent); (3) Onward Transfer (i.e., subsequent disclosures); (4) Security; (5) Data Integrity; (6) Access; and (7) Enforcement. Department of Commerce, Safe Harbor Principles, July 21, 2000 (“Principles”). They do not apply to manually processed data.
of Privacy, Legal Authorizations and Mergers and Takeovers in U.S. Law 5 (July 17, 2000); Department of Commerce, Safe Harbor Privacy Principles Issued by the U.S. Department of Commerce on July 21, 2000, 65 FR 45666 (2000). The Principles and our privacy regulation are based on common principles of fair information practices. We believe they are essentially consistent and that an organization complying with our privacy regulation can fairly and correctly self-certify that it complies with the Principles. If a true conflict arises between the privacy regulation and the Principles, the Department of Commerce’s guidance provides that an entity must comply with the U.S. law.

Part 160—Subpart C—Compliance and Enforcement

Proposed § 164.522 included five paragraphs addressing activities related to the Secretary’s enforcement of the rule. These provisions were based on procedures and requirements in various civil rights regulations. Proposed § 164.522(a) provided that the Secretary would, to the extent practicable, seek the cooperation of covered entities in obtaining compliance, and could provide technical assistance to covered entities to help them comply voluntarily. Proposed § 164.522(b) provided that individuals could file complaints with the Secretary. However, where the complaint related to the alleged failure of a covered entity to amend or correct protected health information as proposed in the rule, the Secretary would not make certain determinations such as whether protected health information was accurate or complete. This paragraph also listed the requirements for filing complaints and indicated that the Secretary may investigate such complaints and what might be reviewed as part of such investigation.

Under proposed § 164.522(c), the Secretary would be able to conduct compliance reviews. Proposed § 164.522(d) described the responsibilities that covered entities keep records and reports as prescribed by the Secretary, cooperate with compliance reviews, permit the Secretary to have access to their facilities, books, records, and other sources of information during normal business hours, and seek records held by other persons. This paragraph also stated that the Secretary would maintain the confidentiality of protected health information she collected and prohibit covered entities from taking retaliatory action against individuals for filing complaints or for other activities.

Proposed § 164.522(e) provided that the Secretary would inform the covered entity and the individual complainant if an investigation or review indicated a failure to comply and would seek to resolve the matter informally if possible. If the matter could not be resolved informally, the Secretary would be able to issue written findings, be required to inform the covered entity and the complainant, and be able to pursue civil enforcement action or make a criminal referral. The Secretary would also be required to inform the covered entity and the individual complainant if no violation was found.

We make the following changes and additions to proposed § 164.522 in the final rule. First, we have moved this section to part 160, as a new subpart C, “Compliance and Enforcement.” Second, we add new sections that explain the applicability of the regulations and incorporate certain definitions. Accordingly, we change the proposed references to violations of “this subpart” to violations of “the applicable requirements of part 160 and the applicable standards, requirements, and implementation specifications of subpart E of part 164 of this subchapter.” Third, the final rule at § 160.306(a) provides that any person, not just an “individual” (the person who is the subject of the individually identifiable health information) may file a complaint with the Secretary. Other references in this subpart to an individual have been changed accordingly. Fourth, we delete the proposed § 164.522(a) language that indicated that the Secretary would not determine whether information was accurate or complete, or whether errors or omissions might have an adverse effect on the individual. While the policy is not changed in that the Secretary will not make such determinations, we believe the language is unnecessary and may suggest that we would make all other types of determinations, such as all determinations in which the regulation defers to the professional judgment of the covered entity. Fifth, § 160.306(b)(3) requires that complaints be filed within 180 days of when the complainant knew or should have known that the act or omission complained of occurred, unless this time limit is waived by the Secretary for good cause shown. Sixth, § 160.310(b) requires cooperation with investigations as well as compliance reviews. Seventh, § 160.310(c)(1) provides that the Secretary must be provided access to a covered entity’s facilities, books, records, accounts, and other sources of information, including

protected health information, at any time and without notice where exigent circumstances exist, such as where documents might be hidden or destroyed. Eighth, the provision proposed at § 164.522(d) that would prohibit covered entities from taking retaliatory action against individuals for filing a complaint with the Secretary or for certain other actions has been changed and moved to § 164.530. Ninth, § 160.312(a)(2) deletes the reference in the proposed rule to using violation findings as a basis for initiating action to secure penalties. This deletion is not a substantive change. This language was removed because penalties will be addressed in the enforcement regulation. As in the NPRM, the Secretary may promulgate alternative procedures for complaints relating to national security. For example, to protect classified information, we may promulgate rules that would allow an intelligence community agency to create a separate body within that agency to receive complaints.

The Department plans to issue an Enforcement Rule that applies to all of the regulations that the Department issues under the Administrative Simplification provisions of HIPAA. This regulation will address the imposition of civil monetary penalties and the referral of criminal cases where there has been a violation of this rule. Penalties are provided for under section 262 of HIPAA. The Enforcement Rule would also address the topics covered by Subpart C below. It is expected that this Enforcement Rule would replace Subpart C.

Part 164—Subpart A—General Provisions

Section 164.102—Statutory Basis

In the NPRM, we provided that the provisions of this part are adopted pursuant to the Secretary’s authority to prescribe standards, requirements, and implementation standards under part C of title XI of the Act and section 264 of Public Law 104–191. The final rule adopts this language.

Section 164.104—Applicability

In the NPRM, we provided that except as otherwise provided, the provisions of this part apply to covered entities: health plans, health care clearinghouses, and health care providers who transmit health information in electronic form in connection with any transaction referred to in section 1173(a)(1) of the Act. The final rule adopts this language.
Section 164.106—Relationship to Other Parts

The final rule adds a new provision stating that in complying with the requirements of this part, covered entities are required to comply with the applicable provisions of parts 160 and 162 of this subchapter. This language references Subchapter C in this regulation, Administrative Data Standards and Related Requirements; Part 160, General Administrative Requirements; and Part 162, Administrative Requirements. Part 160 includes requirements such as keeping records and submitting compliance reports to the Secretary and cooperating with the Secretary’s complaint investigations and compliance reviews. Part 162 includes requirements such as requiring a covered entity that conducts an electronic transaction, adopted under this part, with another covered entity to conduct the transaction as a standard transaction as adopted by the Secretary.

Part 164—Subpart B—Reserved

Part 164—Subpart E—Reserved

Section 164.500—Applicability

The discussion below describes the entities and the information that are subject to the final regulation. Many of the provisions of the regulation are presented as “standards.” Generally, the standards indicate what must be accomplished under the regulation and implementation specifications describe how the standards must be achieved.

Covered Entities

We proposed in the NPRM to apply the standards in the regulation to health plans, health care clearinghouses, and to any health care provider who transmits health information in electronic form in connection with transactions referred to in section 1173(a)(1) of the Act. The proposal referred to these entities as “covered entities.” We have revised § 164.500 to clarify the applicability of the rule to health care clearinghouses. As we stated in the preamble to the NPRM, we believe that, in most instances health care clearinghouses will receive protected health information as a business associate to another covered entity. This understanding was confirmed by the comments and by our fact finding. Clearinghouses rarely have direct contact with individuals, and usually will not be in a position to create protected health information or to receive it directly from them. Unlike health plans or providers, clearinghouses usually convey and repackage information and do not add materially to the substance of protected health information of an individual.

The revised language provides that clearinghouses are not subject to certain requirements in the rule when acting as business associates of other covered entities. As revised, a clearinghouse acting as a business associate is subject only to the provisions of this section to the definitions, to the general rules for uses and disclosures of protected health information (subject to limitations), to the provision relating to health care components, to the provisions relating to uses and disclosures for which consent, individual authorization or an opportunity to agree or object is not required (subject to limitations), to the transition requirements and to the compliance date. With respect to the uses and disclosures authorized under § 164.502 or § 164.512, a clearinghouse acting as a business associate is not authorized by the rule to make any use or disclosure not permitted by its business associate contract. Clearinghouses acting as business associates and that are subject to the other requirements of this rule, which include the provisions relating to procedural requirements, requirements for obtaining consent, individual authorization or agreement, provision of a notice, individual rights to request privacy protection, access and amend information and receive an accounting of disclosures and the administrative requirements.

We note that, even as business associates, clearinghouses that remain covered entities, like other covered entities, are responsible under this regulation for abiding by the terms of business associate contracts. For example, while the provisions regarding individuals’ access to and right to request corrections to protected health information about them apply only to health plans and covered health care providers, clearinghouses may have some responsibility for providing such access under their business associate contracts. A clearinghouse (or any other covered entity) that violates the terms of a business associate contract also is in direct violation of this rule and, as a covered entity, is subject to compliance and enforcement action.

We clarify that a covered entity is only subject to these rules to the extent that they possess protected health information. Moreover, these rules only apply with regard to protected health information. For example, if a covered entity does not disclose or receive from its business associate any protected health information and no protected health information is created or received by its business associate on behalf of the covered entity, then the business associate requirements of this rule do not apply.

We clarify that the Department of Defense or any other federal agency and any non-governmental organization acting on its behalf, is not subject to this rule when it provides health care in another country to foreign national beneficiaries. The Secretary believes that this exemption is warranted because application of the rule could have the unintended effect of impeding or frustrating the conduct of such activities, such as interfering with the ability of military command authorities to obtain protected health information on prisoners of war, refugees, or detainees for whom they are responsible under international law. See the preamble to the definition of “individual” for further discussion.

Covered Information

We proposed in the NPRM to apply the requirements of the rule to individually identifiable health information that is or has been electronically transmitted or maintained by a covered entity. The provisions would have applied to the information itself, referred to as protected health information in the rule, and not to the particular records in which the information is contained. We proposed that once information was maintained or transmitted electronically by a covered entity, the protections would follow the information in whatever form, including paper records, in which it exists while held by a covered entity. The proposal would not have applied to information that was never electronically maintained or transmitted by a covered entity.

In the final rule, we extend the scope of protections to all individually identifiable health information in any form, electronic or non-electronic, that is held or transmitted by a covered entity. This includes individually identifiable health information in paper records that never has been electronically stored or transmitted. (See § 164.501, definition of “protected health information,” for further discussion.)

Section 164.501—Definitions

Correctional Institution

The proposed rule did not define the term correctional institution. The final rule defines correctional institution as any penal or correctional facility, jail, reformatory, detention center, work farm, halfway house, or residential community program center operated by, or under contract to, the United States,
a state, a territory, a political subdivision of a state or territory, or an Indian tribe, for the confinement or rehabilitation of persons charged with or convicted of a criminal offense or other persons held in lawful custody. Other persons held in lawful custody includes juvenile offenders adjudicated delinquent, aliens detained awaiting deportation, persons committed to mental institutions through the criminal justice system, witnesses, or others awaiting charges or trial. This language was necessary to explain the privacy rights and protections of inmates in this regulation.

Covered Functions

We add a new term, “covered functions,” as a shorthand way of expressing and referring to the functions that the entities covered by section 1172(a) of the Act perform. Section 1171 defines the terms “health plan”, “health care provider”, and “health care clearinghouse”, in functional terms. Thus, a “health plan” is an individual or group plan “that provides, or pays the cost of, medical care * * *.” A “health care provider” “furnish[es] health care services or supplies,” and a “health care clearinghouse” is an entity that represents “groups of health care providers.” The term “covered functions” is not intended to include various support functions, such as computer support, payroll and other office support, and similar support functions, although we recognize that these support functions must occur in order for the entity to carry out its health care functions. Because such support functions are often also performed for parts of an organization that are not doing functions related to the health care functions and may involve access to and/or use of protected health information, the rules below describe requirements for ensuring that workforce members who perform these support functions do not impermissibly use or disclose protected health information. See § 164.504.

Data Aggregation

The NPRM did not include a definition of data aggregation. In the final rule, data aggregation is defined, with respect to protected health information received by a business associate in its capacity as the business associate of a covered entity, as the combining of such protected health information by the business associate with protected health information received by the business associate in its capacity as a business associate of another covered entity, to permit the creation of data for analyses that relate to the health care operations of the respective covered entities. The definition is included in the final rule to help describe how business associates can assist covered entities to perform health care operations that involve comparative analysis of protected health information from otherwise unaffiliated covered entities. Data aggregation is a service that gives rise to a business associate relationship if the performance of the service involves disclosure of protected health information by the covered entity to the business associate.

Designated Record Set

In the proposed rule, we defined designated record set as “a group of records under the control of a covered entity from which information is retrieved by the name of the individual or by some identifying number, symbol, or other identifying particular assigned to the individual and which is used by the covered entity to make decisions about the individual.” We defined a “record” as “any item, collection, or grouping of protected health information maintained, collected, used, or disseminated by a covered entity.” In the final rule, we modify the definition of designated record set to specify certain records maintained by or for a covered entity that are always part of a covered entity’s designated record sets and to include other records that are used to make decisions about individuals. We do not use the means of retrieval of a record as a defining criterion.

For health plans, designated record sets include, at a minimum, the enrollment, payment, claims adjudication, and case or medical management record systems of the plan. For covered health care providers, designated record sets include, at a minimum, the medical record and billing record about individuals maintained by or for the provider. In addition to these records, designated record sets include any other group of records that are used, in whole or in part, by or for a covered entity to make decisions about individuals. We note that records that otherwise meet the definition of designated record set and which are held by a business associate of the covered entity are part of the covered entity’s designated record sets. Although we do not specify particular types of records that are always included in the designated record sets of clearinghouses when they are not acting as business associates, this definition includes a group of records that such a clearinghouse uses, in whole or in part, to make decisions about individuals.

For the most part we retain, with slight modifications, the definition of “record,” defining it as any item, collection, or grouping of information that includes protected health information and is maintained, collected, used, or disseminated.

Direct Treatment Relationship

This term was not included in the proposed rule. Direct treatment relationship means a relationship between a health care provider and an individual that is not an indirect treatment relationship (see definition of indirect treatment relationship, below). For example, outpatient pharmacists and Web-based providers generally have direct treatment relationships with patients. Outpatient pharmacists fill prescriptions written by other providers, but they furnish the prescription and advice about the prescription directly to the patient, not through another treating provider. Web-based providers generally deliver health care independently, without the orders of another provider.

A provider may have direct treatment relationships with some patients and indirect treatment relationships with others. In some provisions of the final rule, providers with indirect treatment relationships are excepted from requirements that apply to other providers. See § 164.506 regarding consent for uses and disclosures of protected health information for treatment, payment, and health care operations, and § 164.520 regarding notice of information practices. These exceptions apply only with respect to the individuals with whom the provider has an indirect treatment relationship.

Disclosure

We proposed to define “disclosure” to mean the release, transfer, provision of access to, or divulging in any other manner of information outside the entity holding the information. The final rule is unchanged. We note that the transfer of protected health information from a covered entity to a business associate is a disclosure for purposes of this regulation.

Health Care Operations

The preamble to the proposed rule explained that in order for treatment and payment to occur, protected health...
information must be used within entities and shared with business partners. In the proposed rule we provided a definition for “health care operations” to clarify the activities we considered to be “compatible with and directly related to” treatment and payment and for which protected health information could be used or disclosed without individual authorization. These activities included conducting quality assessment and improvement activities, reviewing the competence or qualifications and accrediting/licensing of health care professionals and plans, evaluating health care professional and health plan performance, training future health care professionals, insurance activities relating to the renewal of a contract for insurance, conducting or arranging for medical review and auditing services, and compiling and analyzing information in anticipation of or for use in a civil or criminal legal proceeding. Recognizing the dynamic nature of the health care industry, we acknowledged that the specified categories may need to be modified as the industry evolves.

The preamble discussion of the proposed general rules listed certain activities that would not be considered health care operations because they were sufficiently unrelated to treatment and payment to warrant requiring an individual to authorize such use or disclosure. Those activities included: marketing of health and non-health items and services; disclosure of protected health information for sale, rent or barter; protected health information by a non-health related division of an entity; disclosure of protected health information for eligibility, enrollment, underwriting, or risk rating determinations prior to an individuals’ enrollment in a health plan; disclosure to an employer for employment determinations; and fundraising.

In the final rule, we do not change the general approach of defining health care operations: health care operations are the listed activities undertaken by the covered entity that maintains the protected health information (i.e., one covered entity may not disclose protected health information for the operations of a second covered entity); a covered entity may use any protected health information it maintains for its operations (e.g., a plan may use protected health information about former enrollees as well as current enrollees); we expand the proposed list to reflect many changes requested by commenters.

We modify the proposal that health care operations represent activities “in support of” treatment and payment functions. Instead, in the final rule, health care operations are the enumerated activities to the extent that the activities are related to the covered entity’s functions as a health care provider, health plan or health care clearinghouse, i.e., the entity’s “covered functions.” We make this change to clarify that health care operations includes general administrative and business functions necessary for the covered entity to remain a viable business. While it is possible to draw a connection between all the enumerated activities and “treatment and payment,” for some general business activities (e.g., audits for financial disclosure statements) that connection may be tenuous. The proposed concept also did not include the operations of those health care clearinghouses that may be covered by this rule outside their status as business associate to a covered entity. We expand the definition to include disclosures for the enumerated activities of organized health care arrangements in which the covered entity participates. See also the definition of organized health care arrangements, below.

In addition, we make the following changes and additions to the enumerated subparagraphs:

(1) We add language to clarify that the primary purpose of the studies encompassed by “quality assessment and improvement activities” must not be to obtain generalizable knowledge. A study with such a purpose would meet the rule’s definition of research, and use or disclosure of protected health information would have to meet the requirements of §§ 164.508 or 164.512(i). Thus, studies may be conducted as a health care operation if development of generalizable knowledge is not the primary goal. However, if the study changes and the covered entity intends the results to be generalizable, the change should be documented by the covered entity as proof that, when initiated, the primary purpose was health care operations. We add population-based activities related to improving health or reducing health care costs, protocol development, case management and care coordination, contacting of health care providers and patients with information about treatment alternatives, and related functions that do not entail direct patient care. Many commenters recommended adding the term “disease management” to health care operations. We were unable, however, to find a generally accepted definition of the term. Rather than rely on this label, we include many of the functions often included in discussions of disease management in this definition or in the definition of treatment. This topic is discussed further in the comment responses below.

(2) We have deleted “undergraduate and graduate” as a qualifier for “students,” to make the term more general and inclusive. We add the term “practitioners.” We expand the purposes encompassed to include situations in which health care providers are working to improve their skills. The rule also adds the training of non-health care professionals.

(3) The rule expands the range of insurance related activities to include those related to the creation, renewal or replacement of a contract for health insurance or health benefits, as well as ceding, securing, or placing a contract for reinsurance of risk relating to claims for health care (including stop-loss and excess of loss insurance). For these activities, we also eliminate the proposed requirement that these uses and disclosures apply only to protected health information about individuals already enrolled in a health plan. Under this provision, a group health plan that wants to replace its insurance carrier may disclose certain protected health information to insurance issuers in order to obtain bids on new coverage, and an insurance carrier interested in bidding on new business may use protected health information obtained from the potential new client to develop the product and pricing it will offer. For circumstances in which no new contract is issued, we add a provision in § 164.514(g) restricting the recipient health plan from using or disclosing protected health information obtained for this purpose, other than as required by law. Uses and disclosures in these cases come within the definition of “health care operations,” provided that the requirements of § 164.514(g) are met, if applicable. See § 164.504(f) for requirements for such disclosures by group health plans, as well as specific restrictions on the information that may be disclosed to plan sponsors for such purposes. We note that a covered health care provider must obtain an authorization under § 164.508 in order to disclose protected health information about an individual for purposes of pre-enrollment underwriting; the underwriting is not an “operation” of the provider and that disclosure is not otherwise permitted by a provision of this rule.

(4) We delete reference to the “compiling and analyzing information in anticipation of or for use in a civil or criminal legal proceeding” and replace it with a broader reference to
conducting or arranging for “legal services.”

We add two new categories of activities:

(5) Business planning and development, such as conducting cost-management and planning-related analyses related to managing and operating the entity, including formulary development and administration, development or improvement of methods of payment or coverage policies.

(6) Business management activities and general administrative functions, such as management activities relating to implementation of and compliance with the requirements of this subchapter, fundraising for the benefit of the covered entity to the extent permitted without authorization under §164.514(f), and marketing of certain services to individuals served by the covered entity, to the extent permitted without authorization under §164.514(f) (see discussion in the preamble to that section, below). For example, under this category we permit uses or disclosures of protected health information to determine from whom an authorization should be obtained, for example, to generate a mailing list of individuals who would receive an authorization request.

We add to the definition of health care operations disclosure of protected health information for due diligence to a covered entity that is a potential successor in interest. This provision includes disclosures pursuant to the sale of a covered entity’s business as a going concern, mergers, acquisitions, consolidations, and other similar types of corporate restructuring between covered entities, including a division of a covered entity, and to an entity that is not a covered entity but will become a covered entity if the transfer or sale is completed. Other types of sales of assets, or disclosures to organizations that are not and would not become covered entities, are not included in the definition of health care operations and could only occur if the covered entity obtained valid authorization for such disclosure in accordance with §164.508, or if the disclosure is otherwise permitted under this rule.

We also add to health care operations disclosure of protected health information for resolution of internal grievances. These uses and disclosures include disclosure to an employee and/or employee representative, for example when the employee needs protected health information to demonstrate that the allegations of improper conduct are untrue. We note that such employees and employee representatives are not providing services to or for the covered entity, and, therefore, no business associate contract is required. Also included are resolution of disputes from patients or enrollees regarding the quality of care and similar matters.

We also add use for customer service, including the provision of data and statistical analyses for policyholders, plan sponsors, or other customers, as long as the protected health information is not disclosed to such persons. We recognize that part of the general management of a covered entity is customer service. We clarify that customer service may include the use of protected health information to provide data and statistical analyses. For example, a plan sponsor may want to understand why its costs are rising faster than average, or why utilization in one plant location is different than in another location. An association that sponsors an insurance plan for its members may want information on the relative costs of its plan in different areas. Some plan sponsors may want more detailed analyses that attempt to identify health problems in a work site. We note that when a plan sponsor has several different group health plans, or when such plans provide insurance or coverage through more than one health insurance issuer or HMO, the covered entities may jointly engage in this type of analysis as a health care operation of the organized health care arrangement.

This activity qualifies as a health care operation only if it does not result in the disclosure of protected health information to the customer. The results of the analyses must be presented in a way that does not disclose protected health information. A disclosure of protected health information to the customer as a health care operation under this provision violates this rule. This provision is not intended to permit covered entities to circumvent other provisions in this rule, including requirements relating to disclosures of protected health information to plan sponsors or other business associates of the covered entity. For example, a covered academic medical center may disclose certain protected health information to community health care providers who participate in one of its continuing medical education programs, whether or not such providers are covered health care providers under this rule. A provider attending a continuing education program is not thereby performing services for the covered entity sponsoring the program and, thus, is not a business associate for that purpose. Similarly, health plans may disclose for due diligence purposes to another entity that may or may not be a covered entity or a business associate.

### Health Oversight Agency

The proposed rule would have defined “health oversight agency” as “an agency, person, or entity, including the employees or agents thereof, (1) That is: (i) A public agency; or (ii) A person or entity acting under grant of authority from or contract with a public agency; and (2) Which performs or oversees the performance of any audit; investigation; inspection; licensure or discipline; civil, criminal, or administrative proceeding or action; or other activity necessary for appropriate oversight of the health care system, government benefit programs for which health information is relevant to beneficiary eligibility, or of government regulatory programs for which health information is necessary for determining compliance with program standards.” The proposed rule also described the functions of health oversight agencies in the proposed health oversight section (§164.510(c)) by repeating much of this definition.

In the final rule, we modify the definition of health oversight agency by eliminating from the definition the language in proposed §164.510(c) (now §164.512(d)). In addition, the final rule clarifies that a “health oversight agency” is an agency or authority of the United States,
a state, a territory, a political subdivision of a state or territory, or an Indian tribe, or a person or entity acting under a grant of authority from or contract with such public agency, including the employees or agents of such public agency or its contractors or grantees, that is authorized by law to oversee the health care system or government programs in which health information is necessary to determine eligibility or compliance, or to enforce civil rights laws for which health information is relevant.

The preamble to the proposed rule listed the following as examples of health oversight agencies that conduct oversight activities relating to the health care system: state insurance commissions, state health professional licensure agencies, Offices of Inspectors General of federal agencies, the Department of Justice, state Medicaid fraud control units, Defense Criminal Investigative Services, the Pension and Welfare Benefit Administration, the HHS Office for Civil Rights, and the FDA. The proposed rule listed the Social Security Administration and the Department of Education as examples of health oversight agencies that conduct oversight of government benefit programs for which health information is relevant to beneficiary eligibility. The proposed rule listed the Occupational Health and Safety Administration and the Environmental Protection Agency as examples of oversight agencies that conduct oversight of government regulatory programs for which health information is necessary for determining compliance with program standards.

In the final rule, we include the following as additional examples of health oversight activities: (1) The U.S. Department of Justice’s civil rights enforcement activities, and in particular, enforcement of the Civil Rights of Institutionalized Persons Act (42 U.S.C. 1997–1997j) and the Americans with Disabilities Act (42 U.S.C. 12101 et seq.), as well as the EEOC’s civil rights enforcement activities under titles I and V of the ADA; (2) the FDA’s oversight of food, drugs, biologics, devices, and other products pursuant to the Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.) and the Public Health Service Act (42 U.S.C. 201 et seq.); and (3) data analysis—performed by a public agency or by a person or entity acting under grant of authority from or under contract with a public agency—to detect health care fraud.

“Overseeing the health care system,” which is included in the definition of health oversight, encompasses activities such as: oversight of health care plans; oversight of health benefit plans; oversight of health care providers; oversight of health care and health care delivery; oversight activities that involve resolution of consumer complaints; oversight of pharmaceuticals, medical products and devices, and dietary supplements; and a health oversight agency’s analysis of trends in health care costs, quality, health care delivery, access to care, and health insurance coverage for health oversight purposes.

We recognize that the health oversight agencies, such as the U.S. Department of Labor’s Pension and Welfare Benefits Administration, may perform more than one type of health oversight. For example, agencies may sometimes perform audits and investigations and at other times conduct general oversight of health benefit plans. Such entities are considered health oversight agencies under the rule for any and all of the health oversight functions that they perform.

The definition of health oversight agency does not include private organizations, such as private-sector accrediting groups. Accreditation organizations are performing health care operations functions on behalf of health plans and covered health care providers. Accordingly, in order to obtain protected health information without individuals’ authorizations, accrediting groups must enter into business associate agreements with health plans and covered health care providers for these purposes. Similarly, private entities, such as coding committees, that help government agencies that are health plans make coding and payment decisions are performing health care payment functions on behalf of the government agencies and, therefore, must enter into business associate agreements in order to receive protected health information from the covered entity (absent individuals’ authorization for such disclosure).

Indirect Treatment Relationship

This term was not included in the proposed rule. An “indirect treatment relationship” is a relationship between a health care provider and an individual in which the provider delivers health care to the individual based on the orders of another health care provider and the health care services, products, diagnoses, or results are typically furnished to the patient through another provider, rather than directly. For example, radiologists and pathologists generally have indirect treatment relationships with patients because they deliver diagnostic services based on the orders of other providers and the results of those services are furnished to the patient through the direct treating provider. This definition is necessary to clarify the relationships between providers and individuals in the regulation. For example, see the consent discussion at § 164.506.

Individual

We proposed to define “individual” to mean the person who is the subject of the protected health information. We proposed that the term include, with respect to the signing of authorizations and other rights (such as access, copying, and correction), the following types of legal representatives:

(1) With respect to adults and emancipated minors, legal representatives (such as court-appointed guardians or persons with a power of attorney), to the extent to which applicable law permits such legal representatives to exercise the person’s rights in such contexts.

(2) With respect to unemancipated minors, a parent, guardian, or person acting in loco parentis, provided that when a minor lawfully obtains a health care service without the consent of or notification to a parent, guardian, or other person acting in loco parentis, the minor shall have the exclusive right to exercise the rights of an individual with respect to the protected health information relating to such care.

(3) With respect to deceased persons, an executor, administrator, or other person authorized under applicable law to act on behalf of the decedent’s estate.

In addition, we proposed to exclude from the definition:

(1) Foreign military and diplomatic personnel and their dependents who receive health care provided by or paid for by the Department of Defense or other federal agency or by an entity acting on its behalf, pursuant to a country-to-country agreement or federal statute.

(2) Overseas foreign national beneficiaries of health care provided by the Department of Defense or other federal agency or by a non-governmental organization acting on its behalf.

In the final rule, we eliminate from the definition of “individual” the provisions designating a legal representative as the “individual” for purposes of exercising certain rights with regard to protected health information. Instead, we include in the final rule a separate standard for “personal representatives.” A covered entity must treat a personal representative of an individual as the individual except under specified circumstances. See discussion in
§ 164.502(g) regarding personal representatives.

In addition, we eliminate from the definition of “individual” the above exclusions for foreign military and diplomatic personnel and overseas foreign national beneficiaries. We address the special circumstances for use and disclosure of protected health information about individuals who are foreign military personnel in § 164.512(k). We address overseas foreign national beneficiaries in § 164.500, “Applicability.” The protected health information of individuals who are foreign diplomatic personnel and their dependents are not subject to special treatment under the final rule.

Individually identifiable health information about one individual may exist in the health records of another individual; health information about one individual may include health information about a second person. For example, a patient’s medical record may contain information about the medical conditions of the patient’s parents, children, and spouse, as well as their names and contact information. For the purpose of this rule, if information about a second person is included within the protected health information of an individual, the second person is not the person who is the subject of the protected health information. The second person is not the “individual” with regard to that protected health information, and under this rule thus does not have the individual’s rights (e.g., access and amendment) with regard to that information.

Individually Identifiable Health Information

We proposed to define “individually identifiable health information” to mean information that is a subset of health information, including demographic information collected from an individual, and that:

(1) Is created by or received from a health care provider, health plan, employer, or health care clearinghouse; and

(2) Relates to the past, present, or future physical or mental health or condition of an individual, the provision of health care to an individual, or the past, present, or future payment for the provision of health care to an individual, and

(i) Which identifies the individual, or

(ii) With respect to which there is a reasonable basis to believe that the information can be used to identify the individual.

In the final rule, we change “created by or received from a health care provider * * *” to “created or received by a health care provider * * * “in order to conform to the statute. We otherwise retain the definition of “individually identifiable health information” without change in the final rule.

Inmate

The proposed rule did not define the term inmate. In the final rule, it is defined as a person incarcerated in or otherwise confined to a correctional institution. The addition of this definition is necessary to explain the privacy rights and protections of inmates in this regulation.

Law Enforcement Official

The proposed rule would have defined a “law enforcement official” as “an official of an agency or authority of the United States, a state, a territory, a political subdivision of a state or territory, or an Indian tribe, who is empowered by law to conduct: (1) An investigation or official proceeding inquiring into a violation of, or failure to comply with, any law; or (2) a criminal, civil, or administrative proceeding arising from a violation of, or failure to comply with, any law.”

The final rule modifies this definition slightly. The definition in the final rule recognizes that law enforcement officials are empowered to prosecute cases as well as to conduct investigations and civil, criminal, or administrative proceedings. In addition, the definition in the final rule reflects the fact that when investigations begin, often it is not clear that law has been violated. Thus, the final rule describes law enforcement investigations and official proceedings as inquiring into a potential violation of law. In addition, it describes law enforcement-related civil, criminal, or administrative proceedings as arising from alleged violation of law.

Marketing

The proposed rule did not include a definition of “marketing.” The proposed rule generally required that a covered entity would need an authorization from an individual to use or disclose protected health information for marketing.

In the final rule we define marketing as a communication about a product or service a purpose of which is to encourage recipients of the communication to purchase or use the product or service. The definition does not limit the type or means of communication that are considered marketing.

The definition of marketing contains three exceptions. If a covered entity receives direct or indirect remuneration from a third party for making a written communication otherwise described in an exception, then the communication is not excluded from the definition of marketing. The activities we except from the definition of marketing are encompassed by the definitions of treatment, payment, and health care operations. Covered entities may therefore use and disclose protected health information for these excepted activities without authorization under § 164.508 and pursuant to any applicable consent obtained under § 164.506.

The first exception applies to communications made by a covered entity for the purpose of describing the entities participating in a provider network or health plan network. It also applies to communications made by a covered entity for the purpose of describing if and the extent to which a product or service, or payment for a product or service, is provided by the covered entity or included in a benefit plan. This exception permits covered entities to use or disclose protected health information when discussing topics such as the benefits and services available under a health plan, the payment that may be made for a product or service, and whether a provider is part of a network or whether (and what amount of) payment will be provided with respect to the services of particular providers. This exception expresses our intent not to interfere with communications made to individuals about their health benefits.

The second exception applies to communications tailored to the circumstances of a particular individual, made by a health care provider to an individual as part of the treatment of the individual, and for the purpose of furthering the treatment of that individual. This exception leaves health care providers free to use or disclose protected health information as part of a discussion of its products and services, or the products and services of others, and to prescribe, recommend, or sell such products or services, as part of the treatment of an individual. This exception includes activities such as referrals, prescriptions, recommendations, and other communications that address how a product or service may relate to the individual’s health. This exception expresses our intent not to interfere with communications made to individuals about their treatment.

The third exception applies to communications tailored to the...
circumstances of a particular individual and made by a health care provider or health plan to an individual in the course of managing the treatment of that individual or for the purpose of directing or recommending to that individual alternative treatments, therapies, providers, or settings of care. As with the previous exception, this exception permits covered entities to discuss freely their products and services and the products and services of third parties, in the course of managing an individual’s care or providing or discussing treatment alternatives with an individual, even when such activities involve the use or disclosure protected health information.

Section 164.514 contains provisions governing use or disclosure of protected health information in marketing communications, including a description of certain marketing communications that may use or include protected health information but that may be made by a covered entity without individual authorization. The definition of health care operations includes those marketing communications that may be made without an authorization pursuant to § 164.514. Covered entities may therefore use and disclose protected health information for these activities pursuant to any applicable consent obtained under § 164.506, or, if they are not required to obtain a consent under § 164.506, without one.

**Organized Health Care Arrangement**

This term was not used in the proposed rule. We define the term in order to describe certain arrangements in which participants need to share protected health information about their patients to manage and benefit the common enterprise. To allow uses and disclosures of protected health information for these arrangements, we also add language to the definition of “health care operations.” See discussion of that term above.

We include five arrangements within the definition of organized health care arrangement. The arrangements involve clinical or operational integration among legally separate covered entities in which it is often necessary to share protected health information for the joint management and operations of the arrangement. They may range in legal structure, but a key component of these arrangements is that individuals who obtain services from them have an expectation that these arrangements are integrated and that they jointly manage their operations. We include within the definition a clinically integrated care setting in which individuals typically receive health care from more than one health care provider. Perhaps the most common example of this type of organized health care arrangement is the hospital setting, where a hospital and a physician with staff privileges at the hospital together provide treatment to the individual. Participants in such clinically integrated settings need to be able to share health information freely not only for treatment purposes, but also to improve their joint operations. For example, any physician with staff privileges at a hospital must be able to participate in the hospital’s morbidity and mortality reviews, even when the particular physician’s patients are not being discussed. Nurses and other hospital personnel must also be able to participate. These activities benefit the common enterprise, even when the benefits to a particular participant are not evident. While protected health information may be freely shared among providers for treatment purposes under other provisions of this rule, some of these joint activities also support the health care operations of one or more participants in the joint arrangement. Thus, special rules are needed to ensure that this rule does not interfere with legitimate information sharing among the participants in these arrangements.

We also include within the definition an organized system of health care in which more than one covered entity participates, and in which the participating covered entities hold themselves out to the public as participating in a joint arrangement, and in which the joint activities of the participating covered entities include at least one of the following: utilization review, in which health care decisions by participating covered entities are reviewed by other participating covered entities or by a third party on their behalf; quality assessment and improvement activities, in which treatment provided by participating covered entities are reviewed by other participating covered entities or by a third party on their behalf; or payment activities, if the financial risk for delivering health care is shared in whole or in part by participating covered entities through the joint arrangement and if protected health information created or received by a covered entity is reviewed by other participating covered entities or by a third party on their behalf for the purpose of administering the sharing of financial risk. A common example of this type of organized health care arrangement is an independent practice association formed by a large number of physicians. They may advertise themselves as a common enterprise (e.g., Acme IPA), whether or not they are under common ownership or control, whether or not they practice together in an integrated clinical setting, and whether or not they share financial risk.

If such a group engages jointly in one or more of the listed activities, the participating covered entities will need to share protected health information to undertake such activities and to improve their joint operations. In this example, the physician participants in the IPA may share financial risk through common withhold pools with health plans or similar arrangements. The IPA participants who manage the financial arrangements need protected health information about all the participants’ patients in order to manage the arrangement. (The participants may also hire a third party to manage their financial arrangements.) If the participants in the IPA engage in joint quality assurance or utilization review activities, they will need to share protected health information about their patients much as participants in an integrated clinical setting would. Many joint activities that require the sharing of protected health information benefit the common enterprise, even when the benefits to a particular participant are not evident.

We include three relationships related to group health plans as organized health care arrangements. First, we include a group health plan and an issuer or HMO with respect to the group health plan within the definition, but only with respect to the protected health information of the issuer or HMO that relates to individuals who are or have been participants or beneficiaries in the group health plan. We recognize that many group health plans are funded partially or fully through insurance, and that in some cases the group health plan and issuer or HMO need to coordinate operations to properly serve the enrollees. Second, we include a group health plan and one or more other group health plans each of which are maintained by the same plan sponsor. We recognize that in some instances plan sponsors provide health benefits through a combination of group health plans, and that they may need to coordinate the operations of such plans to better serve the participants and beneficiaries of the plans. Third, we include a combination of group health plans maintained by the same plan sponsor and the health insurance issuers and HMOs with respect to such plans, but again only with respect to the protected health information of such issuers and HMOs that relates to
individuals who are or have been enrolled in such group health plans. We recognize that is some instances a plan sponsor may provide benefits through more than one group health plan, and that such plans may fund the benefits through one or more issuers or HMOs. Again, coordinating health care operations among these entities may be necessary to serve the participants and beneficiaries in the group health plans. We note that the necessary coordination may necessarily involve the business associates of the covered entities and may involve the participation of the plan sponsor to the extent that it is providing plan administration functions and subject to the limits in §164.504.

Payment

We proposed the term payment to mean:

(1) The activities undertaken by or on behalf of a covered entity that is:

(i) A health plan, or by a business partner on behalf of a health plan, to obtain premiums or to determine or fulfill its responsibility for coverage under the health plan and for provision of benefits under the health plan; or

(ii) A health care provider or health plan, or a business partner on behalf of such provider or plan, to obtain reimbursement for the provision of health care.

(2) Activities that constitute payment include:

(i) Determinations of coverage, adjudication or subrogation of health benefit claims;

(ii) Risk adjusting amounts due based on enrollee health status and demographic characteristics;

(iii) Billing, claims management, and medical data processing;

(iv) Review of health care services with respect to medical necessity, coverage under a health plan, appropriateness of care, or justification of charges; and

(v) Utilization review activities, including precertification and preauthorization of services.

In the final rule, we maintain the general approach of defining of payment: payment activities are described generally in the first clause of the definition, and specific examples are given in the second clause. Payment activities relate to the covered entity that maintains the protected health information (i.e., one covered entity may not disclose protected health information for the payment activities of a second covered entity). A covered entity may use or disclose only the protected health information about the individual to whom care was rendered, for its payment activities (e.g., a provider may disclose protected health information only about the patient to whom care was rendered in order to obtain payment for that care, or only the protected health information about persons enrolled in the particular health plan that seeks to audit the provider's records). We expand the proposed list to reflect many changes requested by commenters.

We add eligibility determinations as an activity included in the definition of payment. We expand coverage determinations to include the coordination of benefits and the determination of a specific individual’s cost-sharing amounts. The rule deletes activities related to the improvement of methods of paying or coverage policies from this definition and instead includes them in the definition of health care operations. We add to the definition “collection activities.” We replace “medical data processing” activities with health care data processing related to billing, claims management, and collection activities. We add activities for the purpose of obtaining payment under a contract for reinsurance (including stop-loss and excess of loss insurance). Utilization review activities now include concurrent and retrospective review of services.

In addition, we modify this definition to clarify that the activities described in section 1179 of the Act are included in the definition of “payment.” We add new subclause (vi) allowing covered entities to disclose to consumer reporting agencies any individual’s name, address, date of birth, social security number and payment history, account number, as well as the name and address of the individual’s health care provider and/or health plan, as appropriate. Covered entities may make disclosure of this protected health information to consumer reporting agencies for purposes related to collection of premiums or reimbursement. This allows reporting not just of missed payments and overdue debt but also of subsequent positive payment experience (e.g., to expunge the debt). We consider such positive payment experience to be “related to” collection of premiums or reimbursement.

The remaining activities described in section 1179 are included in other language in this definition. For example, “authorizing, processing, clearing, settling, billing, transferring, reconciling or collecting, a payment for, or related to, health plan premiums or health care” are covered by paragraph (2)(ii) of the definition, which allows use and disclosure of protected health information for “billing, claims management, collection activities and related health care data processing.” “Claims management” also includes auditing payments, investigating and resolving payment disputes and responding to customer inquiries regarding payments. Disclosure of protected health information for compliance with civil or criminal subpoenas, or with other applicable laws, are covered under §164.512 of this regulation. (See discussion above regarding the interaction between 1179 and this regulation.)

We modify the proposed regulation text to clarify that payment includes activities undertaken to reimburse health care providers for treatment provided to individuals.

Covered entities may disclose protected health information for payment purposes to any other entity, regardless of whether it is a covered entity. For example, a health care provider may disclose protected health information to a financial institution in order to cash a check or to a health care clearinghouse to initiate electronic transactions. However, if a covered entity engages another entity such as a billing service or a financial institution, to conduct payment activities on its behalf, the other entity may meet the definition of “business associate” under this rule. For example, an entity is acting as a business associate when it is operating the accounts receivable system on behalf of a health care provider.

Similarly, payment includes disclosure of protected health information by a health care provider to an insurer that is not a “health plan” as defined in this rule, to obtain payment. For example, protected health information may be disclosed to obtain reimbursement from a disability insurance carrier. We do not interpret the definition of “payment” to include activities that involve the disclosure of protected health information by a covered entity, including a covered health care provider, to a plan sponsor for the purpose of obtaining payment under a group health plan maintained by such plan sponsor, or for the purpose of obtaining payment from a health insurance issuer or HMO with respect to a group health plan maintained by such plan sponsor, unless the plan sponsor is performing plan administration pursuant to §164.504(f).

The Transactions Rule adopts standards for electronic health care transactions, including two for processing payment. We adopted the ASC X12N 835 transaction standard for “Health Care Payment and Remittance
Advice” transactions between health plans and health care providers, and the ASC X12N 820 standard for “Health Plan Premium Payments” transactions between entities that arrange for the provision of health care or provide health care coverage payments and health plans. Under these two transactions, information to effect funds transfer is transmitted in a part of the transaction separable from the part containing any individually identifiable health information.

We note that a covered entity may conduct the electronic funds transfer portion of the two payment standard transactions with a financial institution without restriction, because it contains no protected health information. The protected health information contained in the electronic remittance advice or the premium payment enrollee data portions of the transactions is not necessary either to conduct the funds transfer or to forward the transactions. Therefore, a covered entity may not disclose the protected health information to a financial institution for these purposes. A covered entity may transmit the portions of the transactions containing protected health information through a financial institution if the protected health information is encrypted so it can be read only by the intended recipient. In such cases no protected health information is disclosed and the financial institution is acting solely as a conduit for the individually identifiable data.

Plan Sponsor

In the final rule we add a definition of “plan sponsor.” We define plan sponsor by referencing the definition of the term provided in (3)(16)(B) of the Employee Retirement Income Security Act (ERISA). The plan sponsor is the employer or employee organization, or both, that establishes and maintains an employee benefit plan. In the case of a plan established by two or more employers, it is the association, committee, joint board of trustees, or other similar group or representative of the parties that establish and maintain the employee benefit plan. This term includes church health plans and government health plans. Group health plans may disclose protected health information to plan sponsors who conduct payment and health care operations activities on behalf of the group health plan if the requirements for group health plans in §164.504 are met.

The preamble to the Transactions Rule noted that plan sponsors of group health plans are not covered entities and, therefore, are not required to use the standards established in that regulation to perform electronic transactions, including enrollment and disenrollment transactions. We do not change that policy through this rule. Plan sponsors that perform enrollment functions are doing so on behalf of the participants and beneficiaries of the group health plan and not on behalf of the group health plan itself. For purposes of this rule, plan sponsors are not subject to the requirements of §164.504 regarding group health plans when conducting enrollment activities.

Protected Health Information

We proposed to define “protected health information” to mean individually identifiable health information that is or has been electronically maintained or electronically transmitted by a covered entity, as well as such information when it takes any other form. For purposes of this definition, we proposed to define “electronically transmitted” as including information exchanged with a computer using electronic media, such as the movement of information from one location to another by magnetic or optical media, transmissions over the Internet, Extranet, leased lines, dial-up lines, private networks, telephone voice response, and “faxback” systems. We proposed that this definition not include “paper-to-paper” faxes, or person-to-person telephone calls, video conferencing, or messages left on voice-mail.

Further, “electronically maintained” was proposed to mean information stored by a computer or on any other form or medium. We refer to electronic media, as defined in §162.103, which means the mode of electronic transmission. It includes the Internet (wide-open), Extranet (using Internet technology to link a business with information only accessible to collaborating parties), leased lines, dial-up lines, private networks, and those transmissions that are physically moved from one location to another using magnetic tape, disk, or compact disk media.

The definition of protected health information is set out in this form to emphasize the severability of this provision. As discussed below, we believe we have ample legal authority to cover all individually identifiable health information transmitted or maintained by covered entities. We have structured the definition this way so that, if a court were to disagree with our view of our authority in this area, the rule would still be operational, albeit with respect to a more limited universe of information.

Other provisions of the rules below may also be severable, depending on their scope and operation. For example, if the rule itself provides a fallback, as it does with respect to the various discretionary uses and disclosures permitted under §164.512, the provisions would be severable under case law.

The definition in the final rule retains the exception relating to individually identifiable health information in “education records” governed by FERPA. We also exclude the records described in 20 U.S.C. 1232g(a)(4)(B)(iv). These are records of students held by post-secondary educational institutions or of students 18 years of age or older, used exclusively for health care treatment and which have not been disclosed to anyone other than a health care provider at the student’s request. (See discussion of FERPA above.)

We have removed the exception for individually identifiable health information of inmates of correctional facilities and detainees in detention facilities. Individually identifiable health information about inmates is protected health information under the final rule, and special rules for use and disclosure of the protected health
information about inmates and their ability to exercise the rights granted in this rule are described below.

**Psychotherapy Notes**

Section 164.508(a)(3)(iv)(A) of the proposed rule defined psychotherapy notes as notes recorded (in any medium) by a health care provider who is a mental health professional documenting or analyzing the contents of conversation during a private counseling session or a group, joint, or family counseling session. The proposed definition excluded medication prescription and monitoring, counseling session start and stop times, the modalities and frequencies of treatment furnished, results of clinical tests, and any summary of the following items: Diagnosis, functional status, the treatment plan, symptoms, prognosis and progress. Furthermore, we stated in the preamble of the proposed rule that psychotherapy notes would have to be maintained separately from the medical record.

In this final rule, we retain the definition of psychotherapy notes that we had proposed, but add to the regulation text the requirement that, to meet the definition of psychotherapy notes, the information must be separated from the rest of the individual’s medical record.

**Public Health Authority**

The proposed rule would have defined “public health authority” as “an agency or authority of the United States, a state, a territory, or an Indian tribe that is responsible for public health matters as part of its official mandate.”

The final rule changes this definition slightly to clarify that a “public health authority” also includes a person or entity acting under a grant of authority from or contract with a public health agency. Therefore, the final rule defines this term as an agency or authority of the United States, a state, a territory, a political subdivision of a state or territory, or an Indian tribe, or a person or entity acting under a grant of authority from or contract with such public agency, including the employees or agents of such public agency or its contractors or persons or entities to whom it has granted authority, that is responsible for public health matters as part of its official mandate.

**Required By Law**

In the preamble to the NPRM, we did not include a definition of “required by law.” We discussed what it meant for an action to be considered to be “required” or “mandated” by law and included several examples of activities that would be considered as required by law for the purposes of the proposed rule, including a valid Inspector General subpoena, grand jury subpoena, civil investigative demand, or a statute or regulation requiring production of information justifying a claim would constitute a disclosure required by law.

In the final rule we include a new definition, move the preamble clarifications to the regulatory text and add several items to the illustrative list. For purposes of this regulation, “required by law” means a mandate contained in law that compels a covered entity to make a use or disclosure of protected health information and that is enforceable in a court of law. Among the examples listed in definition are Medicare conditions of participation with respect to health care providers participating in that program, court-ordered warrants, and subpoenas issued by a court. We note that disclosures “required by law” include disclosures of protected health information required by this regulation in §164.502(a)(1). It does not include contracts between private parties or similar voluntary arrangements. This list is illustrative only and is not intended in any way to limit the scope of this paragraph or other paragraphs in §164.512 that permit uses or disclosures to the extent required by other laws. We note that nothing in this rule compels a covered entity to make a use or disclosure required by the legal demands or prescriptions listed in this clarification only if, by any legal process, and a covered entity remains free to challenge the validity of such laws and processes.

**Research**

We proposed to define “research” as it is defined in the Federal Policy for the Protection of Human Subjects, at 45 CFR part 46, subpart A (referred to elsewhere in this rule as “Common Rule”), and in addition, elaborated on the meaning of the term “generalizable knowledge.” In §164.504 of the proposed rule we defined research as “* * * a systematic investigation, including research development, testing and evaluation, designed to develop or contribute to generalizable knowledge. ‘Generalizable knowledge’ is knowledge related to health that can be applied to populations outside of the population served by the covered entity.”

The final rule eliminates the further elaboration of “generalizable knowledge.” Therefore, the rule defines “research” as “the term is defined in the Common Rule: a systematic investigation, including research development, testing and evaluation, designed to develop or contribute to generalizable knowledge. Research Information Unrelated to Treatment

We delete this definition and the associated requirements from the final rule. Refer to §164.508(f) for new requirements regarding authorizations for research that includes treatment of the individual.

**Treatment**

The proposed rule defined “treatment” as the provision of health care by, or the coordination of health care (including health care management of the individual through risk assessment, case management, and disease management) among, health care providers; the referral of a patient from one provider to another; or the coordination of health care or other services among health care providers and third parties authorized by the health plan or the individual. The preamble noted that the definition was intended to relate only to services provided to an individual and not to an entire enrolled population.

In the final rule, we do not change the general approach to defining treatment: treatment means the listed activities undertaken on behalf of a single patient, not a population. Activities are considered treatment only if delivered
by a health care provider or a health care provider working with another party. Activities of health plans are not considered to be treatment. Many services, such as a refill reminder communication or nursing assistance provided through a telephone service, are considered treatment activities if performed by or on behalf of a health care provider, such as a pharmacist, but are regarded as health care operations if done on behalf of a different type of entity, such as a health plan.

We delete specific reference to risk assessment, case management, and disease management. Activities often referred to as risk assessment, disease and case management are treatment activities only to the extent that they are services provided to a particular patient by a health care provider; population based analyses or records review for the purposes of treatment protocol development or modification are health care operations, not treatment activities. If a covered entity is licensed as both a health plan and a health care provider, a single activity could be considered to be both treatment and health care operations; for compliance purposes we would consider the purpose of the activity. Given the integration of the health care system we believe that further classification of activities into either treatment or health care operations would not be helpful. See the definition of health care operations for additional discussion.

Use

We proposed to define “use” to mean the employment, application, utilization, examination, or analysis of information within an entity that holds the information. In the final rule, we clarify that use refers to the use of individually identifiable health information. We replace the term “holds” with the term “maintains.” These changes are for clarity only, and are not intended to effect any substantive change.

Section 164.502—General Rules for Uses and Disclosures of Protected Health Information

Section 164.502(a)—Use and Disclosure for Treatment, Payment and Health Care Operations

As a general rule, we proposed in the NPRM to prohibit covered entities from using or disclosing protected health information except as authorized by the individual who is the subject of such information or as explicitly permitted by the proposed rule explicitly would have permitted covered entities to use or disclose an individual’s protected health information without authorization for treatment, payment, and health care operations. The proposal would not have restricted to whom disclosures could be made for the purposes of treatment, payment, or operations. The proposal would have allowed disclosure of the protected health information of one individual for the treatment or payment of another, as appropriate. We also proposed to prohibit covered entities from seeking individual authorization for uses and disclosures for treatment, payment, and health care operations unless required by state or other applicable law.

We proposed two exceptions to this general rule which prohibited covered entities from using or disclosing research information unrelated to treatment or psychotherapy notes for treatment, payment, or health care operations purposes unless a specific authorization was obtained from the subject of the information. In addition, we proposed that a covered entity be prohibited from conditioning treatment, enrollment in a health plan or payment decisions on a requirement that the individual provide a specific authorization for the disclosure of these two types of information (see proposed §164.508(a)(3)(iii)).

We also proposed to permit covered entities to use or disclose an individual’s protected health information for specified public and public policy-related purposes, including public health, research, health oversight, law enforcement, and use by coroners. In addition, the proposal would have permitted covered entities to use and disclose protected health information when required to do so by other law or pursuant to an authorization from the individual allowing them to use or disclose the information for purposes other than treatment, payment or health care operations.

We proposed to require covered entities to disclose protected health information for only two purposes: to permit individuals to inspect and copy protected health information about themselves and for enforcement of the rule.

We proposed not to require covered entities to vary the level of protection accorded to protected health information based on the sensitivity of such information. In addition, we proposed to require that each affected entity assess its own needs and devise, implement, and maintain appropriate privacy policies, procedures, and documentation to address its business requirements.

In the final rule, the general standard remains that covered entities may use or disclose protected health information only as permitted or required by this rule. However, we make significant changes to the conditions under which uses and disclosures are permitted.

We revise the application of the general standard to require covered health care providers who have a direct treatment relationship with an individual to obtain a general “consent” from the individual in order to use or disclose protected health information about the individual for treatment, payment and health care operations (for details on who must obtain such consents and the requirements they must meet, see §164.506). These consents are intended to accommodate both the covered provider’s need to use or disclose protected health information for treatment, payment, and health care operations, and also the individual’s interest in understanding and acquiescing to such uses and disclosures. In general, other covered entities are permitted to use and disclose protected health information to carry out treatment, payment, or health care operations (as defined in this rule) without obtaining such consent, as in the proposed rule. Covered entities must, as under the proposed rule, obtain the individual’s “authorization” in order to use or disclose psychotherapy notes for most purposes: see §164.508(a)(2) for exceptions to this rule. We delete the proposed special treatment of “research information unrelated to treatment.”

We revise the application of the general standard to require all covered entities to obtain the individual’s verbal “agreement” before using or disclosing protected health information for facility directories, to persons assisting in the individual’s care, and for other purposes described in §164.510. Unlike “consent” and “authorization,” verbal agreement may be informal and implied from the circumstances (for details on who must obtain such agreements and the requirements they must meet, see §164.510). Verbal agreements are intended to accommodate situations where it is neither appropriate to remove from the individual the ability to control the protected health information nor appropriate to require formal, written permission to share such information. For the most part, these provisions reflect current practices.

As under the proposed rule, we permit covered entities to use or disclose protected health information without the individual’s consent, authorization or agreement for specified
public policy purposes, in compliance with the requirements in §164.512.

We permit covered entities to disclose protected health information to the individual who is the subject of that information without any condition. We note that this may include disclosures to "personal representatives" of individuals as provided by §164.502(g).

We permit a covered entity to use or disclose protected health information for other lawful purposes if the entity obtains a written "authorization" from the individual, consistent with the provisions of §164.508. Unlike "consents," these "authorizations" are specific and detailed. For details on who must obtain such authorizations and the requirements they must meet, see §164.508. They are intended to provide the individuals with concrete information about, and control over, the uses and disclosures of protected health information about themselves.

The final rule retains the provision that requires a covered entity to disclose protected health information only in two instances: When individuals request access to information about themselves, and when disclosures are compelled by the Secretary for compliance and enforcement purposes.

Finally, §164.502(a)(1) also requires covered entities to use or disclose protected health information in compliance with the other provisions of §164.502, for example, consistent with the minimum necessary standard, to create de-identified information, or to a personal representative of an individual. These provisions are described below.

We note that a covered entity may use or disclose protected health information as permitted by and in accordance with a provision of this rule, regardless of whether that use or disclosure fails to meet the requirements for use or disclosure under another provision of this rule.

Section 164.502(b)—Minimum Necessary Uses and Disclosures

The proposed rule required a covered entity to make all reasonable efforts not to use or disclose more than the minimum amount of protected health information necessary to accomplish the intended purpose of the use or disclosure (proposed §164.506(b)). This final rule significantly modifies the proposed requirements for implementing the minimum necessary standard. In the final rule, §164.502(b) contains the basic standard and §164.514 describes the requirements for implementing the standard. Therefore, we discuss all aspects of the minimum necessary standard and specific requirements below in the discussion of §164.514(d).

Section 164.502(c)—Uses and Disclosures Under a Restriction Agreement

The proposed rule would have required that covered health care providers permit individuals to request restrictions of uses and disclosures of protected health information and would have prohibited covered providers from using or disclosing protected health information in violation of any agreed-to restriction.

The final rule retains an individual’s right to request restrictions on uses or disclosures for treatment, payment or health care operations and prohibits a covered entity from using or disclosing protected health information in a way that is inconsistent with an agreed upon restriction between the covered entity and the individual, but makes some changes to this right. Most significantly, under the final rule individuals have the right to request restrictions of all covered entities. This standard is set forth in §164.522. Details about the changes to the standard are explained in the preamble discussion to §164.522.

Section 164.502(d)—Creation of De-identified Information

In proposed §164.506(d) of the NPRM, we proposed to permit use of protected health information for the purpose of creating de-identified information and we provided detailed mechanisms for doing so.

In §164.502(d) of the final rule, we permit a covered entity to use protected health information to create de-identified information, whether or not the de-identified information is to be used by the covered entity. We clarify that de-identified information created in accordance with our procedures (which have been moved to §164.514(a)) is not subject to the requirements of these privacy rules unless it is re-identified. Disclosure of a key or mechanism that could be used to re-identify such information is also defined to be disclosure of protected health information. See the preamble to §164.514(a) for further discussion.

Section 164.502(e)—Business Associates

In the proposed rule, other than for purposes of consultation or referral for treatment, we would have allowed a covered entity to disclose protected health information to a business partner only pursuant to a written contract that would, among other specified provisions, limit the business partner’s uses and disclosures of protected health information to those permitted by the contract, and would impose certain security, inspection and reporting requirements on the business partner. We proposed to define the term “business partner” to mean, with respect to a covered entity, a person to whom the covered entity discloses protected health information so that the person can carry out, assist with the performance of, or perform on behalf of, a function or activity for the covered entity.

In the final rule, we change the term “business partner” to “business associate” and in the definition clarify the full range of circumstances in which a person is acting as a business associate of a covered entity. (See definition of “business associate” in §160.103.) These changes mean that §164.502(e) requires a business associate contract (or other arrangement, as applicable) not only when the covered entity discloses protected health information to a business associate, but also when the business associate creates or receives protected health information on behalf of the covered entity.

In the final rule, we modify the proposed standard and implementation specifications for business associates in a number of significant ways. These modifications are explained in the preamble discussion of §164.504(e).

Section 164.502(f)—Deceased Individuals

We proposed to extend privacy protections to the protected health information of a deceased individual for two years following the date of death. During the two-year time frame, we proposed in the definition of “individual” that the right to control the deceased individual’s protected health information would be held by an executor or administrator, or other person (e.g., next of kin) authorized under applicable law to act on behalf of the decedent’s estate. The only proposed exception to this standard allowed for uses and disclosures of a decedent’s protected health information for research purposes without the authorization of a legal representative and without the Institutional Review Board (IRB) or privacy board approval required (in proposed §164.510(f)) for most other uses and disclosures for research.

In the final rule (§164.502(f)), we modify the standard to extend protection of protected health information about deceased individuals for as long as the covered entity maintains the information. We retain the exemption for uses and disclosures for research purposes, now part of §164.512(i), but also require that the
covered entity take certain verification measures prior to release of the decedent’s protected health information for such purposes (see §§164.514(h) and 164.512(j)(1)(iii)).

We remove from the definition of “individual” the provision related to deceased persons. Instead, we create a standard for “personal representatives” (§164.502(g), see discussion below) that requires a covered entity to treat a personal representative of an individual as the individual in certain circumstances, i.e., allows the representative to exercise the rights of the individual. With respect to deceased individuals, the final rule describes when a covered entity must allow a person who otherwise is permitted under applicable law to act with respect to the interest of the decedent or on behalf of the decedent’s estate, to make decisions regarding the decedent’s protected health information.

The final rule also adds a provision to §164.512(g), that permits covered entities to disclose protected health information to a funeral director, consistent with applicable law, as necessary to carry out their duties with respect to the decedent. Such disclosures are permitted both after death and in reasonable anticipation of death.

Section 164.502(g)—Personal Representatives

In the proposed rule we defined “individual” to include certain persons who were authorized to act on behalf of the person who is the subject of the protected health information. For adults and emancipated minors, the NPRM provided that “individual” includes a legal representative to the extent to which applicable law permits such legal representative to exercise the individual’s rights in such contexts.

With respect to unemancipated minors, we proposed that the definition of “individual” include a parent, guardian, or person acting in loco parentis, (hereinafter referred to as “parent”) except when an unemancipated minor obtained health care services without the consent of, or notification to, a parent. Under the proposed rule, if a minor obtained health care services under these conditions, the minor would have had the exclusive rights of an individual with respect to the protected health information related to such health care services.

In the final rule, the definition of “individual” is limited to the subject of the protected health information, which includes unemancipated minors and other individuals who may lack capacity to act on their own behalf. We remove from the definition of “individual” the provisions regarding legal representatives. The circumstances in which a representative must be treated as an individual for purposes of this rule are addressed in a separate standard titled “personal representatives.” (§164.502(g)). The standard regarding personal representatives incorporates some changes to the proposed provisions regarding legal representatives.

In general, under the final regulation, the “personal representatives” provisions are directed at the more formal representatives, while §164.510(b) addresses situations in which persons are informally acting on behalf of an individual.

With respect to adults or emancipated minors, we clarify that a covered entity must treat a person as a personal representative of an individual if such person is, under applicable law, authorized to act on behalf of the individual in making decisions related to health care. This includes a court-appointed guardian and a person with a power of attorney, as set forth in the NPRM, but may also include other persons. The authority of a personal representative under this rule is limited: the representative must be treated as the individual only to the extent that protected health information is relevant to the matters on which the personal representative is authorized to represent the individual. For example, if a person’s authority to make health care decisions for an individual is limited to decisions regarding treatment for cancer, such person is a personal representative and must be treated as the individual with respect to protected health information related to the cancer treatment of the individual. Such a person is not the personal representative of the individual with respect to all protected health information about the individual, and therefore, a covered entity may not disclose protected health information that is not relevant to the cancer treatment to the person, unless otherwise permitted under the rule. We intend this provision to apply to persons empowered under state or other law to make health related decisions for an individual, whether or not the instrument or law granting such authority specifically addresses health information.

In addition, we clarify that with respect to an unemancipated minor, if under applicable law a parent may act on behalf of an unemancipated minor in making decisions related to health care, a covered entity must treat such person as a personal representative under this rule with respect to protected health information relevant to such personal representation, with three exceptions. Under the general rule, in most circumstances the minor would not have the capacity to act as the individual, and the parent would be able to exercise rights and authorities on behalf of the minor. Under the exceptions to the rule on personal representatives of unemancipated minors, the minor, and not the parent, would be treated as the individual and able to exercise the rights and authorities of an individual under the rule. These exceptions occur if: (1) The minor consents to a health care service; no other consent to such health care service is required by law, regardless of whether the consent of another person has also been obtained; and the minor has not requested that such person be treated as the personal representative; (2) the minor may lawfully obtain such health care service without the consent of a parent, and the minor, a court, or another person authorized by law consents to such health care service; or (3) a parent assents to an agreement of confidentiality between a covered health care provider and the minor with respect to such health care service. We note that the definition of health care includes services, but we use “health care service” in this provision to clarify that the scope of the rights of minors under this rule is limited to the protected health information related to a particular service.

Under this provision, we do not provide a minor with the authority to act under the rule unless the state has given them the ability to obtain health care without consent of a parent, or the parent has assented. In addition, we defer to state law where the state authorizes or prohibits disclosure of protected health information to a parent. See part 160, subpart B, Preemption of State Law. This rule does not affect parental notification laws that permit or require disclosure of protected health information to a parent. However, the rights of a minor under this rule are not otherwise affected by such notification. In the final rule, the definition of “personal representatives of deceased individuals has been changed to clarify the provision. The policy has not changed substantively from the NPRM.

Finally, we added a provision in the final rule to permit covered entities to elect not to treat a person as a personal representative in abusive situations.

Under this provision, a covered entity need not treat a person as a personal representative of an individual if the covered entity, in the exercise of professional judgment, decides that it is
not in the best interest of the individual to treat the person as the individual’s personal representative and the covered entity has a reasonable belief that the individual has been or may be subjected to domestic violence, abuse, or neglect by such person, or that treating such person as the personal representative could endanger the individual.

Section 164.502(g) requires a covered entity to treat a person that meets the requirements of a personal representative as the individual (with the exceptions described above). We note that disclosure of protected health information to a personal representative is mandatory under this rule only if disclosure to the individual is mandatory. Disclosure to the individual is mandatory only under §§164.524 and 164.528. Further, as noted above, the personal representative’s rights are limited by the scope of its authority under other law. Thus, this provision does not constitute a general grant of authority to personal representatives.

We make disclosure to personal representatives mandatory to ensure that an individual’s rights under §§164.524 and 164.528 are preserved even when individuals are incapacitated or otherwise unable to act for themselves to the same degree as other individuals. If the covered entity were to have the discretion to recognize a personal representative as the individual, there could be situations in which no one could invoke an individual’s rights under these sections.

We continue to allow covered entities to use their discretion to disclose certain protected health information to family members, relatives, close friends, and other persons assisting in the care of an individual, in accordance with §164.510(b). We recognize that many health care decisions take place on an informal basis, and we permit disclosures in certain circumstances to permit this practice to continue. Health care providers may continue to use their discretion to address these informal situations.

Section 164.502(h)—Confidential Communications

In the NPRM, we did not directly address the issue of whether an individual could request that a covered entity restrict the manner in which it communicated with the individual. The NPRM did provide individuals with the right to request that health care providers restrict uses and disclosures of protected health information for treatment, payment, and health operations, but providers were not required to agree to such a restriction.

In the final rule, we require covered providers to accommodate reasonable requests by patients about how the covered provider communicates with the individual. For example, an individual who does not want his or her family members to know about a certain treatment may request that the provider communicate with the individual at his or her place of employment, or to send communications to a designated address. Covered providers must accommodate the request unless it is unreasonable. Similarly, the final rule permits individuals to request that health plans communicate with them by alternative means, and the health plan must accommodate such a request if it is reasonable and the individual states that disclosure of the information could endanger the individual. The specific provisions relating to confidential communications are in §164.522.

Section 164.502(i)—Uses and Disclosures Consistent with Notice

We proposed to prohibit covered entities from using or disclosing protected health information in a manner inconsistent with their notice of information practices. We retain this provision in the final rule. See §164.520 regarding notice content and distribution requirements.

Section 164.502(j)—Disclosures by Whistleblowers and Workforce Member Crime Victims

Disclosures by Whistleblowers

In §164.518(c)(4) of the NPRM we addressed the issue of whistleblowers by proposing that a covered entity not be held in violation of this rule because a member of its workforce or a person associated with a business associate of the covered entity used or disclosed protected health information that such person believed was evidence of a civil or criminal violation, and any disclosure was: (1) Made to relevant oversight agencies or law enforcement or (2) made to an attorney to allow the attorney to determine whether a violation of criminal or civil law had occurred or to assess the remedies or actions at law that may be available to the person disclosing the information.

We included an extensive discussion on how whistleblower actions can further the public interest, including reference to the need in some circumstances to utilize protected health information for this purpose as well as reference to the qui tam provisions of the Federal False Claims Act.

In the final rule we retitle the provision and include it in §164.502 to reflect the fact that these disclosures are not made by the covered entity and therefore this material does not belong in the section on safeguarding information against disclosure.

We retain the basic concept in the NPRM of providing protection to a covered entity for the good faith whistleblower action of a member of its workforce or a business associate. We clarify that a whistleblower disclosure by an employee, subcontractor, or other person associated with a business associate is considered a whistleblower disclosure of the business associate under this provision. However, in the final rule, we modify the scope of circumstances under which a covered entity is protected in whistleblower situations. A covered entity is not in violation of the requirements of this rule when a member of its workforce or a business associate of the covered entity discloses protected health information to: (i) A health oversight agency or public health authority authorized by law to investigate or otherwise oversee the relevant conduct or conditions of the covered entity; (ii) an appropriate health care accreditation organization; or (iii) an attorney, for the purpose of determining his or her legal options with respect to whistleblowing. We delete disclosures to a law enforcement official.

We expand the scope of this section to cover disclosures of protected health information to an oversight or accreditation organization for the purpose of reporting breaches of professional standards or problems with quality of care. The covered entity will not in violation of this rule, provided that the disclosing individual believes in good faith that the covered entity has engaged in conduct which is unlawful or otherwise violates professional or clinical standards, or that the care, services or conditions provided by the covered entity potentially endanger one or more patients, workers or the public. Since these provisions only relate to whistleblower actions in relation to the covered entity, disclosure of protected health information to expose malfeasant conduct by another person, such as knowledge gained during the course of treatment about an individual’s illicit drug use, would not be protected activity.

We clarify that this section only applies to protection of a covered entity, based on the whistleblower action of a member of its workforce or business associates. Since the HIPAA legislation only applies to covered entities, not their workforces, it is beyond the scope of this rule to directly regulate the
whistleblower actions of members of a covered entity’s workforce.

In the NPRM, we had proposed to require covered entities to apply sanctions to members of its workforce who improperly disclose protected health information. In this final rule, we retain this requirement in § 164.530(e)(1) but modify the proposed provision on sanctions to clarify that the sanctions required under this rule do not apply to workforce members of a covered entity for whistleblower disclosures.

**Disclosures by Workforce Members Who Are Crime Victims**

The proposed rule did not address disclosures by workforce members who are victims of a crime. In the final rule, we clarify that a covered entity is not in violation of the rule when a workforce member of a covered entity who is the victim of a crime discloses protected health information to law enforcement officials about the suspected perpetrator of the crime. We limit the amount of protected health information that may be disclosed to the limited information for identification and location described in § 164.512(f)(2).

We note that this provision is similar to the provision in § 164.512(f)(5), which permits a covered entity to disclose protected health information to law enforcement that the covered entity believes in good faith constitutes evidence of criminal conduct that occurred on the premises of the covered entity. This provision differs in that it permits the disclosure even if the crime occurred somewhere other than on the premises of the covered entity. For example, if a hospital employee is the victim of an attack outside of the hospital, but the perpetrator seeks medical care at the hospital, the workforce member who was attacked may notify law enforcement of the perpetrator’s location and other identifying information. We do not permit, however, the disclosure of protected health information other than that described in § 164.512(f)(2).

**Section 164.504—Uses and Disclosures—Organizational Requirements—Component Entities, Affiliated Entities, Business Associates and Group Health Plans**

**Section 164.504(a)–(c)—Health Care Component (Component Entities)**

In the preamble to the proposed rule we introduced the concept of a “component entity” to differentiate the health care unit of a larger organization from the larger organization. In the proposal we noted that some organizations that are primarily involved in non-health care activities do provide health care services or operate health plans or health care clearinghouses. Examples included a school with an on-site health clinic and an employer that self-administers a sponsored health plan. In such cases, the proposal said that the health care component of the entity would be considered the covered entity, and any release of information from that component to another office or person in the organization would be a regulated disclosure. We would have required such entities to create barriers to prevent protected health information from being used or disclosed for activities not authorized or permitted under the proposal.

We discuss group health plans and their relationships with plan sponsors below under “Requirements for Group Health Plans.”

In the final rule we address the issue of differentiating health plan, covered health care provider and health care clearinghouse activities from other functions carried out by a single legal entity in paragraphs (a)–(c) of § 164.504. We have created a new term, “hybrid entity”, to describe the situation where a health plan, health care provider, or health care clearinghouse is part of a larger legal entity; under the definition, a “hybrid entity” is “a single legal entity that is a covered entity and whose covered functions are not its primary functions.” The term “covered functions” is discussed above under § 164.501. By “single legal entity” we mean a legal entity, such as a corporation or partnership, that cannot be further differentiated into units with their own legal identities. For example, for purposes of this rule a multinational corporation composed of multiple subsidiary companies would not be a single legal entity, but a small manufacturing firm and its health clinic, if not separately incorporated, could be a single legal entity.

The health care component rules are designed for the situation in which the health care functions of the legal entity are not its dominant mission. Because some part of the legal entity meets the definition of a health plan or other covered entity, the legal entity as a whole could be required to comply with the rules below. However, in such a situation, it makes sense not to require the entire entity to comply with the requirements of the rules below, when most of its activities may have little or nothing to do with the provision of health care; rather, as a practical matter, it makes sense for such an entity to focus its compliance efforts on the component that is actually performing the health care functions. On the other hand, where most of what the covered entity does consist of covered functions, it makes sense to require the entity as a whole to comply with the rules. The provisions at §§ 164.504(a)–(c) provide that for a hybrid entity, the rules apply only to the part of the entity that is the health care component. At the same time, the lack of corporate boundaries increases the risk that protected health information will be used in a manner that would not otherwise be permitted by these rules. Thus, we require that the covered entity erect firewalls to protect against the improper use or disclosure within or by the organization. See § 164.504(c)(2).

The term “primary functions” in the definition of “hybrid entity” is not meant to operate with mathematical precision. Rather, we intend that a more common sense evaluation take place: Is most of what the covered entity does related to its health care functions? If so, then the whole entity should be considered the covered entity. Entities with different insurance lines, if not separately incorporated, present a particular issue with respect to this analysis. Because the definition of “health plan” excludes many types of insurance products (in the exclusion under paragraph (2)(i) of the definition), we would consider an entity that has one or more of these lines of insurance in addition to its health insurance lines to come within the definition of “hybrid entity,” because the other lines of business constitute substantial parts of the total business operation and are required to be separate from the health plan(s) part of the business.

An issue that arises in the hybrid entity situation is what records are covered in the case of an office of the hybrid entity that performs support functions for both the health care component of the entity and for the rest of the entity. For example, this situation could arise in the context of a company with an on-site clinic (which we will assume is a covered health care provider), where the company’s business office maintains both clinic records and the company’s personnel records. Under the definition of the term “health care component,” the business office is part of the health care component (in this hypothetical, the clinic) “to the extent that” it is performing covered functions on behalf of the clinic involving the use or disclosure of protected health information that it receives from, creates or maintains for the clinic. Part of the business office, therefore, is part of the
health care component, and part of the business office is outside the health care component. This means that the non-health care component part of the business office is not covered by the rules below. Under our hypothetical, then, the business office would not be required to handle its personnel records in accordance with the rules below. The hybrid entity would be required to establish firewalls with respect to these record systems, to ensure that the clinic records were handled in accordance with the rules.

With respect to excepted benefits, the rules below operate as follows.

(Excepted benefits include accident, disability income, liability, workers’ compensation and automobile medical payment insurance.) Excepted benefit programs are excluded from the health care component (or components) through the definition of “health plan.” If a particular organizational unit performs both excepted benefits functions and covered functions, the activities associated with the excepted benefits program may not be part of the health care component. For example, an accountant who works for a covered entity with both a health plan and a life insurer would have his or her accounting functions performed for the health care component, but not the life insurance accounting function. See § 164.504(c)(2)(iii). We require this segregation of excepted benefits because HIPAA does not cover such programs, policies and plans, and we do not permit any use or disclosure of protected health information for the purposes of operating or performing the functions of the excepted benefits without authorization from the individual, except as otherwise permitted in this rule.

In § 164.504(c)(2) we require covered entities with a health care component to establish safeguard policies and procedures to prevent any access to protected health information by its other organizational units that would not be otherwise permitted by this rule. We note that section 1173(d)(1)(B) of HIPAA requires policies and procedures to isolate the activities of a health care clearinghouse from a “larger organization” to prevent unauthorized access by the larger organization. This safeguard provision is consistent with the statutory requirement and extends to any covered entity that performs “non-covered entity functions” or operates or conducts functions of more than one type of covered entity.

Because, as noted, the covered entity in the hybrid entity situation is the legal entity itself, we state explicitly what is implicitly the case, that the covered entity (legal entity) remains responsible for compliance vis-a-vis subpart C of part 160. See § 164.504(c)(3)(i). We do this simply to make these responsibilities clear and to avoid confusion on this point. Also, in the hybrid entity situation the covered entity/legal entity has control over the entire workforce, not just the workforce of the health care component. Thus, the covered entity is in a position to implement policies and procedures to ensure that the part of its workforce that is doing mixed or non-covered functions does not impermissibly use or disclose protected health information. Its responsibility to do so is clarified in § 164.504(c)(3)(ii).

Section 164.504(d)—Affiliated Entities

Some legally distinct covered entities may share common administration of organizationally differentiated but similar activities (for example, a hospital chain). In § 164.504(d) we permit legally distinct covered entities that share common ownership or control to designate themselves, or their health care components, together to be a single covered entity. Common control exists if an entity has the power, directly or indirectly, significantly to influence or direct the actions or policies of another entity. Common ownership exists if an entity or entities possess an ownership or equity interest of 5 percent or more in another entity.

Such organizations may promulgate a single shared notice of information practices and a consent form. For example, a corporation with hospitals in twenty states may designate itself as a covered entity and, therefore, able to merge information for joint marketplace analyses. The requirements that apply to a covered entity also apply to an affiliated covered entity. For example, under the minimum necessary provisions, a hospital in one state could not share protected health information about a particular patient with another hospital if such a use is not necessary for treatment, payment or health care operations. The covered entities that together make the affiliated covered entity are separately subject to liability under this rule. The safeguarding requirements for affiliated covered entities track the requirements that apply to health care components.

Section 164.504(e)—Business Associates

In the NPRM, we proposed to require a contract between a covered entity and a business associate, except for disclosures of protected health information to a covered entity that is a health care provider to another health care provider for the purposes of consultation or referral. A covered entity would have been in violation of this rule if the covered entity knew or reasonably should have known of a material breach of the contract by a business associate and it failed to take reasonable steps to cure the breach or terminate the contract. We proposed in the preamble that when a covered entity acted as a business associate to another covered entity, the covered entity that was acting as business associate also would have been responsible for any violations of the regulation.

We also proposed that covered health care providers receiving protected health information for consultation or referral purposes would still have been subject to this rule, and could not have used or disclosed such protected health information for a purpose other than the purpose for which it was received (i.e., the consultation or referral). Further, we noted that providers making disclosures for consultations or referrals should be careful to inform the receiving provider of any special limitations or conditions to which the disclosing provider had agreed to impose (e.g., the disclosing provider had provided notice to its patients that it would not make disclosures for research).

We proposed that business associates would not have been permitted to use or disclose protected health information in ways that would not have been permitted of the covered entity itself under these rules, and covered entities would have been required to take reasonable steps to ensure that protected health information disclosed to a business associate remained protected.

In the NPRM (proposed § 164.506(e)(2)) we would have required that the contractual agreement between a covered entity and a business associate be in writing and contain provisions that would:

• Prohibit the business associate from further using or disclosing the protected health information in a manner that would violate the requirements of this proposed rule if it were done by the covered entity.

• Require the business associate to maintain safeguards as necessary to ensure that the protected health information is not used or disclosed except as provided by the contract.

• Require the business associate to report to the covered entity any use or disclosure of the protected health information of which the business
with each covered entity that supplied addition, the business associate would have had to have been authorized, in

the contract or arrangement with each covered entity that supplied

the protected health information to combine or aggregate the information. A

covered entity would not have been permitted to obtain protected health information through a business associate that it could not otherwise obtain itself.

In the final rule we retain the overall approach proposed: covered entities may disclose protected health information to persons that meet the rule’s definition of business associate, or hire such persons to obtain or create protected health information for them, only if covered entities obtain specified satisfactory assurances from the business associate that it will appropriately handle the information; the regulation specifies the elements of such satisfactory assurances; covered entities have responsibilities when such specified satisfactory assurances are violated by the business associate. We retain the requirement that specified satisfactory assurances must be obtained if a covered entity’s business associate is also a covered entity. We note that a master business associate contract or MOU that otherwise meets the requirements regarding specified satisfactory assurances meets the requirements with respect to all the signatories.

A covered entity may disclose protected health information to a business associate, consistent with the other requirements of the final rule, as necessary to permit the business associate to perform functions and activities for or on behalf of the covered entity, or to provide services specified in the business associate definition to or for the covered entity. As discussed below, a business associate may only use the protected health information it receives in its capacity as a business associate to a covered entity as permitted by its contract or agreement with the covered entity.

We do not attempt to directly regulate business associates, but pursuant to our authority to regulate covered entities we place restrictions on the flow of information from covered entities to non-covered entities. We add a provision to clarify that a violation of a business associate agreement by a covered entity that is a business associate of another covered entity constitutes a violation of this rule.

In the final rule, we make significant changes to the requirements regarding business associates. As explained below in more detail: we make significant changes to the content of the required contractual satisfactory assurances; we include exceptions for arrangements that would otherwise meet the
clears checks, initiates or processes electronic funds transfers, or conducts any other activity that directly facilitates or effects the transfer of funds for compensation for health care. A typical consumer-conducted payment transaction is when a consumer pays for health care or health insurance premiums using a check or credit card. In these cases, the identity of the consumer is always included and some health information (e.g., diagnosis or procedure) may be implied through the name of the health care provider or health plan being paid. Covered entities that initiate such payment activities must meet the minimum necessary disclosure requirements described in the preamble to §164.514.

In the final rule, we reduce the extent to which a covered entity must monitor the actions of its business associate and we make it easier for covered entities to identify the circumstances that will require them to take actions to correct a business associate’s material violation of the contract, in the following ways. We delete the proposed language requiring covered entities to “take reasonable steps to ensure” that each business associate complies with the rule’s requirements. Additionally, we now require covered entities to take reasonable steps to cure a breach or terminate the contract for business associate behaviors only if they know of a material violation by a business associate. In implementing this standard, we will view a covered entity that has substantial and credible evidence of a violation as knowing of such violation. While this standard relieves the covered entity of the need to actively monitor its business associates, a covered entity nonetheless is expected to investigate when they receive complaints or other information that contain substantial and credible evidence of violations by a business associate, and it must act upon any knowledge of such violation that it possesses. We note that a whistleblowing disclosure by a business associate of a covered entity that meets the requirements of §164.502(j)(1) does not put the covered entity in violation of this rule, and the covered entity has no duty to correct or cure, or to terminate the relationship.

We also qualify the requirement for terminating contracts with non-compliant business associates. The final rule still requires that the business associate contract authorize the covered entity to terminate the contract, if the covered entity determines that the business associate has violated a material term of the contract, and it requires the covered entity to terminate the contract if steps to cure such a material breach fail. The rule now stipulates, however, that if the covered entity is unable to cure a material breach of the business associate’s obligation under the contract, it is expected to terminate the contract, when feasible. This qualification has been added to accommodate circumstances where terminating the contract would be unreasonably burdensome on the covered entity, such as when there are no viable alternatives to continuing a contract with that particular business associate. It does not mean, for instance, that the covered entity can choose to continue the contract with a non-compliant business associate merely because it is more convenient or less costly than contracts with other potential business associates. We also require that if a covered entity determines that it is not feasible to terminate a non-compliant business associate, the covered entity must notify the Secretary.

We retain all of the requirements for a business associate contract that were listed in proposed §164.506(e)(2), with some modifications. See §164.504(e)(2).

We retain the requirement that the business associate contract must provide that the business associate will not use or further disclose the information other than as permitted or required by the contract or as required by law. We do not mean by this requirement that the business associate contract must specify each and every use and disclosure of protected health information to the business associate. Rather, the contract must state the purposes for which the business associate may use and disclose protected health information, and must indicate generally the reasons and types of persons to whom the business associate may make further disclosures. For example, attorneys often need to provide information to potential witnesses, opposing counsel, and others in the course of their representation of a client. The business associate contract pursuant to which protected health information is provided to its attorney may include a general statement permitting the attorney to disclose protected health information to these types of people, within the scope of its representation of the covered entity.

We retain the requirement that a business associate contract may not authorize a business associate to use or further disclose protected health information in a manner that would violate the requirements of this subpart if done by the covered entity in order to permit the combining or aggregation of protected health information received in its capacity as a business associate of another covered entity, to permit the creation of data for analyses that relate to the health care operations of the respective covered entities. We added this service to the business associate definition to clarify the ability of covered entities to contract with business associates to undertake quality assurance and comparative analyses that involve the protected health information of more than one contracting covered entity. We except data aggregation from the general requirement that a business associate contract may not authorize a business associate to use or further disclose protected health information in a manner that would violate the requirements of this subpart if done by the covered entity in order to permit the combining or aggregation of protected health information received in its capacity as a business associate of different covered entities when it is performing this service. In many cases, the combining of this information for the respective health care operations of the covered entities is not something that the covered entities could do—a covered entity cannot generally disclose protected health information to another covered entity for the disclosing covered entity’s health care operations. However, we permit covered entities that enter into business associate contracts with a business associate for data aggregation to permit the business associate to combine or aggregate the protected health information they
disclose to the business associate for their respective health care operations.

We note that there may be other instances in which a business associate may combine or aggregate protected health information received in its capacity as a business associate of different covered entities, such as when it is performing health care operations on behalf of covered entities that participate in an organized health care arrangement. A business associate that is performing payment functions on behalf of different covered entities also may combine protected health information when it is necessary, such as when the covered entities share financial risk or otherwise jointly bill for services.

In the final rule we clarify that the business associate contract must require the business associate to make available protected health information for amendment and to incorporate such amendments. The business associate contract must also require the business associate to retain the information required to provide an accounting of disclosures. We provide more flexibility to the requirement that all protected health information be returned by the business associate upon termination of the contract. The rule now stipulates that if feasible, the protected health information should be destroyed or returned at the end of a contract. Accordingly, a contract with a business associate must state that if there are reasons that the return or destruction of the information is not feasible, an alternative action must be retained for specific reasons and uses, such as for future audits, privacy protections must continue after the contract ends, for as long as the business associate retains the information. The contract also must state that the uses of information after termination of the contract must be limited to the specific set of uses or disclosures that make it necessary for the business associate to retain the information.

We also remove the requirement that business associate contracts contain a provision stating that individuals whose protected health information is disclosed under the contract are intended third-party beneficiaries of the contract. Third party beneficiary or similar responsibilities may arise under these business associate arrangements by operation of state law; we do not intend in this rule to affect the operation of such state laws.

We modify the requirement that a business associate contract require the business associate to ensure that agents abide by the provisions of the business associate contract. We clarify that agents includes subcontractors, and we note that a business associate contract must make the business associate responsible for ensuring that any person to whom it delegates a function, activity or service which is within its business associate contract with the covered entity agrees to abide by the restrictions and conditions that apply to the business associate under the contract. We note that a business associate will need to consider the purpose for which protected health information is being disclosed in determining whether the recipient must be bound to the restrictions and conditions of the business associate contract. When the disclosure is a delegation of a function, activity or service that the business associate has agreed to perform for a covered entity, the recipient who undertakes such a function steps into the shoes of the business associate and must be bound to the restrictions and conditions. When the disclosure is to a third party who is not performing business associate functions, activities or services for on behalf of the covered entity, but is the type of disclosure that the covered entity itself could make without giving rise to a business associate relationship, the business associate is not required to ensure that the restrictions or conditions of the business associate contract are maintained.

For example, if a business associate acts as the billing agent of a health care provider, and discloses protected health information on behalf of the hospital to health plans, the business associate has no responsibility with respect to further uses or disclosures by the health plan. In the example above, where a covered entity has a business associate contract with a lawyer, and the lawyer discloses protected health information to an expert witness in preparation for litigation, the lawyer again would have no responsibility under this subpart with respect to uses or disclosures by the expert witness, because such witness is not undertaking the functions, activities or services that the business associate has agreed to perform. However, if a covered entity contracts with a third party administrator to provide claims management, and the administrator delegates management of the pharmacy benefits to a third party, the business associate third party administrator must ensure that the pharmacy manager abides by the restrictions and conditions in the business associate contract between the covered entity and the third party administrator.

We provide in § 164.504(c)(3) several methods other than a business associate contract that will satisfy the requirement for satisfactory assurances under this section. First, when a government agency is a business associate of another government agency that is a covered entity, we permit memorandum of understanding between the agencies to constitute satisfactory assurance for the purposes of this rule, if the memorandum fulfills each of the objectives of the business associate contract. We recognize that the relationships of government agencies are often organized as a matter of law, and that it is not always feasible for one agency to contract with another for all of the purposes provided for in this section. We also recognize that it may be incorrect to view one government agency as “acting on behalf of” the other government agency; under law, each agency may be acting to fulfill a statutory mission. We note that in some instances, it may not be possible for the agencies to include the right to terminate the arrangement because the relationship may be established under law. In such instances, the covered entity government agency would need to fulfill the requirement to report known violations of the memorandum to the Secretary.

Where the covered entity is a government agency, we consider the satisfactory assurances requirement to be satisfied if other law contains requirements applicable to the business associate that accomplish each of the objectives of the business associate contract. We recognize that in some cases, covered entities that are government agencies may be able to impose the requirements of this section directly on the persons acting as their business associates. We also recognize that often one government agency is acting as a business associate of another government agency, and either party may have the legal authority to establish the requirements of this section by regulation. We believe that imposing these requirements directly on business associates provides greater protection than we can otherwise provide under this section, and so we recognize such other laws as sufficient to substitute for a business associate contract.

We also recognize that there may be some circumstances where the relationship between covered entities and business associates is otherwise mandated by law. In the final rule, we provide that where a business associate is required by law to act as a business associate to a covered entity, the covered entity may disclose protected health information to the business associate to the extent necessary to comply with the legal mandate without
meeting the requirement to have a business associate contract (or, in the case of government agencies, a memorandum of understanding or law pertaining to the business associate) if it makes a good faith attempt to obtain satisfactory assurances required by this section and, if unable to do so, documents the attempt and the reasons that such assurances cannot be obtained. This provision addresses situations where law requires one party to act as the business associate of another party. The fact that the parties have contractual obligations that may be enforceable is not sufficient to meet the required by law test in this provision.

This provision recognizes that in some instances the law requires that a government agency act as a business associate of a covered entity. For example, the United States Department of Justice is required by law to defend tort suits brought against certain covered entities; in such circumstances, however, the United States, and not the individual covered entity, is the client and is potentially liable. In such situations, covered entities must be able to disclose protected health information needed to carry out the representation, but the particular requirements that would otherwise apply to a business associate relationship may not be possible to obtain. Subsection (iii) makes clear that, where the relationship is required by law, the covered entity complies with the rule if it attempts, in good faith, to obtain satisfactory assurances as are required by this paragraph and, if such attempt fails, documents the attempts and the reasons that such assurances cannot be obtained.

The operation of the final rule maintains the construction discussed in the preamble to the NPRM that a business associate (including a business associate that is a covered entity) that has business associate contracts with more than one covered entity generally may not use or disclose the protected health information that it creates or receives in its capacity as a business associate of one covered entity for the purposes of carrying out its responsibilities as a business associate of another covered entity, unless doing so would be a lawful use or disclosure for each of the covered entities and the business associate’s contract with each of the covered entities permits the business associate to undertake the activity. For example, a business associate performing a function under health care operations on behalf of an organized health care arrangement would be permitted to combine or aggregate the protected health information obtained from covered entities participating in the arrangement to the extent necessary to carry out the authorized activity and in conformance with its business associate contracts. As described above, a business associate providing data aggregation services to different covered entities also could combine and use the protected health information of the covered entities to assist with their respective health care operations. A covered entity that is undertaking payment activities on behalf of different covered entities also may use or disclose protected health information obtained as a business associate of one covered entity when undertaking such activities as a business associate of another covered entity where the covered entities have authorized the activities and where they are necessary to secure payment for the entities. For example, when a group of providers share financial risk and contract with a business associate to conduct payment activities on their behalf, the business associate may use the protected health information received from the covered entities to assist them in managing their shared risk arrangement.

Finally, we note that the requirements imposed by this provision are intended to extend privacy protection to situations in which a covered entity discloses substantial amounts of protected health information to other persons so that those persons can perform functions or activities on its behalf or deliver specified services to it. A business associate contract basically requires the business associate to maintain the confidentiality of the protected health information that it receives and generally to use and disclose such information for the purposes for which it was provided. This requirement does not interfere with the relationship between a covered entity and business associate, or require the business associate to subordinate its professional judgment to that of a covered entity. Covered entities may rely on the professional judgment of their business associate to the type and amount of protected health information that is necessary to carry out a permitted activity. The requirements of this provision are aimed at securing the continued confidentiality of protected health information disclosed to third parties that are serving the covered entity’s interests.

Section 164.504(f)—Group Health Plans

Covered entities under HIPAA include health care clearinghouses, health care providers and health plans. Specifically included in the definition of “health plan” are group health plans (as defined in section 2791(a) of the Public Health Service Act) with 50 or more participants or those of any size that are administered by an entity other than the employer who established and maintains the plan. These group health plans may be fully insured or self-insured. Neither employers nor other group health plan sponsors are defined as covered entities. However, employers and other plan sponsors—particularly those sponsors with self-insured group health plans—may perform certain functions that are integrally related to or similar to the functions of group health plans and, in carrying out these functions, often require access to individual health information held by the group health plan.

Most group health plans are also regulated under the Employee Retirement Income Security Act of 1974 (ERISA). Under ERISA, a group health plan must be a separate legal entity from its plan sponsor. ERISA-covered group health plans usually do not maintain a corporate presence, in other words, they may not have their own employees and sometimes do not have their own assets (i.e., they may be fully insured or the benefits may be funded through the general assets of the plan sponsor, rather than through a trust). Often, the only tangible evidence of the existence of a group health plan is the contractual agreement that describes the rights and responsibilities of covered participants, including the benefits that are offered and the eligible recipients.

ERISA requires the group health plan to identify a “named fiduciary,” a person responsible for ensuring that the plan is operated and administered properly and with ultimate legal responsibility for the plan. If the plan documents under which the group health plan was established and is maintained permit, the named fiduciary may delegate certain responsibilities to trustees and may hire advisors to assist it in carrying out its functions. While generally the named fiduciary is an individual, it may be another entity. The plan sponsor or employees of the plan sponsor are often the named fiduciaries. These structural and operational relationships present a problem in our ability to protect health information from being used inappropriately in employment-related decisions. On the one hand, the group health plan, and any health insurance issuer or HMO providing health insurance or health coverage to the group health plan, are covered entities under the regulation and may only disclose protected health information as authorized under the
regulation or with individual consent. On the other hand, plan sponsors may need access to protected health information to carry out administration functions on behalf of the plan, but under circumstances in which securing individual consent is impractical. We note that we sometimes refer in the rule and preamble to health insurance issuers and HMOs that provide health insurance or health coverage to a group health plan as health insurance issuers or HMOs with respect to a group health plan.

The proposed rule used the health care component approach for employers and other plan sponsors. Under this approach, only the component of an employer or other plan sponsor would be treated as a covered entity. The component of the plan sponsor would have been able to use protected health information for treatment, payment, and health care operations, but not for other purposes, such as discipline, hiring and firing, placement and promotions. We have modified the final rule in a number of ways.

In the final rule, we recognize plan sponsors’ legitimate need for health information in certain situations while, at the same time, protecting health information from being used for employment-related functions or for other functions related to other employee benefit plans or other benefits provided by the plan sponsor. We do not attempt to directly regulate employers or other plan sponsors, but pursuant to our authority to regulate health plans, we place restrictions on the flow of information from covered entities to non-covered entities.

The final rule permits group health plans, and allows them to authorize health insurance issuers or HMOs with respect to the group health plan, to disclose protected health information to plan sponsors if the plan sponsors voluntarily agree to use and disclose the information only as permitted or required by the regulation. The information may be used only for plan administration functions performed on behalf of the group health plan which are specified in plan documents. The group health plan is not required to have a business associate contract with the plan sponsor to disclose the protected health information or allow the plan sponsor to create protected health information on its behalf, if the conditions of § 164.504(e) are met.

In order for the group health plan to disclose protected health information to a plan sponsor, the plan documents under which the plan was established and is maintained must be amended to: (1) Describe the permitted uses and disclosures of protected health information; (2) specify that disclosure is permitted only upon receipt of a certification from the plan sponsor that the plan documents have been amended and the plan sponsor has agreed to certain conditions regarding the use and disclosure of protected health information; and (3) provide adequate firewalls to: identify the employees or classes of employees who will have access to protected health information; restrict access solely to the employees identified and only for the functions performed on behalf of the group health plan; and provide a mechanism for resolving issues of noncompliance.

Any employee of the plan sponsor who receives protected health information for payment, health care operations or other matters related to the group health plan must be identified in the plan documents either by name or function. We assume that since individuals employed by the plan sponsor may change frequently, the group health plan would likely describe such individuals in a general manner. Any disclosure to employees or classes of employees not identified in the plan documents is not a permissible disclosure. To the extent a group health plan does have its own employees separate from the plan sponsor’s employees, as the workforce of a covered entity (i.e., the group health plan), they also are bound by the permitted uses and disclosures of this rule.

The certification that must be given to the group health plan must state that the plan sponsor agrees to: (1) Not use or further disclose protected health information other than as permitted or required by the plan documents or as required by law; (2) ensure that any subcontractors or agents to whom the plan sponsor provides protected health information agree to the same restrictions; (3) not use or disclose the protected health information for employment-related actions; (4) report to the group health plan any use or disclosure that is inconsistent with the plan documents or this regulation; (5) make the protected health information accessible to individuals; (6) allow individuals to amend their information; (7) provide an accounting of its disclosures; (8) make its practices available to the Secretary for determining compliance; (9) return and destroy all protected health information when no longer needed, if feasible; and (10) ensure that the firewalls have been established.

We have included this certification requirement in part, as a way to reduce the burden on health insurance issuers and HMOs. Without a certification, health insurance issuers and HMOs would need to review the plan documents in order to ensure that the amendments have been made before they could disclose protected health information to plan sponsors. The certification, however, is a simple statement that the amendments have been made and that the plan sponsor has agreed to certain restrictions on the use and disclosure of protected health information. The receipt of the certification therefore, is sufficient basis for the health insurance issuer or HMO to disclose protected health information to the plan sponsor.

Many activities included in the definitions of health care operations and payment are commonly referred to as plan administration functions in the ERISA group health plan context. For purposes of this rule, plan administration activities are limited to activities that would meet the definition of payment or health care operations, but do not include functions to modify, amend, or terminate the plan or solicit bids from prospective issuers. Plan administration functions include quality assurance, claims processing, auditing, monitoring, and management of carve-out plans—such as vision and dental. Under the final rule, “plan administration” does not include any employment-related functions or functions in connection with any other benefits or benefit plans, and group health plans may not disclose information for such purposes absent an authorization from the individual. For purposes of this rule, enrollment functions performed by the plan sponsor on behalf of its employees are not considered plan administration functions.

Plan sponsors have access to protected health information only to the extent group health plans have access to protected health information and plan sponsors are permitted to use or disclose protected health information only as would be permitted by group health plans. That is, a group health plan may permit a plan sponsor to have access to or to use protected health information only for purposes allowed by the regulation.

As explained above, where a group health plan purchases insurance or coverage from a health insurance issuer or HMO, the provision of insurance or coverage by the health insurance issuer or HMO to the group health plan does not make the health insurance issuer or HMO a business associate. In such case, the activities of the health insurance issuer or HMO are on their own behalf and not on the behalf of the group
health plan. We note that where a group health plan contracts with a health insurance issuer or HMO to perform functions or activities or to provide services that are in addition to or not directly related to the provision of insurance, the health insurance issuer or HMO may be a business associate with respect to those additional functions, activities, or services. In addition, group health plans that provide health benefits only through an insurance contract and do not create, maintain, or receive protected health information (except for summary information described below or information that merely states whether an individual is enrolled in or has been disenrolled from the plan) do not have to meet the notice requirements of § 164.520 or the administrative requirements of § 164.530, except for the documentation requirement in § 164.530(j), because these requirements are satisfied by the issuer or HMO that is providing benefits under the group health plan. A group health plan, however, may not permit a health insurance issuer or HMO to disclose protected health information to a plan sponsor unless the notice required in 164.520 indicate such disclosure may occur.

The final rule also permits a health plan that is providing insurance to a group health plan to provide summary information to the plan sponsor to permit the plan sponsor to solicit premium bids from other health plans or for the purpose of modifying, amending, or terminating the plan. The rule provides that summary information is information that summarizes claims history, claims expenses, or types of claims experienced by individuals for whom the plan sponsor has provided health benefits under a group health plan, provided that specified identifiers are not included. Summary information may be disclosed under this provision even if it does not meet the definition of de-identified information. As part of the notice requirements in § 164.520, health plans must inform individuals that they may disclose protected health information to plan sponsors. The provision to allow summaries of claims experience to be disclosed to plan sponsors that purchase insurance will allow them to shop for replacement coverage, and get meaningful bids from prospective issuers. It also permits a plan sponsor to get summary information as part of its consideration of whether or not to change the benefits that are offered or employees or whether or not to terminate a group health plan. We note that a plan sponsor may perform enrollment functions on behalf of its employees without meeting the conditions above and without using the standard transactions described in the Transactions Rule.

Section 164.504(g)—Multiple Covered Function Entities

Although not addressed in the proposed rule, this final rule also recognizes that a covered entity may as a single legal entity, affiliated entity, or other arrangement combine the functions or operations of health care providers, health plans and health care clearinghouses (for example, integrated health plans and health care delivery systems may function as both health plans and health care providers). The rule permits such covered entities to use or disclose the protected health information of its patients or members for all covered entity functions, consistent with the other requirements of this rule. The health care component must meet the requirements of this rule that apply to a particular type of covered entity when it is functioning as that entity: e.g., when a health care component is operating as a health care provider it must meet the requirements of this rule applicable to a health care provider. However, such covered entities may not use or disclose the protected health information of an individual who is not involved in a particular covered entity function for that function, and such information must be segregated from any joint information systems. For example, an HMO may integrate data about health plan members and clinic services to members, but a health care system may not share information about a patient in its hospital with its health plan if the patient is not a member of the health plan.

Section 164.506—Uses and Disclosures for Treatment, Payment, and Health Care Operations

Introduction: “Consent” versus “Authorization”

In the proposed rule, we used the term “authorization” to describe the individual’s written permission for a covered entity to use and disclose protected health information, regardless of the purpose of the use or disclosure. Authorization would have been required for all uses and disclosures that were not otherwise permitted or required under the NPM. We proposed to permit covered entities, subject to limited exceptions for psychotherapy notes and research information unrelated to treatment, to use and disclose protected health information to carry out treatment, payment, and health care operations without authorization. See proposed § 164.506(a)(1).

We also proposed to prohibit covered entities from requiring individuals to sign authorizations for uses and disclosures of protected health information for treatment, payment, and health care operations, unless required by other applicable law. See proposed § 164.508(a)(iv). We instead proposed requiring covered entities to produce a notice describing their information practices, including practices with respect to uses and disclosures to carry out treatment, payment, and health care operations.

In the final rule, we retain the requirement for covered entities to obtain the individual’s written permission (an “authorization”) for uses and disclosures of protected health information that are not otherwise permitted or required under the rule. However, under the final rule, we add a second type of written permission for use or disclosure of protected health information: a “consent” for uses and disclosures to carry out treatment, payment, and health care operations. In the final rule, we permit, and in some cases require, covered entities to obtain the individual’s written permission for the covered entity to use or disclose protected health information other than psychotherapy notes to carry out treatment, payment, and health care operations. We refer to this written permission as a “consent.”

The “consent” and the “authorization” do not overlap. The requirement to obtain a “consent” applies in different circumstances than the requirement to obtain an authorization. In content, a consent and an authorization differ substantially from one another.

As described in detail below, a “consent” allows use and disclosure of protected health information only for treatment, payment, and health care operations. It is written in general terms and refers the individual to the covered entity’s notice for further information about the covered entity’s privacy practices. It allows use and disclosure of protected health information by the covered entity seeking the consent, not by other persons. Most persons who obtain a consent will be health care providers; health plans and health care clearinghouses may also seek a consent. The consent requirements appear in § 164.506 and are described in this section of the preamble.

With a few exceptions, an “authorization” allows use and disclosure of protected health information for purposes other than treatment, payment, and health care operations.
operations. In order to make uses and disclosures that are not covered by the consent requirements and not otherwise permitted or required under the final rule, covered entities must obtain the individual’s “authorization.” An “authorization” must be written in specific terms. It may allow use and disclosure of protected health information by the covered entity seeking the authorization, or by a third party. In some instances, a covered entity may not refuse to treat or cover individuals based on the fact that they refuse to sign an authorization. See § 164.508 and the corresponding preamble discussion regarding authorization requirements.

Section 164.506(a)—Consent Requirements

We make significant changes in the final rule with respect to uses and disclosures of protected health information to carry out treatment, payment, and health care operations. We do not cover those situations where the covered entity is unable to obtain the individual’s consent, as described below.

Except as described below, we instead require covered health care providers to obtain the individual’s consent prior to using or disclosing protected health information to carry out treatment, payment, or health care operations. If the covered provider does not obtain the individual’s consent, the provider is prohibited from using or disclosing protected health information about the individual for purposes of treating the individual, obtaining payment for health care delivered to the individual, or for the provider’s health care operations. See § 164.506(a)(1).

We except two types of health care providers from this consent requirement. First, covered health care providers that have an indirect treatment relationship with an individual are not required to obtain the individual’s consent prior to using or disclosing protected health information about the individual to carry out treatment, payment, and health care operations. An “indirect treatment relationship” is defined in § 164.501 and described in the corresponding preamble. These providers may use and disclose protected health information as otherwise permitted under the rule and consistent with its notice of privacy practices (see § 164.520 regarding notice requirements and § 164.502(i) regarding requirements to adhere to the notice). For example, a covered provider that provides consultation services to another provider without seeing the patient would have an indirect treatment relationship with that patient and would not be required to obtain the patient’s consent to use protected health information about the patient for the consultation. These covered providers are, however, permitted to obtain consent, as described below.

Second, covered health care providers that create or receive protected health information in the course of providing health care to inmates of a correctional institution are not required to obtain the inmate’s consent prior to using or disclosing protected health information about the inmate to carry out treatment, payment, and health care operations. See § 164.501 and the corresponding preamble discussion regarding the definitions of “correctional institution” and “inmate.” These providers may use and disclose protected health information as otherwise permitted under the rule. These providers are permitted, however, to obtain consent, as described below.

In addition, we permit covered health care providers to use and disclose protected health information, without consent, to carry out treatment, payment, and health care operations, if the protected health information was created or received in certain treatment situations. In the treatment situations described in § 164.506(a)(3) and immediately below, the covered health care provider must attempt to obtain the individual’s consent. If the covered provider is unable to obtain consent, but documents the attempt and the reason consent was not obtained, the covered provider may, without consent, use and disclose the protected health information resulting from the treatment as otherwise permitted under the rule. All other protected health information about that individual that the covered health care provider creates or receives, however, is subject to the consent requirements.

This exception to the consent requirement applies to protected health information created or received in any of three treatment situations. First, the exception applies to protected health information created or received in emergency treatment situations. In these situations, covered providers must attempt to obtain the consent as soon as reasonably practicable after the delivery of the emergency treatment. Second, the exception applies to protected health information created or received in situations where the covered health care provider is required by law to treat the individual (that is, certain publicly funded providers) and the covered health care provider attempts to obtain such consent. Third, the exception applies to protected health information created or received in treatment situations where there are substantial barriers to communicating with the individual and, in the exercise of professional judgment, the covered provider clearly infers from the circumstances the individual’s consent to receive treatment. For example, there may be situations in which a mentally incapacitated individual seeks treatment from a health care provider but is unable to provide informed consent to undergo such treatment and does not have a personal representative available to provide such consent on the individual’s behalf. If the covered provider, in her professional judgment, believes she can legally provide treatment to that individual, we also permit the provider to use and disclose protected health information resulting from the treatment without the individual’s consent. We intend covered health care providers that legally provide treatment without the individual’s consent to that treatment to be able to use and disclose protected health information resulting from that treatment to carry out treatment, payment, or health care operations without obtaining the individual’s consent for such use or disclosure. We do not intend to impose unreasonable barriers to individuals’ ability to receive, and health care providers’ ability to provide, health care.

Under § 164.506(a)(4), covered health care providers that have an indirect treatment relationship with an individual, as well as health plans and health care clearinghouses, may elect to seek consent for their own uses and disclosures to carry out treatment, payment, and health care operations. If such a covered entity seeks consent for these purposes, the consent must meet the minimum requirements described below.

If a covered health care provider with an indirect treatment relationship, a health plan, or a health care clearinghouse does seek consent, the covered entity may use or disclose protected health information to carry out treatment, payment, or health care operations as otherwise permitted under the rule and consistent with its notice of privacy practices (see § 164.520 regarding notice requirements and § 164.502(i) regarding requirements to adhere to the notice).

If a covered health care provider with an indirect treatment relationship, a health plan, or a health care clearinghouse does not have an individual to sign a consent, and the individual does not do so, the covered entity is...
prohibited under § 164.502(a)(1) from using or disclosing protected health information for the purpose(s) included in the consent. A covered entity that seeks a consent must adhere to the individual’s decision. In § 164.506(a)(5), we specify that a consent obtained by one covered entity is not effective to permit another covered entity to use or disclose protected health information, unless the consent is a joint consent. See § 164.506(f) and the corresponding preamble discussion below regarding joint consents. A consent provides the individual’s permission only for the covered entity that obtains the consent to use or disclose protected health information for treatment, payment, and health care operations. A consent under this section does not operate to authorize another covered entity to use or disclose protected health information, except where the other covered entity is operating as a business associate. We note that, where a covered entity is acting as a business associate of another covered entity, the business associate covered entity is acting for or on behalf of the principal covered entity, and its actions for or on behalf of the principal covered entity are authorized by the consent obtained by the principal covered entity. Thus, under this section, a health plan can obtain a consent that permits the health plan and its business associates to use and disclose protected health information that the health plan and its business associates create or receive. That consent, however, permits another covered entity (that is not a business associate) to disclose protected health information to the health plan or to any other person.

If a covered entity wants to obtain the individual’s permission for another covered entity to disclose protected health information to it for treatment, payment, or health care operations purposes, it must seek an authorization in accordance with § 164.508(e). For example, when a covered provider asks the individual for written permission to obtain the individual’s medical record from another provider for treatment purposes, it must do so with an authorization, not a consent. Since the permission is for disclosure of protected health information by another person, a consent may not be used.

Section 164.506(b)—Consent General Requirements

In the final rule, we permit a covered health care provider to condition the provision of treatment on the receipt of the individual’s consent for the covered provider to use and disclose protected health information to carry out treatment, payment, and health care operations. Covered providers may refuse to treat individuals who do not consent to uses and disclosures for these purposes. See § 164.506(b)(1). We note that there are exceptions to the consent requirements for covered health care providers that are required by law to treat individuals. See § 164.506(a)(3), described above.

Similarly, in the final rule, we permit health plans to condition an individual’s enrollment in the health plan on the receipt of the individual’s consent for the health plan to use and disclose protected health information to carry out treatment, payment, and health care operations, if the consent is sought in conjunction with the enrollment process. If the health plan seeks the individual’s consent outside of the enrollment process, the health plan may not condition any services on obtaining such consent.

Under § 164.520, covered entities must produce notice of privacy practices. A consent may not be combined in a single document with the notice of privacy practices. See § 164.506(b)(3).

Under § 164.506(b)(4), consents for uses and disclosures of protected health information to carry out treatment, payment, and health care operations may be combined in a single document covering all three types of activities and may be combined with other types of legal permission from the individual. For example, a consent to use or disclose protected health information under this rule may be combined with an informed consent to receive treatment, a consent to assign payment of benefits to a provider, or narrowly tailored consents required under state law for the use or disclosure of specific types of protected health information (e.g., state laws requiring specific consent for any sharing of information related to HIV/AIDS).

Within a single consent document, the consent for use and disclosure of protected health information required or permitted under this rule must be visually and organizationally separate from the other consents or authorizations and must be separately signed by the individual and dated.

Where research includes treatment of the individual, a consent under this rule may be combined with the authorization for the use or disclosure of protected health information created for the research, in accordance with § 164.508(f). (This is the only case in which an authorization under § 164.508 of this rule may be combined with a consent under § 164.506 of this rule. See § 164.508(b)(3).) The covered entity that is creating protected health information for the research may elect to combine the consent required under this section with the research-related authorization required under § 164.508(f). For example, a covered health care provider that provides health care to an individual for research purposes and for non-research purposes must obtain a consent under this section for all of the protected health information it maintains. In addition, it must obtain an authorization in accordance with § 164.508(f) which describes how it will use and disclose the protected health information it creates for the research for purposes of treatment, payment, and health care operations. Section 164.506(b)(4) permits the covered entity to satisfy these two requirements with a single document. See § 164.508(f) and the corresponding preamble discussion for a more detailed description of research authorization requirements.

Under § 164.506(b)(5), individuals may revoke a consent in writing at any time, except to the extent that the covered entity has taken action in reliance on the consent. Upon receipt of the written revocation, the covered entity must stop processing the information for use or disclosure, except to the extent that it has taken action in reliance on the consent. A covered health care provider may refuse, under this rule, to continue to treat an individual that revokes his or her consent. A health plan may disenroll an individual that revokes a consent that was sought in conjunction with the individual’s enrollment in the health plan.

Covered entities must document and retain any signed consent as required by § 164.530(j).

Section 164.506(c)—Consent Content Requirements

Under § 164.506(c), the consent must be written in plain language. See the preamble discussion regarding notice of privacy practices for a description of plain language requirements. We do not provide a model consent in this rule. We will provide further guidance on drafting consent documents prior to the compliance date.

Under § 164.506(c)(1), the consent must inform the individual that protected health information may be used and disclosed by the covered entity to carry out treatment, payment, or health care operations. The covered entity must determine which of these elements (use and/or disclosure; treatment, payment, and/or health care operations) to include in the consent.
document, as appropriate for the covered entity’s practices. For covered health care providers that are required to obtain consent, the requirement applies only to the extent the covered provider uses or discloses protected health information. For example, if all of a covered provider’s health care operations are conducted by members of the covered provider’s own workforce, the covered provider may choose to obtain consent only for uses, not disclosures, of protected health information to carry out health care operations. If an individual pays out of pocket for all services received from the covered provider and the provider will not disclose any information about the patient to a third party payor, the provider may choose not to obtain the individual’s consent to disclose information for payment purposes.

In order for a covered provider to be able to use and disclose information for all three purposes, however, all three purposes must be included in the consent.

Under §§ 164.506(c)(2) and (3), the consent must refer the individual to the covered entity’s notice for additional information about the uses and disclosures of information described in the consent. The consent must also indicate that the individual has the right to review the notice prior to signing the consent. If the covered entity has reserved the right to change its privacy practices in accordance with § 164.520(b)(1)(v)(C), the consent must indicate that the terms of the notice may change, and must describe how the individual may obtain a revised notice. See § 164.520 and the corresponding preamble discussion regarding notice requirements.

Under § 164.506(c)(4), the consent must inform individuals that they have the right to request restrictions on uses and disclosures of protected health information for treatment, payment, and health care operations purposes. It must also state that the covered entity is not required to agree to an individual’s request, but that if the covered entity does agree to the request, the restriction is binding on the covered entity. See § 164.522(a) regarding the right to request restrictions.

Under § 164.506(c)(5), the consent must indicate that the individual has the right to revoke the consent in writing, except to the extent that the covered entity has taken action in reliance on the consent.

Under § 164.506(c)(6), the consent must include the individual’s signature and the purpose. Once we adopt the standards for electronic signature, another of the required administrative simplification standards we are required to adopt under HIPAA, an electronic signature that meets those standards will be sufficient under this rule. We do not require any verification of the individual’s identity or authentication of the individual’s signature.

We expect covered health care providers that are required to obtain consent to employ the same level of scrutiny to these signatures as they do to the signature obtained on a document regarding the individual’s consent to undergo treatment by the provider.

Section 164.506(d)—Defective Consents

Under § 164.506(d), there is no “consent” within the meaning of the rule if the completed document lacks a required element or if the individual has revoked the consent in accordance with § 164.506(b)(5).

Section 164.506(e)—Resolving Conflicting Consents and Authorizations

Situations may arise where a covered entity that has obtained the individual’s consent for the covered entity to use or disclose protected health information to carry out treatment, payment, or health care operations is asked to disclose protected health information pursuant to another written legal permission from the individual, such as an authorization, that was obtained by another person. Under § 164.506(e), when the terms of a covered entity’s consent conflict with the terms of another written legal permission from the individual to use or disclose protected health information (such as a consent obtained under state law by another covered entity or an authorization), the covered entity must adhere to the more restrictive document. By conflict, we mean that the consent and authorization contain inconsistencies. In implementing this section, we note that the consent under this section references the notice provided to the individual and the individual’s right to request restrictions. In determining whether the covered entity’s consent conflicts with another written legal permission provided by the individual, the covered entity must consider any limitations on its uses or disclosures resulting from the notice provided to the individual or from restrictions to which it has agreed. For example, a covered nursing home may elect to ask the patient to sign an authorization for the patient’s covered primary care physician to forward the patient’s medical records to the nursing home. The physician may have previously obtained the individual’s consent for disclosure for treatment purposes. If the authorization obtained by the nursing home grants permission for the physician to disclose particular types of information, such as genetic information, but the consent obtained by the physician excludes such information or the physician has agreed to a restriction on that type of information, the physician may not disclose that information. The physician must adhere to the more restrictive written legal permission from the individual.

When a conflict between a consent and another written legal permission from the individual exists, as described above, the covered entity may attempt to resolve the conflict with the individual by either obtaining a new consent from the individual or by having a discussion or otherwise communicating with the individual to determine the individual’s preference regarding the use or disclosure. If the individual’s preference is communicated orally, the covered entity must document the individual’s preference and act in accordance with that preference. In the example described above, the primary care physician could ask the patient to sign a new consent that would permit the disclosure of the genetic information. Alternatively, the physician could ask the patient whether the patient intended for the genetic information to be disclosed to the nursing home. If the patient confirms that he or she intended for the genetic information to be shared, the physician can document that fact (e.g., by making a notation in the medical record) and disclose the information to the nursing home.

We believe covered entities will rarely be faced with conflicts between consents and other written legal permission from the individual for uses and disclosures to carry out treatment, payment, and health care operations purposes. Under § 164.506(a)(5), we specify that a consent only permits the covered entity that obtains the consent to use or disclose protected health information. A consent obtained by one covered entity is not effective to permit another different covered entity to use or disclose protected health information. Conflicting consents obtained by covered entities, therefore, are not possible. We expect authorizations that permit another covered entity to use and disclose protected health information for treatment, payment, and health care operations purposes will rarely be necessary, because we expect covered entities that maintain protected health information to obtain consents that permit them to make anticipated uses and disclosures for these purposes. Nevertheless, covered entities are permitted under § 164.508(e) to obtain
authorization for another covered entity to use or disclose protected health information to carry out treatment, payment, and health care operations. We recognize these authorizations may be useful to demonstrate an individual’s intent and relationship to the intended recipient of the information. For example, these authorizations may be useful in situations where a health plan wants to obtain information from one provider in order to determine payment of a claim for services provided by a different provider (e.g., information from a primary care physician that is necessary to determine payment of services provided by a specialist) or where an individual’s new physician wants to obtain the individual’s medical records from prior physicians. Other persons not covered by this rule may also seek authorizations and state law may require written permission for specific types of information, such as information related to HIV/AIDS or to mental health. Because an individual may sign conflicting documents over time, we clarify that the covered entity maintaining the protected health information to be used or disclosed must adhere to the more restrictive permission the individual has granted, unless the covered entity resolves the conflict with the individual.

Section 164.506(f)—Joint Consents

Covered entities that participate in an organized health care arrangement and that develop a joint notice under § 164.520(d) may develop a joint consent in which the individual consents to the uses and disclosures of protected health information by each of the covered entities in the arrangement to carry out treatment, payment, and/or health care operations. The joint consent must identify with reasonable specificity the covered entities, to which the joint consent applies and must otherwise meet the consent requirements. If an individual revokes a joint consent, the covered entity that receives the revocation must inform the other entities covered by the joint consent of the revocation as soon as practicable.

If any one of the covered entities included in the joint consent obtains the individual’s consent, as required above, the consent requirement is met for all of the other covered entities to which the consent applies. For example, a covered hospital and the clinical laboratory and emergency departments with which it participates in an organized health care arrangement may produce a joint notice and obtain consent. If the covered hospital obtains the individual’s joint consent upon admission, and some time later the individual is readmitted through the associated emergency department, the emergency department’s consent requirement will already have been met. These joint consents are the only type of consent by which one covered entity can obtain the individual’s permission for another covered entity to use or disclose protected health information to carry out treatment, payment, or health care operations.

Effect of Consent

These consents, as well as the authorizations described in § 164.508, should not be construed to waive, directly or indirectly, any privilege granted under federal, state, or local law or procedure. Consents obtained under this regulation are not appropriate for the disposition of more technical and legal proceedings and may not comport with procedures and standards of federal, state, or local judicial practice. For example, state courts and other decision-making bodies may choose to examine more closely the circumstances and propriety of such consent and may adopt more protective standards for application in their proceedings. In the judicial setting, as in the legislative and executive settings, states may provide for greater protection of privacy. Additionally, both the Congress and the Secretary have established a general approach to protecting from explicit preemption state laws that are more protective of privacy than the protections set forth in this regulation.

Section 164.508—Uses and Disclosures for Which an Authorization Is Required

Section 164.508(a)—Standard

We proposed to require covered entities to obtain the individual’s authorization for all uses and disclosures of protected health information not otherwise permitted or required under the proposed rule. Uses and disclosures that would have been permitted without individual authorization included uses and disclosures for national priority purposes such as public health, law enforcement, and research (see proposed § 164.510) and uses and disclosures of protected health information, other than psychotherapy notes and research information unrelated to treatment, for purposes of treatment, payment, and health care operations (see proposed § 164.506). We also proposed to require covered entities to disclose protected health information to the individual for inspection and copying (see proposed § 164.514) and to the Secretary as required for enforcement of the rule (see proposed § 164.522). Individual authorization would not have been required for these uses and disclosures.

We proposed to require covered entities to obtain the individual’s authorization for all other uses and disclosures of protected health information. Under proposed § 164.508(a), uses and disclosures that would have required individual authorization included, but were not limited to, the following:

- Use for marketing of health and non-health items and services by the covered entity;
- Use by sale, rental, or barter;
- Use and disclosure to non-health related divisions of the covered entity, e.g., for use in marketing life or casualty insurance or banking services;
- Use, disclosure, prior to an individual’s enrollment in a health plan, to the health plan or health care provider for making eligibility or enrollment determinations relating to the individual or for underwriting or risk rating determinations;
- Disclosure to an employer for use in employment determinations; and
- Use or disclosure for fundraising.

In the preamble to the proposed rule, we stated that covered entities would be bound by the terms of authorizations. Uses or disclosures by the covered entity for purposes inconsistent with the statements made in the authorization would have constituted a violation of the rule.

In the final rule, under § 164.508(a), as in the proposed rule, covered entities must have authorization from individuals before using or disclosing protected health information for any purpose not otherwise permitted or required by this rule. Specifically, except for psychotherapy notes (see below), covered entities are not required to obtain the individual’s authorization to use or disclose protected health information to carry out treatment, payment, and health care operations. (Covered entities may, however, be required to obtain the individual’s consent for these uses and disclosures. See the preamble regarding § 164.506 for a discussion of “consent” versus “authorization.”) We also do not require covered entities to obtain the individual’s authorization for uses and disclosures of protected health information permitted under §§ 164.510 or 164.512, for disclosures to the individual, or for required disclosures to the Secretary under subpart C of part 160 of this subchapter for enforcement of this rule.

In the final rule, we clarify that covered entities are bound by the
statements provided on the authorization; use or disclosure by the covered entity for purposes inconsistent with the statements made in the authorization constitutes a violation of this rule.

Unlike the proposed rule, we do not include in the regulation examples of the types of uses and disclosures that require individual authorization. We eliminated two examples from the proposed list due to potential confusion as to our intent: disclosure by sale, rental, or barter and use and disclosure to non-health related divisions of the covered entity. We recognize that covered entities sometimes make these types of uses and disclosures for purposes that are permitted under the rule without authorization. For example, a covered health care provider may sell its accounts receivable to a collection agency for payment purposes and a health plan may disclose protected health information to its life insurance company for payment purposes. We do not intend to require authorization for uses and disclosures made by sale, rental, or barter or for disclosures made to non-health related divisions of the covered entity, if those uses or disclosures could otherwise be made without authorization under this rule. As with any other use or disclosure, however, uses and disclosures of protected health information for these purposes do require authorization if they are not otherwise permitted under the rule.

We also eliminated the remaining proposed examples from the final rule due to concern that these examples might be misinterpreted as an exhaustive list of all of the uses and disclosures that require individual authorization. We discuss the examples here, however, to clarify the interaction of the authorization requirements and the provisions of the rule that permit uses and disclosures without authorization and/or with consent. Uses and disclosures for which covered entities must have the individual’s authorization include, but are not limited to, the following activities.

**Marketing**

As in the proposed rule, covered entities must obtain the individual’s authorization before using or disclosing protected health information for marketing purposes. In the final rule, we add a new definition of marketing (see §164.501). For more detail on what activities constitute marketing, see §164.501, definition of “marketing,” and §164.514(e).

**Pre-Enrollment Underwriting**

As in the proposed rule, covered entities must obtain the individual’s authorization to use or disclose protected health information for the purpose of making eligibility or enrollment determinations relating to an individual or for underwriting or risk rating determinations, prior to the individual’s enrollment in a health plan (that is, for purposes of pre-enrollment underwriting). For example, if an individual applies for new coverage with a health plan in the non-group market and the health plan wants to review protected health information from the individual’s covered health care providers before extending an offer of coverage, the individual first must authorize the covered providers to share the information with the health plan. If the individual applies for renewal of existing coverage, however, the health plan would not need to obtain an authorization to review its existing claims records about that individual, because this activity would come within the definition of health care operations and be permissible. We also note that under §164.504(f), a group health plan and a health insurance issuer that provides benefits with respect to a group health plan are permitted in certain circumstances to disclose summary health information to the plan sponsor for the purpose of obtaining premium bids. Because these disclosures fall within the definition of health care operations, they do not require authorization.

**Employment Determinations**

As in the proposed rule, covered entities must obtain the individual’s authorization to use or disclose protected health information for employment determinations. For example, a covered health care provider must obtain the individual’s authorization to disclose the results of a pre-employment physical to the individual’s employer. The final rule provides that a covered entity may condition the provision of health care that is solely for the purpose of creating protected health information for disclosure to a third party on the provision of authorization for the disclosure of the information to the third party.

**Fundraising**

Under the proposed regulation, we would have required authorization before a covered entity could have used or disclosed protected health information for fundraising. In the final rule, we narrow the circumstances under which covered entities must obtain the individual’s authorization to use or disclose protected health information for fundraising purposes. As provided in §164.514(f) and described in detail in the corresponding preamble, authorization is not required when a covered entity uses or discloses demographic information and information about the dates of health care provided to an individual for the purpose of raising funds for its own benefit, nor when it discloses such information to an institutionally related foundation to raise funds for the covered entity.

Any use or disclosure for fundraising purposes that does not meet the requirements of §164.514(f) and does not fall within the definition of health care operations (see §164.501), requires authorization. Specifically, covered entities must obtain the individual’s authorization to use or disclose protected health information to raise funds for any entity other than the covered entity. For example, a covered entity must have the individual’s authorization to use protected health information about the individual to solicit funds for a non-profit organization that engages in research, education, and awareness efforts about a particular disease.

**Psychotherapy Notes**

In the NPRM, we proposed different rules with respect to psychotherapy notes than we proposed with respect to all other protected health information. The proposed rule would have required covered entities to obtain an authorization for any use or disclosure of psychotherapy notes to carry out treatment, payment, or health care operations, unless the use was by the person who created the psychotherapy notes. With respect to all other protected health information, we proposed to prohibit covered entities from requiring authorization for uses and disclosures for these purposes.

We significantly revise our approach to psychotherapy notes in the final rule. With a few exceptions, covered entities must obtain the individual’s authorization to use or disclose psychotherapy notes to carry out treatment, payment, or health care operations. A covered entity must obtain the individual’s consent, but not an authorization, for the person who created the psychotherapy notes to use the notes to carry out treatment and for the covered entity to use or disclose psychotherapy notes for conducting training programs in which students, trainees, or practitioners in mental health learn under supervision to
practice or improve their skills in group, joint, family, or individual counseling. A covered entity may also use psychotherapy notes to defend a legal action or other proceeding brought by the individual pursuant to a consent, without a specific authorization. We note that, while this provision allows disclosure of these records to the covered entity’s attorney to defend against the action or proceeding, disclosure to others in the course of a judicial or administrative proceeding is governed by §164.512(e). This special provision is necessary because disclosure of protected health information for purposes of legal representatives may be made under the general consent as part of “health care operations.” Because we require an authorization for disclosure of psychotherapy notes for “health care operations,” an exception is needed to allow covered entities to use protected health information about an individual to defend themselves against an action threatened or brought by that individual without asking that individual for authorization to do so. Otherwise, a consent under §164.506 is not sufficient for the use or disclosure of psychotherapy notes to carry out treatment, payment, or health care operations. Authorization is required.

We anticipate these authorizations will rarely be necessary, since psychotherapy notes do not include information that covered entities typically need for treatment, payment, or other types of health care operations.

In the NPRM, we proposed to permit covered entities to use and disclose psychotherapy notes for all other purposes permitted or required under the rule without authorization. In the final rule, we specify a more limited set of uses and disclosures of psychotherapy notes that covered entities are permitted to make without authorization. An authorization is not required for use or disclosure of psychotherapy notes when required for enforcement purposes, in accordance with subpart C of part 160 of this subchapter; when mandated by law, in accordance with §164.512(a); when needed for oversight of the health care provider who created the psychotherapy notes, in accordance with §164.512(d); when needed by a coroner or medical examiner, in accordance with §164.512(g)(1); or when needed to avert a serious and imminent threat to health or safety, in accordance with §164.512(j)(3). We also provide transition provisions in §164.532 regarding the effect of express legal permission obtained from an individual prior to the compliance date of this rule.

Section 164.508(b)—Implementation Specifications for Authorizations

Valid and Defective Authorizations

We proposed to require a minimum set of elements for authorizations requested by the individual and an additional set of elements for authorizations requested by a covered entity. We would have permitted covered entities to use and disclose protected health information pursuant to authorizations containing the applicable required elements. We would have prohibited covered entities from acting on an authorization if the submitted document had any of the following defects:

- The expiration date had passed;
- The form had not been filled out completely;
- The covered entity knew the authorization had been revoked;
- The completed form lacked a required element; or
- The covered entity knew the information on the form was false.

In §164.508(b)(1) of the final rule, we specify that an authorization containing the applicable required elements (as described below) is a valid authorization. We clarify that a valid authorization may contain additional, non-required elements, provided that these elements are not inconsistent with the required elements. Covered entities are not required to use or disclose protected health information pursuant to a valid authorization. Our intent is to clarify that a covered entity that uses or discloses protected health information pursuant to an authorization meeting the applicable requirements will be in compliance with this rule.

We retain the provision prohibiting covered entities from acting on an authorization if the submitted document had any of the listed defects, with a few changes. First, in §164.508(c)(1)(iv) we specify that an authorization may expire upon a certain event or on a specific date. For example, a valid authorization may state that it expires upon acceptance or rejection of an application for insurance or upon the termination of employment (for example, in an authorization for disclosure of protected health information for fitness-for-duty purposes) or similar event. The expiration event must, however, be related to the individual or the purpose of the use or disclosure. An authorization that purported to expire on the date when the stock market reached a specified level would not be valid. Under §164.508(b)(2)(i), if the expiration event is known by the covered entity to have occurred, the authorization is defective. Second, we clarify that certain compound authorizations, as described below, are defective. We also clarify that authorizations that are not completely filled out with respect to the required elements are defective. Finally, we clarify that an authorization with information that the covered entity knows to be false is defective only if the information is material.

As under the proposed regulation, an authorization that the covered entity knows has been revoked is not a valid authorization. We note that, although an authorization must be revoked in writing, the covered entity may not always “know” that an authorization has been revoked. The writing required for an individual to revoke an authorization may not always trigger the “knowledge” required for a covered entity to consider an authorization defective. Conversely, a copy of the written revocation is not required before a provider “knows” that an authorization has been revoked.

Many authorizations will be obtained by persons other than the covered entity. If the individual revokes an authorization by writing to that other person, and neither the individual nor the other person informs the covered entity of the revocation, the covered entity will not “know” that the authorization has been revoked. For example, a government agency may obtain an individual’s authorization for “all providers who have seen the individual in the past year” to disclose protected health information to the agency for purposes of determining eligibility for benefits. The individual may revoke the authorization by writing to the government agency requesting such revocation. We cannot require the agency to inform all covered entities to whom it has presented the authorization that the authorization has been revoked. If a covered entity does not know of the revocation, the covered entity will not violate this rule by acting pursuant to the authorization. At the same time, if the individual does inform the covered entity of the revocation, even orally, the covered entity “knows” that the authorization has been revoked and can no longer treat the authorization as valid under this rule. Thus, in this example, if the individual tells a covered entity that the individual has revoked the authorization, the covered entity “knows” of the revocation and must consider the authorization defective under §164.508(b)(2).
Compound Authorizations

Except for authorizations requested in connection with a clinical trial, we proposed to prohibit covered entities from combining an authorization for use or disclosure of protected health information for purposes other than treatment, payment, or health care operations with an authorization or consent for treatment (e.g., an informed consent to receive care) or payment (e.g., an assignment of benefits).

We clarify the prohibition on compound authorizations in the final rule. Other than as described below, § 164.508(b)(3) prohibits a covered entity from acting on an authorization required under this rule that is combined with any other document, including any other written legal permission from the individual. For example, an authorization under this rule may not be combined with a consent for use or disclosure of protected health information under § 164.506, with the notice of privacy practices under § 164.520, with any other form of written legal permission for the use or disclosure of protected health information, with an informed consent to participate in research, or with any other form of consent or authorization for treatment or payment.

There are three exceptions to this prohibition. First, under § 164.508(f) (described in more detail, below), an authorization for the use or disclosure of protected health information created for research that includes treatment of the individual may be combined with a consent for the use or disclosure of that protected health information to carry out treatment, payment, or health care operations under § 164.506 and with other documents as provided in § 164.508(f). Second, authorizations for the use or disclosure of psychotherapy notes for multiple purposes may be combined in a single document, but may not be combined with authorizations for the use or disclosure of other protected health information.

Third, authorizations for the use or disclosure of protected health information other than psychotherapy notes may be combined, provided that the covered entity has not conditioned the provision of treatment, payment, enrollment, or eligibility on obtaining the authorization. If a covered entity conditions any of these services on obtaining an authorization from the individual, as permitted in § 164.508(b)(4) and described below, the covered entity must not combine the authorization with any other document.

The following are examples of valid compound authorizations: an authorization for the disclosure of information created for clinical research combined with a consent for the use or disclosure of other protected health information to carry out treatment, payment, and health care operations, and the informed consent to participate in the clinical research; an authorization for disclosure of psychotherapy notes for both treatment and research purposes; and an authorization for the disclosure of the individual’s demographic information for both marketing and fundraising purposes.

Examples of invalid compound authorizations include: an authorization for the disclosure of protected health information for treatment, for research, and for determining payment of a claim for benefits, when the covered entity will refuse to pay the claim if the individual does not sign the authorization; or an authorization for the disclosure of psychotherapy notes combined with an authorization to disclose any other protected health information.

Prohibition on Conditioning Treatment, Payment, Eligibility, or Enrollment

We proposed to prohibit covered entities from conditioning treatment or payment on the provision by the individual of an authorization, except when the authorization was requested in connection with a clinical trial. In the case of authorization for use or disclosure of psychotherapy notes or research information unrelated to treatment, we proposed to prohibit covered entities from conditioning treatment, payment, or enrollment in a health plan on obtaining such an authorization.

We retain this basic approach but refine its application in the final rule. In addition to the general prohibition on conditioning treatment and payment, covered entities are also prohibited (with certain exceptions described below) from conditioning eligibility for benefits or enrollment in a health plan on obtaining an authorization. This prohibition extends to all authorizations, not just authorizations for use or disclosure of psychotherapy notes. This prohibition is intended to prevent covered entities from coercing individuals into signing an authorization for a use or disclosure that is not necessary to carry out the primary services that the covered entity provides to the individual. For example, a health care provider could not refuse to treat an individual because the individual refused to authorize a disclosure to a pharmaceutical manufacturer for the purpose of marketing a new product.

We clarify the proposed research exception to this prohibition. Covered entities seeking authorization in accordance with § 164.508(f) to use or disclose protected health information created for the purpose of research that includes treatment of the individual, including clinical trials, may condition the research-related treatment on the individual’s authorization. Permitted use of protected health information is part of the decision to receive care through a clinical trial, and health care providers conducting such trials should be able to condition research-related treatment on the individual’s willingness to authorize the use or disclosure of his or her protected health information for research associated with the trial.

In addition, we permit health plans to condition eligibility for benefits and enrollment in the health plan on the individual’s authorization for the use or disclosure of protected health information for purposes of eligibility or enrollment determinations relating to the individual or for its underwriting or risk-rating determinations. We also permit health plans to condition payment of a claim for specified benefits on the individual’s authorization for the disclosure of information maintained by another covered entity to the health plan, if the disclosure is necessary to determine payment of the claim. These exceptions do not apply, however, to authorization for the use or disclosure of psychotherapy notes. Health plans may not condition payment, eligibility, or enrollment on the receipt of an authorization for the use or disclosure of psychotherapy notes, even if the health plan intends to use the information for underwriting or payment purposes.

Finally, when a covered entity provides treatment for the sole purpose of providing information to a third party, the covered entity may condition the treatment on the receipt of an authorization to use or disclose protected health information related to that treatment. For example, a covered health care provider may have a contract with an employer to provide fitness-for-duty exams to the employer’s employees. The provider may refuse to conduct the exam if an individual refuses to authorize the provider to disclose the results of the exam to the employer. Similarly, a covered health care provider may have a contract with a life insurer to provide pre-enrollment physicals to applicants for life insurance coverage. The provider may refuse to conduct the physical if an individual refuses to authorize the provider to disclose the results of the physical to the life insurer.
Revocation of Authorizations

We proposed to allow individuals to revoke an authorization at any time, except to the extent that the covered entity had taken action in reliance on the authorization.

We retain this provision, but specify that the individual must revoke the authorization in writing. When an individual revokes an authorization, a covered entity that knows of such revocation must stop making uses and disclosures pursuant to the authorization to the greatest extent practical. A covered entity may continue to use and disclose protected health information in accordance with the authorization only to the extent the covered entity has taken action in reliance on the authorization. For example, a covered entity is not required to retrieve information that it has already disclosed in accordance with the authorization. (See above for discussion of how written revocation of an authorization and knowledge of that revocation may differ.)

We also include an additional exception. Under §164.508(b)(5), individuals do not have the right to revoke an authorization if the authorization was obtained as a condition of obtaining insurance coverage and other applicable law provides the insurer that obtained the authorization with the right to contest a claim under the policy. We intend this exception to permit insurers to obtain necessary protected health information during contestability periods under state law. For example, an individual may not revoke an authorization for the disclosure of protected health information to a life insurer for the purpose of investigating material misrepresentation if the individual’s policy is still subject to the contestability period.

Documentation

In the final rule, we clarify that a covered entity must document and retain any signed authorization as required by §164.530(j) (see below).

Section 164.508(c)—Core Elements and Requirements

We proposed to require authorizations requested by individuals to contain a minimum set of elements: a description of the information to be used or disclosed; the name of the covered entity, or class of entities or persons, authorized to make the use or disclosure; the name or types of recipients of the information; an expiration date; the individual’s signature and date of signature; if signed by a representative, a description of the representative’s authority or relationship to the individual; a statement regarding the individual’s right to revoke the authorization; and a statement that the information may no longer be protected by the federal privacy law. We proposed a model authorization form that entities could have used to satisfy the authorization requirements. If the model form was not used, we proposed to require covered entities to use authorization forms written in plain language.

We modify the proposed approach, by eliminating the distinction between authorizations requested by the individuals and authorizations requested by others. Instead, we prescribe a minimum set of elements for authorizations and certain additional elements when the authorization is requested by a covered entity for its own use or disclosure of protected health information it maintains or for receipt of protected health information from another covered entity to carry out treatment, payment, or health care operations.

The core elements are required for all authorizations, not just authorizations requested by individuals. Individuals seek disclosure of protected health information about them to others in many circumstances, such as when applying for life or disability insurance, when government agencies conduct suitability investigations, and in seeking certain job assignments when health status is relevant. Another common instance is when an individual’s attorney needs individually identifiable health information to evaluate an injury claim and asks the individual to authorize disclosure of records relating to the injury to the attorney. In each of these situations, the individual may go directly to the covered entity and ask it to send the relevant information to the intended recipient. Alternatively, the intended recipient may ask the individual to complete a form, which the recipient will submit to the covered entity on the individual’s behalf, that authorizes the covered entity to disclose the information. Whether the authorization is submitted to the covered entity by the individual or by another person on the individual’s behalf, the covered entity maintaining protected health information may not use or disclose it pursuant to an authorization unless the authorization meets the following requirements.

First, the authorization must include a description of the information to be used or disclosed, with sufficient specificity to allow the covered entity to know which information the authorization references. For example, the authorization may include a description of “laboratory results from July 1998” or “all laboratory results” or “results of MRI performed in July 1998.” The covered entity can then use or disclose that information and only that information. If the covered entity does not understand what information is covered by the authorization, the use or disclosure is not permitted unless the covered entity clarifies the request.

There are no limitations on the information that can be authorized for disclosure. If an individual wishes to authorize a covered entity to disclose his or her entire medical record, the authorization can so specify. In order for the covered entity to disclose the entire medical record, the authorization must be specific enough to ensure that the individual has a clear understanding that the entire record will be disclosed. For example, if the Social Security Administration seeks authorization for release of all health information to facilitate the processing of benefit applications, then the description on the authorization form must specify “all health information” or the equivalent.

In some instances, a covered entity may be reluctant to undertake the effort to review the record and select portions relevant to the request (or redact portions not relevant). In such circumstances, covered entities may provide the entire record to the individual, who may then redact and release the more limited information to the requestor. This rule does not require a covered entity to disclose information pursuant to an individual’s authorization.

Second, the authorization must include the name or other specific identification of the person(s) or class of persons that are authorized to use or disclose the protected health information. If an authorization permits a class of covered entities to disclose information to an authorized person, the class must be stated with sufficient specificity so that a covered entity presented with the authorization will know with reasonable certainty that the individual intended the covered entity to release protected health information. For example, a covered licensed nurse practitioner presented with an authorization for “all physicians” to disclose protected health information could not know with reasonable certainty that the individual intended for the practitioner to be included in the authorization.

Third, the authorization must include the name or other specific identification of the person(s) or class of persons to
whom the covered entity is authorized to make the use or disclosure. The authorization must identify these persons with sufficient specificity to reasonably permit a covered entity responding to the authorization to identify the authorized user or recipient of the protected health information.

Often, individuals provide authorizations to third parties, who present them to one or more covered entities. For example, an authorization could be completed by an individual and given to a government agency, authorizing the agency to receive medical information from any health care provider that has treated the individual within a defined period of time. Such an authorization is permissible (subject to the other requirements of this part) if it sufficiently identifies the government entity that is authorized to receive the disclosed protected health information.

Fourth, the authorization must state an expiration date or event. This expiration date or event must either be a specific date (e.g., January 1, 2001), a specific time period (e.g., one year from the date of signature), or an event directly relevant to the individual or the purpose of the use or disclosure (e.g., for the duration of the individual’s enrollment with the health plan that is authorized to make the use or disclosure). We note that the expiration date or event is subject to otherwise applicable and more stringent law. For example, the National Association of Insurance Commissioners’ Insurance Information and Privacy Protection Model Act, adopted in at least fifteen states, specifies that authorizations signed for the purpose of collecting information in connection with an application for a life, health, or disability insurance policy are permitted to remain valid for no longer than thirty months. In those states, the longest such an authorization may remain in effect is therefore thirty months, regardless of the expiration date or event indicated on the form.

Fifth, the authorization must state that the individual has the right to revoke an authorization in writing, except to the extent that action has been taken in reliance on the authorization or, if applicable, during a contestability period. The authorization must include instructions on how the individual may revoke the authorization. For example, the person obtaining the authorization from the individual can include an address where the individual can send a written request for revocation.

Sixth, the authorization must inform the individual that, when the information is used or disclosed pursuant to the authorization, it may be subject to re-disclosure by the recipient and may no longer be protected by this rule.

Seventh, the authorization must include the individual’s signature and the date of the signature. Once we adopt the standards for electronic signature, another of the required administrative simplification standards we are required to adopt under HIPAA, an electronic signature that meets those standards will be sufficient under this rule. We do not require verification of the individual’s identity or authentication of the individual’s signature.

Finally, if the authorization is signed by a personal representative of the individual, the representative must indicate his or her authority to act for the individual.

As in the proposed rule, the authorization must be written in plain language. See the preamble discussion regarding notice of privacy practices (§ 164.520) for a discussion of the plain language requirement. We do not provide a model authorization in this rule. We will provide further guidance on this issue prior to the compliance date.

Section 164.508(d) – Authorizations Requested by a Covered Entity for Its Own Uses and Disclosures

We proposed to require covered entities to include additional elements in authorizations initiated by the covered entity. Before a covered entity could use or disclose protected health information of an individual pursuant to a request the covered entity made, we proposed to require the entity to obtain an authorization containing the minimum elements described above and the following additional elements: except for authorizations requested for clinical trials, a statement that the entity will not condition treatment or payment on the individual’s authorization; a description of the purpose of the requested use or disclosure; a statement that the individual may inspect or copy the information to be used or disclosed and may refuse to sign the authorization; and, if the use or disclosure of the requested information will result in financial gain to the entity, a statement that such gain will result.

We additionally proposed to require covered entities, when requesting an individual’s authorization, to request only the minimum amount of information necessary to accomplish the purpose for which the request was made. We also proposed to require covered entities to provide the individual with a copy of the executed authorization.

We retain the proposed approach, but apply these additional requirements when the covered entity requests the individual’s authorization for the entity’s own use or disclosure of protected health information maintained by the covered entity itself. For example, a health plan may ask individuals to authorize the plan to disclose protected health information to a subsidiary to market life insurance to the individual. A pharmaceutical company may also ask a covered provider to recruit patients for drug research; if the covered provider asks patients to sign an authorization for the provider to disclose protected health information to the pharmaceutical company for this research, this is also an authorization requested by a covered entity for disclosure of protected health information maintained by the covered entity. When covered entities initiate the authorization by asking individuals to authorize the entity to use or disclose protected health information that the entity maintains, the authorization must include all of the elements required above as well as several additional elements.

Authorizations requested by covered entities for the covered entity’s own use or disclosure of protected health information must state, as applicable under § 164.508(b)(4), that the covered entity will not condition treatment, payment, enrollment, or eligibility on the individual’s authorization for the use or disclosure. For example, if a health plan asks an individual to sign an authorization for the health plan to disclose protected health information to a non-profit advocacy group for the advocacy group’s fundraising purposes, the authorization must contain a statement that the health plan will not condition treatment, payment, enrollment in the health plan, or eligibility for benefits on the individual providing the authorization.

Authorizations requested by covered entities for their own uses and disclosures of protected health information must also identify the purpose for which the information is to be used or disclosed. The required statement of purpose(s) must provide individuals with the facts they need to make an informed decision whether to allow release of the information. We prohibit the use of broad or blanket authorizations requesting the use or disclosure of protected health information for a wide range of unspecified purposes. Both the information that is to be used or disclosed and the specific purpose(s) for such uses or disclosures must be stated in the authorization.
Authorizations requested by covered entities for their own uses and disclosures must also advise individuals of certain rights available to them under this rule. The authorization must state that the individual may inspect or copy the information to be used or disclosed as provided in §164.524 regarding access for inspection and copying and that the individual may refuse to sign the authorization.

We alter the proposed requirements with respect to authorizations for which the covered entity will receive financial gain. When the covered entity initiates the authorization and the covered entity will receive direct or indirect remuneration from a third party (rather than financial gain, as proposed) in exchange for using or disclosing the protected health information, the authorization must include a statement that such remuneration will result. For example, a health plan may wish to sell or rent its enrollee mailing list or a pharmaceutical company may offer a covered provider a discount on its products if the provider obtains authorization to disclose the demographic information of patients with certain diagnoses so that the company can market new drugs to them directly. In each case, the covered entity must obtain the individual's authorization, and the authorization must include a statement that the covered entity will receive remuneration.

In §164.508(d)(2), we continue to require a covered entity that requests an authorization for its own use or disclosure of protected health information to provide the individual with a copy of the signed authorization. While we eliminate from this section the provision requiring covered entities to obtain authorization for use or disclosure of the minimum necessary protected health information, §164.514(d)(4) requires covered entities to request only the minimum necessary protected health information to accomplish the purpose for which the request is made. This requirement applies to these authorizations, as well as other requests.

Section 164.508(e)—Authorizations Requested by a Covered Entity for Disclosures by Others

In the proposed rule, we would have prohibited all covered entities from requiring the individual's written legal permission (as proposed, an "authorization") for the use or disclosure of protected health information to carry out treatment, payment, or health care operations. We generally eliminate this prohibition in the final rule, except to specify that a consent obtained by one covered entity is not effective to permit another covered entity to use or disclose protected health information. See §164.506(a)(5) and the corresponding preamble discussion.

In the final rule, if a covered entity seeks the individual's written legal permission to obtain protected health information about the individual from another covered entity for any purpose, it must obtain the individual's authorization for the covered entity that maintains the protected health information to make the disclosure. If the authorization is for the purpose of obtaining protected health information for purposes other than treatment, payment, or health care operations, the authorization need only contain the core elements required by §164.508(c) and described above.

If the authorization, however, is for the purpose of obtaining protected health information to carry out treatment, payment, or health care operations, the authorization must meet the requirements of §164.508(e). We expect such authorizations will rarely be necessary, because we expect covered entities that maintain protected health information to obtain consents that permit them to make anticipated uses and disclosures for these purposes. An authorization obtained by another covered entity that authorizes the covered entity maintaining the protected health information to make a disclosure for the same purpose, therefore, would be unnecessary.

We recognize, however, that these authorizations may be useful to demonstrate an individual’s intent and relationship to the intended recipient of the information when the intent or relationship is not already clear. For example, a long term care insurer may need information from an individual’s health care providers about the individual’s ability to perform activities of daily living in order to determine payment of a long term care claim. The providers that hold the information may not be providing the long term care and may not, therefore, be aware of the individual’s coverage under the policy or that the individual is receiving long term care services. An authorization obtained by the long term care insurer will help to demonstrate these facts to the providers holding the information, which will make them more confident that the individual intends for the information to be shared. Similarly, an insurer with subrogation obligations may need authorization from the enrollee’s providers to assess or prosecute the claim. A patient’s new physician may also need medical records from the patient’s prior providers in order to treat the patient. Without an authorization that demonstrates the patient’s intent for the information to be shared, the covered entity that maintains the protected health information may be reluctant to provide the information, even if that covered entity’s consent permits such disclosure to occur.

These authorizations may also be useful to accomplish clinical coordination and integration among covered entities that do not meet the definitions of affiliated covered entities or organized health care arrangements. For example, safety-net providers that participate in the Community Access Program (CAP) may not qualify as organized health care arrangements but may want to share protected health information with each other in order to develop and expand integrated systems of care for uninsured people. An authorization under this section would permit such providers to receive protected health information from other CAP participants to engage in such activities.

Because of such concerns, we permit a covered entity to request the individual’s authorization to obtain protected health information from another covered entity to carry out treatment, payment, and health care operations. In these situations, the authorization must contain the core elements described above and must also describe each purpose of the requested disclosure.

With one exception, the authorization must also indicate that the authorization is voluntary. It must state that the individual may refuse to sign the authorization and that the covered entity requesting the authorization will not condition the provision of treatment, payment, enrollment in the health plan, or eligibility for benefits on obtaining the individual’s authorization. If the authorization is for a disclosure of information that is necessary to determine payment of a claim for specified benefits, however, the health plan requesting the authorization may condition the payment of the claim on obtaining the authorization from the individual. See §164.508(b)(4)(iii). In this case, the authorization does not have to state that the health plan will not condition payment on obtaining the authorization.

The covered entity requesting the authorization must provide the individual with a copy of the signed authorization. We note that the covered entity requesting the authorization is also subject to the requirements in

---

Note: The text is a legal document, specifically a part of the Federal Register, which discusses the Health Insurance Portability and Accountability Act (HIPAA). The text pertains to the use and disclosure of protected health information, including the requirements for obtaining patient authorizations.
§ 164.514 to request only the minimum necessary information needed for the purpose of the authorization.

We additionally note that, when the covered entity that maintains the protected health information has already obtained a consent for disclosure of protected health information to carry out treatment, payment, and/or health care operations under § 164.506, and that consent conflicts with an authorization obtained by another covered entity under § 164.508(e), the covered entity maintaining the protected health information is bound by the more restrictive document. See § 164.506(e) and the corresponding preamble discussion for further explanation.

Section 164.508(f)—Authorizations for Uses and Disclosures of Protected Health Information Created for Research That Includes Treatment of Individuals

In the proposed rule, we would have required individual authorization for any use or disclosure of research information unrelated to treatment. In the final rule, we eliminate the special rules for this category of information and, instead, require covered entities to obtain an authorization for the use or disclosure of protected health information the covered entity creates for the purpose of research that includes treatment of individuals, except as otherwise permitted by § 164.512(i).

The intent of this provision is to permit covered entities that conduct research involving treatment to bind themselves to a more limited scope of uses and disclosures of research information than they would otherwise be permitted to make with non-research information. Rather than creating a single definition of “research information,” we allow covered entities the flexibility to define that subset of protected health information they create during clinical research that is not necessary for treatment, payment, or health care operations and that the covered entity will use or disclose under more limited circumstances than it uses or discloses other protected health information. In designing their authorizations, we expect covered entities to be mindful of the often highly sensitive nature of research information and the impact of individuals’ privacy concerns on their willingness to participate in research.

Covered entities seeking authorization to use or disclose protected health information they create for the purpose of research that includes treatment of individuals during clinical trials must include in the authorization (in addition to the applicable elements required above) a description of the extent to which some or all of the protected health information created for the research will also be used or disclosed for purposes of treatment, payment, and health care operations. For example, if the covered entity intends to seek reimbursement from the individual’s health plan for the routine costs of care associated with the research protocol, it must explain in the authorization the types of information that it will provide to the health plan for this purpose. This information, and the circumstances under which disclosures will be made for treatment, payment, and health care operations, may be more limited than the information and circumstances described in the covered entity’s general consent and notice of privacy practices. To the extent the covered entity limits itself to a subset of uses or disclosures that are otherwise permissible under the rule and the covered entity’s consent and notice, the covered entity is bound by the statements made in the research-related authorization. In these circumstances, the authorization must indicate that the authorization, not the general consent and notice, controls.

If the covered entity’s primary interaction with the individual is through the research, the covered entity may combine the general consent for treatment, payment, and health care operations required under § 164.506 with this research authorization and need not obtain an additional consent under § 164.506. If the entity has already obtained a consent to obtain, a separate consent as required under § 164.506, the research authorization must refer to that consent and state that the practices described in the research-related authorization are binding on the covered entity as to the information covered by the research-related authorization. The research-related authorization may also be combined in the same document as the informed consent for participation in the research. This is an exception to the general rule in § 164.508(b)(3) that an authorization under this section must be combined with any other document (see above).

The covered entity must also include in the authorization a description of the extent to which it will not use or disclose the protected health information it obtains in connection with the research protocol for purposes that are permitted without individual authorization under this rule (under §§ 164.510 and 164.512). To the extent that the entity limits itself to a subset of uses or disclosures that are otherwise permissible under the rule and the entity’s notice, the entity is bound by the statements made in the research-related authorization. In these circumstances, the authorization must indicate that the authorization, not the notice, controls. The covered entity may not, however, purport to preclude itself from making uses or disclosures that are required by law or that are necessary to avert a serious and imminent threat to health or safety.

In some instances, the covered entity may wish to make a use or disclosure of the research information that it did not include in its general consent or notice or for which authorization is required under this rule. To the extent the entity includes uses or disclosures in the research authorization that are otherwise not permissible under the rule and the entity’s consent and notice of information practices, the entity must include all of the elements required by §§ 164.508(c) and (d) in the research-related authorization. The covered entity is bound by these statements.

Research that involves the delivery of treatment to participants sometimes relies on existing health information, such as to determine eligibility for the trial. We note that under § 164.508(b)(3)(iii), the covered entity may combine the research-related authorization required under § 164.508(f) with any other authorization for the use or disclosure of protected health information (other than psychotherapy notes), provided that the covered entity does not condition the provision of treatment on the individual signing the authorization. For example, a covered health care provider that had a treatment relationship with an individual prior to the individual’s enrollment in a clinical trial, but that is now providing research-related treatment to the individual, may elect to request a compound authorization from the individual: an authorization under § 164.508(d) for the provider to use the protected health information it created prior to the initiation of the research that involves treatment, combined with an authorization under § 164.508(f) regarding use and disclosure of protected health information the covered provider will create for the purpose of the clinical trial. This compound authorization would be valid, provided the covered provider did not condition the research-related treatment on obtaining the authorization required under § 164.508(f), as permitted in § 164.508(b)(4)(i).

However, we anticipate that covered entities will almost always, if not always, condition the provision of research-related treatment on the individual signing the authorization under § 164.508(f) for the covered
entity’s use or disclosure of protected health information created for the research. Therefore, we expect that the vast majority of covered providers who wish to use or disclose protected health information about an individual that will be created for research that includes treatment and wish to use existing protected health information about that individual for the research that includes treatment, will be required to obtain two authorizations from the individual: (1) an authorization for the use and disclosure of protected health information to be created for the research that involves treatment of the individual (as required under § 164.508(f)), and (2) an authorization for the use of existing protected health information for the research that includes treatment of the individual (as required under § 164.508(d)).

Effect of Authorization
As noted in the discussion about consents in the preamble to § 164.506, authorizations under this rule should not be construed to waive, directly or indirectly, any privilege granted under federal, state, or local laws or procedures.

Section 164.510—Uses and Disclosures Requiring an Opportunity for the Individual To Agree or To Object

Introduction
Section 164.510 of the NPRM proposed the uses and disclosures of protected health information that covered entities could make for purposes other than treatment, payment, or health care operations and for which an individual authorization would not have been required. These allowable uses and disclosures were designed to permit and promote key national health care priorities, and to promote the smooth operation of the health care system. In each of these areas, the proposal permitted, but would not have required, covered entities to use or disclose protected health information.

We proposed to require covered entities to obtain the individual’s oral agreement before making a disclosure to a health care facility’s directory or to the individual’s next-of-kin or to another person involved in the individual’s health care. Because there is an expectation in these two areas that individuals will have some input into a covered entity’s decision to use or disclose protected health information, we decided to place disclosures to health facility directories and to persons involved in an individual’s care in a separate section. In the final rule, requirements regarding disclosure of protected health information for facility directories and to others involved in an individual’s care are included in § 164.510(a) and § 164.510(b), respectively. In the final rule, we include in § 164.510(b) provisions to address a type of disclosure not addressed in the NPRM: disclosures to entities providing relief and assistance in disasters such as floods, fires, and terrorist attacks. Requirements for most of the remaining categories of disclosures addressed in proposed § 164.510 of the NPRM are included in a new § 164.512 of the final rule, as discussed below.

Section 164.510 of the final rule addresses situations in which the interaction between the covered entity and the individual is relatively informal and agreements are made orally, without written authorizations for use or disclosure. In general, under the final rule, to disclose or use protected health information for these purposes, covered entities must inform individuals in advance and must provide a meaningful opportunity for the individual to prevent or restrict the disclosure. In exceptional circumstances, where even this informal discussion cannot practicably take place, covered entities are permitted to make decisions regarding disclosure or use based on the exercise of professional judgment of what is in the individual’s best interest.

Section 164.510(a)—Use and Disclosure for Facility Directories

The NPRM proposed to allow covered health care providers to disclose through an inpatient facility’s directory a patient’s name, location in the facility, and general health condition, provided that the individual had agreed to the disclosure. The NPRM would have allowed this agreement to be oral. Pursuant to the NPRM, when making decisions about incapacitated individuals, a covered health care provider could have disclosed such information at the entity’s discretion and consistent with good medical practice and any prior expressions of patient preference of which the covered entity was aware.

The preamble to the NPRM listed several factors that we encouraged covered entities to take into account when making decisions about whether to include an incapacitated patient’s information in the directory. These factors included: (1) Whether disclosing that an individual is in the facility could reasonably cause harm or danger to the individual (e.g., if it appeared that an unconscious patient had been abused and disclosing the information could give the attacker sufficient information to seek out the person and repeat the abuse); (2) whether disclosing a patient’s location within a facility implicitly would give information about the patient’s condition (e.g., whether a patient’s room number revealed that he or she was in a psychiatric ward); (3) whether it was necessary or appropriate to give information about patient status to family or friends (e.g., if giving information to a family member about an unconscious patient could help a physician administer appropriate medications); and (4) whether an individual had, prior to becoming incapacitated, expressed a preference not to be included in the directory. The preamble stated that if a covered entity learned of such a preference, it would be required to act in accordance with the preference.

The preamble to the NPRM said that when individuals entered a facility in an incapacitated state and subsequently gained the ability to make their own decisions, health facilities should ask them within a reasonable time period for permission to include their information in the facility’s directory. In the final rule, we change the NPRM’s opt-in authorization requirement to an opt-out approach for inclusion of patient information in a health care facility’s directory. The final rule allows covered health care providers—which in this case are health care facilities—to include patient information in their directory only if: (1) They inform incoming patients of their policies regarding the directory; (2) they give patients a meaningful opportunity to opt out of the directory listing or to restrict some or all of the uses and disclosures that can be included in the directory; and (3) the patient does not object to being included in the directory. A patient must be allowed, for example, to have his or her name and condition included in the directory while not having his or her religious affiliation included. The facility’s notice and the individual’s opt-out or restriction may be oral.

Under the final rule, subject to the individual’s right to object, or known prior expressed preferences, a covered health care provider may disclose the following information to persons who inquire about the individual by name: (1) The individual’s general condition in terms that do not communicate specific medical information about the individual (e.g., fair, critical, stable, etc.); and (2) location in the facility. This approach represents a slight change to the NPRM, which did not require members of the general public to ask for a patient by name in order to obtain directory information and which,
in fact, would have allowed covered entities to disclose the individual’s name as part of directory information. Under the final rule, we also establish provisions for disclosure of directory information to clergy that are slightly different from those which apply for disclosure to the general public. Subject to the individual’s right to object or restrict the disclosure, the final rule permits a covered entity to disclose to a member of the clergy: (1) The individual’s name; (2) the individual’s general condition in terms that do not communicate specific medical information about the individual; (3) the individual’s location in the facility; and (4) the individual’s religious affiliation. A disclosure of directory information may be made to members of the clergy even if they do not inquire about an individual by name. We note that the rule in no way requires a covered health care provider to inquire about the religious affiliation of an individual, nor must individuals supply that information to the facility. Individuals are free to determine whether they want their religious affiliation disclosed to clergy through facility directories.

We believe that allowing clergy to access patient information pursuant to this section does not violate the Establishment Clause of the First Amendment, which prohibits laws “respecting an establishment of religion.” Courts traditionally turn to the Lemon test when evaluating laws that might raise Establishment Clause concerns. A law does not violate the Clause if it has a secular purpose, is not primarily to advance religion, and does not cause excessive government entanglement with religion. The privacy regulation passes this test because its purpose is to protect the privacy of individuals—regardless of their religious affiliation—and it does not cause excessive government entanglement.

More specifically, although this section provides a special rule for members of the clergy, it does so as an accommodation to patients who seek to engage in religious conduct. For example, restricting the disclosure of an individual’s religious affiliation, room number, and health status to a priest could cause significant delay that would inhibit the ability of a Catholic patient to obtain sacraments provided during the last rites. We believe this accommodation does not violate the Establishment Clause, because it avoids a government-imposed restriction on the disclosure of information that could disapprove the practice of religion. In that way, it is no different from accommodations upheld by the U.S. Supreme Court, such as exceptions to laws banning the use of alcohol in religious ceremonies.

The final rule expands the circumstances under which health care facilities can disclose specified health information to the patient directory without the patient’s agreement. Besides allowing such disclosures when patients are incapacitated, as the NPRM would have allowed, the final rule allows such disclosures in emergency treatment circumstances. For example, when a patient is conscious and capable of making a decision, but is so seriously injured that asking permission to include his or her information in the directory would delay treatment such that the patient’s health would be jeopardized, health facilities can make decisions about including the patient’s information in the directory according to the same rules that apply when the patient is incapacitated. The final rule modifies the NPRM requirements for cases in which an incapacitated patient is admitted to a health care facility. Whereas the NPRM would have allowed health care providers to disclose an incapacitated patient’s information to the facility’s directory “at its discretion and consistent with good medical practice and any prior expressions of preference of which the covered entity [was] aware,” the final rule states that in these situations (and in other emergency treatment circumstances), covered health care providers must make the decision on whether to include the patient’s information in the facility’s directory in accordance with professional judgment as to the patient’s best interest. In addition, when making decisions involving incapacitated patients and patients in emergency situations, covered health care providers may decide to include some portions of the patient’s information (such as name) but not other information (such as location in the facility) in order to protect patient interests.

As in the preamble to the NPRM, we encourage covered health care providers to take into account the four factors listed above when making decisions about whether to include patient information in a health care facility’s directory when patients are incapacitated or are in an emergency treatment circumstance. In addition, we retain the requirement stated in the preamble of the NPRM that if a covered health care provider learns of an incapacitated patient’s prior expression of preference not to be included in a facility’s directory, the facility must not include the patient’s information in the directory. For cases involving patients admitted to a health care facility in an incapacitated or emergency treatment circumstance who during the course of their stay become capable of decisionmaking, the final rule takes an approach similar to that described in the NPRM. The final rule states that when an individual who was incapacitated or in an emergency treatment circumstance upon admission to an inpatient facility and whose condition stabilizes such that he or she is capable of decisionmaking, a covered health care provider must, when it becomes practicable, inform the individual about its policies regarding the facility’s directory and provide the opportunity to object to the use or disclosure of protected health information about themselves for the directory.

Section 164.510(b)—Uses and Disclosures for Involvement in the Individual’s Care and Notification Purposes

In cases involving an individual with the capacity to make health care decisions, the NPRM would have allowed covered entities to disclose protected health information about the individual to a next-of-kin, to other family members, or to close personal friends of the individual if the individual had agreed orally to such disclosure. If such agreement could not practicably or reasonably be obtained (e.g., when the individual was incapacitated), the NPRM would have allowed disclosure of protected health information that was directly relevant to the person’s involvement in the individual’s health care, consistent with good health professional practices and ethics. The NPRM defined next-of-kin as defined under state law.

Under the final rule, we specify that covered entities may disclose to a person involved in the current health care of the individual (such as a family member, other relative, close personal friend, or any other person identified by the individual) protected health information directly related to the person’s involvement in the current health care of an individual or payment related to the individual’s health care. Such persons involved in care and other contact persons might include, for example: blood relatives; spouses; roommates; boyfriends and girlfriends; domestic partners; neighbors; and colleagues. Inclusion of this list is intended to be illustrative only, and it is not intended to change current practices with respect to: (1) Involvement of other persons in individuals’ treatment decisions; (2) informational information among individuals involved in a person’s care; or (3) sharing of protected health
information to contact persons during a disaster. The final rule also includes new language stating that covered entities may use or disclose protected health information to notify or assist in notification of family members, personal representatives, or other persons responsible for an individual’s care with respect to an individual’s location, condition, or death. These provisions allow, for example, covered entities to notify a patient’s adult child that his father has suffered a stroke and to tell the person that the father is in the hospital’s intensive care unit.

The final rule includes separate provisions for situations in which the individual is present and for when the individual is not present at the time of disclosure. When the individual is present and has the capacity to make his or her own decisions, a covered entity may disclose protected health information only if the covered entity: (1) Obtains the individual’s agreement to disclose to the third parties involved in their care; (2) provides the individual with an opportunity to object to such disclosure and the individual does not express an objection; or (3) reasonably infers from the circumstances, based on the exercise of professional judgment, that the individual does not object to the disclosure. Situations in which covered providers may infer an individual’s agreement to disclose protected health information pursuant to option (3) include, for example, when a patient brings a spouse into the doctor’s office when treatment is being discussed, and when a colleague or friend has brought the individual to the emergency room for treatment.

We proposed that when a covered entity could not practically obtain oral agreement to disclose protected health information to next-of-kin, relatives, or those with a close personal relationship to the individual, the covered entity could make such disclosures consistent with good health professional practice and ethics. In such instances, we proposed that covered entities could disclose only the minimum information necessary for the friend or relative to provide the assistance he or she was providing. For example, health care providers could not disclose to a friend or relative simply driving a patient home from the hospital extensive information about the patient’s surgery or past medical history when the friend or relative had no need for this information.

The final rule takes a similar approach. Under the final rule, when an individual is not present (for example, when a friend of a patient seeks to pick up the patient’s prescription at a pharmacy) or when the opportunity to agree or object to the use or disclosure cannot practicably be provided due to the individual’s incapacity or an emergency circumstance, covered entities may, in the exercise of professional judgment, determine whether the disclosure is in the individual’s best interests and if so, disclose only the protected health information that is directly relevant to the person’s involvement with the individual’s health care. For example, this provision allows covered entities to inform relatives or others involved in a patient’s care, such as the person who accompanied the individual to the emergency room, that a patient has suffered a heart attack and to provide updates on the patient’s progress and prognosis when the patient is incapacitated and unable to make decisions about such disclosures. In addition, this section allows covered entities to disclose functional information to individuals assisting in a patient’s care; for example, it allows hospital staff to give information about a person’s mobility limitations to a friend driving the patient home from the hospital. It also allows covered entities to use professional judgment and experience with common practice to make reasonable inferences of the individual’s best interest in allowing a person to act on an individual’s behalf to pick up filled prescriptions, medical supplies, X-rays, or other similar forms of protected health information. Thus, under this provision, pharmacists may release a prescription to a patient’s friend who is picking up the prescription for him or her. Section 164.510(b) is not intended to disrupt most covered entities’ current practices or state law with respect to these types of disclosures.

This provision is intended to allow disclosures directly related to a patient’s current condition and should not be construed to allow, for example, disclosure of extensive information about the patient’s medical history that is not relevant to the patient’s current condition and that could prove embarrassing to the patient. In addition, if a covered entity suspects that an incapacitated patient is a victim of domestic violence and that a person seeking information about the patient may have abused the patient, covered entities should not disclose information to the suspected abuser if there is reason to believe that such a disclosure could cause the patient serious harm. In all of these situations regarding possible disclosures of protected health information about an patient who is not present or is unable to agree to such disclosures due to incapacity or other emergency circumstance, disclosures should be in accordance with the exercise of professional judgment as to the patient’s best interest.

This section is not intended to provide a loophole for avoiding the rule’s other requirements, and it is not intended to allow disclosures to a broad range of individuals, such as journalists who may be curious about a celebrity’s health status. Rather, it should be construed narrowly, to allow disclosures to those with the closest relationships with the patient, such as family members, in circumstances when a patient is unable to agree to disclosure of his or her protected health information. Furthermore, when a covered entity cannot practically obtain an individual’s agreement before disclosing protected health information to a relative or to a person involved in the individual’s care and is making decisions about such disclosures consistent with the exercise of professional judgment regarding the individual’s best interest, covered entities must take into account whether such a disclosure is likely to put the individual at risk of serious harm.

Like the NPRM, the final rule does not require covered entities to verify the identity of relatives or other individuals involved in the individual’s care. Rather, the individual’s act of involving the other persons in his or her care suffices as verification of their identity. For example, the fact that a person brings a family member into the doctor’s office when treatment information will be discussed constitutes verification of the involved person’s identity for purposes of this rule. Likewise, the fact that a friend arrives at a pharmacy and asks to pick up a specific prescription for an individual effectively verifies that the friend is involved in the individual’s care, and the rule allows the pharmacist to give the filled prescription to the friend.

We also clarify that the final rule does not allow covered entities to assume that an individual’s agreement at one point in time to disclose protected health information to a relative or to another person assisting in the individual’s care implies agreement to disclose protected health information indefinitely in the future. We encourage the exercise of professional judgment in determining the scope of the person’s involvement in the individual’s care and the time period for which the individual is agreeing to the other person’s involvement. For example, if a friend simply picks up a patient from the hospital but has played no other role...
in the individual’s care, hospital staff should not call the friend to disclose lab test results a month after the initial encounter with the friend. However, if a patient routinely brings a spouse into the doctor’s office when treatment is discussed, a physician can infer that the spouse is playing a long-term role in the patient’s care, and the rule allows disclosure of protected health information to the spouse consistent with his or her role in the patient’s care, for example, discussion of treatment options.

The NPRM did not specifically address situations in which disaster relief organizations may seek to obtain protected health information from covered entities to help coordinate the individual’s care, or to notify family or friends of an individual’s location or general condition in a disaster situation. In the final rule, we account for disaster situations in this paragraph. Specifically, we allow covered entities to use or disclose protected health information without individual agreement to federal, state, or local government agencies engaged in disaster relief activities, as well as to private disaster relief or disaster assistance organizations (such as the Red Cross) authorized by law or by their charters to assist in disaster relief efforts, to allow these organizations to carry out their responsibilities in a specific disaster situation. Covered entities may make these disclosures to disaster relief organizations, for example, so that these organizations can help family members, friends, or others involved in the individual’s care to locate individuals affected by a disaster and to inform them of the individual’s general health condition. This provision also allows disclosure of information to disaster relief or disaster assistance organizations so that these organizations can help individuals obtain needed medical care for injuries or other health conditions caused by a disaster.

We encourage disaster relief organizations to protect the privacy of individual health information to the extent practicable in a disaster situation. However, we recognize that the nature of disaster situations often makes it impossible or impracticable for disaster relief organizations and covered entities to seek individual agreement or authorization before disclosing protected health information necessary for providing disaster relief. Thus, we note that we do not intend to impede disaster relief organizations in their critical mission to save lives and reunite loved ones and friends in disaster situations.

Section 164.512—Uses and Disclosures for Which Consent, an Authorization, or Opportunity To Agree or Object Is Not Required

Introduction

The final rule’s requirements regarding disclosures for directory information and to family members or others involved in an individual’s care are in a section separate from that covering disclosures allowed for other national priority purposes. In the final rule, we place most of the other disclosures for national priority purposes in a new §164.512.

As in the NPRM, in §164.512 of the final rule, we allow covered entities to make these national priority uses and disclosures without individual authorization. As in the NPRM, these uses and disclosures are discretionary. Covered entities are free to decide whether or not to use or disclose protected health information for any or all of the permitted categories. However, as in the NPRM, nothing in the final rule provides authority for a covered entity to restrict or refuse to make a use or disclosure mandated by other law.

The new §164.512 includes paragraphs on: Uses and disclosures required by law; uses and disclosures for public health activities; disclosures about victims of abuse, neglect, or domestic violence; uses and disclosures for health oversight activities; disclosures for judicial and administrative proceedings; disclosures for law enforcement purposes; uses and disclosures about decedents; uses and disclosures for cadaveric donation of organs, eyes, or tissues; uses and disclosures for research purposes; uses and disclosures to avert a serious threat to health or safety; and uses and disclosures for national priority purposes.

While the right to request restrictions under §164.522 and the consents required under §164.506 do not apply to the use and disclosure of protected health information under §164.512, we do not intend to preempt any state or other restrictions, or any right to enforce such agreements or consents under other law.

We note that a covered entity may use or disclose protected health information as permitted by and in accordance with one of the paragraphs of §164.512, regardless of whether that use or disclosure fails to meet the requirements for use or disclosure under a different paragraph in §164.512 or elsewhere in the rule.

Verification for Disclosures Under §164.512

In §164.510(a) of the NPRM, we proposed that covered entities verify the identity and authority of persons to whom they made disclosure under the section. In the final rule, we generally have retained the proposed requirements. Verification requirements are discussed in §164.514 of the final rule.

Section 164.512(a)—Uses and Disclosures Required by Law

In the NPRM we would have allowed covered entities to use or disclose protected health information without individual authorization where such use...
as long as the use or disclosure met all relevant requirements of such law.

However, a legally mandated use or disclosure which fell into one or more of the national priority purposes expressly identified in proposed § 164.510 of the NPRM would have been subject to the terms and conditions specified by the applicable paragraph of proposed § 164.510. Thus, a disclosure required by law would have been allowed only to the extent it was not otherwise prohibited or restricted by another provision in proposed § 164.510. For example, mandatory reporting to law enforcement officials would not have been allowed unless such disclosures conformed to the requirements of proposed § 164.510(f) of the NPRM, on uses and disclosures for law enforcement purposes. As explained in the NPRM, this provision was not intended to obstruct access to information deemed important enough by federal, state or other government authorities to require it by law.

In § 164.512(a) of the final rule, we retain the proposed approach, and we permit covered entities to comply with laws requiring the use or disclosure of protected health information, provided the use or disclosure meets and is limited to the relevant requirements of such other laws. To more clearly address where the substantive and procedural requirements of other provisions in this section apply, we have deleted the general sentence from the NPRM which stated that the provision applies to uses or disclosures that are covered by paragraphs (b) through (m) of proposed § 164.510. Instead, in § 164.512(a)[2] we list the specific paragraphs that have additional requirements with which covered entities must comply. They are disclosures about victims of abuse, neglect or domestic violence (§ 164.512(c)), for judicial and administrative proceedings (§ 164.512(e)), and for law enforcement purposes (§ 164.512(f)). We include a new definition of “required by law.” See § 164.514. We clarify that the requirements provided for in § 164.514(h) relating to verification apply to disclosures under this paragraph. Those provisions require covered entities to verify the identity and authority of persons to whom they make disclosures. We note that the minimum necessary requirements of § 164.514(d) do not apply to disclosures made under this paragraph.

We note that this rule does not affect what is required by other law, nor does it compel a covered entity to make a use or disclosure of protected health information required by the legal demands or reporting requirements listed in the definition of “required by law.” Covered entities will not be sanctioned under this rule for responding in good faith to such legal process and reporting requirements.

However, nothing in this rule affects, either by expanding or contracting, a covered entity’s right to challenge such process or reporting requirements under other laws. The only disclosures of protected health information compelled by this rule are disclosures to an individual (or the personal representative of an individual) or to the Secretary for the purposes of enforcing this rule.

Uses and disclosures permitted under this paragraph must be limited to the protected health information necessary to meet the requirements of the law that compels the use or disclosure. For example, disclosures pursuant to an administrative subpoena are limited to the protected health information authorized to be disclosed on the face of the subpoena.

Section 164.512(b)—Uses and Disclosures for Public Health Activities

The NPRM would have allowed covered entities to disclose protected health information without individual authorization to: (1) A public health authority authorized by law to collect or receive such information for the purpose of preventing or controlling disease, injury, or disability, including, but not limited to, the reporting of disease, injury, vital events such as birth or death, and the conduct of public health surveillance, public health investigations, and public health interventions; (2) a public health authority or other appropriate authority authorized by law to receive reports of child abuse or neglect; (3) a person or entity other than a governmental authority that could demonstrate or demonstrated that it was acting to comply with requirements or direction of a public health authority; or (4) a person who may have been exposed to a communicable disease or may otherwise be at risk of contracting or spreading a disease or condition and was authorized by law to be notified as necessary in the conduct of a public health intervention or investigation.

In the final rule, we broaden the scope of permissible disclosures pursuant to item (1) listed above. We narrow the scope of disclosures permissible under item (3) of this list, and we add language to clarify the scope of permissible disclosures with respect to item (4) on the list. We broaden the scope of allowable disclosures regarding item (1) by allowing covered entities to disclose protected health information not only to U.S. public health authorities but also, at the direction of a public health authority, to an official of a foreign government agency that is acting in collaboration with a public health authority. For example, we allow covered entities to disclose protected health information to a foreign government agency that is collaborating with the Centers for Disease Control and Prevention to limit the spread of infectious disease.

We narrow the conditions under which covered entities may disclose protected health information to non-government entities. We allow covered entities to disclose protected health information to a person subject to the FDA’s jurisdiction, for the following activities: to report adverse events (or similar reports with respect to food or dietary supplements), product defects or problems, or biological product deviations. If the disclosure is made to the person required or directed to report such information to the FDA; to track products if the disclosure is made to a person required or directed by the FDA to track the product; to enable product recalls, repairs, or replacement, including locating and notifying individuals who have received products regarding product recalls, withdrawals, or other problems; or to conduct post-marketing surveillance to comply with requirements or at the direction of the FDA.

The terms included in § 164.512(b)(iii) are intended to have both their commonly understood meanings, as well as any specialized meanings, pursuant to the Food, Drug, and Cosmetic Act (21 U.S.C. 321 et seq.) or the Public Health Service Act (42 U.S.C. 201 et seq.). For example, “post-marketing surveillance” is intended to mean activities related to determining the safety or effectiveness of a product after it has been approved and is in commercial distribution, as well as certain Phase IV (post-approval) commitments by pharmaceutical companies. With respect to devices, “post-marketing surveillance” can be construed to refer to requirements of section 522 of the Food, Drug, and Cosmetic Act regarding certain implanted, life-sustaining, or life-supporting devices. The term “track” includes, for example, tracking devices under section 519(e) of the Food, Drug, and Cosmetic Act, units of blood or other blood products, as well as tracebacks of contaminated food.

In § 164.512(b)(ii), the term “required” refers to requirements in statute, regulation, order, or other...
legally binding authority exercised by the FDA. The term “directed,” as used in this section, includes other official agency communications such as guidance documents.

We note that under this provision, a covered entity may disclose protected health information to a non-governmental organization without individual authorization for inclusion in a private data base or registry only if the disclosure is otherwise for one of the purposes described in this provision (e.g., for tracking products pursuant to FDA direction or requirements, for post-marketing surveillance to comply with FDA requirements or direction.)

To make a disclosure that is not for one of these activities, covered entities must obtain individual authorization or must meet the requirements of another provision of this rule. For example, covered entities may disclose protected health information to employers for inclusion in a workplace surveillance database only with individual authorization. Disclosure is required by law; if the disclosure meets the requirements of § 164.512(b)(v); or if the disclosure meets the conditions of another provision of this regulation, such as § 154.512(i) relating to research. Similarly, if a pharmaceutical company seeks to create a registry containing protected health information about individuals who had taken a drug that the pharmaceutical company had developed, covered entities may disclose protected health information without authorization to the pharmaceutical company pursuant to FDA requirements or direction. If the pharmaceutical company’s registry is not for any of these purposes, covered entities may disclose protected health information to it only with patient authorization, if required by law, or if disclosure meets the conditions of another provision of this rule.

The final rule continues to permit covered entities to disclose protected health information without individual authorization directly to public health authorities, such as the Food and Drug Administration, the Occupational Safety and Health Administration, the Centers for Disease Control and Prevention, as well as state and local public health departments, for public health purposes as specified in the NPRM.

The final rule retains the NPRM provision allowing covered entities to disclose protected health information to public health authorities or other appropriate government authorities authorized by law to receive reports of childhood infections. In addition, we clarify the NPRM’s provision regarding disclosure of protected health information to persons who may have been exposed to a communicable disease or who may otherwise be at risk of contracting or spreading a disease or condition. Under the final rule, covered entities may disclose protected health information to such individuals when the covered entity or public health authority is authorized by law to notify these individuals as necessary in the conduct of a public health intervention or investigation.

In addition, as in the NPRM, under the final rule, a covered entity that is acting as a public health authority—for example, a public hospital conducting infectious disease surveillance in its role as an arm of the public health department—may use protected health information in all cases for which it is allowed to disclose such information for public health activities as described above.

The proposed rule did not contain a specific provision relating to disclosures by covered health care providers to employers concerning work-related injuries or illnesses or workplace medical surveillance. Under the proposed rule, a covered entity would have been permitted to disclose protected health information without individual authorization for public health purposes to private person if the person could demonstrate that it was acting to comply with requirements or at the direction of a public health authority.

As discussed above, in the final rule we narrow the scope of this paragraph as it applies to disclosures to persons other than public health authorities. To ensure that covered health care providers may make disclosures of protected health information without individual authorization to employers when appropriate under federal and state laws addressing work-related injuries and illnesses or workplace medical surveillance, we include a new provision in the final rule. The provision permits covered health care providers who have health care as a workforce member of or at the request of an employer to disclose to that employer protected health information concerning work-related injuries or illnesses or workplace medical surveillance in situations where the employer has a duty under OSHA and MSHA requirements, or under a similar state law, to keep records on or act on such information.

We require health care providers who make disclosures to employers under this provision to provide notice to individuals that it discloses protected health information to employers relating to the medical surveillance of the workplace and work-related illnesses and injuries. The notice required under this provision is separate from the notice required under § 164.520. The notice required under this provision may be met giving a copy of the notice to the individual at the time it provides the health care services, or, if the health care services are provided on the work site of the employer, by posting the notice in a prominent place at the location where the health care services are provided.

This provision applies only when a covered health care provider provides health care services as a workforce member of or at the request of an employer and for the purposes described above. This provision does not affect the application of this rule to other health care provided to
individuals or to their relationship with health care providers that they select. Section 164.512(c)—Disclosures About Victims of Abuse, Neglect or Domestic Violence

The NPRM included two provisions related to disclosures about persons who are victims of abuse. In the NPRM, we would have allowed covered entities to report child abuse to a public health authority or other appropriate authority authorized by law to receive reports of child abuse or neglect. In addition, under proposed § 164.510(f)(3) of the NPRM, we would have allowed covered entities to disclose protected health information about a victim of a crime, abuse or other harm to a law enforcement official under certain circumstances. The NPRM recognized that most, if not all, states had laws that mandated reporting of child abuse or neglect to the appropriate authorities. Moreover, HIPAA expressly carved out state laws on child abuse and neglect from preemption or any other interference. The NPRM further acknowledged that most, but not all, states had laws mandating the reporting of abuse, neglect or exploitation of the elderly or other vulnerable adults. We did not intend to impede reporting in compliance with these laws.

The final rule includes a new paragraph, § 164.512(c), which allows covered entities to report protected health information to specified authorities in abuse situations other than those involving child abuse and neglect. In the final rule, disclosures of protected health information related to child abuse continues to be addressed in the paragraph allowing disclosure for public health activities (§ 164.512(b)), as described above. Because HIPAA addresses child abuse specifically in connection with a state’s public health activities, we believe it would not be appropriate to include child abuse-related disclosures in this separate paragraph on abuse. State laws continue to apply with respect to child abuse, and the final rule does not in any way interfere with a covered entity’s ability to comply with these laws.

In the final rule, we address disclosures about other victims of abuse, neglect and domestic violence in § 164.512(c) rather than in the law enforcement paragraph. Section 164.512(c) establishes conditions for disclosure of protected health information in cases involving domestic violence other than child abuse (e.g., spousal abuse), as well as those involving neglect (e.g., abuse of nursing home residents or residents of facilities for the mentally retarded). This paragraph addresses reports to law enforcement as well as to other authorized public officials. The provisions of this paragraph supersede the provisions of § 164.512(a) and § 164.512(f)(1)(i) to the extent that those provisions address the subject matter of this paragraph.

Under the circumstances described below, the final rule allows covered entities to disclose protected health information about an individual whom the covered entity reasonably believes to be a victim of abuse, neglect, or domestic violence. In this paragraph, references to “individual” should be construed to mean the individual believed to be the victim. The rule allows such disclosure to any governmental authority authorized by law to receive reports of such abuse, neglect, or domestic violence. These entities may include, for example, adult protective or social services agencies, state survey and certification agencies, ombudsmen for the aging or those in long-term care facilities, and law enforcement or oversight.

The final rule specifies three circumstances in which disclosures of protected health information is allowed in order to report abuse, neglect or domestic violence. First, this paragraph allows disclosure of protected health information related to abuse if required by law and the disclosure complies with and is limited to the relevant requirements of such law. As discussed below, the final rule requires covered entities that make such disclosures pursuant to a state’s mandatory reporting law to inform the individual of the report.

Second, this paragraph allows covered entities to disclose protected health information related to abuse if the individual has agrees to such disclosure. When considering the possibility of disclosing protected health information in an abuse situation pursuant to this section, we encourage covered entities to seek the individual’s agreement whenever possible.

Third, this paragraph allows covered entities to disclose protected health information about an individual without the individual’s agreement if the disclosure is expressly authorized by statute or regulation and either: (1) The covered entity, in the exercise of its professional judgment, believes that the disclosure is necessary to prevent serious harm to the individual or to another potential victims; or (2) if the individual is unable to agree due to incapacity, a law enforcement or other public official authorized to receive the report represents that the protected health information for which disclosure is sought is not intended to be used against the individual, and that an immediate law enforcement activity that depends on the disclosure would be materially and adversely affected by waiting until the individual is able to agree to the disclosure.

We emphasize that disclosure under this third part of the paragraph also may be made only if it is expressly authorized by statute or regulation. We use this formulation, rather than the broader “required by law,” because of the heightened privacy and safety concerns in these situations. We believe it appropriate to defer to other public determinations regarding reporting of this information only where a legislative or executive body has determined the reporting to be of sufficient importance to warrant enactment of a law or promulgation of a regulation. Law and regulations reflect a clear decision to authorize the particular disclosure of protected health information, and reflect greater public accountability (e.g., through the required public comment process or by use enacted by elected representatives).

For example, a Wisconsin law (Wis. Stat § 46.904(1)) states that any person may report to a county agency or state official that he or she believes that abuse or neglect has occurred. Pursuant to § 164.512(c)(1)(ii), a covered entity may make a report only if the specific type or subject matter of the report (e.g., abuse or neglect of the elderly) is included in the law authorizing the report, and such a disclosure may only be made to a public authority specifically identified in the law authorizing the report. Furthermore, we note that disclosures under this part of the paragraph are further limited to two circumstances. In the first case, a covered entity, in the exercise of professional judgment, must believe that the disclosure is necessary to prevent serious harm to the individual or to other potential victims. The second case addresses situations in which an individual who is a victim of abuse, neglect or domestic violence is unable to agree due to incapacity and a law enforcement or other public official authorized to receive the report represents that the protected health information for which disclosure is sought is not intended to be used against the individual and that an immediate law enforcement activity that depends on the disclosure would be materially and adversely affected by waiting until the individual is able to agree to the disclosure. We note that, in this second case, a covered entity may exercise discretion, consistent with professional judgment as to the patient’s
best interest, in deciding whether to make the requested disclosure.

The rules governing disclosure in this third set of circumstances are different from those governing disclosures pursuant to § 164.512(f)(3) regarding disclosure to law enforcement about victims of crime and other harm. We believe that in abuse situations—to a greater extent than in situations involving crime victims in general—there is clear potential for abusers to cause further serious harm to the victim or to others, such as other family members in a household or other residents of a nursing home. The provisions allowing reporting of abuse when authorized by state law, as described above, are consistent with principles articulated by the AMA’s Council on Ethical and Judicial Affairs, which state that when reporting abuse is voluntary under state law, it is justified when necessary to prevent serious harm to a patient. Through the provisions of § 164.512(c), we recognize the unique circumstances surrounding abuse and domestic violence, and we seek to provide an appropriate balance between individual privacy interests and important societal interests such as preventing serious harm to other individuals. We note that here we are relying on covered entities, in the exercise of professional judgment, to determine what is in the best interests of the patient.

Finally, we require covered entities to inform the individual in all of the situations described above that the covered entity has disclosed protected health information to report abuse, neglect, or domestic violence. We allow covered entities to provide this information orally. We do not require written notification, nor do we encourage it, due to the sensitivity of abuse situations and the potential for the abuser to cause further harm to the individual if, for example, a covered entity sends written notification to the home of the individual and the abuser. Whenever possible, covered entities should inform the individual at the same time that they determine abuse has occurred and decide that the abuse should be reported. In cases involving patient incapacity, we encourage covered entities to inform the individual of such disclosures as soon as it is practicable to do so.

The rule provides two exceptions to the requirement to inform the victim about a report to a government authority, one based on concern for future harm and one based on past harm. First, the covered entity need not inform the victim if the covered entity, in the exercise of professional judgment, believes that informing the individual would place the individual at risk of serious harm. We believe that this exception is necessary to address the potential for future harm, either physical or emotional, that the individual may face from knowing that the report has been made. Second, a covered entity may choose not to meet the requirement for informing the victim, if the covered entity actually would be informing a personal representative (such as a parent of a minor) and the covered entity reasonably believes that such person is responsible for the abuse, neglect, or other injury that has already occurred and that informing that person would not be in the individual’s best interests.

Section 164.512(d)—Uses and Disclosures for Health Oversight Activities

Under § 164.510(c) of the NPRM, we proposed to permit covered entities to disclose protected health information to health oversight agencies for oversight activities authorized by law, including audit, investigation, inspection, civil, criminal, or administrative proceeding or action, or other activity necessary for appropriate oversight of: (i) the health care system; (ii) government benefit programs for which health information is relevant to beneficiary eligibility; or (iii) government regulatory programs for which health information is necessary for determining compliance with program standards.

In § 164.512(d) of the final rule, we modify the proposed language to include civil and criminal investigations. In describing “other activities necessary for oversight” of particular entities, we add the phrase “entities subject to civil rights laws for which health information is necessary for determining compliance.” In addition, in the final rule, we add “licensure or disciplinary actions” to the list of oversight activities authorized by law for which covered entities may disclose protected health information to health oversight agencies. The NPRM’s definition of “health oversight agency” (in proposed § 164.504) included this phrase, but it was inadvertently excluded from the regulation text at proposed § 164.510(c). We make this change in the regulation text of the final rule to conform to the NPRM’s definition of health oversight agency and to reflect the full range of activities for which we intend to allow covered entities to disclose protected health information to health oversight agencies.

The NPRM would have allowed, but would not have required, covered entities to disclose protected health information to public oversight agencies and to private entities acting under grant of authority from or under contract with oversight agencies for oversight purposes without individual authorization for health oversight activities authorized by law. When a covered entity was also an oversight agency, it also would have been permitted to use protected health information in all cases in which it would have been allowed to disclose such information for health oversight purposes. The final rule, which does not establish any new administrative or judicial process prior to disclosure for health oversight, nor would it have permitted disclosures forbidden by other law. The proposed rule also would not have created any new right of access to health records by oversight agencies, and it could not have been used as authority to obtain records not otherwise legally available to the oversight agency.

The final rule retains this approach to health oversight. As in the NPRM, the final rule provides that when a covered entity is also an oversight agency, it is allowed to use protected health information in all cases in which it is allowed to disclose such information for health oversight purposes. For example, if a state insurance department is acting as a health plan in operating the state’s Medicaid managed care program, the final rule allows the insurance department to use protected health information in all cases for which the plan can disclose the protected health information for health oversight purposes. For example, the state insurance department in its capacity as the state Medicaid managed care plan can use protected health information in the process of investigating and disciplining a state Medicaid provider for attempting to defraud the Medicaid system. As in the NPRM, the final rule does not establish any new administrative or judicial process prior to disclosure for health oversight, nor does it prohibit covered entities from making any disclosures for health oversight that are otherwise required by law. Like the NPRM, it does not create any new right of access to health records by oversight agencies and it cannot be used as authority to obtain records not otherwise legally available to the oversight agency.

Overlap Between Law Enforcement and Oversight

Under the NPRM, the proposed definitions of law enforcement and oversight, and the rules governing disclosures for these purposes
overlapped. Specifically, this overlap occurred because: (1) The NPRM preamble, but not the NPRM regulation text, indicated that agencies conducting both oversight and law enforcement activities would be subject to the oversight requirements when conducting oversight activities; and (2) the NPRM addressed some disclosures for investigations of health care fraud in the law enforcement paragraph (proposed § 164.510(f)(5)(ii)), while health care fraud investigations are central to the purpose of health care oversight agencies (covered under proposed § 164.510(c)). In the final rule, we make substantial changes to these provisions, in an attempt to prevent confusion.

In § 164.512(d)(2), we include explicit decision rules indicating when an investigation is considered law enforcement and when an investigation is considered oversight under this regulation. An investigation or activity is not considered health oversight for purposes of this rule if: (1) The individual is the subject of the investigation or activity; and (2) The investigation or activity does not arise out of and is not directly related to: (a) The receipt of health care; (b) a claim for public benefits related to health; or (c) qualification for, or receipt of public benefits or services where a patient’s health is integral to the claim for benefits or services. In such cases, where the individual is the subject of the investigation and the investigation does not relate to issues (a) through (c), the rule allows disclosure for law enforcement purposes (see § 164.512(f)) to apply. For the purposes of this rule, we intend for investigations regarding issues (a) through (c) above to mean investigations of health care fraud. Where the individual is not the subject of the activity or investigation, or where the investigation or activity relates to the subject matter in (a) through (c) of the preceding sentence, a covered entity may make a disclosure pursuant to § 164.512(d)(1). For example, when the U.S. Department of Labor’s Pension and Welfare Benefits Administration (PWBA) needs to analyze protected health information about health plan enrollees in order to conduct an audit or investigation of the health plan (i.e., the enrollees are not subjects of the investigation) to investigate potential fraud by the plan, the health plan may disclose protected health information to the PWBA under the health oversight rules. These rules and distinctions are discussed in greater detail in our responses to comments.

To clarify further that health oversight disclosure rules apply generally in health care fraud investigations (subject to the exception described above), in the final rule, we eliminate proposed § 164.510(f)(5)(ii), which would have established requirements for disclosure related to health care fraud for law enforcement purposes. All disclosures of protected health information that would have been permitted under proposed § 164.510(f)(5)(ii) are permitted under § 164.512(d).

In the final rule, we add new language (§ 164.512(d)(3)) to address situations in which health oversight activities are conducted in conjunction with an investigation regarding a claim for public benefits not related to health (e.g., claims for Food Stamps). In such situations, for example, when a state Medicaid agency is working with the Food Stamps program to investigate suspected fraud involving Medicaid and Food Stamps, covered entities may disclose protected health information to the entities conducting the joint investigation under the health oversight provisions of the rule.

In the proposed rule, the definitions of “law enforcement proceeding” and “oversight activity” both included the phrase “criminal, civil, or administrative proceeding.” For reasons explained below, the final rule retains this phrase in both definitions. The final rule does not attempt to distinguish between these activities based on the agency undertaking them or the applicable enforcement procedures. Rather, as described above, the final rule carves out certain activities which must always be considered law enforcement for purposes of disclosure of protected health information under this rule.

Additional Considerations

We note that covered entities are permitted to initiate disclosures that are permitted under this paragraph. For example, a covered entity could disclose protected health information in the course of reporting suspected health care fraud to a health oversight agency.

We delete language in the NPRM that would have allowed disclosure under this section only to law enforcement officials conducting or supervising an investigation, official inquiry, or a criminal, civil or administrative proceeding authorized by law. In some instances, a disclosure by a covered entity under this section will initiate such an investigation or proceeding, but it will not already be ongoing at the time the disclosure is made.

Section 164.512(e)—Disclosures and Uses for Judicial and Administrative Proceedings

Section 164.512(e) addresses when a covered entity is permitted to disclose protected health information in response to requests for protected health information that are made in the course of judicial and administrative proceedings—for example, when a non-party health care provider receives a subpoena (under Federal Rule of Civil Procedure Rule 45 or similar provision) for medical records from a party to a lawsuit. In the NPRM we would have allowed covered entities to disclose protected health information in the course of any judicial or administrative proceeding: (1) In response to an order of a court or administrative tribunal; or (2) where an individual was a party to the proceeding and his or her medical condition or history was at issue and the disclosure was pursuant to lawful process or otherwise authorized by law. Under the NPRM, if the request for disclosure of protected health information was accompanied by a court order, a covered entity could have disclosed protected health information which the court order authorized to be disclosed. If the request for disclosure of protected health information were not accompanied by a court order, covered entities could not have disclosed the information requested unless a request authorized by law had been made by the agency requesting the information or by legal counsel representing a party to litigation, with a written statement certifying that the protected health information requested concerned a litigant to the proceeding and that the health condition of the litigant was at issue at the proceeding.

In § 164.512(e) of the final rule, we permit covered entities to disclose protected health information in a disclosed that protected health information is made through or pursuant to an order from a court or administrative tribunal or in response to a subpoena or discovery request from, or other lawful process by a party to the proceeding. When a request is made pursuant to an order from a court or administrative tribunal, a covered entity may disclose the information requested without additional process. For example, a subpoena issued by a court constitutes a disclosure which is required by law as defined in this rule, and nothing in this rule is intended to interfere with the ability of the covered entity to comply with such subpoena.
However, absent an order of, or a subpoena issued by, a court or administrative tribunal, a covered entity may respond to a subpoena or discovery request from, or other lawful process by, a party to the proceeding only if the covered entity obtains either: (1) Satisfactory assurances that reasonable efforts have been made to give the individual whose information has been requested notice of the request; or (2) satisfactory assurances that the party seeking such information has made reasonable efforts to secure a protective order that will guard the confidentiality of the information. In meeting the first test, a covered entity is considered to have received satisfactory assurances from the party seeking the information if that party demonstrates that it has made a good faith effort (such as by sending a notice to the individual’s last known address) to provide written notice to the individual whose information is the subject of the request, that the written notice included sufficient information about the proceeding to permit the individual to raise an objection, and that the time for the individual to raise objections to the court or administrative tribunal has elapsed and no objections were filed or any objections filed by the individual have been resolved.

Unless required to do so by other law, the covered entity is not required to explain the procedures (if any) available for the individual to object to the disclosure. Under the rule, the individual exercises the right to object before the court or other body having jurisdiction over the proceeding, and not to the covered entity. The provisions in this paragraph are not intended to disrupt current practice whereby an individual who is a party to a proceeding and has put his or her medical condition at issue will not prevail without consenting to the production of his or her protected health information. In such cases, we presume that parties will have ample notice and an opportunity to object in the context of the proceeding in which the individual is a party.

As described above, in this paragraph we also permit a covered entity to disclose protected health information in response to a subpoena, discovery request, or other lawful process if the covered entity receives satisfactory assurances that the party seeking the information has made reasonable efforts to seek a qualified protective order that would protect the privacy of the information. A “qualified protective order” means an order of a court or of an administrative tribunal or a stipulation that: (1) Prohibits the parties from using or disclosing the protected health information for any purpose other than the litigation or proceeding for which the records are requested; and (2) requires the return to the covered entity of destruction of the protected health information (including all copies made) at the end of the litigation or proceeding. Satisfactory assurances of reasonable efforts to secure a qualified protective order are a statement and documentation that the parties to the dispute have agreed to a protective order and that it has been submitted to the court or administrative tribunal with jurisdiction, or that the party seeking the protected health information has requested a qualified protective order from such court or tribunal. We encourage the development of “model” protective orders that will facilitate adherence with this subpart.

In the final rule we also permit the covered entity itself to satisfy the requirement to make reasonable efforts to notify the individual whose information has been requested or to seek a qualified protective order. We intend this to be a permissible activity for covered entities: we do not require covered entities to undertake these efforts in response to a subpoena, discovery request, or similar process (other than an order from a court or administrative tribunal). If a covered entity receives such a request without receiving the satisfactory assurances described above from the party requesting the information, the covered entity is free to object to the disclosure and is not required to undertake the reasonable efforts itself.

We clarify that the provisions of this paragraph do not supersede or otherwise invalidate other provisions of this rule that permit uses and disclosures of protected health information. For example, the fact that protected health information is the subject of a matter before a court or tribunal does not prevent its disclosure under another provision of the rule, such as §§164.512(b), 164.512(d), or 164.512(f), even if a public agency’s method of requesting the information is pursuant to an administrative proceeding. For example, where a public agency commences a disciplinary action against a health professional, and requests protected health information as part of its investigation, the disclosure made be made to the agency under paragraph (d) of this section (relating to health oversight) even if the method of making the request is through the proceeding. As with any request for disclosure under this section, the covered entity will need to verify the authority under which the request is being made, and we expect that public agencies will identify their authority when making such requests. We note that covered entities may reasonably rely on assertions of authority made by government agencies.

Additional Considerations

Where a disclosure made pursuant to this paragraph is required by law, such as in the case of an order from a court or administrative tribunal, the minimum necessary requirements in §164.514(d) do not apply to disclosures made under this paragraph. A covered entity making a disclosure under this paragraph, however, may of course disclose only that protected health information that is within the scope of the permitted disclosure. For instance, in response to an order of a court or administrative tribunal, the covered entity may disclose only the protected health information that is expressly authorized by such an order. Where a disclosure is not considered under this rule to be required by law, the minimum necessary requirements apply, and the covered entity must make reasonable efforts to limit the information disclosed to that which is reasonably necessary to fulfill the request. A covered entity is not required to second guess the scope or purpose of the request, or take action to resist the request because they believe that it is over broad. In complying with the request, however, the covered entity must make reasonable efforts not to disclose more information than is requested. For example, a covered entity may not provide a party free access to its medical records under the theory that the party can identify the information necessary for the request. In some instances, it may be appropriate for a covered entity, presented with a relatively broad discovery request, to permit access to a relatively large amount of information in order for a party to identify the relevant information. This is permissible as long as the covered entity makes reasonable efforts to circumscribe the access as appropriate.

The NPRM indicated that when a covered entity was itself a government agency, the covered entity could use protected health information in all cases in which it would have been allowed to disclose such information in the course of any judicial or administrative proceeding. As explained above, the final rule does not include this provision.
Section 164.512(f)—Disclosure for Law Enforcement Purposes

Disclosures Pursuant to Process and as Otherwise Required by Law

In the NPRM we would have allowed covered entities to disclose protected health information without individual authorization as required by other law. However, as explained above, if a legally mandated use or disclosure fell into one or more of the national priority purposes expressly identified in other paragraphs of proposed § 164.510, the disclosure would have been subject to the terms and conditions specified by the applicable paragraph of proposed § 164.510. For example, mandatory reporting to law enforcement officials would not have been allowed unless such disclosures conformed to the requirements of proposed § 164.510(f) of the NPRM. Proposed § 164.510(f)(1) did not explicitly recognize disclosures required by other laws, and it would not have permitted covered entities to comply with some state and other mandatory reporting laws that require covered entities to disclose protected health information to law enforcement officials, such as the reporting of gun shot wounds, stab wounds, and/or burn injuries.

We did not intend to preempt generally state and other mandatory reporting laws, and in § 164.512(f)(1)(i) of the final rule, we explicitly permit covered entities to disclose protected health information for law enforcement purposes as required by other law. This provision permits covered entities to comply with these state and other laws. Under this provision, to the extent that a mandatory reporting law falls under the provisions of § 164.512(c)(1)(i) regarding reporting of abuse, neglect, or domestic violence, the requirements of those provisions supersede.

In the final rule, we specify that covered entities may disclose protected health information pursuant to this provision in compliance with and as limited by the relevant requirements of legal process or other law. In the NPRM, for the purposes of this portion of the law enforcement paragraph, we proposed to define “law enforcement inquiry or proceeding” as an investigation or official proceeding inquiring into a violation of or failure to comply with law; or a criminal, civil or administrative proceeding arising from a violation of or failure to comply with law. In the final rule, we do not include this definition in § 164.512(f), because it is redundant with the definition of “law enforcement official” in § 164.501.

Proposed § 164.510(f)(1) of the NPRM would have authorized disclosure of protected health information to a law enforcement official conducting or supervising a law enforcement inquiry or proceeding authorized by law pursuant to process, under three circumstances.

First, we proposed to permit such disclosures pursuant to a warrant, subpoena, or other order issued by a judicial officer that documented a finding by the officer. The NPRM did not specify requirements for the nature of the finding. In the final rule, we eliminate the requirement for a “finding,” and we make changes to the list of orders in response to which covered entities may disclose under this provision. Under the final rule, covered entities may disclose protected health information in compliance with and as limited by relevant requirements of: a court order or court-ordered warrant, or a subpoena or summons issued by a judicial officer. We made this change to the list to conform to the definition of “required by law” in § 164.501.

Second, we proposed to permit such disclosures pursuant to a state or federal grand jury subpoena. In the final rule, we leave this provision of the NPRM unchanged.

Third, we proposed to permit such disclosures pursuant to an administrative request, including an administrative subpoena or summons, a civil investigative demand, or similar process, under somewhat stricter standards than exist today for such disclosures. We proposed to permit a covered entity to disclose protected health information pursuant to an administrative request only if the request met three conditions, as follows: (i) The information sought was relevant and material to a legitimate law enforcement inquiry; (ii) the request was as specific and narrowly drawn as reasonably practicable; and (iii) de-identified information could not reasonably have been used to meet the purpose of the request.

The final rules generally adopts this provision of the NPRM. In the final rule, we modify the list of orders in response to which covered entities may disclose protected health information, to include administrative subpoenas or summons, civil or authorized investigative demands, or similar process authorized by law. We made this change to the list to conform with the definition of “required by law” in § 164.501. In addition, we slightly modify the second of the three conditions under which covered entities may respond to such requests, if the request is specific and is limited in scope to the extent reasonably practicable in light of the purpose for which the information is sought.

Limited Information for Identification and Location Purposes

The NPRM would have allowed covered entities to disclose “limited identifying information” for purposes of identifying a suspect, fugitive, material witness, or missing person, in response to a law enforcement request. We proposed to define “limited identifying information” as (i) name; (ii) address; (iii) Social Security number; (iv) date of birth; (v) place of birth; (vi) type of injury or other distinguishing characteristic; and (vii) date and time of treatment.

The final rules generally adopts this provision of the NPRM with a few modifications. In the final rule, we expand the circumstances under which limited information about suspects, fugitives, material witnesses, and missing persons may be disclosed, to include not only cases in which law enforcement officials are seeking to identify such individuals, but also cases in which law enforcement officials are seeking to locate such individuals. In addition, the final rule modifies the list of elements that may be disclosed under this provision, in several ways. We expand the list of elements that may be disclosed under these circumstances, to include ABO blood type and Rh factor, as well as date and time of death, if applicable. We remove “other distinguishing characteristic” from the list of items that may be disclosed for the location and identification purposes described in this paragraph, and instead allow covered entities to disclose only a description of distinguishing physical characteristics, such as scars and tattoos, height, weight, gender, race, hair and eye color, and the presence or absence of facial hair such as a beard or moustache. In addition, in the final rule, protected health information associated with the following cannot be disclosed pursuant to § 164.512(f)(2): DNA data and analyses; dental records; or typing, samples or analyses of tissues or bodily fluids other than blood (e.g., saliva). If a covered entity discloses additional information under this provision, the covered entity will be out of compliance and subject to sanction.

We clarify our intent not to allow covered entities to initiate disclosures of limited identifying information to law enforcement in the absence of a law enforcement request; a covered entity may disclose protected health information under this provision only in response to a request from law enforcement. We allow a “law enforcement official’s request” to be
made orally or in writing, and we intend for it to include requests by a person acting on behalf of law enforcement, for example, requests by a media organization making a television or radio announcement seeking the public’s assistance in identifying a suspect. Such a request also may include a “Wanted” poster and similar postings.

Disclosure About a Victim of Crime

The NPRM would have allowed covered entities to disclose protected health information about a victim of a crime, abuse or other harm to a law enforcement official, if the law enforcement official represented that: (i) The information was needed to determine whether a violation of law by a person other than the victim had occurred; and (ii) immediate law enforcement activity that depended on obtaining the information may have been necessary.

The final rule modifies the conditions under which covered entities can disclose protected health information about victims. In addition, as discussed above, the final rule includes a new § 164.512(c), which establishes conditions for disclosure of protected health information about victims of abuse, neglect or domestic violence. In addition, as discussed above, we have added § 164.512(f)(1)(i) to this paragraph to explicitly recognize that in some cases, covered entities’ disclosure of protected health information is mandated by state or other law. The rule’s requirements for disclosure in situations not covered under mandatory reporting laws are different from the rule’s provisions regarding disclosure pursuant to a mandatory reporting law.

The final rule requires covered entities to obtain individual agreement as a condition of disclosing the protected health information about victims to law enforcement, unless the disclosure is permitted under § 164.512(b) or (c) or § 164.512(f)(1) above. The required agreement may be obtained orally, and does not need to meet the requirements of § 164.508 of this rule (regarding authorizations). The rule waives the requirement for individual agreement if the victim is unable to agree due to incapacity or other emergency circumstance and: (1) The law enforcement official represents that the protected health information is needed to determine whether a violation of law by a person other than the victim has occurred and the information is not intended to be used against the victim; (2) the law enforcement official represents that immediate law enforcement activity that depends on such disclosure would be materially and adversely affected by waiting until the individual is able to agree to the disclosure; and (3) the covered entity, in the exercise of professional judgment, determines that the disclosure is in the individual’s best interests. We intend that assessing the individual’s best interests includes taking into account any further risk of harm to the individual. This provision does not allow covered entities to initiate disclosures of protected health information to law enforcement; the disclosure must be in response to a request from law enforcement.

We do not intend to create a new legal duty on the part of covered entities with respect to the safety of their patients. Rather, we intend to ensure that covered entities can continue to exercise their professional judgment in these circumstances, on a case-by-case basis, as they do today.

In some cases, a victim may also be a fugitive or suspect. For example, an individual may receive a gunshot wound during a robbery and seek treatment in a hospital emergency room. In such cases, when law enforcement officials are requesting protected health information because the individual is a suspect (and thus the information may be used against the individual), covered entities may disclose the protected health information pursuant to § 164.512(f)(2) regarding suspects and not pursuant to § 164.512(f)(3) regarding victims. Thus, in these situations, covered entities may disclose only the limited identifying information listed in § 164.512(f)(2)—not all of the protected health information that may be disclosed under § 164.512(f)(3).

The proposed rule did not address whether a covered entity could disclose protected health information to a law enforcement official to alert the official of the individual’s death.

Disclosures About Decedents

In the final rule, we add a new provision § 164.512(f)(4) in which we permit covered entities to disclose protected health information about an individual who has died to a law enforcement official for the purpose of alerting law enforcement of the death if the covered entity has a suspicion that such death may have resulted from criminal conduct. In such circumstances consent of the individual is not available and it may be difficult to determine the identity of a personal representative and gain consent for disclosure of protected health information. Such disclosures in this circumstance will permit law enforcement officials to begin their investigation into the death more rapidly, increasingly the likelihood of success.

Intelligence and National Security Activities

Section 164.510(f)(4) of the NPRM would have allowed covered entities to disclose protected health information to a law enforcement official without individual authorization for the conduct of lawful intelligence activities conducted pursuant to the National Security Act of 1947 (50 U.S.C. 401 et seq.) or in connection with providing protective services to the President or other individuals pursuant to section 3056 of title 18, United States Code. In the final rule, we move provisions regarding disclosures of protected health information for intelligence and protective services activities to § 164.512(k) regarding uses and disclosures for specialized government functions.

Criminal Conduct on the Premises of a Covered Entity

The NPRM would have allowed covered entities on their own initiative to disclose to law enforcement officials protected health information that the covered entity believed in good faith constituted evidence of criminal conduct that arose out of and was directly related to: (A) The receipt of health care or payment for health care, including a fraudulent claim for health care; (B) qualification for or receipt of benefits, payments, or services based on a fraudulent statement or material misrepresentation of the health of the individual; that occurred on the covered entity’s premises or was witnessed by a member of the covered entity’s workforce.

In the final rule, we modify this provision substantially, by eliminating language allowing disclosures already permitted in other sections of the regulation. The proposed provision overlapped with other sections of the NPRM, in particular proposed § 164.510(c) regarding disclosure for health oversight activities. In the final regulation, we clarify that this provision applies only to disclosures to law enforcement officials of protected health information that the covered entity believes in good faith constitutes evidence of a crime committed on the premises. We eliminate proposed § 164.510(f)(5)(i) regarding health care fraud from the law enforcement section, because all disclosures that would have been allowed under that provision are allowed under § 164.512(f) of the final rule (health oversight). Similarly, in the final rule, we eliminate proposed...
§ 164.510(f)(5)(iii) on disclosure of protected health information to law enforcement officials regarding criminal activity witnessed by a member of a health plan workforce. All disclosures that would have been permitted by that provision are included in § 164.512(f)(5), which allows disclosure of information to report a crime committed on the covered entity’s premises, and by § 164.502, which provides that a covered entity is not in violation of the rule when a member of its workforce or person working for a business associate uses or discloses protected health information while acting as a “whistle blower.” Thus, § 164.512(f)(5) allows covered entities to disclose health information only on the good faith belief that it constitutes evidence of a crime on their premises. The preamble to the NPRM said that if the covered entity disclosed protected health information in good faith but was wrong in its belief that the information was evidence of a violation of law, the covered entity would not be subject to sanction under this regulation. The final rule retains this approach.

Reporting Crime in Emergencies

The proposed rule did not address disclosures by emergency medical personnel to a law enforcement official intended to alert law enforcement about the commission of a crime. Because the provisions of proposed rule were limited to individually identifiable health information that was reduced to electronic form, many communications that occur between emergency medical personnel and law enforcement officials at the scene of a crime would not have been covered by the proposed provisions.

In the final rule we include a new provision § 164.512(f)(6) that addresses “911” calls for emergency medical technicians as well as other emergency health care in response to a medical emergency. The final rule permits a covered health care provider providing emergency health care in response to a medical emergency, other than such emergency on the premises of the covered health care provider, to disclose protected health information to a law enforcement official if such disclosure appears necessary to alert law enforcement to (1) the commission and nature of a crime, (2) the location of such crime or of the victim(s) of such crime, and (3) the identity, description, and location of the perpetrator of such crime. A disclosure is not permitted under this section if health care provider believes that the medical emergency is the result of abuse, neglect, or domestic violence of the individual in need of emergency health care. In such cases, disclosures to law enforcement would be governed by paragraph (c) of this section.

This added provision recognizes the special role of emergency medical technicians and other providers who respond to medical emergencies. In emergencies, emergency medical personnel often arrive on the scene before or at the same time as police officers, firefighters, and other emergency response personnel. In these cases, providers may be in the best position, and sometimes be the only ones in the position, to alert law enforcement about criminal activity. For instance, providers may be the first persons aware that an individual has been the victim of a battery or an attempted murder. They may also be in the position to report in real time, through use of radio or other mechanism, information that may immediately contribute to the apprehension of a perpetrator of a crime.

We note that disclosure under this provision is at the discretion of the health care provider. Disclosures in some instances may be governed more strictly, such as by applicable ethical standards and state and local laws.

Finally, the NPRM also included a proposed § 164.510(f)(5), which duplicated proposed § 164.510(f)(3). The final rule does not include this duplicate provision.

Additional Considerations

As stated in the NPRM, this paragraph is not intended to limit or preclude a covered entity from asserting any lawful defense or otherwise contesting the nature or scope of the process when the procedural rules governing the proceeding so allow. At the same time, it is not intended to create a basis for appealing to federal court concerning a request by state law enforcement officials. Each covered entity will continue to have available legal procedures applicable in the appropriate jurisdiction to contest such requests where warranted.

As was the case with the NPRM, this rule does not create any new affirmative requirement for disclosure of protected health information. Similarly, this section is not intended to limit a covered entity from disclosing protected health information to law enforcement officials where other sections of the rule permit such disclosure, e.g., as permitted by § 164.512(j) to avert an imminent threat to health or safety, for health oversight, to coroners or medical examiners, and in other circumstances permitted by the rule. For additional provisions permitting covered entities to disclose protected health information to law enforcement officials, see § 164.512(j)(1)(i) and (ii).

Under the NPRM and under the final rule, to obtain protected health information, law enforcement officials must comply with whatever other law is applicable. In certain circumstances, while this provision could authorize a covered entity to disclose protected health information to law enforcement officials, there could be additional applicable statutes or rules that further govern the specific disclosure. If the preemption provisions of this regulation do not apply, the covered entity must comply with the requirements or limitations established by such other law, regulation or judicial precedent. See §§ 160.201 through 160.205. For example, if state law permits disclosure only after compulsory process with court review, a provider or payor is not allowed to disclose information to state law enforcement officials unless the officials have complied with that requirement. Similarly, disclosure of substance abuse patient records subject to, 42 U.S.C. 290dd–2, and the implementing regulations, 42 CFR part 2, continue to be governed by those provisions.

In some instances, disclosure of protected health information to law enforcement officials will be compelled by other law, for example, by compulsory judicial process or compulsory reporting laws (such as laws requiring reporting of wounds from violent crimes, suspected child abuse, or suspected theft of controlled substances). As discussed above, disclosure of protected health information under such other mandatory law is permitted under § 164.512(a).

In the responses to comments we clarify that items such as cells and tissues are not protected health information, but that analyses of them is. The same treatment would be given other physical items, such as clothing, weapons, or a bloody knife. We note, however, that while these items are not protected health information and may be disclosed, some communications that could accompany the disclosure will be protected health information under the rule. For example, if a person provides cells to a researcher, and tells the researcher that these are an identified individual’s cancer cells, that accompanying statement is protected health information about that individual. Similarly, if a person provides a bullet to law enforcement, and tells law enforcement that the bullet was extracted from an identified
individual, the person has disclosed the fact that the individual was treated for a wound, and the additional statement is a disclosure of protected health information.

To be able to make the additional statement accompanying the provision of the bullet, a covered entity must look to the rule to find a provision under which a disclosure may be made to law enforcement. Section 164.512(f) of the rule addresses disclosures for law enforcement purposes. Under § 164.512(f)(1), the additional statement may be disclosed to a law enforcement official if required by law or with appropriate process. Under § 164.512(f)(2), we permit covered entities to disclose limited identifying information without legal process in response to a request from a law enforcement official for the purpose of identifying or locating a suspect, fugitive, material witness, or missing person. Thus, in the case of bullet described above, the covered entity may, in response to a law enforcement request, provide the extracted bullet and such additional limited identifying information as is permitted under § 164.512(f)(2).

Section 164.512(g)—Uses and Disclosures About Decedents

In the NPRM we proposed to allow covered entities to disclose protected health information without individual authorization to coroners and medical examiners, consistent with applicable law, for identification of a deceased person or to determine cause of death. In § 164.512(g) of the final rule, we permit covered entities to disclose protected health information to coroners, medical examiners, and funeral directors as part of a new paragraph on disclosures related to death. The final rule retains the NPRM approach regarding disclosure of protected health information to coroners and medical examiners, and it allows the information disclosed to coroners and medical examiners to include identifying information about other persons that may be included in the individual’s medical record. Redaction of such names is not required prior to disclosing the individual’s record to coroners or medical examiners. Since covered entities may also perform duties of a coroner or medical examiner, where a covered entity is itself a coroner or medical examiner, the final rule permits the covered entity to use protected health information in all cases in which it is proposed to disclose such information for its duties as a coroner or medical examiner.

Section 164.512(g) allows covered entities to disclose protected health information to funeral directors, consistent with applicable law, as necessary to carry out their duties with respect to a decedent. For example, the rule allows hospitals to disclose to funeral directors the fact that an individual has donated an organ or tissue, because this information has implications for funeral home staff duties associated with embalming. When necessary for funeral directors to carry out their duties, covered entities may disclose protected health information prior to and in reasonable anticipation of the individual’s death.

Whereas the NPRM did not address the issue of disclosure of psychotherapy notes without individual authorization to coroners and medical examiners, the final rule allows such disclosures. The NPRM did not include in proposed § 164.510(e) language stating that where a covered entity was itself a coroner or medical examiner, it could use protected health information for investigating purposes of engaging in a coroner’s or a medical examiner’s activities. The final rule includes such language to address situations such as where a public hospital performs medical examiner functions. In such cases, the hospital’s on-staff coroners can use protected health information while conducting post-mortem investigations, and other hospital staff can analyze any information associated with these investigations, for example, as part of the process of determining the cause of the individual’s death.

Section 164.512(h)—Uses and Disclosures for Cadaveric Donation of Organs, Eyes, or Tissues

In the NPRM we proposed to include the procurement or banking of blood, sperm, organs, or any other tissue for administration to patients in the definition of “health care” (described in proposed § 160.103). The NPRM’s proposed approach did not differentiate between situations in which the donor was competent to consent to the donation—for example, when an individual is donating blood, sperm, a kidney, or a liver or lung lobe—and situations in which the donor was deceased, for example, when cadaveric organs and tissues were being donated. We also proposed to allow use and disclosure of protected health information for treatment without consent.

In the final rule, we take a different approach. In § 164.512(b), we permit covered entities to disclose protected health information without individual authorization to organ procurement organizations or other entities engaged in the procurement, banking, or transplantation of cadaveric organs, eyes, or tissue for donation and transplantation. This provision is intended to address situations in which an individual has not previously indicated whether he or she seeks to donate organs, eyes, or tissues (and therefore authorized release of protected health information for this purpose). In such situations, this provision is intended to allow covered entities to initiate contact with organ and tissue donation and transplantation organizations to facilitate transplantation of cadaveric organs, eyes, and tissues.

Disclosures and Uses for Government Health Data Systems

In the NPRM we proposed to permit covered entities to disclose protected health information to a government agency, or to a private entity acting on behalf of a government agency, for inclusion in a government health data system collecting health data for analysis in support of policy, planning, regulatory, or management functions authorized by law. The NPRM stated that when a covered entity was itself a government agency collecting health data for these functions, it could use protected health information in all cases for which it was permitted to disclose such information to government health data systems.

In the final rule, we eliminate the provision that would have allowed covered entities to disclose protected health information to government health data systems without authorization. Thus, under the final rule, covered entities cannot disclose protected health information without authorization to government health data systems—or to private health data systems—unless the disclosure is permissible under another provision of the rule.

Disclosures for Payment Processes

In the NPRM we proposed to permit covered entities to disclose, in connection with routine banking activities or payment by debit, credit, or other payment card, or other payment means, the minimum amount of protected health information necessary to complete a banking or payment activity to financial institutions or to entities acting on behalf of financial institutions to authorize, process, clear, settle, bill, transfer, reconcile, or collect payments for financial institutions.

The preamble to the NPRM clarified the NPRM’s intent regarding disclosure of diagnostic and treatment information along with payment...
information to financial institutions. The preamble to the proposed rule said that diagnostic and treatment information never was necessary to process a payment transaction. The preamble said we believed that in most cases, the permitted disclosure would include only: (1) The name and address of the account holder; (2) the name and address of the payor or provider; (3) the amount of the charge for health services; (4) the date on which health services were rendered; (5) the expiration date for the payment mechanism, if applicable; and (6) the individual’s signature. The preamble noted that the proposed regulation text did not include an exclusion list of information that could lawfully be disclosed to process payments, and it solicited comments on whether more elements would be needed for banking and payment transactions and on whether including a specific list of protected health information that could be disclosed was an appropriate approach.

The preamble also noted that under section 1179 of HIPAA, certain activities of financial institutions were exempt from this rule, to the extent that these activities constituted authorizing, processing, clearing, settling, billing, transferring, reconciling, or collecting payments for health care or health plan premiums.

In the final rule, we eliminate the NPRM’s provision on “banking and payment processes.” All disclosures that would have been allowed pursuant to proposed § 164.510() are allowed under § 164.502(a) of the final rule, regarding disclosure for payment purposes.

Section 164.512(i)—Uses and Disclosures for Research Purposes

The NPRM would have permitted covered entities to use and disclose protected health information for research—regardless of funding source—without individual authorization, provided that the covered entity obtained documentation of the following:

1. A waiver, in whole or in part, of authorization for the use or disclosure of protected health information was approved by an Institutional Review Board (IRB) or a privacy board that was composed as stipulated in the proposed rule;

2. The date of approval of the waiver, in whole or in part, of authorization by an IRB or privacy board;

3. The IRB or privacy board had determined that the waiver, in whole or in part satisfied the following criteria:

(i) The use or disclosure of protected health information involves no more than minimal risk to the subjects;
(ii) The waiver will not adversely affect the rights and welfare of the subjects;
(iii) The research could not practicably be conducted without the waiver;
(iv) Whenever appropriate, the subjects will be provided with additional pertinent information after participation;
(v) The research could not practicably be conducted without access to and use of the protected health information;
(vi) The research is of sufficient importance so as to outweigh the intrusion of the privacy of the individual whose information is subject to the disclosure;
(vii) There is an adequate plan to protect the identifiers from improper use and disclosure; and
(viii) There is an adequate plan to destroy the identifiers at the earliest opportunity consistent with the conduct of the research, unless there is a health or research justification for retaining the identifiers; and

4. The written documentation was signed by the chair of, as applicable, the IRB or the privacy board.

The NPRM also proposed that IRBs and privacy boards be permitted to adopt procedures for “expedited review” similar to those provided in the Common Rule (Common Rule § .107), and the privacy board would need to indicate that the IRB had been constituted as required by the Common Rule (§ .107), and the privacy board had been composed as follows: “(A) Has members with varying backgrounds and appropriate professional competency as necessary to review the research protocol; (B) Includes at least one member who is not affiliated with the entity conducting the research, or related to a person who is affiliated with such entity; and (C) Does not have any member participating in a review of any project in which the member has a conflict of interest” (§ 164.510(j)(1)(ii)).

The final rule modifies the first of the requirements for the composition of a privacy board to focus on the effect of the research protocol on the individual’s privacy rights and related interests. Therefore, under the final rule, the required documentation must indicate that the privacy board has members with varying backgrounds and appropriate professional competency as necessary to review the effect of the research protocol on the individual’s privacy rights and related interests.

In addition, the final rule further restricts the NPRM’s proposed requirement that the privacy board include at least one member who was
not affiliated with the entity conducting the research, or related to a person who is affiliated with such entity. Under the final rule, the board must include at least one member who is not affiliated with the covered entity, not affiliated with any entity conducting or sponsoring the research, and not related to any person who is affiliated with such entities.

The other documentation requirements for the composition of an IRB and privacy board remain the same.

2. Waiver of authorization criteria.

The NPRM proposed to prohibit the use or disclosure of protected health information for research without individual authorization as stipulated in proposed §164.508 unless the covered entity had documentation indicating that an IRB or privacy board had determined that the following waiver criteria had been met:

(i) The use or disclosure of protected health information involves no more than minimal risk to the subjects;

(ii) The waiver will not adversely affect the rights and welfare of the subjects;

(iii) The research could not practicably be conducted without the waiver;

(iv) Whenever appropriate, the subjects will be provided with additional pertinent information after participation;

(v) The research could not be practicably be conducted without access to and use of the protected health information;

(vi) The research is of sufficient importance so as to outweigh the intrusion of the privacy of the individual whose information is subject to the disclosure;

(vii) There is an adequate plan to protect the identifiers from improper use and disclosure; and

(viii) There is an adequate plan to destroy the identifiers at the earliest opportunity consistent with the conduct of the research, unless there is a health or research justification for retaining the identifiers.

The final rule continues to permit the documentation of waiver of authorization to be signed by (1) the chair of, as applicable, the IRB or the privacy board, or (2) a member of the IRB or privacy board, or (3) a member of the research project itself.

In addition, the final rule (1) eliminates proposed waiver criterion iv, (2) modifies proposed waiver criteria ii, iii, vi, and viii, and (3) adds a waiver criterion.

Proposed waiver criterion ii (waiver criterion §164.512(i)(2)(ii)(B) in the final rule) is revised as follows to focus more narrowly on the privacy interests of individuals, and to clarify that it also pertains to alterations of individual authorization: “the alteration or waiver will not adversely affect the privacy rights and the welfare of the individuals.” Under criterion §164.512(i)(2)(ii)(B), the question is whether the alteration or waiver of individual authorization would adversely affect the privacy rights and the welfare of individuals, whether the research project itself would adversely affect the privacy rights or the welfare of individuals.

Proposed waiver criterion iii (waiver criterion §164.512(i)(2)(ii)(C) in the final rule) is revised as follows to clarify that it also pertains to alterations of individual authorization: “the research could not practicably be conducted without the alteration or waiver.”

Proposed waiver criterion vi (waiver criterion §164.512(i)(2)(ii)(E) in the final rule) is revised as follows to be more consistent with one of the Common Rule’s requirements for the approval of human subjects research (Common Rule, §111(a)(2)): “the privacy risks to individuals whose protected health information is to be used or disclosed are reasonable in relation to anticipated benefits if any to individuals, and the importance of the knowledge that may reasonably be expected to result from the research.” Under criterion §164.512(i)(2)(ii)(E), the question is whether the risks to an individual’s privacy from participating in the research are reasonable in relation to the anticipated benefits from the research. This criterion is unlike waiver criterion §164.512(i)(2)(ii)(B) in that it focuses on the privacy risks and benefits of the research project more broadly, not on the waiver of individual authorization.

Proposed waiver criterion viii (waiver criterion §164.512(i)(2)(ii)(G) in the final rule) is revised as follows: “there is an adequate plan to destroy the identifiers at the earliest opportunity consistent with the conduct of the research, unless there is a health or research justification for retaining the identifiers, or such retention is otherwise required by law.”

In addition, the final rule includes another criterion: waiver criterion §164.512(i)(2)(ii)(H). The NPRM proposed no restriction on a researcher’s further use or disclosure of protected health information that had been received under proposed §164.510(j). The final rule requires that the covered entity obtain written agreement from the person or entity receiving protected health information under §164.510 not to re-use or disclose protected health information to any other person or entity, except: (1) As required by law, (2) for authorized oversight of the research project, or (3) for other research for which the use or disclosure of protected health information would be permitted by this subpart. For instance, in assessing whether this criterion has been met, we encourage IRBs and privacy boards to obtain adequate assurances that the protected health information will not be disclosed to an individual’s employer for employment decisions without the individual’s authorization.

3. Required signature. The rule broadens the types of individuals who are permitted to sign the required documentation of IRB or privacy board approval. The final rule requires the documentation of the alteration or waiver of authorization to be signed by (1) the chair of, as applicable, the IRB or the privacy board, or (2) a member of the IRB or privacy board, as applicable, who is designated by the chair to sign the documentation.

Furthermore, the final rule makes the following three additions to the proposed documentation requirements for the alteration or waiver of authorization:

1. Identification of the IRB or privacy board. The NPRM did not propose that the documentation of waiver include a statement identifying the IRB or privacy board that approved the waiver of authorization. In the final rule we require that such a statement be included in the documentation of alteration or waiver of individual authorization. By this requirement we mean that the name of the IRB or privacy board must be included in such documentation, not the names of individual members of the board.

2. Description of protected health information approved for use or disclosure. The NPRM did not propose that the documentation of waiver include a description of the protected health information that the IRB or privacy board had approved for use or disclosure without individual authorization. In considering waiver of authorization criterion §164.512(i)(2)(ii)(D), we expect the IRB or privacy board to consider the amount of information that is minimally needed for the study. The final rule requires that the documentation of IRB or
privacy board approval of the alteration or waiver of authorization describe the protected health information for which use or access has been determined to be necessary for the research by the IRB or privacy board. For example, if the IRB or privacy board approves only the use or disclosure of certain information from patients’ medical records, and not patients’ entire medical record, this must be stated on the document certifying IRB or privacy board approval.

3. Review and approval procedures. The NPRM would not have required documentation of IRBs’ or privacy boards’ review and approval procedures. In the final rule, the documentation of the alteration or waiver of authorization must state that the alteration or waiver has been reviewed and approved by: (1) an IRB that has followed the voting requirements stipulated in the Common Rule (§ .108(b)), or the expedited review procedures as stipulated in § .110(b); or (2) a privacy board that has reviewed the proposed research at convened meetings at which a majority of the privacy board members are present, including at least one member who is not affiliated with the covered entity, not affiliated with any entity conducting or sponsoring the research, and not related to any person who is affiliated with any such entities, and the alteration or waiver of authorization is approved by the majority of privacy board members present at the meeting, unless an expedited review procedure is used.

For documentation of IRB approval that used an expedited review procedure, the covered entity must ensure that the documentation indicates that the IRB followed the expedited review requirements of the Common Rule (§ .110). For documentation of privacy board approval that used an expedited review procedure, the covered entity must ensure that the documentation indicates that the privacy board met the expedited review requirements of the privacy rule. In the final rule, a privacy board may use an expedited review procedure if the research involves no more than minimal risk to the privacy of the individuals who are the subject of the protected health information for which disclosure is being sought. If a privacy board elects to use an expedited review procedure, the review and approval of the alteration or waiver of authorization may be carried out by the chair of the privacy board, or by one or more members of the privacy board as designated by the chair. Use of the expedited review mechanism permits review by a single member of the IRB or privacy board, but continues to require that the covered entity obtain documentation that all of the specified waiver criteria have been met.

Reviews Preparatory to Research

Under the NPRM, if a covered entity used or disclosed protected health information for research, but the researcher did not record the protected health information in a manner that persons could be identified, such an activity would have constituted a research use or disclosure that would have been subject to either the individual authorization requirements of proposed § 164.508 or the documentation of the waiver of authorization requirements of proposed § 164.510(j).

The final rule permits the use and disclosure of protected health information for research without requiring authorization or documentation of the alteration or waiver of authorization, if the research is conducted in such a manner that only de-identified protected health information is recorded by the researchers and the protected health information is not removed from the premises of the covered entity. For such uses and disclosures of protected health information, the final rule requires that the covered entity obtain from the researcher representations that use or disclosure is sought solely to review protected health information as necessary to prepare a research protocol or for similar purposes preparatory to research, no protected health information is to be removed from the covered entity by the researcher in the course of the review, and the protected health information for which use or access is sought is necessary for the research purposes. The intent of this provision is to permit covered entities to use and disclose protected health information to assist in the development of a research hypothesis and aid in the recruitment of research participants. We understand that researchers sometimes require access to protected health information to develop a research protocol, and to determine whether a specific covered entity has protected health information of prospective research participants that would meet the eligibility criteria for enrollment into a research study. Therefore, this provision permits covered entities to use and disclose protected health information for these preliminary research activities without individual authorization and without documentation that an IRB or privacy board has altered or waived individual authorization.

Research on Protected Health Information of the Deceased

The NPRM would have permitted the use and disclosure of protected health information of deceased persons for research without the authorization of a legal representative, and without the requirement for written documentation of IRB or privacy board approval in proposed § 164.510(j). In the final rule, we retain the exception for uses and disclosures for research purposes but in addition require that the covered entity take certain protective measures prior to release of the decedent’s protected health information for such purposes. Specifically, the final rule requires that the covered entity obtain representation that the use or disclosure is sought solely for research on the protected health information of decedent, and representation that the protected health information for which use or disclosure is sought is necessary for the research purposes. In addition, the final rule allows covered entities to request from the researcher documentation of the death of the individuals about whom protected health information is being sought.

Good Faith Reliance

The final rule clarifies that covered entities are allowed to rely on the IRB’s or privacy board’s representation that the research proposal meets the documentation requirements of § 164.512(ii)(1)(i) and the minimum necessary requirements of § 164.514. In addition, when using or disclosing protected health information for reviews preparatory to research (§ 164.512(ii)(1)(ii)) or for research solely on the protected health information of decedents (§ 164.512(1)(iii)), the final rule clarifies that the covered entity may rely on the requesting researcher’s representation that the purpose of the request is for one of these two purpose, and that the request meets the minimum necessary requirements of § 164.514. Therefore, the covered entity has not violated the rule if the requesting researcher misrepresents his or her intended use of the protected health information to the covered entity.

Additional Research Provisions

Research Including Treatment

To the extent that a researcher provided treatment to persons as part of a research study, the NPRM would have covered such researchers as health care providers for purposes of that treatment, and required that the researcher comply with all of the provisions of the rule that
would be applicable to health care providers. The final rule retains this requirement.

**Individual Access to Research Information**

Under proposed § 164.514, the NPRM would have applied the proposed provision regarding individuals' access to records to research that includes the delivery of treatment. The NPRM proposed an exception to individuals' right to access protected health information for research that includes treatment of the individual in whole or in part, of the research would be reinstated once the research is in progress. Section 164.524 of the final rule retains this exception to access for research that includes treatment. In addition, the final rule requires that participants in such research be informed that their right of access to protected health information about them will be reinstated once the research is complete.

**Obtaining the Individual's Authorization for Research**

The NPRM would have required covered entities obtaining individuals' authorization for the use or disclosure of information for research to comply with the requirements applicable to individual authorization for the release of protected health information (proposed § 164.508(a)(2)). If an individual had initiated the use or disclosure of his/her protected health information for research, or any other purpose, the covered entity would have been required to obtain a completed authorization for the use or disclosure of protected health information as proposed in § 164.508(c).

The final rule retains these requirements for research conducted with authorization, as required by § 164.508. In addition, for the use and disclosure of protected health information created by a covered entity for the purpose, in whole or in part, of research that includes treatment of the individual, the covered entity must meet the requirements of § 164.508(f).

**Interaction with the Common Rule**

The NPRM stated that the proposed rule would not override the Common Rule. Where both the NPRM and the Common Rule would have applied to research conducted by the covered entity—either with or without individuals' authorization—both sets of regulations would have needed to be followed. This statement remains true in the final rule. In addition, we clarify that FDA's human subjects regulations must also be followed if applicable.

**Section 164.512(j)—Uses and Disclosures to Avert a Serious Threat to Health or Safety**

In the NPRM we proposed to allow covered entities to use or disclose protected health information without individual authorization—consistent with applicable law and ethics standards—based on a reasonable belief that use or disclosure of the protected health information was necessary to prevent or lessen a serious and imminent threat to health or safety of an individual or of the public. Pursuant to the NPRM, covered entities could have used or disclosed protected health information in these emergency circumstances to a person or persons reasonably able to prevent or lessen the threat, including the target of the threat. The NPRM stated that covered entities that made disclosures in these circumstances were presumed to have acted under a reasonable belief if the disclosure was made in good faith, based on credible representation by a person with apparent knowledge or authority. The NPRM did not include verification requirements specific to this paragraph.

In § 164.512(j) of the final rule, we retain the NPRM's approach to uses and disclosures made to prevent or lessen serious and imminent threats to health or safety, as well as its language regarding the presumption of good faith. We also clarify that: (1) Rules governing these situations, which the NPRM referred to as "emergency circumstances," are not intended to apply to emergency care treatment, such as health care delivery in a hospital emergency room; and (2) the "presumption of good faith belief" is intended to apply only to this provision and not to all disclosures permitted without individual authorization. The final rule allows covered entities to use or disclose protected health information without an authorization on their own initiative in these circumstances, when necessary to prevent or lessen a serious and imminent threat, consistent with other applicable ethical or legal standards.

The rule's approach is consistent with the "duty to warn" third persons at risk, which has been established through case law. In *Tarasoff v. Regents of the University of California* (17 Cal. 3d 425 (1977)), it was found that when a therapist's patient had made credible threats against the physical safety of a specific person, the therapist had an obligation to use reasonable care to protect the intended victim of his patient against danger, including warning the victim of the danger. Many states have adopted, through either statutory or case law, versions of the Tarasoff duty to warn. The rule is not intended to create a duty to warn or disclose. Rather, it permits disclosure to avert a serious and imminent threat to health or safety consistent with other applicable legal or ethical standards. If disclosure in these circumstances is prohibited by state law, this rule would not allow the disclosure.

As indicated above, in some situations (for example, when a person is both a fugitive and a victim and thus covered entities could disclose protected health information pursuant to § 164.512(f)(2) regarding fugitives or to § 164.512(f)(3) establishing conditions for disclosure about victims), more than one section of this rule potentially could apply with respect to a covered entity's potential disclosure of protected health information. Similarly, in situations involving a serious and imminent threat to public health or safety, law enforcement officials may be seeking protected health information from covered entities to locate a fugitive. In the final rule, we clarify that if a situation fits one section of the rule (for example, § 164.512(j) on serious and imminent threats to health or safety), covered entities may disclose protected health information.

The proposed rule did not address situations in which covered entities could make disclosures to law enforcement officials about oral statements admitting participation in violent conduct or about escapees. In the final rule we permit, but do not require, covered entities to use or disclose protected health information, consistent with applicable law and standards of ethical conduct, in specific situations in which the covered entity, in good faith, believes the use or disclosure is necessary to permit law enforcement authorities to identify or apprehend an individual. Under paragraph (j)(1)(ii)(A) of this section, a covered entity may take such action because of a statement by an individual admitting participation in a violent crime that the covered entity reasonably believes may have resulted in serious physical harm to the victim. The
protected health information that is disclosed in this case is limited to the statement and to the protected health information included under the limited identifying and location information in §164.512(f)(2), such as name, address, and type of injury. Under paragraph (jj)(1)(ii)(B) of this section, a covered entity may take such action where it appears from all the circumstances that the individual has escaped from a correctional institution or from lawful custody.

A disclosure may not be made under paragraph (jj)(1)(ii)(A) for a statement admitting participation in a violent crime if the covered entity learns the information in the course of counseling or therapy. Similarly, such a disclosure is not permitted if the covered entity learns the information in the course of treatment to affect the propensity to commit the violent crimes that are described in the individual’s statements. We do not intend to discourage individuals from speaking accurately in the course of counseling or therapy sessions, or to discourage other treatment that specifically seeks to reduce the likelihood that someone who has acted violently in the past will do so again in the future. This prohibition on disclosure is triggered once an individual has made a request to initiate or be referred to such treatment, therapy, or counseling.

The provision permitting use and disclosure has been added in light of the broadened definition in the final rule of protected health information. Under the NPRM, protected health information meant individually identifiable health information that is or has been electronically transmitted or electronically maintained by a covered entity. Under the final rule, protected health information includes information transmitted by electronic media as well as such information transmitted or maintained in any other form or medium. The new definition includes oral statements to covered entities as well as individually identifiable health information transmitted “in any other form.”

The definition of protected health information, for instance, would now apply to a statement by a patient that is overheard by a hospital security guard in a waiting room. Such a statement would have been outside the scope of the proposed rule (unless it was memorialized in an electronic record), but is within the scope of the final rule. For the example with the hospital guard, the new provision permitting disclosure of a statement by an individual admitting participation in a violent crime would have the same effect as the proposed rule—the statement could be disclosed to law enforcement, so long as the other aspects of the regulation are followed. Similarly, where it appears from all the circumstances that the individual has escaped from prison, the expanded definition of protected health information should not prevent the covered entity from deciding to report this information to law enforcement.

The disclosures that covered entities may elect to make under this paragraph are entirely at their discretion. These disclosures to law enforcement are in addition to other disclosure provisions in the rule. For example, under paragraph §164.512(f)(2) of this section, a covered entity may disclose limited categories of protected health information in response to a request from a law enforcement officer for the purpose of identifying or locating a suspect, fugitive, material witness, or missing person. Paragraph §164.512(f)(1) of this section permits a covered entity to make disclosures that are required by other laws, such as state mandatory reporting laws, or are required by legal process such as court orders or grand jury subpoena.

Section 164.512(k)—Uses and Disclosures for Specialized Government Functions

Application to Military Services

In the NPRM we would have permitted a covered entity providing health care to Armed Forces personnel to use and disclose protected health information for activities deemed necessary by appropriate military command authorities to assure the proper execution of the military mission, where the appropriate military authority had published by notice in the Federal Register (in the NPRM, we proposed that the Department of Defense would publish this Federal Register notice in the future.) The final rule takes a similar approach while making some modifications to the NPRM. One modification concerns the information that will be required in the Federal Register notice. The NPRM would have required a listing of (i) appropriate military command authorities; (ii) the circumstances for which use or disclosure without individual authorization would be required; and (iii) activities for which such use or disclosure would occur in order to assure proper execution of the military mission. In the final rule, we eliminate the third category and also slightly modify language in the second category to read: “the purposes for which the protected health information may be used or disclosed.”

An additional modification concerns the rule’s application to foreign military and diplomatic personnel. The NPRM would have excluded foreign diplomatic and military personnel, as well as their dependents, from the proposed definition of “individual,” thereby excluding any protected health information created about these personnel from the NPRM’s privacy protections. Foreign military and diplomatic personnel affected by this provision include, for example, allied military personnel who are in the United States for training. The final rule applies a more limited exemption to foreign military personnel only (Foreign diplomatic personnel will have the same protections granted to all other individuals under the rule). Under the final rule, foreign military personnel are not excluded from the definition of “individual.” Covered entities will be able to use and disclose protected health information of foreign military personnel to their appropriate foreign military authority for the same purposes for which uses and disclosures are permitted for U.S. Armed Forces personnel under the notice to be published in the Federal Register. Foreign military personnel do have the same rights of access, notice, right to request privacy protection, copying, amendment, and accounting as do other individuals pursuant to §§164.520–164.526 (sections on access, notice, right to request privacy protection for protected health information, amendment, inspection, copying) of the rule.

The NPRM likewise would have exempted overseas foreign national beneficiaries from the proposed rule’s requirements by excluding them from the definition of “individual.” Under the final rule, these beneficiaries no longer are exempt from the definition of “individual.” However, the rule’s provisions do not apply to the individually identifiable health information of overseas foreign nationals who receive care provided by the Department of Defense, other federal agencies, or by non-governmental organizations incident to U.S. sponsored missions or operations. The final rule includes a new provision to address separation or discharge from military service. The preamble to the NPRM noted that upon completion of individuals’ military service, DOD and the Department of Transportation routinely transfer entire military service records, including protected health information to the Department of Veterans Affairs so that
the file can be retrieved quickly if the individuals or their dependents apply for veterans benefits. The NPRM would have required consent for such transfers. The final rule no longer requires consent in such situations. Thus, under the final rule, a covered entity that is a component of DOD or the Department of Transportation may disclose to DVA the protected health information of an Armed Forces member upon separation or discharge from military service for the purpose of a determination by DVA of the individual’s eligibility for or entitlement to benefits under laws administered by the Secretary of Veterans Affairs.

**Department of Veterans Affairs**

Under the NPRM, a covered entity that is a component of the Department of Veterans Affairs could have used and disclosed protected health information to other components of the Department that determine eligibility for, or entitlement to, or that provide benefits under laws administered by the Secretary of Veterans Affairs. In the final rule, we retain this approach.

**Application to Intelligence Community**

The NPRM would have provided an exemption from its proposed requirements to the intelligence community. As defined in section 4 of the National Security Act, 50 U.S.C. 401a, the intelligence community includes: the Office of the Director of Central Intelligence Agency; the Office of the Deputy Director of Central Intelligence; the National Intelligence Council and other such offices as the Director may designate; the Central Intelligence Agency; the National Security Agency; the Defense Intelligence Agency; the National Imagery and Mapping Agency; the National Reconnaissance Office; other offices within the DOD for the collection of specialized national intelligence through reconnaissance programs; the intelligence elements of the Army, the Navy, the Air Force, the Marine Corps, the Federal Bureau of Investigation, the Department of the Treasury, and the Department of Energy; the Bureau of Intelligence and Research of the Department of State; and such other elements of any other department or agency as may be designated by the President, or designated jointly by the Director of Central Intelligence and the head of the department or agency concerned, as an element of the intelligence community. It would have allowed a covered entity to use without individual authorization protected health information of employees of the intelligence community, and of their dependents, if such dependents were being considered for posting abroad. The final rule does not include such an exemption. Rather, the final rule does not except intelligence community employees and their dependents from the general rule requiring an authorization in order for protected health information to be used and disclosed.

**National Security and Intelligence Activities**

The NPRM included a provision, in § 164.510(f)—Disclosure for Law Enforcement Purposes—that would allow covered entities to disclose protected health information without consent for the conduct of lawful intelligence activities under the National Security Act, and in connection with providing protective services to the President or to foreign heads of state pursuant to 18 U.S.C. 3056 and 22 U.S.C. 2709(a)(3) respectively. The final rule preserves these exemptions, with slight modifications, but moves them from proposed § 164.510(f) to § 164.512(k). It also divides this area into two paragraphs—one called “National Security and Intelligence Activities” and the second called “Protective services for the President and Others.”

The final rule, with modifications, allows a covered entity to disclose protected health information to an authorized federal official for the conduct of lawful intelligence, counter-intelligence, and other national security activities authorized by the National Security Act and implementing authority (e.g., Executive Order 12333). The references to “counter-intelligence and other national security activities” are now to the final rule. The reference to “implementing authority (e.g., Executive Order 12333)” is also new. The final rule also adds specificity to the provision on protective services. It states that a covered entity may disclose protected health information to authorized federal officials for the conduct of protective services if the President or designees authorized by 18 U.S.C. 3056, or to foreign heads of state or other persons as authorized by 22 U.S.C. 2709(a)(3), or for the conduct of investigations authorized by 18 U.S.C. 871 and 879.

**Application to the State Department**

The final rule creates a narrower exemption for Department of State for uses and disclosures of protected health information (1) for purposes of a required security clearance conducted pursuant to Executive Orders 10450 and 12698; (2) as necessary to meet the requirements of determining worldwide availability or availability for mandatory service abroad under Sections 101(a)(4) and 504 of the Foreign Service Act; and (3) for a family member to accompany a Foreign Service Officer abroad, consistent with Section 101(b)(5) and 904 of the Foreign Service Act.

Regarding security clearances, nothing prevents any employer from requiring that individuals provide authorization for the purpose of obtaining a security clearance. For the Department of State, however, the final rule provides a limited exemption that allows a component of the Department of State without an authorization to (1) use protected health information to make medical suitability determinations and (2) disclose whether or not the individual was determined to be medically suitable to authorized officials in the Department of State for the purpose of a security clearance investigation conducted pursuant to Executive Order 10450 and 12698.

Section 101(a)(4) and 504 of the Foreign Service Act require that Foreign Service members be available to serve in assignments throughout the world. The final rule permits disclosures to officials who need protected health information to determine availability for duty worldwide.

**Application to Correctional Facilities**

The NPRM would have excluded the individually identifiable health information of correctional facility inmates and detention facility detainees from the definition of protected health information. Thus, none of the NPRM’s...
The final rule takes a different approach. First, to clarify that we are referring to individuals who are incarcerated in correctional facilities that are part of the criminal justice system or in the lawful custody of a law enforcement official—and not to individuals who are “detained” for non-criminal reasons, for example, in psychiatric institutions—§ 164.512(k) covers disclosure of protected health information to correctional institutions or law enforcement officials having such lawful custody. In addition, where a covered health care provider is also a health care component of a correctional institution, the final rule permits the covered entity to use protected health information in all cases in which it is permitted to disclose such information.

We define correctional institution as defined pursuant to 28 U.S.C. 13725(b)(1), as a “prison, jail, reformatory, work farm, detention center, or halfway house, or any other similar institution designed for the confinement or rehabilitation of criminal offenders.” The rules regarding disclosure and use of protected health information specified in § 164.512(k) cover individuals who are in transitional homes, and other facilities in which they are required by law to remain for correctional reasons and from which they are not allowed to leave. This section also covers individuals who are confined to psychiatric institutions for correctional reasons and who are not allowed to leave; however, it does not apply to disclosure of information about individuals in psychiatric institutions for treatment purposes only, who are not there due to a crime or under a mandate from the criminal justice system. The disclosure rules described in this section do not cover release of protected health information about individuals in pretrial release, probation, or on parole, such persons are not considered to be incarcerated in a correctional facility.

As described in § 164.512(k), correctional facility inmates’ individually identifiable health information is not excluded from the definition of protected health information. When individuals are released from correctional facilities, they will have the same privacy rights that apply to all other individuals under this rule.

Section 164.512(k) of the final rule states that while individuals are in a correctional facility or in the lawful custody of a law enforcement official, covered entities (for example, the prison’s clinic) can use or disclose protected health information about these individuals without authorization to the correctional facility or the law enforcement official having custody as necessary for: (1) the provision of health care to such individuals; (2) the health and safety of such individual or other inmates; (3) the health and safety of the officers of employees of or others at the correctional institution; and (4) the health and safety of such individuals and officers or other persons responsible for the transporting of inmates or their transfer from one institution or facility to another; (5) law enforcement on the premises of the correctional institution; and (6) the administration and maintenance of the safety, security, and good order of the correctional institution. This section is intended to allow, for example, a prison’s doctor to disclose to a van driver transporting a criminal that the individual is a diabetic and frequently has seizures, as well as information about the appropriate action to take if the individual has a seizure while he or she is being transported.

We permit covered entities to disclose protected health information about these individuals if the correctional institution or law enforcement official represents that the protected health information is necessary for these purposes. Under 164.514(h), a covered entity may reasonably rely on the representation of such public officials.

Application to Public Benefits Programs Required to Share Eligibility Information

We create a new provision for covered entities that are a government program providing public benefits. This provision allows the following disclosures of protected health information.

First, where other law requires or expressly authorizes information relating to the eligibility for, or enrollment in more than one public program to be shared among such public programs and/or maintained in a single or combined data system, a public agency that is administering a health plan may maintain such a data base and may disclose information relating to such eligibility or enrollment in the health plan to the extent authorized by such other law.

Where another public entity has determined that the appropriate balance between the need for efficient administration of public programs and public funds and individuals’ privacy interests is to allow information sharing for these limited purposes, we do not upset that determination. For example, section 1137 of the Social Security Act requires a variety of public programs, including the Social Security program, state medical aid programs, the food stamp program, certain unemployment compensation programs, and others, to participate in a joint income and eligibility verification system. Similarly, section 222 of the Social Security Act requires the Social Security Administration to provide information to certain state vocational rehabilitation programs for eligibility purposes. In some instances, it is a covered entity that first collects or creates the information that is then disclosed for these systems. We do not prohibit those disclosures.

This does not authorize these entities to share information for claims determinations or ongoing administration of these public programs. This provision is limited to the agencies and activities described above.

Second, § 164.512(k)(6) permits a covered entity that is a government agency administering a government program providing public benefits to disclose protected health information relating to the program to another covered entity that is a government agency administering a government program providing public benefits if the programs serve the same or similar populations and the disclosure of protected health information is necessary to coordinate the covered functions of such programs.

The second provision permits covered entities that are government programs providing public benefits that serve the same or similar populations to share protected health information for the purposes of coordinating covered functions of the programs and for general management and administration relating to the covered functions of the programs. Often, similar government health programs are administered by different government agencies. For example, in some states, the Medicaid program and the State Children’s Health Insurance Program are administered by different agencies, although they serve similar populations. Many states coordinate eligibility for these two programs, and sometimes offer services through the same delivery systems and contracts. This provision would permit the covered entities administering these programs to share protected health information of program participants to coordinate enrollment and services and to generally improve health care operations of the programs. We note that this provision does not authorize the
agencies to use or disclose the protected health information that is shared for purposes other than as provided for in this paragraph.

**Section 164.512(l)—Disclosures For Workers’ Compensation**

The NPRM did not contain special provisions permitting covered entities to disclose protected health information for the purpose of complying with workers’ compensation and similar laws. Under HIPAA, workers’ compensation and certain other forms of insurance (such as automobile or disability insurance) are “excepted benefits.” Insurance carriers that provide this coverage are not covered entities even though they provide coverage for health care services. To carry out their insurance functions, these non-covered insurers typically seek individually identifiable health information from covered health care providers and group health plans. In drafting the proposed rule, the Secretary was faced with the challenge of trying to carry out the statutory mandate of safeguarding the privacy of individually identifiable health information by regulating the flow of such information from covered entities while at the same time respecting the Congressional intent to shield workers’ compensation carriers and other excepted benefit plans from regulation as covered entities.

In the proposed rule we allowed covered entities to disclose protected health information without individual consent for purposes of treatment, payment or health care operations—even when the disclosure was to a non-covered entity such as a workers’ compensation carrier. In addition, we allowed protected health information to be disclosed if required by state law for purposes of determining eligibility for coverage or fitness for duty. The proposed rule also required that whenever a covered entity disclosed protected health information to a non-covered entity, even though authorized under the rule, the individual who was the subject of the information must be informed that the protected health information was no longer subject to privacy protections.

Like other disclosures under the proposed rule, the information provided to workers’ compensation carriers for treatment, payment or health care operations was subject to the minimum necessary standard. However, to the extent that protected health information was disclosed to the carrier because it was required by law, it was not subject to the minimum necessary standard. In addition, individuals were entitled to an accounting when protected health information was disclosed for purposes other than treatment, payment or health care operations. In the final rule, we include a new provision in this section that clarifies the ability of covered entities to disclose protected health information without authorization to comply with workers’ compensation and similar programs established by law that provide benefits for work-related illnesses or injuries without regard to fault. Although most disclosures for workers’ compensation would be permissible under other provisions of this rule, particularly the provisions that permit disclosures for payment and as required by law, we are aware of the significant variability among workers’ compensation and similar laws, and include this provision to ensure that existing workers’ compensation systems are not disrupted by this rule. We note that the minimum necessary standard applies to disclosures under this paragraph.

Under this provision, a covered entity may disclose protected health information regarding an individual to a party responsible for payment of workers’ compensation benefits to the individual, and to an agency responsible for administering and/or adjudicating the individual’s claim for workers’ compensation benefits. For purposes of this paragraph, workers’ compensation benefits include benefits under programs such as the Black Lung Benefits Act, the federal Employees’ Compensation Act, the Longshore and Harbor Workers’ Compensation Act, and the Energy Employees’ Occupational Illness Compensation Program Act.

**Additional Considerations**

We have included a general authorization for disclosures under workers’ compensation systems to be consistent with the intent of Congress, which defined workers’ compensation carriers as excepted benefits under HIPAA. We recognize that there are significant privacy issues raised by how individually identifiable health information is used and disclosed in workers’ compensation systems, and believe that states or the federal government should enact standards that address those concerns.

**Section 164.514—Other Procedural Requirements Relating To Uses and Disclosures of Protected Health Information**

**Section 164.514(a)—De-identification**

In § 164.506(d) of the NPRM, we proposed that the privacy standards would apply to “individually identifiable health information,” and not to information that does not identify the subject individual. The statute defines individually identifiable health information as certain health information:

(i) Which identifies the individual, or
(ii) With respect to which there is a reasonable basis to believe that the information can be used to identify the individual.

As we pointed out in the NPRM, difficulties arise because, even after removing obvious identifiers (e.g., name, social security number, address), there is always some probability or risk that any information about an individual can be attributed to that individual.

The NPRM proposed two alternative methods for determining when sufficient identifying information has been removed from a record to render the information de-identified and thus not subject to the rule. First, the NPRM proposed the establishment of a “safe harbor”: if all of a list of 19 specified items of information had been removed, and the covered entity had no reason to believe that the remaining information could be used to identify the subject of the information (alone or in combination with other information), the covered entity would have been presumed to have created de-identified information. Second, the NPRM proposed an alternative method so that covered entities with sufficient statistical experience and expertise could remove or encrypt a combination of information different from the enumerated list, using commonly accepted scientific and statistical standards for disclosure avoidance. Such covered entities would have been able to include information from the enumerated list of 19 items if they (1) believed that the probability of re-identification was very low, and (2) removed additional information if they had a reasonable basis to believe that the resulting information could be used to re-identify someone.

We proposed that covered entities and their business partners be permitted to use protected health information to create de-identified health information using either of these two methods. Covered entities would have been permitted to further use and disclose such de-identified information in any way, provided that they did not disclose the key or other mechanism that would have enabled the information to be re-identified, and provided that they reasonably believed that such use or disclosure of de-identified information would not have resulted in the use or
Disclosure of protected health information.

A number of examples were provided of how valuable such de-identified information would be for various purposes. We expressed the hope that covered entities, their business partners, and others would make greater use of de-identified health information than they do today, when it is sufficient for the purpose, and that such practice would reduce the burden and the confidentiality concerns that result from the use of individually identifiable health information for some of these purposes.

In §§ 164.514(a)-(c) of this final rule, we make several modifications to the provisions for de-identification. First, we explicitly adopt the statutory standard as the basic regulatory standard for whether health information is individually identifiable health information under this rule. Information is not individually identifiable under this rule if it does not identify the individual, or if the covered entity has no reasonable basis to believe it can be used to identify the individual. Second, in the implementation specifications we reformulate the two ways in which a covered entity can demonstrate that it has met the standard.

One way a covered entity may demonstrate that it has met the standard is if a person with appropriate knowledge and experience applying generally accepted statistical and scientific principles and methods for rendering information not individually identifiable makes a determination that the risk is very small that the information could be used, either by itself or in combination with other available information, by anticipated recipients to identify a subject of the information. The covered entity must also document the analysis and results that justify the determination. We provide guidance regarding this standard in our responses to the comments we received on this provision.

We also include an alternate, safe harbor, method by which covered entities can demonstrate compliance with the standard. Under the safe harbor, a covered entity is considered to have met the standard if it has removed all of a list of enumerated identifiers, and if the covered entity has no actual knowledge that the information could be used alone or in combination to identify a subject of the information. We note that in the NPRM, we had proposed that to meet the safe harbor, a covered entity must have “no reason to believe” that the information remained identifiable after the enumerated identifiers were removed. In the final rule, we have changed the standard to one of actual knowledge in order to provide greater certainty to covered entities using the safe harbor approach.

In the safe harbor, we explicitly allow age and some geographic location information to be included in the de-identified information, but all dates directly related to the subject of the information must be removed or limited to the year, and zip codes must be removed or aggregated (in the form of most 3-digit zip codes) to include at least 20,000 people. Extreme ages of 90 and over must be aggregated to a category of 90+ to avoid identification of very old individuals. Other demographic information, such as gender, race, ethnicity, and marital status are not included in the list of identifiers that must be removed.

The intent of the safe harbor is to provide a means to produce some de-identified information that could be used for many purposes with a very small risk of privacy violation. The safe harbor is intended to involve a minimum of burden and convey a maximum of certainty that the rules have been met by interpreting the statutory “reasonable basis to believe that the information can be used to identify the individual” to produce an easily followed, cook book approach.

Covered entities may use codes and similar means of marking records so that they may be linked or later re-identified, if the code does not contain information about the subject of the information (for example, the code may not be a derivative of the individual’s social security number), and if the covered entity does not use or disclose the code for any other purpose. The covered entity is also prohibited from disclosing the mechanism for re-identification, such as tables, algorithms, or other tools that could be used to link the code with the subject of the information.

Language to clarify that covered entities may contract with business associates to perform the de-identification has been added to the section on business associates.

Section 164.514(d)—Minimum Necessary

The proposed rule required a covered entity to make all reasonable efforts not to use or disclose more than the minimum amount of protected health information necessary to accomplish the intended purpose of the use or disclosure (proposed § 164.506(b)).

The proposed minimum necessary standard did not apply to uses or disclosures that were made by covered entities at the request of the individual, either to allow the individual access to protected health information about him or her or pursuant to an authorization initiated by the individual. The requirement also did not apply to uses and disclosures made: pursuant to the compliance and enforcement provisions of the rule; as required by law and permitted by the regulation without individual authorization; by a covered health care provider to a health plan, when the information was requested for audit and related purposes. Finally, the standard did not apply to the HIPAA administrative simplification transactions.

The proposed implementation specifications would have required a covered entity to have procedures to: (i) Identify appropriate persons within the entity to determine what information should be used or disclosed consistent with the minimum necessary standard; (ii) ensure that those persons make the minimum necessary determinations, when required; and (iii) within the limits of the entity’s technological capabilities, provide for the making of such determinations individually. The proposal allowed a covered entity, when making disclosures to public officials that were permitted without individual authorization but not required by other law, to reasonably rely on the representations of such officials that the information requested was the minimum necessary for the stated purpose(s).

The preamble provided further guidance. The preamble explained that covered entities could not have general policies of approving all requests (or all requests of a particular type) without carefully considering certain criteria (see “Criteria,” below) as well as other information specific to the request. The minimum necessary determination would have needed to be consistent with and directly related to the purpose of the use or disclosure. Where there was ambiguity regarding the information to be used or disclosed, the preamble directed covered entities to interpret the “minimum necessary” standard to “require” the covered entity to make some effort to limit the amount of protected health information used/disclosed.

The proposal would have required the minimum necessary determination to take into consideration the ability of a covered entity to delimit the amount of information used or disclosed. The preamble noted that these determinations would have to be made under a reasonableness standard: covered entities would be required to make reasonable efforts and to incur reasonable expense to limit the use or
disclosure. The “reasonableness” of limiting particular uses or disclosures was to be determined based on the following factors (which were not included in the regulatory text):
a. The extent to which the use or disclosure would extend the number of persons with access to the protected health information.
b. The likelihood that further uses or disclosures of the protected health information could occur.
c. The amount of protected health information that would be used or disclosed.
d. The importance of the use or disclosure.
e. The potential to achieve substantially the same purpose with de-identified information. For disclosures, each covered entity would have been required to have policies for determining when protected health information must be stripped of identifiers.
f. The technology available to limit the amount of protected health information used/disclosed.
g. The cost of limiting the use/disclosure.
h. Any other factors that the covered entity believed were relevant to the determination.

The proposal shifted the “minimum necessary” burden off of covered providers when they were being audited by a health plan. The preamble explained that the duty would have been shifted to the payor to request the minimum necessary information for the audit purpose, although the regulatory text did not include such a requirement. Outside of the audit context, the preamble stated that a health plan would be required, when requesting a disclosure, to limit its requests to the information required to achieve the purpose of the request; the regulation text did not include this requirement.

The preamble stated that disclosure of an entire medical record, in response to a request for something other than the entire medical record, would presumptively violate the minimum necessary standard.

This final rule significantly modifies the proposed requirements for implementing the minimum necessary standard. For all uses and many disclosures and requests for disclosures from other covered entities, we require covered entities to implement policies and procedures for “minimum necessary” uses and disclosures.

Implementation of such policies and procedures is required in lieu of making the “minimum necessary” determination for each separate use or disclosure as discussed in the proposal.

Disclosures to or requests by a health care provider for treatment purposes are not subject to the standard (see § 164.502).

Specifically (and as further described below), the proposed requirement for individual review of all uses of protected health information is replaced with a requirement for covered entities to implement policies and procedures that restrict access and uses based on the specific roles of members of the covered entity’s workforce. Routine disclosures also are not subject to individual review; instead, covered entities must implement policies and procedures to limit the protected health information in routine disclosures to the minimum necessary to achieve the purpose of that type of disclosure. The proposed exclusion of disclosures to health plans for audit purposes is deleted and replaced with a general requirement that covered entities must limit requests to other covered entities for individually identifiable health information to what is reasonably necessary for the use or disclosure intended. The other exclusions from the standard are unchanged from the proposed rule (e.g., for individuals’ access to information about themselves, pursuant to an authorization initiated by the individual, for enforcement of this rule, as required by law).

The language of the basic “standard” itself is largely unchanged; covered entities must make reasonable efforts to use or disclose or to request from another covered entity, only the minimum amount of protected health information required to achieve the purpose of a particular use or disclosure. We delete the word “all” from the “reasonable efforts” that covered entities must take in making a “minimum necessary” determination. The implementation specifications are significantly modified, and differ based on whether the activity is a use or disclosure.

Similarly, a “minimum necessary” disclosure for oversight purposes in accordance with § 164.512(d) could include large numbers of records to allow oversight agencies to perform statistical analyses to identify deviations in payment or billing patterns, and other data analyses.

Uses of Protected Health Information
A covered entity must implement policies and procedures to identify the persons or classes of persons in the entity’s workforce who need access to protected health information to carry out their specific responsibilities. Covered entities also must implement policies and procedures to limit the protected health information to which such persons or classes need access, and the conditions, as appropriate, that would apply to such access. Covered entities must also implement policies and procedures to limit access to only the identified persons, and only to the identified protected health information. The policies and procedures must be based on reasonable determinations regarding the persons or classes of persons who require protected health information, and the nature of the health information they require, consistent with their job responsibilities.

For example, a hospital could implement a policy that permitted nurses access to all protected health information of patients in their ward while they are on duty. A health plan could permit its underwriting analysts unrestricted access to aggregate claims information for rate setting purposes, but require documented approval from its department manager to obtain specific identifiable claims records of a member for the purpose of determining the cause of unexpected claims that could influence renewal premium rate setting.

The “minimum necessary” standard is intended to reflect and be consistent with, not override, professional judgment and standards. For example, we expect that covered entities will implement policies that allow persons involved in treatment to have access to the entire record, as needed.

Disclosures of Protected Health Information
For any type of disclosure that is made on a routine, recurring basis, a covered entity must implement policies and procedures (which may be standard protocols) that permit only the disclosure of the minimum protected health information reasonably necessary to achieve the purpose of the disclosure. Individual review of each disclosure is not required. Instead, under § 164.514(d)(3), these policies and procedures must identify the types of protected health information to be disclosed, the types of persons who would receive the protected health information, and the conditions that would apply for such access. We recognize that specific disclosures within a type may vary, and require that the policies address what is the norm for the type of disclosure involved. For example, a covered entity may decide to participate in research studies and therefore establish a protocol to minimize the information released for such purposes, e.g., by requiring researchers requesting disclosure of data contained in paper-based records to review the paper records on-site and to
abstract only the information relevant to the research. Covered entities must develop policies and procedures (which may be standard protocols) to apply to disclosures to routinely hired types of business associates. For instance, a standard protocol could describe the subset of information that may be disclosed to medical transcription services.

For non-routine disclosures, a covered entity must develop reasonable criteria for determining, and limiting disclosure to, only the minimum amount of protected health information necessary to accomplish the purpose of the disclosure. They also must establish and implement procedures for reviewing such requests for disclosures on an individual basis in accordance with these criteria.

Disclosures to health care providers for treatment purposes are not subject to these requirements.

Covered entities’ policies and procedures must provide that disclosure of an entire medical record will not be made except pursuant to policies which specifically justify why the entire medical record is needed. For instance, a health plan’s request for all protected health information from an applicant for insurance would not necessarily violate the regulation, because the entire record may be the “minimum necessary” for its purpose. Covered entities may establish policies allowing for and justifying such a request. A request for the entire medical record absent such documented justification is a presumptive violation of this rule.

Reasonable Reliance

A covered entity may reasonably rely on the assertion of a requesting covered entity that it is requesting the minimum protected health information necessary for the stated purpose. A covered entity may also rely on the assertions of a professional (such as attorneys and accountants) who is a member of its workforce or its business associate regarding what protected health information he or she needs in order to provide professional services to the covered entity when such person represents that the information requested is the minimum necessary. As we proposed in the NPRM, covered entities making disclosures to public officials that are permitted under §164.512 may rely on the representation of a public official that the information requested is the minimum necessary.

Uses and Disclosures for Research

In making a minimum necessary determination regarding the use or disclosure of protected health information for research purposes, a covered entity may reasonably rely on documentation from an IRB or privacy board describing the protected health information needed for research and consistent with the requirements of §164.512(b). “Uses and Disclosures for Research Purposes.” A covered entity may also reasonably rely on a representation made by the requestor that the information is necessary to prepare a research protocol or for research on decedents. The covered entity must ensure that the representation or documentation of IRB or privacy board approval it obtains from a researcher describes with sufficient specificity the protected health information necessary for the research. Covered entities must use or disclose such protected health information in a manner that minimizes the scope of the use or disclosure.

Standards for Electronic Transactions

We clarify that under §164.502(b)(2)(v), covered entities are not required to apply the minimum necessary standard to the required or situational data elements specified in the implementation guides for HIPAA administrative simplification standard transactions in the Transactions Rule. The standard does apply for uses or disclosures in standard transactions that are made at the option of the covered entity.

Section 164.514(e)—Marketing

In the proposed rule, we would have required covered entities to obtain the individual’s authorization in order to use or disclose protected health information to market health and non-health items and services.

We have made a number of changes in the final rule that relate to marketing. In the final rule, we retain the general rule that covered entities must obtain the individual’s authorization before making uses or disclosures of protected health information for marketing. However, we add a new definition of “marketing” that clarifies that certain activities, such as communications made by a covered entity for the purpose of describing the products and services it provides, are not marketing. See §164.501 and the associated preamble regarding the definition of marketing. In the final rule we also permit covered entities to use and disclose protected health information for certain marketing activities without individual authorization, subject to conditions enumerated at §164.514(e).

First, §164.514(e) permits a covered entity to use or disclose protected health information without individual authorization to make a marketing communication if the communication occurs in a face-to-face encounter with the individual. This provision would permit a covered entity to discuss any services and products, including those of a third-party, without restriction during a face-to-face communication. A covered entity also could give the individual sample products or other information in this setting.

Second, we permit a covered entity to use or disclose protected health information without individual authorization to make marketing communications involving products or services of only nominal value. This provision ensures that covered entities do not violate the rule when they distribute calendars, pens and other merchandise that generally promotes the covered entity.

Third, we permit a covered entity to use or disclose protected health information without individual authorization to make marketing communications about the health-
related products or services of the covered entity or of a third party if the communication: (1) Identifies the covered entity as the party making the communication; (2) to the extent that the covered entity receives direct or indirect remuneration from a third-party for making the communication, prominently states that fact; (3) except in the case of a general communication (such as a newsletter), contains instructions describing how the individual may opt-out of receiving future communications about health-related products and services; and (4) where protected health information is used to target the communication about a product or service to individuals based on their health status or health condition, explains why the individual has been targeted and how the product or service relates to the health of the individual. The final rule also requires a covered entity to make a determination, prior to using or disclosing protected health information to target a communication to individuals based on their health status or condition, that the product or service may be beneficial to the health of the type or class of individual targeted to receive the communication.

This third provision accommodates the needs of health care entities to be able to discuss their own health-related products and services, or those of third parties, as part of their everyday business and as part of promoting the health of their patients and enrollees. The provision is restricted to uses by covered entities or disclosures to their business associates pursuant to a contract that requires confidentiality, ensuring that protected health information is not distributed to third parties. To provide individuals with a better understanding of how their protected health information is being used for marketing, the provision requires that the communication identify that the covered entity is the source of the communication; a covered entity may not send out information about the product of a third party without disclosing to the individual where the communication originated. We also require covered entities to disclose any direct or indirect remuneration from third parties. This requirement permits individuals to better understand why they are receiving a communication, and to weigh the extent to which their information is being used to promote their health or to enrich the covered entity. Covered entities also are required to include in their communication (unless it is a general newsletter or similar device) how the individual may prevent further communications about health-related products and services. This provision enhances individuals' control over how their information is being used. Finally, where a covered entity targets communications to individuals on the basis of their health status or condition, we require that the entity make a determination that the product or service being communicated may be beneficial to the health of the type of individuals targeted, and that the communication to the targeted individuals explain why they have been targeted and how the product or service relates to their health. This final provision balances the advantages that accrue from health care entities informing their patients and enrollees of new or valuable health products with individuals' expectations that their protected health information will be used to promote their health.

Section 164.514(f)—Fundraising

We proposed in the NPRM to require covered entities to obtain authorization from an individual in order to use the individual's protected health information for fundraising activities. As noted in §164.501, in the final rule we define fundraising on behalf of a covered entity to be a health care operation. In §164.514, we permit a covered entity to use protected health information without individual authorization for fundraising on behalf of itself, provided that it limits the information that it uses to demographic information about the individual and the dates that it has provided service to the individual (see the §164.501 discussion of “health care operations”). In addition, we require fundraising materials to explain how the individual may opt out of any further fundraising communications, and covered entities are required to honor such requests. We permit a covered entity to disclose the limited protected health information to a business associate for fundraising on its own behalf. We also permit a covered entity to disclose the information to an institutionally related foundation.

By “institutionally related foundation,” we mean a foundation that qualifies as a nonprofit charitable foundation under section 501(c)(3) of the Internal Revenue Code and that has in its charter statement of charitable purposes an explicit linkage to the covered entity. An institutionally related foundation may, as explicitly stated in its charter, support the covered entity as well as other covered entities or health care providers in its community. For example, a covered hospital may disclose for fundraising on its own behalf the specified protected health information to a nonprofit foundation established for the specific purpose of raising funds for the hospital or to a foundation that has as its mission the support of the members of a particular hospital chain that includes the covered hospital. The term does not include an organization with a general charitable purpose, such as to support research about or to provide treatment for certain diseases, that may give money to a covered entity, because its charitable purpose is not specific to the covered entity.

Section 164.514(g)—Underwriting

As described under the definition of “health care operations” (§164.501), protected health information may be used or disclosed for underwriting and other activities relating to the creation, renewal, or replacement of a contract of health insurance or health benefits. This final rule includes a requirement, not included in the NPRM, that health plans receiving such information for these purposes may not use or disclose it for any other purpose, except as may be required by law, if the insurance or benefits contract is not placed with the health plan.

Section 164.514(h)—Verification of Identity and Authority of Persons Requesting Protected Health Information

Disclosure of Protected Health Information

We reorganize the provision regarding verification of identity of individuals requesting protected health information to improve clarity, but we retain the substance of requirements proposed in the NPRM in §164.518(c), as follows.

The covered entity must establish and use written policies and procedures (which may be standard protocols) that are reasonably designed to verify the identity and authority of the requestor where the covered entity does not know the person requesting the protected health information. The knowledge of the person may take the form of a known place of business, address, phone or fax number, as well as a known human being. Where documentation, statements or representations, whether oral or written, from the person requesting the protected health information is a condition of disclosure under this rule or other law, this verification must involve obtaining such documentation statement, or representation. In such a case, additional verification is only required where this regulation (or other law)
requires additional proof of authority and identity.

The NPRM proposed that covered entities would be permitted to rely on the required documentation of IRB or privacy board approval to constitute sufficient verification that the person making the request was a researcher and that the research is authorized. The final rule retains this provision.

For most disclosures, verifying the authority for the request means taking reasonable steps to verify that the request is lawful under this regulation. Additional proof is required by other provisions of this regulation where the request is made pursuant to §164.512 for national priority purposes. Where the person requesting the protected health information is a public official, covered entities must verify the identity of the requester by examination of reasonable evidence, such as a written statement of identity on agency letterhead, an identification badge, or similar proof of official status. Similarly, covered entities are required to verify the legal authority supporting the request by examination of reasonable evidence, such as a written request provided on agency letterhead that describes the legal authority for requesting the release. Where §164.512 explicitly requires written evidence of legal process or other authority before a disclosure may be made, a public official’s proof of identity and the official’s oral statement that the request is authorized by law are not sufficient to constitute the required reasonable evidence of legal authority; under these provisions, only the required written evidence will suffice.

In some circumstances, a person or entity acting on behalf of a government agency may make a request for disclosure of protected health information under these subsections. For example, public health agencies may contract with a nonprofit agency to collect and analyze certain data. In such cases, the covered entity is required to verify the requestor’s identity and authority through examination of reasonable documentation that the requestor is acting on behalf of the government agency. Reasonable evidence includes a written request provided on agency letterhead that describes the legal authority for requesting the release and states that the person or entity is acting under the agency’s authority, or other documentation, including a contract, a memorandum of understanding, or purchased arrangements that confirm that the requestor is acting on behalf of the government agency.

In some circumstances, identity or authority will be verified as part of meeting the underlying requirements for disclosure. For example, a disclosure under §164.512(j)(1)(i) to avert an imminent threat to safety is lawful only if made in the good faith belief that the disclosure is necessary to prevent or lessen a serious and imminent threat to the health or safety of a person or the public, and to a person reasonably able to prevent or lessen the threat. If these conditions are met, no further verification is needed. In such emergencies, the covered entity is not required to demand written proof that the person requesting the protected health information is legally authorized. Reasonable reliance on verbal representations are appropriate in such situations.

Similarly, disclosures permitted under §164.510(a) for facility directories may be made to the general public; the covered entity’s policies and procedures do not need to address verifying the identity and authority for these disclosures. In §164.510(b) we do not require verification of identity for persons assisting in an individual’s care or for notification purposes. For disclosures when the individual is not present, such as when a friend is picking up a prescription, we allow the covered entity to use professional judgment and experience with common practice to make reasonable inferences.

Under §164.524, a covered entity is required to give individuals access to protected health information about them (under most circumstances). Under the general verification requirements of §164.514(h), the covered entity is required to take reasonable steps to verify the identity of the individual making the request. We do not mandate particular identification requirements (e.g., drivers license, photo ID), but rather leave this to the discretion of the covered entity. The covered entity must also establish and document procedures for verification of identity and authority of personal representatives, if not known to the entity. For example, a health care provider can require a copy of a power of attorney, or can ask questions to determine that an adult acting for a young child has the requisite relationship to the child.

In Subpart C of Part 160, we require disclosure to the Secretary for purposes of enforcing this regulation. When a covered entity is asked by the Secretary to disclose protected health information for compliance purposes, the covered entity must verify the same information that it is required to verify for any other law enforcement or oversight request for disclosure.

Use of Protected Health Information

The proposed rule’s verification requirements applied to any person requesting protected health information, whether for a use or a disclosure. In the final regulation, the verification provisions apply only to disclosures of protected health information. The requirements in §164.514(d), for implementation of policies and procedures for “minimum necessary” uses of protected health information, are sufficient to ensure that only appropriate persons within a covered entity will have access to protected health information.

Section 164.520—Notice of Privacy Practices for Protected Health Information

Section 164.520(a)—Right to Notice

We proposed to establish a right for individuals to receive adequate notice of how covered health care providers and health plans use and disclose protected health information, and of the individual’s rights with respect to that information.

In the final regulation, we retain the general right for individuals to receive and the requirement for covered entities to produce a notice of privacy practices, with significant modifications to the content and distribution requirements.

We also modify the requirements with respect to certain covered entities. First, in §164.500(b)(2), we clarify that a health care clearinghouse that creates or receives protected health information other than as a business associate of a covered entity must produce a notice. If a health care clearinghouse creates or receives protected health information only as a business associate of other covered entities, it is not required to produce a notice.

Second, in §164.520(a)(2), we clarify the notice requirements with respect to group health plans. Individuals who receive health benefits under a group health plan other than through insurance are entitled to a notice from the group health plan; self-insured group health plans must maintain a notice that meets the requirements of this section and must provide the notice in accordance with the requirements of §164.520(c). At a minimum, the self-insured group health plan’s notice must describe the group health plan’s privacy practices with respect to the protected health information it creates or receives through its self-insured arrangements. For example, if a group health plan maintains both fully-insured and self-insured arrangements, the group health plan must, at a minimum, maintain and provide a notice that describes its
privacy practices with respect to protected health information it creates or receives through the self-insured arrangements. This notice would be distributed to all participants in the self-insured arrangements (in accordance with §164.520(c)(1)) and would also be available on request to other persons, including participants in the fully-insured arrangements.

Individuals who receive health benefits under a group health plan through an insurance contract (i.e., a fully-insured group health plan) are entitled to a notice from the issuer or HMO through which they receive their health benefits. The health insurance issuer or HMO must maintain and provide the notice in accordance with §164.520(c)(1). In addition, some fully-insured group health plans are required to maintain and provide a notice of the group health plan’s privacy practices. If a group health plan provides health benefits solely through an insurance contract with a health insurance issuer or HMO, and the group health plan creates or receives protected health information in addition to summary information (as defined in §164.504(a)) and information about individuals’ enrollment in or disenrollment from a health insurance issuer or HMO offered by the group health plan, the group health plan must maintain a notice that meets the requirements of this section and must provide the notice upon request of any person. The group health plan is not required to meet the other distribution requirements of §164.520(c)(1). Individuals enrolled in such group health plans have the right to notice of the health insurance issuer or HMO’s privacy practices and, on request, to notice of the group health plan’s privacy practices. If the group health plan, however, provides health benefits solely through an insurance contract with a health insurance issuer or HMO, and the only protected health information the group health plan creates or receives is summary information (as defined in §164.504(a)) and information about individuals’ enrollment in or disenrollment from a health insurance issuer or HMO offered by the group health plan, the group health plan is not required to maintain or provide a notice under this section.

In this case, the individuals enrolled in the group health plan would receive notice of the health insurance issuer or HMO’s privacy practices, but would not be entitled to notice of the group health plan’s privacy practices.

Third, in §164.520(a)(3), we clarify that inmates do not have a right to notice under this section and a correctional institution that is a covered entity is not required to produce a notice. No person, including a current or former inmate, has the right to notice of such a covered entity’s privacy practices.

Section 164.520(b)—Content of Notice

We proposed to require the notice to be written in plain language and contain each of the following elements:

1. A description of the uses and disclosures expected to be made without individual authorization;
2. Statements that other uses and disclosures would be made only with the individual’s authorization and that the individual could revoke such authorization;
3. Descriptions of the rights to request restrictions, inspect and copy protected health information, amend or correct protected health information, and receive an accounting of disclosures of protected health information;
4. Statements about the entity’s legal requirements to protect privacy, provide notice, and adhere to the notice; a statement about how individuals would be informed about the entity’s policies and procedures; instructions on how to make complaints with the entity or Secretary; the name and telephone number of a contact person or office; and the date the notice was produced.

We provided a model notice of information policies and procedures for covered health care providers.

In §164.520(b), and immediately below in this preamble, we describe the notice content requirements for the final rule. As described in detail, below, we make substantial changes to the uses and disclosures of protected health information that must be described in the notice. Unlike the proposed rule, we do not include a model notice. We intend to develop further guidance on notice requirements prior to the compliance date of this rule. In this section of the final rule, we also refer to the covered entity’s privacy “practices,” rather than its “policies and procedures.” The purpose of this change in vocabulary is to clarify that a covered entity’s “policies and procedures” is a detailed documentation of all of the entity’s privacy practices as required under this rule, not just those described in the notice. For example, we require covered entities to have policies and procedures implementing the requirements for “minimum necessary” uses and disclosures of protected health information, but these policies and procedures need not be reflected in the entity’s notice. Similarly, we require covered entities to have policies and procedures for assuring individuals access to their information about them. While such policies and procedures will need to include documentation of the designated record sets subject to access, who is authorized to determine when information will be withheld from an individual, and similar details, the notice need only explain generally that individuals have the right to inspect and copy information about them, and tell individuals how to exercise that right.

A covered entity that adopts and follows the notice content and distribution requirements described below will have provided adequate notice. However, the requirements for the content of the notice are not intended to be exclusive. As with the rest of the rule, we specify minimum requirements, not best practices.

Covered entities may want to include more detail. We note that all federal agencies must still comply with the Privacy Act of 1974. This means that federal agencies that are covered entities or have covered health care components must comply with the notice requirements of the Privacy Act as well as those included in this rule.

In addition, covered entities may want or be required to produce more than one notice in order to satisfy the notice content requirements under this rule. For example, a covered entity that conducts business in multiple states with different laws regarding the uses and disclosures that the covered entity is permitted to make without authorization may be required to produce a different notice for each state. A covered entity that conducts business both as a part of an organized health care arrangement or affiliated covered entity and as an independent enterprise (e.g., a physician who sees patients through an on-call arrangement with a hospital and through an independent private practice) may want to adopt different privacy practices with respect to each line of business; such a covered entity would be required to produce a different notice describing the practices for each line of business. Covered entities must produce notices that accurately describe the privacy practices that are relevant to the individuals receiving the notice.

Required Elements

Plain Language

As in the proposed rule, we require the notice to be written in plain language. A covered entity can satisfy the plain language requirement if it makes a reasonable effort to: organize material to serve the needs of the reader; write short sentences in the active voice, using “you” and other pronouns; use common, everyday words in sentences; and divide material into short sections.

We do not require particular formatting specifications, such as easy-to-read design features (e.g., lists, tables, graphics, contrasting colors, and white space), type face, and font size. However, the purpose of the notice is to inform the recipients about their rights and how protected health information collected about them may be used or disclosed. Recipients who cannot understand the covered entity’s notice will miss important information about their rights under this rule and about how the covered entity is protecting health information about them. One of the goals of this rule is to create an environment of open communication and transparency with respect to the use and disclosure of protected health information. A lack of clarity in the notice could undermine this goal and create misunderstandings. Covered entities have an incentive to make their notice statements clear and concise. We believe that the more understandable the notice is, the more confidence the public will have in the covered entity’s commitment to protecting the privacy of health information.

It is important that the content of the notice be communicated to all recipients and therefore we encourage the covered entity to consider alternative means of communicating with certain populations. We note that any covered entity that is a recipient of federal financial assistance is generally obligated under Title VI of the Civil Rights Act of 1964 to provide material ordinarily distributed to the public in the primary languages of persons with limited English proficiency in the recipients’ service areas. Specifically, this Title VI obligation provides that, where a significant number or proportion of the population eligible to be served or likely to be directly affected by a federally assisted program needs service or information in a language other than English in order to effectively informed of or participate in the program, the recipient shall take reasonable steps, considering the scope of the program and the size and concentration of such population, to provide information in languages appropriate to such persons. For covered entities not subject to Title VI, the Title VI standards provide helpful guidance for effectively communicating the content of their notices to non-English speaking populations.

We also encourage covered entities to be attentive to the needs of individuals who cannot read. For example, an employee of the covered entity could read the notice to individuals upon request or the notice could be incorporated into a video presentation that is played in the waiting area.

Header

Unlike the proposed rule, covered entities must include prominent and specific language in the notice that indicates the importance of the notice. This is the only specific language we require covered entities to include in the notice. The header must read, “THIS NOTICE DESCRIBES HOW MEDICAL INFORMATION ABOUT YOU MAY BE USED AND DISCLOSED AND HOW YOU CAN GET ACCESS TO THIS INFORMATION. PLEASE REVIEW IT CAREFULLY.”

Uses and Disclosures

We proposed to require covered entities to describe in plain language the uses and disclosures of protected health information, and the covered entity’s policies and procedures with respect to such uses and disclosures, that the health plan or covered provider expected to make without individual authorization. The covered provider or health plan would have had to distinguish between those uses and disclosures required by law and those permitted but not required by law.

We also proposed to require covered health care providers and health plans to state in the notice that all other uses and disclosures would be made only with the individual’s authorization and that such authorization could be revoked. The notice would also have been required to state that the individual could request restrictions on certain uses and disclosures and that the covered entity would not be required to agree to such a request.

We significantly modify these requirements in the final rule. Covered entities must describe all uses and disclosures of protected health information that they are permitted or required to make under this rule without authorization, including those uses and disclosures subject to the consent requirements under §164.506. If other applicable law prohibits or materially limits the covered entity’s ability to make any uses or disclosures that would otherwise be permitted under the rule, the covered entity must describe only the uses and disclosures permitted under the more stringent law.

Covered entities must separately describe each purpose for which they are permitted to use or disclose protected health information under this rule without authorization, and must do so in sufficient detail to place the individual in a position to decide whether to agree to such a request. Covered entities must separately describe each purpose for which they are permitted to use or disclose protected health information under this rule without authorization, and must do so in sufficient detail to place the individual in a position to decide whether to agree to such a request.

In addition, a group health plan, or a health insurance issuer or HMO with respect to a group health plan, wants the option to disclose protected health information to a group health plan sponsor without authorization as permitted under §164.504(f), the group health plan, health insurance issuer or HMO must describe that practice in its notice.

As in the proposed rule, the notice must state that all other uses and disclosures will be made only with the individual’s authorization and that the individual has the right to revoke such authorization.

We anticipate this requirement will lead to significant standardization of the notice. This language could be the same for every covered entity of a particular type within a state, territory, or other locale. We encourage state professional associations, and other organizations to develop model language to assist covered entities in preparing their notices.

Individual Rights

As in the proposed rule, covered entities must describe individuals’ rights under the rule and how individuals may exercise those rights with respect to the covered entity. Covered entities must describe each of the following rights, as provided under the rule: the right to request restrictions...
on certain uses and disclosures, including a statement that the covered entity is not required to agree to a requested restriction (§ 164.522(a)); the right to receive confidential communications of protected health information (§ 164.522(b)); the right to inspect and copy protected health information (§ 164.524); the right to amend protected health information (§ 164.526); and the right to an accounting of disclosures of protected health information (§ 164.528). We additionally require the notice to describe the right of an individual, including an individual that has agreed to receive the notice electronically, to obtain a paper copy of the notice upon request.

Covered Entity’s Duties

As in the proposed rule, covered entities must state in the notice that they are required by law to maintain the privacy of protected health information, to provide a notice of their legal duties and privacy practices, and to abide by the terms of the notice currently in effect. In the final rule, we additionally require the covered entity, if it wishes to reserve the right to change its privacy practices and apply the revised practices to protected health information previously created or received, to make a statement to that effect and describe how it will provide individuals with a revised notice. (See below for a more detailed discussion of a covered entity’s responsibilities when it changes its privacy practices.)

Complaints

As in the proposed rule, a covered entity’s notice must inform individuals about how they can lodge complaints with the covered entity if they believe their privacy rights have been violated. See § 164.530(d) and the corresponding preamble discussion for the requirements on covered entities for receiving complaints. The notice must also state that individuals may file complaints with the Secretary. In the final rule, we additionally require the notice to include a statement that the individual will not suffer retaliation for filing a complaint.

Contact

As in the proposed rule, the notice must identify a point of contact where the individual can obtain additional information about any of the matters identified in the notice.

Effective Date

The notice must include the date the notice went into effect, rather than the proposed requirement to include the effective date the notice was produced. The effective date cannot be earlier than the date on which the notice was first printed or otherwise published. Covered entities may wish to highlight or otherwise emphasize any material modifications that it has made, in order to help the individual recognize such changes.

Optional Elements

As described above, we proposed to require covered entities to describe the uses and disclosures of protected health information that the covered entity in fact expected to make without the individual’s authorization. We did not specify any optional elements.

While the final rule requires covered entities to describe all of the types of uses and disclosures permitted or required by law (not just those that the covered entity intends to make), we also permit and encourage covered entities to include optional elements that describe the actual, more limited, uses and disclosures they intend to make without authorization. We anticipate that some covered entities will want to distinguish themselves on the basis of their more stringent privacy practices. For example, covered health care providers who routinely treat patients with particularly sensitive conditions may wish to assure their patients that, even though the law permits them to disclose information for a wide array of purposes, the covered health care provider will only disclose information in very specific circumstances, as required by law, and to avert a serious and imminent threat to health or safety. A covered entity may not include statements in the notice that purport to limit the entity’s ability to make uses or disclosures that are required by law or necessary to avert a serious and imminent threat to health or safety. As described above, if the covered entity wishes to reserve the right to change its privacy practices with respect to the more limited uses and disclosures and apply the revised practices to protected health information previously created or received, it must make a statement to that effect and describe how it will provide individuals with a revised notice. (See below for a more detailed discussion of a covered entity’s responsibilities when it changes its privacy practices.)

Revisions to the Notice

We proposed to require a covered entity to adhere to the terms of its notice, and would have permitted it to change its policies and procedures at any time. We would have required covered health care providers and health plans to update the notice to reflect material changes to the information policies and procedures described in the notice. Changes to the notice would have applied to all protected health information held by the covered entity, including information collected under prior notices. That is, we would not have required covered entities to segregate their records according to the notice in effect at the time the record was created. We proposed to prohibit covered entities from implementing a change to an information policy or procedure described in the notice until the notice was updated to reflect the change, unless a compelling reason existed to make a use or disclosure or take other action that the notice would not have permitted. In these situations, we proposed to require covered entities to document the compelling reason and, within 30 days of the use, disclosure, or other action, change its notice to permit the action.

As in the proposed rule, covered entities are required to adhere to the terms of the notice currently in effect. See § 164.502(i). When a covered entity materially changes any of the uses or disclosures, the individual’s rights, the covered entity’s legal duties, or other privacy practices described in its notice, it must promptly revise its notice accordingly. See § 164.520(b)(3). (Pursuant to § 164.530(i), it must also revise its policies and procedures.) Except when required by law, a material change to any term in the notice may not be implemented prior to the effective date of the notice in which such material change is reflected. In the final rule, however, we revise the circumstances under and extent to which the covered entity may revise the practices stated in the notice and apply the new practices to protected health information it created or received under prior notice.

Under § 164.530(i), a covered entity that wishes to change its practices over time without segregating its records according to the notice in effect at the time the records were created must reserve the right to do so in its notice. For example, a covered hospital that states in its notice that it will only make public health disclosures required by law, and that does not reserve the right to change this practice, is prohibited from making any discretionary public health disclosures of protected health information created or received during the effective period of that notice. If the covered hospital wishes at some point in the future to make discretionary disclosures for public health purposes, it must revise its notice to so state, and...
must segregate its records so that protected health information created or received under the prior notice is not disclosed for discretionary public health purposes. This hospital may then make discretionary public health disclosures of protected health information created or received after the effective date of the revised notice.

If a second covered hospital states in its notice that it will only make public health disclosures required by law, but does reserve the right to change its practices, it is prohibited from making any discretionary public health disclosures of protected health information created or received during the effective period of that notice. If this hospital wishes to provide public health information in the future, it may first obtain a copy of the notice of the other hospital as of the compliance date; after enrollment, health plan as of the compliance date; or by providing the relevant notice to the individual within 60 days of a material change to the notice. After this one year period, covered providers may satisfy the distribution requirement by providing the notice that is relevant to the particular individual or other person requesting the notice. For example, a health insurance issuer may have contracts with two different group health plans. One contract specifies that the issuer may use and disclose protected health information about the participants in the group health plan for research purposes without authorization (subject to the requirements of this rule) and one contract specifies that the issuer must always obtain authorizations for these uses and disclosures. The issuer accordingly develops two notices reflecting these different practices and satisfies its distribution requirement by making the relevant notice available to the participants.

We proposed to require covered health care providers with face-to-face contact with individuals to provide the notice to all such individuals at the first service delivery to the individual during the one year period after the compliance date. After this one year period, covered providers with face-to-face contact with individuals would have been required to distribute the notice to all new patients at the first service delivery. Covered providers without face-to-face contact with individuals would have been required to provide the notice in a reasonable period of time following first service delivery.

We proposed to require all covered providers to post the notice in a clear and prominent location where it would be accessible to individuals seeking services from the covered provider to be able to read the notice. We would have required revisions to be posted promptly.

In the final rule, we vary the distribution requirements according to whether the covered health care provider has a direct treatment relationship with an individual, rather than whether the covered health care provider has face-to-face contact with an individual. See §164.501 and the corresponding discussion in the preamble regarding the definition of direct treatment relationship. Covered health care providers that have direct treatment relationships with individuals must provide the notice to such individuals as of the first service delivery after the compliance date. This requirement applies whether the first service is delivered electronically or in person. Covered providers may satisfy this requirement by sending the notice to all of their patients at once, by giving the notice to each patient as he or she comes into the provider’s office or facility or contacts the provider electronically, or by some combination of these approaches. Covered providers that maintain a physical service delivery site must prominently post the notice where it is reasonable to expect individuals seeking service from the provider to be able to read the notice. The notice must also be available on site for individuals to take on request. In the event of a revision to the notice, the covered provider must promptly post the revision and make it available on site.

Covered health care providers that have indirect treatment relationships with individuals are only required to produce the notice upon request, as described above.

The proposed rule was silent regarding electronic distribution of the notice. Under the final rule, a covered entity that maintains a web site describing the services and benefits it offers must make its privacy notice prominently available through the site.

A covered entity may satisfy the applicable distribution requirements described above by providing the notice to the individual electronically, if the individual agrees to receiving materials from the covered entity electronically and the individual has not withdrawn his or her agreement. If the covered entity knows that the electronic transmission has failed, the covered entity must provide a paper copy of the notice to the individual.

If an individual’s first service delivery from a covered provider occurs electronically, the covered provider must provide electronic notice automatically and contemporaneously in response to the individual’s first request for service. For example, the first time an individual requests to fill a prescription through a covered internet pharmacy, the pharmacy must automatically and contemporaneously provide the individual with the
pharmacy’s notice of privacy practices. An individual that receives a covered entity’s notice electronically retains the right to request a paper copy of the notice as described above. This right must be described in the notice.

We note that the Electronic Signatures in Global and National Commerce Act (Pub. L. 106–229) may apply to documents required under this rule to be provided in writing. We do not intend to affect the application of that law to documents required under this rule.

Section 164.520(d)—Joint Notice by Separate Covered Entities

The proposed rule was silent regarding the ability of legally separate covered entities to produce a single notice.

In the final rule, we allow covered entities that participate in an organized health care arrangement to comply with this section by producing a single notice that describes their combined privacy practices. See § 164.501 and the corresponding preamble discussion regarding the definition of organized health care arrangement. (We note that, under § 164.504(d), covered entities that are under common ownership or control may designate themselves as a single affiliated covered entity. Joint notice requirements do not apply to such entities. Single affiliated covered entities must produce a single notice, consistent with the requirements described above for any other covered entity. Covered entities under common ownership or control that elect not to designate themselves as a single affiliated covered entity, however, may elect to produce a joint notice if they meet the definition of an organized health care arrangement.)

The joint notice must meet all of the requirements described above. The covered entities must agree to abide by the terms of the notice with respect to protected health information created or received by the covered entities as part of their participation in the organized health care arrangement. In addition, the joint notice must reasonably identify the covered entities, or class of covered entities, to which the joint notice applies and the service delivery sites, or classes of service delivery sites, to which the joint notice applies. If the covered entities participating in the organized health care arrangement will share protected health information with each other as necessary to carry out treatment, payment, or health care operations relating to the arrangement, that fact must be stated in the notice.

Typical examples where this policy may be useful are health care facilities where physicians and other providers who have offices elsewhere also provide services at the facility (e.g., hospital staff privileges, physicians visiting their patients at a residential facility). In these cases, a single notice may cover both the physician and the facility, if the above conditions are met. The physician is required to have a separate notice covering the privacy practices at the physician’s office if those practices are different than the practices described in the joint notice.

If any one of the covered entities included in the joint notice distributes the notice to an individual, as required above, the distribution requirement is met for all of the covered entities included in the joint notice.

Section 164.520(e)—Documentation

As in the proposed rule, we establish documentation requirements for covered entities subject to this provision. In the final rule, we specify that covered entities must retain copies of the notice(s) they issue in accordance with § 164.530(j). See § 164.530(j) and the corresponding preamble discussion for further description of the documentation requirements.

Section 164.522—Rights To Request Privacy Protection for Protected Health Information

Section 164.522(a)—Right of An Individual To Request Restriction of Uses and Disclosures

We proposed that individuals have the right to request that a covered health care provider restrict the use or disclosure of protected health information for treatment, payment, or health care operations. Providers would not have been required to agree to requested restrictions. However, a covered provider that agreed to a restriction could not use or disclose protected health information inconsistent with the restriction. The requirement would not have applied to permissible uses or disclosures under proposed § 164.510, including uses and disclosures in emergency circumstances under proposed § 164.510(k); when the health care services provided were emergency services; or to required disclosures to the Secretary under proposed § 164.522. We would have required covered providers to have procedures for individuals to request restrictions, for agreed-upon restrictions to be documented, for the provider to honor such restrictions, and for notification of the existence of a restriction to others to whom such protected health information is disclosed.

In the final rule, we retain the general right of an individual to request that uses and disclosures of protected health information be restricted and the requirement for covered entities to adhere to restrictions to which they have agreed. However, we include some significant changes and clarifications.

Under the final rule, we extend the right to request restrictions to health plans and to health care clearinghouses that create or receive protected health information other than as a business associate of another covered entity. All covered entities must permit individuals to request that uses and disclosures of protected health information to carry out treatment, payment, and health care operations be restricted and must adhere to restrictions to which they have agreed. A covered entity is not required to agree to a restriction. We note that restrictions between an individual and a covered entity for these or other purposes may be otherwise enforceable under other law.

Under § 164.522(a)(1)(i)(B), the right to request restrictions applies to disclosures to persons assisting in the individual’s care under § 164.510(b). An individual may request that a covered entity agree not to disclose protected health information to persons assisting with the individual’s care, even if such disclosure is permissible in accordance with § 164.510(b). For example, if an individual requests that a covered entity never disclose protected health information to a particular family member, and the covered entity agrees to that restriction, the covered entity is prohibited from disclosing protected health information to that family member, even if the disclosure would otherwise be permissible under § 164.510(b). We note that individuals additionally have the opportunity to agree or object to disclosures to persons assisting in the individual’s care under § 164.510(b)(2). The individual retains the right to agree or object to such disclosures under § 164.510(b)(2), in accordance with the restriction of that provision, regardless of whether the individual has requested a restriction under § 164.522(a). See § 164.510(b) and the corresponding preamble discussion regarding the individual’s right to agree or object to disclosures to persons assisting in the individual’s care.

In §§ 164.522(a)(1)(iii) and (iv) we clarify the requirements with respect to emergency treatment situations. In emergency treatment situations, a covered entity that has agreed to a restriction may use, or disclose to a health care provider, restricted protected health information that is
necessary to provide the emergency treatment. If the covered entity discloses restricted protected health information to a health care provider for emergency treatment purposes, it must request that the provider not further use or disclose the information. We expect covered entities to consider the need for access to protected health information for treatment purposes when considering a request for a restriction, to discuss this need with the individual making the request for restriction, and to agree to restrictions that will not foreseeably impede the individual’s treatment. Therefore, we expect covered entities will rarely need to use or disclose restricted protected health information in emergency treatment situations. We do not intend, however, to adversely impact the delivery of health care. We therefore provide a means for the use and disclosure of restricted protected health information in emergency treatment situations, where an unexpected need for the information could arise and there is insufficient time to secure the individual’s permission to use or disclose the restricted information.

In §164.522(a)(1)(v) we clarify that restrictions are not effective under this rule to prevent uses and disclosures required by §164.502(a)(2)(ii) or permitted under §164.510(a) (regarding facility directories) or §164.512 (regarding uses and disclosures for which consent, individual authorization, or opportunity to agree or object is not required). Covered entities are permitted to agree to such restrictions, but if they do so, the restrictions are not enforceable under this rule. For example, a provider who makes a disclosure under §164.512(j)(1)(ii) relating to serious and imminent threats will not be in violation of this rule even if the disclosure is contrary to a restriction agreed to under this paragraph.

In §164.522(a)(2) we clarify a covered entity’s ability to terminate a restriction to which it has agreed. A covered entity may terminate a restriction with the individual’s written or oral agreement. If the individual agrees to terminate the restriction, the covered entity may use and disclose protected health information as otherwise permitted under the rule. If the covered entity wants to terminate the restriction without the individual’s agreement, it may only terminate the restriction with respect to protected health information it creates or receives after it informs the individual of the termination. The restriction continues to apply to protected health information created or received prior to informing the individual of the termination. That is, any protected health information that had been collected before the termination may not be used or disclosed in a way that is inconsistent with the restriction, but any information that is collected after informing the individual of the termination of the restriction may be used or disclosed as otherwise permitted under the rule.

In §164.522(a)(3), we clarify that a covered entity must document a restriction to which it has agreed. We do not require a specific form of documentation; a note in the medical record or similar notation is sufficient. The documentation must be retained for six years from the date it was created or the date it was last in effect, whichever is later, in accordance with §164.530(j).

We eliminate the requirement from the NPRM for entities to inform persons to whom they disclose protected health information of the existence of any restriction on that information. A restriction is only binding on the covered entity that agreed to the restriction. We encourage covered entities to inform others of the existence of a restriction often amounts to a de facto disclosure of the restricted information itself. If a restriction does not permit a covered entity to disclose protected health information to a particular person, the covered entity must carefully consider whether disclosing the existence of the restriction to that person would also violate the restriction.

Section 164.522(b)—Confidential Communications Requirements

In the NPRM, we did not directly address the issue of whether an individual could request that a covered entity restrict the manner in which it communicated with the individual. As described above, the NPRM would have provided individuals with the right to request that health care providers restrict uses and disclosures of protected health information for treatment, payment and health care operations, but would not have required providers to agree to such a restriction.

In the final rule, we require covered entities to permit individuals to request that the covered entity provide communications from the covered entity to the individual, and also communications from the covered entity that would otherwise be sent to the named insured of an insurance policy that covers the individual as a dependent of the named insured. Individuals may request that the covered entity send such communications by alternative means or at alternative locations. For example, an individual who does not want his or her family members to know about a certain treatment may request that the provider communicate with the individual about that treatment at the individual’s place of employment, by mail to a designated address, or by phone to a designated phone number. Similarly, an individual may request that the provider send communications in a closed envelope rather than a post card, as an “alternative means.” Covered health care providers must accommodate all reasonable requests. Health plans must accommodate all reasonable requests, if the individual clearly states that the disclosure of all or part of the protected health information could endanger the individual. For example, if an individual requests that a health plan send explanations of benefits about particular services to the individual’s work rather than home address because the individual is concerned that a member of the individual’s household (e.g., the named insured) might read the explanation of benefits and become abusive towards the individual, the health plan must accommodate the request.

The reasonableness of a request made under this paragraph must be determined by a covered entity solely on the basis of the administrative difficulty of complying with the request and as otherwise provided in this section. A covered health care provider or health plan cannot refuse to accommodate a request based on its perception of the merits of the individual’s reason for making the request. A covered health care provider may not require the individual to provide a reason for a request as a condition of accommodating the request. As discussed above, a health plan is not required to accommodate a request unless the individual indicates that the disclosure could endanger the individual. If the individual indicates such endangerment, however, the covered entity cannot further consider the individual’s reason for making the request in determining whether it must accommodate the request.

A covered health care provider or health plan may refuse to accommodate a request, however, if the individual has
not provided information as to how payment, if applicable, will be handled, or if the individual has not specified an alternative address or method of contact.

Section 164.524—Access of Individuals to Protected Health Information

Section 164.524(a)—Right of Access

In the NPRM, we proposed to establish a right for individuals to access (i.e., inspect and obtain a copy of) protected health information about them maintained by a covered provider or health plan, or its business partners, in a designated record set. As in the proposed rule, in the final rule we provide that individuals have a right of access to protected health information that is maintained in a designated record set. This right applies to health plans, covered health care providers, and health care clearinghouses that create or receive protected health information other than as a business associate of another covered entity (see § 164.500(b)). In the final rule, however, we modify the definition of designated record set. For a discussion of the significant changes made to the definition of designated record set, see § 164.501 and the corresponding preamble.

Under the revised definition, individuals have a right of access to any protected health information that is used, in whole or in part, to make decisions about individuals. This information includes, for example, information used to make health care decisions or information used to determine whether an insurance claim will be paid. Covered entities often incorporate the same protected health information into a variety of different data systems, not all of which will be utilized to make decisions about individuals. For example, information systems that are used for quality control or peer review analyses may not be used to make decisions about individuals. In that case, the information systems would not fall within the definition of designated record set. We do not require entities to grant an individual access to protected health information maintained in these types of information systems.

Duration of the Right of Access

As in the proposed rule, covered entities must provide access to individuals for as long as the protected health information is maintained in a designated record set.

Exceptions to the Right of Access

In the NPRM, we proposed to establish a right for individuals to access any protected health information maintained in a designated record set. Though we proposed to permit covered entities to deny access in certain situations relating to the particular individual requesting access, we did not specifically exclude any protected health information from the right of access.

In the final rule, we specify three types of information to which individuals do not have a right of access, even if the information is maintained in a designated record set. They are psychotherapy notes, information compiled in reasonable anticipation of, or for use in, a civil, criminal, or administrative action or proceeding, and certain protected health information maintained by a covered entity that is subject to or exempted from the Clinical Laboratory Improvements Amendments of 1988 (CLIA). Covered entities may, but are not required to, provide access to this information.

First, unlike the proposed rule, we specify that individuals do not have a right of access to psychotherapy notes. Second, individuals do not have a right of access to information compiled in reasonable anticipation of, or for use in, a civil, criminal, or administrative action or proceeding. In the final rule, we clarify that a legal proceeding includes civil, criminal, and administrative actions and proceedings. In the final rule, we clarify that an individual does not have a right to this information by including it in the list of exceptions rather than stating that a covered entity may deny access to this information. Under this exception, the covered entity may deny access to any information that relates specifically to legal preparations but may not deny access to the individual’s underlying health information. We do not intend to require covered entities to provide access to documents protected by attorney work-product privilege nor do we intend to alter rules of discovery.

Third, unlike the proposed rule, individuals do not have a right of access to protected health information held by clinical laboratories if CLIA prohibits such access. CLIA states that clinical laboratories may provide clinical laboratory test records and reports only to “authorized persons,” as defined primarily by state law. The individual who is the subject of the information is not always included in this set of authorized persons. When an individual is not an authorized person, this restriction effectively prohibits the clinical laboratory from providing an individual access to this information. We do not intend to preempt CLIA and, therefore, do not require covered clinical laboratories to provide an individual access to this information if CLIA prohibits them from doing so. We note, however, that individuals have the right of access to this information if it is maintained by a covered health care provider, clearinghouse, or health plan that is not subject to CLIA.

Finally, unlike the proposed rule, individuals do not have access to protected health information held by certain research laboratories that are exempt from the CLIA regulations. The CLIA regulations specifically exempt the components or functions of “research laboratories that test human specimens but do not report patient specific results for the diagnosis, prevention or treatment of any disease or impairment of, or the assessment of the health of individual patients.” 42 CFR 493.3(a)(2). If subject to the access requirements, these laboratories, or the applicable components of them, would be forced to comply with the CLIA regulations once they provided an individual with the access under this privacy rule. Therefore, to alleviate this additional regulatory burden, we have exempted these laboratories, or the relevant components of them, from the access requirements of this regulation.

Grounds for Denial of Access

In the NPRM we proposed to permit covered health care providers and health plans to deny an individual access to inspect and copy protected health information about them for five reasons: (1) a licensed health care professional determined the inspection and copying was reasonably likely to endanger the life or physical safety of the individual or another person; (2) the information was about another person (other than a health care provider) and a licensed health care professional determined the inspection and copying was reasonably likely to cause substantial harm to that other person; (3) the information was obtained under a promise of confidentiality from someone other than a health care provider and the inspection and copying was likely to reveal the source of the information; (4) the information was obtained by a covered provider in the course of a clinical trial, the individual agreed to the denial of access in consenting to participate in the trial, and the trial was still in progress; and (5) the information was compiled in reasonable anticipation of, or for use in, a legal
proceeding. In the NPRM, covered entities would not have been permitted to use these grounds to deny individuals access to protected health information that was also subject to the Privacy Act.

In the final rule, we retain all of these grounds for denial, with some modifications. One of the proposed grounds for denial (regarding legal proceedings) is retained as an exception to the right of access. (See discussion above.) We also include additional grounds for denial and create a right for individuals to request review of certain denials.

There are five types of denials covered entities may make without providing the individual with a right to have the denial reviewed.

First, a covered entity may deny an individual access to any information that is excepted from the right of access under § 164.524(a)(1). (See discussion above.)

Second, we add a new provision that permits a covered entity that is a correctional institution or covered health care provider acting under the direction of a correctional institution to deny an inmate's request to obtain a copy of protected health information if obtaining a copy would jeopardize the health, safety, security, custody, or rehabilitation of the individual or other inmates or the safety of any officer, employee or other person at the correctional institution or responsible for the transporting of the inmate. This ground for denial is restricted to an inmate's request to obtain a copy of protected health information. If an inmate requests inspection of protected health information, the request must be granted unless one of the other grounds for denial applies. The purpose for this exception, and the reason that the exception is limited to denying an inmate a copy and not to denying a right to inspect, is to give correctional institutions the ability to maintain order in these facilities and among inmates without denying an inmate the right to review his or her protected health information.

Third, as in the proposed rule, a covered entity may deny an individual access to protected health information obtained by a covered provider in the course of research that includes treatment of the research participants, while such research is in progress. For this exception to apply, the individual must have agreed to the denial of access in conjunction with the individual's consent to participate in the research and the covered provider must have informed the individual that the right of access will be reinstated upon completion of the research. If either of these conditions is not met, the individual has the right to inspect and copy the information (subject to the other exceptions we provide here). In all cases, the individual has the right to inspect and copy the information after the research is complete.

As with all the grounds for denial, covered entities are not required to deny access under the research exception. We expect all researchers to maintain a high level of ethical consideration for the welfare of research participants and provide access in appropriate circumstances. For example, if a participant has a severe adverse reaction, disclosure of information during the course of the research may be necessary to give the participant adequate information for proper treatment decisions.

Fourth, we clarify the ability of a covered entity to deny individuals access to protected health information that is also subject to the Privacy Act. In the final rule, we specify that a covered entity may deny an individual access to protected health information that is contained in records that are subject to the Privacy Act if such denial is permitted under the Privacy Act. This ground for denial exists in addition to the other grounds for denial available under this rule. If an individual requests access to protected health information that is also subject to the Privacy Act, a covered entity may deny access to that information for any of the reasons permitted under the Privacy Act and for any of the reasons permitted under this rule.

Fifth, as in the proposed rule, a covered entity may deny an individual access to protected health information if the request is reasonably likely to endanger the life or physical safety of the individual or another person. The most commonly cited example is when an individual exhibits suicidal or homicidal tendencies. If a licensed health care professional determines that an individual exhibits such tendencies and that permitting inspection or copying of some of the individual's protected health information is reasonably likely to result in the individual committing suicide, murder, or other physical violence, then the health care professional may deny the individual access to that information. Under this reason for denial, covered entities may not deny access on the basis of the sensitivity of the health information or the potential for causing emotional or psychological harm.

Second, as in the proposed rule, covered entities may deny an individual access to protected health information if the information requested makes reference to someone other than the individual (and other than a health care provider) and a licensed health care professional has determined, in the exercise of professional judgment, that the access requested is reasonably likely to cause serious harm to that other person. On some occasions when health information about one person is relevant to the care of another, a physician may incorporate it into the latter's record, such as information from group therapy sessions and information about illnesses with a genetic component. This provision permits a covered entity to withhold information in such cases if harm the individual or others. In the final rule, we specify that a covered entity may only deny access for these reasons if the covered entity provides the individual with a right to have the denial reviewed. (See below for a discussion of the right to review.)

There are three types of denials for which covered entities must provide the individual with a right to review. A denial under these provisions requires a determination by a licensed health care professional (such as a physician, physician's assistant, or nurse) based on an assessment of the particular circumstances and current professional medical standards of harm. Therefore, when the request is made to a health plan or clearinghouse, the covered entity will need to consult with a licensed health care professional before denying access under this provision.

First, as in the proposed rule, covered entities may deny individuals access to protected health information about them if a licensed health care professional has determined, in the exercise of professional judgment, that the access requested is reasonably likely to endanger the life or physical safety of the individual or another person. The most commonly cited example is when an individual exhibits suicidal or homicidal tendencies. If a licensed health care professional determines that an individual exhibits such tendencies and that permitting inspection or copying of some of the individual's protected health information is reasonably likely to result in the individual committing suicide, murder, or other physical violence, then the health care professional may deny the individual access to that information. Under this reason for denial, covered entities may not deny access on the basis of the sensitivity of the health information or the potential for causing emotional or psychological harm.

Second, as in the proposed rule, covered entities may deny an individual access to protected health information if the information requested makes reference to someone other than the individual (and other than a health care provider) and a licensed health care professional has determined, in the exercise of professional judgment, that the access requested is reasonably likely to cause serious harm to that other person. On some occasions when health information about one person is relevant to the care of another, a physician may incorporate it into the latter's record, such as information from group therapy sessions and information about illnesses with a genetic component. This provision permits a covered entity to withhold information in such cases if
the release of such information is reasonably likely to cause substantial physical, emotional, or psychological harm.

Third, we add a new provision regarding denial of access requested by personal representatives. Under § 164.502(g), a person that is a personal representative of an individual may exercise the rights of the individual, including the right to inspect and copy protected health information about the individual that is relevant to such person’s representation. The provision permits covered entities to refuse to treat a personal representative as the individual, generally, if the covered entity has a reasonable belief that the individual has been or will be subjected to domestic violence, abuse or neglect by the personal representative, or that treating the personal representative as the individual may endanger the individual and, in its professional judgment, the covered entity decides that it is not in the best interest of the individual to treat such person as the personal representative.

In addition to that provision, we add a new provision at § 164.524(a)(3)(iii) to clarify that a covered entity may deny a request to inspect or copy protected health information if the information is requested by a personal representative of the individual and a licensed health care professional has determined that, in the exercise of professional judgment, such access is reasonably likely to cause substantial harm to the individual who is the subject of the information or to another person. The health care professional need not have a reasonable belief that the personal representative has abused or neglected the individuals and the harm that is likely to result need not be limited to the individual who is the subject of the requested protected health information. Therefore, a covered entity can recognize a person as a personal representative but deny such person access to protected health information as a personal representative.

We do not intend these provisions to create a legal duty for the covered entity to review all of the relevant protected health information before releasing it. Rather, we are preserving the flexibility and judgment of covered entities to deny access under appropriate circumstances. Denials are not mandatory; covered entities may always elect to provide requested health information to the individual. For each request by an individual, the covered entity may provide all of the information required or evaluate the circumstances surrounding the individual’s request, and make a determination as to whether that request should be granted or denied, in whole or in part, in accordance with the reasons for denial under this rule. We intend to create narrow exceptions to the right of access and we expect covered entities to employ these exceptions rarely, if at all. Covered entities may only deny access for the reasons specifically provided in the rule.

Review of a Denial of Access

In the NPRM, we proposed to require covered entities, when denying an individual’s request for access, to inform the individual of how to make a complaint to the covered entity and the Secretary. We retain in the final rule the proposed approach (see below). In addition, if the covered entity denies the request on the basis of one of the reviewable grounds for denial described above, the individual has the right to have the denial reviewed by a licensed health care professional who is designated by the covered entity to act as a reviewing official and who did not participate in the original decision to deny access. The covered entity must provide access in accordance with the reviewing official’s determination. (See below for further description of the covered entity’s requirements under § 164.524(d)(4) if the individual requests a review of denial of access.)

Section 164.524(c)—Provision of Access

In the NPRM, we proposed to require covered health care providers and health plans, upon accepting a request for access, to notify the individual of the decision and of any steps necessary to fulfill the request; to provide the information requested in the form or format requested, if readily producible in such form or format; and to facilitate the process of inspection and copying.

We generally retain the proposed approach in the final rule. If a covered entity accepts a request, in whole or in part, it must notify the individual of the decision and provide the access requested. Individuals have the right both to inspect and to copy protected health information in a designated record set. The individual may choose whether to inspect the information, to copy the information, or to do both.

In the final rule, we clarify that if the same protected health information is maintained in more than one designated record set or at more than one location, the covered entity is required to produce the information only once per request for access.

In the final rule, we clarify that if the same protected health information is maintained in more than one designated record set or at more than one location, the covered entity is required to produce the information only once per request for access. We intend this provision to reduce covered entities’ burden in complying with requests without reducing individuals’ access to protected health information. We note that summary information and reports...
are not the same as the underlying information on which the summary or report was based. Individuals have the right to obtain access both to summaries and to the underlying information. An individual retains the right of access to the underlying information even if the individual requests access to, or production of, a summary. (See below regarding requests for summaries.)

The covered entity must provide the information requested in the form or format requested if it is readily producible in such form or format. For example, if the covered entity maintains health information electronically and the individual requests an electronic copy, the covered entity must accommodate such request, if possible. Additionally, we specify that if the information is not available in the form or format requested, the covered entity must produce a readily readable hard copy of the information or another form or format to which the individual and covered entity can agree. If the individual agrees, including agreeing to any associated fees (see below), the covered entity may provide access to a summary of information rather than all protected health information in designated record sets. Similarly, a covered entity may provide an explanation in addition to the protected health information, if the individual agrees in advance to the explanation and any associated fees.

The covered entity must provide the access requested in a timely manner, as described above, and arrange for a mutually convenient time and place for the individual to inspect the protected health information or obtain a copy. If the individual requests that the covered entity mail a copy of the information, the covered entity must do so, and may charge certain fees for copying and mailing. For requests to inspect information that is maintained electronically, the covered entity may print a copy of the information and allow the individual to view the print-out on-site. Covered entities may discuss with the individual as necessary to facilitate the timely provision of access. For example, if the individual requested a copy of the information by mail, but the covered entity is able to provide the information faster by providing it electronically, the covered entity may discuss this option with the individual.

We proposed in the NPRM to permit the covered entity to charge a reasonable, cost-based fee for copying the information. We clarify this provision in the final rule. If the individual requests a copy of protected health information, a covered entity may charge a reasonable, cost-based fee for the copying, including the labor and supply costs of copying. If hard copies are made, this would include the cost of paper. If electronic copies are made to a computer disk, this would include the cost of the computer disk. Covered entities may not charge any fees for retrieving or handling the information or for processing the request. If the individual requests the information to be mailed, the fee may include the cost of postage. Fees for copying and postage provided under state law, but not for other costs excluded under this rule, are presumed reasonable. If such per page costs include the cost of retrieving or handling the information, such costs are not acceptable under this rule.

If the individual requests an explanation or summary of the information provided, and agrees in advance to any associated fees, the covered entity may charge for preparing the explanation or summary as well. The inclusion of a fee for copying is not intended to impede the ability of individuals to copy their records. Rather, it is intended to reduce the burden on covered entities. If the cost is excessively high, some individuals will not be able to obtain a copy. We encourage covered entities to limit the fee for copying so that it is within reach of all individuals.

We do not intend to affect the fees that covered entities charge for providing protected health information to anyone other than the individual. For example, we do not intend to affect current practices with respect to the fees one health care provider charges for forwarding records to another health care provider for treatment purposes.

Section 164.524(d)—Denial of Access

We proposed in the NPRM to require a covered health care provider or health plan that elects to deny a request for inspection or copying to make any other protected health information requested available to the individual to the extent possible, consistent with the denial.

In the final rule, we clarify the proposed approach. A covered entity that denies access, in whole or in part, must, to the extent possible, give the individual access to any other protected health information requested after excluding the protected health information to which the covered entity has a ground to deny access. We intend covered entities to redact or otherwise exclude only the information that falls within one or more of the denial criteria described above and to permit inspection and copying of all remaining information, to the extent it is possible to do so.

We also proposed to require covered providers and health plans, upon denying a request for access in whole or in part, to provide the individual with a written statement in plain language of the basis for the denial and how the individual could make a complaint to the covered entity or the Secretary.

We retain the proposed approach. A covered entity that denies access, in whole or in part, must provide the individual with a written denial in plain language that explains the basis for the denial. The written denial could include a direct reference to the section of the regulation relied upon for the denial, but the regulatory citation alone does not sufficiently explain the reason for the denial. The written denial must also describe how the individual can complain to the covered entity and the Secretary and must include the name or title and the telephone number of the covered entity’s contact person or office that is responsible for receiving complaints.

In the final rule, we impose two additional requirements when the covered entity denies access, in whole or in part. First, if a covered entity denies a request on the basis of one of the reviewable grounds for denial, the written denial must describe the individual’s right to a review of the denial and how the individual may exercise this right. Second, if the covered entity denies the request because it does not maintain the requested information, and the covered entity knows where the requested information is maintained, the covered entity must inform the individual where to direct the request for access.

Finally, we specify a covered entity’s responsibilities when an individual requests a review of a denial. If the individual requests a review of a denial made under §164.524(a)(3), the covered entity must designate a licensed health care professional to act as the reviewing official. This reviewing official must not have been involved in the original decision to deny access. The covered entity must promptly receive a request for review to the designated reviewing official. The reviewing official must determine, within a reasonable period of time, whether or not to deny the access requested based on the standards in §164.524(a)(3). The covered entity must promptly provide the individual with written notice of the reviewing official’s decision and otherwise carry out the decision in accordance with the requirements of this section.
Section 164.524(e)—Policies, Procedures, and Documentation

As in the proposed rule, we establish documentation requirements for covered entities that are subject to this provision. In accordance with §164.530(j), the covered entity must retain documentation of the designated record sets that are subject to access by individuals and the titles of the persons or offices responsible for receiving and processing requests for access by individuals.

Section 164.526—Amendment of Protected Health Information

Section 164.526(a)—Right to Amend

In proposed §164.516, we proposed to establish the individual’s right to request a covered health care provider or health plan to amend or correct protected health information about the individual for as long as the covered entity maintains the information. In §164.526 of the final rule, we retain the general proposed approach, but establish an individual’s right to have the covered entity amend, rather than amend or correct, protected health information. This right applies to protected health information and records in a designated record set for as long as the information is maintained in the designated record set. In the final rule, covered health care providers, health plans, and health care clearinghouses that create or receive protected health information other than as a business associate must comply with these requirements.

Denial of Amendment

We proposed to permit a covered health care provider or health plan to deny a request for amendment if it determined that the protected health information that was the subject of the request was not created by the covered provider or health plan, would not be available for inspection and copying under proposed §164.514, or was accurate and complete. A covered entity would have been permitted, but not required, to deny a request if any of these conditions were met.

As in the proposed rule, the final rule permits a covered entity to deny a request for amendment if the covered entity did not create the protected health information or record that is the subject of the request for amendment. We add one exception to this provision: if the individual provides a reasonable basis to believe that the originator of the protected health information is no longer available to act on the requested amendment, the covered entity must address the request for amendment as though the covered entity had created the information.

As in the proposed rule, a covered entity also may deny a request for amendment if the protected health information that is the subject of the request for amendment is not part of a designated record set or would not otherwise be available for inspection under §164.524. We eliminate the ability to deny a request for amendment if the information or record that is the subject of the request would not be available for copying under the rule. Under §164.524(a)(2)(ii), an inmate may be denied a copy of protected health information about the inmate. We intend to preserve an inmate’s ability to request amendments to information, even if a copy of the information would not be available to the inmate, subject to the other exceptions provided in this section.

Finally, as in the proposed rule, a covered entity may deny a request for amendment if the covered entity determines that the information in dispute is accurate and complete. We draw this concept from the Privacy Act of 1974, governing records held by federal agencies, which permits an individual to request correction or amendment of a record “which the individual believes is not accurate, relevant, timely, or complete.” (5 U.S.C. 552a(d)(2)). We adopt the standards of “accuracy” and “completeness” and draw on the clarification and analysis of these terms that have emerged in administrative and judicial interpretations of the Privacy Act during the last 25 years. We note that for federal agencies that are also covered entities, this rule does not diminish their present obligations under the Privacy Act of 1974.

This right is not intended to interfere with medical practice or to modify standard business record keeping practices. Perfect records are not required. Instead, a standard of reasonable accuracy and completeness should be used. In addition, this right is not intended to provide a procedure for substantive review of decisions such as coverage determinations by payors. It is intended only to affect the content of records, not the underlying truth or correctness of materials recounted therein. Attempts under the Privacy Act of 1974 to use this mechanism as a basis for collateral attack on agency determinations have generally been rejected by the courts. The same results are intended here.

Section 164.526(b)—Requests for Amendment and Timely Action

We proposed to require covered health care providers and health plans to provide a means for individuals to request amendment of protected health information about them. Under the NPRM, we would have required covered health care providers and health plans to take action on a request for amendment or correction within 60 days of the request.

As in the proposed rule, covered entities must permit individuals to request that the covered entity amend protected health information about them. We also permit certain specifications for the form and content of the request. If a covered entity informs individuals of such requirements in advance, a covered entity may require individuals to make requests for amendment in writing and to provide a reason to support a requested amendment. If the covered entity imposes such a requirement and informs individuals of the requirement in advance, the covered entity is not required to act on an individual’s request that does not meet the requirements.

We retain the requirement for covered entities to act on a request for amendment within 60 days of receipt of the request. In the final rule, we specify the nature of the action the covered entity must take within the time frame. The covered entity must inform the individual, as described below, that the request has been either accepted or denied, in whole or in part. It must also take certain actions pursuant to its decision to accept or deny the request, as described below. If the covered entity is unable to meet the deadline, the covered entity may extend the deadline by no more than 30 days. The covered entity must inform the individual in writing, within the initial 60-day period, of the reason for the delay and the date by which the covered entity will complete its action on the request. A covered entity may only extend the deadline one time per request for amendment.

Section 164.526(c)—Accepting the Amendment

If a covered health care provider or health plan accepted a request for amendment, in whole or in part, we proposed to require the covered entity to make the appropriate change. The covered entity would have had to identify the challenged entries as amended or corrected and indicate the location of the amended or corrected information.
We also proposed to require the covered provider or health plan to make reasonable efforts to notify certain entities of the amendment: 1) entities the individual identified as needing to be notified and 2) entities the covered provider or health plan knew had received the erroneous or incomplete information and who may have relied, or could foreseeably rely, on such information to the detriment of the individual.

The covered provider or health plan would also have been required to notify the individual of the decision to amend the information.

As in the proposed rule, if a covered entity accepts an individual’s request for amendment or correction, it must make the appropriate amendment. In the final rule, we clarify that, at a minimum, the covered entity must identify the records in the designated record set that are affected by the amendment and must append or otherwise provide a link to the location of the amendment. We do not require covered entities to expunge any protected health information. Covered entities may expunge information if doing so is consistent with other applicable law and the covered entity’s record keeping practices.

We alter some of the required procedures for informing the individual and others of the accepted amendment. As in the proposed rule, the covered entity must inform individuals about accepted amendments. In the final rule, the covered entity must obtain the individual’s agreement to have the amended information shared with certain persons. If the individual agrees, the covered entity must make reasonable efforts to provide a copy of the amendment within a reasonable time to: (1) Persons the individual identifies as having received protected health information about the individual and needing the amendment; and (2) persons, including business associates, that the covered entity knows have the unamended information and who may have relied, or could foreseeably rely, on the information to the detriment of the individual. For example, a covered entity must make reasonable efforts to inform a business associate that uses protected health information to make decisions about individuals about amendments to protected health information used for such decisions.

Section 164.526(d)—Denying the Amendment

If a covered health care provider or health plan denied a request for amendment, in whole or in part, we proposed to require the covered entity to provide the individual with a written statement in plain language of the basis for the denial, a description of how the individual could submit a written statement of disagreement with the denial, and a description of how the individual could make a complaint with the covered entity and the Secretary.

We proposed to require covered health care providers and health plans to have procedures to permit the individual to file a written statement of disagreement with the denial and to include the covered entity’s statement of denial and the individual’s statement of disagreement with any subsequent disclosure of the disputed information. Covered entities would have been permitted to establish a limit to the length of the individual’s statement of disagreement and to summarize the statement if necessary. We also proposed to permit covered entities to provide a rebuttal to the individual’s statement with future disclosures.

As in the proposed rule, if a covered entity accepts a request for amendment, it must provide the individual with a statement of denial written in plain language. The written denial must include the basis for the denial, how the individual may file a written statement disagreeing with the denial, and how the individual may make a complaint to the covered entity and the Secretary.

In the final rule, we additionally require the covered entity to inform individuals of their options with respect to future disclosures of the disputed information in order to ensure that an individual is aware of his or her rights. The written denial must state that if the individual chooses not to file a statement of disagreement, the individual may request that the covered entity include the individual’s request for amendment and the covered entity’s denial of the request with any future disclosures of the protected health information that is the subject of the requested amendment.

As in the proposed rule, the covered entity must permit the individual to submit a written statement disagreeing with the denial and the basis of such disagreement. The covered entity may reasonably limit the length of a statement of disagreement and may prepare a written rebuttal to the individual’s statement of disagreement. If the covered entity prepares a rebuttal, it must provide a copy to the individual.

The covered entity must identify the record or protected health information that is the subject of the disputed amendment and append or otherwise link the following to the designated record set: the individual’s request for amendment; the covered entity’s denial of the request, the individual’s statement of disagreement (if any), and the covered entity’s rebuttal (if any). If the individual submits a written statement of disagreement, all of the appended or linked information, or an accurate summary of it, must be included with any subsequent disclosure of the protected health information to which the disagreement relates. If the individual does not submit a written statement of disagreement, the covered entity must include the appended or linked information only if the individual requests that the covered entity do so.

In the final rule, we clarify that when a subsequent disclosure is a standard transaction adopted under the Transactions Rule that cannot accommodate the additional materials described above, the covered entity may separately disclose the additional material to the recipient of the transaction.

Section 164.526(e)—Actions on Notices of Amendment

We proposed to require any covered entity that received a notification of amendment to have procedures in place to make the amendment in any of its designated record sets and to notify its business associates, if appropriate, of amendments.

We retain the proposed approach in the final rule. If a covered entity receives a notification of amended protected health information from another covered entity as described above, the covered entity must make the necessary amendment to protected health information in designated record sets it maintains. In addition, covered entities must require their business associates who receive such notifications to incorporate any necessary amendments to designated record sets maintained on the covered entity’s behalf. (See § 164.504 regarding business associate requirements.)

Section 164.526(f)—Policies, Procedures, and Documentation

As in the proposed rule, we establish documentation requirements for covered entities subject to this provision. In accordance with § 164.530(j), the covered entity must document the titles of the persons or offices responsible for receiving and processing requests for amendment.

§ 164.528—Accounting of Disclosures of Protected Health Information

Right to an Accounting of Disclosures

We proposed in the NPRM to grant individuals a right to receive an
accounting of all disclosures of protected health information about them by a covered entity for purposes other than treatment, payment, and health care operations. We proposed this right to exist for as long as the covered entity maintained the protected health information.

We also proposed that individuals would not have a right to an accounting of disclosures to health oversight or law enforcement agencies if the agency provided a written request for exclusion for a specified time period and the request stated that access by the individual during that time period would be reasonably likely to impede the agency’s activities.

We generally retain the proposed approach in the final rule. As in the proposed rule, individuals have a right to receive an accounting of disclosures made by a covered entity, including disclosures by or to a business associate of the covered entity, for purposes other than treatment, payment, and health care operations, subject to certain exceptions as discussed below.

We revise the duration of this right under the final rule. Individuals have a right to an accounting of the applicable disclosures that have been made in the 6 year period prior to the date of a request for an accounting. We additionally clarify in §164.528(b)(1) that an individual may request, and a covered entity may then provide, an accounting of disclosures for a period of time less than 6 years from the date of the request. For example, an individual could request an accounting only of disclosures that occurred during the year prior to the request.

In the final rule, we exclude several additional types of disclosures from the accounting requirement. Covered entities are not required to include in the accounting disclosures to the individual as provided in §164.502; disclosures for facility directories; disclosures to persons involved in the individual’s care, or other disclosures for notification purposes as provided in §164.510; disclosures for national security or intelligence purposes as provided in §164.512(k)(2); disclosures to correctional institutions or law enforcement officials as provided in §164.512(k)(5); or any disclosures that were made by the covered entity prior to the compliance date of the rule for that covered entity.

We retain the time-limited exclusion for disclosures to health oversight and law enforcement agencies, but require rather than permit the exclusion for the specified time period. Covered entities must exclude disclosures to a health oversight agency or law enforcement official from the accounting for the time period specified by the applicable agency or official if the agency or official provides the covered entity with a statement that inclusion of the disclosure(s) in the accounting to the individual during that time period would be reasonably likely to impede the agency or official’s activities. The agency or official’s statement must specifically state how long the information must be excluded. At the expiration of that period, the covered entity is required to include the disclosure(s) in an accounting for the individual. If the agency or official’s statement is made orally, the covered entity must document the identity of the agency or official who made the statement and must exclude the disclosure(s) for no longer than 30 days from the date of the oral statement, unless a written statement is provided during that time. If the agency or official provides a written statement, the covered entity must exclude the disclosure(s) for the time period specified in the written statement.

Content of the Accounting

We proposed in the NPRM to require the accounting to include all disclosures as described above, including disclosures authorized by the individual. The accounting would have been required to contain the date of each disclosure; the name and address of the organization or person who received the protected health information; a brief description of the information disclosed; and copies of all requests for disclosures. For disclosures other than those made at the request of the individual, the accounting would have also included the purpose for which the information was disclosed.

We generally retain the proposed approach in the final rule, but do not require covered entities to make copies of authorizations or other requests for disclosures available with the accounting. Instead, we require the accounting to contain a brief statement of the purpose of the disclosure. The statement must reasonably inform the individual of the basis for the disclosure. In lieu of the statement of purpose, a covered entity may include a copy of the individual’s authorization under §164.508 or a copy of a written request for disclosure, if any, under §§164.502(a)(2)(ii) or 164.512. We also clarify that covered entities are only required to include the address of the recipient of the disclosed protected health information if the covered entity knows the address.

We add a provision allowing for a summary accounting of recurrent disclosures. For multiple disclosures to the same recipient pursuant to a single authorization under §164.508 or for a single purpose under §§164.502(a)(2)(ii) or 164.512, the covered entity may provide a summary accounting addressing the series of disclosures rather than a detailed accounting of each disclosure in the series. In this circumstance, a covered entity may limit the accounting of the series of disclosures to the following information: the information otherwise required above for the first disclosure in the series during the accounting period; the frequency, periodicity, or number of disclosures made during the accounting period; and the date of the most recent disclosure in the series. For example, if under §164.512(b), a covered entity discloses the same protected health information to a public health authority for the same purpose every month, it can account for those disclosures by including in the accounting the date of the first disclosure, the public health authority to whom the disclosures were made and the public health authority’s address, a brief description of the information disclosed, a brief description of the purpose of the disclosures, the fact that the disclosures were made every month during the accounting period, and the date of the most recent disclosure.

Provision of the Accounting

We proposed in the NPRM to require covered entities to provide individuals with an accounting of disclosures as soon as possible, but not later than 30 days following receipt of the request for the accounting. In the final rule, we eliminate the requirement for the covered entity to act as soon as possible. We recognize that circumstances may arise in which an individual will request an accounting on an expedited basis. We encourage covered entities to implement procedures for handling such requests. The time limitation is intended to be an outside deadline, rather than an expectation. We expect covered entities always to be attentive to the circumstances surrounding each request and to respond in an appropriate time frame.

In the final rule, covered entities must provide a requested accounting no later than 60 days after receipt of the request. If the covered entity is unable to meet the deadline, the covered entity may extend the deadline by no more than 30 days. The covered entity must inform the individual in writing, within the standard 60-day deadline of the reason for the delay and the date by which the covered entity will provide the request.
A covered entity may only extend the deadline one time per request for accounting.

The NPRM did not address whether a covered entity could charge a fee for the accounting of disclosures.

In the final rule, we provide that individuals have a right to receive one free accounting per 12 month period. For each additional request by an individual within the 12 month period, the covered entity may charge a reasonable, cost-based fee. If it imposes such a fee, the covered entity must inform the individual of the fee in advance and provide the individual with an opportunity to withdraw or modify the request in order to avoid or reduce the fee.

**Procedures and Documentation**

As in the proposed rule, we establish documentation requirements for covered entities subject to this provision. In accordance with § 164.530(j), for disclosures that are subject to the accounting requirement, the covered entity must retain documentation of the information required to be included in the accounting. The covered entity must also retain a copy of any accounting provided and must document the titles of the persons or offices responsible for receiving and processing requests for an accounting.

**Section 164.530—Administrative Requirements**

**Designation of a Privacy Official and Contact Person**

In § 164.518(a) of the NPRM, we proposed that covered entities be required to designate an individual as the covered entity’s privacy official, responsible for the implementation and development of the entity’s privacy policies and procedures. We also proposed that covered entities be required to designate a contact person to receive complaints about privacy and provide information about the matters covered by the entity’s notice. We indicated that the contact person could be, but was not required to be, the person designated as the privacy official. We proposed to leave implementation details to the discretion of the covered entity. We expected implementation to vary widely depending on the size and nature of the covered entity, with small offices assigning this as an additional duty to an existing staff person, and large organizations creating a full-time privacy official. In proposed § 164.512, we also proposed to require the covered plan or provider’s privacy notice to include the name of a contact person for privacy matters.

The final regulation retains the requirements for a privacy official and contact person as specified in the NPRM. These designations must be documented. The designation of privacy official and contact person positions within affiliated entities will depend on how the covered entity chooses to designate the covered entity(ies) under § 164.504(b). If a subsidiary is defined as a covered entity under this regulation, then a separate privacy official and contact person is required for that covered entity. If several subsidiaries are designated as a single covered entity, pursuant to § 164.504(b), then together they need have only a single privacy officer and contact person. If several covered entities share a notice for services provided on the same premises, pursuant to § 164.520(d), that notice need designate only one privacy official and contact person for the information collected under that notice. These requirements are consistent with the approach recommended by the Joint Commission on Accreditation of Healthcare Organizations, and the National Committee for Quality Assurance, in its paper “Protecting Personal Health Information: A framework for Meeting the Challenges in a Managed Care Environment.” This paper notes that “accountability is enhanced by having focal points who are responsible for assessing compliance with policies and procedures * * *” (p. 29).

**Training**

In § 164.518(b) of the NPRM we proposed to require that covered entities provide training on the entities’ policies and procedures to all members of the workforce likely to have access to protected health information. Each entity would be required to provide initial training by the date on which this rule became applicable. After that date, each covered entity would have to provide training to new members of the workforce within a reasonable time after joining the entity. In addition, we proposed that when a covered entity made material changes in its privacy policies or procedures, it would be required to retrain those members of the workforce whose duties were related to the change within a reasonable time of making the change.

The NPRM would have required that, upon completion of the training, the trainee would be required to sign a statement certifying that he or she received the information training and would honor all of the entity’s privacy policies and procedures. Entities would determine the most effective means of achieving this training requirement for their workforce. We also proposed that, at least every three years after the initial training, covered entities would be required to have each member of the workforce sign a new statement certifying that he or she would honor all of the entity’s privacy policies and procedures. The covered entity would have been required to document its policies and procedures for complying with the training requirements.

The final regulation requires covered entities to train all members of their workforce on the policies and procedures with respect to protected health information required by this rule, as necessary and appropriate for the members of the workforce to carry out their functions within the covered entity. We do not change the proposed time lines for training existing and new members of the workforce, or for training due to material changes in the covered entity’s policies and procedures. We eliminate both the requirement for employees to sign a certification following training and the triennial re-certification requirement.

Covered entities are responsible for implementing policies and procedures to meet these requirements and for documenting that training has been provided.

**Safeguards**

In § 164.518(c) of the NPRM, we proposed to require covered entities to put in place administrative, technical, and physical safeguards to protect the privacy of protected health information. We made reference in the preamble to similar requirements proposed for certain electronic information in the Notice of Proposed Rulemaking entitled the Security and Electronic Signature Standards (HCFA–0049–P). We stated that we were proposing parallel and consistent requirements for safeguarding the privacy of protected health information. In § 164.518(c)(3) of the NPRM, we required covered entities to have safeguards to ensure that information was not used in violation of the requirements of this subpart or by people who did not have proper authorization to access the information.

We do not change the basic proposed requirements that covered entities have administrative, technical and physical safeguards to protect the privacy of protected health information. We combine the proposed requirements into a single standard that requires covered entities to safeguard protected health information from access on intentional use or disclosure that is a violation of the requirements of this rule.
and to protect against the inadvertent disclosure of protected health information to persons other than the intended recipient. Limitations on access to protected health information by the covered entities workforce will also be covered by the policies and procedures for “minimum necessary” use of protected health information, pursuant to § 164.514(d). We expect these provisions to work in tandem.

We do not prescribe the particular measures that covered entities must take to meet this standard, because the nature of the required policies and procedures will vary with the size of the covered entity and the type of activities that the covered entity undertakes. (That is, as with other provisions of this rule, this requirement is “scalable.”)

Examples of appropriate safeguards include requiring that documents containing protected health information be shredded prior to disposal, and requiring that doors to medical records departments (or to file cabinets housing such records) remain locked and limited personnel are authorized to have the key or pass-code. We intend this to be a common sense, scalable, standard. We do not require covered entities to guarantee the safety of protected health information against all assaults. Theft of protected health information may or may not signal a violation of this rule, depending on the circumstances and whether the covered entity had reasonable policies to protect against theft. Organizations such as the Association for Testing and Materials (ASTM) and the American Health Information Management Association (AHIMA) have developed a body of recommended practices for handling of protected health information that covered entities may find useful.

We note that the proposed HIPAA Security Standards would require covered entities to safeguard the privacy and integrity of health information. For electronic information, compliance with both regulations will be required.

In § 164.518(c)(2) of the NPRM we proposed requirements for verification procedures to establish identity and authority for permitted disclosures of protected health information.

In the final rule, this material has been moved to § 164.514(h).

Use or Disclosure of Protected Health Information by Whistleblowers

In § 164.518(c)(4) of the NPRM, this provision was entitled “Implementation Specification: Disclosures by whistleblowers.” It is now retitled “Disclosures by whistleblowers,” with certain changes, and moved to § 164.502(j)(1).
either members of their workforce or by their business associates.

We eliminate the language regarding potential breaches of business associate contracts from this section. All other requirements with respect to business associates are stated in § 164.504.

Refusing from Intimidating or Retaliatory Acts

In § 164.522(d)(4) of the NPRM, in the Compliance and Enforcement section, we proposed that the responsibilities of a covered entity would be to refrain from intimidating or retaliatory acts. Specifically, the rule provided that “[a] covered entity may not intimidate, threaten, coerce, discriminate against, or take other retaliatory action against any individual for filing a complaint under this section, for testifying, assisting, participating in any manner in an investigation, compliance review, proceeding or hearing under this Act, or opposing any act or practice made unlawful by this subpart.”

In the final rule, we continue to require that entities refrain from intimidating or retaliatory acts; however, the provisions have been moved to the Administrative Requirements provisions in § 164.530. This change is not just clerical; in making this change, we apply this provision to the privacy rule alone rather than to all the HIPAA administrative simplification rules. (The compliance and enforcement provisions that were in § 164 are now in Part 160, Subpart C.)

We continue to prohibit retaliation against individuals for filing a complaint with the Secretary, but also prohibit retaliation against any other person who files such a complaint. This is the case because the term “individual” is generally limited to the person who is the subject of the information. The final rule prohibits retaliation against persons, not just individuals, for testifying, assisting, or participating in an investigation, compliance review, proceeding or hearing under Part C of Title XI. The proposed regulation referenced the “Act,” which is defined in Part 160 as the Social Security Act. Because we only intend to protect activities such as participation in investigations and hearings under the Administrative Simplification provisions of HIPAA, the final rule references Part C of Title XI of the Social Security Act.

The proposed rule would have prohibited retaliatory actions against individuals for exercising any act or practice made unlawful by this subpart. The final rule retains this provision, but applies it to any person, only if the person “has a good faith belief that the practice opposed is unlawful, the manner of the opposition is reasonable and does not involve a disclosure of protected health information in violation of this subpart.” The final rule provides additional protections, which had been included in the preamble to the proposed rule. Specifically, we prohibit retaliatory actions against individuals who exercise any right, or participate in any process established by the privacy rule (Part 164 Subpart E), and include as an example the filing of a complaint with the covered entity.

Waiver of Rights

In the final regulation, but not in the proposed regulation, we provide that a covered entity may not require individuals to waive their rights to file a complaint with the Secretary or their other rights under this rule as a condition of the provision of treatment, payment, enrollment in a health plan or eligibility for benefits. This provision ensures that covered entities do not take away the rights that individuals have been provided in Parts 160 and 164.

Requirements for Policies and Procedures, and Documentation Requirements

In § 164.520 of the NPRM, we proposed to require covered entities to develop and document their policies and procedures for implementing the requirements of the rule. In the final regulation we retain this approach, but specify which standards must be documented in each of the relevant sections. In this section, we state the general administrative requirements applicable to all policies and procedures required throughout the regulation. In § 164.530(i), (j), and (k) of the final rule, we amend the NPRM language in several respects. In § 164.530(i) we require that the policies and procedures be reasonably designed to comply with the standards, implementation specifications, and other requirements of the relevant part of the regulation, taking into account the size of the covered entity and the nature of the activities undertaken by the covered entity that relate to protected health information. However, we clarify that the requirements that policies and procedures be reasonably designed may not be interpreted to permit or excuse any action that violates the privacy regulation. Where the covered entity has stated in its notice that it reserves the right to change information practices, we allow the new practice to apply to information created or collected prior to the effective date of the new practice and establish requirements for making this change. We also establish the conditions for making changes if the covered entity has not reserved the right to change its practices.

We require covered entities to modify in a prompt manner their policies and procedures to comply with changes in relevant law and, where the change also affects the practices stated in the notice, to change the notice. We make clear that nothing in our requirements regarding changes to policies and procedures or changes to the notice may be used by a covered entity to excuse a failure to comply with applicable law.

In § 164.530(j), we require that the policies and procedures required throughout the regulation be maintained in writing, and that any other communication, action, activity, or designation that must be documented under this regulation be documented in writing. We note that “writing” includes electronic storage; paper records are not required. We also note that, if a covered entity is required to document the title of a person, we mean the job title or similar description of the relevant position or office.

We require covered entities to retain any documentation required under this rule for at least six years (the statute of limitations period for the civil penalties) from the date of the creation of the documentation, or the date when the document was last in effect, which ever is later. This generalizes the NPRM provision to cover all documentation required under the rule. The language on “last was in effect” was dropped from the NPRM which was worded “unless a longer period applies under this subpart.”

This approach is consistent with the approach recommended by the Joint Commission on Accreditation of Healthcare Organizations, and the National Committee for Quality Assurance, in its paper “Protecting Personal Health Information: A framework for Meeting the Challenges in a Managed Care Environment.” This paper notes that “MCOs [Managed Care Organizations] should have clear and well-defined policies and procedures for dealing with confidentiality issues.” (p. 29).

Standards for Certain Group Health Plans

We add a new provision (§ 164.530(k)) to clarify the administrative responsibilities of group health plans that offer benefits through issuers and HMOs. Specifically, a group health plan that provides benefits solely through an issuer or HMO, and that does not create, receive or maintain protected health
information other than summary health information or information regarding enrollment and disenrollment, is not subject to the requirements of this section regarding designation of a privacy official and contact person, workforce training, safeguards, complaints, mitigation, or policies and procedures. Such a group health plan is only subject to the requirements of this section regarding documentation with respect to its plan documents. Issuers and HMOs are covered entities under this rule, and thus have independent obligations to comply with this section with respect to the protected health information they maintain about the enrollees in such group health plans. The group health plans subject to this provision will have only limited protected health information. Therefore, imposing these requirements on the group health plan would impose burdens not outweighed by a corresponding enhancement in privacy protections.

Section 164.532—Transition Provisions

In the NPRM, we did not address the effect of the regulation on consents and authorizations covered entities obtained prior to the compliance date of the regulation. In the final rule, we clarify that, in certain circumstances, a covered entity may continue to rely upon consents, authorizations, or other express legal permissions obtained prior to the applicable requirements of §§ 164.506 or 164.508.

We realize that a covered entity may wish to rely upon a consent, authorization, or other express legal permission obtained from an individual before the applicable compliance date of this regulation so long as the use or disclosure is consistent with the requirements of this regulation. However, a covered entity will need to obtain a consent that meets the requirements of § 164.506 to use or disclose this previously obtained protected health information as long as the use or disclosure is consistent with the requirements of this section. Therefore, a covered entity will need to obtain a consent that meets the requirements of § 164.506 to the extent that it is required to obtain a consent under § 164.506 from an individual before it may use or disclose any protected health information it creates or receives after the date by which it must comply with this rule. Similarly, we recognize that a covered entity may wish to rely upon a consent, authorization, or other express legal permission obtained from an individual prior to the applicable compliance date of this regulation. In the final rule, we permit a covered entity to rely upon such a consent, authorization, or permission to use or disclose individually identifiable health information that it created or received before the applicable compliance date of the regulation for the specific activities described in the consent, authorization, or permission as long as the covered entity complies with two requirements. First, the covered entity may not make any use or disclosure that is expressly excluded from the consent, authorization, or permission. Second, the covered entity must comply with all limitations expressed in the consent, authorization, or permission. Thus, we do not require a covered entity to obtain an authorization that meets the requirements of § 164.506 to use or disclose this previously obtained protected health information so long as the use or disclosure is consistent with the requirements of this section. However, a covered entity will need to obtain an authorization that meets the requirements of § 164.508, to the extent that it is required to obtain an authorization under this rule, from an individual before it may use or disclose any protected health information it creates or receives after the date by which it must comply with this rule.

Additionally, the final rule acknowledges that covered entities may wish to rely upon consents, authorizations, or other express legal permission obtained from an individual prior to the applicable compliance date for a specific research project that includes the treatment of individuals, such as clinical trials. These consents, authorizations, or permissions may specifically permit a use or disclosure of individually identifiable health information for purposes of the project. Alternatively, they may be general consents to participate in the project. A covered entity may use or disclose protected health information it created or received before or after to the applicable compliance date of this rule for purposes of the project provided that the covered entity complies with all limitations expressed in the consent, authorization, or permission.

If, pursuant to this section, a covered entity relies upon a previously obtained consent, authorization, or other express legal permission and agrees to a restriction by an individual under § 164.522(a), any subsequent use or disclosure under that consent, authorization, or permission must comply with the agreed upon restriction as well.

We believe it is necessary to grandfather in previously obtained consents, authorizations, or other express legal permissions in these circumstances to ensure that important functions of the health care system are not impeded. We link the effectiveness of such consents, authorizations, or permissions in these circumstances to the applicable compliance date to give covered entities sufficient notice of the requirements set forth in §§ 164.506 and 164.508.

The rule does not change the past effectiveness of consents, authorizations, or other express legal permissions that do not come within this section. This means that uses or disclosures of individually identifiable health information made prior to the compliance date of this regulation are not subject to sanctions, even if they were made pursuant to documents or permissions that do not meet the requirements of this rule or were made without permission. This rule alters only the future effectiveness of the previously obtained consents, authorizations, or permissions. Covered entities are not required to rely upon these consents, authorizations, or permissions and may obtain new consents or authorizations that meet the applicable requirements of §§ 164.506 and 164.508.

When reaching this decision, we considered requiring all covered entities to obtain new consents or authorizations consistent with the requirements of §§ 164.506 and 164.508, but there may be cases where the covered entities would be able to use or disclose protected health information obtained...
of the preamble is organized to follow comments to that section. We present our responses to the provisions section-by-section. Following each response, we refer to the corresponding section of this preamble, while many people believe that they must be asked permission prior to any release of health information about them, current laws generally do not impose such a requirement. Similarly, as discussed in more detail later in this preamble, judicial review is required today only for a small proportion of releases of health information.

III. Section-by-Section Discussion of Comments

The following describes the provisions in the final regulation, and the changes we made to the proposed provisions section-by-section. Following each section are our responses to the comments to that section. This section of the preamble is organized to follow the corresponding section of the final rule, not the NPRM.

General Comments

We received many comments on the rule overall, not to a particular provision. We respond to those comments here. Similar comments, but directed to a specific provision in the proposed rule, are answered below in the corresponding section of this preamble.

Comments on the Need for Privacy Standards, and Effects of this Regulation on Current Protections

Comment: Many commenters expressed the opinion that federal legislation is necessary to protect the privacy of individuals’ health information. One comment advocated Congressional efforts to provide a comprehensive federal health privacy law that would integrate the substance abuse regulations with the privacy regulation.

Response: We agree that comprehensive privacy legislation is urgently needed. This administration has urged the Congress to pass such legislation. While this regulation will improve the privacy of individuals’ health information, only legislation can provide the full array of privacy protection that individuals need and deserve.

Comment: Many commenters noted that they do not go to a physician, or do not completely share health information with their physician, because they are concerned about who will have access to that information. Many physicians commented on their patients’ reluctance to share information because of fear that their information will later be used against them.

Response: We agree that strong federal privacy protections are necessary to enhance patients’ trust in the health care system.

Comment: Many commenters expressed concerns that this regulation will allow access to health information by those who today do not have such access, or would allow their physician to disclose information which may not lawfully be disclosed today. Many of these commenters stated that today, they consent to every disclosure of health information about them, and that absent their consent the privacy of their health information is “absolute.” Others stated that, today, health information is disclosed only pursuant to a judicial order. Several commenters were concerned that this regulation would override stronger state privacy protection.

Response: This regulation does not, and cannot, reduce current privacy protections. The statutory language of the HIPAA specifically mandates that this regulation does not preempt state laws that are more protective of privacy.

As discussed in more detail in later this preamble, while many people believe that they must be asked permission prior to any release of health information about them, current laws generally do not impose such a requirement. Similarly, as discussed in more detail later in this preamble, judicial review is required today only for a small proportion of releases of health information.

Comment: Many commenters asserted that today, medical records “belong” to patients. Others asserted that patients own their medical information and health care providers and insurance companies who maintain health records should be viewed as custodians of the patients’ property.

Response: We do not intend to change current law regarding ownership of or responsibility for medical records. In developing this rule we reviewed current law on this and related issues, and built on that foundation.

Under state laws, medical records are often the property of the health care provider or medical facility that created them. Some state laws also provide patients with access to medical records or an ownership interest in the health information in medical records. However, these laws do not divest the health care provider or the medical facility of its ownership interest in medical records. These statutes typically provide a patient the right to inspect or copy health information from the medical record, but not the right to take the provider’s original copy of an item in the medical record. If a particular state law provides greater ownership rights, this regulation leaves such rights in place.

Comment: Some commenters argued that the use and disclosure of sensitive personal information must be strictly regulated, and violation of such regulations should subject an entity to significant penalties and sanctions.

Response: We agree, and share the commenters’ concern that the penalties in the HIPAA statute are not sufficient to fully protect individuals’ privacy interests. The need for stronger penalties is among the reasons we believe Congress should pass comprehensive privacy legislation.

Comment: Many commenters expressed the opinion that the proposed rule should provide stricter privacy protections.
Response: We received nearly 52,000 comments on the proposed regulation, and make substantial changes to the proposal in response to those comments. Many of these changes will strengthen the protections that were proposed in the NPRM.

Comment: Many comments express concerns that their health information will be given to their employers.

Response: We agree that employer access to health information is a particular concern. In this final regulation, we make significant changes to the NPRM that clarify and provide additional safeguards governing when and how the health plans covered by this regulation may disclose health information to employers.

Comment: Several commenters argued that individuals should be able to sue for breach of privacy.

Response: We agree, but do not have the legislative authority to grant a private right of action to sue under this statute. Only Congress can grant that right.

Objections to Government Access to Protected Health Information

Comment: Many commenters urged the Department not to create a government database of health information, or a tracking system that would enable the government to track individuals health information.

Response: This regulation does not create such a database or tracking system, nor does it enable future creation of such a database. This regulation describes the ways in which health plans, health care clearinghouses, and certain health care providers may use and disclose identifiable health information with and without the individual’s consent.

Comment: Many commenters objected to government access to or control over their health information, which they believe the proposed regulation would provide.

Response: This regulation does not increase current government access to health information. This rule sets minimum privacy standards. It does not require disclosure of health information, other than to the subject of the records or for enforcement of this rule. Health plans and health care providers are free to use their own professional ethics and judgement to adopt stricter policies for disclosing health information.

Comment: Some commenters viewed the NPRM as creating fewer hurdles for government access to protected health information than for access to protected health information by private organizations. Some health care providers commented that the NPRM would impose substantial new restrictions on private sector use and disclosure of protected health information, but would make government access to protected health information easy. One consumer advocacy group made the same observation.

Response: We acknowledge that many of the national priority purposes for which we allow disclosure of protected health information without consent or authorization are for government functions, and that many of the governmental recipients of such information are not governed by this rule. It is the role of government to undertake functions in the broader public interest, such as public health activities, law enforcement, identification of deceased individuals through coroners’ offices, and military activities. It is these public purposes which can sometimes outweigh an individual’s privacy interest. In this rule, we specify the circumstances in which that balance is tipped toward the public interest with respect to health information. We discuss the rationale behind each of these permitted disclosures in the relevant preamble sections below.

Miscellaneous Comments

Comment: Many commenters objected to the establishment of a unique identifier for health care or other purposes.

Response: This regulation does not create an identifier. We assume these comments refer to the unique health identifier that Congress directed the Secretary to promulgate under section1173(b) of the Social Security Act, added by section 262 of the HIPAA. Because of the public concerns about such an identifier, in the summer of 1998 Vice President Gore announced that the Administration would not promulgate such a regulation until comprehensive medical privacy protections were in place. In the fall of that year, Congress prohibited the Department from promulgating such an identifier, and that prohibition remains in place. The Department has no plans to promulgate a unique health identifier.

Comment: Many commenters asked that we withdraw the proposed regulation and not publish a final rule.

Response: Under section 264 of the HIPAA, the Secretary is required by Congress to promulgate a regulation establishing standards for health information privacy. Further, for the reasons raised throughout this preamble above, we believe that the need to protect health information privacy is urgent and that this regulation is in the public’s interest.

Comment: Many commenters express the opinion that their consent should be required for all disclosure of their health information.

Response: We agree that consent should be required prior to release of health information for many purposes, and impose such a requirement in this regulation. Requiring consent prior to all release of health information, however, would unduly jeopardize public safety and make many operations of the health care system impossible. For example, requiring consent prior to release of health information to a public health official who is attempting to track the source of an outbreak or epidemic could endanger thousands of lives. Similarly, requiring consent before an oversight official could audit a health plan would make detection of health care fraud all but impossible; it could take health plans months or years to locate and obtain the consent of all current and past enrollees, and the health plan would not have a strong incentive to do so. These uses of medical information are clearly in the public interest.

In this regulation, we must balance individuals’ privacy interests against the legitimate public interests in certain uses of health information. Where there is an important public interest, this regulation imposes procedural safeguards that must be met prior to release of health information, in lieu of a requirement for consent. In some instances the procedural safeguards consist of limits on the circumstances in which information may be disclosed, in others the safeguards consist of limits on what information may be disclosed, and in other cases we require some form of legal process (e.g., a warrant or subpoena) prior to release of health information. We also allow disclosure of health information without consent where other law mandates the disclosures. Where such other law exists, another public entity has made the determination that the public interests outweigh the individual’s privacy interests, and we do not upset that determination in this regulation. In short, we tailor the safeguards to match the specific nature of the public purpose. The specific safeguards are explained in each section of this regulation below.

Comment: Many comments address matters not relevant to this regulation, such as alternative fuels, hospital reimbursement, and gulf war syndrome.
Comment: A few commenters questioned why this level of detail is needed in response to the HIPAA Congressional mandate.

Response: This level of detail is necessary to ensure that individuals’ rights with respect to their health information are clear, while also ensuring that information necessary for important public functions, such as protecting public health, promoting biomedical research, fighting health care fraud, and notifying family members in disaster situations, will not be impaired by this regulation. We designed this rule to reflect current practices and change some of them. The comments and our fact finding revealed the complexity of current health information practices, and we believe that the complexity entailed in reflecting those practices is better public policy than a perhaps simpler rule that disturbed important information flows.

Comment: A few comments stated that the goal of administrative simplification should never override the privacy of individuals.

Response: We believe that privacy is a necessary component of administrative simplification. The standardization of electronic health information mandated by the HIPAA makes it easier to share that information for legitimate purposes also make the inappropriate sharing of that information easier. For this reason, Congress included a mandate for privacy standards in this section of the HIPAA. Without appropriate privacy protections, public fear and instances of abuse would make it impossible for us to take full advantage of the administrative and costs benefits inherent in the administrative simplification standards.

Comment: At least one commenter asked us to require psychotherapists to assert any applicable legal privilege on patients’ behalf when protected health information is requested.

Response: Whether and when to assert a claim of privilege on a patient’s behalf is a matter for other law and for the ethics of the individual health care provider. This is not a decision that can or should be made by the federal government.

Comment: One commenter called for HHFS to consider the privacy regulation in conjunction with the other HIPAA standards. In particular, this comment focused on the belief that the Security Standards should be compatible with the existing and emerging health care and information technology industry standards.

Response: We agree that both this regulation and the final Security Regulation should be compatible with existing and emerging technology industry standards. This regulation is “technology neutral.” We do not mandate the use of any particular technologies, but rather set standards which can be met through a variety of means.

Comment: Several commenters claimed that the statutory authority given under HIPAA cannot provide meaningful privacy protections because many entities with access to protected health information, such as employers, worker’s compensation carriers, and life insurance companies, are not covered entities. These commenters expressed support for comprehensive legislation to close many of the existing loopholes.

Response: We agree with the commenters that comprehensive legislation is necessary to provide full privacy protection and have called for members of Congress to pass such legislation to prevent unauthorized and potentially harmful uses and disclosures of information.

Part 160—Subpart A—General Provisions

Section 160.103—Definitions

Business Associate

The response to comments on the definition of “business partner,” renamed in this rule as “business associate,” is included in the response to comments on the requirements for business associates in the preamble discussion of §164.504.

Covered Entity

Comment: A number of commenters urged the Department to expand or clarify the definition of “covered entity” to include certain entities other than health care clearinghouses, health plans, and health care providers who conduct standard transactions. For example, several commenters asked that the Department generally expand the scope of the rule to cover all entities that receive or maintain individually identifiable health information; others specifically urged the Department to cover employers, marketing firms, and legal entities that have access to individually identifiable health information. Some commenters asked that life insurance and casualty insurance carriers be considered covered entities for purposes of this rule. One commenter recommended that Pharmacy Benefit Management (PBM) companies be considered covered entities so that they may use and disclose protected health information without authorization.

In addition, a few commenters asked the Department to clarify that the definition includes providers who do not directly conduct electronic transactions if another entity, such as a billing service or hospital, does so on their behalf.

Response: We understand that many entities may use and disclose individually identifiable health information. However, our jurisdiction under the statute is limited to health plans, health care clearinghouses, and health care providers who transmit any health information electronically in connection with any of the standard financial or administrative transactions in section 1173(a) of the Act. These are the entities referred to in section 1173(a)(1) of the Act and thus listed in §160.103 of the final rule.

Consequently, once protected health information leaves the purview of one of these covered entities, their business associates, or other related entities (such as plan sponsors), the information is no longer afforded protection under this rule. We again highlight the need for comprehensive federal legislation to eliminate such gaps in privacy protection.

We also provide the following clarifications with regard to specific entities.

We clarify that employers and marketing firms are not covered entities. However, employers may be plan sponsors of a group health plan that is a covered entity under the rule. In such a case, specific requirements apply to the group health plan. See the preamble on §164.504 for a discussion of specific “firewall” and other organizational requirements for group health plans and their employer sponsors. The final rule also contains provisions addressing when an insurance issuer providing benefits under a group health plan may disclose summary health information to a plan sponsor.

With regard to life and casualty insurers, we understand that such benefit providers may use and disclose individually identifiable health information. However, Congress did not include life insurers and casualty insurance carriers as “health plans” for the purposes of this rule and therefore they are not covered entities. See the discussion regarding the definition of “health plan” and excepted benefits.
In addition, we clarify that a PBM is a covered entity only to the extent that it meets the definition of one or more of the entities listed in § 160.102. When providing services to patients through managed care networks, it is likely that a PBM is acting as a business associate of a health plan, and may thus use and disclose protected health information pursuant to the relevant provisions of this rule. PBMs may also be business associates of health care providers. See the preamble sections on §§ 164.502, 164.504, and 164.506 for discussions of the specific requirements related to business associates and consent.

Lastly, we clarify that health care providers who do not submit HIPAA transactions in standard form become covered by this rule when other entities, such as a billing service or a hospital, transmit standard electronic transactions on their behalf. The provider could not circumvent these requirements by assigning the task to a contractor.

Comment: Many commenters urged the Department to restrict or clarify the definition of “covered entity” to exclude certain entities, such as department-operated hospitals (public hospitals); state Crime Victim Compensation Programs; employers; and certain lines of insurers, such as workers’ compensation insurers, property and casualty insurers, reinsurers, and stop-loss insurers. One commenter expressed concern that clergy, religious practitioners, and other faith-based service providers would have to comply with this rule and asked that the Department exempt prayer healing and non-medical health care.

Response: The Secretary provides the following clarifications in response to these comments. To the extent that a “department-operated hospital” meets the definition of a “health care provider” and conducts any of the standard transactions, it is a covered entity for the purposes of this rule. We agree that a state Crime Victim Compensation Program is not a covered entity if it is not a health care provider that conducts standard transactions, health plan, or health care clearinghouse. Further, as described above, employers are not covered entities.

In addition, we agree that workers’ compensation insurers, property and casualty insurers, reinsurers, and stop-loss insurers are not covered entities, as they do not meet the statutory definition of “health plan.” See further discussion in the preamble of § 160.103 regarding the definition of “health plan.” However, activities related to coding, securing, or placing a contract for reinsurance, including stop-loss insurance, are health care operations in the final rule. As such, reinsurers and stop-loss insurers may obtain protected health information from covered entities.

Also, in response to the comment regarding religious practitioners, the Department clarifies that “health care” as defined under the rule does not include methods of healing that are solely spiritual. Therefore, clergy or other religious practitioners that provide solely religious healing services are not health care providers within the meaning of this rule, and consequently not covered entities for the purposes of this rule.

Comment: A few commenters requested that the Department clarify that device manufacturers are not covered entities. They stated that the proposal did not provide enough guidance in cases where the “manufacturer supplier” has only one part of its business that acts as the “supplier,” and additional detail is needed about the relationship of the “supplier component” of the company to the rest of the business. Similarly, another commenter asserted that drug, biologics, and device manufacturers should not be covered entities simply by virtue of their manufacturing activities.

Response: We clarify that if a supplier manufacturer is a Medicare supplier, then it is a health care provider, and it is a covered entity if it conducts standard transactions. Further, we clarify that a manufacturer of supplies related to the health of a particular individual, e.g., prosthetic devices, is a health care provider because the manufacturer is providing “health care” as defined in the rule. However, that manufacturer is a covered entity only if it conducts standard transactions. We do not intend that a manufacturer of supplies that are generic and not customized or otherwise specifically designed for particular individuals, e.g., ace bandages for a hospital, is a health care provider. Such a manufacturer is not providing “health care” as defined in the rule and is therefore not a covered entity. We note that, even if such a manufacturer is a covered entity, it may be an “indirect treatment provider” under this rule, and thus not subject to all of the rule’s requirements.

With regard to a “supplier component,” the final rule addresses the status of the unit or unit(s) of a larger entity that constitute a “health care component.” See further discussion under § 164.504 of this preamble.

Finally, we clarify that drug, biologics, and device manufacturers are not health care providers simply by virtue of their manufacturing activities. The manufacturer must be providing health care consistent with the final
rule’s definition in order to be considered a health care provider. 

Comment: A few commenters asked that the Department clarify that pharmaceutical manufacturers are not covered entities. It was explained that pharmaceutical manufacturers provide support and guidance to doctors and patients with respect to the proper use of their products, provide free products for doctors to distribute to patients, and operate charitable programs that provide pharmaceutical drugs to patients who cannot afford to buy the drugs they need.

Response: A pharmaceutical manufacturer is only a covered entity if the manufacturer provides “health care” according to the rule’s definition and conducts standard transactions. In the above case, a pharmaceutical manufacturer that provides support and guidance to doctors and patients regarding the proper use of their products is providing “health care” for the purposes of this rule, and therefore, is a health care provider to the extent that it provides such services. The pharmaceutical manufacturer that is a health care provider is only a covered entity, however, if it conducts standard transactions. We note that this rule permits a covered entity to disclose protected health information to any person for treatment purposes, without specific authorization from the individual. Therefore, a covered health care provider is permitted to disclose protected health information to a pharmaceutical manufacturer for treatment purposes. Providing free samples to a health care provider does not in itself constitute health care. For further analysis of pharmacy assistance programs, see response to comment on § 164.501, definition of “payment.”

Comment: Several commenters asked about the definition of “covered entity” and its application to health care entities within larger organizations.

Response: A detailed discussion of the final rule’s organizational requirements and firewall restrictions for “health care components” of larger entities, as well as for affiliated, and other entities is found at the discussion of § 164.504 of this preamble. The following responses to comments provide additional information with respect to particular “component entity” circumstances.

Comment: Several commenters asked that we clarify the definition of covered entity to state that with respect to persons or organizations that provide health care or have created health plans but are engaged in other unrelated businesses, the term “covered entity” encompasses only the health care components of the entity. Similarly, others recommended that only the component of a government agency that is a provider, health plan, or clearinghouse should be considered a covered entity.

Response: The Department understands that in today’s health care industry, the relationships among health care entities and non-health care organizations are highly complex and varied. Accordingly, the final rule gives covered entities some flexibility to segregate or aggregate its operations for purposes of the application of this rule. The new component entity provision can be found at §§ 164.504(b)-(c). In response to comment, clarification on whether the rule would apply to a research component of the covered entity, we point out that if the research activities fall outside of the health care component they would not be subject to the rule. One organization may have one or several “health care component(s)” that perform one or more of the health care functions of a covered entity, i.e., health care provider, health plan, health care clearinghouse. In addition, the final rule permits covered entities that are affiliated, i.e., share common ownership or control, to designate themselves, or their health care components, together to be a single covered entity for purposes of the rule.

It appears from the comments that there is not a common understanding of the meaning of “integrated delivery system.” Arrangements that apply this label to themselves operate and share information in many different ways, and may or may not be financially or clinically integrated. In some cases, separate entities hold themselves out as a single enterprise and engage together in clinical or financial activities. In others, separate entities share information but do not provide treatment together or share financial risk. Many health care providers participate in more than one such arrangement.

Therefore, we do not include a separate category of “covered entity” under this rule for “integrated delivery systems” but instead accommodate the operations of these varied arrangements through the functional provisions of the rule. For example, covered entities that operate as “organized health care arrangements” as defined in this rule may share protected health information for the operation of such arrangement without becoming business associates of one another. Similarly, the regulation does not require a business associate arrangement when protected health information is shared for purposes of providing treatment. The application of this rule to any particular “integrated system” will depend on the nature of the common activities the participants in the system perform. When the participants in such an arrangement are “affiliated” as defined in this rule, they may consider themselves a single covered entity (see § 164.504).

The arrangements between academic health centers, faculty practice plans, universities, and hospitals are similarly diverse. We cannot describe a blanket rule that covers all such arrangements. The application of this rule will depend on the purposes for which the participants in such arrangements share protected health information, whether some or all participants are under common ownership or control, and similar matters. We note that physicians who have staff privileges at a covered...
hospital do not become part of that hospital covered entity by virtue of having such privileges.

We reject the recommendation to apply the rule only to components of an entity that engage in the transactions. This would omit as covered entities, for example, the health plan components that do not directly engage in the transactions, including components that engage in important health plan functions such as coverage determinations and quality review. Indeed, we do not believe that the statute permits this result with respect to health plans or health care clearinghouses as a matter of negative implication from section 1172(a)(3). We clarify that only a health care provider must conduct transactions to be a covered entity for purposes of this rule.

We also clarify that health care providers (such as doctors or nurses) who work for a larger organization and do not conduct transactions on their own behalf are workforce members of the covered entity, not covered entities themselves.

Comment: A few commenters asked the Department to clarify the definition to provide that a multi-line insurer that sells insurance coverages, some of which do and others which do not meet the definition of “health plan,” is not a covered entity with respect to actions taken in connection with coverages that are not “health plans.”

Response: The final rule clarifies that the requirements below apply only to the organizational unit or units of the organization that are the “health care component” of a covered entity, where the “covered functions” are not the primary functions of the entity. Therefore, for a multi-line insurer, the “health care component” is the insurance line(s) that conduct, or support the conduct of, the health care function of the covered entity. Also, it should be noted that excepted benefits, such as life insurance, are not included in the definition of “health plan.” (See preamble discussion of § 164.504).

Comment: A commenter questioned whether the Health Care Financing Administration (HCFA) is a covered entity and how HCFA will share data with Medicare managed care organizations. The commenter also questioned why the regulation must apply to Medicaid since the existing Medicaid statute requires that states have privacy standards in place. It was also requested that the Department provide a definition of “health plan” to clarify that state Medicaid Programs are considered as such.

Response: HCFA is a covered entity because it administers Medicare and Medicaid, which are both listed in the statute as health plans. Medicare managed care organizations are also covered entities under this regulation. As noted elsewhere in this preamble, covered entities that jointly administer a health plan, such as Medicare Choice, are both covered entities, and are not business associates of each other by virtue of such joint administration.

We do not exclude state Medicaid programs. Congress explicitly included the Medicaid program as a covered health plan in the HIPAA statute. Comment: A commenter asked the Department to provide detailed guidance as to when providers, plans, and clearinghouses become covered entities. The commenter provided the following example: if a provider submits claims only in paper form, and a coordination of benefits (COB) transaction is created due to other insurance coverage, will the original provider need to be notified that the claim is now in electronic form, and that it has become a covered entity?

Another commentor voiced concern as to whether physicians who do not conduct electronic transactions would become covered entities if another entity using its records downstream transmits information in connection with a standard transaction on their behalf.

Response: We clarify that health care providers who submit the transactions in standard electronic form, health plans, and health care clearinghouses are covered entities if they meet the respective definitions. Health care providers become subject to the rule if they conduct standard transactions. In the above example, the health care provider would not be a covered entity if the coordination of benefits transaction was generated by a payor. We also clarify that health care providers who do not submit transactions in standard form become covered by this rule when other entities, such as a billing service or a hospital, transmit standard electronic transactions on the provider’s behalf. However, where the downstream transaction is not conducted on behalf of the health care provider, the provider does not become a covered entity due to the downstream transaction.

Comment: Several commenters discussed the relationship between section 1179 of the Act and the privacy regulations. One commenter suggested that HHS retain the statement that a covered entity means “the entities to which part C of title XI of the Act applies.” The commenter observed that section 1179 of the Act provides that part C of title XI of the Act does not apply to financial institutions or to entities acting on behalf of such institutions that are covered by the section 1179 exemption. Thus, under the definition of covered entity, they comment that financial institutions and other entities that come within the scope of the section 1179 exemption are appropriately not covered entities.

Other commenters maintained that section 1179 of the Act means that the Act’s privacy requirements do not apply to the request for, or the use or disclosure of, information by a covered entity with respect to payment: (a) For transferring receivables; (b) for auditing; (c) in connection with—(i) a customer dispute; or (ii) an inquiry from or to a customer; (d) in a communication to a customer of the entity regarding the customer’s transactions payment card, account, check, or electronic funds transfer; (e) for reporting to consumer reporting agencies; or (f) for complying with: (i) a civil or criminal subpoena; or (ii) a federal or state law regulating the entity. These companies expressed concern that the proposed rule did not include the full text of section 1179 when discussing the list of activities that were exempt from the rule’s requirements. Accordingly, they recommended including in the final rule either a full listing of or a reference to section 1179’s full list of exemptions. Furthermore, these firms opposed applying the proposed rule’s minimum necessary standard for disclosure of protected health information to financial institutions because of section 1179.

These commenters suggest that in light of section 1179, HHS lacks the authority to impose restrictions on financial institutions and other entities when they engage in activities described in that section. One commenter expressed concern that even though proposed § 164.510(i) would have permitted covered entities to disclose certain information to financial institutions for banking and payment processes, it did not state clearly that financial institutions and other entities described in section 1179 are exempt from the rule’s requirements.

Response: We interpret section 1179 of the Act to mean that entities engaged in the activities of a financial institution, and those acting on behalf of a financial institution, are not subject to this regulation when they are engaged in authorizing, processing, clearing, settling, billing, transferring, reconciling, or collecting payments for a financial institution. The statutory reference to 12 U.S.C. 3401 indicates that Congress chose to adopt the definition of financial institutions found
in the Right to Financial Privacy Act, which defines financial institutions as any office of a bank, savings bank, card issuer, industrial loan company, trust company, savings association, building and loan, homestead association, cooperative bank, credit union, or consumer finance institution located in the United States or one of its Territories. Thus, when we use the term “financial institution” in this regulation, we turn to the definition with which Congress provided us. We interpret this provision to mean that when a financial institution, or its agent, conducts the activities described in section 1179, the privacy regulation will not govern the activity.

If, however, these activities are performed by a covered entity or by another entity, including a financial institution, on behalf of a covered entity, the activities are subject to this rule. For example, if a bank operates the accounts payable system or other “back office” functions for a covered health care provider, that activity is not described in section 1179. In such instances, because the bank would meet the rule’s definition of “business associate,” the provider must enter into a business associate contract with the bank before disclosing protected health information pursuant to this relationship. However, if the same provider maintains an account through which he/she cashes checks from patients, no business associate contract would be necessary because the bank’s activities are not undertaken for or on behalf of the covered entity, and fall within the scope of section 1179. In part to give effect to section 1179, in this rule we do not consider a financial institution to be acting on behalf of a covered entity when it processes consumer-conducted financial transactions by debit, credit or other payment card, clears checks, initiates or processes electronic funds transfers, or conducts any other activity that directly facilitates or effects the transfer of funds for compensation for health care. We do not agree with the comment that section 1179 of the Act means that the privacy regulation’s requirements cannot apply to the activities listed in that section; rather, it means that the entities expressly mentioned, financial institutions (as defined in the Right to Financial Privacy Act), and their agents that engage in the listed activities for the financial institution are not within the scope of the regulation. Nor do we interpret section 1179 to support an exemption for disclosures to financial institutions from the minimum necessary provisions of this regulation.

Comment: One commenter recommended that HHS include a definition of “entity” in the final rule because HIPAA did not define it. The commenter explained that in a modern health care environment, the organization acting as the health plan or health care provider may involve many interrelated corporate entities and that this could lead to difficulties in determining what “entities” are actually subject to the regulation.

Response: We reject the commenter’s suggestion. We believe it is clear in the final rule that the entities subject to the regulation are those listed at § 160.102. However, we acknowledge that how the rule applies to integrated or other complex health systems needs to be addressed; we have done so in § 164.504 and in other provisions, such as those addressing organized health care arrangements.

Comment: The preamble should clarify that self-insured group health and workmen’s compensation plans are not covered entities or business partners.

Response: In the preamble to the proposed rule we stated that certain types of insurance entities, such as workers’ compensation, would not be covered entities under the rule. We do not change this position in this final rule. The statutory definition of health plan does not include workers’ compensation products, and the regulatory definition of the term specifically excludes them. However, HIPAA specifically includes most group health plans within the definition of “health plan.”

Comment: A health insurance issuer asserted that health insurers and third party administrators are usually required by employers to submit reports describing the volume, amount, payee, basis for services rendered, types of claims paid and services for which payment was requested on behalf of it covered employees. They recommended that the rule permit the disclosure of protected health information for such purposes.

Response: We agree that health plans should be able to disclose protected health information to employers sponsoring health plans under certain circumstances. Section 164.504(f) explains the conditions under which protected health information may be disclosed to plan sponsors. We believe that this provision gives sponsors access to the information they need, but protects individual’s information to the extent possible under our legislative authority.

Group Health Plan

For response to comments relating to “group health plan,” see the response to comments on “health plan” below and the response to comments on § 164.504.

Health Care

Comment: A number of commenters asked that we include disease management activities and other similar health improvement programs, such as preventive medicine, health education services and maintenance, health and case management, and risk assessment, in the definition of “health care.” Commenters maintained that the rule should avoid limiting technological advances and new health care trends intended to improve patient “health care.”

Response: Review of these and other comments, and our fact-finding, indicate that there are multiple, different, understandings of the definition of these terms. Therefore, rather than create a blanket rule that includes such terms in or excludes such terms from the definition of “health care,” we define health care based on the underlying activities that constitute health care. The activities described by these commenters are considered “health care” under this rule to the extent that they meet this functional definition. Listing activities by label or title would create the risk that important activities would be left out and, given the lack of consensus on what these terms mean, could also create confusion.

Comment: Several commenters urged that the Department clarify that the activities necessary to procure and distribute eyes and eye tissue will not be hampered by the rule. Some of these commenters explicitly requested that we include “eyes and eye tissue” in the list of procurement biologicals as well as “eye procurement” in the definition of “health care.” In addition, it was argued that “administration to patients” be excluded in the absence of a clear definition. Also, commenters recommended that the definition include other activities associated with the transplantation of organs, such as processing, screening, and distribution.

Response: We delete from the definition of “health care” activities related to the procurement or banking of blood, sperm, organs, or any other tissue for administration to patients. We do so because persons who make such donations are not seeking to be treated, diagnosed, or assessed or otherwise seeking health care for themselves, but are seeking to contribute to the health care of others. In addition, the nature of
these activities entails a unique kind of information sharing and tracking necessary to safeguard the nation’s organ and blood supply, and those seeking to donate are aware that this information sharing will occur. Consequently, such procurement or banking activities are not considered health care and the organizations that perform such activities are not considered health care providers for purposes of this rule.

With respect to disclosure of protected health information by covered entities to facilitate cadaveric organ and tissue donation, the final rule explicitly permits a covered entity to disclose protected health information without authorization, consent, or agreement to organ procurement organizations or other entities engaged in the procurement, banking, or transplantation of cadaveric organs, eyes, or tissue for the purpose of facilitating donation and transplantation. See § 164.512(h). We do not include blood or sperm banking in this provision because, for those activities, there is direct contact with the donor, and thus opportunity to obtain the individual’s authorization.

Comment: A large number of commentators urged that the term “assessment” be included in the list of services in the definition, as “assessment” is used to determine the baseline health status of an individual. It was explained that assessments are conducted in the initial step of diagnosis and treatment of a patient. If assessment is not included in the list of services, they pointed out that the services provided by occupational health nurses and employee health information may not be covered.

Response: We agree and have added the term “assessment” to the definition to clarify that this activity is considered “health care” for the purposes of the rule.

Comment: One commenter asked that we revise the definition to explicitly exclude plasmapheresis from paragraph (3) of the definition. It was explained that plasmapheresis centers do not have direct access to health care recipients or their health information, and that the limited health information collected about plasma donors is not used to provide health care services as indicated by the definition of health care.

Response: We address the commenters’ concerns by removing the provision related to procurement and banking of human products from the definition.

Health Care Clearinghouse

Comment: The largest set of comments relating to health care clearinghouses focused on our proposal to exempt health care clearinghouses from the patient notice and access rights provisions of the regulation. In our NPRM, we proposed to exempt health care clearinghouses from certain provisions of the regulation that deal with the covered entities’ notice of information practices and consumers’ rights to inspect, copy, and amend their records. The rationale for this exemption was based on our belief that health care clearinghouses engage primarily in business-to-business transactions and do not initiate or maintain direct relationships with individuals. We proposed this position with the caveat that the exemptions would be void for any health care clearinghouse that had direct contact with individuals in a capacity other than that of a business partner. In addition, we indicated that, in most instances, clearinghouses also would be considered business partners under this rule and would be bound by their contracts with covered plans and providers. They also would be subject to the notice of information practices developed by the plans and providers with whom they contract.

Response: Where a health care clearinghouse creates or receives protected health information other than as a business associate, however, it must comply with all the standards, requirements, and implementation specifications of the rule. We describe and delimit the exact nature of the exemption in the regulatory text. See § 164.500(b). We will monitor developments in this sector should the basic business-to-business relationship change.

Comment: A number of comments relate to the proposed definition of health care clearinghouse. Many commenters suggested that we expand the definition. They suggested that additional types of entities be included in the definition of health care clearinghouse, specifically medical transcription services, billing services, coding services, and “intermediaries.” One commenter suggested that the definition be expanded to add entities that receive standard transactions, process them and clean them up, and then send them on, without converting them to any standard format. Another commenter suggested that the health care clearinghouse definition be expanded to include entities that do not perform translation but may receive protected health information in a standard format and have access to that information. Another commenter stated that the list of covered entities should include any organization that receives or maintains individually identifiable health information. One organization recommended that we expand the health care clearinghouse definition to include the concept of a research data clearinghouse, which would collect individually identifiable health information from other covered entities to generate research data files for release as de-identified data or with appropriate confidentiality safeguards. One commenter stated that HHS had gone beyond Congressional intent by including billing services in the definition.

Response: We cannot expand the definition of “health care clearinghouse” to cover entities not covered by the definition of this term in the statute. In the final regulation, we
make a number of changes to address public comments relating to definition. We modify the definition of health care clearinghouse to conform to the definition published in the Transactions Rule (with the addition of a few words, as noted above). We clarify in the preamble that, while the term “health care clearinghouse” may have other meanings and connotations in other contexts, for purposes of this regulation an entity is considered a health care clearinghouse only to the extent that it actually meets the criteria in our definition. Entities performing other functions but not meeting the criteria for a health care clearinghouse are not clearinghouses, although they may be business associates. Billing services are included in the regulatory definition of “health care clearinghouse,” if they perform the specified clearinghouse functions. Although we have not added or deleted any entities from our original definition, we will monitor industry practices and may add other entities in the future as changes occur in the health system.

Comment: Several commenters suggested that we clarify that an entity acting solely as a conduit through which individually identifiable health information is transmitted or through which protected health information flows but is not stored is not a covered entity, e.g., a telephone company or Internet Service Provider. Other commenters indicated that once a transaction leaves a provider or plan electronically, it may flow through several entities before reaching a clearinghouse. They asked that the regulation protect the information in that interim stage, just as the security NPRM established a chain of trust arrangement for such a network. Others noted that these “conduit” entities are likely to be business partners of the provider, clearinghouse or plan, and we should clarify that they are subject to business partner obligations as in the proposed Security Rule.

Response: We clarify that entities acting as simple and routine communications conduits and carriers of information, such as telephone companies and Internet Service Providers, are not clearinghouses as defined in the rule unless they carry out the functions outlined in our definition. Similarly, we clarify that value added networks and switches are not health care clearinghouses unless they carry out the functions outlined in the definition, and clarify that such entities may be business associates if they meet the definition in the regulation.

Comment: Several commenters, including the large clearinghouses and their trade associations, suggested that we not treat health care clearinghouses as playing a dual role as covered entity and business partner in the final rule because such a dual role causes confusion as to which rules actually apply to clearinghouses. In their view, the definition of health care clearinghouse is sufficiently clear to stand alone and identify a health care clearinghouse as a covered entity, and allows health care clearinghouses to operate under one consistent set of rules.

Response: For reasons explained in § 164.504 of this preamble, we do not create an exception to the business associate requirements when the business associate is also a covered entity. We retain the concept that a health care clearinghouse may be a covered entity and a business associate of a covered entity under the regulation. As business associates, they would be bound by their contracts with covered plans and providers.

Health Care Provider

Comment: One commenter pointed out that the preamble referred to the obligations of providers and did not use the term, “covered entity,” and thus created ambiguity about the obligations of health care providers who may be employed by persons other than covered entities, e.g., pharmaceutical companies. It was suggested that a better reading of the statute and rule is that where neither the provider nor the company is a covered entity, the rule does not impose an obligation on either the provider-employee or the employer.

Response: We agree. We use the term “covered entity” whenever possible in the final rule, except for the instances where the final rule treats the entities differently, or where use of the term “health care provider” is necessary for purposes of illustrating an example.

Comment: Several commenters stated that the proposal’s definition was broad, unclear, and/or confusing. Further, we received many comments requesting clarification as to whether specific entities or persons were “health care providers” for the purposes of our rule. One commenter questioned whether affiliated members of a health care group (even though separate legal entities) would be considered as one primary health care provider.

Response: We permit legally distinct covered entities that share common ownership or control to designate themselves together to be a single covered entity. Our regulations may promulgate a single shared notice of information practices and a consent form. For more detailed information, see the preamble discussion of § 164.504(d).

We understand the need for additional guidance on whether specific entities or persons are health care providers under the final rule. We provide guidance below and will provide additional guidance as the rule is implemented.

Comment: One commenter observed that sections 1171(3), 1861(s) and 1861(u) of the Act do not include pharmacists in the definition of health care provider or pharmacist services in the definition of “medical or other health services,” and questioned whether pharmacists were covered by the rule.

Response: The statutory definition of “health care provider” at section 1171(3) includes “any other person or organization who furnishes, bills, or is paid for health care in the normal course of business.” Pharmacists’ services are clearly within this statutory definition of “health care.” There is no basis for excluding pharmacists who meet these statutory criteria from this regulation.

Comment: Some commenters recommended that the scope of the definition be broadened or clarified to cover additional persons or organizations. Several commenters argued for expanding the reach of the health care provider definition to cover entities such as state and local public health agencies, maternity support services (provided by nutritionists, social workers, and public health nurses and the Special Supplemental Nutrition Program for Women, Infants and Children), and those companies that conduct cost-effectiveness reviews, risk management, and benchmarking studies. One commenter queried whether auxiliary providers such as child play therapists, and speech and language therapists are considered to be health care providers. Other commenters questioned whether “alternative” or “complementary” providers, such as naturopathic physicians and acupuncturists would be considered health care providers covered by the rule.

Response: As with other aspects of this rule, we do not define “health care provider” based on the title or label of the professional. The professional activities of these kinds of providers vary; a person is a “health care provider” if those activities are consistent with the rule’s definition of “health care provider.” Thus, health care providers include persons, such as those noted by the commenters, to the extent that they meet the definition. We note that health care providers are only
subject to this rule if they conduct certain transactions. See the definition of “covered entity.”

However companies that conduct cost-effectiveness reviews, risk management, and benchmarking studies are not health care providers for the purposes of this rule unless they perform other functions that meet the definition. These entities would be business associates if they perform such activities on behalf of a covered entity.

Comment: Another commenter recommended that the Secretary expand the definition of health care provider to cover health care providers who transmit or “receive” any health care information in electronic form.

Response: We do not accept this suggestion. Section 1172(a)(3) states that providers that “transmit” health information in connection with one of the HIPAA transactions are covered, but does not use the term “receive” or a similar term.

Comment: Some comments related to online companies as health care providers and covered entities. One commenter argued that there was no reason “why an Internet pharmacy should not also be covered” by the rule as a health care provider. Another commenter stated that online health care service and content companies, including online medical record companies, should be covered by the definition of health care provider.

Another commenter pointed out that the definitions of covered entities cover “Internet providers who ‘bill’ or are ‘paid’ for health care services or supplies, but not those who finance those services in other ways, such as through sale of identifiable health information or advertising.” It was pointed out that thousands of Internet sites use information provided by individuals who access the sites for marketing or other purposes.

Response: We agree that online companies are covered entities under the rule if they otherwise meet the definition of health care provider or health plan and satisfy the other requirements of the rule, i.e., providers must also transmit health information in electronic form in connection with a HIPAA transaction. We restate here the language in the preamble to the proposed rule that “An individual or organization that bills and/or is paid for health care services or supplies in the normal course of business, such as an “online” pharmacy accessible on the Internet, is also a health care provider for purposes of this statute” (64 FR 3996).

Comment: We received many comments related to the reference to “health clinic or licensed health care professional located at a school or business in the preamble’s discussion of “health care provider.” It was stated that including “licensed health care professionals located at a school or business” highlights the need for these individuals to understand they have the authority to disclose information to the Social Security Administration (SSA) without authorization.

However, several commenters urged HHS to create an exception for or delete that reference in the preamble discussion to primary and secondary schools because of employer or business partner relationships. One federal agency suggested that the reference “licensed health care professionals located at a school” be deleted from the preamble because the definition of health care provider does not include a reference to schools. The commenter also suggested that the Secretary consider: adding language to the preamble to clarify that the rules do not apply to clinics or school health care providers that only maintain records that have been excepted from the definition of protected health information, adding an exception to the definition of covered entities for those schools, and limiting paperwork requirements for these schools. Another commenter argued for deleting references to schools because the proposed rule appeared to supersede or create ambiguity as to the Family Educational Rights and Privacy Act (FERPA), which gives parents the right to access “education” and health records of their unemancipated minor children. However, in contrast, one commenter supported the inclusion of health care professionals who provide services at schools or businesses.

Response: We realize that our discussion of schools in the NPRM may have been confusing. Therefore, we address these concerns and set forth our policy regarding protected health information in educational agencies and institutions in the “Relationship to Other Federal Laws” discussion of FERPA, above.

Comment: Many commenters urged that direct contact with the patient be necessary for an entity to be considered a health care provider. Commenters suggested that persons and organizations that are remote to the patient and have no direct contact should not be considered health care providers. Several commenters argued that the definition of health care provider covers a person that provides health care services or supplies only when the provider furnishes to or bills the patient directly. It was stated that the Secretary did not intend that manufacturers, such as pharmaceutical, biologics, and device manufacturers, health care suppliers, medical-surgical supply distributors, health care vendors that offer medical record documentation templates and that typically do not deal directly with the patient, be considered health care providers and thus covered entities. However, in contrast, one commenter argued that, as an in vitro diagnostics manufacturer, it should be covered as a health care provider.

Response: We disagree with the comments that urged that direct dealings with an individual be a prerequisite to meeting the definition of health care provider. Many providers included in the statutory definition of provider, such as clinical labs, do not have direct contact with patients. Further, the use and disclosure of protected health information by indirect treatment providers can have a significant effect on individuals’ privacy. We acknowledge, however, that providers who treat patients indirectly need not have the full array of responsibilities as direct treatment providers, and modify the NPRM to make this distinction with respect to several provisions (see, for example § 164.506 regarding consent). We also clarify that manufacturers and health care suppliers who are considered providers by Medicare are providers under this rule.

Comment: Some commenters suggested that blood centers and plasma donor centers that collect and distribute plasma not be considered covered health care providers because the centers do not provide “health care services” and the blood donors are not “patients” seeking health care. Similarly, commenters expressed concern that organ procurement organizations might be considered health care providers.

Response: We agree and have deleted from the definition of “health care” the term “procurement or banking of blood, sperm, organs, or any other tissue for administration to patients.” See prior discussion under “health care.”

Comment: Several commenters proposed to restrict coverage to only those providers who furnished and were paid for services and supplies. It was argued that a salaried employee of a covered entity, such as a hospital-based provider, should not be covered by the rule because that provider would be subject both directly to the rule as a covered entity and indirectly as an employee of a covered entity.

Response: The “dual” direct and indirect situation described in these comments can arise only when a health
care provider conducts standard HIPAA transactions both for itself and for its employer. For example, when the services of a provider such as a hospital-based physician are billed through a standard HIPAA transaction conducted for the employer, in this example the hospital, the physician does not become a covered provider. Only when the provider uses a standard transaction on its own behalf does he or she become a covered health care provider. Thus, the result is typically as suggested by this commenter. When a hospital-based provider is not paid directly, that is, when the standard HIPAA transaction is not on its behalf, it will not become a covered provider.

Comment: Other commenters argued that an employer who provides health care services to its employees for whom it neither bills the employee nor pays for the health care should not be considered health care providers covered by the proposed rule.

Response: We clarify that the employer is a health care provider under the rule, and may be covered by the rule if it conducts standard transactions. The provisions of §164.504 may also apply.

Comment: Some commenters were confused about the preamble statement: “in order to implement the principles in the Secretary’s Recommendations, we must impose any protections on the health care providers that use and disclose the information, rather than on the researcher seeking the information,” with respect to the rule’s policy that a researcher who provides care to subjects in a trial will be considered a health care provider. Some commenters were also unclear about whether the individual researcher providing health care to subjects in a trial would be considered a health care provider.

Response: We clarify that, in general, a researcher is also a health care provider if the researcher provides health care to subjects in a clinical research study and otherwise meets the definition of “health care provider” under the rule. However, a health care provider is only a covered entity and subject to the rule if that provider conducts standard transactions. With respect to the above preamble statement, we meant that our jurisdiction under the statute is limited to covered entities. Therefore, we cannot apply any restrictions or requirements on a researcher in his or her role as a researcher. However, if a researcher is also a health care provider that conducts standard transactions, that researcher/provider is subject to the rule with regard to its provider activities.

As to applicability to a researcher/provider versus the researcher’s home institution, we provide the following guidance. The rule applies to the researcher as a covered entity if the researcher is a health care provider who conducts standard transactions for services on his or her own behalf, regardless of whether he or she is part of a larger organization. However, if the services and transactions are conducted on behalf of the home institution, then the home institution is the covered entity for purposes of the rule and the researcher/provider is a workforce member, not a covered entity.

Comment: One commenter expressed confusion about those instances when a health care provider was a covered entity one day, and one who “works under a contract” for a manufacturer the next day.

Response: If persons are covered under the rule in one role, they are not necessarily covered entities when they participate in other activities in another role. For example, that person could be a covered health care provider in a hospital one day but the next day read research records for a different employer. In its role as researcher, the person is not covered, and protections do not apply to those research records.

Comment: One commenter suggested that the Secretary modify proposed §160.102, to add the following clause at the end (after (c)) (regarding health care provider), “With respect to any entity whose primary business is not that of a health plan or health care provider licensed under the applicable laws of any state, the standards, requirements, and implementation specifications of this subchapter shall apply solely to the component of the entity that engages in the transactions specified in §160.103.” (Emphasis added.) Another commenter also suggested that the definition of “covered entity” be revised to mean entities that are “primarily or exclusively engaged in health care-related activities as a health plan, health care provider, or health care clearinghouse.”

Response: The Secretary rejects these suggestions because they will impermissibly limit the entities covered by the rule. An entity that is a health plan, health care provider, or health care clearinghouse meets the statutory definition of covered entity regardless of how much time is devoted to carrying out health care-related functions, or regardless of what percentage of their total business applies to health care-related functions.

Comment: Several commenters sought to distinguish a health care provider from a business partner as proposed in the NPRM. For example, a number of commenters argued that disease managers that provide services “on behalf of” health plans and health care providers, and case managers (a variation of a disease management service) are business partners and not “health care providers.” Another commenter argued that a disease manager should be recognized (presumably as a covered entity) because of its involvement from the physician-patient level through complex interactions with health care providers.

Response: To the extent that a disease or case manager provides services on behalf of or to a covered entity as described in the rule’s definition of business associate, the disease or case manager is a business associate for purposes of this rule. However, if services provided by the disease or case manager meet the definition of treatment and the person otherwise meets the definition of “health care provider,” such a person is a health care provider for purposes of this rule.

Comment: One commenter argued that pharmacy employees who assist pharmacists, such as technicians and cashiers, are not business partners.

Response: We agree. Employees of a pharmacy that is a covered entity are workforce members of that covered entity for purposes of this rule.

Comment: A number of commenters requested that we clarify the definition of health care provider (“* * * who furnishes, bills, or is paid for health care services or supplies in the normal course of business”) by defining the various terms “furnish”, “supply”, and “in the normal course of business.” For instance, it was stated that this would help employers recognize when services such as an employee assistance program constituted health care covered by the rule.

Response: Although we understand the concern expressed by the commenters, we decline to follow their suggestion to define terms at this level of specificity. These terms are in common use today, and an attempt at specific definition would risk the inadvertent creations of conflict with industry practices. There is a significant variation in the way employers structure their employee assistance programs (EAPs) and the type of services that they provide. If the EAP provides direct treatment to individuals, it may be a health care provider.
Health Information

The response to comments on health information is included in the response to comments on individually identifiable health information, in the preamble discussion of § 164.501.

Health Plan

Comment: One commenter suggested that to eliminate any ambiguity, the Secretary should clarify that the catch-all category under the definition of health plan includes “24-hour coverage plans” (whether insured or self-insured) that integrate traditional employee health benefits coverage and workers’ compensation coverage for the treatment of on-the-job injuries and illnesses under one program. It was stated that this clarification was essential if the Secretary persisted in excluding workers’ compensation from the final rule.

Response: We understand concerns that such plans may use and disclose individually identifiable health information. We therefore clarify that the extent that 24-hour coverage plans have a health care component that meets the definition of “health plan” in the final rule, such components must abide by the provisions of the final rule. In the final rule, we have added a new provision to § 164.512 that permits covered entities to disclose information under workers’ compensation and similar laws. A health plan that is a 24-hour plan is permitted to make disclosures as necessary to comply with such laws.

Comment: A number of commenters urged that certain types of insurance entities, such as workers’ compensation and automobile insurance carriers, property and casualty insurance health plans, and certain forms of limited benefits coverage, be included in the definition of “health plan.” It was argued that consumers deserve the same protection with respect to their health information, regardless of the entity using it, and that it would be inequitable to subject health insurance carriers to more stringent standards than other types of insurers that use individually identifiable health information.

Response: The Congress did not include these programs in the definition of a “health plan” under section 1171 of the Act. Further, HIPAA’s legislative history shows that the House Report’s (H. Rep. 104–496) definition of “health plan” originally included certain benefit programs, such as workers’ compensation and liability insurance, but was later amended to clarify the definition and remove these programs. Thus, since the statutory definition of a health plan both on its face and through legislative history evidence Congress’ intention to exclude such programs, we do not have the authority to require that these programs comply with the standards. We have added explicit language to the final rule which excludes the excepted benefit programs, as defined in section 2971(c)(1) of the PHS Act, 42 U.S.C. 300gg-91(c)(1).

Comment: Some commenters urged HHS to include entities such as stop loss insurers and reinsurers in the definition of “health plan.” It was observed that such entities have come to play important roles in managed care delivery systems. They asserted that increasingly, capitated health plans and providers contract with their reinsurers and stop loss carriers to medically manage their high cost outlier cases such as organ and bone marrow transplants, and therefore should be specifically cited as subject to the regulations.

Response: Stop-loss and reinsurers do not meet the statutory definition of health plan. They do not provide or pay for the costs of medical care, as described in the statute, but rather insure health plans and providers against unexpected losses. Therefore, we cannot include them as health plans in the regulation.

Comment: A commenter asserted that there is a significant discrepancy between the effect of the definition of “group health plan” as proposed in § 160.103, and the anticipated impact in the cost estimates of the proposed rule at 64 FR 60014. Paragraph (1) of the proposed definition of “health plan” defined a “group health plan” as an ERISA-defined employee welfare benefit plan that provides medical care and that: “(i) Has 50 or more participants, or (ii) Is administered by an entity other than the employer that established and maintains the plan.” (emphasis added) According to this commenter, under this definition, the only insured or self-insured ERISA plans that would not be regulated “health plans” would be those that have less than 50 participants and are self administered. The commenter presumed that the we had intended to exclude from the definition of “health plan” (and from coverage under the proposed rule) all ERISA plans that are small (less than 50 participants) or are administered by a third party, whether large or small, based on the statement at 64 FR 60014, note 18. That footnote stated that the Department had “not included the 3.9 million ‘other’ employer-health plans listed in HCFA’s administrative simplification regulations because these plans are administered by a third party. The proposed regulation will not regulate the employer plans but will regulate the third party administrators of the plan.” The commenter urged us not to repeat the statutory definition, and to adopt the policy implied in the footnote.

Response: We agree with the commenter’s observation that footnote 18 (64 FR 60014) was inconsistent with the proposed definition. We erred in drafting that note. The definition of “group health plan” is adopted from the statutory definition at section 1171(5)(A), and excludes from the rule as “health plans” only the few insured or self-insured ERISA plans that have less than 50 participants and are self administered. We reject the commenter’s proposed change to the definition as inconsistent with the statute.

Comment: A number of insurance companies asked that long term care insurance policies be excluded from the definition of “health plan.” It was argued that such policies do not provide sufficiently comprehensive coverage of the cost of medical care, and are limited benefit plans that provide or pay for the cost of custodial and other related services in connection with a long term, chronic illness or disability.

These commenters asserted that HIPAA recognizes this nature of long term care insurance, observing that, with respect to HIPAA’s portability requirements, Congress enacted a series of exclusions for certain defined types of health plan arrangements that do not typically provide comprehensive coverage. They maintained that Congress recognized that long term care insurance is excluded, so long as it is not a part of a group health plan. Where a long term care policy is offered separately from a group health plan it is considered an excepted benefit and is not subject to the portability and guarantee issue requirements of HIPAA. Although this exception does not appear in the Administrative Simplification provisions of HIPAA, it was asserted that it is guidance with respect to the treatment of long term care insurance as a limited benefit coverage and not as coverage that is so “sufficiently comprehensive” that it is to be treated in the same manner as a typical, comprehensive major medical health plan arrangement.

Another commenter offered a different perspective observing that there are some long term care policies— that do not pay for medical care and therefore are not “health plans.” It was noted that most long-term care policies are reimbursement policies—that is,
they reimburse the policyholder for the actual expenses that the insured incurs for long-term care services. To the extent that these constitute "medical care," this commenter presumed that these policies would be considered "health plans." Other long-term care policies, they pointed out, simply pay a fixed dollar amount when the insured becomes chronically ill, without regard to the actual cost of any long-term care services received, and thus are similar to fixed indemnity critical illness policies. The commenter suggested that while there was an important distinction between indemnity based long-term care policies and expenses based long-term care policies, it may be wise to exclude all long-term care policies from the scope of the rule to achieve consistency with HIPAA.

Response: We disagree. The statutory language regarding long-term care policies in the portability title of HIPAA is different from the statutory language regarding long-term care policies in the Administrative Simplification title of HIPAA. Section 1171(5)(G) of the Act means that issuers of long-term care policies are considered health plans for purposes of administrative simplification. We also interpret the term "comprehensive" to refer to the breadth or scope of coverage of a policy. "Comprehensive" policies are those that cover a range of possible service options. These policies are defined as including health plans for the purposes of the HIPAA regulations. The Secretary, therefore, explicitly excluded nursing home fixed-indemnity policies, not all long-term care policies, from the definition of "health plan." We interpret the term "comprehensive" to mean that issuers of long-term care policies are considered health plans under this rule.

Comment: One commenter was concerned about the potential impact of the proposed regulations on "unfunded health plans," which the commenter described as programs used by smaller companies to provide their associates with special employee discounts or other membership incentives so that they can obtain health care, including prescription drugs, at reduced prices. The commenter asserted that if these discount and membership incentive programs were covered by the regulation, many smaller employers might discontinue offering them to their employees, rather than deal with the administrative burdens and costs of complying with the rule.

Response: Only those special employee discounts or membership incentives that are "employee welfare benefit plans" as defined in section 3(1) of the Employee Retirement Income Security Act of 1974, 29 U.S.C. 1002(1), and provide "medical care" (as defined in section 2791(a)(2) of the Public Health Service Act, 42 U.S.C. 300gg-91(a)(2)), are health plans for the purposes of this rule. Discount or membership incentive programs that are not group health plans are not covered by the rule.

Comment: Several commenters agreed with the proposal to exclude "excepted benefits" such as disability income insurance policies, fixed indemnity critical illness policies, and per diem long-term care policies from the definition of "health plan," but were concerned that the language of the proposed rule did not fully reflect this intent. They asserted that clarification was necessary in order to avoid confusion and costs to both consumers and insurers.

One commenter stated that, while HHS did not intend for the rule to apply to every type of insurance coverage that paid for medical care, the language of the proposed rule did not bear this out. The problem, it was asserted, is that under the proposed rule any insurance policy that pays for "medical care" would technically be a "health plan." It was argued that despite the statements in the narrative, there are no provisions that would exempt any of the "excepted benefits" from the definition of "health care." It was stated that:

Although (with the exception of long-term care insurance), the proposed rule does not include the 'excepted benefits' in its list of sixteen examples of a health plan (proposed 45 CFR 160.104), it does not explicitly exclude them either. Because these types of policies in some instances pay benefits that could be construed as payments for medical care, we are concerned by the fact that they are not explicitly excluded from the definition of 'health plan' or the requirements of the proposed rule.

Several commenters proposed that HHS adopt the same list of "excepted benefits" contained in 29 U.S.C. 1191b, suggesting that they could be adopted either as exceptions to the definition of "health plan" or as exceptions to the requirements imposed on "health plans." They asserted that this would promote consistency in the federal regulatory structure for health plans.

It was suggested that HHS clarify whether the definition of health plan, particularly the "group health plan" and "health insurance issuer" components, includes a disability plan or disability insurer. It was noted that a disability plan or disability insurer may cover only income lost from disability and, as mentioned above, some rehabilitation services, or a combination of lost income, rehabilitation services and medical care. The commenter suggested that in addressing this coverage issue, it may be useful to refer to the definitions of group health plan, health insurance issuer and medical care set forth in Part I of HIPAA, which the statutory provisions of the Administrative Simplification subtitle expressly reference. See 42 U.S.C. 1320d(5)(A) and (B).

Response: We agree that the NPRM may have been ambiguous regarding the types of plans the rule covers. To remedy this confusion, we have added language that specifically excludes from the definition any policy, plan, or program providing or paying the cost of the excepted benefits, as defined in section 2971(c)(1) of the PHS Act, 42 U.S.C. 300gg-91(c)(1). As defined in the statute, this includes but is not limited to benefits under one or more (or any combination thereof) of the following: coverage only for accident, or disability income insurance, or any combination thereof; liability insurance, including general liability insurance and automobile liability insurance; and workers' compensation or similar insurance.

However, the other excepted benefits as defined in section 2971(c)(2) of the PHS Act, 42 U.S.C. 300gg-91(c)(2), such as limited scope dental or vision benefits, not explicitly excepted from the regulation could be considered "health plans" under paragraph (1)(xvii) of the definition of "health plan" in the final rule if and to the extent that they meet the criteria for the definition of "health plan." Such plans, unlike the programs and plans listed at section 2971(c)(1), directly and exclusively provide health insurance, even if limited in scope.

Comment: One commenter recommended that the Secretary clarify that "health plan" does not include property and casualty benefit providers. The commenter stated that the clarifying language is needed given the "catchall" category of entities defined as "any other individual plan or group health plan, or combination thereof, that
providers or pays for the cost of medical care,” and asserted that absent clarification there could be serious confusion as to whether property and casualty benefit providers are “health plans” under the rule.

Response: We agree and as described above have added language to the final rule to clarify that the “excepted benefits” as defined under 42 U.S.C. 300gg–91(c)(1), which includes liability programs such as property and casualty benefit providers, are not health plans for the purposes of this rule.

Comment: Some commenters recommended that the Secretary replace the term “medical care” with “health care.” It was observed that “health care” was defined in the proposal, and that this definition was used to define what a health care provider does. However, they observed that the definition of “health plan” refers to insurance or broad-scope programs of care under a contract or statutory entitlement. However, paragraph (16) in this list opens the door to broader interpretation through the catchall phrase, “any other individual or group plan that provides or pays for the cost of medical care.” Commenters assert that clarification is needed.

Response: We agree with the first recommendation. We understand that the term “medical care” can be easily confused with the term “health care.” However, the two terms are not synonymous. The term “medical care” is a statutorily defined term and its use is critical in making a determination as to whether a health plan is considered a “health plan” for purposes of administrative simplification. In addition, since the term “medical care” is used in the regulation only in the context of the definition of “health plan” and we believe that its inclusion in the regulatory text may cause confusion, we did not add a definition of “medical care” in the final rule. However, consistent with the second recommendation above, the statutory cite for “medical care” was added to the definition of “health plan” in the Transactions Rule, and thus is reflected in this final rule.

Comment: A number of commenters urged that the Secretary define more narrowly what characteristics would make a government program that pays for specific health care services a “health plan.” Commenters argued that there are many “payment” programs that should not be included, as discussed below, and that if no distinctions were made, “health plan” would mean the same as “purchaser” or even “payer.”

Commenters asserted that there are a number of state programs that pay for “health care” (as defined in the rule) but that are not health plans. They said that examples include the WIC program (Special Supplemental Nutrition Program for Women, Infants, and Children) which pays for nutritional assessment and counseling, among other services; the AIDS Client Services Program (including AIDS prescription drug payment) under the federal Ryan White Care Act and state law; the distribution of federal family planning funds under Title X of the Public Health Services Act; and the breast and cervical health program which pays for cancer screening in targeted populations. Commenters argued that these are not insurance plans and do not fall within the “health plan” definition’s list of examples, all of which are either insurance or broad-scope programs of care under a contract or statutory entitlement. However, paragraph (16) in this list opens the door to broader interpretation through the catchall phrase, “any other individual or group plan that provides or pays for the cost of medical care.” Commenters assert that clarification is needed.

Response: We agree with the commenters that clarification is needed as to the rule’s application to government programs that pay for health care services. Accordingly, in the final rule we have excepted from the definition of “health plan” a government funded program which does not have as its principal purpose the provision of, or payment for, the cost of health care or which has as its principal purpose the provision, either directly or by grant, of health care. For example, the principal purpose of the WIC program is not to provide or pay for the cost of health care, and thus, the WIC program is not a health plan for purposes of this rule. The program of health care services for individuals detained by the INS provides health care directly, and so is not a health plan. Similarly, the family planning program authorized by Title X of the Public Health Service Act pays for care exclusively through grants, and so is not a health plan under this rule. These programs (the grantees under the Title X program) may be or include health care providers and may be covered entities if they conduct standard transactions.

We further clarify that, where a public program meets the definition of “health plan,” the government agency that administers the program is the covered entity. Where two agencies administer a program jointly, they are both a health plan. For example, both the Health Care Financing Administration and the insurers that offers a Medicare-Choice plan are “health plans” with respect to Medicare beneficiaries. An agency that does not administer a program but which provides services for such a program is not a covered entity by virtue of providing such services. Whether an agency providing services is a business associate of the covered entity depends on whether its functions for the covered entity meet the definition of business associate in §164.501 and, in the example described by this comment, in particular on whether the arrangement falls into the exception in §164.504(e)(1)(ii)(C) for government agencies that collect eligibility or enrollment information for covered government programs.

Comment: Some commenters expressed support for retaining the category in paragraph (16) of the proposal’s definition: “Any other individual or group health plan, or combination thereof, that provides or pays the cost of medical care.” Others asked that the Secretary clarify this category. One commenter urged that the final rule clearly define which plans would meet the criteria for this category.

Response: As described in the proposed rule, this category implements the language at the beginning of the statutory definition of the term “health plan”: “The term ‘health plan’ means an individual or group plan that provides, or pays the cost of, medical care * * * Such term includes the following, and any combination thereof * * *” This statutory language is general, not specific, and as such, we are leaving it general in the final rule. However, as described above, we add explicit language which excludes certain “excepted benefits” from the definition of “health plan” in an effort to clarify which plans are not health plans for the purposes of this rule. Therefore, to the extent that a certain benefits plan or program otherwise meets the definition of “health plan” and is not explicitly excepted, that program or plan is considered a “health plan” under paragraph (1)(xvii) of the final rule.

Comment: A commenter explained that HIPAA defines a group health plan by expressly crossing the statutory sections in the PHS Act and the Employee Retirement Income Security Act of 1974. The commenter requested that the Secretary provide a similar definition for the final rule. We disagree with the first comment and the commenter’s analysis. We do not believe that HIPAA provides a comprehensive definition of a health plan. This would be redundant, and would confuse the reader. We believe that the proposed rule correctly defines a health plan. With the addition of the clarification of the definition of “excepted benefits,” we believe that we have eliminated any possibility of confusion or misunderstanding.
Security Act of 1974 (ERISA), 29 U.S.C. 1001, et seq., which define the terms “group health plan,” “employee welfare benefit plan” and “participant.” See 29 U.S.C. 1002(1) (definition of “employee welfare benefit plan,” which is the core of the definition of group health plan under both ERISA and the PHS Act); 29 U.S.C. 100217) (definition of participant); 29 U.S.C. 1193(a) (definition of “group health plan,” which is identical to that in section 2791(a) of the PHS Act).

It was pointed out that the preamble and the text of the proposed rule both limit the definition of all three terms to their current definitions. The commenter reasoned that since the ERISA definitions may change over time through statutory amendment, Department of Labor regulations or judicial interpretation, it would not be clear what point in time is to be considered current. Therefore, they suggested deleting references to “current” or “currently” in the preamble and in the regulation with respect to these three ERISA definitions.

In addition, the commenter stated that as the preamble to the NPRM correctly reflected, HIPAA expressly cross-references ERISA’s definition of “participant” in section 3(7) of ERISA, 29 U.S.C. 1002(7). 42 U.S.C. 1320d(5)[A]. The text of the privacy regulation, however, omits this cross-reference. It was suggested that the reference to section 3(7) of ERISA, defining “participant,” be included in the regulation.

Finally, HIPAA incorporates the definition of a group health plan as set forth in section 2791(a) of the PHS Act, 42 U.S.C. 300gg–91(a)(l). That definition refers to the provision of medical care “directly or through insurance, reimbursement, or otherwise.” The word “reimbursement” is omitted in both the preamble and the text of the regulation; the commenter suggested restoring it to both.

Response: We agree. These changes were made to the definition of “health plan” as promulgated in the Transactions rule, and are reflected in this final rule.

Small Health Plan

Comment: One commenter recommended that we delete the reference to $5 million in the definition and instead define a “small health plan” as a health plan with fewer than 50 participants. It was stated that using a dollar limitation to define a “small health plan” is not meaningful for self-insured plans and some other types of health plan coverage arrangements. A commenter pointed out that the general definition of a health plan refers to “50 or more participants,” and that using a dollar factor to define a “small health plan” would be inconsistent with this definition.

Response: We disagree. The Small Business Administration (SBA) promulgates size standards that indicate the maximum number of employees or annual receipts allowed for an concern (13 CFR 121.105) and its affiliates to be considered “small.” The size standards themselves are expressed either in number of employees or annual receipts (13 CFR 121.201). The size standards for compliance with programs of other agencies are those for SBA programs which are most comparable to the programs of such other agencies, unless otherwise agreed by the agency and the SBA (13 CFR 121.902). With respect to the insurance industry, the SBA has specified that annual receipts of $5 million is the maximum allowed for a concern and its affiliates to be considered small (13 CFR 121.201). Consequently, we retain the proposal’s definition in the final rule to be consistent with SBA requirements.

We understand there may be some confusion as to the meaning of “annual receipts” when applied to a health plan. For our purposes, therefore, we consider “pure premiums” to be equivalent to “annual receipts.”

Workforce

Comment: Some commenters requested that we exclude “volunteers” from the definition of workforce. They stated that volunteers are important contributors within many covered entities, and in particular hospitals. They argued that it was unfair to ask that these people donate their time and at the same time subject them to the penalties placed upon the paid employees by these regulations, and that it would discourage people from volunteering in the health care setting.

Response: We disagree. We believe that differentiating those persons under the direct control of a covered entity who are paid from those who are not is irrelevant for the purposes of protecting the privacy of health information, and for a covered entity’s management of its workforce. In either case, the person is working for the covered entity. With regard to implications for the individual, persons in a covered entity’s workforce are not held personally liable for violating the standards or requirements of the final rule. Rather, the Secretary has the authority to impose penalties and in some cases criminal penalties for such violations on only the covered entity.

Comment: One commenter asked that the rule clarify that employees administering a group health or other employee welfare benefit plan on their employers’ behalf are considered part of the covered entity’s workforce.

Response: As long as the employees have been identified by the group health plan in plan documents as performing functions related to the group health plan (consistent with the requirements of § 164.504(f)), those employees may have access to protected health information. However, they are not permitted to use or disclose protected health information for employment-related purposes or in connection with any other employee benefit plan or employee benefit of the plan sponsor.

Part 160—Subpart B—Preemption of State Law

We summarize and respond below to comments received in the Transactions rulemaking on the issue of preemption, as well as those received on this topic in the Privacy rulemaking. Because no process was proposed in the Transactions rulemaking for granting exceptions under section 1178(a)(2)[A], a process for making exception determinations was not adopted in the Transactions Rule. Instead, since a process for making exception determinations was proposed in the Privacy rulemaking, we decided that the comments received in the Transactions rulemaking should be considered and addressed in conjunction with the comments received on the process proposed in the Privacy rulemaking. See 65 FR 50318 for a fuller discussion.

Accordingly, we discuss the preemption comments received in the Transactions rulemaking where relevant below.

Comment: The majority of comments on preemption addressed the subject in general terms. Numerous comments, particularly from plans and providers, argued that the proposed preemption provisions were burdensome, ineffective, or insufficient, and that complete federal preemption of the “patchwork” of state privacy laws is needed. They also argued that the proposed preemption provisions are likely to invite litigation. Various practical arguments in support of this position were made. Some of these comments recognized that the Secretary’s authority under section 1178 of the Act is limited and acknowledged that the Secretary’s proposals were within her statutory authority. One commenter suggested that the exception determination process would result in a very costly and laborious and sometimes inconsistent analysis of the occasions in which state law would
survive federal preemption, and thus suggested the final privacy regulations preempt state law with only limited exceptions, such as reporting child abuse. Many other comments, however, recommended changing the proposed preemption provisions to preempt state privacy laws on an as blanket a basis as possible.

One comment argued that the assumption that more stringent privacy laws are better is not necessarily true, citing a 1999 GAO report finding evidence that the stringent state confidentiality laws of Minnesota halted the collection of comparative information on health care quality.

Several comments in this vein were also received in the Transactions rulemaking. The majority of these comments took the position that exceptions to the federal standards should either be prohibited or discouraged. It was argued that granting exceptions to the standards, particularly the transactions standards, would be inconsistent with the statute’s objective of promoting administrative simplification through the use of uniform transactions.

Many other commenters, however, endorsed the “federal floor” approach of the proposed rules. (These comments were made in the context of the proposed privacy regulations.) These comments argued that this approach was preferable because it would not impair the effectiveness of state privacy laws that are more protective of privacy, while raising the protection afforded medical information in states that do not enact laws that are as protective as the rules below. Some comments argued, however, that the rules should give even more deference to state law, questioning in particular the definitions and the proposed addition to the “other purposes” criterion for exception determinations in this regard.

Response: With respect to the exception process provided for by section 1178(a)(2)(A), the contention that the HIPAA standards should uniformly control is an argument that should be addressed to the Congress, not this agency. Section 1178 of the Act expressly gives the Secretary authority to grant exceptions to the general rule that the HIPAA standards preempt contrary state law in the circumstances she determines come within the provisions at section 1178(a)(2)(A). We agree that the underlying statutory goal of standardizing financial and administrative health care transactions dictates that exceptions should be granted on narrow grounds.

Nonetheless, Congress clearly intended to accommodate some state laws in these areas, and the Department is not free to disregard this Congressional choice. As is more fully explained below, we have interpreted the statutory criteria for exceptions under section 1178(a)(2)(A) to balance the need for relative uniformity with respect to the HIPAA standards with state needs to set certain policies in the statutorily defined areas.

The situation is different with respect to state laws relating to the privacy of protected health information. Many of the comments arguing for uniform standards were particularly concerned with discrepancies between the federal privacy standards and various state privacy requirements. Unlike the situation with respect to the transactions standards, where states have generally not entered the field, all states regulate the privacy of some medical information to a greater or lesser extent. Thus, we understand the private sector’s concern at having to reconcile differing state and federal privacy requirements. This is, however, likewise an area where the policy choice has been made by Congress. Under section 1178(a)(2)(B) of the Act and section 264(c)(2) of HIPAA, provisions of state privacy laws that are contrary to and more stringent than the corresponding federal standard, requirement, or implementation specification are not preempted. The effect of these provisions is to let the law that is most protective of privacy control (the “federal floor” approach referred to by many commenters) and this policy choice is one with which we agree. Thus, the statute makes it impossible for the Secretary to accommodate the requests to establish uniformly controlling federal privacy standards, even if doing so were viewed as desirable.

Comment: Numerous comments stated support for the proposal at proposed Subpart B to issue advisory opinions with respect to the preemption of state laws relating to the privacy of individually identifiable health information. A number of these comments appeared to assume that the Secretary’s advisory opinions would be dispositive of the issue of whether or not a state law was preempted. Many of these commenters suggested what they saw as improvements to the proposed process, but supported the proposal to have the Department undertake this function.

Response: Despite the general support for the advisory opinion proposal, we decided not to specifically for the issuance of such opinions. The following considerations led to this decision. First, the assumption by commenters that an advisory opinion would establish what law applied in a given situation and thereby simplify the task of ascertaining what legal requirements apply to a covered entity or entities is incorrect. Any such opinion would be advisory only. Although an advisory opinion issued by the Department would indicate to covered entities how the Department would resolve the legal conflict in question and would apply the law in determining compliance, it would not bind the courts. While we assume that most courts would give such opinions deference, the outcome could not be guaranteed.

Second, the thousands of questions raised in the public comment about the interpretation, implications, and consequences of all of the proposed regulatory provisions have led us to conclude that significant advice and technical assistance about all of the regulatory requirements will have to be provided on an ongoing basis. We recognize that the preemption concerns that would have been addressed by the proposed advisory opinions were likely to be substantial. However, there is no reason to assume that they will be the most substantial or urgent of the questions that will most likely need to be addressed. It is our intent to provide as much technical advice and assistance to the regulated community as we can with the resources available. Our concern is that setting up an advisory opinion process for just one of the many types of issues that would have to be addressed will lead to a non-optimal allocation of those resources. Upon careful consideration, therefore, we have decided that we will be better able to prioritize our workload and be better able to be responsive to the most urgent and substantial questions raised to the Department, if we do not provide for a formal advisory opinion process on preemption as proposed.

Comment: A few commenters argued that the Privacy Rule should preempt state laws that would impose more stringent privacy requirements for the conduct of clinical trials. One commenter asserted that the existing federal regulations and guidelines for patient informed consent, together with the proposed rule, would adequately protect patient privacy.

Response: The Department does not have the statutory authority under HIPAA to preempt state laws that would impose more stringent privacy requirements on covered entities. HIPAA provides that the rules promulgated by the Secretary may not preempt state laws that are in conflict
Section 160.201—Applicability

Comment: Several commenters indicated that the guidance provided by the definitions at proposed § 160.202 would be of substantial benefit both to regulated entities and to the public. However, these commenters argued that the applicability of such definitions would be too limited as drafted, since proposed § 160.201 provided that the definitions applied only to
“determinations and advisory opinions issued by the Secretary pursuant to 42 U.S.C. 1320d–7.” The commenters stated that it would be far more helpful to make the definitions in proposed § 160.202 more broadly applicable, to provide general guidance on the issue of preemption.

Response: We agree with the comments on this issue, and have revised the applicability provision of subpart B below accordingly. Section 160.201 below sets out that Subpart B implements section 1178. This means, in our view, that the definitions of the statutory terms at § 160.202 are legislative rules that apply when those statutory terms are employed, whether by HHS, covered entities, or the courts.

Section 160.202—Definitions

Contrary

Comment: Some commenters asserted that term “contrary” as defined at § 160.202 was overly broad and that its application would be time-consuming and confusing for states. These commenters argued that, under the proposed definition, a state would be required to examine all of its laws relating to health information privacy in order to determine whether or not its law were contrary to the requirements proposed. It was also suggested that the definition contain examples of how it would work in practical terms.

A few commenters, however, argued that the definition of “contrary” as proposed was too narrow. One commenter argued that the Secretary erred in her assessment of the case law analyzing what is known as “conflict preemption” and which is set forth in shorthand in the tests set out at § 160.202.

Response: We believe that the definition proposed represents a policy that is as clear as is feasible and which can be applied nationally and uniformly. As was noted in the preamble to the proposed rules (at 64 FR 59997), the tests in the proposed definition of “contrary” are adopted from the jurisprudence of “conflict preemption.” Since preemption is a judicially developed doctrine, it is reasonable to interpret this term as indicating that the statutory analysis should tie in to the analytical formulations employed by the courts. Also, while the court-developed tests may not be as clear as commenters would like, they represent a long-term, thoughtful consideration of the problem of defining when a state/federal conflict exists. They will also, we assume, generally be employed by the courts when conflict issues arise under the rules below. We thus see no practical alternative to the proposed definition and have retained it unchanged. With respect to various suggestions for shorthand versions of the proposed tests, such as the arguably broader term “inconsistent with,” we see no operational advantages to such terms.

Comment: One comment urged the Department to take the position that if state law is not preempted, then the federal law would not also apply.

Response: This comment raises two issues, both of which deserve discussion. First, a state law may not be preempted because there is no conflict with the analogous federal requirement; in such a situation, both laws can, and must, be complied with. We thus do not accept this suggestion, to the extent that it suggests that the federal law would give way in this situation. Second, a state law may also not be preempted because it comes within section 1178(a)(2)(B), section 1178(b), or section 1178(c); in this situation, a contrary federal law will give way.

Comment: One comment urged the Department to consider that where state law exists and no analogous federal requirement exists, the state requirement would not be “contrary to” the federal requirement and would therefore not trigger preemption.

Response: We agree with this comment.

Comment: One commenter criticized the definition as unhelpful in the multi-state transaction context. For example, it was asked whether the issue of whether a state law was “contrary to” should be determined by the law of the state where the treatment is provided, where the claim processor is located, where the payment is issued, or the data maintained, assuming all are in different states.

Response: This is a choice of law issue, and, as is discussed more fully below, is a determination that is routinely made today in connection with multi-state transactions. See discussed in more detail under Exception Determinations (Criteria for Exception Determinations).

State Law

Comment: Comments noted that the definition of “state law” does not explicitly include common law and recommended that it be revised to do so or to clarify that the term includes evidentiary privileges recognized at state law. Guidance concerning the impact of state privileges was also requested.

Response: As requested, we clarify that the definition of “state law” includes common law by including the term “common law.” In our view, this phrase encompasses evidentiary privileges recognized at state law (which may also, we note, be embodied in state statutes).

Comment: One comment criticized this definition as unwieldy, in that locating state laws pertaining to privacy is likely to be difficult. It was noted that Florida, for example, has more than 60 statutes that address health privacy.

Response: To the extent that state laws currently apply to covered entities, they have presumably determined what those laws require in order to comply with them. Thus, while determining which laws are “contrary” to the federal requirements will require additional work in terms of comparing state law with the federal requirements, entities should already have acquired the knowledge of state law needed for this task in the ordinary course of doing business.

Comment: The New York City Department of Health noted that in many cases, provisions of New York State law are inapplicable within New York City, because the state legislature has recognized that the local code is tailored to the particular needs of the City. It urged that the New York City Code be treated as state law, for preemption purposes.

Response: We agree that, to the extent a state treats local law as substituting for state law it could be considered to be “state law” for purposes of this definition. If, however, a local law is local in scope and effect, and a tier of state law exists over the same subject matter, we do not think that the local law could or should be treated as “state law” for preemption purposes. We do not have sufficient information to assess the situation raised by this comment with respect to this principle, and so express no opinion thereon.

More Stringent

Comment: Many commenters supported the policy in the proposed definition of “individual” as proposed § 164.502, which would have permitted unemancipated minors to exercise, on
their own behalf. Rights granted to individuals in cases where they consent to the underlying health care. Commenters stated, however, that the proposed preemption provision would leave in place state laws authorizing or prohibiting disclosure to parents of the protected health information of their minor children and would negate the proposed policy for the treatment of minors under the rule. The comments stated that such state laws should be treated like other state laws, and preempted to the extent that they are less protective of the privacy of minors.

Other commenters supported the proposed preemption provision—not to preempt a state law to the extent it authorizes or prohibits disclosure of protected health information regarding a minor to a parent.

Response: Laws regarding access to health care for minors and confidentiality of their medical records vary widely; this regulation recognizes and respects the current diversity of state law in this area. Where states have considered the balance involved in protecting the confidentiality of minors' health information and have explicitly acted, for example, to authorize disclosure, defer the decision to disclose to the discretion of the health care provider, or prohibit disclosure of minor’s protected health information to a parent, the rule defers to these decisions to the extent that they regulate such disclosures.

Comment: The proposed definition of “more stringent” was criticized as affording too much latitude to granting exceptions for state laws that are not protective of privacy. It was suggested that the test should be “most protective of the individual’s privacy.”

Response: We considered adopting this test. However, for the reasons set out at 64 FR 59997, we concluded that this test would not provide sufficient guidance. The comments did not address the concerns we raised in this regard in the preamble to the proposed rules, and we continue to believe that they are valid.

Comment: A drug company expressed concern with what it saw as the expansive definition of this term, arguing that state governments may have less experience with the special needs of researchers than federal agencies and may unknowingly adopt laws that have a deleterious effect on research. A provider group expressed concern that allowing stronger state laws to prevail could result in diminished ability to get enough patients to complete high quality clinical trials.

Response: These concerns are fundamentally addressed to the “federal floor” approach of the statute, not to the definition proposed: even if the definition of “more stringent” were narrowed, these concerns would still exist. As discussed above, since the “federal floor” approach is statutory, it is not within the Secretary’s authority to change the dynamics that are of concern.

Comment: One comment stated that the proposed rule seemed to indicate that the “more stringent” and “contrary to” definitions implied that these standards would apply to ERISA plans as well as to non-ERISA plans.

Response: The concern underlying this comment is that ERISA plans, which are not now subject to certain state laws because of the “field” preemption provision of ERISA but which are subject to the rules below, will become subject to state privacy laws that are “more stringent” than the federal requirements, due to the operation of sections 1178(a)(2)(B) together with section 264(c)(2). We disagree that this is the case. While the courts will have the final say on these questions, it is our view that these sections simply leave in place more stringent state laws that would otherwise apply; to the extent that such state laws do not apply to ERISA plans because they are preempted by ERISA, we do not think that section 264(c)(2) overcomes the preemption effected by section 514(a) of ERISA. For more discussion of this point, see 64 FR 60001.

Comment: The Lieutenant Governor’s Office of the State of Hawaii requested a blanket exemption for Hawaii from the federal rules, on the ground that its recently enacted comprehensive health privacy law is, as a whole, more stringent than the proposed federal standards. It was suggested that, for example, special weight should be given to the severity of Hawaii’s penalties. It was suggested that a new definition (“comprehensive”) be added, and that “more stringent” be defined in that context as whether the state act or code as a whole provides greater protection.

An advocacy group in Vermont argued that the Vermont legislature was poised to enact stronger and more comprehensive privacy laws and stated that the group would resist a federal prohibition on that.

Response: The premise of these comments appears to be that the provision-by-provision approach of Subpart B, which is expressed in the definition of the term “contrary,” is wrong. As we explained in the preamble to the proposed rules (at 64 FR 59995), however, the statute dictates a provision-by-provision comparison of state and federal requirements, not the overall comparison suggested by these comments. We also note that the approach suggested would be practically and analytically problematic, in that it would be extremely difficult, if not impossible, to determine what is a legitimate stopping point for the provisions to be weighed on either the state side or the federal side of the scale in determining which set of laws was the “more stringent.” We accordingly do not accept the approach suggested by these comments.

With respect to the comment of the Vermont group, nothing in the rules below prohibits or places any limits on states enacting stronger or more comprehensive privacy laws. To the extent that states enact privacy laws that are stronger or more comprehensive than contrary federal requirements, they will presumably not be preempted under section 1178(a)(2)(B). To the extent that such state laws are not contrary to the federal requirements, they will act as an overlay on the federal requirements and will have effect.

Comment: One comment raised the issue of whether a private right of action is a greater penalty, since the proposed federal rule has no comparable remedy.

Response: We have reconsidered the proposed “penalty” provision of the proposed definition of “more stringent” and have eliminated it. The HIPAA statute provides for only two types of penalties: fines and imprisonment. Both types of penalties could be imposed in addition to the same type of penalty imposed by a state law, and should not interfere with the imposition of other types of penalties that may be available under state law. Thus, we think it is unlikely that there would be a conflict between state and federal law in this respect, so that the proposed criterion is unnecessary and confusing. In addition, the fact that a state law allows an individual to file a lawsuit to protect privacy does not conflict with the HIPAA penalty provisions.

Relates to the Privacy of Individually Identifiable Health Information

Comment: One comment criticized the definition of this term as too narrow in scope and too uncertain. The commenter argued that determining the specific purpose of a state law may be difficult and speculative, because many state laws have incomplete, inaccessible, or non-existent legislative histories. It was suggested that the definition be revising the word “specific” before the word “purpose.” Another commenter argued
that the definition of this term should be narrowed to minimize reverse preemption by more stringent state laws. One commenter generally supported the proposed definition of this term.

Response: We are not accepting the first comment. The purpose of a given state enactment should be ascertainable, if not from legislative history or a purpose statement, then from the statute viewed as a whole. The same should be true of state regulations or rulings. In any event, it seems appropriate to restrict the field of state laws that may potentially trump the federal standards to those that are clearly intended to establish state public policy and operate in the same area as the federal standards. To the extent that the definition in the rules below does this, we have accommodated the second comment. We note, however, that we do not agree that the definition should be further restricted to minimize “reverse preemption,” as suggested by this comment, as we believe that state laws that are more protective of privacy than contrary federal standards should remain, in order to ensure that the privacy of individuals’ health information receives the maximum legal protection available.

Sections 160.203 and 160.204—Exception Determinations and Advisory Opinions

Most of the comments received on proposed Subpart B lumped together the proposed process for exception determinations under section 1178(a)(2)(A) with the proposed process for issuing advisory opinions under section 1178(a)(2)(B), either because the substance of the comment applied to both processes or because the commenters did not draw a distinction between the two processes. We address these general comments in this section.

Comment: Numerous commenters, particularly providers and provider groups, recommended that exception determinations and advisory opinions not be limited to states and advocated allowing all covered entities (including individuals, providers and insurers), or private sector organizations, to request determinations and opinions with respect to preemption of state laws. Several commenters argued that limiting requests to states would deny third party stakeholders, such as life and disability income insurers, any means of resolving complex questions as to what rule they are subject to. One commenter noted that because it is an insurer who will be liable if it incorrectly analyzes the interplay between laws and reaches an incorrect conclusion, there would be little incentive for the states to request clarification. It would also cause large administrative burdens which, it was stated, would be costly and confusing. It was also suggested that the request for the exception be made to the applicable state’s attorney general or chief legal officer, as well as the Secretary. Various changes to the language were suggested, such as adding that “a covered entity, or any other entity impacted by this rule” be allowed to submit the written request.

Response: We agree, and have changed § 164.204(a) below accordingly. The decision to eliminate advisory opinions makes this issue moot with respect to those opinions. Comment: Several commenters noted that it was unclear under the proposed rule which state officials would be authorized to request a determination.

Response: We agree that the proposed rule was unclear in this respect. The final rule clarifies who may make the request for a state, with respect to exception determinations. See, § 160.204(a). The language adopted should ensure that the Secretary receives an authoritative statement from the state. At the same time, this language provides states with flexibility, in that the governor or other chief elected official may choose to designate other state officials to make such requests.

Comment: Many commenters recommended that a process be established whereby HHS performs an initial state-by-state critical analysis to provide guidance on which state laws will not be preempted; most suggested that such an analysis (alternatively referred to as a database or clearinghouse) should be completed before providers would be required to come into compliance. Many of these comments argued that the Secretary should bear the cost for the analyses of state law, disagreeing with the premise stated in the preamble to the proposed rules that it is more efficient for the private market to complete the state-by-state review. Several comments also requested that HHS continue to maintain and monitor the exception determination process, and update the database over time in order to provide guidance and certainty on the interaction of the federal rules with newly enacted or amended state laws that are produced after the final rule. Some comments recommended that each state be required to certify agreement with the IHS analyses.

In contrast, one hospital association noted that an analysis of state laws by health care attorneys in each jurisdiction would only be attempted by experienced health care attorneys in each jurisdiction. Response: These comments seem to be principally concerned with potential conflicts between state privacy laws and the privacy standards, because, as is more fully explained below, preemption of contrary state laws not relating to privacy is automatic unless the Secretary affirmatively acts under section 1178(a)(2)(A) to grant an exception. We recognize that the provisions of sections 1178(b) (state public health laws), and 1178(c) (state regulation of health plans) similarly preserve state laws in those areas, but very little of the public comment appeared to be concerned with these latter statutory provisions. Accordingly, we respond below to what we see as the commenters’ main concern.

The Department will not do the kind of global analysis requested by many of these comments. What these comments are in effect seeking is a global advisory opinion as to when the federal privacy standards will control and when they will not. We understand the desire for certainty underlying these comments. Nonetheless, the reasons set out above as the basis for our decision not to establish a formal advisory opinion process apply equally to these requests. We also do not agree that the task of evaluating the requirements below in light of existing state law is unduly burdensome or unreasonable. Rather, it is common for new federal requirements to necessitate an examination by the regulated entities of the interaction between existing state law and the federal requirements incident to coming into compliance.

We agree, however, that the case is different where the Secretary has affirmatively acted, either through granting an exception under section 1178(a)(2)(A) or by making a specific determination about the effect of a particular state privacy law in, for example, the course of determining an entity’s compliance with the privacy standards. As is discussed below, the Department intends to make notice of exception determinations that it makes routinely available. We do not agree with the comments suggesting that compliance by covered entities be delayed pending completion of an analysis by the Secretary and that states be required to certify agreement with the Secretary’s analysis, as we are not institutionalizing the advisory opinion/analysis process upon which these comments are predicated.
Furthermore, with respect to the suggestion regarding delaying the compliance date, Congress provided in section 1175(b) of the Act for a delay in when compliance is required to accommodate the needs of covered entities to address implementation issues such as those raised by these comments. With respect to the suggestion regarding requiring states to certify their agreement with the Secretary’s analysis, we have no authority to do this.

Comment: Several commenters criticized the proposed provision for annual publication of determinations and advisory opinions in the Federal Register as inadequate. They suggested that more frequent notices should be made and the regulation be changed accordingly, to provide for publication either quarterly or within a few days of a determination. A few commenters suggested that any determinations made, or opinions issued, by the Secretary be published on the Department’s website within 10 days or a few days of the determination or opinion.

Response: We agree that the proposed provision for annual publication was inadequate and have accordingly deleted it. Subpart B contains no express requirement for publication, as the Department is free to publish its determinations absent such a requirement. It is our intention to publish notice of exception determinations on a periodic basis in the Federal Register. We will also consider posting such decisions publicly available as we move into the implementation process.

Comment: A few commenters argued that the process for obtaining an exception determination or an advisory opinion from the Secretary will result in a period of time in which there is confusion as to whether state or federal law applies. The proposed regulations say that the federal provisions will remain effective until the Secretary makes a determination concerning the preemption issue. This means that, for example, a state law that was enacted and enforced for many years will be preempted by federal law for the period of time during which it takes the Secretary to make a determination. Then if the Secretary determines that the state law is not preempted, the state law will again become effective. Such situations will result in confusion and unintended violations of the law. One of the commenters suggested that requests for exceptions be required only when a challenge against a particular state law, and that a presumption of validity should lie with state laws.

Another commenter, however, urged that “instead of the presumption of preemption, the state laws in question would be presumed to be subject to the exception unless or until the Secretary makes a determination to the contrary.”

Response: It is true that the effect of section 1178(a)(2)(A) is that the federal standards will preempt contrary state law and that such preemption will not be removed unless and until the Secretary acts to grant an exception under that section (assuming, of course, that another provision of section 1178 does not apply). We do not agree, however, that confusion should result, where the issue is whether a given state law has been preempted under section 1178(a)(2)(A). Because preemption is automatic with respect to state laws that do not come within the other provisions of section 1178 (i.e., sections 1178(a)(2)(B), 1178(b), and 1178(c)), such state laws are preempted until the Secretary affirmatively acts to preserve them from preemption by granting an exception under section 1178(a)(2)(A).

Comment: Several comments recommended that exception determinations or advisory opinions encompass a state act or code in its entirety (in lieu of a provision-specific evaluation) if it is considered more stringent as a whole than the regulation. It was argued that since the provisions of a given law are typically interconnected and related, adopting or overriding them on a provision-by-provision basis would result in distortions and/or unintended consequences or loopholes. For example, when a state law includes authorization provisions, some of which are consistent with the federal requirements and some which are not, the cleanest approach is to view the state law as inconsistent with the federal requirements and thus preempted in its entirety. Similarly, another comment suggested that state confidentiality laws written to address the specific needs of individuals served within a discreet system of care be considered as a whole in assessing whether they are as stringent or more stringent than the federal requirements. Another comment requested explicit clarification that state laws with a broader scope than the regulation will be viewed as more stringent and be allowed to stand.

Response: We have not adopted the approaches suggested by these comments. As discussed above with respect to the definition of the term “more stringent,” it is our view that the statute precludes the approach suggested. We also suggest that this approach ignores the fact that each separate provision of law usually represents a nuanced policy choice to, for example, permit this use or prohibit that disclosure; the aggregated approach proposed would fail to recognize and weigh such policy choices.

Comment: One comment recommended that the final rule: permit requests for exception determinations and advisory opinions as of the date of publication of the final rule, require the Secretary to notify the requestor within a specified short period of time of all additional information needed, and prohibit enforcement action until the Secretary issues a response.

Response: With respect to the first recommendation, we clarify that requests for exception determinations may be made at any time; since the process for issuing advisory opinions has not been adopted, this recommendation is moot as it pertains
to advisory opinions. With respect to the second recommendation, we will undertake to process exception requests as expeditiously as possible, but, for the reasons discussed below in connection with the comments relating to setting deadlines for those determinations, we cannot commit at this time to a “specified short period of time” within which the Secretary may request additional information. We see no reason to agree to the third recommendation. Because contrary state laws for which an exception is available only under section 1178(a)(2)(A) will be preempted by operation of law unless and until the Secretary acts to grant an exception, there will be an ascertainable compliance standard for compliance purposes, and enforcement action would be appropriate where such compliance did not occur.

Sections 160.203(a) and 160.204(a) — Exception Determinations

Section 160.203(a) — Criteria for Exception Determinations

Comment: Numerous comments criticized the proposed criteria for their substance or lack thereof. A number of commenters argued that the effectiveness language that was added to the third statutory criterion made the exception so massive that it would swallow the rule. These comments generally expressed concern that laws that were less protective of privacy would be granted exceptions under this language. Other commenters criticized the criteria generally as creating a large loophole that would let state laws that do not protect privacy trump the federal privacy standards.

Response: We agree with these comments. The scope of the statutory criteria is ambiguous, but they could be read so broadly as to largely swallow the federal protections. We do not think that this was Congress’s intent. Accordingly, we have added language to most of the statutory criteria clarifying their scope. With respect to the criteria at 1178(a)(2)(A)(i), this clarifying language generally ties the criteria more specifically to the concern with protecting and making more efficient the health care delivery and payment system that underlies the Administrative Simplification provisions of HIPAA, but, with respect to the catch-all provision at section 1178(a)(2)(A)(ii), also requires that privacy interests be balanced with such concerns, to the extent relevant. We require that exceptions for rules to ensure appropriate state regulation of insurance and health plans be stated in a statute or regulation, so that such exceptions will be clearly tied to statements of priorities made by publicly accountable bodies (e.g., through the public comment process for regulations, and by elected officials through statutes). With respect to the criterion at section 1178(a)(2)(A)(ii), we have further delineated what “addresses controlled substances” means. The language provided, which builds on concepts at 21 U.S.C. 821 and the Medicare regulations at 42 CFR 1001.2, delineates the area within which the government traditionally regulates controlled substances, both civilly and criminally; it is our view that HIPAA was not intended to displace such regulation.

Comment: Several commenters urged that the request for determination by the Secretary under proposed § 160.204(a) be limited to cases where an exception is absolutely necessary, and that in making such a determination, the Secretary should be required to make a determination that the benefits of granting an exception outweigh the potential harm and risk of disclosure in violation of the regulation.

Response: We have not further defined the statutory term “necessary”, as requested. We believe that the determination of what is “necessary” will be fact-specific and context dependent, and should not be further circumscribed absent such specifics. The state will need to make its case that the state law in question is sufficiently “necessary” to accomplish the particular statutory goal for exception that will trump the contrary federal standard, requirement, or implementation specification.

Comment: One commenter noted that a state should be required to explain whether it has taken any action to correct any less stringent state law for which an exception has been requested. This commenter recommended that a section be added to proposed § 160.204(a) stating that “a state must specify what, if any, action has been taken to amend the state law to comply with the federal regulations.” Another comment, received in the Transactions rulemaking, took the position that exception determinations should be granted only if the state standards in question exceeded the national standards.

Response: The first and last comments appear to confuse the “more stringent” criterion that applies under section 1178(a)(2)(B) of the Act with the criteria that apply to exceptions under section 1178(a)(2)(A). We are also not adopting the language suggested by the first comment, because we do not agree that states should necessarily have to try to amend their state laws as a precondition to requesting exceptions under section 1178(a)(2)(A). Rather, the question should be whether the state has made a convincing case that the state law in question is sufficiently necessary for one of the statutory purposes that it should trump the contrary federal policy.

Comment: One commenter stated that exceptions for state laws that are contrary to the federal standards should not be preempted where the state and federal standards are found to be equal.

Response: This suggestion has not been adopted, as it is not consistent with the statute. With respect to the administrative simplification standards in general, it is clear that the intent of Congress was to preempt contrary state laws except in the limited areas specified as exceptions or carve-outs. See, section 1178. This statutory approach is consistent with the underlying goal of simplifying health care transactions through the adoption of uniform national standards. Even with respect to state laws relating to the privacy of medical information, the statute shields such state laws from preemption by the federal standards only if they are “more” stringent than the related federal standard or implementation specification.

Comment: One commenter noted that determinations would apply only to transactions that are wholly intrastate. Thus, any element of a health care transaction that would implicate more than one state’s law would automatically preclude the Secretary’s evaluation as to whether the laws were more or less stringent than the federal requirement. Other commenters expressed confusion about this proposed requirement, noting that providers and plans operate now in a multi-state environment.

Response: We agree with the commenters and have dropped the proposed requirement. As noted by the commenters, health care entities now typically operate in a multi-state environment, so already make the choice of law judgements that are necessary in multi-state transactions. It is the result of that calculus that will have to be weighed against the federal standards, requirements, and implementation specifications in the preemption analysis.

Comment: One comment received in the Transactions rulemaking suggested that the Department should allow exceptions to the standard transactions to accommodate abbreviated transactions between multi-agencies, such as claims between a public health department and the state Medicaid
agency. Another comment requested an exception for Home and Community Based Waiver Services from the transactions standards.

Response: The concerns raised by these comments would seem to be more properly addressed through the process established for maintaining and modifying the transactions standards. If the concerns underlying these comments cannot be addressed in this manner, however, there is nothing in the rules below to preclude states from requesting exceptions in such cases. They will then have to make the case that one or more grounds for exception applies.

Section 160.204(a)—Process for Exception Determinations—Comments and Responses

Comment: Several comments received in the Transactions rulemaking stated that the process for applying for and granting exception determinations (referred to as “waivers” by some) needed to be spelled out in the final rule.

Response: We agree with these comments. As noted above, since no process was proposed in the Transactions rulemaking, a process for making exception determinations was not adopted in those final rules. Subpart B below adopts a process for making exception determinations, which responds to these comments.

Comment: Comments stated that the exception process would be burdensome, unyieldy, and time-consuming for state agencies as well as the Department. One comment took the position that states should not be required to submit exception requests to the Department under proposed § 160.203(a), but could provide documentation that the state law meets one of the conditions articulated in proposed § 160.203.

Response: We disagree that the process adopted at § 164.204 below will be burdensome, unyieldy, or time-consuming. The only thing the regulation describes is the showings that a requestor must make as part of its submission, and all are relevant to the issue to be determined by the Secretary. How much information is submitted is, generally speaking, in the requestor’s control, and the regulation places no restrictions on how the requestor obtains it, whether by acting directly, by working with providers and/or plans, or by working with others. With respect to the suggestion that states not be required to submit exception requests, we disagree that this suggestion is either statutorily authorized or advisable. We read this comment as implicitly suggesting that the Secretary must proactively identify instances of conflict and evaluate them. This suggestion is, thus, at bottom the same as the many suggestions that we create a database or compendium of controlling law, and it is rejected for the same reasons.

Comment: Several comments urged that all state requests for non-preemption include a process for public participation. These comments believe that members of the public and other interested stakeholders should be allowed to submit comments on a state’s request for exception, and that these comments should be reviewed and considered by the Secretary in determining whether the exception should be granted. One comment suggested that the Secretary at least give notice to the citizens of the state prior to granting an exception.

Response: The revision to § 160.204(a), to permit requests for exception determinations by any person, responds to these comments.

Comment: Many commenters noted that the lack of a clear and reasonable time line for the Secretary to issue an exception determination would not provide sufficient assurance that the questions regarding what rules apply will be resolved in a time frame that will allow business to be conducted properly, and argued that this would increase confusion and uncertainty about which statutes and regulations should be followed. Timeframes of 60 or 90 days were suggested. One group suggested that, if a state does not receive a response from HHS within 60 days, the waiver should be deemed approved.

Response: The workload prioritization and management considerations discussed above with respect to advisory opinions are also relevant here and make us reluctant to agree to a deadline for making exception determinations. This is particularly true at the outset, since we have no experience with such requests. We therefore have no basis for determining how long processing such requests will take, how many requests we will need to process, or what resources will be available for such processing. We agree that states and other requesters should receive timely responses and will make every effort to make determinations as expeditiously as possible, but we cannot commit to firm deadlines in this initial rule. Once we have experience in handling exception requests, we will consult with states and others in regard to their experiences and concerns and their suggestions for improving the Secretary’s expeditious handling of such requests.

We are not accepting the suggestion that requests for exception be deemed approved if not acted upon in some defined time period. Section 1178(a)(2)(A) requires a specific determination by the Secretary. The suggested policy would not be consistent with this statutory requirement. It is also inadvisable from a policy standpoint, in that it would tend to maximize exceptions. This would be contrary to the underlying statutory policy in favor of uniform federal standards.

Comment: One commenter took exception to the requirement for states to seek a determination from the Department that a provision of state law is necessary to prevent fraud and abuse or to ensure appropriate state regulation of insurance plans, contending that this mandate could interfere with the Insurance Commissioners’ ability to do their jobs. Another commenter suggested that the regulation specifically recognize the broad scope of state insurance department activities, such as market conduct examinations, enforcement investigations, and consumer complaint handling.

Response: The first comment raises an issue that lies outside our legal authority to address, as section 1178(a)(2)(A) clearly mandates that the Secretary make a determination in these areas. With respect to the second comment, to the extent these concerns pertain to health plans, we believe that the provisions at § 164.512 relating to oversight and disclosures required by law should address the concerns underlying this comment.

Section 160.204(a)(4)—Period of Effectiveness of Exception Determinations

Comment: Numerous commenters stated that the proposed three year limitation on the effectiveness of exception determinations would pose significant problems and should be limited to one year, since a one year limitation would provide more frequent review of the necessity for exceptions. The commenters expressed concern that state laws which provide less privacy protection than the federal regulation would be given exceptions by the Secretary and thus argued that the exceptions should be more limited in duration or that the Secretary should require that each request, regardless of duration, include a description of the length of time such an exception would be needed.

One state government commenter, however, argued that the 3 year limit should be eliminated entirely, on the ground that requiring a redetermination
every three years would be burdensome for the states and be a waste of time and resources for all parties. Other commenters, including two state agencies, suggested that the exemption should remain effective until either the state law or the federal regulation is changed. Another commenter suggested that the three-year sunset be deleted and that the final rule provide for automatic review to determine if changes in circumstance or law would necessitate amendment or deletion of the opinion. Other recommendations included deeming the state law as continuing in effect upon the submission of a state application for an exemption rather than waiting for a determination by the Secretary that may not occur for a substantial period of time.

Response: We are persuaded that the proposed 3-year limit on exception determinations does not make sense where neither law providing the basis for the exception has changed in the interim. We also agree that where either law has changed, a previously granted exception should not continue. Section 160.205(a) below addresses these concerns.

Sections 160.203(b) and 160.204(b)—Advisory Opinions

Section 160.203(b)—Effect of Advisory Opinions

Comment: Several commenters questioned whether or not DHHS has standing to issue binding advisory opinions and recommended that the Department clarify this issue before implementation of this regulation. One respondent suggested that the Department clarify in the final rule the legal issue on which it will opine in advisory opinion requests, and state that in responding to requests for advisory opinions the Department will not opine on the preemptive force of ERISA with respect to state laws governing the privacy of individually identifiable health information, since interpretations as to the scope and extent of ERISA’s preemption provisions are outside of the Department’s jurisdictional authority.

One commenter asked whether a state could enforce a state law which the Secretary had indicated through an advisory opinion is preempted by federal law. This commenter also asked whether the state would be subject to penalties if it chose to continue to enforce its own law.

Response: As discussed above, in part for reasons raised by these comments, the Department has decided not to have a formal process for issuing advisory opinions, as proposed.

Several of these concerns, however, raise issues of broader concern that need to be addressed. First, we disagree that the Secretary lacks legal authority to opine on whether or not state privacy laws are preempted. The Secretary is charged by law with determining compliance, and where state law and the federal requirements conflict, a determination of which law controls will have to be made in order to determine whether the federal standard, requirement, or implementation specification at issue has been violated. Thus, the Secretary cannot carry out her enforcement functions without making such determinations. It is further reasonable that, if the Secretary makes such determinations, she can make those determinations known, for whatever persuasive effect they may have.

The questions as to whether a state could enforce, or would be subject to penalties if it chose to continue to enforce, its own laws following a denial by the Secretary of an advisory request under §160.203 or a holding by a court of competent jurisdiction that a state privacy law had been preempted by a contrary federal privacy standard raise several issues. First, a state law is preempted under the Act only to the extent that it applies to covered entities; thus, a state is free to continue to enforce a “preempted” state law against non-covered entities to which the state law applies. If there is a question of coverage, states may wish to establish processes to ascertain which entities within their borders are covered entities within the meaning of these rules. Second, with respect to covered entities, if a state were to try to enforce a preempted state law against such entities, it would presumably be acting without legal authority in so doing. We cannot speak to what remedies might be available to covered entities to protect themselves against such wrongful state action, but we assume that covered entities could seek judicial relief, if all else failed. With respect to the issue of imposing penalties on states, we do not see this as likely. The only situation that we can envision in which penalties might be imposed on a state would be if a state agency were itself a covered entity and followed a preempted state law, thereby violating the contrary federal standard, requirement, or implementation specification.

Section 160.204(b)—Process for Advisory Opinions

Comment: Several commenters stated that it was unclear whether a state should be required to submit a request for an advisory opinion in order for the law to be considered more stringent and thus not preempted. The Department should clarify whether a state law could be non-preempted even without such an advisory opinion. Another commenter requested that the final rule explicitly state that the stricter rule always applies, whether it be state or federal, and regardless of whether there is any conflict between state and federal law.

Response: The elimination of the proposed process for advisory opinions renders moot the first question. Also, the preceding response clarifies that which law preempts in the privacy context (assuming that the state law and federal requirement are “contrary”) is a matter of which one is the “more stringent.” This is not a matter which the Secretary will ultimately determine; rather, this is a question about which the courts will ultimately make the final determination. With respect to the second comment, we believe that §160.203(b) below responds to this issue, but we would note that the statute already provides for this.

Comment: Several commenters supported the decision to limit the parties who may request advisory opinions to the state. These commenters did not believe that insurers should be allowed to request an advisory opinion and open every state law up to challenge and review.

Several commenters requested that guidance on advisory opinions be provided in all circumstances, not only at the Secretary’s discretion. It was suggested that proposed §160.204(b)(2)(iv) be revised to read as follows: “A state may submit a written request to the Secretary for an advisory opinion under this paragraph. The Secretary will make the final determination. With respect to the issue of imposing penalties on states, we do not see this as likely. The only situation that we can envision in which penalties might be imposed on a state would be if a state agency were itself a covered entity and followed a preempted state law, thereby violating the contrary federal standard, requirement, or implementation specification, including how the state law meets the criteria at §160.203(b).”

Response: The decision not to have a formal process for issuing advisory opinions renders these issues moot.

Sections 160.203(c) and 160.203(d)—Statutory Carve-Outs

Comment: Several commenters asked that the Department provide more specific examples itemizing activities traditionally regulated by the state that could constitute “carve-out” exceptions. These commenters also requested that the Department include language in the regulation stating that if a state law falls within several different exceptions, the state chooses which determination exception shall apply.
Response: We are concerned that itemizing examples in this way could leave out important state laws or create inadvertent negative implications that laws not listed are not included. However, as explained above, we have designed the types of activities that are permissible disclosures for public health under § 164.512(b) below in part to come within the carve-out effected by section 1178(b); while the state regulatory activities covered by section 1178(c) will generally come within § 164.512(d) below. With respect to the comments asking that a state get to “choose” which exception it comes under, we have in effect provided for this with respect to exceptions under section 1178(a)(2)(A), by giving the state the right to request an exception under that section. With respect to exceptions under section 1178(a)(2)(B), those exceptions occur by operation of law, and it is not within the Secretary’s power to “let” the state choose whether an exception occurs under that section.

Comment: Several commenters took the position that the Secretary should not limit the procedural requirements in proposed § 160.204(a) to only those applications under proposed § 160.203(a). They urged that the requirements of proposed § 160.204(a) should also apply to preemption under sections 1178(a)(2)(B), 1178(b) and 1178(c). It was suggested that the rules should provide for exception determinations with respect to the matters covered by these provisions of the statute; such additional provisions would provide clear procedures for states to follow and ensure that requests for exceptions are adequately documented.

A slightly different approach was taken by several commenters, who recommended that proposed § 160.204(b) be amended to clarify that the Secretary will also issue advisory opinions as to whether a state law constitutes an exception under proposed §§ 160.203(c) and 160.203(d). This change would, they argued, give states the same opportunity for guidance that they have under § 160.203(a) and (b), and as such, avoid costly lawsuits to preserve state laws.

Response: We are not taking either of the recommended courses of action. With respect to the recommendation that we expand the exception determination process to encompass exceptions under sections 1178(a)(2)(B), 1178(b), and 1178(c), we do not have the authority to grant exceptions under these sections. Under section 1178, the Secretary has authority to make exception determinations only with respect to the matters covered by section 1178(a)(2)[A]; contrary state laws coming within section 1178(a)(2)[B] are preempted if not more stringent, while if a contrary state law comes within section 1178(b) or section 1178(c), it is not preempted. These latter statutory provisions operate by their own terms. Thus, it is not within the Secretary’s authority to establish the determination process which these comments seek.

With respect to the request seeking advisory opinions in the section 1178(b) and 1178(c) situations, we agree that we have the authority to issue such opinions. However, the considerations described above that have led us not to adopt a formal process for issuing advisory opinions in the privacy context apply with equal force and effect here.

Comment: One commenter argued that it would be unnecessarily burdensome for state health data agencies (whose focus is on the cost of healthcare or improving Medicare/Medicaid, or the healthcare system) to obtain a specific determination from the Department for an exception under proposed § 160.203(c). States should be required only to notify the Secretary of their own determination that such collection is necessary. It was also argued that cases where the statutory carve-outs apply should not require a Secretarial determination.

Response: We clarify that no Secretarial determination is required for activities that fall into one of the statutory carve-outs. With respect to data collections for state health data agencies, we note that provision has been made for many of these activities in several provisions of the rules below, such as the provisions relating to disclosures required by law (§ 164.512(a)), disclosures for oversight (§ 164.512(d)), and disclosures for public health (§ 164.512(b)). Some disclosures for Medicare and Medicaid purposes may also come within the definition of health care operations. A fuller discussion of this issue appears in connection with § 164.512 below.

Constitutional Comments and Responses

Comment: Several commenters suggested that as a general matter the rule is unconstitutional.

Response: We disagree. The particular grounds for this conclusion are set out with respect to particular constitutional issues in the responses below. With respect to the comments that simply made this general assertion, the lack of detail of the comments makes a substantive response impossible.

Article II

Comment: One commenter contended that the Secretary improperly delegated authority to private entities by requiring covered entities to enter into contracts with, monitor, and take action for violations of the contract against their business partners. These comments assert that the selection of these entities to “enforce” the regulations violates the Executive Powers Clause and the Appointments and Take Care Clauses.

Response: We reject the assertion that the business associate provisions constitute an improper delegation of executive power to private entities. HIPAA provides HHS with authority to enforce the regulation against covered entities. The rules below regulate only the conduct of the covered entity; to the extent a covered entity chooses to conduct its funding through a business associate, those functions are still functions of the covered entity. Thus, no improper delegation has occurred because what is being regulated are the actions of the covered entity, not the actions of the business associate in its independent capacity.

We also reject the suggestion that the business associates provisions constitute an improper appointment of covered entities to enforce the regulation and violate the Take Care Clause. Because the Secretary has not delegated authority to covered entities, the inference that she has appointed covered entities to exercise such authority misses the mark.

Commerce Clause

Comment: A few commenters suggested that the privacy regulation regulates activities that are not in interstate commerce and which are, therefore, beyond the powers the U.S. Constitution gives the federal government.

Response: We disagree. Health care providers, health plans, and health care clearinghouses are engaged in economic and commercial activities, including the exchange of individually identifiable health information electronically across state lines. These activities constitute interstate commerce. Therefore, they come within the scope of Congress’ power to regulate interstate commerce.

Nondelegation Doctrine

Comment: Some commenters objected to the manner by which Congress provided the Secretary authority to promulgate this regulation. These comments asserted that Congress violated the nondelegation doctrine by (1) not providing an “intelligible principle” to guide the agency, (2) not
establishing “ascertainable standards,” and (3) improperly permitting the Secretary to make social policy decisions.

Response: We disagree. HIPAA clearly delineates Congress’ general policy to establish strict privacy protections for individually identifiable health information to encourage electronic transactions. Congress also established boundaries limiting the Secretary’s authority. Congress established these limitations in several ways, including by calling for privacy standards for “individually identifiable health information”; specifying that privacy standards must address individuals’ rights regarding their individually identifiable health information, the procedures for exercising those rights, and the particular uses and disclosures to be authorized or required; restricting the direct application of the privacy standards to “covered entities,” which Congress defined; requiring consultation with the National Committee on Vital and Health Statistics and the Attorney General; specifying the circumstances under which the federal requirements would supersede state laws; and specifying the civil and criminal penalties the Secretary could impose for violations of the regulation. These limitations also serve as “ascertainable standards” upon which reviewing courts can rely to determine the validity of the exercise of authority.

Although Congress could have chosen to impose expressly an exhaustive list of specifications that must be met in order to achieve the protective purposes of HIPAA, it was entirely permissible for Congress to entrust to the Secretary the task of providing these specifications based on her experience and expertise in dealing with these complex and technical matters.

We disagree with the comments that Congress improperly delegated Congressional policy choices to her. Congress clearly decided to create federal standards protecting the privacy of “individually identifiable health information” and not to preempt state laws that are more stringent. Congress also determined over whom the Secretary would have authority, the type of information protected, and the minimum level of regulation.

Separation of Powers

Comment: Some commenters asserted that the federal government may not preempt state laws that are not as strict as the privacy regulation because to do so would violate the separation of powers in the U.S. Constitution. One comment suggested that the rules raised a substantial constitutional issue because, as proposed, they permitted the Secretary to make determinations on preemption, which is a role reserved for the judiciary.

Response: We disagree. We note that this comment only pertains to determinations under section 1178(a)(2)(A); as discussed above, the rules below provide for no Secretarial determinations with respect to state privacy laws coming within section 1178(a)(2)(B). With respect to determinations under section 1178(a)(2)(A), however, the final rules, like the proposed rules, provide that at a state’s request the Secretary may make certain determinations regarding the preemptive effect of the rules on a particular state law. As usually the case with any administrative decisions, these are subject to judicial review pursuant to the Administrative Procedure Act.

First Amendment

Comment: Some comments suggested that the rules violated the First Amendment. They asserted that if the rule included Christian Science practitioners as covered entities it would violate the separation of church and state doctrine.

Response: We disagree. The First Amendment does not always prohibit the federal government from regulating secular activities of religious organizations. However, we address concerns relating to Christian Science practitioners more fully in the response to comments discussion of the definition of “covered entity” in § 160.103.

Fourth Amendment

Comment: Many comments expressed Fourth Amendment concerns about various proposed provisions. These comments fall into two categories—general concerns about warrantless searches and specific concerns about administrative searches. Several comments argued that the proposed regulations permit law enforcement and government officials access to protected health information without first requiring a judicial search warrant or an individual’s consent. These comments rejected the applicability of any of the existing exceptions permitting warrantless searches in this context. Another comment argued that federal and state police should be able to obtain personal medical records only with the informed consent of an individual.

Response: We disagree that the provisions of these rules that permit disclosures for law enforcement purposes and governmental health data systems generally violate the Fourth Amendment. The privacy regulation does not create new access rights for law enforcement. Rather, it refrains from placing a significant barrier in front of access rights that law enforcement currently has under existing legal authority. While the regulation may permit a covered entity to make disclosures in specified instances, it does not require the covered entity to make the disclosure. Thus, because we are not modifying existing law regarding disclosures to law enforcement officials, except to strengthen the requirements related to requests already authorized under law, and are not requiring any such disclosures, the privacy regulation does not infringe upon individual’s Fourth Amendment rights. We discuss the rationale underlying the permissible disclosures to law enforcement officials more fully in the preamble discussion relating to § 164.512(f).

We note that the proposed provision relating to disclosures to government health data systems has been eliminated in the final rule. However, to the extent that the comments can be seen as raising concern over disclosure of protected health information to government agencies for public health, health oversight, or other purposes permitted by the final rule, the reasoning in the previous paragraph applies.

Comment: One commenter suggested that the rules violate the Fourth Amendment by requiring covered entities to provide access to the Secretary to their books, records, accounts, and facilities to ensure compliance with these rules. The commenter also suggested that the requirement that covered entities enter into agreements with their business partners to make their records available to the Secretary for inspection as well also violates the warrant requirement of the Fourth Amendment.

Response: We disagree. These requirements are consistent with U.S. Supreme Court cases holding that warrantless administrative searches of commercial property are not per se violations of the Fourth Amendment. The provisions requiring that covered entities provide access to certain material to determine compliance with the regulation come within the well-settled exception regarding closely regulated businesses and industries to the warrant requirement. From state and local licensure laws to the Federal Fraud Abuse Statutes and regulations, the health care industry is one of the most...
tightly regulated businesses in the country. Because the industry has such an extensive history of government oversight and involvement, those operating within it have no reasonable expectation of privacy from the government such that a warrant would be required to determine compliance with the rules.

In addition, the cases cited by the commenters concern unannounced searches of the premises and facilities of particular entities. Because our enforcement provisions only provide for the review of books, records, and other information and only during normal business hours with notice, except for exceptional situations, this case law does not apply.

As for business associates, they voluntarily enter into their agreements with covered entities. This agreement, therefore, functions as knowing and voluntary consents to the search (even assuming it could be understood to be a search) and obviates the need for a warrant.

Fifth Amendment

Comment: Several comments asserted that the proposed rules violated the Fifth Amendment because in the commenters’ views they authorized the taking of privacy property without just compensation or due process of law.

Response: We disagree. The rules set forth below do not address the issue of who owns an individual’s medical record. Instead, they address what uses and disclosures of protected health information may be made by covered entities with or without a consent or authorization. As described in response to a similar comment, medical records have been the property of the health care provider or medical facility that created them, historically. In some states, statutes directly provide these entities with ownership. These laws are limited by laws that provide patients or their representatives with access to the records or that provide the patient with an ownership interest in the information within the records. As we discuss, the final rule is consistent with current state law that provides patients access to protected health information, but not ownership of medical records. State laws that provide patients with greater access would remain in effect.

Therefore, because patients do not own their records, no taking can occur. As for their interest in the information, the final rule retains their rights. As for covered entities, the final rule does not take away their ownership rights or make their ownership interest in the protected health information worthless.

Ninth and Tenth Amendments

Comment: Several comments asserted that the proposed rules violated the Ninth and Tenth Amendments. One commenter suggested that the Ninth Amendment prohibits long and complicated regulations. Other commenters suggested that the proposed rules authorized the compelled disclosure of individually identifiable health information in violation of State constitutional provisions, such as those in California and Florida. Similarly, a couple of commenters asserted that the privacy rules violate the Tenth Amendment.

Response: We disagree. The Ninth and Tenth Amendments address the rights retained by the people and acknowledge that the States or the people are reserved the powers not delegated to the federal government and not otherwise prohibited by the Constitution. Because HHS is regulating under a delegation of authority from Congress in an area that affects interstate commerce, we are within the powers provided to Congress in the Constitution. Nothing in the Ninth Amendment, or any other provision of the Constitution, restricts the length or complexity of any law. Additionally, we do not believe the rules below impermissibly authorize behavior that violates State constitutions. This rule requires disclosure only to the individual or to the Secretary to enforce this rule. A sound basis for the preemption discussion of “Preemption,” these rules do not preempt State laws, including constitutional provisions, that are contrary to and more stringent, as defined at § 160.502, than these rules. See the discussion of “Preemption” for further clarification. Therefore, if these State constitutions are contrary to the rule below and provide greater protection, they remain in full force; if they do not, they are preempted, in accordance with the Supremacy Clause of the Constitution.

Right to Privacy

Comment: Several comments suggested that the proposed regulation would violate the right to privacy guaranteed by the First, Fourth, Fifth, and Ninth Amendments because it would permit covered entities to disclose protected health information without the consent of the individual.

Response: These comments did not provide specific facts or legal basis for the claim, but instead requested that the rule requires disclosures only to the individual or to the Secretary to determine compliance with this rule. Other uses or disclosures under this rule are permissive, not required. Therefore, if a particular use or disclosure under this rule is viewed as interfering with a right that prohibited the use or disclosure, the rule itself is not what requires the use or disclosure.

Void for Vagueness

Comment: One comment suggested that the Secretary’s use of a “reasonableness” standard is unconstitutionally vague. Specifically, this comment objected to the requirement that covered entities use “reasonable” efforts to use or disclose the minimum amount of protected health information, to ensure that business partners comply with the privacy provisions of their contracts, to notify business partners of any amendments or corrections to protected health information, and to verify the identity of individuals requesting information, as well as charge only a “reasonable” fee for inspecting and copying health information. This comment asserted that the Secretary provided “inadequate guidance” as to what qualifies as “reasonable.”

Response: We disagree with the comment’s suggestion that by applying a “reasonableness” standard, the regulation has failed to provide for “fair warning” or “fair enforcement.” The “reasonableness” standard is well-established in law; for example, it is the foundation of the common law of torts. Courts also have consistently held as constitutional statutes that rely upon a “reasonableness” standard. Our reliance upon a “reasonableness” standard, thus, provides covered entities with constitutionally sufficient guidance.

Criminal Intent

Comment: One comment argued that the regulation’s reliance upon a “reasonableness” standard criminalizes “unreasonable efforts” without requiring criminal intent or mens rea.

Response: We reject this suggestion because HIPAA clearly provides the criminal intent requirement. Specifically, HIPAA provides that a “person who knowingly and in violation of this part—(1) uses or causes to be used a unique health identifier; (2) obtains individually identifiable health information relating to an individual; or (3) discloses individually identifiable health information to another person, shall be punished as provided in subsection (b) of section 1177 (emphasis added). Subsection (b) also relies on a knowledge standard in
outlining the three levels of criminal sanctions. Thus, Congress, not the Secretary, established the mens rea by including the term “knowingly” in the criminal penalty provisions of HIPAA.

Data Collection

Comment: One commenter suggested that the U.S. Constitution authorized the collection of data on individuals only for the purpose of the census.

Response: While it might be true that the U.S. Constitution expressly discusses the national census, it does not forbid federal agencies from collecting data for other purposes. The ability of agencies to collect non-census data has been upheld by the courts.

Relationship to Other Federal Laws

Comment: We received several comments that sought clarification of the interaction of various federal laws and the privacy regulation. Many of these comments simply listed federal laws and regulations with which the commenter currently must comply. For example, commenters noted that they must comply with regulations relating to safety, public health, and civil rights, including Medicare and Medicaid, the Americans with Disabilities Act, the Family and Medical Leave Act, the Federal Aviation Administration regulations, the Department of Transportation regulations, the Federal Highway Administration regulations, the Occupational Safety and Health Administration regulations, and the Environmental Protection Agency regulations, and alcohol and drug free workplace rules. These commenters suggested that the regulation state clearly and unequivocally that uses or disclosures of protected health information for these purposes were permissible. Some suggested modifying the definition of health care operations to include these uses specifically.

Another suggestion was to add a section that permitted the transmission of protected health information to employers when reasonably necessary to comply with federal, state, or municipal laws and regulations, or when necessary for public or employee safety and health.

Response: Although we sympathize with entities’ needs to evaluate the existing laws with which they must comply in light of the requirements of the final regulation, we are unable to respond substantially to comments that do not pose specific questions. We offer, however, the following guidance: If an covered entity is required to disclose protected health information pursuant to a specific statutory or regulatory scheme, the covered entity generally will be permitted under §164.512(a) to make these disclosures without a consent or authorization; if, however, a statute or regulation merely suggests a disclosure, the covered entity will need to determine if the disclosure comes within another category of permissible disclosure under §§164.510 or 164.512 or, alternatively, if the disclosure would otherwise come within §164.502. If not, the entity will need to obtain a consent or authorization for the disclosure.

Comment: One commenter sought clarification as to when a disclosure is considered to be “required” by another law versus “permitted” by that law.

Response: We use these terms according to their common usage. By “required by law,” we mean that a covered entity has a legal obligation to disclose the information. For example, if a statute states that a covered entity must report the names of all individuals presenting with gun shot wounds to the emergency room or else be fined $500 for each violation, a covered entity would be required by law to disclose the protected health information necessary to comply with this mandate. The privacy regulation permits this type of disclosure, but does not require it. Therefore, if a covered entity chose not to comply with the reporting statute it would violate only the reporting statute and not the privacy regulation.

On the other hand, if a statute stated that a covered entity may or is permitted to report the names of all individuals presenting with gun shot wounds to the emergency room and, in turn, would receive $500 for each month it made these reports, a covered entity would not be permitted by §164.512(a) to disclose the protected health information. Of course, if another permissible provision applied to these facts, the covered entity could make the disclosure under that provision, but it would not be considered to be a disclosure. See discussion under §164.512(a) below.

Comment: Several commenters suggested that the proposed rule was unnecessarily duplicative of existing regulations for federal programs, such as Medicare, Medicaid, and the Federal Employee Health Benefit Program.

Response: Congress specifically subjected certain federal programs, including Medicare, Medicaid, and the Federal Employee Health Benefit Program to the privacy regulation by including them within the definition of “health plan.” Therefore, covered entities subject to requirements of existing federal programs will also have to comply with the privacy regulation.

Comment: One commenter asserts that the regulation would not affect current federal requirements if the current requirements are weaker than the requirements of the privacy regulation. This same commenter suggested that current federal requirements will trump both state law and the proposed regulation, even if Medicaid transactions remain wholly intrastate.

Response: We disagree. As noted in our discussion of “Relationship to Other Federal Laws,” each law or regulation will need to be evaluated individually. We similarly disagree with the second assertion made by the commenter. The final rule will preempt state laws only in specific instances. For a more detailed analysis, see the preamble discussion of “Preemption.”

Administrative Subpoenas

Comment: One comment stated that the final rule should not impose new standards on administrative subpoenas that would conflict with existing laws or administrative or judicial rules that establish standards for issuing subpoenas. Nor should the final rule conflict with established standards for the conduct of administrative, civil, or criminal proceedings, including the rules regarding the discovery of evidence. Other comments sought further restrictions on access to protected health information in this context.

Response: Section 164.512(e) below addresses disclosures for judicial and administrative proceedings. The final rules generally do not interfere with these existing processes to the extent an individual served with a subpoena, court order, or other similar process is able to raise objections already available. See the discussion below under §164.512(e) for a fuller response.

Americans with Disabilities Act

Comment: Several comments discussed the intersection between the proposed Privacy Rule and the Americans with Disabilities Act (“ADA”) and sections 503 and 504 of the Rehabilitation Act of 1973. One comment suggested that the final rule explicitly allows disclosures authorized by the Americans with Disabilities Act without an individual’s authorization, because this law, in the commenter’s view, provides more than adequate protection for the confidentiality of medical records in the employment context. The comment noted that under these laws employers may receive information related to fitness for duty, pre-employment physicals, routine examinations, return to work examinations, examinations regarding other types of absences, examinations triggered by specific events, changes in...
circumstances, requests for reasonable accommodations, leave requests, employee wellness programs, and medical monitoring.

Other commenters suggested that the ADA requires the disclosure of protected health information to employers so that the employee may take advantage of the protections of these laws. They suggested that the final rules clarify that employment may be conditioned on obtaining an authorization for disclosure of protected health information for lawful purposes and provide guidance concerning the interaction of the ADA with the final regulation’s requirements. Several commenters wanted clarification that the privacy regulation would not permit employers to request or use protected health information in violation of the ADA.

Response: We disagree with the comment that the final rule should allow disclosures of protected health information authorized by the ADA without an individual’s authorization. We learned from the comments that access to and use of protected health information by employers is of particular concern to many people. With regard to employers, we do not have statutory authority to regulate them. Therefore, it is beyond the scope of this regulation to prohibit employers from requesting or obtaining protected health information. Covered entities may disclose protected health information about individuals who are members of an employer’s workforce with an individual’s authorization. Nothing in the privacy regulation prohibits employers from obtaining that authorization as a condition of employment. We note, however, that employers must comply with other laws that govern them, such as nondiscrimination laws. For example, if an employer receives a request for a reasonable accommodation, the employer may require reasonable documentation about the employee’s disability and the functional limitations that require the reasonable accommodation, if the disability and the limitations are not obvious. If the individual provides insufficient documentation and does not provide the missing information in a timely manner after the employer’s subsequent request, the employer may require the individual to go to an appropriate health professional of the employer’s choice. In this situation, the employee does not authorize the disclosure of information to substantiate the disability and the need for reasonable accommodation, the employer needs not provide the accommodation.

We agree that this rule does not permit employers to request or use protected health information in violation of the ADA or other antidiscrimination laws.

Appropriations Laws

Comment: One comment suggested that the penalty provisions of HIPAA, if extended to the privacy regulation, would require the Secretary to violate “Appropriations Laws” because the Secretary could be in the position of assessing penalties against her own and other federal agencies in their roles as covered entities. Enforcing penalties on these entities would require the transfer of agency funds to the General Fund.

Response: We agree. Although we anticipate achieving voluntary compliance and resolving any disputes prior to the actual assessment of penalties, the Department of Justice’s Office of Legal Counsel has determined in similar situations that federal agencies have authority to assess penalties against other federal agencies and that doing so is not in violation of the Anti-Deficiency Act, 31 U.S.C. 1341.

Balanced Budget Act of 1997

Comment: One comment expressed concern that the regulation would place tremendous burdens on providers already struggling with the effects of the Balanced Budget Act of 1997.

Response: We appreciate the costs covered entities face when complying with other statutory and regulatory requirements, such as the Balanced Budget Act of 1997. However, HHS cannot address the impact of the Balanced Budget Act or other statutes in the context of this regulation.

Comment: Another comment stated that the regulation is in direct conflict with the Balanced Budget Act of 1997 (“BBA”). The comment asserts that the regulation’s compliance date conflicts with the BBA, as well as Generally Acceptable Accounting Principles. According to the comment, covered entities that made capital acquisitions to ensure compliance with the year 2000 (“Y2K”) problem would not be able to account for the full depreciation of these systems until 2005. Because HIPAA requires compliance before that time, the regulation would force premature obsolescence of this equipment because while it is Y2K compliant, it may be HIPAA non-compliant.

Response: This comment raises two distinct issues—(1) the investment in new equipment and (2) the compliance date. With regard to the first issue, we recognize that the regulation requires covered entities to purchase new information systems or information technology equipment, but realize that some covered entities may need to update their equipment. We have tried to minimize the costs, while responding appropriately to Congress’ mandate for privacy rules. We have dealt with the cost issues in detail in the “Regulatory Impact Analysis” section of this preamble. With regard to the second issue, Congress, not the Secretary, defined the compliance date at section 1175(b) of the Act.

Civil Rights of Institutionalized Persons Act

Comment: A few comments expressed concern that the privacy regulation would inadvertently hinder the Department of Justice Civil Rights Divisions’ investigations under the Civil Rights of Institutionalized Persons Act (“CRIPA”). These comments suggested clearly including civil rights enforcement activities as health care oversight.

Response: We agree with this comment. We do not intend for the privacy rules to hinder CRIPA investigations. Thus, the final rule includes agencies that are authorized by law to “enforce civil rights laws for which health information is relevant” in the definition of “health oversight agency” at § 164.501. Covered entities are permitted to disclose protected health information to health oversight agencies under § 164.512(d) without an authorization. Therefore, we do not believe the final rule should hinder the Department of Justice’s ability to conduct investigations pursuant to its authority under CRIPA.

Clinical Laboratory Improvement Amendments

Comment: One comment expressed concern that the proposed definition of health care operations did not include activities related to the quality control clinical studies performed by laboratories to demonstrate the quality of patient test results. Because the Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) requires these studies that the comment asserted require the use of protected health information, the comment suggested including this specific activity in the definition of “health care operations.”

Response: We do not intend for the privacy regulation to impede the ability of laboratories to comply with the requirements of CLIA. Quality control activities come within the definition of “health care operations” in § 164.501 because they come within the meaning of the term “clinical laboratory activities.” To the extent they would not come within health care operations, but
are required by CLIA, the privacy regulation permits clinical laboratories that are regulated by CLIA to comply with mandatory uses and disclosures of protected health information pursuant to § 164.512(a).

Comment: One comment stated that the proposed regulation’s right of access for inspection and copying provisions were contrary to CLIA in that CLIA permits laboratories to disclose lab test results only to “authorized persons.” This comment suggested that the final rule include language adopting this restriction to ensure that patients not obtain laboratory test results before the appropriate health care provider has reviewed and explained those results to the patients.

A similar comment stated that the lack of preemption of state laws could create problems for clinical laboratories under CLIA. Specifically, this comment noted that CLIA permits clinical laboratories to perform tests only upon the written or electronic request of, and to provide the results to, an “authorized person.” State laws define who is an “authorized person.” The comment expressed concern as to whether the regulation would preempt state laws that only permit physicians to receive test results.

Response: We agree that CLIA controls in these cases. Therefore, we have amended the right of access, § 164.524(a), so that a covered entity that is subject to CLIA does not have to provide access to the individual to the extent such access would be prohibited by law. Because of this change, we believe the preemption concern is moot.

Controlled Substance Act

Comment: One comment expressed concern that the privacy regulation as proposed would restrict the Drug Enforcement Agency’s (“the DEA”) enforcement of the Controlled Substances Act (“CSA”). The comment suggested including enforcement activities in the definition of “health oversight agency.”

Response: In our view, the privacy regulation should not impede the DEA’s ability to enforce the CSA. First, to the extent the CSA requires disclosures to the DEA, these disclosures would be permissible under § 164.512(a). Second, some of the DEA’s CSA activities come within the exception for health oversight agencies which permits disclosures to health oversight agencies for:

- Activities authorized by law, including audits; civil, administrative, or criminal investigations; inspections * * * civil, administrative, or criminal proceedings or actions; and other activity necessary for appropriate oversight of the health care system.

Therefore, to the extent the DEA is enforcing the CSA, disclosures to it in its capacity as a health oversight agency are permissible under § 164.512(d). Alternatively, CSA required disclosures to the DEA for law enforcement purposes are permitted under § 164.512(f). When acting as a law enforcement agency under the CSA, the DEA may obtain the information pursuant to § 164.512(f). Thus, we do not agree that the privacy regulation will impede the DEA’s enforcement of the CSA. See the preamble discussion of § 164.512 for further explanation.

Comment: One commenter suggested clarifying the provisions allowing disclosures that are “required by law” to ensure that the mandatory reporting requirements the CSA imposes on covered entities, including making available reports, inventories, and records of transactions, are not preempted by the regulation.

Response: We agree that the privacy regulation does not alter covered entities’ obligations under the CSA. Because the CSA requires covered entities manufacturing, distributing, and/or dispensing controlled substances to maintain and provide to the DEA specific records and reports, the privacy regulation permits these disclosures under § 164.512(a). In addition, when the DEA seeks documents to determine an entity’s compliance with the CSA, such disclosures are permitted under § 164.512(d).

Comment: The same commenter expressed concern that the proposed privacy regulation inappropriately limits voluntary reporting and would prevent or deter employees of covered entities from providing the DEA with information about violations of the CSA.

Response: We agree with the general concerns expressed in this comment. We do not believe the privacy rules will limit voluntary reporting of violations of the CSA. The CSA requires certain entities to maintain several types of records that may include protected health information. Although reports that included protected health information may be restricted under these rules, reporting the fact that an entity is not maintaining proper reports is not. If it were necessary to obtain protected health information during the investigatory stages following such a voluntary report, the DEA would be able to obtain the information in other ways, such as by following the administrative procedures described in § 164.512(e).

We also agree that employees of covered entities who report violations of the CSA should not be subjected to retaliation by their employers. Under § 164.502(j), we specifically state that a covered entity is not considered to have violated the regulation if a workforce member or business associate in good faith reports violations of laws or professional standards by covered entities to appropriate authorities. See discussion of § 164.502(j) below.

Department of Transportation

Comment: Several commenters stated that the Secretary should recognize in the preamble that it is permissible for employers to condition employment on an individual’s delivering a consent to certain medical tests and/or examinations, such as drug-free workplace programs and Department of Transportation (“DOT”)-required physical examinations. These comments also suggested that employers should be able to receive certain information, such as pass/fail test and examination results, fitness-to-work assessments, and other legally required or permissible physical assessments without obtaining an authorization.

Response: We reject the suggestion to define “health information,” which Congress defined in HIPAA, so that it excludes individually identifiable health information that may be relevant to employers for these types of examinations and programs. We do not regulate employers. Nothing in the rules prohibit employers from conditioning employment on an individual signing the appropriate consent or authorization. By the same token, however, the rules below do not relieve employers from their obligations under the ADA and other laws that restrict the disclosure of individually identifiable health information.

Comment: One commenter asserted that the proposed regulation conflicts with the DOT guidelines regarding positive alcohol and drug tests that require the employer be notified in writing of the results. This document contains protected health information. In addition, the treatment center records must be provided to the Substance Abuse Professional (“SAP”) and the employer must receive a report from SAP with random drug testing recommendations.

Response: It is our understanding that DOT requires drug testing of all applicants for employment in safety-sensitive positions or individuals being transferred to such positions.
Employers, pursuant to DOT regulations, may condition an employee’s employment or position upon first obtaining an authorization for the disclosure of results of these tests to the employer. Therefore, we do not believe the final rules conflict with the DOT requirements, which do not prohibit obtaining authorizations before such information is disclosed to employers.

**Developmental Disabilities Act**

**Comment:** One commenter urged HHS to ensure that the regulation would not impede access to individually identifiable health information to entities that are part of the Protection and Advocacy System to investigate abuse and neglect as authorized by the Developmental Disabilities Bill of Rights Act.

**Response:** The Developmental Disabilities Assistance and Bill of Rights Act of 2000 (“DD Act”) mandates specific disclosures of individually identifiable health information to Protection and Advocacy systems designated by the chief elected official of the states and Territories. Therefore, covered entities may make these disclosures under § 164.512(a) without first obtaining an individual’s authorization, except in those circumstances in which the DD Act requires the individual’s authorization. Therefore, the rules below will not impede the functioning of the existing Protection and Advocacy System.

**Employee Retirement Income Security Act of 1974**

**Comment:** Several commenters objected to the fact that the NPRM did not clarify the scope of preemption of state laws under the Employee Retirement Income Security Act of 1974 (ERISA). These commenters asserted that the final rule must state that ERISA preempts all state laws (including those relating to the privacy of individually identifiable health information) so that multistate employers could continue to administer their group health plans using a single set of rules. In contrast, other commenters criticized the Department for its analysis of the current principles governing ERISA preemption of state law, pointing out that the Department has no authority to interpret ERISA.

**Response:** This Department has no authority to issue regulations under ERISA as requested by some of these commenters, so the rule below does not contain the statement requested. See the discussion of this point under “Preemption” above.

**Comment:** One commenter requested that the final rule clarify that section 264(c)(2) of HIPAA does not save state laws that would otherwise be preempted by the Federal Employees Health Benefits Program. The commenter noted that in the NPRM this statement was made with respect to Medicare and ERISA, but not the law governing the FEHBP.

**Response:** We agree with this comment. The preemption analysis set out above with respect to ERISA applies equally to the Federal Employees Health Benefit Program.

**Comment:** One commenter noted that the final rule should clarify the interplay between state law, the preemption standards in Subtitle A of Title I of HIPAA (Health Care Access, Portability and Renewability), and the preemption standards in the privacy requirements in Subtitle F of Title II of HIPAA (Administrative Simplification).

**Response:** The NPRM described only the preemption standards that apply with respect to the statutory provisions of HIPAA that were implemented by the proposed rule. We agree that the preemption standards in Subtitle A of Title I of HIPAA are different. Congress expressly provided that the preemption provisions of Title I apply only to Part 7, which addresses portability, access, and renewability requirements for Group Health Plans. To the extent state laws contain provisions regarding portability, access, or renewability, as well as privacy requirements, a covered entity will need to evaluate the privacy provisions under the Title II preemption provisions, as explained in the preemption provisions of the rules, and the other provisions under the Title I preemption requirements.

**European Union Privacy Directive and U.S. Safe Harbors**

**Comment:** Several comments stated that the privacy regulation should be consistent with the European Union’s Directive on Data Protection. Others sought guidance as to how to comply with both the E.U. Directive on Data Protection and the U.S. Safe Harbor Privacy Principles.

**Response:** We appreciate the need for covered entities obtaining personal data from the European Union to understand how the privacy regulation intersects with the Data Protection Directive. We have provided guidance as to this interaction in the “Other Federal Laws” provisions of the preamble.

**Comment:** A few comments expressed concern that the proposed definition of “individual” excluded foreign military and diplomatic personnel and their dependents, as well as overseas foreign national beneficiaries. They noted that the distinctions are based on nationality and are inconsistent with the stance of the E.U. Directive on Data Protection and the Department of Commerce’s assurances to the European Commission.

**Response:** We agree with the general principle that privacy protections should protect every person, regardless of nationality. As noted in the discussion of the definition of “individual,” the final regulation’s definition does not exclude foreign military and diplomatic personnel, their dependents, or overseas foreign national beneficiaries from the definition of individual. As described in the discussion of § 164.512 below, the final rule applies to foreign diplomatic personnel and their dependents like all other individuals. Foreign military personnel receive the same treatment under the final rule as U.S. military personnel do, as discussed with regard to § 164.512 below. Overseas foreign national beneficiaries to the extent they receive care for the Department of Defense or a source acting on behalf of the Department of Defense remain generally excluded from the final rules protections. For a more detailed explanation, see § 164.500.

**Fair Credit Reporting Act**

**Comment:** A few commenters requested that we exclude information maintained, used, or disclosed pursuant to the Fair Credit Reporting Act (“FCRA”) from the requirements of the privacy regulation. These commenters noted that the protection in the privacy regulation duplicate those in the FCRA.

**Response:** Although we realize that some overlap between FCRA and the privacy rules may exist, we have chosen not to remove information that may come within the purview of FCRA from the scope of our rules because FCRA’s focus is not the same as our Congressional mandate to protect individually identifiable health information.

To the extent a covered entity seeks to engage in collection activities or other payment-related activities, it may do so pursuant to the requirements of this rule related to payment. See discussion of §§ 164.501 and 164.502 below.

We understand that some covered entities may be part of, or contain components that are, entities which meet the definition of “consumer reporting agencies.” As such, these entities are subject to the FCRA. As described in the preamble to § 164.504, covered entities must determine that parts of their organizations will be treated as covered entities for the
purposescape punctuation. The covered entity component will need to comply with these rules, while the components that are consumer reporting agencies will need to comply with FCRA.

Comment: One comment suggested that the privacy regulation would conflict with the FCRA if the regulation’s requirement applied to information disclosed to consumer reporting agencies.

Response: To the extent a covered entity is required to disclose protected health information to a consumer reporting agency, it may do so under § 164.512(a). See also discussion under the definition of “payment” below.

Fair Debt Collection and Practices Act

Comment: Several comments expressed concern that health plans and health care providers be able to continue using debt collectors in compliance with the Fair Debt Collections Practices Act and related laws.

Response: In our view, health plans and health care providers will be able to continue using debt collectors. Using the services of a debt collector to obtain payment for the provision of health care comes within the definition of “payment” and is permitted under the regulation. Thus, so long as the use of debt collectors is consistent with the regulatory requirements (such as, providers obtain the proper consents, the disclosure is of the minimum amount of information necessary to collect the debt, the provider or health plan enter into a business associate agreement with the debt collector, etc.), relying upon debt collectors to obtain reimbursement for the provision of health care would not be prohibited by the regulation.

Family Medical Leave Act

Comment: One comment suggested that the proposed regulation adversely affects the ability of an employer to determine an employee’s entitlement to leave under the Family Medical Leave Act (“FMLA”) by affecting the employer’s right to receive medical certification of the need for leave, additional certifications, and fitness for duty certification at the end of the leave. The commenter sought clarification as to whether a provider could disclose information to an employer without first obtaining an individual’s consent or authorization. Another commenter suggested that the final rule explicitly exclude from the rule disclosures authorized by the FMLA, because, in the commenter’s view, it provides more than adequate protection for the confidentiality of medical records in the employment context.

Response: We disagree. Because we provide adequate privacy protections for individually identifiable health information. As we understand the FMLA, the need for employers to obtain protected health information under the statute is analogous to the employer’s need for protected health information under the ADA. In both situations, employers may need protected health information to fulfill their obligations under these statutes, but neither statute requires covered entities to provide the information directly to the employer. Thus, covered entities in these circumstances will need an individual’s authorizations before the disclosure is made to the employer.

Federal Common Law

Comment: One commenter did not want the privacy rules to interfere with the federal common law governing collective bargaining agreements permitting employers to insist on the cooperation of employees with medical fitness evaluations.

Response: We do not seek to interfere with legal medical fitness evaluations. These rules require a covered entity to have an individual’s authorization before the information resulting from such evaluations is disclosed to the employer unless another provision of the rule applies. We do not prohibit employers from conditioning employment, accommodations, or other benefits, when legally permitted to do so, upon the individual/employee providing an authorization that would permit the disclosure of protected health information to employers by covered entities. See § 164.508(b)(4) below.

Federal Educational Rights and Privacy Act

Comment: A few commenters supported the exclusion of “education records” from the definition of “protected health information.” However, one commenter requested that “treatment records” of students who are 18 years or older attending post-secondary education institutions be excluded from the definition of “protected health information” as well to avoid confusion.

Response: We agree with these commenters. See “Relationship to Other Federal Laws” for a description of our exclusion of FERPA “education records” and records described at 20 U.S.C. 1232g(a)(4)(B)(iv) held by educational agencies and institutions subject to FERPA from the definition of protected health information, only non-FERPA schools would be subject to the administrative requirements. Most of these school clinics will also not be covered entities because they are not engaged in HIPAA transactions and these administrative requirements will not apply to them. However, to the extent a school clinic is within the definition of a health care provider, as Congress defined the term, and the school clinic is engaged in HIPAA transactions, it will be a covered entity and must comply with the rules below.
Comment: Several commenters expressed concern that the privacy regulation would eliminate the parents’ ability to have access to information in their children’s school health records. Because the proposed regulation suggests that school-based clinics keep health records separate from other educational files, these comments argued that the regulation is contrary to the spirit of FERPA, which provides parents with access rights to their children’s educational files.

Response: As noted in the “Relationship to Other Federal Laws” provision of the preamble, to the extent information in school-based clinics is not protected health information because it is an education record, the FERPA access requirements apply and this regulation does not. For more detail regarding the rule’s application to unemancipated minors, see the preamble discussion about “Personal Representatives.”

Federal Employees Compensation Act

Comment: One comment noted that the Federal Employees Compensation Act (“FECA”) requires claimants to sign a release form when they file a claim. This commenter suggested that the privacy regulation should not place additional restrictions on this type of release form.

Response: We agree. In the final rule, we have added a new provision, § 164.512(l), that permits covered entities to make disclosures authorized under workers’ compensation and similar laws. This provision would permit covered entities to make disclosures authorized under FECA and not require a different release form.

Federal Employees Health Benefits Program

Comment: A few comments expressed concern about the preemption effect on FEHBP and wanted clarification that the privacy regulation does not alter the existing preemptive scope of the program.

Response: We do not intend to affect the preemptive scope of the FEHBP. The Federal Employee Health Benefit Act of 1998 preempts any state law that “relates to” health insurance or plans. 5 U.S.C. 8902(m). The final rule does not attempt to alter the preemptive scope Congress has provided to the FEHBP.

Comment: One comment suggested that in the context of FEHBP HHS should place the enforcement responsibilities of the privacy regulation with the Office of Personnel Management, as the agency responsible for administering the program.

Response: We disagree. Congress placed enforcement with the Secretary. See section 1176 of the Act.

Federal Rules of Civil Procedure

Comment: A few comments suggested revising proposed § 164.510(d) so that it is consistent with the existing discovery procedure under the Federal Rules of Civil Procedure or local rules.

Response: We disagree that the rules regarding disclosures and uses of protected health information for judicial and administrative procedures should provide only those protections that exist under existing discovery rules.

Although the current process may be appropriate for other documents and information requested during the discovery process, the current system, as exemplified by the Federal Rules of Civil Procedure, does not provide sufficient protection for protected health information. Under current discovery rules, private attorneys, government officials, and others who develop such requests make the initial determinations as to what information or documentation should be disclosed. Independent third-party review, such as that by a court, only becomes necessary if a person of whom the request is made refuses to provide the information. If this happens, the person seeking discovery must obtain a court order or move to compel discovery. In our view this system does not provide sufficient protections to ensure that unnecessary and unwarranted disclosures of protected health information does not occur. For a related discuss, see the preamble regarding “Disclosures for Judicial and Administrative Proceedings” under § 164.512(e).

Federal Rules of Evidence

Comment: Many comments requested clarification that the privacy regulation does not conflict or interfere with the federal or state privileges. In particular, one of these comments suggested that the final regulation provide that disclosures for a purpose recognized by the regulation not constitute a waiver of federal or state privileges.

Response: We do not intend for the privacy regulation to interfere with federal or state rules of evidence that create privileges. Consistent with The Uniform Health-Care Information Act drafted by the National Conference of Commissioners on Uniform State Laws, we do not view a consent or an authorization to function as a waiver of federal or state privileges. For further discussion of the effect of consent or authorization and others who state privileges, see preamble discussions in §§ 164.506 and 164.508.

Comment: Other comments applauded the Secretary’s references to Jaffee v. Redman, 518 U.S. 1 (1996), which recognized a psychotherapist-patient privilege, and asked the Secretary to incorporate expressly this privilege into the final regulation.

Response: We agree that the psychotherapist-patient relationship is an important one that deserves protection. However, it is beyond the scope our mandate to create specific evidentiary privileges. It is also unnecessary because the United States Supreme Court has adopted this privilege.

Comment: A few comments discussed whether one remedy for violating the privacy regulation should be to exclude or suppress evidence obtained in violation of the regulation. One comment supported using this penalty, while another opposed it.

Response: We do not have the authority to mandate that courts apply or not apply the exclusionary rule to evidence obtained in violation of the regulation. This issue is in the purview of the courts.

Federal Tort Claims Act

Comment: One comment contended that the proposed regulation’s requirement mandating covered entities to name the subjects of protected health information disclosed under a business partner contract as third party intended beneficiaries under the contract would have created an impermissible right of action against the government under the Federal Tort Claims Act (“FTCA”).

Response: Because we have deleted the third party beneficiary provisions from the final rules, this comment is moot.

Comment: Another comment suggested the regulation would hamper the ability of federal agencies to disclose protected health information to their attorneys, the Department of Justice, during the initial stages of the claims brought under the FTCA.

Response: We disagree. The regulation applies only to federal agencies that are covered entities. To the extent an agency is not a covered entity, it is not subject to the regulation; to the extent an agency is a covered entity, it must comply with the regulation. A covered entity that is a federal agency may disclose relevant information to its attorneys, who are business associates, for purposes of health care operations, which includes uses or disclosures for legal functions. See § 164.501 (definitions of “business associate” and “health care operations”) . The final rule provides specific provisions describing how federal agencies may provide
adequate assurances for these types of disclosures of protected health information. See § 164.504(e)(3).

Food and Drug Administration

Comment: A few comments expressed concerns about the use of protected health information for reporting activities to the Food and Drug Administration (“FDA”). Their concern focused on the ability to obtain or disclose protected health information for pre-and post-marketing adverse event reports, device tracking, and post-marketing safety and efficacy evaluation.

Response: We agree with this comment and have provided that covered entities may disclose protected health information to persons subject to the jurisdiction of the FDA, to comply with the requirements of, or at the direction of, the FDA with regard to reporting adverse events (or similar reports with respect to dietary supplements), the tracking of medical devices, other post-marketing surveillance, or other similar requirements described at § 164.512(b).

Foreign Standards

Comment: One comment asked how the regulation could be enforced against foreign countries (or presumably entities in foreign countries) that solicit medical records from entities in the United States.

Response: We do not regulate solicitations of information. To the extent a covered entity wants to comply with a request for disclosure of protected health information to foreign countries or entities within foreign countries, it will need to comply with the privacy rules before making the disclosure. If the covered entity fails to comply with the rules, it will be subject to enforcement proceedings.

Freedom of Information Act

Comment: One comment asserted that the proposed privacy regulation conflicts with the Freedom of Information Act (“FOIA”). The comment argued that the proposed restriction on disclosures by agencies would not come within one of the permissible exemptions to the FOIA. In addition, the comment noted that only in exceptional circumstances would the protected health information of deceased individuals come within an exemption because, for the most part, death extinguishes an individual’s right to privacy.

Response: Section 164.512(a) below permits covered entities to disclose protected health information when such disclosures are required by other laws as long as they follow the requirements of those laws. Therefore, the privacy regulation will not interfere with the ability of federal agencies to comply with FOIA, when it requires the disclosure.

We disagree, however, that most protected health information will not come within Exemption 6 of FOIA. See the discussion above under “Relationship to Other Federal Laws” for our review of FOIA. Moreover, we disagree with the comment’s assertion that the protected health information of deceased individuals does not come within Exemption 6. Courts have recognized that a deceased individual’s surviving relatives may have a privacy interest that federal agencies may consider when balancing privacy interests against the public interest in disclosure of the requested information. Federal agencies will need to consider not only the privacy interests of the subject of the protected health information in the record requested, but also, when appropriate, those of a deceased individual’s family consistent with judicial rulings.

If an agency receives a FOIA request for the disclosure of protected health information of a deceased individual, it will need to determine whether or not the disclosure comes within Exemption 6. This evaluation must be consistent with the court’s rulings in this area. If the exemption applies, the federal agency will not have to release the information. If the federal agency determines that the exemption does not apply, may provide it under § 164.512(a) of this regulation.

Comment: One commenter expressed concern that our proposal to protect the individually identifiable health information about the deceased for two years following death would impede public interest reporting and would be at odds with many state Freedom of Information laws that make death records and autopsy reports public information. The commenter suggested permitting medical information to be available upon the death of an individual or, at the very least, that an appeals process be permitted so that health information trustees would be allowed to balance the interests in privacy and in public disclosure and release or not release the information accordingly.

Response: These rules permit covered entities to make disclosures that are required by state Freedom of Information Act (FOIA) laws under § 164.512(a). Thus, if a state FOIA law requires covered entities to provide health records and autopsy reports as public information that must be disclosed, a covered entity may disclose it without an authorization under the rule. To the extent that such information is required to be disclosed by FOIA or other law, such disclosures are permitted under the final rule. In addition, to the extent that death records and autopsy reports are obtainable from non-covered entities, such as state legal authorities, access to this information is not impeded by this rule.

If another law does not require the disclosure of death records and autopsy reports generated and maintained by a covered entity, which are protected health information, covered entities are not allowed to disclose such information except as permitted or required by the final rule, even if another entity discloses them.

Comment: One comment sought clarification of the relationship between the Freedom of Information Act, the Privacy Act, and the privacy rules.

Response: We have provided this analysis in the “Relationship to Other Federal Laws” section of the preamble in our discussion of the Freedom of Information Act.

Gramm-Leach-Bliley

Comment: One commenter noted that the Financial Services Modernization Act, also known as Gramm-Leach-Bliley (“GLB”), requires financial institutions to provide detailed privacy notices to individuals. The commenter suggested that the privacy regulation should not require financial institutions to provide additional notice.

Response: We disagree. To the extent a covered entity is required to comply with the notice requirements of GLB and those of our rules, the covered entity must comply with both. We will work with the FTC and other agencies implementing GLB to avoid unnecessary duplication. For a more detailed discussion of GLB and the privacy rules, see the “Relationship to Other Federal Laws” section of the preamble.

Comment: A few commenters asked that the Department clarify that financial institutions, such as banks, that serve as payors are covered entities. The comments explained that with the enactment of the Gramm-Leach-Bliley Act, banks are able to form holding companies that will include insurance companies (that may be covered entities). They recommended that banks be held to the rule’s requirements and be required to obtain authorization to conduct non-payment activities, such as for the marketing of health and non-health items and services or the use and disclosure to non-health related divisions of the covered entity.
Response: These comments did not provide specific facts that would permit us to provide a substantive response. An organization will need to determine whether it comes within the definition of “covered entity.” An organization may also need to consider whether or not it contains a health care component. Organizations that are uncertain about the application of the regulation to them will need to evaluate their specific facts in light of this rule.

Inspector General Act

Comment: One comment requested the Secretary to clarify in the preamble that the privacy regulation does not preempt the Inspector General Act.

Response: We agree that to the extent the Inspector General Act requires uses or disclosures of protected health information, the privacy regulation does not preempt it. The final rule provides that to the extent required under subsection 201(a)(5) of the Act, nothing in this subchapter should be construed to diminish the authority of any Inspector General, including the authority provided in the Inspector General Act of 1978. See discussion of § 160.102 above.

Medicare and Medicaid

Comment: One comment suggested possible inconsistencies between the regulation and Medicare/Medicaid requirements, such as those under the Quality Improvement System for Managed Care. This commenter asked that HHS expand the definition of health care operations to include health promotion activities and avoid potential conflicts.

Response: We disagree that the privacy regulation would prohibit managed care plans operating in the Medicare or Medicaid programs from fulfilling their statutory obligations. To the extent a covered entity is required by law to use or disclose protected health information in a particular manner, the covered entity may make such a use or disclosure under § 164.512(a). Additionally, quality assessment and improvement activities come within the definition of “health care operations.” Therefore, the specific example provided by the commenter would seem to be a permissible use or disclosure under § 164.502, even if it were not a use or disclosure “required by law.”

Comment: One commenter stated that Medicare should not be able to require the disclosure of psychotherapy notes because it would destroy a practitioner’s ability to treat patients effectively.

Response: If the Title XVIII of the Social Security Act requires the disclosure of psychotherapy notes, the final rule permits, but does not require, a covered entity to make such a disclosure under § 164.512(a). If, however, the Social Security Act does not require such disclosures, Medicare does not have the discretion to require the disclosure of psychotherapy notes as a public policy matter because the final rule provides that covered entities, with limited exceptions, must obtain an individual’s authorization before disclosing psychotherapy notes. See § 164.508(a)(2).

National Labor Relations Act

Comment: A few comments expressed concern that the regulation did not address the obligation of covered entities to disclose protected health information to collective bargaining representatives under the National Labor Relations Act.

Response: The final rule does not prohibit disclosures that covered entities must make pursuant to other laws. To the extent a covered entity is required by law to disclose protected health information to collective bargaining representatives under the NLRA, it may to so without an authorization. Also, the definition of “health care operations” at § 164.501 permits disclosures to employee representatives for purposes of grievance resolution.

Organ Donation

Comment: One commenter expressed concern about the potential impact of the regulation on the organ donation program under 42 CFR part 482.

Response: In the final rule, we add provisions allowing the use or disclosure of protected health information to organ procurement organizations or other entities engaged in the procurement, banking, or transplantation of cadaveric organs, eyes, or tissue for the purpose of facilitating donation and transplantation. See § 164.512(h).

Privacy Act Comments

Comment: One comment suggested that the final rule unambiguously permit the continued operation of the statutorily established or authorized discretionary routine uses permitted under the Privacy Act for both law enforcement and health oversight.

Response: We disagree. See the discussion of the Privacy Act in “Relationship to Other Federal Laws” above.

Public Health Services Act

Comment: One comment suggested that the Public Health Service Act places more stringent rules regarding the disclosure of information on Federally Qualified Health Centers than the proposed privacy regulation suggested. Therefore, the commenter suggested that the final rule exempt Federally Qualified Health Centers from the rules requirements

Response: We disagree. Congress expressly included Federally Qualified Health Centers, a provider of medical or other health services under the Social Security Act section 1861(s), within its definition of health care provider in section 1711 of the Act; therefore, we cannot exclude them from the regulation.

Comment: One commenter noted that no conflicts existed between the proposed rule and the Public Health Services Act.

Response: As we discuss in the “Relationship to Other Federal Laws” section of the preamble, the Public Health Service Act contains explicit confidentiality requirements that are so general as not to create problems of inconsistency. We recognized, however, that in some cases, that law or its accompanying regulations may contain greater restrictions. In those situations, a covered entity’s ability to make what are permissive disclosures under this privacy regulation would be limited by these laws.

Reporting Requirement

Comment: One comment noted that federal agencies must provide information to certain entities pursuant to various federal statutes. For example, federal agencies must not withhold information from a Congressional oversight committee or the General Accounting Office. Similarly, some federal agencies must provide the Bureau of the Census and the National Archives and Records Administration with certain information. This comment expressed concern that the privacy regulation would conflict with these requirements. Additionally, the commenter asked whether the privacy notice would need to contain these uses and disclosures and recommended that a general statement that these federal agencies would disclose protected health information when required by law be considered sufficient to meet the privacy notice requirements.

Response: To the extent a federal agency acting as a covered entity is required by federal statute to disclose protected health information, the regulation permits the disclosure as required by law under § 164.512(a). The notice provisions at § 164.520(b)(1)(ii)(B) require covered entities to provide a brief description of the purposes for which the covered
entity is permitted or required by the rules to use or disclose protected health information without an individual’s written authorization. If these statutes require the disclosures, covered entities subject to the requirement may make the disclosure pursuant to § 164.512(a). Thus, their notice must include a description of the category of these disclosures. For example, a general statement such as the covered entity “will disclose your protected health information to comply with legal requirements” should suffice. Comment: One commenter stressed that the final rule should not inadvertently preempt mandatory reporting laws duly enacted by federal, state, or local legislative bodies. This commenter also suggested that the final rule not prevent the reporting of violations to law enforcement agencies.

Response: We agree. Like the proposed rule, the final rule permits covered entities to disclose protected health information when required by law under § 164.512(a). To the extent a covered entity is required by law to make a report to law enforcement agencies or is otherwise permitted to make a disclosure to a law enforcement agency as described in § 164.512(f), it may do so without an authorization. Alternatively, a covered entity may always request that individuals authorize these disclosures.

Security Standards

Comment: One comment called for HHS to consider the privacy regulation in conjunction with the other HIPAA standards. In particular, this comment focused on the belief that the security standards should be compatible with the existing and emerging health care and information technology industry standards.

Response: We agree that the security standards and the privacy rules should be compatible with one another and are working to ensure that the final rules in both areas function together. Because we are addressing comments regarding the privacy rules in this preamble, we will consider the comment about the security standard as we finalize that set of rules.

Substance Abuse Confidentiality Statute and Regulations

Comment: Several commenters noted that many health care providers are bound by the federal restrictions governing alcohol and drug abuse records. One commenter noted that the NPRM differed substantially from the substance abuse regulations and would have caused a host of practical problems for covered entities. Another commenter, however, supported the NPRM’s analysis that stated that more stringent provisions of the substance abuse provisions would apply. This commenter suggested an even stronger approach of including in the text a provision that would preserve existing federal law. Yet, one comment suggested that the regulation as proposed would confuse providers by making it difficult to determine when they may disclose information to law enforcement because the privacy regulation would permit disclosures that the substance abuse regulations would not.

Response: We appreciate the need of some covered entities to evaluate the privacy rules in light of federal requirements regarding alcohol and drug abuse records. Therefore, we provide a more detailed analysis in the “Relationship to Other Federal Laws” section of the preamble.

Comment: Some of these commenters also noted that state laws contain strict confidentiality requirements. A few commenters suggested that HHS reassess the regulations to avoid inconsistencies with state privacy requirements, implying that problems exist because of conflicts between the federal and state laws regarding the confidentiality of substance abuse information.

Response: As noted in the preamble section discussing preemption, the final rules do not preempt state laws that provide more privacy protections. For a more detailed analysis of the relationship between state law and the privacy rules, see the “Preemption” provisions of the preamble.

Tribal Law

Comments: One commenter suggested that the consultation process with tribal governments described in the NPRM was inadequate under Executive Order No. 13084. In addition, the commenter expressed concern that the disclosures for research purposes as permitted by the NPRM would conflict with a number of tribal laws that offer individuals greater privacy rights with respect to research and reflects cultural appropriateness. In particular, the commenter referenced the Health Research Code for the Navajo Nation which creates a entity with broader authority over research conducted on the Navajo Nation than the local IRB and requires informed consent by study participants. Other laws mentioned by the commenter included the Navajo Nation Privacy and Access to Information Policy applicable to all health care providers within the Navajo Nation. The commenter expressed concern that the proposed regulation research provisions would override these tribal laws.

Response: We disagree with the comment that the consultation with tribal governments undertaken prior to the proposed regulation is inadequate under Executive Order No. 13084. As stated in the proposed regulation, the Department consulted with representatives of the National Congress of American Indians and the National Indian Health Board, as well as others, about the proposals and the application of HIPAA to the Tribes, and the potential variations based on the relationship of each Tribe with the IHS for the purpose of providing health services. In addition, Indian and tribal governments had the opportunity to, and did, submit substantive comments on the proposed rules.

Additionally, disclosures permitted by this regulation do not conflict with the policies as described by this commenter. Disclosures for research purposes under the final rule, as in the proposed regulation, are permissive disclosures only. The rule describes the outer boundaries of permissible disclosures. A covered health care provider that is subject to the tribal laws of the Navajo Nation must continue to comply with those tribal laws. If the tribal laws impose more stringent privacy standards on disclosures for research, such as requiring informed consent in all cases, nothing in the final rule would preclude compliance with those more stringent privacy standards. The final rule does not interfere with the internal governance of the Navajo Nation or otherwise adversely affect the policy choices of the tribal government with respect to the cultural appropriateness of research conducted in the Navajo Nation.

TRICARE

Comment: One comment expressed concern regarding the application of the “minimum necessary” standard to investigations of health care providers under the TRICARE (formerly the CHAMPUS) program. The comment also expressed concern that health care providers would be able to avoid providing their records to such investigators because the proposed § 164.510 exceptions were not mandatory disclosures.

Response: In our view, neither the minimum necessary standard nor the final §§ 164.510 and 164.512 permissive disclosures will impede such investigations. The regulation requires covered entities to make all reasonable efforts not to disclose more than the minimum amount of protected health
information necessary to accomplish the intended purpose of the use or disclosure. This requirement, however, does not apply to uses or disclosures that are required by law. See § 164.502(b)(2)(iv). Thus, if the disclosure to the investigators is required by law, the minimum necessary standard will not apply. Additionally, the final rule provides that covered entities rely, if such reliance is reasonable, on assertions from public officials about what information is reasonably necessary for the purpose for which it is being sought. See § 164.514(d)(3)(iii).

We disagree with the assertion that providers will be able to avoid providing their records to investigators. Nothing in this rule permits covered entities to avoid disclosures required by other laws.

Veterans Affairs

Comment: One comment sought clarification about how disclosures of protected health information would occur within the Veterans Affairs programs for veterans and their dependents.

Response: We appreciate the commenter’s request for clarification as to how the rules will affect disclosures of protected health information in the specific context of Veteran’s Affairs programs. Veterans health care programs under 38 U.S.C. chapter 17 are defined as “health plans.” Without sufficient details as to the particular aspects of the Veterans Affairs programs that this comment views as problematic, we cannot comment substantively on this concern.

Comment: One comment suggested that the final regulation clarify that the analysis applied to the substance abuse regulations apply to laws governing Veteran’s Affairs health records.

Response: Although we realize some difference may exist between the laws, we believe the discussion of federal substance abuse confidentiality regulations in the “Relationship to Other Federal Laws” preamble provides guidance that may be applied to the laws governing Veteran’s Affairs (“VA”) health records. In most cases, a conflict will not exist between these privacy rules and the VA programs. For example, some disclosures allowed without patient consent or authorization under the privacy regulation may not be within the VA statutory list of permissible disclosures without a written consent. In such circumstances, the covered entity would have to abide by the VA statute, and no conflict exists. If the disclosures permitted by the VA statute come within the permissible disclosures of our rules, no conflict exists. In some cases, our rules may demand additional requirements, such as obtaining the approval of a privacy board or Institutional Review Board if a covered entity seeks to disclose protected health information for research purposes without the individual’s authorization. A covered entity subject to the VA statute will need to ensure that it meets the requirements of both that statute and the regulation below. If a conflict arises, the covered entity should evaluate the specific potential conflicting provisions under the implied repeal analysis set forth in the “Relationship to Other Federal Laws” discussion in the preamble.

WIC

Comment: One comment called on other federal agencies to examine their regulations and policies regarding the use and disclosure of protected health information. The comment suggested that other agencies revise their regulations and policies to avoid duplicative, contradictory, or more stringent requirements. The comment noted that the U.S. Department of Agriculture’s Special Supplemental Nutrition Program for Women, Infants, and Children (“WIC”) does not release WIC data. Because the commenter believed the regulation would not prohibit the disclosure of WIC data, the comment stated that the Department of Agriculture should now release such information.

Response: We support other federal agencies to whom the rules apply in their efforts to review existing regulations and policies regarding protected health information. However, we do not agree with the suggestion that other federal agencies that are not covered entities must reduce the protections or access-related rights they provide for individually identifiable health information they hold.

Part 160, Subpart C—Compliance and Enforcement

Section 160.306(a)—Who Can File Complaints With the Secretary

Comment: The proposed rule limited those who could file a complaint with the Secretary to individuals. A number of commenters suggested that other persons with knowledge of a possible violation should also be able to file complaints. Examples that were provided included a mental health care provider with first hand knowledge of a health plan improperly requiring disclosure of psychotherapy notes and an occupational health nurse with knowledge that her human resources manager is improperly reviewing medical records. A few comments raised the concern that permitting any person to file a complaint lends itself to abuse and is not necessary to ensure privacy rights and that the complainant should be a person for whom there is a duty to protect health information.

Response: As discussed below, the rule defines “individual” as the person who is the subject of the individually identifiable health information. However, the covered entity may allow other persons, such as personal representatives, to exercise the rights of the individual under certain circumstances, e.g., for a deceased individual. We agree with the commenters that any person may become aware of conduct by a covered entity that is in violation of the rule. Such persons could include the covered entity’s employees, business associates, patients, or accrediting, health oversight, or advocacy agencies or organizations. Many persons, such as the covered entity’s employees, may, in fact, be in a better position than the “individual” to know that a violation has occurred. Another example is a state Protection and Advocacy group that may represent persons with developmental disabilities. We have decided to allow complaints from any person. The term “person” is not restricted here to human beings or natural persons, but also includes any type of association, group, or organization.

Allowing such persons to file complaints may be the only way the Secretary may learn of certain possible violations. Moreover, individuals who are the subject of the information may not be willing to file a complaint because of fear of embarrassment or retaliation. Based on our experience with various civil rights laws, such as Title VI of the Civil Rights Act of 1964 and Title II of the Americans with Disabilities Act, that allow any person to file a complaint with the Secretary, we do not believe that this practice will result in abuse. Finally, upholding privacy protections benefits all persons who have or may be served by the covered entity as well as the general public, and not only the subject of the information.

If a complaint is received from someone who is not the subject of protected health information, the person who is the subject of this information may be concerned with the Secretary’s investigation of this complaint. While we did not receive comments on this issue, we want to protect the privacy rights of this individual. This might
involve the Secretary seeking to contact the individual to provide information as to how the Secretary will address individual’s privacy concerns while resolving the complaint. Contacting all individuals may not be practicable in the case of allegations of systemic violations (e.g., where the allegation is that hundreds of medical records were wrongfully disclosed).

**Requiring That a Complainant Exhaust the Covered Entity’s Internal Complaint Process Prior to Filing a Complaint With the Secretary**

Comment: A number of commenters, primarily health plans, suggested that individuals should not be permitted to file a complaint with the Secretary until they exhaust the covered entity’s own complaint process. Commenters stated that covered entities should have a certain period of time, such as ninety days, to correct the violation. Some commenters asserted that providing for filing a complaint with the Secretary will be very expensive for both the public and private sectors of the health care industry to implement. Other commenters suggested requiring the Secretary to inform the covered entity of any complaint it has received and not initiate an investigation or “take enforcement action” before the covered entity has time to address the complaint.

Response: We have decided, for a number of reasons, to retain the approach as presented in the proposed rule. First, we are concerned that requiring that complainants first notify the covered entity would have a chilling effect on complaints. In the course of investigating individual complaints, the Secretary will often need to reveal the identity of the complainant to the covered entity. However, in the investigation of cases of systemic violations and some individual violations, individual names may not need to be identified. Under the approach suggested by these commenters, the covered entity would learn the names of all persons who file complaints with the Secretary. Some individuals might feel uncomfortable or fear embarrassment or retaliation revealing their identity to the covered entity they believe has violated the regulation. Individuals may also feel they are being forced to enter into negotiations with this entity before they can file a complaint with the Secretary.

Second, because some potential complainants would not bring complaints to the covered entity, possible violations might not become known to the Secretary and might continue. Third, the delay in the complaint coming to the attention of the Secretary because of the time allowed for the covered entity to resolve the complaint may mean that significant violations are not addressed expeditiously. Finally, the process proposed by these commenters is arguably unnecessary because an individual who believes that an agreement can be reached with the covered entity, can, through the entity’s internal complaint process or other means, seek resolution before filing a complaint with the Secretary.

Our approach is consistent with other laws and regulations protecting individual rights. None of the civil rights laws enforced by the Secretary require a complainant to provide any notification to the entity that is alleged to have engaged in discrimination (e.g., Americans with Disabilities Act, section 504 of the Rehabilitation Act, Title VI of the Civil Rights Act, and the Age Discrimination Act). The concept of “exhaustion” is used in laws that require individuals to pursue administrative remedies, such as that provided by a governmental agency, before bringing a court action. Under HIPAA, individuals do not have a right to court action.

Some commenters seemed to believe that the Secretary would pursue enforcement action without notifying the covered entity. It has been the Secretary’s practice in investigating cases under other laws, such as various civil rights laws, to inform entities that we have received a complaint against them and to seek early resolution if possible. In enforcing the privacy rule, the Secretary will generally inform the covered entity of the nature of any complaints it has received against the entity. (There may be situations where information is withheld to protect the privacy interests of the complainant or others or where revealing information would impede the investigation of the covered entity.) The Secretary will also generally afford the entity an opportunity to share information with the Secretary that may result in an early settlement. Settlements will be to seek informal resolution of complaints whenever possible, which includes allowing covered entities a reasonable amount of time to work with the Secretary to come into compliance before initiating action to seek civil monetary penalties.

**Section 160.308(b)(3)—Requiring That Complaints Be Filed With the Secretary Within a Certain Period of Time**

Comment: A number of commenters, primarily privacy and disability advocacy organizations, suggested that the regulation require that complaints be filed with the Secretary by a certain time. These commenters generally recommended that the time period for filing a complaint should commence to run from the time when the individual knew or had reason to know of the violation or omission. Another comment suggested that a requirement to file a complaint with the Secretary within 180 days of the alleged noncompliance is a problem because a patient may, because of his or her medical condition, be unable to access his or her records within that time frame.

Response: We agree with the commenters that complainants should generally be required to submit complaints in a timely fashion. Federal regulations implementing Title VI of the Civil Rights Act of 1964 provide that “[a] complaint must be filed not later than ‘180 days from the date of the alleged discrimination’ unless the time for filing is extended by the responsible Department official or his designee.” 45 CFR 80.7(b). Other civil rights laws, such as the Age Discrimination Act, section 504 of the Rehabilitation Act, and Title II of the Americans with Disabilities Act (ADA) (state and local government services), also use this approach. Under civil rights laws administered by the EEOC, individuals have 180 days of the alleged discriminatory act to file a charge with EEOC (or 300 days if there is a state or local fair employment practices agency involved).

Therefore, in the final rule we require that complaints be filed within 180 days of when the complainant knew or should have known that the act or omission complained of occurred unless this time limit is waived by the Secretary for good cause shown. We believe that an investigation of a complaint is likely to be most effective if persons can be interviewed and documents reviewed as close to the time of the alleged violation as possible. Requiring that complaints generally be filed within a certain period of time increases the likelihood that the Secretary will have complete and reliable information. Moreover, we are taking this approach in order to encourage complainants to file complaints as soon as possible. By receiving complaints in a timely fashion, we can, if such complaints prove valid, reduce the harm caused by the violation.

**Section 160.308—Basis for Conducting Compliance Reviews**

Comment: A number of comments expressed concern that the Secretary would conduct compliance reviews.
without having received a complaint or having reason to believe there is noncompliance. A number of these commenters appeared to believe that the Secretary would engage in “routine visits.” Some commenters suggested that the Secretary should only be able to conduct compliance reviews if the Secretary has initiated an investigation of a complaint regarding the covered entity in the preceding twelve months. Some commenters suggested that there should only be compliance reviews based on established criteria for reviews (e.g., finding of “reckless disregard”). Many of these commenters stated that cooperating with compliance reviews is potentially burdensome and expensive.

One commenter asked whether the Secretary will have a process for reviewing all covered entities to determine how they are complying with requirements. This commenter questioned whether covered entities will be required to submit plans and wait for Departmental approval. Another suggested that the Secretary specify a time limit for the completion of a compliance review.

Response: We disagree with the commenters that the final rule should restrict the Secretary’s ability to conduct compliance reviews. The Secretary needs to maintain the flexibility to conduct whatever reviews are necessary to ensure compliance with the rule.

Section 160.310 (a) and (c)—The Secretary’s Access to Information in Determining Compliance

Comment: Some commenters raised objections to provisions in the proposed rule which required that covered entities maintain records and submit compliance reports as the Secretary determines is necessary to determine compliance and required that covered entities permit access by the Secretary during normal business hours to its books, records, accounts, and other sources of information, including protected health information, and its facilities, that are pertinent to ascertaining compliance with this subpart. One commenter stated that the Secretary’s access to private health information without appropriate patient consent is contrary to the intent of HIPAA. Another commenter expressed the view that, because covered entities face criminal penalties for violations, these provisions violate the Fifth Amendment protections against forced self-incrimination. Other commenters stated that covered entities should be given the reason the Secretary needs to have access to its books and records. Another commenter stated that there should be a limit to the frequency or extent of intrusion by the federal government into the business practices of a covered entity and that these provisions violate the Fourth Amendment of the Constitution.

Provision of Technical Assistance

Comment: A number of commenters inquired as to how a covered entity can request technical assistance from the Secretary to come into compliance. A number of commenters suggested that the Secretary provide interpretive guidance to assist with compliance. Others recommended that the Secretary have a contact person or privacy official, available by telephone or email, to provide guidance on the appropriateness of a disclosure or a denial of access. One commenter suggested that there be a formal process for a covered entity to submit compliance activities to the Secretary for prior approval and clarification. This commenter suggested that clarifications be published on a contemporaneous basis in the Federal Register to help correct any ambiguities and confusion in implementation. It was also suggested that the Secretary undertake an assessment of “best practices” of covered entities and document and promote the findings to serve as a convenient “road map” for other covered entities. Another commenter suggested that we work with providers to create implementation guidelines modeled after the interpretative...
guidelines that HCFA creates for surveyors on the conditions of participation for Medicare and Medicaid contractors.

Response: While we have not in the final rule committed the Secretary to any specific model of providing guidance or assistance, we do state our intent, subject to budget and staffing constraints, to develop a technical assistance program that will include the provision of written material when appropriate to assist covered entities in achieving compliance. We will consider other models including HCFA’s Medicare and Medicaid interpretative guidelines. Further information regarding the Secretary’s technical assistance program may be provided in the Federal Register and on the HHS Office for Civil Rights (OCR) Web Site. While OCR plans to have fully trained staff available to respond to questions, its ability to provide individualized advice in regard to such matters as the appropriateness of a particular disclosure or the sufficiency of compliance activities will be based on staff resources and demands. The idea of looking at “best practices” and sharing information with all covered entities is a good one and we will explore how best to do this. We note that a covered entity is not excused from compliance with the regulation because of any failure to receive technical assistance or guidance.

Basis for Violation Findings and Enforcement

Comment: A number of commenters asked that covered entities not be liable for violations of the rule if they have acted in good faith. One commenter indicated that enforcement actions should not be pursued against covered entities that make legitimate business decisions about how to comply with the privacy standards.

Response: The commenters seemed to argue that even if a covered entity does not comply with a requirement of the rule, the covered entity should not be liable if there was an honest and sincere intention or attempt to fulfill its obligations. The final rule, however, does not take this approach but instead draws careful distinctions between what a covered entity must do unconditionally, and what a covered entity must make certain reasonable efforts to do. In addition, the final rule is clear as to the specific provisions where “good faith” is a consideration. For example, a covered entity is permitted to use and disclose protected health information without authorization based on criteria that includes a good faith belief that such use or disclosure is necessary to avert an imminent threat to health or safety (§ 164.512(j)(1)(i)). Therefore, covered entities need to pay careful attention to the specific language in each requirement. However, we note that many of these provisions can be implemented in a variety of ways; e.g., covered entities can exercise business judgement regarding how to conduct staff training.

As to enforcement, a covered entity will not necessarily suffer a penalty solely because an act or omission violates the rule. As we discuss elsewhere, the Department will exercise discretion to consider not only the harm done, but the willingness of the covered entity to achieve voluntary compliance. Further, the Administrative Simplification provisions of HIPAA provide that whether a violation was known or not is relevant in determining whether civil or criminal penalties apply. In addition, if a civil penalty applies, HIPAA allows the Secretary, where the failure to comply was due to reasonable cause and not to willful neglect, to delay the imposition of the penalty to allow the covered entity to comply. The Department will develop and release for public comment an enforcement regulation applicable to all the administrative simplification regulations that will address these issues.

Comment: One commenter asked whether hospitals will be vicariously liable for the violations of their employees and expressed concern that hospitals and other providers will be the ones paying large fines.

Response: The enforcement regulation will address this issue. However, we note that section 1128A(1) of the Social Security Act, which applies to the imposition of civil monetary penalties under HIPAA, provides that a principal is liable for penalties for the actions of its agent acting within the scope of the agency. Therefore, a covered entity will generally be responsible for the actions of its employees such as where the employee discloses protected health information in violation of the regulation.

Comment: A commenter expressed concern that if a covered entity acquires a non-compliant health plan, it would be liable for financial penalties. This commenter suggested that, at a minimum, the covered entity be given a grace period of at least a year, but not less than six months to bring any acquisition up to standard. The commenter stated that the Secretary should encourage compliant companies to acquire non-compliant ones. Another commenter expressed a general concern about resolution of enforcement if an entity faced with a HIPAA complaint acquires or merges with an entity not covered by HIPAA.

Response: As discussed above, the Secretary will encourage voluntary efforts to cure violations of the rule, and will consider that fact in determining whether to bring a compliance action. We do not agree, however, that we should limit our authority to pursue violations of the rule if the situation warrants it.

Comment: One commenter was concerned about the “undue risk” of liability on originators of information, stemming from the fact that “the number of covered entities is limited and they are unable to restrict how a recipient of information may use or re-disclose information.”

Response: Under this rule, we do not hold covered entities responsible for the actions of recipients of protected health information, unless the recipient is a business associate of the covered entity. We agree that it is not fair to hold covered entities responsible for the actions of persons with whom they have no on-going relationship, but believe it is fair to expect covered entities to hold their business associates to appropriate standards of behavior with respect to health information.

Other Compliance and Enforcement Comments

Comment: A number of comments raised questions regarding the Secretary’s priorities for enforcement. A few commenters stated that they supported deferring enforcement until there is experience using the proposed standards. One organization asked that we clarify that the regulation does not replace or otherwise modify the self-regulatory/consumer empowerment approach to consumer privacy in the online environment.

Response: We have not made any decisions regarding enforcement priorities. It appears that some commenters believe that no enforcement action will be taken against a given covered entity until that entity has had some time to comply. Covered entities have two years to come into compliance with the regulation (three years in the case of small health plans). Some covered entities will have had experience using the standards prior to the compliance date. We do not agree that we should defer enforcement where violations of the rule occur. It would be wrong, for covered entities to believe that enforcement action is based on their not having much experience in
using a particular standard or meeting another requirement. We support a self-regulation approach in that we recognize that most compliance will be achieved by the voluntary activities of covered entities rather than by our enforcement activities. Our emphasis will be on education, technical assistance, and voluntary compliance and not on finding violations and imposing penalties. We also support a consumer empowerment approach. A knowledgeable consumer is key to the effectiveness of this rule. A consumer familiar with the requirements of this rule will be equipped to make choices regarding which covered entity will best serve their privacy interests and will know their rights under the rule and how they can seek redress for violations of this rule. Privacy-minded consumers will seek to protect the privacy rights of others by bringing concerns to the attention of covered entities, the public, and the Secretary. However, we do not agree that we should defer enforcement where violations of the rule occur.

Comment: One commenter expressed concern that by filing a complaint an individual would be required to reveal sensitive information to the public. Another commenter suggested that complaints regarding noncompliance in regard to psychotherapy notes should be made to a panel of mental health professionals designated by the Secretary. This commenter also proposed that all patient information be maintained as privileged, not be revealed to the public, and be kept under seal after the case is reviewed and closed.

Response: We appreciate this concern and will seek to ensure that individually identifiable health information and other personal information contained in complaints will not be available to the public. The privacy regulation provides, at § 160.310(c)(3), that protected health information obtained by the Secretary in connection with an investigation or compliance review will not be disclosed except if necessary for ascertaining or enforcing compliance with the regulation or if required by law. In addition, this Department generally seeks to protect the privacy of individuals to the fullest extent possible, while permitting the exchange of records required to fulfill its administrative and program responsibilities. The Freedom of Information Act, 5 U.S.C. 552, and the HHS implementing regulation, 45 CFR part 5, provide substantial protection for records where disclosure would constitute an unwarranted invasion of their personal privacy. In implementing the privacy regulation, OCR plans to continue its current practice of protecting its complaint files from disclosure. OCR treats these files as investigatory records compiled for law enforcement purposes. Moreover, OCR maintains that disclosing protected health information in these files generally constitutes an unwarranted invasion of personal privacy.

It is not clear in regarding the use of mental health professionals, whether the commenter believes that such professionals should be involved because they would be best able to keep psychotherapy notes confidential or because such professionals can best understand the meaning or relevance of such notes. OCR anticipates that it will not have to obtain a copy or review psychotherapy notes in investigating most complaints regarding noncompliance in regard to such notes. There may be some cases where a review of the notes may be needed such as where we need to identify that the information a covered entity disclosed was in fact psychotherapy notes. If we need to obtain a copy of psychotherapy notes, we will keep these notes confidential and secure. OCR investigative staff will be trained to ensure that they fully respect the confidentiality of personal information. In addition, while the specific contents of these notes is generally not relevant to violations under this rule, if such notes are relevant, we will secure the expertise of mental health professionals if needed in reviewing psychotherapy notes.

Comment: A member of Congress and a number of privacy and consumer groups expressed concern with whether OCR has adequate funding to carry out the major responsibility of enforcing the complaint process established by this rule. The Senator stated that “due to the limited enforcement ability allowed for in this rule by HIPAA, it is essential that OCR have the capacity to enforce the regulations. Now is the time for OCR to begin building the necessary infrastructure to enforce the regulation effectively.”

Response: We agree and are committed to an effective enforcement program. We are working with Congress to ensure that the Secretary has the necessary funds to secure voluntary compliance through education and technical assistance, to investigate complaints and conduct compliance reviews, to provide states with exemptions from civil and criminal penalties when necessary. We will continue to work with Congress and within the new Administration in this regard.

Coordination With review Authorities

Comment: A number of commenters referenced other entities that already consider the privacy of health information. One commenter indicated opposition to the delegation of inspections to third party organizations, such as the Joint Commission on the Accreditation of Healthcare Organizations (JCAHO). A few commenters indicated that state agencies are already authorized to investigate violations of state privacy standards and that we should rely on those agencies to investigate alleged violations of the privacy rules or delegate its complaint process to states that wish to carry out this responsibility or to those states that have a complaint process in place. Another commenter argued that individuals should be required to exhaust any state processes before filing a complaint with the Secretary. Others referenced the fact that state medical licensing boards investigate complaints against physicians for violating patient confidentiality. One group asked that the federal government streamline all of these activities so physicians can have a single entity to whom they must be responsive. Another group suggested that OMB should be given responsibility for ensuring that FEHB Plans operate in compliance with the privacy standards and for enforcement.

A few commenters stated that the regulation might be used as a basis for violation findings and subsequent penalties under other Department authorities, such as under Medicare’s Conditions of Participation related to patient privacy and right to confidentiality of medical records. One commenter wanted some assurance that this regulation will not be used as grounds for sanctions under Medicare. Another commenter indicated support for making compliance with the privacy regulation a Condition of Participation under Medicare.

Response: HIPAA does not give the Secretary the authority to delegate her responsibilities to other private or public agencies such as JCAHO or state agencies. However, we plan to explore ways that we may benefit from current activities that also serve to protect the privacy of individually identifiable health information. For example, if we conduct an investigation or review of a covered entity, that entity may want to share information regarding findings of other bodies that conducted similar reviews. We would welcome such
information. In developing its enforcement program, we may explore ways that it can coordinate with other regulatory or oversight bodies so that we can efficiently and effectively pursue our joint interests in protecting privacy.

We do not accept the suggestion that individuals be required to exhaust their remedies under state law before filing a complaint with the Secretary. Our rationale is similar to that discussed above in regard to the suggestion that covered entities be required to exhaust a covered entity’s internal complaint process before filing a complaint with the Secretary. Congress provided for federal privacy protection and we want to allow individuals the right to this protection without barriers or delay. Covered entities may in their privacy notice inform individuals of any rights they have under state law including any right to file privacy complaints. We do not have the authority to interfere with state processes and HIPAA explicitly provides that we cannot preempt state laws that provide greater privacy protection.

We have not yet addressed the issue as to whether this regulation might be used as a basis for violation findings or penalties under other Department authorities. We note that Medicare conditions of participation require participating providers to have procedures for ensuring the confidentiality of patient records, as well as afford patients with the right to the confidentiality of their clinical records.

Penalties

Comment: Many commenters considered the statutory penalties insufficient to protect privacy, stating that the civil penalties are too weak to have the impact needed to reduce the risk of inappropriate disclosure. Some commenters took the opposing view and stated that large fines and prison sentences for violations would discourage physicians from transmitting any sort of health care information to any other agency, regardless of the medical necessity. Another comment expressed the concern that doctors will be at risk of going to jail for protecting the privacy of individuals (by not disclosing information the government believes should be released).

Response: The enforcement regulation will address the application of the civil monetary and criminal penalties under HIPAA. The regulation will be published in the Federal Register as a proposed regulation and the public will have an opportunity to comment. We do not believe that our rule, and the penalties available under it, will discourage physicians and other providers from using or disclosing necessary information. We believe that the rule permits physicians to make the disclosures that they need to make under the health care system without exposing themselves to jeopardy under the rule. We believe that the penalties under the statute are woefully inadequate. We support legislation that would increase the amount of these penalties.

Comment: A number of commenters stated that the regulations should permit individuals to sue for damages caused by breaches of privacy under these regulations. Some of these commenters specified that damages, equitable relief, attorneys fees, and punitive damages should be available. Conversely, one comment stated that strong penalties are necessary and would preclude the need for a private right of action. Another commenter stated that he does not believe that the statute intended to give individuals the equivalent of a right to sue, which results from making individuals third party beneficiaries to contracts between business partners.

Response: We do not have the authority to provide a private right of action by regulation. As discussed below, the final rule deletes the third party beneficiary provision that was in the proposed rule.

However, we believe that, in addition to strong civil monetary penalties, federal law should allow any individual whose rights have been violated to bring an action for actual damages and equitable relief. The Secretary’s Recommendations, which were submitted to Congress on September 11, 1997, called for a private right of action to permit individuals to enforce their privacy rights.

Comment: One comment stated that, in calculating civil monetary penalties, the criteria should include aggravating or mitigating circumstances and whether the violation is a minor or first time violation. Several comments stated that penalties should be tiered so that those that commit the most egregious violations face stricter civil monetary penalties.

Response: As mentioned above, issues regarding civil fines and criminal penalties will be addressed in the enforcement regulation.

Comment: One comment stated that the regulation should clarify whether a single disclosure that involved the health information of multiple parties would constitute a single or multiple infractions, for the purpose of calculating the penalty amount.

Response: The enforcement regulation will address the calculation of penalties. However, we note that section 1176 subjects persons to civil monetary penalties of not more than $1000 for each violation of a requirement or prohibition and not more than $25,000 in a calendar year for all violations of an identical requirement or prohibition. For example, if a covered entity fails to permit amendment of protected health information for 10 patients in one calendar year, the entity may be fined up to $1000 ($100 times 10 violations equals $1000).

Part 164—Subpart A—General Requirements

Part 164—Subpart B—Reserved

Part 164—Subpart E—Privacy

Section 164.500—Applicability

Covered Entities

The response to comments on covered entities is included in the response to comments on the definition of “covered entity” in the preamble discussion of § 160.103.

Covered Information

The response to comments on covered information is included in the response to comments on the definition of “protected health information” in the preamble discussion of § 164.501.

Section 164.501—Definitions

Designated record set

Comment: Many commenters generally supported our proposed definition of designated record set. Commenters suggested different methods for narrowing the information accessible to individuals, such as excluding information obtained without face-to-face interaction (e.g., phone consultations). Other commenters recommended broadening the information accessible to individuals, such as allowing access to “the entire medical record,” not just a designated record set. Some commenters advocated for access to all information about individuals. A few commenters generally supported the provision but recommended that consultation and interpretative assistance be provided when the disclosure may cause harm or misunderstanding.

Response: We believe individuals should have a right to access any protected health information that may be used to make decisions about them and modify the final rule to accomplish this result. This approach facilitates an open and cooperative relationship between individuals and covered health care providers and health plans and allows individuals fair opportunities to know what health information may be
used to make decisions about them. We list certain records that are always part of the designated record set. For covered providers these are the medical record and billing record. For health plans these are the enrollment, payment, claims adjudication, and case or medical management records. The purpose of these specified records is management of the accounts and health care of individuals. In addition, we include in the designated record set to which individuals have access any record used, in whole or in part, by or for the covered entity to make decisions about individuals. Only protected health information that is in a designated record set is covered. Therefore, if a covered provider has a phone conversation, information obtained during that conversation is subject to access only to the extent that it is recorded in the designated record set.

We do not require a covered entity to provide access to all individually identifiable health information, because the benefits of access to information not used to make decisions about individuals is limited and is outweighed by the burdens on covered entities of locating, retrieving, and providing access to such information. Such information may be found in many types of records that include significant information not relevant to the individual as well as information about other persons. For example, a hospital’s peer review files that include protected health information about many patients but are used only to improve patient care at the hospital, and not to make decisions about individuals, are not part of that hospital’s designated record sets.

We encourage but do not require covered entities to provide interpretive assistance to individuals accessing their information, because such a requirement could impose administrative burdens that outweigh the benefits likely to accrue.

The importance to individuals of having the right to inspect and copy information about them is supported by a variety of industry groups and is recognized in current state and federal law. The July 1977 Report of the Privacy Protection Study Commission recommended that individuals have access to medical records and medical record information. The Privacy Act (5 U.S.C. 552a) requires government agencies to permit individuals to review records and have a copy made in a form comprehensible to the individual. In its report “Best Principles for Health Privacy,” the Health Privacy Working Group recommended that individuals should have the right to access information about them. The National Association of Insurance Commissioners’ Health Information Privacy Model Act establishes the right of an individual to examine or receive a copy of protected health information in the possession of the carrier or a person acting on behalf of the carrier.

Many states also establish a right for individuals to access health information about them. For example, Alaska law (AK Code 18.23.005) entitles patients “to inspect and copy any records developed or maintained by a health care provider or other person pertaining to the health care rendered to the patient.” Hawaii law (HRS section 323C–11) requires health care providers and health plans, among others, to permit individuals to inspect and copy protected health information about them. Many other states have similar provisions. Industry and standard-setting organizations also have developed policies to enable individual access to health information. The National Committee for Quality Assurance and the Joint Commission on Accreditation of Healthcare Organizations issued recommendations stating, “Patients’ confidence in the protection of their information requires that they have the means to know what is contained in their records. The opportunity for patients to review their records will enable them to correct any errors and may provide them with a better understanding of their health status and treatment.”

Standards of the American Society for Testing and Materials state, “The patient or his or her designated personal representative has access rights to the data and information in his or her health record and other health information databases except as restricted by law. An individual should be able to inspect or see his or her health information or request a copy of all or part of the health information, or both.”

We build on this well-established principle in this final rule.

---


individuals, the burdens of requiring a covered entity to find it and to redact information about other individuals outweigh any benefits to the individual of having access to the information. When the information might be used to affect the individual’s interests, however, that balance changes and the benefits outweigh the burdens. We confirm that this regulation does not require covered entities to maintain any particular record set by name or identifier.

Comment: A few commenters recommended denial of access for information relating to investigations of claims, fraud, and misrepresentations. Many commenters suggested that sensitive, proprietary, and legal documents that are “typical state law privileges” be excluded from the right to access. Specific suggestions for exclusion, either from the right of access or from the definition of designated record set, include quality assurance activities, information related to medical appeals, peer review and credentialing, attorney-client information, and compliance committee activities. Some commenters suggested excluding information already supplied to individuals on previous requests and information related to health care operations. However, some commenters felt that such information was already excluded from the definition of designated record set. Other commenters requested clarification that this provision will not prevent patients from getting information related to medical malpractice.

Response: We do not agree that records in these categories are never used to affect the interests of individuals. For example, while protected health information used for peer review and quality assurance activities typically would not be used to make decisions about individuals, and, thus, typically would not be part of a designated record set, we cannot say that this is true in all cases. We design this provision to be sufficiently flexible to work with the varying practices of covered entities.

The rule addresses several of these comments by excepting from the access provisions (§164.524) information compiled in reasonable anticipation of, or for use in, a civil, criminal, or administrative action or proceeding. Similarly, nothing in this rule requires a covered entity to divulge information covered by physician-patient or similar privilege. Under the access provisions, a covered entity may redact information in a record about other persons or information obtained under a promise of confidentiality, prior to releasing the information to the individual. We clarify that nothing in this provision would prevent access to information needed to prosecute or defend a medical malpractice action; the rules of the relevant court determine such access.

We found no persuasive evidence to support excluding information already supplied to individuals on previous requests. The burdens of tracking requests and the information provided pursuant to requests outweigh the burdens of providing the access requested. A covered entity may, however, discuss the scope of the request for access with the individual to facilitate the timely provision of access. For example, if the individual agrees, the covered entity could supply only the information created or received since the date access was last granted.

Disclosure

Comment: A number of commenters asked that the definition of “disclosure” be modified so that it is clear that it does not include the release, transfer, provision of access to, or divulging in any other manner of protected health information to the individual who is the subject of that information. It was suggested that we revise the definition in this way to clarify that a health care provider may release protected health information to the subject of the information without first requiring that the patient complete an authorization form.

Response: We agree with the commenters’ concern, but accomplish this result through a different provision in the regulation. In §164.502 of this final rule, we specify that disclosures of protected health information to the individual are not subject to the limitations on disclosure of protected health information otherwise imposed by this rule.

Comment: A number of commenters stated that the regulation should not apply to disclosures occurring within or among different subsidiaries or components of the same entity. One commenter interpreted “disclosure” to mean outside the agency or, in the case of a state Department of Health, outside sister agencies and offices that directly assist the Secretary in performing Medicaid functions and are listed in the state plan as entitled to receive Medicaid data.

Response: We agree that there are circumstances under which related organizations may be treated as a single covered entity for purposes of protecting the privacy of health information, and we modify the rule to accommodate such circumstances. In §164.504 of the final rule, we specify the conditions under which affiliated companies may combine into a single covered entity and similarly describe which components of a larger organization must comply with the requirements of this rule. For example, transfers of information within the designated component or affiliated entity are uses while transfers of information outside the designated component or affiliated entity are disclosures. See the discussion of §164.504 for further information and rationale. It is not clear from these comments whether the particular organizational arrangements described could constitute a single covered entity.

Comment: A commenter noted that the definition of “disclosure” should reflect that health plan correspondence containing protected health information, such as Explanation of Benefits (EOBs), is frequently sent to the policyholder. Therefore, it was suggested that the words “provision of access to” be deleted from the definition and that a “disclosure” be clarified to include the conveyance of protected health information to the policyholder.

Response: The definition is, on its face, broad enough to cover the transfers of information described and so is not changed. We agree that health plans must be able to send EOBs to policyholders. Sending EOB correspondence to a policyholder by a covered entity is a disclosure for purposes of this rule, but it is a disclosure for purposes of payment. Therefore, subject to the provisions of §164.522(b) regarding Confidential Communications, it is permitted even if it discloses to the policyholder protected health information about another individual (see below).

Health care operations

Comment: Several commenters stated that the list of activities within the definition of health care operations was too broad and should be narrowed. They asserted that the definition should be limited to exclude activities that have little or no connection to the care of a particular patient or to only include emergency treatment situations or situations constituting a clear and present danger to oneself or others.

Response: We disagree. We believe that narrowing the definition in the manner requested will place serious burdens on covered entities and impair their ability to conduct legitimate business and management functions.

Comment: Many commenters, including physician groups, consumer groups, and privacy advocates, argued that we should limit the information that can be used for health care operations to de-identified data. They
argued that if an activity could be done with de-identified data, it should not be incorporated in the definition of health care operations.

Response: We disagree. We believe that many activities necessary for the business and administrative operations of health plans and health care providers are not possible with de-identified information or are possible only under unduly burdensome circumstances. For example, identified information may be used or disclosed during an audit of claims, for a plan to contact a provider about alternative treatments for specific patients, and in reviewing the competence of health care professionals. Further, not all covered entities have the same ability to de-identify protected health information. Covered entities with highly automated information systems will be able to use de-identified data for many purposes. Other covered entities maintain most of their records on paper, so a requirement to de-identify information would place too great a burden on the legitimate and routine business functions included in the definition of health care operations. Small business, which are most likely to have largely paper records, would find such a blanket requirement particularly burdensome.

Protected health information that is de-identified pursuant to § 164.514(a) is not subject to this rule. We hope this provides covered entities capable of de-identifying information with the incentive to do so.

Comment: Some commenters requested that we permit the use of demographic data (geographic, location, age, gender, and race) separate from all other data for health care operations. They argued that demographic data was needed to establish provider networks and monitor providers to ensure that the needs of ethnic and minority populations were being addressed.

Response: The use of demographic data for the stated purposes is within the definition of health care operations; a special rule is not necessary.

Comment: Some commenters pointed out that the definition of health care operations is similar to, and at times overlaps with, the definition of research. In addition, a number of commenters questioned whether or not research conducted by the covered entity or its business partner must only be applicable to and used within the covered entity to be considered health care operations. Others questioned whether such studies or research performed internal to a covered entity are “health care operations” even if generalizable results may be produced.

Response: We agree that some health care operations have many of the characteristics of research studies and in the NPRM asked for comments on how to make this distinction. While a clear answer was not suggested in any of the comments, the comments generally together with our fact finding lead to the provisions in the final rule. The distinction between health care operations and research rests on whether the primary purpose of the study is to produce “generalizable knowledge.” We have modified the definition of health care operations to include “quality assessment and improvement activities, including outcomes evaluation and development of clinical guidelines, provided that the obtaining of generalizable knowledge is not the primary purpose of any studies resulting from such activities.” If the primary purpose of the activity is to produce generalizable knowledge, the activity fits within this rule’s definition of “research” and the covered entity must comply with §§ 164.508 or 164.512, including obtaining an authorization or the approval of an institutional review board or privacy board. If not and the activity otherwise meets the definition of health care operations, the activity is not research and may be conducted under the health care operations provisions of this rule.

In some instances, the primary purpose of the activity may change as preliminary results are analyzed. An activity that was initiated as an internal outcomes evaluation may produce information that the covered entity wants to generalize. If the purpose of a study changes and the covered entity does intend to generalize the results, the covered entity should document the change in status of the activity to establish that they did not violate the requirements of this rule. (See definition of “research,” below, for further information on the distinction between “research” and “health care operations.”) We note that the difficulty in determining when an activity is for the internal operations of an entity and when it is a research activity is a long-standing issue in the industry. The variation among commenters’ views is one of many indications that, today, there is not consensus on how to draw this line. We do not resolve the larger issue here, but instead provide requirements specific to the information covered by this rule.

Comment: Several commenters asked that disease management and disability management activities be explicitly included in the definition of health care operations. Many health plans asserted that they would not be able to provide disease management, wellness, and health promotion activities if the activity were solely captured in the rule’s definition of “treatment.” They also expressed concern that “treatment” usually applies to an individual, not to a population, as is the practice for disease management.

Response: We were unable to find generally accepted definitions of the terms “disease management” and “disability management.” Rather than rely on this label, we include many of the functions often included in discussions of disease management in this definition or in the definition of treatment, and modify both definitions to address the commenters’ concerns. For example, we have revised the definition of health care operations to include population-based activities related to improving health or reducing health care costs. This topic is discussed further in the comment responses regarding the definition of “treatment,” below.

Comment: Several commenters urged that the definition of health care operations be illustrative and flexible, rather than structured in the form of a list as in the proposed rule. They believed it would be impossible to identify all the activities that constitute health care operations. Commenters representing health plans were concerned that the “static” nature of the definition would stifl innovation and could not reflect the new functions that health plans may develop in the future that benefit consumers, improve quality, and reduce costs. Other commenters expressed support for the approach taken in the proposed rule, but felt the list was too broad.

Response: In the final rule, we revise the proposed definition of health care operations to broaden the list of activities included, but we do not agree with the comments asking for an illustrative definition rather than an inclusive list. Instead, we describe the activities that constitute health care operations in broad terms and categories, such as “quality assessment” and “business planning and development.” We believe the use of broadly stated categories will allow industry innovation, but without the privacy risks entailed in an illustrative approach.

Comment: Several commenters noted that utilization review and internal quality review should be included in the definition. They pointed out that both of these activities were discussed in the preamble to the proposed rule but were not incorporated into the regulation text.
Response: We agree and have modified the regulation text to incorporate quality assessment and improvement activities, including the development of clinical guidelines and protocol development.

Comment: Several commenters stated that the proposal did not provide sufficient guidance regarding compiling and analyzing information in anticipation of or for use in legal proceedings. In particular, they raised concerns about the lack of specificity as to when “anticipation” would be triggered.

Response: We agree that this provision was confusing and have replaced it with a broader reference to conducting or arranging for legal services generally.

Comment: Hospital representatives pointed out the pressure on health care facilities to improve cost efficiencies, make cost-effectiveness studies, and benchmark essential health care operations. They emphasized that such activities often use identifiable patient information, although the products of the analyses usually do not contain identifiable health information. Commenters representing state hospital associations pointed out that they routinely receive protected health information from hospitals for analyses that are used by member hospitals for such things as quality of care benchmark comparisons, market share analysis, determining physician utilization of hospital resources, and charge comparisons.

Response: We have expanded the definition of health care operations to include use and disclosure of protected health information for the important functions noted by these commenters. We also allow a covered entity to engage a business associate to provide data aggregation services. See § 164.504(e).

Comment: Several commenters argued that many activities that are integral to the day-to-day operations of a health plan have not been included in the definition. Examples provided by the commenters include: issuing plan identification cards, customer service, computer maintenance, storage and back-up of radiologic images, and the installation and servicing of medical equipment or computer systems.

Response: We agree with the commenters that there are activities not directly part of treatment and payment that are more closely associated with the administrative or clerical functions of the plan or provider that need to be included in the definition. To include such activities in the definition of health care operations, we eliminate the requirement that health care operations be directly related to treatment and payment, and we add to this definition the new categories of business management (including general administrative activities) and business planning activities.

Comment: One commenter asked for clarification on whether cost-related analyses could also be done by providers as well as health plans.

Response: Health care operations, including business management functions, are not limited to health plans. Any covered entity can perform health care operations.

Comment: One commenter stated that the proposed rule did not address what happens to records when a covered entity is sold or merged with another entity.

Response: We agree and add “activities relating to the replacement of a contract of insurance” to cover such disclosures. See § 164.504 for the rules for plan sponsors of group health plans to obtain such information.

Comment: Commenters from the business community supported our recognition of the importance of financial risk transfer mechanisms in the health care marketplace by including “reinsurance” in the definition of health care operations. However, they stated that the term “reinsurance” alone was not adequate to capture “stop-loss insurance” (also referred to as excess of loss insurance), another type of risk transfer insurance.

Response: We agree with the commenters that stop-loss and excess of loss insurance are functionally equivalent to reinsurance and add these to the definition of health care operations.

Comment: Commenters from the employer community explained that there is a trend among employers to contract with a single insurer for all their insurance needs (health, disability, workers’ compensation). They stated that in these integrated systems, employee health information is shared among the various programs in the system. The commenters believed the existing definition poses obstacles for those employers utilizing an integrated health system because of the need to obtain authorizations before being permitted to use protected health information from the health plan to administer or audit their disability or workers’ compensation plan.

Other commenters representing employers stated that some employers wanted to combine health information from different insurers and health plans providing employee benefits to their workforces, including its group health plan, workers’ compensation insurers, and disability insurers, so that they could have more information in order to better manage the risk of disability and illness among their workforces. They expressed concern...
that the proposed rule would not permit such sharing of information.

Response: While we agree that integrating health information from different benefit programs may produce efficiencies as well as benefits for individuals, the integration also raises significant privacy concerns, particularly if there are no safeguards on uses and disclosures from the integrated data. Under HIPAA, we do not have jurisdiction over many types of insurers that use health information, such as workers’ compensation insurers or insurers providing disability income benefits, and we cannot address the extent to which they provide individually identifiable health information to a health plan, nor do we prohibit a health plan from receiving such information. Once a health plan receives identifiable health information, however, the information becomes protected and may only be used and disclosed as otherwise permitted by this rule.

We clarify, however, that a covered entity may provide data and statistical analyses for its customers as a health care operation, provided that it does not disclose protected health information in a way that would otherwise violate this rule. A group health plan or health insurance issuer or HMO, or their business associate on their behalf, may perform such analyses for an employer customer and provide the results in de-identified form to the customer, using integrated data received from other insurers, as long as protected health information is not disclosed in violation of this rule. See the definition of “health care operations.” § 164.501. If the employer sponsors more than one group health plan, or if its group health plan provides coverage through more than one health insurance issuer or HMO, the different covered entities may be an organized health care arrangement and be able to jointly participate in such an analysis as part of the health care operations of such organized health care arrangement. See the definitions of “health care operations” and “organized health care arrangement.” § 164.501. We further clarify that a plan sponsor providing plan administration to a group health plan may participate in such an analysis, provided that the requirements of § 164.504(f) and other parts of this rule are met.

The results described above are the same whether the health information that is being combined is from separate insurers or from one entity that has a health component and also provides exception benefits. See the discussion relating to health care components, § 164.504.

We note that under the arrangements described above, the final rule provides substantial flexibility to covered entities to provide general data and statistical analyses, resulting in the disclosure of de-identified information, to employers and other customers. An employer also may receive protected health information from a covered entity for any purpose, including those described in comment above, with the authorization of the individual. See § 164.508.

Comment: A number of commenters asserted that the proposed definition appeared to limit training and educational activities to that of health care professionals, students, and trainees. They asked that we expand the definition to include other education-related activities, such as continuing education for providers and training of non-health care professionals as needed for supporting treatment or payment.

Response: We agree with the commenters that the definition of health care operations was unnecessarily limiting with respect to educational activities and expand the definition of health care operations to include “conducting training programs in which students, trainees, or practitioners in areas of health care learn under supervision to practice or improve their skills as health care providers.” We clarify that medical rounds are considered treatment, not health care operations.

Comment: A few commenters outlined the need to include the training of non-health care professionals, such as health data analysts, administrators, and computer programmers within the definition of health care operations. It was argued that, in many cases, these professionals perform functions which support treatment and payment and will need access to protected health information in order to carry out their responsibilities.

Response: We agree and expand the definition of health care operations to include training of non-health care professionals.

Comment: One commenter stated that the definition did not explicitly include physician credentialing and peer review.

Response: We have revised the definition to specifically include “licensing or credentialing activities.” In addition, peer review activities are captured in the definition as reviewing the competence or qualifications of health care professionals and evaluating practitioner and provider performance.

Health Oversight Agency

Comment: Some commenters sought to have specific organizations defined as health oversight agencies. For example, some commenters asked that the regulation text, rather than the preamble, explicitly list state insurance departments as an example of health oversight agencies. Medical device manufacturers recommended expanding the definition to include government contractors such as coding committees, which provide data to HCFA to help the agency make reimbursement decisions.

One federal agency sought clarification that several of its sub-agencies were oversight agencies; it was concerned about its status in part because the agency fits into more than one of the categories of health oversight agency listed in the proposed rule. Other commenters recommended expanding the definition of oversight agency to include private-sector accreditation organizations. One commenter recommended stating in the final rule that private companies providing information to insurers and employers are not included in the definition of health oversight agency.

Response: Because the range of health oversight agencies is so broad, we do not include specific examples in the definition. We include many examples in the preamble above and provide further clarification here.

As under the NPRM, state insurance departments are an example of a health oversight agency. A commenter concerned about state trauma registries did not describe the registries’ activities or legal charters, so we cannot clarify whether such registries may be health oversight agencies. Government contractors such as coding committees, which provide data to HCFA to support payment processes, are not thereby health oversight agencies under this rule. We clarify that public agencies may fit into more than one category of health oversight agency.

The definition of health oversight agency does not include private-sector accreditation organizations. While their work can promote quality in the health care delivery system, private accreditation organizations are not authorized by law to oversee the health care system or government programs in which health information is necessary to determine eligibility or compliance, or to enforce civil rights laws for which health information is relevant. Under the final rule, we consider private accrediting groups to be performing a health care operations function for covered entities. Thus, disclosures to private accrediting organizations are
disclosures for health care operations, not for oversight purposes.

When they are performing accreditation activities for a covered entity, private accrediting organizations will meet the definition of business associate, and the covered entity must enter into a business associate contract with the accrediting organization in order to disclose protected health information. This is consistent with current practice; today, accrediting organizations perform their work pursuant to contracts with the accredited entity. This approach is also consistent with the recommendation by the Joint Commission on Accreditation of Healthcare Organizations and the National Committee for Quality Assurance, which stated in their report titled Protecting Personal Health Information: A Framework for Meeting the Challenges in a Managed Care Environment (1998) that “Oversight organizations, including accrediting bodies, states, and federal agencies, should include in their contracts terms that describe their responsibility to maintain the confidentiality of any personally identifiable health information that they review.”

We agree with the commenter who believed that private companies providing information to insurers and employers are not performing an oversight function; the definition of health oversight agency does not include such companies.

In developing and clarifying the definition of health oversight in the final rule, we seek to achieve a balance in accounting for the full range of activities that public agencies may undertake to perform their health oversight functions while establishing clear and appropriate boundaries on the definition so that it does not become a catch-all category that public and private agencies could use to justify any request for information.

Individual

Comment: A few commenters stated that foreign military and diplomatic personnel, and their dependents, and overseas foreign national beneficiaries, should not be excluded from the definition of “individual.”

Response: We agree with concerns stated by commenters and eliminate these exclusions from the definition of “individual” in the final rule. Special rules for use and disclosure of protected health information about foreign military personnel are stated in §164.512(k). Under the final rule, protect health information about diplomatic personnel is not accorded special treatment. While the exclusion of overseas foreign national beneficiaries has been deleted from the definition of “individual,” we have revised §164.500 to indicate that the rule does not apply to the Department of Defense or other federal agencies or non-governmental organizations acting on its behalf when providing health care to overseas foreign national beneficiaries. This means that the rule will not cover any health information created incident to the provision of health care to foreign nationals overseas by U.S. sponsored missions or operations. (See §164.500 and its corresponding preamble for details and the rationale for this policy.)

Comment: Several commenters expressed concern about the interrelationship of the definition of “individual” and the two year privacy protection for deceased persons.

Response: In the final rule, we eliminate the two year limit on privacy protection for protected health information about deceased individuals and require covered entities to comply with the requirements of the rule with respect to the protected health information of deceased individuals as long as they hold such information. See discussion under §164.502.

Individually Identifiable Health Information

Comment: A number of commenters suggested that HHS revise the definitions of health information and individually identifiable health information to include consistent language in paragraph (1) of each respective definition. They observed that paragraph (1) of the definition of health information reads: “(1) Is created by or received from a health care provider, health plan, public health authority, employer, life insurer, school or university, or health care clearinghouse * * *;” in contrast to paragraph (1) of the definition of individually identifiable health information, which reads: “(1) Is created by or received from a health care provider, health plan, employer, or health care clearinghouse * * *.” [Emphasis added.]

Another commenter asked that we delete from the definition of health information, the words “health or” to make the definition more consistent with the definition of “health care,” as well as the words “whether oral or.”

Response: We define these terms in the final rule as they are defined by Congress in sections 1171(4) and 1171(6) of the Act, respectively. We have, however, changed the word “from” in the definition of “individually identifiable health information” to conform to the statute.
that the definition of individually identifiable health information includes “employer,” whereas protected health information pertains only to covered entities for which employers are not included. The commenter argued that this was an “incongruity” between the definitions of individually identifiable health information and protected health information and recommended that we remove “employer” from the definition of individually identifiable health information.

Response: We define individually identifiable health information in the final rule generally as it is defined by Congress in section 1171(6) of the Act. Because “employer” is included in the statutory definition, we cannot accept the comment to remove the word “employer” from the regulatory definition.

We use the phrase “protected health information” to distinguish between the individually identifiable health information that is used or disclosed by the entity that are subject to this rule and the entire universe of individually identifiable health information. “Individually identifiable health information” as defined in the statute is not limited to health information used or disclosed by covered entities, so the qualifying phrase “protected health information” is necessary to define that individually identifiable health information to which this rule applies.

Comment: One commenter noted that the definition of individually identifiable health information in the NPRM appeared to be the same definition used in the other HIPAA proposed rule, Security and Electronic Signature Standards (63 FR 43242). However, the commenter stated that the additional condition in the privacy NPRM, that protected health information is or has been electronically transmitted or electronically maintained by a covered entity and includes such information in any other form, appears to create potential disparity between the requirements of the two rules. The commenter questioned whether the provisions in proposed § 164.518(c) were an attempt to install similar security safeguards for such situations.

Response: The statutory definition of individually identifiable health information applies to the entire Administrative Simplification subtitle of HIPAA and, thus, was included in the proposed Security Standards. At this time, however, the final Security Standards have not been published, so the definition of protected health information is not directly linked to HIPAA’s privacy standards and is, therefore, included in subpart E of part 164 only.

We clarify that the requirements in the proposed Security Standards are distinct and separate from the privacy safeguards promulgated in this final rule.

Comment: Several commenters expressed confusion and requested clarification as to what is considered health information or individually identifiable health information for purposes of the rule. For example, one commenter was concerned that information exists in collection agencies, credit bureaus, etc., which could be included under the proposed regulation but may or may not have been originally obtained by a covered entity. The commenter noted that generally this information is not clinical, but it could be inferred from the data that a health care provider provided a person or member of person’s family with health care services. The commenter urged the Secretary to define more clearly what and when information is covered.

One commenter queried how a non-medical record keeper could tell when personal information is health information within the meaning of rule, e.g., when a worker asks for a low salt meal in a company cafeteria, when a travel voucher of an employee indicates that the traveler returned from an area that had an outbreak of fever, or when an airline passenger requests a wheelchair. It was suggested that the rule cover health information in the hands of schools, employers, and life insurers only when they receive individually identifiable information from a covered entity or when they create it while providing treatment or making payment.

Response: This rule applies only to individually identifiable health information that is held by a covered entity. Credit bureaus, airlines, schools, and life insurers are not covered entities, so the information described in the above comments is not protected health information. Similarly, employers are not covered entities under the rule. Covered entities must comply with this regulation in their health care capacity, not in their capacity as employers. For example, information in hospital personnel files about a nurses’ sick leave is not protected health information under this rule.

Comment: One commenter recommended that the privacy of health information should relate to actual medical records. The commenter expressed concern about the definition’s broadness and commented that applying prescriptive rules to information that health plans hold will not only delay processing of claims and coverage decisions, but ultimately affect the quality and cost of care for health care consumers.

Response: We disagree. Health information about individuals exists in many types of records, not just the formal medical record about the individual. Limiting the rule’s protections to individually identifiable health information contained in medical records, rather than individually identifiable health information in any form, would omit a significant amount of individually identifiable health information, including much information in covered transactions.

Comment: One commenter voiced a need for a single standard for individually identifiable health information and disability and workers’ compensation information; each category of information is located in their own electronic data base, but would be subjected to a different set of access and transmission rules.

Response: We agree that a uniform, comprehensive privacy standard is desirable. However, our authority under the HIPAA is limited to individually identifiable health information as it is defined in the statute. The legislative history of HIPAA makes clear that workers’ compensation and disability benefits programs were not intended to be covered by the rule. Entities are of course free to apply the protections required by this rule to all health information they hold, including the excepted benefits information, if they wish to do so (for example, in order to reduce administrative burden).

Comment: Commenters recommended that the definition of individually identifiable health information not include demographic information that does not have any additional health, treatment, or payment information with it. Another commenter recommended that protected health information should not include demographic information at all.

Response: Congress explicitly included demographic information in the statutory definition of this term, so we include such language in our regulatory definition of it.

Comments: A number of commenters expressed concern about whether references to personal information about individuals, such as “John Doe is fit to work as a pipe fitter * * *” or “Jane Roe can stand no more than 2 hours * * *,” would be considered individually identifiable health information. They argued that such “fitness-to-work” and “fitness-for-duty” statements are not health care because they do not reveal the type of
information (such as the diagnosis) that is detrimental to an individual’s privacy interest in the work environment.

Response: References to personal information such as those suggested by the commenters could be individually identifiable health information if the references were created or received by a health care provider, health plan, employer, or health care clearinghouse and they related to the past, present, or future physical or mental health or condition, the provision of health care to an individual, or the past, present, or future payment for the provision of health care to an individual. Although these fitness for duty statements may not reveal a diagnosis, they do relate to a present physical or mental condition of an individual because they describe the individual’s capacity to perform the physical and mental requirements of a particular job at the time the statement is made (even though there may be other non-health-based qualifications for the job). If these statements were created or received by one of more of the entities described above, they would be individually identifiable health information.

Law Enforcement Official

Comment: Some commenters, particularly those representing health care providers, expressed concern that the proposed definition of “law enforcement official” could have allowed many government officials without health care oversight duties to obtain access to protected health information without patient consent.

Response: We do not intend for the definition of “law enforcement official” to be limited to officials with responsibilities directly related to health care. Law enforcement officials may need protected health information for investigations or prosecutions unrelated to health care, such as investigations of violent crime, criminal fraud, or crimes committed on the premises of health care providers. For these reasons, we believe it is not appropriate to limit the definition of “law enforcement official” to persons with responsibilities of oversight of the health care system.

Comment: A few commenters expressed concern that the proposed definition could include any county or municipal official, even those without traditional law enforcement training.

Response: We do not believe that determining training requirements for law enforcement officials is appropriately within the purview of this regulation; therefore, we do not make the changes that these commenters requested.

Comment: Some commenters, particularly those from the district attorney community, expressed general concern that the proposed definition of “law enforcement official” was too narrow to account for the variation in state interpretations of law enforcement officials’ power. One group noted specifically that the proposed definition could have prevented prosecutors from gaining access to needed protected health information.

Response: We agree that protected health information may be needed by law enforcement officials for both investigations and prosecutions. We did not intend to exclude the prosecutorial function from the definition of “law enforcement official,” and accordingly we modify the definition of law enforcement official to reflect their involvement in prosecuting cases. Specifically, in the final rule, we define law enforcement official as an official of any agency or authority of the United States, a state, a territory, a political subdivision of a state or territory, or an Indian tribe, who is empowered by law to: (1) Investigate or conduct an inquiry into a potential violation of law; or (2) prosecute or otherwise conduct a criminal, civil, or administrative proceeding arising from an alleged violation of law.

Comment: One commenter recommended making the definition of law enforcement official broad enough to encompass Medicaid program auditors, because some matters requiring civil or criminal law enforcement action are first identified through the audit process.

Response: We disagree. Program auditors may obtain protected health information necessary for their audit functions under the oversight provision of this regulation (§ 164.512(d)).

Comment: One commenter suggested that the proposed definition of “law enforcement official” could be construed as limited to circumstances in which an official “knows” that law has been violated. This commenter was concerned that, because individuals are presumed innocent and because many investigations, such as random audits, are opened without an agency knowing that there is a violation, the definition would not have allowed disclosure of protected health information for these purposes. The commenter recommended modifying the definition to include investigations into “whether” the law has been violated.

Response: We do not intend for lawful disclosures of protected health information by law enforcement purposes to be limited to those in which a law enforcement official knows that law has been violated. Accordingly, we revise the definition of “law enforcement official” to include investigations of “potential” violations of law.

Marketing

Comment: Comments related to “marketing” are addressed in the responses to comments regarding § 164.514(e).

Payment

Comment: One commenter urged that the Department not permit protected health information to be disclosed to a collection agency for collecting payment on a balance due on patient accounts. The commenter noted that, at best, such a disclosure would only require the patient’s and/or insured’s address and phone number.

Response: We disagree. A collection agency may require additional protected health information to investigate and assess payment disputes for the covered entity. For example, the collection agency may need to know what services the covered entity rendered in order to resolve disputes about amounts due. The information necessary may vary, depending on the nature of the dispute. Therefore we do not specify the information that may be used or disclosed for collection activities. The commenter’s concern may be addressed by the minimum necessary requirements in § 164.514. Under those provisions, when a covered entity determines that a collection agency only requires limited information for its activities, it must make reasonable efforts to limit disclosure to that information.

Comment: A number of commenters supported retaining the expansive definition in the proposed rule so that current methods of administering the claims payment process would not be hindered by blocking access to protected health information.

Response: We agree and retain the proposed overall approach to the definition.

Comment: Some commenters argued that the definition of “payment” should be narrowly interpreted as applying only to the individual who is the subject of the information.

Response: We agree with the commenter and modify the definition to clarify that payment activities relate to the individual to whom health care is provided.

Comment: Another group of commenters asserted that the doctor-patient relationship was already being interfered with by the current practices of managed care. For example, it was argued that the definition expanded the
power of government and other third party “payers,” turning them into controllers along with managed care companies. Others stated that activities provided for under the definition occur primarily to fulfill the administrative function of managed health plans and that an individual’s privacy is lost when his or her individually identifiable health information is shared for administrative purposes.

Response: Activities we include in the definition of payment reflect core functions through which health care and health insurance services are funded. It would not be appropriate for a rule about health information privacy to hinder mechanisms by which health care is delivered and financed. We do not through this rule require any health care provider to disclose protected health information to governmental or other third party payors for the activities listed in the payment definition. Rather, we allow these activities to occur, subject to and consistent with the requirements of this rule.

Comment: Several commenters requested that we expand the definition to include “coordination of benefits” as a permissible activity.

Response: We agree and modify the definition accordingly.

Comment: A few commenters raised concerns that the use of “medical data processing” was too restrictive. It was suggested that a broader reference such as “health related” data processing would be more appropriate.

Response: We agree and modify the definition accordingly.

Comment: Some commenters suggested that the final rule needed to clarify that drug formulary administration activities are payment related activities.

Response: While we agree that uses and disclosures of protected health information for drug formulary administration and development are common and important activities, we believe these activities are better described as health care operations and that these activities come within that definition.

Comment: Commenters asked that the definition include calculation of prescription drug costs, drug discounts, and maximum allowable costs and copayments.

Response: Calculations of drug costs, discounts, or copayments are payment activities if performed with respect to a specific individual and are health care operations if performed in the aggregate for a group of individuals.

Comment: We were urged to specifically exclude “therapeutic substitution” from the definition.

Response: We reject this suggestion. While we understand that there are policy concerns regarding therapeutic substitution, those policy concerns are not primarily about privacy and thus are not appropriately addressed in this regulation.

Comment: A few commenters asked that patient assistance programs (PAPS) be excluded from the definition of payment. Such programs are run by or on behalf of manufacturers and provide free or discounted medications to individuals who could not afford to purchase them. Commenters were concerned that including such activities in the definition of payment could harm these programs.

For example, a university school of pharmacy may operate an outreach program and serve as a clearinghouse for information on various pharmaceutical manufacturer PAPS. Under the program state residents can submit a simple application to the program (including medication regimen and financial information), which is reviewed by program pharmacists who study the eligibility criteria and/or directly call the manufacturer’s program personnel to help evaluate eligibility for particular PAPS. The program provides written guidance to the prescribing physicians that includes a suggested approach for helping their indigent patients obtain the medications that they need and enrollment information for particular PAPS.

Response: We note that the concerns presented are not affected by definition of “payment.” The application of this rule to patient assistance programs activities will depend on how the individual programs operate and are affected primarily by the definition of treatment. Each of these programs function differently, so it is not possible to state a blanket rule for whether and how the rule affects such programs.

Under the example provided, the physician who contacts the program on behalf of a patient is managing the patient’s care. If the provider is also a covered entity, he or she would be permitted to make such a “treatment” disclosure of protected health information if a general consent had been obtained from the patient. Depending on the particular facts, the manufacturer, by providing the prescription drugs for an individual, could also be providing health care under this rule. Even so, however, the manufacturer may or may not be a covered entity, depending on whether or not it engages in any of the standard electronic transactions (see the definition of a covered entity). It also may be an indirect treatment provider, since it may be providing the product through another provider, not directly to the patient. In this example, the relevant disclosures of protected health information by any covered health care provider with a direct treatment relationship with the patient would be permitted subject to the general consent requirements of § 164.506.

Whether and how this rule affects the school of pharmacy is equally dependent on the specific facts. For example, if the school merely provides a patient or a physician with the name of a manufacturer and a contact phone number, it would not be functioning as a health care provider and would not be subject to the rule. However, if the school is more involved in the care of the individual, its activities could come in within the definition of “health care provider” under this rule.

Comment: Commenters pointed out that drugs may or may not be “covered” under a plan. Individuals, on the other hand, may or may not be “eligible” for benefits under a plan. The definition should incorporate both terms to clarify that determinations of both coverage and eligibility are payment activities.

Response: We agree and modify the rule to include “eligibility”.

Comment: Several commenters urged that “concurrent and retrospective review” were significant utilization review activities and should be incorporated.

Response: We agree and modify the definition accordingly.

Comment: Commenters noted that the proposed rule was not clear as to whether the covered health information could be used to resolve disputes over coverage, including appeals or complaints regarding quality of care.

Response: We modify the definition of payment to include resolution of payment and coverage disputes; the final definition of payment includes “the adjudication * * * of health benefit claims.” The other examples provided by commenters, such as arranging, conducting, or assistance with primary and appellate level review of enrollee coverage appeals, also fall within the scope of adjudication of health benefits claims. Uses and disclosures of protected health information to resolve disputes over quality of care may be made under the definition of “health care operations” (see above).

Comment: Some commenters suggested that if an activity falls within the scope of payment it should not be considered marketing. Commenters supported an approach that would bar such an activity from being construed as “marketing” even if performing that
activity would result in financial gain to the covered entity.

Response: We agree that the proposed rule did not clearly define “marketing,” leaving commenters to be concerned about whether payment activities that result in financial gain might be considered marketing. In the final rule we add a definition of marketing and clarify when certain activities that would otherwise fall within that definition can be accomplished without authorization. We believe that these changes will clarify the distinction between marketing and payment and address the concerns raised by commenters.

Comment: Commenters asserted that HHS should not include long-term care insurance within the definition of “health plan.” If they are included, the commenters argued that the definition of payment must be modified to reflect the activities necessary to support the payment of long-term care insurance claims. As proposed, commenters argued that the definition of payment would not permit long term care insurers to use and disclose protected health information without authorization to perform functions that are “compatible with and directly relate to * * * payment” of claims submitted under long-term care policies.

Response: Long-term care policies, except for nursing home fixed-indemnity policies, are defined as health plans by the statute (see definition of “health plan,” above). We disagree with the assertion that the definition of payment does not permit long term care insurers to undertake these necessary activities. Processing of premium payments, claims administration, and other activities suggested for inclusion by the commenters are covered by the definition. The rule permits protected health information to be used or disclosed by a health plan to determine or fulfill its responsibility for provision of benefits under the health plan.

Comment: Some commenters argued that the definition needs to be expanded to include the functions of obtaining stop-loss and ceding reinsurance.

Response: We agree that use and disclosure of protected health information for these activities should be permitted without authorization, but have included them under health care operation rather than payment.

Comment: Commenters asked that the definition be modified to include collection of accounts receivable or outstanding accounts. Commenters raised concern that the proposed rule, without changes, might unintentionally prevent the flow of information between medical providers and debt collectors.

Response: We agree that the proposed definition of payment did not explicitly provide for “collection activities” and that this oversight might have impeded a covered entity’s debt collection efforts. We modify the regulatory text to add “collection activities.”

Comment: The preamble should clarify that self-insured group health and workers’ compensation plans are not covered entities or business partners.

Response: The statutory definition of health plan does not include workers’ compensation plans. See the discussion of “health plan” under § 160.103 above.

Comment: Certain commenters explained that third party administrators usually communicate with employees through Explanation of Benefit (EOB) reports on behalf of their dependents (including those who might not be minor children). Thus, the employee might be apprised of the medical encounters of his or her dependents but not of medical diagnoses unless there is an over-riding reason, such as a child suspected of drug abuse due to multiple prescriptions. The commenters urged that the current claim processing procedures be allowed to continue.

Response: We agree. We interpret the definition of payment and, in particular the term “claims management,” to include such disclosures of protected health information.

Comment: One private company noted that pursuant to the proposed Transactions Rule standard for payment and remittance advice, the ASC X12N 835 can be used to make a payment, send a remittance advice, or make a payment and send remittance advice by a health care payor and a health care provider, either directly or through a designated financial institution. Because a remittance advice includes diagnostic or treatment information, several private companies and a few public agencies believed that the proposed Transactions Rule conflicted with the proposed privacy rule. Two health plans requested guidance as to whether, pursuant to the ASC X12N 835 implementation guide, remittance advice information is considered “required” or “situational.” They sought guidance on whether covered entities could include benefits information in payment of claims and transfer of remittance information.

One commenter asserted that if the transactions covered health information were prohibited, health plans may be required to strip remittance advice information from the ASC X12N 835 when making health care payments. It recommended modifying the proposed rule to allow covered entities to provide banks or financial institutions with the data specified in any transaction set mandated under the Transactions Rule for health care claims payment.

Similarly, a private company and a state health data organization recommended broadening the scope of permissible disclosures pursuant to the banking section to include integrated claims processing information, as contained in the ASC X12N 835 and proposed for adoption in the proposed Transactions Rule; this transaction standard includes diagnostic and treatment information. The company argued that inclusion of diagnostic and treatment information in the data transmitted in claims processing was necessary for comprehensive and efficient integration in the provider’s patient accounting system of data corresponding with payment that financial institutions credit to the provider’s account.

A state health data organization recommended applying these rules to financial institutions that process electronic remittance advice pursuant to the Transactions Rule.

Response: The Transactions Rule was published August 17, 2000, after the issuance of the privacy proposed rule. As noted by the commenters, the ASC X12N 835 we adopted as the “Health Care Payment and Remittance Advice” standard in the Transactions Rule has two parts. They are the electronic funds transfer (EFT) and the electronic remittance advice (ERA). The EFT part is optional and is the mechanism that payors use to electronically instruct one financial institution to move money from one account to another at the same or at another financial institution. The EFT includes information about the payor, the payee, the amount, the payment method, and a reassociation trace number. Since the EFT is used to initiate the transfer of funds between the accounts of two organizations, typically a payor to a provider, it includes no individually identifiable health information, not even the names of the patients whose claims are being paid. The funds transfer information may also be transmitted manually (by check) or by a variety of other electronic means, including various formats of electronic transactions sent through a payment network, such as the Automated Clearing House (ACH) Network. The ERA, on the other hand, contains specific information about the patients and the medical procedures for which
the money is being paid and is used to update the accounts receivable system of the provider. This information is always needed to complete a standard Health Care Payment and Remittance Advice transaction, but is never needed for the funds transfer activity of the financial institution. The only information the two parts of this transaction have in common is the reassociation trace number.

Under the ASC X12N 835 standard, the ERA may be transmitted alone, directly from the health plan to the health care provider and the reassociation trace number is used by the provider to match the ERA information with a specific payment conducted in some other way (e.g., EFT or paper check). The standard also allows the EFT to be transmitted alone, directly to the financial institution that will initiate the payment. It also allows both parts to be transmitted together, even though the intended recipients of the two parts are different (the financial institution and the provider). For example, this would be done when the parties agree to use the ACH system to carry the ERA through the provider’s bank to the provider when it is more efficient than sending the ERA separately through a different electronic medium.

Similarly, the ASC X12N 820 standard for premium payments has two parts, an EFT part (identical to that of the 835) and a premium data part containing identity and health information about the individuals for whom health insurance premiums are being paid.

The transmission of both parts of the standards are payment activities under this rule, and permitted subject to certain restrictions. Because a financial institution does not require the remittance advice or premium data parts to conduct funds transfers, disclosure of those parts by a covered entity to it (absent a business associate arrangement to use the information to conduct other activities) would be a violation of this rule.

We note that additional requirements may be imposed by the final Security Rule. Under the proposed Security Rule, the ACH system and similar systems would have been considered “open networks” because transmissions flow unpredictably through and become available to member institutions who are not party to any business associate agreements (in a way similar to the internet). The proposed Security Rule would require that protected health information transferred through the ACH or similar system to be encrypted.

**Comment:** A few commenters noted the Gramm-Leach-Bliley (GLB) Act (Pub. L. 106–102) allows financial holding companies to engage in a variety of business activities, such as insurance and securities, beyond traditional banking activities. Because the term “banking” may take on a broader meaning in light of these changes, the commenter recommended modifying the proposed rule to state that disclosure of diagnostic and treatment information to banks along with payment information would constitute a violation of the rule. Specifically, the organization recommended clarifying in the final rule that the provisions included in the proposed section on banking and payment processes (proposed § 164.510(l)) govern payment processes only and that all activities of financial institutions that did not relate directly to payment processes must be conducted through business partner contracts. Furthermore, this group recommended clarifying that if financial institutions act as payors, they will be covered entities under the rule.

**Response:** We recognize that implementation of the GLB Act will expand significantly the scope of activities in which financial holding companies engage. However, unless a financial institution also meets the definition of a “covered entity,” it cannot be a covered entity under this rule.

We agree with the commenters that disclosure of diagnostic and specific treatment information to financial institutions for the purpose of processing payments may not be consistent with the minimum necessary requirements of this final rule. We also agree with the commenters that financial institutions are business associates if they receive protected health information when they engage in activities other than funds processing for covered entities. For example, if a health care provider contracts with a financial institution to conduct “back office” billing and accounts receivable activities, we require the provider to enter into a business associate contract with the institution.

**Comment:** Two commenters expressed support for the proposed rule’s approach to disclosure for banking and payment processes. On the other hand, many other commenters were opposed to disclosure of protected health information without authorization to banks. One commenter said that no financial institution should have individually identifiable health information. Another commenter said there were technological means for separating identity from information necessary for financial transactions. Some commenters believed that implementation of the proposed rule’s banking provisions could lead banks to deny loans on the basis of individuals’ health information.

**Response:** We seek to achieve a balance between protecting patient privacy and facilitating the efficient operation of the health care system. While we agree that financial institutions should not have access to extensive information about individuals’ health, we recognize that even the minimal information required for processing of payments may effectively reveal a patient’s health condition; for example, the fact that a person has written a check to a provider suggests that services were rendered to the person or a family member. Requiring authorization for disclosure of protected health information to a financial institution in order to process every payment transaction in the health care system would make it difficult, if not impossible, for the health care system to operate effectively. See also discussion of section 1179 of the Act above.

**Comment:** Under the proposed rule, covered entities could have disclosed the following information without consent to financial institutions for the purpose of processing payments: (1) The account holder’s name and address; (2) the payor or provider’s name and address; (3) the amount of the charge for health services; (4) the date on which services were rendered; (5) the expiration date for the payment mechanism, if applicable (e.g., credit card expiration date); and (6) the individual’s signature. The proposed rule solicited comments on whether additional data elements would be necessary to process payment transactions from patients to covered entities.

One commenter believed that it was unnecessary to include this list in the final rule, because information that could have been disclosed under the proposed minimum necessary rule would have been sufficient to process banking and payment information. Another private company said that its extensive payment systems experience indicated that we should avoid attempts to enumerate a list of information allowed to be disclosed for banking and payment processing. Furthermore, the commenter said, the proposed rule’s list of information allowed to be disclosed was not sufficient to perform the range of activities necessary for the operation of modern electronic payment systems. Finally, the commenter said, inclusion of specific data elements allowed to be
disclosed for banking and payment processes rule would stifle innovation in continually evolving payment systems. Thus, the commenter recommended that in the final rule, we eliminate the minimum necessary requirement for banking and payment processing and that we do not include a list of specific types of information allowed to be disclosed for banking and payment processes.

On the other hand, several other commenters supported applying the minimum necessary standard to covered entities’ disclosures to financial institutions for payment processing. In addition, these groups said that because financial institutions are not covered entities under the proposed rule, they urged Congress to enact comprehensive privacy legislation to limit financial institutions’ use and re-disclosure of the minimally necessary protected health information they could receive under the proposed rule. Several of these commenters said that, in light of the increased ability to manipulate data electronically, they were concerned that financial institutions could use the minimal protected health information they received for making financial decisions. For example, one of these commenters said that a financial institution could identify an individual who had paid for treatment of domestic violence injuries and subsequently could deny the individual a mortgage based on that information.

Response: We agree with the commenters who were concerned that a finite list of information could hamper systems innovation, and we eliminate the proposed list of data items. However, we disagree with the commenters who argued that the requirement for minimum necessary disclosures not apply to disclosures to financial institution or for payment activities. They presented no persuasive reasons why these disclosures differ from others to which the standard applies, nor did they suggest alternative means of protecting individuals’ privacy. Further, with the elimination of the proposed list of items that may be disclosed, it will be necessary to rely on the minimum necessary disclosure requirement to ensure that disclosures for payment purposes do not include information unnecessary for that purpose. In practice, the following is the information that generally will be needed: the name and address of the individual; the name and address of the payor or provider; the amount of the charge for health services; the date on which fees services were rendered; the expiration date for the payment mechanism, if applicable (i.e., credit card expiration date); the individual’s signature; and relevant identification and account numbers.

Comment: One commenter said that the minimum necessary standard would be impossible to implement with respect to information provided on its standard payment claim, which, it said, was used by pharmacies for concurrent drug utilization review and that was expected to be adopted by HHS as the national pharmacy payment claim.

Two other commenters also recommended clarifying in the final rule that pharmacy benefit cards are not considered a type of “other payment card” pursuant to the rule’s provisions governing payment processes. These commenters were concerned that if pharmacy benefit cards were covered by the rule’s payment processing provisions, their payment claim, which they said was expected to be adopted by HHS as the national pharmacy payment claim, may have to be modified to comply with the minimum necessary standard that was required pursuant to proposed §164.510(i) on banking and payment processes. One of these commenters noted that its payment claim facilitates concurrent drug utilization review, which was mandated by Congress pursuant to the Omnibus Budget Reconciliation Act of 1990 and which creates the real-time ability for pharmacies to gain access to information that may be necessary to meet requirements of this and similar state laws. The commenter said that information on its standard payment claim may be information that could be used to provide professional pharmacy services, such as compliance, disease management, and outcomes programs.

Response: We make an exception to the minimum necessary disclosure provision of this rule for the required and situational data elements of the standard transactions adopted in the Transactions Rule, because those elements were agreed to through the ANSI-accredited consensus development process. The minimum necessary requirements do apply to optional elements in such standard transactions, because industry consensus has not resulted in precise and unambiguous situation specific language to describe their usage. This is particularly relevant to the NCPDP standards for retail pharmacy transactions referenced by these commenters, in which the current standard leaves most fields optional. For this reason, we do not accept this suggestion.

The term ‘payment card’ was intended to apply to a debit or credit card used to initiate payment transactions with a financial institution. We clarify that pharmacy benefit cards, as well as other health benefit cards, are used for identification of individual, plan, and benefits and do not qualify as “other payment cards.”

Comment: Two commenters asked the following questions regarding the banking provisions of the proposed rule: (1) Does the proposed regulation stipulate that disclosures to banks and financial institutions can occur only once a patient has presented a check or credit card to the provider, or pursuant to a standing authorization?; and (2) Does the proposed rule ban disclosure of diagnostic or other related detailed payment information to financial institutions?

Response: We do not ban disclosure of diagnostic information to financial institutions, because such information may be evident simply from the name of the payee (e.g., when payment is made to a substance abuse clinic). This type of disclosure, however, is permitted only when reasonably necessary for the transaction (see requirements for minimum necessary disclosure of protected health information, in §164.502 and §164.514).

Similarly, we do not stipulate that such disclosure may be made only once a patient has presented a check or credit card, because some covered entities hire financial institutions to perform services such as management of accounts receivables and other back office functions. In providing such services to covered entities, the financial institution will need access to protected health information. (In this situation, the disclosure will typically be made under a business associate arrangement that includes provisions for protection of the information.)

Comment: One commenter was concerned that the proposed rule’s section on financial institutions, when considered in conjunction with the proposed definition of “protected health information,” could have been construed as making covered entities’ disclosures of consumer payment history information to consumer reporting agencies subject to the rule. It noted that covered entities’ reporting of payment history information to consumer reporting agencies was not explicitly covered by the proposed rule’s provisions regarding disclosure of protected health information without authorization. It was concerned that the proposed rule’s minimum necessary standard could have been interpreted to
prevent covered entities and their business partners from disclosing appropriate and complete information to consumer reporting agencies. As a result, it said, consumer reporting agencies might not be able to compile complete consumer reports, thus potentially creating an inaccurate picture of a consumer’s credit history that could be used to make future credit decisions about the individual.

Furthermore, this commenter said, the proposed rule could have been interpreted to apply to any information disclosed to consumer reporting agencies, thus creating the possibility for conflicts between the rule’s requirements and those of the Fair Credit Reporting Act. They indicated that areas of potential overlap included: limits on subsequent disclosures; individual access rights; safeguards; and notice requirements.

Response: We have added to the definition of “payment” disclosure of certain information to consumer reports with respect to the remaining concerns, this rule does not apply to consumer reporting agencies if they are not covered entities.

Comment: Several commenters recommended prohibiting disclosure of psychotherapy notes under this provision and under all of the sections governing disclosure without consent for national priority purposes.

Response: We agree that psychotherapy notes should not be disclosed without authorization for payment purposes, and the final rule does not allow such disclosure. See the discussion under § 164.508.

Protected Health Information

Comment: An overwhelmingly large number of commenters urged the Secretary to expand privacy protection to all individually identifiable health information, regardless of form, held or transmitted by a covered entity.

Commenters provided many arguments in support of their position. They asserted that expanding the scope of covered information under the rule would increase patient confidence in their health care providers and the health care system in general. Commenters stated that patients may not seek care or honestly discuss their health conditions with providers if they do not believe that all of their health information is confidential. In particular, many suggested that this fear would be particularly strong with certain classes of patients, such as persons with disabilities, who may be concerned about potential discrimination, embarrassment or stigmatization, or domestic violence victims, who may hide the real cause of their injuries.

In addition, commenters felt that a more uniform standard that covered all records would reduce the complexity, burden, cost, and enforcement problems that would result from the NPRM’s proposal to treat electronic and non-electronic records differently. Specifically, they suggested that such a standard would eliminate any confusion regarding how to treat mixed records (paper records that include information that has been stored or transmitted electronically) and would eliminate the need for health care providers to keep track of which portions of a paper record have been (or will be) stored or transmitted electronically, and which are not. Many of these commenters argued that limiting the definition to information that is or has at one time been electronic would result in different protections for electronic and paper records, which they believe would be unwarranted and give consumers a false sense of security. Other comments argued that the proposed definition would cause confusion for providers and patients and would likely cause difficulties in claims processing. Many others complained about the difficulty of determining whether information has been maintained or transmitted electronically. Some asked us to explicitly list the electronic functions that are intended to be excluded, such as voice mail, fax, etc. It was also recommended that the definitions of “electronic transmission” and “electronic maintenance” be deleted. It was stated that the rule may apply to many medical devices that are regulated by the FDA. A commenter also asserted that the proposal’s definition was technically flawed in that computers are also involved in analog electronic transmissions such as faxes, telephone, etc., which is not the intent of the language. Many commenters argued that limiting the definition to information that has been electronic would create a significant administrative burden, because covered entities would have to figure out how to apply the rule to some but not all information.

Others argued that covering all individually identifiable health information would eliminate any disincentives for covered entities to convert from paper to computerized record systems. These commenters asserted that under the proposed limited coverage, contrary to the intent of HIPAA’s administrative simplification standards, providers would avoid converting paper records to computerized systems in order to bypass the provisions of the regulation.

They argued that treating all records the same is consistent with the goal of increasing the efficiency of the administration of health care services.

Lastly, in the NPRM, we explained that while we chose not to extend our regulatory coverage to all records, we did have the authority to do so. Several commenters agreed with our interpretation of the statute and our authority and reiterated such statements in arguing that we should expand the scope of the rule in this regard.

Response: We find these commenters’ arguments persuasive and extend protections to individually identifiable health information transmitted or maintained by a covered entity in any form (subject to the exception for “education records” governed by FERPA) and records described at 20 U.S.C. 1232g(a)(4)(B)(iv)). We so do for the reasons described by the commenters and in our NPRM, as well as because we believe that the approach in the final rule creates a logical, consistent system of protections that recognizes the dynamic nature of health information use and disclosure in a continually shifting health care environment. Rules that are specific to certain formats or media, such as “electronic” or “paper,” cannot address the privacy threats resulting from evolving forms of data capture and transmission or from the transfer of the information from one form to another. This approach avoids the somewhat artificial boundary issues that stem from defining what is and is not electronic.

In addition, we have reevaluated our reasons for not extending privacy protections to all paper records in the NPRM and after review of comments believe such justifications to be less compelling than we originally thought. For example, in the NPRM, we explained that we chose not to cover all paper records in order to focus on the public concerns about health information confidentiality in electronic communications, and out of concern that the potential additional burden of covering all records may not be justified because of the lower privacy risks presented by records that are in paper form only. As discussed above however, a great many commenters asserted that dealing with a mixture of protected and non-protected records is more burdensome, and that public concerns over health information confidentiality are not at all limited to electronic communications.

We note that medical devices in and of themselves, for example, pacemakers, are protected information for purposes of this regulation. However, information in or from the device may...
be protected health information to the extent that it otherwise meets the definition.

Comment: Numerous commenters argued that the proposed coverage of any information other than that which is transmitted electronically and/or in a HIPAA transaction exceeds the Secretary’s authority under section 264(c)(1) of HIPAA. The principal argument was that the initial language in section 264(c)(1) (“If language governing standards with respect to the privacy of individually identifiable health information transmitted in connection with the transactions described in section 1173(a) of the Social Security Act * * * is not enacted by [August 21, 1999], the Secretary * * * shall promulgate final regulations containing such standards* * *”) limits the privacy standards to “information transmitted in connection with the [HIPAA] transactions.” The precise argument made by some commenters was that the grant of authority is contained in the words “such standards,” and that the referent of that phrase was “standards with respect to the privacy of individually identifiable health information transmitted in connection with the transactions described in section 1173(a)* * *”.

Commenters also argued that this limitation on the Secretary’s authority is discernible from the statutory purpose statement at section 261 of HIPAA, from the title to section 1173(a) (“Standards to Enable Electronic Exchange”), and from various statements in the legislative history, such as the statement in the Conference Report that the “Secretary would be required to establish standards and modifications to such standards regarding the privacy of individually identifiable health information that is in the health information network.” H. Rep. No. 104–736, 104th Cong., 2d Sess., at 265. It was also argued that extension of coverage beyond the HIPAA transactions would be inconsistent with the underlying statutory trade-off between facilitating accessibility of information in the electronic transactions for which standards are adopted under section 1173(a) and protecting that information through the privacy standards.

Other commenters argued more generally that the Secretary’s authority was limited to information in electronic form only, not information in any other form. These comments tended to focus on the statutory concern with regulating transactions in electronic form and argued that there was no need to have the privacy standards apply to information in paper form, because there is significantly less risk of breach of privacy with respect to such information.

The primary justifications provided by commenters for restricting the scope of covered individually identifiable health information under the regulation were that such an approach would reduce the complexity, burden, cost, and enforcement problems that would result from a rule that treats electronic and non-electronic records differently; would appropriately limit the rule’s focus to the security risks that are inherent in electronic transmission or maintenance of individually identifiable health information; and would conform these provisions of the rule more closely with their interpretation of the HIPAA statutory language.

Response: We disagree with these commenters. We believe that restricting the scope of covered information under the rule consistent with any of the comments described above would generate a number of policy concerns. Any restriction in the application of privacy protections based on the media used to maintain or transmit the information is by definition arbitrary, unrelated to the potential use or disclosure of the information itself and therefore not responsive to actual privacy risks. Information contained in a paper record may be scanned and transmitted worldwide almost as easily as the same information contained in an electronic claims transaction, but would potentially not be protected.

In addition, application of the rule to only the standard transactions would leave large gaps in the amount of health information covered. This limitation would be particularly harmful for information used and disclosed by health care providers, who are likely to maintain a great deal of information never contained in a transaction.

We disagree with the arguments that the Secretary lacks legal authority to cover all individually identifiable health information transmitted or maintained by covered entities. The arguments raised by these comments have two component parts: (1) That the Secretary’s authority is limited by form, to individually identifiable health information in electronic form only; and (2) that the Secretary’s authority is limited by content, to individually identifiable health information that is contained in what commenters generally termed the “HIPAA transactions,” i.e., information contained in a transaction for which a standard has been adopted under section 1173(a) of the Act.

With respect to the issue of form, the statutory definition of “health information” at section 1171(4) of the Act defines such information as “any information, whether oral or recorded in any form or medium” (emphasis added) which is created or received by certain entities and relates to the health condition of an individual or the provision of health care to an individual (emphasis added). “Individually identifiable health information”, as defined at section 1171(6) of the Act, is information that is created or received by a subset of the entities listed in the definition of “health information”, relates to the same subjects as “health information,” and is, in addition, individually identifiable. Thus, “individually identifiable health information” is, as the term itself implies, a subset of “health information.” As “health information,” “individually identifiable health information” means, among other things, information that is “oral or recorded in any form or medium.” Therefore, the statute does not limit “individually identifiable health information” to information that is in electronic form only.

With respect to the issue of content, the limitation of the Secretary’s authority to information in HIPAA transactions under section 264(c)(1) is more apparent than real. While the first sentence of section 264(c)(1) may be read as limiting the regulations to standards with respect to the privacy of individually identifiable health information “transmitted in connection with the [HIPAA] transactions,” what that sentence in fact states is that the privacy regulations must “contain” such standards, not be limited to such standards. The first sentence thus sets a statutory minimum, first for Congress, then for the Secretary. The second sentence of section 264(c)(1) directs that the regulations “address at least the subjects in subsection (b) of section 264.” Section 264(b), in turn, refers only to “individually identifiable health information”; with no qualifying language, and refers back to subsection (a) of section 264, which is not limited to HIPAA transactions. Thus, the first and second sentences of section 264(c)(1) can be read as consistent with each other, in which case they direct the issuance of privacy standards with respect to individually identifiable health information. Alternatively, they can be read as ambiguous, in which case one must turn to the legislative history.

The legislative history of section 264 does not reflect the content limitation of the first sentence of section 264(c)(1). Rather, the Conference Report
summarizes this section as follows: “If Congress fails to enact privacy legislation, the Secretary is required to develop standards with respect to privacy of individually identifiable health information not later than 42 months from the date of enactment.” Id., at 270. This language indicates that the overriding purpose of section 264(c)(1) was to postpone the Secretary’s duty to issue privacy standards (which otherwise would have been controlled by the time limits at section 1174(a)), in order to give Congress more time to pass privacy legislation. A corollary inference, which is also supported by other textual evidence in section 264 and Part C of title XI, is that if Congress failed to act within the time provided, the original statutory scheme was to kick in. Under that scheme, which is set out in section 1173(e) of the House bill, the standards to be adopted were “standards with respect to the privacy of individually identifiable health information.” Thus, the legislative history of section 264 supports the statutory interpretation underlying the rules below.

Comment: Many commenters were opposed to the rule covering specific forms of communication or records that could potentially be considered covered information, i.e., faxes, voice mail messages, etc. A subset of these commenters took issue particularly with the inclusion of oral communications within the scope of covered information. The commenters argued that covering information when it takes oral form (e.g., verbal discussions of a submitted claim) makes the regulation extremely costly and burdensome, and even impossible to administer. Another commenter also offered that it would make it nearly impossible to discuss health information over the phone, as the covered entity cannot verify that the person on the other end is in fact who he or she claims to be.

Response: We disagree. Covering oral communications is an important part of keeping individually identifiable health information private. If the final rule were not to cover oral communication, a conversation about a person’s protected health information could be shared with anyone. Therefore, the same protections afforded to paper and electronically based information must apply to verbal communication as well. Moreover, the Congress explicitly included “oral” information in the statutory definition of health information.

Comment: A few commenters suggested, without any change, the approach proposed in the NPRM to limit the scope of covered information to individually identifiable health information in any form once the information is transmitted or maintained electronically. These commenters asserted that our statutory authority limited us accordingly. Therefore, they believed we had proposed protections to the extent possible within the bounds of our statutory authority and could not expand the scope of such protections without new legislative authority.

Response: We disagree with these commenters regarding the limitations under our statutory authority. As explained above, we have the authority to extend the scope of the regulation as we have done in the final rule. We also note here that most of these commenters who supported the NPRM’s proposed approach, voiced strong support for extending the scope of coverage to all individually identifiable health information in any form, but concluded that we had done what we could within the authority provided.

Comment: One commenter argued that the term “transaction” is generally understood to denote a business matter, and that the NPRM applied the term too broadly by including hospital directory information, communication with a patient’s family, researchers’ use of data and many other non-business activities.

Response: This comment reflects a misunderstanding of our use of the term “transaction.” The uses and disclosures described in the comment are not “transactions” as defined in § 160.103. The authority to regulate the types of uses and disclosures described is provided under section 264 of Pub. L. 104–191. The conduct of the activities noted by the commenters are not related to the determination of whether a health care provider is a covered entity. We explain in the preamble that a health care provider is a covered entity if it transmits health information in electronic form in connection with transactions referred to in section 1173(a)(1) of the Act.

Comment: A few commenters asserted that the Secretary has no authority to regulate “use” of protected health information. They stated that although section 264(b) mentions that the Secretary should address “uses and disclosures,” no other section of HIPAA employs the term “use.”

Response: We disagree with these commenters. As they themselves note, the authority to regulate use is given in section 264(b) and is sufficient.

Comment: Some commenters requested clarification as to how certain types of health information, such as photographs, faxes, X-Rays, CT-scans, and others would be classified as protected or not under the rule.

Response: All types of individually identifiable health information in any form, including those described, when maintained or transmitted by a covered entity are covered in the final rule.

Comment: A few commenters requested clarification with regard to the differences between the definitions of individually identifiable health information and protected health information.

Response: In expanding the scope of covered information in the final rule, we have simplified the distinction between the two definitions. In the final rule, protected health information is the subset of individually identifiable health information that is maintained or transmitted by covered entity, and thereby protected by this rule. For additional discussion of protected health information and individually identifiable health information, see the descriptive summary of § 164.501.

Comment: A few commenters remarked that the federal government has no right to access or control any medical records and that HHS must get consent in order to store or use any individually identifiable health information.

Response: We understand the commenters’ concern. It is not our intent, nor do we through this rule create any government right of access to medical records, except as needed to investigate possible violations of the rule. Some government programs, such as Medicare, are authorized under other law to gain access to certain beneficiary records for administrative purposes. However, these programs are covered by the rule and its privacy protections apply.

Comment: Some commenters asked us to clarify how schools would be treated by the rule. Some of these commenters worried that privacy would be compromised if schools were exempted from the provisions of the final rule. Other commenters thought that school medical records were included in the provisions of the NPRM.

Response: We agree with the request for clarification and provide guidance regarding the treatment of medical records in schools in the “Relationship to Other Federal Laws” preamble discussion of FERPA, which governs the privacy of education records.

Comment: One commenter was concerned that only some information from a medical chart would be included as covered information. The commenter was especially concerned that transcribed material might not be considered covered information.
Response: As stated above, all individually identifiable health information in any form, including transcribed or oral information, maintained or transmitted by a covered entity is covered under the provisions of the final rule.

Comment: In response to our solicitation of comments on the scope of the definition of protected health information, many commenters asked us to narrow the scope of the proposed definition to include only information in electronic form. Others asked us to include only information from the HIPAA standard transactions.

Response: For the reasons stated by the commenters who asked us to expand the proposed definition, we reject these comments. We reject these approaches for additional reasons, as well. Limiting the protections to electronic information would, in essence, protect information only as long as it remained in a computer or other electronic medium; the protections in the rule could be avoided simply by printing out the information. This approach would thus result in the illusion, but not the reality, of privacy protections. Limiting protection to information in HIPAA transactions has many of the problems in the proposed approach: it would fail to protect significant amounts of health information, would force covered entities to figure out which information had and had not been in such a transaction, and could cause the administrative burdens the commenters feared would result from protecting some but not all information.

Comment: A few commenters asserted that the definition of protected health information should explicitly include “genetic” information. It was argued that improper disclosure and use of such information could have a profound impact on individuals and families.

Response: We agree that the definition of protected health information includes genetic information that otherwise meets the statutory definition. But we believe that singling out specific types of protected health information for special mention in the regulation text could wrongly imply that other types are not included.

Comment: One commenter recommended that the definition of protected health information be modified to clarify that an entity does not become a ‘covered entity’ by providing a device to an individual on which protected health information may be stored, provided that the company itself does not store the individual’s health information.

Response: We agree with the commenter’s analysis, but believe the definition is sufficiently clear without a specific amendment to this effect.

Comment: One commenter recommended that the definition be amended to explicitly exclude individually identifiable health information maintained, used, or disclosed pursuant to the Fair Credit Reporting Act, as amended, 15 U.S.C. 1681. It was stated that a disclosure of payment history to a consumer reporting agency by a covered entity should not be considered protected health information. Another commenter recommended that health information, billing information, and a consumer’s credit history be exempted from the definition because this flow of information is regulated by both the Fair Credit Reporting Act (FCRA) and the Fair Debt Collection Practices Act (FDCPA).

Response: We disagree. To the extent that such information meets the definition of protected health information, it is covered by this rule. These statutes primarily regulate entities that are not covered by this rule, minimizing the potential for overlap or conflict. The protections in this rule are more appropriate for protecting health information. However, we add provisions to the definition of ‘payment’ which should address these concerns. See the definition of ‘payment’ in § 164.501.

Comment: An insurance company recommended that the rule require that medical records containing protected health information include a notation on a cover sheet on such records.

Response: Since we have expanded the scope of protected health information, there is no need for covered entities to distinguish among their records, and such a notation is not needed. This uniform coverage eliminates the mixed record problem and resultant potential for confusion.

Comment: A government agency requested clarification of the definition to address the status of information that flows through dictation services.

Response: A covered entity may disclose protected health information for transcription of dictation under the definition of health care operations, which allows disclosure for “general administrative” functions. We view transcription and clerical services generally as part of a covered entity’s general administrative functions. An entity transcribing dictation on behalf of a covered entity meets this rule’s definition and may receive protected health information under a business associate contract with the covered entity and subject to the other requirements of the rule.

Comment: A commenter recommended that information transmitted for employee drug testing be exempted from the definition.

Response: We disagree that it is necessary to specifically exclude such information from the definition of protected health information. If a covered entity is involved, triggering this rule, the employer may obtain authorization from the individuals to be tested. Nothing in this rule prohibits an employer from requiring an employee to provide such an authorization as a condition of employment.

Comment: A few commenters addressed our proposal to exclude individually identifiable health information in education records covered by FERPA. Some expressed support for the exclusion. One commenter recommended adding another exclusion to the definition for the treatment records of students who attend institutions of post-secondary education or who are 18 years old or older to avoid confusion with rules under FERPA. Another commenter suggested that the definition exclude health information of participants in “Job Corps programs” as it has for educational records and inmates of correctional facilities.

Response: We agree with the commenter on the potential for confusion regarding records of students who attend post-secondary schools or who are over 18, and therefore in the final rule we exclude records defined at 20 U.S.C. 1232g(a)(4)(B)(iv) from the definition of protected health information. For a detailed discussion of this change, refer to the “Relationship to Other Federal Laws” section of the preamble. We find no similar reason to exclude “Job Corps programs” from the requirements of this regulation.

Comment: Some commenters voiced support for the exclusion of the records of inmates from the definition of protected health information, maintaining that correctional agencies have a legitimate need to share some health information internally without authorization between health service units in various facilities and for purposes of custody and security. Other commenters suggested that the proposed exclusion be extended to individually identifiable health information: created by covered entities providing services to inmates or detainees under contract to such facilities; of “former” inmates; and of persons who are in the custody of law enforcement officials, such as the United States Marshals Service and local police agencies. They stated that
corrections and detention facilities must be able to share information with law enforcement agencies such as the United States Marshals Service, the Immigration and Naturalization Services, county jails, and U.S. Probation Offices.

Another commenter said that there is a need to have access to records of individuals in community custody and explained that these individuals are still under the control of the state or local government and the need for immediate access to records for inspections and/or drug testing is necessary.

A number of commenters were opposed to the proposed exclusion to the definition of protected health information, arguing that the proposal was too sweeping. Commenters stated that while access without consent is acceptable for some purposes, it is not acceptable in all circumstances. Some of these commenters concurred with the sharing of health care information with other medical facilities when the inmate is transferred for treatment. These commenters recommended that we delete the exception for jails and prisons and substitute specific language about what information could be disclosed and the limited circumstances or purposes for which such disclosures could occur.

Others recommended omission of the proposed exclusion entirely, arguing that excluding this information from protection sends the message that, with respect to this population, abuses do not matter. Commenters argued that inmates and detainees have a right to privacy of medical records and that individually identifiable health information obtained in these settings can be misused, e.g., when communicated indiscriminately, health information can trigger assaults on individuals with stigmatized conditions by fellow inmates or detainees. It can also lead to the denial of privileges, or inappropriately influence the deliberations of bodies such as parole boards.

A number of commenters explicitly took issue with the exclusion relative to individuals, and in particular youths, with serious mental illness, seizure disorders, and emotional or substance abuse disorders. They argued that these individuals come in contact with criminal justice authorities as a result of behaviors stemming directly from their illness and assert that these provisions will cause serious problems. They argue that disclosing the fact that an individual was treated for mental illness while incarcerated could seriously impair the individual’s reintegration into the community. Commenters stated that such disclosures could put the individual or family members at risk of discrimination by employers and in the community at large.

Some commenters asserted that the rule should be amended to prohibit jails and prisons from disclosing private medical information of individuals who have been discharged from these facilities. They argued that such disclosures may seriously impair individuals’ rehabilitation into society and subject them to discrimination as they attempt to re-establish acceptance in the community.

Response: We find commenters’ arguments against a blanket exemption from privacy protection for inmates persuasive. We agree health information in these settings may be misused, which consequently poses many risks to the inmate or detainee and in some cases, their families as described above by the commenters. Accordingly, we delete this exception from the definition of “protected health information” in the final rule. The final rule considers individual identifiable health information of individuals who are prisoners and detainees to be protected health information to the extent that it meets the definition and is maintained or transmitted by a covered entity.

At the same time, we agree with those commenters who explained that correctional facilities have legitimate needs for use and sharing of individually identifiable health information inmates without authorization. Therefore, we add a new provision (§ 164.512(k)(5)) that permits a covered entity to disclose protected health information about inmates without individual consent, authorization, or agreement to correctional institutions for specified health care and other custodial purposes. For example, covered entities are permitted to disclose for the purposes of providing health care to the individual who is the inmate, or for the health and safety of other inmates or officials and employees of the facility. In addition, a covered entity may disclose protected health information as necessary for the administration and maintenance of the safety, security, and good order of the institution. See the preamble discussion of the specific requirements at § 164.512(k)(5), as well as discussion of certain limitations on the rights of individuals who are inmates with regard to their protected health information at §§ 164.506, 164.520, 164.524, and 164.528.

We also provide the following clarifications. Covered entities that enter into contract to correctional institutions must treat protected health information about inmates in accordance with this rule and are permitted to use and disclose such information to correctional institutions as allowed under § 164.512(k)(5). As to former inmates, the final rule considers such persons who are released on parole, probation, supervised release, or are otherwise no longer in custody, to be individuals who are not inmates. Therefore, the permissible disclosure provision at § 164.512(k)(5) does not apply in such cases. Instead, a covered entity must apply privacy protections to the protected health information about former inmates in the same manner and to the same extent that it protects the protected health information of other individuals. In addition, individuals who are former inmates hold the same rights as all other individuals under the rule.

As to individuals in community custody, the final rule considers inmates to be those individuals who are incarcerated in or otherwise confined to a correctional institution. Thus, to the extent that community custody confines an individual to a particular facility, § 164.512(k)(5) is applicable.

Psychotherapy Notes

Comment: Some commenters thought the definition of psychotherapy notes was contrary to standard practice. They claimed that reports of psychotherapy are typically part of the medical record and that psychologists are advised, for ethical reasons and liability risk management purposes, not to keep two separate sets of notes. Others acknowledged that therapists may maintain separate notations of therapy sessions for their own purpose. These commenters asked that we make clear that psychotherapy notes, at least in summary form, should be included in the medical record. Many plans and providers expressed concern that the proposed definition would encourage the creation of “shadow” records which may be dangerous to the patient and may increase liability for the health care providers. Some commenters claimed that psychotherapy notes contain information that is often essential to treatment.

Response: We conducted fact-finding with providers and other knowledgeable parties to determine the standard practice of psychotherapists and determined that only some psychotherapists keep separate files with notes pertaining to psychotherapy sessions. These notes are often referred to as “process notes,” distinguishable from “progress notes” -- “the medical record,” or “official records.” These process notes capture the therapist’s
impressions about the patient, contain details of the psychotherapy conversation considered to be inappropriate for the medical record, and are used by the provider for future sessions. We were told that process notes are often kept separate to limit access, even in an electronic record system, because they contain sensitive information relevant to no one other than the treating provider. These separate “process notes” are what we are calling “psychotherapy notes.”

Summary information, such as the current state of the patient, symptoms, summary of the theme of the psychotherapy session, diagnoses, medications prescribed, side effects, and any other information necessary for treatment or payment, is always placed in the patient’s medical record. Information from the medical record is routinely sent to insurers for payment.

Comment: Various associations and their constituents asked that the exceptions for psychotherapy notes be extended to health care information from other health care providers. These commenters argued that psychotherapists are not the only providers or even the most likely providers to discuss sensitive and potentially embarrassing issues, as treatment and counseling for mental health conditions, drug abuse, HIV/AIDS, and sexual problems are often provided outside of the traditional psychiatric settings. One writer stated, “A prudent health care provider will always assess the past and present psychiatric medical history and symptoms of a patient.”

Many commenters believed that psychotherapy notes should include frequencies of treatment, results of clinical tests, and summary of diagnosis, functional status, the treatment plan, symptoms, prognosis and progress to date. They claimed that this information is highly sensitive and should not be released without the individual’s written consent, except in cases of emergency. One commenter suggested listing the types of mental health information that can be requested by third party payors to make payment determinations and defining the meaning of each term.

Response: As discussed above and in the NPRM, the rationale for providing special protection for psychotherapy notes is not only that they contain particularly sensitive information, but also that they are the personal notes of the therapist, intended to help him or her recall the therapy discussion and are of little or no use to others not involved in the therapy. Information in these notes is not intended to communicate to, or even be seen by, persons other than the therapist. Although all psychotherapy information may be considered sensitive, we have limited the definition of psychotherapy notes to only that information that is kept separate by the provider for his or her own purposes. It does not refer to the medical record and other sources of information that would normally be disclosed for treatment, payment, and health care operations.

Comment: One commenter was particularly concerned that the use of the term “counseling” in the definition of psychotherapy notes would lead to confusion because counseling and psychotherapy are different disciplines.

Response: In the final rule, we continue to use the term “counseling” in the definition of “psychotherapy.” During our fact-finding, we learned that “counseling” had no commonly agreed upon definition, but seemed to be widely understood in practice. We do not intend to limit the practice of psychotherapy to specific professional disciplines.

Comment: One commenter noted that the public mental health system is increasingly being called upon to integrate and coordinate services among other providers of mental health services and they have developed an integrated electronic medical record system for state-operated hospitals, part of which includes psychotherapy notes, and which cannot be easily modified to provide different levels of confidentiality. Another commenter recommended allowing use or disclosure of psychotherapy notes by members of an integrated health care facility as well as the originator.

Response: The final rule makes it clear that any notes that are routinely shared with others, whether as part of the medical record or otherwise, are, by definition, not psychotherapy notes, as we have defined them. To qualify for the definition and the increased protection, the notes must be created and maintained for the use of the provider who created them i.e., the originator, and must not be the only source of any information that would be critical to the treatment of the patient or for getting payment for the treatment. The types of notes described in the comment would not meet our definition for psychotherapy notes.

Comment: Many providers expressed concern that if psychotherapy notes were maintained separately from other protected health information, other health providers involved in the individual’s care would be unable to treat the patient properly. Some recommended that if the patient does not consent to sharing of psychotherapy notes for treatment purposes, the treating provider should be allowed to decline to treat the patient, providing a referral to another provider.

Response: The final rule retains the policy that psychotherapy notes be separated from the remainder of the medical record in order to receive additional protection. We based this decision on conversations with mental health providers who have told us that information that is critical to the treatment of individuals is normally maintained in the medical record and that psychotherapy notes are used by the provider who created them and rarely for other purposes. A strong part of the rationale for the special treatment of psychotherapy notes is that they are the personal notes of the treating provider and are of little or no use to others who were not present at the session to which the notes refer.

Comment: Several commenters requested that we clarify that the information contained in psychotherapy notes is being protected under the rule and not the notes themselves. They were concerned that the protection for psychotherapy notes would not be meaningful if health plans could demand the same information in a different format.

Response: This rule provides special protection for the information in psychotherapy notes, but it does not extend that protection to the same information that may be found in other locations. We do not require the notes to be in a particular format, such as hand-written. They may be typed into a word processor, for example. Copying the notes into a different format, per se, would not allow the information to be accessed by a health plan. However, the requirement that psychotherapy notes be kept separate from the medical record and solely for the use of the provider who created them means that the special protection does not apply to the same information in another location.

Public Health Authority

Comment: A number of the comments called for the elimination of all permissible disclosures without authorization, and some specifically cited the public health section and its liberal definition of public health authority as an inappropriately broad loophole that would allow unfettered access to private medical information by various government authorities.

Other commenters generally supported the provision allowing disclosure to public health authorities and to non-governmental entities.
authorized by law to carry out public health activities. They further supported the broad definition of public health authority and the reliance on broad legal or regulatory authority by public health entities although explicit authorities were preferable and better informed the public.

Response: In response to comments arguing that the provision is too broad, we note that section 1178(b) of the Act, as explained in the NPRM, explicitly carves out protection for state public health laws. This provision states that: “[N]othing in this part shall be construed to invalidate or limit the authority, power, or procedures established under any law providing for the reporting of disease or injury, child abuse, birth or death, public health surveillance, or public health investigation or intervention.” In light of this broad Congressional mandate not to interfere with current public health practices, we believe the broad definition of “public health authority” is appropriate to achieve that end.

Comment: Some commenters said that they performed public health activities in analyzing data and information. These comments suggested that activities conducted by provider and health plan organizations that compile and compare data for benchmarking performance, monitoring, utilization, and determining the health needs of a given market should be included as part of the public health exemption. One commenter recommended amending the regulation to permit covered entities to disclose protected health information to private organizations for public health reasons.

Response: We disagree that such a change should be made. In the absence of some nexus to a government public health authority or other underlying legal authority, covered entities would have no basis for determining which data collections are “legitimate” and how the confidentiality of the information will be protected. In addition, the public health functions carved out for special protection by Congress are explicitly limited to those established by law.

Comment: Two commenters asked for additional clarification as to whether the Occupational Safety and Health Administration (OSHA) and the Mine Safety and Health Administration (MSHA) would be considered public health authorities as indicated in the preamble. They suggested specific language for the final rule. Commenters also suggested that we specify that states operating OSHA-approved programs also are considered public health authorities. One comment applauded the Secretary’s recognition of OSHA as both a health oversight agency and public health authority. It suggested adding OSHA-approved programs that operate in states to the list of entities included in these categories. In addition, the comment requested the final regulation specifically mention these entities in the text of the rule as well.

Response: We agree that OSHA, MSHA and their state equivalents are public health authorities when carrying out their activities related to the health and safety of workers. We do not specifically reference any agencies in the regulatory definition, because the definition of public health authority and this preamble sufficiently address this issue. As defined in the final rule, the definition of “public health authority” at § 164.501 continues to include OSHA as a public health authority. State agencies or authorities responsible for public health matters as part of their official mandate, such as OSHA-approved programs, also come within this definition. See discussion of § 164.512(b) below. We have refrained, however, from listing specific agencies and have retained a general descriptive definition.

Comments: Several commenters recommended expanding the definition of public health authority to encompass other governmental entities that may collect and hold health data as part of their official duties. One recommended changing the definition of public health authority to read as follows: Public health authority means an agency or authority * * that is responsible for public health matters or the collection of health data as part of its official mandate.

Response: We do not adopt this recommendation. The public health provision is not intended to cover agencies that are not responsible for public health matters but that may in the course of their responsibilities collect health-related information. Disclosures to such authorities may be permissible under other provision of this rule.

Comment: Many commenters asked us to include a formal definition of “required by law” incorporating the material noted in this preamble and additional suggested disclosures.

Response: We agree generally and modify the definition accordingly. See discussion above.

Research

Comment: We received many comments from supporting the proposed definition of “research.” These commenters agreed that the definition of “research” should be the same as the definition in the Common Rule. These commenters argued that it was important that the definition of “research” be consistent with the Common Rule’s definition to ensure the coherent oversight of medical research. In addition, some of these commenters also supported this definition because they believed it was already well-understood by researchers and provided reasonably clear guidance needed to distinguish between research and health care operations.

Some commenters, believed that the NPRM’s definition was too narrow. Several of these commenters agreed that the Common Rule’s definition should be adopted in the final rule, but argued that the proposed definition of “generalizable knowledge” within the definition of “research,” which limited generalizable knowledge to knowledge that is “related to health,” was too narrow. For example, one commenter stated that gun shot wound, spousal abuse, and other kinds of information from emergency room statistics are often used to conduct research with ramifications for social policy, but may not be “related to health.” Several of these commenters recommended that the definition of research be revised to delete the words “related to health.” Additional commenters who argued that the definition was too narrow raised the following concerns: the difference between “research” and “health care operations” is irrelevant from the patients’ perspective, and therefore, the proposed rule should have required documentation of approval by an IRB or privacy board before protected health information could be used or disclosed for either of these purposes, and the proposed definition was too limited because it did not capture research conducted by non-profit entities to ensure public health goals, such as disease-specific registries.

Commenters who argued that the definition was too broad recommended that certain activities should be explicitly excluded from the definition. In general, these commenters were concerned that if certain activities were considered to be “research” the rule’s research requirements would represent a problematic level of regulation on industry initiatives. Some activities that these commenters recommended be explicitly excluded from the definition of “research” included: marketing research, health and productivity management, quality assessment and improvement activities, and internal research conducted to improve health.

Response: We agree that the final rule’s definition of “research” should be
consistent with the Common Rule’s definition of this term. We also agree that our proposal to limit “generalizable knowledge” to knowledge that is “related to health,” and “knowledge that could be applied to populations outside of the population served by the covered entity,” was too narrow. Therefore, in the final rule, we retain the Common Rule’s definition of “research” and eliminate the further elaboration of “generalizable knowledge.” We understand knowledge to be generalizable when it can be applied to either a population inside or outside of the population served by the covered entity. Therefore, knowledge may be “generalizable” even if a research study uses only the protected health information held within a covered entity, and the results are generalizable only to the population served by the covered entity. For example, generalizable knowledge could be generated from a study conducted by the HCFA, using only Medicare data held by HCFA, even if the knowledge gained from the research study is applicable only to Medicare beneficiaries.

We rejected the other arguments claiming that the definition of “research” was either too narrow or too broad. While we agree that it is sometimes difficult to distinguish between “research” and “health care operations,” we disagree that the difference between these activities is irrelevant from the patients’ perspective. We believe, based on many of the comments, that individuals expect that individually identifiable health information about themselves will be used for health care operations such as reviewing the competence or qualifications of health care professionals, evaluating provider and plan performance, and improving the quality of care. A large number of commenters, however, indicated that they did not expect that individually identifiable health information about themselves would be used for research purposes without their authorization. Therefore, we retain more stringent protections for research disclosures without patient authorization.

We also disagree with the commenters who were concerned that the proposed definition was too limited because it did not capture research conducted by non-profit entities to ensure public health goals, such as disease-specific registries. Such activities conducted by either non-profit or for-profit entities could meet the rule’s definition of research, and therefore are not necessarily excluded from this definition.

We also disagree with many of the commenters who argued that certain activities should be explicitly excluded from the definition of research. We found no persuasive evidence that, when particular activities are also systematic investigations designed to contribute to generalizable knowledge, they should be treated any different from other such activities.

We are aware that the National Bioethics Advisory Commission (NBAC) is currently assessing the Common Rule’s definition of “research” as part of a report they are developing on the implementation and adequacy of the Common Rule. Since we agree that a consistent definition is important to the conduct and oversight of research, if the Common Rule’s definition of “research” is modified in the future, the Department of Health and Human Services will consider whether the definition should also be modified for this subpart.

Comment: Some commenters urged the Department to establish precise definitions for “health care operations” and “research” to provide clear guidance to covered entities and adequate privacy protections for the subjects of the information whose information is disclosed for these purposes. One commenter supported the definition of “research” proposed in the NPRM, but was concerned about the “crossover” from data analyses that begin as health care operations but later become “research” because the analytical results are of such importance that they should be shared through publication, thereby contributing to generalizable knowledge. To distinguish between the definitions of “health care operations” and “research,” a few commenters recommended that the rule make this distinction based upon whether the activity is a “use” or a “disclosure.” These commenters recommend that the “use” of protected health information for research without patient authorization should be exempt from the proposed research provisions provided that protected health information was not disclosed in the final analysis, report, or publication.

Response: We agree with commenters that at times it may be difficult to distinguish projects that are health operations and projects that are research. We note that this ambiguity exists today, and disagree that we can address this issue with more precise definitions of research and health care operations. Today, the issue is largely one of intent. Under the Common Rule, the ethical and regulatory obligations of the researcher stem from the intent of the activity. We follow that approach here. If such a project is a systematic investigation that designed to develop or contribute to generalizable knowledge, it is considered to be “research,” not “health care operations.”

In some instances, the primary purpose of the activity may change as preliminary results are analyzed. An activity that was initiated as an internal outcomes evaluation may produce information that could be generalized. If the purpose of a study changes and the covered entity does intend to generalize the results, the covered entity should document the fact as evidence that the activity was not subject to § 164.512(j) of this rule.

We understand that for research that is subject to the Common Rule, this is not the case. The Office for Human Research Protection interprets 45 CFR part 46 to require IRB review as soon as an activity meets the definition of research, regardless of whether the activity began as “health care operations” or “public health,” for example. The final rule does not affect the Office of Human Research Protection’s interpretation of the Common Rule.

We were not persuaded that an individual’s privacy interest is of less concern when covered entities use protected health information for research purposes than when covered entities disclose protected health information for research purposes. We do not agree generally that internal activities of covered entities do not potentially compromise the privacy interests of individuals. Many persons within a covered entity may have access to protected health information. When the activity is a systematic investigation, the number of persons who may be involved in the records review and analysis may be substantial. We believe that IRB or privacy board approval of the waiver of authorization will provide important privacy protections to individuals about whom protected health information is used or disclosed for research. If a covered entity wishes to use protected health information about its enrollees for research purposes, documentation of an IRBs’ or privacy board’s assessment of the privacy impact of such a use is as important as if the same research study required the disclosure of protected health information. This conclusion is consistent with the Common Rule’s requirement for IRB review of all human subjects research.

Treatment

Comment: Some commenters advocated for a narrow interpretation of
treatment that applies only to the individual who is the subject of the information. Other commenters asserted that treatment should be broadly defined when activities are conducted by health care providers to improve or maintain the health of the patient. A broad interpretation may raise concerns about potential misuse of information, but too limited an interpretation will limit beneficial activities and further contribute to problems in patient compliance and medical errors.

Response: We find the commenters’ arguments for a broad definition of treatment persuasive. Today, health care providers consult with one another, share information about their experience with particular therapies, seek advice about how to handle unique or challenging cases, and engage in a variety of other discussions that help them maintain and improve the quality of care they provide. Quality of care improves when providers exchange information about treatment successes and failures. These activities require sharing of protected health information. We do not intend this rule to interfere with these important activities. We therefore define treatment broadly and allow use and disclosure of protected health information about one individual for the treatment of another individual.

Under this definition, only health care providers or a health care provider working with a third party can perform treatment activities. In this way, we temper the breadth of the definition by limiting the scope of information sharing. The specificity of professional ethics also help assure that information sharing among providers for treatment purposes will be appropriate.

We note that poison control centers are health care providers for purposes of this rule. We consider the counseling and follow-up consultations provided by poison control centers with individual providers regarding patient outcomes to be treatment. Therefore, poison control centers and other health care providers can share protected health information about the treatment of an individual without a business associate contract.

Comment: Many commenters suggested that “treatment” activities should include services provided to both a specific individual and larger patient populations and therefore urged that the definition of treatment specifically allow for such activities, sometimes referred to as “disease management” activities. Some argued that an analysis of an overall population is important when individuals would benefit from disease management services. Thus, an analysis of health care claims for enrolled populations enables proactive contact with those identified individuals to notify them of the availability of services. Certain commenters noted that “disease management” services provided to their patient populations, such as reminders about recommended tests based on nationally accepted clinical guidelines, are integral components of quality health care.

Response: We do not agree that population based services should be considered treatment activities. The definition of “treatment” is closely linked to the § 160.103 definition of “health care,” which describes care, services and procedures related to the health of an individual. The activities described by “treatment,” therefore, all involve health care providers supplying health care to a particular patient. While many activities beneficial to patients are offered to entire populations or involve examining health information about entire populations, treatment involves health services provided by a health care provider and tailored to the specific needs of an individual patient. Although a population-wide analysis or intervention may prompt a health care provider to offer specific treatment to an individual, we consider the population-based analyses to improve health care or reduce health care costs to be health care operations (see definition of “health care operations,” above).

Comment: A number of commenters requested clarification about whether prescription drug compliance management programs would be considered “treatment.” One commenter urged HHS to clarify that provision by a pharmacy to a patient of customized prescription drug information about the risks, benefits, and conditions of use of a prescription drug being dispensed is considered a treatment activity. Others asked that the final rule expressly recognize that prescription drug advice provided by a dispensing pharmacist, such as a customized pharmacy letter, is within the scope of treatment.

Response: The activities that are part of prescription drug compliance management programs were not fully described by these commenters, so we cannot state a general rule regarding whether such activities constitute treatment. We agree that pharmacists’ provision of customized prescription drug information and advice about the prescription drug being dispensed is a treatment activity. Pharmacists’ provisions of information and counseling to their customers constitute treatment, and we exclude certain communications made in the treatment context from the definition of marketing. (See discussion above.)

Comment: Some commenters noted the issues and recommendations raised in the Institutes of Medicine report “To Err Is Human” and the critical need to share information about adverse drug and other medical events, evaluation of the information, and its use to prevent future medical errors. They noted that privacy rules should not be so stringent as to prohibit the sharing of patient data needed to reduce errors and optimize health care outcomes. To bolster the notion that other programs associated with the practice of pharmacy must be considered as integral to the definition of health care and treatment, they reference OBRA ’90 (42 U.S.C. 1396r–8) and the minimum required activities for dispensing drugs; they also note that virtually every state Board of Pharmacy adopted regulations imposing OBRA ’90 requirements on pharmacies for all patients and not just Medicaid recipients.

Response: We agree that reducing medical errors is critical, and do not believe that this regulation impairs efforts to reduce medical errors. We define treatment broadly and include quality assessment and improvement activities in the definition of health care operations. Covered pharmacies may conduct such activities, as well as treatment activities appropriate to improve quality and reduce errors. We believe that respect for the privacy rights of individuals and appropriate protection of the confidentiality of their health information are compatible with the goal of reducing medical errors.

Comment: Some commenters urged us to clarify that health plans do not perform “treatment” activities; some of these were concerned that a different approach in this regulation could cause conflict with state corporate practice of medicine restrictions. Some commenters believed that the proposed definition of treatment crossed into the area of cost containment, which would seem to pertain more directly to payment. They supported a narrower definition that would eliminate any references to third party payors. One commenter argued that the permissible disclosure of protected health information to carry out treatment is too broad for health plans and that health plans that have no responsibility for treatment or care coordination should have no authority to release health information without authorization for treatment purposes.

Response: We do not consider the activities of third party payors, including health plans, to be
“treatment.” Only health care providers, not health plans, conduct “treatment” for purposes of this rule. A health plan may, however, disclose protected health information without consent or authorization for treatment purposes if that disclosure is made to a provider. Health plans may have information the provider needs, for example information from other providers or information about the patient’s treatment history, to develop an appropriate plan of care. Comment: We received many comments relating to “disease management” programs and whether activities described as disease management should be included in the definition of treatment. One group of commentators supported the proposed definition of treatment that includes disease management. One commenter offered the position that disease management services are more closely aligned with treatment because they involve the coordination of treatment whereas health care operations are more akin to financial and ministerial functions of plans.

Some recommended that the definition of treatment be limited to direct treatment of individual patients and not allow for sharing of information for administrative or other programmatic reasons. They believed that allowing disclosures for disease management opens a loophole for certain uses and disclosures, such as marketing, that should only be permitted with authorization. Others recommended that the definition of disease management be restricted to prevent unauthorized use of individual health records to target individuals in a health plan or occupational health program. Many asked that the definition of disease management be clarified to identify those functions that, although some might consider them to be subsumed by the term, are not permitted under this regulation without authorization, such as marketing and disclosures of protected health information to employers. They suggested that disease management may describe desirable activities, but is subject to abuse and therefore should be restricted and controlled. One commenter recommends that we adopt a portion of the definition adopted by the Disease Management Association of America in October 1999.

On the other hand, many comments urged that disease management be part of the “treatment” definition or the “health care operations” definition and asked that specific activities be included in a definition. They viewed disease management as an important element of comprehensive health care services and cost management efforts. They recommended that the definition of disease management include services directed at an entire population and not just individual care, in order to identify individuals who would benefit from services based on accepted clinical guidelines. They recommended that disease management be included under health care operations and include population level services. A commenter asserted that limiting disease management programs to the definition of treatment ignores that these programs extend beyond providers, especially since NCQA accreditation standards strongly encourage plans and insurers to provide these services.

Response: Disease management appeared to represent different activities to different commenters. Our review of the literature, industry materials, state and federal statutes, and discussions with physician groups, health plan groups and disease management associations confirm that a consensus definition from the field has not yet evolved, although efforts are underway. Therefore, rather than rely on this label, we delete “disease management” from the treatment definition and instead include the functions often discussed as disease management activities in this definition or in the definition of health care operations and modify both definitions to address the commenters’ concerns.

We add population-based activities to improve health care or reduce health care costs to the definition of health care operations. Outreach programs as described by the commenter may be considered either health care operations or treatment, depending on whether population-wide or patient-specific activities occur, and if patient-specific, whether the individualized communication with a patient occurs on behalf of health care provider or a health plan. For example, a call placed by a nurse in a doctor’s office to a patient to discuss follow-up care is a treatment activity. The same activity performed by a nurse working for a health plan would be a health care operation. In both cases, the database analysis that created a list of patients that would benefit from the intervention would be a health care operation. Use or disclosure of protected health information to provide education materials to patients may similarly be either treatment or operations, depending on the circumstances and on who is sending the materials. We cannot say in the abstract whether any such activities constitute marketing under this rule. See §§ 164.501 and 164.514 for details on what communications are marketing and when the authorization of the individual may be required.

Comment: Many commentators were concerned that the definition of treatment would not permit Third Party Administrators (TPAs) to be involved with disease management programs without obtaining authorization. They asserted that while the proposed definition of treatment included disease management conducted by health care providers it did not recognize the role of employers and TPAs in the current disease management process.

Response: Covered entities disclose protected health information to other persons, including TPAs, that they hire to perform services for them or on their behalf. If a covered entity hires a TPA to perform the disease management activities included in the definition of treatment and health care operations that disclosure will not...
require authorization. The relationship between the covered entity and the TPA may be subject to the business associate requirements of §§ 164.502 and 164.504. Disclosures by covered entities to plan sponsors, including employers, for the purpose of plan administration are addressed in § 164.504.

Comment: Commenters suggested that as disease management is defined only as an element of treatment, it could only be carried out by health care providers, and not health plans. They opposed this approach because health plans also conduct such programs, and are indeed required to do it by accreditation standards and HICFA Managed Care Organization standards.

Response: We agree that the placement of disease management in the proposed definition of treatment suggested that health plans could not conduct such programs. We revise the final rule to clarify that health plans may conduct population based care management programs as a health care operation activity.

Comment: Some commenters stated that the rule should require that disease management only be done with the approval of the treating physician or at least with the knowledge of the physician.

Response: We disagree with this comment because we do not believe that this privacy rule is an appropriate venue for setting policies regarding the management of health care costs or treatment.

Comment: Some industry groups stated that if an activity involves selling products, it is not disease management. They asked for a definition that differentiates use of information for the best interests of patient from uses undertaken for “ulterior purposes” such as advertising, marketing, or promoting separate products.

Response: We eliminate the definition of “disease management” from the rule. Often however, treatment decisions involve discussing the relevant advantages and disadvantages of products and services. Health plans, as part of payment and operations, sometimes communicate with individuals about particular products and services. We address these distinctions in the definitions of marketing and “health care operations” in § 164.501, and in the requirements for use and disclosure of protected health information for marketing in § 164.514.

Comment: Some health care providers noted that there is a danger that employers will “force” individual employees to take a medical condition into self-care or compliance programs in ways that violate both the employee’s privacy interest and his or her right to control own medical care.

Response: Employers are not covered entities under HIPAA, so we cannot prohibit them under this rule from undertaking these or other activities with respect to health information. In § 164.504 we limit disclosure of health information from group health plans to the employers sponsoring the plans. However, other federal and/or state laws, such as disability nondiscrimination laws, may govern the rights of employees under such circumstances.

Comment: Many commenters urged that disease management only be allowed with the written consent of the individual. Others also desired consent but suggested that an opt-out would be sufficient. Other commenters complained that the absence of a definition for disease management created uncertainty in view of the proposed rule’s requirement to get authorization for marketing. They were concerned that the effect would be to require patient consent for many activities that are desirable, not practicably done if authorization is required, and otherwise classifiable as treatment, payment, or health care operations. Examples provided include reminders for appointments, reminders to get preventive services like mammograms, and information about home management of chronic illnesses.

Response: We agree with the commenters who stated that the requirement for specific authorization for certain activities considered part of disease management could impede the ability of health plans and covered providers to implement effective health care management and cost containment programs. In addition, this approach would require us to distinguish activities undertaken as part of a formal disease management program from the same activities undertaken outside the context of disease management program. For example, we see no clear benefit to privacy in requiring written authorization before a physician may call a patient to discuss treatment options in all cases, nor do we see a sound basis for requiring it only when the physician was following a formal protocol as part of a population based intervention. We also are not persuaded that the risk to privacy for these activities warrants a higher degree of protection than do other payment, health care operations or treatment activities for which specific authorization was not suggested by commenters.

Comment: A few commenters asked that we clarify that disclosure of protected health information about a prospective patient to a health care provider (e.g., a possible admission to an assisted living facility from a nursing facility) is a treatment activity that does not require authorization.

Response: We agree that the described activity is “treatment,” because it constitutes referral and coordination of health care.

Comment: Comments called for the removal of “other services” from the definition.

Response: We disagree with the concept that only health care services are appropriately included in the treatment definition. We have modified this definition to instead include “the provision, coordination, or management of health care and related services.” This definition allows health care providers to offer or coordinate social, rehabilitative, or other services that are associated with the provision of health care. Our use of the term “related” prevents “treatment” from applying to the provision of services unrelated to health care.

Comment: Several commenters stated that the definition of treatment should include organ and tissue recovery activities. They asserted that the information exchanged and collected to request consent, evaluate medical information about a potential donor and perform organ recoveries relates to treatment and are not administrative activities. When hospitals place a patient on the UNOS list it is transferring individually identifiable health information. Also, when an organ procurement organization registers a donor with UNOS it could be disclosing protected health information. Commenters questioned whether these activities would be administrative or constitute treatment.

Response: In the proposed rule we included in the definition of “health care” activities related to the procurement or organs, blood, eyes and other tissues. This final rule deletes those activities from the definition of “health care.” We do so because, while organ and tissue procurement organizations are integral components of the health care system, we do not believe that the testing, procurement, and other procedures they undertake describe “health care” offered to the donors of the tissues or organs themselves. See the discussion under the definition of “health care” in § 160.103.

Comment: Some commenters recommended including health promotion activities in the definition of health care.
Response: We consider health promotion activities to be preventive care, and thus within the definition of health care. In addition, such activities that are population based are included in the definition of health care operations.

Comment: We received a range of comments regarding the proper placement of case and disease management in the definitions and the perceived overlap between health care operations and treatment. Some consider that these activities are a function of improving quality and controlling costs. Thus, they recommend that the Secretary move risk assessment, case and disease management to the definition of health care operations.

Response: In response to these comments, we remove these terms from the definition of treatment and add case management to the definition of health care operations. We explain our treatment of disease management in response to comments above. Whether an activity described as disease or case management falls under treatment or health care operations would depend in part on whether the activity is focused on a particular individual or a population. A single program described as a “case management” effort may include both health care operations activities (e.g., records analysis, protocol development, general risk assessment) and treatment activities (e.g., particular services provided to or coordinated for an individual, even if applying a standardized treatment protocol).

Comment: We received comments that argued for the inclusion of “disability management” in the treatment definition. They explained that through disability management, health care providers refer and coordinate medical management and they require contemporaneous exchange of an employee’s specific medical data for the provider to properly manage.

Response: To the extent that a covered provider is coordinating health care services, the provider is providing treatment. We do not include the term “disability management” because the scope of the activities covered by that term is not clear. In addition, the commenters did not provide enough information for us to make a fact-based determination of how this rule applies to the uses and disclosures of protected health information that are made in a particular “disability management” program.

Use

Comment: One commenter asserted that the scope of the proposal had gone beyond the intent of Congress in addressing uses of information within the covered entity, as opposed to transactions and disclosures outside the covered entity. This commenter argued that, although HIPAA mentions use, it is unclear that the word “use” in the proposed rule is what Congress intended. The commenter pointed to the legislative history to argue that “use” is related to an information exchange outside of the entity.

Response: We disagree with the commenter regarding the Congress’ intent. Section 264 of HIPAA requires that the Secretary develop and send to Congress recommendations on standards with respect to the privacy of individually identifiable health information (which she did on September 11, 1997) and prescribes that the recommendations address among other items “the uses and disclosures of such information that should be authorized or required.” Section 264 explicitly requires the Secretary to promulgate standards that address at least the subjects described in these recommendations. It is therefore our interpretation that Congress intended to cover “uses” as well as disclosures of individually identifiable health information. We find nothing in the legislative history to indicate that Congress intended to deviate from the common meaning of the term “use.”

Comment: One commenter observed that the definition could encompass the processing of data by computers to execute queries. It was argued that this would be highly impracticable because computers are routinely used to identify subsets of data sets. It was explained that in performing this function, computers examine each record in the data set and return only those records in the data set that meet specific criteria. Consequently, a human being will see only the subset of data that the computer returns. Thus, the commenter stated that it is only this subset that could be used or disclosed.

Response: We interpret “use” to mean only the use of the product of the computer processing, not the internal computer processing that generates the product.

Comments: Some commenters asked that the Department clarify that individualized medical information obtained through a fitness for duty examination is not subject to the privacy protections under the regulation.

Response: As discussed above, we have clarified that the definition of “treatment” to include assessments of an individual. If the assessment is performed by a covered health care provider, the health information resulting from the assessment is protected health information. We note that a covered entity is permitted to condition the provision of health care when the sole purpose is to create protected health information for the benefit of a third person. See §164.508(b). For example, a covered health care provider may condition the provision of a fitness for duty examination to an individual on obtaining an authorization from the individual for disclosure to the employer who has requested the examination.

Section 164.502—Uses and Disclosures of Protected Health Information: General Rules

Section 164.502(a)—General Standard

Comment: A few commenters requested an exemption from the rule for the Social Security and Supplemental Security Income Disability Programs so that disability claimants can be served in a fair and timely manner. The commenters were concerned that the proposal would be narrowly interpreted, thereby impeding the release of medical records for the purposes of Social Security disability programs.

Another commenter similarly asked that a special provision be added to the proposal’s general rule for uses and disclosures without authorization for treatment, payment, and health care operations purposes to authorize disclosure of all medical information from all sources to the Social Security Administration, including their contracted state agencies handling disability determinations.

Response: A complete exemption for disclosures for these programs is not necessary. Under current practice, the Social Security Administration obtains authorization from applicants for providers to release an individual’s records to SSA for disability and other determinations. Thus, there is no reason to believe that an exemption from the authorization required by this rule is needed to allow these programs to function effectively. Further, such an exemption would reduce privacy protections from current levels. When this rule goes into effect, those authorizations will need to meet the requirements for authorization under §164.508 of this rule.

We do, however, modify other provisions of the proposed rule to accommodate the special requirements of these programs. In particular, Social Security Disability and other federal programs, and public benefits programs run by the states, are authorized by law
to share information for eligibility purposes. Where another public body has determined that the appropriate balance between need for efficient administration of public programs and public funds and individuals’ privacy interests is to allow information sharing for these limited purposes, we do not upset that determination. Where the sharing of enrollment and eligibility information is required or expressly authorized by law, this rule permits such sharing of information for eligibility and enrollment purposes (see § 164.512(k)(6)(i)), and also excepts these arrangements from the requirements for business associate agreements (see § 164.502(e)(1)).

Comment: A few commenters asked that the rule be revised to authorize disclosures to clergy, for directory purposes, to organ and tissue procurement organizations, and to the American Red Cross without patient authorization.

Response: We agree and revise the final rule accordingly. The new policies and the rationale for these policies are found in §§ 164.510 and 164.512, and the corresponding preamble.

Comment: One commenter recommended that the rule apply only to the “disclosure” of protected health information by covered entities, rather than to both “use” and “disclosure.” The commenter stated that the application of the regulation to a covered entity’s use of individually identifiable health information offers little benefit in terms of protecting protected health information, yet imposes costs and may hamper many legitimate activities, that fall outside the definition of treatment, payment or health care operations.

Another commenter similarly urged that the final regulation draw substantive distinctions between restrictions on the “use” of individually identifiable health information and on the “disclosure” of such information, with broader latitude for “uses” of such information. The commenter believed that internal “uses” of such information generally do not raise the same issues and concerns that a disclosure of that information might raise. It was argued that any concerns about the potential breadth of use of this information could be addressed through application of the “minimum necessary” standard. The commenter also argued that Congressional intent was that a “disclosure” of individually identifiable health information is potentially much more significant than a “use” of that information.

Response: We do not accept the commenter’s broad recommendation to apply the regulation only to the “disclosure” of protected health information and not to “use” of such information. Section 264 charges the Secretary with promulgating standards that address, among other things, “the uses and disclosures” of individually identifiable health information. We also do not agree that applying the regulation to “use” offers little benefit to protecting protected health information. The potential exists for misuse of protected health information within entities. This potential is even greater when the covered entity also provides services or products outside its role as a health care provider, health plan, or health care clearinghouse for which “use” of protected health information offers economic benefit to the entity. For example, if this rule did not limit “uses” generally to treatment, payment and health care operations, a covered entity that also offered financial services could be able to use protected health information without authorization to market or make coverage or rate decisions for its financial services products. Without the minimum necessary standard for uses, a hospital would not be constrained from allowing their appointment scheduling clerks free access to medical records.

We agree, however, that it is appropriate to apply somewhat different requirements to uses and disclosures of protected health information permitted by this rule. We therefore modify the application of the minimum necessary standard to accomplish this. See the preamble to § 164.514 for a discussion of these changes.

Comment: A commenter argued that the development, implementation, and use of integrated computer-based patient medical record systems, which requires efficient information sharing, will likely be impeded by regulatory restrictions on the “use” of protected health information and by the minimum necessary standard.

Response: We have modified the proposed approach to regulating “uses” of protected health information within an entity, and believe our policy is compatible with the development and implementation of computer-based medical record systems. In fact, we drew part of the revised policy on “minimum necessary” use of protected health information from the role-based access approach used in several computer-based records systems today. These policies are described further in § 164.514.

Comment: One commenter asked that the general rules for uses and disclosures be amended to permit covered entities to disclose protected health information for purposes relating to property and casualty benefits. The commenter argued that the proposal could affect its ability to obtain protected health information from covered entities, thereby constraining the flow of medical information needed to administer property and casualty benefits, particularly in the workers’ compensation context. It was stated that this could seriously impede property and casualty benefit providers’ ability to conduct business in accordance with state law.

Response: We disagree that the rule should be expanded to permit all uses and disclosures that relate to property and casualty benefits. Such a broad provision is not in keeping with protecting the privacy of individuals. Although we generally lack the authority under HIPAA to regulate the practices of this industry, the final rule addresses when covered entities may disclose protected health information to property and casualty insurers. We believe that the final rule permits property and casualty insurers to obtain the protected health information that they need to maintain their promises to their policyholders. For example, the rule permits a covered entity to use or disclose protected health information relating to an individual when authorized by the individual. Property and casualty insurers are free to obtain authorizations from individuals for release by covered entities of the health information that the insurers need to administer claims, and this rule does not affect their ability to condition payment on obtaining such an authorization from insured individuals. Property and casualty insurers providing payment on a third-party basis have an opportunity to obtain authorization from the individual and to condition payment on obtaining such authorization. The final rule also permits covered entities to make disclosures to obtain payment, whether from a health plan or from another person such as a property and casualty insurer. For example, where an automobile insurer is paying for medical benefits on a first-party basis, a health care provider may disclose protected health information to the insurer as part of a request for payment. We also include in the final rule a new provision that permits covered entities to use or disclose protected health information as authorized by workers’ compensation or similar programs established by law addressing work-related injuries or illnesses. See § 164.514. These statutory programs establish channels of information sharing that are necessary.
Comment: A few commenters suggested that the Department specify "prohibited" uses and disclosures rather than "permitted" uses and disclosures.
Response: We reject these commenters' because we believe that the best privacy protection in most instances is to require the individual's authorization for use or disclosure of information, and that the role of this rule is to specify those uses and disclosures for which the balance between the individuals' privacy interest and the public's interests dictates a different approach. The opposite approach would require us to anticipate the much larger set of all possible uses of information that do not implicate the public's interest, rather than to specify the public interests that merit regulatory protection.

Comment: A commenter recommended that the rule be revised to more strongly discourage the use of individually identifiable health information where de-identified information could be used.
Response: We agree that the use of de-identified information wherever possible is good privacy practice. We believe that by requiring covered entities to implement these privacy restrictions only with respect to individually identifiable health information, the final rule strongly encourages covered entities to use de-identified information as much as practicable.

Comment: One commenter recommended that when information from health records is provided to authorized external users, this information should be accompanied by a statement prohibiting use of the information for other than the stated purpose; prohibiting disclosure by the recipient to any other party without written authorization from the patient, or the patient's legal representative, unless such information is urgently needed for the patient's continuing care or otherwise required by law; and requiring destruction of the information after the stated need has been fulfilled.
Response: We agree that restricting other uses or re-disclosure of protected health information by a third party that may receive the information for treatment, payment, and health care operations purposes or other purposes permitted by rule would be ideal with regard to privacy protection. However, as described elsewhere in this preamble, once protected health information leaves the custody of the Department no longer has jurisdiction under the statute to apply protections to the information. Since we would have no enforcement authority, the costs and burdens of requiring covered entities to produce and distribute such a statement to all recipients of protected health information, including those with whom the covered entity has no ongoing relationship, would outweigh any benefits to be gained from such a policy. Similarly, where protected health information is disclosed for routine treatment, payment and operations purposes, the sheer volume of these disclosures makes the burden of providing such a statement unacceptable. Appropriate protection for these disclosures requires law or regulation directly applicable to the recipient of the information, not further burden on the disclosing entity. Where, however, the recipient of protected health information is providing a service to or on behalf of the covered entity this balance changes. It is consistent with long-standing legal principles to hold the covered entity to a higher degree of responsibility for the actions of its agents and contractors. See § 164.504 for a discussion of the responsibilities of covered entities for the actions of their business associates with respect to protected health information.

Section 164.502(b)—Minimum Necessary

Comments on the minimum necessary standard are addressed in the preamble to § 164.514(d).

Section 164.502(c)—Uses or Disclosures of Protected Health Information Subject to an Agreed Upon Restriction

Comments on the agreed upon restriction standard are addressed in the preamble to § 164.522(a).

Section 164.502(d)—Uses and Disclosures of De-Identified Protected Health Information

Comments on the requirements for de-identifying information are addressed in the preamble to § 164.514(a)–(c).

Section 164.502(e)—Business Associates

Comments on business associates are addressed in the preamble to § 164.504(e).

Section 164.502(f)—Deceased Individuals

Comment: Most commenters on this topic generally did not approve of the Secretary's proposal with regard to protected health information about deceased individuals. The majority of these commenters argued that our proposal was not sufficiently protective of such information. Commenters agreed with the statements made in the preamble to the proposed rule that the privacy concerns addressed by this policy are not limited to the confidential protection of the deceased individual but instead also affects the decedent's family, as genetic information and information pertinent to hereditary diseases and risk factors for surviving relatives and direct family members may be disclosed through the disclosure of the deceased individual's confidential data. It was argued that the proposal would be inadequate to protect the survivors who could be negatively affected and in most cases will outlive the two-year period of protection. A number of medical associations asserted that individuals may avoid genetic testing, diagnoses, and treatment and suppress information important to their health care if they fear family members will suffer discrimination from the release of their medical information after their death. One commenter pointed out that ethically little distinction can be made between protecting an individual's health information during life and protecting it post-mortem. Further, it was argued that the privacy of the deceased individual and his or her family is far more important than allowing genetic information to be abstracted by an institutional or commercial collector of information. A few commenters asked that we provide indefinite protection on the protected health information about a deceased person contained in psychotherapy notes. One commenter asked that we extend protections on records of children who have died of cancer for the lifetime of a deceased child's siblings and parents.

The majority of commenters who supported increased protections on the protected health information about the deceased asked that we extend protections on such information indefinitely or for as long as the covered entity maintains the information. It was also argued that the administrative burden of perpetual protection would be no more burdensome than it is now as current practice is that the confidentiality of identifiable patient information continues after death. A number of others pointed out that there was no reason to set a different privacy standard for deceased individuals than we had for living individuals and that it has been standard practice to release the information of deceased individuals with a valid consent of the executor, next of kin, or specific court order. In addition, commenters referred to Hawaii's health care information privacy law (see Haw. Rev. Stat. section
323C–43) as at least one example of a state law where the privacy and access provisions of the law continue to apply to the protected health information of a deceased individual following the death of that individual.

Response: We find the arguments raised by these commenters persuasive. We have reconsidered our position and believe these arguments for maintaining privacy on protected health information without temporal limitations outweigh any administrative burdens associated with maintaining such protections. As such, in the final rule we revise our policy to extend protections on the protected health information about a deceased individual to remain in effect for as long as the covered entity maintains the information.

For purposes of this regulation, this means that, except for uses and disclosures for research purposes (see §164.512(i)), covered entities must under this rule protect the protected health information about a deceased individual in the same manner and to the same extent as required for the protected health information of living individuals. This policy alleviates the burden on the covered entity from having to determine whether or not the person has died and if so, how long ago, when determining whether or not the information can be released.

Comment: One commenter asked us to delete our standard for deceased individuals, asserting that the deceased have no constitutional right to privacy and state laws are sufficient to maintain protections for protected health information about deceased individuals.

Response: We understand that traditional privacy law has historically stripped privacy protection on information at the time the subject of the information dies. However, as we pointed out in the preamble to the proposed rule, the dramatic proliferation of electronic-based interchanges and maintenance of information has enabled easier and more ready access to information that once may have been de facto protected for most people because of the difficulty of its collection and aggregation. It is also our understanding that current state laws vary widely with regard to the privacy protection of a deceased individual’s individually identifiable health information. Some are less protective than others and may not take into account the implications of disclosure of genetic and hereditary information on living individuals. For these reasons, a regulatory standard is needed in order to adequately protect the privacy interests of those who are living.

Comment: Another commenter expressed concern over the administrative problems that the proposed standard would impose, particularly in the field of retrospective health research.

Response: For certain research purposes, we permit a covered entity to use and disclose the protected health information of a deceased individual without authorization by a personal representative and absent review by an IRB or privacy board. The verification standard (§164.514(b)) requires that covered entities obtain an oral or written representation that the protected health information sought will be used or disclosed solely for research, and §164.512(i)(1)(iii) requires the covered entity to obtain from the researcher documentation of the death of the individual. We believe the burden on the covered entity will be small, because it can reasonably rely on the representation of purpose and documentation of death presented by the researcher.

Comment: A few commenters argued that the standard in the proposed rule would cause significant administrative burdens on their record retention and storage policies. Commenters explained that they have internal policy record-retention guidelines which do not envision the retention of records beyond a few years. Some commenters complained about the burden of having to track dates of death, as the commenters are not routinely notified when an individual has died.

Response: The final rule does not dictate any record retention requirements for the records of deceased individuals. Since we have modified the NPRM to cover protected health information about deceased individuals for as long as the covered entity maintains the information, there will be no need for the covered entity to track dates of death.

Comment: A few commenters voiced support for the approach proposed in the proposal to maintain protections for a period of two years.

Response: After consideration of public comments, we chose not to retain this approach because the two-year period would be both inadequate and arbitrary. As discussed above, we agree with commenter arguments in support of providing indefinite protection.

Comment: A few commenters expressed concern that the regulations may be interpreted as providing a right of access to a deceased’s records only for a two-year period after death. They asked the Department to clarify that the right of access of an individual, including the representatives of a deceased individual, exists for the entire period the information is held by a covered entity.

Response: We agree with these comments, given the change in policy discussed above.

Comment: A few commenters suggested that privacy protections on protected health information about deceased individuals remain in effect for a specified time period longer than 2 years, arguing that two years was not long enough to protect the privacy rights of living individuals. These commenters, however, were not in agreement as to what other period of protection should be imposed, suggesting various durations from 5 to 20 years.

Response: We chose not to extend protections in this way because specifying another time period would raise many of the same concerns voiced by the commenters regarding our proposed two-year period and would not reduce the administrative burden of having to track or learn dates of death. We believe that the policy in this final rule extending protections for as long as the covered entity maintains the information addresses commenter concerns regarding the need for increased protections on the protected health information about the deceased.

Comment: Some commenters asserted that information on the decedent from the death certificate is important for assessment and research purposes and requested that the Department clarify accordingly that death certificate data be allowed for use in traditional public health assessment activities.

Response: Nothing in the final rule impedes reporting of death by covered entities as required or authorized by other laws, or access to death certificate data to the extent that such data is available publicly from non-covered entities. Death certificate data maintained by a covered entity is protected health information and must only be used or disclosed by a covered entity in accordance with the requirements of this regulation. However, the final rule permits a covered entity to disclose protected health information about a deceased individual for research purposes without authorization and absent IRB or privacy board approval.

Comment: A few commenters asked that we include in the regulation a mechanism to provide for notification of date of death. These commenters questioned how a covered entity or business partner would be notified of a death and subsequently to determine whether the two-year period of protection had expired and if they...
were permitted to use or disclose the protected health information about the deceased. One commenter further stated that absent such a mechanism, a covered entity would continue to protect the information as if the individual were still living. This commenter recommended that the burden for providing notification and confirmation of death be placed on any authorized entity requesting information from the covered entity beyond the two-year period.

Response: In general, such notification is no longer necessary as, except for uses and disclosures for research purposes, the final rule protects the protected health information about a deceased individual for as long as the covered entity holds the record. With regard to uses and disclosures for research, the researcher must provide covered entities with appropriate documentation of proof of death, the burden is not on the covered entity.

Comment: A few commenters pointed to the sensitivity of genetic and hereditary information and its potential impact on the privacy of living relatives as a reason for extending protections on the information about deceased individuals for as long as the covered entity maintains the information. However, a few commenters recommended additional protections for genetic and hereditary information. For example, one commenter suggested that researchers should be able to use sensitive information of the deceased but the burden of proving to publish findings in de-identified form. Another commenter recommended that protected health information about a deceased individual be protected as long as it implicates health problems that could be developed by living relatives.

Response: We agree with many of the commenters regarding the sensitivity of genetic or hereditary information and, in part for this reason, extended protections on the protected health information of deceased individuals. Our reasons for retaining the exception for research are explained above.

We agree with and support the practice of publishing research findings in de-identified form. However, we cannot regulate researchers who are not otherwise covered entities in this regulation.

Comment: One commenter asked that the final rule allow for disclosure of protected health information to funeral directors as necessary for facilitating funeral and disposition arrangements. The commenter believed that our proposal could seriously disrupt a family’s ability to make funeral arrangements as hospitals, hospices, and other health care providers would not be allowed to disclose the time of death and other similar information critical to funeral directors for funeral preparation. The commenter also noted that funeral directors are already precluded by state licensing regulations and ethical standards from inappropriately disclosing confidential information about the deceased.

Further, the commenter stated that funeral directors have legitimate needs for protected health information of the deceased or of an individual when death is anticipated. For example, often funeral directors are contacted when death is foreseen in order to begin the process of planning funeral arrangements and prevent unnecessary delays. In addition, the embalming of the body is affected by the medical condition of the body.

In addition, it was noted that funeral directors need to be aware of the presence of a contagious or infectious disease in order to advise family members of funeral and disposition options and how they may be affected by state law. For example, certain states may prohibit cremation of remains for a certain period unless the death was caused by a contagious or infectious disease, or prohibit family members from assisting in preparing the body for disposition if there is a risk of transmitting a communicable disease from the corpse.

Response: We agree that disclosures to funeral directors for the above purposes should be allowed. Accordingly, the final rule at §164.512(g)(2) permits covered entities to disclose protected health information to funeral directors, consistent with applicable law, as necessary to carry out their duties with respect to the deceased. Such disclosures are also permitted prior to, and in reasonable anticipation of, the individual’s death.

Comment: Several commenters urged that the proposed standard for deceased individuals be clarified to allow access by a family member who has demonstrated a legitimate health-related reason for seeking the information when there is no executor, administrator, or other person authorized under applicable law to exercise the right of access of the individual.

Response: We have deleted the reference to “power of attorney.” Under the final rule, a person is a personal representative of a living individual if, under applicable law, such person has authority to act on behalf of an individual in making decisions related to health care. "Decisions relating to health care” is broader than consenting to treatment on behalf of an individual.

Another commenter asked that the rule differentiate between blood relatives and family members and address their different access concerns, such as with genetic information versus information about transmittable diseases. The commenter recommended that the regulation allow access to protected health information by blood-related relatives prior to the end of the two-year period and provide them with the authority to extend the proposed two-year period of protection if they see fit. Lastly, the commenter suggested that the regulation address the concept of when the next-of-kin may not be appropriate to control a deceased person’s health information.

Response: We agree that family members may need access to the protected health information of a deceased individual, and this regulation permits such disclosure in two ways. First, a family member may qualify as a “personal representative” of the individual (see §164.502(g)). Personal representatives include anyone who has authority to act on behalf of a deceased individual or such individual’s estate, not just legally-appointed executors. We also allow disclosure of protected health information to health care providers for purposes of treatment, including treatment of persons other than the individual. Thus, where protected health information about a deceased person is relevant to the treatment of a family member, the family member’s physician may obtain that information. Because we limit these disclosures to disclosures for treatment purposes, there is no need to distinguish between disclosure of information about communicable diseases and disclosure of genetic information.

With regard to fitness to control information, we defer to existing state and other laws that address this matter.

Section 164.502(g)—Personal Representative

Comment: It was observed that under the proposed regulation, legal representatives with “power of attorney” for matters unrelated to health care would have unauthorized access to confidential medical records. Commenters recommended that access to a person’s protected health information be limited to those representatives with a “power of attorney” for health care matters only. Related comments asked that the rule limit the definition of “power of attorney” to include only those instruments granting specific power to deal with health care functions and health care records.

Response: We have deleted the reference to “power of attorney.” Under the final rule, a person is a personal representative of a living individual if, under applicable law, such person has authority to act on behalf of an individual in making decisions related to health care. "Decisions relating to health care” is broader than consenting to treatment on behalf of an individual;
for example, it would include decisions relating to payment for health care. We clarify that the rights and authorities of a personal representative under this rule are limited to protected health information relevant to the rights of the person to make decisions about an individual under other law. For example, if a husband has the authority only to make health care decisions about his wife in an emergency, he would have the right to access protected health information related to that emergency, but he may not have the right to access information about treatment that she had received ten years ago.

We note that the rule for deceased individuals differs from that of living individuals. A person may be a personal representative of a deceased individual if they have the authority to act on behalf of such individual or such individual’s estate for any decision, not only decisions related to health care. We create a broader scope for a person who is a personal representative of a deceased individual because the deceased individual cannot request that information be disclosed pursuant to an authorization, whereas a living individual can do so.

Comment: Some commenters asked that the NPRM provision allowing informal decision-makers access to the protected health information of an incapacitated individual should be maintained in the final rule.

Response: We agree with the commenters, and retain permission for covered entities to share protected health information with informal decision-makers, under conditions specified in §164.510(b). A person need not be a personal representative for such disclosure of protected health information to be made to an informal decision-maker.

Comment: Commenters urged that individuals with mental retardation, who can provide verbal agreement or authorization, should have control over dissemination of their protected health information, in order to increase the privacy rights of such individuals.

Response: Individuals with mental retardation have control over dissemination of their protected health information under this rule to the extent that state law provides such individuals with the capacity to act on their own behalf. We note that a covered entity need not disclose information pursuant to a consent or authorization. Therefore, even if state law determines that an individual with mental retardation is not capable, and a personal representative provides authorization for a disclosure, a covered entity may choose not to disclose such information if the individual who lacks capacity to act expresses his or her desire that such information not be disclosed.

Comment: A commenter suggested that the final rule should provide health plans with a set of criteria for formally identifying an incapacitated individual’s decision-maker. Such criteria would give guidance to health plans that would help in not releasing information to the wrong person.

Response: The determination about who is a personal representative under this rule is based on state or other applicable law. We require that a covered entity verify the authority of a personal representative, in accordance with §164.514(b) in order to disclose information to such person.

Comment: Commenters were troubled by the inclusion of minors in the definition of “individual” and believed that the presumption should be that parents have the right to care for their children.

Response: We agree that a parent should have access to the protected health information about their unemancipated minor children, except in limited circumstances based on state law. The approach in the final rule helps clarify this policy. The definition of “individual” is simplified in the final rule to “the person who is the subject of protected health information.” (§164.501). We created a new section (§164.502(g)) to address “personal representatives,” which includes parents and guardians of unemancipated minors. Generally, we provide that if under applicable law a parent has authority to act on behalf of an unemancipated minor in making decisions relating to health care about the minor, a covered entity must treat the parent as the personal representative with respect to protected health information relevant to such personal representation. The regulation provides only three limited exceptions to this rule based upon current state law and physician practice.

Comment: Many commenters agreed with our approach in the NPRM to give minors who may lawfully access health care the rights to control the protected health information related to such health care.

Response: We adopt this policy in the final rule. If the minor consents to a health care service, and no other consent to such health care service is required by law, or when the minor may lawfully obtain a health care service without the consent of a parent, and the minor, a court, or another person authorized by law consents to such service. The third exception is based on guidelines of the American Pediatric Association, current practice, and agreement by parents. If a parent assents to an agreement of confidentiality between a covered provider and a minor with respect to a health care service, the parent is not the personal representative of the minor with respect to the protected health information created or received subject to that confidentiality agreement. In such circumstances, the minor would have the authority to act as an individual, with respect to such protected health information.

Comment: Some commenters requested that we permit minors to exercise the rights of an individual when applicable law requires parental notification as opposed to parental consent.

Response: We adopt this policy in the final rule. If the minor consents to a health care service, and no other consent to such health care service is required by law, regardless of whether the consent of another person has also been obtained or notification to another person has been given, only the minor may be treated as the individual with respect to the protected health information relating to such health care service. The rule does not affect state law that authorizes or requires notification to a parent of a minor’s decision to obtain a health care service to the extent authorized or required by such law. In addition, state parental notification laws do not affect the rights of minors under this regulation.
Comment: Some commenters requested clarification that when a minor may obtain a health care service without parental consent and voluntarily chooses to involve a parent, the minor retains the rights, authorities and confidentiality protections established in this rule.

Response: We agree that minors should be encouraged to voluntarily involve a parent or other responsible adult in their health care decisions. The rule is not intended to require that minors choose between involving a parent and maintaining confidentiality protections. We have added language in §164.502(g)(3) to clarify that when a minor consents to a health care service and no other consent is required by law, if the minor voluntarily chooses to involve a parent or other adult, the minor nonetheless maintains the exclusive ability to exercise their rights under the rule. This is true even if a parent or other person also has consented to the health care service for which the minor lawfully consented. Under the rule, a minor may involve a parent and still preserve the confidentiality of their protected health information. In addition, a minor may choose to have a parent act as his or her personal representative even if the minor could act on his or her own behalf under the rule. If the minor requests that a covered entity treat a parent as his or her personal representative, the covered entity must treat such person as the minor’s personal representative even if the minor is able to exercise health care service and no other consent to such health care service is required by law.

Comment: Some commenters requested that the rule provide for the preservation of patient confidences if a health care provider and a minor patient enter into an agreement of confidentiality and a parent assents to this arrangement.

Response: We have addressed this concern in the final rule by adding a provision that ensures that a minor maintains the confidentiality protections provided by the rule for information that is created or received pursuant to a confidential communication between a provider and a minor when the minor’s parent assents to an agreement of confidentiality between the provider and the minor. (§164.502(g)(3)(ii)). The American Academy of Pediatrics Guidelines for Health Supervision III, which are meant to serve as “a framework to help clinicians focus on important issues at developmentally appropriate time intervals,” recommends that physicians interview children alone beginning at the age of twelve (or as early as the age of ten if it is comfortable for the child). This recommendation is based on the fact that adolescents tend to underutilize existing health care resources, in part, because of a concern for confidentiality.7 The recommended interview technique in the Guidelines states that the provider discuss the rules of confidentiality with the adolescent and the parent and that the adolescent’s confidentiality should be respected. We do not intend to interfere with these established protocols or current practices. Covered entities will need to establish procedures to separate protected health information over which the minor maintains control from protected health information with respect to which the minor’s parent has rights as a personal representative of the minor. A covered provider may disclose protected health information to a parent, regardless of a confidentiality agreement, if there is an imminent threat to the minor or another person, in accordance with §164.512(h)(1)(i).

Comment: Several commenters suggested that we add a provision in the final rule to provide minors and parents with concurrent rights under certain circumstances, particularly when the minor reaches 16 years of age or when a parent authorizes his or her minor child to exercise these rights concurrently.

Response: We do not add such provision in the final rule. We believe that establishing concurrent rights through this rule could result in problems that effect the quality of health care if the minor and the parent were to disagree on the exercise of their rights. The rule would not prevent a parent from allowing a minor child to make decisions about his or her protected health information and acting consistently with the minor’s decision. In all cases, either the parent has the right to act for the individual with respect to protected health information, or the minor has the right to act for himself or herself. The rule does not establish concurrent rights for parents and minors.

Comment: Commenters requested clarification about the rights of an adult or emancipated minor with respect to protected health information concerning health care services rendered while the person was an unemancipated minor.

Response: Once a minor becomes emancipated or attains the age of majority, as determined by applicable state law, the parent is no longer the personal representative under §164.502(g)(3) of such individual, unless the parent has the authority to act on behalf of the individual for some reason other than their authority as a parent. An adult or emancipated minor has rights under the rule with respect to all protected health information about them, including information obtained while the individual was an unemancipated minor.

Comment: One commenter pointed out that language in the definition of individual in the NPRM that grants a minor the rights of an individual when he or she “lawfully receives care without the consent of, or notification to, a parent * * *” would have the effect of granting rights to an infant minor who receives emergency care when the parent is not available.

Response: This result was not our intent. We have changed the language in §164.502(g)(3)(i) of the final rule to provide a minor the right to act as an individual when the minor can obtain care without the consent of a parent and the minor consents to such care. Because an infant treated in an emergency situation would not be able to consent to care, the infant’s parent would be treated as the personal representative of the infant. Section 164.502(g)(3)(i) provides that the parent is not the personal representative of the minor under the rule if the minor may obtain health care without the consent of a parent and the minor, a court, or another person authorized by law consents to such service. If an infant obtains emergency care without the consent of a parent, a health care provider may provide such care without consent to treatment. This situation would fall outside the second exception, and the parent would remain the personal representative of the minor.

Comment: Commenters were concerned about the interaction of this rule with FERPA with respect to parents’ right to access the medical records of their children.

Response: We direct the commenters to a discussion of the interaction between our rule and FERPA in the “Relationship to Other Federal Laws” section of the preamble.

Section 164.502(h)—Confidential Communications

Comments on confidential communications are addressed in the preamble to §164.522(b).
Section 164.502(j)—Uses and Disclosures Consistent With Notice

Comments on the notice requirements are addressed in the preamble to § 164.520.

Section 164.502(j)—Uses and Disclosures by Whistleblowers and Workforce Crime Victims

Comments: Some commenters wanted to see more limitations put on the ability to whistleblow in the final rule. These commenters were concerned about how disclosed protected health information would be used during and subsequent to the whistleblowing event and felt that adding additional limitations to the ability to whistleblow would help to alleviate these concerns. Some of these commenters were concerned that there was no protection against information later being leaked to the public or re-released after the initial whistleblowing event, and that this could put covered entities in violation of the law. Many commenters wanted to see the whistleblower provision deleted entirely. According to a number of health care associations who commented on this topic, current practices already include adequate mechanisms for informing law enforcement, oversight and legal counsel of possible violations without the need for patient identifiable information; thus, the provision allowing whistleblowers to share protected health information is unnecessary. Additionally, some commenters felt that the covered entity needs to be allowed to prohibit disclosures outside of legitimate processes. Some commenters were concerned about not having any recourse if the whistleblower’s suspicions were unfounded.

Response: In this rule, we do not regulate the activities of whistleblowers. Rather, we regulate the activities of covered entities, and determine when they may be held responsible under this rule for whistleblowing activities of their workforce or business associates when that whistleblowing involves the disclosure of protected health information. Similarly, we regulate when covered entities must and need not sanction their workforce who disclose protected health information in violation of the covered entity’s policies and procedures, when that disclosure is for whistleblowing purposes. See § 164.530(e). This rule does not address a covered entity’s recourse against a whistleblower under other applicable law.

We do not hold covered entities responsible under this rule for whistleblowing disclosures of protected health information under the circumstances described in § 164.502(j). Our purpose in including this provision is to make clear that we are not erecting a new barrier to whistleblowing, and that covered entities may not use this rule as a mechanism for sanctioning workforce members or business associates for whistleblowing activity. We do not find convincing commenters’ arguments for narrowing or eliminating the scope of the whistleblowing which triggers this protection.

Congress, as well as several states, have recognized the importance of whistleblower activity to help identify fraud and mismanagement and protect the public’s health and safety. Whistleblowers, by their unique insider position, have access to critical information not otherwise easily attainable by oversight and enforcement organizations.

While we recognize that in many instances, de-identified or anonymous information can be used to accomplish whistleblower objectives, there are instances, especially involving patient care and billing, where this may not be feasible. Oversight investigative agencies such as the Department of Justice rely on identifiable information in order to issue subpoenas that are enforceable. Relevant court standards require the government agency issuing the subpoena to explain why the specific records requested are relevant to the subject of the investigation, and without such an explanation the subpoena will be quashed. Issuing a subpoena for large quantities of individual records to find a few records involving fraud is cost prohibitive as well as likely being unenforceable.

We note that any subsequent inappropriate disclosure by a recipient of whistleblower information would not put the covered entity in violation of this rule, since the subsequent disclosure is not covered by this regulation.

Comments: A few commenters felt that the whistleblower should be held to a “reasonableness standard” rather than a “belief” that a violation has taken place before engaging in whistleblowing activities. The commenters felt that a belief standard is too subjective. By holding the whistleblower to this higher standard, this would serve to protect protected health information from being arbitrarily released. Some commenters saw the whistleblower provision as a loophole that gives too much power to disgruntled employees to inadvertently release information in order to cause problems for the employer.

On the other hand, some commenters felt that all suspicious activities should be reported. This would ease potential whistleblowers’ concerns over whether or not they had a legitimate concern by leaving this decision up to someone else. A number of commenters felt that employees should be encouraged to report violations of professional or clinical standards, or when a patient, employee, or the public would be put at risk. A small number of commenters felt that the whistleblower should raise the issue within the covered entity before going to the attorney, oversight agency, or law enforcement entity.

Response: We do not attempt to regulate the conduct of whistleblowers in this rule. We address uses and disclosures of protected health information by covered entities, and when a covered entity will violate this rule due to the actions of a workforce member or business associate. In the final rule, we provide that a covered entity is not in violation of the rule when a workforce member or business associate has a good faith belief that the conduct being reported is unlawful or otherwise violates professional or clinical standards, or potentially endangers patients, employees or the public. We concur that the NPRM language requiring only a “belief” was insufficient. Consequently, we have strengthened the standard to require a good faith belief that an inappropriate behavior has occurred.

Comment: A number of commenters believe that employees should be encouraged to report violations of professional or clinical standards, or report situations where patients, employees, or the public would be put at risk. Their contention is that employees, especially health care employees, may not know whether the problem they have encountered meets a legal threshold of wrongdoing, putting them at jeopardy of sanction if they are incorrect, even if the behavior did not reflect violation of professional and clinical standards or put patients, employees, or the public at risk.

Response: We agree that covered entities should be protected when their employees and others engage in the conduct described by these commenters. We therefore modify the proposal to protect covered entities when the whistleblowing relates to violations of professional or clinical standards, or situations where the public may be at risk, and eliminate the reference to “evidence.”

Comments: A significant number of those commenting on the whistleblower provision felt that this provision was contrary to the rest of the rule.
Whistleblowers could very easily release protected health information under this provision despite the fact that the rest of this rule works very hard to ensure privacy of protected health information in all other contexts. To this end, some commenters felt that whistleblowers should not be exempt from the minimum necessary requirement.

Response: As stated above, we do not regulate the conduct of whistleblowers. We discuss above the importance of whistleblowing, and our intention not to erect a new barrier to such activity. The minimum necessary standard applies to covered entities, not to whistleblowers.

Comments: Some commenters felt that disclosures of suspected violations should only be made to a law enforcement official or oversight agency. Other commenters said that whistleblowers should be able to disclose their concerns to long-term care ombudsmen or health care accreditation organizations, particularly because certain protected health information may contain evidence of abuse. Some commenters felt that whistleblowers should not be allowed to freely disclose information to attorneys. They felt that this may cause more lawsuits within the health care industry and be costly to providers. Furthermore, allowing whistleblowers to go to attorneys increases the number of people who have protected health information without any jurisdiction for the Secretary to do anything to protect this information.

Response: We agree with the commenters who suggested that we recognize other appropriate entities to which workforce members and business associates might reasonably make a whistleblowing disclosure. In the final rule we expand the provision to protect covered entities for disclosures of protected health information made to accreditation organizations by whistleblowers. We agree with the commenters that whistleblowers may see these organizations as appropriate recipients of health information, and do not believe that covered entities should be penalized for such conduct.

We also agree that covered entities should be protected when whistleblowers disclose protected health information to any health oversight agency authorized by law to investigate or oversee the conditions of the covered entity, including state Long-Term Care Ombudsmen appointed in accordance with the Older Americans Act. Among their mandated responsibilities are their duty to identify, investigate and resolve complaints that are made by, or on behalf of, residents related to their health, safety, welfare, or rights. Nursing home staff often bring complaints regarding substandard care or abuse to ombudsmen. Ombudsmen provide a potentially more attractive outlet for whistleblowers since resolution of problems may be handled short of legal action or formal investigation by an oversight agency.

We disagree with commenters that the provision permitting disclosures to attorneys is too broad. Workforce members or business associates may not understand their legal options or their legal exposure when they come into possession of information about unlawful or other inappropriate or dangerous conduct. Permitting potential whistleblowers to consult an attorney provides them with a better understanding of their legal options. We rephrase the provision to improve its clarity.

Comment: One commenter suggested that a notice of information practices that omits disclosure for voluntary reporting of fraud will chill internal whistleblowers who will be led to believe falsely—that they would violate federal privacy law, and be lawfully subject to sanction by their employer, if they reported fraud to health oversight agencies.

Response: The notice of information practices describes a covered entity’s information practices. A covered entity does not make whistleblower disclosures of protected health information, nor can it be expected to anticipate any such disclosures by its workforce.

Comment: One commenter suggested that the whistleblower provisions could allow covered entities to make illegal disclosures to police through the back door by having an employee who believes there is a violation of law do the disclosing. Any law could have been violated and the violator could be anyone (a patient, a member of the patient’s family, etc.)

Response: We have eliminated whistleblower disclosures for law enforcement purposes from the list of circumstances in which the covered entity will be protected under this rule. This provision is intended to protect the covered entity when a member of its workforce or a business associate discloses protected health information to whistleblower on the covered entity (or its business associates); it is not intended for disclosures of conduct by the individual who is the subject of the information or third parties.

Section 164.504—Uses and Disclosures—Organizational Requirements—Component Entities, Affiliated Entities, Business Associates and Group Health Plans

Section 164.504(a)–(c)—Health Care Component (Component Entities) and Section 164.504(d)—Affiliated Entities

Comment: A few commenters asked that the concept of “use” be modified to allow uses within an integrated healthcare delivery system. Commenters argued that the rule needs to ensure that the full spectrum of treatment is protected from the need for authorizations at the points where treatment overlaps entities. It was explained that, for example, treatment for a patient often includes services provided by various entities, such as by a clinic and hospital, or that treatment may also necessitate referrals from one provider entity to another unrelated entity. Further, the commenter argued that the rule needs to ensure that the necessary payments for the services and operations can be carried out across entities without authorizations.

Response: The Department understands that in today’s health care industry, the organization of and relationships among health care entities are highly complex and varied. We modify the proposed rule significantly to allow affiliated entities to designate themselves as a single covered entity. A complex organization, depending on how it self-designates, may have one or several “health care component(s)” that are each a covered entity. Aggregation into a single covered entity will allow the entities to use a single notice of information practices and will allow providers that must obtain consent for uses and disclosures for treatment, payment, and operations to obtain a single consent.

We do not allow this type of aggregation for unrelated entities, as suggested by some commenters, because unrelated entities’ information practices will be too disparate to be accurately reflected on a single consent or notice form. Our policies on when consent and authorization are required for sharing information among unrelated entities, and the rationale for these policies, is described in §§ 164.506 and 164.508 and corresponding preamble.

As discussed above, in the final rule we have added a definition of organized health care arrangement and permit covered entities participating in such arrangements to disclose protected health information to support the health care arrangement. See the preamble discussion of the definitions of organized health care.
functions of the health care component unless they support the non-health related divisions of the covered entity to non-health related divisions if the disclosure is for marketing purposes.

Response: In the final rule, we remove the example of use and disclosure to non-health related divisions of the covered entity from the list of examples of uses and disclosures requiring authorization in § 164.508. We determined that the example could lead covered entities to the mistaken conclusion that some uses or disclosures that would otherwise be permitted under the rule without authorization would require authorization when made to a non-health related division of the covered entity. In the final rule, we clarify that disclosure to a non-health related division does not require authorization if the use or disclosure is otherwise permitted or required under the rule. For example, in § 164.501 we define health care operations to include conducting or arranging for legal and auditing services. A covered entity that is the health care component of a larger entity is permitted under the final rule to include the legal department of the larger entity as part of the health care component. The covered entity may not, however, generally permit the disclosure of protected health information from the health care component to non-health related divisions unless they support the functions of the health care component and there are policies and procedures in place to restrict the further use to the support of the health related functions.

Comment: Many commenters, especially those who employed providers, supported our position in the proposed rule to consider only the health care component of an entity to be the covered entity. They stated that this was a balanced approach that would allow them to continue conducting business. Some commenters felt that there was ambiguity in the regulation text of the proposed rule and requested that the final rule explicitly clarify that only the health care component is considered the covered entity, not the entity itself. Similarly, another commenter requested that we clarify that having a health care component alone did not make the larger entity a covered entity under the rule.

Response: We appreciate the support of the commenters on the health care component approach and we agree that there was some ambiguity in the proposed rule. The final rule creates a new § 164.504(b) for health care components. Under § 164.504(b), for a covered entity that is a single legal entity which predominantly performs functions other than the functions performed by a health plan, provider, or clearinghouse, the privacy rules apply only to the entity’s health care component. A policy, plan, or program that is an “excepted benefit” under section 2791(c)(1) of HIPAA cannot be part of a health care component because it is expressly excluded from the definition of “health plan” for the purposes discussed above. The health care component is prohibited from sharing protected health information outside of the component, except as otherwise permitted or required by the regulation.

At a minimum, the health care component includes the organizational units of the covered entity that operate outside of the component, except as otherwise permitted or required by the regulation. The requirements of this rule apply only to the uses and disclosures of the protected health information by the component entity. See § 164.504(b). Comment: Some commenters stated that the requirement to erect firewalls between different components would unnecessarily delay treatment, payment, and health care operations and thereby increase costs. Other commenters stressed that it is necessary to create firewalls between the health care component and the larger entity to prevent unauthorized disclosures of protected health information.

Response: We believe that the requirement to implement firewalls or safeguards is necessary to provide meaningful privacy protections, particularly because the health care component is part of a larger legal organization that performs functions other than those covered under this rule. Without the safeguard requirement the covered component will not share protected health information with the larger entity.

While we do not specifically identify the safeguards that are required, the covered entity must implement policies and procedures to ensure that: the health care component’s use and disclosure of protected health information complies with the regulation; members of the health care component who perform duties for the larger entity do not use and disclose protected health information obtained through the health care component while performing non-component functions unless otherwise permitted or required by the regulation; and when a covered entity conducts multiple functions regulated under this rule, the health care component adheres to the appropriate requirements (e.g., when acting as a health plan, adheres to the health plan requirements) and uses or discloses protected health information of individuals who receive limited functions from the component only for the appropriate functions. See §§ 164.504(c)(2) and 164.504(g). For example, a covered entity that includes both a hospital and a health plan may not use protected health information obtained from an individual’s hospitalization for the health plan, unless the individual is also enrolled in the health plan. We note that covered entities are permitted to make a disclosure to a health care provider for treatment of an individual without restrictions.

Comment: One commenter stated that multiple health care components of a single organization should be able to be treated as a single component entity for the purposes of this rule. Under this approach, they argued, one set of policies and procedures would govern the entire component and protected health information could be shared among components without authorization. Similarly, other commenters stated that corporate subsidiaries and affiliated entities should not be treated as separate covered entities.

Response: We agree that some efficiencies may result from designating multiple component entities as a single covered entity. In the final rule we allow legally distinct covered entities that share common ownership or control to designate themselves or their health care components as a single covered entity. See § 164.504(d). Common ownership is defined as an ownership or equity interest of five percent or more. Common control exists if an entity has the power—directly or indirectly—to significantly influence or direct the actions or policies of another entity. If the affiliated entity contains health care components, it must implement safeguards to prevent the
larger entity from using protected health information maintained by the component entity. As stated above, organizations that perform multiple functions may designate a single component entity as long as it does not include the functions of an excepted benefit plan that is not covered under the rule. In addition, it must adhere to the appropriate requirements when performing its functions (e.g., when acting as a health plan, adhere to the health plan requirements) and uses or discloses protected health information of individuals who receive limited functions from the component only for the appropriate functions. At the same time, a component that is outside of the health care component may perform activities that otherwise are not permitted by a covered entity, as long as it does not use or disclose protected health information created or received by or on behalf of the health care component in ways that violate this rule.

Comment: Some commenters asked whether or not workers’ compensation carriers could be a part of the health care component as described in the proposed rule. They argued that this would allow for sharing of information between the group health plan and workers’ compensation insurers.

Response: Under HIPAA, workers’ compensation is an excepted benefit program and is excluded from the definition of “health plan.” As such, a component of a covered entity that provides such excepted benefits may not be part of health care component that performs the functions of a health plan. If workforce members of the larger entity perform functions for both the health care component and the non-covered component, they may not use protected health information created or received by or on behalf of the health care component for the purposes of the non-covered component, unless otherwise permitted by the rule. For example, information may be shared between the components for coordination of benefits purposes.

Comment: Several commenters requested specific guidance on identifying the health care component entity. They argued that we underestimated the difficulty in determining the component and that many organizations have multiple functions with the same people performing duties for both the component and the larger entity.

Response: With the diversity of organizational structures, it is impossible to provide a single specific guidance for identifying health care components that will meet the needs of all organizations. Covered entities must designate their health care components consistent with the definition at §164.504(a). We have tried to frame this definition to delineate what comes within a health care component and what falls outside the component.

Comment: A commenter representing a government agency recommended that only the component of the agency that runs the program be considered a covered entity, not the agency itself. In addition, this commenter stated that often subsets of other government agencies work in partnership with the agency that runs the program to provide certain services. For example, one state agency may provide maternity support services to the Medicaid program which is run by a separate agency. The commenter read the rule to mean that the agency providing the maternity support services would be a business associate of the Medicaid agency, but was unclear as to whether it would also constitute a health care component within its own agency.

Response: We generally agree. We expect that in most cases, government agencies that run health plans or provide health care services would typically meet the definition of a “hybrid entity” under §164.504(a), so that such an agency would be required to designate the health care component or components that run the program or programs in question under §164.504(c)(3), and the rules would not apply to the remainder of the agency’s operations, under §164.504(b). In addition, we have created an exception to the business associate contract requirement for government agencies who perform functions on behalf of other government agencies. Government agencies can enter into a memorandum of understanding with another government entity or adopt a regulation that applies to the other government entity in lieu of a business associate contract, as long as the memorandum or regulation contains certain terms. See §164.504(e).

Comment: One commenter representing an insurance company stated that different product lines should be treated separately under the rule. For example, the commenter argued, because an insurance company offers both life insurance and health insurance, it does not mean that the insurance company itself is a covered entity, rather only the health insurance component is a covered entity. Another commenter requested clarification of the use of the term “product line” in the proposed rule. This commenter stated that product line should differentiate between different lines of coverage such as life vs. health insurance, not different variations of the same coverage, such as HMO vs. PPO. Finally, one commenter stated that any distinction among product lines is unworkable because insurance companies need to share information across product lines for coordinating benefits. This sharing of information, the commenter urged, should be able to take place whether or not all product lines are covered under the rule.

Response: We agree that many forms of insurance do not and should not come within the definition of “health plan,” and we have excepted them from the definition of this term in §160.103 applies. This point is more fully discussed in connection with that definition. Although we do not agree that the covered entity is only the specific product line, as this comment suggests, the hybrid entity rules in §164.504 address the substance of this concern. Under §164.504(c)(3), an entity may create a health plan component which would include all its health insurance lines of business or separate health care components for each health plan product line. Finally, the sharing of protected health information across lines of business is allowed if it meets the permissive or required disclosures under the rule. The commenter’s example of coordination of benefits would be allowed under the rule as payment.

Comment: Several commenters representing occupational health care providers supported our use of the component approach to protect unauthorized disclosures of protected health information. They requested that the regulation specifically authorize them to deny requests for disclosures outside of the component entity when the disclosure was not otherwise permitted or required by the regulation.

Response: We appreciate the commenters’ support of the health care component approach. As members of a health care component, occupational health providers are prohibited from sharing protected health information with the larger entity (i.e., the employer), unless otherwise permitted or required by the regulation.

Comment: One commenter asked how the regulation affects employers who carry out research. The commenter questioned whether the employees carrying out the research would be component entities under the rule.

Response: If the employer is gathering its own information rather than obtaining it from an entity regulated by this rule, the information does not constitute protected health information since the employer is not a covered...
entity. If the employer is obtaining protected health information from a covered entity, the disclosure by the covered entity must meet the requirements of § 164.512(i) regarding disclosures for research.

Comment: One commenter stated that the proposed rule did not clearly articulate whether employees who are health care providers are considered covered entities when they collect and use individually identifiable health information acting on behalf of an employer. Examples provided include, administering mandatory drug testing, making fitness-for-duty and return-to-work determinations, testing for exposure to environmental hazards, and making short and long term disability determinations. This commenter argued that if disclosing information gained through these activities requires authorization, many of the activities are meaningless. For example, an employee who fails a drug test is unlikely to give authorization to the provider to share the information with the employer.

Response: Health care providers are covered entities under this rule if they conduct standard transactions. A health care provider who is an employee and is administering drug testing on behalf of the employer, but does not conduct standard transactions, is not a covered entity. If the health care provider is a covered entity, then we require authorization for the provider to disclose protected health information to an employer. Nothing in this rule, however, prohibits the employer from conducting an individual’s employment on agreeing to the drug testing and requiring the individual to sign an authorization allowing his or her drug test results to be disclosed to the employer.

Comment: One commenter stated its belief that only a health center at an academic institution would be a covered entity under the component approach. This commenter believed it was less clear whether or not other components that may create protected health information “incidentally” through conducting research would also become covered entities.

Response: While a covered entity must designate as a health care component the functions that make it a health care provider, the covered entity remains responsible for the actions of its workforce. Components that create protected health information through research would be covered entities to the extent they performed one of the required transactions described in § 164.501. However, it is possible that the research program would not be part of the health care component, depending on whether the research program performed or supported covered functions.

Comment: Several commenters stated that employers need access to protected health information in order to provide employee assistance programs, wellness programs, and on-site medical testing to their employees.

Response: This rule does not affect disclosure of health information by employees to the employer if the information is not obtained from a covered entity. The employer’s access to information from an EAP, wellness program, or on-site medical clinic will depend on whether the program or clinic is a covered entity.

Comment: One commenter stated that access to workplace medical records by the occupational medical physicians is fundamental to workplace and community health and safety. Access is necessary whether it is a single location or multiple sites of the same company, such as production facilities of a national company located throughout the country.

Response: Health information collected by the employer directly from providers who are not covered entities is outside the scope of this regulation. We note that the disclosures which this comment concerns should be covered by § 164.512(b).

Section 164.504(e)—Business Associates

Comment: Many commenters generally opposed the business partner standard and questioned the Secretary’s legal authority under section 1172(a) of HIPAA to require business partner contracts. Others stated that the proposed rule imposed too great a burden on covered entities with regard to monitoring their business partners’ actions. Commenters stated that they did not have the expertise to adequately supervise their business partners’ activities—including billing, accounting, and legal activities—to ensure that protected health information is not inappropriately disclosed. Commenters argued that business partners are not “under the control” of health care providers, and that the rule would significantly increase the cost of medical care. Many commenters stated that the business partner provisions would be very time consuming and expensive to implement, noting that it is not unusual for a health plan or hospital to have hundreds of business partners, especially if independent physicians and local pharmacies are considered business partners. Many physician groups pointed out that their business partners are large providers, hospitals, national drug supplier and medical equipment companies, and asserted that it would be impossible, or very expensive, for a small physician group to attempt to monitor the activity of large national companies. Commenters stated that complex contract terms and new obligations would necessitate the investment of significant time and resources by medical and legal personnel, resulting in substantial expenses. Many commenters proposed that the duty to monitor be reduced to a duty to terminate the contractual arrangement upon discovery of a failure to comply with the privacy requirements.

In addition, many commenters argued that covered entities should have less responsibility for business partners’ actions regarding the use and disclosure of protected health information. The proposed rule would have held covered entities responsible for the actions of their business partners when they “knew or reasonably should have known” of improper use of protected health information and failed to take reasonable steps to cure a breach of the business partner contract or terminate the contract. Many commenters urged that the term “knew or should have known” be clearly defined, with examples. Some commenters stated that covered entities should be liable only when they have actual knowledge of the material breach of the privacy rules by the business partner. Others recommended creation of a process by which a business partner could seek advice to determine if a particular disclosure would be appropriate. Some commenters stated that, in order to create an environment that would encourage covered entities to report misuses of protected health information, a covered entity should not be punished if it discovered an inappropriate disclosure.

Response: With regard to our authority to require business associate contracts, we clarify that Congress gave the Department explicit authority to regulate what uses and disclosures of protected health information by covered entities are “authorized.” If covered entities were able to circumvent the requirements of these rules by the simple expedient of contracting out the performance of various functions, these rules would afford no protection to individually identifiable health information and be rendered meaningless. It is thus reasonable to place restrictions on disclosures to business associates that are designed to ensure that the personal medical information disclosed to them continues to be protected and used and further
disclosed only for appropriate (i.e., permitted or required) purposes.

We do not agree that business associate contracts would necessarily have complex terms or result in significant time and resource burdens. The implementation specifications for business associate contracts set forth in §164.504 are straightforward and clear. Nothing prohibits covered entities from having standard contract forms which could require little or no modification for many business associates.

In response to comments that the "knew or should have known" standard in the proposed rule was too vague or difficult to apply, and concerns that we were asking too much of small entities in monitoring the activities of much larger business associates, we have changed the rule. Under the final rule, we put responsibility on the covered entity to take action when it "knew of a pattern of activity or practice of the business associate that constituted, respectively, a material breach or violation of the business associate's obligation under the contract." This will preclude confusion about what a covered entity 'should have known.' We interpret the term "knew" to include the situation where the covered entity has credible evidence of a violation. Covered entities cannot avoid responsibility by intentionally ignoring problems with their contractors. In addition, we have eliminated the requirement that a covered entity actively monitor and ensure protection by its business associates. A covered entity must investigate credible evidence of a violation by a business associate and act upon any such knowledge.

In response to the concern that the covered entity should not be punished if it discovers an inappropriate disclosure by its business associate, §164.504(e) provides that the covered entity is not in compliance with the rule if it fails to take reasonable steps to cure the breach or end the violation, while §164.530(l) requires the covered entity to mitigate, to the extent practicable, any resultant harm. The breach itself does not cause a violation of this rule.

Comment: Some commenters voiced support for the concept of business partners. Moreover, some commenters urged that the rule apply directly to those entities that act as business partners, by restricting disclosures of protected health information after a covered entity has disclosed it to a business partner.

Response: We are pleased that commenters supported the business associate standard and we agree that there are advantages to legislation that directly regulates most entities that use or disclose protected health information. However, we reiterate that our jurisdiction under the statute limits us to regulate only those covered entities listed in §160.102.

Comment: Many commenters strongly opposed the provision in the proposed rule requiring business partner contracts to state that individuals whose protected health information is disclosed under the contract are intended third-party beneficiaries of the contract. We do not intend this change to affect existing laws regarding when individuals may be third party beneficiaries of contracts. If existing law allows individuals to claim third party beneficiary rights, or prohibits them from doing so, we do not intend to affect those rules. Rather, we intend to leave this matter to such other law.

Response: We modify the proposed requirement that the business associate must return or destroy all protected health information received from the covered entity at the termination of the business partner contract. Commenters argued that business partners will need to maintain business records for legal and/or financial auditing purposes, which would preclude the return or destruction of the information. Moreover, they argued that computer back-up files may contain protected health information, but business partners cannot be expected to destroy entire electronic back-up files just because part of the information that they contain is from a client for whom they have completed work.

Response: We modify the proposed requirement that the business associate must return or destroy all protected health information received from the covered entity when the business associate contract is terminated. Under the final rule, a business associate must return or destroy all protected health information when the contract is terminated if feasible and lawful. The business partner contract must state that privacy protections continue after the contract ends, if there is a need for the business associate to retain any of the protected health information and for as long as the information is retained. In addition, the permissible uses of information after termination of the contract must be limited to those activities that make return or destruction of the information not feasible.

Response: We modify the proposed requirement that the business associate must return or destroy all protected health information received from the covered entity at the termination of the business partner contract. Commenters argued that business partners will need to maintain business records for legal and/or financial auditing purposes, which would preclude the return or destruction of the information. Moreover, they argued that computer back-up files may contain protected health information, but business partners cannot be expected to destroy entire electronic back-up files just because part of the information that they contain is from a client for whom they have completed work.

Response: We modify the proposed requirement that the business associate must return or destroy all protected health information received from the covered entity when the business associate contract is terminated. Under the final rule, a business associate must return or destroy all protected health information when the contract is terminated if feasible and lawful. The business partner contract must state that privacy protections continue after the contract ends, if there is a need for the business associate to retain any of the protected health information and for as long as the information is retained. In addition, the permissible uses of information after termination of the contract must be limited to those activities that make return or destruction of the information not feasible.
be required to have written contracts with and monitor the privacy practices of each physician with privileges, and each physician would be required to do the same for the hospital. Another commenter argued that consultations between covered entities for treatment or referral purposes should not be subject to the business partner contracting requirement.

Response: The final rule retains the general requirement that, subject to the exceptions below, a covered entity must enter into a business associate contract with another covered entity when one is providing services to or acting on behalf of the other. We retain this requirement because we believe that a covered entity that is a business associate should be restricted from using or disclosing the protected health information it creates or receives through its business associate function for any purposes other than those that are explicitly detailed in its contract.

However, the final rule expands the proposed exceptions for disclosures of protected health information by a covered health care provider to another health care provider. The final rule allows such disclosures without a business associate contract for any activities that fall under the definition of “treatment.” We agree with the commenter that the administrative burdens of requiring contracts in staff privileges arrangements would not be outweighed by any potential privacy enhancements from such a requirement. Although the exception for disclosure of protected health information in the course of the relationship could be sufficient to relieve physicians and hospitals of the contract requirement, we also believe that this arrangement does not meet the true meaning of “business associate,” because both the hospital and physician are providing services to the patient, not to each other. We therefore also add an exception to § 164.502(e)(1) that explicitly states that a contract is not required when the association involves a health care facility and another health care provider with privileges at that facility, if the purpose is providing health care to the individual. We have also added other exceptions in § 164.502(e)(1)(ii) to the requirement to obtain “satisfactory assurances” under § 164.502(e)(1)(i). We do not require a business associate arrangement between group health plans and their plan sponsors because other, albeit analogous, requirements apply under § 164.504(f) that are more tailored to the specifics of that legal relationship. We do not require business associate arrangements between government health plans providing public benefits and other agencies conducting certain functions for the health plan, because these arrangements are typically very constrained by other law.

Comment: Many commenters expressed concern that required contracts for federal agencies would adversely affect oversight activities, including investigations and audits. Some health plan commenters were concerned that if HMOs are business partners of an employer then the employer would have a right to all personal health information collected by the HMO. A commenter wanted to be sure that authorization would not be required for accreditation agencies to access information. A large manufacturing company wanted to make sure that business associate contracts were not required between affiliates and a parent corporation that provides administrative services for a sponsored health plan. Attorney commenters asserted that a business partner contract would undermine the attorney/client relationship, interfere with attorney/client privilege, and was not necessary to protect client confidences. A software vendor wanted to be excluded because the requirements for contracts were burdensome and government oversight intrusive. Some argued that because the primary purpose of medical device manufacturers is supplying devices, not patient care, they should be excluded.

Response: We clarify in the above discussion of the definition of “business associate” that a health insurance issuer or an HMO acts as a business associate of a group health plan, the group health plan has no right of access to the other protected health information maintained by the health insurance issuer or HMO. The business associate contract must constrain the uses and disclosures of protected health information obtained by the business associate through the relationship, but does not give the covered entity any right to request the business associate to disclose protected health information that it maintains outside of the business associate relationship to the group health plan. Under HIPAA, employers are not covered entities, so a health insurance issuer or HMO cannot act as a business associate of an employer. See § 164.504(f) with respect to disclosures to plan sponsors from a group health plan or health insurance issuer or HMO with respect to a group health plan.

With respect to attorneys generally, the reasons the commenters put forward to exempt attorneys from this requirement were not persuasive. The business associate requirements will not prevent attorneys from disclosing protected health information as necessary to find and prepare witness, nor from doing their work generally, because the business associate contract can allow disclosures for these purposes. We do not require business associate contracts to identify each disclosure to be made by the business associate; these disclosures can be identified by type or purpose. We believe covered entities and their attorneys can craft agreements that will allow for uses and disclosures of protected health information as necessary for these activities. The requirement for a business associate contract does not interfere with the attorney-client relationship, nor does it override professional judgement of business associates regarding the protected health information they need to discharge their responsibilities. We do not require covered entities to second guess their professional business associates’ reasonable requests to use or disclose protected health information in the course of the relationship.

The attorney-client privilege covers only a small portion of information provided to attorneys to represent patients, and serves as a substitute for this requirement. More important, attorney-client privilege belongs to the client, in this case the covered entity, and not to the individual who is the subject of the information. The business associate requirements are intended to protect the subject of the information.

With regard to government attorneys and other government agencies, we recognize that federal and other law often does not allow standard legal contracts among governmental entities, but instead requires agreements to be made through the Economy Act or other mechanisms; these are generally reflected in a memorandum of understanding (MOU). We therefore modify the proposed requirements to allow government agencies to meet the required “satisfactory assurance” through such MOUs that contain the same provisions required of business associate contracts. As discussed elsewhere, we believe that direct regulation of entities that create protected health information can be as or more effective in protecting health information.
information as contracts. We therefore also allow government agencies to meet the required “satisfactory assurances” if law or regulations impose requirements on business associates consistent with the requirements specified for business associate contracts.

We do not believe that the requirement to have a business associate contract with agencies that are performing the specified services for the covered entity or undertaking functions or activities on its behalf undermines the government functions being performed. A business associate arrangement requires the business associate to maintain the confidentiality of the protected health information and generally to use and disclose the information only for the purposes for which it was provided. This does not undermine government functions. We have exempted from the business associate requirement certain situations in which the law has created joint uses or custody over health information, such as when law requires another government agency to determine the eligibility for enrollment in a covered health plan. In such cases, information is generally shared across a number of government programs to determine eligibility, and often is jointly maintained. We also clarify that health oversight activities do not give rise to a business associate relationship, and that protected health information may be disclosed by a covered entity to a health oversight agency pursuant to §164.512(d).

We clarify for purposes of the final rule that accreditation agencies are business associates of a covered entity and are explicitly included within the definition. During accreditation, covered entities disclose substantial amounts of protected health information to other private persons. A business associate contract basically requires the business associate to maintain the confidentiality of the protected health information that it receives and generally to use and disclose such information only for the purposes for which it was provided. As with attorneys, we believe that requiring a business associate contract in this instance provides substantial additional privacy protection without interfering with the functions that are being provided by the business associate.

With regard to affiliates, §164.504(d) permits affiliates to designate themselves as a single covered entity for purposes of this rule. (See §164.504(d) for specific organizational requirements.) Affiliates that choose to designate themselves as a single covered entity for purposes of this rule will not need business associate contracts to share protected health information. Absent such designation, affiliates are business associates of the covered entity if they perform a function or service for the covered entity that necessitates the use or disclosure of protected health information.

Software vendors are business associates if they perform functions or activities on behalf of, or provide specified services to, a covered entity. The mere provision of software to a covered entity would not appear to give rise to a business associate relationship, although if the vendor needs access to the protected health information of the covered entity to assist with data management or to perform functions or activities on the covered entity’s behalf, the vendor would be a business associate. We note that when an employee of a contractor, like a software or IT vendor, has his or her primary duty station on-site at a covered entity, the covered entity may choose to treat the employee of the vendor as a member of the covered entity’s workforce, rather than as a business associate. See the preamble discussion to the definition of workforce, §160.103.

With regard to medical device manufacturers, we clarify that a device manufacturer that provides “health care” consistent with the rule’s definition, including being a “supplier” under the Medicare program, is a health care provider under the final rule. We do not require a business associate contract when protected health information is used by health care providers for treatment purposes. However, a device manufacturer that does not provide “health care” must be a business associate of a covered entity if that manufacturer receives or creates protected health information in the performance of functions or activities on behalf of, or the provision of specified services to, a covered entity.

As to financial institutions, they are business associates under this rule when they conduct activities that cause them to meet the definition of business associate. See the preamble discussion of the definition of “payment” in §164.501, for an explanation of activities of a financial institution that do not require it to have a business associated contract.

Disease managers may be health care providers or health plans, if they otherwise meet the respective definitions and perform disease management activities on their own behalf. However, such persons may also be business associates if they perform disease management functions or services for a covered entity.

Comment: Other commenters recommended that certain entities be included within the definition of “business partner,” such as transcription services; employee representatives; in vitro diagnostic manufacturers; private state and comparative health data organizations; state hospital associations; warehouses; “whistleblowers,” credit card companies that deal with health billing; and patients.

Response: We do not list all the types of entities that are business associates, because whether an entity is a business associate depends on what the entity does, not what the entity is. That is, this is a definition based on function; any entity performing the function described in the definition is a business associate. Using one of the commenters’ examples, a state hospital association may be a business associate if it performs a service for a covered entity for which protected health information is required. It is not a business associate by virtue of the fact that it is a hospital association, but by virtue of the service it is performing.

Comment: A few commenters urged that certain entities, i.e., collection agencies and case managers, be business partners rather than covered entities for purposes of this rule.

Response: Collection agencies and case managers are business associates to the extent that they provide specified services to or perform functions or activities on behalf of a covered entity. A collection agency is not a covered entity for purposes of this rule. However, a case manager may be a covered entity because, depending on the case manager’s activities, the person may meet the definition of either a health care provider or a health plan. See definitions of “health care provider” and “health plan” in §164.501.

Comment: Several commenters complained that the proposed HIPAA security regulation and privacy regulation were inconsistent with regard to business partners.

Response: We will conform these policies in the final Security Rule.

Comment: One commenter expressed concern that the proposal appeared to give covered entities the power to limit by contract the ability of their business partners to disclose protected health information obtained from the covered entity regardless of whether the disclosure was permitted under proposed §164.510, “Uses and disclosures for which individual authorization is not required” (§164.512 in the final rule). Therefore, the commenter argued that the covered
entity could prevent the business partner from disclosing protected health information to oversight agencies or law enforcement by omitting them from the authorized disclosures in the contract.

In addition, the commenter expressed concern that the proposal did not authorize business partners and their employees to engage in whistleblowing. The commenter concluded that this omission was unintended since the proposal’s provision at proposed § 164.518(c)(4) relieved the covered entity, covered entity’s employees, business partner, and the business partner’s employees from liability for disclosing protected health information to law enforcement and to health oversight agencies when reporting improper activities, but failed to specifically authorize business partners and their employees to engage in whistleblowing in proposed § 164.510(f). “Disclosures for law enforcement.”

Response: Under our statutory authority, we cannot directly regulate entities that are not covered entities; thus, we cannot regulate most business associates, or ‘authorize’ them to use or disclose protected health information. We agree with the result sought by the commenter, and accomplish it by ensuring that such whistle blowing disclosures by business associates and others do not constitute a violation of this rule on the part of the covered entity.

Comment: Some commenters suggested that the need to terminate contracts that had been breached would be particularly problematic when the contracts were with single-source business partners used by health care providers. For example, one commenter explained that when the Department awards single-source contracts, such as to a Medicare carrier acting as a fiscal intermediary that then becomes a business partner of a health care provider, the physician is left with no viable alternative if required to terminate the contract.

Response: In most cases, we expect that there will be other entities that could be retained by the covered entity as a business associate to carry out those functions on its behalf or provide the necessary services. We agree that under certain circumstances, however, it may not be possible for a covered entity to terminate a contract with a business associate. Accordingly, although the rule still generally requires a covered entity to terminate a contract if steps to cure such a material breach fail, it also allows an exception to this to accommodate those infrequent circumstances where there simply are no viable alternatives to continuing a contract with that particular business associate. It does not mean, however, that the covered entity can choose to continue the contract with a non-compliant business associate merely because it is more convenient or less costly than doing business with other potential business associates. We also require that if a covered entity determines that it is not feasible to terminate a non-compliant business associate, the covered entity must notify the Secretary.

Comment: Another commenter argued that having to renegotiate every existing contract within the 2-year implementation window so a covered entity can attest to “satisfactory assurance” that its business partner will appropriately safeguard protected health information is not practical.

Response: The 2-year implementation period is statutorily required under section 1175(b) of the Act. Further, we believe that two years provides adequate time to come into compliance with the regulation.

Comment: A commenter recommended that the business partner contract specifically address the issue of data mining because of its increasing prevalence within and outside the health care industry.

Response: We agree that protected health information should only be used by business associates for the purposes identified in the business associate contract. We address the issue of data mining by requiring that the business associate contract explicitly identify the uses or disclosures that the business associate is permitted to make with the protected health information. Aside from disclosures for data aggregation and business associate management, the business associate contract cannot authorize any uses or disclosures that the covered entity itself cannot make. Therefore, data mining by the business associate for any purpose not specified in the contract is a violation of the contract and grounds for termination of the contract by the covered entity.

Comment: One commenter stated that the rule needs to provide the ability to contract with persons and organizations to complete clinical studies, provide clinical expertise, and increase access to experts and quality of care.

Response: We agree, and do not prohibit covered entities from sharing protected health information under a business associate contract for these purposes.

Comment: A commenter requested clarification as to whether sister agencies are considered business partners when working together.

Response: It is unclear from the comment whether the “sister agencies” are components of a larger entity, are affiliated entities, or are otherwise linked. Requirements regarding sharing protected health information among affiliates and components are found in § 164.504.

Comment: One commenter stated that some union contracts specify that the employer and employees jointly conduct patient quality of care reviews. The commenter requested clarification as to whether this arrangement made the employee a business partner.

Response: An employer organization that agrees to perform quality assurance for a group health plan meets the definition of a business associate. We note that the employee representatives acting on behalf of the employee organization would be performing the functions of the organization, and the employee organization would be responsible under the business associate contract to ensure that the representatives abided by the restrictions and conditions of the contract. If the employee organization is a plan sponsor of the group health plan, the similar provisions of § 164.504(f) would apply instead of the business associate requirements. See § 164.502(e)(1).

Comment: Some commentators supported regulating employers as business partners of the health plan. These commenters believed that this approach provided flexibility by giving employers access to information when necessary while still holding employers accountable for improper use of the information. Many commentators, however, stressed that this approach would turn the relationship between employers, employees and other agents “on its head” by making the employer subordinate to its agents. In addition, several commenters objected to the business partner approach because they alleged it would place employers at risk for greater liability.

Response: We do not require a business associate contract for disclosure of protected health information from group health plans to employers. We do, however, put other conditions on the disclosure of protected health information from group health plans to employers who sponsor the plan. See further discussion in § 164.504 on disclosure of protected health information to employers.
Response: We design the rule’s requirements with respect to volunteers and pro bono services to allow flexibility to the covered entity so as not to disturb these arrangements. Specifically, when such volunteers work on the premises of the covered entity, the covered entity may choose to treat them as members of the covered entity’s workforce or as business associates. See the definitions of business associate and workforce in § 160.103. If the volunteer performs its work off-site and needs protected health information, a business associate arrangement will be required. In this instance, where protected health information leaves the premises of the covered entity, privacy concerns are heightened and it is reasonable to require an agreement to protect the information. We believe that pro bono contractors will easily develop standard contracts to allow those activities to continue smoothly while protecting the health information that is shared.

Section 164.504(f)—Group Health Plans

Comment: Several commenters interpreted the preamble in the proposed rule to mean that only self-insured group health plans were covered entities. Another commenter suggested there was an error in the definition of group health plans because it only included plans with more than 50 participants or plans administered by an entity other than the employer (emphasis added by commenter). This commenter believed the “or” should be an “and” because almost all plans under 50 are administered by another entity and therefore this definition does not exclude most small plans.

Response: We did not intend to imply that only self-insured group health plans are covered health plans. We clarify that all group health plans, both self-insured and fully-funded, with 50 or more participants are covered health plans if they are administered by another entity, and that group health plans with fewer than 50 participants are covered health plans if they are administered by another entity. While we agree with the commenter that few group health plans with fewer than 50 participants are self-administered, the “or” is dictated by the statute. Therefore, the statute only exempts group health plans with fewer than 50 participants that are not administered by an entity other than the employer.

Comment: Several commenters stated that the proposed rule mis-characterized the relationship between the employer and the group health plan. The comment was that under ERISA and the Internal Revenue Code group health plans are separate legal entities from their employer sponsors. The group health plan itself, however, generally does not have any employees. Most operations of the group health plan are contracted out to other entities or are carried out by employees of the employer who sponsors the plan. The commenters stressed that while group health plans are clearly covered entities, the Department does not have the statutory authority to cover employers or other entities that sponsor group health plans. In contrast, many commenters stated that without covering employers, meaningful privacy protection is unattainable.

Response: We agree that group health plans are separate legal entities from their plan sponsors and that the group health plan itself may be operated by employees of the plan sponsor. We make significant modification to the proposed rule to better reflect this reality. We design the requirements in the final regulation to use the existing regulatory tools provided by ERISA, such as the plan documents required by that law and the constellation of plan administration functions defined by that law that established and maintain the group health plan.

We recognize plans’ legitimate need for health information in certain situations while, at the same time, protecting health information from being used for employment-related functions or for other functions related to other employee benefit plans or other benefits provided by the plan sponsor. We do not attempt to directly regulate plan sponsors, but instead, we authorize our authority to regulate health plans, we place restrictions on the flow of information from covered entities to non-covered entities. The final rule permits group health plans to disclose protected health information to plan sponsors, and allows them to authorize health insurance issuers or HMOs to disclose protected health information to plan sponsors, if the plan sponsors agree to use and disclose the information only as permitted or required by the regulation. The information may also be used only for plan administration functions performed on behalf of the group health plan and specified in the plan documents. Hereafter, any reference to employer in a response to a comment uses the term “plan sponsor,” since employers can only receive protected health information in their role as plan sponsors, except as otherwise permitted under this rule, such as with an authorization.

Specifically, in order for a plan sponsor to receive protected health information from a group health plan, health insurance issuer, or HMO, the documents under which the group health plan was established and is maintained must be amended to: (1) Describe the permitted uses and disclosures of protected health information by the plan sponsor (see above for further explanation); (2) specify that disclosure is permitted only upon receipt of a written certification that the plan documents have been amended; and (3) provide adequate firewalls. The firewalls must identify the employees or classes of employees or other persons under the plan sponsor’s control who will have access to protected health information; restrict access to only the employees identified and only for the administrative functions performed on behalf of the group health plan; and provide a mechanism for resolving issues of noncompliance by the employees identified. Any employee of the plan sponsor who receives protected health information in connection with the group health plan must be included in the amendment to the plan documents. As required by ERISA, the named fiduciary is responsible for ensuring the accuracy of amendments to the plan documents.

Group health plans, and health insurance issuers or HMOs with respect to the group health plan, that disclose protected health information to plan sponsors are bound by the minimum necessary standard as described in § 164.514.

Group health plans, to the extent they provide health benefits only through an insurance contract with a health insurance issuer or HMO and do not create, receive, or maintain protected health information (except for summary information or enrollment and disenrollment information), are not required to comply with the requirements of §§ 164.520 or 164.530, except for the documentation requirements of § 164.530(b). In addition, because the group health plan does not have access to protected health information, the requirements of §§ 164.524, 164.526, and 164.528 are not applicable. Individuals enrolled in a group health plan that provides benefits only through an insurance contract with a health insurance issuer or HMO would have access to all rights provided by this regulation through the health insurance issuer or HMO, because they are covered entities in their own right.

Comment: We received several comments from self-insured plans who stated that the proposed rule did not fully appreciate the dual nature of an employer as a plan sponsor and as an insurer. These commenters stated that
the regulation should have an exception for employers who are also insurers. 

Response: We believe the approach we have taken in the final rule recognizes the special relationship between plan sponsors and group health plans, including group health plans that provide benefits through a self-insured arrangement. The final rule allows plan sponsors and employees of plan sponsors access to protected health information for purposes of plan administration. The group health plan is bound by the permitted uses and disclosures of the regulation, but may disclose protected health information to plan sponsors under certain circumstances. To the extent that group health plans do not provide health benefits through an insurance contract, they are required to establish a privacy officer and provide training to employees who have access to protected health information, as well as meet the other applicable requirements of the regulation.

Comment: Some commenters supported our position not to require individual consent for employers to have access to protected health information for purposes of treatment, payment, and health care operations. For employer sponsored insurance to continue to exist as it does today, the commenters stressed, this policy is essential. Other commenters encouraged the Department to amend the regulation to require authorization for disclosure of information to employers. These commenters stressed that because the employer administered entity, individual consent is the only way to prohibit potential abuses of information.

Response: In the final rule, we maintain the position in the proposed rule that a health plan, including a group health plan, need not obtain individual consent for use and disclosure of protected health information for treatment, payment and or health care operations purposes. However, we impose conditions (described above) for making such disclosures to the plan sponsor. Because employees of the plan sponsor often perform health care operations and payment (e.g. plan administration) functions, such as claims payment, quality review, and auditing, they may have legitimate need for such information. Requiring authorization from every participant in the plan could make such fundamental plan administration activities impossible. We therefore impose regulatory restrictions, rather than a consent requirement, to prevent the potential conflicts, for example, the plan sponsor must certify that any protected health information obtained by its employees through such plan administration activities will not be used for employment-related decisions.

Comment: Several commenters stressed that the regulation must require the establishment of firewalls between group health plans and employers. These commenters stated that firewalls were necessary to prevent the employer from accessing information improperly and using it in making job placements, promotions, and firing decisions. In addition, one commenter stated that employees with access to protected health information must be empowered through this regulation to deny unauthorized access to protected health information to corporate managers and executives.

Response: We agree with the commenters that firewalls are necessary to prevent unauthorized use and disclosure of protected health information. Among the conditions for group health plans to disclose information to plan sponsors, the plan sponsor must establish firewalls to prevent unauthorized uses and disclosures of information. The firewalls include: describing the employees or classes of employees with access to protected health information; restricting access to and use of the protected health information to the plan administration functions performed on behalf of the group health plan and described in plan documents; and providing an effective mechanism for resolving issues of noncompliance.

Comment: Several commenters supported our proposal to cover the health care component of an employer in its capacity as an administrator of the group health plan. These commenters felt the component approach was necessary to prevent the disclosure of protected health information to other parts of the employer where it might be used or disclosed improperly. Other commenters believed the component approach was unworkable and that distinguishing who was in the covered entity would not be as easy as assumed in the proposed rule. One commenter stated it was unreasonable for an employer to go through its workforce division by division and employee by employee designating who is included in the component and who is not. In addition, some commenters argued that we did not have the statutory authority to regulate employers at all, including their health care components.

One commenter requested more guidance with respect to identifying the health care component as proposed under the final rule. In particular, the commenter requested that the regulation clearly define how to identify such persons and what activities and functional areas may be included. The commenter alleged that identification of persons needing access to protected health information will be administratively burdensome. Another commenter requested clarification on distinguishing the component entity from non-component entities within an organization and how to administer such relationships. The commenter stated that individuals included in the covered entity could change on a daily basis and advocated for a simpler set of rules governing intra-organizational relationships as opposed to inter-organizational relationships.

Response: While we have not adopted the component approach for plan sponsors in the final rule, plan sponsors who want protected health information must still identify who in the organization will have access to the information. Several of the changes we made to the NPRM will make this designation easier. First, we move from “component” to a more familiar functional approach. We limit the employees of the plan sponsor who may receive protected health information to those employees performing plan administration functions, as that term is understood with respect to ERISA compliance, and as limited by this rule’s definitions of payment and health care operation. We also allow designation of a class of employees (e.g., all employees assigned to a particular department) or individual employees.

Although some commenters have asked for guidance, we have intentionally left the process flexible to accommodate different organizational structures. Plan sponsors may identify who will have access to protected health information in whatever way best reflects their business needs as long as participants can reasonably identify who will have access. For example, persons may be identified by naming individuals, job titles (e.g. Director of Human Resources), functions (e.g. employees with oversight responsibility for the outside third party claims administrator), divisions of the company (e.g. Employee Benefits) or other entities related to the plan sponsor. We believe this flexibility will also ease any administrative burden that may result from the identification process. Identification in terms such as “individuals who from time to time may need access to protected health information” or in other broad or generic ways, however, would not be sufficient.

Comment: In addition to the comments on the component approach itself, several commenters pointed out
that many employees wear two hats in the organization, one for the group health plan and one for the employer. The commenters stressed that these employees should not be regulated when they are performing group health plan functions. This arrangement is necessary, particularly in small employers where the plan fiduciary may also be in charge of other human resources functions. The commenter recommended that employees be allowed access to information when necessary to perform health plan functions while prohibiting them from using the information for non-health plan functions.

Response: We agree with the commenters that many employees perform multiple functions in an organization and we design these provisions specifically to accommodate this way of conducting business. Under the approach taken in the final regulation, employees who perform multiple functions (i.e. group health plan and employment-related functions) may receive protected health information from group health plans, but among other things, the plan documents must certify that these employees will not use the information for activities not otherwise permitted by this rule including for employment-related activities.

Comment: Several commenters pointed out that the amount of access needed to protect health information varies greatly from employer to employer. Some employers may perform many plan administration functions themselves which are not possible without access to protected health information. Other employers may simply offer health insurance by paying a premium to a health insurance issuer rather than provide or administer health benefits themselves. Some commenters argued that fully insured plans should not be covered under the rule. Similarly, some commenters argued that the regulation was overly burdensome on small employers, most of whom fully insure their group health plans. Other commenters pointed out that health insurance issuers—even in fully insured arrangements—are often asked for identifiable health information, sometimes for legitimate purposes such as auditing or quality assurance, but sometimes not. One commenter, representing an insurer, gave several examples of employer requests, including claims reports for employees, individual and aggregate amounts paid for employees, identity of employees using certain drugs, and the identity, diagnosis and anticipated future costs for “high cost” employees. This same commenter requested guidance in what types of information can be released to employers to help them determine the organization’s responsibilities and liabilities.

Response: In the final regulation we recognize the diversity in plans’ need for protected health information. Many plan sponsors need access to protected health information to perform plan administration functions, including eligibility and enrollment functions, quality assurance, claims processing, auditing, monitoring, trend analysis, and management of carve-out plans (such as vision and dental plans). In the final regulation we allow group health plans to disclose protected health information to plan sponsors if the plan sponsor voluntarily agrees to use the information only in accordance with the purposes stated in the plan documents and as permitted by the regulation. We clarify, however, that plan administration does not include any employment-related decisions, including fitness for duty determinations, or duties related to other employee benefits or plans. Plan documents may only permit health insurance issuers to disclose protected health information to a plan sponsor as is otherwise permitted under this rule and consistent with the minimum necessary standard.

Some plan sponsors, including those with a fully insured group health plan, do not perform plan administration functions on behalf of group health plans, but still may require health information for other purposes, such as modifying, amending or terminating the plan or soliciting bids from prospective issuers or HMOs. In the ERISA context actions undertaken to modify, amend or terminate a group health plan may be known as “settlor” functions (see Lockheed Corp. v. Spink, 517 U.S. 882 (1996)). For example, a plan sponsor may require access to information to evaluate whether to adopt a three-tiered drug formulary. Additionally, a prospective health insurance issuer may need claims information from a plan sponsor in order to provide rating information. The final rule permits plan sponsors to receive summary health information with identifiers removed in order to carry out such functions. Summary health information is information that summarizes the claims history, expenses, or types of claims by individuals enrolled in the group health plan. In addition, the identifiers listed in §164.514(b)(2)(i) must be removed prior to disclosing the information to a plan sponsor for purposes of modifying, amending, or terminating the plan. See §164.504(a). This information does not constitute de-identified information because there may be a reasonable basis to believe the information is identifiable to the plan sponsor, especially if the number of participants in the group health plan is small. A group health plan, however, may not permit an issuer or HMO to disclose protected health information to a plan sponsor unless the requirement in §164.520 states that this disclosure may occur.

Comment: Several commenters stated that health insurance issuers cannot be held responsible for employers’ use of protected health information. They stated that the issuer is the agent of the employer and it should not be required to monitor the employer’s use and disclosure of information.

Response: Under this regulation, health insurance issuers are covered entities and responsible for their own uses and disclosures of protected health information. A group health plan must require a health insurance issuer or HMO providing coverage to the group health plan to disclose information to the plan sponsor only as provided in the plan documents.

Comment: Several commenters urged us to require de-identified information to be used to the greatest extent possible when information is being shared with employers.

Response: De-identified information is not sufficient for many functions plan sponsors perform on behalf of their group health plans. We have created a process to allow plan sponsors and their employees access to protected health information when necessary to administer the plan. We note that all uses and disclosures of protected health information by the group health plan are bound by the minimum necessary standard.

Comment: One commenter representing church plans argued that the regulation should treat such plans differently from other group health plans. The commenter was concerned about the level of access to information the Secretary would have in performing compliance reviews and suggested that a higher degree of sensitivity is needed for information related to church plans than information related to other group health plans. This sensitivity is needed, the commenter alleged, to reduce unnecessary intrusion into church operations. The commenter also advocated that church plans found to be out of compliance should be able to self-correct within a stated time frame (270 days) and avoid paying penalty taxes as allowed in the Internal Revenue Code.

Response: We do not believe there is sufficient reason to treat church plans differently than other covered entities.
The intent of the compliance reviews is to determine whether or not the plan is abiding by the regulation, not to gather information on the general operations of the church. As required by § 160.310(c), the covered entity must provide access only to information that is pertinent to ascertaining compliance with part 160 or subpart E of 164.

**Comment:** Several commenters stated that employers often advocate on behalf of their employees in benefit disputes and appeals, answer questions with regard to the health plan, and generally help them navigate their health benefits. These commenters questioned whether this type of assistance would be allowed under the regulation, whether individual consent was required, and whether this intervention would make them a covered entity.

**Response:** The final rule does nothing to hinder or prohibit plan sponsors from advocating on behalf of group health plan participants or providing assistance in understanding their health plan. In contrast, however, the plan sponsor could not obtain any information from the group health plan or a covered provider unless authorization was given. We do not believe obtaining authorization when advocating or providing assistance will be impractical or burdensome since the individual is requesting assistance and therefore should be willing to provide authorization. Advocating on behalf of participants or providing other assistance does not make the plan sponsor a covered entity.

**Section 164.506—Consent for Treatment, Payment, and Health Care Operations**

**Comment:** Many commenters supported regulatory authorization for treatment, payment, and health care operations. In particular, health plans, employers, and institutional providers supported the use of regulatory authorization for treatment, payment, and health care operations.

In contrast, a large number of commenters, particularly health care professionals, patients, and patient advocates, suggested that consent for treatment, payment, and health care operations should be required. Many commenters supported the use of consent for treatment, payment, and health care operations, considering this a requirement for maintaining the integrity of the health care system. Some commenters made a distinction between requiring and permitting providers to obtain consent.

Commenters nearly uniformly agreed that covered health care providers, health plans, and clearinghouses should not be prohibited from seeking authorization for treatment, payment, and health care operations. Some commenters stated that the prohibition against obtaining an authorization goes against professional ethics, undermines the patient-provider relationship, and is contrary to current industry practice.

Some commenters specifically noted the primacy of the doctor-patient relationship regarding consent. In general, commenters recommended that individually identifiable health information not be released by doctors without patient consent. A few commenters stated that prohibiting health care providers from obtaining consent could cause the patient to become suspicious and distrustful of the health care provider. Other commenters believed that clinicians have the responsibility for making sure that patients are fully informed about the consequences of releasing information. A few commented that the process of obtaining consent provided an opportunity for the patient and provider to negotiate the use and disclosure of patient information.

Commenters discussed how, when, and by whom consent should be sought. For example, some commenters viewed a visit between a health care provider and patient as the appropriate place for consent to be discussed and obtained. While others did not necessarily dispute the appropriateness of health care providers obtaining consent for uses and disclosures of protected health information from individuals, some said that it was appropriate for health plans to be permitted to obtain consent.

**Response:** In the NPRM we stated our concern that the blanket consents that individuals sign today provide these individuals with neither notice nor control over how their information is to be used. While we retain those concerns, we also understand that for many who participate in the health care system, the acts of providing and obtaining consent represent important values that these parties wish to retain. Many individuals argued that providing consent enhances their control; many advocates argued that the act of consent focuses patient attention on the transaction; and many health care providers argued that obtaining consent is part of ethical behavior.

The final rule amends our proposed approach and requires most covered health care providers to obtain a consent from their patients to use or disclose protected health information for treatment, payment, and health care operations. Providers who have an indirect treatment relationship with the patient, as defined in § 164.501, cannot be expected to have an opportunity to obtain consent and may continue to rely on regulatory authorization for their uses and disclosures for these purposes. As described in the comments, it is the relationship between the health care provider and the patient that is the basis for many decisions about uses and disclosures of protected health information. Much of the individually identifiable health information that is the subject of this rule is created when a patient interacts with a health care provider. By requiring covered providers to obtain consent for treatment, payment, and health care operations, the individual will have appropriate opportunity to consider the appropriate uses and disclosures of his or her protected health information.

We also require that the consent contain a reference to the provider’s notice, which contains a more detailed description of the provider’s practices relating to uses and disclosures of protected health information. This combination provides the basis for an individual to have an informed conversation with his or her provider and to request restrictions.

It is our understanding that it is common practice for providers to obtain consent for this type of information-sharing today. Many providers and provider organizations stated that they are ethically obligated to obtain the patient’s consent and that it is their practice to do so. A 1998 study by Merz, et al, published in the Journal of Law, Medicine and Ethics examined hospital consent forms regarding disclosure of medical information. They found that 97% of all hospitals seek consent for the release of information for payment purposes; 45% seek consent for disclosure for utilization review, peer review, quality assurance, and/or prospective review; and 50% seek consent for disclosure to providers, other health care facilities, or others for continuity of care purposes. All of these activities fall within our definitions of treatment, payment, or health care operations.

In the final rule we have not required that health plans or health care clearinghouses obtain consent for their uses and disclosures of protected health information for treatment, payment, or health care operations. The rationale underlying the consent requirements for uses and disclosures by health care providers do not pertain to health plans and health care clearinghouses. First, current practice is varied, and there is little history of health plans obtaining

---

consent relating to their own information practices unless required to do so by some other law. This is reflected in the public comments, in which most health plans supported the regulatory authorization approach proposed in the NPRM. Further, unlike many health care providers, health plans did not maintain that they were ethically obligated to seek the consent of their patients for their use and disclosure activities. Finally, it is the unique relationship between an individual and his or her health care provider that provides the foundation for a meaningful consent process. Requiring that consent process between an individual and a health plan or clearinghouse, when no such unique relationship exists, we believe is not necessary.

Unlike their relationship with health care providers, individuals in most instances do not have a direct opportunity to engage in a discussion with a health plan or clearinghouse at the time that they enter into a relationship with those entities. Most individuals choose a health plan through their employer and often sign up through their employer without any direct contact with the health plan. We concluded that providing for a signed consent in such a circumstance would add little to the proposed approach, which would have required health plans to provide a detailed notice to their enrollees. In the final rule, we also clarify that an individual can request a restriction from a health plan or health care clearinghouse. Since individuals rarely if ever have any direct contact with clearinghouses, we concluded that requiring a signed consent would have virtually no effect beyond the provision of the notice and the opportunity to request restrictions.

We agree with the comments we received objecting to the provision prohibiting covered entities from obtaining consent from individuals. As discussed above, in the final rule we require covered health care providers with direct treatment relationships to obtain consent to use or disclose protected health information for treatment, payment, and health care operations. In addition, we have eliminated the provision prohibiting other covered entities from obtaining such consents. We note that the consents that covered entities are permitted to obtain relate to their own uses and disclosures of protected health information for treatment, payment, and health care operations and not to the practices of others. If a covered entity wants to obtain the individual’s permission to receive protected health information from another covered entity, it must do so using an authorization under §164.508.

“Consent” versus “Authorization”

Comment: In general, commenters did not distinguish between “consent” and “authorization.” Commenters used both terms to refer to the individual’s giving permission for the use and disclosure of protected health information by any entity.

Response: In the final rule we have made an important distinction between consent and authorization. Under the final rule, we refer to the process by which a covered entity seeks agreement from an individual regarding how it will use and disclose the individual’s protected health information for treatment, payment, and health care operations as “consent.” The provisions in the final rule relating to consent are largely contained in §164.506. The process by which a covered entity seeks agreement from an individual to use and disclose protected health information for other purposes, or to authorize another covered entity to disclose protected health information to the requesting covered entity, are termed “authorizations” and the provisions relating to them are found in §164.508.

Consent Requirements

Comment: Many commenters believed that consent might be problematic in that it could allow covered entities to refuse enrollment or services if the individual does not grant the consent. Some commenters proposed that covered entities be allowed to condition treatment, payment, or health care operations on whether or not an individual granted consent. Other commenters said that consent should be voluntary and not coerced.

Response: In the final rule (§164.506(b)(1)), we permit covered health care providers to condition treatment on the individual’s consent to the covered provider’s use or disclosure of protected health information to carry out treatment, payment, and health care operations. We recognize that it would be difficult, if not impossible, for health care providers to treat their patients and run their businesses without being able to use or disclose protected health information for these purposes. For example, a health care provider could not be reimbursed by a health plan unless the provider could share protected health information about the individual with the health plan. Under the final rule, if the individual refuses to grant consent for this disclosure, the health care provider may refuse to treat the individual. We encourage health care providers to exhaust other options, such as making alternative payment arrangements with the individual before refusing to treat the individual on these grounds.

We also permit health plans to condition enrollment in the health plan on the individual’s consent for the health plan to use and disclose protected health information to carry out treatment, payment, and health care operations (see §164.506(b)(2)). The health plan must seek the consent in conjunction with the individual’s enrollment in the plan for this provision to apply. For example, a health plan’s application for enrollment may include a consent for the health plan to use or disclose protected health information to carry out treatment, payment, and/or health care operations. If the individual does not sign this consent, the health plan, under §164.502(a)(1), is prohibited from using or disclosing protected health information about the individual for the purposes stated in the consent form. Because the health plan may not be able adequately to provide services to the individual without these uses and disclosures, we permit the health plan to refuse to enroll the individual if the consent is not signed.

Comment: Some commenters were concerned that the NPRM conflicted with state law regarding when covered entities would be required to obtain consent for uses and disclosures of protected health information.

Response: We have modified the provisions in the final rule to require certain health care providers to obtain consent for uses and disclosures for treatment, payment, and health care operations and to permit other covered entities to do so. A consent under this rule may be combined with other types of written legal permission from the individual, such as state-required consents for uses and disclosures of certain types of health information (e.g., information relating to HIV/AIDS or mental health). We also permit covered entities to seek authorization from the individual for another covered entity’s use or disclosure of protected health information for these purposes, including if the covered entity is required to do so by other law. Though we do not believe any states currently require such authorizations, we wanted to avoid future conflicts. These changes should resolve the concerns raised by commenters regarding conflicts with state laws that require consent, authorization, or other types of written legal permission for uses and disclosures of protected health information.
Comment: Some commenters noted that there would be circumstances when consent is impossible or impractical. A few commenters suggested that in such situations patient information be de-identified or reviewed by an objective third party to determine if consent is necessary.

Response: Covered health care providers with direct treatment relationships are required to obtain consent to use or disclose protected health information to carry out treatment, payment, and health care operations. In certain treatment situations where the provider is permitted or required to treat an individual without the individual's written consent to receive health care, the provider may use and disclose protected health information created or obtained in the course of that treatment without the individual's consent under this rule (see §164.506(a)(3)). In these situations, the provider must attempt to obtain the individual's consent and, if the provider is unable to obtain consent, the provider must document the attempt and the reason consent could not be obtained. Together with the uses and disclosures permitted under §§164.510 and 164.512, the concerns raised regarding situations in which it is impossible or impractical for covered entities to obtain the individual's permission to use or disclose protected health information about the individual have been addressed.

Comment: An agency that provides care to individuals with mental retardation or developmental disabilities expressed concern that many of their consumers lack capacity to consent to the release of their records and may not have a surrogate readily available to provide consent on their behalf.

Response: Under §164.506(a)(3), we provide exceptions to the consent requirement for certain treatment situations in which consent is difficult to obtain. In these situations, the covered provider must attempt to obtain consent and must document the reason why consent was not obtained. If these conditions are met, the provider may use and disclose the protected health information created or obtained during the treatment for treatment, payment, or health care operations purposes, without consent.

Comment: Many commenters were concerned that covered entities working together in an integrated health care system would each separately be required to obtain consent for use and disclosure of protected health information for treatment, payment, and health care operations. These commenters recommend that the rule permit covered entities that are part of the same integrated health care system to obtain a single consent allowing each of the covered entities to use and disclose protected health information in accordance with that consent form. Some commenters said that it would be confusing to patients and administratively burdensome to require separate consents for health care systems that include multiple covered entities.

Response: We agree with commenters' concerns. In §164.506(f) of the final rule we permit covered entities that participate in an organized health care arrangement to obtain a single consent on behalf of the arrangement. See §164.501 and the corresponding preamble discussion regarding organized health care arrangements. To obtain a joint consent, the covered entities must have a joint notice and must refer to the joint notice in the joint consent. See §164.520(d) and the corresponding preamble discussion regarding joint notice. The joint consent must also identify the covered entities to which it applies so that individuals will know who is permitted to use and disclose information about them.

Comment: Many commenters stated that individuals own their medical records and, therefore, should have absolute control over them, including knowing by whom and for what purpose protected health information is used, disclosed, and maintained. Some commenters asserted that, according to existing law, a patient owns the medical records of which he is the subject.

Response: We disagree. In order to assert an ownership interest in a medical record, a patient must demonstrate some legitimate claim of entitlement to it under a state law that establishes property rights or under state contract law. Historically, medical records have been the property of the health care provider or medical facility that created them, and some state statutes directly provide that medical records are the property of a health care provider or a medical facility. The final rule is consistent with current state law that provides patients access to protected health information but not ownership of medical records. Furthermore, state laws that are more stringent than the rule, that is, state laws that provide a patient with greater access to protected health information, remain in effect. See discussion of "Preemption" above.

Electronic Health Data

Comment: Some commenters stated that privacy concerns would be significantly reduced if patient information is not stored electronically. One commenter suggested that consent should be given for patient information to be stored electronically. One commenter believed that information stored in data systems should not be individually identifiable.

Response: We agree that storing and transmitting health information electronically creates concerns about the privacy of health information. We do not agree, however, that covered entities should be expected to maintain health information outside of an electronic system, particularly as health care providers and health plans extend their reliance on electronic transactions. We do not believe that it would be feasible to permit individuals to opt out of electronic transactions by withholding their consent. We note that individuals can ask providers and health plans whether or not they store information electronically, and can choose only providers who do not do so or who agree not to do so. We also do not believe that it is practical or efficient to require that electronic data bases contain only de-identified information. Electronic transactions have achieved tremendous savings in the health care system and electronic records have enabled significant improvements in the quality and coordination of health care. These improvements would not be possible with de-identified information.

Section 164.508—Uses and Disclosures For Which Authorization Is Required

Uses and Disclosures Requiring Authorization

Comment: We received many comments in general support of requiring authorization for the use or disclosure of protected health information. Some comments suggested, however, that we should define those uses and disclosures for which authorization is required and permit covered entities to make all other uses and disclosures without authorization.

Response: We retain the requirement for covered entities to obtain authorization for all uses and disclosures of protected health information that are not otherwise permitted or required under the rule without authorization. We define exceptions to the general rule requiring authorization for the use or disclosure of protected health information, rather than defining narrow circumstances in which authorization is required.

We believe this approach is consistent with well-established legal principles, with other law, and with industry standards and ethical
guidelines. The July 1977 Report of the Privacy Protection Study Commission recommended that “each medical-care provider be considered to owe a duty of confidentiality to any individual who is the subject of a medical record it maintains, and that, therefore, no medical care provider should disclose, or be required to disclose, in individually identifiable form, any information about any such individual without the individual’s explicit authorization, unless the disclosures would be” for specifically enumerated purposes such as treatment, audit or evaluation, research, public health, and law enforcement.9 The Commission made similar recommendations with respect to insurance institutions.10 The Privacy Act (5 U.S.C. 552a) prohibits government agencies from disclosing records except pursuant to the written request of or pursuant to a written consent of the individual to whom the record pertains, unless the disclosure is for certain specified purposes. The National Association of Insurance Commissioners’ Health Information Privacy Model Act states, “A carrier shall not collect, use or disclose protected health information without a valid authorization from the subject of the protected health information, except as permitted by * * * this Act or as permitted or required by law or court order. Authorization for the disclosure of protected health information may be obtained for any purpose, provided that the authorization meets the requirements of this section.” In its report “Best Principles for Health Privacy,” the Health Privacy Working Group stated, “Personally identifiable health information should not be disclosed without patient authorization, except in limited circumstances” such as when required by law, for oversight, and for research.11 The American Medical Association’s Council on Ethical and Judicial Affairs has issued an opinion stating, “The physician should not reveal confidential communications or information without the express consent of the patient, unless required to do so by law [and] subject to certain exceptions which are ethically and legally justified because of overriding social considerations.” 12 We build on these standards in this final rule.

Comment: Some comments suggested that, under the proposed rule, a covered entity could not use protected health information to solicit authorizations from individuals. For example, a covered entity could not use protected health information to generate a mailing list for sending an authorization for marketing purposes.

Response: We agree with this concern and clarify that covered entities are permitted to use protected health information in this manner without authorization as part of the management activities relating to implementation of and compliance with the requirements of this rule. See § 164.501 and the corresponding preamble regarding the definition of health care operations.

Comment: We received several comments suggesting that we not require written authorizations for disclosures to the individual or for disclosures initiated by the individual or the individual’s legal representative.

Response: We agree with this concern and in the final rule we clarify that disclosures of protected health information to the individual who is the subject of the information do not require the individual’s authorization. See § 164.502(a)(1). We do not intend to impose barriers between individuals and disclosures of protected health information to them.

When an individual requests that the covered entity disclose protected health information to a third party, however, the covered entity must obtain the individual’s authorization, unless the third party is a personal representative of the individual with respect to such protected health information. See § 164.502(g). If under applicable law a person has authority to act on behalf of an individual in making decisions related to health care, except under limited circumstances, that person must be treated as the personal representative under this rule with respect to protected health information related to such representation. A legal representative is a personal representative under this rule if, under applicable law, such person is able to act on behalf of an individual in making decisions related to health care, with respect to the protected health information related to such decisions. For example, an attorney of an individual may or may not be a personal representative under the rule depending on the attorney’s authority to act on behalf of the individual in decisions related to health care. If the attorney is the personal representative under the rule, he may obtain a copy of the protected health information relevant to such personal representation under the individual’s right to access. If the attorney is not the personal representative under the rule, or if the attorney wants a copy of more protected health information than that which is relevant to his personal representation, the individual would have to authorize such disclosure.

Comment: Commenters expressed concern about whether a covered entity could rely on authorizations made by parents on behalf of their minor children once the child has reached the age of majority and recommended that covered entities be able to rely on the most recent, valid authorization, whether it was authorized by the parent or the minor.

Response: We agree. If an authorization is signed by a parent, who is the personal representative of the minor child at the time the authorization is signed, the covered entity may rely on the authorization for as long as it is a valid authorization, in accordance with § 164.508(b). A valid authorization remains valid until it expires or is revoked. This protects a covered entity’s reasonable reliance on such authorization. The expiration date of the authorization may be the date the minor will reach the age of majority. In that case, the covered entity would be required to have the individual sign a new authorization form in order to use or disclose information covered in the expired authorization form.

Comment: Some commenters were concerned that covered entities working together in an integrated system would each be required to obtain authorization separately. These commenters suggested the rule should allow covered entities that are part of the same system to obtain a single authorization allowing each of the covered entities to use and disclose protected health information in accordance with that authorization.

Response: If the rule does not permit or require a covered entity to use or disclose protected health information without the individual’s authorization, the covered entity must obtain the individual’s authorization to make the use or disclosure. Multiple covered entities working together as an integrated delivery system or otherwise may satisfy this requirement in at least three ways. First, each covered entity may separately obtain an authorization directly from the individual who is the subject of the protected health information to be used or disclosed. Second, one covered entity may obtain

---

a compound authorization in accordance with §164.508(b)(3) that authorizes multiple covered entities to use and disclose protected health information. In accordance with §164.508(c)(1)(ii), each covered entity, or class of covered entities, that is authorized to make the use or disclosure must be clearly identified. Third, if the requirements in §164.504(d) are met, the integrated delivery system may elect to designate itself as a single affiliated covered entity. A valid authorization obtained by that single affiliated covered entity would satisfy the authorization requirements for each covered entity within the affiliated covered entity. Whichever option is used, because these authorizations are being requested by a covered entity for its own use or disclosure, the authorization must contain both the core elements in §164.508(c) and the additional elements in §164.508(d).

Sale, Rental, or Barter

Comment: Proposed §164.508 listed examples of activities that would have required authorization, which included disclosure by sale, rental, or barter. Some commenters requested clarification that this provision is not intended to affect mergers, sale, or similar transactions dealing with entire companies or their individual divisions. A few commenters stated that covered entities should be allowed to sell protected health information, including claims data, as an asset of the covered entity.

Response: We clarify in the definition of health care operations that a covered entity may sell or transfer its assets, including protected health information, to a successor in interest that is or will become a covered entity. See §164.501 and the corresponding preamble discussion regarding this change. We believe this change meets commenters' business needs without compromising individuals' privacy interests.

Comment: Some commenters supported the requirement for covered entities to obtain authorization for the sale, rental, or barter of protected health information. Some commenters argued that protected health information should never be bought or sold by anyone, even with the individual's authorization.

Response: We removed the reference to sale, rental, or barter in the final rule because we determined that the term was overly broad. For example, if a researcher reimbursed a provider for the cost of configuring health data to be disclosed through the research provisions at §164.512(i), there may have been ambiguity that this was a sale and, therefore, required authorizations from the individuals who were the subjects of the information. We clarify in the final rule that if the use or disclosure is otherwise permitted or required under the rule without authorization, such authorization is not required simply because the disclosure is made by sale, rental, or barter.

Psychotherapy Notes

Comment: Public response to the concept of providing additional protections for psychotherapy notes was divided. Many individuals and most providers, particularly mental health practitioners, advocated requiring consent for use or disclosure of all or most protected health information, but particularly sensitive information such as mental health information, not necessarily limited to psychotherapy notes. Others thought there should be special protections for psychotherapy information based on the federal psychotherapist-patient privilege created by the U.S. Supreme Court in Jaffee v. Redmond and the need for an atmosphere of trust between therapist and patient that is required for effective psychotherapy. Several consumer groups recommended prohibiting disclosure of psychotherapy notes for payment purposes.

Some commenters, however, saw no need for special protections for psychotherapy communications and thought that the rules should apply the same protections for all individually identifiable information. Other commenters who advocated for no special protections based their opposition on the difficulty in drawing a distinction between physical and mental health and that special protections should be left to the states. Many health plans and employers did not support additional protections for psychotherapy notes because they stated they need access to this information to assess the adequacy of treatment, the severity of a patient's condition, the extent of a disability, or the ability to monitor the effectiveness of an individual's mental health care and eligibility for benefits. Other commenters, many from insurance companies, cited the need to have psychotherapy notes to detect fraud.

A few commenters said that it was not necessary to provide additional protections to psychotherapy notes because the "minimum necessary" provisions of the NPRM provide sufficient protections.

Response: In the final rule, a covered entity generally must obtain an authorization for disclosure of psychotherapy notes, or for use by a person other than the person who created the psychotherapy notes. This authorization is specific to psychotherapy notes and is in addition to the consent an individual may have given for the use or disclosure of other protected health information to carry out treatment, payment, and health care operations. This additional level of individual control provides greater protection than a general application of the "minimum necessary" rule. Nothing in this regulation weakens existing rules applicable to mental health information that provide more stringent protections. We do not intend to alter the holding in Jaffee v. Redmond.

Generally, we have not treated sensitive information differently from other protected health information; however, we have provided additional protections for psychotherapy notes because of Jaffee v. Redmond and the unique role of this type of information. There are few reasons why other health care entities should need access to psychotherapy notes, and in those cases, the individual is in the best position to determine if the notes should be disclosed. As we have defined them, psychotherapy notes are primarily of use to the mental health professional who wrote them, maintained separately from the medical record, and not involved in the documentation necessary to carry out treatment, payment, or health care operations.

Since psychotherapy notes have been defined to exclude information that health plans would typically need to process a claim for benefits, special authorization for payment purposes should be rare. Unlike information shared with other health care providers for the purposes of treatment, psychotherapy notes are more detailed and subjective and are today subject to unique privacy and record retention practices. In fact, it is this separate existence and isolated use that allows us to grant the extra protection without causing an undue burden on the health care system.
Comment: Many commenters suggested we prohibit disclosure of psychotherapy notes without authorization for uses and disclosures under proposed §164.510 of the NPRM, or that protections should be extended to particular uses and disclosures, such as disclosures for public health, law enforcement, health oversight, and judicial and administrative proceedings. One of these commenters stated that the only purpose for which psychotherapy notes should be disclosed without authorization is for preventing or lessening a serious or imminent threat to health or safety (proposed §154.510(k)). Another commenter stated that the rule should allow disclosure of psychotherapy notes without authorization for this purpose, or as required by law in cases of abuse or neglect.

Other commenters did not want these protections to be extended to certain national priority activities. They claimed that information relative to psychotherapy is essential to states’ activities to protect the public from dangerous mentally ill offenders and abusers, to deliver services to individuals who are unable to authorize release of health care information, and for public health assessments. One commenter requested clarification of when psychotherapy notes could be released in emergency circumstances. Several commenters stated that psychotherapy notes should not be disclosed for public health purposes.

Response: We agree with the commenters who suggested extending protections of psychotherapy notes and have limited the purposes for which psychotherapy notes may be disclosed without authorization for purposes other than treatment, payment, or health care operations. The final rule requires covered entities to obtain authorization to use or disclose psychotherapy notes for purposes listed in §164.512, with the following exceptions: An authorization is not required for use or disclosure of psychotherapy notes when the use or disclosure is required for enforcement of this rule, in accordance with §164.502(a)(2)(iii); when required by law, in accordance with §164.512(a); when needed for oversight of the covered health care provider who created the psychotherapy notes, in accordance with §164.512(d); when needed by a coroner or medical examiner, in accordance with §164.512(g)(1); or when needed to avert a serious and imminent threat to health or safety, in accordance with §164.512(j)(i). (i).

Comment: A commenter suggested that we follow the federal regulations governing confidentiality of alcohol and substance abuse records as a model for limited disclosure of psychotherapy notes for audits or evaluations. Under these regulations, a third party payor or a party providing financial assistance may access confidential records for auditing purposes if the party agrees in writing to keep the records secure and destroy any identifying information upon completion of the audit. (42 CFR part 2)

Response: We agree that the federal regulations concerning alcohol and drug abuse provide a good model for protection of information. However, according to our fact-finding discussions, audit or evaluation should not require access to psychotherapy notes. Protected health information kept in the medical record about an individual should be sufficient for these purposes. The final rule does not require authorization for use or disclosure of psychotherapy notes when needed for oversight of the covered health care provider who created the psychotherapy notes.

Comment: A provider organization urged that the disclosure of psychotherapy notes be strictly prohibited except to the extent needed in litigation brought by the client against the mental health professional on the grounds of professional malpractice or disclosure in violation of this section.

Response: We agree that psychotherapy notes should be available for the defense of the provider who created the notes when the individual who is the subject of the notes puts the contents of the notes at issue in a legal case. In the final rule, we allow the provider to disclose the notes to his or her lawyer for the purpose of preparing a defense. Any other disclosure related to judicial and administrative proceedings is governed by §164.512(e).

Comment: One commenter requested that we prohibit mental health information that has been disclosed from being re-disclosed without patient authorization.

Response: Psychotherapy notes may only be disclosed pursuant to an authorization, except under limited circumstances. Covered entities must adhere to the terms of authorization and not disclose psychotherapy notes to persons other than those identified as intended recipients or for other purposes. A covered entity that receives psychotherapy notes must adhere to the terms of this rule—including obtaining an authorization for any further use or disclosure. We do not have the authority, however, to prohibit non-covered entities from re-disclosing psychotherapy notes or any other protected health information.

Comment: A provider organization argued for inclusion of language in the final rule that specifies that real or perceived “ownership” of the mental health record does not negate the requirement that patients must specifically authorize the disclosure of their psychotherapy notes. They cited a July 1999 National Mental Health Association survey, which found that for purposes of utilization review, every managed care plan policy reviewed “maintains the right to access the full medical record (including detailed psychotherapy notes) of any consumer covered under its benefit plan at its whim.” At least one of the major managed health plans surveyed considered the patient record to be the property of the health plan and governed by the health plan’s policies.

Response: Although a covered entity may own a mental health record, the ability to use or disclose an individual’s information is limited by state law and this rule. Under this rule, a mental health plan would not have access to psychotherapy notes created by a covered provider unless the individual who is the subject of the notes authorized disclosure to the health plan.

Comment: Some commenters expressed concern regarding the burden created by having to obtain multiple authorizations and requested clarification as to whether separate authorization for use and disclosure of psychotherapy notes is required.

Response: For the reasons explained above, we retain in the final rule a requirement that a separate authorization must be obtained for most uses or disclosures of psychotherapy notes, including those for treatment, payment, and health care operations. The burden of such a requirement is extremely low, however, because under our definition of psychotherapy notes, the need for such authorization will be very rare.

Comment: One commenter stated that Medicare should not be able to require the disclosure of psychotherapy notes because it would destroy a practitioner’s ability to treat patients effectively.

Response: We agree. As in the proposed rule, covered entities may not disclose psychotherapy notes for payment purposes without an authorization. If a specific provision of law requires the disclosure of these notes, a covered entity may make the disclosure under §164.512(a). The final rule, however, does not require the disclosure of these notes to Medicare.

Comment: One commenter expressed concern that by filing a complaint an
individual would be required to reveal sensitive information to the public.

Another commenter suggested that complaints regarding noncompliance in regard to psychotherapy notes should be made to a panel of mental health professionals designated by the Secretary. This commenter also proposed that all patient information would be maintained as privileged, would not be revealed to the public, and would be kept under seal after the case is reviewed and closed.

Response: We appreciate this concern and the Secretary will ensure that individually identifiable health information and other personal information contained in complaints will not be available to the public. This Department seeks to protect the privacy of individuals to the fullest extent possible, while permitting the exchange of records required to fulfill its administrative and program responsibilities. The Freedom of Information Act, 5 U.S.C. 552, and the HHS implementing regulation, 45 CFR part 2, protect records about individuals if the disclosure would constitute an unwarranted invasion of their personal privacy, as does the Privacy Act, 5 U.S.C. 552a. See the discussion of FOIA and the Privacy Act in the “Relationship to Other Federal Laws” section of the preamble. Information that the Secretary routinely withholds from the public in its current enforcement activities includes individual names, addresses, and medical information. Additionally, the Secretary attempts to guard against the release of information that might involve a violation of personal privacy by someone being able to “read between the lines” and piece together items that would constitute information that normally would be protected from release to the public. In implementing the privacy rule, the Secretary will continue this practice of protecting personal information.

It is not clear whether the commenter with regard to the use of mental health professionals believes that such professionals should be involved because they would be best able to keep psychotherapy notes confidential or because such professionals can best understand the meaning or relevance of such notes. We anticipate that we would not have to obtain a copy or review psychotherapy notes in investigating most complaints regarding noncompliance in regard to such notes. There may be some cases in which a quick review of the notes may be needed, such as when we need to identify that information a covered entity disclosed was in fact psychotherapy notes. If we need to obtain a copy of psychotherapy notes, we will keep these notes confidential and secure. Investigative staff will be trained in privacy to ensure that they fully respect the confidentiality of personal information. In addition, while the content of these notes is generally not relevant to violations under this rule, we will secure the expertise of mental health professionals if needed in reviewing psychotherapy notes.

Comment: A mental health organization recommended prohibiting health plans and covered health care providers from disclosing psychotherapy notes to coroners or medical examiners.

Response: In general, we have severely limited disclosures of psychotherapy notes without the individual’s authorization. One case where the information may prove invaluable, but authorization by the individual is impossible and authorization by a surrogate is potentially contraindicated, is in the investigation of the death of the individual. The final rule allows for disclosures to coroners or medical examiners in this limited case.

Comment: One commenter recommended prohibiting disclosure without authorization of psychotherapy notes to government health data systems.

Response: The decision to eliminate the general provision permitting disclosures to government health data systems addresses this comment.

Comment: Several commenters were concerned that in practice, a treatment team in a mental health facility shares information about a patient in order to care for the patient and that the provision requiring authorization for use and disclosure of psychotherapy notes would expose almost all privileged information to disclosure. They requested that we add a provision that any authorization or disclosure under that statute shall not constitute a waiver of the psychotherapist-patient privilege.

Response: Because of the restricted definition we have adopted for psychotherapy notes, we do not expect that members of a team will share such information. Information shared in order to care for the patient is, by definition, not protected as psychotherapy notes. With respect to waiving privilege, however, we believe that the consents and authorizations described in §§ 164.506 and 164.508 should not be construed as waivers of a patient’s evidentiary privilege. See the discussions under § 164.506 and “Relationship to Other Laws,” above.

Research Information Unrelated to Treatment

Definition of Research Information Unrelated to Treatment

Comment: The majority of commenters, including many researchers and health care providers, objected to the proposed definition of research information unrelated to treatment, asserting that the privacy rule should not distinguish research information unrelated to treatment from other forms of protected health information. Even those who supported the proposed distinction between research information related and unrelated to treatment suggested alternative definitions for research information unrelated to treatment.

A large number of commenters were concerned that the definition of research information unrelated to treatment was vague and unclear and, therefore, would be difficult or impossible to apply. These commenters asserted that in many instances it would not be feasible to ascertain whether research information bore some relation to treatment. In addition, several commenters asserted that the need for distinguishing research information unrelated to treatment from other forms of protected health information was not necessary because the proposed rule’s general restrictions for the use and disclosure of protected health information and the existing protections for research information were sufficiently strong.

Of the commenters who supported the proposed distinction between research information related and unrelated to treatment, very few supported the proposed definition of research unrelated to treatment. A few commenters recommended that the definition incorporate a good faith provision and apply only to health care providers, because they thought it was unlikely that a health plan or health care clearinghouse would be conducting research. One commenter recommended defining research information unrelated to treatment as information which does not directly affect the treatment of the individual patient. As a means of clarifying and standardizing the application of this definition, one commenter also asserted that the definition should be based on whether the research information was for publication. In addition, one commenter specifically objected to the provision of the proposed definition that would have required that research information unrelated to treatment be information “with respect to which the covered entity has not requested payment from
a third party payor.” This commenter asserted that patient protection should not be dependent on whether a health plan will pay for certain care.

Response: We agree with the commenters who found the proposed definition of research information unrelated to treatment to be impractical and infeasible to apply and have eliminated this definition and its related provisions in the final rule. Although we share concerns raised by some commenters that research information generated from research studies that involve the delivery of treatment to individual subjects may need additional privacy protection, we agree with the commenters who asserted that there is not always a clear distinction between research information that is related to treatment and research information that is not. We found that the alternative definitions proposed by commenters did not alleviate the serious concerns raised by the majority of comments received on this definition.

In the final rule, we require covered entities that create protected health information for the purpose, in whole or in part, of research that includes treatment of individuals to include additional elements in authorizations they request for the use or disclosure of that protected health information. As discussed in § 164.508(f), these research-related authorizations must include a description of the extent to which some or all of the protected health information created for the research will also be used or disclosed for purposes of treatment, payment, and health care operations. For example, if the covered entity intends to seek reimbursement from the individual’s health plan for the routine costs of care associated with the research protocol, it must explain in the authorization the types of information that it will provide to the health plan for this purpose. This information, and the circumstances under which disclosures will be made for treatment, payment, and health care operations, may be more limited than the information and circumstances described in the covered entity’s general notice of information practices and are binding on the covered entity.

Under this approach, the covered entity that creates protected health information for research has discretion to determine whether there is a subset of research information that will have fewer allowable disclosures without authorization, and prospective research subjects will be informed about how research information about them would be used and disclosed should they agree to participate in the research study. We believe this provision in the final rule provides covered entities that participate in research necessary flexibility to enhance privacy protections for research information and provides prospective research subjects with needed information to determine whether their privacy interests would be adequately protected before agreeing to participate in a research study that involves the delivery of health care.

The intent of this provision is to permit covered entities that participate in research to bind themselves to a more limited scope of uses and disclosures for all or identified subsets of research information generated from research that involves the delivery of treatment than it may apply to other protected health information. In designing their authorizations, we expect covered entities to be mindful of the often highly sensitive nature of research information and the impact of individuals’ privacy concerns on their willingness to participate in research. For example, a covered entity conducting a study which involves the evaluation of a new drug, as well as an assessment of a new un-validated genetic marker of a particular disease, could choose to stipulate in the research authorization that the genetic information generated from this study will not be disclosed without authorization for some of the public policy purposes that would otherwise be permitted by the rule under §§ 164.510 and 164.512 and by the covered entity’s notice. A covered entity may not, however, include a limitation affecting its right to make a use or disclosure that is either required by law or is necessary to avert a serious and imminent threat to health or safety.

The final rule also permits the covered entity to combine the research authorization under § 164.508(f) with the consent to participate in research, such as the informed consent document as stipulated under the Common Rule or the Food and Drug Administration’s human subjects regulations.

Enhance Privacy Protections for Research Information

Comment: A number of commenters argued that research information unrelated to treatment should have fewer allowable disclosures without authorization than those that would have been permitted by the proposed rule. The commenters who made this argument included those commenters who recommended that the privacy rule not cover the information we proposed to constitute research information unrelated to treatment, as well as those who asserted that the rule should cover such information. These commenters agreed with the concern expressed in the proposed rule that patients would be reluctant to participate in research if they feared that research information could be disclosed without their permission or used against them. They argued that fewer allowable disclosures should be permitted for research information because the clinical utility of the research information is most often unknown, and thus, it is unsuitable for use in clinical decision making. Others also argued that it is critical to the conduct of clinical research that researchers be able to provide individual research subjects, and the public at large, the greatest possible assurance that their privacy and the confidentiality of any individually identifiable research information will be protected from disclosure.

Several commenters further recommended that only the following uses and disclosures be permitted for research information unrelated to treatment without authorization: (1) For the oversight of the researcher or the research study; (2) for safety and efficacy reporting required by FDA; (3) for public health; (4) for emergency circumstances; or (5) for another research study. Other commenters recommended that the final rule explicitly prohibit law enforcement officials from gaining access to research records.

In addition, several commenters asserted that the rule should be revised to ensure that once protected health information was classified as research information unrelated to treatment, it could not be re-classified as something else at a later date. These commenters believed that if this additional protection were not added, this information would be vulnerable to disclosure in the future, if the information were later to gain scientific validity. They argued that individuals may rely on this higher degree of confidentiality when consenting to the collection of the information in the first instance, and that confidentiality should not be betrayed in the future just because the utility of the information has changed.

Response: We agree with commenters who argued that special protections may be appropriate for research information in order to provide research subjects with assurances that their decision to participate in research will not result in harm stemming from the misuse of the research information. We are aware that some researchers currently retain separate research records and medical records as a means of providing more stringent privacy protections for the research record. The final rule permits
covered entities that participate in research to continue to provide more stringent privacy protections for the research record, and the Secretary strongly encourages this practice to protect research participants from being harmed by the misuse of their research information.

As discussed above, in the final rule, we eliminate the special rules for this proposed definition of research information unrelated to treatment and its related provisions, so the comments regarding its application are moot.

Comment: Some commenters recommended that the final rule prohibit a covered entity from conditioning treatment, enrollment in a health plan, or payment on a requirement that the individual authorize the use or disclosure of information we proposed to constitute research information unrelated to treatment.

Response: Our decision to eliminate the definition of research information unrelated to treatment and its related provisions in the final rule renders this comment moot.

Comment: A few commenters opposed distinguishing between research information related to treatment and research information unrelated to treatment, arguing that such a distinction could actually weaken the protection afforded to clinically-related health information that is collected in clinical trials. These commenters asserted that Certificates of Confidentiality shield researchers from being compelled to disclose individually identifiable health information relating to biomedical or behavioral research information that an investigator considers sensitive.

Response: Our decision to eliminate the definition of research information unrelated to treatment and its related provisions in the final rule renders this comment moot. We would note that nothing in the final rule overrides Certificates of Confidentiality, which protect against the compelled disclosure of identifying information about subjects of research, clinical, and other research as provided by the Public Health Service Act section 301(d), 42 U.S.C. 241(d).

Privacy Protections for Research Information Too Stringent

Comment: Many of the commenters who opposed the proposed definition of research information unrelated to treatment and its related provisions believed that the proposed rule would have required authorization before research information unrelated to treatment could have been used or disclosed for any of the public policy purposes outlined in proposed § 164.510, and that this restriction would have significantly hindered many important activities. Many of these commenters specifically opposed this provision, arguing that the distinction would undermine and impede research by requiring patient authorization before research information unrelated to treatment could be used or disclosed for research.

Furthermore, some commenters recommended that the disclosure of research information should be governed by an informed consent agreement already in place as part of a clinical protocol, or its disclosure should be considered by an institutional review board or privacy board.

Response: Our decision to eliminate the definition of research information unrelated to treatment and its related provisions in the final rule renders the first two comments moot.

We disagree with the comment that suggests that existing provisions under the Common Rule are sufficient to protect the privacy interests of individuals who are subjects in research that involves the delivery of treatment. As discussed in the NPRM, not all research is subject to the Common Rule. In addition, we are not convinced that existing procedures adequately inform individuals about how their information will be used as part of the informed consent process. In the final rule, we provide for additional disclosure to subjects of research that involves the delivery of treatment as part of the research authorization under § 164.508(f). We also clarify that the research authorization could be combined with the consent to participate in research, such as the informed consent document as stipulated under the Common Rule or the Food and Drug Administration’s human subjects regulations. The Common Rule (§ .116(a)(5)) requires that “informed consent” include “a statement describing the extent, if any, to which confidentiality of records identifying an individual will be maintained.” We believe that the research authorization requirements of § 164.508(f) complement the Common Rule’s requirement for informed consent.

The Secretary’s Authority

Comment: Several commenters, many from the research community, asserted that the coverage of “research information unrelated to treatment” was beyond the Department’s legal authority since HIPAA did not give the Secretary authority to regulate researchers. These commenters argued that the research records held by researchers who are performing clinical trials and who keep separate research records should not be subject to the final rule. These commenters strongly disagreed that a health provider-researcher cannot carry out two distinct functions while performing research and providing clinical care to research subjects and, thus, asserted that research information unrelated to treatment that is kept separate from the medical record, would not be covered by the privacy rule.

Response: We do not agree the Secretary lacks the authority to adopt standards relating to research information, including research information unrelated to treatment. HIPAA provides authority for the Secretary to set standards for the use and disclosure of individually identifiable health information created or received by covered entities. For the reasons commenters identified for why it was not practical or feasible to divide research information into two categories—research information related to treatment and research information unrelated to treatment—we also determined that for a single research study that includes the treatment of research subjects, it is not practical or feasible to divide a researcher into two categories—a researcher who provides treatment and a researcher who does not provide treatment to research subjects. When a researcher is interacting with research subjects for a research study that involves the delivery of health care to subjects, it is not always clear to either the researcher or the research subject whether a particular research activity will generate research information that will be pertinent to the health care of the research subject. Therefore, we clarify that a researcher may also be a health care provider if that researcher provides health care, e.g., provides treatment to subjects in a research study, and otherwise meets the definition of a health care provider, regardless of whether there is a component of the research study that is unrelated to the health care of the research subjects. This researcher/health care provider is then a covered entity with regard to her provider activities if she conducts standard transactions.

Valid Authorizations

Comment: In proposed § 164.508(b)(1), we specified that an authorization containing the applicable required elements “must be accepted by the covered entity.” A few comment requested clarification of this requirement.
Response: We agree with the commenters that the proposed provision was ambiguous and we remove it from the final rule. We note that nothing in the rule requires covered entities to act on authorizations that they receive, even if those authorizations are valid. A covered entity presented with an authorization is permitted to make the disclosure authorized, but is not required to do so.

We want to be clear, however, that covered entities will be in compliance with this rule if they use or disclose protected health information pursuant to an authorization that meets the requirements of § 164.508. We have made changes in § 164.508(b)(1) to clarify this point. First, we specify that an authorization containing the applicable required elements is a valid authorization. A covered entity may not reject as invalid an authorization containing such elements. Second, we clarify that a valid authorization may contain elements or information in addition to the required elements, as long as the additional elements are not inconsistent with the required elements.

Comment: A few comments requested that we provide a model authorization or examples of wording the “plain language” requirement. One commenter requested changes to the language in the model authorization to avoid confusion when used in conjunction with an insurer’s authorization form for application for life or disability income insurance. Many other comments, however, found fault with the proposed model authorization form.

Response: Because of the myriad of types of forms that could meet these requirements and the desire to encourage covered entities to develop forms that meet their specific needs, we do not include a model authorization form in the final rule. We intend to issue additional guidance about authorization forms prior to the compliance date. We also encourage standard-setting organizations to develop model forms meeting the requirements of this rule.

Defective Authorizations

Comment: Some commenters suggested we insert a “good-faith reliance” or “substantial compliance” standard into the authorization requirements. Commenters suggested that covered entities should be permitted to rely on an authorization as long as the individual has signed and dated the document. They stated that individuals may not fill out portions of a form that they feel are irrelevant or for which they do not have an answer. They argued that requiring covered entities to follow up with each individual to complete the form will cause unwarranted delays. In addition, commenters were concerned that large covered entities might act in good faith on a completed authorization, only to find out that a component of the entity “knew” some of the information on the form to be false or that the authorization had been revoked. These commenters did not feel that covered entities should be held in violation of the rule in such situations.

Response: We retain the provision as proposed and include one additional element: the authorization is invalid if it is combined with other documents in violation of the standards for compound authorizations. We also clarify that an authorization is invalid if material information on the form is known to be false. The elements we require to be included in the authorization are intended to ensure that individuals knowingly and willingly authorize the use or disclosure of protected health information about them. If these elements are missing or incomplete, the covered entity cannot know which protected health information to use or disclose to whom and cannot be confident that the individual intends for the use or disclosure to occur.

We have attempted to make the standards for defective authorizations as unambiguous as possible. In most cases, the covered entity will know whether the authorization is defective by looking at the form itself. Otherwise, the covered entity must know that the authorization has been revoked, that material information on the form is false, or that the expiration date or event has occurred. If the covered entity does not know these things and the authorization is otherwise satisfactory on its face, the covered entity is permitted to make the use or disclosure in compliance with this rule.

We have added two provisions to make it easier for covered entities to “know” when an authorization has been revoked. First, under § 164.508(b)(5), the revocation must be made in writing. Second, under § 164.508(c)(3)(v), authorizations must include instructions for how the individual may revoke the authorization. Written revocations submitted in the manner appropriate for the covered entity should ease covered entities’ compliance burden.

Compound Authorizations

Comment: Many commenters raised concerns about the specificity of the authorization requirement. Some commenters recommended that we permit covered entities to include multiple uses and disclosures in a single authorization and allow individuals to authorize or not authorize specific uses and disclosures in the authorization. Other commenters asked whether a single authorization is sufficient for multiple uses or disclosures for the same purpose, for multiple uses and disclosures for related purposes, and for uses and disclosures of different types of information for the same purpose.

Some comments from health care providers noted that specific authorizations would aid their compliance with requests.

Response: As a general rule, we prohibit covered entities from combining an authorization for the use or disclosure of protected health information with any other document. For example, an authorization may not be combined with a consent to receive treatment or a consent to assign payment of benefits to a provider. We intend the authorizations required under this rule to be voluntary for individuals, and, therefore, they need to be separate from other forms of consent that may be a condition of treatment or payment or that may otherwise be coerced.

We do, however, permit covered entities to combine authorizations for uses and disclosures for multiple purposes into a single authorization. The only limitations are that an authorization for the use or disclosure of psychotherapy notes may not be combined with an authorization for the use or disclosure of other types of protected health information and that an authorization that is a condition of treatment, payment, enrollment, or eligibility may not be combined with any other authorization.

In § 164.508(b)(3), we also permit covered entities to combine an authorization for the use or disclosure of protected health information created for purposes of research including treatment of individuals with certain other documents.

We note that covered entities may only make uses or disclosures pursuant to an authorization that are consistent with the terms of the authorization. Therefore, if an individual agrees to one of the disclosures described in the compound authorization but not another, the covered entity must comply with the individual’s decision. For example, if a covered entity asks an individual to sign an authorization to disclose protected health information for both marketing and fundraising purposes, but the individual only agrees to the fundraising disclosure, the...
covered entity is not permitted to make the marketing disclosure.

Prohibition on Conditioning Treatment, Payment, Eligibility, or Enrollment

Comment: Many commenters supported the NPRM’s prohibition of covered entities from conditioning treatment or payment on the individual’s authorization of uses and disclosures. Some commenters requested clarification that employment can be conditioned on an authorization. Some commenters recommended that we eliminate the requirement for covered entities to state on the authorization form that the authorization is not a condition of treatment or payment. Some commenters suggested that we prohibit the provision of anything of value, including employment, from being conditioned on receipt of an authorization.

We proposed to prohibit covered entities from conditioning treatment, payment, or enrollment in a health plan on an authorization for the use or disclosure of psychotherapy notes (see proposed § 164.506(a)(3)(iii)). We proposed to prohibit covered entities from conditioning treatment or payment on authorization for the use or disclosure of any other protected health information (see proposed § 164.508(a)(2)(iii)).

We resolve this inconsistency by clarifying in § 164.508(b)(4) that, with certain exceptions, a covered entity may not condition the provision of treatment, payment, enrollment in a health plan, or eligibility for benefits on an authorization for the use or disclosure of psychotherapy notes, including psychotherapy notes. We intend to minimize the potential for covered entities to coerce individuals into signing authorizations for the use or disclosure of protected health information when such information is not essential to carrying out the relationship between the individual and the covered entity.

Pursuant to that goal, we have created limited exceptions to the prohibition. First, a covered health care provider may condition research-related treatment of an individual or obtaining the individual’s authorization to use or disclose protected health information created for the research. Second, except with respect to psychotherapy notes, a health plan may condition the individual’s enrollment or eligibility in the health plan on obtaining an authorization for the use or disclosure of protected health information for making enrollment or eligibility determinations relating to the individual or for its underwriting or risk rating determinations. Third, a health plan may condition payment of a claim for specified benefits on obtaining an authorization under § 164.508(e) for disclosure to the plan of protected health information necessary to determine payment of the claim. Fourth, a covered entity may condition the provision of health care that is solely for the purpose of creating protected health information for disclosure to a third party (such as fitness-for-duty exams and physicals necessary to obtain life insurance coverage) on obtaining an authorization for the disclosure of the protected health information. We recognize that covered entities need protected health information in order to carry out these functions and provide services to the individual; therefore, we allow authorization for the disclosure of the protected health information to be a condition of obtaining the services.

We believe that we have prohibited covered entities from conditioning the services they provide to individuals on obtaining an authorization for uses and disclosures that are not essential to those services. Due to our limited authority, however, we cannot entirely prevent individuals from being coerced into signing these forms. We do not, for example, have the authority to prohibit an employer from requiring its employees to sign an authorization as a condition of employment. Similarly, a program such as the Job Corps may make such an authorization a condition of enrollment in the Job Corps program. While the Job Corps may include a health care component, the non-covered component of the Job Corps may require that as a condition of enrollment that the individual authorize the health care component to disclose protected health information to a non-covered component. See § 164.504(b). However, we note that other nondiscrimination laws may limit the ability to condition these authorizations as well.

Comment: A Medicaid fraud control association stated that many states require or permit state Medicaid agencies to obtain an authorization for the use and disclosure of protected health information for payment purposes as a condition of enrolling an individual as a Medicaid recipient. The commenter, therefore, urged an exception to the prohibition on conditioning enrollment on obtaining an authorization.

Response: As explained above, under § 164.506(a)(4), health plans and other covered entities may seek the individual’s consent for the covered entity’s use and disclosure of protected health information to carry out treatment, payment, or health care operations. If the consent is sought in conjunction with enrollment, the health plan may condition enrollment in the plan on obtaining the individual’s consent.

Under § 164.506(a)(5), we specify that a consent obtained by one covered entity is not effective to permit another covered entity to use or disclose protected health information for payment purposes. If state law requires a Medicaid agency to obtain the individual’s authorization for providers to disclose protected health information to the Medicaid agency for payment purposes, the agency may do so under § 164.508(e). This authorization must not be a condition of enrollment or eligibility, but may be a condition of payment of a claim for specified benefits if the disclosure is necessary to determine payment of the claim.

Revocation of Authorizations

Comment: Many commenters supported the right to revoke an authorization. Some comments, however, suggested that we require authorizations to remain valid for a minimum period of time, such as one year or the duration of the individual’s enrollment in a health plan.

Response: We retain the right for individuals to revoke an authorization at any time, with certain exceptions. We believe this right is essential to ensuring that the authorization is voluntary. If an individual determines that an authorized use or disclosure is no longer in her best interest, she should be able to withdraw the authorization and prevent any further uses or disclosures.

Comment: Several commenters suggested that we not permit individuals to revoke an authorization if the revocation would prevent an investigation of material misrepresentation or fraud. Other commenters similarly suggested that we permit additional exceptions to the right to revoke an authorization. Individuals do not have the right to revoke an authorization obtained as a condition of insurance coverage during any contestability...
period under other law. For example, if a life insurer obtains the individual’s authorization for the use or disclosure of protected health information to determine eligibility or premiums under the policy, the individual does not have the right to revoke the authorization during any period of time in which the life insurer can contest a claim for benefits under the policy in accordance with state law. If an individual were able to revoke the authorization after enrollment but prior to making a claim, the insurer would be forced to pay claims without having the necessary information to determine whether the benefit is due. We believe the existing exception for covered entities that have acted in reliance on the authorization is insufficient to address this concern because it is another person, not the covered entity, that has acted in reliance on the authorization. In the life insurance example, it is the life insurer that has taken action (i.e., issued the policy) in reliance on the authorization. The life insurer is not a covered entity, therefore the covered entity exception is inapplicable.

**Comment:** Some comments suggested that a covered entity that had compiled, but not yet disclosed, protected health information would have already taken action in reliance on the authorization and could therefore disclose the information even if the individual revoked the authorization.

**Response:** We intend for covered entities to refrain from further using or disclosing protected health information to the maximum extent possible once an authorization is revoked. The exception exists only to the extent the covered entity has taken action in reliance on the authorization. If the covered entity has not yet used or disclosed the protected health information, it must refrain from doing so, pursuant to the revocation. If, however, the covered entity has already disclosed the information, it is not required to retrieve the information.

**Comment:** One comment suggested that the rule allow protected health information to be only rented, not sold, because there can be no right to revoke authorization for disclosure of protected health information that has been sold.

**Response:** We believe this limitation would be an unwarranted abrogation of covered entities’ business practices and outside the scope of our authority. We believe individuals should have the right to authorize any uses or disclosures they feel are appropriate. We have attempted to create authorizations that make the individual’s decisions as clear and voluntary as possible.  

**Comment:** One commenter expressed concern as to whether the proposed rule’s standard to protect the protected health information about a deceased individual for two years would interfere with the payment of death benefit claims. The commenter asked that the regulation permit the beneficiary or payee under a life insurance policy to authorize disclosure of protected health information pertaining to the cause of death of a decedent or policyholder. Specifically, the commenter explained that when substantiating a claim a beneficiary, such as a fiancee or friend, may be unable to obtain the authorization required to release information to the insurer, particularly if, for example, the decedent’s estate does not require probate or if the beneficiary is not on good terms with the decedent’s next of kin. Further, the commenter stated that particularly in cases where the policyholder dies within two years of the policy’s issuance (within the policy’s contestable period) and the cause of death is uncertain, the insurer’s inability to access relevant protected health information would significantly interfere with claim payments and increase administrative costs.

**Response:** We do not believe this will be a problem under the final regulation, because we create an exception to the right to revoke an authorization if the authorization was obtained as a condition of obtaining insurance coverage and other applicable law provides the insurer that obtained the authorization with the right to contest a claim under the policy. Thus, if a policyholder dies within the two year contestability period, the authorization the insurer obtained from the policyholder prior to death could not be revoked during the contestability period.

**Core Elements and Requirements**

**Comment:** Many commenters raised concerns about the required elements for a valid authorization. They argued that the requirements were overly burdensome and that covered entities should have greater flexibility to craft authorizations that meet their business needs. Other commenters supported the required elements as proposed because the elements help to ensure that individuals make meaningful, informed choices about the use and disclosure of protected health information about them.

**Response:** As in the proposed rule, we define specific elements that must be included in any authorization. We draw on established laws and guidelines for these requirements. For example, the

---


Comment: Some commenters urged us to permit authorizations that designate a class of entities, rather than specifically named entities, that are authorized to use or disclose protected health information. Commenters made similar recommendations with respect to the authorized recipients. Commenters suggested these changes to prevent covered entities from having to seek, and individuals from having to sign, multiple authorizations for the same purpose.

Response: We agree. Under § 164.508(c)(1), we require authorizations to identify both the person or persons authorized to use or disclose the protected health information and the person(s) authorized to receive protected health information. In both cases, we permit the authorization to identify either a specific person or a class of persons.

Comment: Many commenters requested clarification that covered entities may rely on electronic authorizations, including electronic signatures.

Response: All authorizations must be in writing and signed. We intend e-mail and electronic documents to qualify as written documents. Electronic signatures are sufficient, provided they meet standards to be adopted under HIPAA. In addition, we do not intend to interfere with the application of the Electronic Signature in Global and National Commerce Act.

Comment: Some commenters requested that we permit covered entities to use and disclose protected health information pursuant to verbal authorizations.

Response: To ensure compliance and mutual understanding between covered entities and individuals, we require all authorizations to be in writing.

Comment: Some commenters asked whether covered entities can rely on copies of authorizations rather than the original. Other comments asked whether covered entities can rely on the assurances of a third party, such as a government entity, that a valid authorization has been obtained to use or disclose protected health information. These commenters suggested that such procedures would promote the timely provision of benefits for programs that require the collection of protected health information from multiple sources, such as determinations of eligibility for disability benefits.

Response: Covered entities must obtain the individual’s authorization to use or disclose protected health information for any purpose not otherwise permitted or required under this rule. They may obtain this authorization directly from the individual or from a third party, such as a government agency, on the individual’s behalf. In accordance with the requirements of § 164.530(j), the covered entity must retain a written record of authorization forms signed by the individual. Covered entities must, therefore, obtain the authorization in writing. They may not rely on assurances from others that a proper authorization exists. They may, however, rely on copies of authorizations if doing so is consistent with other law.

Comment: We requested comments on reasonable steps that a covered entity could take to be assured that the individual who requests the disclosure is whom she or he purports to be. Some commenters stated that it would be extremely difficult to verify the identity of the person signing the authorization, particularly when the authorization is not obtained in person. Other comments recommended requiring authorizations to be notarized.

Response: To reduce burden on covered entities, we are not requiring verification of identities of individuals signing authorization forms or notarization of the forms.

Comment: A few commenters asked for clarification regarding the circumstances in which a covered entity may consider a non-response as an authorization.

Response: Non-responses to requests for authorizations cannot be considered authorizations. Authorizations must be signed and have the other elements of a valid authorization described above.

Comment: Most commenters generally supported the requirement for an expiration date on the authorization. Commenters recommended expiration dates from 6 months to 3 years and/or proposed that the expiration be tied to an event such as duration of enrollment or when an individual changes health plans. Others requested no expiration requirement for some or all authorizations.

Response: We have clarified that an authorization may include an expiration date in the form of a specific date, a specific time period, or an event directly related to the individual or the purpose of the authorization. For example, a valid authorization could expire upon the individual’s disenrollment from a health plan or upon termination of a research project. We prohibit an authorization from having an indeterminate expiration date.

These changes were intended to address situations in which a specific date for the termination of the purpose for the authorization is difficult to determine. An example may be a research study where it may be difficult to predetermine the length of the project.

Comment: A few commenters requested that the named insured be permitted to sign an authorization on behalf of dependents.

Response: We disagree with the commenter that a named insured should always be able to authorize uses and disclosures for other individuals in the family. Many dependents under group health plans have their own rights under this rule, and we do not assume that one member of a family has the authority to authorize uses or disclosures of the protected health information of other family members.

A named insured may sign a valid authorization for an individual if the named insured is a personal representative for the individual in accordance with § 164.502(g). The determination of whether an individual is a personal representative under this rule is based on other applicable law that determines when a person can act on behalf of an individual in making decisions related to health care. This rule limits a person’s rights and authorities as a personal representative to only the protected health information relevant to the matter for which he or she is a personal representative under other law. For example, a parent may be a personal representative of a child for most health care treatment and payment decisions under state law. In that case, a parent, who is a named insured for her minor child, would be able to provide authorization with respect to most protected health information about her dependent child. However, a wife who is the named insured for her husband who is a dependent under a health insurance policy may not be a personal representative for her husband under other law or may be a personal representative only for limited purposes, such as for making decisions regarding payment of disputed claims. In this case, she may have limited authority to access protected health information related to the payment of disputed claims, but would not have the authority to authorize that her husband’s information be used for
marketing purposes, absent any other authority to act for her husband. See § 164.502(g) for more information regarding personal representatives.

Comment: One commenter suggested that authorizations should be dated on the day they are signed.

Response: We agree and have retained this requirement in the final rule.

Additional Elements and Requirements for Authorizations Requested by the Covered Entity for Its Own Uses and Disclosures

Comment: Some commenters suggested that we should not require different elements in authorizations initiated by the covered entity versus authorizations initiated by the individual. The commenters argued the standards were unnecessary, confusing, and burdensome.

Response: The proposed authorization requirements are intended to ensure that an individual’s authorization is truly voluntary. The additional elements required for authorizations initiated by the covered entity for its own uses and disclosures or for receipt of protected health information from other covered entities to carry out treatment, payment, or health care operations address concerns that are unique to these forms of authorization. (See above regarding requirements for research authorizations under §164.508(f).)

First, when applicable, these authorizations must state that the covered entity will not condition treatment, payment, eligibility, or enrollment on the individual’s providing authorization for the requested use or disclosure. This statement is not appropriate for authorizations initiated by the individual or another person who does not have the ability to withhold services if the individual does not authorize the use or disclosure.

Second, the authorization must state that the individual may refuse to sign the authorization. This statement is intended to signal to the individual that the authorization is voluntary and may not be accurate if the authorization is obtained by a person other than a covered entity.

Third, these authorizations must describe the purpose of the use or disclosure. We do not include this element in the core requirements because we understand there may be times when the individual does not want the covered entity maintaining the protected health information to know the purpose for the use or disclosure. For example, an individual contemplating litigation may not want the covered entity to know that litigation is the purpose of the disclosure. If the covered entity is initiating the authorization for its own use or disclosure, however, the individual and the covered entity maintaining the protected health information should have a mutual understanding of the purpose of the use or disclosure. Similarly, when a covered entity is requesting authorization for a disclosure by another covered entity that may have already obtained the individual’s consent for the disclosure, the individual and covered entity that maintains the protected health information should be aware of this potential conflict.

There are two additional requirements for authorizations requested by a covered entity for its own use or disclosure of protected health information it maintains. First, we require the covered entity to describe the individual’s right to inspect or copy the protected health information to be used or disclosed. Individuals may want to review the information to be used or disclosed before signing the authorization and should be reminded of their ability to do so. This requirement is not appropriate for authorizations for a covered entity to receive protected health information from another covered entity, however, because the covered entity requesting the authorization is not the covered entity that maintains the protected health information and cannot therefore, grant or describe the individual’s right to access the information.

If applicable, we also require a covered entity that requests an authorization for its own use or disclosure of the protected health information will result in direct or indirect remuneration to the entity. Individuals should be aware of any conflicts of interest or financial incentives on the part of the covered entity requesting the use or disclosure. These statements are not appropriate, however, in relation to uses and disclosures to carry out treatment, payment, and health care operations. Uses and disclosures for these purposes will often involve remuneration by the nature of the use or disclosure, not due to any conflict of interest on the part of either covered entity.

We note that authorizations requested by a covered entity include authorizations requested by the covered entity’s business associate on the covered entity’s behalf. Authorizations requested by a business associate on the covered entity’s behalf and that authorize the use or disclosure of protected health information by the covered entity or the business associate must meet the requirements in §164.508(d). Similarly, authorizations requested by a business associate on behalf of a covered entity to accomplish the disclosure of protected health information to that business associate or covered entity as described in §164.508(e) must meet the requirements of that provision.

We disagree that these elements are unnecessary, confusing, or burdensome. We require them to ensure that the individual has a complete understanding of what he or she is agreeing to permit.

Comment: Many commenters suggested we include in the regulation text a provision stated in the preamble that entities and their business partners must limit their uses and disclosures to the purpose(s) specified by the individual in the authorization.

Response: We agree. In accordance with §164.508(a)(3), covered entities may only use or disclose protected health information consistent with the authorization. In accordance with §164.504(e)(2), a business associate may not make any uses or disclosures that the covered entity couldn’t make.

Comment: Some comments suggested that authorizations should identify the source and amount of financial gain, if any, resulting from the proposed disclosure. Others suggested that the proposed financial gain requirements were too burdensome and would decrease trust between patients and providers. Commenters recommended that the requirement either should be eliminated or should only require covered entities, when applicable, to state that direct and foreseeable financial gain to the covered entity will result. Others requested clarification of how the requirement for covered entities to disclose financial gain relates to the criminal penalties that accrue for offenses committed with intent to sell, transfer, or use individually identifiable health information for commercial advantage, personal gain, or malicious harm. Some commenters advocated use of the term “financial compensation” rather than “financial gain” to avoid confusion with in-kind compensation rules. Some comments additionally suggested excluding marketing uses and disclosures from the requirements regarding financial gain.

Response: We agree that clarification is warranted. In §164.508(d)(1)(iv) of the final rule, we require a covered entity that asks an individual to sign an authorization for the covered entity’s use or disclosure of protected health information to state that the individual may refuse to sign the authorization if the use or disclosure will result in financial gain to the covered entity or the business associate. This requirement is not appropriate for authorizations for the covered entity to accomplish the disclosure of protected health information to a business associate or covered entity as described in §164.508(e).
or indirect remuneration from a third party for the use or disclosure, to state that fact in the authorization. Remuneration from a third party includes payments such as a fixed price per disclosure, compensation for the costs of compiling and sending the information to be disclosed, and, with respect to marketing communications, a percentage of any sales generated by the marketing communication. For example, a device manufacturer may offer to pay a fixed price per name and address of individuals with a particular diagnosis, so that the device manufacturer can market its new device to people with the diagnosis. The device manufacturer may also offer the covered entity a percentage of the profits from any sales generated by the marketing materials sent. If a covered entity seeks an authorization to make such a disclosure, the authorization must state that the remuneration will occur. We believe individuals should have the opportunity to weigh the covered entity’s potential conflict of interest when deciding to authorize the covered entity’s use or disclosure of protected health information. We believe that the term “remuneration from a third party” clarifies our intent to describe a direct, tangible exchange, rather than the mere fact that parties intend to profit from their enterprises.

Comment: One commenter suggested we require covered entities to request authorizations in a manner that does not in itself disclose sensitive information.

Response: We agree that covered entities should make reasonable efforts to avoid unintentional disclosures. In § 164.530(c)(2), we require covered entities to have in place appropriate administrative, technical, and physical safeguards to protect the privacy of protected health information.

Comment: Some commenters requested clarification that covered entities are permitted to seek authorization at the time of enrollment or when individuals otherwise first interact with covered entities. Similarly, commenters requested clarification that covered entities may disclose protected health information created after the date the authorization was signed but prior to the expiration date of the authorization. These commenters were concerned that otherwise multiple authorizations would be required to accomplish a single purpose. Other comments suggested that we prohibit prospective authorizations (i.e., authorizations requested prior to the creation of protected health information to be disclosed under the authorization) because it is not possible for individuals to make informed decisions about these authorizations.

Response: We confirm that covered entities may act on authorizations signed in advance of the creation of the protected health information to be released. We note, however, that all of the required elements must be completed, including a description of the protected health information to be used or disclosed pursuant to the authorization. This description must identify the information in a specific and meaningful fashion so that the individual can make an informed decision as to whether to sign the authorization.

Comment: Some commenters suggested that the final rule prohibit financial incentives, such as premium discounts, designed to encourage individuals to sign authorizations.

Response: We do not prohibit or require financial incentives for authorizations. We have attempted to ensure that authorizations are entered into voluntary. If a covered entity chooses to offer a financial incentive for the individual to sign the authorization, and the individual chooses to accept it, they are free to do so.

Section 164.510—Uses and Disclosures Requiring an Opportunity for the Individual to Agree or to Object

Section 164.510(a)—Use and Disclosure for Facility Directories

Comment: Many hospital organizations opposed the NPRM’s proposed opt-in approach to disclosure of directory information. These groups noted the preamble’s statement that most patients welcomed the convenience of having their name, location, and general condition included in the patient directory. They said that requiring hospitals to obtain authorization before including patient information in the directory would cause harm to many patients’ needs in an effort to serve the needs of the small number of patients who may not want their information to be included. Specifically, they argued that the proposed approach ultimately could have the effect of making it difficult or impossible for clergy, family members, and florists to locate patients for legitimate purposes. In making this argument, commenters pointed to problems that occurred after enactment of privacy legislation in the State of Maine in 1999. The legislation, which never was officially implemented, was interpreted by hospitals to prohibit disclosure of patient information to directories without written consent. As a result, when hospitals began complying with the law based on their interpretation, family members and clergy had difficulty locating patients in the hospital.

Response: We share commenters’ concern about the need to ensure that family members and clergy who have a legitimate need to locate patients are not prevented from doing so by excessively stringent restrictions on disclosure of protected health information to health care facilities’ directories. Accordingly, the final rule takes an opt-out approach, stating that health care institutions may include the name, general condition, religious affiliation, and location of a patient within the facility in the facility’s directory unless the patient explicitly objects to the use or disclosure of protected health information for directory purposes. To ensure that this opt-out can be exercised, the final rule requires facilities to notify individuals of their right not to be included in the directory and to give them the opportunity to opt out. The final rule indicates that the notice and opt-out must be oral. The final rule that allows health care facilities to disclose to clergy the four types of protected health information specified above without requiring the clergy to ask for the individual by name will allow the clergy to identify the members of his or her faith who are in the facility, thus ensuring that this rule will not significantly interfere with the exercise of religion, including the clergy’s traditional religious mission to provide services to individuals.

Comment: A small number of commenters recommended requiring written authorization for all disclosures of protected health information for directory purposes. These commenters believed that the NPRM’s proposed provision allowing oral agreement would not provide sufficient privacy protection; that it did not sufficiently hold providers accountable for complying with patient wishes; and that it could create liability issues for providers.

Response: The final rule does not require written authorization for disclosure of protected health information for directory purposes. We believe that requiring written authorization in these cases would increase substantially the administrative burdens and costs for covered health care providers and could lead to significant inconvenience for families and others attempting to locate individuals in health care institutions. Experience from the State of Maine suggests that requiring written authorization before patient information may be included in facility directories...
can be disruptive for providers, families, clergy, and others.

Comment: Domestic violence organizations raised concerns that including information about domestic violence victims in health care facilities’ directories could result in further harm to victims. The NPRM addressed the issue of potential danger to patients by stating that when patients were incapacitated, covered health care providers could exercise discretion—consistent with good medical practice and prior expression of patient preference—regarding whether to disclose protected health information for directory purposes. Several commenters recommended prohibiting providers from including information in a health care facility’s directory about incapacitated individuals when the provider reasonably believed that the injuries to the individual could have been caused by domestic violence. These groups believed that such a prohibition was necessary to prevent abusers from locating and causing further harm to domestic violence patients.

Response: We share commenters’ concerns about protecting victims of domestic violence from further abuse. We are also concerned, however, that imposing an affirmative duty on institutions not to disclose information any time injuries to the individual could have been the result of domestic violence would place too high a burden on health care facilities, essentially requiring them to rule out domestic violence as a causal factor of the injuries before disclosing to family members that an incapacitated person is in the institution.

We do believe, however, that it is appropriate to require covered health care providers to consider whether including the individual’s name and location in the directory could lead to serious harm. As in the preamble to the NPRM, in the preamble to the final rule, we encourage covered health care providers to consider several factors when deciding whether to include an incapacitated patient’s information in a health care facility’s directory. One of these factors is whether disclosing an individual’s presence in the facility could reasonably cause harm or danger to the individual (for example, if it appeared that an unconscious patient had been abused and disclosing that the individual is in the facility could give the attacker sufficient information to seek out the person and repeat the abuse). Under the final rule, when the opportunity to uses and disclosures for a facility’s directory cannot practicably be provided due to an individual’s incapacity or an emergency treatment circumstance, covered health care providers may use or disclose some or all of the protected health information that the rule allows to be included in the directory, if the disclosure is: (1) consistent with the individual’s prior expressed preference, if known to the covered health care provider; and (2) in the individual’s best interest, as determined by the covered health care provider in the exercise of professional judgement. The rule allows covered health care providers making decisions about incapacitated patients to include some portions of the patient’s information (such as name) but not other information (such as location in the facility) to protect patient interests.

Section 164.510(b)—Uses and Disclosures for Involvement in the Individual’s Care and Notification Purposes

Comment: A number of comments supported the NPRM’s proposed approach, which would have allowed covered entities to disclose protected health information to the individual’s next of kin, family members, or other close personal friends when the individual verbally agreed to the disclosure. These commenters agreed that the presumption should favor disclosures to the next of kin, and they believed that health care providers should encourage individuals to share genetic information and information about transmissible diseases with family members at risk. Others agreed with the general approach but suggested the individual’s agreement be noted in the medical record. These commenters also supported the NPRM’s proposed reliance on good professional practices and ethics to determine when disclosures should be made to the next of kin when the individual’s agreement could not practicably be obtained.

A few commenters recommended that the individual’s agreement be in writing for the protection of the covered entity and to facilitate the monitoring of compliance with the individual’s wishes. These commenters were concerned that, absent the individual’s written agreement, the covered entity would become embroiled in intra-family disputes concerning the disclosures. Others argued that the individual’s authorization should be obtained for all disclosures, even to the next of kin.

One commenter favored disclosures to family members and others unless the individual actively objected, as long as the disclosure was consistent with sound medical uses and purposes. Others believed that no agreement by the individual was necessary unless sensitive medical information would be disclosed or unless the health care provider was aware of the individual’s prior objection. These commenters recommended that good professional practice and ethics determine when disclosures were appropriate and that disclosure should relate only to the individual’s current treatment. A health care provider organization said that the ethical and legal obligations of the medical professional alone should control in this area, although it believed the proposed rule was generally consistent with these obligations.

Response: The diversity of comments regarding the proposal on disclosures to family members, next of kin, and other persons, reflects a wide range of current practice and individual expectations. We believe that the NPRM struck the proper balance between the competing interests of individual privacy and the need that covered health care providers may have, in some cases, to have routine, informal conversations with an individual’s family and friends regarding the individual’s treatment.

We do not agree with the comments stating that all such disclosures should be made only with consent or with the individual’s written authorization. The rule does not prohibit obtaining the agreement of the individual in writing; however, we believe that imposing a requirement for consent or written authorization in all cases for disclosures to individuals involved in a person’s care would be unduly burdensome for all parties. In the final rule, we clarify the circumstances in which these disclosures are permissible. The rule allows covered entities to disclose to family members, other relatives, close personal friends of the individual, or any other person identified by the individual, the protected health information directly relevant to such person’s involvement with the individual’s care or payment related to the individual’s health care. In addition, the final rule allows covered entities to use or disclose protected health information to notify, or assist in the notification of (including identifying or locating) a family member, a personal representative of the individual, or another person responsible for the care of the individual, of the individual’s location, general condition, or death. The final rule includes separate provisions for situations in which the individual is present and for when the individual is not present at the time of disclosure. When the individual is present and can make his or her own decisions, a covered entity may disclose protected health information only if the covered entity: (1) Obtains the
individual’s agreement to disclose to the third parties involved in the individual’s care; (2) provides the individual with the opportunity to object to the disclosure, and the individual does not express an objection; or (3) reasonably infers from the circumstances, based on the exercise of professional judgement, that the individual does not object to the disclosure. The final rule continues to permit disclosures in circumstances when the individual is not present or when the opportunity to agree or object to the use or disclosure cannot practically be provided due to the individual’s incapacity or an emergency circumstance. In such instances, covered entities may, in the exercise of professional judgement, determine whether the disclosure is in the individual’s best interests and if so, disclose only the protected health information that is directly relevant to the person’s involvement with the individual’s health care.

As discussed in the preamble for this section, we do not intend to disrupt most covered entities’ current practices with respect to informing family members and others with whom a patient has a close personal relationship about a patient’s specific health condition when a patient is incapacitated due to a medical emergency and the family member or close personal friend comes to the covered entity to ask about the patient’s condition. To the extent that disclosures to family members and others in these situations currently are allowed under state law and covered entities’ own rules, § 164.510(b) allows covered entities to continue making them in these situations, consistent with the exercise of professional judgement as to the patient’s best interest. As indicated in the preamble above, this section is not intended to provide a loophole for avoiding the rule’s other requirements, and it is not intended to allow disclosures to a broad range of individuals, such as journalists who may be curious about a celebrity’s health status.

Comments: A few comments supported the NPRM approach because it permitted the current practice of allowing someone other than the patient to pick up prescriptions at pharmacies. One commenter noted that this practice occurs with respect to 25–40% of the prescriptions dispensed by community retail pharmacies. These commenters strongly supported the proposal’s reliance on the professional judgement of pharmacists in allowing others to pick up prescriptions for bedridden or otherwise incapacitated patients, noting that in most cases it would be impracticable to verify that the person was acting with the individual’s permission. Two commenters requested that the rule specifically allow this practice. One comment opposed the practice of giving prescriptions to another person without the individual’s authorization, because a prescription implicitly could disclose medical information about the individual.

Response: As stated in the NPRM, we intended for this provision to authorize pharmacies to dispense prescriptions to family or friends who are sent by the individual to the pharmacy to pick up the prescription. We believe that stringent consent or verification requirements would place an unreasonable burden on numerous transactions. In addition, such requirements would be contrary to the expectations and preferences of all parties to these transactions. Although prescriptions are protected health information under the rule, we believe that the risk to individual privacy in allowing this practice to continue is minimal. We agree with the suggestion that the final rule should state explicitly that pharmacies have the authority to operate in this manner. Therefore, we have added a sentence to § 164.510(b)(3) allowing covered entities to use professional judgement and experience with common practice to make reasonable inferences of an individual’s best interest in allowing a person to act on the individual’s behalf to pick up filled prescriptions, medical supplies, X-rays, or other similar forms of protected health information. In such situations, as when making disclosures of protected health information about an individual who is not present or is unable to agree to such disclosures, covered entities should disclose only information which directly relates to the person’s involvement in the individual’s current health care. Thus, when dispensing a prescription to a friend who is picking it up on the patient’s behalf, the pharmacist should not disclose unrelated health information about medical that the patient has taken in the past which could prove embarrassing to the patient.

Comment: We received a few comments that misunderstood the provision as addressing disclosures related to deceased individuals.

Response: We understand that use of the term next of kin in this section may cause confusion. To promote clarity in the final rule, we eliminate the term “next of kin,” as well as the term’s proposed inclusion in § 164.510. In the final rule, we address comments on next of kin and the deceased in the section on disclosure of protected health information about deceased individuals in § 164.512.

Comments: A number of commenters expressed concern for the interaction of the proposed section with state laws. Some of these comments interpreted the NPRM’s use of the term next of kin as referring to individuals with health care power of attorney and thus they believed that the proposed rule’s approach to next of kin was inappropriately informal and in conflict with state law. Others noted that some state laws did not allow health care information to be disclosed to family or friends without consent or other authorization. One commenter said that case law may be evolving toward imposing a more affirmative duty on health care practitioners to inform next of kin in a variety of circumstances. One commenter noted that state laws may not define clearly who is considered to be the next of kin.

Response: The intent of this provision was not to interfere with or change current practice regarding health care powers of attorney or the designation of other personal representatives. Such designations are formal, legal actions which give others the ability to exercise the rights of or make treatment decisions related to individuals. While persons with health care powers of attorney could have access to protected health information under the personal representatives provision (§ 164.502(g)), and covered entities may disclose to such persons under this provision, such disclosures do not grant individuals substantive authority to act for or on behalf of the individual with respect to health care decisions. State law requirements regarding health care powers of attorney continue to apply. The comments suggesting that state laws may not allow the disclosures otherwise permitted by this provision or, conversely, that they may impose a more affirmative duty, did not provide any specifics with which to judge the effect of such laws. In general, however, state laws that are more protective of an individual’s privacy interests than the rule by prohibiting a disclosure of protected health information continue to apply. The rule’s provisions regarding disclosure of protected health information to family or friends of the individual are permissive only, enabling covered entities to abide by more stringent state laws without violating our rules. Furthermore, if the state law creates an affirmative and binding legal obligation on the covered entity to make disclosures to family or friends under specific circumstances, the final rule allows covered entities to comply...
with these legal obligations. See § 164.512(a).

Comments: A number of commenters supported the proposal to limit disclosures to family or friends to the protected health information that is directly relevant to that person’s involvement in the individual’s health care. Some comments suggested that this standard apply to all disclosures to family or friends, even when the individual has agreed to or not objected to the disclosure. One commenter objected to the proposal, stating that it would be too difficult to administer. According to this comment, it is accepted practice for health care providers to communicate with family and friends about an individual’s condition, regardless of whether the person is responsible for or otherwise involved in the individual’s care.

Other comments expressed concern for disclosures related to particular types of information. For example, two commenters recommended that psychotherapy notes not be disclosed without patient authorization. One commenter suggested that certain sensitive medical information associated with social stigma not be disclosed to family members or others without patient consent.

Response: We agree with commenters who advocated limiting permissible disclosures to relatives and close personal friends to information consistent with a person’s involvement in the individual’s care. Under the final rule, we clarify the NPRM provision to state that covered entities may disclose protected health information to family members, relatives, or close personal friends of an individual or any other person identified by the individual, to the extent that the information directly relates to the person’s involvement in the individual’s current health care. It is not intended to allow disclosure of past medical history that is not relevant to the individual’s current condition. In addition, as discussed above, we do not intend to disrupt covered entities’ current practices with respect to disclosing specific information about a patient’s condition to family members or others when the individual is incapacitated due to a medical emergency and the family member or other individual comes to the covered entity seeking specific information about the patient’s condition. For example, this section allows a hospital to disclose to a family member the fact that a patient had a heart attack, and to provide updated information to the family member about the patient’s progress and prognosis during his or her period of incapacity.

We agree with the recommendation to require written authorization for a disclosure of psychotherapy notes to family, close personal friends, or others involved in the individual’s care. As discussed below, the final rule allows disclosure of psychotherapy notes without authorization in a few limited circumstances; disclosure to individuals involved in a person’s care is not among those circumstances. See § 164.508 for a further discussion of the final rule’s provisions regarding disclosure of psychotherapy notes.

We do not agree, however, with the suggestion to treat some medical information as more sensitive than others. In most cases, individuals will have the opportunity to prohibit or limit such disclosures. For situations in which an individual is unable to do so, covered entities may, in the exercise of professional judgement, determine whether the disclosure is in the individual’s best interests and, if so, disclose only the protected health information that is directly relevant to the person’s involvement with the individual’s health care.

Comment: One commenter suggested that this provision should allow disclosure of protected health information to the clergy and to the Red Cross. The commenter noted that clergy have ethical obligations to ensure confidentiality and that the Red Cross often notifies the next of kin regarding an individual’s condition in certain circumstances. Another commenter recommended allowing disclosures to law enforcement for the purpose of locating individuals injured or killed. One commenter sought clarification that “close personal friend” was intended to include domestic partners and same-sex couples in committed relationships.

Response: As discussed above, § 164.510(a) allows covered health care providers to disclose to clergy protected health information from a health care facility’s directory. Under § 164.510(b), an individual may identify any person, including clergy, as involved in his or her care. This approach provides more flexibility than the proposed rule would have provided.

As discussed in the preamble of the final rule, this provision allows disclosures to domestic partners and others in same-sex relationships when such individuals are involved in an individual’s care or are the point of contact for notification in a disaster. We do not intend to change current practices with respect to involvement of others in treatment decisions; informal information-sharing among persons involved; or the sharing

of protected health information during a disaster. As noted above, a power of attorney or other legal relationship to an individual is not necessary for these informal discussions about the individual for the purpose of assisting in or providing a service related to the individual’s care.

We agree with the comments noting that the Red Cross and other organizations may play an important role in locating and communicating with the family about individuals injured or killed in an accident or disaster situation. Therefore, the final rule includes new language, in § 164.510(b)(4), which allows covered entities to use or disclose protected health information to a public or private entity authorized by law or its charter to assist in disaster relief efforts, for the purpose of coordinating with such entities to notify, or assist in the notification of (including identifying or locating) a family member, an individual’s personal representative, or another person responsible for the individual’s care regarding the individual’s location, general condition, or death. The Red Cross is an example of a private entity that may obtain protected health information pursuant to these provisions. We recognize the role of the Red Cross and similar organizations in disaster relief efforts, and we encourage cooperation with these entities in notification efforts and other means of assistance.

Comment: One commenter recommended stating that individuals who are mentally retarded and unable to agree to disclosures under this provision do not, thereby, lose their access to further medical treatment. This commenter also proposed stating that mentally retarded individuals who are able to provide agreement have the right to control the disclosure of their protected health information. The commenter expressed concern that the parent, relative, or other person acting in loco parentis may not have the individual’s best interest in mind in seeking or authorizing for the individual the disclosure of protected health information.

Response: The final rule regulates only uses and disclosures of protected health information, not the delivery of health care. Under the final rule’s section on personal representatives (§ 164.502(g)), a person with authority to make decisions about the health care of an individual, under applicable law, may make decisions about the protected health information of that individual, to the extent that the protected health information is relevant to such person’s representation.
Section 164.512—Uses and Disclosures For Which Consent, Authorization, or Opportunity to Agree or Object Is Not Required

Section 164.512(a)—Uses and Disclosures Required by Law

Comment: Numerous commenters addressed directly or by implication the question of whether the provision permitting uses and disclosures of protected health information if required by other law was necessary. Other commenters generally endorsed the need for such a provision. One such commenter approved of the provision as a needed fail-safe mechanism should the enumeration of permissible uses and disclosures of protected health information in the NPRM prove to be incomplete. Other commenters cited specific statutes which required access to protected health information, arguing that such a provision was necessary to ensure that these legally mandated disclosures would continue to be permitted. For example, some commenters argued for continued access to protected health information to investigate and remedy abuse and neglect as currently required by the Developmental Disabilities Assistance and Bill of Rights, 42 U.S.C. 6042, and the Protection and Advocacy for Mentally Ill Individuals Act, 42 U.S.C. 10801.

Some comments urged deletion of the provision for uses and disclosures required by other law. This concern appeared to be based on a generalized concern that the provision fostered government intrusion into individual medical information. Finally, a number of commenters also urged that the required by law provision be deleted. These commenters argued that the proposed provision would have undermined the intent of the statute to preempt state laws which were less protective of individual privacy. As stated in these comments, the provision for uses and disclosures required by other law was “broadly written and could apply to a variety of state laws that are contrary to the proposed rule and less protective of privacy. (Indeed, a law requiring disclosure is the least protective of privacy since it allows for no discretion.) The breadth of this provision greatly exceeds the exceptions to preemption contained in HIPAA.”

Response: We agree with the comments that proposed § 164.510(n) was necessary to harmonize the rule with existing state and federal laws mandating uses and disclosures of protected health information. Therefore, in the final rule, the provision permitting uses and disclosures as required by other law is retained. To accommodate other reorganization of the final rule, this provision has been designated as § 164.512(a).

We do not agree with the comments expressing concern for increased governmental intrusion into individual privacy under this provision. The final rule does not create any new duty or obligation to disclose protected health information. Rather, it permits covered entities to use or disclose protected health information when they are required by law to do so.
We likewise disagree with the characterization of the proposed provision as inconsistent with or contrary to the preemption standards in the statute or Part 160 of the rule. As described in the NPRM, we intend this provision to preserve access to information considered important enough by state or federal authorities to require its disclosure by law.

The importance of these required uses or disclosures is evidenced by the legislative or other public process necessary for the government to create a legally binding obligation on a covered entity. Furthermore, such required uses and disclosures arise in a myriad of other areas of law, ranging from topics addressing national security (uses and disclosures to obtain security clearances), to public health (reporting of communicable diseases), to law enforcement (disclosures of gun shot wounds). Required uses and disclosures also may address broad national concerns or particular regional or state concerns. It is not possible, or appropriate, for HHS to reassess the legitimacy of or the need for each of these mandates in each of their specialized contexts. In some cases where particular concerns have been raised by legal mandates in other laws, we allow disclosure as required by law, and we establish additional requirements to protect privacy (for example, informing the individual as required in §164.512(c)) when covered entities make a legally mandated disclosure.

We also disagree with commenters who suggest that the approach in the final rule is contrary to the preemption provisions in HIPAA. HIPAA provides HHS with broad discretion in fashioning privacy protections. Recognizing the legitimacy of existing legal requirements is certainly within the Secretary’s discretion. Additionally, given the variety of these laws, the varied contexts in which they arise, and their significance in ensuring that important public policies are achieved, we do not believe that Congress intended to preempt each such law unless HHS specifically recognized the law or purpose in the regulation.

Comment: A number of commenters urged that the provision permitting uses and disclosures required by other law be amended by deleting the last sentence which stated: “This paragraph does not apply to uses or disclosures that are covered by paragraphs (b) through (m) of this section.” Some commenters sought deletion of this sentence to avoid any inadvertent preemption of mandatory reporting laws, and requested clarification of the effect on specific statutes.

The majority of the commenters focused their concerns on the potential conflict between mandatory reporting laws to law enforcement and the limitations imposed by proposed §164.510(f), on uses and disclosures to law enforcement. For example, the comments raised concerns that mandatory reporting to law enforcement of injuries resulting from violent acts and abuse require the health care provider to initiate such reports to local law enforcement or other state agencies, while the NPRM would have allowed such reporting on victims of crimes only in response to specific law enforcement requests for information. Similarly, mandatory reports of violence-related injuries may implicate suspected perpetrators, as well as victims, and compliance with such laws could be blocked by the proposed requirement that disclosures about suspects was similarly limited to a response to law enforcement inquiries for the specific purpose of identifying the suspect. The NPRM also would have limited the type of protected health information that could have been disclosed about a suspect or fugitive.

In general, commenters sought to resolve the overlap by removing the condition that the required-other-law provision applied only when no other national priority purpose addressed the particular use or disclosure. The suggested change would permit the covered entity to comply with legally mandated uses and disclosures as long as the relevant requirements of that law were met. Alternatively, other commenters suggested that the restrictions on disclosures to law enforcement be lifted to permit full compliance with laws requiring reporting for these purposes.

Finally, some comments sought clarification of when a use or disclosure was “covered by paragraphs (b) through (m).” These commenters were confused as to whether a particular use or disclosure had to be specifically addressed by another provision of the rule or simply within the scope of the one of the national priority purposes specified by proposed paragraphs (b) through (m).

Response: We agree with the commenters that the provision as proposed would have inadvertently interfered with many state and federal laws mandating the reporting to law enforcement or others of protected health information.

In response to these comments, we have modified the final rule to clarify how this section interacts with the other provisions in the rule.

Comment: A number of commenters sought expanded authority to use and disclosure protected health information when permitted by other law, not just when required by law. These comments specified a number of significant duties or potential societal benefits from disclosures currently permitted or authorized by law, and they expressed concern that these beneficial uses and disclosures no longer be allowed if not specifically recognized by the rule. For example, one commenter listed 25 disclosures of health records that are currently permitted, but not required, by state law. This commenter was concerned that many of these authorized uses and disclosures would not be covered by any of the national priority purposes specified in the NPRM, and, therefore, would not be a permissible use or disclosure under the rule.

To preserve these important uses and disclosures, the comments recommended that provision be made for any use or disclosure which is authorized or permitted by other law.

Response: We do not agree with the comments that seek general authority to use and disclose protected health information as permitted, but not required, by other law. The uses and disclosures permitted in the final rule reflect those purposes and circumstances which we believe are of sufficient national importance or relevance to the needs of the health care system to warrant the use or disclosure of protected health information in the absence of either the individual’s express authorization or a legal duty to make such use or disclosure. In permitting specific uses and disclosures that are not required by law, we have considered the individual privacy interests at stake in each area and crafted conditions or limitations in each identified area as appropriate to balance the competing public purposes and individual privacy needs. A general rule authorizing any use or disclosure that is permitted, but not required, by other law would undermine the careful balancing in the final rule.

In making this judgment, we have distinguished between laws that mandate uses or disclosures and laws that merely permit them. In the former case, jurisdictions have determined that public policy purposes cannot be achieved absent the use of certain protected health information, and we have chosen in general not to disturb their judgments. On the other hand, where jurisdictions have determined that certain protected health information is not necessary to achieve
a public policy purpose, and only have permitted its use or disclosure, we do not believe that those judgments reflect an interest in use or disclosure strong enough to override the Congressional goal of protecting privacy rights.

Moreover, the comments failed to present any compelling circumstance to warrant such a general provision. Despite commenters’ concerns to the contrary, most of the beneficial uses and disclosures that the commenters referenced to support a general provision were, in fact, uses or disclosures already permissible under the rule. For example, the general statutory authorities relied on by one state health agency to investigate disease outbreaks or to comply with health data-gathering guidelines for reporting to certain federal agencies are permissible disclosures to public health agencies.

Finally, in the final rule, we add new provisions to § 164.512 to address three examples raised by commenters of uses and disclosures that are authorized or permitted by law, but may not be required by law. First, commenters expressed concern for the states that provide for voluntary reporting to law enforcement or state protective services of domestic violence or of abuse, neglect or exploitation of the elderly or other vulnerable adults. As discussed below, a new section, § 164.512(c), has been added to the final rule to specifically address uses and disclosures of protected health information in cases of abuse, neglect, or domestic violence. Second, commenters were concerned about state or federal laws that permitted coordination and cooperation with organizations or entities involved in cadaveric organ, eye, or tissue donation and transplantation. In the final rule, we add a new section, § 164.512(h), to permit disclosures to facilitate such donation and transplantation functions. Third, a number of commenters expressed concern for uses and disclosure permitted by law in certain custodial settings, such as those involving correctional or detention facilities. In the final rule, we add a new subsection to the section on uses and disclosures for specialized government functions, § 164.512(k), to identify custodial settings in which special rules are necessary and to specify the additional uses and disclosures of the protected health information of inmates or detainees which are necessary in such facilities.

Comment: A number of commenters asked for clarification of the term “law” and the phrase “required by law” for purposes of the provision permitting uses or disclosures that are required by law. Some of the commenters noted that “state law” was a defined term in Part 160 of the NPRM and that the terms should be used consistently. Other commenters were concerned about differentiating between laws that required a use or disclosure and those that merely authorize or permit a use or disclosure. A number of commenters recommended that the final rule include a definitive list of the laws that mandate a use or disclosure of protected health information.

Response: In the final rule, we clarify that, consistent with the “state law” definition in § 160.202, “law” is intended to be read broadly to include the full array of binding legal authority, such as constitutions, statutes, rules, regulations, common law, or other governmental actions having the effect of law. However, for the purposes of § 164.512(a), law is not limited to state action; rather, it encompasses federal, state or local actions with legally binding effect, as well as those by territorial and tribal governments.

For more detail on the meaning of “required by law,” see § 164.501. Only where the law imposes a duty on the health care professional to report would the disclosure be considered to be required by law.

The final rule does not include a definitive list of the laws that contain legal mandates for disclosures of protected health information. In light of the breadth of the term “law” and number of federal, state, local, and territorial or tribal authorities that may engage in the promulgation of binding legal authority, it would be impossible to compile and maintain such a list. Covered entities have an independent duty to be aware of their legal obligations to federal, state, local and territorial or tribal authorities. The rule’s approach is simply intended to avoid any obstruction to the health plan or covered health care provider’s ability to comply with its existing legal obligations.

Comment: A number of commenters recommended that the rule compel covered entities to use or disclose protected health information as required by law. They expressed concern that covered entities could refuse or delay compliance with legally mandated disclosures by misplaced reliance on a rule that permits, but does not require, a use or disclosure required by other law.

Response: We do not agree that the final rule should require covered entities to use or disclose protected health information mandated by law. The purpose of this rule is to protect privacy, and to allow those disclosures consistent with sound public policy. Consistent with this purpose, we mandate disclosure only to the individual who is the subject of the information, and for purposes of enforcing the rule. Where a law imposes a legal duty on the covered entity to use or disclose protected health information, it is sufficient that the privacy rule permit the covered entity to comply with such law. The enforcement of that legal duty, however, is a matter for that other law.

Section 164.512(b)—Uses and Disclosures for Public Health Activities

Comment: Several non-profit entities commented that medical records research by nonprofit entities to ensure public health goals, such as disease-specific registries, would not have been covered by this provision. These organizations collect information without relying on a government agency or law. Commenters asserted that such activities are essential and must continue. They generally supported the provisions allowing the collection of individually identifiable health information without authorization for registries. One stated that both governmental and non-governmental cancer registries should be exempt from the regulation. They stated that “such entities, by their very nature, collect health information for legitimate public health and research purposes.” Another, however, addressed its comments only to “disclosure to non-government entities operating such system as required or authorized by law.”

Response: We acknowledge that such entities may be engaged in disease-specific or other data collection activities that provide a benefit to their members and others affected by a particular malady and that they contribute to the public health and scientific database on low incidence or little known conditions. However, in the absence of some nexus to a government public health authority or other underlying legal authority, it is unclear upon what basis covered entities can determine which registries or collections are “legitimate” and how the confidentiality of the registry information will be protected. Commenters did not suggest methods for “validating” these private registry programs, and no such methods currently exist at the federal level. It is unknown whether any states have such a program. Broadening the exemption could provide a loophole for private data collections for inappropriate
purposes or uses under a “public health” mask.

In this rule, we do not seek to make judgments as to the legitimacy of private entities’ disease-specific registries or of private data collection endeavors. Rather, we establish the general terms and conditions for disclosure and use of protected health information. Under the final rule, covered entities may obtain authorization to disclose protected health information to private entities seeking to establish registries or other databases; they may disclose protected health information as required by law; or they may disclose protected health information to such entities if they meet the conditions of one of the provisions of §§164.510 or 164.512. We believe that the circumstances under which covered entities may disclose protected health information to private entities should be limited to specified national priority purposes, as reflected through the FDA requirements or directives listed in §164.512(b)(iii), and to enable recalls, repairs, or replacements of FDA-regulated products. Disclosures by covered health care providers who are workforce members of an employer or are conducting evaluations relating to work-related injuries or illnesses or workplace surveillance also may disclose protected health information to employers of findings of such evaluations that are necessary for the employer to comply with requirements under OSHA and related laws.

Comment: Several commenters said that the NPRM did not indicate how to distinguish between public health data collections and government health data systems. They suggested eliminating proposed §164.510(g) on disclosures and uses for government health data systems, because they believed that such disclosures and uses were adequately covered by proposed §164.510(b) on public health.

Response: As discussed below, we agree with the commenters who suggested that the proposed provision that would have permitted disclosures to government health data bases was overly broad, and we remove it from the final rule. We reviewed the important purposes for which some commenters said government agencies needed protected health information, and we believe that most of those needs can be met through the other categories of permitted uses and disclosures without authorization allowed under the final rule, including provisions permitting covered entities to disclose information (subject to certain limitations) to government agencies for public health, health oversight, law enforcement, and otherwise as required by law. For example, the final rule continues to allow collection of protected health information without authorization to monitor trends in the spread of infectious disease, morbidity and mortality.

Comment: Several commenters recommended expanding the scope of disclosures permissible under proposed §164.510(b)(1)(iii), which would have allowed covered entities to disclose protected health information to private entities that could demonstrate that they were acting to comply with FDA requirements, or at the direction, of a public health authority. These commenters said that they needed to collect individually identifiable health information in the process of drug and device development, approval, and post-market surveillance—activities that are related to, and necessary for, the FDA regulatory process. However, they noted that the specific data collections involved were not required by FDA regulations. Some commenters said that they often used their own data collection methods, and that health care providers disclosed information to companies voluntarily for activities such as post-marketing surveillance and efficacy surveys. Commenters said they used this information to comply with FDA requirements such as reporting adverse events, filing other reports, or recordkeeping. Commenters indicated that the FDA encouraged but did not require them to establish other data collection mechanisms, such as pregnancy registries that track maternal exposure to drugs and the outcomes.

Accordingly, several commenters recommended modifying proposed §164.510(b) to allow covered entities to disclose protected health information without authorization to manufacturers registered with the FDA to manufacture, distribute, or sell a prescription drug, device, or biological product, in connection with post-marketing safety and efficacy surveillance or for the entity to obtain information about the drug, device, or product or its use. One commenter suggested including in the regulations an illustrative list of examples of FDA-related requirements, and stating in the preamble that all activities taken in furtherance of compliance with FDA regulations are “public health activities.”

Response: We recognize that the FDA conducts or oversees many activities that are critical to help ensure the safety or effectiveness of the many products it regulates. These activities include, for example, reporting of adverse events; product defects and problems; product tracking; and post-marketing surveillance. In addition, we believe that removing defective or harmful products from the market is a critical national priority and is an important tool in FDA efforts to promote the safety and efficacy of the products it regulates. We understand that in most cases, the FDA lacks statutory authority to require product recalls. We also recognize that the FDA typically does not conduct recalls, repairs, or product replacement surveillance directly, but rather, that it relies on the private entities it regulates to collect data, notify patients when applicable, repair and replace products, and undertake other activities to promote the safety and effectiveness of FDA-regulated products.

We believe, however, that modifying the NPRM to allow disclosure of protected health information to private entities as part of any data-gathering activity related to a drug, device, or biological product or its use, or for any activity that is consistent with, or that appears to promote objectives specified, in FDA regulation would represent an appropriately broad exception to the general requirement to obtain authorization prior to disclosure. Such a change could allow, for example, drug companies to collect protected health information without authorization to use for the purpose of marketing pharmaceuticals. We do not agree that all activities taken to promote compliance with FDA regulations represent public health activities as that term is defined in this rule. In addition, we believe it would not be appropriate to include in the regulation a text an “illustrative list” of requirements “related to” the FDA. The regulation text and preamble list the FDA-related activities for which we believe disclosure of protected health information to private entities without authorization is warranted.

We believe it is appropriate to allow disclosure of protected health information without authorization to private entities only: For purposes that the FDA has, in effect, identified as national priorities by issuing regulations or express directions requiring such disclosure; or if such disclosure is necessary for a product recall. For example, we believe it is appropriate to allow covered health care providers to disclose to a medical device manufacturer recalling defective heart valves the names and last known addresses of patients in whom the provider implanted the valves. Thus, in the final rule, we allow covered entities to disclose protected health information to entities subject to FDA jurisdiction for the following activities: To report adverse events (or similar reports with
respect to food or dietary supplements, product defects or problems (including problems with the use or labeling of a product), or biological product deviations, if the disclosure is made to the person required or directed to report such information to the FDA; to track products if the disclosure is made to a person required or directed by the FDA to track the product; to enable product recalls, repairs, or replacement (including locating and notifying individuals who have received products of product recalls, withdrawals, or other problems); or to conduct post-marketing surveillance to comply with requirements or at the direction of the FDA. The preamble above provides further detail on the meaning of some of the terms in this list. Covered entities may disclose protected health information to entities for activities other than those described above only as required by law; with authorization; or if permissible under another section of this rule.

We understand that many private registries, such as pregnancy registries, currently obtain patient authorization for data collection. We believe the approach of § 164.512(b) strikes an appropriate balance between the objective of promoting patient privacy and control over their health information and the objective of allowing private entities to collect data that ultimately may have important public health benefits.

Comment: One commenter remarked that our proposal may impede fatal/infant mortality and child fatality reviews.

Response: The final rule permits a covered entity to disclose protected health information to a public health authority authorized by law to conduct public health activities, including the collection of data relevant to death or disease, in accordance with § 164.512(b). Such activities may also meet the definition of “health care operations.” We therefore do not believe this rule impedes these activities.

Comment: Several comments requested that the final regulation clarify that employers be permitted to use and/or disclose protected health information pursuant to the requirements of the Occupational Safety and Health Act and its accompanying regulations (“OSHA”). A few comments asserted that the regulation should not only permit employers to use and disclose protected health information without first obtaining an authorization consistent with OSHA requirements, but also permit employers to use and disclose protected health information if the use or disclosure is consistent with the spirit of OSHA. One commenter supported the permissibility of these types of uses and disclosures, but warned that the regulation should not grant employers unfettered access to the entire medical record of employees for the purpose of meeting OSHA requirements. Other commenters noted that OSHA not only requires disclosures to the Occupational Safety and Health Administration, but also to third parties, such as employers and employee representatives. Thus, this comment asked HHS to clarify that disclosures to third parties required by OSHA are also permissible under the regulation.

Response: Employers as such are not covered entities under HIPAA and we generally do not have authority over their actions. When an employer has a health care component, such as an on-site medical clinic, and the components meet the requirements of a covered health care provider, health plan or health care clearinghouse, the uses and disclosures of protected health information by the health care component, including disclosures to the larger employer entity, are covered by this rule and must comply with its provisions.

A covered entity, including a covered health care provider, may disclose protected health information to OSHA under § 164.512(a), if the disclosure is required by law, or if the disclosure is a discretionary one for public health activities, under § 164.512(b). Employers may also request employees to provide authorization for the employer to disclose protected health information from covered entities to conduct analyses of work-related health issues. See § 164.508.

We also permit covered health care providers who provide health care as a workforce member of an employer or at the request of an employer to disclose protected health information to the employer concerning work-related injuries or illnesses or workplace medical surveillance in situations where the employer has a duty to keep records on or act on such information under the OSHA or similar laws. We added this provision to ensure that employers are able to obtain the information that they need to meet federal and state laws designed to promote safer and healthier workplaces. These laws are vital to protecting the health and safety of workers and we permit specified covered health care providers to disclose protected health information as necessary to carry out these purposes.

Comment: A few comments suggested that the regulation not clarify how it would interact with existing and pending OSHA requirements. One of these comments requested that the Secretary delay the effective date of the regulation until reviews of existing requirements are complete.

Response: As noted in the “Relationship to Other Federal Laws” section of the preamble, we are not undertaking a complete review of all existing laws with which covered entities might have to comply. Instead we have described a general framework under which such laws may be evaluated. We believe that adopting national standards to protect the privacy of individually identifiable health information is an urgent national priority. We do not believe that it is appropriate to delay the effective date of this regulation.

Comment: One commenter asserted that the proposed regulation conflicted with the OSHA regulation requirement that when a designated representative (to whom the employee has already provided a written authorization to obtain access) requests a release form for access to employee medical records, the form must include the purpose for which the disclosure is sought, which the proposed privacy regulation does not require.

Response: We do not agree that this difference creates a conflict for covered entities. If an employer seeks to obtain a valid authorization under § 164.508, it may add a purpose statement to the authorization so that it complies with OSHA’s requirements and is a valid authorization under § 164.508 upon which a covered entity may rely to make a disclosure of protected health information to the employer.

Comment: One commenter stated that access to workplace medical records by the occupational medical physicians is fundamental to workplace and community health and safety. Access is necessary whether it is a single location or multiple sites of the same company, such as production facilities of a national company located throughout the country.

Response: We permit covered health care providers who provide health care as a workforce member of an employer or at the request of an employer to disclose protected health information to the employer concerning work-related injuries or illnesses or workplace medical surveillance, as described in this paragraph. Information obtained by an employer under this paragraph would be available for it to use, consistent with other laws and regulations, as it chooses and throughout the national company. We do not regulate uses or disclosures of individually identifiable health
information by employers acting as employers.

Section 164.512(c)—Disclosures About Victims of Abuse, Neglect, or Domestic Violence

The NPRM did not include a paragraph specifically addressing covered entities’ disclosures of protected health information regarding victims of abuse, neglect, or domestic violence. Rather, the NPRM addressed disclosures about child abuse pursuant to proposed §164.510(b), which would have allowed covered entities to report child abuse to a public health authority or to another appropriate authority authorized by law to receive reports of child abuse or neglect. We respond to comments regarding victims of domestic violence or abuse throughout the final rule where relevant. (See responses to comments on §§164.502(g), 164.510(b), 164.512(f)(3), 164.522, and 164.524.)

Comment: Several commenters urged us to require that victims of domestic violence be notified about requests for or disclosures of protected health information about them, so that victims could take safety precautions.

Response: We agree that, in balancing the burdens on covered entities from such a notification requirement against the benefits to be gained, victims of domestic abuse merit heightened concern. For this reason, we generally require covered entities to inform the individual when they disclose protected health information to authorized government authorities. As the Family Violence Prevention Fund has noted in its Health Privacy Principles for Protecting Victims of Domestic Violence (October 2000), victims of domestic violence and abuse sometimes are subject to retaliatory violence. By informing a victim of abuse or domestic violence of a disclosure to law enforcement or other authorities, covered entities give victims the opportunity to take appropriate safety precautions. See the above preamble discussion of §164.512(c) for more detail about the requirements for disclosing protected health information about victims of domestic violence.

Comment: Some commenters argued that a consent requirement should apply at a minimum to disclosures involving victims of crime or victims of domestic violence.

Response: We agree, and we modify the proposed rule to require covered entities to obtain an individual’s agreement prior to disclosing protected health information in most instances involving victims of a crime or of abuse, neglect, or domestic violence. See the above preamble discussions of §164.512(c), on disclosures about victims of abuse, neglect, or domestic violence, and §164.512(f)(3), on disclosures to law enforcement about crime victims.

Section 164.512(d)—Uses and Disclosures for Health Oversight Activities

Comment: A couple of commenters supported the NPRM’s approach to health oversight. Several other commenters generally supported the NPRM’s approach to disclosure of protected health information for national priority purposes, and they recommended some clarification regarding disclosure for health oversight.

Response: The final rule permits disclosures to public agencies that meet the definition of a health oversight agency and that are authorized by law to receive reports of the particular areas described in the statute. Section 164.512(a) of the final rule permits disclosures that are required by law. As discussed in the responses to comments of §164.512(a), we do not in the final rule permit disclosures merely authorized by other laws that do not fit within the other public policy purposes recognized by the rule.

Comment: One commenter recommended clarifying in the final rule that covered entities are not required to establish business partner contracts with health oversight agencies or public health authorities to release individually identifiable information to them for purposes exempt from HIPAA and sanctioned by state law.

Response: The final rule does not require covered entities to establish business associate contracts with health oversight agencies when they disclose protected health information to these agencies for oversight purposes.

Comment: Two commenters recommended clarifying in the regulation that the health oversight section does not create a new right of access to protected health information.

Response: We agree and include such a statement in the preamble of §164.512(d) of the final rule.

Comment: Several commenters were concerned that the proposed oversight section allowed but did not require disclosure of protected health information to health oversight agencies for oversight activities.

Response: This rule’s purpose is to protect the privacy of individually identifiable health information. Except to enforce the rule and to establish individuals’ right to access their own protected health information (see §164.502(a)(2)), we do not require disclosure of protected health information to any person or entity. We allow such disclosure for situations in which other laws require disclosure. Comment: Some commenters were concerned that the NPRM would have allowed health oversight agencies to re-use and re-disclose protected health information to other entities, and they were particularly concerned about re-disclosure to and re-use by law enforcement agencies. One commenter believed that government agencies would use the label of health oversight to gain access to protected health information from covered entities—thereby avoiding the procedural requirements of the law enforcement section (proposed §164.510(l)) and subsequently would turn over information to law enforcement officials. Thus, these groups were concerned that the potential for access to protected health information under the rule to become the “back door” to law enforcement access to such information.

Based on their concerns, these commenters recommended establishing a general prohibition on the re-use and re-disclosure of protected health information obtained by health oversight agencies in actions against individuals. One health plan expressed general concern about re-disclosure among all of the public agencies covered in the proposed §164.510(l).

Comment: Many of the commenters concerned about re-disclosure of protected health information obtained for oversight purposes said that if the Secretary lacked statutory authority to regulate oversight agencies’ re-disclosure of protected health information and the re-use of this information by other agencies covered in proposed §164.510, the President should issue an Executive Order barring such re-disclosure and re-use. One of these groups specified that the Executive Order should bar re-use and re-disclosure of protected health information in actions against individuals.

In contrast, some commenters advocated information-sharing between law enforcement and oversight agencies. Most of these commenters recognized that the NPRM would have allowed re-use and re-disclosure of protected health information from oversight to law
enforcement agencies, and they supported this approach.

Response: We believe that the language we have added to the rule, at § 164.512(d)(2) and the corresponding explanation in the preamble, to clarify the boundary between disclosures for health oversight and for law enforcement purposes should partially address the concern expressed by some that oversight agencies will be the back door for access by law enforcement. In situations when the individual is the subject of an investigation or activity and the investigation or activity is not related to health care fraud, the requirements for disclosure to law enforcement must be met, and an oversight agency cannot request the information under its more general oversight authority.

We acknowledge, however, that there will be instances under the rule when a health oversight agency (or a law enforcement agency in its oversight capacity) that has obtained protected health information appropriately will be able to redisclose the information to a law enforcement agency for law enforcement purposes. Under HIPAA, we have the authority to restrict re-disclosure of protected health information only by covered entities. Re-disclosures by public agencies such as oversight agencies are not within the purview of this rule. We support the enactment of comprehensive privacy legislation that would govern such public agencies’ re-use and re-disclosure of this information. Furthermore, in an effort to prevent health oversight provisions from becoming the back door to law enforcement access to protected health information, the President is issuing an Executive Order that places strict limitations on the use of protected health information gathered in the course of an oversight investigation for law enforcement activities. For example, such use will be subject to review by the Deputy Attorney General.

Comment: Several commenters recommended modifying the proposed oversight section to require health oversight officials to justify and document their need for identifiable information.

Response: We encourage covered entities to work with health oversight agencies to determine the scope of information needed for health oversight inquiries. However, we believe that requiring covered entities to obtain extensive documentation of health oversight information needs could compromise oversight agencies’ ability to complete investigations, particularly when an oversight agency is investigating the covered entity from which it is seeking information.

Comment: Several commenters believed that health oversight activities could be conducted without access to individually identifiable health information. Some of these groups recommended requiring information provided to health oversight agencies to be de-identified to the extent possible.

Response: We encourage health oversight agencies to use de-identified information whenever possible to complete their investigations. We recognize, however, that in some cases, health oversight agencies need identifiable information to complete their investigations. For example, as noted in the preamble to the NPRM, to determine whether a hospital has engaged in fraudulent billing practices, it may be necessary to examine billing records for a set of individual cases. Similarly, to determine whether a health plan is complying with federal or state health care quality standards, it may be necessary to examine individually identifiable health information in comparison with such standards. Thus, to allow health oversight agencies to conduct the activities that are central to their mission, the final rule does not require covered entities to de-identify protected health information before disclosing it to health oversight organizations.

Comment: One commenter recommended requiring whistleblowers, pursuant to proposed § 164.518(a)(4) of the NPRM, to raise the issue of a possible violation of law with the affected covered entity before disclosing such information to an oversight agency, attorney, or law enforcement official.

Response: We believe that such a requirement would be inappropriate, because it would create the potential for covered entities that are the subject of whistleblowing to take action to evade law enforcement and oversight action.

Comment: One commenter recommended providing an exemption from the proposed rule’s requirements for accounting for disclosures when such disclosures were for health oversight purposes.

Response: We recognize that in some cases, informing individuals that their protected health information has been disclosed to a law enforcement official or to a health oversight agency could compromise the ability of law enforcement and oversight officials to perform their duties appropriately. Therefore, in the final rule, we retain the approach of proposed § 164.515 of the NPRM, to modify section to require health oversight agencies subject to a suspension to occur, the agency or official must provide the affected covered entity with a written request stating that an accounting to the individual would be reasonably likely to impede the agency’s activity. The request must specify the time for which the suspension is required. We believe that providing a permanent exemption to the right to accounting for disclosures for health oversight purposes would fail to ensure that individuals are sufficiently informed about the extent of disclosures of their protected health information.

Comment: One commenter recommended making disclosures to health oversight agencies subject to a modified version of the NPRM’s proposed three-part test governing disclosure of protected health information to law enforcement pursuant to an administrative request (as described in proposed § 164.510(f)(1)).

Response: We disagree that it would be appropriate to apply the procedural requirements for law enforcement to health oversight. We apply more extensive procedural requirements to law enforcement disclosures than to disclosures for health oversight because we believe that law enforcement investigations more often involve situations in which the individual is the subject of the investigation (and thus could suffer adverse consequences), and we believe that it is appropriate to provide greater protection to individuals in such cases. Health oversight involves investigations of institutions that use health information as part of business functions, or of individuals whose health information has been used to obtain a public benefit. These circumstances justify broader access to information.

Overlap Between Law Enforcement and Oversight

Comment: Some commenters expressed concern that the NPRM’s provisions permitting disclosures for health oversight and disclosures for law enforcement overlapped, and that the overlap could create confusion among covered entities, members of the public, and government agencies. The commenters identified particular factors that could lead to confusion, including that (1) the phrase “criminal, civil, or administrative proceeding” appeared in the definitions of both law enforcement
and oversight; (2) the examples of oversight agencies listed in the preamble included a number of organizations that also conduct law enforcement activities; (3) the NPRM addressed the issue of disclosures to investigate health care fraud in the law enforcement section (§ 164.510(f)(5)), yet health care fraud investigations are central to the mission of some health care oversight agencies; (4) the NPRM established more stringent rules for disclosure of protected health information pursuant to an administrative subpoena issued for law enforcement than for disclosure pursuant to an oversight agency’s administrative subpoena; and (5) the preamble, but not the NPRM regulation text, indicated that agencies conducting both oversight and law enforcement activities would be subject to the oversight requirements when conducting oversight activities.

Some commenters said that covered entities would be confused by the overlap between law enforcement and oversight and that this concern would lead to litigation over which rules should apply when an entity engaged in more than one of the activities listed under the exceptions in proposed § 164.510. Other commenters believed that covered entities could manipulate the NPRM’s ambiguities in their favor, claim that the more stringent law enforcement disclosure rules always should apply, and thereby delay investigations. A few comments suggested that the confusion could be clarified by making the regulation text consistent with the preamble, by stating that when agencies conducting both law enforcement and oversight seek protected health information as part of their oversight activities, the oversight rules would apply.

Response: We agree that the boundary between disclosures for health oversight and disclosures for law enforcement proposed in the NPRM could have been more clear. Because many investigations, particularly investigations involving public benefit programs, have both health oversight and law enforcement aspects to them, and because the same agencies often perform both functions, drawing any distinction between the two functions is necessarily difficult. For example, traditional law enforcement agencies, such as the Federal Bureau of Investigation, have a significant role in health oversight. At the same time, traditional health oversight agencies, such as federal Offices of Inspectors General, often participate in criminal investigations.

To clarify the boundary between law enforcement and oversight for purposes of complying with this rule, we add new language in the final rule, at § 164.512(d)(2). This section indicates that health oversight activities do not include an investigation or activity in which the individual is the subject of the investigation or activity and the investigation or activity does not arise out of and is not directly related to health care fraud. In this rule, we describe investigations involving suspected health care fraud as investigations related to: (1) the receipt of health care; (2) a claim for public benefits related to health; or (3) qualification for, or receipt of public benefits or services where a patient’s health is integral to the claim for public benefits or services. In such cases, where the individual is the subject of the investigation and the investigation does not relate to health care fraud, identified as investigations regarding issues (a) through (c), the rules regarding disclosure for law enforcement purposes (see § 164.512(f)) apply.

Where the individual is not the subject of the activity or investigation, or where the investigation or activity relates to health care fraud, a covered entity may make a disclosure pursuant to § 164.512(d)(1), allowing uses and disclosures for health oversight activities. For example, when the U.S. Department of Labor’s Pension and Welfare Benefits Administration (PWBA) needs to analyze protected health information about health plan enrollees in order to conduct an audit or investigation of the health plan (i.e., the enrollee’s health plan), the enrollee is not the subject of the investigation, and the information is protected health information for the purpose of health oversight activities. Therefore, the health plan may disclose protected health information to the PWBA under the health oversight rules.

To clarify further that health oversight disclosure rules apply generally in health care fraud investigations (subject to the exception described above), in the final rule, we eliminate proposed § 164.510(f)(5)(i), which would have established requirements for disclosure related to health fraud for law enforcement purposes. All disclosures of protected health information that would have been permitted under proposed § 164.510(f)(5)(i) are permitted under § 164.512(d).

We also recognize that sections 201 and 202 of HIPAA, which established a federal Fraud and Abuse Control Program and the Medicare Integrity Program to fight health care fraud, are critical national priorities. Accordingly, under the final rule, in joint law enforcement/oversight investigations involving suspected health care fraud, the health oversight disclosures apply, even if the individual also is the subject of the investigation.

We also recognize that in some cases, health oversight agencies may conduct joint investigations with other oversight agencies involved in investigating claims for benefits unrelated to health. For example, in some cases, a state Medicaid agency may be working with officials of the Food Stamps program to investigate suspected fraud involving Medicaid and Food Stamps. While this issue was not raised specifically in the comments, we add new language (§ 164.512(d)(3)) to provide guidance to covered entities in such situations. Specifically, we clarify that if a health oversight investigation is conducted in conjunction with an oversight activity related to a claim for benefits unrelated to health, the joint activity or investigation is considered health oversight for purposes of the rule, and the covered entities may disclose protected health information pursuant to the health oversight provisions.

Comment: An individual commenter recommended requiring authorization for disclosure of patient records in fraud investigations, unless the individual was the subject or target of the investigation. This commenter recommended requiring a search warrant for cases in which the individual was the subject and stating that fraud investigators should have access to the minimum necessary patient information.

Response: As described above, we recognize that in some cases, activities include elements of both law enforcement and health oversight. Because we consider both of these activities to be critical national priorities, we do not require covered entities to obtain authorization for disclosure of protected health information to law enforcement or health oversight agencies—including those oversight activities related to health care fraud. We believe that investigations involving health care fraud represent health oversight rather than law enforcement. Accordingly, as indicated above, we remove proposed § 164.510(f)(5)(i) from the law enforcement section of the proposed rule and clarify that all disclosures of protected health information for health oversight are permissible without authorization. As discussed in greater detail in § 164.514, the final rule’s minimum necessary standard applies to disclosures under § 164.512 unless the disclosure is required by law under § 164.512(a).
Comment: A large number of commenters expressed concern about the potential for health oversight agencies to become, in effect, the “back door” for law enforcement access to such information. The commenters suggested that health oversight agencies could use their relatively unencumbered access to protected health information to circumvent the more stringent process requirements that otherwise would apply to disclosures for law enforcement purposes. These commenters urged us to prohibit health oversight agencies from re-disclosing protected health information to law enforcement.

Response: As indicated above, we do not intend for the rule’s permissive approach to health oversight or the absence of specific documentation to permit the government to gather large amounts of protected health information for purposes unrelated to health oversight as defined in the rule, and we do not intend for these oversight provisions to serve as a “back door” for law enforcement access to protected health information. While we do not have the statutory authority to regulate law enforcement and oversight agencies’ re-use and re-disclosure of protected health information, we strongly support enactment of comprehensive privacy legislation that would govern public agencies’ re-use and re-disclosure of this information. Furthermore, in an effort to prevent health oversight provisions from becoming the back door to law enforcement access to protected health information, the President is issuing an Executive Order that places strict limitations on the use of protected health information gathered in the course of an oversight investigation for law enforcement activities.

Comment: One commenter asked us to allow the requesting agency to decide whether a particular request for protected health information was for law enforcement or oversight purposes.

Response: As described above, we clarify the overlap between law enforcement disclosures and health oversight disclosures based on the privacy and liberty interests of the individual (whether the individual also is the subject of the official inquiry) and the nature of the public interest (whether the inquiry relates to health care fraud or to another potential violation of law). We believe it is more appropriate to establish these criteria than to leave the decision to the discretion of an agency that has a stake in the outcome of the investigation.

Section 164.512(e)—Disclosures for Judicial and Administrative Proceedings

Comment: A few commenters suggested that the final rule not permit disclosures without an authorization for judicial and administrative proceedings.

Response: We disagree. Protected health information is necessary for a variety of reasons in judicial and administrative proceedings. Often it may be critical evidence that may or may not be about a party. Requiring an authorization for all such disclosures would severely impede the review of legal and administrative claims. Thus, we have tried to balance the need for the information with the individual’s privacy. We believe the approach described above provides individuals with the opportunity to object to disclosures and provides a mechanism through which their privacy interests are taken into account.

Comment: A few commenters sought clarification about the interaction between permissible disclosures for judicial and administrative proceedings, law enforcement, and health oversight.

Response: In the final rule, we state that the provision permitting disclosures without an authorization for judicial and administrative proceedings does not supersede other provisions in §164.512 that would otherwise permit or restrict the use or disclosure of protected health information. Additionally, in the descriptive preamble of §164.512, we provide further explanation of how these provisions relate to one another.

Comments: Many commenters urged the Secretary to revise the rule to state that it does not preempt or supersede existing rules and statutes governing judicial proceedings, including rules of evidence, procedure, and discovery. One commenter asserted that dishonest health care providers and others should not be able to withhold their records by arguing that state subpoena and criminal discovery statutes compelling disclosure are preempted by the privacy regulation. Other commenters maintained that there is no need to replace providers’ current practice, which typically requires either a signed authorization from the patient or a subpoena to release medical information.

Response: These comments are similar to many of the more general preemption comments we received. For a full discussion of the Secretary’s response on preemption issues, see part 160—subpart B.

Comment: One commenter stated that the proposed rule creates a conflict with existing rules and statutes governing judicial proceedings, including rules of evidence and discovery. This commenter stated that the rule runs afoul of state judicial procedures for enforcement of subpoenas that require judicial involvement only when a party seeks to enforce a subpoena.

Response: We disagree with this comment. The final rule permits covered entities to disclose protected health information for any judicial or administrative procedure in response to a subpoena, discovery request, or other lawful process if the covered entity has received satisfactory assurances that the party seeking the disclosure has made reasonable efforts to ensure that the individual has been given notice of the request or has made reasonable efforts to secure a qualified protective order from a court or administrative tribunal. A covered entity may disclose protected health information in response to a subpoena, discovery request, or other lawful process without a satisfactory assurance if it has made reasonable efforts to provide the individual with such notice or to seek a qualified protective order itself. These rules do not require covered entities or parties seeking the disclosure of protected health information to involve the judiciary; they may choose the notification option rather than seeking a qualified protective order.

Many states have already enacted laws that incorporate these concepts. In California, for instance, an individual must be given ten days notice that his or her medical records are being subpoenaed from a health care provider and state law requires that the party seeking the records furnishes the health care provider with proof that the notice was given to the individual. In Montana, a party seeking discovery or compulsory process of medical records must give notice to the individual at least ten days in advance of serving the request on a health care provider. Service of the request must be accompanied by written certification that the procedure has been followed. In Rhode Island, an individual must be given notice that his or her medical records are being subpoenaed and notice of his or her right to object. The party serving the subpoena on the health care provider must provide written certification to the provider that: (1) This procedure has been followed, (2) twenty days have passed from the date of service, and (3) no challenge has been made to the disclosure or the court has ordered disclosure after resolution of a legal court challenge. In Washington, an individual must be given at least fourteen days from the date of service of notice that his or her health information is the subject of a law enforcement or administrative proceeding. These rules do not relate to judicial proceedings.
discovery request or compulsory process to obtain a protective order. The notice must identify the health care provider from whom the information is sought, specify the health care information that is sought, and the date by which a protective order must be obtained in order to prevent the provider from disclosing the information. These commenters stated that current practice is to obtain information using subpoenas.

Other commenters argued that disclosure of protected health information for judicial and administrative proceedings should require a court order and/or judicial review unless the subject of the information consents to disclosure. These commenters believed that an attorney’s certification should not be considered sufficient authority to override an individual’s privacy, and that the proposed rule made it too easy for a party to litigation to obtain information about the other party. Response: As a general matter, we agree with these comments. As noted, the final rule deletes the provision that would permit a covered entity to disclose protected health information pursuant to an attorney’s certification that the individual is a party to the litigation and has put his or her medical condition or history at issue. Under the final rule, covered entities may disclose protected health information in response to a court or administrative order, provided that only the protected health information expressly authorized by the order is disclosed. Covered entities may also disclose protected health information in response to a subpoena, discovery request, or other lawful process without a court order, but only if the covered entity receives satisfactory assurances that the party seeking disclosure has made reasonable efforts to ensure that the individual has been notified of the request or to seek a qualified protective order. Additional, a covered entity may disclose protected health information in response to a subpoena, discovery request, or other lawful process without a satisfactory assurance if it makes reasonable efforts to provide the individual with such notice or to seek a qualified protective order itself. Therefore, a party may obtain the information even if the subject of the information is not a party to the litigation or deceased.

Comment: A few commenters argued that disclosure of protected health information should be limited only to those cases in which the individual has consented or a court order has been issued compelling disclosure. Response: The Secretary believes that such an approach would impose an unreasonable burden on covered entities and the judicial system and that greater flexibility is necessary to assure that the judicial and administrative systems function smoothly. We understand that even those states that have enacted specific statutes to protect the privacy of health information have not imposed requirements as strict as these commenters would suggest.

Comment: Many commenters asked that the final rule require the notification of the disclosure be provided to the individual whose health information is subject to disclosure prior to the disclosure as part of a judicial or administrative proceeding. Most of these commenters also asked that the rule require that the individual who is the subject of a disclosure be given an opportunity to object to the disclosure. A few commenters suggested that patients be given ten days to object before requested information may be disclosed and recommend that the rule require the requestor to provide a certification that notice has been provided and that ten days have passed...
with no objection from the subject of the information. Some commenters suggested that if a subpoena for disclosure is not accompanied by a court order, the covered entities be prohibited from disclosing protected health information unless the individual has been given notice and an opportunity to object. Another commenter recommended requiring, in most circumstances, notice and an opportunity to object before a court order is issued and requiring the requestor of information to provide a signed document attesting the date of notification and forbidding disclosure until ten days after notice is given.

Response: We agree that in some cases the provision of notice with an opportunity to object to the disclosure is appropriate. Thus, in the final rule we provide that a covered entity may disclose protected health information in response to a subpoena, discovery request or other lawful process that is not accompanied by a court order if it receives satisfactory assurance from the party seeking the request that the requesting party has made a good faith attempt to provide written notice to the individual that includes sufficient information about the litigation or proceeding to permit the individual to raise an objection to the court or administrative tribunal and that the time for the individual to raise objections has elapsed (and that none were filed or all have been resolved). Covered entities may make reasonable efforts to provide such notice as well.

In certain instances, however, the final rule permits covered entities to disclose protected health information for judicial and administrative proceedings without notice to the individual if the party seeking the request has made reasonable efforts to seek a qualified protective order, as described in the rule. A covered entity may also make reasonable efforts to seek a qualified protective order in order to make the disclosure. Additionally, a covered entity may disclose protected health information for judicial and administrative proceedings in response to an order of a court or administrative tribunal provided that the disclosure is limited to only that information that is expressly authorized by the order. The Secretary believes notice is not necessary in these instances because a court or administrative tribunal is in the best position to evaluate the merits of the arguments of the party seeking disclosure and the party who seeks to block it before issues the order and that imposing further procedural obstacles before a covered entity may honor that disclosure request is unnecessary.

Comment: Many commenters urged the Secretary to require specific criteria for court and administrative orders. Many of these commenters proposed that a provision be added to the rule that would require court and administrative orders to safeguard the disclosure and use of protected health information. These commenters urged that the information sought must be relevant and material, as specific and narrowly drawn as reasonably practicable, and only disclosed if de-identified information could not reasonably be used.

Response: The Secretary’s authority is limited to covered entities. Therefore, we do not impose requirements on courts and administrative tribunals. However, we note that the final rule limits the permitted disclosures by covered entities in court or administrative proceedings to only that information which is specified in the order from a court or an administrative body should provide a degree of protection for individuals from unnecessary disclosure.

Comment: Several commenters asked that the “minimum necessary” standard not apply to disclosures made pursuant to a court order because individuals could then use the rule to contest the scope of discovery requests. However, many other commenters recommended that the rule permit disclosure only of information “reasonably necessary” to respond to a subpoena. These commenters raised concerns with applying the “minimum necessary” standard in judicial and administrative proceedings, but did not believe the holder of protected health information should have blanket authority to disclose all protected health information. Some of the commenters urged that disclosure of any information about third parties may be included in the medical records of another person—an example, the HIV status of a partner—be prohibited. Finally, some commenters disagreed with the proposed rule because it did not require covered entities to evaluate the validity of subpoenas and discovery requests to determine whether these requests ask for the “minimum necessary” or “reasonably necessary” amount of information.

Response: Under the final rule, if the disclosure is pursuant to an order of a court or administrative tribunal, covered entities may disclose only the protected health information expressly authorized by the order. If the disclosure is pursuant to a court or administrative tribunal, the covered entity is not required to make a determination whether or not the order might otherwise meet the minimum necessary requirement.

If the disclosure is pursuant to a satisfactory assurance from the party seeking the disclosure, at least a good faith attempt has been made to notify the individual in writing of the disclosure before it is made or the parties have sought a qualified protective order that prohibits them from using or disclosing the protected health information for any purpose other than the litigation or proceeding for which the information was requested and that the information will be returned to the covered entity or destroyed at the end of the litigation or the proceeding. Alternatively, the covered entity may seek such notice or qualified protective order itself. This approach provides the individual with protections and places the burden on the parties to resolve their differences about the appropriateness and scope of disclosure as part of the judicial or administrative procedure itself before the order is issued, rather than requiring the covered entity to get involved in evaluating the merits of the dispute in order to determine whether or not the particular request is appropriate or too broad. In these cases, the covered entity must disclose only the protected health information that is the minimum amount necessary to achieve the purpose for which the information is sought.

We share the concern of the commenters that covered entities should redact any information about third parties before disclosing an individual’s protected health information. During the fact-finding stage of our consideration of revisions to the proposed rule, we discussed this issue with representatives of covered entities. Currently, information about third parties is sometimes redacted by medical records personnel responding to requests for information. In particular, information regarding HIV status is treated with special sensitivity by these professionals. Although we considered including a special provision in the final rule prohibiting such disclosure, we decided that the revisions made to the proposed rule would provide sufficient protection. By restricting disclosure of protected health information to only that information specified in a court or administrative order or released pursuant to other types of lawful process only if the individual had notice and an opportunity to object or if the information was subject to a protective order, individuals who are concerned about disclosure of information concerning third parties will have the opportunity to raise that...
issue prior to the request for disclosure being presented to the covered entity. We are reluctant to put the covered entity in the position of having to resolve disputes concerning the type of information that may be disclosed when that dispute should more appropriately be settled through the judicial or administrative procedure itself.

Comment: One commenter asked that the final regulation clarify that a court order is not required when disclosure would otherwise be permitted under the rule. This commenter noted that the preamble states that the requirement for a court order would not apply if the disclosure would otherwise be permitted under the rule. For example, disclosures of protected health information pursuant to administrative, civil, and criminal proceedings relating to “health oversight” are permitted, even if no court or administrative orders have been issued. However, the commenter was concerned that this principle only appeared in the preamble and not in the rule itself.

Response: Section 164.512(e)(4) of the final regulation contains this clarification.

Comment: One commenter was concerned that the rule is unclear as to whether governmental entities are given a special right to “use” protected health information that private parties do not have under the proposed regulation or whether governmental entities that seek or use protected health information are treated the same as private parties in their use of such information. This commenter urged that we clarify our intent regarding the use of protected health information by governmental entities.

Response: Generally governmental entities are treated the same as private entities under the rule. In a few clearly defined cases, a special rule applies. For instance, under § 164.504(e)(3), when a covered entity and its business associate are both governmental entities, they may enter into a memorandum of understanding or adopt a regulation with the force and effect of law that incorporates the requirements of a business associate contract, rather than having to negotiate a business associate contract itself.

Comment: One commenter recommended that final rule state that information developed as part of a quality improvement or medical error reduction program may not be disclosed under this provision. The commenter explained that peer review information developed to identify and correct systemic problems in delivery of care must be protected from disclosure to allow a full discussion of the root causes of such events so they may be identified and addressed. According to the commenter, this is consistent with peer review protections afforded this information by the states.

Response: The question of whether or not such information should be protected is currently the subject of debate in Congress and in the states. It would be premature for us to adopt a position on this issue until a clear consensus emerges. Under the final rule, no special protection against disclosure is provided for peer review information of the type the commenter describes. However, unless the request for disclosure fits within one of the categories of permitted or required disclosures under the regulation, it may not be disclosed. For instance, if disclosure of peer review information is required by another law (such as Medicare or a state law), covered entities subject to that law may disclose protected health information consistent with the law.

Response: One commenter stated that the requirements of this section are in conflict with Medicare contractor current practices, as defined by the HCFA Office of General Counsel and suggested that the final rule include more specific guidelines.

Response: Because the commenter failed to indicate the nature of these conflicts, we are unable to respond.

Comment: One commenter stated that the rule should require rather than permit disclosure pursuant to court orders.

Response: Under the statutory framework adopted by Congress in HIPAA, a presumption is established that the data contained in an individual’s medical record belongs to the individual and must be protected from disclosure to third parties. The only instance in which covered entities holding that information must disclose it is if the individual requests access to the information himself or herself. In the final rule (as in the proposed rule), covered entities may use or disclose protected health information under certain enumerated circumstances, but are not required to do so. We do not believe that this basic principle should be compromised merely because a court order has been issued. Consistent with this principle, we provide covered entities with the flexibility to deal with circumstances in which the covered entity may have valid reasons for declining to release the protected health information without violating this regulation.

Comment: One commenter noted that in some states, public health records are not subject to discovery, and that the proposed rule would not permit disclosure of protected health information pursuant to court order or subpoena if the disclosure is not allowed by state law. The commenter requested clarification as to whether a subpoena in a federal civil action would require disclosure if a state law prohibiting the release of public health records existed.

Response: As explained above, the final rule permits, but does not require, disclosure of protected health information pursuant to a court order. Under the applicable preemption provisions of HIPAA, state laws relating to the privacy of medical information that are more stringent than the federal rules are not preempted. To the extent that an applicable state law precludes disclosure of protected health information that would otherwise be permitted under the final rule, state law governs.

Comment: A number of commenters expressed concern that the proposed rule would negatively affect state and federal benefits programs, particularly social security and workers’ compensation. One commenter requested that the final rule remove any possible ambiguity about application of the rule to the Social Security Administration’s (SSA) evidence requests by permitting disclosure to all administrative level of benefit programs. In addition, several commenters stated that requiring SSA or states to provide the covered entity holding the protected health information with an individual’s consent before it could disclose the information would create a huge administrative and paperwork burden with no added value to the individual. In addition, several other commenters indicated that states that make disability determinations for SSA also support special accommodation for SSA’s determination process. They expressed concern that providers will narrowly interpret the HIPAA requirements, resulting in significant increases in processing time and program costs for obtaining medical evidence (especially purchased consultative examinations when evidence of record cannot be obtained). A few commenters were especially concerned about the impact on states and SSA if the final rule were to eliminate the NPRM’s provision for a broad consent for “all evidence from all sources.”

Some commenters also note that it would be inappropriate for a provider to make a minimum necessary determination in response to a request from SSA because the provider usually will not know the legal parameters of SSA’s programs, or have access to the
individual’s other sources of evidence. In addition, one commenter urged the Secretary to be sensitive to these concerns about delay and other negative impacts on the timely determination of disability by SSA for mentally impaired individuals.

Response: Under the final rule, covered entities may disclose protected health information pursuant to an administrative order so the flow of protected health information from covered entities to SSA and the states should not be disrupted.

Although some commenters urged that special rules should be included for state and federal agencies that need protected health information, the Secretary rejects that suggestion because, wherever possible, the public and the private sectors should operate under the same rules regarding the disclosure of health information. To the extent the activities of SSA constitute an actual administrative tribunal, covered entities must follow the requirements of §164.512(d) if they wish to disclose protected health information to SSA in those circumstances. Not all administrative inquiries are administrative tribunals, however. If SSA’s request for protected health information comes within another category of permissible exemptions, a covered entity, following the requirements of the applicable section, may disclose the information to SSA. For example, if SSA seeks information for purposes of health oversight, a covered entity that wishes to disclose the information to SSA may do so under §164.512(d) and not §164.512(e). If the disclosure does not come within one of the other permissible disclosures would a covered entity need to meet the requirements of §164.512(e). If the SSA request does not come within another permissible disclosure, the agency will be treated like anyone else under the rules.

The Secretary recognizes that even under current circumstances professional medical records personnel do not always respond unquestioningly to an agency’s request for health information. During the fact finding process, professionals charged with managing provider response to requests for protected health information indicated to us that when an agency’s request for protected health information is over broad, the medical records professional will contact the agency and negotiate a more limited request. In balancing the interests of individuals against the need of governmental entities to receive protected health information, we think that applying the minimum necessary standard is appropriate and that covered entities should be responsible for ensuring that they disclose only that protected health information that is necessary to achieve the purpose for which the information is sought.

Comment: In a similar vein, one commenter expressed concern that the proposed rule would adversely affect the informal administrative process usually followed in processing workers’ compensation claims. Using formal discovery is not always possible, because some programs do not permit it. The commenter urged that the final rule must permit administrative agencies, employers, and workers’ compensation carriers to use less formal means to obtain relevant medical evidence while the matter is pending before the agency. This commenter asked that the rule be revised to permit covered entities to disclose protected health information without authorization for purposes of federal or state benefits determinations at all levels of processing, from the initial application through continuing disability reviews.

Response: If the disclosure is required by a law relating to workers’ compensation, a covered entity may disclose protected health information as authorized by and to the extent necessary to comply with that law under §164.512(l). If the request for protected health information in connection with a workers’ compensation claim is part of an administrative proceeding, a covered entity must meet the requirements set forth in §164.512(e), and discussed above, before disclosing the information. As noted, one permissible manner by which a covered entity may disclose protected health information under §164.512(e) is if the party seeking the disclosure makes reasonable efforts to provide notice to the individual as required by this provision. Under this method, the less formal process noted by the commenter would not be disturbed. Covered entity may disclose protected health information in response to other types of requests only as permitted by this regulation.

Section 164.512(f)—Disclosures for Law Enforcement Purposes

General Comments on Proposed §164.510(f)

Comment: Some commenters argued that current law enforcement use of protected health information was legitimate and important. These commenters cited examples of investigations and prosecutions for which protected health information is needed, from white collar insurance fraud to violent assault, to provide incriminating evidence or to exonerate a suspect, to determine what charges are warranted and for bail decisions. For example, one commenter argued that disclosure of protected health information for law enforcement purposes should be exempt from the rule, because the proposed regulation would hamper Drug Enforcement Administration investigations. A few commenters argued that effective law enforcement requires early access to as much information as possible, to rule out suspects, assess severity of criminal acts, and for other purposes. A few commenters noted the difficulties criminal investigators and prosecutors face when fighting complex criminal schemes. In general, these commenters argued that all disclosures of protected health information to law enforcement should be allowed, or for elimination of the process requirements proposed in §164.510(f)(1).

Response: The importance and legitimacy of law enforcement activities was not an issue in this regulation. We permit disclosure of protected health information to law enforcement officials without authorization in some situations precisely because of the importance of these activities to public safety. At the same time, individuals’ privacy interests also are important and legitimate. As with all the other disclosures of protected health information permitted under this regulation, the rules we impose attempt to balance competing and legitimate interests.

Comment: Law enforcement representatives stated that law enforcement agencies had a good track record of protecting patient privacy and that additional restrictions on their access and use of information were not warranted. Some commenters argued that no new limitations on law enforcement access to protected health information were necessary, because sufficient safeguards exist in state and federal laws to prevent inappropriate disclosure of protected health information by law enforcement.

Response: Disclosure of protected health information by law enforcement is not at issue in this regulation. Law enforcement access to protected health information in the first instance, absent any re-disclosure by law enforcement, impinges on individuals’ privacy interests and must therefore be justified by a public purpose that outweighs individuals’ privacy interests.

We do not agree that sufficient safeguards already exist in this area. We are not aware of, and the comments did
not provide, evidence of a minimum set of protections for individuals relating to access by law enforcement to their protected health information. Federal and state laws in this area vary considerably, as they do for other areas addressed in this final rule. The need for standards in this area is no less critical than in the other areas addressed by this rule.

Comment: Many commenters argued that no disclosures of protected health information should be made to law enforcement (absent authorization) without a warrant issued by a judicial officer after a finding of probable cause. Others argued that a warrant or subpoena should be required prior to disclosure of protected health information unless the disclosure is for the purposes of identifying a suspect, fugitive, material witness, or missing persons, as described in proposed §164.510(f)(2). Some commenters argued that judicial review prior to release of protected health information to law enforcement should be required absent exigent and urgent circumstances identified in the NPRM in §164.510(f)(3) and (5), or absent “a compelling need” or similar circumstances.

Response: In the final rule, we attempt to match the level of procedural protection for privacy required by this rule with the nature of the law enforcement need for access, the existence of other procedural protections, and individuals’ privacy interests. Where other rules already impose procedural protections, this rule generally relies on those protections rather than imposing new ones. Thus, where access to protected health information is granted after review by an independent judicial officer (such as a court order or court-ordered warrant, or a subpoena or summons issued by a judicial officer), no further requirements are necessary. Similarly, because information disclosed to a grand jury is vital to law enforcement purposes and is covered by secrecy protection, this rule allows disclosure with no further process.

We set somewhat stricter standards for disclosure of protected health information pursuant to administrative process, such as administrative subpoenas, summonses, and civil or authorized investigative demands. In these cases, the level of existing procedural protections is lower than for judicially-approved or grand jury disclosures. We therefore require a greater showing, specifically, the three-part test described in §164.512(f)(1)(ii), before the covered entity is permitted to release protected health information.

Where the information to be disclosed is about the victim of a crime, privacy interests are heightened and we require the victim’s agreement prior to disclosure in most instances.

In the limited circumstances where law enforcement interests are heightened, we allow disclosure of protected health information without prior legal process or agreement, but we impose procedural protections such as limits on the information that may lawfully be disclosed, limits on the circumstances in which the information may be disclosed, and requirements for verifying the identity and authority of the person requesting the disclosures. For example, in some cases law enforcement officials may seek limited but focused information needed to obtain a warrant. A witness to a shooting may know the time of the incident and the fact that the perpetrator was shot in the left arm, but not the identity of the perpetrator. Law enforcement would then have a legitimate need to ask local emergency rooms whether anyone had presented with a bullet wound to the left arm near the time of the incident. Law enforcement may not have sufficient information to obtain a warrant, but instead would be seeking such information. In such cases, when only limited identifying information is disclosed and the purpose is solely to ascertain the identity of a person, the invasion of privacy would be outweighed by the public interest. For such circumstances, we allow disclosure of protected health information in response to a law enforcement inquiry where law enforcement is seeking to identify a suspect, fugitive, material witness, or missing person, but allow only disclosure of a limited list of information.

Similarly, it is in the public interest to allow covered entities to take appropriate steps to protect the integrity and safety of their operations. Therefore, we permit covered entities on their own initiative to disclose to law enforcement officials protected health information for this purpose. However, we limit such disclosures to protected health information that the covered entity believes in good faith constitutes evidence of criminal conduct that occurred on the premises of the covered entity.

We shape the rule’s provisions with respect to law enforcement according to the limited scope of our regulatory authority under HIPAA, which applies only to the covered entities and not to law enforcement officials. We believe the rule sets the correct standards for when an exception to the rule of non-disclosure is appropriate for law enforcement purposes. There may be advantages, however, to legislation that applies the appropriate standards directly to judicial officers, prosecutors in grand juries, and to those making administrative or other requests for protected health information, rather than to covered entities. These advantages could include measures to hold officials accountable if they seek or receive protected health information contrary to the legal standard. In Congressional consideration of law enforcement access, there have also been useful discussions of other topics, such as limits on re-use of protected health information gathered in the course of health oversight activities. The limitations on our regulatory authority provide additional reason to support comprehensive medical privacy legislation.

Comment: A few commenters cited existing sanctions for law enforcement officials who violate the rights of individuals in obtaining evidence, ranging from suppression of that evidence to monetary penalties, and argued that such sanctions are sufficient to protect patients’ privacy interests.

Response: After-the-fact sanctions are important, but they are effective only when coupled with laws that establish the ground rules for appropriate behavior. That is, a sanction applies only where some other rule has been violated. This regulation sets such basic ground rules. Further, under the HIPAA statutory authority, we may impose sanctions on law enforcement officials or require suppression of evidence. We must therefore rely on rules that regulate disclosure of protected health information by covered entities in the first instance.

Comment: Several commenters argued that disclosure of protected health information under §164.510(f) should be mandatory, not just permitted. Others argued that we should mandate disclosure of protected health information in response to Inspector General subpoenas. A few commenters argued that we should require all covered entities to include disclosure of protected health information to law enforcement in their required notice of privacy practices.

Response: The purpose of this regulation is to protect individuals’ privacy interests, consistent with other important public activities. Other laws set the rules governing those public activities, including when health information is necessary for their effective operation. See discussion of §164.512(a).
Comment: Some commenters questioned whether the Secretary had statutory authority to directly or indirectly impose new procedural or substantive requirements on otherwise lawful legal process issued under existing federal and state rules. They argued that, while the provisions are imposed on “covered entities,” the rule would result in law enforcement officials being compelled to modify current practices to harmonize them with the requirements this rule imposes on covered entities. A number of state law enforcement agencies argued that the rule would place new burdens on state administrative subpoenas and requests that are intrusive in state functions. At least one commenter argued that the requirement for prior process places unreasonable restrictions on the right of the states to regulate law enforcement activities.

Response: This rule regulates the ability of health care clearinghouses, health plans, and covered health care providers to use and disclose health information. It does not regulate the behavior of law enforcement officials or the courts, nor does it prevent states from regulating law enforcement officials. All regulations have some effects on entities that are not directly regulated. We have considered those effects in this instance and have determined that the provisions of the rule are necessary to protect the privacy of individuals.

Comment: One commenter argued that state licensing boards should be exempt from restrictions placed on law enforcement officials, because state licensing and law enforcement are different activities.

Response: Each state’s law determines what authorities are granted to state licensing boards. Because state laws differ in this regard, we cannot make a blanket determination that state licensing officials are or are not law enforcement officials under this regulation. We note, however, that the oversight of licensed providers generally is included as a health oversight activity at § 164.512(d).

Relationship to Existing Rules and Practices

Comment: Many commenters expressed concern that the proposed rule would have expanded current law enforcement access to protected health information. Many commenters said that the NPRM would have weakened their current privacy practices with respect to law enforcement access to health records. For example, some of the commenters argued that a warrant or subpoena should be required prior to disclosure of protected health information unless the disclosure is for the purposes of identifying a suspect, fugitive, material witness, or missing persons, did so because they believed that such a rule would be consistent with current state law practices.

Response: This regulation does not expand current law enforcement access to protected health information. We do not mandate any disclosures of protected health information to law enforcement officials, nor do we make lawful any disclosures of protected health information which are unlawful under other rules and regulations. Similarly, this regulation does not describe a set of “best practices.” Nothing in this regulation should cause a covered entity to change practices that are more protective of privacy than the floor of protections provided in this regulation.

This regulation sets forth the minimum practices which a covered entity must undertake in order to avoid sanctions under HIPAA. We expect and encourage covered entities to exercise their judgment and professional ethics in using and disclosing health information, and to continue any current practices that provide privacy protections greater than those mandated in this regulation.

Comment: Many commenters asserted that, today, consent or judicial review is required by law. See § 164.512(a). We agree, and in the final rule we have specifically added language to the paragraph addressing disclosures for law enforcement that permits covered entities to comply with current routine uses for law enforcement under the Privacy Act.

Response: This issue is discussed in the “Relationship to Other Federal Laws” preamble discussion of the Privacy Act.

Comment: A few commenters expressed concern that people will be less likely to provide protected health information for public health purposes if they fear the information could be used for law enforcement purposes.

Response: This regulation does not affect law enforcement access to records held by public health authorities, nor does it expand current law enforcement access to records held by covered entities. These agencies are for the most part not covered entities under HIPAA. Therefore, this regulation should not reduce current cooperation with public health efforts.

Relationship to Other Provisions of This Regulation

Comment: Several commenters pointed out an unintended interaction between proposed §§ 164.510(f) and 164.510(n). Because proposed § 164.510(n), allowing disclosures mandated by other laws, applied only if the disclosure would not fall into one of the categories of disclosures provided for in § 164.510 (b)–(m), disclosures of protected health information mandated for law enforcement purposes by other law would have been preempted.

Response: We agree, and in the final rule we address this unintended interaction. It is not our intent to preempt these laws. To clarify the interaction between these provisions, in the final rule we have specified added language to the paragraph addressing disclosures for law enforcement that permits covered entities to comply with legal mandates, and have included a specific cross reference in the provision of the final rule that permits covered entities to make other disclosures required by law. See § 164.512(a).

Comment: Several commenters argued that, when a victim of abuse or of a crime has requested restrictions on disclosure, the restrictions should be communicated to any law enforcement officials who receive that protected health information.

Response: We do not have the authority to regulate law enforcement
use and disclosure of protected health information, and therefore we could not enforce any such restrictions communicated to law enforcement officials. For this reason, we determined that the benefits to be gained from requiring communication of restrictions would not outweigh the burdens such a requirement would place on covered entities. We expect that professional ethics will guide health care providers’ communications to law enforcement officials about the welfare of victims of abuse or other crime. 

Comment: Some commenters argued against imposing the “minimum necessary” requirement on disclosure of protected health information to law enforcement officials. Some law enforcement commenters expressed concern that the “minimum necessary” test could be “manipulated” by a covered entity that wished to withhold relevant evidence. A number of covered entities complained that they were ill-equipped to substitute their judgment for that of law enforcement for what was the minimum amount necessary, and they also argued that the burden of determining the “minimum necessary” information should be transferred to law enforcement agencies. Some commenters argued that imposing such “uninformed” discretion on covered entities would delay or thwart legitimate investigations, and would result in withholding information that might exculpate an individual or might be necessary to present a defendant’s case. One comment suggested that covered entities have “immunity” for providing too much information to law enforcement. 

Response: The “minimum necessary” standard is discussed at § 164.514. 

Comment: A few commenters asked us to clarify when a disclosure is for a “Judicial or Administrative Proceeding” and when it is for “Law Enforcement” purposes. 

Response: In the final rule we have clarified that § 164.512(e) relating to disclosures for judicial or administrative proceedings does not supersede the authority of a covered entity to make disclosures under other provisions of the rule.

Use of Protected Health Information After Disclosure to Law Enforcement 

Comment: Many commenters recommended that we restrict law enforcement officials’ re-use and re-disclosure of protected health information. Some commenters asked us to impose such restrictions, while other commenters noted that the need for such restrictions underscores the need for legislation. Another argued for judicial review prior to release of protected health information to law enforcement because this regulation cannot limit further uses or disclosures of protected health information once it is in the hands of law enforcement agencies. 

Response: We agree that there are advantages to legislation that imposes appropriate restrictions directly on the re-use and re-disclosure of protected health information by many persons who may lawfully receive protected health information under this regulation, but whom we cannot regulate under the HIPAA legislative authority, including law enforcement agencies. 

Comment: A few commenters expressed concern that protected health information about persons who are not suspects may be used in court and thereby become public knowledge. These commenters urged us to take steps to minimize or prevent such protected health information from becoming part of the public record. 

Response: We agree that individuals should be protected from unnecessary public disclosure of health information about them. However, we do not have the statutory authority in this regulation to require courts to impose protective orders. To the extent possible within the HIPAA statutory authority, we address this problem in § 164.512(e), Judicial and Administrative Proceedings. 

Comment: Some commenters argued that evidence obtained in violation of the regulation should be inadmissible at trial. 

Response: In this regulation, we do not have the authority to regulate the courts. We can neither require nor prohibit courts from excluding evidence obtained in violation of this regulation. 

Comments Regarding Proposed § 164.510(f)(1), Disclosures to Law Enforcement Pursuant to Process Comments Supporting or Opposing a Requirement of Consent or Court Order 

Comment: Some commenters argued that a rule that required a court order for every instance that law enforcement sought protected health information would impose substantial financial and administrative burdens on federal and state law enforcement and courts. Other commenters argued that imposing a new requirement of prior judicial process would compromise the time-sensitive nature of many investigations. 

Response: We do not impose such a requirement in this regulation. 

Comment: Many commenters argued that proposed § 164.510(f)(1) would have given law enforcement officials the choice of obtaining records with or without a court order, and that law enforcement “will choose the least restrictive means of obtaining records, those that do not require review by a judge or a prosecutor.” Several commenters argued that this provision would have provided the illusion of barriers—but no real barriers—to law enforcement access to protected health information. A few argued that this provision would have allowed law enforcement to regulate itself. 

Response: We agree with commenters that, in some cases, a law enforcement official may have discretion to seek health information under more than one legal avenue. Allowing a choice in these circumstances does not mean an absence of real limits. Where law enforcement officials choose to obtain protected health information through administrative process, they must meet the three-part test required by this regulation. 

Comment: At least one commenter argued for judicial review prior to disclosure of health information because the rule will become the “de facto” standard for release of protected health information. 

Response: We do not intend for this regulation to become the “de facto” standard for release of protected health information. Nothing in this regulation limits the ability of states and other governmental authorities to impose stricter requirements on law enforcement access to protected health information. Similarly, we do not limit the ability of covered entities to adopt stricter policies for disclosure of protected health information not mandated by other laws. 

Comment: A few commenters expressed concern that proposed § 164.510(f)(1) would have overburdened the judicial system. 

Response: The comments did not provide any factual basis for evaluating this concern. 

Comment: Some commenters argued that, while a court order should be required, the standard of proof should be something other than “probable cause.” For example, one commenter argued that the court should apply the three-part test proposed in § 164.510(f)(1)(i)(C). Another commenter suggested a three-part test: The information is necessary, the need cannot be met with non-identifiable information, and the need of law enforcement outweighs the privacy interest of the patient. Some commenters suggested that we impose a “clear and convincing” standard. Another suggested that we require clear and convincing evidence that: (1) The
information sought is relevant and material to a legitimate criminal investigation; (2) the request is as specific and narrow as is reasonably practicable; (3) de-identified information, for example coded records, could not reasonably be used; (4) on balance, the need for the information outweighs the potential harm to the individuals and to patient care generally; and (5) safeguards appropriate to the situation have been considered and imposed. This comment also suggested the following as such safeguards: granting only the right to inspect and take notes; allowing copying of only certain portions of records; prohibiting removing records from the premises; placing limits on subsequent use and disclosure; and requiring return or destruction of the information at the earliest possible time.) Others said the court order should impose a “minimum necessary” standard.

Response: We have not revised the regulation in response to comments suggesting that we impose additional standards relating to disclosures to comply with court orders. Unlike administrative subpoenas, where there is no independent review of the order, court orders are issued by an independent judicial officer, and we believe that covered entities should be permitted under this rule to comply with them. Court orders are issued in a wide variety of cases, and we do not know what hardships might arise by imposing standards that would require judicial officers to make specific findings related to privacy.

Comment: At least one commenter argued that the proposed rule would have placed too much burden on covered entities to evaluate whether to release information in response to a court order. This comment suggested that the regulation allow disclosure to attorneys for assessment of what the covered entity should release in response to a court order.

Response: This regulation does not change current requirements on or rights of covered entities with respect to court orders for the release of health information. Where such disclosures are required today, they continue to be required under this rule. Where other law allows a covered entity to challenge a court order today, this rule will not reduce the ability of a covered entity to mount such a challenge. Under § 164.514, a covered entity will be permitted to rely on the face of a court order to meet this rule’s requirements for verifying the identity and authority of the person requesting the request for information. A covered entity may disclose protected health information to its attorneys as needed, to perform health care operations, including to assess the covered entity’s appropriate response to court orders. See definition of “health care operations” under § 164.501.

Comment: Many commenters argued that the regulation should prohibit disclosures of protected health information to law enforcement absent patient consent.

Response: We disagree with the comment. Requiring consent prior to any release of protected health information to a law enforcement official would unduly jeopardize public safety. Law enforcement officials need protected health information for their investigations in a variety of circumstances. The medical condition of a defendant could be relevant to whether a crime was committed, or to the seriousness of a crime. The medical condition of a witness could be relevant to the reliability of that witness. Health information may be needed from emergency rooms to locate a fleeing prisoner, escapee or criminal suspect who was injured and is believed to have stopped to seek medical care.

These and other uses of medical information are in the public interest. Requiring the authorization of the subject prior to disclosure could make apprehension or conviction of some criminals difficult or impossible. In many instances, it would not be possible to obtain such consent, for example because the subject of the information could not be located in time (or at all). In other instances, the covered entity may not wish to undertake the burden of obtaining the consent. Rather than an across-the-board consent requirement, to protect individuals’ privacy interests while also promoting public safety, we impose a set of procedural safeguards (described in more detail elsewhere in this regulation) that covered entities must ensure are met before disclosing protected health information to law enforcement officials.

In most instances, such procedural safeguards consist of some prior legal process, such as a warrant, grand jury subpoena, or an administrative subpoena that meets a three-part test for protecting privacy interests. When the information to be disclosed is about the victim of a crime, privacy interests are heightened and we require the victim’s agreement prior to disclosure in most instances. In the limited circumstances where law enforcement interests are heightened and we allow disclosure of protected health information without prior legal process or agreement, the procedural protections include limits on the information that may lawfully be disclosed, the circumstances in which the information may be disclosed, and requirements for verifying the identity and authority of the person requesting the disclosures.

We also allow disclosure of protected health information to law enforcement officials without consent when other law mandates the disclosures. When such other law exists, another public entity has made the determination that law enforcement interests outweigh the individual’s privacy interests in the situations described in that other law, and we do not upset that determination in this regulation.

Comment: Several commenters recommended requiring that individuals receive notice and opportunity to contest the validity of legal process under which their protected health information will be disclosed, prior to disclosure of their records to law enforcement. Some of these commenters recommended adding this requirement to provisions proposed in the NPRM, while others recommended establishing this requirement as part of a new requirement for a judicial warrant prior to all disclosures of protected health information to law enforcement. At least one of these commenters proposed an exception to such a notice requirement where notice might lead to destruction of the records.

Response: Above we discuss the reasons why we believe it is inappropriate to require consent or a judicial order prior to any release of protected health information to law enforcement. Many reasons apply here, and they lead us not to impose such a notice requirement.

Comment: A few commenters believed that the proposed requirements in § 164.510(f)(1) would hinder investigations under the Civil Rights for Institutionalized Persons Act (CRIPA). Response: We did not intend that provision to apply to investigations under CRIPA, and we clarify in the final rule that covered entities may disclose protected health information for such investigations under the oversight provisions of this regulation (see § 164.512(d) for further detail).

Comments Suggesting Changes to the Proposed Three-Part Test

Comment: Many commenters argued for changes to the proposed three-part test that would make the test more difficult to meet. Many of these urged greater, but unspecified, restrictions. Others argued that the proposed test was too stringent, and that it would have hampered criminal investigations and prosecutions. Some argued that it
was too difficult for law enforcement to be specific at the beginning of an investigation. Some argued that there was no need to change current practices, and they asked for elimination of the three-part test because it was “more stringent” than current practices and would make protected health information more difficult to obtain for law enforcement purposes. These commenters urged elimination of the three-part test so that administrative bodies could continue current practices without additional restrictions. Some of these argued for elimination of the three-part test for all administrative subpoenas; others argued for elimination of the three-part test for administrative subpoenas from various Inspectors General offices. A few commenters argued that the provisions in proposed § 164.510(f)(1) should be eliminated because they would have burdened criminal investigations and prosecutions but would have served “no useful public purpose.”

Response: We designed the proposed three-part test to require proof that the government’s interest in the health information was sufficiently important and sufficiently focused to overcome the individual’s privacy interest. If the test were weakened or eliminated, the individual’s privacy interest would be insufficiently protected. At the same time, if the test were significantly more difficult to meet, law enforcement’s ability to protect the public interest could be unduly compromised.

Comment: At least one comment argued that, in the absence of a judicial order, protected health information should be released only pursuant to specific statutory authority.

Response: It is impossible to predict all the facts and circumstances, for today and into the future, in which law enforcement’s interest in health information outweighs individuals’ privacy interests. Recognizing this, states and other governments have not acted to list all the instances in which health information should be available to law enforcement officials. Rather, they specify some such instances, and rely on statutory, constitutional, and other limitations to place boundaries on the activities of law enforcement officials. Since the statutory authority to which the commenter refers does not often exist, many uses of protected health information that are in the public interest (described above in more detail) would not be possible under such an approach.

Comment: At least one commenter, an administrative agency, expressed concern that the proposed rule would have required its subpoenas to be approved by a judicial officer.

Response: This rule does not require judicial approval of administrative subpoenas. Administrative agencies can avoid the need for judicial review under this regulation by issuing subpoenas for protected health information only where the three-part test has been met.

Comment: Some commenters suggested alternative requirements for law enforcement access to protected health information. A few suggested replacing the three-part test with a requirement that the request for protected health information from law enforcement be in writing and signed by a supervisory official, and/or that the request “provide enough information about their needs to allow application of the minimum purpose rule.”

Response: A rule requiring only that the request for information be in writing and signed fails to impose appropriate substantive standards for release of health information. A rule requiring only sufficient information for the covered entity to make a “minimum necessary” determination would leave these decisions entirely to covered entities’ discretion. We believe that protection of individuals’ privacy interests must start with a minimum floor of protections applicable to all. We believe that while covered entities may be free to provide additional protections (within the limits of the law), they should not have the ability to allow unjustified access to health information.

Comment: Some commenters argued that the requirement for an unspecified “finding” for a court order should be removed from the proposed rule, because it would have been confusing and would have provided no guidance to a court as to what finding would be sufficient.

Response: We agree that the requirement would have been confusing, and we delete this language from the final regulation.

Comment: A few commenters argued that the proposed three-part test should not be applied where existing federal or state law established a standard for issuing administrative process.

Response: It is the content of such a standard, not its mere existence, that determines whether the standard strikes an appropriate balance between individuals’ privacy interests and the public interest in effective law enforcement activities. We assume that current authorities to issue administrative subpoena are all subject to some standards. When an existing standard provides at least as much protection as the three-part test imposed by this regulation, the existing standard is not disturbed by this rule. When, however, an existing standard for issuing administrative process provides less protection, this rule imposes new requirements.

Comment: Some covered entities said that they should not have been asked to determine whether the proposed three-part test has been met. Some argued that they were ill-equipped to make a judgment on whether an administrative subpoena actually met the three-part test, or that it was unfair to place the burden of making such determinations on covered entities. Some argued that the burden should have been on law enforcement, and that it was inappropriate to shift the burden to covered entities. Other commenters argued that the proposal would have given too much discretion to the record holders to withhold evidence without having sufficient expertise or information on which to make such judgments. At least one comment said that this aspect of the proposal would have caused delay and expense in the detection and prevention of health care fraud. The commenter believed that this delay and expense could be prevented by shifting to law enforcement and health care oversight the responsibility to determine whether standards have been met.

At least one commenter recommended eliminating the three-part test for disclosures of protected health information by small providers.

Some commenters argued that allowing covered entities to rely on law enforcement representation that the three-part test has been met would render the test meaningless.

Response: Because the statute does not bring law enforcement officials within the scope of this regulation, the rule must rely on covered entities to implement standards that protect individuals’ privacy interests, including the three-part test for disclosure pursuant to administrative subpoenas. To reduce the burden on covered entities, we do not require a covered entity to second-guess representations by law enforcement officials that the three-part test has been met. Rather, we allow covered entities to disclose protected health information to law enforcement when the subpoena or other administrative request indicates on its face that the three-part test has been met, or where a separate document so indicates. Because we allow such reliance, we do not believe that it is necessary or appropriate to reduce privacy protections for individuals who obtain care from small health care providers.
Comment: Some commenters ask for modification of the three-part test to include a balancing of the interests of law enforcement and the privacy of the individual, pointing to such provisions in the Leahy-Kennedy bill.
Response: We agree with the comment that the balancing of these interests is important in this circumstance. We designed the regulation’s three-part test to accomplish that result.
Comment: At least one commenter recommended that “relevant and material” be changed to “relevant,” because “relevant” is a term at the core of civil discovery rules and is thus well understood, and because it would be difficult to determine whether information is “material” prior to seeing the documents. As an alternative, this commenter suggested explaining what we meant by “material.”
Response: Like the term “relevant,” the term “material” is commonly used in legal and well understood.
Comment: At least one commenter suggested deleting the phrase “reasonably practical” from the second prong of the test, because, the commenter believed, it was not clear who would decide what is “reasonably practical” if the law enforcement agency and covered entity disagreed.
Response: We allow covered entities to rely on a representation on the face of the subpoena that the three-part test, including the “reasonably practical” criteria, is met. If a covered entity believes that a subpoena is not valid, it may challenge that subpoena in court just as it may challenge today any subpoena that it believes is not lawfully issued. This is true regardless of the specific test that a subpoena must meet, and it is not a function of the “could not reasonably be used” criteria.

Comments Regarding Proposed § 164.510(f)(2), Limited Information for Identifying Purposes
Comment: A number of commenters recommended deletion of this provision. These commenters argued that the legal process requirements in proposed § 164.510(f)(1) should apply when protected health information is disclosed for identification purposes. At least one privacy group recommended that if the provision were not eliminated in its entirety, “suspects” should be removed from the list of individuals whose protected health information may be disclosed for identifying purposes. Many commenters expressed concern that this provision would allow compilation of large data bases of health information that could be use for purposes beyond those specified in this provision.
Response: We retain this provision in the final rule. We continue to believe that identifying fugitives, material witnesses, missing persons, and suspects is an important national priority and that allowing disclosure of limited identifying information for this purpose is in the public interest. Eliminating this provision— or eliminating suspects from the list of types of individuals about whom disclosure of protected health information to law enforcement is allowed—would impede law enforcement agencies’ ability to apprehend fugitives and suspects and to identify material witnesses and missing persons. As a result, criminals could remain at large for longer periods of time, thereby posing a threat to public safety, and missing persons could be more difficult to locate and thus encouraged.

However, as described above and in the following paragraphs, we make significant changes to this provision, to narrow the information that may be disclosed and make clear the limited purpose of the provision. For example, the proposed rule did not state explicitly whether covered entities would have been allowed to initiate—in the absence of a request from law enforcement—disclosure of protected health information to law enforcement officials for the purpose of identifying a suspect, fugitive, material witness or missing person. In the final rule, we clarify that covered entities may disclose protected health information for identifying purposes only in response to a request by a law enforcement official or agency. A “request by a law enforcement official or agency” is not limited to direct requests, but also includes oral or written requests by individuals acting on behalf of a law enforcement agency, such as a media organization broadcasting a request for the public’s assistance in identifying a suspect on the evening news. It includes “Wanted” posters, public announcements, and similar requests to the general public for assistance in locating suspects or fugitives.

Comment: A few commenters recommended additional restrictions on disclosure of protected health information for identification purposes. For example, one commenter recommended that the provision should either (1) require that the information to be disclosed for identifying purposes be relevant and material to a legitimate law enforcement inquiry and that the request be as specific and narrowly drawn as possible; or (2) limit disclosures to circumstances in which (a) a crime of violence has occurred and the perpetrator is at large, (b) the perpetrator received an injury during the commission of the crime, (c) the inquiry states with specificity the type of injury received and the time period during which treatment would have been provided, and (d) “probable cause” exists to believe the perpetrator received treatment from the provider.
Response: We do not agree that these additional restrictions are appropriate for disclosures of limited identifying information for purposes of locating or identifying suspects, fugitives, material witnesses or missing persons. The purpose of this provision is to permit law enforcement to obtain limited time-sensitive information without the process requirements applicable to disclosures for other purposes. Only limited information may be disclosed under this provision, and disclosure is permitted only in limited circumstances. We believe that these
safeguards are sufficient, and that creating additional restrictions would undermine the purpose of the provision and that it would hinder law enforcement’s ability to obtain essential, time-sensitive information.

Comment: A number of law enforcement agencies recommended that the provision in the proposed rule be broadened to permit disclosure to law enforcement officials for the purpose of “locating” as well as “identifying” a suspect, fugitive, material witness or missing person. Response: We agree with the comment and have changed the provision in the final rule. We believe that locating suspects, fugitives, material witnesses and missing persons is an important public policy priority, and that it can be critical to identifying these individuals. Further, efforts to locate suspects, fugitives, material witnesses, and missing persons can be at least as time-sensitive as identifying such individuals.

Comment: Several law enforcement agencies requested that the provision be broadened to permit disclosure of additional pieces of identifying information, such as ABO blood type and Rh factor, DNA information, dental records, fingerprints, and/or body fluid and tissue typing, samples and analysis. These commenters stated that additional identifying information may be necessary to permit identification of suspects, fugitives, material witnesses or missing persons. On the other hand, privacy and consumer advocates, as well as many individuals, were concerned that this section would allow all computerized medical records to be stored in a large law enforcement data base that could be scanned for matches of blood, DNA, or other individually identifiable information.

Response: The final rule seeks to strike a balance in protecting privacy and facilitating legitimate law enforcement inquiries. Specifically, we have broadened the NPRM’s list of data elements that may be disclosed pursuant to this section, to include disclosure of ABO blood type and Rh factor for the purpose of identifying or locating suspects, fugitives, material witnesses or missing persons. We agree with the commenters that these pieces of information are important to law enforcement investigations and are no more invasive of privacy than the other pieces of protected health information that may be disclosed under this provision.

However, as explained below, protected health information associated with DNA and DNA analysis; dental records; or typing, samples or analyses of tissues and bodily fluids other than blood (e.g., saliva) cannot be disclosed for the location and identification purposes described in this section. Allowing disclosure of this information is not necessary to accomplish the purpose of this provision, and would be substantially more intrusive into individuals’ privacy. In addition, we understand commenters’ concern about the potential for such information to be compiled in law enforcement data bases. Allowing disclosure of such information could make individuals reluctant to seek care out of fear that health information about them could be compiled in such a data base.

Comment: Many commenters argued that proposed § 164.510(f)(2) should be deleted because it would permit law enforcement to engage in “fishing expeditions” or to create large data bases that could be searched for suspects and others.

Response: Some of this fear may have stemmed from the inclusion of the phrase “other distinguishing characteristic”—which could be construed broadly—in the list of items that could have been disclosed pursuant to this section. In the final rule, we delete the phrase “other distinguishing characteristic” from the list of items that can be disclosed pursuant to § 164.512(f)(2). In its place, we allow disclosure of a description of distinguishing physical characteristics, such as scars, tattoos, height, weight, gender, race, hair and eye color, and the presence or absence of facial hair such as a beard or mustache. We believe that such a change, in addition to the changes described in the paragraph above, responds to commenters’ concern that the NPRM would have allowed creation of a government data base of personal identifying information. Further, this modification provides additional guidance to covered entities regarding the type of information that may be disclosed under this provision.

Comment: At least one commenter recommended removing social security numbers (SSNs) from the list of items that may be disclosed pursuant to proposed § 164.510(f)(2). The commenter was concerned that including SSNs in the (f)(2) list would cause law enforcement agencies to demand that providers collect SSNs. In addition, the commenter was concerned that allowing disclosure of SSNs could lead to theft of identity by unscrupulous persons in policy departments and health care organizations.

Response: We disagree. We believe that the potential benefits from use of SSNs for this purpose outweigh the potential privacy intrusion from such use of SSNs. For example, SSNs can help law enforcement officials identify suspects are using aliases.

Comments Regarding Proposed § 164.510(f)(3), Information About a Victim of Crime or Abuse

Comment: Some law enforcement organizations expressed concern that proposed § 164.510(f)(3) could inhibit compliance with state mandatory reporting laws.

Response: We recognize that the NPRM could have preempted such state mandatory reporting laws, due to the combined impact of proposed §§ 164.510(m) and 164.510(f). As explained in detail in § 164.512(a) above, we did not intend that result, and we modify the final rule to make clear that this rule does not preempt state mandatory reporting laws.

Comment: Many commenters, including consumer and provider groups, expressed concern that allowing covered entities to disclose protected health information without authorization to law enforcement regarding victims of crime, abuse, and other harm could endanger victims, particularly victims of domestic violence, who could suffer further abuse if their abuser learned that the information had been reported. Provider groups also expressed concern about undermining provider-patient relationships. Some law enforcement representatives noted that in many cases, health care providers’ voluntary reports of abuse or harm can be critical for the successful prosecution of violent crime. They argued, that by precluding providers from voluntarily reporting to law enforcement evidence of potential abuse, the proposed rule could make it more difficult to apprehend and prosecute criminals.

Response: We recognize the need for heightened sensitivity to the danger facing victims of crime in general, and victims of domestic abuse or neglect in particular. As discussed above, the final rule includes a new section (§ 164.512(c)) establishing strict conditions for disclosure of protected health information about victims of abuse, neglect, and domestic violence. Victims of crime other than abuse, neglect, or domestic violence can also be placed in further danger by disclosure of protected health information relating to the crime. In § 164.512(f)(3) of the final rule, we establish conditions for disclosure of protected health information in these circumstances, and we make significant modifications to the proposed rule’s provision for such disclosures. Under the final rule, unless a state or other...
government authority has enacted a law requiring disclosure of protected health information about a victim to law enforcement officials, in most instances, covered entities must obtain the victim’s agreement before disclosing such information to law enforcement officials. This requirement gives victims control over decision making about their health information where their safety could be at issue, helps promote trust between patients and providers, and is consistent with health care providers’ ethical obligation to seek patient authorization whenever possible before disclosing protected health information.

At the same time, the rule strikes a balance between protecting victims and providing law enforcement access to information about potential crimes that cause harm to individuals, by waiving the requirement for agreement in two situations. In allowing covered entities to disclose protected health information about a crime victim pursuant to a state or other mandatory reporting law, we defer to other governmental bodies’ judgments on when certain public policy objectives are important enough to warrant mandatory disclosure of protected health information to law enforcement. While some mandatory reporting laws are written more broadly than others, we believe that it is neither appropriate nor practicable to distinguish in federal regulations between what we consider overly broad and sufficiently focused mandatory reporting laws.

The final rule waives the requirement for agreement if the covered entity is unable to obtain the individual’s agreement due to incapacity or other emergency circumstance, and (1) the law enforcement official represents that the information is needed to determine whether a violation of law by a person other than the victim has occurred and the information is not intended to be used against the victim; (2) the law enforcement official represents that immediate law enforcement activity that depends on the disclosure would be materially and adversely affected by waiting until the individual is able to agree to the disclosure; and (3) the covered entity determines, in the exercise of professional judgment, that the disclosure is in the individual’s best interests. By allowing covered entities, in the exercise of professional judgment, to determine whether such disclosures are in the individual’s best interests, the final rule recognizes the importance of the provider-patient relationship.

In addition, the final rule allows covered entities to initiate disclosures of protected health information about victims without the victim’s permission to law enforcement officials only if such disclosure is required under a state mandatory reporting law. In other circumstances, plans and providers may disclose protected health information only in response to a request from a law enforcement official. We believe that such an approach recognizes the importance of promoting trust between victims and their health care providers. If providers could initiate reports of victim information to law enforcement officials absent a legal reporting mandate, victims may avoid giving their providers health information that could facilitate their treatment, or they may avoid seeking treatment completely.

Comment: Many commenters believed that access to medical records pursuant to this provision should occur only after judicial review. Others believed that it should occur only with patient consent or after notifying the patient of the disclosure to law enforcement. Similarly, some commenters said that the minimum necessary standard should apply to this provision, and they recommended restrictions on law enforcement agencies’ re-use of the information.

Response: As discussed above, the final rule generally requires individual agreement as a condition for disclosure of a victim’s health information; this requirement provides greater privacy protection and individual control than would a requirement for judicial review. We also discuss above the situations in which this requirement for agreement may be waived, and why that is appropriate. The requirement that covered entities disclose the minimum necessary protected health information consistent with the purpose of the disclosure applies to disclosures of protected health information about victims to law enforcement, unless the disclosure is required by law. (See § 164.514 for more detail on the requirements for minimum necessary use and disclosure of protected health information.) As described above, HIPAA does not provide statutory authority for HHS to regulate law enforcement agencies’ re-use of protected health information that they obtain pursuant to this rule.

Comment: A few commenters expressed concern that the NPRM would not have required law enforcement agencies’ requests for protected health information about victims to be in writing. They believed that written requests could promote clarity in law enforcement requests, as well as greater accountability among law enforcement officials seeking information.

Response: We do not impose this requirement in the final rule. We believe that such a requirement would not provide significant new protection for victims and would unduly impede the completion of legitimate law enforcement investigations.

Comment: A provider group was concerned that it would be difficult for covered entities to evaluate law enforcement officials’ claims that information is needed and that law enforcement activity may be necessary. Some comments from providers and individuals expressed concern that the proposed rule would have provided open-ended access by law enforcement to victims’ medical records because of this difficulty in evaluating law enforcement claims of their need for the information.

Response: We modify the NPRM in several ways that reduce covered entities’ decisionmaking burdens. The final rule clarifies that covered entities may disclose protected health information about a victim of crime where a report is required by state or other law, and it requires the victim’s agreement for disclosure in most other instances. The covered entity must make the decision whether to disclose only in limited circumstances: when there is no mandatory reporting law; or when the victim is unable to provide agreement and the law enforcement official represents that: the protected health information is needed to determine whether a violation of law by a person other than the victim has occurred, that the information will not be used against the victim, and that immediate law enforcement activity that depends on such information would be materially and adversely affected by waiting until the individual is able to agree to the disclosure. In these circumstances, we believe it is appropriate to rely on the covered entity, in the exercise of professional judgment, to determine whether the disclosure is in the individual’s best interests. Other sections of this rule allow covered entities to reasonably rely on certain representations by law enforcement officials (see § 164.514, regarding verification,) and require disclosure of the minimum necessary protected health information for this purpose. Together, these provisions do not allow open-ended access or place undue responsibility on providers.

Comments Regarding Proposed § 164.510(f)(4). Intelligence and National Security Activities

In the final rule, we recognize that disclosures for intelligence and national security activities do not always involve
law enforcement. Therefore, we delete the provisions of proposed § 164.510(f)(4), and we address disclosures for intelligence and national security activities in § 164.512(k), on uses and disclosures for specialized government functions. Comments and responses on these issues are included below, in the comments for that section.

Comments Regarding Proposed § 164.510[(f)(5). Health Care Fraud, Crimes on the Premises, and Crimes Witnessed by the Covered Entity’s Workforce

Comment: Many commenters noted that proposed § 164.510[(f)(5)i, which covered disclosures for investigations and prosecutions of health care fraud, overlapped with proposed § 164.510(c) which covered disclosures for health oversight activities.

Response: As discussed more fully in § 164.512(d) of this preamble, above, we agree that proposed § 164.510[(f)(5)i created confusion because all disclosures covered by that provision were already permitted under proposed § 164.510(c) without prior process. In the final rule, therefore, we delete proposed § 164.510[(f)(5)i.

Comment: One commenter was concerned the proposed provision would not have allowed an emergency room physician to report evidence of abuse when the suspected abuse had not been committed on the covered entity’s premises.

Response: Crimes on the premises are only one type of crime that providers may report to law enforcement officials. The rules for reporting evidence of abuse to law enforcement officials are described in § 164.512(c) of the rule, and described in detail in § 164.512(c) of the preamble. An emergency room physician may report evidence of abuse if the conditions in § 164.512(c) are met, regardless of where the abuse occurred.

Comment: One commenter argued that covered entities should be permitted to disclose information that “indicates the potential existence” of evidence, not just information that “constitutes evidence” of crimes on the premises or crimes witnessed by a member of the covered entity’s workforce.

Response: We agree that covered entities should not be required to guess correctly whether information will be admitted to court as evidence. For this reason, we include a good-faith standard in this provision. Covered entities may disclose information that it believes in good faith constitutes evidence of a crime on the premises. If the covered entity discloses protected health information in good faith but is wrong in its belief that the information is evidence of a violation of law, the covered entity will not be subject to sanction under this regulation.

Section 164.512—Uses and Disclosures About Decedents

Coroners and Medical Examiners

Comment: We received several comments, for example, from state and county health departments, a private foundation, and a provider organization, in support of the NPRM provision allowing disclosure without authorization to coroners and medical examiners.

Response: The final rule retains the NPRM’s basic approach to disclosure of coroners and medical examiners. It allows covered entities to disclose protected health information without authorization to coroners and medical examiners, for identification of a deceased person, determining cause of death, or other duties authorized by law.

Comment: In the preamble to the NPRM, we said we had considered but rejected the option of requiring covered entities to redact from individuals’ medical records any information identifying other persons before disclosing the record to a coroner or medical examiner. We solicited comment on whether health care providers routinely identify other persons specifically in an individual’s medical record and if so, whether in the final rule we should require health care providers to redact information about the other person before providing it to a coroner or medical examiner.

A few commenters said that medical records typically do not include information about persons other than the patient. One commenter said that patient medical records occasionally reference others such as relatives or employers. These commenters recommended requiring redaction of such information in any report sent to a coroner or medical examiner. On the other hand, other commenters said that redaction should not be required. These commenters generally based their recommendation on the burden and delay associated with redaction. In addition to citing the complexity and time involved in redaction of medical records provided to coroners, one commenter said that health plans and covered health care providers were not trained to determine the identifiable information necessary for coroners and medical examiners to do thorough investigations. Another commenter said that redaction should not be required because coroners and medical examiners needed some additional family information to determine what would be done with the deceased after their post-mortem investigation is completed.

Response: We recognize the burden associated with redacting medical records to remove the names of persons other than the patient. In addition, as stated in the preamble to the NPRM, we recognize that there is a limited time period after death within which an autopsy must be conducted. We believe that the delay associated with this burden could make it impossible to conduct a post-mortem investigation within the required time frame. In addition, we agree that health plans and covered health care providers may lack the training necessary to determine the identifiable information necessary for coroners and medical examiners to do thorough investigations. Thus, in the final rule, we do not require health plans or covered providers to redact information about persons other than the patient who may be identified in a patient’s medical record before disclosing the record to a coroner or medical examiner.

Comment: One commenter said that medical records sent to coroners and medical examiners were considered their work product and thus were not released from their offices to anyone else. The commenter recommended that HHS establish regulations on how to dispose of medical records and that we create a “no re-release” statement to ensure that individual privacy is maintained without compromising coroners’ or medical examiners’ access to protected health information. The organization said that such a policy should apply regardless of whether the investigation was civil or criminal.

Response: HIPAA does not provide HHS with statutory authority to regulate coroners’ or medical examiners’ re-use or re-disclosure of protected health information unless the coroner or medical examiner is also a covered entity. However, we consistently have supported comprehensive privacy legislation to regulate disclosure and use of individually identifiable health information by all entities that have access to it.

Funeral Directors

Comment: One commenter recommended modifying the proposed rule to allow disclosure without authorization to funeral directors. To accomplish this change, the commenter suggested either: (1) Adding another subsection to proposed § 164.510 of the NPRM, to allow disclosure without authorization to funeral directors as needed to make arrangements for
funeral services and for disposition of a deceased person's remains; or (2) revising proposed § 164.510(e) to allow disclosure of protected health information to both coroners and funeral directors. According to this commenter, funeral directors often need certain protected health information for the embalming process, because a person's medical condition may affect the way in which embalming is performed. For example, the commenter noted, funeral directors increasingly receive bodies after organ and tissue donation, which has implications for funeral home staff duties associated with embalming.

**Response:** We agree with the commenter. In the final rule, we permit covered entities to disclose protected health information to funeral directors, consistent with applicable law, as necessary to carry out their duties with respect to a decedent. When necessary for funeral directors to carry out their duties, covered entities may disclose protected health information prior to and in reasonable anticipation of the individual's death.

**Comment:** One commenter recommended clarifying in the final rule that it does not restrict law enforcement agencies' release of medical information that many state records laws require to be reported, for example, as part of autopsy reports. The commenter recommended stating that law enforcement officials may independently gather medical information, that such information would not be covered by these rules, and that it would continue to be covered under applicable state and federal access laws.

**Response:** HIPAA does not give HHS statutory authority to regulate law enforcement officials' use or disclosure of protected health information. As stated elsewhere, we continue to support enactment of comprehensive privacy legislation to cover disclosure and use of all individually identifiable health information.

**Comment:** One commenter recommended prohibiting health plans and covered health care providers from disclosing psychotherapy notes to coroners or medical examiners.

**Response:** We disagree with the commenter who asserted that psychotherapy notes should only be used by or disclosed to coroners and medical examiners with authorization. Psychotherapy notes are sometimes needed by coroners and medical examiners to determine cause of death, such as in cases where suicide is suspected as the cause of death. We understand that several states require the disclosure of protected health information, including psychotherapy notes, to medical examiners and coroners. However, in the absence of a state law requiring such disclosure, we do not intend to prohibit coroners or medical examiners from obtaining the protected health information necessary to determine an individual's cause of death.

**Section 164.512(h)—Uses and Disclosures for Organ Donation and Transplantation Purposes**

**Comment:** Commenters noted that under the organ donation system, information about a patient is disclosed before seeking consent for donation from families. These commenters offered suggestions for ensuring that the system could continue to operate without consent for information sharing with organ procurement organizations and tissue banks. Commenters suggested that organ and tissue procurement organizations should be "covered entities" or that the procurement of organs and tissues be included in the definition of health care operations or treatment, or in the definition of emergency circumstances.

**Response:** We agree that organ and tissue donation is a special situation due to the need to protect potential donors' families from the stress of considering whether their loved one should be a donor before a determination has been made that donation would be medically suitable. Rather than list the entities that are "covered entities" or modify the definitions of health care operations and treatment or emergency circumstances to explicitly include organ procurement organizations and tissue banks, we have modified § 164.512 to permit covered entities to use or disclose protected health information to organ procurement organizations or other entities engaged in the procurement, banking, or transplantation of cadaveric organs, eyes, or tissues.

**Comment:** Commenters asked that the rule clarify that organ procurement organizations are health care providers but not business partners of the hospitals.

**Response:** We agree that organ procurement organizations and tissue banks are generally not business associates of hospitals.

**Disclosures and Uses for Government Health Data Systems**

**Comment:** We received a number of comments supporting the exception for disclosure of protected health information to government health data systems. Some supporters stated a general belief that the uses of such information were important to improve and protect the health of the public. Commenters said that state agencies used the information from government health data systems to contribute to the improvement of the health care system by helping prevent fraud and abuse and helping improve health care quality, efficiency, and cost-effectiveness. Commenters asserted that state agencies take action to ensure that data they release based on these data systems do not identify individuals.

We also received a large volume of comments opposed to the exception for use and disclosure of protected health information for government health data systems. Many commenters expressed general concern that the provision threatened their privacy, and many believed that their health information would be subject to abuse by government employees. Commenters expressed concern that the provision would facilitate collection of protected health information in one large centralized government health database that could threaten privacy. Others argued that the proposed rule would facilitate law enforcement access to protected health information and could, in fact, become a database for law enforcement use.

Many commenters asserted that this provision would make individuals concerned about confiding in their health care providers. Some commenters argued that the government should not be allowed to collect individually identifiable health information without patient consent, and that the government could use de-identified data to perform the public policy analyses. Many individual commenters said that HHS lacked statutory and Constitutional authority to give the government access and control of their medical records without consent.

Many commenters believed that the NPRM language on government health data systems was too broad and would allow virtually any government collection of data to be covered. They argued that the government health data system exception was unnecessary because there were other provisions in the proposed rules providing sufficient authority for government agencies to obtain the information they need.

Some commenters were concerned that the NPRM's government health data system provisions would allow disclosure of protected health information for purposes unrelated to health care. These commenters recommended narrowing the provision to allow disclosure of protected health information to government health data systems.
information without consent to government health data systems in support of health care-related policy, planning, regulatory, or management functions. Others recommended narrowing the exception to allow use and disclosure of protected health information for government health databases only when a specific statute or regulation has authorized collection of protected health information for a specific purpose.

Response: We agree with the commenters who suggested that the proposed provision that would have permitted disclosures to government health data bases was overly broad, and we remove it from the final rule.

We reviewed the important purposes identified in the comments for government access to protected health information, and believe that the disclosures of protected health information that should appropriately be made without individuals’ authorization can be achieved through the other provisions provided for in the final rule, including provisions permitting covered entities to disclose information (subject to certain limitations) to government agencies for public health, research, health oversight, law enforcement, and otherwise as required by law. For example, the final rule continues to allow a covered entity to disclose protected health information without authorization to a public health authority to monitor trends in the spread of infectious disease, morbidity, and mortality. Unless the rule’s health oversight provision, covered entities can continue to disclose protected health information to public agencies for purposes such as analyzing the cost and quality of services provided by covered entities; evaluating the effectiveness of federal, state, and local public programs; examining trends in health insurance coverage of the population; and analyzing variations in access to health coverage among various segments of the population. We believe that it is better to remove proposed provision for government health data systems generally and to rely on other, more narrowly tailored provisions in the rule to authorize appropriate disclosures to government agencies.

Comment: Some provider groups, private companies, and industry organizations recommended expanding the exception for government health data systems to include data collected by private entities. These commenters said that such an expansion would be justified because private entities often perform the same functions as public agencies collecting health data.

Response: We eliminate the exception for government health data systems because it was over broad and the uses and disclosures we were trying to permit are permitted by other provisions. We note that private organizations may use or disclose protected health information pursuant to multiple provisions of the rule.

Comment: One commenter recommended clarifying in the final rule that the government health data system provisions apply to: (1) Manufacturers providing data to HCFA and its contractors to help the agency make reimbursement and related decisions; and (2) third-party payors that must provide data collected by device manufacturers to HCFA to help the agency make reimbursement and related decisions.

Response: The decision to eliminate the general provision permitting disclosures to government health data systems makes this issue moot with respect to such disclosures. We note that the information used by manufacturers to support coverage determinations is gathered pursuant to patient authorization (as part of informed consent for research) or as an approved research project. There are many cases in which information can be de-identified before it is disclosed. Where HCFA hires a contractor to collect such protected health information, the contractor may do so under HCFA’s authority, subject to the business associate provisions of this rule.

Comment: One commenter recommended stating in the final rule that de-identified information from government health data systems can be disclosed to other entities.

Response: HHS does not have the authority to regulate re-use or re-disclosure of information by agencies or institutions that are not covered entities under the rule. However, we support the policies and procedures that public agencies already have implemented to de-identify any information that they redisclose, and we encourage the continuation of these activities.

Disclosures for Payment Processes

Proposed § 164.510(j) of the NPRM would have allowed disclosure of protected health information without authorization for banking and payment processes. In the final rule, we eliminate this provision. Disclosures that would have been allowed under it, as well as comments received on proposed § 164.510(j), are covered under § 164.501 of the final rule, under the definition of “payment.”

Section 164.512(i)—Uses and Disclosures for Research Purposes

Documentation Requirements of IRB or Privacy Board Approval of Waiver

Comment: A number of commenters argued that the proposed research requirements of § 164.510(j) exceeded the Secretary’s authority under section 246(c) of HIPAA. In particular, several commenters argued that the Department was proposing to extend the Common Rule and the use of the IRB or privacy boards beyond federally-funded research projects, without the necessary authority under HIPAA to do so. One commenter stated that, “Section 246(c) of HIPAA requires the Secretary to issue a regulation setting privacy standards for individually identifiable health information transmitted in connection with the transactions described in section 1173(a),” and thus concluded that the disclosure of health information to researchers is not covered. Some of these commenters also argued that the documentation requirements of proposed § 164.510(j), did not shield the NRPM from having the effect of regulating research by placing the onus on covered health care providers to seek documentation that certain standards had been satisfied before providing protected health information to researchers. These commenters argued that the proposed rule had the clear and intended effect of directly regulating researchers who wish to obtain protected health information from a covered entity.

Response: As discussed above, we do not agree with commenters that the Secretary’s authority is limited to individually identifiable health information transmitted in connection with the transactions described in section 1173(a) of HIPAA. We also disagree that the proposed research documentation requirements would have constituted the unauthorized regulation of researchers. The proposed requirements established conditions for the use of protected health information by covered entities for research and the disclosure of protected health information by covered entities to researchers. HIPAA authorizes the Secretary to regulate such uses and disclosures, and the final rule retains documentation requirements similar to those proposed.

Comment: Several commenters believed that the NPRM was proposing either directly or indirectly to modify the Common Rule and, therefore, stated that such modification was beyond the Secretary’s authority under HIPAA. Many of these commenters arrived at this conclusion because the waiver of
authorization criteria proposed in § 164.510(j) differed from the Common Rule's criteria for the waiver of informed consent (Common Rule, § .116(d)).

Response: We do not agree that the proposed provision relating to research would have modified the Common Rule. The provisions that we proposed and provisions that we include in the final rule place conditions that must be met before a covered entity may use or disclose protected health information. Those conditions are in addition to any conditions required of research entities under the Common Rule. Covered entities will certainly be subject to laws and regulations in addition to the rule, but the rule does not require compliance with these other laws or regulations. For covered health care providers and health plans that are subject to both the final rule and the Common Rule, both sets of regulations will need to be followed.

Comment: A few commenters suggested that the Common Rule should be extended to all research, regardless of funding source.

Response: We generally agree with the commenters on the need to provide protections to all human subjects research, regardless of funding source. HIPAA, however, did not provide the Department with authority to extend the Common Rule beyond its current purview. For research that relies on the use or disclosure of protected health information by covered entities without authorization, the final rule applies the Common Rule's principles for protecting research subjects by, in most instances, requiring documentation of independent board review, and a finding that specified criteria designed to protect the privacy of prospective research subjects have been met.

Comment: A large number of commenters agreed that the research use and disclosure of protected health information should not require authorization. Of these commenters, many supported the proposed rule’s approach to research uses and disclosures without authorization, including many from health care provider organizations, the mental health community, and members of Congress. Others, while they agreed that the research use and disclosure should not require authorization disagreed with the NPRM’s approach and proposed alternative models.

The commenters who supported the NPRM’s approach to permitting researchers access to protected health information with authorization argued that it was appropriate to apply “Common Rule-like” provisions to privately funded research. In addition, several commenters explicitly argued that the option to use a privacy board, in lieu of an IRB, must be maintained because requiring IRB review to include all aspects of patient privacy could diffuse focus and significantly compromise an IRB’s ability to execute its primary patient protection role. Furthermore, several commenters believed that privacy board review should be permitted, but wanted equal oversight and accountability for privacy boards and IRBs.

Many other commenters agreed that the research use and disclosure should not require authorization, but disagreed with the proposed rule’s approach and proposed alternative models. Several of these commenters argued that the final rule should eliminate the option for privacy board review and that all research to be subject to IRB review. These commenters stated that having separate and unequal systems to approve research based on its funding source would complicate compliance and go against the spirit of the regulations. Several of these commenters, many from patient and provider organizations, opposed the permitted use of privacy boards to review research studies and instead argued that IRB review should be required for all studies involving the use or disclosure of protected health information. These commenters argued that although privacy board requirements would be similar, they are not equitable; for example, only three of the Common Rule’s six requirements for the membership of IRBs were proposed to be required for the membership on privacy boards, and there was no proposed requirement for annual review of ongoing research studies that used protected health information. These commenters argued that although privacy board requirements would be similar, they are not equitable; for example, only three of the Common Rule’s six requirements for the membership of IRBs were proposed to be required for the membership on privacy boards, and there was no proposed requirement for annual review of ongoing research studies that used protected health information. Several commenters were concerned that the proposed option to obtain documentation of privacy board review, in lieu of IRB review, would perpetuate the divide in the oversight of federally-funded versus publically-funded research, rather than eliminate the differential in publically-funded and privately-funded research, with the former still being held to a stricter standard. Some of these commenters argued that these unequal protections would be especially apparent for the disclosure of research with authorization, since under the Common Rule, IRB review of human subjects studies is required, regardless of the subject’s consent, before the study may be conducted.

Response: Although we share the concern raised by commenters that the option for the documentation of privacy board approval for an alteration or waiver of authorization may perpetuate the unequal mechanisms of protecting the privacy of human research subjects for federally-funded versus publically-funded research, the final rule is limited by HIPAA to addressing only the use and disclosure of protected health information by covered entities, not the protection of human research subjects more generally. Therefore, the rule cannot standardize human subjects protections throughout the country. Given the limited scope of the final rule with regard to research, the Department believes that the option to obtain documentation of privacy board approval for an alteration or waiver of authorization in lieu of IRB approval provides covered entities with needed flexibility. Therefore, in the final rule we have retained the option for covered entities to rely on documentation of privacy board approval that specified criteria have been met.

We disagree with the rationale suggested by commenters who argued that the option for privacy board review must be maintained because requiring IRB review to include all aspects of patient privacy could diffuse focus and significantly compromise an IRB’s ability to execute its primary patient protection role. For research that involves the use of individually identifiable health information, assessing the risk to the privacy of research subjects is currently one of the key risks that must be assessed and addressed by IRBs. In fact, we expect that many research organizations that have existing IRBs to rely on these IRBs to meet the documentation requirements of § 164.512(i).

Comment: One health care provider organization recommended that the IRB or privacy board mechanism of review should be applied to non-research uses and disclosures.

Response: We disagree. Imposing documentation of privacy board approval for other public policy uses and disclosures permitted by § 164.512 would result in undue delays in the use or disclosure of protected health information that could harm individuals and the public. For example, requiring that covered health care providers obtain third-party review before permitting them to alert a public health authority that an individual was infected with a serious communicable disease could cause delay appropriate intervention by a public health authority and could present a serious threat to the health of many individuals.

Comment: A number of commenters, including several members of Congress,
argued that since the research provisions in proposed § 164.510(j) were modeled on the existing system of human subjects protections, they were inadequate and would shatter public trust if implemented. Similarly, some commenters, asserted that IRBs are not accustomed to reviewing and approving utilization reviews, outcomes research, or disease management programs and, therefore, IRB review may not be an effective tool for protecting patient privacy in connection with these activities. Some of these commenters noted that proposed § 164.510(j) would exacerbate the problems inherent in the current federal human subjects protection system especially in light of the recent GAO reports that indicate the IRB system is already over-extended.

Furthermore, a few commenters argued that the Common Rule’s requirements may be suited for interventional research involving human subjects, but is ill suited to the archival and health services research typically performed using medical records without authorization. Therefore, these commenters concluded that extending “Common Rule-like” provisions to the private sector would be inadequate to protect human subjects and would result in significant and unnecessary cost increases.

Response: While the vast majority of government-supported and regulated research adheres to strict protocols and the highest ethical standards, we agree that the federal system of human subjects protections can and must be strengthened. To work toward this goal, on May 23, the Secretary announced several additional initiatives to enhance the safety of subjects in clinical trials, strengthen government oversight of medical research, and reinforce clinical researchers’ responsibility to follow federal guidelines. As part of this initiative, the National Institutes of Health have undertaken an aggressive effort to ensure IRB members and IRB staff receive appropriate training in bioethics and other issues related to research involving human subjects, including research that involves the use of individually identifiable health information. With these added improvements, we believe that the federal system of human subjects protections continues to be a good model to protect the privacy of individually identifiable health information that is used for research purposes. This model of privacy protection is also consistent with the recent recommendations of both the Institute of Medicine in their report entitled, “Protecting Data Privacy in Health Services Research,” and the Joint Commission on Accreditation of Healthcare Organizations and the National Committee for Quality Assurance in their report entitled, “Protecting Personal Health Information: A Framework for Meeting the Challenges in a Managed Care Environment.” Both of these reports similarly concluded that health services research that involves the use of individually identifiable health information should undergo IRB review or review by another board with sufficient expertise in privacy and confidentiality protection.

Furthermore, it is important to recognize that the Common Rule applies not only to interventional research, but also to research that uses individually identifiable health information, including archival research and health services research. The National Bioethics Advisory Commission (NBAC) is currently developing a report on the federal oversight of human subjects research, which is expected to address the unique issues raised by non-interventional human subjects research. The Department looks forward to receiving NBAC’s report, and carefully considering the Commission’s recommendations. This final rule is the first step in enhancing patients’ privacy and we will propose modifications to the rule if changes are warranted by the Commission’s findings and recommendations.

Comment: Many commenters argued that the proposed research provision would have a chilling effect on the willingness of health plans and covered providers to participate in research because of the criminal and civil penalties that could be imposed for failing to meet the requirements that would have been required by proposed § 164.510(j). Some of these commenters cautioned, that over time, research could be severely hindered if covered entities choose not to disclose protected health information to researchers. In addition, one commenter recommended that a more reasonable approach would be to require IRB or privacy board approval only if the results of the research were to be broadly published. Another commenter expressed concern that the privacy rule could influence IRBs or privacy boards to refuse to recognize the validity of decisions by other IRBs or privacy boards and specifically recommended that the privacy rule include a preamble statement that: (1) The “risk” balancing consider only the risk to the patient, not the research to the population; and (2) add a phrase that the decision by the initial IRB or privacy board to approve the research shall be given deference by other IRBs or privacy boards. This commenter also recommended that to determine whether IRBs or privacy boards were giving such deference to prior IRB or privacy board review, HHS should monitor the disapproval rate by IRB or privacy boards conducting secondary reviews.

Response: As the largest federal sponsor of medical research, we understand the important role of research in improving our Nation’s health. However, the benefits of research must be balanced against the risks, including the privacy risks, for those who participate in research. An individual’s rights and welfare must never be sacrificed for scientific or medical progress. We believe that the requirements for the use and disclosure of protected health information for research without authorization provides an appropriate balance. We understand that some covered health care providers and health plans may conclude that the rule’s documentation requirements for research uses and disclosures are too burdensome.

We rejected the recommendation that documentation of IRB or privacy board approval of the waiver of authorization should only be required if the research were to be “broadly published.” Research findings that are published in de-identified form have little influence on the privacy interests of individuals. We believe that it is the use or disclosure of individually identifiable health information to a researcher that poses the greater risk to individuals’ privacy, not publication of de-identified information.

We agree with the commenters that IRB or privacy board review should address the privacy interests of individuals and not institutions. This provision is intended to protect individuals from unnecessary uses and disclosures of their health information and does not address institutional privacy.

We disagree with the comment that documentation of IRB or privacy board approval of the waiver of authorization should be given deference by other IRBs or privacy boards conducting secondary reviews. We do not believe that it is appropriate to restrict the deliberations or judgments of privacy boards, nor do we have the authority under this rule to instruct IRBs on this issue. Instead, we reiterate that all disclosures for research purposes under § 164.512(j) are voluntary, and that institutions may choose to impose additional requirements for any use and disclosure permitted under § 164.512.
Comment: Some commenters were concerned about the implications of proposed § 164.510(j) on multi-center research. These commenters argued that for multi-center research, researchers may require protected health information from multiple covered entities, each of whom may have different requirements for the documentation of IRB or privacy board review. Therefore, there was concern that documentation that may suffice for one covered entity, may not for another, thereby hindering multi-center research.

Response: Since § 164.512(i) establishes minimum documentation standards for covered health care providers and health plans using or disclosing protected health information for research purposes, we understand that some covered providers and health plans may choose to require additional documentation requirements for researchers. We note, however, that nothing in the final rule would preclude a covered health care provider or health plan from developing the consistent documentation requirements provided they meet the requirements of § 164.512(i).

Comment: One commenter who was also concerned that the minimum necessary requirements of proposed § 164.506(b) would negatively affect multi-center research because covered entities participating in multi-site research studies would no longer be permitted to rely upon the consent form approved by a central IRB, and nor would participating entities be permitted to report data to the researcher using the case report form approved by the central IRB to guide what data points to include. This commenter noted that the requirement that each site would need to undertake a separate minimum necessary review for each disclosure would erect significant barriers to the conduct of research and may compromise the integrity and validity of data combined from multiple sites. This commenter recommended that the Secretary absolve a covered entity of the responsibility to make its own individual minimum necessary determinations if the entity is disclosing information pursuant to an IRB or privacy board-approved protocol.

Response: The minimum necessary requirements in the final rule have been revised to permit covered entities to rely on the documentation of IRB or privacy board approval as meeting the minimum necessary requirements of § 164.514. However, we anticipate that much multi-site research, such as multi-site clinical trials, will be conducted with patients’ informed consent as required by the Common Rule and FDA’s protection of human subjects regulations, and that patients’ authorization will also be sought for the use or disclosure of protected health information for such studies. Therefore, it should be noted that the minimum necessary requirements do not apply for uses or disclosures made with an authorization. In addition, the final rule allows a covered health care provider or health plan to use or disclose protected health information pursuant to an authorization that was approved by a single IRB or privacy board, provided the authorization met the requirements of § 164.508. The final rule does not, however, require IRB or privacy board review for the use or disclosure of protected health information for research conducted with individuals’ authorization.

Comment: Some commenters believed that proposed § 164.510(j) would have required documentation of both IRB and privacy board review before a covered entity would be permitted to disclose protected health information for research purposes without an individual’s authorization.

Response: This is incorrect. Section 164.512(i)(1)(i) of the final rule requires documentation of alteration or waiver approval by either an IRB or a privacy board.

Comment: Some commenters believed that the proposed rule would have required that patients be notified whenever protected health information about themselves was disclosed for research purposes.

Response: This is incorrect. Covered entities are not required to inform individuals that protected health information about themselves has been disclosed for research purposes. However, as required in § 164.520 of the final rule, the covered entity must include research disclosures in their notice of information practices. In addition, as required by § 164.528 of the rule, covered health care providers and health plans must provide individuals, upon request, with an accounting of disclosures made of protected health information about the individual.

Comment: One commenter recommended that IRB and privacy boards also be required to be accredited.

Response: While we agree that the issue of accrediting IRBs and privacy boards deserves further consideration, we believe it is premature to require covered entities to ensure that the IRB or privacy board that approves an alteration or waiver of authorization is accredited. Currently, there are no accreditation standards for IRBs or privacy boards, nor a designated accreditation body. Recognizing the need for and value of greater uniformity and public accountability in the review and approval process, HHS, with support from the Office of Human Research Protection, National Institutes of Health, Food and Drug Administration, Centers for Disease Control and Prevention, and Agency for Health Care Research and Quality, has engaged the Institute of Medicine to recommend uniform performance resource-based standards for private, voluntary accreditation of IRBs. This effort will draw upon work already undertaken by major national organizations to develop and test these standards by the spring of 2001, followed by initiation of a formal accreditation process before the end of next year. Once the Department has received the Institute of Medicine’s recommended accreditation standards and process for IRBs, we plan to consider whether this accreditation model would also be applicable to privacy boards.

Comment: A few commenters also noted that if both an IRB and a privacy board reviewed a research study and came to conflicting decisions, proposed § 164.510(j) was unclear about which board’s decision would prevail.

Response: The final rule does not stipulate which board’s decision would prevail if an IRB and a privacy board came to conflicting decisions. The final rule requires covered entities to obtain documentation that one IRB or privacy board has approved of the alteration or waiver of authorization. The covered entity, however, has the right to request information about the findings of all IRBs and/or privacy boards that have reviewed a research proposal. We strongly encourage researchers to notify IRBs and privacy boards of any prior IRB or privacy board review of a research protocol.

Comment: Many commenters noted that the NPRM included no guidance on how the privacy board should approve or deny researchers’ requests. Some of these commenters recommended that the regulation stipulate that privacy boards be required to follow the same voting rules as required under the Common Rule.

Response: We agree that the Common Rule (§ .108(b)) provides a good model of voting procedures for privacy boards and incorporate such procedures to the extent they are relevant. In the final rule, we require that the documentation of alteration or waiver of authorization state that the alteration or waiver has been reviewed and approved by either the IRB that has first discretion in the voting requirements of the Common Rule (§ .108(b)), or the expedited review
procedures of the Common Rule (§ 160.110); or (2) unless an expedited review procedure is used, a privacy board that has reviewed the proposed research at a convened meeting at which a majority of the privacy board members are present, including at least one member who is not affiliated with the covered entity, not affiliated with any entity conducting or sponsoring the research, and not related to any person who is affiliated with any such entities, and the alteration or waiver of authorization is approved by the majority of privacy board members present at the meeting.

Comment: A few commenters were concerned that the research provisions would be especially onerous for small non-governmental entities, furthering the federal monopoly on research.

Response: We understand that the documentation requirements of § 164.512(i), as well as other provisions in the final rule, may be more onerous for small entities than for larger entities. We believe, however, that when protected health information is to be used or disclosed for research without an individual’s authorization, the additional privacy protections in § 164.512(i) are essential to reduce the risk of harm to the individual.

Comment: One commenter believed that it was paradoxical that, under the proposed rule, the disclosure of protected health information for research conducted with an authorization would have been more heavily burdened than research that was conducted without authorization, which they reasoned was far less likely to bring personal benefit to the research subjects.

Response: It was not our intent to impose more requirements on covered entities using or disclosing protected health information for research conducted with authorization than for research conducted without authorization. In fact, the proposed rule would have required only authorization as stipulated in proposed § 164.508 for research disclosures made with authorization, and would have been exempt from the documentation requirements in proposed § 164.510(j). We retain this treatment in the final rule. We disagree with the commenter who asserted that the requirements for research conducted with authorization are more burdensome for covered health care providers and plans than the documentation provisions of this paragraph.

Comment: A number of commenters were concerned that HIPAA did not give the Secretary the authority to protect information once it was disclosed to researchers who were not covered entities.

Response: The Secretary shares these commenters’ concerns about the Department’s limited authority under HIPAA. We strongly support the enactment of additional federal legislation to fill these crucial gaps in the Secretary’s authority.

Comment: We agree that HIPAA did not give us the authority to incorporate this requirement into the final rule.

Comment: One commenter recommended that whenever health information is used for research or administrative purposes, a plan is in place to evaluate whether to and how to feed patient-specific information back to the health system to benefit an individual or group of patients from whom the health information was derived.

Response: While we agree that this recommendation is consistent with the requirements of § 164.512(i).

Comment: One commenter recommended that IRBs be required to maintain web sites with information on proposed and approved projects.

Response: We agree that it could be useful for IRBs and privacy boards to maintain web sites with information on proposed and approved projects. However, requiring this of IRBs and privacy boards is beyond the scope of our authority under HIPAA. In addition, this recommendation raises concerns that would need to be addressed, including concerns about protecting the confidentiality of research participants and propriety information that may be contained in research proposals. For these reasons, we decided not to incorporate this requirement into the final rule.

Comment: A few commenters were concerned that HIPAA did not give us the authority to require the Secretary to collect data on research-related breaches of confidentiality and investigate existing anecdotal reports of such breaches.

Response: This recommendation is beyond HIPAA’s legal authority, since HIPAA did not give us the authority to regulate researchers. Therefore, this recommendation was not included in the final rule.

Comment: A number of commenters were concerned that HIPAA did not give the Secretary the authority to protect information once it was disclosed to researchers who were not covered entities.

Response: The Secretary shares these commenters’ concerns about the Department’s limited authority under HIPAA. We strongly support the enactment of additional federal legislation to fill these crucial gaps in the Secretary’s authority.

Comment: One commenter recommended that covered entities should be required to retain the IRB’s or privacy board’s documentation of approval of the waiver of individuals’ authorization for at least six years from when the waiver was obtained.

Response: We agree with this comment and have included such a requirement in the final rule. See § 164.530(j).
responsible conduct of research, HIPAA did not give us the authority to regulate research. Therefore, this recommendation was not included in the final rule.

Comment: A few commenters recommended that contracts between covered entities and researcher be pursued. Comments received in favor of requiring contractual agreements argued that such a contract would be enforceable under law, and should prohibit secondary disclosures by researchers. Some of these commenters recommended that contracts between covered entities and researchers should be the same as, or modeled on, the proposed requirements for business partners. In addition, some commenters argued that contracts between covered entities and researchers should be required as a means of placing equal responsibility on the researcher for protecting health information and for not improperly re-identifying information.

Response: In the final rule, we have added an additional waiver criteria to require that there are adequate written assurances from the researcher that protected health information will not be re-used or disclosed to any other person or entity, except as required by law, for authorized oversight of the research project, or for other research for which the use or disclosure of protected health information would be permitted by this subpart. We believe that this additional waiver criteria provides additional assurance that protected health information will not be misused by researchers, while not imposing the additional burdens of a contractual requirement on covered health care providers and health plans. We were not persuaded by the comments received that contractual requirements would provide necessary additional protections, that would not also be provided by the less burdensome waiver criteria for adequate written assurance that the researcher will not re-use or disclose protected health information, with few exceptions. Our intent was to strengthen and extend existing contractual requirements in the Common Rule, on which our proposed requirements for research uses and disclosures were modeled.

Comment: Many commenters recommended that the privacy rule permit individuals to opt out of having their records used for the identified “important” public policy purposes in § 164.510, including for research purposes. These commenters asserted that permitting the use and disclosure of their protected health information without their consent, or without an opportunity to “opt out” of having their information used or disclosed, abridged individuals’ right to decide who should be permitted access to their medical records. In addition, one commenter argued that although the research community has been sharply critical of a Minnesota law that limits access to health records (Minnesota Statute Section 144.335 (1998)), researchers have cited a lack of response to mailed consent forms as the primary factor behind a decrease in the percentage of medical records available for research. This commenter argued that an opt-out provision would not be subject to this “nonresponder” problem.

Response: We believe that a meaningful right to “opt out” of a research study requires that individuals be contacted and informed about the study for which protected health information about themselves is being requested by a researcher. We concluded, therefore, that an “opt out” provision of this nature may suffer from
the same decliner bias that has been experienced by researchers who are subject to laws that require patient consent for medical records research. Furthermore, evidence on the effect of a mandatory “opt out” provision for medical records research is only fragmentary at this time, but at least one study has preliminarily suggested that those who refuse to consent for research access to their medical records may differ in statistically significant ways from those who consent with respect to variables such as age and disease category [SJ Jacobsen et al. “Potential Effect of Authorization Bias on Medical Records Research.” Mayo Clin Proc 74: (1999) 330–338]. For these reasons, we disagree with the commenters who recommended that an “opt out” provision be included in the final rule. In the final rule, we do require covered entities to include research disclosures in their notice of information practices. Therefore, individuals who do not wish for protected health information about themselves to be disclosed for research purposes without their authorization could select a health care provider or health plan on this basis. In addition, the final rule also permits covered health care providers or health plans to agree not to disclose protected health information for research purposes, even if research disclosures would otherwise be permitted under their notice of information practices. Such an agreement between a covered health care provider or health plan and an individual would not be enforceable under the final rule, but might be enforceable under applicable state law. 

Comment: Some commenters explicitly recommended that there should be no provision permitting individuals to opt out of having their information used for research purposes.

Response: We agree with these commenters for the reasons discussed above.

IRB and Privacy Board Review

Comments: The NPRM imposed no requirements for the location or sponsorship of the IRB or privacy board. One commenter supported the proposed approach to permit covered entities to rely on documentation of a waiver by a IRB or privacy board that was convened by the covered entity, the researcher, or another entity.

In contrast, a few commenters recommended that the NPRM require that the IRB or privacy board be outside of the entity conducting the research, although the rationale for these recommendations was not provided. Several industry and consumer groups alternatively recommended that the regulation require that privacy boards be based at the covered entity. These comments argued that “if the privacy board is to be based at the entity receiving data, and that entity is not a covered entity, there will be little ability to enforce the regulation or study the effectiveness of the standards.”

Response: We agree with the comment supporting the proposed rule’s provision to impose no requirements for the location or sponsorship of the IRB or privacy board that was convened to review a research proposal for the alteration or waiver of authorization criteria. In the absence of a rationale, we were not persuaded by the comments asserting that the IRB or privacy board should be convened outside of the covered entity. In addition, while we agree with the comments that asserted HHS would have a greater ability to enforce the rule if a privacy board was established at the covered entity rather than an unaffiliated entity, we concluded that the additional burden that such a requirement would place on covered entities was unwarranted. Furthermore, under the Common Rule and FDA’s protection of human subjects regulations, IRB review often occurs at the site of the recipient researchers’ institution, and it was not our intent to change this practice. Therefore, in the final rule, we continue to impose no requirements for the location or sponsorship of the IRB or privacy board.

Privacy Board Membership

Comment: Some commenters were concerned that the proposed composition of the privacy board did not adequately address potential conflicts of interest of the board members, particularly since the proposed rule would have permitted the board’s “unaffiliated” member to be affiliated with the entity disclosing the protected health information for research purposes. To address this concern, some commenters recommended that the required composition of privacy boards be modified to require ** * at least one member who is not affiliated with the entity receiving or disclosing protected health information.” These commenters believed that this addition would be more sound and more consistent with the Common Rule’s requirements for the composition of IRBs. Furthermore, it was argued that this requirement would prohibit covered entities from creating a privacy board comprised entirely of its own employees.

Response: We agree with these comments. In the final rule we have revised the proposed membership for privacy board to reduce potential conflict of interest among board members. The final rule requires that documentation of alteration or waiver from a privacy board, is only valid under § 164.512(f) if the privacy board includes at least one member who is not affiliated with the covered entity, not affiliated with any entity conducting or sponsoring the research, and not related to a person who is affiliated with such entities.

Comment: One commenter recommended that privacy boards be required to include more than one unaffiliated member to address concerns about conflict of interest among members.

Response: We disagree that privacy boards should be required to include more than one unaffiliated member. We believe that the revised membership criterion for the unaffiliated member of the privacy board, and the criterion that requires that the board have no member participating in a review of any project in which the member has a conflict of interest, are sufficient to ensure that no member of the board has a conflict of interest in a research proposal under their review.

Comment: Many commenters also recommended that the membership of privacy boards be required to be more similar to that of IRBs. These commenters were concerned that privacy boards, as described in the proposed rule, would not have the needed expertise to adequately review and oversee research involving the use of protected health information. A few of these commenters also recommended that IRBs be required to have at least one member trained in privacy or security matters.

Response: We disagree with the comments asserting that the membership of privacy boards should be required be more similar to IRBs. Unlike IRBs, privacy boards only have responsibility for reviewing research proposals that involve the use or disclosure of protected health information without authorization. We agree, however, that the proposed rule may not have ensured that the privacy board had the necessary expertise to protect adequately individuals’ privacy rights and interests. Therefore, in the final rule, we have modified one of the membership criteria for privacy board to require that the board has members with varying backgrounds and appropriate professional competency as necessary to review the effect of the research protocol on the individual’s privacy rights and related interests.

Comment: Two commenters recommended that IRBs and privacy
boards be required to include patient advocates.

Response: The Secretary’s legal authority under HIPAA does not permit HHS to modify the membership of IRBs. Moreover, we disagree with the comments recommending that IRBs and privacy boards should be required to include patient advocates. We were not persuaded that patient advocates are the only persons with the needed expertise to protect patients’ privacy rights and interests. Therefore, in the final rule, we do not require that patient advocates be included as members of a privacy board. However, under the final rule, IRBs and privacy board members could include patient advocates provided they met the required membership criteria in § 164.512(i).

Comment: A few commenters requested clarification of the term “conflict of interest” as it pertained to the proposed rule’s criteria for IRB and privacy board membership. In particular, some commenters recommended that the final rule clarify what degree of involvement in a research project by a privacy board member would constitute a conflict, thereby precluding that individual’s participation in a review. One commenter specifically requested clarification about whether employment by the covered entity constituted a conflict of interest, particularly if the covered entity is receiving a financial gain from the conduct of the research.

Response: We understand that determining what constitutes conflict of interest can be complex. We do not believe that employees of covered entities or employees of the research institution requesting protected health information for research purposes are necessarily conflicted, even if those employees may benefit financially from the research. However, there are many factors that should be considered in assessing whether a member of an IRB has a conflict of interest, including financial and intellectual conflicts.

As part of a separate, but related effort to the final rule, during the summer of 2000, HHS held a conference on human subject protection and financial conflicts of interest. In addition, HHS solicited comments from the public about financial conflicts of interest associated with human subjects research for researchers, IRB members and staff, and research sponsors. The findings from the conference and the public comments received are forming the basis for guidance that HHS is now developing on financial conflicts of interest.

Privacy Training for IRB and Privacy Boards

Comment: A few commenters expressed support for training IRB members and chairs about privacy issues, recommending that such training either be required or that it be encouraged in the final rule.

Response: We agree with these comments and thus encourage institutions that administer IRBs and privacy boards to ensure that the members of these boards are adequately trained to protect the privacy rights and welfare of individuals about whom protected health information is used for research purposes. In the final rule, we require that privacy board members have varying backgrounds and appropriate professional competency as necessary to review the effect of the research protocol on the individual’s privacy rights and related interests. We believe that this criterion for privacy board membership requires that members already have the necessary knowledge or that they be trained to address privacy issues that arise in the conduct of research that involves the use of protected health information. In addition, we note that the Common Rule (§.107(a)) already imposes a general requirement that IRB members possess adequate training and experience to adequately evaluate the research which it reviews. IRBs are also authorized to obtain the services of consultants (§.107(f)) to provide expertise not available on the IRB. We believe that these existing requirements in the Common Rule already require that an IRB have the necessary privacy expertise.

Waiver Criteria

Comment: A large number of comments supported the proposed rule’s criteria for the waiver of authorization by an IRB or privacy board.

Response: While we agree that several of the waiver criteria should be retained in the final rule, we have made changes to the waiver criteria to address some of the comments we received on specific criteria. These reason for these changes are discussed in the response to comments below.

Comment: In addition to the proposed waiver criteria, several commenters recommended that the final rule also instruct IRBs and privacy boards to consider the type of protected health information and the sensitivity of the information to be disclosed in determining whether to grant a waiver, in whole or in part, of the authorization requirements.

Response: We agree with these comments, but believe that the requirement to consider the type and sensitivity of protected health information was already encompassed by the proposed waiver criteria. We encourage and expect that IRBs and privacy boards will take into consideration the type and sensitivity of protected health information, as appropriate, in considering the waiver criteria included in the final rule.

Comment: Many commenters were concerned that the criteria were not appropriate in the context of privacy risks and recommended that the waiver criteria be rewritten to more precisely focus on the protection of patient privacy. In addition, some commenters argued that the proposed waiver criteria were redundant with the Common Rule and were confusing because they mix elements of the Common Rule’s waiver criteria—some of which they argued were relevant only to interventional research. In particular, a number of commenters raised these concerns about proposed criterion (ii). Some of these commenters suggested that the word “privacy” be inserted before “rights.”

Response: We agree with these comments. To focus all of the criterion on individuals’ privacy interests, in the final rule, we have modified one of the proposed waiver criteria, eliminated one proposed criterion, and added an additional criterion: (1) the proposed criterion which stated, “the waiver will not adversely affect the rights and welfare of the subjects,” has been revised in the final rule as follows: “the alteration or waiver will not adversely affect the privacy rights and the welfare of the individuals;” (2) the proposed criterion which stated, “whenever appropriate, the subjects will be provided with additional pertinent information after participation,” has been eliminated; and (3) a criterion has been added in the final rule which states, “there are adequate written assurances that the protected health information will not be re-used or disclosed to any other person or entity, except as required by law, for authorized oversight of the research project, or for other research for which the use or disclosure of protected health information would be permitted by this subpart.” In addressing these criteria, we expect that IRBs and privacy boards will not only consider the immediate privacy interests of the individual that would arise from the proposed research study, but also the possible implications from a loss of privacy, such as a loss of employment, loss or change in cost of health insurance, and social stigma.
Comment: A number of commenters were concerned about the interaction between the proposed rule and the Common Rule. One commenter opposed the four proposed waiver criteria which differed from the Common Rule’s criteria for the waiver of informed consent (§ .116(d)) on the grounds that the four criteria proposed in addition to the Common Rule’s waiver criteria would apply only to the research use and disclosure of protected health information by covered entities. This commenter argued that this would lead to different standards for the protection of other kinds of individually identifiable health information used in research that will fall outside of the scope of the final rule. This commenter concluded that this inconsistency would be difficult for IRBs to administer, difficult for IRB members to distinguish, and would be ethically questionable. For these reasons, many commenters recommended that the final rule should permit the waiver criteria of the Common Rule, to be used in lieu of the waiver criteria identified in the proposed rule.

Response: We disagree with the comments recommending that the waiver criteria of the Common Rule should be permitted to be used in lieu of the waiver criteria identified in the proposed rule. The Common Rule’s waiver criteria were designed to protect research subjects from all harms associated with research, not specifically to protect individuals’ privacy interests. We understand that the waiver criterion of the final rule may initially cause confusion for IRBs and researchers that must attend to both the final rule and the Common Rule, but we believe that the additional waiver criteria adopted in the final rule are essential to ensure that individuals’ privacy rights and welfare are adequately safeguarded when protected health information about themselves is used for research without their authorization. We agree that ensuring that the privacy rights and welfare of all human subjects—involving in all forms of research—is ethically required, and the new Office of Human Research Protection will immediately initiate plans to review the confidentiality provisions of the Common Rule.

In addition, at the request of the President, the National Bioethics Advisory Commission has begun an examination of the current federal human system for the protection of human subjects in research. The current scope of the federal regulatory protections for protecting human subjects in research is just one of the issues that will be addressed in the by the Commission’s report, and the Department looks forward to receiving the Commission’s recommendations.

Concerns About Specific Waiver Criteria

Comment: One commenter argued that the term “welfare” was vague and recommended that it be deleted from the proposed waiver of authorization criterion which stated, “the welfare will not adversely affect the rights and welfare of the subjects.”

Response: We disagree with the comment recommending that the final rule eliminate the term “welfare” from this waiver criterion. As discussed in the National Bioethics Advisory Commission’s 1999 report entitled, “Research Involving Human Biological Materials: Ethical Issues and Policy Guidance,” “Failure to obtain consent may adversely affect the rights and welfare of subjects in two basic ways. First, the subject may be improperly denied the opportunity to choose whether to allow the research project. In the case of research that the research presents, and second, the subject may be harmed or wronged as a result of his or her involvement in research to which he or she has not consented * * *. Subjects’ interest in controlling information about themselves is tied to their interest in, for example, not being stigmatized and not being discriminated against in employment and insurance.” Although this statement by the Commission was made in the context of research involving human biological materials, we believe research that involves the use of protected health information similarly requires that social and psychological harms be considered when assessing whether an alteration or waiver will adversely affect the privacy rights and welfare of individuals. We believe it would be insufficient to attend only to individuals’ privacy “rights” since some of the harms that could result from a breach of privacy, such as stigmatization, and discrimination in employment or insurance, may not be tied directly to an individual’s “rights,” but would have a significant impact on their welfare. Therefore, in the final rule, we have retained the term “welfare” in this criterion for the alteration or waiver of authorization but modified the criterion as follows to focus more specifically on privacy concerns and to clarify that it pertains to alterations of authorization: “the alteration or waiver will not adversely affect the privacy rights and the welfare of the individual.”

Comment: A few commenters recommended that the proposed waiver criterion that stated, “the research could not practically be conducted without the waiver,” be modified to eliminate the term “practically.” These commenters believed that determining “practically” was subjective and that its elimination would facilitate IRBs’ and privacy boards’ implementation of this criterion. In addition, one commenter was concerned that this term could be construed to require authorization if enough weight is given to a privacy interest, and little weight is given to cost or administrative burden. This commenter recommended that the criterion be changed to allow a waiver if the “disclosure is necessary to accomplish the research or statistical purpose for which the disclosure is to be made.”

Response: We disagree with the comments recommending that the term “practicability” be deleted from this waiver criterion. We believe that an assessment of practicability is necessary to account for research that may be possible to conduct with authorization but that would be impracticable if authorization were required. For example, in research study that involves thousands of records, it may be possible to track down all potential subjects, but doing so may entail costs that would make the research impracticable. In addition, IRBs have experience implementing this criterion since it is nearly identical to a waiver criterion in the Common Rule (§ .116(d)(3)).

We also disagree with the recommendation to change the criterion to state, “disclosure is necessary to accomplish the research or statistical purpose for which the disclosure is to be made.” We believe it is essential that consideration be given as to whether it would be practicable for research to be conducted with authorization in determining whether a waiver of authorization is justified. If the research could practicably be conducted with authorization, then authorization must be sought. Authorization must not be waived simply for convenience.

Therefore, in the final rule, we have retained this criterion and clarified that it also applies to alterations of authorization. This waiver criterion in the final rule states, “the research could not practicably be conducted without the alteration or waiver.”

Comment: Some commenters argued that the criterion which stated, “whenever appropriate, the subjects will be provided with additional pertinent information after participation,” should be deleted. Some comments recommended that the criterion should be deleted for privacy reasons, arguing it is inappropriate to create a reason for the researcher to contact the individual
whose data were analyzed, without IRB review of the proposed contact as a patient intervention. Other commenters argued for the deletion of the criterion on grounds that requiring researchers to contact patients whose records were used for archival research would be unduly burdensome, while adding little to the patient’s base of information. Several commenters also argued that the criterion was not pertinent to non-interventional retrospective research requiring access to archived protected health information.

In addition, one commenter asserted that this criterion was inconsistent with the Secretary’s rationale for prohibiting disclosures of “research information unrelated to treatment” for purposes other than research. This commenter argued that the privacy regulations should not mandate that a covered entity provide information with unknown validity or utility directly to patients. This commenter recommended that a patient’s physician, not the researcher, be the one to contact a patient to discuss the significance of new research findings for that individual patient’s care.

Response: Although we disagree with the arguments made by commenters recommending that this criterion be eliminated in the final rule, we concluded that the criterion was not directly related to ensuring the privacy rights and welfare of individuals. Therefore, we eliminated this criterion in the final rule.

Comment: A few commenters recommended that the criterion, which required that “the research would be impracticable to conduct without access to and use of the protected health information,” be deleted because it would be too subjective to be meaningful.

Response: We disagree with comments asserting that this proposed criterion would be too subjective. We believe that researchers should be required to demonstrate to an IRB or privacy board why protected health information is necessary for their research proposal. If a researcher could practically use de-identified health information for a research study, protected health information should not be used or disclosed for the study without individuals’ authorization. Therefore, we retain this criterion in the final rule. In considering this criterion, we expect IRBs and privacy boards to consider the amount of information that is needed for the study. To ensure the covered health care provider or health plan is informed of what information the IRB or privacy board has determined may be used or disclosed without authorization, the final rule also requires that the documentation of IRB or privacy board approval of the alteration or waiver describe the protected health information for which use or access has been determined to be necessary.

Comment: A large number of comments objected to the proposed waiver criterion, which stated that, “the research is of sufficient importance so as to outweigh the intrusion of the privacy of the individual whose information is subject to the disclosure.” The majority of these commenters argued that the criterion was overly subjective, and that due to its subjectivity, IRBs and privacy boards would inevitably apply it inconsistently. Several commenters asserted that this criterion was unsound in that it would impose on reviewing bodies the explicit requirement to form and debate conflicting value judgments about the relative weights of the research proposal versus an individual’s right to privacy. Furthermore, these commenters argued that this criterion was also unnecessary because the Common Rule already has a requirement that deals with this issue more appropriately. In addition, one commenter argued that the rule eliminate this criterion because common purposes should not override individual rights in a democratic society. Based on these arguments, these commenters recommended that this criterion be deleted.

Response: We disagree that it is inappropriate to ask IRBs and privacy boards to ensure that there is a just balance between the expected benefits and risks to individual participants from the research. As noted by several commenters, IRBs currently conduct such a balancing of risks and benefits because the Common Rule contains a similar criterion for the approval of human subjects research (§ 46.111(a)(2)). However, we disagree with the comments asserting that the proposed criterion was unnecessary because the Common Rule already contains a similar criterion. The Common Rule does not explicitly address the privacy interests of research participants and does not apply to all research that involves the use or disclosure of protected health information. However, we agree that the relevant Common Rule criterion for the approval of human subjects research provides better guidance to IRBs and privacy boards for assessing the privacy risks and benefits of a research proposal. Therefore, in the final rule, we modeled the criterion on the relevant Common Rule requirements for the approval of human subjects research, and revised the proposed criterion to state: “the privacy risks to individuals whose protected health information is to be used or disclosed are reasonable in relation to the anticipated benefits if any to the individuals, and the importance of the knowledge that may reasonably be expected to result from the research.”

Comment: One commenter asserted that as long as the research organization has adequate privacy protections in place to keep the information from being further disclosed, it is unnecessary for the IRB or privacy board to make a judgment on whether the value of the research outweighs the privacy intrusion.

Response: The Department disagrees with the assertion that adequate safeguards of protected health information are sufficient to ensure that the privacy rights and welfare of individuals are adequately protected. We believe it is imperative that there be an assessment of the privacy risks and anticipated benefits of a research study that proposes to use protected health information without authorization. For example, if a research study was so scientifically flawed that it would provide no useful knowledge, any risk to patient privacy that might result from the use or disclosure of protected health information without individuals’ authorization would be too great.

Comment: A few commenters asserted that the proposed criterion requiring “an adequate plan to destroy the identifiers at the earliest opportunity consistent with the conduct of the research, unless there is a health or research justification for retaining identifiers,” conflicted with the regulations of the FDA on clinical record keeping (21 CFR 812.140(d)) and the International Standard Organization on control of quality records (ISO 13483, 4.16), which require that relevant data be kept for the life of a device.

In addition, one commenter asserted that this criterion could prevent follow up care. Similarly, other commenters argued that the new waiver criteria would be likely to confuse IRBs and may impair researchers’ ability to go back to IRBs to request extensions of time for which samples or data can be stored if researchers are unable to anticipate future uses of the data.

Response: We do not agree with the comment that there is a conflict between either the FDA or the ISO regulations and the proposed waiver criteria in the rule. We believe that compliance with such recordkeeping requirements would be “consistent with the conduct of research” which is subject to such requirements. Nonetheless, to avoid any confusion, in the final rule we have added the phrase “or such retention is
otherwise required by law” to this waiver criterion.

We also disagree with the comments that this criterion would prevent follow up care to individuals or unduly impair researchers from retaining identifiers on data for future research. We believe that patient care would qualify as a “health * * * justification for retaining identifiers.” In addition, we understand that researchers may not always be able to anticipate that the protected health information they receive from a covered health care provider or health plan for one research project may be useful for the conduct of future research studies. However, we believe that the concomitant risk to patient privacy of permitting researchers to retain identifiers they obtained without authorization would undermine patient trust, unless researchers could identify a health or research justification for retaining the identifiers. In the final rule, an IRB or privacy board is not required to establish a time limit on a researcher’s retention of identifiers.

Additional Waiver Criteria

Comment: A few comments recommended that there be a additional waiver criterion to safeguard or limit subsequent use or disclosure of protected health information by the researcher.

Response: We agree with these comments. In the final rule, we include a waiver criterion requiring “there are adequate written assurances that the protected health information will not be re-used or disclosed to any other person or entity, except as required by law, for authorized oversight of the research project, or for other research for which the use or disclosure of protected health information would be permitted by this subpart."

Waiving Authorization, in Whole or in Part

Comment: A few commenters requested that the final rule clarify what “in whole or in part” means if authorization is waived or altered.

Response: In the proposed rule, it was HHS’ intent to permit IRBs and privacy boards to either waive all of the elements for authorization, or alternatively, waive only some of the elements of authorization. Furthermore, we also intended to permit IRBs and privacy boards to alter the authorization requirements. Therefore, in the final rule, we clarify that the alteration to and waiver of authorization, in whole or in part, are permitted as stipulated in § 164.512(i).

Expedited Review

Comment: One commenter asserted that the proposed rule would prohibit expedited review as permitted under the Common Rule. Many commenters supported the proposal in the rule to incorporate the Common Rule’s provision for expedited review, and strongly recommended that this provision be retained in the final rule. Several of these commenters argued that the expedited review mechanism provides IRBs with the much-needed flexibility to focus volunteer-IRB members’ limited resources.

Response: We agree that expedited review should be available, and included a provision permitting expedited review under specified conditions. We understand that the National Bioethics Advisory Commission is currently developing a report on the federal oversight of human subjects research, which is expected to address the Common Rule’s requirements for expedited review. HHS looks forward to receiving the National Bioethics Advisory Commission’s report, and will modify the provisions for expedited review in the privacy rule if changes are warranted by the Commission’s findings and recommendations.

Required Signature

Comment: A few commenters asserted that the proposed requirement that the written documentation of IRB or privacy board approval be signed by the chair of the IRB or the privacy board was too restrictive. Some commenters recommended that the final rule permit the documentation of IRB or privacy board approval to be signed by persons other than the IRB or privacy board chair, including: (1) Any person authorized to exercise executive authority under IRB’s or privacy board’s written procedures; (2) the IRB’s or privacy board’s acting chair or vice chair in the absence of the chair, if permitted by IRB procedures; and (3) the covered entity’s privacy official.

Response: We agree with the commenters who argued that the final rule should permit the documentation of IRB or privacy board approval to be signed by someone other than the chair of the board. In the final rule, we permit the documentation of alteration or waiver of authorization to be signed by the chair or other member, as designated by the chair of the IRB or privacy board, as applicable.

Research Use and Disclosure With Authorization

Comment: Some commenters, including several industry and consumer groups, argued that the proposed rule would establish a two-tiered system for public and private research. Privately funded research conducted with an authorization for the use or disclosure of protected health information would not require IRB or privacy board review, while publically funded research conducted with authorization would require IRB review as required by the Common Rule. Many of these commenters argued that authorization is insufficient to protect patients involved in research studies and recommended that IRB or privacy board review should be required for all research regardless of sponsor. These commenters asserted that it is not sufficient to obtain authorization, and that IRBs and privacy boards should review the authorization document, and assess the risks and benefits to individuals posed by the research.

Response: For the reasons we rejected the recommendation that we eliminate the option for privacy board review and require IRB review for the waiver of authorization, we also decided against requiring documentation of IRB or privacy board approval for research conducted with authorization. HHS strongly agrees that IRB review is essential for the adequate protection of human subjects involved in research, regardless of whether informed consent and/or individuals’ authorization is obtained. In fact, IRB review may be even more important for research conducted with subjects’ informed consent and authorization since such research may present greater than minimal risk to participants. However, HHS’ authority under HIPAA is limited to safeguarding the privacy of protected health information, and does not extend to protecting human subjects more broadly. Therefore, in the final rule we have not required documentation of IRB or privacy board review for the research use or disclosure of protected health information conducted with individuals’ authorization. As mentioned above, HHS looks forward to receiving the recommendations of the National Bioethics Advisory Commission, which is currently examining the current scope of federal regulatory protections for protecting human subjects in research as part of its overarching report on the federal oversight of human subjects protections.

Comment: Due to concern about several of the elements of authorization, many commenters recommended that the final rule stipulate that “informed consent” obtained pursuant to the Common Rule be deemed to meet the requirements for “authorization.” These commenters argued that the NPRM’s
additional authorization requirements offered no additional protection to research participants but would be a substantive impediment to research.

Response: We disagree with the comments asserting that the proposed requirements for authorization for the use or disclosure of protected health information would have offered research subjects no additional privacy protection. Because the purposes of authorization and informed consent differ, the proposed rule’s requirements for authorization pursuant to a request from a researcher (§ 164.508) and the Common Rule’s requirements for informed consent (Common Rule, § 116) contain important differences. For example, unlike the Common Rule, the proposed rule would have required that the authorization include a description of the information to be used or disclosed that identifies the information in a specific and meaningful way, an expiration date, and where, use of disclosure of the requested information will result in financial gain to the entity, a statement that such gain will result. We believe that the authorization requirements provide individuals with information necessary to determine whether to authorize a specific use or disclosure of protected health information about themselves, that are not required by the Common Rule.

Therefore, in the final rule, we retain the requirement for authorization for all uses and disclosures of protected health information not otherwise permitted without authorization by the rule. Some of the proposed requirements for authorization were modified in the final rule as discussed in the preamble on § 164.508. The comments received on specific proposed elements of authorization as they would have pertained to research are addressed below.

Comment: A number of commenters, including several from industry and consumer groups, recommended that the final rule require patients’ informed consent as stipulated in the Common Rule. These commenters asserted that the proposed authorization document was inadequate for research uses and disclosures of protected health information since it included fewer elements than required for informed consent under the Common Rule, including for example, the Common Rule’s requirement that the informed consent document include: (1) A description of any reasonably foreseeable discomforts to the subject; (2) a description of any benefits to the subject or to others which may reasonably be expected from the research (Common Rule, § 116(a)).

Response: While we agree that the ethical conduct of research requires the voluntary informed consent of research subjects, as stipulated in the Common Rule, as we have stated elsewhere, the privacy rule is limited to protecting the confidentiality of individually identifiable health information, and not protecting human subjects more broadly. Therefore, we believe it would not be within the scope of the final rule to require informed consent as stipulated by the Common Rule for research uses and disclosures of protected health information.

Comment: Several commenters specifically objected to the authorization requirement for a “expiration date.” To remedy this concern, many of these commenters proposed that the rule exempt research from the requirement for an expiration date if an IRB has reviewed and approved the research study. In particular, some commenters asserted that the requirement for an expiration date would be impracticable in the context of clinical trials, where the duration of the study depends on several different factors that cannot be predicted in advance. These commenters argued that determining an exact date would be impossible due to the legal requirements that manufactures and the Food and Drug Administration be able to retrospectively audit the source documents when patient data are used clinically. In other situations, some commenters asserted that a requirement for an expiration date would force researchers to designate specific expiration dates so far into the future as to render them meaningless.

Response: We agree with commenters that an expiration date is not always possible or meaningful. In the final rule, we continue to require an identifiable expiration, but permit it to be a specific date or an event directly relevant to the individual or the purpose of the authorization (e.g., for the duration of a specific research study) in which the individual is a participant.

Comment: A number of commenters, including those from the pharmaceutical industry, were concerned about the authorization requirement that gave patients the right to revoke consent for participation in clinical research. These commenters argued that such a right to revoke authorization for the use of their protected health information would result in the premature expiration of information that was collected, nor retrieve protected health information that was disclosed under such an authorization. However, once an individual has revoked an authorization, no additional protected health information may be used or disclosed unless otherwise permitted by this rule.

Response: We agree with these concerns. In the final rule we have clarified that an individual cannot revoke an authorization to the extent that action has been taken in reliance on the authorization. Therefore, if a covered entity has already used or disclosed protected health information for a research study pursuant to an authorization obtained as required by § 164.508, the covered entity is not required under the rule, unless it agreed otherwise, to destroy protected health information that was collected, nor retrieve protected health information that was disclosed under such an authorization.

Comment: Some commenters were concerned that the authorization requirement to disclose “financial gain” would be problematic. In the common Rule, it would pertain to research. These commenters asserted that this requirement could mislead patients and would make it more difficult to attract volunteers to participate in research. One commenter recommended that the statement be revised to state “that the clinical investigator will be compensated for the value of his/her services in administering this clinical trial.”

Response: We strongly believe that a requirement for the disclosure of financial gain is imperative to ensure that individuals are informed about how and why protected health information about themselves will be used or disclosed. We agree, however, that the language of the proposed requirement could cause confusion, because most activities involve some type of financial gain. Therefore, in the final rule, we have modified the language to provide that when the covered entity initiates the retrieval of individually identifiable health information that has already been blinded and anonymized, is not only burdensome, but should this become a widespread practice, would render the trial invalid. One commenter suggested that the Secretary modify the proposed regulation to allow IRBs or privacy boards to determine the duration of authorizations and the circumstances under which a research participant should be permitted to retroactively revoke his or her authorization to use data already collected by the researcher.
the authorization and the covered entity will receive direct or indirect remuneration (rather than financial gain) from a third party in exchange for using or disclosing the health information, the authorization must include a statement that such remuneration will result.

Comment: A few commenters asserted that the requirement to include a statement in which the patient acknowledged that information used or disclosed to any entity other than a health plan or health care provider may no longer be protected by federal privacy law would be inconsistent with existing protections implemented by IRBs under the Common Rule. In particular they stated that this inconsistency exists because IRBs are required to consider the protections in place to protect patients’ confidential information and that IRBs are charged with ensuring that researchers comply with the confidentiality provisions of the informed consent document.

Response: We disagree that this proposed requirement would pose a conflict with the Common Rule since the requirement was for a statement that the “information may no longer be protected by the federal privacy law.” This statement does not pertain to the protections provided under the Common Rule. In addition, while we anticipate that IRBs and privacy boards will most often waive all or none of the authorization requirements, we clarify an IRB or privacy board could alter this requirement, among others, if the documentation requirements of §164.512(i) have been met.

Reviews Preparatory to Research

Comment: Some industry groups expressed concern that the research provision would prohibit physicians from using patient information to recruit subjects into clinical trials. These commenters recommended that researchers continue to have access to hospitals’ and clinics’ patient information in order to recruit patients for studies.

Response: Under the proposed rule, even if the researcher only viewed the medical record at the site of the covered entity and did not record the protected health information in a manner that patients could be identified, such an activity would have constituted a use or disclosure that would have been subject to proposed §164.506 or proposed §164.510. Based on the comments received and the fact finding we conducted with the research community, we concluded that documentation of IRB or privacy board approval could halt the development of research hypotheses that require access to protected health information before a formal protocol can be developed and brought to an IRB or privacy board for approval. To avoid this unintended result, the final rule permits covered health care providers and health plans to use or disclose protected health information for research if the covered entity obtains from the researcher representations that: (1) Use or disclosure is sought solely to review protected health information as necessary to prepare a research protocol or for similar purposes preparatory to research; (2) no protected health information is to be removed from the covered entity by the researcher in the course of the review; and (3) the protected health information for which use or access is sought is necessary for the research purposes.

Comment: A few commenters asserted that the final rule should eliminate the possibility that research requiring access to protected health information could be determined to be “exempt” from IRB review, as provided by the Common Rule (§164.510(b)(4)).

Response: The rule did not propose nor intend to modify any aspect of the Common Rule, including the provision that exempts from coverage, “research involving the collection or study of existing data, documents, records, pathological specimens, or diagnostic specimens, if these sources are publically available, or if the information is recorded by the investigator in such a manner that subjects cannot be identified, directly or indirectly through identifiers linked to the subjects’’ (§164.510(b)(4)). For the reasons discussed above, we have included a provision in the final rule for reviews preparatory to research that was modeled on this exemption to the Common Rule.

Deceased Persons Exception for Research

Comment: A few commenters expressed support for the proposal to allow use and disclosure of protected health information about decedents for research purposes without the protections afforded to the protected health information of living individuals. One commenter, for example, explained that it extensively uses such information in its research, and any restrictions would likely to impede its efforts. Alternately, a number of commenters provided arguments for eliminating the research exception for deceased persons. They commented that the same concerns regarding use and disclosure of genetic and hereditary information for other purposes apply in the research context.

They believed that in many cases the risk of identification was greater in the research context because researchers may attempt to identify genetic and hereditary conditions of the deceased. Finally, they argued that while information of the deceased does not necessarily identify living relatives by name, living relatives could be identified and suffer the same harm as if their own medical records were used or disclosed for research purposes.

Another commenter stated that the exception was unnecessary, and that existing research could and should proceed under the requirements in proposed §164.510 that dictated the IRB/privacy board approval process or be conducted using de-identified information. This commenter further stated that in this way, at least there would be some degree of assurance that all reasonable steps are taken to protect deceased persons’ and their families’ confidentiality.

Response: Although we understand the concerns raised by commenters, we believe those concerns are outweighed by the need to keep the research-related policies in this rule as consistent as possible with standard research practice under the Common Rule, which does not consider deceased persons to be “human subjects.” Thus, we retain the exception in the final rule. With regard to the protected health information about a deceased individual, therefore, a covered entity is permitted to use or disclose such information for research purposes without obtaining authorization from a personal representative and absent approval by an IRB or privacy board as governed by §164.512(i). We note that the National Bioethics Advisory Committee (NBAC) is currently considering revising the Common Rule’s definition of “human subject” with regard to coverage of the deceased. However, at this time, NBAC’s deliberations on this issue are not yet completed and any reliance on such discussions would be premature.

The final rule requires at §164.512(i)(1)(iii) that covered entities obtain from the researcher (1) representation that the use or disclosure is sought solely for research on the protected health information of decedents; (2) documentation, at the request of the covered entity, of the death of such individuals; and (3) representation that the protected health information for which use or disclosure is sought is necessary for the research purposes. It is our intention with this change to reduce the burden and ambiguity on the part of the covered entity to determine whether or not the
Modification of the Common Rule

Comment: Some commenters, in their support of the research exception, requested that HHS clarify in the final rule that protected health information obtained during the donation process of eyes and eye tissue could continue to be used or disclosed to or by eye banks for research purposes without an authorization and without IRB approval. They expressed concern over the impediments to this type of research these approvals would impose, such as added administrative burden and vulnerabilities to the time sensitive nature of the process.

Another commenter similarly expressed the position that, with regard to uses and disclosures of protected health information for tissue, fluid, or organ donation, the regulation should not present an obstacle to the transfer of donations unsuitable for transplant to the research community. However, they believed that consent can be obtained for such use since the donor or donor’s family must generally consent to any transplant purposes, it would seem to be a minimal additional obligation to seek consent for research purposes at the same time, should the material be unsuitable for transplant.

Response: Protected health information about a deceased individual, including information related to eyes and eye tissue, can be used or disclosed further for research purposes by a covered entity in accordance with § 164.512(i)(1)(iii) with or without IRB or privacy board approval. This rule does not address whether organs unsuitable for transplant may be transferred to researchers with or without consent.

Modification of the Common Rule

Comment: We received a number of comments that interpreted the proposed rule as having unnecessarily and inappropriately amended the Common Rule. Assuming that the Common Rule was being modified, these comments argued that the rule was legally deficient under the Administrative Procedures Act, the Regulatory Flexibility Act, and other controlling Executive orders or laws.

In addition, one research organization expressed concern that, by involving IRBs in the process of approving a waiver of authorization for disclosure purposes and establishing new criteria for such waiver approvals, the proposed rule would have subjected covered entities whose IRBs failed to comply with the requirements for reviewing and approving research to potential sanctions under HIPAA. The comment recommended that the rule be changed to eliminate such a punitive result. Specifically, the comment recommended that the existing Common Rule structure be preserved for IRB-approved research, and that the waiver of authorization criteria for privacy purposes be kept separate from the other functions of the IRB.

Response: We disagree with the comments asserting the proposed rule attempted to change the Common Rule. It was not our intent to modify or amend the Common Rule or to regulate the activities of the IRBs with respect to the underlying research. We therefore reject the comments about legal deficiencies in the rule which are based on the mistaken perception that the Common Rule was being amended. The proposed rule established new requirements for covered entities before they could use or disclose protected health information for research without authorization. The proposed rule provided that one method by which a covered entity could obtain the necessary documentation was to receive it from an IRB. We did not mandate IRBs to perform such reviews, and we expressly provided for means other than through IRBs for covered entities to obtain the required documentation.

In the final rule, we also have clarified our intent not to interfere with existing requirements for IRBs by amending the language in the waiver criteria to make clear that these criteria relate to the privacy interests of the individual and are separate from the criteria that would be applied by an IRB to any evaluation of the underlying research. Moreover, we have restructured the final rule to also make clear that we are regulating only the content and conditions of the documentation upon which a covered entity may rely in making a disclosure of protected health information for research purposes.

We cannot and do not purport to regulate IRBs or modify the Common Rule through this regulation. We cannot under this rule penalize an IRB for failure to comply with the Common Rule, nor can we sanction an IRB based on the documentation requirements in the rule. Health plans and covered health care providers may rely on documentation from an IRB or privacy board concerning the alteration or waiver of authorization for the disclosure of protected health information for research purposes, provided the documentation, on its face, meets the requirements in the rule. Health plans and covered health care providers will not be penalized for relying on facially adequate documentation from an IRB. Health plans and covered health care providers will only be penalized for their own errors or omissions in following the requirements of the rule, and not those of the IRB.

Use Versus Disclosure

Comment: Many of the comments supported the proposed rule’s provision that would have imposed the same requirements for both research uses and research disclosures of protected health information.

Response: We agree with these comments. In the final rule we retain identical use and disclosure requirements for research uses and disclosures of protected health information by covered entities.

Comment: In contrast, a few commenters recommended that there be fewer requirements on covered entities for internal research uses of protected health information.

Response: For the reasons discussed above in § 164.501 on the definition of “research,” we disagree that an individual’s privacy interest is of less concern when covered entities use protected health information for research purposes than when covered entities disclose protected health information for research purposes without authorization.

Additional Resources for IRBs

Comment: A few commenters recommended that HHS work to provide additional resources to IRBs to assist them in meeting their new responsibilities.

Response: This recommendation is beyond our statutory authority under HIPAA, and therefore, cannot be addressed by the final rule. However, we fully agree that steps should be taken to moderate the workload of IRBs and to ensure adequate resources for the activities. Through the Office for Human Research Protections, the Department is committed to working with institutions and IRBs to identify efficient ways to optimize utilization of resources, and is committed to developing guidelines for appropriate staffing and workload levels for IRBs.

Additional Suggested Requirements

Comment: One commenter recommended that the documentation of IRB or privacy board approval also be required to state that, “the health researcher has fully disclosed which of
the protected health information to be collected or created would be linked to other protected health information, and that appropriate safeguards be employed to protect information against re-identification or subsequent unauthorized linkages.”

Response: The proposed provision for the use or disclosure of protected health information for research purposes without authorization only pertained to individually identifiable health information. Therefore, since the information to be obtained would be individually identifiable, we concluded that it was illogical to require IRBs and privacy boards document that the researcher had “fully disclosed that * * * appropriate safeguards be employed to protect information against re-identification or subsequent unauthorized linkages.” Therefore, we did not incorporate this recommendation into the final rule.

Section 164.512(j)—Uses and Disclosures To Avert a Serious Threat to Health or Safety

Comment: Several commenters generally stated support for proposed § 164.510(k), which was titled “Uses and Disclosures in Emergency Circumstances.” One commenter said that “narrow exceptions to confidentiality should be permitted for emergency situations such as duty to warn, duty to protect, and urgent law enforcement needs.” Another commented that the standard “* * * based on a reasonable belief that the disclosures are necessary to prevent or lessen a serious and imminent threat to the health or safety of an individual” would apply in only narrow treatment circumstances. Some commenters suggested that the provision be further narrowed, for example, with language specifically identifying “imminent threats” and a “chain-of-command clearance process,” or by limiting permissible disclosures under this provision to “public health emergencies,” or “national emergencies.” Others proposed procedural requirements, such as specifying that such determinations may only be made by the patient’s treating physician, a licensed mental health care professional, or as validated by three physicians. One commenter recommended stating that the rule is not intended to create a duty to warn or to disclose protected health information but rather permits such disclosure in emergency circumstances, consistent with other applicable legal or ethical standards.

Response: We agree with the commenters who noted that the proposed provision would apply in rare circumstances. We clarify, however, that we did not intend for the proposed provision to apply to emergency treatment scenarios as discussed below. In the final rule, to avoid confusion over the circumstances in which we intend this section to apply, we retitle it “Uses and Disclosures to Avert a Serious Threat to Health or Safety.”

We do not believe it would be appropriate to narrow further the scope of permissible disclosures under this section to respond to specifically identified “imminent threats,” a “public health emergency,” or a “national emergency.” We believe it would be impossible to enumerate all of the scenarios that may warrant disclosure of protected health information pursuant to this section. Such cases may involve a small number of people and may not necessarily involve a public health emergency or a national emergency.

Furthermore, in response to comments arguing that the proposed provision was too broad, we note that under both the NPRM and the final rule, we allow but do not require disclosures in situations involving serious and imminent threats to health or safety. Health plans and covered health care providers may make the disclosures allowed under § 164.512(j) consistent with applicable law and standards of ethical conduct. As indicated in the preamble to the NPRM, the proposed approach is consistent with statutory and case law addressing this issue. The most well-known case on the topic is Tarasoff v. Regents of the University of California, 17 Cal. 3d 425 (1976), which established a duty to warn those at risk of harm when a therapist’s patient made credible threats against the physical safety of a specific person. The Supreme Court of California found that the therapist involved in the case had an obligation to use reasonable care to protect the intended victim of his patient against danger, including warning the victim of the peril. Many states have adopted, in statute or through case law, versions of the Tarasoff duty to warn or protect. Although Tarasoff involved a psychiatrist, this provision is not limited to disclosures by psychiatrists or other mental health professionals. As stated in the preamble of the NPRM, we clarify that § 164.512(j) is not intended to create a duty to warn or disclose protected health information.

Comment: Several comments addressed the portion of proposed § 164.510(k) that would have provided a presumption of good faith to covered entities that disclosed protected health information pursuant to this provision, when such disclosures were made in good faith, based on credible representation by a person with apparent knowledge or authority. Some commenters recommended that this standard be applied to all permissible disclosures without consent or to such disclosures to law enforcement officials.

Alternatively, a group representing health care provider management firms believed that the proposed presumption of reasonable belief would not have provided covered entities with sufficient protection from liability exposure associated with improper uses or disclosures. This commenter recommended that a general good-faith standard apply to covered entities’ decisions to disclose protected health information to law enforcement officials. A health plan said that HHS should consider applying the standard of reasonable belief to all uses and disclosures that would have been allowed under proposed § 164.510. Another commenter questioned how the good-faith presumption would apply if the information came from a confidential informant or from a person rather than a doctor, law enforcement official, or government official. (The NPRM listed doctors, law enforcement officials, and other government officials as examples of persons who may make credible representations pursuant to this section.)

Response: As discussed above, this provision is intended to apply in rare circumstances—circumstances that occur much less frequently than those described in other parts of the rule. Due to the importance of averting serious and imminent threats to health and safety, we believe it is appropriate to apply a presumption of good faith to covered entities disclosing protected health information under this section. We believe that the extremely time-sensitive and urgent conditions surrounding the need to avert a serious and imminent threat to the health or safety are fundamentally different from those involved in disclosures that may be made pursuant to other sections of the rule. Therefore, we do not believe it would be appropriate to apply to other sections of the rule the presumption of good faith that applies in § 164.512(j). We clarify that we intend for the presumption of good faith to apply if the disclosure is made in good faith based upon a credible representation by any person with apparent knowledge or authority—not just by doctors, law enforcement or other government officials. Our listing of persons in the NPRM was illustrative only, and it was not intended to limit the types of

VerDate 11<MAY>2000 19:16 Dec 27, 2000 Jkt 194001 PO 00000 Frm 00243 Fmt 4701 Sfmt 4700 E:\FR\FM\28DER2.SGM pfrm08 PsN: 28DER2
persons who could make such a credible representation to a covered entity.

Comment: One commenter questioned under what circumstances proposed § 164.510(k) would apply instead of proposed § 164.510(f)(5), “Urgent Circumstances,” which permitted covered entities to disclose protected health information to law enforcement officials about individuals who are or are suspected to be victims of a crime, abuse, or other harm, if the law enforcement official represents that the information is needed to determine whether a violation of law by a person other than the victim has occurred and immediate law enforcement activity that depends upon obtaining such information may be necessary.

Response: First, we note that inclusion of this provision as § 164.510(f)(5) was a drafting error which subsequently was clarified in technical corrections to the NPRM. In fact, proposed § 164.510(f)(3) addressed the identical circumstances, which in this section is titled “Information about a Victim of Crime or Abuse.” The scenarios described under § 164.510(f)(3) may or may not involve serious and imminent threats to health or safety.

Second, as discussed in the main section of the preamble to § 164.512(j), we recognize that in some situations, more than one section of this rule potentially could apply with respect to a covered entity’s potential disclosure of protected health information. We clarify that if a situation fits one section of the rule (e.g., § 164.512(j) on serious and imminent threats to health or safety), health plans and covered health care providers may disclose protected health information pursuant to that section, regardless of whether the disclosure also could be made pursuant to another section (e.g., §§ 164.512(f)(2) or 164.512(f)(3), regarding disclosure of protected health information about suspects or victims to law enforcement officials), except as otherwise stated in the rule.

Comment: A state health department indicated that the disclosures permitted under this section may be seen as conflicting with existing law in many states.

Response: As indicated in the regulation text for § 164.512(j), this section allows disclosure consistent with applicable law and standards of ethical conduct. We do not preempt any state law that would prohibit disclosure of protected health information in the circumstances to which this section applies. (See Part 160, Subpart B.)

Comment: Many commenters stated that the rule should require that any disclosures should not modify “duty to warn” case law or statutes.

Response: The rule does not affect case law or statutes regarding “duty to warn.” In § 164.512(j), we specifically permit covered entities to disclose protected health information without authorization for the purpose of protecting individuals from imminent threats to health and safety, consistent with state laws and ethical obligations.

Section 164.512(k)—Uses and Disclosures for Specialized Government Functions

Military Purposes

Armed Forces Personnel and Veterans

Comment: A few comments opposed the proposed rule’s provisions on the military, believing that they were too broad. Although acknowledging that the Armed Forces may have legitimate needs for access to protected health information, the commenters believed that the rule failed to provide adequate procedural protections to individuals. A few comments said that, except in limited circumstances or emergencies, covered entities should be required to obtain authorization before using or disclosing protected health information.

A few comments also expressed concern over the proposed rule’s lack of specific safeguards to protect the health information of victims of domestic violence and abuse. Some commenters said they understood why the military needed access to health information, but that they did not believe the rule would impede such access by providing safeguards for victims of domestic violence or abuse.

Response: We note that the military comprises a unique society and that members of the Armed Forces do not have the same freedoms as do civilians. The Supreme Court held in Goldman v. Weinberger, 475 US 503 (1986), that the military must be able to command its members to sacrifice a great many freedoms enjoyed by civilians and to endure certain limits on the freedoms they do enjoy. The Supreme Court also held in Parker v. Levy, 417 US 733 (1974), that the different character of the military community and its mission required a different application of Constitutional protections. What is permissible in the civilian world may be impermissible in the military. We also note that individuals entering military service are aware that they will not have, and enjoy, the same rights as others.

The proposed rule would have authorized covered entities to use and disclose protected health information about armed forces personnel only for activities considered necessary by appropriate military command authorities to assure the proper execution of the military mission. In order for the military mission to be achieved and maintained, military command authorities need protected health information to make determinations regarding individuals’ medical fitness to perform assigned military duties.

The proposed rule required the Department of Defense (DoD) to publish a notice in the Federal Register identifying its intended uses and disclosures of protected health information, and we have retained this approach in the final rule. This notice will serve to limit command authorities’ access to protected health information to circumstances in which disclosure of protected health information is necessary to assure proper execution of the military mission.

With respect to comments regarding the lack of procedural safeguards for individuals, including those who are victims of domestic violence and abuse, we note that the rule does not provide new authority for covered entities providing health care to individuals who are Armed Forces personnel to use and disclose protected health information. Rather, the rule allows the Armed Forces to use and disclose such information only for those military mission purposes which will be published separately in the Federal Register. In addition, we note that the Privacy Act of 1974, as implemented by the DoD, provides numerous protections to individuals.

We modify the proposal to publish privacy rules for the military in the Federal Register. The NPRM would have required this notice to include information on the activities for which use or disclosure of protected health information would occur in order to assure proper execution of the military mission. We believe that this proposed portion of the notice is redundant and thus unnecessary in light of the rule’s application to military services. In the final rule, we eliminate this proposed section of the notice, and we state that health plans and covered health care providers may use and disclose protected health information of Armed Forces personnel for activities considered necessary by appropriate military command authorities to assure the proper execution of a military mission, where the appropriate military authority has published a Federal Register notice identifying (1) the appropriate military command authorities; and (2) the purposes for
which protected health information may be used or disclosed.

Comment: A few commenters, members of the affected beneficiary class, which numbers approximately 2.6 million (active duty and reserve military personnel), opposed proposed § 164.510(m) because it would have allowed a non-governmental covered entity to provide protected health information without authorization to the military. These commenters were concerned that military officials could use the information as the basis for taking action against individuals.

Response: The Secretary does not have the authority under HIPAA to regulate the military’s re-use or re-disclosure of protected health information obtained from health plans and covered health care providers. This provision’s primary intent is to ensure that proper military command authorities can obtain needed medical information held by covered entities so that they can make appropriate determinations regarding the individual’s medical fitness or suitability for military service. Determination that an individual is not medically qualified for military service would lead to his or her discharge from or rejection for service in the military. Such actions are necessary in order for the Armed Forces to have medically qualified personnel, ready to perform assigned duties. Medically unqualified personnel not only jeopardize the possible success of a mission, but also pose an unacceptable risk or danger to other personnel. We have allowed such uses and disclosures for military activities because it is in the Nation’s interest.

Separation or Discharge from Military Service

Comment: The preamble to the NPRM solicited comments on the proposal to permit the DoD to transfer, without authorization, a service member’s military medical record to the Department of Veterans Affairs (DVA) when the individual completed his or her term of military service. A few commenters opposed the proposal, believing that authorization should be obtained. Both the DoD and the DVA supported the proposal, noting that transfer allows the DVA to make timely determinations as to whether a veteran is eligible for benefits under programs administered by the DVA.

Response: We note that the transfer program was established based on recommendations by Congress, veterans groups, and veterans; that it has existed for many years; and that there has been no objection to, or problems associated with, the program. We also note that the Department of Transportation (DoT) and the Department of Veterans Affairs operate an analogous transfer program with respect to United States Coast Guard personnel, who comprise part of the U.S. Armed Forces. The protected health information involved the DoD/DVA transfer program is being disclosed and used for a limited purpose that directly benefits the individual. This information is covered by, and thus subject to the protections of, the Privacy Act. For these reasons, the final rule retains the DoD/DVA transfer program proposed in the NPRM. In addition, we expand the NPRM’s proposed provisions regarding the Department of Veterans Affairs to include the DoT/DVA program, to authorize the continued transfer of these records.

Comment: The Department of Veterans Affairs supported the NPRM’s proposal to allow it to use and disclose protected health information among components of the Department so that it could make determinations on whether an individual was entitled to benefits under laws administered by the Department. Some commenters said that the permissible disclosure pursuant to this section appeared to be sufficiently narrow in scope, to respond to an apparent need. Some commenters also said that the DVA’s ability to make benefit determinations would be hampered if an individual declined to authorize release of his or her protected health information. A few commenters, however, questioned whether such an exchange of information currently occurs between the components. A few commenters also believed the proposed rule should be expanded to permit sharing of information with other agencies that administer benefit programs.

Response: The final rule retains the NPRM’s approach regarding use and disclosure of protected health information without authorization among components of the DVA for the purpose of making eligibility determinations based on commenters’ assessment that the provision was narrow in scope and that an alternative approach could negatively affect benefit determinations for veterans. We modify the NPRM language slightly, to clarify that it refers to a health plan or covered health care provider that is a component of the DVA. These component entities may use or disclose protected health information without authorization among various components of the Department to determine eligibility for or entitlement to veterans’ benefits. The final rule does not expand the scope of permissible disclosures under this provision to allow the DVA to share such information with other agencies. Other agencies may obtain this information only with authorization, subject to the requirements of § 164.508.

Foreign Military Personnel

Comments: A few comments opposed the exclusion of foreign diplomatic and military personnel from coverage under the rule. These commenters said that the mechanisms that would be necessary to identify these personnel for the purpose of exempting them from the rule’s protections as other individuals.

Foreign Military Personnel

Response: We agree with the commenters’ statement that the NPRM’s exclusion of foreign military and diplomatic personnel with regard to other laws, and that it would allow exploitation of these individuals’ health information. These commenters believed that the rule’s exclusion of foreign military and diplomatic personnel was unnecessarily broad and that it should be narrowed to meet a perceived need. Finally, they noted that the proposed exclusion could be affected by the European Union’s Data Protection Directive.

Response: We agree with the commenters’ statement that the NPRM’s exclusion of foreign military and diplomatic personnel with regard to other laws, and that it would allow exploitation of these individuals’ health information. These commenters believed that the rule’s exclusion of foreign military and diplomatic personnel was unnecessarily broad and that it should be narrowed to meet a perceived need. Finally, they noted that the proposed exclusion could be affected by the European Union’s Data Protection Directive.

Intelligence Community

Comments: A few commenters opposed the NPRM’s provisions regarding protected health information of intelligence community employees and their dependents being considered for postings overseas, on the grounds that the scope of permissible disclosure without authorization was too broad. While acknowledging that the intelligence community may have legitimate needs for its employees’ protected health information, the commenters believed that the NPRM
failed to provide adequate procedural protections for the employees’ information. A few comments also said that the intelligence community should be able to obtain their employees’ health information only with authorization. In addition, commenters said that the intelligence community should make disclosure of protected health information a condition of employment.

Response: Again, we agree that the NPRM’s provision allowing disclosure of the protected health information of intelligence community employees without authorization was overly broad. Thus we eliminate it in the final rule. The intelligence community can obtain this information with authorization (pursuant to § 164.508), for example, when employees or their family members are being considered for an overseas assignment and when individuals are applying for employment with or seeking a contract from an intelligence community agency.

National Security and Intelligence Activities and Protective Services for the President and Others

Comment: A number of comments opposed the proposed “intelligence and national security activities” provision of the law enforcement section (§ 164.510(f)(4)), suggesting that it was overly broad. These commenters were concerned that the provision lacked sufficient procedural safeguards to prevent abuse of protected health information. The Central Intelligence Agency (CIA) and the Department of Defense (DoD) also expressed concern over the provision’s scope. The agencies said that if implemented as written, the provision would have failed to accomplish fully its intended purpose of allowing the disclosure of protected health information to officials carrying out intelligence and national security activities other than law enforcement activities. The CIA and DoD believed that the provision should be moved to another section of the rule, possibly to proposed § 164.510(m) on specialized classes, so that authorized intelligence and national security officials could obtain individuals’ protected health information without authorization when lawfully engaged in intelligence and national security activities.

Response: In the final rule, we clarify that this provision does not provide new authority for intelligence and national security officials to acquire health information that they otherwise would not be able to obtain. Furthermore, the rule does not confer new authority for intelligence, security, or Presidential protective service activities. Rather, the activities permissible under this section are limited to those authorized under current law and regulation (e.g., for intelligence activities, 50 U.S.C. 401, et seq., Executive Order 12333, and agency implementing regulatory authorities). For example, the provision regarding national security activities pertains only to foreign persons that are the subjects of legitimate and lawful intelligence, counteringintelligence, or other national security activities. In addition, the provision regarding protective services pertains only to those persons who are the subjects of legitimate investigations for threatening or otherwise exhibiting an inappropriate direction of interest toward U.S. Secret Service protectees pursuant to 18 U.S.C. 871, 879, and 3056. Finally, the rule leaves intact the existing State Department regulations that strictly limit the disclosure of health information pertaining to employees (e.g., Privacy Issuances at State-24 Medical Records).

We believe that because intelligence/ national security activities and Presidential protective service activities are discrete functions serving different purposes, they should be treated consistently but separately under the rule. For example, medical information is used as a complement to other investigative data that are pertinent to conducting comprehensive threat assessment and risk prevention activities pursuant to 18 U.S.C. 3056. In addition, information on the health of world leaders is important for the provision of protective services and other functions. Section 164.512(k) of the final rule includes separate subsections for national security/ intelligence activities and for disclosures related to protective services to the President and others.

We note that the rule does not require or compel a health plan or covered health care provider to disclose protected health information. Rather, two subsections of § 164.512(k) allow covered entities to disclose information for intelligence and national security activities and for protective services to the President and others only to authorized federal officials conducting these activities, when such officials are performing functions authorized by law.

We agree with DoD and CIA that the NPRM, by including these provisions in the law enforcement section (proposed § 164.510(f)), would have allowed covered entities to disclose protected health information for national security, intelligence, and Presidential protective activities only to law enforcement officials. We believe that many officials authorized by law to carry out intelligence, national security, and Presidential protective functions are not law enforcement officials. Therefore, the final rule allows covered entities to disclose protected health information pursuant to this provision not only to law enforcement officials, but to all federal officials authorized by law to carry out the relevant activities. In addition, we remove this provision from the law enforcement section and include it in § 164.512(k) on uses and disclosures for specialized government functions.

Medical Suitability Determinations

Comment: A few comments opposed the NPRM’s provision allowing the Department of State to use protected health information for medical clearance determinations. These commenters believed that the scope of permissible disclosures under the proposed provision was too broad. While acknowledging that the Department may have legitimate needs for access to protected health data, the commenters believed that the implementation of the proposed provision would not have provided adequate procedural safeguards for the affected State Department employees. A few comments said that the State Department should be able to obtain protected health information for medical clearance determinations only with authorization. A few comments also said that the Department should be able to disclose such information only when required for national security purposes. Some commenters believed that the State Department should be subject to the Federal Register notice requirement that the NPRM would have applied to the Department of Defense. A few comments also opposed the proposed provision on the basis that it would conflict with the Rehabilitation Act of 1973 or that it appeared to represent an invitation to discriminate against individuals with mental disorders.

Response: We agree with commenters who believed that the NPRM’s provision regarding the State Department’s use of protected health information without authorization was unnecessarily broad. Therefore, in the final rule, we restrict significantly the scope of protected health information that the State Department may use and disclose without authorization. First, we allow health plans and covered health care providers that are a component of the State Department to use and disclose protected health information without authorization when making medical suitability determinations for security clearance purposes. For the purposes of a security investigation, these
components may disclose to authorized State Department officials whether or not the individual was determined to be medically suitable. Furthermore, we note that the rule does not confer authority on the Department to disclose such information that it did not previously possess. The Department remains subject to applicable law regarding such disclosures, including the Rehabilitation Act of 1973.

The preamble to the NPRM solicited comment on whether there was a need to add national security determinations under Executive Order 10450 to the rule’s provision on State Department uses and disclosures of protected health information for security determinations. While we did not receive comment on this issue, we believe that a limited addition is warranted and appropriate. Executive Orders 10450 and 12968 direct Executive branch agencies to make certain determinations regarding whether their employees’ access to classified information is consistent with the national security interests of the United States. Specifically, the Executive Orders state that access to classified information shall be granted only to those individuals whose personal and professional history affirmatively indicates, inter alia, strength of character, trustworthiness, reliability, and sound judgment. In reviewing the personal history of an individual, Executive branch agencies may investigate and consider any matter, including a mental health issue or other medical condition, that relates directly to any of the enumerated factors.

In the vast majority of cases, Executive agencies require their security clearance investigators to obtain the individual’s express consent in the form of a medical release, pursuant to which the agency can conduct its background investigation and obtain any necessary health information. This rule does not interfere with agencies’ ability to require medical releases for purposes of security clearances under these Executive Orders.

In the case of the Department of State, however, it may be impracticable or infeasible to obtain an employee’s authorization when exigent circumstances arise overseas. For example, when a Foreign Service Officer is serving at an overseas post and he or she develops a critical medical problem which may or may not require a medical evacuation or other equally severe response, the Department’s medical staff have access to the employee’s medical records for the purpose of making a medical suitability determination under Executive Orders 10450 and 12968. To restrict the Department’s access to information at such a crucial time due to a lack of employee authorization leaves the Department no option but to suspend the employee’s security clearance. This action automatically would result in an immediate forced departure from post, which negatively would affect both the Department, due to the unexpected loss of personnel, and the individual, due to the fact that a forced departure can have a long-term impact on his or her career in the Foreign Service.

For this reason, the rule contains a limited security clearance exemption for the Department of State. The exemption allows the Department’s own medical staff to continue to have access to an employee’s medical file for the purpose of making a medical suitability determination for security purposes. The medical staff can convey a simple “yes” or “no” response to those individuals conducting the security investigation within the Department. In this way, the Department is able to make security determinations in exigent circumstances without disclosing any specific medical information to any employees other than the medical personnel who otherwise have routine access to these same medical records in an everyday non-security context.

Second, and similarly, the final rule establishes a similar system for disclosures of protected health information necessary to determine worldwide availability or availability for mandatory service abroad under sections 101(b)(5) and 904 of the Foreign Service Act. The Act requires that Foreign Service members be suitable for posting throughout the world and for certain specific assignments. For this reason, we permit a limited exemption to serve the purposes of the statute. Again, the medical staff can convey availability determinations to State Department officials who need to know if certain Foreign Service members are available to serve at post.

Third, and finally, the final rule recognizes the special statutory obligations that the State Department has regarding family members of Foreign Service members under sections 101(b)(5) and 904 of the Foreign Service Act. Section 101(b)(5) of the Foreign Service Act requires the Department of State to mitigate the impact of hardships, disruptions, and other unusual conditions on families of Foreign Service Officers. Section 904 requires the Department to establish a health care program to promote and maintain the mental health of Foreign Service member family members. The final rule permits disclosure of protected health information to officials who need protected health information to determine whether a family member can accompany a Foreign Service member abroad.

Given the limited applicability of the rule, we believe it is not necessary for the State Department to publish a notice in the Federal Register to identify the purposes for which the information may be used or disclosed. The final rule identifies these purposes, as described above.

Correctional Institutions

Comments about the rule’s application to correctional institutions are addressed in § 164.501, under the definition of “individual.”

Section 164.512(l)—Disclosures for Workers’ Compensation

Comment: Several commenters stated that workers’ compensation carriers are excepted under the HIPAA definition of group health plan and therefore we have no authority to regulate them in this rule. These commenters suggested clarifying that the provisions of the proposed rule did not apply to certain types of insurance entities, such as workers’ compensation carriers, and that such non-covered entities should have full access to protected health information without meeting the requirements of the rule. Other commenters argued that a complete exemption for workers’ compensation carriers was inappropriate.

Response: We agree with commenters that the proposed rule did not intend to regulate workers’ compensation carriers. In the final rule we have incorporated a provision that clarifies that the term “health plan” excludes “any policy, plan, or program to the extent that it provides, or pays for the cost of, excepted benefits as defined in section 2791(c)(1) of the PHS Act.” See discussion above under the definition of “health plan” in § 164.501.

Comment: Some commenters argued that the privacy rule should defer to other laws that regulate the disclosure of information to employers and workers’ compensation carriers. They commented that many states have laws that require sharing of information—without consent—between providers and employers or workers’ compensation carriers.

Response: We agree that the privacy rule should permit disclosures necessary for the administration of state and other workers’ compensation systems. To assure that workers’ compensations systems are not disrupted, we have added a new
provisions to the final rule. The new § 164.512(l) permits covered entities to disclose protected health information as authorized by and to the extent necessary to comply with workers’ compensation or other similar programs established by law that provide benefits for work-related injuries or illnesses without regard to fault. We also note that where a state or other law requires a use or disclosure of protected health information under a workers’ compensation or similar scheme, the disclosure would be permitted under § 164.512(a).

Comment: Several commenters stated that if workers’ compensation carriers are to receive protected health information, they should only receive the minimum necessary as required in § 164.514. The commenters argued that employers and workers’ compensation carriers should not have access to the entire medical history or portions of the medical history that have nothing to do with the injury in question. Further, the covered provider and not the employer or carrier should determine minimum necessary since the provider is a covered entity and only covered entities are subject to sanctions for violations of the rule. These commenters stated that the rule should clearly indicate the ability of covered entities to refuse to disclose protected health information if it went beyond the scope of the injury. Workers’ compensation carriers, on the other hand, argued that permitting providers to determine the minimum necessary was inappropriate because determining necessity for benefits is an insurance function, not a medical function. They stated that workers’ compensation carriers need access to the full range of information regarding treatment for the injury underlying the claim, the claimants’ current condition, and any preexisting conditions that can either mitigate the claim or aggravate the impact of the injury.

Response: Under the final rule, covered entities must comply with the minimum necessary provisions unless the disclosure is required by law. Our review of state workers’ compensation laws suggests that many of these laws address the issue of the scope of information that is available to carriers and employers. The rule permits a provider to disclose information that is authorized by such a law to the extent necessary to comply with such law. Where the law is silent, the workers’ compensation carrier and covered health care provider will need to discuss what information is necessary for the carrier to administer the claim, and the health care provider may disclose that information. We note that if the workers’ compensation insurer has secured an authorization from the individual for the release of protected health information, the covered entity may release the protected health information described in the authorization.

Section 164.514 Requirements for Uses and Disclosures
Section 164.514(a)–(c)–De-identification

General Approach

Comments: The comments on this topic almost unanimously supported the concept of de-identification and efforts to expand its use. Although a few comments suggested deleting one of the proposed methods or the other, most appeared to support the two method approach for entities with differing levels of statistical expertise.

Many of the comments argued that the standard for creation of de-identified information should be whether there is a “reasonable basis to believe” that the information has been de-identified. Others suggested that the “reasonable basis” standard was too vague.

A few commenters suggested that we consider information to be de-identified if all personal identifiers that directly reveal the identity of the individual or provide a direct means of identifying individuals have been removed, encrypted or replaced with a code. Essentially, this recommendation would require only removal of “direct” identifiers (e.g., name, address, and ID numbers) and allow retention of all “indirect” identifiers (e.g., zip code and birth date) in “de-identified” information. These comments did not suggest a list or further definition of what identifiers should be considered “direct” identifiers.

Some commenters suggested that the standard be modified to reflect a single standard that applies to all covered entities in the interest of reducing uncertainty and complexity. According to these commenters, the standard for covered entities to meet for de-identification of protected health information should be generally accepted standards in the scientific and statistical community, rather than focusing on a specified list of identifiers that must be removed.

A few commenters believed that no record of information about an individual can be truly de-identified and that all such information should be treated and protected as identifiable because more and more information about individuals is being made available to the public, such as voter registration lists and motor vehicle and driver’s license lists, that would enable someone to match (and identify) records that otherwise appear to be not identifiable.

Response: In the final rule, we reformulate the method for de-identification to more explicitly use the statutory standard of “a reasonable basis to believe that the information can be used to identify the individual”—just as information is “individually identifiable” if there is a reasonable basis to believe that it can be used to identify the individual, it is “de-identified” if there is no reasonable basis to believe it can be so used. We also define more precisely how the standard should be applied.

We did not accept comments that suggested that we allow only one method of de-identifying information. We find support for both methods in the comments but find no compelling logic for how the competing interests could be met cost-effectively with only one method.

We also disagree with the comments that advocated using a standard which required removing only the direct identifiers. Although such an approach may be more convenient for covered entities, we judged that the resulting information would often remain identifiable, and its dissemination could result in significant violations of privacy. While we encourage covered entities to remove direct identifiers whenever possible as a method of enhancing privacy, we do not believe that the resulting information is sufficiently blinded as to permit its general dissemination without the protections provided by this rule.

We agree with the comments that said that records of information about individuals cannot be truly de-identified, if that means that the probability of attribution to an individual must be absolutely zero. However, the statutory standard does not allow us to take such a position, but envisions a reasonable balance between risk of identification and usefulness of the information.

We disagree with those comments that advocated releasing only truly anonymous information (which has been changed sufficiently so that it no longer represents actual information about real individuals) and those that supported using only sophisticated statistical analysis before allowing uncontrolled disclosures. Although these approaches would provide a marginally higher level of privacy protection, they would preclude many of the laudable and important uses discussed in the NPRM (in § 164.506(d)) and would impose too great a burden on
less sophisticated covered entities to be justified by the small decrease in an already small risk of identification.

We conclude that compared to the alternatives advanced by the comments, the approach proposed in the NPRM, as refined and modified below in response to the comments, most closely meets the intent of the statute.

Comments: A few comments complained that the proposed standards were so strict that they would expose covered entities to liability because arguably no information could ever be de-identified.

Response: In the final rule we have modified the mechanisms by which a covered entity may demonstrate that it has complied with the standard in ways that provide greater certainty. In the standard method for de-identification, we have clarified the professional standard to be used, and anticipate issuing further guidance for covered entities to use in applying the standard. In the alternative method, we reduced the amount of judgment that a covered entity must apply. We believe that these mechanisms for de-identification are sufficiently well-defined to protect covered entities that follow them from undue liability.

Comments: Several comments suggested that the rule prohibit any linking of de-identified data, regardless of the probability of identification.

Response: Since our methods of de-identification include consideration of how the information might be used in combination with other information, we believe that linking de-identified information does not pose a significantly increased risk of privacy violations. In addition, since our authority extends only to the regulation of individually identifiable health information, we cannot regulate de-identified information because it no longer meets the definition of individually identifiable health information. We also have no authority to regulate entities that might receive and desire to link such information yet that are not covered entities; thus such a prohibition would have little protective effect.

Comments: Several commenters suggested that we create incentives for covered entities to use de-identified information. One commenter suggested that we mandate an assessment to see if de-identified information could be used before the use or disclosure of identified information would be allowed.

Response: We believe that this final rule establishes a reasonable mechanism for the creation of de-identified information and the fact that this de-identified information can be used without having to follow the policies, procedures, and documentation required to use individually identifiable health information should provide an incentive to encourage its use where appropriate. We disagree with the comment suggesting that we require an assessment of whether de-identified information could be used for each use or disclosure. We believe that such a requirement would be too burdensome on covered entities, particularly with respect to internal uses, where entire records are often used by medical and other personnel. For disclosures, we believe that such an assessment would add little to the protection provided by the minimum necessary requirements in this final rule.

Comments: One commenter asked if de-identification was equivalent to destruction of the protected health information (as required under several of the provisions of this final rule).

Response: The process of de-identification creates a new dataset in addition to the dataset containing the protected health information. This process does not substitute for actual destruction of the source data.

Modifications to the Proposed Standard for De-Identification

Comments: Several commenters called for clarification of proposed language in the NPRM that would have permitted a covered entity to treat information as de-identified, even if specified identifiers were retained, as long as the probability of identifying subject individuals would be very low. Commenters expressed concern that the “very low” standard was vague. These comments expressed concern that covered entities would not have a clear and easy way to know when information meets this part of the standard.

Response: We agree with the comments that covered entities may need additional guidance on the types of analyses that they should perform in determining when the probability of re-identification of information is very low. We note that in the final rule, we reformulate the standard somewhat to require that a person with appropriate knowledge and experience apply generally accepted statistical and scientific methods relevant to the task to make a determination that the risk of re-identification is very small. In this context, we do not view the difference between a very low probability and a very small risk to be substantive. After consulting representatives of the federal agencies that routinely de-identify and anonymize information for public release, we attempt here to provide some guidance for the method of de-identification.

As requested by some commenters, we include in the final rule a requirement that covered entities (not following the safe harbor approach) apply generally accepted statistical and scientific principles and methods for rendering information not individually identifiable when determining if information is de-identified. Although such guidance will change over time to keep up with technology and the current availability of public information from other sources, as a starting point the Secretary approves the use of the following as guidance to such generally accepted statistical and scientific principles and methods:

(1) Statistical Policy Working Paper 22—Report on Statistical Disclosure Limitation Methodology (http://www.fcsm.gov/working-papers/wp22.html) (prepared by the Subcommittee on Disclosure Limitation Methodology, Federal Committee on Statistical Methodology, Office of Management and Budget); and

We agree with commenters that such guidance will need to be updated over time and we will provide such guidance in the future.

According to the Statistical Policy Working Paper 22, the two main sources of disclosure risk for de-identified records about individuals are the existence of records with very unique characteristics (e.g., unusual occupation or very high salary or age) and the existence of external sources of records with matching data elements which can be used to link with the de-identified information and identify individuals (e.g., voter registration records or driver’s license records). The risk of disclosure increases as the number of variables common to both types of records increases, as the accuracy or resolution of the data increases, and as the number of external sources increases. As outlined in Statistical Policy Working Paper 22, an expert disclosure analysis would also consider the probability that an individual who is the target of an attempt at re-identification is represented on both
files, the probability that the matching variables are recorded identically on the two types of records, the probability that the target individual is unique in the population for the matching variables, and the degree of confidence that a match would correctly identify a unique person.

Statistical Policy Working Paper 22 also describes many techniques that can be used to reduce the risk of disclosure that should be considered by an expert when de-identifying health information. In addition to removing all direct identifiers, these include the obvious choices based on the above causes of the risk; namely, reducing the number of variables on which a match might be made and limiting the distribution of the records through a “data use agreement” or “restricted access agreement” in which the recipient agrees to limits on who can use/receive the data. The techniques also include more sophisticated manipulations: recoding variables into fewer categories to provide less precise detail (including rounding of continuous variables); setting top-codes and bottom-codes to limit details for extreme values; disturbing the data by adding noise by swapping certain variables between records, replacing some variables in random records with mathematically imputed values or averages across small random groups of records, or randomly deleting or duplicating a small sample of records; and replacing actual records with synthetic records that preserve certain statistical properties of the original data.

Modifications to the “Safe Harbor”

Comments: Many commenters argued that stripping all 19 identifiers is unnecessary for purposes of de-identification. They felt that such items as zip code, city (or county), and birth date, for example, do not identify the individual and only such identifiers as name, street address, phone numbers, fax numbers, email, Social Security number, driver’s license number, voter registration number, motor vehicle registration, identifiable photographs, finger prints, voice prints, web universal resource locator, and Internet protocol address number need to be removed to reasonably believe that data has been de-identified.

Other commenters felt that removing the full list of identifiers would significantly reduce the usefulness of the data. Many of these comments focused on research and, to a lesser extent, marketing and undefined “statistical analysis.” Commenters who represented various industries and research institutions expressed concern that they would not be able to continue current activities such as development of service provider networks, conducting “analysis” on behalf of the plan, studying use of medication and medical devices, community studies, marketing and strategic planning, childhood immunization initiatives, patient satisfaction surveys, and solicitation of contributions. The requirements in the NPRM to strip off zip code and date of birth were of particular concern. These commenters stated that their ability to do research and quality analysis with this data would be compromised without access to some level of information about patient age and/or geographic location.

Response: While we understand that removing the specified identifiers may reduce the usefulness of the resulting data to third parties, we remain convinced by the evidence found in the MIT study that we referred to in the preamble to the proposed rule and the analyses discussed below that there remains a significant risk of identification of the subjects of health information from the inclusion of indirect identifiers such as birth date and zip code and that in many cases there will be a reasonable basis to believe that such information remains identifiable. We note that a covered entity not relying on the safe harbor may determine that information from which sufficient other identifiers have been removed but which retains birth date or zip code is not reasonably identifiable. As discussed above, such a determination must be made by a person with appropriate knowledge and expertise applying generally accepted statistical and scientific methods for rendering information not identifiable.

Although we have determined that all of the specified identifiers must be removed before a covered entity meets the safe harbor requirements, we made modifications in the final rule to the specified identifiers on the list to permit some information about age and geographic area to be retained in de-identified information.

For age, we specify that, in most cases, year of birth may be retained, which can be combined with the age of the subject to provide sufficient information about age for most uses. After considering current and evolving practices and consulting with federal experts on this topic, including members of the Confidentiality and Data Access Committee of the Federal Committee on Statistical Methodology, Office of Management and Budget, we concluded that in general, age is sufficiently broad to be allowed in de-identified information, although all dates that might be directly related to the subject of the information must be removed or aggregated to the level of year to prevent deduction of birth dates. Extreme ages—90 and over—must be aggregated further (to a category of 90+ for example) to avoid identification of very old individuals (because they are relatively rare). This reflects the minimum requirement of the current recommendations of the Bureau of the Census. For research or other studies relating to young children or infants, we note that the rule would not prohibit age of an individual from being expressed as an age in months, days, or hours.

For geographic area, we specify that the initial three digits of zip codes may be retained for any three-digit zip code that contains more than 20,000 people as determined by the Bureau of the Census. As discussed above, there are currently only 18 three-digit zip codes containing fewer than 20,000 people. We note that this number may change when information from the 2000 Decennial Census is analyzed.

In response to concerns expressed in the comments about the need for information on geographic area, we investigated the potential of allowing 5-digit zip codes or 3-digit zip codes to remain in the de-identified information. According to 1990 Census data, the populations in geographical areas delineated by 3-digit zip codes vary a great deal, from a low of 394 to a high of 3,006,997, with an average size of 282,304. There are two 3-digit zip codes containing fewer than 500 people and six 3-digit zip codes containing fewer than 1,000 people each. Of the total of 881 3-digit zip codes, there are 18 with fewer than 20,000 people, 71 with fewer than 50,000 people, and 215 containing fewer than 100,000 population. We also looked at two-digit zip codes (the first 2 digits of the 5-digit zip code) and found that the smallest of the 98 2-digit zip codes contains 188,638 people.

We also investigated the practices of several other federal agencies which are mandated by Congress to release data...
from national surveys while preserving confidentiality and which have been dealing with these issues for decades. The problems and solutions being used by these agencies are laid out in detail in the Statistical Policy Working Paper 22 cited earlier.

To protect the privacy of individuals providing information to the Bureau of Census, the Bureau has determined that a geographical region must contain at least 100,000 people. This standard has been used by the Bureau of the Census for many years and is supported by simulation studies using Census data. These studies showed that after a certain point, increasing the size of a geographic area does not significantly decrease the percentage of unique records (i.e., those that could be identified by simulation), but that the point of diminishing returns is dependent on the number and type of demographic variables on which matching might occur. For a small number of demographic variables (6), this point was quite low (about 20,000 population), but it rose quickly to about 50,000 for 10 variables and to about 80,000 for 15 variables. The Bureau of the Census releases sets of data to the public that it considers safe from re-identification because it limits geographical areas to those containing at least 100,000 people and limits the number and detail of the demographic variables in the data. At the point of approximately 100,000 population, 7.3% of records were unique (and therefore potentially identifiable) on 6 demographic variables from the 1990 Census Short Form: Age in years (90 categories), race (180 categories), sex (2 categories), marital status (5 categories), employment status (2 categories), occupation (42 categories). Even when some of the variables are aggregated or coded, from the perspective of a large statistical agency desiring to release data to the public, the study concluded that a population size of 500,000 was not sufficient to provide a reasonable guarantee that certain individuals could not be identified. About 2.5% of the sample from the population of 500,000 was uniquely identifiable, regardless of sample size. This percentage rose as the size of the population decreased, to about 14% for a population of 100,000 and to about 25% for a population of 25,000. Eliminating the occupation variable (which is less likely to be found in health data) reduced this percentage significantly to about 0.4%, 3%, and 10% respectively. These percentages of unique records (and thus the potentials for re-identification) are highly dependent on the number of variables (which must also be available in other databases which are identified to be considered in a disclosure risk analysis), the categorical breakdowns of those variables, and the level of geographic detail included.

With respect to how we might clarify the requirement to achieve a “low probability” that information could be identified, the Statistical Policy Working Paper 22 referenced above discusses the attempts of several researchers to define mathematical measures of disclosure risk only to conclude that “more research into defining a computable measure of risk is necessary.” When we considered whether we could specify a maximum level of risk of disclosure with some precision (such as a probability or risk of identification of <0.01), we concluded that it is premature to assign mathematical precision to the “art” of de-identification.

After evaluating current practices and recognizing the expressed need for some geographic indicators in otherwise de-identified databases, we concluded that permitting geographic identifiers that define populations of greater than 20,000 individuals is an appropriate standard that balances privacy interests against desirable uses of de-identified data. In making this determination, we focused on the studies by the Bureau of Census cited above which seemed to indicate that a population size of 20,000 was an appropriate cut off if there were relatively few (6) demographic variables in the database. Our belief is that, after removing the required identifiers to meet the safe harbor standards, the number of demographic variables retained in the databases will be relatively small, so that it is appropriate to accept a relatively low number as a minimum geographic size.

In applying this provision, covered entities must replace the (currently 18) forbidden 3-digit zip codes with zeros and thus treat them as a single geographic area (with >20,000 population). The list of the forbidden 3-digit zip codes will be maintained as part of the updated Secretarial guidance referred to above. Currently, these are: 2022, 036, 059, 102, 203, 555, 556, 602, 821, 823, 830, 831, 876, 879, 884, 893, 987, and 994. This will result in an average 3-digit zip code area population of 287,858 which should result in an average of about 4% unique records using the 6 variables described above from the Census Short Form. Although this level of unique records will be much higher in the smaller geographic areas, the actual risk of identification will be much lower because of the limited availability of comparable data in publically available, identified databases, and will be further reduced by the low probability that someone will expend the resources to try to identify records when the chance of success is so small and uncertain. We think this compromise will meet the current need for an easy method to identify geographic area while providing adequate protection from re-identification. If a greater level of geographical detail is required for a particular use, the information will have to be obtained through the previously permitted mechanism or be subjected to a specific de-identification determination as described above. We will monitor the availability of identified public data and the concomitant re-identification risks, both theoretical and actual, and adjust this safe harbor in the future as necessary.

As we stated above, we understand that many commenters would prefer a looser standard for determining when information is de-identified, both generally and with respect to the standards for identifying geographic...
of these 19 identifiers created a difficult problem. The number of demographic variables within them still appears to be fairly limited. The number of cases of privacy violation from health records which have been identified in this way is small.

Response: We agree that our proposed requirement to remove all photographic images was more than necessary. Many photographs of lesions, for example, which cannot usually be used alone to identify an individual, are included in health records. In this final rule, the only absolute requirement is the removal of full-face photographs, and we define “catch-all” of “any other unique * * * characteristic * * *” to pick up the unusual case where another type of photographic image might be used to identify an individual.

Comments: A number of commenters felt that the proposed bar for removal had been set too high; that the removal of these 19 identifiers created a difficult standard, since some identifiers may be buried in lengthy text fields.

Response: We understand that some identifiers that accompany photographs are often needed to interpret the image and that it would be difficult to use the image alone to identify the individual.

Comments: Some comments noted that identifiers that accompany photographs are often needed to interpret the image and that it would be difficult to use the image alone to identify the individual.

Response: We agree that our proposed requirement to remove all photographic images was more than necessary. Many photographs of lesions, for example, which cannot usually be used alone to identify an individual, are included in health records. In this final rule, the only absolute requirement is the removal of full-face photographs, and we define “catch-all” of “any other unique * * * characteristic * * *” to pick up the unusual case where another type of photographic image might be used to identify an individual.

Comments: A number of commenters felt that the proposed bar for removal had been set too high; that the removal of these 19 identifiers created a difficult standard, since some identifiers may be buried in lengthy text fields.

Response: We understand that some identifiers that accompany photographs are often needed to interpret the image and that it would be difficult to use the image alone to identify the individual. In addition, we believe that such unstructured text fields have little or no value in a de-identified information set and would be removed in any case. With time, we expect that such identifiers will be kept out of places where they are hard to locate and expunge.

Comments: Some commenters asserted that this requirement creates a disincentive for covered entities to de-identify data and would compromise the Secretary’s desire to see de-identified data used for a multitude of purposes. Others stated that the “no reason to believe” test creates an unreasonable burden on covered entities, and would actually chill the release of de-identified information, and set an impossible standard.

Response: We recognize that the proposed standards might have imposed a burden that could have prevented the widespread use of de-identified information. We believe that our modifications to the final rule discussed above will make the process less burdensome and remove some of the disincentive. However, we could not loosen the standards as far as many commenters wanted without seriously jeopardizing the privacy of the subjects of the information. As discussed above, we modify the “no reason to know” standard that was part of the safe harbor provision and replace it in the final rule with an “actual knowledge” standard. We believe that this change provides additional certainty to covered entities using the safe harbor and should eliminate any chilling effect. We believe that our changes to the definitions of identifiers and characteristic are critical for quality patient care. They argued that the proposed standard would be unworkable in daily treatment situations. They argued that the standard to a “gag clause” in that it limited the exchange of information critical to the care of individual patients. They argued that this standard would be potentially dangerous in that it could cause practitioners to withhold information that could be essential for later care.

Comments: Some suggested that the final regulation may be too low; that, in some cases, it would be possible to re-identify information. Under the rule, the covered entity that created the de-identified information to re-identify it. However, we include a requirement that, when a unique record identifier is included in the de-identified information, such identifier must not be such that someone other than the covered entity could use it to identify the individual (such as when a derivative of the individual’s name is used as the unique record identifier).

Section 164.514(d)—Minimum Necessary Identifier

Comment: A number of commenters objected to the application of the proposed “minimum necessary” standard for uses and disclosures of protected health information to uses and disclosures for treatment purposes. Some suggested that the final rule should establish a good faith exception or safe harbor for disclosures made for treatment.

The overwhelming majority of comments, generally from the medical community, argued that application of the proposed standard would be contrary to sound medical practice, increase medical errors, and lead to an increase in liability. Some likened the standard to a “gag clause” in that it limited the exchange of information critical to the care of individual patients. They argued that this standard would be potentially dangerous in that it could cause practitioners to withhold information that could be essential for later care.

Comments: A few commenters asked us to prohibit anyone from re-identifying de-identified health information.

Response: We do not have the authority to regulate persons other than covered entities, so we cannot affect attempts by entities outside of this rule to re-identify information. Under the rule, we permit the covered entity that created the de-identified information to re-identify it. However, we include a requirement that, when a unique record identifier is included in the de-identified information, such identifier must not be such that someone other than the covered entity could use it to identify the individual (such as when a derivative of the individual’s name is used as the unique record identifier).
complete picture of the patient’s health to make a diagnosis and develop a treatment plan.

Other commenters noted that the complexity of medicine is such that it is unreasonable to think that anyone will know the exact parameters of the information another caregiver will need for proper diagnosis and treatment or that a plan will need to support quality assurance and improvement activities. They therefore suggested that the minimum necessary standard be applied instead as an administrative requirement.

Providers also emphasized that they already have an ethical duty to limit the sharing of unnecessary medical information, and most already have well-developed guidelines and practice standards in place. Concerns were also voiced that attempts to provide the minimum necessary information in the treatment setting would lead to multiple editions of a record or creation of summaries that turn out to omit crucial information resulting in confusion and error.

Response: In response to these concerns, we substantially revise the minimum necessary requirements. As suggested by certain commenters, we provide, in § 164.502(b), that disclosures of protected health information to or requests by health care providers for treatment are not subject to the minimum necessary standard. We also modify the requirements for uses of protected health information. This final rule requires covered entities to make determinations of minimum necessary use, including use for treatment purposes, based on the role of the person or class of workforce members rather than at the level of specific uses. A covered entity must establish policies and procedures that identify the types of persons who are to have access to designated categories of information and the conditions, if any, of that access. We establish no requirements specific to a particular use of information. Covered entities are responsible for establishing and documenting these policies and procedures. This approach is consistent with the argument of many commenters that guidelines and practice standards are appropriate means for protecting the privacy of patient information.

Comment: Some commenters argued that the standard should be retained in the treatment setting for uses and disclosures pertaining to mental health information. Some of these commenters asserted that other providers do not need to know the mental status of a patient for treatment purposes.

Response: We agree that the standard should be retained for uses of mental health information in the treatment setting. However, we believe that the arguments for excepting disclosures of protected health information for treatment purposes from application of the minimum necessary standard are also persuasive with respect to mental health information. An individual’s mental health can interact with proper treatment for other conditions in many ways. Psychoactive medications may have harmful interactions with drugs routinely prescribed for other purposes; an individual’s mental health history may help another health care provider understand the individual’s ability to abide by a complicated treatment regimen. For these reasons, it is also not reasonable to presume that, in every case, a health care provider will not need to know an individual’s mental health status to provide appropriate treatment.

Providers’ comments noted existing ethical duties to limit the sharing of unnecessary medical information, and well-developed guidelines and practice standards for this purpose. Under this rule, providers may use these tools to guide their discretion in disclosing health information for treatment.

Comment: Several commenters urged that covered entities should be required to conspicuously label records to show that they are not complete. They argued that absent such labeling, patient care could be compromised.

Response: We believe that the final policy to except disclosures of protected health information for treatment purposes from application of the minimum necessary standard addresses these commenters’ concerns.

Comment: Some commenters argued that the audit exception to the minimum necessary requirements needs to be clarified or expanded, because “audit” and “payment” are essentially the same thing.

Response: We eliminate this exception. The proposed exclusion of disclosures to health plans for audit purposes is replaced with a general requirement that covered entities must limit requests to other covered entities for individually identifiable health information to what is reasonably necessary for the purpose intended.

Comment: Many commenters argued that the proposed standard was unworkable as applied to “uses” by a covered entity’s employees, because the proposal appeared not to allow providers to create general policy as to the types of records that particular employees may have access to but instead required each decision be made “individually,” which providers interpret as “case-by-case.” Commenters argued that the standard with regard to “uses” would be impossible to implement and prohibitively expensive, requiring both medical and legal input to each disclosure decision.

Some commenters recommended deletion of the minimum necessary standard with regard to “uses.” Other commenters specifically recommended deletion of the requirement that the standard be applied on an individual, case-by-case basis. Rather, they suggested that the covered entity be allowed to establish general policies to meet the requirement. Another commenter similarly urged that the standard not apply to internal disclosures or for internal health care operations such as quality improvement/assurance activities. The commenter recommended that medical groups be allowed to develop their own standards to ensure that these activities are carried out in a manner that best helps the group and its patients.

Other commenters expressed confusion and requested clarification as to how the standard as proposed would actually work in day-to-day operations within an entity.

Response: Commenters’ arguments regarding the workability of this standard as proposed were persuasive, and we therefore make significant modification to address these comments and improve the workability of the standard. For all uses and many disclosures, we require covered entities to include in their policies and procedures (see § 164.530), which may be standard protocols, for “minimum necessary” uses and disclosures. We require implementation of such policies in lieu of making the “minimum necessary” determination for each separate use and disclosure.

For uses, covered entities must implement policies and procedures that restrict access to and use of protected health information based on the specific professional roles of members of the covered entity’s workforce. The policies and procedures must identify the persons or classes of persons in the entity’s workforce who need access to protected health information to carry out their duties and the category or categories of protected health information to which such persons or classes need access. These role-based access rules must also identify the conditions, as appropriate, that would apply to such access. For example, an institutional health care provider could allow physicians access to all records under the condition that the viewing of medical records not under their care is recorded and reviewed. Other health professionals’ access could
be limited to time periods when they are on duty. Information available to staff who are responsible for scheduling surgical procedures could be limited to certain data. In many instances, use of order forms or selective copying of relevant portions of a record may be appropriate policies to meet this requirement. Routine disclosures also are not subject to individual review; instead, covered entities must implement policies and procedures (which may be standard protocols) to limit the protected health information in routine disclosures to the minimum information reasonably necessary to achieve the purpose of that type of disclosure. For non-routine disclosures, a covered entity must develop reasonable criteria to limit the protected health information disclosed to the minimum necessary to accomplish the purpose for which disclosure is sought, and to implement procedures for review of disclosures on an individual basis. We modified the proposed standard to require the covered entity to make “reasonable efforts” to meet the minimum necessary standard (not “all reasonable efforts, as proposed). What is reasonable will vary with the circumstances. When it is practical to use order forms or selective copying of relevant portions of the record, the covered entity is required to do so. Similarly, this flexibility in the standard takes into account the ability of the covered entity to configure its record system to allow selective access to only certain fields, and the practicality of organizing systems to allow this capacity. It might be reasonable for a covered entity with a highly computerized information system to implement a system under which employees with certain functions have access to only limited fields in a patient records, while other employees have access to the complete records. Such a system might not be reasonable for a covered entity with a largely paper records system. Covered entities’ policies and procedures must provide that disclosure of an entire medical record will not be made except pursuant to policies which specifically justify why the entire medical record is needed. We believe that these modifications significantly improve the workability of this standard. At the same time, we believe that asking covered entities to assess their practices and establish rules for themselves will lead to significant improvements in the privacy of health information. See the preamble for § 164.514 for a more detailed discussion.  

Comment: The minimum necessary standard should not be applied to uses and disclosures for payment or health care operations.  
Response: Commenter’s arguments for exempting these uses and disclosures from the minimum necessary standard were not compelling. We believe that our modifications to application of the minimum necessary standard to internal uses of protected health information, and to routine disclosures, address many of the concerns raised, particularly the concerns about administrative burdens and the concerns about having the information necessary for day-to-day operations. We do not eliminate this standard in part because we also remain concerned that covered entities may be tempted to disclose an entire medical record when only a few items of information are necessary, to avoid the administrative step of extracting the necessary information (or redacting the unnecessary information). We also believe this standard will cause covered entities to reassess their privacy practices, give the privacy interests of their patients and enrollees greater attention, and make improvements that might otherwise not have been made. For this reason, the privacy benefits of retaining the minimum necessary standard for these purposes outweigh the burdens involved. We note that the minimum necessary standard is tied to the purpose of the disclosure; thus, providers may disclose protected health information as necessary to obtain payment.  

Comment: Other commenters urged us to apply a “good faith” provision to all disclosures subject to the minimum necessary standard. Commenters presented a range of options to modify the proposed provisions which, in their view, would have mitigated their liability if they failed to comply with minimum necessary standard.  
Response: We believe that the modifications to this standard, described above, substantially address these commenters’ concerns. In addition to allowing the covered entity to use standard protocols for routine disclosures, we modify the standard to require a covered entity to make “reasonable efforts,” not “all” reasonable efforts as proposed, in making the “minimum necessary” disclosure.  

Comments: Some commenters complained that language in the proposed rule was vague and provided little guidance, and should be abandoned.  
Response: In the preamble for § 164.504 and those responses to comments, we provide further guidance on how a covered entity can develop its policies for the minimum necessary use and disclosure of protected health information. We do not abandon this standard for the reasons described above. We remain concerned about the number of persons who have access to identifiable health information, and believe that causing covered entities to examine their practices will have significant privacy benefits.  

Comment: Some commenters asked that the minimum necessary standard should not be applied to disclosures to business partners. Many of these commenters articulated the burdens they would bear if every disclosure to a business partner was required to meet the minimum necessary standard.  
Response: We do not agree. In this final rule, we minimize the burden on covered entities in the following ways: in circumstances where disclosures are made on a routine, recurring basis, such as in on-going relationships between covered entities and business associates, individual review of each routine disclosure has been eliminated; covered entities are required only to develop standard protocols to apply to such routine disclosures made to business associates (or types of business associates). In addition, we allow covered entities to rely on the representation of a professional hired to provide professional services as to what information is the minimum necessary for that purpose.  

Comment: Some commenters were concerned that applying the standard in research settings will result in providers declining to participate in research protocols.  
Response: We have modified the proposal to reduce the burden on covered entities that wish to disclose protected health information for research purposes. The final rule requires covered entities to obtain documentation or statements from persons requesting protected health information for research that, among other things, describe the information necessary for the research. We allow covered entities to reasonably rely on the documentation or statements as describing the minimum necessary disclosure.  

Comment: Some commenters argued that government requests should not be subject to the minimum necessary standard, whether or not they are “authorized by law.”  
Response: We found no compelling reason to exempt government requests from this standard, other than when a disclosure is required by law. (See preamble to § 164.512(a) for the
When a disclosure is required by law, the minimum necessary standard does not apply, whether the recipient of the information is a government official or a private individual.

At the same time, we understand that when certain government officials make requests for protected health information, some covered entities might feel pressure to comply that might not be present when the request is from a private individual. For this reason, we allow (but do not require) covered entities to reasonably rely on the representations of public officials as to the minimum necessary information for the purpose.

Comment: Some commenters argued that requests under proposed § 164.510 should not be subject to the minimum necessary standard, whether or not they are “authorized by law.” Others argued that for disclosures made for administrative proceedings pursuant to proposed § 164.510, the minimum necessary standard should apply unless they are subject to a court order.

Response: We found no compelling reason to exempt disclosures for purposes listed in the regulation from this standard, other than for disclosures required by law. When there is no such legal mandate, the disclosure is voluntary on the part of the covered entity, and it is therefore reasonable to expect the covered entity to make some effort to protect privacy before making such a disclosure. If the covered entity finds that redacting unnecessary information, or extracting the requested information, prior to making the disclosure, is too burdensome, it need not make the disclosure. Where there is ambiguity regarding what information is needed, some effort on the part of the covered entity can be expected in these circumstances.

We also found no compelling reason to limit the exemption for disclosures “required by law” to those made pursuant to a court order. The judgment of a state legislature or regulatory body that a disclosure is required is entitled to no less deference than the same decision made by a court. For further rationale for this policy, see the preamble to § 164.512(a).

Comment: Some commenters argued that, in cases where a request for disclosure is not required by law, covered entities should be permitted to rely on the representations by public officials, that they have requested no more than the minimum amount necessary.

Response: We agree, and retain the proposed provision which allows reasonable reliance on the representations of public officials.

Comment: Some commenters argued that it is inappropriate to require covered entities to distinguish between disclosures that are “required by law” and those that are merely “authorized by law,” for the purposes of determining when the standard applies.

Response: We do not agree. Covered entities have an independent duty to be aware of their legal obligations to federal, state, local and territorial or tribal authorities. In addition, § 164.514(b) allows covered entities to reasonably rely on the oral or written representation of public officials that a disclosure is required by law.

Comment: The minimum necessary standard should not be applied to pharmacists, or to emergency services.

Response: We believe that the final rule’s exemption of disclosures of protected health information to health care providers for treatment purposes from the minimum necessary standard addresses these commenters concerns about emergency services. Together with the other changes we make to the proposed standard, we believe we have also addressed most of the commenters concerns about pharmacists. With respect to pharmacists, the comments offered no persuasive reasons to treat pharmacists differently from other health care providers. Our reasons for retaining this standard for other uses and disclosures of protected health information are explained above.

Comment: A number of commenters argued that the standard should not apply to disclosures to attorneys, because it would interfere with the professional duties and judgment of attorneys in their representation of covered entities. Commenters stated that if a layperson within a covered entity makes an improper decision as to what the minimum necessary information is in regard to a request by the entity’s attorney, the attorney may end up lacking information that is vital to representation. These commenters stated that attorneys are usually going to make an improper decision as to what information is the minimum necessary for effective counsel and representation of the client.

Response: We found no compelling reason to treat attorneys differently from other business associates. However, to ensure that this rule does not inadvertently cause covered entities to second-guess the professional judgment of the attorneys and other professionals they hire, we modify the proposed policy to regarding the ability of covered entities to rely on the representation of a professional hired to provide professional services as to what information is the minimum necessary for that purpose.

Comment: Commenters from the law enforcement community expressed concern that providers may attempt to misuse the minimum necessary standard as a means to restrict access to information, particularly with regard to disclosures for health oversight or to law enforcement officials.

Response: The minimum necessary standard does not apply to disclosures required by law. Since the disclosures to law enforcement officials to which this standard applies are all voluntary, there would be no need for a covered entity to “manipulate” the standard; it could decline to make the disclosure.

Comment: Some commenters argued that the only exception to the application of the standard should be when an individual requests access to his or her own information. Many of these commenters expressed specific concerns about victims of domestic violence and other forms of abuse.

Response: We do not agree with the general assertion that disclosure to the individual is the only appropriate exception to the minimum necessary standard. There are other, limited, circumstances in which application of the minimum necessary standard could cause significant harm. For reasons described above, disclosures of protected health information for treatment purposes are not subject to this standard. Similarly, as described in detail in the preamble to § 164.512(a), where another public body has mandated the disclosure of health information, upsetting that judgment in this regulation would not be appropriate.

The more specific concerns expressed about victims of domestic violence and other forms of abuse are addressed in a new provision regarding disclosure of protected health information related to domestic violence and abuse (see § 164.512(c)), and in new limitations on disclosures to persons involved in the individual’s care (see § 164.516(b)). We believe that the limitations we place on disclosure of health information in those circumstances address the concerns of these commenters.

Comment: Some commenters argued that disclosures to next of kin should be restricted to minimum necessary protected health information, and to protected health information about only the current medical condition.

Response: In the final regulation, we change the proposed provision regarding “next of kin” to more clearly focus on the disclosures we intended to target: Disclosures to persons involved
in the individual’s care. We allow such disclosure only with the agreement of the individual, or where the covered entity has offered the individual the opportunity to object to the disclosure and the individual did not object. If the opportunity to object cannot practically be provided because of the incapacity of the individual or other emergency, we require covered entities to exercise professional judgment in the best interest of the patient in deciding whether to disclose information. In such cases, we permit disclosure only of that information directly relevant to the person’s involvement with the individual’s health care. (This provision also includes limited disclosure to certain persons seeking to identify or locate an individual.) See §164.510(b).

Some additional concerns expressed about victims of domestic violence and other forms of abuse are also addressed in a new section on disclosure of protected health information related to domestic violence and abuse. See §164.512(c). We believe that the limitations we place on disclosure of health information in these provisions address the concerns of these commenters.

Comment: Some commenters argued that covered entities should be required to determine whether de-identified information could be used before disclosing information under the minimum necessary standard.

Response: We believe that requiring covered entities’ policies and procedures for minimum necessary disclosures to address whether de-identified information could be used in all instances would impose burdens on some covered entities that could outweigh the benefits of such a requirement. There is significant variation in the sophistication of covered entities’ information systems. Some covered entities can reasonably implement policies and procedures that make significant use of de-identified information; other covered entities would find such a requirement excessively burdensome. For this reason, we chose instead to require “reasonable efforts,” which can vary according to the situation of each covered entity.

In addition, we believe that the fact that we allow de-identified information to be disclosed without regard to the policies, procedures, and documentation required for disclosure of identifiable health information will provide an incentive to encourage its use where appropriate.

Comment: Some commenters argued that standard transactions should not be subject to the standard.

Response: We agree that data elements that are required or situationally required in the standard transactions should not be, and are not, subject to this standard. However, in many cases, covered entities have significant discretion as to the information included in these transactions. Therefore, this standard does apply to those optional data elements.

Comment: Some commenters asked for clarification to understand how the minimum necessary standard is intended to interact with the security NPRM.

Response: The proposed Security Rule included requirements for electronic health information systems to include access management controls. Under this regulation, the covered entity’s privacy policies will determine who has access to what protected health information. We will make every effort to ensure consistency prior to publishing the final Security Rule.

Comment: Many commenters, representing health care providers, argued that if the request was being made by a health plan, the health plan should be required to request only the minimum protected health information necessary. Some of these commenters stated that the requestor is in a better position to know the minimum amount of information needed for their purposes. Some of these commenters argued that the minimum necessary standard should be imposed only on the requesting entity. A few of these commenters argued that both the disclosing and the requesting entity should be subject to the minimum necessary standard, to create “internal tension” to assure the standard is honored.

Response: We agree, and in the final rule we require that a request for protected health information made by one covered entity to another covered entity must be limited to the minimum amount necessary for the purpose. As with uses and disclosures of protected health information, covered entities may have standard protocols for routine requests. Similarly, this requirement does not apply to requests made to health care providers for treatment purposes.

Comment: A few commenters suggested that there should be a process for resolving disputes between covered entities over what constitutes the “minimum necessary” information.

Response: We do not intend that this rule change the way covered entities currently handle their differences regarding the disclosure of health information. We understand that the scope of information requested from providers by health plans is a source of tension in the industry today, and we believe it would not be appropriate to use this regulation to affect that debate. As discussed above, we require both the requesting and the disclosing covered entity to take privacy concerns into account, but do not inject additional tension into the on-going discussions.

Section 164.514(e)—Marketing

Comment: Many commenters requested clarification of the boundaries between treatment, payment, health care operations, and marketing. Some of these commenters requested clarification of the apparent inconsistency between language in proposed §164.506(a)(1)(i) (a covered entity is permitted to use or disclose protected health information without authorization “to carry out” treatment, payment, or health care operations) and proposed §164.508(a)(2)(A) (a covered entity must obtain an authorization for all uses and disclosures that are not “compatible with or directly related to” treatment, payment, or health care operations). They suggested retaining the language in proposed §164.508(a)(2)(A), which would permit a broader range of uses and disclosures without authorization, in order to engage in health promotion activities that might otherwise be considered marketing.

Response: In the final rule, we make several changes to the definitions of treatment, payment, and health care operations that are intended to clarify the uses and disclosures of protected health information that may be made for each purpose. See §164.501 and the corresponding preamble discussion regarding the definitions of these terms. We also have added a definition of the term “marketing” to help establish the boundary between marketing and treatment, payment, and health care operations. See §164.501. We also clarify the conditions under which authorization is or is not required for uses and disclosures of protected health information for marketing purposes. See §164.514(e). Due to these changes, we believe it is appropriate to retain the wording from proposed §164.506(a)(1)(i).
Comment: We received a wide variety of suggestions with respect to authorization for uses and disclosures of protected health information for marketing purposes. Some commenters supported requiring authorization for all such uses and disclosures. Other commenters suggested permitting all such uses and disclosures without authorization. Some commenters suggested we distinguish between marketing to benefit the covered entity and marketing to benefit a third party. For example, a few commenters suggested we should prohibit covered entities from seeking authorization for any use or disclosure for marketing purposes that benefit a third party. These commenters argued that the third parties should be required to obtain the individual's authorization directly from the individual, not through a covered entity, due to the potential for conflicts of interest. While a few commenters suggested that we require covered entities to obtain authorization to use or disclose protected health information for the purpose of marketing its own products and services, the majority argued these types of marketing activities are vital to covered entities and their customers and should therefore be permitted to occur without authorization. For example, commenters suggested covered entities should be able to use and disclose protected health information without authorization in order to provide appointment reminders, newsletters, information about new initiatives, and programs and benefits.

Finally, many commenters argued we should not require authorization for the use or disclosure of protected health information to market any health-related goods and services, even if those goods and services are offered by a third party. Some of these commenters suggested that individuals should have an opportunity to opt out of these types of marketing activities rather than requiring authorization.

Response: We have modified the final rule in ways that address a number of the issues raised in the comments. First, the final rule defines the term marketing, and excepts certain communications from the definition. See § 164.501. These exceptions include communications made by covered entities for the purpose of describing network providers or other available products, services, or benefits and communications made by covered entities for certain treatment-related purposes. These exceptions only apply to oral communications or to written communications for which the covered entity receives no third-party remuneration. The exceptions to the definition of marketing fall within the definitions of treatment and/or health care operations, and therefore uses, or disclosures to a business associate, of protected health information for these purposes are permissible under the rule without authorization.

The final rule also permits covered entities to use protected health information to market health-related products and services, whether they are the products and services of the covered entity or of a third party, subject to a number of limitations. See § 164.514(e). We permit these uses to allow entities in the health sector to inform their patients and enrollees about products that may benefit them. The final rule contains significant restrictions, including requirements that the covered entity disclose itself as the source of a marketing communication, that it disclose any direct or indirect remuneration from third parties for making the disclosure, and that, except in the cases of general communications such as a newsletter, the communication disclose how the individual can opt-out of receiving additional marketing communications. Additional requirements are imposed if the communication is targeted based on the health status or condition of the proposed recipients.

We believe that these modifications address many of the issues raised by commenters and provide a substantial amount of flexibility as to when a covered entity may communicate about a health-related product or service to a patient or enrollee. These communications may include appointment reminders, newsletters, and information about new health products. These changes, however, do not permit a covered entity to disclose protected health information to third parties for marketing (other than to a business associate to make a marketing communication on behalf of the covered entity) without authorization under § 164.508.

Comment: A few commenters suggested we prohibit health care clearinghouses from seeking authorization for the use or disclosure of protected health information for marketing purposes.

Response: We do not prohibit clearinghouses from seeking authorizations for these purposes. We believe, however, that health care clearinghouses will almost always create or obtain protected health information in a business associate capacity and as such may only engage in activities involving the use or disclosure of protected health information, including seeking or acting on an authorization, to the extent their contracts allow them to do so. When a clearinghouse creates or receives protected health information other than as a business associate of a covered entity, it is permitted and required to obtain authorizations to the same extent as any other covered entity.

Comment: A few commenters suggested we require covered entities to publicly disclose, on the covered entity's website or upon request, all of their marketing arrangements.

Response: While we agree that such a requirement would provide individuals with additional information about how their information would be used, we do not feel that such a significant intrusion into the business practices of the covered entity is warranted.

Comment: Some commenters argued that if an activity falls within the scope of payment, it should not be considered marketing. Commenters strongly supported an approach which would bar an activity from being construed as “marketing” even if performing that activity would result in financial gain to the covered entity. In a similar vein, we were urged to adopt the position that if an activity was considered payment, treatment or health care operations, it could not be further evaluated to determine whether it should be excluded as marketing.

Response: We considered the approach offered by commenters but decided against it. Some activities, such as the marketing of a covered entity’s own health-related products or services, are now included in the definition of health care operations, provided certain requirements are met. Other types of activities, such as the sale of a patient list to a marketing firm, would not be permitted under this rule without authorization from the individual. We do not believe that we can envision every possible disclosure of health information that would violate the privacy of an individual, so any list would be incomplete. Therefore, whether or not a particular activity is considered marketing, payment, treatment or health care operations will be a fact-based determination based on the activity’s congruence with the particular definition.

Comment: Some industry groups stated that if an activity involves selling products, it is not disease management. They suggested we adopt a definition of disease management that differentiates use of information for the best interests of patient from uses undertaken for “marketing purposes” such as advertising, marketing, or promoting separate products.
Response: We agree in general that the sale of unrelated products to individuals is not a population-based activity that supports treatment and payment. However, in certain circumstances marketing activities are permitted as a health care operation; see the definition of “health care operations” in § 164.501 and the related marketing requirements of § 164.514.

Comment: Some commenters complained that the absence of a definition for disease management created uncertainty, in view of the proposed rule’s requirement to get authorization for marketing. They expressed concern that the effect would be to require patient consent for many activities that are desirable, not practically done if authorization is required, and otherwise classifiable as treatment, payment, or health care operations. Examples provided include reminders for appointments, reminders to get preventive services like mammograms, and information about home management of chronic illnesses. They also stated that the proposed rule would prevent many disease management and preventive health activities.

Response: We agree that the distinction in the NPRM between disease management and marketing was unclear. Rather than provide a definition of disease management, this final rule defines marketing. We note that overlap between disease management and marketing exists today in practice and they cannot be distinguished easily with a definitional label. However, for purposes of this rule, the revised language makes clear for what activities an authorization is required. We note that under this rule many of the activities mentioned by commenters will not require authorizations under most circumstances. See the discussion of disease management under the definition of “treatment” in § 164.501.

Section 164.514(f)—Fundraising

Comment: Many comments objected to the requirement that an authorization from the individual be obtained for use and disclosure of protected health information for fundraising purposes. They argued that, in the case of not-for-profit health care providers, having to obtain authorization would be time consuming and costly, and that such a requirement would lead to a decrease in charitable giving. The commenters also urged that fundraising be included within the definition of health care operations. Numerous commenters suggested that they did not need unfettered access to patient information in order to carry out their fundraising campaigns. They stated that a limited data set restricted to name, address, and telephone number would be sufficient to meet their needs. Several commenters suggested that we create a voluntary opt-out provision so people can avoid solicitations.

Response: We agree with commenters that our proposal could have adversely effected charitable giving, and accordingly make several modifications to the proposal. First, the final rule allows a covered entity to use or disclose to a business associate protected health information without authorization to identify individuals for fundraising for its own benefit. Permissible fundraising activities include appeals for money, sponsorship of events, etc. They do not include royalties or remittances for the sale of products of third parties (except auctions, rummage sales, etc).

Second, the final rule allows a covered entity to disclose protected health information without authorization to an institutionally related foundation that has as its mission to benefit the covered entity. This special provision is necessary to accommodate tax code provisions which may not allow such foundations to be business associates of their associated covered entity. We also agree that broad access to protected health information is unnecessary for fundraising and unnecessarily intrudes on individual privacy. The final rule limits protected health information to be used or disclosed for fundraising to demographic information and the date that treatment occurred. Demographic information is not defined in the rule, but will generally include in this context name, address and other contact information, age, gender, and insurance status. The term does not include any information about the illness or treatment.

We also agree that a voluntary opt-out is an appropriate protection, and require in § 164.520 that covered entities provide information on their fundraising activities in their “Notice of Information Practices.” As part of the notice and in any fundraising materials, covered entities must provide information explaining how individuals may opt out of fundraising communications.

Comment: Some commenters stated that use and disclosure of protected health information for fundraising, without authorization should be limited to not-for-profit entities. They suggested that not-for-profit entities were in greater need of charitable contributions and as such, they should be exempt from the authorization requirement while for-profit organizations should have to comply with the requirement.

Response: We do not agree that the profit status of a covered entity should determine its allowable use of protected health information for fundraising. Many for-profit entities provide the same services and have similar missions to not-for-profit entities. Therefore, the final rule does not make this distinction.

Comment: Several commenters suggested that the final rule should allow the internal use of protected health information for fundraising, without authorization, but not disclosure for fundraising. These commenters suggested that by limiting access of protected health information to only internal development offices concerns about misuse would be reduced.

Response: We do not agree. A number of commenters noted that they have related charitable foundations that raise funds for the covered entity, and we permit disclosures to such foundations to ensure that this rule does not interfere with charitable giving.

Comment: Several commenters asked us to address the content of fundraising letters. They pointed out that disease or condition-specific letters requesting contributions, if opened by the wrong person, could reveal personal information about the intended recipient.

Response: We agree that such communications raise privacy concerns. In the final rule, we limit the information that can be used or disclosed for fundraising, and exclude information about diagnosis, nature of services, or treatment.

Section 164.514(g)—Verification

Comment: A few commenters suggested that verification guidelines may need to be different as they apply to emergency clinical situations as opposed to routine data collection where delays do not threaten health.

Response: We agree, and make special provisions in §§ 164.510 and 164.512 for disclosures of protected health information by a covered entity without authorization where the individual is unable to agree or object to disclosure due to incapacity or other emergency circumstance.

For example, a health care provider may need to make disclosures to family members, close personal friends, and others involved in the individual’s care in emergency situations. Similarly, a health care provider may need to respond to a request from a hospital seeking protected health information in
a circumstance described as an emergency. In each case, we require only that the covered entity exercise professional judgment, in the best interest of the patient, in deciding whether to make a disclosure. Based on the comments and our fact finding, this reflects current practice.

Comment: A few commenters stated the rules should include provisions for electronic verification of identity (such as Public Key Infrastructure (PKI)) as established in the regulations on Security and Electronic Signatures. One commenter suggested that some kind of PKI credentialing certificate should be required.

Response: This regulation does not address specific technical protocols utilized to meet the verification requirements. If the requirements of the rule are otherwise met, the mechanism for meeting them can be determined by the covered entity.

Comment: A few commenters wanted more clarification on the verification procedures. One commenter wanted to know if contract number is enough for verification. A few commenters wanted to know if a callback or authorization on a letterhead is acceptable. A few commenters wanted to know if plans are considered to “routinely do business” with all of their members.

Response: In the final rule, we modify the proposed provision and require covered entities to have policies and procedures reasonably designed to verify the identity and authority of persons requesting protected health information. Whether knowledge of a contract number is reasonable evidence of authority and identity will depend on the circumstances. Call-backs and letterhead are typically used today for verification, and are acceptable under this rule if reasonable under the circumstances. For communications with health plan members, the covered entity will already have information about each individual, collected during enrollment, that can be used to establish identity, especially for verbal or electronic inquiries. For example, today many banks use the social security or policy number of individuals seeking information or assistance by telephone. How this verification is done is left up to the covered entity.

Comment: One commenter expressed the need for consistency on verification requirements between this rule and the Security regulation.

Response: We will make every effort to ensure consistency prior to publishing the final Security Rule.

Comment: A few commenters stated that the verification language in proposed §164.518(c)(2)(ii)(B)(1) would have created a presumption that “a request for disclosure made by official legal process issued by a[n] administrative body” is reasonable legal authority to disclose the protected health information. The commenter was concerned that this provision could be interpreted to permit a state agency to demand the disclosure of protected health information merely on the basis of a letter signed by an agency representative. The commenter believed that the rule specifically should defer to state or federal law on the disclosure of protected health information pursuant to legal process.

Response: The verification provisions in this rule are minimum requirements that covered entities must meet before disclosing protected health information under this regulation. They do not mandate disclosure, nor do they preempt state laws which impose additional restrictions on disclosure. Where state law regarding disclosures is more stringent, the covered entity must adhere to state law.

Comment: A few commenters wanted the verification requirements to apply to disclosures of protected health information for treatment, payment and operations purposes.

Response: We agree. This verification requirement applies to all disclosures of protected health information permitted by this rule, including for treatment, payment and operations, where the identity of the recipient is not known to the covered entity. Routine communications between providers, where existing relationships have been established, do not require special verification procedures.

Comment: A few commenters were concerned that a verbal inquiry for next of kin verification is not consistent with the verification guidelines of this verification subsection and that verbal inquiry would create problems because anyone who purports to be a next of kin could easily obtain information under false pretenses.

Response: In the final rule in §164.514, we require the covered entity to verify the identity and authority of persons requesting protected health information, where the identity and authority of such person is not known to the covered entity. This applies to next of kin situations. Procedures for disclosures to next of kin, other family members and persons assisting in an individual’s care are also discussed in §164.510(b), which allows the covered entity to exercise professional judgment as to whether the disclosure is in the individual’s best interest when the individual is not available to agree to the disclosure or is incapacitated.

Requiring written proof of identity in many of these situations, such as when a family member is seeking to locate a relative in an emergency or disaster situation, would create enormous burden without a corresponding enhancement of privacy, and could cause unnecessary delays in these situations. We therefore believe that reliance on professional judgment provides a better framework for balancing the need for privacy with the need to locate and identify individuals.

Comment: A few commenters stated that the verification requirements will provide great uncertainty to providers who receive authorizations from life, disability income and long-term care insurers in the course of underwriting and claims investigation. They are unaware of any breaches of confidentiality associated with these circumstances and believe the rule creates a solution to a non-existent problem. Another commenter stated that it is too burdensome for health care providers to verify requests that are normally received verbally or via fax.

Response: This rule requires covered health care providers to adhere to current best practices for verification. That is, when the requester is not known to the covered provider, the provider makes a reasonable effort to determine that the protected health information is being sent to the entity authorized to receive it. Our fact finding reveals that this is often done by sending the information to a recognizable organizational address or if being transmitted by fax or phone by calling the requester back through the main organization switchboard rather than through a direct phone number. We agree that these procedures seem to work reasonably well in current practice and are sufficient to meet the relevant requirements in the final rule.

Comments: One comment suggested requiring a form of photo identification such as a driver’s license or certain personal information such as date of birth to verify the identity of the individual.

Response: These are exactly the types of standard procedures for verifying the identity of individuals that are envisioned by the final rule. Most health care entities already conduct such procedures successfully. However, it is unwise to prescribe specific means of verification for all situations. Instead, we require policies and procedures reasonably designed for purposes of verification.

Comment: One professional association said that the example procedure described in the NPRM for asking questions to verify that an adult
acting for a young child had the requisite relationship to the child would be quite complex and difficult in practice. The comment asked for specific guidance as to what questions would constitute an adequate attempt to verify such a relationship.

Response: The final rule requires the covered entity to implement policies and procedures that are reasonably designed to comply with the verification requirement in §164.514. It would not be possible to create the requested specific guidance which could deal with the infinite variety of situations that providers must face, especially the complex ones such as that described by the commenter. As with many of the requirements of this final rule, health care providers are given latitude and expected to make decisions regarding disclosures, based on their professional judgment and experience with common practice, in the best interest of the individual.

Comment: One commenter asserted that ascertaining whether a requestor has the appropriate legal authority is beyond the scope of the training or expertise of most employees in a physician’s office. They believe that health care providers must be able to reasonably rely on the authority of the requestor.

Response: In the final regulation we require covered entities to have policies and procedures reasonably designed to verify the identity and authority of persons requesting health information. The requestor is a public official and legal authority is at issue, we provide detailed descriptions of the acceptable methods for such verification in the final rule. For others, the covered entity must implement policies and procedures that are reasonably designed to comply with the requirement to verify the identity and authority of a requestor, but only if the requestor is unknown to the covered entity. As described above, we expect these policies and procedures to document currently used best practices and reliance on professional judgment in the best interest of the individual.

Comment: One commenter expressed concern that the verification/identification procedures may eliminate or significantly reduce their ability to utilize medical records copy services. As written, they believe the NPRM provides the latitude to set up copy service arrangements, but any change that would add restrictions would adversely affect their ability to process an individual’s disability claim.

Response: The covered entity can establish reasonable policies and procedures to address verification in routine disclosures under business associate agreements, with, for example, medical records copy services. Nothing in the verification provisions would preclude those activities, nor have we significantly modified the NPRM provision on this issue.

Section 164.520—Notice of Privacy Practices for Protected Health Information

Comment: Many commenters supported the proposal to require covered entities to produce a notice of information practices. They stated that such notice would improve individuals’ understanding of how their information may be used and disclosed and would help to build trust between individuals and covered entities. A few comments, however, argued that the notice requirement would be administratively burdensome and expensive without providing significant benefit to individuals.

Response: We retain the requirement for covered health care providers and health plans to produce a notice of information practices. We additionally require health care clearinghouses that create or receive protected health information other than as a business associate of another covered entity to produce a notice. We believe the notice will provide individuals with a clearer understanding of how their information may be used and disclosed and is essential to inform individuals of their privacy rights. The notice will focus individuals on privacy issues, and prompt individuals to have discussions about privacy issues with their health plans, health care providers, and other persons.

The importance of providing individuals with notice of the uses and disclosures of their information and of their rights with respect to that information is well supported by current state and federal law. The July 1977 Report of the Privacy Protection Study Commission recommended that “each medical-care provider be required to notify an individual on whom it maintains a medical record of the disclosures that may be made of information in the record without the individual’s express authorization.”

The Commission also recommended that “an insurance institution notify (an applicant or principal insured) as to: * * * the types of parties to whom and circumstances under which information about the individual may be disclosed without his authorization, and the types of information that may be disclosed; [and] * * * the procedures whereby the individual may correct, amend, delete, or dispute any resulting record about himself.” The Privacy Act (5 U.S.C. 552a) requires government agencies to provide notice of the routine uses of information the agency collects and the rights individuals have with respect to that information. In its report “Best Principles for Health Privacy,” the Health Privacy Working Group stated, "Individuals should be given notice about the use and disclosure of their health information and their rights with regard to that information.”

The National Association of Insurance Commissioners’ Health Information Privacy Model Act requires carriers to provide a written notice of health information policies, standards, and procedures, including a description of the uses and disclosures prohibited and permitted by the Act, the procedures for authorizing and limiting disclosures and for revoking authorizations, and the procedures for accessing and amending protected health information.

Some states require additional notice. For example, Hawaii requires health care providers and health plans, among others, to produce a notice of confidentiality practices, including a description of the individual’s privacy rights and a description of the uses and disclosures of protected health information permitted under state law without the individual’s authorization. (HRS section 323C–13)

Today, health plan handbooks and evidences of coverage include some of what is required to be in the notice. Industry and standard-setting organizations have also developed notice requirements. The National Committee for Quality Assurance accreditation guidelines state that an accredited managed care organization “communicates to prospective members its policies and practices regarding the collection, use, and disclosure of medical information [and] * * * informs members * * * of its policies and procedures on * * * allowing members access to their medical records.”


“Organizations and individuals who collect, process, handle, or maintain health information should provide individuals and the public with a notice of information practices.” They recommend that the notice include, among other elements, “a description of the rights of individuals, including the right to inspect and copy information and the right to seek amendments [and] a description of the types of uses and disclosures that are permitted or required by law without the individual’s authorization.”27 We build on this well-established principle in this final rule. 

Comment: We received many comments on the model notice provided in the proposed rule. Some commenters argued that patients seeing similar documents would be less likely to become disoriented when examining a new notice. Other commenters, however, opposed the inclusion of a model notice or expressed concern about particular language included in the model. They maintained that a uniform model notice would never capture the varying practices of covered entities. Many commenters opposed requirements for a particular format or specific language in the notice. They stated that covered entities should be afforded maximum flexibility in fashioning their notices. Other commenters requested inclusion of specific language as a header to indicate the importance of the notice. A few commenters recommended specific formatting requirements, such as font size or type.

Response: On the whole, we found commenters’ arguments for flexibility in the regulation more persuasive than those arguing for more standardization. We agree that a uniform notice would not capture the wide variation in information practices across covered entities. We therefore do not include a model notice in the final rule, and do not require inclusion of specific language in the notice (except for a standard header). We also do not require particular formatting. We do, however, require the notice to be written in plain language. (See above for guidance on writing documents in plain language.) We also agree with commenters that the notice should contain a standard header to draw the individual’s attention to the notice and facilitate the individual’s ability to recognize the notice across covered entities.

We believe that post-publication guidance will be a more effective mechanism for helping covered entities design their notices than the regulation itself. After the rule is published, we can provide guidance on notice content and format tailored to different types of health plans and providers. We believe such specially designed guidance will be more useful than a one-size-fits-all model notice we might publish with this regulation.

Comment: Commenters suggested that the rule should require that the notice regarding privacy practices include specific provisions related to health information of unemancipated minors.

Response: Although we agree that minors and their parents should be made aware of practices related to confidentiality of protected health information of unemancipated minors, we do not require covered entities that treat minors or use their protected health information to include provisions in their notice that are not required of other covered entities. In general, the content of notice requirements in §164.520(b) do not depend on the status of the individual being served. We have decided to maintain consistency by declining to prescribe specific notice requirements for minors. The rule does permit a covered entity to provide individuals with notice of its policies and procedures with respect to anticipated uses and disclosures of protected health information (§164.520(b)(2)), and providers are encouraged to do so.

Comment: Some commenters argued that covered entities should not be required to distinguish between those uses and disclosures that are required by law and those that are permitted by law without authorization, because these distinctions may not always be clear and will vary across jurisdictions. Some commenters maintained that simply stating that the covered entity would make all disclosures required by law would be sufficient. Other comments suggested that covered entities should be able to produce very broadly stated notices so that repeated revisions and mailings of those revisions would not be necessary.

Response: While we believe that covered entities have an independent duty to understand the laws to which they are subject, we also recognize that it could be difficult to convey such legal distinctions clearly and concisely in a notice. We therefore eliminate the proposed requirement for covered entities to distinguish between those uses and disclosures that are required by and those that are permitted by law. We instead require that covered entities describe each purpose for which they are permitted or required to use or disclose protected health information under this rule and other applicable law without individual consent or authorization. Specifically, covered entities must describe the types of uses and disclosures they are permitted to make for treatment, payment, and health care operations. They must also describe each of the purposes for which the covered entity is permitted or required by this subpart to use or disclose protected health information without the individual’s written consent or authorization (even if they do not plan to make a permissive use or disclosure). We believe this requirement provides individuals with sufficient information to understand how information about them can be used and disclosed and to prompt them to ask for additional information to obtain a clearer understanding, while minimizing covered entities’ burden.

A notice that stated only that the covered entity would make all disclosures required by law, as suggested by some of these commenters, would fail to inform individuals of the uses and disclosures of information about them that are permitted, but not required, by law. We clarify that each and every disclosure required by law need not be listed on the notice. Rather, the covered entity can include a general statement that disclosures required by law will be made.

Comment: Some comments argued that the covered entity should not have to provide notice about uses and disclosures that are permitted under the rule without authorization. Other comments suggested that the notice should inform individuals about all of the uses and disclosures that may be made, with or without the individual’s authorization.

Response: When the individual’s permission is not required for uses and disclosures of information, we believe providing the required notice is the most effective means of ensuring that individuals are aware of how information about them may be shared. The notice need not describe uses and disclosures for which the individual’s permission is required, because the individual will be informed of these at the time permission to use or disclose the information is requested.

We additionally require covered entities, even those required to obtain the individual’s consent for use and disclosure of protected health information for treatment, payment, and health care operations, to describe those uses and disclosures in their notice. (§164.506 and the corresponding preamble discussion regarding consent requirements.) We require these uses.
and disclosures to be described in the notice in part in order to reduce the administrative burden on covered providers that are required to obtain consent. Rather than obtaining a new consent each time the covered provider’s information policies and procedures are materially revised, covered providers may revise and redistribute their notice. We also expect that the description of how information may be used to carry out treatment, payment, and health care operations in the notice will be more detailed than in the more general consent document.

Comment: Some commenters argued that covered entities should not be required to provide notice of the right to request restrictions, because doing so would be burdensome to the covered entity and distracting to the individual; because individuals have the right whether they are informed of such right or not; and because the requirement would be unlikely to improve patient care.

Response: We disagree. We believe that the ability of an individual to request restrictions is an important privacy right and that informing people of their rights improves their ability to exercise those rights. We do not believe that adding a sentence to the notice is burdensome to covered entities.

Comment: We received comments supporting inclusion of a contact point in the notice, so that individuals will be able to function at the reading level otherwise providing the notice in writing may not achieve the goal of informing individuals of how their information will be handled, because some individuals may not be literate or able to function at the reading level used in the notice. Others argued that entities should have the flexibility to choose alternative modes of communicating the information in the notice, including voice disclosure. In contrast, some commenters were concerned that requirements to provide the notice in plain language or in languages other than English would be overly burdensome.

Response: We do not agree that adding such a requirement would strengthen the notice. The purpose of the notice is to inform individuals of their privacy rights, and of the purposes for which protected health information about them may be used or disclosed. Informing individuals that covered entities may use and disclose only the minimum necessary protected health information for a purpose would not increase individuals’ understanding of their rights or the purposes for which information may be used or disclosed.

Comment: A few commenters supported allowing covered entities to apply changes in their information practices to protected health information obtained prior to the change. They argued that requiring different protections for information obtained at different times would be inefficient and extremely difficult to administer. Some commenters supported requiring covered entities to state in the notice that the information policies and procedures are subject to change.

Response: We agree. In the final rule, we provide a mechanism by which covered entities may revise their privacy practices and apply those revisions to protected health information they already maintain. We permit, but do not require, covered entities to reserve the right to change their practices and apply the revised practices to information previously created or obtained. If a covered entity wishes to reserve this right, it must make a statement to that effect in its notice. If it does not make such a statement, the covered entity may still revise its privacy practices, but it may apply the revised practices only to protected health information created or obtained after the effective date of the notice in which the revised practices are reflected. See § 164.530(i) and the corresponding preamble discussion of requirements regarding changes to information policies and procedures.

Comment: Some commenters requested clarification of the term “material change” so that entities will be comfortable that they act properly after making changes to their information practices. Some comments stated that entities should notify individuals whenever a new category of disclosures to be made without authorization is created.

Response: The concept of “material change” appears in other notice laws, such as the ERISA requirements for summary plan descriptions. We therefore retain the “materiality” condition for revision of notices, and encourage covered entities to draw on the concept as it has developed through those other laws. We agree that the addition of a new category of use or disclosure of health information that may be made without authorization would likely qualify as a material change.

Comment: We proposed to permit covered entities to implement revised policies and procedures without first revising the notice if a compelling reason existed to do so. Some commenters objected to this proposal because they were concerned that the “compelling reason” exception would give covered entities broad discretion to engage in post hoc violations of its own information practices.

Response: We agree and eliminate this provision. Covered entities may not implement revised information policies and procedures before properly documenting the revisions and updating their notice. See § 164.530(i). Because in the final rule we require the notice to include all disclosures that may be made, not only those the covered entity intends to make, we no longer need this provision to accommodate emergencies.

Comment: Some comments suggested that we require covered entities to maintain a log of all past notices, with changes from the previous notice highlighted. They further suggested we require covered entities to post this log on their web sites.

Response: In accordance with § 164.530(j)(2), a covered entity must retain for six years a copy of each notice it issues. We do not require highlighting of changes to the notice or posting of prior notices, due to the associated administrative burdens and the complexity such a requirement would build into the notice over time. We encourage covered entities, however, to make such materials available upon request.

Comment: Several commenters requested clarification about when, relative to the compliance date, covered entities are required to produce their notice. One commenter suggested that covered entities be allowed a period not less than 180 days after adoption of the final rule to develop and distribute the notice. Other comments requested that the notice compliance date be consistent with other HIPAA regulations.

Response: We require covered entities to have a notice available upon request as of the compliance date of this rule (or the compliance date of the covered entity if such date is later). See § 164.534 and the corresponding preamble discussion of the compliance date.

Comment: Some commenters suggested that covered entities, particularly covered health care providers, should be required to discuss the notice with individuals. They argued that posting a notice or otherwise providing the notice in writing may not achieve the goal of informing individuals of how their information will be handled, because some individuals may not be literate or able to function at the reading level used in the notice. Others argued that entities should have the flexibility to choose alternative modes of communicating the information in the notice, including voice disclosure. In contrast, some commenters were concerned that requirements to provide the notice in plain language or in languages other than English would be overly burdensome.
Response: We require covered entities to write the notice in plain language so that the average reader will be able to understand the notice. We encourage, but do not require, covered entities to consider alternative means of communicating with certain populations. We note that any covered entity that is a recipient of federal financial assistance is generally obligated under Title VI of the Civil Rights Act of 1964 to provide material ordinarily distributed to the public in the primary languages of persons with limited English proficiency in the recipients’ service areas. While we believe the notice will prompt individuals to initiate discussions with their health plans and health care providers about the use and disclosure of health information, we believe this should be a matter left to each individual and that requiring covered entities to initiate discussions with each individual would be overly burdensome.

Comment: Some commenters suggested that covered entities, particularly health plans, should be permitted to distribute their notice in a newsletter or other communication with individuals.

Response: We agree, so long as the notice is sufficiently separate from other important documents. We therefore prohibit covered entities from combining the notice in a single document with either a consent (§ 164.506) or an authorization (§ 164.508), but do not otherwise prohibit covered entities from including the notice in or with other documents the covered entity shares with individuals.

Comment: Some comments suggested that covered entities should not be required to respond to requests for the notice from the general public. These comments indicated that the requirement would place an undue burden on covered entities without benefitting individuals.

Response: We proposed that the notice be publicly available so that individuals may use the notice to compare covered entities’ privacy practices and to select a health plan or health care provider accordingly. We therefore retain the proposed requirement for covered entities to provide the notice to any person who requests a copy, including members of the general public.

Comment: Many commenters argued that the distribution requirements for health plans should be less burdensome. Some suggested distributing upon material revision, but not every three years. Some suggested that health plans should only be required to distribute their notice annually or upon re-enrollment. Some suggested that health plans should only have to distribute their notice upon initial enrollment, not re-enrollment. Other commenters supported the proposed approach.

Response: We agree that the notice distribution requirements for health plans can be less burdensome than in the NPRM while still being effective. In the final rule, we reduce health plans’ distribution burden in several ways. First, we require health plans to remind individuals every three years of the availability of the notice and of how to obtain a copy of the notice, rather than requiring the notice to be distributed every three years as proposed. Second, we clarify that health plans only have to distribute the notice to new enrollees on enrollment, not to current members of the health plan upon re-enrollment. Third, we specifically allow all covered entities to distribute the notice electronically in accordance with § 164.520(c)(3).

We retain the requirement for health plans to distribute the notice within 60 days of a material revision. We believe the revised distribution requirements will ensure that individuals are adequately informed of health plans’ information practices and any changes to those procedures, without unduly burdening health plans.

Comment: Many commenters argued that health plans should not be required to distribute their notice to every person covered by the plan. They argued that distributing the notice to every family member would be unnecessarily duplicative, costly, and difficult to administer. They suggested that health plans only be required to distribute the notice to the primary participant or to each household with one or more insured individuals.

Response: We agree, and clarify in the final rule that a health plan may satisfy the distribution requirement by providing the notice to the named insured on behalf of the dependents of that named insured. For example, a group health plan may satisfy its notice requirement by providing a single notice to each covered employee of the plan sponsor. We do not require the group health plan to distribute the notice to each covered employee and to each covered dependent of those employees.

Response: We require health plans to distribute their notice to individuals covered by the health plan. Health plans may elect to hire or otherwise arrange for others, including group health plan sponsors and health care providers affiliated with the health plan, to carry out this distribution. We require covered providers to distribute only their own notices, and neither require nor prohibit health plans and health care providers from devising whatever arrangements they find suitable to meet the requirements of this rule. However, if a covered entity arranges for another person or entity to distribute the covered entity’s notice on its behalf and individuals do not receive such notice, the covered entity would be in violation of the rule.

Comment: Some comments stated that covered providers without direct patient contact, such as clinical laboratories, might not have sufficient patient contact information to be able to mail the notice. They suggested we require or allow such providers to form agreements with referring providers or other entities to distribute notices on their behalf or to include their practices in the referring entity’s own notice.

Response: We agree with commenters’ concerns about the potential administrative and financial burdens of requiring covered providers that have indirect treatment relationships with individuals, such as clinical laboratories, to distribute the notice. Therefore, we require these covered providers to provide the notice only upon request. In addition, these covered providers may elect to reach agreements with other entities distribute their notice on their behalf, or to participate in an organized health care arrangement that produces a joint notice. See § 164.520(d) and the corresponding preamble discussion of joint notice requirements.

Comment: Some commenters requested that covered health care providers be permitted to distribute their notice prior to an individual’s initial visit so that patients could review the information in advance of the visit. They suggested that distribution in advance would reduce the amount of time covered health care providers’ staff would have to spend explaining the notice to patients in the office. Other comments argued that providers should...
distribute their notice to patients at the time the individual visits the provider, because providers lack the administrative infrastructure necessary to develop and distribute mass communications and generally have difficulty identifying active patients.

Response: In the final rule, we clarify that covered providers with direct treatment relationships must provide the notice to patients no later than the first service delivery to the patient after the compliance date. For the reasons identified by these commenters, we do not require covered providers to send their notice to the patient in advance of the patient’s visit. We do not prohibit distribution in advance, but only require distribution to the patient as of the time of the visit. We believe this flexibility will allow each covered provider to develop procedures that best meet its and its patients’ needs.

Comment: Some comments suggested that covered providers should be required to distribute the notice as of the compliance date. They noted that if the covered provider waited to distribute the notice until first service delivery, it would be possible (pursuant to the rule) for a use or disclosure to be made without the individual’s authorization, but before the individual receives the notice.

Response: Because health care providers generally lack the administrative infrastructure necessary to develop and distribute mass communications and generally have difficulty identifying active patients, we do not require covered providers to distribute the notice until the first service delivery after the compliance date. We acknowledge that this policy allows use and disclosure of health information without individuals’ consent or authorization before the individual receives the notice. We require covered entities, including covered providers, to have the notice available upon request as of the compliance date of the rule. Individuals may request a copy of the notice from their provider at any time.

Comment: Many commenters were concerned with the requirement that covered providers post their notice. Some commenters suggested that covered hospital-based providers should be able to satisfy the distribution requirements by posting their notice in multiple locations at the hospital, rather than handing the notice to patients—particularly with respect to distribution after material revisions have been made. Some additionally suggested that these covered providers should have copies of the notice available on-site. Some commenters emphasized that the notice must be clear and conspicuous to give individuals meaningful and effective notice of their rights. Other commenters noted that posting the notice will not inform former patients who no longer see the provider.

Response: We clarify in the final rule that the requirement to post a notice does not substitute for the requirement to give individuals a notice or make notices available upon request. Covered providers with direct treatment relationships, including covered hospitals, must give a copy of the notice to the individual as of first service delivery after the compliance date. After giving the individual a copy of the notice as of that first visit, the covered provider has no other obligation to actively distribute the notice. We believe it is unnecessarily burdensome to require covered providers to mail the notice to all current and former patients each time the notice is revised, because unlike health plans, providers may have a difficult time identifying active patients. All individuals, including those who no longer see a covered provider, have the right to receive a copy of the notice on request.

If the covered provider maintains a physical delivery site, it must also post the notice (including revisions to the notice) in a clear and prominent location where it is reasonable to expect individuals seeking service from the covered provider to be able to read the notice. The covered provider must also have the notice available on site for individuals to be able to request and take with them. Some commenters requested clarification about the distribution requirements for a covered entity that is a health plan and a covered health care provider.

Response: Under § 164.504(g), discussed above, covered entities that conduct multiple types of covered functions, such as the kind of entities described in the above comments, are required to comply with the provisions applicable to a particular type of health care function when acting in that capacity. Thus, in the example described above, the covered entity is required by § 164.504(g) to follow the requirements for health plans with respect to its actions as a health plan and to follow the requirements for health care providers with respect to its actions as a health care provider.

Response: We received many comments about the ability of covered entities to distribute their notices electronically. Many commenters suggested that we permit covered entities to distribute the notice electronically, either via a web site or e-mail. They argued that covered entities are increasingly using electronic technology to communicate with patients and otherwise administer benefits. They also noted that other regulations permit similar documents, such as ERISA-required summary plan descriptions, to be delivered electronically. Some commenters suggested that electronic distribution should be permitted unless the individual specifically requests a hard copy or lacks electronic access. Some argued that entities should be able to choose a least-cost alternative that allows for periodic changes without excessive mailing costs. A few commenters suggested requiring covered entities to distribute notices electronically.

Response: We clarify in the final rule that covered entities may elect to distribute their notice electronically, provided the individual agrees to receiving the notice electronically and has not withdrawn such agreement. We do not require any particular form of agreement. For example, a covered provider could ask an individual at the time the individual requests a copy of the notice whether she prefers to receive it in hard copy or electronic form. A health plan could ask an individual applying for coverage to provide an e-mail address where the health plan can send the individual information. If the individual provides an e-mail address, the health plan can infer agreement to obtain information electronically.

An individual who has agreed to receive the notice electronically, however, retains the right to request a hard copy of the notice. This right must be described in the notice. In addition, if the covered entity knows that electronic transmission of the notice has failed, the covered entity must produce a hard copy of the notice. We believe this provision allows covered entities flexibility to provide the notice in the form that best meets their needs without compromising individuals’ right to adequate notice of covered entities’ information practices.

We note that covered entities may also be subject to the Electronic Signatures in Global and National Commerce Act. This rule is not intended to alter covered entities’ requirements under that Act.

Response: Some commenters were concerned that covered providers with “face-to-face” patient contact would have a competitive disadvantage against covered internet-based providers, because the face-to-face providers would be required to distribute the notice in hard copy while internet-based providers could satisfy the requirement...
by requiring review of the notice on the web site before processing an order. They suggested allowing face-to-face covered providers to satisfy the distribution requirement by asking patients to review the notice posted on site.

Response: We clarify in the final rule that covered health care providers that provide services to individuals over the internet have direct treatment relationships with those individuals. Covered internet-based providers, therefore, must distribute the notice at the first service delivery after the compliance date by automatically and contemporaneously providing the notice electronically in response to the individual’s first request for service, provided the individual agrees to receiving the notice electronically.

Even though we require all covered entity web sites to post the entity’s notice prominently, we note that such posting is not sufficient to meet the distribution requirements. A covered internet-based provider must send the notice electronically at the individual’s first request for service, just as other covered providers with direct treatment relationships must give individuals a copy of the notice as of the first service delivery after the compliance date.

We do not intend to create competitive advantages among covered providers. A web-based and a non-web-based covered provider each have the same alternatives available for distribution of the notice. Both types of covered providers may provide either a paper copy or an electronic copy of the notice.

Comment: We received several comments suggesting that some covered entities should be exempted from the notice requirement or permitted to combine notices with other covered entities. Many comments argued that the notice requirement would be burdensome for hospital-based physicians and result in numerous, duplicative notices that would be meaningless or confusing to patients. Other comments suggested that multiple health plans offered through the same employer should be permitted to produce a single notice.

Response: We retain the requirement for all covered health care providers and health plans to produce a notice of information practices. Health care clearinghouses are required to produce a notice of information practices only to the extent the clearinghouse creates or receives protected health information other than as a business associate of a covered entity under § 164.500(b)(2). Two other types of covered entities are not required to produce a notice: a correctional institution that is a covered entity and a group health plan that provides benefits only through one or more contracts of insurance with health insurance issuers or HMOs.

We clarify in § 164.504(d), however, that affiliated covered entities under common ownership or control may designate themselves as a single covered entity for purposes of this rule. An affiliated covered entity is only required to produce a single notice.

In addition, covered entities that participate in an organized health care arrangement—which could include hospitals and their associated physicians—may choose to produce a single, joint notice, if certain requirements are met. See § 164.501 and the corresponding preamble discussion of organized health care arrangements.

We clarify that each covered entity included in a joint notice must meet the applicable distribution requirements. If any one of the covered entities, however, provides the notice to a given individual, the distribution requirement with respect to that individual is met for all of the covered entities included in the joint notice. For example, a covered hospital and its attending physicians may elect to produce a joint notice. When an individual is first seen at the hospital, the hospital must provide the individual with a copy of the joint notice. Once the hospital has done so, the notice distribution requirement for all of the attending physicians that provide treatment to the individual at the hospital and that are included in the joint notice is satisfied.

Comment: We solicited and received comments on whether to require covered entities to obtain the individual’s signature on the notice. Some commenters suggested that requiring a signature would convey the importance of the notice, would make it more likely that individuals read the notice, and could have some of the same benefits of a consent. They noted that at least one state already requires entities to obtain a signed notice. Other comments noted that the signature would be useful for compliance and risk management purposes because it would document that the individual had received the notice.

The majority of commenters on this topic, however, argued that a signed acknowledgment would be administratively burdensome, inconsistent with the intent of the Administrative Simplification requirements of HIPAA, impossible to receive in advance of individuals, difficult to achieve for covered entities that do not have direct contact with patients, inconsistent with other notice requirements under other laws, misleading to individuals who might interpret their signature as an agreement, inimical to the concept of permitting uses and disclosures without authorization, and an insufficient substitute for authorization.

Response: We agree with the majority of commenters and do not require covered entities to obtain the individual’s signed acknowledgment of receipt of the notice. We believe that we satisfied most of the arguments in support of requiring a signature with the new policy requiring covered health care providers with direct treatment relationships to obtain a consent for uses and disclosures of protected health information to carry out treatment, payment, and health care operations. See § 164.506 and the corresponding preamble discussion of consent requirements. We note that this rule does not preempt other applicable laws that require a signed notice and does not prohibit a covered entity from requesting an individual to sign the notice.

Comment: Some commenters supported requiring covered entities to adhere to their privacy practices, as described in their notice. They argued that the notice is meaningless if a covered entity does not actually have to follow the practices contained in its notice. Other commenters were concerned that the rule would prevent a covered entity from using or disclosing protected health information in otherwise lawful and legitimate ways because of an intentional or inadvertent omission from its published notice. Some of these commenters suggested requiring the notice to include a description of some or all disclosures that are required or permitted by law. Some commenters stated that the adherence requirement should be eliminated because it would generally inhibit covered entities’ ability to innovate and would be burdensome.

Response: We agree that the value of the notice would be significantly diminished absent a requirement that covered entities adhere to the statements they make in their notices. We therefore retain the requirement for covered entities to adhere to the terms of the notice. See § 164.502(i).

Many of these commenters’ concerns regarding a covered entity’s inability to use or disclose protected health information due to an intentional or inadvertent omission from the notice are addressed in our revisions to the proposed content requirements for the notice. Rather than require covered entities to describe only those uses and...
disclosures they anticipate making, as proposed, we require covered entities to describe all uses and disclosures they are required or permitted to make under the rule without the individual’s consent or authorization. We permit a covered entity to provide a statement that it will disclose protected health information that is otherwise required by law, as permitted in §164.512(a), without requiring them to list all state laws that may require disclosure. Because the notice must describe all legally permissible uses and disclosures, the notice will not generally preclude covered entities from making any uses or disclosures they could otherwise make without individual consent or authorization. This change will also ensure that individuals are aware of all possible uses and disclosures that may occur without their consent or authorization, regardless of the covered entity’s current practices.

We encourage covered entities, however, to additionally describe the more limited uses and disclosures they actually anticipate making in order to give individuals a more accurate understanding of how information about them will be shared. We expect that certain covered entities will want to distinguish themselves on the basis of their privacy protections. We note that a covered entity that chooses to exercise this option must clearly state that, at a minimum, the covered entity may make disclosures that are required by law and that are necessary to avert a serious and imminent threat to health or safety.

Section 164.522—Rights To Request Privacy Protection for Protected Health Information

Section 164.522(a)—Right of an Individual To Request Restriction of Uses and Disclosures

Comment: Several commenters supported the language in the NPRM regarding the right to request restrictions. One commenter specifically stated that this is a balanced approach that addresses the needs of the few who would have reason to restrict disclosures without negatively affecting the majority of individuals. At least one commenter explained that if we required consent or authorization for use and disclosure of protected health information for treatment, payment, and health care operations then we must also have a right to request restrictions of such disclosure in order to make the consent meaningful. Many commenters requested that we delete this option, claiming it would interfere with patient care, payment, and data integrity. Most of the commenters that presented this position asserted that the framework of giving patients control over the use or disclosure of their information is contrary to good patient care because incomplete medical records may lead to medical errors, misdiagnoses, or inappropriate treatment decisions. Other commenters asserted that covered entities need complete data sets on the populations they serve to effectively conduct research and quality improvement projects and that restrictions would hinder research, skew findings, impede quality improvement, and compromise accreditation and performance measurement.

Response: We acknowledge that widespread restrictions on the use and disclosure of protected health information could result in some difficulties related to payment, research, quality assurance, etc. However, in our efforts to protect the privacy of health information about individuals, we have sought a balance in determining the appropriate level of individual control and the smooth operation of the health care system. In the final rule, we require certain covered providers and permit all covered entities to obtain consent from individuals for use and disclosure of protected health information for treatment, payment, and health care operations (see §164.506). In order to give individuals some control over their health information for uses and disclosures of protected health information for treatment, payment, and health care operations, we provide individuals with the opportunity to request restrictions of such uses and disclosures.

Because the right to request restrictions encourages discussions about how protected health information may be used and disclosed and about an individual’s concerns about such uses and disclosures, it may improve communications between a provider and patient and thereby improve care. According to a 1999 survey on the Confidentiality of Medical Records by the California HealthCare Foundation, one out of every six people engage in behavior to protect themselves from unwanted disclosures of health information, such as lying to providers or avoiding seeking care. This indicates that, without the ability to request restrictions, individuals would have incentives to remain silent about important health information that could have an effect on their health and health care, rather than consulting a health care provider. Further, this policy is not a dramatic change from the status quo. Today, many state laws restrict disclosures for certain types of health information without patient’s authorization. Even if there is no mandated requirement to restrict disclosures of health information, providers may agree to requests for restrictions of disclosures when a patient expresses particular sensitivity and concern for the disclosure of health information.

We agree that there may be instances in which a restriction could negatively affect patient care. Therefore, we include protections against this occurrence. First, the right to request restrictions is a right of individuals to make the request. A covered entity may refuse to restrict uses and disclosures or may agree only to certain aspects of the individual’s request if there is concern for the quality of patient care in the future. For example, if a covered provider believes that it is not in the patient’s best medical interest to have such a restriction, the provider may discuss the request for restriction with the patient and give the patient the opportunity to explain the concern for disclosure. Also, a covered provider who is concerned about the implications on future treatment can agree to use and disclose sensitive protected health information for treatment purposes only and agree not to disclose information for payment and operation purposes. Second, a covered provider need not comply with a restriction that has been agreed to if the individual who requested the restriction is in need of emergency treatment and the restricted protected health information is needed to provide the emergency treatment. This exception should limit the harm to health that may otherwise result from restricting the use or disclosure of protected health information. We encourage covered providers to discuss with individuals that the information may be used or disclosed in emergencies. We require that the covered entity that discloses restricted protected health information in an emergency request that the health care provider that receives such information not further use or re-disclose the information.

Comment: Some health plans stated that an institutionalized right to restrict can interfere with payment and thus make it easier for unscrupulous providers or patients to commit fraud on insurance plans. They were concerned that individuals could enter into restrictions with providers to withhold information to insurance companies so that the insurance company would not know about certain conditions when underwriting a policy.
Response: This rule does not enhance the ability of unscrupulous patients or health care providers to engage in deceptive or fraudulent withholding of information. This rule grants a right to request a restriction, not an absolute right to restrict. Individuals can make such requests today. Other laws criminalize insurance fraud; this regulation does not change those laws.

Comment: One commenter asserted that patients cannot anticipate the significance that one aspect of their medical information will have on treatment of other medical conditions, and therefore, allowing them to restrict use or disclosure of some information is contrary to the patient’s best interest.

Response: We agree that patients may find it difficult to make such a calculus, and that it is incumbent on health care providers to help them do so. Health care providers may deny requests for or limit the scope of the restriction requested if they believe the restriction is not in the patient’s best interest.

Comment: A commenter asked whether an individual’s restriction to disclosure of information will be a bar to liability for misdiagnosis or failure to diagnose by a covered entity who can trace its error back to the lack of information resulting from such restriction.

Response: Decisions regarding liability and professional standards are determined by state and other law. This rule does not establish or limit liability for covered entities under those laws. We expect that the individual’s request to restrict the disclosure of their protected health information would be considered in the decision of whether or not a covered entity is liable.

Comment: One commenter requested that we allow health plans to deny coverage or reimbursement when a covered health care provider’s agreement to restrict use or disclosure prevents the plan from getting the information that is necessary to determine eligibility or coverage.

Response: In this rule, we do not modify insurers’ rules regarding information necessary for payment. We recognize that restricting the disclosure of information may result in a denial of payment. We expect covered providers to explain this possibility to individuals when considering their requests for restrictions and to make alternative payment arrangements with individuals if necessary.

Comment: Some commenters discussed the administrative burden and cost of the requirement that individuals have the right to request restrictions and that trying to segregate certain portions of information for protection may be impossible. Others stated that the administrative burden would make providers unable to accommodate restrictions, and would therefore give patients false expectations that their right to request restrictions may be acted upon. One commenter expressed concern that large covered providers would have a particularly difficult time establishing a policy whereby the covered entity could agree to restrictions and would have an even more difficult time implementing the restrictions since records may be kept in multiple locations and accessed by multiple people within the organization. Still other commenters believed that the right to request restrictions would invite argument, delay, and litigation.

Response: We do not believe that this requirement is a significant change from current practice. Providers already respond to requests by patients regarding sensitive information, and are subject to state law requirements not to disclose certain types of information without authorization. This right to request is permissive so that covered entities can balance the needs of particular individuals with the entity’s ability to manage specific accommodations.

Comment: Some commenters were concerned that a covered entity would agree to a restriction and then realize later that the information must be disclosed to another caregiver for important medical care purposes.

Response: Some individuals seek treatment only on the condition that information about that treatment will not be shared with others. We believe it is necessary and appropriate, therefore, that when a covered provider agrees to such a restriction, the individual must be able to rely on that promise. We strongly encourage covered providers to consider future treatment implications of agreeing to a restriction. We encourage covered entities to inform others of the existence of a restriction when appropriate, provided that such notice does not amount to a de facto disclosure of the restricted information. If the covered provider subject to the restriction believes that disclosing the protected health information that was created or obtained subject to the restriction is necessary to avert harm (and it is not for emergency treatment), the provider must ask the individual for permission to terminate or modify the restriction. If the individual agrees to the termination of the restriction, the provider must document this termination by noting this agreement in the medical record or by obtaining a written agreement of termination from the individual and may use or disclose the information for treatment. If the individual does not agree to terminate or modify the restriction, however, the provider must continue to honor the restriction with respect to protected health information that was created or received subject to the restriction. We note that if the restricted protected health information is needed to provide emergency treatment to the individual who requested the restriction, the covered entity may use or disclose such information for such treatment.

Comment: Commenters asked that we require covered entities to keep an accounting of the requests for restrictions and to report this information to the Department in order for the Department to determine whether covered entities are showing “good faith” in dealing with these requests.

Response: We require that covered entities that agree to restrictions with individuals document such restrictions. A covered entity must retain such documentation for six years from the date of its creation or the date when it last was in effect, whichever is later. We do not require covered entities to keep a record of all requests made, including those not agreed to, nor that they report such requests to the Department. The decision to agree to restrictions is that of the covered entity. Because there is no requirement to agree to a restriction, there is no reason to impose the burden to document requests that are denied. Any reporting requirement could undermine the purpose of this provision by causing the sharing, or appearance of sharing, of information for which individuals are seeking extra protection.

Comment: One commenter asserted that providers that currently allow such restrictions will choose not to do so under the rule based on the guidance of legal counsel and loss prevention managers, and suggested that the Secretary promote competition among providers with respect to privacy by developing a third-party ranking mechanism.

Response: We believe that providers will do what is best for their patients, in accordance with their ethics codes, and will continue to find ways to accommodate requested restrictions when they believe that it is in the patients’ best interests. We anticipate that providers who find such action to be of commercial benefit will notify consumers of their willingness to be responsive to such requests. Involving third parties could undermine the purpose of this provision, by causing the sharing, or appearance of sharing, of information for which individuals are seeking extra protection.
Comment: One commenter said that any agreement regarding patient-requested restrictions should be in writing before a covered provider would be held to standards for compliance.

Response: We agree that agreed to restrictions must be documented in writing, and we require that covered entities that agree to restrictions document those restrictions in accordance with §164.530(j). The writing need not be formal; a notation in the medical record will suffice. We disagree with the request that an agreed to restriction be reduced to writing in order to be enforced. If we adopted the requested policy, a covered entity could agree to a restriction with an individual, but avoid being held to this agreed to restriction under the rule by failing to document the restriction. This would give a covered entity the opportunity to agree to a restriction and then, at its sole discretion, determine if it is enforceable by deciding whether or not to make a note of the restriction in the record about the individual. Because the covered entity has the ability to agree or fail to agree to a restriction, we believe that once the restriction is agreed to, the covered entity must honor the agreement. Any other result would be deceptive to the individual and could lead an individual to disclose health information under the assumption that the uses and disclosures will be restricted. Under §164.522, a covered entity could be found to be in violation of the rule if it fails to put an agreed-upon restriction in writing and also if it uses or discloses protected health information inconsistent with the restriction.

Comment: Some commenters said that the right to request restrictions should be extended to some of the uses and disclosures permitted without authorization in §164.510 of the NPRM, such as disclosures to next of kin, for judicial and administrative proceedings, for law enforcement, and for governmental health data systems. Other commenters said that these uses and disclosures should be preserved without an opportunity for individuals to opt out.

Response: We have not extended the right to request restrictions under this rule to disclosures permitted in §164.512 of the final rule. However, we do not preempt other law that would enforce such agreed-upon restrictions. As discussed in more detail, above, we have extended the right to request restrictions to disclosures to persons assisting in the individual’s care, such as next of kin, under §164.510(b). Any restriction that a covered entity agrees to with respect to persons assisting in the individual’s care in accordance with the rule will be enforceable under the rule.

Comment: A few commenters raised the question of the effect of a restriction agreed to by one covered entity that is part of a larger covered entity, particularly a hospital. Commenters were also concerned about who may speak on behalf of the covered entity.

Response: All covered entities are required to establish policies and procedures for providing individuals the right to request restrictions, including policies for who may agree to such restrictions on the covered entity’s behalf. Hospitals and other large entities that are concerned about employees agreeing to restrictions on behalf of the organization will have to make sure that their policies are communicated appropriately to those employees. The circumstances under which members of a covered entity’s workforce can bind the covered entity are a function of other law, not of this regulation.

Comment: Some commenters expressed confusion about the intended effect of any agreed-upon restrictions on downstream covered entities. They asserted that it would be extremely difficult for a requested restriction to be followed through the health care system and that it would be unfair to hold covered entities to a restriction when they did not agree to such restriction. Specifically, commenters asked whether a covered provider that receives protected health information in compliance with this rule from a physician or medical group that has agreed to limit certain uses of the information must comply with the original restriction. Other commenters expressed concern that not applying a restriction to downstream covered entities is a loophole and that all downstream covered providers and health plans should be bound by the restrictions.

Response: Under the final rule, a restriction that is agreed to between an individual and a covered entity is only binding on the covered entity that agreed to the restriction and not on downstream entities. It would also be binding on any business associate of the covered entity since a business associate can not use or disclose protected health information in any manner that a covered entity would not be permitted to use or disclose such information. We realize that this may limit the ability of an individual to successfully restrict a use or disclosure under all circumstances, but we take this approach for two reasons. First, we allow covered entities to process individuals’ requests for restrictions. Requiring downstream covered entities to abide by a restriction would be tantamount to forcing them to agree to a request to which they otherwise may not have agreed. Second, some covered entities have information systems which will allow them to accommodate such requests, while others do not. If the downstream provider is in the latter category, the administrative burden of such a requirement would be unmanageable.

We encourage covered entities to explain this limitation to individuals when they agree to restrictions, so individuals will understand that they need to ask all their health plans and providers for desired restrictions. We also require that a covered entity that discloses protected health information to a health care provider for emergency treatment, in accordance with §164.522(a)(iii), to request that the recipient not further use or disclose the information.

Comment: One commenter requested that agreed-to restrictions of a covered entity not be applied to business associates.

Response: As stated in §164.504(e)(2), business associates are acting on behalf of, or performing services for, the covered entity and may not, with two narrow exceptions, use or disclose protected health information in a manner that would violate this rule if done by the covered entity. Business associates are agents of the covered entity with respect to protected health information they obtain through the business relationship. If the covered entity agrees to a restriction and, therefore, is bound to such restriction, the business associate will also be required to comply with the restriction. If the covered entity has agreed to a restriction, the satisfactory assurances from the business associate, as required in §164.504(e), must include assurances that protected health information will not be used or disclosed in violation of an agreed to restriction.

Comment: One commenter requested clarification that the right to request restrictions cannot be used to restrict the creation of de-identified information.

Response: We found no reason to treat the use of protected health information to create de-identified information different from other uses of protected health information. The right to request restriction applies to any use or disclosure of protected health information to carry out treatment, payment, or health care operations. If the covered entity uses protected health information to create de-identified information, the covered entity need not agree to a restriction of this use.
Comment: Some commenters stated that individuals should be given a true right to restrict uses and disclosures of protected health information in certain defined circumstances (such as for sensitive information) rather than a right to request restrictions.

Response: We are concerned that a right to restrict could create conflicts with the professional ethical obligations of providers and others. We believe it is better policy to allow covered entities to refuse to honor restrictions that they believe are not appropriate and leave the individual with the option of seeking service from a different covered entity. In addition, many covered entities have information systems that would make it difficult or impossible to accommodate certain restrictions.

Comment: Some commenters requested that self-pay patients have additional rights to restrict protected health information. Others believed that this policy would result in de facto discrimination against those patients that could not afford to pay out-of-pocket.

Response: Under the final rule, the decision whether to tie an agreement to restrict to the way the individual pays for services is left to each covered entity. We have not provided self-pay patients with any special rights under the rule.

Comment: Some commenters suggested that we require restrictions to be clearly noted so that insurers and other providers would be aware that they were not being provided with complete information.

Response: Under the final rule, we do not require or prohibit a covered entity to note the existence of an omission of information. We encourage covered entities to inform others of the existence of a restriction, in accordance with professional practice and ethics, when appropriate to do so. In deciding whether or not to disclose the existence of a restriction, we encourage the covered entity to carefully consider whether disclosing the existence is tantamount to disclosure of the restricted protected health information so as not to violate the agreed to restriction.

Comment: A few commenters said that covered entities should have the right to modify or revoke an agreement to restrict use or disclosure of protected health information.

Response: We agree that, as circumstances change, covered entities should be able to revisit restrictions to which they had previously agreed. At the same time, individuals should be able to rely on agreements to restrict the use or disclosure of information that they believe is particularly sensitive. If a covered entity would like to revoke or modify an agreed-upon restriction, the covered entity must renegotiate the agreement with the individual. If the individual agrees to modify or terminate the restriction, the covered entity must get written agreement from the individual or must document the oral agreement. If the individual does not agree to terminate or modify the restriction, the covered entity must inform the individual that it is modifying or terminating its agreement to the restriction and any modification or termination would apply only with respect to protected health information created or received after the covered entity informed the individual of the termination. Any protected health information created or received during the time between when the restriction was agreed to and when the covered entity informed the individual or such modification or termination remains subject to the restriction.

Comment: Many commenters advocated for stronger rights to request restrictions, particularly that victims of domestic violence should have an absolute right to restrict disclosure of information.

Response: We address restrictions for disclosures in two different ways, the right to request restrictions (§164.522(a)) and confidential communications (§164.522(b)). We have provided all individuals with a right to request restrictions on uses or disclosures of treatment, payment, and health care operations. This is not an absolute right to restrict. Covered entities are not required to agree to requested restrictions; however, if they do, the rule would require them to act in accordance with the restrictions. (See the preamble regarding §164.522 for a more comprehensive discussion of the right to request restrictions.)

In the final rule, we create a new provision that provides individuals with a right to confidential communications, in response to these comments. This provision grants individuals with a right to restrict disclosures of information related to communications made by a covered entity to the individual, by allowing the individual to request that such communications be made to the person at an alternative location or by an alternative means. For example, a woman who lives with an abusive man and is concerned that his knowledge of her health care treatment may lead to additional abuse can request that any mail from the provider be sent to a friend's home or that telephone calls by a covered provider be made to her at work. Other reasonable accommodations may be requested as well, such as requesting that a covered provider never contact the individual by a phone, but only contact her by electronic mail. A provider must accommodate an individual’s request for confidential communications, under this section, without requiring an explanation as to the reason for the request as a condition of accommodating the request. The individual does not need to be in an abusive situation to make such requests of a covered provider. The only conditions that a covered provider may place on an individual is that the request be reasonable with respect to the administrative burden on the provider, the request to be in writing, the request specify an alternative address or other method of contact, and that (where relevant) the individual provide information about how payment will be handled. What is reasonable may vary by the size or type of covered entity; however, additional modest cost to the provider would not be unreasonable.

An individual also has a right to restrict communications from a health plan. The right is the same as with covered providers except it is limited to cases where the disclosure of information could endanger the individual. A health plan may require an individual to state this fact as a condition of accommodating the individual’s request for confidential communications. This would provide victims of domestic violence the right to control such disclosures.

Comment: Commenters opposed the provision of the NPRM (§164.506(c)(1)(ii)(B)) stating that an individual’s right to request restrictions on use or disclosure of protected health information would not apply in emergency situations as set forth in proposed §164.510(k). Commenters asserted that victims who have been harmed by violence may first turn to emergency services for help and that, in such situations, the victim should be able to request that the perpetrator not be told of his or her condition or whereabouts.

Response: We agree with some of the commenters’ concerns. In the final rule, the right to request restrictions is available to all individuals regardless of the circumstances or the setting in which the individual is obtaining care. For example, an individual that seeks care in an emergency room has the same right to request a restriction as an individual seeking care in the office of a covered physician.

However, we continue to permit a covered entity to disclose protected health information to a health care...
provider in an emergency treatment situation if the restricted protected health information is needed to provide the emergency treatment or if the disclosure is necessary to avoid serious and imminent threats to public health and safety. Although we understand the concern of the commenters, we believe that these exceptions are limited and will not cause a covered entity to disclose information to a perpetrator of a crime. We are concerned that a covered provider would be required to delay necessary care if a covered entity had to determine if a restriction exists at the time of such emergency. Even if a covered entity knew that there was a restriction, we permitted this limited exception for emergency situations because, as we had stated in the preamble for § 164.506 of the NPRM, an emergency situation may not provide sufficient opportunity for a patient and health care provider to discuss the potential implications of restricting use and disclosure of protected health information on that emergency. We also believe that the importance of avoiding serious and imminent threats to health and safety and the ethical and legal obligations of covered health care providers to make disclosures for these purposes is so significant that it is not appropriate to apply the right to request restrictions on such disclosures.

We note that we have included other provisions in the final rule intended to avoid or minimize harm to victims of domestic violence. Specifically, we include provisions in the final rule that allow individuals to opt out of certain types of disclosures and require covered entities to use professional judgment to determine whether disclosure of protected health information is in a patient’s best interest (see § 164.510(a) on use and disclosure for facility directories and § 164.510(b) on uses and disclosures for assisting in an individual’s care and notification purposes), although an agreed to restriction under § 164.522 would apply to uses and disclosures for assisting in an individual’s care, the opt out provision in § 164.510(b) can be more helpful to a person who is a victim of domestic violence because the individual can opt out of such disclosure without obtaining the agreement of the covered provider. We permit a covered entity to elect not to treat a person as a personal representative (see § 164.502(g) or to deny access to a personal representative (see § 164.524(a)(3)(iii) where there are concerns is also valid. We also include a new § 164.512(c) which recognizes the unique circumstances surrounding disclosure of protected health information about victims of abuse, neglect, and domestic violence.

Section 164.522(b)—Confidential Communications Requirements

Comment: Several commenters requested that we add a new section to prevent disclosure of sensitive health care services to members of the patient’s family through communications to the individual’s home, such as appointment notices, confirmation or scheduling of appointments, or mailing a bill or explanation of benefits, by requiring covered entities to agree to correspond with the patient in another way. Some commenters stated that this is necessary in order to protect inadvertent disclosure of sensitive information and to protect victims of domestic violence from disclosure to an abuser. A few commenters suggested that a covered entity should be required to obtain an individual’s authorization prior to communicating with the individual at the individual’s home with respect to health care relating to sensitive subjects such as reproductive health, sexually transmissible diseases, substance abuse or mental health.

Response: We agree with commenters’ concerns regarding covered entities’ communications with individuals. We created a new provision, § 164.522(b), to address confidential communications by covered entities. This provision gives individuals the right to request that they receive communications from covered entities at an alternative address or by an alternative means, regardless of the nature of the protected health information involved. Covered providers are required to accommodate reasonable requests by individuals and may not require the individual to explain the basis for the request as a condition of accommodation. Health plans are required to accommodate reasonable requests by individuals as well; however, they may require the individual to provide a statement that disclosure of the information could endanger the individual, and they may condition the accommodation on the receipt of such statement.

Under the rule, we have required covered providers to accommodate requests for communications to alternative addresses or by alternative means, regardless of the reason, to limit risk of harm. Providers have more frequent one-on-one communications with patients, making the safety concerns from an inadvertent disclosure more substantial and the need for confidential disclosure more compelling. We have made the requirement for covered providers absolute and not contingent on the reason for the request because we wanted to make it relatively easy for victims of domestic violence, who face real safety concerns by disclosures of health information, to limit the potential for such disclosures.

The standard we created for health plans is different from the requirement for covered providers, in that we only require health plans to make requested accommodations for confidential communications when the individual asserts that disclosure could be dangerous to the individual. We address health plan requirements in this way because health plans are often issued to a family member (the employee), rather than to each individual member of a family, and therefore, health plans tend to communicate with the named insured rather than with individual family members. Requiring plans to accommodate a restriction for one individual could be administratively more difficult than it is for providers that regularly communicate with individuals. However, in the case of domestic violence or potential abuse, the level of harm that can result from a disclosure of protected health information tips the balance in favor of requiring such restriction to prevent inadvertent disclosure. We have adopted the policy recommended by the National Association of Insurance Commissioners in the Health Information Policy Model Act (1998) as this best reflects the balance of the appropriate level of regulation of the industry compared with the need to protect individuals from harm that may result from inadvertent disclosure of information. This policy is also consistent with recommendations made in the Family Violence Prevention Fund’s publication “Health Privacy Principles for Protecting Victims of Domestic Violence” (October 2000). Of course, health plans may accommodate requests for confidential communications without requiring a statement that the individual would be in danger from disclosure of protected health information.

Comment: One commenter requested that we create a standard that all information from a health plan be sent to the patient and not the policyholder or subscriber.

Response: We require health plans to accommodate certain requests that information not be sent to a particular location or by particular means. A health plan must accommodate reasonable requests by individuals that protected health information about them be sent directly to them and not to a policyholder or subscriber, if the
individual states that he or she may be in danger from disclosure of such information. We did not generally require health plans to send information to the patient and not the policyholder or subscriber because we believed it would be administratively burdensome and because the named insured may have a valid need for such information to manage payment and benefits.

Sensitive Subjects

Comment: Many commenters requested that additional protections be placed on sensitive information, including information regarding HIV/AIDS, sexually transmitted diseases, mental health, substance abuse, reproductive health, and genetics. Many requested that we ensure the regulation adequately protects victims of domestic violence. They asserted that the concern for discrimination or stigma resulting from disclosure of sensitive health information could dissuade a person from seeking needed treatment. Some commenters noted that many state laws provide additional protections for various types of information. They requested that we develop federal standards to have consistent rules regarding the protection of sensitive information to achieve the goals of cost savings and patient protection. Others requested that we require patient consent or special authorization before certain types of sensitive information was disclosed, even for treatment, payment, and health care operations, and some thought we should require a separate request for each disclosure. Some commenters requested that the right to request restrictions be replaced with a requirement for an authorization for specific types of sensitive information. There were recommendations that we require covered entities to develop internal policies to address sensitive information.

Other commenters argued that sensitive information should not be segregated from the record because it may limit a future provider’s access to information necessary for treatment of the individual and it could further stigmatize a patient by labeling him or her as someone with sensitive health care issues. These commenters further maintained that segregation of particular types of information could negatively affect analysis of community needs, research, and would lead to higher costs of health care delivery.

Response: We generally do not differentiate among types of protected health information because all health information is sensitive. The level of sensitivity varies not only with the type of information, but also with the individual and the particular situation faced by the individual. This is demonstrated by the different types of information that commenters singled out as merit special protection, and in the great variation among state laws in defining and protecting sensitive information. Most states have a law providing heightened protection for some type of health information. However, even though most states have considered the issue of sensitive information, the variation among states in the type of information that is specially protected and the requirements for permissible disclosure of such information demonstrates that there is no national consensus.

Where, as in this case, most states have acted and there is no predominant rule that emerges from the state experience with this issue, we have decided to let state law predominate. The final rule only provides a floor of protection for health information and does not preempt state laws that provide greater protection than the rule. Where states have decided to treat certain information as more sensitive than other information, we do not preempt those laws.

To address the variation in the sensitivity of protected health information without defining specially sensitive information, we incorporate opportunities for individuals and covered entities to address specific sensitivities and concerns about uses and disclosures of certain protected health information that the patient and provider believe are particularly sensitive, as follows:

- Covered entities are required to provide individuals with notice of their privacy practices and give individuals the opportunity to request restrictions of the use and disclosure of protected health information by the covered entity. (See §164.522(a) regarding right to request restrictions.)

- Individuals have the right to request, and in some cases require, that communications from the covered entity to them be made to an alternative address or by an alternative means than the covered entity would otherwise use. (See §164.522(b) regarding confidential communications.)

- Covered entities have the opportunity to decide not to treat a person as a personal representative when the covered entity has a reasonable belief that an individual has been subjected to domestic violence, abuse, or neglect by such person or that treating such person as a personal representative could endanger the individual. (See §164.520(g)(5) regarding personal representatives.)

- Covered entities may deny access to protected health information when there are concerns that the access may result in varying levels of harm. (See §164.524(a)(3) regarding denial of access.)

- Covered health care providers may, in some circumstances and consistent with any known prior preferences of the individual, exercise professional judgment in the individual’s best interest to not disclose directory information. (See §164.510(a) regarding directory information.)

- Covered entities may, in some circumstances, exercise professional judgment in the individual’s best interest to limit disclosure to persons assisting in the individual’s care. (See §164.510(b) regarding persons assisting in the individual’s care.)

This approach allows for state law and personal variation in this area.

The only type of protected health information that typically are not used or required for treatment, payment, or health care operations other than by the mental health professional that created the notes. (See §164.508(a)(2) regarding psychotherapy notes.)

Section 164.524—Access of Individuals to Protected Health Information

Comment: Some commenters recommended that there be no access to disease registries.

Response: Most entities that maintain disease registries are not covered entities under this regulation; examples of such non-covered entities are public health agencies and pharmaceutical companies. If, however, a disease registry is maintained by a covered entity and is used to make decisions about individuals, this rule requires the covered entity to provide access to information about a requesting individual unless one of the rule’s conditions for denial of access is met. We found no persuasive reasons why disease registries should be given special treatment compared with other information that may be used to make decisions about an individual.

Comment: Some commenters stated that covered entities should be held accountable for access to information held by business partners so that individuals would not have the burden of tracking down protected health information from a business partner. Many commenters, including insurers
and academic medical centers, recommended that, to reduce burden and duplication, only the provider who created the protected health information should be required to provide individuals access to the information. Commenters also asked that other entities, including business associates, the Medicare program, and pharmacy benefit managers, not be required to provide access, in part because they do not know what information the covered entity already has and they may not have all the information requested. A few commenters also argued that billing companies should not have to provide access because they have a fiduciary responsibility to their physician clients to maintain the confidentiality of records.

Response: A general principle in responding to all of these points is that a covered entity is required to provide access to protected health information in accordance with the rule regardless of whether the covered entity created such information or not. Thus, we agree with the first point: in order to meet its requirements for providing access, a covered entity must not only provide access to such protected health information it holds, but must also provide access to such information in a designated record set of its business associate, pursuant to its business associate contract, unless the information is the same as information maintained directly by the covered entity. We require this because an individual may not be aware of business associate relationships. Requiring an individual to track down protected health information held by a business associate would significantly limit access. In addition, we do not permit a covered entity to limit its duty to provide access by giving protected health information to a business associate.

We disagree with the second point: if the individual directs an access request to a covered entity that has the protected health information requested, the covered entity must provide access (unless it may deny access in accordance with this rule). In order to assure that an individual can exercise his or her access rights, we do not require the individual to make a separate request to each originating provider. The originating provider may no longer be in business or may no longer have the information, or the non-originating provider may have the information in a modified or enhanced form.

We disagree with the third point: other entities must provide access only if they are covered entities or business associates of covered entities, and they must provide access only to protected health information that they maintain (or that their business associates maintain). It would not be efficient to require a covered entity to compare another entity’s information with that of the entity to which the request was addressed. (See the discussion regarding covered entities for information about whether a pharmacy benefit manager is a covered entity.)

We disagree with the fourth point: a billing company will be required by its business associate contract only to provide the requested protected health information to its physician client. This action will not violate any fiduciary responsibility. The physician client would in turn be required by the rule to provide access to the individual.

Response: We consider as duplicative information the same information in different formats, media, or presentations, or which have been standardized. Business associates who have materially altered protected health information are obligated to provide individuals access to it. Summary information and reports, including those of lab results, are not the same as the underlying information on which the summaries or reports were based. A clean document is not a duplicate of the same document with notations. If the same information is kept in more than one location, the covered entity has to produce the information only once per request for access.

Response: We allow covered entities to disclose to third parties without exception at the request of individuals. It was argued that this would facilitate disability determinations when third parties need information to evaluate individuals’ eligibility to benefits. Commenters argued that since covered entities may deny access to individuals under certain circumstances, individuals must have another method of providing third parties with their protected health information.

Response: We allow covered entities to forward protected health information about an individual to a third party, pursuant to an individual’s authorization under § 164.508. We do not require covered entities to disclose information pursuant to such authorizations because the focus of the rule is privacy of protected health information. Requiring disclosures in all circumstances would be counter to this goal. In addition, a requirement of disclosing protected health information to a third party is not a necessary substitute for the right of access to individuals, because we allow denial of access to individuals under rare circumstances. However, if the third party is a personal representative of the individual in accordance with § 164.502(g) and there is no concern regarding abuse or harm to the individual or another person, we require the covered entity to provide access to that third party on the individual’s behalf, subject to specific limitations. We note that a personal representative may obtain access on the individual’s behalf in some cases where covered entity may deny access to the individual. For example, an inmate may be denied a copy of protected health information, but a personal representative may be able to obtain a copy on the individual’s behalf. See § 164.502(g) and the corresponding preamble discussion regarding the ability of a personal representative to act on an individual’s behalf.

Response: The majority of commenters supported granting individuals the right to access protected health information for as long as the covered entity maintains the protected health information; commenters argued that to do otherwise would interfere with existing record retention laws. Some commenters advocated for limiting the right to information that is less than one or two years old. A few commenters explained that frequent changes in technology makes it more difficult to access stored data. The commenters noted that the information obtained prior to the effective date of the rule should not be required to be accessible.

Response: We agree with the majority of commenters and retain the proposal to require covered entities to provide access for as long as the entity maintains the protected health information. We do not agree that information created prior to the effective date of the rule should not be accessible. The reasons for granting individuals access to information about them do not vary with the date the information was created.

Response: A few commenters argued that there should be no grounds for denying access, stating that individuals should always have the right to inspect and copy their protected health information.
Response: While we agree that in the vast majority of instances individuals should have access to information about them, we cannot agree that a blanket rule would be appropriate. For example, where a professional familiar with the particular circumstances believes that providing such access is likely to endanger a person’s life or physical safety, or where granting such access would violate the privacy of other individuals, the benefits of allowing access may not outweigh the harm. Similarly, we allow denial of access where disclosure would reveal the source of confidential information because we do not want to interfere with a covered entity’s ability to maintain implicit or explicit promises of confidence.

We create narrow exceptions to the rule of open access, and we expect covered entities to employ these exceptions rarely, if at all. Moreover, we require covered entities to provide access to any protected health information requested after excluding only the information that is subject to a denial. The categories of permissible denials are not mandatory, but are a means of preserving the flexibility and judgment of covered entities under appropriate circumstances.

Comment: Many commenters supported our proposal to allow covered entities to deny an individual access to protected health information if a professional determines either that such access is likely to endanger the life or physical safety of a person or, if the information is about another person, access is reasonably likely to cause substantial harm to such person.

Some commenters requested that the rule also permit covered entities to deny a request if access might be reasonably likely to cause psychological or mental harm, or emotional distress. Other commenters, however, were particularly concerned about access to mental health information, stating that the lack of access creates resentment and distrust in patients.

Response: We disagree with the comments suggesting that we expand the grounds for denial of access to an individual to include a likelihood of psychological or mental harm of the individual. We did not find persuasive evidence that this is a problem sufficient to outweigh the reasons for providing open access. We do allow a denial for access based on a likelihood of substantial psychological or mental harm, but only if the protected health information includes information about another person and the harm may be inflicted on such other person or if the person requesting the access is a personal representative of the individual and the harm may be inflicted on the individual or another person.

We generally agree with the commenters concerning that denying access specifically to mental health records could create distrust. To balance this concern with other commenters’ concerns about the potential for psychological harm, however, we exclude psychotherapy notes from the right of access. This is the only distinction we make between mental health information and other types of protected health information in the access provisions of this rule. Unlike other types of protected health information, these notes are not widely disseminated through the health care system. We believe that the individual’s privacy interests in having access to these notes, therefore, are outweighed by the potential harm caused by such access. We encourage covered entities that maintain psychotherapy notes, however, to provide individuals access to these notes when they believe it is appropriate to do so.

Comment: Some commenters believed that there is a potential for abuse of the provision allowing denial of access because of likely harm to self. They questioned whether there is any experience from the Privacy Act of 1974 to suggest that patients who requested and received their records have ever endangered themselves as a result.

Response: We are unaware of such problems from access to records that have been provided under the Privacy Act but, since these are private matters, such problems might not come to our attention. We believe it is more prudent to preserve the flexibility and judgment of health care professionals familiar with the individuals and facts surrounding a request for records than to impose the blanket rule suggested by these commenters.

Comment: Commenters asserted that the NPRM did not adequately protect vulnerable individuals who depend on others to exercise their rights under the rule. They requested that the rule permit a covered entity to deny access when the information is requested by someone other than the subject of the information and, in the opinion of a licensed health care professional, access to the information could harm the individual or another person.

Response: We agree with the commenters that such protection is warranted and add a provision in § 164.524(a)(3), which permits a covered health care provider to deny access if a personal representative of the individual is making the request for access and a licensed health care professional has determined, in the exercise of professional judgment, that providing access to such personal representative could result in substantial harm to the individual or another person. Access can be denied even if the potential harm may be inflicted by someone other than the personal representative.

This provision is designed to strike a balance between the competing interests of ensuring access to protected health information and protecting the individual or others from harm. The “substantial harm” standard will ensure that a covered entity cannot deny access in cases where the harm is de minimus.

The amount of discretion that a covered entity has to deny access to a personal representative is generally greater than the amount of discretion that a covered entity has to deny access to an individual. Under the final rule, a covered entity may deny access to an individual if a licensed health care professional determines that the access requested is reasonably likely to endanger the life or physical safety of the individual or another person. In this case, concerns about psychological or emotional harm would not be sufficient to justify denial of access. We establish a relatively high threshold because we want to assure that individuals have broad access to health information about them, and due to the potential harm that comes from denial of access, we believe denials should be permitted only in limited circumstances.

The final rule grants covered entities greater discretion to deny access to a personal representative than to an individual in order to provide protection to those vulnerable people who depend on others to exercise their rights under the rule and who may be subjected to abuse or neglect. This provision applies to personal representatives of minors as well as other individuals. The same standard for denial of access on the basis of potential harm that applies to personal representatives also applies when an individual is seeking access to his or her protected health information, and the information makes reference to another person. Under these circumstances, a covered entity may deny a request for access if such access is reasonably likely to cause substantial harm to such other person. The standard for this provision and for the provision regarding access by personal representatives is the same because both circumstances involve one person obtaining information about another person and the covered entity is balancing the right of access of one person against the right of
a second person not to be harmed by the disclosure.

Under any of these grounds for denial of access to protected health information, the covered entity is not required to deny access to a personal representative under these circumstances, but has the discretion to do so.

In addition to denial of access rights, we also address the concerns raised by abusive or potentially abusive situations in the section regarding personal representatives by giving covered entities discretion to not recognize a person as a personal representative of an individual if the covered entity has a reasonable belief that the individual has been subjected to domestic violence, abuse, or neglect by or would be in danger from a person seeking to act as the personal representative. (See § 164.502(g))

Comment: A number of commenters were concerned that this provision would lead to liability for covered entities if the release of information results in harm to individuals. Commenters requested a “good faith” standard in this provision to relieve covered entities of liability if individuals suffer harm as a result of seeing their protected health information or if the information is found to be erroneous. A few commenters suggested requiring providers (when applicable) to include with any disclosure to a third party a statement that, in the provider’s opinion, the information should not be disclosed to the patient.

Response: We do not intend to create a new duty to withhold information nor to affect other laws on this issue. Some state laws include policies similar to this rule, and we are not aware of liability arising as a result.

Comment: Some commenters suggested that both the individual’s health care professional and a second professional in the relevant field of medicine should review each request. Many commenters suggested that individuals have a right to have an independent review of any denial of access, e.g., review by a health care professional of the individual’s choice.

Response: We agree with the commenters who suggest that denial on grounds of harm to self or others should be determined by a health professional, and retain this requirement in the final rule. We disagree, however, that all denials should be reviewed by a professional of the individual’s choice. We are concerned that the burden such a requirement would place on covered entities would be significantly greater than any benefits to the individual. We believe that any health professional, not just one of the individual’s choice, will exercise appropriate professional judgment. To address some of these concerns, however, we add a provision for the review of denials requiring the exercise of professional judgment. If a covered entity denies access based on harm to self or others, the individual has the right to have the denial reviewed by another health care professional who did not participate in the original decision to deny access.

Comment: A few commenters objected to the proposal to allow covered entities to deny a request for access to health information if the information was obtained from a confidential source that may be revealed upon the individual’s access. They argued that this could be subject to abuse and the information could be inherently less reliable, making the patient’s access to it even more important.

Response: While we acknowledge that information provided by confidential sources could be inaccurate, we are concerned that allowing unfettered access to such information could undermine the trust between a health care provider and patients other than the individual. We retain the proposed policy because we do not want to interfere with a covered entity’s ability to obtain important information that can assist in the provision of health care or to maintain implicit or explicit promises of confidence, which may be necessary to obtain such information. We believe the concerns raised about abuse are mitigated by the fact that the provision does not apply to promises of confidentiality made to a health care provider. We note that a covered entity may provide access to such information.

Comment: Some commenters were concerned that the NPRM did not allow access to information unrelated to treatment, and thus did not permit access to research information.

Response: In the final rule, we eliminate the proposed special provision for “research information unrelated to treatment.” The only restriction on access to research information in this rule applies where the individual agrees in advance to denial of access when consenting to participate in research that includes treatment. In this circumstance, the individual’s right of access to protected health information created in the course of the research may be suspended for as long as the research is in progress, but access would expire upon completion of the trial unless there is a health risk. A few commenters suggested that access should be allowed only if it is included in the informed consent and that the informed consent should note that some information may not be released to the individual, particularly research information that has not yet been validated. Other commenters believed that there should be access if the research is not subject to IRB or privacy board review or if the information can be disclosed to third parties.

Response: We agree with the commenters who support temporary denial of access to information from research that includes treatment if the subject has agreed in advance, and with those who suggested that the denial of access expire upon completion of the research, and retain these provisions in the final rule. We disagree with the commenters who advocate for further denial of this information. These comments did not explain why an individual’s interest in access to health information used to make decisions about them is less compelling with respect to research information. Under this rule, all protected health information for research is subject either to privacy board or IRB review unless a specific authorization to use protected health information for research is obtained from the individual. Thus, this is not a criterion we can use to determine access rights.

Comment: A few commenters believed that it would be “extremely disruptive of and dangerous” to patients to have access to records regarding their current care and that state law provides sufficient protection of patients’ rights in this regard.

Response: We do not agree. Information about current care has immediate and direct impact on individuals. Where a health care professional familiar with the circumstances believes that it is reasonably likely that access to the records would endanger the life or physical safety of the individual or another
person, the regulation allows the professional to withhold access.

Comment: Several commenters requested clarification that a patient not be denied access to protected health information because of failure to pay a bill. A few commenters requested clarification that entities may not deny requests simply because producing the information would be too burdensome.

Response: We agree with these comments, and confirm that neither failure to pay a bill nor burden are lawful reasons to deny access under this rule. Covered entities may deny access only for the reasons provided in the rule.

Comment: Some commenters requested that the final rule not include detailed procedural requirements about how to respond to requests for access.

Response: We intend to provide sufficient procedural guidelines to ensure that individuals have access to their protected health information, while maintaining the flexibility for covered entities to implement policies and procedures that are appropriate to their needs and capabilities. We believe that a limit on the frequency of requests individuals may make would arbitrarily infringe on the individual’s right of access and have, therefore, not included such a limitation. To limit covered entities’ burden, we do not require covered entities to acknowledge receipt of the individuals’ requests, other than to notify the individual once a decision on the request has been made. We also permit covered entities to extend the deadline by up to 30 days if they are unable to complete action on the request within the standard deadline. These time limits are intended to be an outside deadline rather than an expectation. We expect covered entities to be attentive to the circumstances surrounding each request and respond in an appropriate time frame.

Comment: A few commenters suggested that, upon individuals’ requests, covered entities should be required to provide protected health information in a format that would be understandable to a patient, including explanations of codes or abbreviations. The commenters suggested that covered entities be permitted to provide summaries of pertinent information instead of full copies of records; for example, a summary may be more helpful for the patient’s purpose than a series of indecipherable billing codes.

Response: We agree with these commenters’ point that some health information is difficult to interpret. We clarify, therefore, that the covered entity may provide summary information in lieu of the underlying records. A summary may only be provided if the covered entity and the individual agree, in advance, to the summary and to any fees imposed by the covered entity for providing such summary. We similarly permit a covered entity to provide an explanation rather than providing the underlying records. If the covered entity charges a fee for providing an explanation, it must obtain the individual’s agreement to the fee in advance.

Comment: Though there were recommendations that fees be limited to the costs of copying, the majority of commenters on this topic requested that covered entities be able to charge a reasonable, cost-based fee. Commenters suggested that calculation of access costs involve factors such as labor costs for verification of requests, labor and software costs for logging of requests, labor costs for retrieval, labor costs for copying, expense costs for copying, capital cost for copying, expense costs for mailing, postal costs for mailing, billing and bad-debt expenses, and labor costs for refiling. Several commenters recommended specific fee structures.

Response: We agree that covered entities should be able to recoup their reasonable costs for copying of protected health information, and include such provision in the regulation. We are not specifying a set fee because copying costs could vary significantly depending on the size of the covered entity and the form of such copy (e.g., paper, electronic, film). Rather, covered entities are permitted to charge a reasonable, cost-based fee for copying (including the costs of supplies and labor), postage, and summary or explanation (if requested and agreed to by the individual) of information supplied. The rule limits the types of costs that may be imposed for providing access to protected health information, but does not preempt applicable state laws regarding specific allowable fees for such costs. The inclusion of a copying fee is not intended to impede the ability of individuals to copy their records.

Comment: Many commenters stated that if a covered entity denies a request for access because the entity does not hold the protected health information requested, the covered entity should provide, if known, the name and address of the entity that holds the information. Some of these commenters additionally noted that the Uniform Insurance Information and Patient Protection Act, adopted by 16 states, already imposes this notification requirement on insurance entities. Some commenters also suggested requiring providers who leave practice or move offices to inform individuals of that fact and of how to obtain their records.

Response: We agree that, when covered entities deny requests for access because they do not hold the protected health information requested, they should inform individuals of the holder of the information. It is beyond the scope of this provision in the final rule. We do not require health care providers to
notify all patients when they move or leave practice, because the volume of such notifications would be unduly burdensome.

Section 164.326—Amendment of Protected Health Information

Comment: Many commenters strongly encouraged the Secretary to adopt “appendment” rather than “amendment and correction” procedures. They argued that the term “correction” implies a deletion of information and that the proposed rule would have allowed covered entities to remove portions of the record at their discretion. Commenters indicated that appendment rather than correction procedures will ensure the integrity of the medical record and allow subsequent health care providers access to the original information as well as the appended information. They also indicated appendment procedures will protect both individuals and covered entities since medical records are sometimes needed for litigation or other legal proceedings.

Response: We agree with commenters’ concerns about the term “correction.” We have revised the rule and deleted “correction” from this provision in order to clarify that covered entities are not required by this rule to delete any information from the designated record set. We do not intend to alter medical record retention laws or current practice, except to require covered entities to append information as requested to ensure that a record is accurate and complete. If a covered entity prefers to comply with this provision by deleting the erroneous information, and applicable record retention laws allow such deletion, the entity may do so. For example, an individual may inform the entity that someone else’s X-rays are in the individual’s medical record. If the entity agrees that the X-ray is inaccurate, it can indicate and note where in the record the X-ray can be found. Alternatively, the entity may choose to remove the X-ray from the record and replace it with the correct X-ray, if applicable law allows the entity to do so. We intend the term “amendment” to encompass either action.

We believe this approach is consistent with well-established privacy principles, with other law, and with industry standards and ethical guidelines. The July 1977 Report of the Privacy Protection Study Commission recommended that health care providers and other organizations that maintain medical-record information have procedures for individuals to correct or amend the information. The Privacy Act (5 U.S.C. 552a) requires government agencies to permit individuals to request amendment of any record the individual believes is not accurate, relevant, timely, or complete. In its report “Best Principles for Health Privacy,” the Health Privacy Working Group recommended, “An individual should have the right to supplement his or her own medical record. Supplementation should not be implied to mean deletion or alteration of the medical record.” The National Association of Insurance Commissioners’ Health Information Privacy Model Act establishes the right of an individual who is the subject of protected health information to amend protected health information to correct any inaccuracies. The National Conference of Commissioners on Uniform State Laws’ Uniform Health Care Information Act states, “Because accurate health-care information is not only important to the delivery of health care, but for patient applications for life, disability and health insurance, employment, and a great many other issues that might be involved in civil litigation, this Act allows a patient to request an amendment in his record.” Some states also establish a right for individuals to amend health information about them. For example, Hawaii law (HRS section 323C–12) states, “An individual or the individual’s authorized representative may request in writing that a health care provider that generated certain health care information append additional information to the record in order to improve the accuracy or completeness of the information; provided that appending this information does not erase or obliterate any of the original information.” Montana law (MCA section 50–16–543) states, “For purposes of accuracy or completeness, a patient may request in writing that a health care provider correct or amend its record of the patient’s health care information to which he has access.” Connecticut, Georgia, and Maine provide indirect methods to request correction, amendment, or deletion of recorded personal information about them maintained by an insurance institution. Many other states have similar provisions.

Industry and standard-setting organizations have also developed policies for amendment of health information. The National Committee for Quality Assurance and the Joint Commission on Accreditation of Healthcare Organizations issued recommendations stating, “The opportunity for patients to review their records will enable them to correct any errors and may provide them with a better understanding of their health status and treatment. Amending records does not erase the original information. It inserts the correct information with a notation about the date the correct information was available and any explanation about the reason for the error.” Standards of the American Society for Testing and Materials state, “An individual has a right to amend by adding information to his or her record or database to correct inaccurate information in his or her patient record and in secondary records and databases which contain patient identifiable health information.” We build on this well-established principle in this final rule.

Comment: Some commenters supported the proposal to allow individuals to request amendment for as long as the covered provider or plan maintains the information. A few argued that the provision should be time limited, e.g., that covered entities should not have to amend protected health information that is more than two years old. Other comments suggested that the provision should only be applied to protected health information created after the compliance date of the regulation.

Response: The purpose of this provision is to create a mechanism whereby individuals can ensure that information about them is as accurate as possible as it travels through the health care system and is used to make decisions, including treatment decisions, about them. To achieve this result, individuals must have the ability to request amendment for as long as the information used to make decisions about them exists. We therefore retain the proposed approach. For these reasons, we also require covered entities to address requests for amendment of all protected health information within designated record sets, including information created or obtained prior to

---


the compliance date, for as long as the entity maintains the information.

**Comment:** A few commenters were concerned that the proposal implied that the individual is in control of and may personally change the medical record. These commenters opposed such an approach.

**Response:** We do not give individuals the right to alter their medical records. Individuals may request amendment, but they have no authority to determine the final outcome of the request and may not make actual changes to the medical record. The covered entity must review the individual’s request and make appropriate decisions. We have clarified this intent in §164.526(a)(1) by stating that individuals have a right to have a covered entity amend protected health information and in §164.526(b)(2) by stating that covered entities must act on an individual’s request for amendment.

**Comment:** Some commenters argued that the text field in some current transaction formats that would accommodate the extra text required to comply with the amendment provisions (e.g., sending statements of disagreement along with all future disclosures of the information at issue). Commenters argued that this provision will burden the efficient transmission of information, contrary to HIPAA requirements.

**Response:** We believe that most amendments can be incorporated into the standard transactions as corrections of erroneous data. We agree that some of the standard transactions cannot currently accommodate additional material such as statements of disagreement and rebuttals to such statements. To accommodate these rare situations, we modify the requirements in §164.526(d)(iii). The provision now states that if a standard transaction does not permit the inclusion of the additional material required by this section, the covered entity may separately transmit the additional material to the recipient of the standard transaction. Commenters interested in modifying the standard transactions to allow the incorporation of additional materials may also bring the issue up for resolution through the process established by the Transactions Rule and described in its preamble.

**Comment:** The NPRM proposed to allow amendment of protected health information in designated record sets. Some commenters supported the concept of a designated record set and stated that it appropriately limits the type of information available for amendment to information directly related to treatment. Other commenters were concerned about the burden this provision will create due to the volume of information that will be available for amendment. They were primarily concerned with the potential for frivolous, minor, or technical requests. They argued that for purposes of amendment, this definition should be limited to information used to make medical or treatment decisions about the individual. A few commenters requested clarification that individuals do not have a right to seek amendment unless there is verifiable information to support their claim or they can otherwise convince the entity that the information is inaccurate or incomplete.

**Response:** We believe that the same information available for inspection should also be subject to requests for amendment, because the purpose of these provisions is the same: To give consumers access to and the chance to correct errors in information that may be used to make decisions that affect their interests. We thus retain use of the “designated record set” in this provision. However, we share commenters’ concerns about the potential for minor or technical requests. To address this concern, we have clarified that covered entities may deny a request for amendment if the request is not in writing and does not articulate a reason to support the request, as long as the covered entity informs the individual of these requirements in advance.

**Comment:** Many commenters noted the potentially negative impact of the proposal to allow amendment of information may no longer exist or the individual may not know who created the information in question. Other commenters supported the proposal that the originator of the information is responsible for amendments to it. They argued that any extension of this provision requiring covered entities to amend information they have not created is administratively and financially burdensome.

**Response:** In light of the comments, we modify the rule to require the holder of the information to consider a request for amendment if the individual requesting amendment provides a reasonable basis to believe that the originator of the information is no longer available to act on a request. For example, if a request indicates that the information at issue was created by a hospital that has closed, and the request is not denied on other grounds, then the entity must amend the information. This provision is necessary to preserve an individual’s right to amend protected health information about them in certain circumstances.

**Comment:** Some commenters stated that the written contract between a covered entity and its business associate should stipulate that the business associate is required to amend protected health information in accordance with the amendment provisions. Otherwise, these commenters argued, there would be a gap in the individual’s right to have erroneous information corrected, because the covered entity could deny a request for amendment of information created by a business associate.

**Response:** We agree that information created by the covered entity or by the covered entity’s business associates should be subject to amendment. This requirement is consistent with the requirement to make information created by a business associate available for inspection and copying. We have revised the rule to require covered entities to specify in the business associate contract that the business associate will make protected health information available for amendment and will incorporate amendments accordingly. (See §164.504(e.).)

**Comment:** One commenter argued that covered entities should be required to presume information must be corrected where an individual informs the entity that an adjudicative process has made a finding of medical identity theft.

**Response:** Identity theft is one of many reasons why protected health information may be inaccurate, and is one of many subjects that may result in an adjudicative process relevant to the accuracy of protective health information. We believe that this provision accommodates this situation without a special provision for identity theft.

**Comment:** Some commenters asserted that the proposed rule’s requirement that action must be taken on individuals’ requests within 60 days of the receipt of the request was unreasonable and burdensome. A few commenters proposed up to three 30-day extensions for “extraordinary” (as defined by the entity) requests.

**Response:** We agree that 60 days will not always be a sufficient amount of time to adequately respond to these requests. Therefore, we have revised this provision to allow covered entities the option of a 30-day extension to deal with requests that require additional response time. However, we expect that 60 days will be adequate for most cases.

**Comment:** One commenter questioned whether a covered entity could...
appropriately respond to a request by amending the record, without indicating whether it believes the information at issue is accurate and complete.

Response: An amendment need not include a statement by the covered entity as to whether the information is or is not accurate and complete. A covered entity may choose to amend a record even if it believes the information at issue is accurate and complete. If a request for amendment is accepted, the covered entity must notify the individual that the record has been amended. This notification need not include any explanation as to why the request was accepted. A notification of a denied request, however, must contain the basis for the denial.

Comment: A few commenters suggested that when an amendment is made, the date should be noted. Some also suggested that the physician should sign the notation.

Response: We believe such a requirement would create a burden that is not necessary to protect individuals’ interests, and so have not accepted this suggestion. We believe that the requirements of § 164.526(c) regarding actions a covered entity must take when accepting a request will provide an adequate record of the amendment. A covered entity may date and sign an amendment at its discretion.

Comment: The NPRM proposed that covered entities, upon accepting a request for amendment, make reasonable efforts to notify those persons the individual identifies, and other persons whom the covered entity knows have received the erroneous or incomplete information and who may have relied, or could foreseeably rely, on such information to the detriment of the individual. Many commenters argued that this notification requirement was too burdensome and should be narrowed. They expressed concern that covered entities would have to notify anyone who might have received the information, even persons identified by the individual with whom the covered entity had no contact. Other commenters also contended that this provision would require covered entities to determine the reliance another entity might place on the information and suggested that particular part of the notification requirements be removed. Another commenter suggested that the notification provision be eliminated entirely, believing that it was unnecessary.

Response: Although there is some associated administrative burden with this provision, we believe it is a necessary requirement to effectively communicate amendments of erroneous or incomplete information to other parties. The negative effects of erroneous or incomplete medical information can be devastating. This requirement allows individuals to exercise some control in determining recipients they consider important to be notified, and requires the covered entity to communicate amendments to other persons that the covered entity knows have the erroneous or incomplete information and may take some action in reliance on the erroneous or incomplete information to the detriment of the individual. We have added language to clarify that the covered entity must obtain the individual’s agreement to have the amendment shared with the persons the individual and covered entity identifies. We believe these notification requirements appropriately balance covered entities’ burden and individuals’ interest in protecting the accuracy of medical information used to make decisions about them. We therefore retain the notification provisions substantially as proposed.

Comment: Some commenters argued against the proposed provision requiring a covered entity that receives a notice of amendment to notify its business associates, “as appropriate,” of necessary amendments. Some argued that covered entities should only be required to inform business associates of these changes if the amendment could affect the individual’s further treatment, citing the administrative and financial burden of notifying all business associates of changes that may not have a detrimental effect on the patient. Other commenters suggested that covered entities should only be required to inform business associates whom they reasonably know to be in possession of the information.

Response: We agree with commenters that clarification is warranted. Our intent is that covered entities must meet the requirements of this rule with respect to protected health information they maintain, including protected health information maintained on their behalf by their business associates. We clarify this intent by revising the definition of designated record set (see § 164.501) to include records maintained “by or for” a covered entity. Section 164.526(e) requires a covered entity that is informed of an amendment made by another covered entity to incorporate that amendment into designated record sets, whether the designated record set is maintained by the covered entity by a business associate. If a business associate maintains the record at issue on the covered entity’s behalf, the covered entity must fulfill its requirement by informing the business associate of the amendment to the record. The contract with the business associate must require the business associate to incorporate any such amendments. (See § 164.504(e).)

Comment: Some commenters supported the proposal to require covered entities to provide notification of the covered entity’s statement of denial and the individual’s statement of disagreement in any subsequent disclosures of the information to which the dispute relates. They argued that we should extend this provision to prior recipients of disputed information who have relied on it. These commenters noted an inconsistency in the proposed approach, since notification of accepted amendments is provided to certain previous recipients of erroneous health information and to recipients of future disclosures. They contended there is not a good justification for the different treatment and believed that the notification standard should be the same, regardless of whether the covered entity accepts the request for amendment.

These commenters also recommended that the individual be notified of the covered entity’s intention to rebut a statement of disagreement. They suggested requiring covered entities to send a copy of the statement of rebufftal to the individual.

Response: Where a request for amendment is accepted, the covered entity knows that protected health information about the individual is inaccurate or incomplete or the amendment is otherwise warranted; in these circumstances, it is reasonable to ask the covered entity to notify certain previous recipients of the information that reliance on such information could be harmful. Where, however, the request for amendment is denied, the covered entity believes that the relevant information is accurate and complete or the amendment is otherwise unacceptable. In this circumstance, the burden of prior notification outweighs the potential benefits. We therefore do not require notification of prior recipients.

We agree, however, that individuals should know how a covered entity has responded to their requests, and therefore add a requirement that covered entities also provide a copy of any rebuttal statement to the individual.
Comment: Many commenters expressed support for the concept of the right to receive an accounting of disclosures. Others opposed even the concept. One commenter said that it is likely that some individuals will request an accounting of disclosures from each of his or her health care providers and payors merely to challenge the disclosures that the covered entity made.

Some commenters also questioned the value to the individual of providing the right to an accounting. One commenter stated that such a provision would be meaningless because those who deliberately perpetrate an abuse are unlikely to note their breach in a log.

Response: The final rule retains the right of an individual to receive an accounting of disclosures of protected health information. The provision serves multiple purposes. It provides a means of informing the individual as to which information has been sent to which recipients. This information, in turn, enables individuals to exercise certain other rights under the rule, such as the rights to inspection and amendment, with greater precision and ease. The accounting also allows individuals to monitor how covered entities are complying with the rule. Though covered entities who deliberately make disclosures in violation of the rule may be unlikely to note such a breach in the accounting, other covered entities may document inappropriate disclosures that they make out of ignorance and not malfeasance. The accounting will enable the individual to address such concerns with the covered entity.

We believe this approach is consistent with well-established privacy principles, with other law, and with industry standards and ethical guidelines. The July 1977 Report of the Privacy Protection Study Commission recommended that a health care provider should not disclose individually-identifiable information for certain purposes without the individual’s authorization unless “an accounting of such disclosures is kept and the individual who is the subject of the information being disclosed can find out that the disclosure has been made to whom.” § 2

With certain exceptions, the Privacy Act (5 U.S.C. 552a) requires government agencies to “keep an accurate accounting of * * * the date, nature, and purpose of each disclosure of a record to any person or to another agency * * * and * * * the name and address of the person or agency to whom the disclosure is made.” The National Association of Insurance Commissioners’ Health Information Privacy Model Act requires carriers to provide to individuals on request “information regarding disclosure of that individual’s protected health information that is sufficient to exercise the right to amend the information.” We build on these standards in this final rule.

Comment: Many commenters disagreed with the NPRM’s exception for treatment, payment, and health care operations. Some commenters wanted treatment, payment, and health care operations disclosures to be included in an accounting because they believed that improper disclosures of protected health information were likely to be committed by parties within the entity who have access to protected health information for treatment, payment, and health care operations related purposes. They suggested that requiring covered entities to record treatment, payment, and health care operations disclosures would either prevent improper disclosures or enable transgressions to be tracked.

One commenter reasoned that disclosures for treatment, payment, and health care operations purposes should be tracked since these disclosures would be made without the individual’s consent. Others argued that if an individual’s consent is not required for a disclosure, then the disclosure should not have to be tracked for a future accounting to the individual.

One commenter requested that the provision be restated so that no accounting is required for disclosures “compatible with or directly related to” treatment, payment or health care operations. This comment indicated that the change would make § 164.515(a)(1) of the NPRM consistent with § 164.508(a)(2)(i)(A) of the NPRM.

Response: We do not accept the comments suggesting removing the exception for disclosures for treatment, payment, and health care operations. While including all disclosures within the accounting would provide more information to individuals about to whom their information has been disclosed, we believe that documenting all disclosures made for treatment, payment, and health care operations purposes would be unduly burdensome on entities and would result in accountings so voluminous as to be of questionable value. Individuals who seek treatment and payment expect that their information will be used and disclosed for these purposes. In many cases, under this final rule, the individual will have consented to these uses and disclosures. Thus, the additional information that would be gained from including these disclosures would not outweigh the added burdens on covered entities. We believe that retaining the exclusion of disclosures to carry out treatment, payment, and health care operations makes for a manageable accounting both from the point of view of entities and of individuals. We have conformed the language in this section with language in other sections of the rule regarding uses and disclosures to carry out treatment, payment, and health care operations. See § 164.508 and the corresponding preamble discussion regarding our decision to use this language.

Comments: A few commenters called for a record of all disclosures, including a right of access to a full audit trail where one exists. Some commenters stated while audit trails for paper records are too expensive to require, the privacy rule should not discourage audit trails, at least for computer-based records. They speculated that an important reason for maintaining a full audit trail is that most abuses are the result of activity by insiders. On the other hand, other commenters pointed out that an enormous volume of records would be created if the rule requires recording all accesses in the manner of a full audit trail.

One commenter supported the NPRM’s reference to the proposed HIPAA Security Rule, agreeing that access control and disclosure requirements under this rule should be coordinated with the final HIPAA Security Rule. The commenter recommended that HHS add a reference to the final HIPAA Security Rule in this section and keep specific audit log and reporting requirements generic in the privacy rule.

Response: Audit trails and the accounting of disclosures serve different functions. In the security field, an audit trail is typically a record of each time a sensitive record is altered, how it was altered and by whom, but does not usually record each time a record is used or viewed. The accounting required by this rule provides individuals with information about to whom a disclosure is made. An accounting, as described in this rule, would not capture uses. To the extent that an audit trail would capture uses, consumers reviewing an audit trail may not be able to distinguish between
accesses of the protected health information for use and accesses for disclosure. Further, it is not clear the degree to which the field is technologically poised to provide audit trails. Some entities could provide audit trails to individuals upon their request, but we are concerned that many could not.

We agree that it is important to coordinate this provision of the privacy rule with the Security Rule when it is issued as a final rule.

Comments: We received many comments from researchers expressing concerns about the potential impact of requiring an accounting of disclosures related to research. The majority feared that the accounting provision would prove so burdensome that many entities would decline to participate in research. Many commenters believed that disclosure of protected health information for research presents little risk to individual privacy and feared that the accounting requirement could shut down research.

Some commenters pointed out that often only a few data elements or a single element is extracted from the patient record and disclosed to a researcher, and that having to account for so singular a disclosure from what could potentially be an enormous number of records imposes a significant burden. Some said that the impact would be particularly harmful to longitudinal studies, where the disclosures of protected health information occur over an extended period of time. A number of commenters suggested that we not require accounting of disclosures for research, registries, and surveillance systems or other databases unless the disclosure results in the actual physical release of the patient’s entire medical record, rather than the disclosure of discrete elements of information contained within the record.

We also were asked by commenters to provide an exclusion for research subject to IRB oversight or research that has been granted a waiver of authorization pursuant to proposed §164.510, to exempt “in-house” research from the accounting provision, and to allow covered entities to describe the type of disclosures they have made to research projects, without specifically listing each disclosure. Commenters suggested that covered entities could include in an accounting a listing of the various research projects in which they participated during the time period at issue, without regard to whether a particular individual’s protected health information was disclosed to the project.

Response: We disagree with suggestions from commenters that an accounting of disclosures is not necessary for research. While it is possible that informing individuals about the disclosures made of their health information may on occasion discourage worthwhile activities, we believe that individuals have a right to know who is using their health information and for what purposes. This information gives individuals more control over their health information and a better base of knowledge from which to make informed decisions. For the same reasons, we also do not believe that IRB or privacy board review substitutes for providing individuals the right to know how their information has been disclosed. We permit IRBs or privacy boards to determine that a research project would not be feasible if authorization were required because we understand that it could be virtually impossible to get authorization for archival research involving large numbers of individuals or where the location of the individuals is not easy to ascertain. While providing an accounting of disclosures for research may entail some burden, it is feasible, and we do not believe that IRBs or privacy boards would have a basis for waiving such a requirement. We also note that the majority of comments that we received from individuals supported including more information in the accounting, not less.

We understand that requiring covered entities to include disclosures for research purposes in the individual’s record of disclosures entails some burden, but we believe that the benefits described above outweigh the burden.

We do not agree with commenters that we should exempt disclosures where only a few data elements are released or in the case of data released without individuals’ names. We recognize that information other than names can identify an individual. We also recognize that even a few data elements could be clues to an individual’s identity. The actual volume of information released is not an appropriate indicator of whether an individual could have a concern about privacy.

We disagree with comments that suggested that it would be sufficient to provide individuals with a general list of research projects to which information has been disclosed by the covered entity. We believe that individuals are entitled to a level of specificity about disclosures of protected health information about them and should know to which research projects their protected health information has been disclosed, rather than to which projects protected health information may have been disclosed. However, we have added a provision allowing for a summary accounting of recurrent disclosures. For multiple disclosures to the same recipient pursuant to a single authorization or for a single purpose permitted under the rule without authorization, the covered entity may provide a summary accounting addressing the series of disclosures rather than a detailed accounting of each disclosure in the series. This change is designed to ease the burden on covered entities involved in longitudinal projects.

With regard to the suggestion that we exempt “in-house” research from the accounting provision, we note that only disclosures of protected health information must appear in an accounting.

Comments: Several commenters noted that disclosures for public health activities may be of interest to individuals, but add to the burden imposed on entities. Furthermore, some expressed fear that priority public health activities would be compromised by the accounting provision. One commenter from a health department said that covered entities should not be required to provide an accounting to certain index cases, where such disclosures create other hazards, such as potential harm to the reporting provider. This commenter also speculated that knowing protected health information had been disclosed for these public health purposes might cause people to avoid treatment in order to avoid being reported to the public health department.

A provider association expressed concern about the effect that the accounting provision might have on a non-governmental, centralized disease registry that it operates. The provider organization feared that individuals might request that their protected health information be eliminated in the database, which would make the data less useful.

Response: As in the discussion of research above, we reject the contention that we should withhold information from individuals about where their information has been disclosed because informing them could occasionally discourage some worthwhile activities. We also believe that, on balance, individuals’ interest in having broad access to this information outweighs concerns about the rare instances in which providing this information might raise concerns about the person who made the disclosure. As we stated above, we believe that individuals have...
a right to know who is using their health information and for what purposes. This information gives individuals more control over their health information and a better base of knowledge from which to make informed decisions.

Comment: We received many comments about the proposed time-limited exclusion for law enforcement and health oversight. Several commenters noted that it is nearly impossible to accurately project the length of an investigation, especially during its early stages. Some recommended we permit a deadline based on the end of an event, such as conclusion of an investigation. One commenter recommended amending the standard such that covered entities would never be required to give an accounting of disclosures to health oversight or law enforcement agencies. The commenter noted that there are public policy reasons for limiting the extent to which a criminal investigation is made known publicly, including the possibility that suspects may destroy or falsify evidence, hide assets, or flee. The commenter also pointed out that disclosure of an investigation may unfairly stigmatize a person or entity who is eventually found to be innocent of any wrongdoing.

On the other hand, many commenters disagreed with the exemption for recording disclosures related to oversight activities and law enforcement. Many of these commenters stated that the exclusion would permit broad exceptions for government purposes while holding disclosures for private purposes to a more burdensome standard.

Some commenters felt that the NPRM made it too easy for law enforcement to obtain an exception. They suggested that law enforcement should not be excepted from the accounting provision unless there is a court order. One commenter recommended that a written request for exclusion be dated, signed by a supervisory official, and contain a certification that the official is personally familiar with the purpose of the request and the justification for exclusion from accounting.

Response: We do not agree with comments suggesting that we permanently exclude disclosures for oversight or law enforcement from the accounting. We believe generally that individuals have a right to know who is obtaining their health information and for what purposes.

At the same time, we agree with commenters that were concerned that an accounting could tip off subjects of investigations. We have retained a time-limited exclusion period similar to that proposed in the NPRM. To protect the integrity of investigations, in the final rule we require covered entities to exclude disclosures to a health oversight agency or law enforcement official for the time specified by that agency or official, if the agency or official states that including the disclosure in an accounting to the individual would be reasonably likely to impede the agency or official's activities. We require the statement from the agency or official to provide a specific time frame for the exclusion. For example, pursuant to a law enforcement official’s statement, a covered entity could exclude a law enforcement disclosure from the accounting for a period of three months from the date of the official’s statement or until a date specified in the statement.

In the final rule, we permit the covered entity to exclude the disclosure from an accounting to an individual if the agency or official makes the statement orally and the covered entity documents the statement and the identification of the agency or official that made the statement. We recognize that in urgent situations, agencies and officials may not be able to provide statements in writing. If the agency or official’s statement is made orally, however, the disclosure can be excluded from an accounting to the individual for no longer than 30 days from the oral statement. For exclusions longer than 30 days, a covered entity must receive a written statement.

We believe these requirements appropriately balance individuals’ rights to be informed of the disclosures of protected health information while recognizing the public’s interest in maintaining the integrity of health oversight and law enforcement activities.

Comment: One commenter stated that under Minnesota law, providers who are mandated reporters of abuse are limited as to whom they may report the abuse (generally law enforcement authorities and other providers only). This is because certain abusers, such as parents, by law may have access to a victim’s (child’s) records. The commenter requested clarification as to whether these disclosures are exempt from the accounting requirement or whether preemption would apply.

Response: While we do not except mandatory disclosures of abuse from the accounting for disclosure requirement, we believe the commenter’s concerns are addressed in several ways. First, nothing in this regulation invalidates or limits the authority or procedures established under state law providing for the reporting of child abuse. Thus, with respect to child abuse the Minnesota law’s procedures are not preempted even though they are less stringent with respect to privacy.

Second, with respect to abuse of persons other than children, we allow covered entities to refuse to treat a person as an individual’s personal representative if the covered entity believes that the individual has been subjected to domestic violence, abuse, or neglect from the person. Thus, the abuser would not have access to the accounting. We also note that a covered entity must exclude a disclosure, including disclosures to report abuse, from the accounting for specified period of time if the law enforcement official to whom the report is made requests such exclusion.

Comment: A few comments noted the lack of exception for disclosures made to intelligence agencies.

Response: We agree with the comments and have added an exemption for disclosures made for national security or intelligence purposes under §164.512(k)(2). Individuals do not have a right to an accounting of disclosures for these purposes.

Comment: Commenters noted that the burden associated with this provision would, in part, be determined by other provisions of the rule, including the definitions of “individually identifiable,” “treatment,” and “health care operations.” They expressed concern that the covered entity would have to be able to organize on a patient by patient basis thousands of disclosures of information, which they described as “routine.” These commenters point to disclosures for patient directory information, routine banking and payment processes, uses and disclosures in emergency circumstances, disclosures to next of kin, and release of admissions statistics to a health oversight agency.

Response: We disagree with the commenters that ambiguity in other areas of the rule increase the burden associated with maintaining an accounting. The definitions of treatment, payment, and health operations are necessarily broad and there is no accounting required for disclosures for these purposes. These terms cover the vast majority of routine disclosures for health care purposes. (See §164.501 and the associated preamble for a discussion of changes made to these definitions.)

The disclosures permitted under §164.512 are for national priority purposes, and determine whether a disclosure fits within the section is necessary before the disclosure can be
made. There is no additional burden, once such a determination is made, in determining whether it must be included in the accounting.

We agree with the commenters that there are areas where we can reduce burden by removing additional disclosures from the accounting requirement, without compromising individuals’ rights to know how their information is being disclosed. In the final rule, covered entities are not required to include the following disclosures in the accounting: disclosures to the individual, disclosures for facility directories under § 164.510(a), or disclosures to persons assisting in the individual’s care or for other notification purposes under § 164.510(b). For each of these types of disclosures, the individual is likely to already know about the disclosure or to have agreed to the disclosure, making the inclusion of such disclosures in the accounting less important to the individual and unnecessarily burdensome to the covered entity.

Comments: Many commenters objected to requiring business partners to provide an accounting to covered entities upon their request. They cited the encumbrance associated with re-contracting with the various business partners, as well as the burden associated with establishing this type of record keeping.

Response: Individuals have a right to know to whom and for what purpose their protected health information has been disclosed by a covered entity. The fact that a covered entity uses a business associate to carry out a function does not diminish an individual’s right to know.

Comments: One commenter requested clarification as to how far a covered entity’s responsibility would extend, asking whether an entity had to track the entity’s responsibility would extend, clarification as to how far a covered entity would be required to account for their disclosures, or for any further uses or disclosures of the information by that other person.

Comments: Some commenters said that the accounting provision described in the NPRM was ambiguous and created uncertainty as to whether it addresses disclosures only, as the title would indicate, or whether it includes accounting of uses. They urged that the standard address disclosures only, and not uses, which would make implementation far more practicable and less burdensome.

Response: The final rule requires disclosures, not uses, to be included in an accounting. See § 164.501 for definitions of “use” and “disclosure.”

Response: We do not agree that the current reliance on paper records makes the accounting provision unduly burdensome. Covered entities must use the paper records in order to make a disclosure, and have the opportunity when they do so to make a notation in the record or in a separate log. We require an accounting only for disclosures for purposes other than treatment, payment, and health care operations. Such disclosures are not so numerous that they cannot be accounted for, even if paper records are involved.

Comments: We received many comments from providers and other representatives of various segments of the health care industry, expressing the view that a centralized system of recording disclosures was not possible given the complexity of the health care system, in which disclosures are made by numerous departments within entities. For example, commenters stated that a hospital medical records department makes notations regarding information it releases, but that these notations do not include disclosures that the emergency department may make. Several commenters proposed that the rule provide for patients to receive only an accounting of disclosures made by medical records departments or some other central location, which would relieve the burden of centralizing accounting for those entities who depend on paper records and tracking systems.

Response: We disagree with commenters’ arguments that covered entities should not be held accountable for the actions of their subdivisions or workforce members. Covered entities are responsible for accounting for the disclosures of protected health information made by the covered entity, in accordance with this rule. The particular person or department within the entity that made the disclosure is immaterial to the covered entity’s obligation. In the final rule, we require covered entities to document each disclosure that is required to be included in an accounting. We do not, however, require this documentation to be maintained in a central registry. A covered hospital, for example, could maintain separate documentation of disclosures that are made from the medical records department and the emergency department. At the time an individual requests an accounting, this documentation could be integrated to provide a single accounting of disclosures made by the covered hospital. Alternatively, the covered hospital could centralize its processes for making and documenting disclosures. We believe this provision provides covered entities with sufficient flexibility to meet their business needs without compromising individuals’ rights to know how information about them is disclosed.

Comments: Commenters stated that the accounting requirements placed undue burden on covered entities that use paper, rather than electronic, records.

Response: We do not agree that the current reliance on paper records makes the accounting provision unduly burdensome. Covered entities must use the paper records in order to make a disclosure, and have the opportunity when they do so to make a notation in the record or in a separate log. We require an accounting only for disclosures for purposes other than treatment, payment, and health care operations. Such disclosures are not so numerous that they cannot be accounted for, even if paper records are involved.

Comments: The exception to the accounting provision for disclosures of protected health information for treatment, payment, and health care operations purposes was viewed favorably by many respondents. However, at least one commenter stated that since covered entities must differentiate between disclosures that require documentation and those that do not, they will have to document each instance when a patient’s medical record is disclosed to determine the reason for the disclosure. This commenter also argued that the administrative burden of requiring customer services representatives to ask in which category the information falls and then to keep a record that they asked the question and record the answer would be overwhelming for plans. The commenter concluded that the burden of documentation on a covered entity would not be relieved by the stipulation that documentation is not required for treatment, payment, and health care operations.

Response: We disagree. Covered entities are not required to document every disclosure in order to differentiate those for treatment, payment, and health care operations from those for purposes for which an accounting is required. We require that, when a disclosure is made for which an accounting is required, the covered entity be able to produce an accounting of those disclosures upon request. We do not require a covered entity to be able to account for every disclosure. In addition, we believe that we have addressed commenters’ concerns by clarifying in the final rule that disclosures to the
individual, regardless of the purpose for the disclosure, are not subject to the accounting requirement.

Comments: An insurer explained that in the context of underwriting, it may have frequent and multiple disclosures of protected health information to an agent, third party medical provider, or other entity or individual. It requested we reduce the burden of accounting for such disclosures.

Response: We add a provision allowing for a summary accounting of recurrent disclosures. For multiple disclosures to the same recipient pursuant to a single authorization or for a single purpose permitted under the rule without authorization, the covered entity may provide a summary accounting addressing the series of disclosures rather than a detailed accounting of each disclosure in the series.

Comment: Several commenters said that it was unreasonable to expect covered entities to track disclosures that are requested by the individual. They believed that consumers should be responsible for keeping track of their own requests.

Other commenters asked that we specify that entities need not retain and provide copies of the individual’s authorization to disclose protected health information. Some commenters were particularly concerned that if they maintain all patient information on a computer system, it would be impossible to link the paper authorization with the patient’s electronic records.

Another commenter suggested we allow entities to submit copies of authorizations after the 30-day deadline for responding to the individual, as long as the accounting itself is furnished within the 30-day window.

Response: In the final rule we do not require disclosures to the individual to be included in the accounting. Other disclosures requested by the individual must be included in the accounting, unless they are otherwise excepted from the requirement. We do not agree that individuals should be required to track these disclosures themselves. In many cases, an authorization may authorize a disclosure by more than one entity, or by a class of entities, such as all physicians who have provided medical treatment to the individual. Absent the accounting, the individual cannot know whether a particular covered entity has acted on the authorization.

We agree, however, that it is unnecessarily burdensome to require covered entities to provide the individual with a copy of the authorization. We remove the requirement. Instead, we require the accounting to contain a brief statement describing the purpose for which the protected health information was disclosed. The statement must be sufficient to reasonably inform the individual of the basis for the disclosure. Alternatively, the covered entity may provide a copy of the authorization or a copy of the written request for disclosure, if any, under §§164.502(a)(2)(ii) or 164.512.

Comments: We received many comments regarding the amount of information required in the accounting. A few commenters requested that we include additional elements in the accounting, such as the method of transmittal and identity of the employee who accessed the information.

Other commenters, however, felt that the proposed requirements went beyond what is necessary to inform the individual of disclosures. Another commenter stated that if the individual’s right to obtain an accounting extends to disclosures that do not require a signed authorization, then the accounting should be limited to a disclosure of the manner and purpose of disclosures, as opposed to an individual accounting of each entity to whom the protected health information was disclosed. An insurer stated that this section of the proposed rule should be revised to provide more general, rather than detailed, guidelines for accounting of disclosures. The commenter believed that its type of business should be allowed to provide general information regarding the disclosure of protected health information to outside entities, particularly with regard to entities with which the insurer maintains an ongoing, standard relationship (such as a reinsurer).

Response: In general, we have retained the proposed approach, which we believe strikes an appropriate balance between the individual’s right to know to whom and for what purposes their protected health information has been disclosed and the burden placed on covered entities. In the final rule, we clarify that the accounting must include the address of the recipient only if the address is known to the covered entity. As noted above, we also add a provision allowing for a summary accounting of recurrent disclosures. We note that some of the activities of concern to commenters may fall under the definition of health care operations (see §164.501 and the associated preamble).

Comment: A commenter asked that we limit accounting to information pertaining to the medical record itself, as opposed to protected health information more generally. Similarly, commenters suggested that the accounting be limited to release of the medical record only.

Response: We disagree. Protected health information exists in many forms and resides in many sources. An individual’s right to know to whom and for what purposes his or her protected health information has been disclosed would be severely limited if it pertained only to disclosure of the medical record, or information taken only from the record.

Comment: A commenter asked that we make clear that only disclosures external to the organization are within the accounting requirement.

Response: We agree. The requirement only applies to disclosures of protected health information, as defined in §164.501.

Comment: Some commenters requested that we establish a limit on the number of times an individual could request an accounting. One commenter suggested we permit individuals to request one accounting per year; another suggested two accountings per year, except in “emergency situations.” Others recommended that we enable entities to recoup some of the costs associated with implementation by allowing the entity to charge for an accounting.

Response: We agree that covered entities should be able to defray costs of excessive requests. The final rule provides individuals with the right to receive one accounting without charge in a twelve-month period. For additional requests by an individual within a twelve-month period, the covered entity may charge a reasonable, cost-based fee. If it imposes such a fee, the covered entity must inform the individual of the fee in advance and provide the individual with an opportunity to withdraw or modify the request to avoid or reduce the fee.

Comment: In the NPRM, we solicited comments on the appropriate duration of the individual’s right to an accounting. Some commenters supported the NPRM’s requirement that the right exist for as long as the covered entities maintain the protected health information. One commenter, however, noted that most audit control systems do not retain data on activity for indefinite periods of time.

Other commenters noted that laws governing the length of retention of clinical records vary by state and by provider type and suggested that entities be allowed to adhere to state laws or policies established by professional organizations or accrediting bodies. Some commenters suggested that the
language be clarified to state that whatever minimum requirements are in place for the record should also guide covered entities in retaining their capacity to account for disclosures over that same time, but no longer.

Several commenters asked us to consider specific time limits. It was pointed out that proposed § 164.520(f)(6) of the NPRM set a six-year time limit for retaining certain information including authorization forms and contracts with business partners. Included in this list was the accounting of disclosures, but this requirement was inconsistent with the more open-ended language in § 164.515.

Commenters suggested that deferring to this six-year limit would make this provision consistent with other record retention provisions of the standard and might relieve some of the burden associated with implementation. Other specific time frames suggested were two years, three years, five years, and seven years.

Another option suggested by commenters was to keep the accounting record for as long as entities have the information maintained and “active” on their systems. Information permanently taken off the covered entity’s system and sent to “dead storage” would not be covered. One commenter further recommended that we not require entities to maintain records or account for prior disclosures for members who have “disenrolled.”

Response: We agree with commenters who suggested we establish a specific period for which an individual may request an accounting. In the final rule, we provide that individuals have a right to an accounting of the applicable disclosures that have been made in the six-year period prior to a request for an accounting. We adopt this time frame to conform with the other documentation retention requirements in the rule. We also note that an individual may request, and a covered entity may then provide, an accounting of disclosures for a period of time less than six years from the date of the request. For example, an individual could request an accounting only of disclosures that occurred during the year prior to the request. In addition, we note that covered entities do not have to account for disclosures that occurred prior to the compliance date of this rule.

Comments: Commenters asked that we provide more time for entities to respond to requests for accounting. Suggestions ranged from 60 days to 90 days. Another writer suggested that entities be allowed up to three 30-day extensions from the original 30-day deadline. Commenters raised concerns about the proposed requirement that a covered health care provider or health plan act as soon as possible.

Response: We agree with concerns raised by commenters and in the final rule, covered entities are required to provide a requested accounting no later than 60 days after receipt of the request. We also provide for one 30 day extension if the covered entity is unable to provide the accounting within the standard time frame. We eliminate the requirement for a covered entity to act as soon as possible.

We recognize that circumstances may arise in which an individual will request an accounting on an expedited basis. We encourage covered entities to implement procedures for handling such requests. The time limitation is intended to be an outside deadline, rather than an expectation. We expect covered entities always to be attentive to the circumstances surrounding each request and to respond in an appropriate time frame.

Comment: A commenter asked that we provide an exemption for disclosures related to computer upgrades, when protected health information is disclosed to another entity solely for the purpose of establishing or checking a computer system.

Response: This activity falls within the definition of health care operations and is, therefore, excluded from the accounting requirement.

Section 164.530—Administrative Requirements

Section 164.530(a)—Designation of a Privacy Official and Contact Person

Comment: Many of the commenters on this topic objected to the cost of establishing a privacy official, including the need to hire additional staff, which might need to include a lawyer or other highly paid individual.

Response: We believe that designation of a privacy official is essential to ensure a central point of accountability within each covered entity for privacy-related issues. The privacy official is charged with developing and implementing the policies and procedures for the covered entity, as required throughout the regulation, and for compliance with the regulation generally. While the costs for these activities are part of the costs of compliance with this rule, not extra costs associated with the designation of a privacy official, we do anticipate that there will be some cost associated with the designation of the privacy official. The role may be additional responsibility given to an existing employee in the covered entity, such as an office manager in a small entity or an information officer or compliance official in a larger institution. Cost estimates for the privacy official are discussed in detail in the overall cost analysis.

Comment: A few commenters argued for more flexibility in meeting the requirement for accountability. One health care provider maintained that covered entities should be able to establish their own system of accountability. For example, most physician offices already have the patient protections incorporated in the proposed administrative requirements—the commenter urged that the regulation should explicitly promote the application of flexibility and scalability. A national physician association noted that, in small offices, in particular, responsibility for the policies and procedures should be allowed to be shared among several people. A major manufacturing corporation asserted that mandating a privacy official is unnecessary and that it would be preferable to ask for the development of policies that are designed to ensure that processes are maintained to assure compliance.

Response: We believe that a single focal point is needed to achieve the necessary accountability. At the same time, we recognize that covered entities are organized differently and have different information systems. We therefore do not prescribe who within a covered entity must serve as the privacy official, nor do we prohibit combining this function with other duties. Duties may be delegated and shared, so long as there is one point of accountability for the covered entity’s policies and procedures and compliance with this regulation.

Comment: Some commenters echoed the proposal of a professional information management association that the regulation establish formal qualifications for the privacy official, suggesting that this should be a credentialed information management professional with specified minimum training standards. One commenter emphasized that the privacy official should be sufficiently high in management to have influence.

Response: While there may be some advantages to establishing formal qualifications, we concluded the disadvantages outweigh the advantages. Since the job of privacy official will differ substantially among organizations of varying size and function, specifying a set of qualifications would sacrifice flexibility and scalability in implementation.
Comment: A few commenters suggested that we provide guidance on the tasks of the privacy official. One noted that this would reduce the burden on covered entities to clearly identify those tasks during the initial HIPAA implementation phase.

Response: The regulation itself outlines the tasks of the privacy official, by specifying the policies and procedures required, and otherwise explaining the duties of covered entities. Given the wide variation in the function and size of covered entities, providing further detail here would unnecessarily reduce flexibility for covered entities. We will, however, provide technical assistance in the form of guidance on the various provisions of the regulation before the compliance date.

Comment: Some comments expressed concern that the regulation would require a company with subsidiaries to appoint a privacy official within each subsidiary. Instead they argued that the corporate entity should have the option of designating a single corporate official rather than one at each subsidiary.

Response: In the final regulation, we give covered entities with multiple subsidiaries that meet the definition of covered entities under this rule the flexibility to designate whether such subsidiaries are each a separate covered entity or are together a single covered entity. (See § 164.504(b) for the rules requiring such designation.) If only one covered entity is designated for the subsidiaries, only one privacy officer is needed. Further, we do not prohibit the privacy official of one covered entity from serving as the privacy official of another covered entity, so long as all the requirements of this rule are met for each such covered entity.

Section 164.530(b)—Training

Comment: A few commenters felt that the proposed provision was too stringent, and that the content of the training program should be left to the reasonable discretion of the covered entity.

Response: We clarify that we do not prescribe the content of the required training; the nature of the training program is left to the discretion of the covered entity. The scenarios in the NPRM preamble of potential approaches to training for different sized covered entities were intended as examples of the flexibility and scalability of this requirement.

Comment: Most commenters on this provision asserted that recertification/retraining every three years is excessive, restrictive, and costly. Commenters felt that retraining intervals should be left to the discretion of the covered entity. Some commenters supported retraining only in the event of a material change. Some commenters supported the training requirement as specified in the NPRM.

Response: For the reasons cited by the commenters, we eliminate the triennial recertification requirements in the final rule. We also clarify that retraining is not required every three years. Retraining is only required in the case of material changes to the privacy policies and procedures of the covered entity.

Comment: Several commenters objected to the burden imposed by required signatures from employees after they are trained. Many commenters suggested that electronic signatures be accepted for various reasons. Some felt that it would be less costly than manually producing, processing, and retaining the hard copies of the forms. Some suggested sending out the notice to the personal workstation via email or some other electronic format and having staff reply via email. One commenter suggested that the covered entity might opt to give web based training instead of classroom or some other type. The commenter indicated that with web based training, the covered entity could record whether or not an employee had received his or her training through the use of a guest book or registration form on the web site. Thus, a physical signature should not be required.

Response: We agree that there are many appropriate mechanisms by which covered entities can implement their training programs, and therefore remove this requirement for signature. We establish only a general requirement that covered entities document compliance with the training requirement.

Comment: Some commenters were concerned that there was no proposed requirement for business associates to receive training and/or to train their employees. The commenters believed that if the business associate violated any privacy requirements, the covered entity would be held accountable. These commenters urged the Secretary to require periodic training for appropriate management personnel assigned outside of the component unit of the covered entity, including business associates. Other commenters felt that it would not be fair to require covered entities to impose training requirements on business associates.

Response: We do not have the statutory authority directly to require business associates to train their employees. We also believe it would be unnecessarily burdensome to require covered entities to monitor business associates’ establishment of specific training requirements. Covered entities’ responsibility for breaches of privacy by their business associates is described in §§ 164.504(e) and 164.530(f). If a covered entity believes that including a training requirement in one or more of its business associate contracts is an appropriate means of protecting the health information provided to the business associate, it is free to do so.

Comments: Many commenters argued that training, as well as all of the other administrative requirements, are too costly for covered entities and that small practices would not be able to bear the added costs. Commenters also suggested that HHS should provide training materials at little, or no, cost to the covered entity.

Response: For the final regulation, we make several changes to the proposed provisions. We believe that these changes address the issue of administrative cost and burden to the greatest extent possible, consistent with protecting the privacy of health information. In enforcing the privacy rule, we expect to provide general training materials. We also hope to work with professional associations and other groups that target classes of providers, plans and patients, in developing specialized material for these groups.

We note that, under long-standing legal principles, entities are generally responsible for the actions of their workforce. The requirement to train workforce members to implement the covered entity’s privacy policies and procedures, and do such things as pass evidence of potential problems to those responsible, is in line with these principles. For example, the comments and our fact finding indicate that, today, many hospitals require their workforce members to sign a confidentiality agreement, and include confidentiality matters in their employee handbooks.

Section 164.530(c)—Safeguards

Comments: A few comments assert that the rule requires some institutions that do not have adequate resources to develop costly physical and technical safeguards without providing a funding mechanism to do so. Another comment said that the vague definitions of adequate and appropriate safeguards could be interpreted by HHS to require the purchase of new computer systems and reprogram many old ones. A few other comments suggested that the safeguards language was vague and asked for more specifics.

Response: We require covered entities to maintain safeguards adequate for their operations; but do not require that
specific technologies be used to do so. Safeguards need not be expensive or high-tech to be effective. Sometimes, it is an adequate safeguard to put a lock on a door and only give the keys to those who need access. As described in more detail in the preamble to the proposed Security Rule, the final regulation covers all protected health information against all assaults. This requirement is flexible and scalable to allow implementation of required safeguards at a reasonable cost.

Comments: A few commenters noted that once protected health information becomes non-electronic, by being printed for example, it escapes the protection of the safeguards in the proposed Security Rule. They asked if this safeguards requirement is intended to install similar security protections for non-electronic information.

Response: This provision is not intended to incorporate the provisions in the proposed Security regulation into this regulation, or to otherwise require application of those provisions to paper records.

Comments: Some commenters said that it was unclear what “appropriate” safeguards were required by the rule and who establishes the criteria for them. A few noted that the privacy safeguards were not exactly the same as the security safeguards, or that the “other safeguards” section was too vague to implement. They asked for more clarification of safeguards requirements and flexible solutions.

Response: In the preamble discussion of § 164.530, we provide examples of types of safeguards that can be appropriate to satisfy this requirement. Other sections of this regulation require specific safeguards for specific circumstances. The discussion of the requirements for “minimum necessary” uses and disclosures of protected health information includes related guidance for developing role-based access policies for a covered entity’s workforce. The requirements for “component entities” include requirements for firewalls to prevent access by unauthorized persons. The proposed Security Rule included further details on what safeguards would be appropriate for electronic information systems. The flexibility and scalability of these rules allows covered entities to analyze their own needs and implement solutions appropriate for their own environment.

Comments: A few comments asked for a requirement for a firewall between a health care component and the rest of a larger organization as another appropriate safeguard.

Response: We agree, and have incorporated such a requirement in § 164.504.

Comments: One commenter agreed with the need for administrative, physical, and technical safeguards, but took issue with our specification of the type of documentation or proof that the covered entity is taking action to safeguard protected health information.

Response: This privacy rule does not require specific forms of proof for safeguards.

Comments: A few commenters asked that, for the requirement for a signed certification of training and the requirements for verification of identity, we consider the use of electronic signatures that meet the requirements in the proposed security regulation to meet the requirements of this rule.

Response: In this final rule, we drop the requirements for signed certifications of training. Signatures are required elsewhere in this regulation, for example, the Security Rule. In the relevant sections we clarify that electronic signatures are sufficient provided they meet standards to be adopted under HIPAA. In addition, we do not intend to interfere with the application of the Electronic Signature in Global and National Commerce Act.

Comments: A few commenters requested that the privacy requirements for appropriate administrative, technical, and physical safeguards be considered to have been met if the requirements of the proposed Security Rule have been met. Others requested that the safeguards requirements of the proposed Security Rule mirror or be harmonized with the final Security Rule so they do not result in redundant or conflicting requirements.

Response: Unlike the proposed regulation, the final regulation covers all protected health information, not just information that had at some point been electronic. Thus, these commenters’ assumption that the proposed Privacy Rule and the proposed Security Rule covered the same information is not the case, and taking the approach suggested by these comments would leave a significant number of health records unprotected. The safeguards required by this regulation are appropriate for both paper and electronic information. We will take care to ensure that the final Security Rule works in tandem with these requirements.

Comments: One commenter requested that the final privacy rule be published before the final Security Rule, recognizing that the privacy policies must be in place before the security technology used to implement them could be worked out. Another commenter asked that the final Security Rule be published immediately and not wait for an expected delay while privacy policies are worked out.

Response: Now that this final privacy rule has been published in a timely manner, the final Security Rule can be harmonized with it and published soon.

Comments: Several commenters echoed an association recommendation that, for those organizations that have implemented a computer based patient record that is compliant with the requirements of the proposed Security Rule, the minimum necessary rule should be considered to have been met by the implementation of role-based access controls.

Response: The privacy regulation applies to paper records to which the proposed Security Rule does not apply. Thus, taking the approach suggested by these comments would leave a significant number of health records unprotected. Further, since the final Security Rule is not yet published and the number of covered entities that have implemented this type of computer-based patient record systems is still small, we cannot make a blanket statement. We note that this regulation requires covered entities to develop role-based access rules, in order to implement the requirements for “minimum necessary” uses and disclosures of protected health information. Thus, this regulation provides a foundation for the type of electronic system to which these comments refer.

Section 164.530(d)—Complaints to the Covered Entity

Comment: Several commenters felt that some form of due process is needed when it comes to internal complaints. Specifically, they wanted to be assured that the covered entity actually hears the complaints made by the individual and that the covered entity resolves the complaint within a reasonable time frame. Without due process the commenters felt that the internal complaint process is open ended. Some commenters wanted the final rule to include an appeals process for individuals if a covered entity’s determination in regards to the complaint is unfavorable to the individual.

Response: We do not require covered entities to implement any particular due process or appeals process for complaints, because we are concerned about the burden this could impose on covered entities. We provide individuals with an alternative to take their complaints to the Secretary. We believe that this provides incentives for...
covered entities to implement a complaint process that resolves complaints to individuals’ satisfaction.

Comment: Some commenters felt that the individual making the complaint should exhaust all other avenues to resolve their issues before filing a complaint with the Secretary. A number of commenters felt that any complaint being filed with the Secretary should include documentation of the reviews done by the covered entity.

Response: We reject these suggestions, for two reasons. First, we want to avoid establishing particular process requirements for covered entities’ complaint programs. Also, this rule does not require the covered entity to share any information with the complainant, only to document the receipt of the complaint and the resolution, if any. Therefore, we cannot expect the complainant to have this information available to submit to the Secretary.

Second, we believe the individual making the complaint should have the right to share the complaint with the Secretary at any point in time. This approach is consistent with existing civil rights enforcement programs for which the Department is responsible. Based on that experience, we believe that most complaints will come first to covered entities for disposition.

Comment: Some commenters wanted the Department to prescribe a minimum amount of time before the covered entity could dispose of the complaints. They felt that storing these complaints indefinitely would be cumbersome and expensive.

Response: We agree, and in the final rule require entities to keep all items that must be documented, including complaints, for at least six years from the date of creation.

Comments: Some commenters objected to the need for covered entities to have at least one employee, if not more, to deal with complaints. They felt that this would be costly and is redundant in light of the designation of a contact person to receive complaints.

Response: We do not require assignment of dedicated staff to handle complaints. The covered entity can determine staffing based on its needs and business practices. We believe that consumers need one clear point of contact for complaints, in order that this provision effectively inform consumers how to lodge complaints and so that the complaint will get to someone who knows how to respond. The contact person (or office) is for receipt of complaints, but need not handle the complaints.

Section 164.530(e)—Sanctions

Comment: Commenters argued that most covered entities already have strict sanctions in place for violations of a patient’s privacy, either due to current laws, contractual obligations, or good operating practices. Requiring covered entities to create a formal sanctioning process would be superfluous.

Response: We believe it is important for the covered entity to have these sanction policies and procedures documented so that employees are aware of what actions are prohibited and punishable. For entities that already have sanctions policies in place, it should not be problematic to document those policies. We do not define the particular sanctions that covered entities must impose.

Comment: Several commenters agreed that training should be provided and expectations should be clear so that individuals are not sanctioned for doing things that they did not know were wrong or inappropriate. A good faith exception should be included in the final rule to protect these individuals.

Response: We agree that employees should be trained to understand the covered entity’s expectations and understand the consequences of any violation. This is why we are requiring each covered entity to train its workforce. However, we disagree that a good faith exception is explicitly needed in the final rule. We leave the details of sanctions policies to the discretion of the covered entity. We believe it is more appropriate to leave this judgment to the covered entity that will be familiar with the circumstances of the violation, rather than to specify such requirements in the regulation.

Comment: Some commenters felt that the sanctions need to reach business partners as well, not just employees of the covered entities. These commenters felt all violators should be sanctioned, including government officials and agencies.

Response: All members of a covered entity’s workforce are subject to sanctions for violations, including government officials and agencies.

Comments: Some commenters appreciated the flexibility left to the covered entities to determine sanctions. However, some were concerned that the covered entity would need to predict each type of violation and the associated sanction. They argue that, if the Department could not determine this in the NPRM, then the covered entities should be allowed to come up with sanctions as appropriate at the time of the violation. Some commenters wanted a better explanation and understanding of what HHS’ expectation is of when it is appropriate to apply sanctions. Some commenters felt that the sanctioning requirement is nebulous and requires independent judgment of compliance; as a result it is hard to enforce. Offending individuals may use the vagueness of the standard as an defense.

Response: We agree with the commenters that argue that covered entities should be allowed to determine the specific sanctions as appropriate at the time of the violation. We believe it is more appropriate to leave this judgment to the covered entity, because the covered entity will be familiar with the circumstances of the violation and the best way to improve compliance.

Comment: A commenter felt that the self-imposition of this requirement is an inadequate protection, as there is an inherent conflict of interest when an entity must sanction one of its own.

Response: We believe it is in the covered entity’s best interests to appropriately sanction those individuals who do not follow the outlined policies and procedures. Allowing violations to go unpunished may lead bigger problems later, and result in complaints being registered with the Department by aggrieved parties and/or an enforcement action.

Comment: This provision should cover all violations, not just repeat violations.

Response: We do not limit this requirement to repeat offenses.

Section 164.530(f)—Duty To Mitigate

Comments: A few commenters felt that any duty to mitigate would be onerous, especially for small entities. One commenter supported an affirmative duty to mitigate for employees of the covered entity, as long as there is no prescribed mitigation policy. One commenter stated that a requirement for mitigation is unnecessary because any prudent entity would do it.

Some practitioner organizations as well as a health plan, expressed concern about the obligation to mitigate in the context of the business associate relationship. Arguing that it is unnecessary for the regulation to explicitly extend the duty to mitigate to business associates, commenters noted that: Any prudent entity would discipline a vendor or employee that violates a regulation. The matter is best left to the terms of the contract, and that it is difficult and expensive for a
business associate to have a separate set of procedures on mitigation for each client/provider. One commenter suggested that the federal government should fund the monitoring needed to administer the requirement.

Response: Eliminating the requirement to mitigate harm would undermine the purposes of this rule by reducing covered entities’ accountability to their patients for failure to protect their confidential data. To minimize burden, we do not prescribe what mitigation policies and procedures must be implemented. We require only that the covered entity mitigate harm. We also assume that violations will be rare, and so the duty to mitigate harm will rarely be triggered. To the extent a covered entity already has methods for mitigating harm, this rule will not pose significant burden, since we don’t require the covered entity to follow any prescribed method or set of rules. We also modify the NPRM to impose the duty to mitigate only where the covered entity has actual knowledge of harm. Further reducing burden, the rule requires mitigation “to the extent practicable.” It does not require the covered entity to eliminate the harm unless that is practicable. For example, if protected health information is inadvertently provided to a third party without authorization in a domestic abuse situation, the covered entity would be expected to promptly contact the patient as well as appropriate authorities and apprise them of the potential danger.

The harm to the individual is the same, whether the privacy breach was caused by a member of the covered entity’s workforce, or by a contractor. We believe the cost of this requirement to be minimal for covered entities that engage in prudent business practices for exchanging protected health information with their business associates.

Comment: A few commenters noted that it is difficult to determine whether a violation has resulted in a deleterious effect, especially as the entity cannot know all places to which information has gone and uses that have been made of it. Consequently, there should be a duty to mitigate even if a deleterious effect cannot be shown, because the individual has no other redress.

Response: As noted above, this provision only applies if the covered entity has actual knowledge of the harm, and requires mitigation “to the extent practicable.” The covered entity is expected to take reasonable steps based on knowledge of where the information has been disclosed, how it might be used to cause harm to the patient or another individual, and what steps can actually have a mitigating effect in that specific situation.

Comments: Commenters stated that the language of the regulation was in some places vague and imprecise thus providing covered entities with insufficient guidance and allowing variation in interpretation. Commenters also noted that this could result in inconsistency in implementation as well as permitting such inconsistency to be used as a defense by an offending entity. Particular language for which at least one commenter requested clarification included “reasonable steps” and what is entailed in the duty to mitigate.

Response: We considered ways in which we might increase specificity, including defining “to the extent practicable” and “reasonable steps” and relating the mitigating action to the deleterious impact. While this approach could remove from the covered entity the burden of decision-making about actions that actually need to be taken, we believe that other factors outweighed this potential benefit. Not only would there be a loss of desirable flexibility in implementation, but it would not be possible to define “to the extent practicable” in a way that makes sense for all types of covered entities. We believe that allowing flexibility and judgment by those familiar with the circumstances to dictate the approach is the best approach to mitigating harm.

Section 164.530(g)—Refraining From Intimidating or Retaliatory Acts

Comment: Several commenters stated that the regulation should prohibit covered entities from engaging in intimidating or retaliatory acts against any person, not just against the “individual,” as proposed. They suggested adding “or other person or entity” after “any individual.”

Response: We agree, and allow any person to file a compliant with the Secretary. “Person” is not limited to natural persons, but includes any type of organization, association or group such as other covered entities, health oversight agencies and advocacy groups.

Comment: A few commenters suggested deleting this provision in its entirety. One commenter indicated that the whistleblower and retaliation provisions could be inappropriately used against a hospital and that the whistleblower’s ability to report numerous violations will result in a dangerous expansion of liability. Another commenter stated that covered entities would not take action against an employee who had violated the employer’s privacy provisions if this employee files a complaint with the Secretary.

Several commenters suggested deleting “in any manner” and “or opposing any act or practice made unlawful by this subpart” in § 164.522(d)(4). The commenters indicated that, as proposed, the rule would make it difficult to enforce compliance within the workforce. One commenter stated that the proposed § 164.522(d)(4) “is extremely broad and may allow an employee to reveal protected health information to fellow employees, the media and others (e.g., an employee may show a medical record to a friend or relative before filing a complaint with the Department). This commenter further stated that covered entities will “absolutely be prevented from prohibiting such conduct.” One commenter suggested adding that a covered entity may take disciplinary action against any member of its work force or any business partner who uses or discloses individually identifiable health information in violation of this subpart in any manner other than through the processes set forth in the regulation.

Response: To respond to these comments, we make several changes to the proposed provision.

First, where the activity does not involve the filing of a complaint under § 160.306 of this part or participation in an investigation or proceeding initiated by the government under the rule, we delete the phrase “in any manner” and add a requirement that the individual’s opposition to “any act or practice” made unlawful by this subpart be in good faith, and that the expression of that opposition must be reasonable. Second, we add a requirement that the individual’s opposition to “any act or practice” made unlawful by this subpart must not involve a disclosure of protected health information that is in violation of this subpart. Thus, the employee who discloses protected health information to the media or friends is not protected. In providing interpretations of the retaliation provision, we will consider existing interpretations of similar provisions such as the guidance issued by EEOC in this regard.

Section 164.530(h)—Waiver of Rights

There are no comments directly about this section because it was not included in the proposed rule.

Section 164.530(i)—Policies and Procedures and § 164.530(j)—Documentation Requirements

Comments: Many of the comments to this provision addressed the costs and
complexity of the regulation as a whole, not the additional costs of documenting policies and procedures per se. Some did, either implicitly or explicitly, object to the need to develop and document policies and procedures as creating excessive administrative burden. Many of these commenters also asserted that there is a contradiction between the administrative burden of this provision and one of the statutory purposes of this section of the HIPAA to reduce costs through administrative simplification. Suggested alternatives were generally reliance on existing regulations and ethical standards, or on current business practices.

Response: A specific discussion of cost and burden is found in the Regulatory Impact Analysis of this final rule.

We do not believe there is a contradiction between the administrative costs of this provision and of the goal of administrative simplification. In the Administrative Simplifications of the HIPAA, Congress combined a mandate to facilitate the efficiencies and cost savings for the health care industry that the increasing use of electronic technology affords, with a mandate to improve privacy and confidentiality protections. Congress recognized, and we agree, that the benefits of electronic commerce can also cause increased vulnerability to inappropriate access and use of medical information, and so must be balanced with increased privacy protections. By including the mandate for privacy standards in section 264 of the HIPAA, Congress determined that existing regulations and ethical standards, and current business practices were insufficient to provide the necessary protections.

Congress mandated that the total benefits associated with administrative simplification must outweigh its costs, including the costs of implementing the privacy regulation. We are well within this mandate.

Comments: Several commenters suggested that the documentation requirements not be established as a standard under the regulation, because standards are subject to penalties. They recommend we delete the documentation standards and instead provide specific guidance and technical assistance. Several commenters objected to the suggestion in the NPRM that professional associations assist their members by developing appropriate policies for their membership. Several commentators representing professional associations believed this to be an onerous and costly burden for the associations, and suggested instead that we develop specific models which might require only minor modification. Some of these same associations were also concerned about liability issues in developing such guidelines. One commenter argued that sample forms, procedures, and policies should be provided as part of the Final Rule, so that practitioners would not be overburdened in meeting the demands of the regulations. They urged us to apply this provision only to larger entities.

Response: The purpose of requiring covered entities to develop policies and procedures for implementing this regulation is to ensure that important decisions affecting individuals’ rights and privacy interests are made thoughtfully, not on an ad hoc basis. The purpose of requiring covered entities to maintain written documentation of these policies is to facilitate workforce training, and to facilitate creation of the required notice of information practices. We further believe that requiring written documentation of key decisions about privacy will enhance accountability, both within the covered entity and to the Department, for compliance with this regulation.

We do not include more specific guidance on the content of the required policies and procedures because of the vast difference in the size of covered entities and types of covered entities’ businesses. We believe that covered entities should have the flexibility to design the policies and procedures best suited to their business and information practices. We do not exempt smaller entities, because the privacy of their patients is no less important than the privacy of individuals who seek care from large providers. Rather, to address this concern we ensure that the requirements of the rule are flexible so that smaller covered entities need not follow detailed rules that might be appropriate for larger entities with complex information systems.

We understand that smaller covered entities may require some assistance, and intend to provide such technical assistance after publication of this rule. We hope to work with professional associations and other groups that target classes of providers, plans and patients, in developing specialized material for these groups. Our discussions with several such organizations indicate their intent to work on various aspects of model documentation, including forms. Because the associations’ comments regarding concerns about liability did not provide sufficient details, we cannot address them here.

Comment: Many commenters discussed the need for a recognition of scalability of the policies and procedures of an entity based on size, capabilities, and needs of the participants. It was noted that the actual language of the draft regulations under §164.520 did not address scalability, and suggested that some scalability standard be formally incorporated into the regulatory language and not rely solely on the NPRM introductory commentary.

Response: In §164.530(i)(1) of the final rule, we specify that we require covered entities to implement policies and procedures that take into account the size of the covered entity and the types of activities that relate to protected health information undertaken by the covered entity.

Comment: One commenter objected to our proposal to allow covered entities to make uses or disclosures not permitted by their current notice if a compelling reason exists to make the use or disclosure and the entity documents the reasons and changes its policies within 30 days of the use or disclosure. The commenter argued that the subjective language of the regulation might give entities the ability to engage in post hoc justifications for violations of their own information practices and policies. The commenter suggested that there should be an objective standard for reviewing the covered entity’s reasons before allowing the covered entity to amend its policies.

Response: We eliminate this provision from the final rule. The final rule requires each covered entity to include in its notice of information practices a statement of all permitted uses under this rule, not just those in which the covered entity actually engages in at the time of that notice.

Comment: Some commenters expressed concern that the required retention period in the NPRM applied to the retention of medical records.

Response: The retention requirement of this regulation only applies to the documentation required by the rule, for example, keeping a record of accounting for disclosures or copies of policies and procedures. It does not apply to medical records.

Comments: Comments on the six year retention period were mixed. Some commenters endorsed the six-year retention period for maintaining documentation. One of the comments stated this retention period would assist physicians legally. Other commenters believed that the retention period would have an undue burden. One commenter noted that most State Board of Pharmacy regulations require
Section 164.530(k)—Group Health Plans

There were no comments directly about this section because it was not included in the proposed rule.

Section 164.532—Transition Provisions

Comment: Commenters urged the Department to clarify whether the “reach of the transition requirement” is limited to a particular time frame, to the provider’s activities in a particular job, or work for a particular employer. For example, one commenter questioned how long a nurse is a covered entity after she moves from a job reviewing files with protected health information to an administrative job that does not handle protected health information; or whether an occupational health nurse who used to transmit first reports of injury to her company’s workers’ compensation carrier last year but no longer does so this year because of a carrier change still is a covered entity.

Response: Because this comment addresses a question of enforcement, we will address it in the enforcement regulation.

Comment: Several commenters sought clarification as to the application of the privacy rule to research already begun prior to the effective date or compliance date of the final rule. These commenters argued that applying the privacy rule to research already begun prior to the rule’s effective date would substantially overburden IRBs and that the resulting research interruptions could harm participants and threaten the reliability and validity of conclusions based upon clinical trial data. The commenters recommended that the rule grandfather in any ongoing research that has been approved by and is under the supervision of an IRB.

Response: We generally agree with the concerns raised by commenters. In the final rule, we have provided that covered entities may rely upon consents, authorizations, or other express legal permissions obtained from an individual for a specific research project that includes the treatment of individuals to use or disclose protected health information the covered entity obtained after the applicable compliance date of this rule as long as certain requirements are met. These consents, authorizations, or other express legal permissions may specify a use or disclosure of individually identifiable health information for purposes of the project or be a general consent of the individual to participate in the project. A covered entity may use or disclose protected health information it created or received before or after the applicable compliance date of this rule for purposes of the project provided that the covered entity complies with all limitations expressed in the consent, authorization, or permission.

In regard to research projects that include the treatment of individuals, such as clinical trials, covered entities engaged in these projects will have obtained at least an informed consent from the individual to participate in the project. In some cases, the researcher may also have obtained a consent, authorization, or other express legal permission to use or disclose individually identifiable health information in a specific manner. To avoid disrupting ongoing research and because the participants have already agreed to participate in the project (which expressly permits or implies the use or disclosure of their protected health information), we have grandfathered in these consents, authorizations, and other express legal permissions.

It is unlikely that a research project that includes the treatment of individuals could proceed under the Common Rule with a waiver of informed consent. However, to the extent such a waiver has been granted, we believe individuals participating in the project should be able to determine how their protected health information is used or disclosed. Therefore, we require researchers engaged in research projects that include the treatment of individuals who obtained an IRB waiver of informed consent under the Common Rule to obtain an authorization or a waiver of such authorization from an IRB or a privacy board under §164.512(i) of this rule.

If a covered entity obtained a consent, authorization, or other express legal permission from the individual who is the subject of the research, it would be able to rely upon that consent, authorization, or permission, consistent with any limitations it expressed, to use or disclose the protected health information it created or received prior to or after the compliance date of this regulation. If a covered entity wishes to use or disclose protected health information but to such consent, authorization, or permission exists, it must obtain an authorization pursuant to §164.508 or obtain a waiver of authorization under §164.512(i). To the extent such a project is ongoing and the researchers are unable to locate the individuals whose protected health information they are using or disclosing, we believe the IRB or privacy board under the criteria set forth in §164.512(i) will be able to take that circumstance into account when conducting its review. In most instances, we believe this type of research will be able to obtain a waiver of authorization and be able to continue uninterrupted.

Comment: Several comments raised questions about the application of the rule to individually identifiable information created prior to (1) the effective date of the rule, and (2) the compliance dates of the rule. One commenter suggested that the rule should apply only to information gathered after the effective date of the final rule. A drug manufacturer asked what would be the effect of the rule on research on records compiled before the effective date of the rule.

Response: We disagree with the commenter’s suggestion. The requirements of this regulation apply to all protected health information held by a covered entity, regardless of when or how the covered entity obtained the information. Congress required us to adopt privacy standards that apply to individually identifiable health information. While it limited the compliance date for health plans, covered health care providers, and healthcare clearinghouses, it did not provide similar limiting language with regard to individually identifiable health information. Therefore, uses and disclosures of protected health information made by a covered entity after the compliance date of this regulation must meet the requirements of these rules. Uses or disclosures of individually identifiable health information made prior to the compliance date are not affected; covered entities will not be sanctioned under this rule based on past uses or disclosures that are inconsistent with this regulation.

Consistent with the definition of individually identifiable health information in HIPAA, of which protected health information is a subset, we do not distinguish between protected health information in research records and protected health information in other records. Thus, a covered entity’s research records are subject to this regulation to the extent they contain protected health information.
Section 164.534—Effective Date and Compliance Date

Section 1175(b)(1)(A) of the Act requires all covered entities other than small health plans to comply with a standard or implementation specification “not later than 24 months after the date on which an initial standard or implementation specification is adopted or established”; section 1175(b)(1)(B) provides that small health plans must comply not later than 36 months after that date. The proposed rule provided, at proposed § 164.524 (which was titled “Effective date”), that a covered entity was required to be in compliance with the proposed subpart E not later than 24 months following the effective date of the rule, except that small health plans were required to be in compliance not later than 36 months following the effective date of the rule. The final rule retains these dates in the text of Subpart E, but denominate them as “compliance dates,” to distinguish the statutory dates from the date on which the rules become effective. The effective date of the final rules is 60 days following publication in the Federal Register.

Meaning of Effective Date

Comment: A number of commenters expressed confusion about the difference between the effective date of the rule and the effective date on which compliance was required (the statutory compliance dates set out at section 1175(b)(1), summarized above).

Response: The Department agrees that the title of proposed § 164.524 was confusing. Similar comments were received on the Transactions Rule. Those comments were addressed by treating the “effective date” of the rule as the date on which adoption takes effect (the “Effective Date” heading at the beginning of the preamble), while the dates provided for by section 1175(b)(1) of the statute were denominated as “compliance dates.” These changes are reflected in the definition of “compliance date” in § 160.103 below (initially published as part of the Transactions Rule) and are also reflected at § 164.524 below.

Section 164.524 below has also been reorganized to follow the organization of the analogous provisions of the Transactions Rule. The underlying policy, however, remains as proposed.

Extend the Compliance Date

Comment: Some commenters recommended that the compliance date be extended. A number of comments objected that the time frame for compliance with the proposed standards is unrealistically short. It was pointed out that providers and others would have to do the following, among other things, prior to the applicable compliance date: assess their current systems and departments, determine which state laws were preempted and which were not, update and reprogram computer systems, train workers, create and implement the required privacy policies and procedures, and create or update contracts with business partners. One comment also noted that the task of coming into compliance during the same time period with the other regulations being issued under HIPAA would further complicate the task. These comments generally supported an extension of the compliance dates by one or more years. Other comments supported extending the compliance dates on the ground that the complexity of the tasks involved in implementing the regulation would be a heavy financial burden for providers and others, and that they should be given more time to comply, in order to spread the associated capital and workforce costs over a longer period. It was also suggested that there be provision for granting extensions of the compliance date, based on some criteria, such as a good faith effort to comply or that the compliance dates be extended to two years following completion of a “state-by-state preemption analysis” by the Department.

Response: The Secretary acknowledges that covered entities will have to make changes to their policies and procedures during the period between the effective date of the rules below and the applicable compliance dates. The delayed compliance dates which the statute provides for constitute a recognition of the fact changes will be required and are intended to permit covered entities to manage and implement these changes in an orderly fashion. However, because the time frames for compliance with the initial standards are established by statute, the Secretary has no discretion to extend them: Compliance is statutorily required “not later than” the applicable compliance date. Nor do we believe that it would be advisable to accomplish this result by delaying the effective date of the final rules beyond 60 days. Since the Transactions Rule is now in effect, it is imperative to bring the privacy protections afforded by the rules below into effect as soon as possible. Retaining the delayed effective date of 60 days, as originally contemplated, will minimize the gap between transactions covered by those rules and not also afforded protection under the rules below.

Phase-in Requirements

Comment: Several comments suggested that the privacy standards be phased in gradually, to ease the manpower and cost burdens of compliance. A couple of equipment manufacturing groups suggested that updating of various types of equipment would be necessary for compliance purposes, and suggested a phased approach to this—for example, an initial phase consisting of preparation of policies, plans, and risk assessments, a second phase consisting of bringing new equipment into compliance, and a final phase consisting of bringing existing equipment into compliance.

Response: As noted in the preceding response, section 1175(b)(1) does not allow the Secretary discretion to change the time frame within which compliance must be achieved. Congress appears to have intended the phasing in of compliance to occur during the two-year compliance period, not thereafter.

Compliance Gap Vis-a-Vis State Laws and Small Health Plans

Comment: Several comments stated that, as drafted, the preemption provisions would be effective as of the rule’s effective date (i.e., 60 days following publication), even though covered entities would not be required to comply with the rules for at least another two years. According to these comments, the “preempted” state laws would not be in effect in the interim, so that the actual privacy protection would decrease during that period. A couple of comments also expressed concern about how the preemption provisions would work, given the one-year difference in applicable compliance dates for small health plans and other covered entities. A state medical society pointed out that this gap would also be very troublesome for providers who deal with both “small health plans” and other health plans.

One comment asked what entities that decided to come into compliance early would have to do with respect to conflicting state laws and suggested that, since all parties “need to know with confidence which laws govern at the moment,” there should be uniform effective dates.

Response: We agree that clarification is needed with respect to the applicability of state laws in the interim between the effective date and the compliance dates. What the comments summarized above appeared to assume is that the preemption provisions of section 1178 operate to broadly and generally invalidate any state law that comes within their ambit. We do not agree that this is the effect of section
1178. Rather, what section 1178 does—where it acts to preempt—is to preempt the state law in question with respect to the actions of covered entities to which the state law applies. Thus, if a provision of state law is preempted by section 1178, covered entities within that state to which the state law applies do not have to comply with it, and must instead comply with the contrary federal standard, requirement, or implementation specification. However, as compliance with the contrary federal standard, requirement, or implementation specification is not required until the applicable compliance date, we do not view the state law in question as meeting the test of being “contrary.” That is, since compliance with the federal standard, requirement, or implementation standard is not required prior to the applicable compliance date, it is possible for covered entities to comply with the state law in question. See § 160.202 (definition of “contrary”). Thus, since the state law is not “contrary” to an applicable federal standard, requirement, or implementation specification in the period before which compliance is required, it is not preempted.

Several implications of this analysis should be spelled out. First, one conclusion that flows from this analysis is that preemption is specific to covered entities and does not represent a general invalidation of state law, as suggested by many commenters. Second, because preemption is covered entity-specific, preemption will occur at different times for small health plans than it will occur for all other covered entities. That is, the preemption of a given state law for a covered entity, such as a provider, that is covered by the 24-month compliance date of section 1175(b)(1)(A) will occur 12 months earlier than the preemption of the same state law for a small health plan that is covered by the 36-month compliance date of section 1175(b)(1)(B). Third, the preemption occurs only for covered entities; a state law that is preempted under section 1178(b) would not be preempted for persons and entities to which it applies who are not covered entities. Thus, to the extent covered entities or non-covered entities follow the federal standards on a voluntary basis (i.e., the covered entity prior to the applicable compliance date, the non-covered entity at any time), the state law in question will not be preempted for them.

**Small Health Plans**

**Comment:** Several comments, pointing to the “Small Business” discussion in the preamble to the proposed rules, applauded the decision to extend the compliance date to three years for small businesses. It was requested that the final rules clarify that the three year compliance date applies to small doctors offices and other small entities, as well as to small health plans.

**Response:** We recognize that our discussion in the preamble to the proposed rules may have suggested that more covered entities came within the 36 month compliance date than is in fact the case. Again, this is an area in which we are limited by statute. Under section 1175(b) of the Act, only small health plans have three years to come into compliance with the standards below. Thus, other “small businesses” that are covered entities must comply by the two-year compliance date.

**Coordination With the Security Standard**

**Comment:** Several comments suggested that the security standard be issued either with or after the privacy standards. It was argued that both sets of standards deal with protecting health information and will require extensive personnel training and revisions to business practices, so that coordinating them would make sense. An equipment manufacturers group also pointed out that it would be logical for covered entities and their business partners to know what privacy policies are required in purchasing security systems, and that “the policies on privacy are implemented through the security standards rather than having already finalized security standards drive policy.”

**Response:** We agree with these comments, and are making every effort to coordinate the final security standards with the privacy standards below. The privacy standards below are being published ahead of the security standards, which is also responsive to the stated concerns.

**Prospective Application**

**Comment:** Several comments raised questions about the application of the rule to individually identifiable information created prior to (1) the effective date of the rule, and (2) the compliance dates of the rule. One provider group suggested that the rule should apply only to information gathered after the effective date of the final rule. A drug manufacturer asked what would be the effect of the rule on research on records compiled before the effective date of the rule.

**Response:** These comments are addressed in connection with the discussion of § 164.532 above.

**Impact Analyses**

**Cost/Benefit Analysis**

**Comment:** Many commenters made general statements to the effect that the cost estimates for implementing the provisions of the proposed regulation were incomplete or greatly understated.

**Response:** The proposal, including the cost analysis, is, in effect, a first draft. The purpose of the proposal was to solicit public comment and to use those comments to refine the final regulation. As a result of the public comment, the Department has significantly refined our initial cost estimates for implementing this regulation. The cost analysis below reflects a much more complete analysis of the major components of the regulation than was presented in the proposal.

**Comment:** Numerous commenters noted that significant areas of potential cost had not been estimated and that if they were estimated, they would greatly increase the total cost of the regulation. Potential cost areas identified by various respondents as omitted from the analyses include the minimum disclosure requirements; the requisite monitoring by covered entities of business partners with whom they share private health information; creation of de-identified information; internal complaint processes; sanctions and enforcement; the designation of a privacy official and creation of a privacy board; new requirements for research/ optional disclosures; and future litigation costs.

**Response:** We noted in the proposed rule that we did not have data from which to estimate the costs of many provisions, and solicited comments providing such data. The final analysis below reflects the best estimate possible for these areas, based on the information available. The data and the underlying assumptions are explained in the cost analysis section below.

**Comment:** A number of comments suggested that the final regulation be delayed until more thorough analyses could be undertaken and completed. One commenter stated that the Department should refrain from implementing the regulation until a more realistic assessment of costs could be made and include local governments in the process. Similarly, a commenter requested that the Department assemble an outside panel of health industry experts, including systems analysts, legal counsel, and management consultants to develop stronger estimates.

**Response:** The Department has engaged in extensive research, data collection and fact-finding to improve
the quality of its economic analysis. This has included comments from and discussions with the kinds of experts one commenter suggested. The estimates represent a reasonable assessment of the policies proposed.

**Comment:** Several commenters indicated that the proposed regulation would impose significant new costs on providers’ practices. Furthermore, they believe that it runs counter to the explicit statutory intent of HIPAA’s Administrative Simplification provisions which require that “any standard adopted * * * shall be consistent with the objective of reducing the administrative costs of providing and paying for health care.”

**Response:** As the Department explained in the Transactions Rule, this provision applies to the administrative simplification regulations of HIPAA in the aggregate. The Transactions Rule is estimated to save the health care system $29.9 billion in nominal dollars over ten years. Other regulations published pursuant to the administrative simplification authority in HIPAA, including the privacy regulation, will result in costs, but these costs are within the statutory directive so long as they do not exceed the $29.9 billion in estimated savings. Furthermore, as explained in the Transactions Rule, and the preamble to this rule, assuring privacy is essential to sustaining many of the advances that computers will provide. If people do not have confidence that their medical privacy will be protected, they will be much less likely to allow their records to be used for any purpose or might even avoid obtaining necessary medical care.

**Comment:** Several commenters criticized the omission of aggregate, quantifiable benefit estimates in the proposed rule. Some respondents argued that the analysis in the proposed rule used “de minimis” cost estimates to argue only that benefits would certainly exceed such a low barrier. These commenters further characterized the benefits analysis in the Notice of Proposed Rulemaking as “hand waving” used to divert attention from the fact that no real cost-benefit comparison is presented. Another commenter stated that the benefit estimates rely heavily on anecdotal and unsubstantiated inferences. This respondent believes that the benefit estimates are based on postulated, but largely unsubstantiated causal linkages between increased privacy and earlier diagnosis and medical treatment.

**Response:** The benefits of privacy are difficult to quantify. The benefits discussion in the proposal reflects this difficulty. The examples presented in the proposal were meant to be illustrative of the benefits based on a few areas of medicine where some relevant data was available. Unfortunately, no commenters provided either a better methodological approach or better data for assessing the overall benefits of privacy. Therefore, we believe the analysis in the proposal represents a valid illustration of the benefits of privacy, and we do not believe it is feasible to provide an overall dollar estimate of the benefits of privacy in the aggregate.

**Comment:** One commenter criticized the benefit analysis as being incomplete because it did not consider the potential cost of new treatments that might be engendered by increased confidence in medical privacy resulting from the regulation.

**Response:** There is no data or model to reliably assess such long-term behavioral and scientific changes, nor to determine what portion of the increasingly rapid evolution of new improved treatments might stem from improved privacy protections. Moreover, to be complete, such analysis would have to include the savings that might be realized from earlier detection and treatment. It is not possible at this time to project the magnitude or even the direction of the net effects of the response to privacy that the commenter suggests.

**Scope of the Regulation**

**Comment:** Numerous commenters noted the potential cost and burden of keeping track in medical records of information which had been transmitted electronically, which would be subject to the rule, as opposed to information that had only been maintained in paper form.

**Response:** This argument was found to have considerable merit and was one of the reasons that the Department concluded that the final regulation should apply to all medical records maintained by entities including information that had never been transmitted electronically. The costs analysis below reflects the change in scope.

**Notice Requirements**

**Comment:** Several commenters expressed their belief that the administrative and cost burdens associated with the notice requirements were understated in the proposed rule. While some respondents took issue with the policy development cost estimates associated with the notice, more were focused on its projected implementation and production costs. For example, one respondent stated that determining “first service” would be an onerous task for many small practices, and that provider staff will now have to manually review each patient’s chart or access a computer system to determine whether the patient has been seen since implementation of the rule.

**Response:** The policy in the final rule has been changed to make the privacy policy notice to patients less burdensome. Providers will be able to distribute the notice when a patient is seen and will not have to distribute it to a patient more than once, unless substantive changes are made in the notice. This change will significantly reduce the cost of distributing the privacy notices.

**Comment:** Some commenters also took issue with the methodology used to calculate the cost estimates for notices. These respondents believe that the survey data used in the proposed rule to estimate the costs (i.e., “encounters,” “patients,” and “episodes” per year) are very different concepts that, when used together, render the purported total meaningless. Commenters further stated that they can verify the estimate of $43 million patients cited as being seen at least once every five years.

**Response:** In the course of receiving treatment, a patient may go to a number of medical organizations. For example, a person might see a doctor in a physician’s office, be admitted to a hospital, and later go to a pharmacy for medication. Each time a person “encounters” a facility, a medical record may be started or additions made to an existing record. The concept in the proposal was to identify the number of record sets that a person might have for purposes of estimating notice and copying costs. For example, whether a person made one or ten visits in the course of a year to a specific doctor would, for our purposes, be one record set because in each visit the doctor would most likely be adding information to an existing medical record. The comments demonstrated that we had not explained the concept well. As explained below we modified the concept to more effectively measure the number of record sets that exist and explain it more clearly.

**Comment:** Several commenters criticized the lack of supporting evidence for the cost estimates of notice development and dissemination. Another opinion voiced in the comments is that estimated cost for plans of $.075 per insured person is so low that it may cover postage, but it
cannot include labor and capital usage costs.

Response: Based on comments and additional fact finding, the Department was able to gain a better understanding of how covered entities would develop policies and disseminate information. The cost analysis below explains more fully how we derived the final cost estimates for these areas.

Comment: A commenter noted that privacy policy costs assume that national associations will develop privacy policies for members but HHS analysis does not account for the cost to the national associations. A provider cost range of $300–$3,000 is without justification and seems low.

Response: The cost to the national associations was included in the proposal estimates, and it is included in the final analysis (see below).

Comment: A commenter states that the notice costs discussion mixes the terms "patients", "encounters" and "episodes" and 397 million encounter estimate is unclear.

Response: A clearer explanation of the concepts employed in this analysis is provided below.

Systems Compliance Costs

Comment: Numerous commenters questioned the methodology used to estimate the systems compliance cost and stated that the ensuing cost estimates were grossly understated. Some stated that the regulation will impose significant information technology costs to comply with requirement to account for disclosures, additional costs for hiring new personnel to develop privacy policies, and higher costs for training personnel.

Response: Significant comments were received regarding the cost of systems compliance. In response, the Department retained the assistance of consultants with extensive expertise in health care information technology. We have relied on their work to revise our estimates, as described below. The analysis does not include "systems compliance" as a cost item, per se. Rather, in the final analysis we organized estimates around the major policy provisions so the public could more clearly see the costs associated with them. To the extent that the policy might require systems changes (and a number of them do), we have incorporated those costs in the provision’s estimate.

Comment: Items explicitly identified by commenters as significantly adding to systems compliance costs include: tracking disclosures of protected health information and patient authorizations; restricting access to the data; accommodating minimum disclosure provisions; installing notices and disclaimers; creating de-identified data; tracking uses of protected health information by business partners; tracking amendments and corrections; increased systems capacity; and annual systems maintenance. The commenters noted that some of the aforementioned items are acknowledged in the proposed rule as future costs to covered entities, but several others are singularly ignored.

Response: The Department recognizes the validity of much of this criticism. Unfortunately, other than general criticism, commenters provided no specific data or methodological information which might be used to improve the estimates. Therefore, the Department retained consultants with extensive expertise in these areas to assess the proposed regulation, which helped the Department refine its policies and cost estimates.

In addition, it is important to note that the other HIPAA administrative simplification regulations will require systems changes. As explained generally in the cost analysis for the electronic Transactions rule, it is assumed that providers and vendors will undertake systems changes for these regulations collectively, thereby minimizing the cost of changes.

Inspection and Copying

Comment: Numerous commenters disagreed with the cost estimates in the NPRM for inspection and copying of patient records, believing that they were too low.

Response: The Department has investigated the potential costs through a careful reading of the comments and subsequent factfinding discussions with a variety of providers. We believe the estimates, explained more fully below, represent a reasonable estimate in the aggregate. It is important to note, however, that this analysis is not measuring the cost of all inspection and copying because a considerable amount of this already occurs. The Department is only measuring the incremental increase likely to occur as a result of this regulation.

Comment: One commenter speculates that, even at a minimum charge of $.50 per page, (and not including search and retrieval charges), costs could run as high as $450 million annually.

Response: The $.50 per page in the proposal represent an average of several data sources. Subsequently, an industry commenter, which provided extensive medical records copying, stated that this was a reasonable average cost. Hence, we retained the number for the final estimate.

Comment: One respondent states that, since the proposed rules give patients the right to inspect and copy their medical records regardless of storage medium, HHS must make a distinction in its cost estimates between records stored electronically and those which must be accessed by manual means, since those costs will differ.

Response: The cost estimates made for regulations are not intended to provide such refined gradations; rather, they are intended to show the overall costs for the regulation as a whole and its major components. For inspections and copying (and virtually all other areas for which estimates are made) estimates are based on averages; particular providers may experience greater or lesser costs than the average cost used in this analysis.

Comment: Several commenters noted that the Department did not appear to include the cost of establishing storage systems, retrieval fees and the cost of searching for records, and that these costs, if included, would significantly increase the Department’s estimate.

Response: Currently, providers keep and maintain medical records and often provide copies to other providers and patients. Therefore, much of the cost of maintaining records already exists. Indeed, based on public comments, the Department has concluded that there will be relatively few additional copies requested as the result of this regulation (see below). We have measured and attributed to this regulation the incremental cost, which is the standard for conducting this kind of analysis.

Comment: A federal agency expressed concern over the proposal to allow covered entities to charge a fee for copying personal health information based on reasonable costs. The agency requests personal health information from many covered entities and pays a fee that it establishes. Allowing covered entities to establish the fee, the agency fears, may cost them significantly more than the current amounts they pay and as a result, could adversely affect their program.

Response: The proposal and the final rule establish the right to access and copy records only for individuals, not other entities; the “reasonable fee” is only applicable to the individual’s request. The Department’s expectation is that other existing practices regarding fees, if any, for the exchange of records not requested by an individual will not be affected by this rule.
Appendix Records (Amendment and Correction)

Comment: The proposed rule estimated the cost of amending and correcting patients’ records at $75 per instance and $260 million per year for small entities. At least one commenter stated that such requests will rise significantly upon implementation of the regulations and increase in direct proportion to the number of patients served. Another commenter described the more subtle costs associated with record amendment and correction, which would include a case-by-case clinical determination by providers on whether to grant such requests, forwarding the ensuing record changes to business partners, and issuing written statements to patients on the reasons for denials, including a recourse for complaints.

Response: The comments were considered in revising the proposal, and the decision was made to clarify in the final regulation that providers must only append the record (the policy is explained further in the preamble and the regulation text). The provider is now only required to note in the medical record any comments from the patient; they may, but are not required to, correct any errors. This change in policy significantly reduces the cost from the initial proposal estimate.

Comment: Several commenters criticized the proposed rule’s lack of justification for assumptions regarding the percentage of patients who request inspection and copying, who also request amendment and correction. Another commenter pointed out that the cost estimate for amendment and correction is dependent on a base assumption that only 1.5 percent of patients will request inspection of their records. As such, if this estimate were too low by just one percentage point, then the estimates for inspection and copying plus the costs for amendment and correction could rise by 67 percent.

Response: Based on information and data received in the public comments, the estimate for the number of people requesting inspection and copying has been revised. No commenter provided specific information on the number of amended record requests that might result, but the Department subsequently engaged in fact-finding and made appropriate adjustments in its estimates. The revisions are explained further below.

Consent and Authorizations

Comment: One respondent indicated that the development, collection, and data entry of all the authorizations will create a new transaction type for employers, health plans, and providers, and result in duplicated efforts among them. This commenter estimates that the costs of mailing, re-mailing, answering inquiries, making outbound calls and performing data entry in newly created authorization computer systems could result in expenses of close to $2.0 billion nationally. Another commenter indicated that authorization costs will be at least double the notice dissemination costs due to the cost of both outbound and return postage.

Response: Public commenters and subsequent factfinding clearly indicate that most providers with patient contact already obtain authorizations for release of records, so for them there is virtually no new cost. Further, this comment does not reflect the actual regulatory requirement. For example, there is no need to engage in mailing and re-mailing of forms, and we do not foresee any reason why there should be any significant calls involved.

Comment: A commenter criticized the percentage (1%) that we used to calculate the number of health care encounters expected to result in requests to withhold the release of protected information. This respondent postulates that even if one in six patients who encounter the U.S. health care system opt to restrict access to their records, the total expected national cost per year could rise to $900 million.

Response: The final regulation requirements regarding the release of protected health information has been substantially changed, thereby greatly reducing the potential cost burden. A fuller explanation of the cost is provided below in the regulatory impact analysis.

Comment: An additional issue raised by commenters was the added cost of seeking authorizations for health promotion and disease management activities, health care operations that traditionally did not require such action.

Response: In the final regulation, a covered entity can use medical information collected for treatment or operations for its own health promotion and disease management efforts without obtaining additional authorization. Therefore, there is no additional cost incurred.

Business Associates

Comment: A number of commenters were concerned about the cost of monitoring business partners. Specifically, one commenter stated that the provisions of the proposed regulation pertaining to business partners would likely force the discontinuation of outsourcing for some functions, thereby driving up the administrative cost of health care.

Response: The final regulation clarifies the obligations of the business associates in assuring confidentiality. As explained in the preamble, business associates must take reasonable steps to assure confidentiality of health records they may have, and the covered entity must take appropriate action if they become aware of a violation of the agreement they have with the business associate. This does not represent an unreasonable burden; indeed, the provider is required to take the same kind of precautions and provide the same kind of oversight that they would in many other kinds of contractual relationships to assure they obtain the quality and level of performance that they would expect from a business associate.

Comment: HHS failed to consider enforcement costs associated with monitoring partners and litigation costs arising from covered entities seeking restitution from business partners whose behavior puts the covered entity at risk for noncompliance.

Response: The Department acknowledged in the proposal that it was not estimating the cost of compliance with the business associates provision because of inadequate information. It requested information on this issue, but no specific information was provided in the comments. However, based on revisions in the final policy and subsequent factfinding, the Department has provided an estimate for this requirement, as explained below.

Training

Comment: Many of the commenters believe that the Department used unrealistic assumptions in the development of the estimated cost of the training provisions and they provided their own estimates.

Response: The commenters’ estimates varied widely, and could not be used by the Department in revising its analysis because there was inadequate explanation of how the estimates were made.

Comment: Several commenters argued that if even an hour of time of each of the entity’s employees is spent on training instead of “work” and they are paid the minimum wage, an entity would incur $100 of cost for training no more than 20 employees. The commenters noted that the provision of health care services is a labor-intensive enterprise, and many covered entities have thousands of employees, most of whom make well in excess of minimum
wage. They questioned whether the estimates include time taken from the employee’s actual duties (opportunity cost) and the cost of a trainer and materials.

**Response:** As explained in more detail below, the Department made extensive revisions in its training estimate, including the number of workers in the health care sector, the cost of workers in training based on average industry wages, and training costs (instructors and materials). The revised estimate is a more complete and accurate estimate of the costs likely to be borne as a result of the final regulation.

**Comment:** One commenter estimated that simply training an employee could have a burdensome impact on his company. He argued, for example, a 10-hour annual requirement takes 0.5% of an employee’s time if they work a 2000-hour year, but factoring in sick and vacation leave, the effects of industry turnover could significantly increase the effect.

**Response:** In the analysis below, the Department has factored in turnover rates, employment growth and greater utilization based on data obtained from broad-based surveys and a public comment.

**Comment:** Some commenters felt that the regulatory training provisions are overly burdensome. Specific concerns centered around the requirement to train all individuals who may come in contact with protected health information and the requirement to have such individuals sign a new certifying statement at least every three years. Some commenters felt that the content of the training program should be left to the discretion of the covered entity.

**Response:** Changes and clarifications in the training requirements are made in the final regulation, explained below. For example, the certification requirement has been eliminated. As in the NPRM, the content of the training program is left to the discretion of the covered entity. These changes are expected to lessen the training burden and are reflected in the final cost estimates.

**Compliance and Enforcement**

**Comment:** A Member of Congress and A Member of Congress and A Member of Congress and A Member of Congress and A Workgroup on Electronic Data Interchange (WEDI) Report, providers will bear the larger share of implementation costs and will save less than payors.

**Response:** The regulatory flexibility analysis below shows generally the marginal effect of the privacy regulation on small entities. Collectively, the HIPAA administrative standards will save money in the health care system.

**Comment:** The cost of implementing privacy regulations, when added to the cost of other required HIPAA regulations, could increase overhead significantly. As shown in the 1993 Workgroup on Electronic Data Interchange (WEDI) Report, providers will bear the larger share of implementation costs and will save less than payors.

**Response:** The regulatory flexibility analysis below shows generally the marginal effect of the privacy regulation on small entities. Collectively, the HIPAA administrative standards will save money in the health care system. As important, given the rapid expansion of electronic commerce, it is probable that small entities would need to comply with standards for electronic commerce in order to complete effectively, even if the standards were voluntary. The establishment of uniform standards through regulation help small entities because they will not have to invest in multiple systems, which is what they would confront if the system remained voluntary.

**Comment:** One respondent believed that the initial and ongoing costs for small provider offices could be as much as 11 times higher than the estimates provided in the proposed rule. Other commenters stated that the estimates for small entities are “absurdly low”.

**Response:** Although there were a number of commenters highly critical of the small business analysis, none provided alternative estimates or even provided a rationale for their statements. Many appeared to assume that all costs associated with medical record confidentiality should be estimated. This represents a misunderstanding of the purpose of the analysis: to estimate the incremental effects of this regulation, i.e., the new costs (and savings) that will result from changes required by the regulation. The Department has made substantial changes in the final small entities analysis (below), reflecting policy changes in the final rule and additional information and data collected by the Department since the issuance of the proposal last fall. We believe that these estimates reasonably reflect the costs that various types of small entities will experience in general, though the actual costs of particular providers might vary considerably based on their current practices and technology.

**Comment:** A respondent expressed the belief that small providers would bear a disproportionate share of the regulation’s administrative burden because of the likelihood of larger companies incurring fewer marginal costs due to greater in-house resources to aid in the legal and technical analysis of the proposed rule.

**Response:** As explained below, the Department does not agree with the assertion that small entities will be disproportionately affected. Based on discussions with a number of groups, the Department expects many professional and trade associations to provide their members with analysis of the regulation, including model policies, statements and basic training materials. This will minimize the cost for most small entities. Providers that use protected health information for voluntary practices, such as marketing or research, are more likely to need specific legal and technical assistance, but these are likely to be larger providers.

**Comment:** Several commenters took issue with the “top-down” approach that we used to estimate costs for small businesses, believing that this methodology provided only a single point estimate, gave no indication of the variation around the estimate, and was subject to numerous methodological errors since the entities to which the numerator pertained may not have been
the same as the denominator. These respondents further recommended that we prepare a “bottom-up” analysis using case studies and/or a survey of providers to refine the estimates.

Response: The purpose of the regulatory flexibility analysis is to provide a better insight into the relative burden of small businesses compared to larger firms in complying with a regulation. There may be considerable variance around average costs within particular industry sectors, even among small businesses within them. The estimates are based on the best data available, including information from the Small Business Administration, the Census Bureau, and public comments.

Comment: A commenter stated that the proposal’s cost estimate does not account for additional administrative costs imposed on physicians, such as requirements to rewrite contracts with business partners.

Response: Such costs are included in the analysis. The comments were directed specifically at the systems compliance cost estimates for small businesses. One respondent maintained that the initial upgrade cost alone would range from $50 thousand to more than $1 million per covered entity.

Response: The cost estimates for systems compliance varied enormously; unfortunately, none of the commenters provided documentation of how they made their estimates, preventing us from comparing their data and assumptions to the Department’s. Because of concern about the costs in this area, however, the Department retained an outside consultant to provide greater expertise and analysis. The product of this effort has been incorporated in the analysis below.

Comment: One commenter stated that just the development and documentation of new health information policies and procedures (which would require an analysis of the federal regulations and state law privacy provisions), would cost far more than the $396 cited in the Notice of Proposed Rulemaking as the average start-up cost for small businesses.

Response: As explained below in the cost analysis, the Department anticipates that most of the policies and procedures that will be required under the final rule will be largely standardized, particularly for small businesses. Thus, much of the work and cost can be done by trade associations and professional groups, thereby minimizing the costs and allowing it to be spread over a large membership base.

Comment: A number of comments criticized the initial estimates for notices, inspection and copying, amendments and correction, and training as they relate to small businesses.

Response: The Department has made substantial revisions in its estimates for all of these areas which is explained below in the regulatory flexibility analysis.

Comment: One commenter noted that there appeared to be a discrepancy in the number of small entities cited. There is no explanation for the difference and no explanation for difference between “establishments” and “entities.”

Response: There are discrepancies among the data bases on the number of “establishments” and “entities” or “firms.” The problem arises because most surveys count (or survey) establishments, which are physical sites. A single firm or entity may have many establishments. Moreover, although an establishment may have only a few employees, the firm may have a large number of workers (the total of all its various establishments) and therefore not be a small entity.

As discussed below, there is some discrepancy between the aggregate numbers we use for the regulatory impact analysis (RIA) and the regulatory flexibility analysis (RFA). We concluded that for purposes of the RFA, which is intended to measure the effects on small entities, we would use Small Business Administration data, which defines entities based on revenues rather than physical establishments to count the number of small entities in various SIC. This provides a more accurate estimate of small entities affected. For the RIA, which is measuring total effects, we believe the establishment based surveys provide a more reliable count.

Comment: Because small businesses must notify patients of their privacy policies on patients’ first visit after the effective date of the regulation, several commenters argued that staff would have to search records either manually or by computer on a daily basis to determine if patients had been seen since the regulation was implemented.

Response: Under the final regulation, all covered entities will have to provide patients copies of their privacy policy at the first visit after the effective date of the regulation. The Department does not view this as burdensome. We expect that providers will simply place a note or marker at the beginning of a file (electronic or paper) when a patient is given the notice. This is neither time-consuming nor expensive, and it will not require constant searches of records.

Comment: One commenter stated that the definitions of small business, small entity, and a small health plan are inconsistent because the NPRM includes firms with annual receipts of $5 million or less and non-profits.

Response: The Small Business Administration, whose definitions we use for this analysis, includes firms with $5 million or less in receipts and all non-profits as “small businesses.” We recognize that some health plans, though very large in terms of receipts (and insured lives), nonetheless would be considered “small businesses” under this definition because they are non-profits. In the final regulatory flexibility analysis, we generally have maintained the Small Business Administration definitions because it is the accepted standard for these analyses. However, we have added several categories, such as IRBs and employer sponsored group health plans, which are not small entities, per se, but will be affected by the final rule and we were able to identify costs imposed by the regulation on them.

Comment: The same commenter wanted clarification that all non-profit organizations are small entities and that the extended effective date for compliance applies to them.

Response: For purposes of the regulatory flexibility analysis, the Department is utilizing the Small Business Administration guidelines. However, under HIPAA the Secretary may extend the effective compliance date from 24 months to 36 months for “small health plans.” The Secretary is given the explicit discretion of defining the term for purposes of compliance with the regulation. For compliance purposes, the Secretary has decided to define “small health plans” as those with receipts of $5 million or less, regardless of their tax status. As noted above, some non-profit plans are large in terms of revenues (i.e., their revenues exceed $5 million annually). The Department determined that such plans do not need extra time for compliance.

Comment: Several commenters requested that “small providers” [undefined] be permitted to take 36 months to come into compliance with the final regulation, just as small health plans will be permitted to do so.

Response: Congress specified small health plans, but not small providers, as needing extra time to comply. The majority of providers affected by the regulation are “small”, based on the SBA definitions; in other words, granting the delay would be tantamount to making the effective date three years rather than two. In making policy decisions for the final regulation, extensive consideration was given to minimizing the cost and administrative burden associated with implementing
the rule. The Department believes that the requirements of the final rule will not be difficult to fulfill, and therefore, it has maintained the two year effective date.

External Studies

Comment: One commenter submitted a detailed analysis of privacy legislation that was pending and concluded that they might cost over $40 billion.

Response: The study did not analyze the policies in the proposal, and therefore, the estimates do not reflect the costs that would have been imposed by the proposed regulation. In fact, the analysis was prepared before the Administration’s proposed privacy regulation was even published. As a result, the analysis is of limited relevance to the regulation actually proposed.

The following are examples of assumptions and costs in the analysis that do not match privacy policies or requirements stated in the proposed rule. 1. Authorizations: The study assumed rules requiring new authorizations from current subscribers to use their data for treatment, payment of claims, or other health plan operations. The proposed rule would have prohibited providers or plans from obtaining patient authorization to use data for treatment, payment or health care operations, and the final rule makes obtaining consent for these purposes voluntary for all health plans and for providers that do not have direct treatment relationships with individuals.

2. Disclosure History: The study assumes that providers, health plans, and clearinghouses would have to track all disclosures of health information. Under the NPRM and the final rule, plans, providers and clearinghouses are only required to account for disclosures that are not for treatment, payment, and health care operations, a small minority of all disclosures.

3. Inspection, Copying, and Amendment: The study assumed requirements to allow patients and their subscribers to inspect, copy, and amend all information that includes their name, social security number or other identifying feature (e.g. customer service calls, internal memorandum, claim runs). However, the study assumed broader access than provided in the rule, which requires access only to information in records used to make decisions about individuals, not all records with identifiable information.

4. Infrastructure development: The study assumed significant costs to infrastructure implementation of (computer systems, training, and other compliance costs). As explained below, the compliance requirements are much less extensive than assumed in this study. For example, many providers and plans will not be required to modify their privacy systems but will only be required to document their practices and notify patients of these practices, and others will be able to purchase low-cost, off-the-shelf software that will facilitate the new requirements. The final regulation will not require massive capital expenditures; we assumed, based on our consultants’ work, that providers will rely on low-cost incremental adjustments initially, and as their technology becomes outdated, they will replace it with new systems that incorporate the HIPAA standard requirements.

Although many of the policy assumptions in the study are fundamentally different than those in the proposed or final regulation, the study did provide some assistance to the Department in preparing its final analysis. The Department compared data, methodologies and model assumptions, which helped us think more critically about our own analysis and enhanced the quality of our final work.

Response: One commenter submitted a detailed analysis of the NPRM Regulatory Impact Analysis and concluded that it might cost over $64 billion over 5 years. This analysis provided an interesting framework for analyzing the provision for the rule. More precisely, the analysis generally attempted to identify the number of entities would be required to comply with each of the significant provision of the proposed rule, then estimated the numbers of hours required to comply per entity, and finally, estimated an hourly wage.

Response: HHS adopted this general structure for the final RIA because it provided a better framework for analysis than what the Department had done in the NPRM. However, HHS did not agree with many of the specific assumptions used by in this analysis, for several reasons. First, in some instances the assumptions were no longer relevant because the requirements of the NPRM were altered in the final rule. For other assumptions, HHS found more appropriate data sources for the number of covered entities, wages rates and trend rates or other factors affecting costs. In addition, HHS believes that in a few instances, this analysis over-estimated what is required of covered entities to comply. Based on public comments and its own factfinding, the Department believes many of its assumptions used in the final analysis more accurately reflect what is likely to be the real cost of the regulation.

IV. Final Regulatory Impact Analysis

5 U.S.C. 804(2) (as added by section 251 of Pub. L. 104–21), specifies that a “major rule” is any rule that the Office of Management and Budget finds is likely to result in:

• An annual effect on the economy of $100 million or more;

• A major increase in costs or prices for consumers, individual industries, federal, state, or local government agencies, or geographic regions; or

• Significant adverse effects in competition, employment, investment productivity, innovation, or on the ability of United States based enterprises to compete with foreign-based enterprises in domestic and export markets. The impact of this final rule will be over $1 billion in the first year of implementation. Therefore, this rule is a major rule as defined in 5 U.S.C. 804(2).

Executive Order 12866 directs agencies to assess all costs and benefits of available regulatory alternatives and, when regulation is necessary, to select regulatory approaches that maximize net benefits (including potential economic, environmental, public health and safety effects; distributive impacts; and equity). According to Executive Order 12866, a regulatory action is “significant” if it meets any one of a number of specified conditions, including having an annual effect on the economy of $100 million or more adversely affecting in a material way a sector of the economy, competition, or jobs, or if it raises novel legal or policy issues. The purpose of the regulatory impact analysis is to assist decision-makers in understanding the potential ramifications of a regulation as it is being developed. The analysis is also intended to assist the public in understanding the general economic ramifications of a regulation, both in the aggregate as well as the major policy areas of a regulation and how they are likely to affect the major industries or sectors of the economy covered by it.

In accordance with the Small Business Regulatory Enforcement and Fairness Act (Pub. L. 104–121), the Administrator of the Office of Information and Regulatory Affairs of the Office of Management and Budget (OMB) has determined that this rule is a major rule for the purpose of congressional review.

The proposal for the privacy regulation included a preliminary regulatory impact analysis (RIA) which estimated the cost of the rule at $3.8 billion over five years. The preliminary
analysis also noted that a number of significant areas were not included in the estimate due to inadequate information. The proposal solicited public comment on these and all other aspects of the analysis. In this preamble, the Department has summarized the public comments pertinent to the cost analysis and its response to them. However, because of the extensive policy changes incorporated in the final regulation, additional data collected from the public comments and the Department’s fact-finding, and changes in the methodology underlying the estimates, the Department is setting forth in this section a more complete explanation of its revised estimates and how they were obtained. This will facilitate a better understanding by the public of how the estimates were developed and provide more insight into how the Department believes the regulation will ultimately affect the health care sector.

The impact analysis measures the effect of the regulation on current practices. In the case of privacy, as discussed in the preamble, there already exists considerable, though quite varied, efforts to protect the confidentiality of medical information. The RIA is measuring the change in these current practices and the cost of new and additional responsibilities that are required to conform to the new regulation.

To achieve a reasonable level of privacy protection, the Department defined three objectives for the final rule: (1) To establish national baseline standards, implementation specifications, and requirements for health information privacy protection, (2) to protect the privacy of individually identifiable health information maintained or transmitted by covered entities, and (3) to protect the privacy of all individually identifiable health information within covered entities, regardless of its form.

Establishing minimum standards, implementation specifications, and requirements for health information privacy protection creates a level baseline of privacy protection for patients across states. The Health Privacy Project’s report, The State of Health Privacy: An Uneven Terrain 23 makes it clear that under the current system of state laws, privacy protection is extremely variable. The Department’s statutory authority under HIPAA which allows the privacy regulation to preempt any state law if such law is contrary to and not more stringent than privacy protection pursuant to this regulation. This sets a floor, but permits a state to create laws that are more protective of privacy. We discuss preemption in greater detail in other parts of the preamble.

The second objective is to establish a uniform base of privacy protection for individually identifiable health information maintained or transmitted by covered entities. HIPAA restricts the type of entities covered by the rule to three broad categories: health care providers that transmit health information in HIPAA standard transactions, health plans, and health care clearinghouses. However, there are similar public and private entities that are not within the Department’s authority to regulate under HIPAA. For example, life insurance companies are not covered by this rule but may have access to a large amount of individually identifiable health information.

The third objective is to protect the privacy of all individually identifiable health information held by covered entities, including their business associates. Health information is currently stored and transmitted in multiple forms, including electronic, paper, and oral forms. To provide consistent protection to information, and to avoid requiring covered entities from distinguishing between health information that has been transmitted or maintained electronically and that which has not, this rule covers all individually identifiable health information that has been transmitted or maintained electronically and that transmitted by a covered entity.

For purposes of this cost analysis, the Department has assumed all health care providers will be affected by the rule. This results in an overestimation of costs because there are providers that do not engage in any HIPAA standard transactions, and therefore, are not affected. The Department could not obtain any reliable data on the number of such providers, but the available data suggest that there are very few such entities, and given the expected increase in all forms of electronic health care in the coming decade, the number of paper-only providers is likely to decrease.

A. Relationship of This Analysis to Analyses in Other HIPAA Regulations

Congress has recognized that privacy standards, implementation specifications and requirements must accompany the electronic data interchange standards, implementation specifications and requirements because the increased ease of transmitting and sharing individually identifiable health information will result in an increase in concern regarding privacy and confidentiality of such information. The bulk of the first Administrative Simplification section that was debated on the floor of the Senate in 1994 (as part of the Health Security Act) was made up of privacy provisions. The requirement for the issuance of concomitant privacy measures remained a part of the HIPAA bill passed by the House of Representatives in 1996, but the requirement for privacy measures was removed in conference. Instead, Congress added section 264 to Title II of HIPAA, which directs the Secretary to develop and submit to Congress recommendations addressing at least the following:

(1) The rights that an individual who is a subject of individually identifiable health information should have.

(2) The procedures that should be established for the exercise of such rights.

(3) The uses and disclosures of such information that should be authorized or required. The Secretary’s Recommendations were submitted to Congress on September 11, 1997, and are summarized below. Section 264(c)(1) of HIPAA provides that: If legislation governing standards with respect to the privacy of individually identifiable health information transmitted in connection with the transactions described in section 1173(a) of the Social Security Act (as added by section 262) is not enacted by (August 21, 1999), the Secretary of Health and Human Services shall promulgate final regulations containing such standards not later than (February 21, 2000). Such regulations shall address at least the subjects described in subsection (regarding recommendations).

Because the Congress did not enact legislation governing standards with respect to the privacy of individually identifiable health information prior to August 21, 1999, the Department has, in accordance with this statutory mandate, developed final rules setting forth standards to protect the privacy of such information.

Title II of the Health Insurance Portability and Accountability Act (HIPAA) also provides a statutory framework for the promulgation of other administrative simplification regulations. On August 17, 2000, the Transactions Rule was published. Proposals for health care provider identifier (May 1998), employer identifier (June 1998), and security and electronic signature standards (August 1998) have also been published. These
regulations are expected to be made final in the foreseeable future. HIPAA states that, “any standard adopted under this part shall be consistent with the objective of reducing the administrative costs of providing and paying for health care.” (Section 1172 (b)). This provision refers to the administrative simplification regulations in their totality, including this rule regarding privacy standards. The savings and costs generated by the various standards should result in a net savings to the health care system. The Transactions Rule shows a net savings of $29.9 billion over ten years (2002–2011), or a net present value savings of $19 billion. This estimate does not include the growth in “e-health” and “e-commerce” that may be spurred by the adoption of uniform codes and standards.

This final Privacy Rule is estimated to produce net costs of $18.0 billion, with net present value costs of $11.8 billion (2003 dollars) over ten years (2003–2012). This estimate is based on some costs already having been incurred due to the requirements for the rule, including an estimate of a net savings to the health care system of $29.9 billion over ten years (2002 dollars) and a net present value of $19.1 billion. The Department expects that the savings and costs generated by all administrative simplification standards should result in a net savings to the health care system.

B. Summary of Costs and Benefits

Measuring both the economic costs and benefits of health information privacy is difficult. Traditionally, privacy has been addressed by state laws, contracts, and professional practices and guidelines. Moreover, these practices have been evolving as computers have dramatically increased the potential use of medical data; the scope and form of health information is likely to be very different ten years from now than it is today. This final regulation is both altering current health information privacy practice and shaping its evolution as electronic uses expand.

To estimate costs, the Department used information from published studies, trade groups and associations, public comments to the proposed regulation, and fact-finding by staff. The analysis focused on the major policy areas in the regulation that would result in significant costs. Given the vast array of institutions affected by this regulation and the considerable variation in practices, the Department sought to identify the “typical” current practice for each of the major policy areas and estimate the cost of change resulting from the regulation. Because of the paucity of data and incomplete information on current practices, the Department has consistently made conservative assumptions (that is, given uncertainty, we have made assumptions that, if incorrect, are more likely to overstate rather than understate the true cost).

Benefits are difficult to measure because people conceive of privacy primarily as a right, not as a commodity. Furthermore, a wide gap appears to exist between what people perceive to be the level of privacy afforded health information about them and what actually occurs with the use of such information today. Arguably, the “cost” of the privacy regulation is the amount necessary to bring health information privacy to these perceived levels. The benefits of enhanced privacy protections for individually identifiable health information are significant, even though they are hard to quantify. The Department solicited comments on this issue, but no commenters offered a better alternative. Therefore, the Department is essentially reiterating the analysis it offered in the proposed Privacy Rule. The illustrative examples set forth below, using existing data on mental health screening, and HIV/AIDS patients, suggest the level of economic and health benefits that might accrue to individuals and society. Moreover, the benefits of improved privacy protection are likely to increase in the future as patients gain trust in health care practitioners’ ability to maintain the confidentiality of their health information.

The estimated cost of compliance with the final rule is $17.6 billion over the ten year period, 2003–2012. This includes the cost of all the major requirements for the rule, including

35 This was an average discount rate, explained in OMB Circular A–94, and a projected 4.2 percent inflation rate projected over the ten-year period covered by this analysis.

36 The regulatory impact analysis in the Transactions Rule showed a net savings of $29.9 billion (net present value of $19.1 billion in 2002 dollars). The cost estimates included all electronic systems changes that would be necessitated by the HIPAA administrative standards (e.g., security, safeguards, and electronic signatures; eligibility for a health plan; and remittance advice and payment claim status), except privacy. At the time the Transactions Rule was developed, the industry provided estimates for the systems changes in the aggregate. The industry argued that affected parties would seek to make all electronic changes in one effort because that approach would be the most cost-efficient. The Department agreed, and therefore, it “bundled” all the system change cost in the Transactions Rule estimate. Privacy was not included because at the time the Department had not made a decision to develop a privacy rule. As the Department develops other HIPAA administrative simplification standards, there may be additional costs and savings due to the non-electronic components of those regulations, and they will be identified in regulatory impact analyses that accompany those regulations. The Department anticipates that such costs and savings will be relatively small compared to the privacy and Transactions rules. The Department anticipates that the net economic impact of the rules will be a net savings to the health care system.

C. Need for the Final Rule

The need for a national health information privacy framework is described in detail in Section I of the preamble above. In short, privacy is a necessary foundation for delivery of high quality health care—the entire health care system is built upon the willingness of individuals to share the most intimate details of their lives with their health care providers. At the same time, there is increasing public concern about loss of privacy generally, and health privacy in particular. The growing use of interconnected electronic media for business and personal activities, our increasing ability to know an individual’s genetic make-up, and the increasing complexity of the health care system each bring the potential for tremendous benefits to individuals and society, but each also brings new potential for invasions of our privacy.

Concerns about the lack of attention to information privacy in the health care industry are not merely theoretical. Section I of the preamble, above, lists numerous examples of the kinds of deliberate or accidental privacy violations that call for a national legal framework of health privacy protections. Disclosure of health information about an individual can have significant implications well beyond the physical health of that person, including the loss of a job, alienation of family and friends, the loss of health insurance, and public humiliation. The answer to these concerns is not for consumers to withdraw from the health care system, but for society to establish a clear national legal framework for privacy.

This section adds to the discussion in Section I, above, a discussion of the market failures inherent in the current system which create additional and compelling reasons to establish national health information privacy standards. Market failures will arise to the extent that privacy is less well protected than the parties would have agreed to, if they were fully informed and had the ability to monitor and enforce contracts. The chief market failures with respect to privacy of health information concern information, negotiation, and enforcement costs between the entity and the individual. The information costs arise because of the information asymmetry between the company and the patient—the company typically knows far more than the patient about how the protected health information will be used by that company. A health care provider or plan, for instance, knows many details about how protected health information may be generated, combined with other databases, or sold to third parties.

Absent this regulation, patients face at least two layers of cost in learning about how their information is used. First, as with many aspects of health care, patients face the challenge of trying to understand technical medical terminology and practices. A patient generally will have difficulty understanding medical records and the implications of transferring health information about them to a third party. Second, in the absence of consistent national rules, patients may face significant costs in trying to learn and understand the nature of a company’s privacy policies.

The costs of learning about companies’ policies are magnified by the difficulty patients face in detecting whether companies, in fact, are complying with those policies. Patients might try to adopt strategies for monitoring whether companies have complied with their announced policies. These sorts of strategies, however, are both costly (in time and effort) and likely to be ineffective. In addition, modern health care often requires protected health information to flow legitimately among multiple entities for purposes of treatment, payment, health care operations, and other necessary uses. Even if the patient could identify the provider whose data ultimately leaked, the patient could not easily tell which of those multiple entities had impermissibly transferred her information. Therefore, the cost and ineffectiveness of monitoring leads to less than optimal protection of individually identifiable health information.

The incentives facing a company that acquires individually identifiable health information also discourage privacy protection. A company gains the full benefit of using such information, including its own marketing efforts or its ability to sell the information to third parties. The company, however, does not suffer the losses from disclosure of protected health information; the patient does. Because of imperfect monitoring, customers often will not
learn of, and thus not be able to take efficient action to prevent uses or disclosures of sensitive information. Because the company internalizes the gains from using the information, but does not bear a significant share, if any, of the cost to patients (in terms of lost privacy), it will have a systematic incentive to over-use individually identifiable health information. In market failure terms, companies will have an incentive to use individually identifiable health information where the patient would not have freely agreed to such use.

These difficulties are exacerbated by the third-party nature of many health insurance and payment systems. Even where individuals would wish to bargain for privacy, they may lack the legal standing to do so. For instance, employers often negotiate the terms of health plans with insurers. The employee may have no voice in the privacy or other terms of the plan, facing a take-it-or-leave-it choice of whether to be covered by insurance. The current system leads to significant market failures in bargaining privacy protection. Many privacy-protective agreements that patients would wish to make, absent barriers to bargaining, will not be reached.

The economic arguments become more compelling as the medical system shifts from predominantly paper to predominantly electronic records. Rapid changes in information technology should result in increased market failures in the markets for individually identifiable information. Improvements in computers and networking mean that the costs of gathering, analyzing, and disseminating electronic data are plunging. Market forces are leading many health care providers and health plans to shift from paper to electronic records, due both to lower cost and the increased functionality provided by having information in electronic form. These market changes will be accelerated by the administrative simplification implemented by the other regulations promulgated under HIPAA. A chief goal of administrative simplification, in fact, is to create a more efficient flow of medical information, where appropriate. This privacy regulation is an integral part of the overall effort of administrative simplification; it creates a framework for more efficient flows for certain purposes, including treatment and payment, while restricting flows in other circumstances except where appropriate institutional safeguards exist.

If the medical system shifts predominantly to electronic records in the near future, accompanying privacy rules will become more critical to prevent unanticipated, inappropriate, or unnecessary uses or disclosures of individually identifiable health information without patient consent and without effective institutional controls against further dissemination. In terms of the market failure, it will become more difficult for patients to know how their health provider or health plan is using health information about them. It will become more difficult to monitor the subsequent flows of individually identifiable health information, as the number of electronic flows and possible points of leakage both increase.

Similarly, the costs and difficulties of bargaining to get the patients’ desired level of use will likely rise due to the greater number and types of entities that receive protected health information.

As the benefits section, below, discusses in more detail, the protection of privacy and correcting the market failure also have practical implications. Where patients are concerned about lack of privacy protections, they might fail to get medical treatment that they would otherwise seek. This failure to get treatment may be especially likely for certain conditions, including mental health, and HIV. Similarly, patients who are concerned about lack of privacy protections may report health information inaccurately to their providers when they do seek treatment. For instance, they might decide not to mention that they are taking prescription drugs that indicate that they have an embarrassing condition. These inaccurate reports may lead to mis-diagnosis and less-than-optimal treatment, including inappropriate additional medications. In short, the lack of privacy safeguards can lead to efficiency losses in the form of forgone or inappropriate treatment.

In summarizing the economic arguments supporting the need for this regulation, the discussion here has emphasized the market failures that will be addressed by this regulation. These arguments become considerably stronger with the shift from predominantly paper to predominantly electronic records. As discussed in the benefits section below, the proposed privacy protections may prevent or reduce the risk of unfair treatment or discrimination against vulnerable categories of persons, such as those who are HIV positive, and thereby, foster better health. The proposed regulation may also help educate providers, health plans, and the general public about how protected health information is used. This education, in turn, may lead to better information practices in the future.

D. Baseline Privacy Protections

An analysis of the costs and benefits of the regulation requires a baseline from which to measure the regulation’s effects. For some regulations, the baseline is relatively straightforward. For instance, an industry might widely use a particular technology, but a new regulation may require a different technology, which would not otherwise have been adopted by the industry. In this example, the old and widely used technology provides the baseline for measuring the effects of the regulation. The costs and the benefits are the difference between keeping the old technology and implementing the new technology.

Where the underlying technology and industry practices are rapidly changing, however, it can be far more difficult to determine the baseline and thereby measure the costs and benefits of a regulation. There is no simple way to know what technology industry would have chosen to introduce if the regulation had never existed, nor how industry practices would have evolved.

Today, the entities covered by the HIPAA privacy regulation are in the midst of a shift from primarily paper records to electronic records. As covered entities spend significant resources on hardware, software, and other information technology costs, questions arise about which of these costs are fairly attributable to the privacy regulations as opposed to costs that would have been expended even in the absence of the regulations. Industry practices generally are rapidly evolving, as described in more detail in Part I of this preamble. New technological or other measure taken to protect privacy are in part attributable to the expected expense of shifting to electronic medical records, rather than being solely attributable to the new regulations. In addition, the existence of privacy rules in other sectors of the economy help set a norm for what practices will be considered good practices for health information. The level of privacy protection that would exist in the health care sector, in the absence of regulations, thus would likely be affected by regulatory and related developments in other sectors. In short, it is therefore difficult to project a cost or benefits baseline for this rule.

The common security practice of using “firewalls” illustrates how each of the three baselines might apply. Under the first baseline, the first cost of implementing firewalls should be included in a Regulatory Impact
Analysis for a rule that expects entities to have firewalls. Because current law has not required firewalls, a new rule expecting this security measure must include the full cost of creating firewalls. This approach, however, would seem to overstate the cost of such a regulation. Firewalls would seem to be an integral part of the decision to move to an on-line, electronic system of records. Firewalls are also being widely deployed by users and industries where no binding security or privacy regulations have been proposed.

Under the second baseline, the touchstone is the level of risk of security breaches for individually identifiable health information under current practices. There is quite possibly a greater risk of breach for an electronic system of records, especially where such records are accessible globally through the Internet, than for patient records dispersed among various doctors' offices in paper form. Using the second baseline, the costs of firewalls for electronic systems should not be counted as a cost of the regulation except where firewalls create greater security than existed under the previous, paper-based system.

Finally, the third baseline would require an estimate of the typical level of firewall protections that covered entities would adopt in the absence of regulation, and include in the Regulatory Impact Analysis only the costs that exceed what would otherwise have been adopted. For this analysis, the Department has generally assumed that the status quo would otherwise exist throughout the ten-year period (in a few areas we explicitly discuss likely changes). We made this decision for two reasons. First, predicting the level of change that would otherwise occur is highly problematic. Second, it is a “conservative” assumption—that is, any error will likely be an overstatement of the true costs of the regulation.

Privacy practices are most often shaped by professional organizations that publish ethical codes of conduct and by state law. On occasion, state laws defer to professional conduct codes. At present, where professional organizations and states have developed only limited guidelines for privacy practices, an entity may implement privacy practices independently. However, it is worth noting that changes in privacy protection continue to increase in various areas. For example, European Union countries may only send individually identifiable information to companies, including U.S. companies, only with their privacy standards, and the growing use of health data in other areas of commerce, such as finance and general commercial marketing, have also increased the demand for privacy in ways that were not of concern in the past.

1. Professional Codes of Ethics

The Department examined statements issued by five major professional groups, one national electronic network association and a leading managed care association.38 There are a number of common themes that all the organizations appear to subscribe to:

- The need to maintain and protect an individual’s health information;
- The development of policies to ensure the confidentiality of individually identifiable health information;
- A restriction that only the minimum necessary information should be released to accomplish the purpose for which the information is sought.

Beyond these principles, the major associations differ with respect to the methods used to protect individually identifiable health information. There is no common professional standard across the health care field with respect to the protection of individually identifiable health information. One critical area of difference is the extent to which professional organizations should release individually identifiable health information. A major mental health association advocates the release of identifiable patient information “* * * only when de-identified data are inadequate for the purpose at hand.” A major association of physicians counsels members who use electronically maintained and transmitted data to require that they and their patients know in advance who has access to protected patient data, and the purposes for which the data will be used. In another document, the association advises physicians not to “sell” patient information to data collection companies without fully informing their patients of this practice and receiving authorization in advance to release the information.

Only two of the five professional groups state that patients have the right to review their medical records. One group declares this as a fundamental patient right, while the second association qualifies its position by stating that the physician has the final word on whether a patient has access to his or her health information. This association also recommends that its members respond to requests for access to patient information within ten days, and recommends that entities allow for an appeal process when patients are denied access. The association further recommends that when a patient contests the accuracy of the information in his or her record and the entity refuses to accept the patient’s change, the patient’s statement should be included as a permanent part of the patient’s record.

In addition, three of the five professional groups endorse the maintenance of audit trails that can track the history of disclosures of individually identifiable health information.

The one set of standards that we reviewed from a health network association advocated the protection of individually identifiable health information from disclosure without patient authorization and emphasized that encrypting information should be a principal means of protecting individually identifiable health information. The statements of a leading managed care association, while endorsing the general principles of privacy protection, were vague on the release of information for purposes other than treatment. The association suggested allowing the use of protected health information without the patient’s authorization for what they term “health promotion.” It is possible that the use of protected health information for “health promotion” may be construed under the rule as part of marketing activities.

Based on the review of the leading association standards, we believe that the final rule embodies most or all of the major principles expressed in the standards. However, there are some major areas of difference between the rule and the professional standards reviewed. The final rule generally provides stronger, more consistent, and more comprehensive guarantees of privacy for individually identifiable health information than the professional standards. The differences between the rule and the professional codes include the individual’s right of access to health information in the covered entity’s possession, relationships between contractors and covered entities, and the requirement that entities make their privacy policies and practices available to patients through a notice.

and the ability to respond to questions related to the notice. Because the regulation requires that (with a few exceptions) patients have access to their protected health information that a covered entity possesses, large numbers of health care providers may have to modify their current practices in order to allow patient access, and to establish a review process if they deny a patient access. Also, none of the privacy protection standards reviewed require that health care providers or health plans prepare a formal statement of privacy practices for patients (although the major physician association urges members to inform patients about who would have access to their protected health information and how their health information would be used). Only one HMO association explicitly made reference to information released for legitimate research purposes. The regulation allows for the release of protected health information for research purposes without an individual’s authorization, but only if the research where such authorization is waived by an institutional research board or an equivalent privacy board. This research requirement may cause some groups to revise their disclosure authorization standards.

2. State Laws

The second body of privacy protections is found in a complex, and often confusing, myriad of state laws and requirements. To determine whether or not the final rule would preempt a state law, first we identified the relevant laws, and second, we addressed whether state or federal law provides individuals with greater privacy protection.

Identifying the Relevant State Statutes: Health information privacy provisions can be found in laws applicable to many issues including insurance, worker’s compensation, public health, birth and death records, adoptions, education, and welfare. In many cases, state laws were enacted to address a specific situation, such as the reporting of HIV/AIDS, or medical conditions that would impair a person’s ability to drive a car. For example, Florida has over 60 laws that apply to protected health information. According to the Georgetown Privacy Project, Florida is not unique. Every state has laws and regulations covering some aspect of medical information privacy. For the purpose of this analysis, we simply acknowledge the variation in state requirements.

We recognize that covered entities will need to learn the laws of their states in order to comply with such laws that are not contrary to the rule, or that are contrary to and more stringent than the rule. This analysis should be completed in the context of individual markets; therefore, we expect that professional associations or individual businesses will complete this task.

Recognizing the limits of our ability to effectively summarize state privacy laws, we discuss conclusions generated by the Georgetown University Privacy Project’s report, The State of Health Privacy: An Uneven Terrain. The Georgetown report is among the most comprehensive examination of state health privacy laws currently published, although it is not exhaustive. The report, which was completed in July 1999, is based on a 50-state survey.

To facilitate discussion, we have organized the analysis into two sections: access to health information and disclosure of health information. Our analysis is intended to suggest areas where the final rule appears to preempt various state laws; it is not designed to be a definitive or wholly comprehensive state-by-state comparison.

Access to Subject’s Information: In general, state statutes provide individuals with some access to medical records about them. However, only a few states allow individuals access to health information held by all their health care providers and health plans. In 33 states, individuals may access their hospital and health facility records. Only 13 states guarantee individuals access to their HMO records, and 16 states provide individuals access to their medical information when it is held by insurers. Seven states have no statutory right of patient access; three states and the District of Columbia have laws that only assure individuals’ right to access their mental health records. Only one state permits individuals access to records about them held by health care providers, but it excludes pharmacists from the definition of provider. Thirteen states grant individuals statutory right of access to pharmacy records.

The amount that entities are allowed to charge for copying of individuals’ records varies widely from state to state. A study conducted by the American Health Information Management Association found considerable variation in the amounts, structure, and combination of fees for search and retrieval, and the copying of the record.

In 35 states, there are laws or regulations that set a basis for charging individuals inspecting and copying fees. Charges vary not only by state, but also by the purpose of the request and the facility holding the health information. Also, charges vary by the number of pages and whether the request is for X-rays or for standard medical information.

Of the 35 states with laws regulating inspection and copying charges, seven states either do not allow charges for retrieval of records or require that the entity provide the first copy free of charge. Some states may prohibit hospitals from charging patients a retrieval and copying fee, but allow clinics to do so. Many states allow fee structures, while eleven states specify only that the record holder may charge “reasonable/actual costs.”

According to the report by the Georgetown Privacy Project, among states that do grant access to patient records, the most common basis for denying individuals access is concern for the life and safety of the individual or others.

The amount of time an entity is given to supply the individual with his or her record varies widely. Many states allow individuals to amend or correct inaccurate health information, especially information held by insurers. However, few states provide the right to insert a statement in the record challenging the covered entity’s information when the individual and entity disagree.

Disclosure of Health Information: State laws vary widely with respect to disclosure of individually identifiable health information. Generally, states have applied restrictions on the disclosure of health information either to specific entities or for specific health conditions. Only three state laws place broad limits on disclosure of individually identifiable health information without regard for policies and procedures developed by covered entities. Most states require patient authorization before an entity may disclose health information to certain recipients, but the patient often does not have an opportunity to object to any disclosures.

It is also important to point out that none of the states appear to offer individuals the right to restrict disclosure of their health information for treatment.

41 Ibid, Goldman, p. 20.
State statutes often have exceptions to requiring authorization before disclosure. The most common exceptions are for purposes of treatment, payment, or auditing and quality assurance functions. Restrictions on re-disclosure of individually identifiable health information also vary widely from state to state. Some states restrict the re-disclosure of health information, and others do not. The Georgetown report cites state laws that require providers to adhere to professional codes of conduct and ethics with respect to disclosure and re-disclosure of protected health information.

Most states have adopted specific measures to provide additional protections for health information regarding certain sensitive conditions or illnesses. The conditions and illnesses most commonly afforded added privacy protection are:
- Information derived from genetic testing;
- Communicable and sexually-transmitted diseases;
- Mental health; and
- Abuse, neglect, domestic violence, and sexual assault.

Some states place restrictions on releasing condition-specific health information for research purposes, while others allow release of information for research without the patient’s authorization. States frequently require that researchers studying genetic diseases, HIV/AIDS, and other sexually transmitted diseases have different authorization and privacy controls than those used for other types of research.

Some states require approval from an IRB or agreements that the data will be destroyed or identifiers removed at the earliest possible time. Another approach has been for states to require researchers to obtain sensitive, identifiable information from a state public health department. One state does not allow automatic release of protected health information for research purposes without notifying the subjects that their health information may be used in research and allowing them an opportunity to object to the use of their information.

Comparing state statutes to the final rule: The variability of state law regarding privacy of individually identifiable health information and the limitations of the applicability of many such laws demonstrates the need for uniformity and minimum standards for privacy protection. This regulation is designed to meet these goals while allowing stricter state laws to be enacted and remain effective. A comparison of state privacy laws with the final regulation highlights several of the rule’s key implications:

- No state law requires covered entities to make their privacy and access policies available to patients. Thus, all covered entities that have direct contact with patients will be required by this rule to prepare a statement of their privacy protection and access policies. This necessarily assumes that entities have to develop procedures if they do not already have them in place.
- The rule will affect more entities than are covered or encompassed under many state laws.
- Among the three categories of covered entities, it appears that health plans will be the most significantly affected by the access provisions of the rule. Based on the Health Insurance Association of America (HIAA) data, there are approximately 94.7 million non-elderly persons with private health insurance in the 35 states that do not provide patients a legal right to inspect and copy their records.
- Under the rule, covered entities will have to obtain an individual’s authorization before they could use or disclose their information for purposes other than treatment, payment, and health care operations—except in the situations explicitly defined as allowable disclosures without authorization. Although the final rule would establish a generally uniform disclosure and re-disclosure requirement for all covered entities, the entities that currently have the greatest ability and economic incentives to use and disclose protected health information for marketing services to both patients and health care providers without individual authorization.
- While the final rule appears to encompass many of the requirements found in current state laws, it also is clear that within state laws, there are many provisions that cover specific cases and health conditions. Certainly, in states that have no restrictions on disclosure, the rule will establish a baseline standard. But in states that do place conditions on the disclosure of protected health information, the rule may place additional requirements on covered entities.

3. Other Federal Laws
The relationship with other federal statutes is discussed above in the preamble.

E. Costs
Covered entities will be implementing the privacy final rules at the same time many of the administrative simplification standards are being implemented. As described in the overall impact analysis for the Transactions Rule, the data handling change occurring due to the other HIPAA standards will have both costs and benefits. To the extent the changes required for the privacy standards, implementation specifications, and requirements can be made concurrently with the changes required by the other regulations, costs for the combined implementation should be only marginally higher than for the administrative simplification standards alone. The extent of this incremental cost is uncertain, in the same way that the costs associated with each of the individual administrative simplification standards is uncertain.

The costs associated with implementing the requirements under this Privacy Rule will be directly related to the number of affected entities and the number of affected transactions in each entity. There are approximately 12,200 health plans (including self-insured employer and government health plans that are at least partially self-administered)44, 6480 hospitals, and 630,000 non-hospital providers that will bear implementation costs under the final rule.

The relationship between the HIPAA security and privacy standards is particularly relevant. On August 17, 2000, the Secretary published a final rule to implement the HIPAA standards on electronic transactions. That rule adopted standards for eight electronic code sets to be used for those transactions. The proposed rule for security and electronic signature standards was published on August 12, 1998. That proposal specified the security requirements for covered entities that transmit and store information specified in Part C, Title II of the Act. In general, that proposed rule proposed administrative and technical standards for protecting any health information pertaining to an individual that is electronically

43 “Medical records and privacy: Empirical effects of legislation: A memorial to Alice Hersh”; McCarthy, Douglas B; Shatin, Deborah; et al. Health Service Research: April 1, 1999; No. 1, Vol. 34; p. 417. The article details the effects of the Minnesota law conditioning disclosure of protected health information on patient authorization.

maintained or transmitted.” (63 FR 43243). The final Security Rule will detail the system and administrative requirements that a covered entity must meet in order to assure itself and the Secretary that health information is safe from destruction and tampering from people without authorization for its access.

By contrast, the Privacy Rule describes the requirements that govern the circumstances under which protected health information must be used or disclosed with and without patient involvement and when a patient may have access to his or her protected health information.

While the vast majority of health care entities are privately owned and operated, we note that federal, state, and local government providers are reflected in the total costs as well. Federal, state, and locally funded hospitals represent approximately 26 percent of hospitals in the United States. This is a significant portion of hospitals, but it represents a relatively small portion of all provider entities. We estimated that the number of government providers who are employed at locations other than government hospitals is significantly smaller (approximately two percent of all providers). Weighting the relative number of government hospital and non-hospital providers by the revenue these types of providers generate, we estimate that health care services provided directly by government entities represent 3.4 percent of total health care services. Indian Health Service and tribal facilities costs are included in the total, since the adjustments made to the original private provider data to reflect federal providers included them. In developing the rule, the Department consulted with states, representatives of the National Congress of American Indians, representatives of the National Indian Health Board, and a representative of the self-governance tribes. During the consultation we discussed issues regarding the application of Title II of HIPAA to the states and tribes.

The costs associated with this final rule involve, for each provision, consideration of both the degree to which covered entities must modify their existing records management systems and privacy policies under the final rule, and the extent to which there is a change in behavior by both patients and the covered entities as a result of the final rule. The following sections examine these provisions as they apply to the various covered entities under the final rule. The major costs that covered entities will incur are one-time costs associated with implementation of the final rules, and ongoing costs that result in continuous requirements in the final rule.

The Department has quantified the costs imposed by the final regulation to the extent possible. The cost of many provisions were estimated by first using data from the Census Bureau’s Statistics of U.S. Business to identify the number of non-hospital health care providers, hospitals and health plans. Then, using the Census Bureau’s Current Population Survey (CPS) wage data for the classes of employees affected by the rule, the Department identified the hourly wage of the type of employee assumed to be mostly likely responsible for compliance with a given provision. Where the Department believed a number of different types of employees might be responsible for complying with a certain provision, as is often expected to be the case, the Department established a weighted-average wage based on the types of employees involved. Finally, the Department made assumptions regarding the number of person-hours per institution required to comply with the rule.

The Department cannot determine precisely how many person-hours per institution will be required to comply with a given provision, however, the Department attempted to establish reasonable estimates based on fact-finding discussions with private sector health care providers, the advice of the Department’s consultants, and the Department’s own best judgement of the level of burden required to comply with a given provision. For example, the Department recognizes that the number of hours required to comply with a given requirement of the rule will vary from provider to provider and health plan to health plan, particularly given the flexibility and scalability permitted under the rule. Therefore, the Department considers the estimates to be averages across the entire class of health care providers, hospitals, or health plans in question.

Underlying all annual cost estimates are growth projections. For growth in the number of patients, the Department used data from the National Ambulatory Medical Care Survey, the National Hospital Ambulatory Medical Care Survey, the National Home and Hospice Survey, the National Nursing Home Survey, and information from the American Hospital Association. For growth in the number of health care workers, the Department used data from the Bureau of Health Professions in the Department’s Health Resources Services Administration (HRSA). For insurance coverage growth (private and military coverage), we used a five-year average annual growth rate in employer-sponsored, individual, military, and overall coverage growth from the Census Bureau’s CPS, 1995–1999. To estimate growth in the number of Medicare and Medicaid enrollees, the Department used the enrollment projections of the Health Care Financing Administration’s Office of the Actuary. For growth in the number of hospitals, health care providers and health plans, trend rates were derived from the Census Bureau’s Statistics of U.S. Businesses, using SIC code-specific five-year annual average growth rate from 1992–1997 (the most recent data available). For wage growth, the Department used the same assumptions made in the Medicare Trustees’ Hospital Insurance Trust Fund report for 2000.

In some areas, the Department was able to obtain very reliable data, such as survey data from the Statistics of U.S. Businesses and the Medical Expenditures Panel Survey (MEPS). In numerous areas, however, there was too little information or data to support quantitative estimates. As a result, the Department relied on data provided in the public comments or subsequent fact-finding to provide a basis for making key assumptions. We were able to provide a reasonable cost estimate for virtually all aspects of the regulation, except law enforcement. In this latter area, the Department was unable to obtain sufficient data about current practices (e.g., the number of criminal and civil investigations that may involve requests for protected health information, the number of subpoenas for protected health information, etc.) to determine the marginal effects of the regulation. As discussed more fully below, the Department believes the effects of the final rule are marginal because the policies adopted in the final rule appear to largely reflect current practice.

The NPRM included an estimate of $3.8 billion for the privacy proposal. The estimate for the final rule is $18.0 billion. Much of the difference can be explained by two factors. First, the NPRM estimate was for five years; the final rule estimate is for ten years. The Department chose the longer period for the final rule because ten years was also the period of analysis in the Transactions Rule RIA, and we wanted to facilitate comparisons, given that the net benefits and costs of the administrative simplification rules should be considered together. Second, the final impact analysis includes cost estimates for a number of key provisions that were not estimated in the NPRM because the Department did not have adequate information at the time.
Although we received little usable data in the public comments (see comment and response section), the Department was able to undertake more extensive fact-finding and collect sufficient information to make informed assumptions about the level of effort and time various provisions of the final rule are likely to impose on different types of affected entities.

The estimate of $18.0 billion represents a gross cost, not a net cost. As discussed more fully below in the benefits section, the benefits of enhanced privacy and confidentiality of personal health information are very significant. If people believe their information will be used properly and not disseminated beyond certain bounds without their knowledge and consent, they will be much more likely to seek proper health care, provide all relevant health information, and abide by their providers’ recommendations. In addition, more confidence by individuals and covered entities that privacy will be maintained will lead to an increase in electronic transactions and the efficiencies and cost savings that stem from such action. The benefits section quantifies some examples of benefits. The Department was not able to identify data sources or models that would permit us to measure benefits more broadly or accurately. The inability to quantify benefits, however, does not lessen the importance or value that is ultimately realized by having a national standard for health information privacy.

The largest initial costs resulting from the final Privacy Rule stem primarily from the requirement that covered entities use and disclose only the minimum necessary protected health information, that covered entities develop policies and codify their privacy procedures, and that covered entities designate a privacy official and train all personnel with access to individually identifiable health information. The largest ongoing costs will result from the minimum necessary provisions pertaining to internal uses of individually identifiable health information, and the cost of a privacy official. In addition, covered entities will have recurring costs for training, disclosure tracking and notice requirements. A smaller number of large entities may have significant costs for de-identification of protected health information and additional requirements for research.

The privacy costs are in addition to the Transactions Rule estimates. The cost of compliance with the regulation represents approximately 0.23 percent of projected national health expenditures the first year the regulation is enacted. The costs for the first eight years of the final regulation represents 0.07 percent of the increase in national health care costs experienced over the same period.46

Minimum Necessary

The “minimum necessary” policy in the final rule has essentially three components: first, it does not pertain to certain uses and disclosures including treatment-related exchange of information among health care providers; second, for disclosures that are made on a routine and recurring basis, such as insurance claims, a covered entity is required to have policies and procedures for governing such exchanges (but the rule does not require a case-by-case determination); and third, providers must have a process for reviewing non-routine requests on a case-by-case basis to assure that only the minimum necessary information is disclosed.

Based on public comments and subsequent fact-finding, the Department has concluded that the requirements of the final rule are generally similar to the current practice of most providers. For standard disclosure requests, for example, providers generally have established procedures for determining how much health information is released. For non-routine disclosures, providers have indicated that they currently ask questions to discern how much health information is necessary for such disclosure. Under the final rule, we anticipate providers will have to be more thorough in their policies and procedures and more vigilant in their oversight of them; hence, the costs of this provision are significant.

To make the final estimates for this provision, the Department considered the minimum necessary requirement in two parts. First, providers, hospitals, and health plans will need to establish policies and procedures which govern uses and disclosures of protected health information. Next, these entities will need to adjust current practices that do not comply with the rule, such as updating passwords and making revisions to software.

To determine the policies and procedures for the minimum necessary requirement, the Department assumed that each hospital would spend 160 hours, health plans would spend 107 hours, and non-hospital providers would spend 8 hours. As noted above, the time estimates for this and other provisions of the rule are considered an average number of person-hours for the institutions involved. An underlying assumption is that some hospitals, and to a lesser extent health plans, are part of chains or larger entities that will be able to prepare the basic materials at a corporate level for a number of covered entities.

Once the policies and procedures are established, the Department estimates there will be costs resulting from implementing the new policies and procedures to restrict internal uses of protected health information to the minimum necessary. Initially, this will require 560 hours for hospitals, 100 hours for health plans, and 12 hours for non-hospital providers.47 The wage for health care providers and hospitals is estimated at $47.28, a weighted average of various health care professionals based on CPS data; the wage for health plans is estimated to be $33.82, based on average wages in the insurance industry (note that all wage assumptions in this impact analysis assume a 39 percent load for benefits, the standard Bureau of Labor Statistics assumption). In addition, there will be time required on an annual basis to ensure that the implemented practices continue to meet the requirements of the rule. Therefore, the Department estimates that on an annual ongoing basis (after the first year), hospitals will require 320 hours, health plans 100 hours, and non-hospital providers 8 hours to comply with this provision.

The initial cost attributable to the minimum necessary provision is $926 million. The total cost of the provision is $5,757 billion. (These estimates are for the cost of complying with the minimum necessary provisions that restrict internal uses to the minimum necessary. The Department has estimated in the business associates section below the requirement limiting disclosures outside the covered entity to the minimum amount necessary.)

Privacy Official

The final rule requires entities to designate a privacy official who will be responsible for the development and implementation of privacy policies and procedures. In this cost analysis, the Department has estimated each of the primary administrative requirements of the rule (e.g., training, policy and

---

46 Health Care Finance Administration, Office of the Actuary. 2000. Estimates for the national health care expenditure accounts are only available through 2000; hence, we are only able to make the comparison through that year.

47 These estimates were, in part, derived from a report prepared for the Department by the Gartner Group, consultants in health care information technology: “Gartner DHHS Privacy Regulation Study,” by Jim Klein and Wes Kishel, submitted to the Office of the Assistant Secretary for Policy and Evaluation on October 20, 2000.
procedure development, etc.), including the development and implementation costs associated with each specific requirement. These activities will certainly involve the privacy official to some degree; thus, some costs for the privacy official, particularly in the initial years, are subsumed in other cost requirements. Nonetheless, we anticipate that there will be additional ongoing responsibilities that the privacy official will have to address, such as coordinating between departments, evaluating procedures and assuring compliance. To avoid double-counting, the cost calculated in this section is only for the ongoing, operational functions of a privacy official (e.g., clarifying procedures for staff) that are in addition to items discussed in other sections of this impact analysis.

The Department assumes the privacy official role will be an additional responsibility given to an existing employee in the covered entity, such as an office manager in a small entity or a compliance official in a larger institution. Moreover, today any covered entity that handles individually identifiable health information has one or more people with responsibility for handling and protecting the confidentiality of such information. As a result of the specific requirement for a privacy official, the Department assumes covered entities will centralize this function, but the overall effort is not likely to increase significantly. Specifically, the Department has assumed non-hospital providers will need to devote, on average, an additional 30 minutes per week of an official’s time (i.e., 26 hours per year) to compliance with the final regulation for the first two years and 15 minutes per week for the remaining eight years (i.e., 13 hours per year). For hospitals and health plans, which are more likely to have a greater diversity of activities involving privacy issues, we have assumed three hours per week for the first two years (i.e., 156 hours per year), and 1.5 hours per week for the remaining eight years (i.e., 78 hours per year).

For non-hospital providers, the time was calculated at a wage of $34.13 per hour, which is the average wage for managers of medicine and health according to the CPS. For hospitals, we used a wage of $79.44, which is the rate for senior planning officers. For health plans, the Department assumed a wage of $88.42 based on the wage for top claims executives. Although individual hospitals and health plans may not necessarily select their planning officers or claims executives to be their privacy officials, we believe they will be of comparable responsibility, and therefore comparable pay, in larger institutions.

The initial year cost for privacy officials will be $723 million; the ten-year cost will be $5.9 billion.

Internal Complaints

The final rule requires each covered entity to have an internal process to allow an individual to file a complaint concerning the covered entity’s compliance with its privacy policies and procedures. The requirement includes designating a contact person or office responsible for receiving complaints and documenting the disposition of them, if any. This function may be performed by the privacy official, but because it is a distinct right under the final rule and may be performed by someone else, we are costing it separately.

The covered entity only is required to receive and document a complaint (no response is required), which we assume will take, on average, ten minutes (the complaint can be oral or in writing). The Department believes that such complaints will be uncommon. We have assumed that one in every thousand patients will file a complaint, which is approximately 10.6 million complaints over ten years. Based on a weighted-average hourly wage of $47.28 at ten minutes per complaint, the cost of this policy is $6.6 million in the first year. Using wage growth and patient growth assumptions, the cost of this policy is $103 million over ten years.

Disclosure Tracking and History

The final rule requires providers to be able to produce a record of all disclosures of protected health information, except in certain circumstances. The exceptions include disclosures for treatment, payment, health care operations, or disclosures to an individual. This requirement will require a notation in the record (electronic or paper) of when, to whom, and what information was disclosed, as well as the purpose of such disclosure or a copy of an individual’s written authorization or request for a disclosure. Based on information from several hospital sources, the Department assumes that all hospitals already track disclosures of individually identifiable health information and that 15 percent of all patient records held by a hospital will have an annual disclosure that will have to be recorded in an individual’s record. It was more difficult to obtain a reliable estimate for non-hospital providers, though it appears that they receive many fewer requests. The Department assumed a ten percent rate for ambulatory care patients and five percent, for nursing homes, home health, dental and pharmacy providers. (It was difficult to obtain any reliable data for these latter groups, but those we talked to said that they had very few, and some indicated that they currently keep track of them in the records.) These estimated percentages represent about 63 million disclosures that will have to be recorded in the first year, with each recording estimated to require two minutes. At the average nurse’s salary of $30.39 per hour, the cost in the first year is $25.7 million. For health plans, the Department assumed that disclosures of protected health information are more rare than for health care providers. Therefore, the Department assumed that there will be disclosures of protected health information for five percent of covered lives. At the average wage for the insurance industry of $33.82 per hour, the initial cost for health plans is $6.8 million. Using our standard growth rates for wages, patients, and covered entities, the ten-year cost for providers and health plans is $519 million.

In addition, although hospitals generally track patient disclosures today, the Department assumes that hospitals will seek to update software systems to assure full compliance. Based on software upgrade costs provided by the Department’s private sector consultants with expertise in the area (the Gartner Group), the Department assumed that each upgrade would cost $35,000 initially and $6,300 annually thereafter, for a total cost of $572 million over ten years.

The final rule also requires covered entities to provide individuals with an accounting of disclosures upon request. The Department assumes that few patients will request a history of disclosures of their protected medical information. Therefore, we estimate that one in a thousand patients will request such an accounting each year, which is approximately 850,000 requests. If it takes an average of five minutes to copy any disclosures and the work is done by a nurse, the cost for the first year will be $2.1 million. The total ten-year cost is $33.8 million.

De-Identification of Information

The rules allows covered entities to determine that health information is de-identified (i.e., that it is not individually identifiable health information) if certain conditions are met. Currently, some entities release de-identified information for research purposes. De-identified information may originate from automated systems (such as records maintained by pharmacy benefit managers) and non-automated systems (such as individual medical records maintained by providers). As compared with current practice, the rule requires that an expanded list of identifiers be removed for the data (such as driver’s license numbers, and detailed geographic and certain age information). For example, as noted in a number of public comments, currently complete birth dates (day, month, and year) and zip codes are often included in de-identified information. The final rule requires that only the year of birth (except in certain circumstances) and the first three digits of the zip code can be included in de-identified information.

These changes will not require extensive change from current practice. Providers generally remove most of the 19 identifiers listed in the final rule. The Department relied on Gartner Group estimates that some additional programmer time will be required by covered entities that produce de-identified information to make revisions in their procedures to eliminate additional identifiers. Entities that de-identify information will have to review existing and future data flows to assure compliance with the final rule. For example, an automated system may need to be re-programmed to remove additional identifiers from otherwise protected health information. (The costs of educating staff about the de-identification requirements are included in the cost estimate for training staff on privacy policies.)

The Department was not able to obtain any reliable information on the volume of medical data that is currently de-identified. To provide some measure of the potential magnitude, we assumed that health plans and hospitals would have an average of two existing agreements that would need to be reviewed and modified. Based on information provided by our consultants, we estimate that these agreements would require an average of 152 hours by hospitals and 116 hours by health plans to review and revise existing agreements to conform to the final rule. Using the weighted average wage of $47.28, the initial costs will be $124 million. Using our standard growth rates for wages, patients, and covered entities, the total cost of the provision is $1.1 billion over ten years.

The Department expects that the final rule and the increasing trend toward computerization of large record sets will result over time in de-identification being performed by relatively few firms or associations. Whether the covered entity is a small provider with relatively few files or a hospital or health plan with large record files, it will be more efficient to contract with specialists in these firms or associations (as “business associates” of the covered entity) to de-identify files. The process will be different but the ultimate cost is likely to be the same or only slightly higher, if at all, than the costs for de-identification today. The estimate is for the costs required to conform existing and future agreements to the provisions of the rule. The Department has not quantified the benefits that might arise from changes in the market for de-identified information because the centralization and efficiency that will come from it will not be fully realized for several years, and we do not have a reliable means of estimating such changes.

Policy and Procedures Development

The final rule imposes a variety of requirements which collectively will necessitate entities to develop policies and procedures (henceforth in this section to be referred to as policies) to establish and maintain compliance with the regulation. These include policies such as those for inspection and copying, amending records, and receiving complaints. In developing the final regulations, simplifying the administrative burden was a significant consideration. To the extent practical, consistent with maintaining adequate protection of protected health information, the final rule is designed to encourage the development of policies by professional associations and others, that will reduce costs and facilitate greater consistency across providers and other covered entities.

The development of policies will occur at two levels: first, at the association or other large scale level; and second, at the entity level. Because of the generic nature of many of the final rule’s provisions, the Department anticipates that trade, professional associations, and other groups serving large numbers of members or clients will develop materials that can be used broadly. These will likely include the model privacy practice notice that all covered entities will have to provide patients; general descriptions of the regulation’s requirements appropriate for various types of health care providers; checklists of steps entities will have to take to comply; training materials; and recommended procedures or guidelines. The Department spoke with a number of professional associations, and they confirmed that they would expect to provide such materials for their members at either the federal or state level.

Using Faulkner and Gray’s Health Data Directory 2000, we identified 216 associations that would be likely to provide guidance to members. In addition, we assume three organizations (i.e., one for hospitals, health plans, and other health care providers) in each state would also provide some additional services to help covered entities coordinate the requirements of this rule with state laws and requirements. The Department assumed that these associations would each provide 320 hours of legal analysis at $150 per hour, and 640 hours of senior analysts time at $50 per hour. This equals $17.3 million. Hourly rates for legal council are the average billing rate for a staff attorney. The senior analysts rates are based on a salary of $75,000 per year, plus benefits, which was provided by a major professional association.

For larger health care entities such as hospitals and health plans, the Department assumed that the complexity of their operations would require them to seek more customized assistance from outside counsel or consultants. Therefore, the Department assumes that each hospital and health plan (including self-administered, self-insured health plans) will, on average, require 40 hours of outside assistance. The resulting cost for external policy development is estimated to be $112 million.

All covered entities are expected to require some time for internal policy development beyond what is provided by associations or outside consultants. For most non-hospital providers, the external assistance will provide most of the necessary information. Therefore, we expect these health care providers will need only eight hours to adapt these policies for their specific use (training cost is estimated separately in the impact analysis). Hospitals and

50 The cost for policies for minimum necessary, because they will be distinct and extensive, are presented separately, above.

health plans, which employ more individuals and are involved in a wider array of endeavors, are likely to require more specific policies tailored to their operations to comply with the final rule. For these entities, we assume an average of 320 hours of policy development per institution. The total cost for internal policy development is estimated to be $468 million.

The total cost for policy, plan, and procedures development for the final regulation is estimated to be $598 million. All of these costs are initial costs.

Training

The final regulation’s requirements provide covered entities with considerable flexibility in how to best fulfill the necessary training of their workforce. As a result, the actual practices may vary substantially based on such factors as the number of members of the workforce, the types of operations, and experience of the workforce. Training is estimated to cost $737 million over ten years. The Department estimates that at the time of the effective date, approximately 6.7 million health care workers will have to be trained, and in the subsequent ten years, 7 million more will have to be trained because of worker turnover. The estimate of employee numbers is based on 2000 CPS data regarding the number of health care workers who indicated they worked for a health care institution. To estimate a workforce turnover rate, the Department relied on a study submitted in the public comments which used a turnover rate of ten percent or less, depending on the labor category. To be conservative, the Department assumed ten percent for all categories.

Covered entities will need to provide members of the workforce with varying amounts of training depending on their responsibilities, but on average, the Department estimates that each member of the workforce who is likely to have access to protected health information will require one hour of training in the policies and procedures of the covered entity. The initial training cost estimate is based on teacher training with an average class size of ten. After the initial training, the Department expects some training (for example, new employees in larger institutions) will be done by videotape, video conference, or computer, all of which are likely to be less expensive. Training materials were assumed to cost an average of $2 per worker. The opportunity cost for the training time is based on the average wage for each health care labor category listed in the CPS, plus a 39 percent load for benefits. Wages were increased based on the wage inflation factor utilized for the short-term assumptions (which covers ten years) in the Medicare Trustees’ Annual Report for 1999.

Notice

This section describes only the cost associated with the production and provision of a notice. The cost of developing the policy stated in the notice is covered under policies and procedures, above.

Covered health care providers with direct treatment relationships are required to provide a notice of privacy practices no later than the date of the first service delivery to individuals after the compliance date for the covered health care provider. The Department assumed that for most types of health care providers (such as physicians, dentists, and pharmacists) one notice would be distributed to each patient during his or her first visit following the compliance date for the covered provider, but not for subsequent visits. For hospitals, however, the Department assumed that a notice would be provided at each admission, regardless of how many visits an individual has in a given year. In subsequent years, the Department assumed that non-hospital providers would only provide notices to their new patients, because it is assumed that providers can distinguish between new and old patients, although hospitals will continue to provide a notice for each admission. The total number of notices provided in the initial year is estimated to be 816 million.

Under the final rule, only providers that have direct treatment relationships with individuals are required to provide notices to them. To estimate the number of visits that trigger a notice in the initial year and in subsequent years, the Department relied on the Medical Expenditure Panel Survey (MEPS, 1996 data), conducted by the Department’s Agency for Healthcare Research and Quality. This data set provides estimates for the number of total visits to a variety of health care providers in a given year and estimates of the number of patients with at least one visit to each type of each care provider. To estimate the number of new patients in a given year, the Department used the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey, which indicate that for ambulatory care visits to physician offices and hospital ambulatory care departments, 13 percent of all patients are new. This data was used as a proxy for other types of providers, such as dentists and

nursing homes, because the Department did not have estimates for new patients for other types of providers. The number of new patients was increased over time to account for growth in the patient population. Therefore, the number of notices provided in years 2004 through 2012 is estimated to be 5.3 billion.

For health plans, the Department estimated the number of notices by trending forward the average annual rate of growth from 1995 through 1998 (the most recent data available) of private policy holders using the Census Bureau’s Current Population Survey, and also by using Health Care Financing Administration Office of the Actuary’s estimates for growth in Medicare and Medicaid enrollment. It should be noted that the regulation does not require that the notice be mailed to individuals. Therefore, the Department assumed that health plans would include their privacy policy in the annual mailings they make to members, such as by adding a page to an existing information booklet.

Since clinical laboratories generally do not have direct contact with patients, they would not normally be required to provide notices. However, there are some laboratory services that involve direct patient contact, such as patients who have tests performed in a laboratory or at a health fair. We found no data from which we could estimate the number of such visits. Therefore, we have assumed that labs would incur no costs as a result of this requirement.

The printing cost of the policy is estimated to be $0.05, based on data obtained from the Social Security Administration, which does a significant number of printings for distribution. Some large bulk users, such as health plans, can probably reproduce the document for less, and small providers simply may copy the notice, which would also be less than $0.05. Nonetheless, at $0.05, the total cost of the initial notice is $50.8 million.

Using our standard growth rate for patients, the total cost for notices is estimated to be $391 million for the ten-year period.

Requirements on Use and Disclosure for Research

The final regulation places certain requirements on covered entities that supply individually identifiable health information to researchers. As a result of these requirements, researchers who seek such health information and the Institutional Review Boards (IRBs) that review research projects will have additional responsibilities. Moreover, a covered entity doing research, or another entity requesting disclosure of
protected health information for research that is not currently subject to IRB review (research that is 100 percent privately funded and which takes place in institutions which do not have “multiple project assurances”) may need to seek IRB or privacy board approval if they want to avoid the requirement to obtain authorization for use or disclosure of protected health information for research, thereby creating the need for additional IRBs and privacy boards that do not currently exist.

To estimate the additional requirements placed on existing IRBs, the Department relied on a survey of IRBs conducted by James Bell Associates on behalf of NIH and on estimates of the total number of existing IRBs provided by NIH staff. Based on this information, the Department concluded that of the estimated 4,000 IRBs in existence, the median number of initial current research project reviews is 133 per IRB, of which only ten percent do not receive direct consent for the use of protected health information. (Obtaining consent nullifies the need for IRB privacy scrutiny.) Therefore, in the first year of implementation, there will be 76,609 initial reviews affected by the regulation, and the Department assumes that the requirement to consider the privacy protections in the research protocols under review will add an average of 1 hour to each review. The cost to researchers for having to develop protocols which protect protected health information is difficult to estimate, but the Department assumes that each of the affected 76,609 studies will require an average of an additional 8 hours of time for protocol development and implementation. At the average medical scientist hourly wage of $46.61, the initial cost is $32.1 million; the total ten-year cost of these requirements is $468 million over ten years.

As stated above, some privately funded research not subject to any IRB review currently may need to obtain IRB or privacy board approval under the final rule. Estimating how much research exists which does not currently go through any IRB review is highly speculative, because the experts consulted by the Department all agree that there is no data on the volume of privately funded research. Likewise, public comments on this subject provided no useful data. However, the Department assumed that most research that takes place today is subject to IRB review, given that so much research has some government funding and many large research institutions have multiple project assurances. As a result, the Department assumed that the total volume of non-IRB reviewed research is equal to 25 percent of all IRB-reviewed research, leading to 19,152 new IRB or privacy board reviews in the first year of the regulation. Using the same assumptions as used above for wages, time spent developing privacy protection protocols for researchers, and time spent by IRB and privacy board members, the total one-year cost for new IRB and privacy board reviews is $8 million.

For estimating total ten-year costs, the Department used the Bell study, which showed an average annual growth rate of 3.7 percent in the number of studies reviewed by IRBs. Using this growth rate, the total ten-year cost for the new research requirements is $117 million.

**Consent**

Under the final rule, a covered health care provider with direct treatment relationships must obtain an individual’s written consent for use or disclosure of protected health information for treatment, payment, or health care operations. Covered providers with indirect treatment relationships and health plans may obtain such consent if they so choose. Providers and health plans that seek consent under this rule can condition treatment or enrollment upon provision of such consent. Based on public comments and discussions with a wide array of health care providers, it is apparent that most currently obtain written consent for use and disclosure of individually identifiable health information for payment. Under the final rule, they will have to obtain consent for treatment and health care operations, as well, but this may entail only minor changes in the language of the consent to incorporate these other categories and to conform to the rule. Although the Department was unable to obtain any systematic data, the anecdotal evidence suggests that most non-hospital providers and virtually all hospitals follow this practice. For the cost analysis, the Department assumes that 90 percent of the non-hospital providers and all hospitals currently obtain some consent for use and disclosure of individually identifiable health information. For providers that currently obtain written consent, there is only a nominal cost for changing the language on the document to conform to the rule. For this activity, we assumed $0.05 cost per document for revising existing consent documents. For the ten percent of treating providers who do not obtain consent, there is the cost of creating consent documents (which will be standardized), which is also assumed to be $0.05 per document. It is assumed that all providers required to obtain consent under the rule will do so upon the first visit, so there will be no mailing cost. For non-hospital providers, we assume the consent will be maintained in paper form, which is what most providers currently do (electronic form, if available, is cheaper to maintain). There is no new cost for records maintenance because the consent will be kept in active files (paper or electronic).

The initial cost of the consent requirement is estimated to be $166 million. Using our standard assumptions for patient growth, the total costs for the ten years is estimated to be $227 million.

**Authorizations**

Patient authorizations are required for uses or disclosures of protected health information that are not otherwise explicitly permitted under the final rule with or without consent. In addition to uses and disclosures of protected health information for treatment, payment, and health care operations with or without consent, the rule also permits certain uses of protected health information, such as fund-raising for the covered entity and certain types of marketing activity, without prior consent or authorization. Authorizations are generally required if a covered entity wants to provide protected health information to third party for use by the third party for marketing or for research that is not approved by an IRB or privacy board.

The requirement for obtaining authorizations for use or disclosure of protected health information for most marketing activity will make direct third-party marketing more difficult because covered entities may not want to obtain and track such authorizations, or they may obtain too few to make the effort economically worthwhile. However, the final rule permits an alternative arrangement: the covered entity can engage in health-related marketing on behalf of a third party, presumably for a fee. Moreover, the covered entity could retain another party, through a business associate relationship, to conduct the actual health-related marketing, such as mailings or telemarketing, under the covered entity’s name. The Department is unable to estimate the cost of these changes because there is no credible data on the extent of current third party marketing practices or the price that third party marketers currently pay for information from covered entities. The effect of the final rule is to change the
arrangement of practices to enhance accountability of protected health information by the covered entity and its business associates; however, there is nothing inherently costly in these changes.

Examples of other circumstances in which authorizations are required under the final rule include disclosure of protected health information to an employer for an employment physical, pre-enrollment underwriting for insurance, or the sharing of protected health insurance information by an insurer with an employer. The Department assumes there is no new cost associated with these requirements because providers have said that obtaining authorization under such circumstances is current practice.

To use or disclose psychotherapy notes for most purposes (including for treatment, payment, or health care operations), a covered entity must obtain specific authorization by the individual that is distinct from any authorization for use and disclosure of other protected health information. This is current practice, so there is no new cost associated with this provision.

Confidential Communications

The final rule permits individuals to receive communications of protected health information from a covered health care provider or a health plan by an alternative means or at an alternative address. A covered provider and a health plan must accommodate reasonable requests; however, a health plan may require the individual to state that disclosure of such information may endanger the individual. A number of providers and health plans indicated that they currently provide this service for patients who request it. For providers and health plans with electronic records system, maintaining separate addresses for certain information is simple and inexpensive, requiring little or no change in the system. For providers with paper records, the cost may be higher because they will have to manually check records to determine which information must be treated in accordance with such requests. Although some providers currently provide this service, the Department was unable to obtain any reliable estimate of the number of such requests today or the number of providers who perform this service. The cost attributable to this requirement to send materials to alternate addresses does not appear to be significant.

Employers With Insured Group Health Plans

Some group health plans will use or maintain protected health information, particularly group health plans that are self-insured. Also, some plan sponsors that perform administrative functions on behalf of their group health plans, may need protected health information. The final rule permits a group health plan, or a health insurance issuer or HMO that provides benefits on behalf of the group health plan, to disclose protected health information to a plan sponsor who performs administrative functions on its behalf for certain purposes and if certain requirements are met. The plan documents must be amended to: describe the permitted uses and disclosures of protected health information by the plan sponsor; specify that disclosure is permitted only upon receipt of a certification by the plan sponsor that the plan documents have been amended and the plan sponsor agrees to certain restrictions on the use of protected health information; and provide for adequate firewalls to assure unauthorized personnel do not have access to individually identifiable health information.

Some plan sponsors may need information, not to administer the group health plan, but to amend, modify, or terminate the plan. ERISA case law describes such activities as settlor functions. For example, a plan sponsor may want to change its contract from a preferred provider organization to a health maintenance organization (HMO). In order to obtain premium information, the plan sponsor may need to provide the HMO with aggregate claims information. Under the rule, the plan sponsor can obtain summary information with certain identifiers removed, in order to provide it to the HMO and receive a premium rate.

The Department assumes that most plan sponsors who are small employers (those with 50 or fewer employees) will elect not to receive protected health information because they will have little, if any, need for such data. Any needs that plan sponsors of small group health plans may have for information can be accomplished by receiving the information in summary form. The Department has assumed that only 5 percent of plan sponsors of small group health plans that provide coverage through a contract with an issuer will actually take the steps necessary to receive protected health information. This is approximately 96,900 firms. For these firms, the Department assumes it will take one hour to determine procedural and organization issues and an additional 1/3 hour of an attorney’s time to make plan document changes, which will be simple and essentially standardized. This will cost $7.1 million.

Plan sponsors who are employers of medium (51–199 employees) and large (over 200 employees) firms that provide health benefits through contracts with issuers are more likely to want access to protected health information for plan administration, for example to use it to audit claims or perform quality assurance functions on behalf of the group health plan. The Department assumes that 25 percent of plan sponsors of medium sized firms and 75 percent of larger firms will want to receive protected health information. This is approximately 38,000 medium size firms and 27,000 larger firms. To provide access to protected health information by the group health plan, a plan sponsor will have to assess the current flow of protected health information from their issuer and determine what information is necessary and appropriate. The plan sponsors may then have to make internal organizational changes to assure adequate protection of protected health information so that the relevant requirements are met for the group health plan. We assume that medium size firms will take 16 work hours to complete organizational changes, plus one hour of legal time to make changes to plan documents and certify to the insurance carrier that the firm is eligible to receive protected health information. We assume that large firms will require 32 hours of internal organizational work and one hour of legal time. This will cost $52.4 million and is a one-time expense.

Business Associates

The final rule requires a covered entity to have a written contract or other arrangement that documents satisfactory assurance that business associate will appropriately safeguard protected health information in order to disclose it to a business associate based on such an arrangement. The Department expects business associate contracts to be fairly standardized, except for language that will have to be tailored to the specific arrangement between the parties, such as the allowable uses and disclosures of information. The Department assumes the standard language initially will be developed by trade and professional associations for their members. Small providers are likely to simply adopt the language or make minor modifications, while health plans and hospitals may start with the prototype language but may make more specific changes to
meet their institutional needs. The regulation includes a requirement that the covered entity take steps to correct, and in some cases terminate, a contract, if necessary, if they know of violations by a business associate. This oversight requirement is consistent with standard oversight of a contract. The Department could not derive a per entity cost for this work directly. In lieu of this, we have assumed that the trade and professional associations’ work plus any minor tailoring of it by a covered entity would amount to one hour per non-hospital provider and two hours for hospitals and health plans. The larger figure for hospitals and health plans reflects the fact that they are likely to have a more extensive array of relationships with business associates.

The cost for the changes in business associate contracts is estimated to be $103 million. This will be an initial year cost only because the Department assumes that this contract language will become standard in future contracts. In addition, the Department has estimated the cost for business associates to comply with the minimum necessary provisions. As part of the minimum necessary provisions, covered entities will have to establish policies to ensure that only the minimum necessary protected health information is shared with business associates. To the extent that data are exchanged, covered entities will have to review the data and systems programs to assure compliance.

For non-hospital providers, we estimate that the first year will require an average of three hours to review existing agreements, and thereafter, they will require an additional hour to assure business associate compliance. We estimate that hospitals will require an additional 200 hours the first year and 16 hours in subsequent years; health plans will require an additional 112 hours the first year and 8 hours in subsequent years. As in other areas, we have assumed a weighted average wage of $19.7 million in the first year, and a total of $697 million over ten years. (These estimates include the both the cost for the covered entity and the business associates.)

**Inspection and Copying**

In the NPRM estimate, inspection and copying were a major cost. Based on data and information from the public comments and further fact-finding, however, the Department has re-estimated these policies and found them to be much less expensive. The public comments demonstrate that copying of records is wide-spread today. Records are routinely copied, in whole or in part, as part of treatment or when patients change providers. In addition, copying occurs as part of legal proceedings. The amount of inspection and copying of medical records that occurs for these purposes is not expected to change measurably as a result of the final regulation.

The final regulation establishes the right of individuals to access, that is to inspect and obtain a copy of, protected health information about them in designated record sets. Although this is an important right, the Department does not expect it to result in dramatic increases in requests from individuals. The Georgetown report on state privacy laws indicates that 33 states currently give patients some right to access medical information. The most common right of access granted by state law is the right to inspect personal information held by physicians and hospitals. In the process of developing estimates for the cost of providing access, we assumed that most providers currently have procedures for allowing patients to inspect and obtain a copy of individually identifiable health information about themselves. The economic impact of requiring entities to allow individuals to access their records should be relatively small. One public commenter addressed this issue and provided specific data which supports this conclusion.

Few studies address the cost of providing medical records to patients. The most recent was a study in 1998 by the Tennessee Comptroller of the Treasury. It found an average cost of $9.96 per request, with an average of 31 pages per request. The cost per page of providing copies was $0.32 per page. This study was performed on hospitals only. The cost per request may be lower for other types of providers, since those seeking hospital records are more likely to have more complicated records than those in a primary care or other types of offices. An earlier report showed much higher costs than the Tennessee study. In 1992, Rose Dunn published a report based on her experience as a manager of medical records. She estimated a 10-page request would cost $5.32 in labor costs only, equaling labor cost per page of $0.53. However, this estimate appears to reflect costs before computerization. The expected time spent per search was 30.6 minutes; 85 percent of this cost was significantly reduced with computerization (this includes time taken for file retrieval, photocopying, and re-filing; file retrieval is the only time cost that would remain under computerization).

In estimating the cost of copying records, the Department relied on the public comment from a medical records outsourcing industry representative, which submitted specific volume and cost data from a major firm that provides extensive medical record copying services. According to these data, 900 million pages of medical records are copied each year in the U.S., the average medical record is 31 pages, and copying costs are $0.50 per page. In addition, the commenter noted that only 10 percent of all requests are made directly from patients, and of those, the majority are for purposes of continuing care (transfer to another provider), not for purposes of individual inspection. The Department assumed that 25 percent of direct patient requests to copy medical records are for purposes of inspecting their accuracy (i.e., 2.5 percent of all copy requests) or 850,000 in 2003 if the current practice remained unchanged.

To estimate the marginal increase in copying that might result from the regulation, the Department assumed that as patients gained more awareness of their right to inspect and copy their records, more requests will occur. As a result, the Department assumed a ten percent increase in the number of requests to inspect and copy medical records over the current baseline, which would amount to a little over 65,000 additional requests in 2003 at a cost of $1.3 million. Allowing for a 5.3 percent increase in records based on the increase in ambulatory care visits, the highest growth rate among health service sectors (the National Ambulatory Medical Care Survey, 1998), the total cost for the ten-year period would be $16.8 million.

The final rule allows a provider to deny an individual the right to inspect or obtain a copy of protected health information in a designated record set under certain circumstances, and it provides, in certain circumstances, that the patient can request the denial to be reviewed by another licensed health care professional. The initial provider can choose a licensed health care professional to render the second review.

The Department assumes denials and subsequent requests for reviews will be extremely rare. The Department estimates there are about 932,000 annual requests for inspections (i.e., both plus new requests from the regulation), or approximately 11 million over the ten-year period. If one-
tenth of one percent of those requests were to result in a denial in accordance with the rule, the result would be 11,890 cases. Not all these cases would be appealed. If 25 percent were appealed, the result would be 2,972 cases. If a second provider were to spend 15 minutes reviewing the case, the cost would be $6,000 in the first year and $86,360 over ten years.

Amendments to Protected Health Information

Many providers and health plans currently allow patients to amend the information in their medical record, where appropriate. If an error exists, both the patient and the provider or health plan benefit from the correction. However, as with inspection and copying, many states do not provide individuals with the right to request amendment to protected health information about themselves. Based on these assumptions, the Department concludes that the principal economic effect of the final rule would be to expand the right to request amendments to protected health information held by a health plan or provider to those who are not currently covered by amendment requirements under state laws or codes of conduct. In addition, the rule may draw additional attention to the issue of inaccuracies in information and may stimulate patient demand for amendment of medical records, including in those states that currently provide a right to amend medical records.

Under the final regulation, if a patient requests an amendment to his or her medical record, the provider must either accept the amendment or provide the individual with the opportunity to submit a statement disagreeing with the denial. The provider must acknowledge the request and inform the patient of his action.

The cost calculations assume that individuals who request an opportunity to amend their medical record have already obtained a copy of it. Therefore, the administrative cost of amending the patient’s record is completely separate from inspection and copying costs.

Based on fact-finding discussions with a variety of providers, the Department assumes that 25 percent of the projected 850,000 people who request to inspect their records will seek to amend them. This number is the existing demand plus the additional requests resulting from the rule. Over ten years, the number of expected amendment requests will be 2.7 million. Unlike inspections, which currently occur in a small percentage of cases, our fact-finding suggests that patients very rarely seek to amend their records, but that the establishment of this right in the rule will spur more requests. The 25 percent appears to be high based on our discussions with providers but it is being used to avoid an underestimation of the cost.

As noted, the provider or health plan is not required to evaluate any amendment requests, only to append or otherwise link to the request in the record. We expect the responses will vary; sometimes an assistant will only make the appropriate notation in the record, requiring only a few minutes; other times a provider or manager will review the request and make changes if appropriate, which may require as much as an hour. To be conservative in its estimate, the Department has assumed, on average, 30 minutes for each amendment request at a cost of $47.28 per hour (2000 CPS).

The first-year cost for the amendment policy is estimated to be $5 million. The ten-year cost of this provision is $78.8 million.

Law Enforcement and Judicial and Administrative Proceedings

The law enforcement provisions of the final rule allow disclosure of protected health information without patient authorization under four circumstances: (1) Pursuant to legal process or as otherwise required by law; (2) to locate or identify a suspect, fugitive, material witness, or missing person; (3) under specified conditions regarding a victim of crime; and (4) and when a covered entity believes the protected health information constitutes evidence of a crime committed on its premises. As under current law and practice, a covered entity may disclose protected health information to a law enforcement official if such official.

Based on our fact-finding, we are not able to estimate any additional costs from the final rule regarding disclosures to law enforcement officials. The final rule makes it clear that current court orders and grand jury subpoenas will continue to provide a basis for covered entities to disclose protected health information to law enforcement officials. The three-part test, which covered entities must use to decide whether to disclose information in response to an administrative request such as an administrative subpoena, represents a change from current practice. There will be only minimal costs to draft the standard language for such subpoenas. We are unable to estimate other costs attributable to the use of administrative subpoenas. We have not been able to discover any specific information about the costs to law enforcement of establishing the predicates for issuing the administrative subpoena, nor have we been able to estimate the number of such subpoenas that will likely be issued once the final rule is implemented.

A covered entity may disclose protected health information in response to an order in the course of a judicial or administrative proceeding if reasonable efforts have been made to give the individual, who is the subject of the protected health information, notice of and an opportunity to object to the disclosure or to secure a qualified protective order. The Department was unable to estimate any additional costs due to compliance with the final rule’s provisions regarding judicial and administrative proceedings. The provision requiring a covered entity to make efforts to notify an individual that his or her records will be used in proceedings is similar to current practice; attorneys for plaintiffs and defendants agreed that medical records are ordinarily produced after the relevant party has been notified. With regard to protective orders, we believe that standard language for such orders can be created at minimal cost. The cost of complying with such protective orders will also likely be minimal, because attorney’s client files are ordinarily already treated under safeguards comparable to those contemplated under the qualified protective orders. The Department was unable to make an estimate of how many such protective orders might be created annually.

We thus do not make any estimate of the initial or ongoing costs for judicial, administrative, or law enforcement proceedings.

Costs to the Federal Government

The rule will have a cost impact on various federal agencies that administer programs that require the use of individual health information. The federal costs of complying with the regulation and the costs when federal government entities are serving as providers are included in the regulation’s total cost estimate outlined in the impact analysis. Federal agencies or programs clearly affected by the rule are those that meet the definition of a covered entity. However, non-covered agencies or programs that handle medical information, either under permissible exceptions to the disclosure rules or through an individual’s expressed authorization, will likely incur some costs complying with provisions of this rule. A sample of federal agencies encompassed by the...
broad scope of this rule include the: Department of Health and Human Services, Department of Defense, Department of Veterans Affairs, Department of State, and the Social Security Administration.

The greatest cost and administrative burden on the federal government will fall to agencies and programs that act as covered entities, by virtue of being either a health plan or provider. Examples include the Medicare, Medicaid, Children’s Health Insurance and Indian Health Service programs at the Department of Health and Human Services; the CHAMPVA health program at the Department of Veterans Affairs; and the TRICARE health program at the Department of Defense. These and other health insurance or provider programs operated by the federal government are subject to requirements placed on covered entities under this rule, including, but not limited to, those outlined in Section D of the impact analysis. While many of these federal programs already afford privacy protections for individual health information through the Privacy Act and standards set by the Departments and implemented through their contracts with providers, this rule is nonetheless expected to create additional requirements. Further, we anticipate that most federal health programs will, to some extent, need to modify their existing practices to comply fully with this rule. The cost to federal programs that function as health plans will be generally the same as those for the private sector.

A unique cost to the federal government will be in the area of enforcement. The Office for Civil Rights (OCR), located at the Department of Health and Human Services, has the primary responsibility to monitor and audit covered entities. OCR will monitor and audit covered entities in both the private and government sectors, will ensure compliance with requirements of this rule, and will investigate complaints from individuals alleging violations of their privacy rights. In addition, OCR will be required to recommend penalties and other remedies as part of their enforcement activities. These responsibilities represent an expanded role for OCR. Beyond OCR, the enforcement provisions of this rule may have additional costs to the federal government through increased litigation, appeals, and inspector general oversight.

Examples of other unique costs to the federal government may include such activities as public health surveillance at the Centers for Disease Control and Prevention, health research projects at the Agency for Healthcare Research and Quality, clinical trials at the National Institutes of Health, and law enforcement investigations and prosecutions by the Federal Bureau of Investigations. For these and other activities, federal agencies will incur some costs to ensure that protected health information is handled and tracked in ways that comply with the requirements of this title.

We estimate that federal costs under this rule will be approximately $150 million in 2003 and $1.8 billion over ten years. The ten-year federal cost estimate represents about 10.2 percent of the privacy regulation’s total cost. This estimate was derived in two steps. First, we assumed that the proportion of the privacy regulation’s total cost accruing to the federal government in a given year will be equivalent to the proportion of projected federal costs as a percentage of national health expenditures for that year. To estimate these proportions, we used the Health Care Financing Administration’s November 1998 National Health Expenditure projections (the most recent data available) of federal health expenditures as a percent of national health expenditures from 2003 through 2008, trended forward to 2012. We then adjusted these proportions to exclude Medicare and Medicaid spending, reflecting the fact that the vast majority of participating Medicare and Medicaid providers will not be able to pass through the costs of complying with this rule to the government because they are not reimbursed under cost-based payment systems. This calculation yields a partial federal cost of $166 million in 2003 and $770 million over ten years.

Second, we add the Medicare and federal Medicaid costs resulting from the privacy regulation that HCFA’s Office of the Actuary project can be passed through to the federal government. These costs reflect the actuaries’ assumption regarding how much of the total privacy regulation cost burden will fall on participating Medicare and Medicaid providers, based on the November 1998 National Health Expenditure data. Then the actuaries estimate what percentage of the total Medicare and federal Medicaid burden could be billed to the programs, assuming that (1) only 3 percent of Medicare providers and 5 percent of Medicaid providers are still reimbursed under cost-based payment systems, and (2) over time, some Medicaid costs will be incorporated in the state’s Medicaid expenditure projections that are used to develop the federal cost share of Medicaid spending. The results of this actuarial analysis add another $30 million in 2003 and $1.0 billion over ten years to the federal cost estimate. Together, these three steps constitute the total federal cost estimate of $236 million in 2003 and $2.2 billion over ten years.

Costs to State and Local Governments

The rule will also have a cost effect on various state and local agencies that administer programs requiring the use of individually identifiable health information. State and local agencies or programs clearly affected by the rule are those that meet the definition of a covered entity. The costs when government entities are serving as providers are included in the total cost estimates. However, non-covered agencies or programs that handle individually identifiable health information, either under permissible exceptions to the disclosure rules or through an individual’s expressed authorization, need to modify some costs complying with provisions of this rule. Samples of state and local agencies or programs encompassed by the broad scope of this rule include: Medicaid, State Children’s Health Insurance Programs, county hospitals, state mental health facilities, state or local nursing facilities, local health clinics, and public health surveillance activities, among others. We have included state and local costs in the estimation of total costs in this section.

The greatest cost and administrative burden on the state and local government will fall to agencies and programs that act as covered entities, by virtue of being either a health plan or provider, such as Medicaid, State Children’s Health Insurance Programs, and county hospitals. These and other health insurance or provider programs operated by state and local government are subject to requirements placed on covered entities under this rule, including, but not limited to, those outlined in this section (Section E) of the impact analysis. Many of these state and local programs already afford privacy protections for individually identifiable health information through the Privacy Act. For example, state governments often become subject to Privacy Act requirements when they contract with the federal government. This rule is expected to create additional requirements beyond those covered by the Privacy Act. Furthermore, we anticipate that most state and local health programs will, to some extent, need to modify their existing Privacy Act practices to fully comply with this rule. The cost to state
and local programs that function as health plans will be different than the private sector, much as the federal costs vary from private health plans.

A preliminary analysis suggests that state and local government costs will be on the order of $460 million in 2003 and $2.4 billion over ten years. We assume that the proportion of the privacy regulation’s total cost accruing to state and local governments in a given year will be equivalent to the proportion of projected state and local costs as a percentage of national health expenditures for that year. To estimate these proportions, we used the Health Care Financing Administration’s November 1998 National Health Expenditure projections of state and local health expenditures as a percent of national health expenditures from 2003 through 2008, trended forward to 2012. Based on this approach, we assume that over the entire 2003 to 2012 period, 13.6 percent, or $2.4 billion, of the privacy regulation’s total cost will accrue to state and local governments. Of the $2.4 billion state and local government cost, 19 percent will be incurred in the regulation’s first year (2003). In each of the out-years (2004–2012), the average percent of the total cost incurred will be about nine percent per year. These state and local government costs are included in the total cost estimates discussed in the regulatory impact analysis.

F. Benefits

There are important societal benefits associated with improving health information privacy. Confidentiality is a key component of trust between patients and providers, and some studies indicate that a lack of privacy may deter patients from obtaining preventive care and treatment.\(^55\) For these reasons, traditional approaches to estimating the value of a commodity cannot fully capture the value of personal privacy. It may be difficult for individuals to assign value to privacy protection because most individuals view personal privacy as a right. Therefore, the benefits of the proposed regulation are impossible to estimate based on the market value of health information alone. However, it is possible to evaluate some of the benefits that may accrue to individuals as a result of proposed regulation, and these benefits, alone, suggest that the regulation is warranted. Added to these benefits is the intangible value of privacy, the security that individuals feel when personal information is kept confidential. This benefit is very real and very significant but there are no reliable means of measuring dollar value of such benefit.

As noted in the comment and response section, a number of commenters raised legitimate criticisms of the Department’s approach to estimating benefits. The Department considered other approaches, including attempts to measure benefits in the aggregate rather than the specific examples set forth in the NPRM. However, we were unable to identify data or models that would provide credible measures. Privacy has not been studied empirically from an economic perspective, and therefore, we concluded that the approach taken in the NPRM is still the most useful means of illustrating that the benefits of the regulation are significant in relation to the economic costs. Before beginning the discussion of the benefits, it is important to create a framework for how the costs and benefits may be viewed in terms of individuals rather than societal aggregates. We have estimated the value an insured individual would need to place on increased privacy to make the privacy regulation a net benefit to those who receive health insurance. Our estimates are derived from data produced by the 1998 Current Population Survey from the Census Bureau (the most recent available at the time of the analysis), which show that 220 million persons are covered by either private or public health insurance. Joining the Census Bureau data with the costs calculated in Section E, we have estimated the cost of the regulation to be approximately $6.25 per year (or approximately $0.52 per month) for each insured individual (including people in government programs). If we assume that individuals who use the health care system will be willing to pay more than this per year to improve health information privacy, the benefits of the proposed regulation will outweigh the cost.

This is a conservative estimate of the number of people who will benefit from the regulation because it assumes that only those individuals who have health insurance or are in government programs will use medical services or benefit from the provisions of the proposed regulation. Currently, there are 42 million Americans who do not have any form of health care coverage. The estimates do not include those who pay for medical care directly, without any insurance or government support.

By lowering the number of users in the system, we have inflated our estimate of the per-person cost of the regulation; therefore, we assume that our estimate represents the highest possible cost for an individual.

An alternative approach to determining how people would have to value increased privacy for this regulation to be beneficial is to look at the costs divided by the number of encounters with health care professionals annually. Data from the Medical Expenditure Panel Survey (MEPS) produced by the Agency for Healthcare Policy Research (AHCPR) show approximately 776.3 million health care visits (e.g., office visits, hospital and nursing home stays, etc.) in the first year (2003). As with the calculation of average annual cost per insured patient, we divided the total cost of complying with the regulation by the total annual number of health care visits. The cost of instituting requirements of the proposed regulation is $0.19 per health care visit. If we assume that individuals would be willing to pay more than $0.19 per health care visit to improve health information privacy, the benefits of the proposed regulation outweigh the cost.

Qualitative Discussion

A well designed privacy standard can be expected to build confidence among the public about the confidentiality of their medical records. The seriousness of public concerns about privacy in general are shown in the 1994 Equifax-Harris Consumer Privacy Survey, where “84 percent of Americans are either very or somewhat concerned about threats to their personal privacy.”\(^54\) A 1999 report, “Promoting Health and Protecting Privacy” notes “** many people fear their personal health information will be used against them: to deny insurance, employment, and housing, or to expose them to unwanted judgements and scrutiny.”\(^54\) These concerns would be partly allayed by the privacy standard. Fear of disclosure of treatment is an impediment to health care for many Americans. In the 1993 Harris-Equifax Health Information Privacy Survey, seven percent of respondents said they or a member of their immediate family had chosen not to seek medical services due to fear of harm to job prospects or other life opportunities. About two percent reported having chosen not to file an insurance claim because of concerns of lack of privacy or confidentiality.\(^55\) Increased confidence

\(^{52}\) Equifax-Harris Consumer Privacy Survey, 1994.

\(^{53}\) Consumer Privacy Survey, Harris-Equifax, 1994, p vi.

\(^{54}\) Promoting Health: Protecting Privacy, California Health Care Foundation and Consumers Union, January 1999, p 12.

\(^{55}\) Health Information Survey, Harris-Equifax, 1993, pp 49-50.
on the part of patients that their privacy would be protected would lead to increased treatment among people who delay or never begin care, as well as among people who receive treatment but pay directly (to the extent that the ability to use their insurance benefits will reduce cost barriers to more complete treatment). It will also change the dynamic of current payments. Insured patients currently paying out-of-pocket to protect confidentiality will be more likely to file with their insurer and to seek all necessary care. The increased utilization that would result from increased confidence in privacy could be beneficial under many circumstances. For many medical conditions, early and comprehensive treatment can lead to lower costs.

The following are four examples of areas where increased confidence in privacy would have significant benefits. They were chosen both because they are representative of widespread and serious health problems, and because they are areas where reliable and relatively current data are available for this kind of analysis. The logic of the analysis, however, applies to any health condition, including relatively minor conditions. We expect that some individuals might be concerned with maintaining privacy even if they have no significant health problems because it is likely that they will develop a medical condition in the future that they will want to keep private.

Cancer

The societal burden of disease imposed by cancer is indisputable. Cancer is the second leading cause of death in the US, exceeding only by heart disease. In 2000, it is estimated that 1.22 million new cancer cases will be diagnosed. The estimated prevalence of cancer cases (both new and existing cases) in 1999 was 8.37 million. In addition to mortality, incidence, and prevalence rates, the other primary methods of assessing the burden of disease are cost-of-illness and quality of life measures. Cost of illness measures the economic costs associated with treating the disease (direct costs) and lost income associated with morbidity and mortality (indirect costs).

The National Institutes of Health estimates that the overall annual cost of cancer in 1990 was $96.1 billion; $27.5 billion in direct medical costs and $68.7 billion for lost income due to morbidity and mortality. Health-related quality of life measures integrate the mortality and morbidity effects of disease to produce health status scores for an individual or population. For example, the Quality Adjusted Life Year (QALY) combines the pain, suffering, and productivity loss caused by illness into a single measure. The Disability Adjusted Life Year (DALY) is based on the sum of life years lost to premature mortality and years that are lived adjusted for disability. The analysis below is based on the cost-of-illness measure for cancer, which is more developed than the quality of life measure.

Among the most important elements in the fight against cancer are screening, early detection and treatment of the disease. However, many patients are concerned that cancer detection and treatment will make them vulnerable to discrimination by insurers or employers. These privacy concerns have been cited as a reason patients do not seek early treatment for diseases such as cancer. As a result of forgoing early treatment, cancer patients may ultimately face a more severe illness and/or premature death.

Increasing people’s confidence in the privacy of their medical information would encourage more people with cancer to seek cancer treatment earlier, which would increase cancer survival rates and thus reduce the lost wages associated with cancer. For example, only 24 percent of ovarian cancers are diagnosed in the early stages. Of these, approximately 90 percent of patients survive treatment. The survival rate of women who detect breast cancer early is similarly high; more than 90 percent of women who detect and treat breast cancer in its early stages will survive.

We have attempted to estimate the annual savings in foregone wages that would result from earlier treatment due to enhanced protection of the privacy of medical records. We do not assume there would be increased medical costs from earlier treatment because the costs of earlier and longer cancer treatment are probably offset by the costs of treating late-stage cancer among people who would otherwise not be treated until their cases had progressed.

Although figures on the number of individuals who avoid cancer treatment due to privacy concerns do not exist, some indirect evidence is available. A 1993 Harris-Equifax Health Information Privacy Survey (noted earlier) found that seven percent of respondents reported that they or a member of their immediate family had chosen not to seek services for a physical or mental health condition due to fear of harm to job prospects or other life opportunities. It should be noted that this survey is somewhat dated and represents only one estimate. Moreover, given the wording of the question, there are other reasons aside from privacy concerns that led these individuals to respond affirmatively. However, for the purposes of this estimate, we assume that privacy concerns were responsible for the majority of positive responses.

Based on the Harris-Equifax survey estimate that seven percent of people did not seek services for physical or mental health conditions due to fears about job prospects or other opportunities, we assume that the proportion of people diagnosed with cancer who did not seek earlier treatment due to these fears is also seven percent. Applying this seven percent figure to the estimated number of total cancer cases (8.37 million) gives us an estimate of 586,000 people who did not seek earlier cancer treatment due to privacy concerns. We estimate annual lost wages due to cancer morbidity and mortality per cancer patient by dividing total lost wages ($68.7 billion) by the number of cancer patients (8.37 million), which rounds to $8,200. We then assume that cancer patients who seek earlier treatment would achieve a one-third reduction in cancer mortality and morbidity due to earlier treatment. The assumption of a one-third reduction in mortality and morbidity is derived from a study showing a one-third reduction in colorectal cancer mortality due to colorectal cancer screening. We could have chosen a lower or higher treatment success rate. By multiplying 586,000 by $8,200 by one-third, we calculate that $1.6 billion in lost wages could be saved each year by encouraging more people to seek early cancer treatment through enhanced privacy protections. This estimate illustrates the potential savings


61 DALY scores for 10 cancer sites are presented in Brown, “The Burden of Illness of Cancer: Economic Cost and Quality of Life,” figure 1.


in lost wages due to cancer that could be achieved with greater privacy protections.

**HIV/AIDS**

Early detection is essential for the survival of a person with HIV (Human Immunodeficiency Virus). Concerns about the confidentiality of HIV status would likely deter some people from getting tested. For this reason, each state has passed some sort of legislation regarding confidentiality of an individual’s HIV status. However, HIV status can be revealed indirectly through disclosure of HAART (Highly Active Anti-Retroviral Therapy) or similar HIV treatment drug use. In addition, since HIV/AIDS (Acquired Immune Deficiency Syndrome) is often the only specially protected condition, “blacked out” information on medical charts could indicate HIV positive status.64 Strengthening privacy protections beyond this disease could increase confidence in privacy regarding HIV.65 Drug therapy for HIV positive persons has proven to be a life-extending, cost-effective tool.66 A 1998 study showed that beginning treatment with HAART in the early asymptomatic stage is more cost-effective than beginning it late. After five years, only 15 percent of patients with early treatment are estimated to develop an ADE (AIDS-defining event), whereas 29 percent would if treatment began later. Early treatment with HAART prolongs survival (adjusted for quality of life) by 6.2 percent. The overall cost of early HAART treatment is estimated at $23,700 per quality-adjusted year of life saved.66

**Other Sexually Transmitted Diseases**

It is difficult to know how many people are avoiding testing for STDs despite having a sexually transmitted disease. A 1998 study by the Kaiser Family Foundation found that the incidence of disease was 15.3 million in 1996, though there is great uncertainty due to under-reporting.67 For a potentially embarrassing disease such as an STD, seeking treatment requires trust in both the provider and the health care system for confidentiality of such information. Greater trust should lead to more testing and greater levels of treatment. Earlier treatment for curable STDs can mean a decrease in morbidity and the costs associated with complications. These include expensive fertility problems, fetal blindness, ectopic pregnancies, and other reproductive complications.68 In addition, there could be greater overall savings if earlier treatment translates into reduced spread of infections.

**Mental Health Treatment**

When individuals have a better understanding of the privacy practices that we are requiring in this proposed rule, some will be less reluctant to seek mental health treatment. One way that individuals will receive this information is through the notice requirement. Increased use of mental health and services would be expected to be beneficial to the persons receiving the care, to their families, and society at large. The direct benefit to the individual from treatment would include improved quality of life, reduced disability associated with mental conditions, reduced mortality rate, and increased productivity associated with reduced disability and mortality. The benefit to families would include quality of life improvements and reduced medical costs for other family members associated with abusive behavior by the treated individual.

The potential economic benefits associated with improving privacy of individually identifiable health information and thus encouraging some portion of individuals to seek initial mental health treatment or increase service use are difficult to quantify. Nevertheless, using a methodology similar to the one used above to estimate potential savings in cancer costs, one can lay out a range of possible benefit levels to illustrate the possibility of cost savings associated with an expansion of mental health and treatment to individuals who, due to protections offered by the privacy regulation, might seek treatment that they otherwise would not have. This can be illustrated by drawing upon existing data on the economic costs of mental illness and the treatment effectiveness of interventions.

The 1998 Substance Abuse and Mental Health Statistics Source Book from the Substance Abuse and Mental Health Services Administration (SAMHSA) estimates that the economic cost to society of mental illness in 1994 was about $204.4 billion. About $91.7 billion was due to the cost of treatment and medical care and $112.6 billion (1994 dollars) was due to loss of productivity associated with morbidity and mortality and other related costs, such as crime.69 Evidence suggests that appropriate treatment of mental health disorders can result in 50–80 percent of individuals experiencing improvements in these types of conditions. Improvements in patient functioning and reduced hospital stays could result in hundreds of millions of dollars in cost savings annually.

Although figures on the number of individuals who avoid mental health treatment due to privacy concerns do not exist, some indirect evidence is available. As noted in the cancer discussion, the 1993 Harris-Equifax Health Information Privacy Survey found that 7 percent of respondents reported that they or a member of their immediate family had chosen not to seek services for a physical or mental health condition due to fear of harm to job prospects or other life opportunities. (See above for limitations to this data.) We assume that the proportion of people with a mental health disorder who did not seek treatment due to fears about job prospects or other opportunities is the same as the proportion in the Harris-Equifax survey sample who did not seek services for physical or mental health conditions due to the same fears (7 percent). The 1999 Surgeon General’s Report on Mental Health estimates that 28 percent of the U.S. adult population has a diagnosable mental and/or substance abuse disorder and 20 percent of the population has a mental and/or substance abuse disorder for which they do not receive treatment.70 Based on the Surgeon General’s Report, we estimate that 15 percent of the adult population has a mental disorder for which they do not seek treatment.71 Assuming that 7

---


65 For example, Roger Detela, M.D., et al., in “Effectiveness of Potent Anti-retroviral Therapy. Journal of the American Medical Association (JAMA), 1998; 280:1497–1503 note the impact therapy for HIV persons with respect to lengthening the time to development of AIDS, not just delaying death in persons who already have AIDS.


68 Standard Medical information; see http://www.mayohelath.org for examples.


71 According to the Surgeon General’s Report, 28 percent of the adult population have either a mental or addictive disorder, whether or not they receive services: 19 percent have a mental disease alone, 6 percent have a substance abuse disorder alone, and 3 percent have both. Subtracting the 3 percent who have both, about three-quarters of the population with either a mental or addictive disorder have a mental disorder and one-quarter have a substance abuse disorder. We assume that this ratio (three-quarters to one-quarter) is the same for the adult population with either a mental or addictive disorder who do not receive services.
percent of those with mental disorders did not seek treatment due to privacy concerns, we estimate that 1.05 percent of the adult population 72 (15 percent multiplied by 7 percent), or 2.07 million people, did not seek treatment for mental illness due to privacy fears.

The indirect (non-treatment) economic cost of mental illness per person with mental illness is $2,590 ($112.6 billion divided by 43.4 million people with mental illness).73 The treatment cost of mental illness per person with mental illness is $2,110 ($91.7 billion divided by 43.4 million individuals). If we assume that indirect economic costs saved by encouraging more individuals with mental illness to enter treatment are offset by the additional treatment costs, the net savings is about $480 per person.

As stated above, appropriate treatment of mental health disorders can result in 50-80 percent of individuals experiencing improvements in these types of conditions. Therefore, we multiply the number of individuals with mental disorders who would seek treatment with greater privacy protections (2.07 million) by the treatment effectiveness rate by the net savings per effective treatment ($480). Assuming a 50 percent success rate, this equation yields annual savings of $497 million. Assuming an 80 percent success rate, this yields annual savings of $795 million.

Given the existing data on the annual economic costs of mental illness and the rates of treatment effectiveness for these disorders, coupled with assumptions regarding the percentage of individuals who would seek mental health treatment with greater privacy protections, the potential net economic benefits could range from approximately $497 million to $795 million annually.

V. Final Regulatory Flexibility Analysis

A. Introduction

Pursuant to the Regulatory Flexibility Act 5 U.S.C. 601 et seq., the Department must prepare a regulatory flexibility analysis if the Secretary certifies that a final rule would have a significant economic impact on a substantial number of small entities.74

This analysis addresses four issues: (1) The need for, and objective of, the rule; (2) a summary of the public comments to the NPRM and the Department’s response; (3) a description and estimate of the number of small entities affected by the rule; and (4) a description of the steps the agency has taken to minimize the economic impact on small entities, consistent with the law and the intent of the rule. The following sections provide details on each of these issues. A description of the projected reporting and record keeping requirements of the rule are included in Section IX, below.

B. Reasons for Promulgating the Rule

This proposed rule is being promulgated in response to a statutory mandate to do so under section 264 of Public Law 104–191. Additional information on the reasons for promulgating the rule can be found in earlier preamble discussions (see Section I. B. above).

1. Objectives and Legal Basis

This information can be found in earlier preamble discussions (See I. C. and IV., above).


This information can be found in earlier preamble discussions (See I. C., above).

C. Summary of Public Comments

The Department received only a few comments regarding the Initial Regulatory Flexibility Analysis (IRFA) contained in the NPRM. A number of commenters argued that the estimates IRFA were too low or incomplete. The estimates were incomplete to the extent that a number of significant policy provisions in the proposal were not estimated because of too little information at the time. In the final IRFA we have estimates for these provisions. As for the estimates being too low, the Department has sought as much information as possible. The methodology employed for allocating costs to the small business sectors is explained in the following section.

Most of the other comments pertaining to the IRFA criticized specific estimates in the NPRM. Generally, the commenters argued that certain cost elements were not included in the cost estimates presented in the NPRM. The Department has expanded our description of our data and methodology in both the final RIA and this final RFA to try to clarify the data and assumptions made and the rationale for using them.

Finally, a number of commenters suggested that small entities be exempted from coverage from the final rule, or that they be given more time to comply. As the Department has explained in the Response to Comment section above, such changes were considered but rejected. Small entities constitute the vast majority of all entities that are covered; to exempt them would essentially nullify the purpose of the rule. Extensions were also considered but rejected. The rule does not take effect for two years, which is ample time for small entities to learn about the rule and make the necessary changes to come into compliance.

D. Economic Effects on Small Entities

1. Number and Types of Small Entities Affected

The Small Business Administration defines small businesses in the health care sector as those organizations with less than $5 million in annual revenues. Nonprofit organizations are also considered small entities;75 however, individuals and states are not included in the definition of a small entity. Similarly, small government jurisdictions with a population of less than 50,000 are considered small entities.76

Small business in the health care sector affected by this rule may include such businesses as: Nonprofit health plans, hospitals, and skilled nursing facilities (SNFs); small businesses providing health coverage; small physician practices; pharmacies; laboratories; durable medical equipment (DME) suppliers; health care clearinghouses; billing companies; and vendors that supply software applications to health care entities.

The U.S. Small Business Administration reports that as of 1997, there were 562,916 small health care entities77 classified within the SIC 6201-80.

72 According to the Population Estimates Program, Population Division, U.S. Census Bureau, the U.S. population age 20 and older is 197.1 million on Sept. 1, 2000. This estimate of the adult population is used throughout this section.

73 The number of adults with mental illness is calculated by multiplying the U.S. Census Bureau estimate of the U.S. adult population—197.1 million—by the percent of the adult population with mental illness—22 percent, according to the Surgeon General’s Report on Mental Health, which says that 19 percent of the population have a mental disorder alone and three percent have a mental and substance abuse disorder.

74 “Entities” and “establishments” are synonymous in this analysis.

75 “Entities” and “establishments” are used synonymously in this RFA.

76 “Small governments” were not included in this analysis directly; rather we have included the kinds of institutions within those governments that are likely to incur costs, such as government hospitals and clinics.

77 Entities are the physical location where an enterprise conducts business. An enterprise may conduct business in more than one establishment.
codes we have identified as being covered establishments (Table A).

### Table A. -- Number of Health Care Establishments That Meet SBA Size Standards,

<table>
<thead>
<tr>
<th>Standard Industrial Code (SIC)</th>
<th>Industry</th>
<th>Total Number of Health Care Establishments</th>
<th>Number of Establishments that Meet SBA Size Standards or RFA non-profit standard</th>
<th>% of Establishments that Meet SBA Size Standards or RFA non-profit standard</th>
</tr>
</thead>
<tbody>
<tr>
<td>5910</td>
<td>Drug Stores &amp; Proprietary Stores</td>
<td>48,147</td>
<td>23,923</td>
<td>49.7%</td>
</tr>
<tr>
<td>6320</td>
<td>Accident &amp; Health Insurance &amp; Medical Service Plans</td>
<td>8,083</td>
<td>665</td>
<td>8.2%</td>
</tr>
<tr>
<td>7352</td>
<td>Medical Equipment Rental and Leasing</td>
<td>3,346</td>
<td>1,836</td>
<td>54.9%</td>
</tr>
<tr>
<td>8010</td>
<td>Offices &amp; Clinics Of Doctors Of Medicine</td>
<td>190,233</td>
<td>170,962</td>
<td>89.9%</td>
</tr>
<tr>
<td>8020</td>
<td>Offices &amp; Clinics Of Dentists</td>
<td>115,020</td>
<td>113,864</td>
<td>99.0%</td>
</tr>
<tr>
<td>8030</td>
<td>Offices &amp; Clinics Of Doctors Of Osteopathy</td>
<td>9,143</td>
<td>8,850</td>
<td>96.8%</td>
</tr>
<tr>
<td>8040</td>
<td>Offices &amp; Clinics Of Other Health Practitioners</td>
<td>89,482</td>
<td>86,596</td>
<td>96.8%</td>
</tr>
<tr>
<td>8050</td>
<td>Nursing &amp; Personal Care Facilities</td>
<td>33,178</td>
<td>17,727</td>
<td>53.4%</td>
</tr>
<tr>
<td>8060</td>
<td>Hospitals</td>
<td>6,991</td>
<td>3,485</td>
<td>49.8%</td>
</tr>
<tr>
<td>8070</td>
<td>Medical &amp; Dental Laboratories</td>
<td>17,586</td>
<td>13,015</td>
<td>74.0%</td>
</tr>
<tr>
<td>8080</td>
<td>Home Health Care Services</td>
<td>19,562</td>
<td>12,841</td>
<td>65.6%</td>
</tr>
<tr>
<td>8090</td>
<td>Miscellaneous Health &amp; Allied Services</td>
<td>22,145</td>
<td>11,219</td>
<td>50.7%</td>
</tr>
<tr>
<td>n/a</td>
<td>Fully Insured ERISA1</td>
<td>2,125,000</td>
<td>0</td>
<td>NA</td>
</tr>
<tr>
<td>n/a</td>
<td>Institutional Review Boards (IRB)2</td>
<td>450,000</td>
<td>0</td>
<td>NA</td>
</tr>
<tr>
<td>n/a</td>
<td>Total3</td>
<td>562,916</td>
<td>464,983</td>
<td>82.6%</td>
</tr>
</tbody>
</table>

1 Source: Office of Advocacy, U.S. Small Business Administration, from data provided by the Bureau of the Census, Statistics of U.S. Businesses, 1997. Establishments that have less than $5,000,000 in annual revenue are considered small businesses here, as are non-profit establishments (regardless of revenue). We have non-profit data for the following SICs: 8050, 8060, and 8080 and have included the number of non-profits in each category into the table.

2 We have not included the number of fully insured ERISA plans or institutional review boards (IRB) in the total number of health care establishments or the number of establishments that meet SBA standards for small entities, since these are not separate businesses with SIC codes and we do not have sufficient data to impute revenues to them.

3 We have included self-insured, self-administered plans and third party administrators in the total number of health plans, even though neither has individual SIC codes because we have the ability to impute revenues to them. Therefore, the number of health plans in SIC 6320 is greater than the figure usually reported in the Statistics of U.S. Businesses.

These small businesses represent 82.6% of all health care establishments examined.78 Small businesses represent a significant portion of the total number of health care establishments but a small portion of the revenue stream for all health care establishments. In 1997, the small health care businesses represented generated approximately $430 billion in annual receipts, or 30.2% of the total revenue generated by health care establishments (Table B).79 The following sections provide estimates of the number of small health care establishments that will be required to comply with the rule. Note, however, that the SBA's published annual receipts of health care industries differ from the National Health Expenditure data that the Health Care Financing Administration (HCFA) maintains.

---


These data do not provide the specific revenue data required for a RFA; only the SBA data has the requisite establishment and revenue data for this analysis.

Table B.--Annual Receipts of Health Care Entities, 1997

<table>
<thead>
<tr>
<th>Standard Industrial Code (SIC)</th>
<th>Industry</th>
<th>Total Revenue</th>
<th>Revenue Generated by Small Entities</th>
<th>% of Total Revenue Generated by Small Entities</th>
</tr>
</thead>
<tbody>
<tr>
<td>5910</td>
<td>Drug Stores &amp; Proprietary Stores</td>
<td>$100,302,441,000</td>
<td>$25,620,978,000</td>
<td>25.5%</td>
</tr>
<tr>
<td>6320</td>
<td>Accident &amp; Health Insurance &amp; Medical Service Plans (SIC 6320), Self-Insured/ Self Administered (no SIC), Third Party Administrators (no SIC)2</td>
<td>$512,111,493,027</td>
<td>$657,074,000</td>
<td>0.1%</td>
</tr>
<tr>
<td>7332</td>
<td>Medical Equipment Rental &amp; Leasing</td>
<td>$4,040,646,000</td>
<td>$1,193,345,000</td>
<td>29.5%</td>
</tr>
<tr>
<td>8010</td>
<td>Offices &amp; Clinics Of Doctors Of Medicine</td>
<td>$182,148,148,000</td>
<td>$105,334,031,000</td>
<td>57.8%</td>
</tr>
<tr>
<td>8020</td>
<td>Offices &amp; Clinics Of Dentists</td>
<td>$48,766,434,000</td>
<td>$47,218,844,000</td>
<td>96.8%</td>
</tr>
<tr>
<td>8030</td>
<td>Offices &amp; Clinics Of Doctors Of Osteopathy</td>
<td>$4,613,192,000</td>
<td>$4,039,868,000</td>
<td>87.6%</td>
</tr>
<tr>
<td>8040</td>
<td>Offices &amp; Clinics Of Other Health Practitioners</td>
<td>$28,110,189,000</td>
<td>$23,170,899,000</td>
<td>82.4%</td>
</tr>
<tr>
<td>8050</td>
<td>Nursing &amp; Personal Care Facilities</td>
<td>$77,166,537,000</td>
<td>$24,484,098,431</td>
<td>31.7%</td>
</tr>
<tr>
<td>8060</td>
<td>Hospitals</td>
<td>$382,540,791,000</td>
<td>$172,552,388,454</td>
<td>45.1%</td>
</tr>
<tr>
<td>8070</td>
<td>Medical &amp; Dental Laboratories</td>
<td>$19,872,150,000</td>
<td>$6,862,628,000</td>
<td>34.5%</td>
</tr>
<tr>
<td>8080</td>
<td>Home Health Care Services</td>
<td>$31,061,036,000</td>
<td>$12,085,755,906</td>
<td>38.9%</td>
</tr>
<tr>
<td>8090</td>
<td>Miscellaneous Health &amp; Allied Services</td>
<td>$35,034,774,000</td>
<td>$6,812,006,000</td>
<td>19.4%</td>
</tr>
<tr>
<td>N/A</td>
<td>Total Receipts</td>
<td>$1,425,767,831,027</td>
<td>$430,031,915,791</td>
<td>30.2%</td>
</tr>
</tbody>
</table>

1 Source: Office of Advocacy, U.S. Small Business Administration, from data provided by the Bureau of the Census, Statistics of U.S. Businesses, 1997. Entities that have less than $5,000,000 in annual revenue are considered small businesses here, as are non-profit entities (regardless of revenue). We have non-profit data for the following SICs: 8050, 8080, and 8060 and have included the number of non-profits in each category into the table.

2 We have included self-insured/self-administered plans and third party administrators in the total number of health plans, even though neither has individual SIC codes because we have the ability to impute revenues to them.
The Small Business Administration reports that approximately 74 percent of the 18,000 medical laboratories and dental laboratories in the U.S. are small entities. Furthermore, based on SBA data, 55 percent of the 3,300 durable medical equipment suppliers that are not part of drug and proprietary stores in the U.S. are small entities. Over 90 percent of health practitioner offices are small businesses. Doctor offices (90%), dentist offices (99%), osteopathy (97%) and other health practitioner offices (97%) are primarily considered small businesses.

There are also a number of hospitals, home health agencies, non-profit nursing facilities, and skilled nursing facilities that will be affected by the proposed rule. According to the American Hospital Association, there are approximately 3,131 nonprofit hospitals nationwide. Additionally, there are 2,788 nonprofit home health agencies in the U.S. and the Health Care Financing Administration reports that there are 591 nonprofit nursing facilities and 4,280 nonprofit skilled nursing facilities.

Some contractors that are not covered entities but that work with covered health care entities will be required to adopt policies and procedures to protect information. We do not expect that the additional burden placed on contractors will be significant. We have not estimated the effect of the proposed rule on these entities because we cannot reasonably anticipate the number or type of contracts affected by the proposed rule. We also do not know the extent to which contractors would be required to modify their policy practices as a result of the rule.

2. Activities and Costs Associated With Compliance

This section summarizes specific activities that covered entities must undertake to comply with the rule’s provisions and options considered by the Department that would reduce the burden to small entities. In developing this rule, the Department considered a variety of alternatives for minimizing the economic burden that it will create for small entities. We did not exempt small businesses from the rule because they represent such a large and critical proportion of the health care industry (82.6 percent); a significant portion of individually identifiable health information is generated or held by these small businesses.

The guiding principle in our considerations of how to address the burden on small entities has been to make provisions performance rather than specification oriented—that is, the rule states the standard to be achieved but allows institutions flexibility to determine how to achieve the standard within certain parameters. Moreover, to the extent possible, we have allowed entities to determine the extent to which they will address certain issues. This ability to adapt provisions to minimize burden has been addressed in the regulatory impact analysis above, but it will be briefly discussed again in the following section.

Before discussing specific provisions, it is important to note some of the broader questions that were addressed in formulating this rule. The Department considered extending the compliance period for small entities but concluded that it did not have the legal authority to do so (see discussion above). The rule, pursuant to HIPAA, creates an extended compliance time of 36 months (rather than 24 months) only for small health plans and not for other small entities. The Department also considered giving small entities longer response times for time limits set forth in the rule, but decided to establish standard time limits that we believe are reasonable for covered entities of all sizes, with the understanding that larger entities may not need as much time as they have been allocated in certain situations. This permits each covered entity the flexibility to establish policies regarding time limits that are consistent with the entity’s current practices.

Although we considered the needs of small entities during our discussions of all provisions for this final rule, we are highlighting the most significant discussions in the following sections:

Scalability

Wherever possible, the final rule provides a covered entity with flexibility to create policies and procedures that are best suited to the entity’s current practices in order to comply with the standards, implementation specifications, and requirements of the rule. This allows the covered entity to assess its own needs in devising, implementing, and maintaining appropriate privacy policies, procedures, and documentation to address these regulatory requirements. It also will allow a covered entity to take advantage of development of technologies for protecting privacy that will evolve over time in a manner that is best suited to that institution. This approach allows covered entities to strike a balance between protecting privacy of individually identifiable health information and the economic cost of doing so within prescribed boundaries set forth in the rule. Health care entities must consider both factors when devising their privacy solutions. The Department assumes that professional and trade associations will provide guidance to their members in understanding the rule and providing guidance on how they can best achieve compliance. This philosophy is similar to the approach in the Transactions Rule.

The privacy standard must be implemented by all covered entities, regardless of size. However, we believe that the flexible approach under this rule is more efficient and appropriate when a single approach to safeguarding health information privacy. For example, in a small physician practice, the office manager might be designated to serve as the privacy official as one of many of her duties. In a large health plan, the privacy official position may require more time and greater privacy experience, or the privacy official may have the regular support and advice of a privacy staff or board. The entity can decide how to implement this privacy official requirement based on the entity’s structure and needs.

The Department decided to use this scaled approach to minimize the burden on all entities, with an emphasis on small entities. The varying needs and capabilities of entities would be reflected in the policies and procedures adopted by the organization and the overall approach it takes to achieve compliance.

Minimum Necessary

The “minimum necessary” policy in the final rule has essentially three components: first, it does not pertain to certain uses and disclosures including treatment-related exchange of information among health care providers; second, for disclosures that are made on a routine basis, such as insurance claims, a covered entity is required to have policies and procedures governing such exchanges (but the rule does not require a case-by-case determination in such cases); and third, providers must have a process for reviewing non-routine requests on a case-by-case basis to assure that only the minimum necessary information is disclosed. The final rule makes changes to the NPRM that reduce the burden of compliance on small businesses.

Based on public comments and subsequent fact-finding, the Department sought to lessen the burden of this

---

82 Health Care Financing Administration, OSCAR.
provision. The NPRM proposed applying the minimum necessary standard to disclosures to providers for treatment purposes and would have required individual review of all uses of protected health information. The final rule exempts disclosures of protected health information from a covered entity to a health care provider for treatment from the minimum necessary provision and eliminates the case-by-case determinations that would have been necessary under the NPRM. The Department has concluded that the requirements of the final rule are similar to the current practice of most health care providers. For standard disclosure requests, for example, providers generally have established procedures. Under the final rule providers will have to have policies and procedures to determine the minimum amount of protected health information to disclose for standard disclosure requests as well, but may need to review and revise existing procedures to make sure they are consistent with the final rule. For non-routine disclosures, providers have indicated that they currently ask questions to discern how much information should be disclosed. In short, the minimum necessary requirements of this rule are similar to current practice, particularly among small providers.

Policy and Procedures

The rule requires that covered entities develop and document policies and procedures with respect to protected health information to establish and maintain compliance with the regulation. Through the standards, requirements, and implementation specifications, we are proposing a framework for developing and documenting privacy policies and procedures rather than adopting a rigid, prescriptive approach to accommodate entities of different sizes, type of activities, and business practices. Small providers will be able to develop more limited policies and procedures under the rule, than will large providers and health plans, based on the volume of protected health information. We also expect that provider and health plan associations will develop model policies and procedures for their members, which will reduce the burden on small businesses.

Privacy Official

The rule requires covered entities to designate a privacy official who will be responsible for the development and implementation of privacy policies and procedures. The implementation of this requirement may vary based on the size of the entity. For example, a small physician’s practice might designate the office manager as the privacy official in addition to her broader administrative responsibilities. Once the privacy official has been trained, the time required to accomplish the duties imposed on such person is not likely to be much more than under current practice. Therefore, the requirement imposes a minimal burden on small businesses.

Internal Complaints

The final rule requires covered entities to have an internal process for individuals to make complaints regarding the covered entities’ privacy policies and procedures required by the rule and its compliance with such policies. The requirement includes identifying a contact person or office responsible for receiving complaints and documenting all complaints received and the disposition of such complaints, if any. The covered entity only is required to receive and document a complaint (the complaint can be oral or in writing), which should take a short amount of time. The Department believes that complaints about a covered entity’s privacy policies and procedures will be uncommon. Thus, the burden on small businesses should be minimal.

Training

In developing the NPRM, the Department considered a number of alternatives for training, including requiring specific training materials, training certification, and periodic retraining. In the NPRM, the Department recommended flexibility in the materials and training method used, but proposed recertification every three years and retraining in the event of material changes in policy.

Based on public comment, particularly from small businesses, the Department has lessened the burden in the final rule. As in the proposal, the final rule requires all employees who are likely to have contact with protected health information to be trained. Covered entities will have to train employees by the compliance date specific to the type of covered entity and train new employees within a reasonable time of initial employment. In addition, a covered entity will have to train each member of its workforce whose functions are affected by a material change in the policies or procedures of such entity. However, the final rule leaves to the employer the decisions regarding the nature and method of training to achieve this requirement. The Department expects a wide variety of options to be made available by associations, professional groups, and vendors. Methods might include classroom instruction, videos, booklets, or brochures tailored to particular levels of need of workers and employers. Moreover, the recertification requirement of the NPRM has been dropped to ease the burden on small entities.

Consent

The NPRM proposed prohibiting covered entities from requiring individuals to provide written consent for the use and disclosure of protected health information for treatment, payment, and health care operations purposes. The final rule requires certain health care providers to obtain written consent before using or disclosing protected health information for treatment, payment, and health care operations, with a few exceptions. This requirement was included in the final rule in response to comments that this reflects current practice of health care providers health care providers with direct treatment relationships. Because providers are already obtaining such consent, this requirement represents a minimal burden.

Notice of Privacy Rights

The rule requires covered entities to prepare and make available a notice that informs individuals about uses and disclosures of protected health information that may be made by the covered entity and that informs of the individual’s rights and covered entity’s legal duties with respect to protected health information. The final rule makes changes to the NPRM that reduce the burden of this provision on covered entities and allows flexibility. The NPRM proposed the notice describe the uses and disclosures of information that the entity expected to make without individual authorization. The final rule only requires that the notice describe uses and disclosures that the entity is permitted or required to make under the rule without an individual’s written consent or authorization. This change will allow entities to use standardized notice language within a given state, which will minimize the burden of each covered entity preparing a notice. Professional associations may develop model language to assist entities in developing notices required by the rule. While the final rule specifies minimum notice requirements, it allows entities flexibility to add more detail about a covered entity’s privacy policies.

The NPRM also proposed that health plans distribute the notice every three years. The final rule reduced this
burden by requiring health plans (in addition to providing notice to individuals at enrollment and prior to the compliance date of this rule) to inform individuals at least once every three years about the availability of the notice and how to obtain a copy rather than to distribute a copy of the notice.

In discussing the requirement for covered entities to prepare and make available a notice, we considered exempting small businesses (83 percent of entities) or extremely small entities (fewer than 10 employees). The Department decided that informing consumers of their privacy rights and of the activities of covered entities with which they conduct business was too important a goal of this rule to exempt any entities.

In addition to requiring a basic notice, we considered requiring a longer more detailed notice that would be available to individuals on request. However, we decided that it would be overly burdensome to all entities, especially small entities, to require two notice.

We believe that the proposed rule appropriately balances the benefits of providing individuals with information about uses and disclosures of protected health information with covered entities' need for flexibility in describing such information.

Access to Protected Health Information

The public comments demonstrate that inspection and copying of individually identifiable health information is wide-spread today. Individuals routinely request copies of such information, in whole or in part, for purposes that include providing health information to another health care provider or as part of legal proceedings. The amount of inspection and copying of individually identifiable health information that occurs for these purposes is not expected to change as a result of the final regulation.

The final regulation establishes the right of individuals to inspect and copy protected health information about them. Although this is an important right, the Department does not expect it to result in dramatic increases in requests from individuals. We assume that most health care providers currently have procedures for allowing patients to inspect and copy this information. The economic impact on small businesses of requiring covered entities to provide individuals with access to protected health information should be relatively small. Moreover, entities can recoup the costs of copying such information by charging reasonable cost-based fees.

Amendments to Protected Health Information

Many health care providers and health plans currently make provisions to help patients expedite amendments and corrections of their medical record where appropriate. If an error exists, both the patient and the health care provider on health plan benefit from the correction. However, as with inspection and copying, a person's right to request amendment and correction of individually identifiable health information about them is not guaranteed by all states. Based on these assumptions, the Department concludes that the principal economic effect of the final rule will be to expand the right to request amendments to protected health information held by health plans and covered health care providers to those who are currently granted such right by state law. In addition, the rule may draw additional attention to the issue of record inaccuracies and stimulate patient demand for amendment of medical records.

Under the final regulation, if an individual requests an amendment to protected health information about him or her, the health care provider must either accept the amendment or provide the individual with the opportunity to submit a statement disagreeing with the denial. We expect the responses to requests will vary; sometimes an assistant will only make the appropriate notation in the record, requiring only a few minutes; other times a health care provider or manager will review the request and make changes if appropriate, which may require as much as an hour.

Unlike inspections, which currently occur in a small percentage of cases, fact-finding suggests that individuals rarely seek to amend their records today, but the establishment of this right in the rule may spur more requests, including among those who in the past would have only sought to inspect their records. Nevertheless, we expect that the absolute number of additional amendment requests caused by the rule will be small (about 200,000 per per spread over more than 600,000 entities), which will impose only a minor burden on small businesses.

Accounting for Disclosures

The rule grants individuals the right to receive an accounting of disclosures made by a health care provider or plan for purposes other than treatment, payment, or health care operations, with certain exceptions such as disclosures to the individual. The individual may request an accounting of disclosures made up to six years prior to the request. In order to fulfill such requests, covered health care providers and health plans may track disclosures by making a notation in the individual's medical record regarding the (manual or electronic) when a disclosure is made. We have learned through fact-finding that some health care providers currently track various types of disclosures. Moreover, the Department does not expect many individuals will request an accounting of disclosures. Thus, this requirement will impose a minor burden on small businesses.

De-Identification of Information

In this rule, the Department allows covered entities to determine that health information is de-identified (i.e. that it is not individually identifiable health information), if certain conditions are met. Moreover, information that has been de-identified in accordance with the rule is not considered individually identifiable information and may be used or disclosed without regard to the requirements of the regulation. The covered entity may assign a code or other means of record identification to allow de-identified information to be re-identified if requirements regarding derivation and security are met.

As with other components of this rule, the approach used to remove identifiers from data can be scaled to the size of the entity. Individually identifiable health information can be de-identified in one of two ways; by either removing each of the identifiers listed in the rule or by engaging in a statistical and scientific analysis to determine that information is very unlikely to identify an individual. Small entities without the resources to conduct such an analysis can create de-identified information by removing the full list of possible identifiers set forth in this regulation. Unless the covered entity knows that the information could still identify an individual, the requirement of this rule would be fulfilled. However, larger, more sophisticated covered entities may close to determine independently what information needs to be removed based on sophisticated statistical and scientific analysis.

Efforts to remove identifiers from information are optional. If a covered entity can not use or disclose protected health information for a particular purpose but believes that removing identifiers is excessively burdensome, it can choose not to release the protected health information, or it can seek an authorization from individuals for the use or disclosure of protected health
information including some or all of the identifiers.

Finally, as discussed in the Regulatory Impact Analysis, the Department believes that very few small entities engage in de-identification currently. Fewer small entities are expected to engage in such activity in the future because the increasing trend toward computerization of large record sets will result in de-identification being performed by relatively few firms or associations over time. We expect that a small covered entity will find it more efficient to contract with specialists in large firms to de-identify protected health information. Larger entities are more likely to have both the electronic systems and the volume of records that will make them attractive for this business.

Monitoring Business Associates

The final rule requires a covered entity with a business associate to have a written contract or other arrangement that documents satisfactory assurance that the business associate will appropriately safeguard protected health information. The Department expects business associate contracts to be fairly standardized, except for language that will have to be tailored to the specific arrangement between the parties, such as the allowable uses and disclosures of information. The Department assumes the standard language initially will be developed by trade and professional associations for their members. Small health care providers are likely to simply adopt the language or make minor modifications. The regulation includes a requirement that the covered entity take steps to correct, and in some cases terminate, a contract, if necessary, if they know of violations by a business associate. This oversight requirement is consistent with standard oversight of a contract. The Department expects that most entities, particularly smaller ones, will utilize standard language that restricts uses and disclosures of individually identifiable health information their contracts with business associates. This will limit the burden on small businesses.

The NPRM proposed that covered entities be held accountable for the uses and disclosures of individually identifiable health information by their business associates. An entity would have been in violation of the rule if it knew of a breach in the contract by a business associate and failed to cure the breach or terminate the contract. The final rule reduces the extent to which an entity must the actions of its business associates. The entity no longer has to “ensure” that each business associate complies with the rule’s requirements. Entities will be required to cure a breach or terminate a contract for business associate actions only if they knew about a contract violation. The final rule is consistent with the oversight a business would provide for any contract, and therefore, the changes in the final rule will impose no new significant cost for small businesses in monitoring their business associates’ behavior.

Employers With Insured Group Health Plans

Some group health plans will use or maintain individually identifiable health information, particularly group health plans that are self-insured. Also, some plan sponsors that perform administrative functions on behalf of their group health plans may need protected health information. The final rule permits a group health plan, or a health insurance issuer or HMO that provides benefits on behalf of the group health plan, to disclose protected health information to a plan sponsor who performs administrative functions on its behalf for certain purposes and if certain requirements are met. The plan documents must be amended to: describe the permitted uses and disclosures of protected health information by the plan sponsor; specify that disclosure is permitted only upon receipt of a certification by the plan sponsor that the plan documents have been amended and the plan sponsor agrees to certain restrictions on the use of protected health information; and provide for adequate firewalls to assure unauthorized personnel do not have access to individually identifiable health information.

Some plan sponsors may need information, not to administer the group health plan, but to amend, modify, or terminate the health plan. ERISA case law describes such activities as settlor functions. For example a plan sponsor may want to change its contract from a preferred provider organization to a health maintenance organization (HMO). In order to obtain premium information, the health plan sponsor may need to provide the HMO with aggregate claims information. Under the rule, the health plan sponsor can obtain summary information with certain identifiers removed, in order to provide it to the HMO and receive a premium rate.

The Department assumes that most health plan sponsors who are small employers (those with 50 or fewer employees) will not want to receive individually identifiable health information because they will have little, if any, need for such data. Any needs that sponsors of small group health plans may have for information can be accomplished by receiving the information in summary form from their health insurance issuers.

3. The Burden on a Typical Small Business

The Department expects small entities to face a cost burden as a result of complying with the proposed regulation. We estimate that the burden of developing privacy policies and procedures is lower in dollar terms for small businesses than for large businesses, but we recognize that the cost of implementing privacy provisions could be a larger burden to small entities as a proportion of total revenue. Due to these concerns, we have relied on the principle of scalability throughout the rule, and have based our cost estimates on the expectation that small entities will develop less expensive and less complex privacy programs that comply with the rule than large entities.

In many cases, we have specifically considered the impact that rule may have on solo practitioners or rural health care providers. If a health care provider only maintains paper records and does not engage in any electronic transactions, the regulation would not apply to such provider. We assume that those providers will be small health care providers. For small health care providers that are covered health care providers, we expect that they will not be required to change their business practices dramatically, because we based many of the standards, implementation specifications, and requirements on current practice and we have taken a flexible approach to allow scalability based on a covered entity’s activities and size. In developing policies and procedures to comply with the proposed regulation, scalability allows entities to consider their basic functions and the ways in which protected health information is used or disclosed. All covered entities must take appropriate steps to address privacy concerns, and in determining the scope and extent of their compliance activities, businesses should weigh the costs and benefits of alternative approaches and should scale their compliance activities to their structure, functions, and capabilities within the requirements of the rule.

Cost Assumptions

To determine the cost burden to small businesses of complying with the final rule, we used as a starting point the overall cost of the regulation determined
in the regulatory impact analysis (RIA). Then we adopted a methodology that apportions the costs found in the RIA to small business by using Census Bureau’s Statistics of U.S. Businesses. This Census Bureau survey contains data on the number and proportion of establishments, by Standard Industrial Classification Code (SIC code), that have revenues of less than $5 million, which meets the Small Business Administration’s definition of a small business in the health care sector. This data permitted us to calculate the proportion of the cost of each requirement in the rule that is attributable to small businesses. This methodology used for the regulatory flexibility analysis (RFA) section is therefore based on the methodology used in the (RIA), which was discussed earlier.

The businesses accounted for in the SIC codes contain three groups of covered entities: non-hospital health care providers, hospitals, and health plans. Non-hospital health care providers include: drug stores, offices and clinics of doctors, dentists, osteopaths, and other health practitioners, nursing and personal care facilities, medical and dental laboratories, home health care services, miscellaneous health and allied services, and medical equipment rental and leasing establishments. Health plans include accident and health insurance and medical service plans.

**Data Adjustments**

Several adjustments were made to the SIC code data to more accurately determine the cost to small and non-profit businesses. For health plans (SIC code 6278), we adjusted the SIC data to include self-insured, self-administered health plans because these health plans are not included in any SIC code, though they are covered entities under the rule. Similarly, we have added third-party administrators (TPAs) into this SIC. Although they are not covered entities, TPAs are likely to be business associates of covered entities. For purposes of the regulatory analyses, we have assumed that TPAs would bear many of the same costs of the health plans to assure compliance for the covered entity. To make this adjustment, we assumed the self-insured/self administered health plans and TPAs have the average revenue of the health plans contained in the SIC code, and then added those assumed revenues to the SIC code and to the total of all health care expenditures.

Moreover, if not all to account for the cost to non-profit institutions that might receive more than $5 million in revenue, because all non-profit institutions are small businesses regardless of revenue. To make this adjustment for hospitals, nursing homes, and home health agencies, we used data on the number of non-profit institutions from industry sources and from data reported to HCFA. With this data, we assumed the current count of establishments in the SIC codes includes these non-profit entities and that non-profits have the same distribution of revenues as all establishments reported in the applicable SIC codes. The proportions discussed below, which determine the cost for small business, therefore include these non-profit establishments in SIC codes 8030, 8060, and 8080.

The SIC code tables provided in this RFA do not include several categories of businesses that are included in the total cost to small businesses. Claims clearinghouses are not included in the table because claims clearinghouses report their revenues under the SIC 6374 “Computer Processing and Data Preparation,” and the vast majority of businesses in this SIC code are involved in non-medical claims data processing. In addition, claims processing is often just one business-line of companies that may be involved in multiple forms of data processing, and therefore, even if the claims processing line of the business generates less than $5 million in revenue, the company in total may exceed the SBA definition for a small business (the total firm revenue, not each line of business, is the standard for inclusion). Similarly, fully-insured ERISA health plans sponsored by employers are not identified as a separate category in the SIC code tables because employers in virtually all SIC codes may sponsor fully-insured health plans. We have identified the cost for small fully-insured ERISA health plans by using the Department of Labor definition of a small ERISA plan, which is a plan with fewer than 100 insured participants. Using this definition, the initial cost for small fully-insured ERISA health plans is $7.1 million. Finally, Institutional Review Boards (IRBs) will not appear in a separate SIC code because IRBs are not “businesses”; rather, they are committees of researchers who work for institutions where medical research is conducted, such as universities or teaching hospitals. IRB members usually serve as their employment duties and are not paid separately for their IRB duties. Therefore, for provisions like the notice requirement, we used SIC code revenue data in a two-step process. First, we apportioned the cost of each provision among sectors of the health care industry by SIC code. For example, because hospital revenue accounts for 27 percent of all health care revenue, we multiplied the total cost of each such provision by 27 percent to determine the cost for the hospital sector in total. Then to determine the cost for small hospitals specifically, we calculated the proportion of revenue by the overall cost. For example, 45.1 percent of all hospital revenue is generated by small hospitals, so the cost of small hospitals was assumed to account for 45.1 percent of all hospital costs. Estimates, by nature
are inexact. However, we feel this is a reasonable way to determine the small business costs attributable to this regulation given the limited data from which to work.

**Total Costs and Costs Per Establishment for Small Business**

Based on the methodology described above, the total cost of complying with the final rule in the initial year of 2003 is $1.9 billion. The ongoing costs to small business from 2004 to 2012 is $9.3 billion. Table C presents the initial and ongoing costs to small business by each SIC code. According to this table, small doctors offices, small dentists offices and small hospitals will face the highest cost of complying with the final rule.

However, much of the reason for the higher costs faced by these three groups of small health care providers is explained by the fact that there are a significant number of health care providers in these categories.
### Table C.—Annual Cost to Small Business of Implementing Provisions of the Proposed Privacy Regulation

<table>
<thead>
<tr>
<th>SIC</th>
<th>Industry</th>
<th>Initial Cost (Year 1)</th>
<th>Ongoing Cost (Year 2-10)</th>
<th>Total Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>5910</td>
<td>Drug Stores &amp; Proprietary Stores</td>
<td>$153,976,159</td>
<td>$780,573,862</td>
<td>$934,550,021</td>
</tr>
<tr>
<td>6320</td>
<td>Accident &amp; Health Insurance &amp; Medical Service Plans²</td>
<td>$41,348,527</td>
<td>$169,540,638</td>
<td>$210,889,164</td>
</tr>
<tr>
<td>7353</td>
<td>Medical Equipment Rental &amp; Leasing</td>
<td>$7,171,728</td>
<td>$36,256,688</td>
<td>$43,528,416</td>
</tr>
<tr>
<td>8010</td>
<td>Offices &amp; Clinics of Doctors of Medicine</td>
<td>$633,033,192</td>
<td>$3,209,127,747</td>
<td>$3,842,160,938</td>
</tr>
<tr>
<td>8120</td>
<td>Offices &amp; Clinics of Dentists</td>
<td>$283,774,344</td>
<td>$1,438,578,786</td>
<td>$1,722,353,130</td>
</tr>
<tr>
<td>8030</td>
<td>Offices &amp; Clinics of Doctors of Osteopathy</td>
<td>$24,278,673</td>
<td>$123,079,430</td>
<td>$147,358,103</td>
</tr>
<tr>
<td>8040</td>
<td>Offices &amp; Clinics of Other Health Practitioners</td>
<td>$139,251,750</td>
<td>$705,929,263</td>
<td>$845,181,013</td>
</tr>
<tr>
<td>8050</td>
<td>Nursing &amp; Personal Care Facilities</td>
<td>$147,143,775</td>
<td>$745,937,461</td>
<td>$893,081,236</td>
</tr>
<tr>
<td>8060</td>
<td>Hospitals</td>
<td>$355,459,094</td>
<td>$1,199,498,063</td>
<td>$1,554,957,157</td>
</tr>
<tr>
<td>8070</td>
<td>Medical &amp; Dental Laboratories</td>
<td>$41,242,809</td>
<td>$209,078,203</td>
<td>$250,321,012</td>
</tr>
<tr>
<td>8080</td>
<td>Home Health Care Services</td>
<td>$72,632,601</td>
<td>$368,207,067</td>
<td>$440,839,668</td>
</tr>
<tr>
<td>8090</td>
<td>Misc Health &amp; And Allied Services</td>
<td>$40,938,582</td>
<td>$207,535,943</td>
<td>$248,474,525</td>
</tr>
<tr>
<td>n/a</td>
<td>Fully Insured/ ERISA</td>
<td>$7,137,028</td>
<td>$0</td>
<td>$7,137,028</td>
</tr>
<tr>
<td>n/a</td>
<td>IRBs</td>
<td>$88,813</td>
<td>$84,162,446</td>
<td>$84,251,259</td>
</tr>
<tr>
<td>n/a</td>
<td>Total Cost For Small Business</td>
<td>$1,947,477,073</td>
<td>$9,277,605,598</td>
<td>$11,225,082,671</td>
</tr>
</tbody>
</table>

¹ Source: Office of Advocacy, U.S. Small Business Administration, from data provided by the Bureau of the Census, Statistics of U.S. Businesses, 1997. Entities that have less than $5,000,000 in annual revenue are considered small businesses here, as are non-profit entities (regardless of revenue). We have non-profit data for the following SICs: 8050, 8080, and 8060 and have included the number of non-profits in each category into the table.

²The initial costs include all costs in the first year, including costs that recur in subsequent years.

³We have included self-insured/self-administered health plans and third party administrators in the total number of health plans, even though neither has individual SIC codes because we have the ability to impute revenues to them.
On a per-establishment basis, Table D demonstrates that the average cost for small business of complying with the proposed rule in the first year is $4,188 per-establishment. The ongoing costs of privacy compliance are approximately $2,217 each year thereafter. We estimate that the average cost of compliance in the first year for each small non-hospital health care provider is approximately 0.6 percent of per-establishment revenues. In subsequent years, per-establishment costs about 0.3 percent of per-establishment revenues. For small hospitals and health plans, the per-establishment cost of compliance in the first year is 0.2 percent and 6.3 percent of per-establishment revenues respectively. For subsequent years, the cost is only 0.1 percent and 2.9 percent of pre-establishment revenues respectively. These costs may be offset in many firms by the savings realized through requirements of the Transactions Rule.
Table D.—Average Annual per Establishment Privacy Costs$^1$

<table>
<thead>
<tr>
<th>SIC</th>
<th>Industry</th>
<th>Year 1 Privacy Costs Per Establishment</th>
<th>Average Year 2-10 Privacy Costs per Establishment</th>
</tr>
</thead>
<tbody>
<tr>
<td>5910</td>
<td>Drug Stores &amp; Proprietary Stores</td>
<td>$6,436</td>
<td>$3,625</td>
</tr>
<tr>
<td>6320</td>
<td>Accident &amp; Health Insurance &amp; Medical</td>
<td>$62,162</td>
<td>$28,320</td>
</tr>
<tr>
<td></td>
<td>Service Plans$^2$</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7353</td>
<td>Medical Equipment Rental &amp; Leasing</td>
<td>$3,906</td>
<td>$2,290</td>
</tr>
<tr>
<td>8010</td>
<td>Offices &amp; Clinics of Doctors of Medicine</td>
<td>$3,703</td>
<td>$2,086</td>
</tr>
<tr>
<td>8120</td>
<td>Offices &amp; Clinics of Dentists</td>
<td>$2,492</td>
<td>$1,404</td>
</tr>
<tr>
<td>8030</td>
<td>Offices &amp; Clinics of Doctors of Osteopathy</td>
<td>$2,743</td>
<td>$1,545</td>
</tr>
<tr>
<td>8040</td>
<td>Offices &amp; Clinics of Other Health Practitioners</td>
<td>$1,608</td>
<td>$906</td>
</tr>
<tr>
<td>8050</td>
<td>Nursing &amp; Personal Care Facilities</td>
<td>$8,301</td>
<td>$4,676</td>
</tr>
<tr>
<td>8060</td>
<td>Hospitals</td>
<td>$101,999</td>
<td>$38,244</td>
</tr>
<tr>
<td>8070</td>
<td>Medical &amp; Dental Laboratories</td>
<td>$3,169</td>
<td>$1,785</td>
</tr>
<tr>
<td>8080</td>
<td>Home Health Care Services</td>
<td>$5,656</td>
<td>$3,136</td>
</tr>
<tr>
<td>8090</td>
<td>Misc Health &amp; Allied Services</td>
<td>$3,649</td>
<td>$2,055</td>
</tr>
<tr>
<td>n/a</td>
<td>Fully Insured/ERISA$^3$</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>n/a</td>
<td>IRB$^3$</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>n/a</td>
<td>Average for All Small Business</td>
<td>$4,188</td>
<td>$2,217</td>
</tr>
</tbody>
</table>

$^1$ Source: Office of Advocacy, U.S. Small Business Administration, from data provided by the Bureau of the Census, Statistics of U.S. Businesses, 1997. Entities that have less than $5,000,000 in annual revenue are considered small businesses here, as are non-profit entities (regardless of revenue). We have non-profit data for the following SICs: 8050, 8080, and 8060 and have included the number of non-profits in each category into the table.

$^2$ We have included self-insured/self-administered health plans and third party administrators in the total number of health plans, even though neither has individual SIC codes because we have the ability to impute revenues to them.

$^3$ We have not included the number of fully insured ERISA health plans or institutional review boards (IRB) in the total number of health care entities or the number of entities that meet SMA standards for small entities, since these are not separate businesses with SIC codes and we do not have sufficient data to impute revenues to them.
Table E shows the cost to each SIC code of the major cost items of the final rule. Listed are the top-five most costly provisions of the rule (to small business) and then the cost of all other remaining provisions. The costs of the most expensive five provisions represent 90 percent of the cost of the ongoing costs to small business, while the remaining provisions only represent 7 percent.
Table E.—Average Annual Ongoing Cost to Small Business of Implementing Provisions of the Privacy Regulation, After the First Year

<table>
<thead>
<tr>
<th>Industry</th>
<th>Average Annual Ongoing Cost for Privacy Official, per Industry Sector</th>
<th>Average Annual Ongoing Cost for Minimum Necessary, per Industry Sector</th>
<th>Average Annual Ongoing Cost for Disclosure Tracking, per Industry Sector</th>
<th>Average Annual Ongoing Cost for De-Identification, per Industry Sector</th>
<th>Average Annual Ongoing Cost for Training, per Industry Sector</th>
<th>Average Annual Ongoing Cost for Other Provisions, per Industry Sector</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug Stores &amp; Proprietary Stores</td>
<td>$37,997,168</td>
<td>$30,008,085</td>
<td>$3,597,262</td>
<td>$3,751,011</td>
<td>$4,083,677</td>
<td>$7,293,227</td>
</tr>
<tr>
<td>Accident &amp; Health Insurance &amp; Medical Service plans (including Self Insured/ Self Administered Health plans, &amp; TPAs)²</td>
<td>$5,920,267</td>
<td>$5,295,070</td>
<td>$985,072</td>
<td>$3,614,697</td>
<td>$59,086</td>
<td>$2,863,657</td>
</tr>
<tr>
<td>Medical Equipment Rental &amp; Leasing</td>
<td>$1,769,789</td>
<td>$1,397,683</td>
<td>$167,549</td>
<td>$174,710</td>
<td>$190,205</td>
<td>$339,696</td>
</tr>
<tr>
<td>Offices &amp; clinics of Doctors of Medicine</td>
<td>$156,215,538</td>
<td>$123,370,486</td>
<td>$14,789,213</td>
<td>$15,421,311</td>
<td>$16,788,984</td>
<td>$29,984,217</td>
</tr>
<tr>
<td>----------------------------------------------</td>
<td>--------------</td>
<td>--------------</td>
<td>--------------</td>
<td>--------------</td>
<td>--------------</td>
<td></td>
</tr>
<tr>
<td>Offices &amp; clinics of Doctors of Dentists</td>
<td>$70,027,863</td>
<td>$55,304,176</td>
<td>$6,629,667</td>
<td>$6,913,022</td>
<td>$7,526,119</td>
<td></td>
</tr>
<tr>
<td>Offices &amp; clinics of Doctors of Osteopathy</td>
<td>$5,991,323</td>
<td>$4,731,619</td>
<td>$567,210</td>
<td>$591,452</td>
<td>$643,907</td>
<td></td>
</tr>
<tr>
<td>Offices &amp; clinics of Other Health Practitioners</td>
<td>$34,363,581</td>
<td>$27,138,476</td>
<td>$3,253,264</td>
<td>$3,392,310</td>
<td>$3,693,164</td>
<td></td>
</tr>
<tr>
<td>Nursing &amp; Personal care Facilities</td>
<td>$36,311,120</td>
<td>$28,676,536</td>
<td>$3,437,641</td>
<td>$3,584,567</td>
<td>$3,902,472</td>
<td></td>
</tr>
<tr>
<td>Hospitals</td>
<td>$25,475,393</td>
<td>$56,613,285</td>
<td>$19,558,912</td>
<td>$14,153,321</td>
<td>$309,555</td>
<td></td>
</tr>
<tr>
<td>Medical &amp; Dental Laboratories</td>
<td>$10,177,614</td>
<td>$8,037,723</td>
<td>$963,534</td>
<td>$1,004,715</td>
<td>$1,093,821</td>
<td></td>
</tr>
<tr>
<td>Home Health care Services</td>
<td>$17,923,769</td>
<td>$14,155,212</td>
<td>$1,696,876</td>
<td>$1,769,402</td>
<td>$1,926,325</td>
<td></td>
</tr>
<tr>
<td>Misc Health &amp; Allied Health Services</td>
<td>$10,102,539</td>
<td>$7,978,433</td>
<td>$956,426</td>
<td>$997,304</td>
<td>$1,085,752</td>
<td></td>
</tr>
<tr>
<td>Fully Insured/ERISA</td>
<td>&lt;0.01</td>
<td>&lt;0.01</td>
<td>&lt;0.01</td>
<td>&lt;0.01</td>
<td>&lt;0.01</td>
<td></td>
</tr>
<tr>
<td>IRB</td>
<td>&lt;0.01</td>
<td>&lt;0.01</td>
<td>&lt;0.01</td>
<td>&lt;0.01</td>
<td>&lt;0.01</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>$412,275,964</td>
<td>$362,806,784</td>
<td>$56,602,625</td>
<td>$55,367,822</td>
<td>$41,303,067</td>
<td></td>
</tr>
</tbody>
</table>

1 Source: Office of Advocacy, U.S. Small Business Administration, from data provided by the Bureau of the Census, Statistics of U.S. Businesses, 1997. Entities that have less than $5,000,000 in annual revenue are considered small businesses here, as are

2 We have included self-insured, self-administered health plans and third party administrators in the total number of health plans, even though neither has individual SIC codes because we have the ability to impute revenues to them.
VI. Unfunded Mandates

The Unfunded Mandates Reform Act of 1995 (Pub. L. 104–4) requires cost-benefit and other analyses for rules that would cost more than $100 million in a single year. The rule qualifies as a significant rule under the statute. The Department has carried out the cost-benefit analysis in sections D and E of this document, which includes a discussion of unfunded costs to state and local governments resulting from this regulation. In developing this regulation, the Department adopted the least burdensome alternatives, consistent with achieving the rule’s goals.

A. Future Costs

The Department estimates some of the future costs of the rule in Section E of the Preliminary Regulatory Impact Analysis of this document. The estimates made include costs for the ten years after the effective date. As discussed in section E, state and local government costs will be in the order of $460 million in 2003 and $2.4 billion over ten years. Estimates for later years are not practical. The changes in technology are likely to alter the nature of medical record-keeping, and the uses of medical data are likely to vary dramatically over this period. Therefore, any estimates for years beyond 2012 are not feasible.

B. Particular Regions, Communities, or Industrial Sectors

The rule applies to the health care industry and would, therefore, affect that industry disproportionately. Any long-run increase in the costs of health care services would largely be passed on to the entire population of consumers. However, as discussed in the administrative implication regulation, the Transactions Rule is estimated to save the health care industry nearly $30 billion over essentially the same time period. This more than offsets the costs of the Privacy Rule; indeed, as discussed above, the establishment of consistent, national standards for the protection of medical information is essential to fully realize the savings from electronic transactions standards and other advances that may be realized through “e-health” over the next decade. Without strong privacy rules, patients and providers may be very reluctant to fully participate in electronic and e-health opportunities.

C. National Productivity and Economic Growth

The rule is not expected to substantially affect productivity or economic growth. It is possible that productivity and growth in certain sectors of the health care industry could be slightly lower than otherwise because of the need to divert research and development resources to compliance activities. The diversion of resources to compliance activities would be temporary. Moreover, the Department anticipates that, because the benefits of privacy are large, both productivity and economic growth would be higher than in the absence of the final rule. In section I.A of this document, the Department discusses its expectation that this rule will increase communication among consumers, health plans, and providers and that implementation of privacy protections will lead more people to seek health care. The increased health of the population will lead to increased productivity and economic growth.

D. Full Employment and Job Creation

Some of the human resources devoted to the delivery of health care services will be redirected by rule. The rule could lead to some short-run changes in employment patterns as a result of the structural changes within the health care industry. The growth of employment (job creation) for the roles typically associated with health care profession could also temporarily change but be balanced by an increased need for those who can assist entities with complying with this rule. Therefore, while there could be a temporary slowing of growth in traditional health care professions, that will be offset by a temporary increase in growth in fields that may assist with compliance with this rule (e.g. worker training, and management consultants).

E. Exports

Because the rule does not mandate any changes in products, current export products will not be required to change in any way.

The Department consulted with state and local governments, and Tribal governments. See sections X and XI, below.

VII. Environmental Impact

The Department has determined under 21 CFR 25.30(k) that this action is of a type of does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

VIII. Collection of Information Requirements

Under the Paperwork Reduction Act of 1995 (PRA), agencies are required to provide a 30-day notice in the Federal Register and solicit public comment before a collection of information requirement is submitted to the Office of Management and Budget (OMB) for review and approval. In order to fairly evaluate whether an information collection should be approved by OMB, section 3506(c)(2)(A) of the PRA requires that we solicit comment on the following issues:

- Whether the information collection is necessary and useful to carry out the proper functions of the agency;
- The accuracy of the agency’s estimate of the information collection burden;
- The quality, utility, and clarity of the information to be collected; and
- Recommendations to minimize the information collection burden on the affected public, including automated collection techniques.

Under the PRA, the time, effort, and financial resources necessary to meet the information collection requirements referenced in this section are to be considered. Due to the complexity of this regulation, and to avoid redundancy of effort, we are referring readers to Section V (Final Regulatory Impact Analysis) above, to review the detailed cost assumptions associated with these PRA requirements. We explicitly seek, and will consider, public comment on our assumptions as they relate to the PRA requirements summarized in this section.

Section 160.204—Process for Requesting Exception Determinations

Section 160.204 would require persons requesting to except a provision of state law from preemption under §160.203(a) to submit a written request, that meets the requirements of this section, to the Secretary to except a provision of state law from preemption under §160.203. The burden associated with these requirements is the time and effort necessary for a state to prepare and submit the written request for an exception determination to the Secretary for approval. On an annual basis it is estimated that it would take 40 states 16 hours each to prepare and submit a request. The total annual burden associated with this requirement is 640 hours. The Department solicits public comment on the number of requests and hours for others likely to submit requests.

Section 160.306—Complaints to the Secretary

A person who believes that a covered entity is not complying with the applicable requirements of part 160 or the applicable standards, requirements,
and implementation specifications of Subpart E of part 164 of this subchapter may file a complaint with the Secretary. This requirement is exempt from the PRA as stipulated under 5 CFR 1320.4(a)(2), an audit/administrative action exemption.

Section 160.310—Responsibilities of Covered Entities

A covered entity must keep such records and submit such compliance reports, in such time and manner and containing such information, necessary to enable the Secretary to ascertain whether the covered entity has complied or is complying with the applicable requirements of part 160 and the applicable standards, requirements, and implementation specifications of subpart E of part 164. Refer to § 164.530 for discussion.

Section 164.502—Uses and Disclosures of Protected Health Information: General Rules

A covered entity is permitted to disclose protected health information to an individual, and is required to provide and individual with access to protected health information, in accordance with the requirements set forth under § 164.524. Refer to § 164.524 for discussion.

Section 164.504—Uses and Disclosures—Organizational Requirements

Except for disclosures of protected health information by a covered entity that is a health care provider to another health care provider for treatment purposes, § 164.504 requires a covered entity to maintain documentation demonstrating that it is in accordance with the time and effort necessary for a covered entity to obtain written authorization prior to the disclosure of individually identifiable health information. On an annual basis, we estimate that it will take 764,799 entities, an annual average burden per entity of one hour for a total annual burden of 764,799 burden hours.

Section 164.510—Uses and Disclosures Requiring an Opportunity for the Individual To Agree or To Object

Section 164.510 allows, but does not require, covered entities to use or disclose protected health information: (1) for health care institutions, directories; and (2) to family members, close friends, or other persons assisting in an individual’s care, as well as government agencies and disaster relief organizations conducting disaster relief activities. This section of the rule addresses situations in which the interaction between the covered entity and the individual is relatively informal, and agreements may be made orally, without written authorizations for use or disclosure. In general, to disclose protected health information for these purposes, covered entities must inform individuals in advance and must provide a meaningful opportunity for the individual to prevent or restrict the disclosure. In certain circumstances, such as in an emergency, when this informal discussion cannot practicably occur, covered entities can make decisions about disclosure or use, in accordance with the requirements of this section based on the professional judgment of what is in the patient’s best interest. While these provisions are subject to the PRA, we believe that the burden associated with this requirement is exempt from the PRA as stipulated under 5 CFR 1320.3(b)(2).

Section 164.508—Uses and Disclosures for Which Individual Authorization Is Required

Under this section, a covered entity will need to obtain a written authorization from an individual, before it uses or discloses protected health information of the individual if the use or disclosure is not otherwise permitted or required under the rule without authorization. The burden associated with these requirements is the time and effort necessary for a covered entity to obtain written authorization prior to the disclosure of individually identifiable health information. On an annual basis, we estimate that it will take 764,799 entities, an annual average burden per entity of one hour for a total annual burden of 764,799 burden hours.

Section 164.512—Uses and Disclosures For Which Consent, Individual Authorization, or Opportunity To Agree or Object Is Not Required

Section 164.512 includes provisions that allow, but that do not require, covered entities to disclose protected health information without individual authorization for a variety of purposes which represent important national priorities. Pursuant to § 164.512, covered entities may disclose protected health information for specified purposes as follows: as required by law; for public health activities; to public officials regarding victims of abuse, neglect, or domestic violence; for health oversight; for judicial and administrative proceedings; for law enforcement; for specified purposes regarding decedents; for organ donation and transplantation; for research; to avert an imminent threat to health or safety; for specialized government functions (such as for intelligence and national security activities); and to comply with workers’ compensation laws. While these provisions are subject to the PRA, we believe that the burden associated with this requirement is exempt from the PRA as stipulated under 5 CFR 1320.3(b)(2).

For research, if a covered entity wants to use or disclose protected health information without individual authorization, it must obtain documentation that a waiver, in whole or in part, of the individual authorization required by § 164.508 for use or disclosure of protected health information has been approved by either an Institutional Review Board (IRB), established in accordance with 7 CFR 1c.107, 10 CFR 745.107, 14 CFR 1230.107, 15 CFR 27.107, 16 CFR 1028.107, 21 CFR 56.107, 22 CFR 225.107, 28 CFR 46.107, 32 CFR 210.107, 34 CFR 97.107, and 45 CFR 16.107, 40 CFR 26.107, 45 CFR 46.107, 45 CFR 690.107, or 49 CFR 11.107; or a privacy board. The burden associated with these requirements is the time and effort necessary for a covered entity to maintain documentation demonstrating that they have obtained IRB or privacy board approval, which meet the requirements of this section. On an annual basis it is estimated that these requirements will affect 113,524 IRB reviews. We further estimate that it will take an average of 5 minutes per review to meet these requirements on an annual basis. Therefore, the total estimated annual burden associated with this requirement is 9,460 hours.

Section 164.514—Other Procedural Requirements Relating to Uses and Disclosures of Protected Health Information

Prior to any disclosure permitted by this subpart, a covered entity must verify the identity and authority of the person requesting protected health information, if the identity or authority of such person is not known to the
Section 164.520—Notice of Privacy Practices for Protected Health Information

Except in certain circumstances set forth in this section, individuals have a right to adequate notice of the uses and disclosures of protected health information that may be made by the covered entity, and of the individual’s rights and the covered entity’s legal duties with respect to protected health information. To comply with this requirement a covered entity must provide a notice, written in plain language, that includes the elements set forth in this section. For health plans, there will be an average of 160.2 million notices each year. We assume that the most efficient means of distribution for health plans will be to send them out annually as part of the materials they send to current and potential enrollees, even though it is not required by the regulation. The number of notices per health plan per year would be about 10,570. We further estimate that it will require each health plan, on average, only 10 seconds to disseminate each notice. The total annual burden associated with this requirement is calculated to be 267,000 hours. Health care providers with direct treatment relationships would provide a copy of the notice to an individual at the time of first service delivery to the individual, make the notice available at the service delivery site for individuals to request and take with them, whenever the content of the notice is revised, make the notice available upon request and post the notice, if required by this section, and post a copy of the notice in a location where it is reasonable to expect individuals seeking services from the provider to be able to read the notice. The annual number of notices disseminated by all providers is 613 million. We further estimate that it will require each health provider, on average, 10 seconds to disseminate each notice. This estimate is based upon the assumption that required notice will be incorporated into and disseminated with other patient materials. The total annual burden associated with this requirement is calculated to be 1 million hours.

In addition, a covered entity must document compliance with the notice requirements by retaining copies of the notices issued by the covered entity. Refer to § 164.530 for discussion.

Section 164.522—Rights To Request Privacy Protection for Protected Health Information

Given that the burden associated with the following information collection requirements will differ significantly, by the type and size of health plan or health care provider, we are explicitly soliciting comment on the burden associated with the following requirements: as outlined and required by this section, covered entities must provide individuals with the opportunity to request restrictions related to the uses or disclosures of protected health information for treatment, payment, or health care operations. In addition, covered entities must accommodate requests for confidential communications in certain situations.

Section 164.524—Access of Individuals to Protected Health Information

As set forth in this section, covered entities must provide individuals with access to inspect and obtain a copy of protected health information about them in designated record sets, for so long as the protected health information is maintained in the designated record sets. This includes such information in a business associate’s designated record set that is not a duplicate of the information held by the health care provider or health plan for so long as the information is maintained. Where the request is denied in whole or in part, the covered entity must provide the individual with a written statement of the basis for the denial and a description of how the individual may complain to the covered entity pursuant to the complaint procedures established in § 164.530 or to the Secretary pursuant to the procedures established in § 160.306 of this subpart. In certain cases, the covered entity must provide the individual the opportunity to have another health care professional review the denial. Pursuant to public comment, we estimate that each disclosure will contain 31 pages and that 150,000 disclosures will be made on an annual basis. Given that burden associated with the following information collection requirements will differ significantly, by the type and size of health plan or health care provider, we are explicitly soliciting comment on the burden associated with the following requirements: as outlined and required by this section, covered entities must provide an accounting for a period of time less than six years from the date of the individual’s request, as outlined in this section.

Section 164.526—Amendment of Protected Health Information

Given that burden associated with the following information collection requirements will differ significantly, by the type and size of health plan or health care provider, we are explicitly soliciting comment on the burden associated with the following requirements: as outlined and required by this section, covered entities must provide amendment of protected health information are required by this part, Where a communication is required by this subpart to be in writing, a covered entity must maintain such writing, or an electronic copy, as documentation; and where an action or activity is required by this subpart to be documented, it must maintain a written or electronic record of such action or activity. While these requirements are subject to the PRA, we believe the burden associated with these requirements is exempt from the PRA as stipulated under 5 CFR 1320.3(b)(2).
We have submitted a copy of this rule to OMB for its review of the information collection requirements in §§ 160.204, 160.306, 160.310, 164.502, 164.504, 164.506, 164.508, 164.510, 164.512, 164.514, 164.520, 164.522, 164.524, 164.526, 164.528, and Sec. 164.530.

These requirements are not effective until they have been approved by OMB. If you comment on any of these information collection and record keeping requirements, please mail copies directly to the following: Health Care Financing Administration, Office of Information Services, Division of HCFA Enterprise Standards, Room N2–14–26, 7500 Security Boulevard, Baltimore, MD 21244–1850. ATTN: John Burke and to the Office of Information and Regulatory Affairs, Office of Management and Budget, Room 10235, New Executive Office Building, Washington, DC 20503. ATTN: Allison Herrn Eydt, HCFA Desk Officer.

IX. Executive Order 13132: Federalism

The Department has examined the effects of provisions in the final privacy rule on the relationship between the federal government and the states, as required by Executive Order 13132 on “Federalism.” Our conclusion is that the final rule does have federalism implications because the rule has substantial direct effects on states, on the relationship between the national government and states, and on the distribution of power and responsibilities among the various levels of government. The federalism implications of the rule, however, flow from, and are consistent with the underlying statute. The statute allows us to preempt state or local rules that provide less stringent privacy protection requirements than federal law is consistent with this Executive Order.

Overall, the final rule attempts to balance both the autonomy of the states with the necessity to create a federal benchmark to preserve the privacy of personally identifiable health information. It is recognized that the states generally have laws that relate to the privacy of individually identifiable health information. The HIPAA statute dictates the relationship between state law and this final rule. Except for laws that are specifically exempted by the HIPAA statute, state laws continue to be enforceable, unless they are contrary to Part C of Title XI of the standards, requirements, or implementation specifications adopted or pursuant to subpart x. However, under section 264(c)(4), regulations contrary provisions of state privacy laws are preempted; rather, the law provides that contrary provisions of state law relating to the privacy of individually identifiable health information that are also “more stringent” than the federal regulatory requirements or implementation specifications will continue to be enforceable.

Section 3(b) of Executive Order 13132 recognizes that national action limiting the policymaking discretion of states will be imposed “** * only where there is constitutional and statutory authority for the action and the national activity is appropriate in light of the presence of a problem of national significance.” Personal privacy issues are widely identified as a national concern by virtue of the scope of interstate health commerce. HIPAA’s provisions reflect this position. HIPAA attempts to facilitate the electronic exchange of financial and administrative health plan transactions while recognizing challenges that local, national, and international information sharing raise to confidentiality and privacy of health information.

Section 3(d)(2) of the Executive Order 13132 requires the federal government defer to the states to establish standards where possible. HIPAA requires the Department to establish standards, and we have done so accordingly. This approach is a key component of the final Privacy Rule, and it adheres to section 4(a) of Executive Order 13132, which expressly contemplates preemption when there is a conflict between exercising state and federal authority under federal statute. Section 262 of HIPAA enacted Section 1178 of the Social Security Act, developing a “general rule” that state laws or provisions that are contrary to the provisions or requirements of Part C of Title XI, or the standards or implementation specifications adopted, or established thereunder are preempted. Several exceptions to this rule exist, each of which is designed to maintain a high degree of state autonomy.

Moreover, section 4(b) of the Executive Order authorizes preemption of state law in the federal rule making context when there is “the exercise of state authority is directly conflicts with the exercise of federal authority under federal statute * * *.” Section 1178 (a)(2)(B) of HIPAA specifically preempts state laws related to the privacy of individually identifiable health information unless the state law is more stringent. Thus, we have interpreted state and local laws and regulations that would impose less stringent requirements on the protection of individually identifiable health information as undermining the agency’s goal of ensuring that all patients who receive medical services are assured a minimum level of personal privacy. Particularly where the absence of privacy protection undermines an individual’s access to health care services, both the personal and public interest is served by establishing federal rules.

The final rule would establish national minimum standards with respect to the collection, maintenance, access, use, and disclosure of individually identifiable health information. The federal law will preempt state law only where state and federal laws are “contradictory” and the federal regulation is judged to establish “more stringent” privacy protections than state laws.

As required by the previous Executive Order (E.O. 13132), states and local governments were given, through the notice of proposed rule making, an opportunity to participate in the proceedings to preempt state and local laws (section 4(e)). The Secretary also provided a review of preemption issues upon requests from states. In addition, anticipating the promulgation of the Executive Order, appropriate officials and organizations were consulted before this proposed action is implemented (Section 3(a) of Executive Order 13132).

The same section also includes some qualitative discussion of costs that would occur beyond that time period. Most of the costs of proposed rule, however, would occur in the years immediately after the publication of a final rule. Future costs beyond the ten year period will continue but will not be as great as the initial compliance costs.

Finally, we have considered the cost burden that this proposed rule would impose on state and local health care programs, such as Medicaid, county hospitals, and other state health benefits programs. As discussed in Section E of the Regulatory Impact Analysis of this document, we estimate state and local government costs will be in the range of $460 million in 2003 and $2.4 billion over ten years.

The agency concludes that the policy in this final document has been assessed in light of the principles, criteria, and requirements in Executive Order 13132; that this policy is not inconsistent with that Order; that this policy will not impose significant additional costs and burdens on the states; and that this policy will not affect the ability of the states to discharge traditional state governmental functions.

During our consultation with the states, representatives from various state agencies and offices expressed concern that the final regulation would preempt
all state privacy laws. As explained in this section, the regulation would only preempt state laws where there is a direct conflict between state laws and the regulation, and where the regulation provides more stringent privacy protection than state law. We discussed this issue during our consultation with state representatives, who generally accepted our approach to the preemption issue. During the consultation, we requested further information from the states about whether they currently have laws requiring that providers have a “duty to warn” family members or third parties about a patient’s condition other than in emergency circumstances. Since the consultation, we have not received additional comments or questions from the states.

X. Executive Order 13086; Consultation and Coordination With Indian Tribal Governments

In drafting the proposed rule, the Department consulted with representatives of the National Congress of American Indians and the National Indian Health Board, as well as with a representative of the self-governance Tribes. During the consultation, we discussed issues regarding the application of Title II of HIPAA to the Tribes, and potential variations based on the relationship of each Tribe with Tribes, and potential variations based on the relationship of each Tribe with the IHS for the purpose of providing health services. Participants raised questions about the status of Tribal laws regarding the privacy of health information.

List of Subjects

45 CFR Part 160

Electronic transactions, Employer benefit plan, Health, Health care, Health facilities, Health insurance, Health records, Medicaid, Medical research, Medicare, Privacy, Reporting and record keeping requirements.

45 CFR Part 164

Electronic transactions, Employer benefit plan, Health, Health care, Health facilities, Health insurance, Health records, Medicaid, Medical research, Medicare, Privacy, Reporting and record keeping requirements.

Note: to reader: This final rule is one of several proposed and final rules that are being published to implement the Administrative Simplification provisions of the Health Insurance Portability and Accountability Act of 1996. 45 CFR subchapter C consisting of Parts 160 and 162 was added at 65 FR 50365, Aug. 17, 2000. Part 160 consists of general provisions, Part 162 consists of the various administrative simplification regulations relating to transactions and identifiers, and new Part 164 consists of the regulations implementing the security and privacy requirements of the legislation.


Donna Shalala,
Secretary.

For the reasons set forth in the preamble, 45 CFR Subtitle A, Subchapter C, is amended as follows: 1. Part 160 is revised to read as follows:

PART 160—GENERAL ADMINISTRATIVE REQUIREMENTS

Subpart A—General Provisions

§ 160.101 Statutory basis and purpose.

§ 160.102 Applicability.

§ 160.103 Definitions.

§ 160.104 Modifications.

Subpart B—Preemption of State Law

§ 160.201 Applicability.

§ 160.202 Definitions.

§ 160.203 General rule and exceptions.

§ 160.204 Process for requesting exception determinations.

§ 160.205 Duration of effectiveness of exception determinations.

Subpart C—Compliance and Enforcement

§ 160.300 Applicability.

§ 160.302 Definitions.

§ 160.304 Principles for achieving compliance.

§ 160.306 Complaints to the Secretary.

§ 160.308 Compliance reviews.

§ 160.310 Responsibilities of covered entities.

§ 160.312 Secretarial action regarding complaints and compliance reviews.


Subpart A—General Provisions

§ 160.101 Statutory basis and purpose.

The requirements of this subchapter implement sections 1171 through 1179 of the Social Security Act (the Act), as added by section 262 of Public Law 104–191, and section 264 of Public Law 104–191.

§ 160.102 Applicability.

(a) Except as otherwise provided, the standards, requirements, and implementation specifications adopted under this subchapter apply to the following entities:

(1) A health plan.

(2) A health care clearinghouse.

(3) A health care provider who transmits any health information in electronic form in connection with a transaction covered by this subchapter.

(b) To the extent required under section 201(a)(5) of the Health Insurance Portability Act of 1996, (Pub. L. 104–191), nothing in this subchapter shall be construed to diminish the authority of any Inspector General, including such authority as provided in the Inspector General Act of 1978, as amended (5 U.S.C. App.).

§ 160.103 Definitions.

Except as otherwise provided, the following definitions apply to this subchapter:

(2) A health care clearinghouse.

(1) A covered entity participating in an organized health care arrangement (as defined in §164.501 of this subchapter) in which the covered entity participates, but other than in the capacity of a member of the workforce of such covered entity or arrangement, performs, or assists in the performance of:

(A) A function or activity involving the use or disclosure of individually identifiable health information, including claims processing or administration, data analysis, processing or administration, utilization review, quality assurance, billing, benefit management, practice management, and re pricing; or

(B) Any other function or activity regulated by this subchapter; or

(ii) Provides, other than in the capacity of a member of the workforce of such covered entity, legal, actuarial, accounting, consulting, data aggregation (as defined in §164.501 of this subchapter), management, administrative, accreditation, or financial services to or for such covered entity, or to or for an organized health care arrangement in which the covered entity participates, where the provision of the service involves the disclosure of individually identifiable health information from such covered entity or arrangement, or from another business associate of such covered entity or arrangement, to the person.

(2) A covered entity participating in an organized health care arrangement that performs a function or activity as described by paragraph (1)(ii) of this definition for or on behalf of such organized health care arrangement, or that provides a service as described in paragraph (1)(ii) of this definition to or for such organized health care arrangement, does not, simply through the performance of such function or activity the provision of such service,
become a business associate of other covered entities participating in such organized health care arrangement.

(3) A covered entity may be a business associate of another covered entity. Compliance date means the date by which a covered entity must comply with a standard, implementation specification, requirement, or modification adopted under this subchapter.

Covered entity means:

(1) A health plan;

(2) A health care clearinghouse;

(3) A health care provider who transmits any health information in electronic form in connection with a transaction covered by this subchapter.

Group health plan (also see definition of health plan in this section) means an employee welfare benefit plan (as defined in section 3(1) of the Employee Retirement Income and Security Act of 1974 (ERISA), 29 U.S.C. 1002(1)), including insured and self-insured plans, to the extent that the plan provides medical care (as defined in section 2791(a)(2) of the Public Health Service Act (PHS Act), 42 U.S.C. 300gg–91(a)(2)), including items and services paid for as medical care, to employees or their dependents directly or through insurance, reimbursement, or otherwise, that:

(1) Has 50 or more participants (as defined in section 3(7) of ERISA, 29 U.S.C. 1002(7)); or

(2) Is administered by an entity other than the employer that established and maintains the plan.

HCF stands for the Health Care Financing Administration within the Department of Health and Human Services.

HHS stands for the Department of Health and Human Services.

Health care means care, services, or supplies related to the health of an individual. Health care includes, but is not limited to, the following:

(1) Preventive, diagnostic, therapeutic, rehabilitative, maintenance, or palliative care, and counseling, service, assessment, or procedure with respect to the physical or mental condition, or functional status, of an individual or that affects the structure or function of the body; and

(2) Sale or dispensing of a drug, device, equipment, or other item in accordance with a prescription.

Health care clearinghouse means a public or private entity, including a billing service, reparing company, community health management information system or community health information system, and “value-added” networks and switches, that does either of the following functions: (1) Processes or facilitates the processing of health information received from another entity in a nonstandard format or containing nonstandard data content into standard data elements or a standard transaction. (2) Receives a standard transaction from another entity and processes or facilitates the processing of health information into nonstandard format or nonstandard data content for the receiving entity.

Health care provider means a provider of services (as defined in section 1861(u) of the Act, 42 U.S.C. 1395x(u)), a provider of medical or health services (as defined in section 1861(s) of the Act, 42 U.S.C. 1395x(s)), and any other person or organization who furnishes, bills, or is paid for health care in the normal course of business.

Health information means any information, whether oral or recorded in any form or medium, that:

(1) Is created or received by a health care provider, health plan, public health authority, employer, life insurer, school or university, or health care clearinghouse; and

(2) Relates to the past, present, or future physical or mental health or condition of an individual; the provision of health care to an individual; or the past, present, or future payment for the provision of health care to an individual.

Health insurance issuer (as defined in section 2791(b)(2) of the PHS Act, 42 U.S.C. 300gg–91(b)(2) and used in the definition of health plan in this section) means an insurance company, insurance service, or insurance organization (including an HMO) that is licensed to engage in the business of insurance in a State and is subject to State law that regulates insurance. Such term does not include a group health plan.

Health maintenance organization (HMO) (as defined in section 2791(a)(3) of the PHS Act, 42 U.S.C. 300gg–91(a)(3) and used in the definition of health plan in this section) means a federally qualified HMO, an organization recognized as an HMO under State law, or a similar organization regulated for solvency under State law in the same manner and to the same extent as such an HMO.

Health plan means an individual or group plan that provides, or pays the cost of, medical care (as defined in section 2791(a)(2) of the PHS Act, 42 U.S.C. 300gg–91(a)(2)).

(1) Health plan includes the following, singly or in combination:

(i) A group health plan, as defined in this section.

(ii) A health insurance issuer, as defined in this section.

(iii) An HMO, as defined in this section.

(iv) Part A or Part B of the Medicare program under title XVIII of the Act.

(v) The Medicaid program under title XIX of the Act, 42 U.S.C. 1396, et seq.

(vi) An issuer of a Medicare supplemental policy (as defined in section 1862(g)(1) of the Act, 42 U.S.C. 1395ss(g)(1)).

(vii) An issuer of a long-term care policy, excluding a nursing home fixed-indemnity policy.

(viii) An employee welfare benefit plan or any other arrangement that is established or maintained for the purpose of offering or providing health benefits to the employees of two or more employers.

(ix) The health care program for active military personnel under title 10 of the United States Code.

(x) The veterans health care program under 38 U.S.C. chapter 17.

(xi) The Civilian Health and Medical Program of the Uniformed Services (CHAMPUS) (as defined in 10 U.S.C. 1072(4)).

(xii) The Indian Health Service program under the Indian Health Care Improvement Act, 25 U.S.C. 1601, et seq.


(xiv) An approved State child health plan under title XXI of the Act, providing benefits for child health assistance that meet the requirements of section 2103 of the Act, 42 U.S.C. 1397, et seq.


(xvi) A high risk pool that is a mechanism established under State law to provide health insurance coverage or comparable coverage to eligible individuals.

(xvii) Any other individual or group plan, or combination of individual or group plans, that provides or pays for the cost of medical care (as defined in section 2791(a)(2) of the PHS Act, 42 U.S.C. 300gg–91(a)(2)).

(2) Health plan excludes:

(i) Any policy, plan, or program to the extent that it provides, or pays for the cost of, excepted benefits that are listed in section 2791(c)(1) of the PHS Act, 42 U.S.C. 300gg–91(c)(1); and

(ii) A government-funded program (other than one listed in paragraph (1)(i)–(xvi) of this definition):

(A) Whose principal purpose is other than providing, or paying the cost of, health care; or...
(B) Whose principal activity is:
(1) The direct provision of health care to persons; or
(2) The making of grants to fund the direct provision of health care to persons.

Implementation specification means specific requirements or instructions for implementing a standard.

Modify or modification refers to a change adopted by the Secretary, through regulation, to a standard or an implementation specification.

Secretary means the Secretary of Health and Human Services or any other officer or employee of HHS to whom the authority involved has been delegated.

Small health plan means a health plan with annual receipts of $5 million or less.

Standard means a rule, condition, or requirement:
(1) Describing the following information for products, systems, services or practices:
   (i) Classification of components.
   (ii) Specification of materials, performance, or operations; or
   (iii) Delineation of procedures; or
(2) With respect to the privacy of individually identifiable health information.

Standard setting organization (SSO) means an organization accredited by the American National Standards Institute that develops and maintains standards for information transactions or data elements, or any other standard that is necessary for, or will facilitate the implementation of, this part.

State refers to one of the following:
(1) For a health plan established or regulated by Federal law, the States means the setting forth in the applicable section of the United States Code for such health plan.
(2) For all other purposes, State means any of the several States, the District of Columbia, the Commonwealth of Puerto Rico, the Virgin Islands, and Guam.

Trading partner agreement means an agreement related to the exchange of information in electronic transactions, whether the agreement is distinct or part of a larger agreement, between each party to the agreement. (For example, a trading partner agreement may specify, among other things, the duties and responsibilities of each party to the agreement in conducting a standard transaction.)

Transaction means the transmission of information between two parties to carry out financial or administrative activities related to health care. It includes the following types of information transmissions:
(1) Health care claims or equivalent encounter information.
(2) Health care payment and remittance advice.
(3) Coordination of benefits.
(4) Health care claim status.
(5) Enrollment and disenrollment in a health plan.
(6) Eligibility for a health plan.
(7) Health plan premium payments.
(8) Referral certification and authorization.
(9) First report of injury.
(10) Health claims attachments.
(11) Other transactions that the Secretary may prescribe by regulation.

Workforce means employees, volunteers, trainees, and other persons whose conduct, in the performance of work for a covered entity, is under the direct control of such entity, whether or not they are paid by the covered entity.

§160.104 Modifications.
(a) Except as provided in paragraph (b) of this section, the Secretary may adopt a modification to a standard or implementation specification adopted under this subchapter no more frequently than once every 12 months.
(b) The Secretary may adopt a modification at any time during the first year after the standard or implementation specification is initially adopted, if the Secretary determines that the modification is necessary to permit compliance with the standard or implementation specification.
(c) The Secretary will establish the compliance date for any standard or implementation specification modified under this section.
(1) The compliance date for a modification is no earlier than 180 days after the effective date of the final rule in which the Secretary adopts the modification.
(2) The Secretary may consider the extent of the modification and the time needed to comply with the modification in determining the compliance date for the modification.
(3) The Secretary may extend the compliance date for small health plans, as the Secretary determines is appropriate.

Subpart B—Preemption of State Law

§160.201 Applicability.
The provisions of this subpart implement section 1178 of the Act, as added by section 262 of Public Law 104–191.

§160.202 Definitions.
For purposes of this subpart, the following terms have the following meanings:

Contrary, when used to compare a provision of State law to a standard, requirement, or implementation specification adopted under this subchapter, means:
(1) A covered entity would find it impossible to comply with both the State and federal requirements; or
(2) The provision of State law stands as an obstacle to the accomplishment and execution of the full purposes and objectives of part C of title XI of the Act or section 264 of Pub. L. 104–191, as applicable.

More stringent means, in the context of a comparison of a provision of State law and a standard, requirement, or implementation specification adopted under subpart E of part 164 of this subchapter, a State law that meets one or more of the following criteria:
(1) With respect to a use or disclosure, the law prohibits or restricts a use or disclosure in circumstances under which such use or disclosure otherwise would be permitted under this subchapter, except if the disclosure is:
   (i) Required by the Secretary in connection with determining whether a covered entity is in compliance with this subchapter; or
   (ii) To the individual who is the subject of the individually identifiable health information.
(2) With respect to the rights of an individual who is the subject of the individually identifiable health information of access to or amendment of individually identifiable health information, permits greater rights of access or amendment, as applicable; provided that, nothing in this subchapter may be construed to preempt any State law to the extent that it authorizes or prohibits disclosure of protected health information about a minor to a parent, guardian, or person acting in loco parentis of such minor.
(3) With respect to information to be provided to an individual who is the subject of the individually identifiable health information about a use, a disclosure, rights, and remedies, provides the greater amount of information.
(4) With respect to the form or substance of an authorization or consent for use or disclosure of individually identifiable health information, provides requirements that narrow the scope or duration, increase the privacy protections afforded (such as by expanding the criteria for), or reduce the coercive effect of the circumstances surrounding the authorization or consent, as applicable.
(5) With respect to recordkeeping or requirements relating to accounting of disclosures, provides the retention or reporting of more detailed information or for a longer duration.
(6) With respect to any other matter, provides greater privacy protection for the individual who is the subject of the individually identifiable health information.

Relates to the privacy of individually identifiable health information means, with respect to a State law, that the State law has the specific purpose of protecting the privacy of health information or affects the privacy of health information in a direct, clear, and substantial way.

State law means a constitution, statute, regulation, rule, common law, or other State action having the force and effect of law.

§160.203 General rule and exceptions.

A standard, requirement, or implementation specification adopted under this subchapter that is contrary to a provision of State law preempts the provision of State law. This general rule applies, except if one or more of the following conditions is met:

(a) A determination is made by the Secretary under §160.204 that the provision of State law:
   (1) Is necessary:
      (i) To prevent fraud and abuse related to the provision of or payment for health care;
      (ii) To ensure appropriate State regulation of insurance and health plans to the extent expressly authorized by statute or regulation;
      (iii) For State reporting on health care delivery or costs; or
      (iv) For purposes of serving a compelling need related to public health, safety, or welfare, and, if a standard, requirement, or implementation specification under part 164 of this subchapter is at issue, if the Secretary determines that the intrusion into privacy is warranted when balanced against the need to be served; or
   (2) Has as its principal purpose the regulation of the manufacture, registration, distribution, dispensing, or other control of any controlled substances (as defined in 21 U.S.C. 802), or that is deemed a controlled substance by State law.
   (b) The provision of State law relates to the privacy of health information and is more stringent than a standard, requirement, or implementation specification adopted under subpart E of part 164 of this subchapter.
   (c) The provision of State law, including State procedures established under such law, as applicable, provides for the reporting of disease or injury, child abuse, abuse, or death, or for the conduct of public health surveillance, investigation, or intervention.

(d) The provision of State law requires a health plan to report, or to provide access to, information for the purpose of management audits, financial audits, program monitoring and evaluation, or the licensure or certification of facilities or individuals.

§160.204 Process for requesting exception determinations.

(a) A request to except a provision of State law from preemption under §160.203(a) may be submitted to the Secretary. A request by a State must be submitted through its chief elected official, or his or her designee. The request must be in writing and include the following information:
   (1) The State law for which the exception is requested;
   (2) The particular standard, requirement, or implementation specification for which the exception is requested;
   (3) The part of the standard or other provision that will not be implemented based on the exception or the additional data to be collected based on the exception, as appropriate;
   (4) How health care providers, health plans, and other entities would be affected by the exception;
   (5) The reasons why the State law should not be preempted by the federal standard, requirement, or implementation specification, including how the State law meets one or more of the criteria at §160.203(a); and
   (6) Any other information the Secretary may request in order to make the determination.

(b) Requests for exception under this section must be submitted to the Secretary at an address that will be published in the Federal Register. Until the Secretary’s determination is made, the standard, requirement, or implementation specification under this subchapter remains in effect.

(c) The Secretary’s determination under this section will be made on the basis of the extent to which the information provided and other factors demonstrate that one or more of the criteria at §160.203(a) has been met.

§160.205 Duration of effectiveness of exception determinations.

An exception granted under this subpart remains in effect until:

(a) Either the State law or the federal standard, requirement, or implementation specification that provided the basis for the exception is materially changed such that the ground for the exception no longer exists; or
(b) The Secretary revokes the exception, based on a determination that the ground supporting the need for the exception no longer exists.

Subpart C—Compliance and Enforcement

§160.300 Applicability.

This subpart applies to actions by the Secretary, covered entities, and others with respect to ascertaining the compliance by covered entities with and the enforcement of the applicable requirements of this part 160 and the applicable standards, requirements, and implementation specifications of subpart E of part 164 of this subchapter.

§160.302 Definitions.

As used in this subpart, terms defined in §164.501 of this subchapter have the same meanings given to them in that section.

§160.304 Principles for achieving compliance.

(a) Cooperation. The Secretary will, to the extent practicable, seek the cooperation of covered entities in obtaining compliance with the applicable requirements of this part 160 and the applicable standards, requirements, and implementation specifications of subpart E of part 164 of this subchapter.

(b) Assistance. The Secretary may provide technical assistance to covered entities to help them comply voluntarily with the applicable requirements of this part 160 or the applicable standards, requirements, and implementation specifications of subpart E of part 164 of this subchapter.

§160.306 Complaints to the Secretary.

(a) Right to file a complaint. A person who believes a covered entity is not complying with the applicable requirements of this part 160 or the applicable standards, requirements, and implementation specifications of subpart E of part 164 of this subchapter may file a complaint with the Secretary.

(b) Requirements for filing complaints. Complaints under this section must meet the following requirements:
   (1) A complaint must be filed in writing, either on paper or electronically.
   (2) A complaint must name the entity that is the subject of the complaint and describe the acts or omissions believed to be in violation of the applicable requirements of this part 160 or the applicable standards, requirements, and implementation specifications of subpart E of part 164 of this subchapter.
   (3) A complaint must be filed within 180 days of when the complainant knew or should have known that the act or omission complained of occurred, unless this time limit is waived by the Secretary for good cause shown.
must permit access by the Secretary at any time and without notice.
(2) If any information required of a covered entity under this section is in the exclusive possession of any other agency, institution, or person and the other agency, institution, or person fails or refuses to furnish the information, the covered entity must so certify and set forth what efforts it has made to obtain the information.
(3) Protected health information obtained by the Secretary in connection with an investigation or compliance review under this subpart will not be disclosed by the Secretary, except if necessary for ascertaining or enforcing compliance with the applicable requirements of this part 160 and the applicable standards, requirements, and implementation specifications of subpart E of part 164 of this subchapter, or if otherwise required by law.

§ 160.310 Responsibilities of covered entities.
(a) Provide records and compliance reports. A covered entity must keep such records and submit such compliance reports, in such time and manner and containing such information, as the Secretary may determine to be necessary to enable the Secretary to ascertain whether the covered entity has complied or is complying with the applicable requirements of this part 160 and the applicable standards, requirements, and implementation specifications of subpart E of part 164 of this subchapter.
(b) Cooperate with complaint investigations and compliance reviews. A covered entity must cooperate with the Secretary, if the Secretary undertakes an investigation or compliance review of the policies, procedures, or practices of a covered entity to determine whether it is complying with the applicable requirements of this part 160 and the standards, requirements, and implementation specifications of subpart E of part 164 of this subchapter.
(c) Permit access to information. [1] A covered entity must permit access by the Secretary during normal business hours to its facilities, books, records, accounts, and other sources of information, including protected health information, that are pertinent to ascertaining compliance with the applicable requirements of this part 160 and the applicable standards, requirements, and implementation specifications of subpart E of part 164 of this subchapter. If the Secretary determines that exigent circumstances exist, such as when documents may be hidden or destroyed, a covered entity must permit access by the Secretary at any time and without notice.
(2) If any information required of a covered entity under this section is in the exclusive possession of any other agency, institution, or person and the other agency, institution, or person fails or refuses to furnish the information, the covered entity must so certify and set forth what efforts it has made to obtain the information.
(3) Protected health information obtained by the Secretary in connection with an investigation or compliance review under this subpart will not be disclosed by the Secretary, except if necessary for ascertaining or enforcing compliance with the applicable requirements of this part 160 and the applicable standards, requirements, and implementation specifications of subpart E of part 164 of this subchapter, or if otherwise required by law.

Part 164—Security and Privacy

§ 164.102 Statutory basis.
The provisions of this part are adopted pursuant to the Secretary’s authority to prescribe standards, requirements, and implementation standards under part C of title XI of the Act and section 264 of Public Law 104–191.

§ 164.104 Applicability. Except as otherwise provided, the provisions of this part apply to covered entities: health plans, health care clearinghouses, and health care providers who transmit health information in electronic form in connection with any transaction referred to in section 1173(a)(1) of the Act.

§ 164.106 Relationship to other parts. In complying with the requirements of this part, covered entities are required to comply with the applicable provisions of parts 160 and 162 of this subchapter.
implementation specifications of this subpart apply to covered entities with respect to protected health information.

(b) Health care clearinghouses must comply with the standards, requirements, and implementation specifications as follows:

(1) When a health care clearinghouse creates or receives protected health information as a business associate of another covered entity, the clearinghouse must comply with:
   (i) Section 164.500 relating to applicability;
   (ii) Section 164.501 relating to definitions;
   (iii) Section 164.502 relating to uses and disclosures of protected health information, except that a clearinghouse is prohibited from using or disclosing protected health information other than as permitted in the business associate contract under which it created or received the protected health information;
   (iv) Section 164.504 relating to the organizational requirements for covered entities, including the designation of health care components of a covered entity;
   (v) Section 164.512 relating to uses and disclosures for which consent, individual authorization or an opportunity to agree or object is not required, except that a clearinghouse is prohibited from using or disclosing protected health information other than as permitted in the business associate contract under which it created or received the protected health information;
   (vi) Section 164.532 relating to transition requirements; and
   (vii) Section 164.534 relating to compliance dates for initial implementation of the privacy standards.

(2) When a health care clearinghouse creates or receives protected health information other than as a business associate of a covered entity, the clearinghouse must comply with all of the standards, requirements, and implementation specifications of this subpart.

(c) The standards, requirements, and implementation specifications of this subpart do not apply to the Department of Defense or to any other federal agency, or non-governmental organization acting on its behalf, when providing health care to overseas foreign national beneficiaries.

§ 164.501 Definitions.

As used in this subpart, the following terms have the following meanings:

Corrections institution means any penal or correctional facility, jail, reformatory, detention center, work farm, halfway house, or residential community program center operated by, or under contract to, the United States, a State, a territory, a political subdivision of a State or territory, or an Indian tribe, for the confinement or rehabilitation of persons charged with or convicted of a criminal offense or other persons held in lawful custody. Other persons held in lawful custody includes juvenile offenders adjudicated delinquent, aliens detained awaiting deportation, persons committed to mental institutions through the criminal justice system, witnesses, or others awaiting charges or trial.

Covered functions means those functions of a covered entity the performance of which makes the entity a health plan, health care provider, or health care clearinghouse.

Data aggregation means, with respect to protected health information created or received by a business associate in its capacity as the business associate of a covered entity, the combining of such protected health information by the business associate with the protected health information received by the business associate in its capacity as a business associate of another covered entity, to permit data analyses that relate to the health care operations of the respective covered entities.

Designated record set means:

(1) A group of records maintained by or for a covered entity that is:
   (i) The medical records and billing records about individuals maintained by or for a covered health care provider;
   (ii) The enrollment, payment, claims adjudication, and case or medical management record systems maintained by or for a health plan; or
   (iii) Used, in whole or in part, by or for the covered entity to make decisions about individuals.

(2) For purposes of this paragraph, the term record means any item, collection, or grouping of information that includes protected health information and is maintained, collected, used, or disseminated by or for a covered entity.

Direct treatment relationship means a treatment relationship between an individual and a health care provider that is not an indirect treatment relationship.

Disclosure means the release, transfer, provision of access to, or divulging in any other manner of information outside the entity holding the information.

Health care operations means any of the following activities of the covered entity to permit data analyses that are related to covered functions, and any of the following activities of an organized health care arrangement in which the covered entity participates:

(1) Conducting quality assessment and improvement activities, including outcomes evaluation and development of clinical guidelines, provided that the obtaining of generalizable knowledge is not the primary purpose of any studies resulting from such activities;

(2) Reviewing the competence or qualifications of health care professionals, evaluating practitioner and provider performance, health plan performance, conducting training programs in which students, trainees, or practitioners in areas of health care learn under supervision to practice or improve their skills as health care providers, training of non-health care professionals, accreditation, certification, licensing, or credentialing activities;

(3) Underwriting, premium rating, and other activities relating to the creation, renewal or replacement of a contract of health insurance or health benefits, and ceding, securing, or placing a contract for reinsurance of risk relating to claims for health care (including stop-loss insurance and excess of loss insurance), provided that the requirements of § 164.514(g) are met, if applicable;

(4) Conducting or arranging for medical review, legal services, and auditing functions, including fraud and abuse detection and compliance programs;

(5) Business planning and development, such as conducting cost-management and planning-related analyses related to managing and operating the entity, including formulary development and administration, development or improvement of methods of payment or coverage policies; and

(6) Business management and general administrative activities of the entity, including, but not limited to:
   (i) Management activities relating to implementation of and compliance with the requirements of this subchapter;
   (ii) Customer service, including the provision of data analyses for policy holders, plan sponsors, or other customers, provided that protected health information is not disclosed to such policy holder, plan sponsor, or customer;
   (iii) Resolution of internal grievances;
(iv) Due diligence in connection with the sale or transfer of assets to a potential successor in interest, if the potential successor in interest is a covered entity or, following completion of the sale or transfer, will become a covered entity; and

(v) Consistent with the applicable requirements of §164.514, creating de-identified health information, fundraising for the benefit of the covered entity, and marketing for which an individual authorization is not required as described in §164.514(e)(2). Health oversight agency means an agency or authority of the United States, a State, a territory, a political subdivision of a State or territory, or an Indian tribe, which is empowered by law to:

(1) Investigate or conduct an official inquiry into a potential violation of law; or

(2) Prosecute or otherwise conduct a criminal, civil, or administrative proceeding arising from an alleged violation of law.

Marketing means to make a communication about a product or service a purpose of which is to encourage recipients of the communication to purchase or use the product or service.

(1) Marketing does not include communications that meet the requirements of paragraph (2) of this definition and that are made by a covered entity:

(i) For the purpose of describing the entities participating in a health care provider network or health plan network, or for the purpose of describing if and the extent to which a product or service (or payment for such product or service) is provided by a covered entity or included in a plan of benefits; or

(ii) That are tailored to the circumstances of a particular individual and the communications are:

(A) Made by a health care provider to an individual as part of the treatment of the individual, and for the purpose of furthering the treatment of that individual; or

(B) Made by a health care provider or health plan to an individual in the course of managing the treatment of that individual, or for the purpose of directing or recommending to that individual alternative treatments, therapies, health care providers, or settings of care.

(2) A communication described in paragraph (1) of this definition is not included in marketing if:

(i) The communication is made orally; or

(ii) The communication is in writing and the covered entity does not receive direct or indirect remuneration from a third party for making the communication.

Organized health care arrangement means:

(1) A clinically integrated care setting in which individuals typically receive health care from more than one health care provider;

(2) An organized system of health care in which more than one covered entity participates, and in which the participating covered entities:

(i) Hold themselves out to the public as participating in a joint arrangement; and

(ii) Participate in joint activities that include at least one of the following:

(A) Utilization review, in which health care decisions by participating covered entities are reviewed by other participating covered entities or by a third party on their behalf;

(B) Quality assessment and improvement activities, in which treatment provided by participating covered entities is assessed by other participating covered entities or by a third party on their behalf; or

(C) Payment activities, if the financial risk for delivering health care is shared, in part or in whole, by participating covered entities through the joint arrangement and if protected health information created or received by a covered entity is reviewed by other participating covered entities or by a third party on their behalf for the purpose of administering the sharing of financial risk.

(3) A group health plan and a health insurance issuer or HMO with respect to such group health plan, but only with respect to protected health information created or received by such health insurance issuer or HMO that relates to individuals who are or who have been participants or beneficiaries in such group health plan;

(4) A group health plan and one or more other group health plans each of which are maintained by the same plan sponsor; or

(5) The group health plans described in paragraph (4) of this definition and health insurance issuers or HMOs with respect to such group health plans, but only with respect to protected health information created or received by such health insurance issuers or HMOs that relates to individuals who are or have been participants or beneficiaries in any of such group health plans.

Payment means:

(1) The activities undertaken by:

(i) A health plan to obtain premiums or to determine or fulfill its responsibility for coverage and provision of benefits under the health plan; or

(ii) A covered health care provider or health plan to obtain or provide reimbursement for the provision of health care; and

(2) The activities in paragraph (1) of this definition relate to the individual to whom health care is provided and include, but are not limited to:

Inmate means a person incarcerated in or otherwise confined to a correctional institution.

Law enforcement official means an officer or employee of any agency or authority of the United States, a State, a territory, a political subdivision of a State or territory, or an Indian tribe, who is empowered by law to:

(1) Investigate or conduct an official inquiry into a potential violation of law; or

(2) Prosecute or otherwise conduct a criminal, civil, or administrative proceeding arising from an alleged violation of law.

Marketing means to make a communication about a product or service a purpose of which is to encourage recipients of the communication to purchase or use the product or service.

(1) Marketing does not include communications that meet the requirements of paragraph (2) of this definition and that are made by a covered entity:

(i) For the purpose of describing the entities participating in a health care provider network or health plan network, or for the purpose of describing if and the extent to which a product or service (or payment for such product or service) is provided by a covered entity or included in a plan of benefits; or

(ii) That are tailored to the circumstances of a particular individual and the communications are:

(A) Made by a health care provider to an individual as part of the treatment of the individual, and for the purpose of furthering the treatment of that individual; or

(B) Made by a health care provider or health plan to an individual in the course of managing the treatment of that individual, or for the purpose of directing or recommending to that individual alternative treatments, therapies, health care providers, or settings of care.

(2) A communication described in paragraph (1) of this definition is not included in marketing if:

(i) The communication is made orally; or

(ii) The communication is in writing and the covered entity does not receive direct or indirect remuneration from a third party for making the communication.

Organized health care arrangement means:

(1) A clinically integrated care setting in which individuals typically receive health care from more than one health care provider;
(i) Determinations of eligibility or coverage (including coordination of benefits or the determination of cost sharing amounts), and adjudication or subrogation of health benefit claims; (ii) Risk adjusting amounts due based on enrollee health status and demographic characteristics; (iii) Billing, claims management, collection activities, obtaining payment under a contract for reinsurance (including stop-loss insurance and excess of loss insurance), and related health care data processing; (iv) Review of health care services with respect to medical necessity, coverage under a health plan, appropriateness of care, or justification of charges; (v) Utilization review activities, including precertification and preauthorization of services, concurrent and retrospective review of services; and (vi) Disclosure to consumer reporting agencies of any of the following protected health information relating to collection of premiums or reimbursement: (A) Name and address; (B) Date of birth; (C) Social security number; (D) Payment history; (E) Account number; and (F) Name and address of the health care provider and/or health plan.

Plan sponsor is defined as defined at section 3(16)(B) of ERISA, 29 U.S.C. 1002(16)(B).

Protected health information means individually identifiable health information:
(1) Except as provided in paragraph (2) of this definition, that is: (i) Transmitted by electronic media; (ii) Maintained in any medium described in the definition of electronic media at § 162.103 of this subchapter; or (iii) Transmitted or maintained in any other form or medium.

(2) Protected health information excludes individually identifiable health information:

Psychotherapy notes means notes recorded (in any medium) by a health care provider who is a mental health professional documenting or analyzing the contents of conversation during a private counseling session or a group, joint, or family counseling session and that are separated from the rest of the individual's record.

Psychotherapy notes excludes medication prescription and monitoring, counseling session start and stop times, the modalities and frequencies of treatment furnished, results of clinical tests, and any summary of the following items: Diagnosis, functional status, the treatment plan, symptoms, prognosis, and progress to date.

Public health authority means an agency or authority of the United States, a State, a territory, a political subdivision of a State or territory, or an Indian tribe, or a person or entity acting under a grant of authority from or contract with such public agency, including the employees or agents of such public agency or its contractors or persons or entities to whom it has granted authority, that is responsible for public health matters as part of its official mandate.

Required by law means a mandate contained in law that compels a covered entity to make a use or disclosure of protected health information and that is enforceable in a court of law. Required by law includes, but is not limited to, court orders and court-ordered warrants; subpoenas or summons issued by a court, grand jury, a governmental or tribal inspector general, or an administrative body authorized to require the production of information; a civil or an authorized investigative demand; Medicare conditions of participation with respect to health care providers participating in the program; and statutes or regulations that require the production of information, including statutes or regulations that require such information if payment is sought under a government program providing public benefits.

Research means a systematic investigation, including research development, testing, and evaluation, designed to develop or contribute to generalizable knowledge.

Treatment means the provision, coordination, or management of health care and related services by one or more health care providers, including the coordination or management of health care by a health care provider with a third party; consultation between health care providers relating to a patient; or the referral of a patient for health care from one health care provider to another.

Use means, with respect to individually identifiable health information, the sharing, employment, application, utilization, examination, or analysis of such information within an entity that maintains such information.

§ 164.502 Uses and disclosures of protected health information: general rules.

(a) Standard. A covered entity may not use or disclose protected health information, except as permitted or required by this subpart or by subpart C of part 160 of this subchapter.

(1) Permitted uses and disclosures. A covered entity is permitted to use or disclose protected health information as follows:
(i) To the individual;
(ii) Pursuant to and in compliance with a consent that complies with § 164.506, to carry out treatment, payment, or health care operations;
(iii) Without consent, if consent is not required under § 164.506(a) and has not been sought under § 164.506(a)(4), to carry out treatment, payment, or health care operations, except with respect to psychotherapy notes;
(iv) Pursuant to and in compliance with a valid authorization under § 164.508;
(v) Pursuant to an agreement under, or as otherwise permitted by, § 164.510;
and
(vi) As permitted by and in compliance with this section, § 164.512, or § 164.514(e), (f), and (g).

(2) Required disclosures. A covered entity is required to disclose protected health information:
(i) To an individual, when requested under, and required by § 164.524 or § 164.528; and
(ii) When required by the Secretary under subpart C of part 160 of this subchapter to investigate or determine the covered entity’s compliance with this subpart.

(b) Standard: Minimum necessary. (1) Minimum necessary applies. When using or disclosing protected health information or when requesting protected health information from another covered entity, a covered entity must make reasonable efforts to limit protected health information to the minimum necessary to accomplish the intended purpose of the use, disclosure, or request.

(2) Minimum necessary does not apply. This requirement does not apply to:
(i) Disclosures to or requests by a health care provider for treatment;
(ii) Uses or disclosures made to the individual, as permitted under paragraph (a)(1)(i) of this section, as required by paragraph (a)(2)(i) of this section, or pursuant to an authorization under § 164.508, except for authorizations requested by the covered entity under § 164.508(d), (e), or (f);
(iii) Disclosures made to the Secretary in accordance with subpart C of part 160 of this subchapter;
(iv) Uses or disclosures that are required by law, as described by §164.512(a); and
(v) Uses or disclosures that are required for compliance with applicable requirements of this subchapter.

(c) Standard: Uses and disclosures of protected health information subject to an agreed upon restriction. A covered entity that has agreed to a restriction pursuant to §164.522(a)(1) may not use or disclose the protected health information covered by the restriction in violation of such restriction, except as otherwise provided in §164.522(a).

(d) Standard: Uses and disclosures of de-identified protected health information.

(1) Uses and disclosures to create de-identified information. A covered entity may use protected health information to create information that is not individually identifiable health information or disclose protected health information only to a business associate for such purpose, whether or not the de-identified information is to be used by the covered entity.

(2) Uses and disclosures of de-identified information. Health information that meets the standard and implementation specifications for de-identification under §164.514(a) and (b) is considered not to be individually identifiable health information, i.e., de-identified. The requirements of this subpart do not apply to information that has been de-identified in accordance with the applicable requirements of §164.514, provided that:

(i) Disclosure of a code or other means of record identification designed to enable coded or otherwise de-identified information to be re-identified constitutes disclosure of protected health information; and

(ii) If de-identified information is re-identified, a covered entity may use or disclose such re-identified information only as permitted or required by this subpart.

(e)(1) Standard: Disclosures to business associates. (i) A covered entity may disclose protected health information to a business associate and may allow a business associate to create or receive protected health information on its behalf, if the covered entity obtains satisfactory assurance that the business associate will appropriately safeguard the information.

(ii) This standard does not apply:

(A) With respect to disclosures by a covered entity to a health care provider concerning the treatment of the individual;

(B) With respect to disclosures by a group health plan or a health insurance issuer or HMO with respect to a group health plan to the plan sponsor, to the extent that the requirements of §164.504(f) apply and are met; or

(C) With respect to uses or disclosures by a health plan that is a government program providing public benefits, if eligibility for, or enrollment in, the health plan is determined by an agency other than the agency administering the health plan, or if the protected health information used to determine enrollment or eligibility in the health plan is collected by an agency other than the agency administering the health plan, and such activity is authorized by law, with respect to the collection and sharing of individually identifiable health information for the performance of such functions by the health plan and the agency other than the agency administering the health plan.

(iii) A covered entity that violates the satisfactory assurances it provided as a business associate of another covered entity will be in noncompliance with the standard implementation specifications, and requirements of this paragraph and §164.504(e).

(2) Implementation specification: documentation. A covered entity must document the satisfactory assurances required by paragraph (e)(1) of this section through a written contract or other written agreement or arrangement with the business associate that meets the applicable requirements of §164.504(e).

(f) Standard: Deceased individuals. A covered entity must comply with the requirements of this subpart with respect to the protected health information of a deceased individual.

(g)(1) Standard: Personal representatives. As specified in this paragraph, a covered entity must, except as provided in paragraphs (g)(3) and (g)(5) of this section, treat a personal representative as the individual for purposes of this subchapter.

(2) Implementation specification: adults and emancipated minors. If under applicable law a person has authority to act on behalf of an individual who is an adult or an emancipated minor in making decisions related to health care, a covered entity must treat such person as a personal representative under this subchapter, with respect to protected health information relevant to such personal representation.

(3) Implementation specification: unemancipated minors. If under applicable law a parent, guardian, or other person acting in loco parentis has authority to act on behalf of an individual who is an unemancipated minor in making decisions related to health care, a covered entity must treat such person as a personal representative under this subchapter, with respect to protected health information relevant to such personal representation.

(h) Standard: Confidential communications. A covered health care provider or health plan must comply with the applicable requirements of §164.522(b) in communicating protected health information.
(i) Standard: Uses and disclosures consistent with notice. A covered entity that is required by §164.520 to have a notice may not use or disclose protected health information in a manner inconsistent with such notice. A covered entity that is required by §164.520(b)(1)(iii) to include a specific statement in its notice if it intends to engage in an activity listed in §164.520(b)(1)(iii)(A)–(C), may not use or disclose protected health information for such activities, unless the required statement is included in the notice.

(j) Standard: Disclosures by whistleblowers and workforce member crime victims.

(1) Disclosures by whistleblowers. A covered entity is not considered to have violated the requirements of this subpart if a member of its workforce or a business associate discloses protected health information, provided that:

(i) The workforce member or business associate believes in good faith that the covered entity has engaged in conduct that is unlawful or otherwise violates professional or clinical standards, or that the care, services, or conditions provided by the covered entity potentially endangers one or more patients, workers, or the public; and

(ii) The disclosure is to:

(A) A health oversight agency or public health authority authorized by law to investigate or otherwise oversee the relevant conduct or conditions of the covered entity or to an appropriate health care accreditation organization for the purpose of reporting the alleged failure to meet professional standards or misconduct by the covered entity; or

(B) An attorney retained by or on behalf of the workforce member or business associate for the purpose of determining the legal options of the workforce member or business associate with regard to the conduct described in paragraph (j)(1)(i) of this section.

(2) Disclosures by workforce members who are victims of a crime. A covered entity is not considered to have violated the requirements of this subpart if a member of its workforce who is the victim of a criminal act discloses protected health information to a law enforcement official, provided that:

(i) The protected health information disclosed is about the suspected perpetrator of the criminal act; and

(ii) The protected health information disclosed is limited to the information listed in §164.512(f)(2)(i).

§164.504 Uses and disclosures: Organizational requirements.

(a) Definitions. As used in this section:

Common control exists if an entity has the power, directly or indirectly, significantly to influence or direct the actions or policies of another entity.

Common ownership exists if an entity or entities possess an ownership or equity interest of 5 percent or more in another entity.

Health care component has the following meaning:

(1) Components of a covered entity that perform covered functions are part of the health care component.

(2) Another component of the covered entity is part of the entity’s health care component to the extent that:

(i) It performs, with respect to a component that performs covered functions, activities that would make such other component a business associate of the component that performs covered functions if the two components were separate legal entities; and

(ii) The activities involve the use or disclosure of protected health information that such other component creates or receives from or on behalf of the component that performs covered functions.

Hybrid entity means a single legal entity that is a covered entity and whose covered functions are not its primary functions.

Plan administration functions means administration functions performed by the plan sponsor of a group health plan on behalf of the group health plan and excludes functions performed by the plan sponsor in connection with any other benefit or benefit plan of the plan sponsor.

Summary health information means information, that may be individually identifiable health information, and:

(1) That summarizes the claims history, claims expenses, or type of claims experienced by individuals for whom a plan sponsor has provided health benefits under a group health plan; and

(2) From which the information described at §164.514(b)(2)(i) has been deleted, except that the geographic information described in §164.514(b)(2)(i)(B) need only be aggregated to the level of a five digit zip code.

(b) Standard: Health care component.

(1) If a covered entity is a hybrid entity, the requirements of this subpart, other than the requirements of this section, apply only to the health care component(s) of the entity, as specified in this section.

(c)(1) Implementation specification: Application of other provisions. In applying a provision of this subpart, other than this section, to a hybrid entity:

(i) A reference in such provision to a “covered entity” refers to a health care component of the covered entity; and

(ii) A reference in such provision to a “health plan,” “covered health care provider,” or “health care clearinghouse” refers to a health care component of the covered entity if such health care component performs the functions of a health plan, covered health care provider, or health care clearinghouse, as applicable; and

(iii) A reference in such provision to “protected health information” refers to protected health information that is created or received by or on behalf of the health care component of the covered entity.

(2) Implementation specifications: Safeguard requirements. The covered entity that is a hybrid entity must ensure that a health care component of the entity complies with the applicable requirements of this subpart. In particular, and without limiting this requirement, such covered entity must ensure that:

(i) Its health care component does not disclose protected health information to another component of the covered entity in circumstances in which this subpart would prohibit such disclosure if the health care component and the other component were separate and distinct legal entities;

(ii) A component that is described by paragraph (2)(i) of the definition of health care component in this section does not use or disclose protected health information that is within paragraph (2)(ii) of such definition for purposes of its activities other than those described by paragraph (2)(ii) of such definition in a way prohibited by this subpart; and

(iii) If a person performs duties for both the health care component in the capacity of a member of the workforce of such component and for another component of the entity in the same capacity with respect to that component, such workforce member must not use or disclose protected health information created or received in the course of or incident to the member’s work for the health care component in a way prohibited by this subpart.

(3) Implementation specifications: Responsibilities of the covered entity. A covered entity that is a hybrid entity has the following responsibilities:

(i) For purposes of subpart C of part 160 of this subchapter, pertaining to compliance and enforcement, the covered entity has the responsibility to comply with this subpart;

(ii) The covered entity has the responsibility for complying with
§ 164.530(i), pertaining to the implementation of policies and procedures to ensure compliance with this subpart, including the safeguard requirements in paragraph (c)(2) of this section.

(iii) The covered entity is responsible for designating the components that are part of one or more health care components of the covered entity and documenting the designation as required by § 164.530(i).

(d) (1) Standard: Affiliated covered entities. Legally separate covered entities that are affiliated may designate themselves as a single covered entity for purposes of this subpart.

(2) Implementation specifications: Requirements for designation of an affiliated covered entity. (i) Legally separate covered entities may designate themselves (including any health care component of such covered entity) as a single affiliated covered entity, for purposes of this subpart, if all of the covered entities designated are under common ownership or control.

(ii) The designation of an affiliated covered entity must be documented and the documentation maintained as required by § 164.530(i).

(3) Implementation specifications: Safeguard requirements. An affiliated covered entity must ensure that:

(i) The affiliated covered entity’s use and disclosure of protected health information comply with the applicable requirements of this subpart; and

(ii) If the affiliated covered entity combines the functions of a health plan, health care provider, or health care clearinghouse, the affiliated covered entity complies with paragraph (g) of this section.

(e) (1) Standard: Business associate contracts. (i) The contract or other arrangement between the covered entity and the business associate required by § 164.502(e)(2) must meet the requirements of paragraph (e)(2) or (e)(3) of this section, as applicable.

(ii) A covered entity is not in compliance with the standards in § 164.502(e) and paragraph (e) of this section, if the covered entity knew of a pattern of activity or practice of the business associate that constituted a material breach or violation of the business associate’s obligation under the contract or other arrangement, unless the covered entity took reasonable steps to cure the breach or end the violation, as applicable, and, if such steps were unsuccessful:

(A) Terminated the contract or arrangement, if feasible; or

(B) If termination is not feasible, reported the problem to the Secretary.

(2) Implementation specifications: Business associate contracts. A contract between the covered entity and a business associate must:

(i) Establish the permitted and required uses and disclosures of such information by the business associate. The contract may not authorize the business associate to use or further disclose the information in a manner that would violate the requirements of this subpart, if done by the covered entity, except that:

(A) The contract may permit the business associate to use and disclose protected health information for the proper management and administration of the business associate, as provided in paragraph (e)(2) of this section; and

(B) The contract may permit the business associate to provide data aggregation services relating to the health care operations of the covered entity.

(ii) Provide that the business associate will:

(A) Not use or further disclose the information other than as permitted or required by the contract or as required by law;

(B) Use appropriate safeguards to prevent use or disclosure of the information other than as provided for by its contract;

(C) Report to the covered entity any use or disclosure of the information not provided for by its contract of which it becomes aware;

(D) Ensure that any agents, including a subcontractor, to whom it provides protected health information received from, or created or received by the business associate on behalf of, the covered entity agrees to the same restrictions and conditions that apply to the business associate with respect to such information;

(E) Make available protected health information in accordance with § 164.524;

(F) Make available protected health information for amendment and incorporate any amendments to protected health information in accordance with § 164.526;

(G) Make available the information required to provide an accounting of disclosures in accordance with § 164.528;

(H) Make its internal practices, books, and records relating to the use and disclosure of protected health information received from, or created or received by the business associate on behalf of, the covered entity available to the Secretary for purposes of determining the covered entity’s compliance with this subpart; and

(i) At termination of the contract, if feasible, return or destroy all protected health information received from, or created or received by the business associate on behalf of, the covered entity that the business associate still maintains in any form and retain no copies of such information, or, if such return or destruction is not feasible, extend the protections of the contract to the information and limit further uses and disclosures to those purposes that make the return or destruction of the information infeasible.

(iii) Authorize termination of the contract by the covered entity, if the covered entity determines that the business associate has violated a material term of the contract.

(3) Implementation specifications: Other arrangements. (i) If a covered entity and its business associate are both governmental entities:

(A) The covered entity may comply with paragraph (e) of this section by entering into a memorandum of understanding with the business associate that contains terms that accomplish the objectives of paragraph (e)(2) of this section.

(B) The covered entity may comply with paragraph (e) of this section, if other law (including regulations adopted by the covered entity or its business associate) contains requirements applicable to the business associate that accomplish the objectives of paragraph (e)(2) of this section.

(ii) If a business associate is required by law to perform a function or activity on behalf of a covered entity or to provide a service described in the definition of business associate in § 160.103 of this subchapter to a covered entity, such covered entity may disclose protected health information to the business associate to the extent necessary to comply with the legal mandate without meeting the requirements of this paragraph (e), provided that the covered entity attempts in good faith to obtain satisfactory assurances as required by paragraph (e)(3)(i) of this section, and, if such attempt fails, documents the attempt and the reasons that such assurances cannot be obtained.

(iii) The covered entity may omit from its other arrangements the termination authorization required by paragraph (e)(2)(iii) of this section, if such authorization is inconsistent with the statutory obligations of the covered entity or its business associate.

(4) Implementation specifications: Other requirements for contracts and other arrangements. (i) The contract or other arrangement between the covered entity and the business associate may
permit the business associate to use the
information received by the business
associate in its capacity as a business
associate to the covered entity, if
necessary:
(A) For the proper management and
administration of the business associate;
or
(B) To carry out the legal
responsibilities of the business
associate.

(ii) The contract or other arrangement
between the covered entity and the
business associate may permit the
business associate to disclose the
information received by the business
associate in its capacity as a business
associate for the purposes described in
paragraph (e)(4)(i) of this section, if:
(A) The disclosure is required by law;
or
(B)(1) The business associate obtains
reasonable assurances from the person
to whom the information is disclosed
that it will be held confidentially and
used or further disclosed only as
required by law or for the purpose for
which it was disclosed to the person;
and
(2) The person notifies the business
associate of any instances of which it is
aware in which the confidentiality of
the information has been breached.

(f)(1) Standard: Requirements for
group health plans. (i) Except as
provided under paragraph (f)(1)(ii) of
this section or as otherwise authorized
under § 164.508, a group health plan, in
order to disclose protected health
information to the plan sponsor or to
provide for or permit the disclosure of
protected health information to the plan
sponsor by a health insurance issuer or
HMO with respect to the group health
plan, must ensure that the plan
documents restrict uses and disclosures
of such information by the plan sponsor
consistent with the requirements of this
subpart.

(ii) The group health plan, or a health
insurance issuer or HMO with respect to
the group health plan, may disclose
summary health information for the
purpose of:
(A) Obtaining premium bids from
health plans for providing health
insurance coverage under the group
health plan; or
(B) Modifying, amending, or
terminating the group health plan.

(2) Implementation specifications:
Requirements for plan documents. The
plan documents of the group health
plan must be amended to incorporate
provisions to:
(i) Establish the permitted and
required uses and disclosures of such
information by the plan sponsor,
provided that such permitted and
required uses and disclosures may not
be inconsistent with this subpart.

(ii) Provide that the group health plan
will disclose protected health
information to the plan sponsor only
upon receipt of a certification by the
plan sponsor that the plan documents
have been amended to incorporate the
following provisions and that the plan
sponsor agrees to:
(A) Not use or further disclose the
information other than as permitted or
required by the plan documents or as
required by law;
(B) Ensure that any agents, including
a subcontractor, to whom it provides
protected health information received
from the group health plan agree to the
same restrictions and conditions that
apply to the plan sponsor with respect
to such information;
(C) Not use or disclose the
information for employment-related
actions and decisions or in connection
with any other benefit or employee
benefit plan of the plan sponsor;
(D) Report to the group health plan
any use or disclosure of the information
that is inconsistent with the uses or
disclosures provided for of which it
becomes aware;
(E) Make available protected health
information in accordance with
§ 164.524;
(F) Make available protected health
information for amendment and
incorporate any amendments to
protected health information in
accordance with § 164.526;
(G) Make available the information
required to provide an accounting of
disclosures in accordance with
§ 164.528;
(H) Make its internal practices, books,
and records relating to the use and
disclosure of protected health
information received from the group
health plan available to the Secretary for
purposes of determining compliance by
the group health plan with this subpart;
(I) If feasible, return or destroy all
protected health information received
from the group health plan that the
sponsor still maintains in any form and
retain no copies of such information
when no longer needed for the purpose
for which disclosure was made, except
that, if such return or destruction is not
feasible, limit further uses and
disclosures to those purposes that make
the return or destruction of the
information infeasible; and
(J) Ensure that the adequate separation
required in paragraph (f)(2)(iii) of this
section is established;
(iii) Provide for adequate separation
between the group health plan and the
plan sponsor. The plan documents
must:
(A) Describe those employees or
classes of employees or other persons
under the control of the plan sponsor to
be given access to the protected health
information to be disclosed, provided
that any employee or person who
receives protected health information
relating to payment under, health care
operations of, or other matters
pertaining to the group health plan in
the ordinary course of business must be
included in such description;
(B) Restrict the access to and use by
such employees and other persons
described in paragraph (f)(2)(iii)(A) of
this section to the plan administration
functions that the plan sponsor
performs for the group health plan; and
(C) Provide an effective mechanism
for resolving any issues of
noncompliance by persons described in
paragraph (f)(2)(iii)(A) of this section
with the plan document provisions
required by this paragraph.

(3) Implementation specifications:
Uses and disclosures. A group health
plan may:
(i) Disclose protected health
information to a plan sponsor to carry
out plan administration functions that
the plan sponsor performs only
consistent with the provisions of
paragraph (f)(2) of this section;

(ii) Not permit a health insurance
issuer or HMO with respect to the group
health plan to disclose protected health
information to the plan sponsor except
as permitted by this paragraph;

(iii) Not disclose and may not permit
a health insurance issuer or HMO to
disclose protected health information
to a plan sponsor as otherwise permitted
by this paragraph unless a statement
required by § 164.520(b)(1)(iii)(C) is
included in the appropriate notice; and

(iv) Not disclose protected health
information to the plan sponsor for the
purpose of employment-related actions
or decisions or in connection with any
other benefit or employee benefit plan
of the plan sponsor.

g Standard: Requirements for a
covered entity with multiple covered
functions.

(1) A covered entity that performs
multiple covered functions that would
make the entity any combination of a
health plan, a covered health care
provider, and a health care
clearinghouse, must comply with the
standards, requirements, and
implementation specifications of this
subpart, as applicable to the health plan,
health care provider, or health care
clearinghouse covered functions
performed.
(2) A covered entity that performs multiple covered functions may use or disclose the protected health information of individuals who receive the covered entity’s health plan or health care provider services, but not both, only for purposes related to the appropriate function being performed.

§ 164.506 Consent for uses or disclosures to carry out treatment, payment, or health care operations.

(a) Standard: Consent requirement. (1) Except as provided in paragraph (a)(2) or (a)(3) of this section, a covered health care provider must obtain the individual’s consent, in accordance with this section, prior to using or disclosing protected health information to carry out treatment, payment, or health care operations.

(2) A covered health care provider may, without consent, use or disclose protected health information created or received under paragraph (a)(3)(i)–(C) of this section to carry out treatment, payment, or health care operations:

(i) The covered health care provider has an indirect treatment relationship with the individual; or

(ii) The covered health care provider created or received the protected health information in the course of providing health care to an individual who is an inmate.

(3)(i) A covered health care provider may, without prior consent, use or disclose protected health information created or received under paragraph (a)(3)(i)(A)–(C) of this section to carry out treatment, payment, or health care operations:

(A) In emergency treatment situations, if the covered health care provider attempts to obtain such consent as soon as reasonably practicable after the delivery of such treatment;

(B) If the covered health care provider is required by law to treat the individual, and the covered health care provider attempts to obtain such consent but is unable to obtain such consent;

(C) If a covered health care provider attempts to obtain such consent from the individual but is unable to obtain such consent due to substantial barriers to communicating with the individual, and the covered health care provider determines, in the exercise of professional judgment, that the individual’s consent to receive treatment is clearly inferred from the circumstances.

(ii) A covered health care provider that fails to obtain such consent in accordance with paragraph (b)(1)(i) of this section must document its attempt to obtain consent and the reason why consent was not obtained.

(4) If a covered entity is not required to obtain consent by paragraph (a)(1) of this section, it may obtain an individual’s consent for the covered entity’s own use or disclosure of protected health information to carry out treatment, payment, or health care operations, provided that such consent meets the requirements of this section.

(5) Except as provided in paragraph (f)(1) of this section, a consent obtained by a covered entity under this section is not effective to permit another covered entity to use or disclose protected health information.

(b) Implementation specifications: General requirements. (1) A covered health care provider may condition treatment on the provision by the individual of a consent under this section.

(2) A health plan may condition enrollment in the health plan on the provision by the individual of a consent under this section sought in conjunction with such enrollment.

(3) A consent under this section may not be combined in a single document with the notice required by § 164.520.

(4)(i) A consent for use or disclosure may be combined with other types of written legal permission from the individual (e.g., an informed consent for treatment or a consent to assignment of benefits), if the consent under this section:

(A) Is visually and organizationally separate from such other written legal permission; and

(B) Is separately signed by the individual and dated.

(ii) A consent for use or disclosure may be combined with a research authorization under § 164.508(f).

(5) An individual may revoke a consent under this section at any time, except to the extent that the covered entity has taken action in reliance thereon. Such revocation must be in writing.

(6) A covered entity must document and retain any signed consent under this section as required by § 164.530(j).

(c) Implementation specifications: Content requirements. A consent under this section must be in plain language and:

(1) Inform the individual that protected health information may be used and disclosed to carry out treatment, payment, or health care operations;

(2) Refer the individual to the notice required by § 164.520 for a more complete description of such uses and disclosures and state that the individual has the right to review the notice prior to signing the consent;

(3) If the covered entity has reserved the right to change its privacy practices that are described in the notice in accordance with § 164.520(b)(1)(v)(C), state that the terms of its notice may change and describe how the individual may obtain a revised notice;

(4) State that:

(i) The individual has the right to request that the covered entity restrict how protected health information is used or disclosed to carry out treatment, payment, or health care operations;

(ii) The covered entity is not required to agree to requested restrictions; and

(iii) If the covered entity agrees to a requested restriction, the restriction is binding on the covered entity;

(5) State that the individual has the right to revoke the consent in writing, except to the extent that the covered entity has taken action in reliance thereon; and

(6) Be signed by the individual and dated.

(d) Implementation specifications: Defective consents. There is no consent under this section, if the document submitted has any of the following defects:

(1) The consent lacks an element required by paragraph (c) of this section, as applicable; or

(2) The consent has been revoked in accordance with paragraph (b)(5) of this section.

(e) Standard: Resolving conflicting consents and authorizations. (1) If a covered entity has obtained a consent under this section and receives any other authorization or written legal permission from the individual for a disclosure of protected health information to carry out treatment, payment, or health care operations, the covered entity may disclose such protected health information only in accordance with the more restrictive consent, authorization, or other written legal permission from the individual.

(2) A covered entity may attempt to resolve a conflict between a consent and an authorization or other written legal permission from the individual described in paragraph (e)(1) of this section by:

(i) Obtaining a new consent from the individual under this section for the disclosure to carry out treatment, payment, or health care operations; or

(ii) Communicating orally or in writing with the individual in order to determine the individual’s preference in resolving the conflict. The covered entity must document the individual’s preference and may only disclose protected health information in accordance with the individual’s preference.
(f)(1) Standard: Joint consents. Covered entities that participate in an organized health care arrangement and that have a joint notice under § 164.520(d) may comply with this section by a joint consent.

(2) Implementation specifications: Requirements for joint consents. (i) A joint consent must:

(A) Include the name or other specific identification of the covered entities, or classes of covered entities, to which the joint consent applies; and

(B) Meet the requirements of this section, except that the statements required by this section may be altered to reflect the fact that the consent covers more than one covered entity.

(ii) If an individual revokes a joint consent, the covered entity that receives the revocation must inform the other entities covered by the joint consent of the revocation as soon as practicable.

§ 164.508 Uses and disclosures for which an authorization is required.

(a) Standard: Authorizations for uses and disclosures. (1) Authorization required: General rule. Except as otherwise permitted or required by this subchapter, a covered entity may not use or disclose protected health information without an authorization that is valid under this section. When a covered entity obtains or receives a valid authorization for its use or disclosure of protected health information, such use or disclosure must be consistent with such authorization.

(2) Authorization required: psychotherapy notes. Notwithstanding any other provision of this subpart, other than transition provisions provided for in § 164.532, a covered entity must obtain an authorization for any use or disclosure of psychotherapy notes, except:

(i) To carry out the following treatment, payment, or health care operations, consistent with consent requirements in § 164.506:

(A) Use by originator of the psychotherapy notes for treatment;

(B) Use or disclosure by the covered entity in training programs in which students, trainees, or practitioners in mental health learn under supervision to practice or improve their skills in group, joint, family, or individual counseling; or

(C) Use or disclosure by the covered entity to defend a legal action or other proceeding brought by the individual; and

(ii) A use or disclosure that is required by § 164.502(a)(2)(ii) or permitted by § 164.512(a); § 164.512(d) with respect to the oversight of the originator of the psychotherapy notes; § 164.512(g)(1); or § 164.512(j)(1)(i).

(b) Implementation specifications: General requirements.—(1) Valid authorizations.

(i) A valid authorization is a document that contains the elements listed in paragraph (c) and, as applicable, paragraph (d), (e), or (f) of this section.

(ii) A valid authorization may contain elements or information in addition to the elements required by this section, provided that such additional elements or information are not be inconsistent with the elements required by this section.

(2) Defective authorizations. An authorization is not valid, if the document submitted has any of the following defects:

(i) The expiration date has passed or the expiration event is known by the covered entity to have occurred;

(ii) The authorization has not been filled out completely, with respect to an element described by paragraph (c), (d), (e), or (f) of this section, if applicable;

(iii) The authorization is known by the covered entity to have been revoked;

(iv) The authorization lacks an element required by paragraph (c), (d), (e), or (f) of this section, if applicable;

(v) The authorization violates paragraph (b)(3) of this section, if applicable;

(vi) Any material information in the authorization is known by the covered entity to be false.

(3) Compound authorizations. An authorization for use or disclosure of protected health information may not be combined with any other document to create a compound authorization, except as follows:

(i) An authorization for the use or disclosure of protected health information created for research that includes treatment of the individual may be combined as permitted by § 164.506(b)(4)(ii) or paragraph (f) of this section;

(ii) An authorization for a use or disclosure of psychotherapy notes may only be combined with another authorization for a use or disclosure of psychotherapy notes;

(iii) An authorization under this section, other than an authorization for a use or disclosure of psychotherapy notes may be combined with any other such authorization under this section, except when a covered entity has conditioned the provision of treatment, payment, enrollment in the health plan, or eligibility for benefits under paragraph (b)(4) of this section on the provision of one of the authorizations.

(4) Prohibition on conditioning of authorizations. A covered entity may not condition the provision to an individual of treatment, payment, enrollment in the health plan, or eligibility for benefits on the provision of an authorization, except:

(i) A covered health care provider may condition the provision of research-related treatment on provision of an authorization under paragraph (f) of this section;

(ii) A health plan may condition enrollment in the health plan or eligibility for benefits on provision of an authorization requested by the health plan prior to an individual’s enrollment in the health plan, if:

(A) The authorization sought is for the health plan’s eligibility or enrollment determinations relating to the individual or for its underwriting or risk rating determinations; and

(B) The authorization is not for a use or disclosure of psychotherapy notes under paragraph (a)(2) of this section;

(iii) A health plan may condition payment of a claim for specified benefits on provision of an authorization under paragraph (e) of this section, if:

(A) The disclosure is necessary to determine payment of such claim; and

(B) The authorization is not for a use or disclosure of psychotherapy notes under paragraph (a)(2) of this section; and

(iv) A covered entity may condition the provision of health care that is solely for the purpose of creating protected health information for disclosure to a third party on provision of an authorization for the disclosure of the protected health information to such third party.

(5) Revocation of authorizations. An individual may revoke an authorization provided under this section at any time, provided that the revocation is in writing, except to the extent that:

(i) The covered entity has taken action in reliance thereon; or

(ii) If the authorization was obtained as a condition of obtaining insurance coverage, other law provides the insurer with the right to contest a claim under the policy.

(6) Documentation. A covered entity must document and retain any signed authorization under this section as required by § 164.530(j).

(c) Implementation specifications: Core elements and requirements. (1) Core elements. A valid authorization under this section must contain at least the following elements:

(i) A description of the information to be used or disclosed that identifies the information in a specific and meaningful fashion;
(ii) The name or other specific identification of the person(s), or class of persons, authorized to make the requested use or disclosure;

(iii) The name or other specific identification of the person(s), or class of persons, to whom the covered entity may make the requested use or disclosure;

(iv) An expiration date or an expiration event that relates to the individual or the purpose of the use or disclosure;

(v) A statement of the individual’s right to revoke the authorization in writing and the exceptions to the right to revoke, together with a description of how the individual may revoke the authorization;

(vi) A statement that information used or disclosed pursuant to the authorization may be subject to redisclosure by the recipient and no longer be protected by this rule;

(vii) Signature of the individual and date; and

(viii) If the authorization is signed by a personal representative of the individual, a description of such representative’s authority to act for the individual.

(2) Plain language requirement. The authorization must be written in plain language.

(d) Implementation specifications: Authorizations requested by a covered entity for its own uses and disclosures. If an authorization is requested by a covered entity for its own use or disclosure of protected health information that it maintains, the covered entity must comply with the following requirements:

(1) Required elements. The authorization for the uses or disclosures described in this paragraph must, in addition to meeting the requirements of paragraph (c) of this section, contain the following elements:

(i) A description of each purpose of the requested disclosure;

(ii) Except for an authorization on which payment may be conditioned under paragraph (b)(4)(iii) of this section, a statement that the covered entity will not condition treatment, payment, enrollment in the health plan, or eligibility for benefits on the individual’s providing authorization for the requested use or disclosure; and

(iii) A statement that the individual may refuse to sign the authorization.

(2) Copy to the individual. A covered entity must provide the individual with a copy of the signed authorization.

(e) Implementation specifications: Authorizations requested by a covered entity for disclosures by others. If an authorization is requested by a covered entity for another covered entity to disclose protected health information to the covered entity requesting the authorization to carry out treatment, payment, or health care operations, the covered entity requesting the authorization must comply with the following requirements.

(1) Required elements. The authorization for the disclosures described in this paragraph must, in addition to meeting the requirements of paragraph (b)(4)(i) of this section, contain the following elements:

(i) A description of each purpose of the requested use or disclosure;

(ii) A consent to use or disclose protected health information to carry out treatment, payment, or health care operations under §164.506; or

(iii) A notice of privacy practices under §164.520.

§164.510 Uses and disclosures requiring an opportunity for the individual to agree or to object.

A covered entity may use or disclose protected health information without the written consent or authorization of the individual as described by §§164.506 and 164.508, respectively, provided that the individual is informed in advance of the use or disclosure and has the opportunity to agree to or prohibit or restrict the disclosure in accordance with the applicable requirements of this section. The covered entity may orally inform the individual of and obtain the individual’s oral agreement or objection to a use or disclosure permitted by this section.

(a) Standard: use and disclosure for facility directories. (1) Permitted uses and disclosure. Except when an objection is expressed in accordance with paragraphs (a)(2) or (3) of this section, a covered health care provider may:

(i) Use the following protected health information to maintain a directory of individuals in its facility:

(A) The individual’s name;

(B) The individual’s location in the covered health care provider’s facility;

(C) The individual’s condition described in general terms that does not communicate specific medical information about the individual; and

(D) The individual’s religious affiliation; and

(ii) Disclose for directory purposes such information:

(A) To members of the clergy; or
Any such use or disclosure of protected location, general condition, or death.

A covered entity may use or disclose protected health information for such notification purposes must be in accordance with paragraphs (b)(2), (3), or (4) of this section, as applicable.

(2) Uses and disclosures with the individual present. If the individual is present for, or otherwise available prior to, a use or disclosure permitted by paragraph (b)(1) of this section and has the capacity to make health care decisions, the covered entity may use or disclose the protected health information if it:

(i) Obtains the individual's agreement;

(ii) Provides the individual with the opportunity to object to the disclosure, and the individual does not express an objection; or

(iii) Reasonably infers from the circumstances, based the exercise of professional judgment, that the individual does not object to the disclosure.

(3) Limited uses and disclosures when the individual is not present. If the individual is not present for, or the opportunity to agree or object to the use or disclosure cannot practicably be provided because of the individual's incapacity or an emergency treatment circumstance, a covered health care provider may use or disclose some or all of the protected health information permitted by paragraph (a)(1) of this section for the facility's directory, if such disclosure is:

(A) Consistent with a prior expressed preference of the individual, if any, that is known to the covered health care provider; and

(B) In the individual's best interest as determined by the covered health care provider, in the exercise of professional judgment.

(ii) The covered health care provider must inform the individual and provide an opportunity to object to uses or disclosures for directory purposes as required by paragraph (a)(2) of this section when it becomes practicable to do so.

(b) Standard: uses and disclosures for involvement in the individual's care and notification purposes. (1) Permitted uses and disclosures. (i) A covered entity may, in accordance with paragraphs (b)(2) or (3) of this section, disclose to a family member, other relative, or a close personal friend of the individual, or any other person identified by the individual, the protected health information directly relevant to such person's involvement with the individual's care or payment related to the individual's health care.

(ii) A covered entity may use or disclose protected health information to a public or private entity authorized by law or by its charter to assist in disaster relief efforts, for the purpose of coordinating with such entities the uses or disclosures permitted by paragraph (b)(1)(ii) of this section. The requirements in paragraphs (b)(2) and (3) of this section apply to such uses and disclosure to the extent that the covered entity, in the exercise of professional judgment, determines that the requirements do not interfere with the ability to respond to the emergency circumstances.

§ 164.512 Uses and disclosures for which consent, an authorization, or opportunity to agree or object are not required...

A covered entity may use or disclose protected health information without the written consent or authorization of the individual as described in §§ 164.506 and 164.508, respectively, or the opportunity for the individual to agree or object as described in § 164.510, in the situations covered by this section, subject to the applicable requirements of this section. When the covered entity is required by this section to inform the individual of, or when the individual may agree to, a use or disclosure permitted by this section, the covered entity’s information and the individual’s agreement may be given orally.

(a) Standard: Uses and disclosures required by law. (1) A covered entity may use or disclose protected health information to the extent that such use or disclosure is required by law and the use or disclosure complies with and is limited to the relevant requirements of such law.

(2) A covered entity must meet the requirements described in paragraph (c), (e), or (f) of this section for uses or disclosures required by law.

(b) Standard: uses and disclosures for public health activities. (1) Permitted disclosures.

(i) A public health authority that is authorized by law to collect or receive such information for the purpose of preventing or controlling disease, injury, or disability, including, but not limited to, the reporting of disease, injury, vital events such as birth or death, and the conduct of public health surveillance, public health investigations, and public health interventions; or, at the direction of a public health authority, to an official of a foreign government agency that is acting in collaboration with a public health authority:

(ii) A public health authority or other appropriate government authority authorized by law to receive reports of child abuse or neglect;

(iii) A person subject to the jurisdiction of the Food and Drug Administration:

(A) To report adverse events (or similar reports with respect to food or dietary supplements), product defects or problems (including problems with the use or labeling of a product), or biological product deviations if the disclosure is made to the person required or directed to report such information to the Food and Drug Administration;

(B) To track products if the disclosure is made to a person required or directed by the Food and Drug Administration to track a product;

(C) To enable product recalls, repairs, or replacement including locating and
notifying individuals who have received products of product recalls, withdrawals, or other problems; or
[D] To conduct post marketing surveillance to comply with requirements or at the direction of the Food and Drug Administration;
(iv) A person who may have been exposed to a communicable disease or may otherwise be at risk of contracting or spreading a disease or condition, if the covered entity or public health authority is authorized by law to notify such person as necessary in the conduct of a public health intervention or investigation; or
(v) An employer, about an individual who is a member of the workforce of the employer, if:
(A) The covered entity is a covered health care provider who is a member of the workforce of such employer or who provides a health care to the individual at the request of the employer;
(1) To conduct an evaluation relating to medical surveillance of the workplace; or
(2) To evaluate whether the individual has a work-related illness or injury;
(B) The protected health information that is disclosed consists of findings concerning a work-related illness or injury or a workplace-related medical surveillance;
(C) The employer needs such findings in order to comply with its obligations, under 29 CFR parts 1904 through 1928, 30 CFR parts 50 through 90, or under state law having a similar purpose, to record such illness or injury or to carry out responsibilities for workplace medical surveillance;
(D) The covered health care provider provides written notice to the individual that protected health information relating to the medical surveillance of the workplace and workplace-related illnesses and injuries is disclosed to the employer;
(1) By giving a copy of the notice to the individual at the time the health care is provided; or
(2) If the health care is provided on the worksite of the employer, by posting the notice in a prominent place at the location where the health care is provided.
(2) Permitted uses. If the covered entity also is a public health authority, the covered entity is permitted to use protected health information in all cases in which it is permitted to disclose such information for public health activities under paragraph (b)(1) of this section.
(c) Standard: Uses and disclosures about victims of abuse, neglect or domestic violence. (1) Permitted disclosures. Except for reports of child abuse or neglect permitted by paragraph (b)(1)(ii) of this section, a covered entity may disclose protected health information about an individual whom the covered entity reasonably believes to be a victim of abuse, neglect, or domestic violence to a government authority, including a social service or protective services agency, authorized by law to receive reports of such abuse, neglect, or domestic violence:
(i) To the extent the disclosure is required by law and the disclosure complies with and is limited to the relevant requirements of such law;
(ii) If the individual agrees to the disclosure; or
(iii) To the extent the disclosure is expressly authorized by statute or regulation and:
(A) The covered entity, in the exercise of professional judgment, believes the disclosure is necessary to prevent serious harm to the individual or other potential victims; or
(B) If the individual is unable to agree because of incapacity, a law enforcement or other public official authorized to receive the report represents that the protected health information for which disclosure is sought is not intended to be used against the individual and that an immediate enforcement activity that depends upon the disclosure would be materially and adversely affected by waiting until the individual is able to agree to the disclosure.
(2) Informing the individual. A covered entity that makes a disclosure permitted by paragraph (c)(1) of this section must promptly inform the individual that such a report has been or will be made, except if:
(i) The covered entity, in the exercise of professional judgment, believes informing the individual would place the individual at risk of serious harm; or
(ii) The covered entity would be informing a personal representative, and the covered entity reasonably believes the personal representative is responsible for the abuse, neglect, or other injury, and that informing such person would not be in the best interests of the individual as determined by the covered entity, in the exercise of professional judgment.
(d) Standard: Uses and disclosures for health oversight activities. (1) Permitted disclosures. A covered entity may disclose protected health information to a health oversight agency for oversight activities authorized by law, including audits; civil, administrative, or criminal investigative proceedings; licensure or disciplinary actions; civil, administrative, or criminal proceedings or actions; or other activities necessary for appropriate oversight of:
(i) The health care system;
(ii) Government benefit programs for which health information is relevant to beneficiary eligibility;
(iii) Entities subject to government regulatory programs for which health information is necessary for determining compliance with program standards; or
(iv) Entities subject to civil rights laws for which health information is necessary for determining compliance.
(2) Exception to health oversight activities. For the purpose of the disclosures permitted by paragraph (d)(1) of this section, a health oversight activity does not include an investigation or other activity in which the individual is the subject of the investigation or activity and such investigation or other activity does not arise out of and is not directly related to:
(i) The receipt of health care;
(ii) A claim for public benefits related to health; or
(iii) Qualification for, or receipt of, public benefits or services when a patient’s health is integral to the claim for public benefits or services.
(3) Joint activities or investigations. Notwithstanding paragraph (d)(2) of this section, if a health oversight activity or investigation is conducted in conjunction with an oversight activity or investigation relating to a claim for public benefits not related to health, the joint activity or investigation is considered a health oversight activity for purposes of paragraph (d) of this section.
(4) Permitted uses. If a covered entity also is a health oversight agency, the covered entity may use protected health information for health oversight activities as permitted by paragraph (d) of this section.
(e) Standard: Disclosures for judicial and administrative proceedings.
(1) Permitted disclosures. A covered entity may disclose protected health information in the course of any judicial or administrative proceeding:
(i) In response to an order of a court or administrative tribunal, provided that the covered entity discloses only the protected health information expressly authorized by such order; or
(ii) In response to a subpoena, discovery request, or other lawful process, that is not accompanied by an order of a court or administrative tribunal, if:
(A) The covered entity receives satisfactory assurance, as described in paragraph (e)(1)(ii) of this section, from the party seeking the information that reasonable efforts have been made by
such party to ensure that the individual who is the subject of the protected health information that has been requested has been given notice of the request; or

(B) The covered entity receives satisfactory assurance, as described in paragraph (e)(1)(iv) of this section, from the party seeking the information that reasonable efforts have been made by such party to secure a qualified protective order that meets the requirements of paragraph (e)(1)(v) of this section.

(iii) For the purposes of paragraph (e)(1)(ii)(A) of this section, a covered entity receives satisfactory assurances from a party seeking protecting health information if the covered entity receives from such party a written statement and accompanying documentation demonstrating that:

(A) The party requesting such information has made a good faith effort to provide written notice to the individual (or, if the individual’s location is unknown, to mail a notice to the individual’s last known address);

(B) The notice included sufficient information about the litigation or proceeding in which the protected health information is requested to permit the individual to raise an objection to the court or administrative tribunal; and

(C) The time for the individual to raise objections to the court or administrative tribunal has elapsed, and:

(1) No objections were filed; or

(2) All objections filed by the individual have been resolved by the court or the administrative tribunal and the disclosures being sought are consistent with such resolution.

(iv) For the purposes of paragraph (e)(1)(ii)(B) of this section, a covered entity receives satisfactory assurances from a party seeking protected health information, if the covered entity receives from such party a written statement and accompanying documentation demonstrating that:

(A) The parties to the dispute giving rise to the request for information have agreed to a qualified protective order and have presented it to the court or administrative tribunal with jurisdiction over the dispute; or

(B) The party seeking the protected health information has requested a qualified protective order from such court or administrative tribunal.

(v) For purposes of paragraph (e)(1) of this section, a qualified protective order means, with respect to protected health information requested under paragraph (e)(1)(i) of this section, an order of a court or of an administrative tribunal or a stipulation by the parties to the litigation or administrative proceeding that:

(A) Prohibits the parties from using or disclosing the protected health information for any purpose other than the litigation or proceeding for which such information was requested; and

(B) Requires the return to the covered entity or destruction of the protected health information (including all copies made) at the end of the litigation or proceeding.

(vi) Notwithstanding paragraph (e)(1)(ii) of this section, a covered entity may disclose protected health information in response to lawful process described in paragraph (e)(1)(ii) of this section without receiving satisfactory assurance under paragraph (e)(1)(ii)(A) or (B) of this section, if the covered entity makes reasonable efforts to provide notice to the individual sufficient to meet the requirements of paragraph (e)(1)(iii) of this section or to seek a qualified protective order sufficient to meet the requirements of paragraph (e)(1)(iv) of this section.

(2) Other uses and disclosures under this section. The provisions of this paragraph do not supersede other provisions of this section that otherwise permit or restrict uses or disclosures of protected health information.

(3) Standard: Disclosures for law enforcement purposes. A covered entity may disclose protected health information for a law enforcement purpose to a law enforcement official if the conditions in paragraphs (f)(1) through (f)(6) of this section are met, as applicable.

(1) Permitted disclosures: Pursuant to process and as otherwise required by law. A covered entity may disclose protected health information:

(i) As required by law including laws that require the reporting of certain types of wounds or other physical injuries, except for laws subject to paragraph (b)(1)(ii) or (c)(1)(i) of this section; or

(ii) In compliance with and as limited by the relevant requirements of:

(A) A court order or court-ordered warrant, or a subpoena or summons issued by a judicial officer;

(B) A grand jury subpoena; or

(C) An administrative request, including an administrative subpoena or summons, a civil or an authorized investigative demand, or similar process authorized under law, provided that:

(1) The information sought is relevant and material to a legitimate law enforcement inquiry;

(2) The request is specific and limited in scope to the extent reasonably practicable in light of the purpose for which the information is sought; and

(3) De-identified information could not reasonably be used.

(2) Other uses and disclosures under this section. Except for disclosures required by law as permitted by paragraph (f)(1) of this section, a covered entity may disclose protected health information in response to a law enforcement official’s request for such information for the purpose of identifying or locating a suspect, fugitive, material witness, or missing person, provided that:

(i) The covered entity may disclose only the following information:

(A) Name and address;

(B) Date and place of birth;

(C) Social security number;

(D) ABO blood type and Rh factor;

(E) Type of injury;

(F) Date and time of treatment;

(G) Date and time of death, if applicable; and

(H) A description of distinguishing physical characteristics, including height, weight, gender, race, hair and eye color, presence or absence of facial hair (beard or moustache), scars, and tattoos.

(ii) Except as permitted by paragraph (f)(2)(i) of this section, the covered entity may not disclose for the purposes of identification or location under paragraph (f)(2) of this section any protected health information related to the individual’s DNA or DNA analysis, dental records, or typing; samples or analysis of body fluids or tissue.

(3) Permitted disclosure: Victims of a crime. Except for disclosures required by law as permitted by paragraph (f)(1) of this section, a covered entity may disclose protected health information in response to a law enforcement official’s request for such information about an individual who is or is suspected to be a victim of a crime, other than disclosures that are subject to paragraph (b) or (c) of this section, if:

(i) The individual agrees to the disclosure; or

(ii) The covered entity is unable to obtain the individual’s agreement because of incapacity or other emergency circumstance, provided that:

(A) The law enforcement official represents that such information is needed to determine whether a violation of law by a person other than the victim has occurred, and such information is not intended to be used against the victim; and

(B) The law enforcement official represents that immediate law enforcement activity that depends upon the disclosure would be materially and
adversely affected by waiting until the individual is able to agree to the disclosure; and
(C) The disclosure is in the best interests of the individual as determined by the covered entity, in the exercise of professional judgment.

(4) Permitted disclosure: Decedents. A covered entity may disclose protected health information about an individual who has died to a law enforcement official for the purpose of alerting law enforcement of the death of the individual if the covered entity has a suspicion that such death may have resulted from criminal conduct.

(5) Permitted disclosure: Crime on premises. A covered entity may disclose to a law enforcement official protected health information that the covered entity believes in good faith constitutes evidence of criminal conduct that occurred on the premises of the covered entity.

(6) Permitted disclosure: Reporting crime in emergencies. (1) A covered health care provider providing emergency health care in response to a medical emergency, other than such emergency on the premises of the covered health care provider, may disclose protected health information to a law enforcement official if such disclosure appears necessary to alert law enforcement to:
(A) The commission and nature of a crime;
(B) The location of such crime or of the victim(s) of such crime; and
(C) The identity, description, and location of the perpetrator of such crime.

(ii) If a covered health care provider believes that the medical emergency described in paragraph (f)(6)(i) of this section is the result of abuse, neglect, or domestic violence of the individual in need of emergency health care, paragraph (f)(6)(i) of this section does not apply and any disclosure to a law enforcement official for law enforcement purposes is subject to paragraph (c) of this section.

(g) Standard: Uses and disclosures about decedents. (1) Coroners and medical examiners. A covered entity may disclose protected health information to a coroner or medical examiner for the purpose of identifying a deceased person, determining a cause of death, or other duties as authorized by law. A covered entity that also performs the duties of a coroner or medical examiner may use protected health information for the purposes described in this paragraph.

(F) Funeral directors. A covered entity may disclose protected health information to funeral directors, consistent with applicable law, as necessary to carry out their duties with respect to the decedent. If necessary for funeral directors to carry out their duties, the covered entity may disclose the protected health information prior to, and in reasonable anticipation of, the individual’s death.

(h) Standard: Uses and disclosures for cadaveric organ, eye or tissue donation purposes. A covered entity may use or disclose protected health information to organ procurement organizations or other entities engaged in the procurement, banking, or transplantation of cadaveric organs, eyes, or tissue for the purpose of facilitating organ, eye or tissue donation and transplantation.

(i) Standard: Uses and disclosures for research purposes. (1) Permitted uses and disclosures. A covered entity may use or disclose protected health information for research, regardless of the source of funding of the research, provided that:
(i) Board approval of a waiver of authorization. The covered entity obtains documentation that an alteration to or waiver, in whole or in part, of the individual authorization required by §164.508 for use or disclosure of protected health information has been approved by either:
(B) A privacy board that:
(1) Has members with varying backgrounds and appropriate professional competency as necessary to review the effect of the research protocol on the individual’s privacy rights and related interests;
(2) Includes at least one member who is not affiliated with the covered entity, not affiliated with any entity conducting or sponsoring the research, and not related to any person who is affiliated with any of such entities; and
(3) Does not have any member participating in a review of any project in which the member has a conflict of interest.
(ii) Review preparatory to research. The covered entity obtains from the researcher representations that:
(A) Use or disclosure is sought solely to review protected health information as necessary to prepare a research protocol or for similar purposes preparatory to research;
(B) No protected health information is to be removed from the covered entity by the researcher in the course of the review; and
(C) The protected health information for which use or access is sought is necessary for the research purposes.

(ii) Research on decedent’s information. The covered entity obtains from the researcher:
(A) Representation that the use or disclosure is sought solely for research on the protected health information of decedents;
(B) Documentation, at the request of the covered entity, of the death of such individuals; and
(C) Representation that the protected health information for which use or disclosure is sought is necessary for the research purposes.

(2) Documentation of waiver approval. For a use or disclosure to be permitted based on documentation of approval of an alteration or waiver, under paragraph (i)(1)(i) of this section, the documentation must include all of the following:
(i) Identification and date of action. A statement identifying the IRB or privacy board and the date on which the alteration or waiver of authorization was approved;
(ii) Waiver criteria. A statement that the IRB or privacy board has determined that the alteration or waiver, in whole or in part, of authorization satisfies the following criteria:
(A) The use or disclosure of protected health information involves no more than minimal risk to the individuals;
(B) The alteration or waiver will not adversely affect the privacy rights and the welfare of the individuals;
(C) The research could not practically be conducted without the alteration or waiver;
(D) The research could not practically be conducted without access to and use of the protected health information;
(E) The privacy risks to individuals whose protected health information is to be used or disclosed are reasonable in relation to the anticipated benefits if any to the individuals, and the importance of the knowledge that may reasonably be expected to result from the research;
(F) There is an adequate plan to protect the identifiers from improper use and disclosure;
(G) There is an adequate plan to destroy the identifiers at the earliest opportunity consistent with conduct of the research, unless there is a health or research justification for retaining the identifiers, or such retention is otherwise required by law; and
(H) There are adequate written assurances that the protected health
information will not be reused or disclosed to any other person or entity, except as required by law, for authorized oversight of the research project, or for other research for which the use or disclosure of protected health information would be permitted by this subpart.

(iii) Protected health information needed. A brief description of the protected health information for which use or access has been determined to be necessary by the IRB or privacy board has determined, pursuant to paragraph (j)(2)(ii)(D) of this section:

(iv) Review and approval procedures. A statement that the alteration or waiver of authorization has been reviewed and approved under either normal or expedited review procedures, as follows:


(B) A privacy board must review the proposed research at convened meetings at which a majority of the privacy board members are present, including at least one member who satisfies the criterion stated in paragraph (i)(1)(i)(B)(2) of this section, and the alteration or waiver of authorization must be approved by the majority of the privacy board members present at the meeting, unless the privacy board elects to use an expedited review procedure in accordance with paragraph (j)(2)(iv)(C) of this section; and a privacy board may use an expedited review procedure if the research involves no more than minimal risk to the privacy of the individuals who are the subject of the protected health information for which use or disclosure is being sought. If the privacy board elects to use an expedited review procedure, the review and approval of the alteration or waiver of authorization may be carried out by the chair of the privacy board, or by one or more members of the privacy board as designated by the chair; and

(iii) signature. The documentation of the alteration or waiver of authorization must be signed by the chair or other member, as designated by the chair, of the IRB or the privacy board, as applicable.

(j) Standard: Uses and disclosures to avert a serious threat to health or safety. (1) Permitted disclosures. A covered entity may, consistent with applicable law and standards of ethical conduct, use or disclose protected health information, if the covered entity, in good faith, believes the use or disclosure:

(i) (A) Is necessary to prevent or lessen a serious and imminent threat to the health or safety of a person or the public; and

(ii) Is to a person or persons reasonably able to prevent or lessen the threat, including the target of the threat; or

(iii) Is necessary for law enforcement authorities to identify or apprehend an individual:

(A) Because of a statement by an individual admitting participation in a violent crime that the covered entity reasonably believes may have caused serious physical harm to the victim; or

(B) Where it appears from all the circumstances that the individual has escaped from a correctional institution or from lawful custody, as those terms are defined in §164.501.

(2) Use or disclosure not permitted. A use or disclosure pursuant to paragraph (j)(1)(i)(A) of this section may not be made if the information described in paragraph (j)(1)(ii)(A) of this section is learned by the covered entity:

(i) In the course of treatment to affect the propensity to commit the criminal conduct that is the basis for the disclosure under paragraph (j)(1)(i)(A) of this section, or counseling or therapy; or

(ii) Through a request by the individual to initiate or to be referred for the treatment, counseling, or therapy described in paragraph (j)(2)(i) of this section

(3) Limit on information that may be disclosed. A disclosure made pursuant to paragraph (j)(1)(ii)(A) of this section shall contain only the statement described in paragraph (j)(1)(i)(A) of this section and the protected health information described in paragraph (f)(2)(i) of this section.

(4) Presumption of good faith belief. A covered entity that uses or discloses protected health information pursuant to paragraph (j)(1) of this section is presumed to have acted in good faith with regard to a belief described in paragraph (j)(1)(i) or (ii) of this section, if the belief is based upon the covered entity’s actual knowledge or in reliance on a credible representation by a person with apparent knowledge or authority.

(k) Standard: Uses and disclosures for specialized government functions. (1) Military and veterans activities. (i) Armed Forces personnel. A covered entity may use and disclose the protected health information of individuals who are Armed Forces personnel for activities deemed necessary by appropriate military command authorities to assure the proper execution of the military mission, if the appropriate military authority has published by notice in the Federal Register the following information:

(A) Appropriate military command authorities; and

(B) The purposes for which the protected health information may be used or disclosed.

(ii) Separation or discharge from military service. A covered entity that is a component of the Department of Defense or Transportation may disclose to the Department of Veterans Affairs (DVA) the protected health information of an individual who is a member of the Armed Forces upon the separation or discharge of the individual from military service for the purpose of a determination by DVA of the individual’s eligibility for or entitlement to benefits under laws administered by the Secretary of Veterans Affairs.

(iii) Veterans. A covered entity that is a component of the Department of Veterans Affairs may use and disclose protected health information to components of the Department that determine eligibility for or entitlement to, or that provide, benefits under the laws administered by the Secretary of Veterans Affairs.

(iv) Foreign military personnel. A covered entity may use and disclose the protected health information of individuals who are foreign military personnel to their appropriate foreign military authority for the same purposes for which uses and disclosures are permitted for Armed Forces personnel under the notice published in the Federal Register pursuant to paragraph (k)(1)(i) of this section.

(2) National security and intelligence activities. A covered entity may disclose protected health information to authorized federal officials for the conduct of lawful intelligence, counter-intelligence, and other national security activities authorized by the National Security Act (50 U.S.C. 401, et seq.) and implementing authority (e.g., Executive Order 12333).

(3) Protective services for the President and others. A covered entity may disclose protected health
information to authorized federal officials for the provision of protective services to the President or other persons authorized by 18 U.S.C. 3056, or to foreign heads of state or other persons authorized by 22 U.S.C. 2709(a)(3), or to for the conduct of investigations authorized by 18 U.S.C. 871 and 879.

(4) Medical suitability determinations. A covered entity that is a component of the Department of State may use protected health information to make medical suitability determinations and may disclose whether or not the individual was determined to be medically suitable to the officials in the Department of State who need access to such information for the following purposes:

(i) For the purpose of a required security clearance conducted pursuant to Executive Orders 10450 and 12698;

(ii) As necessary to determine worldwide availability or availability for mandatory service abroad under sections 101(a)(4) and 504 of the Foreign Service Act; or

(iii) For a family to accompany a Foreign Service member abroad, consistent with section 101(b)(5) and 904 of the Foreign Service Act.

(5) Correctional institutions and other law enforcement custodial situations. A covered entity may disclose to a correctional institution or a law enforcement official having lawful custody of an inmate or other individual protected health information about such inmate or individual, if the correctional institution or such law enforcement official represents that such protected health information is necessary for:

(A) The provision of health care to such individuals;

(B) The health and safety of such individual or other inmates;

(C) The health and safety of the officers or employees of or others at the correctional institution;

(D) The health and safety of such individuals and officers or other persons responsible for the transporting of inmates or their transfer from one institution, facility, or setting to another;

(E) Law enforcement on the premises of the correctional institution; and

(F) The administration and maintenance of the safety, security, and good order of the correctional institution.

(ii) Permitted uses. A covered entity that is a correctional institution may use protected health information of individuals who are inmates for any purpose for which such protected health information may be disclosed.

(iii) No application after release. For the purposes of this provision, an individual is no longer an inmate when released on parole, probation, supervised release, or otherwise is no longer in lawful custody.

(6) Covered entities that are government programs providing public benefits. (i) A health plan that is a government program providing public benefits may disclose protected health information relating to eligibility for or enrollment in the health plan to another agency administering a government program providing public benefits if the sharing of eligibility or enrollment information among such government agencies or the maintenance of such information in a single or combined data system accessible to all such government agencies is required or expressly authorized by statute or regulation.

(ii) A covered entity that is a government agency administering a government program providing public benefits may disclose protected health information relating to the program to another covered entity that is a government agency administering a government program providing public benefits if the programs serve the same or similar populations and the disclosure of protected health information is necessary to coordinate the covered functions of such programs or to improve administration and management relating to the covered functions of such programs.

(l) Standard: Disclosures for workers’ compensation. A covered entity may disclose protected health information as authorized by and to the extent necessary to comply with laws relating to workers’ compensation or other similar programs, established by law, that provide benefits for work-related injuries or illness without regard to fault.

§164.514 Other requirements relating to uses and disclosures of protected health information.

(a) Standard: de-identification of protected health information. Health information that does not identify an individual and with respect to which there is no reasonable basis to believe that the information can be used to identify an individual is not individually identifiable health information.

(b) Implementation specifications: requirements for de-identification of protected health information. A covered entity may use that health information is not individually identifiable health information only if:

(1) A person with appropriate knowledge of and experience with generally accepted statistical and scientific principles and methods for rendering information not individually identifiable:

(i) Applying such principles and methods, determines that the risk is very small that the information could be used, alone or in combination with other reasonably available information, by an anticipated recipient to identify an individual who is a subject of the information; and

(ii) Documents the methods and results of the analysis that justify such determination; or

(2)(i) The following identifiers of the individual or of relatives, employers, or household members of the individual, are removed:

(A) Names;

(B) All geographic subdivisions smaller than a State, including street address, city, county, precinct, zip code, and their equivalent geocodes, except for the initial three digits of a zip code if, according to the current publicly available data from the Bureau of the Census:

(1) The geographic unit formed by combining all zip codes with the same three initial digits contains more than 20,000 people; and

(2) The initial three digits of a zip code for all such geographic units containing 20,000 or fewer people is changed to 000.

(C) All elements of dates (except year) for dates directly related to an individual, including birth date, admission date, discharge date, date of death; and all ages over 89 and all elements of dates (including year) indicative of such age, except that such ages and elements may be aggregated into a single category of age 90 or older;

(D) Telephone numbers;

(E) Fax numbers;

(F) Electronic mail addresses;

(G) Social security numbers;

(H) Medical record numbers;

(I) Health plan beneficiary numbers;

(J) Account numbers;

(K) Certificate/license numbers;

(L) Vehicle identifiers and serial numbers, including license plate numbers;

(M) Device identifiers and serial numbers;

(N) Web Universal Resource Locators (URLs);

(O) Internet Protocol (IP) address numbers;

(P) Biometric identifiers, including finger and voice prints;

(Q) Full face photographic images and any comparable images; and

(R) Any other unique identifying number, characteristic, or code; and
(ii) The covered entity does not have actual knowledge that the information could be used alone or in combination with other information to identify an individual who is a subject of the information.

(c) Implementation specifications: re-identification. A covered entity may assign a code or other means of record identification to allow information de-identified under this section to be re-identified by the covered entity, provided that:

(1) Derivation. The code or other means of record identification is not derived from or related to information about the individual and is not otherwise capable of being translated so as to identify the individual; and

(2) Security. The covered entity does not use or disclose the code or other means of record identification for any other purpose, and does not disclose the mechanism for re-identification.

(d) (1) Standard: minimum necessary requirements. A covered entity must reasonably ensure that the standards, requirements, and implementation specifications of §164.502(b) and this section relating to a request for or the use and disclosure of the minimum necessary protected health information are met.

(2) Implementation specifications: minimum necessary uses of protected health information. (i) A covered entity must identify:

(A) Those persons or classes of persons, as appropriate, in its workforce who need access to protected health information to carry out their duties; and

(B) For each such person or class of persons, the category or categories of protected health information to which access is needed and any conditions appropriate to such access.

(ii) For any type of disclosure that it makes on a routine and recurring basis, a covered entity must implement policies and procedures (which may be standard protocols) that limit the protected health information disclosed to the amount reasonably necessary to achieve the purpose for which the disclosure is made.

(iii) For all other disclosures, a covered entity must:

(A) Develop criteria designed to limit the protected health information disclosed to the information reasonably necessary to accomplish the purpose for which disclosure is sought; and

(B) Review requests for disclosure on an individual basis in accordance with such criteria.

(iii) A covered entity may rely, if such reliance is reasonable under the circumstances, on a requested disclosure as the minimum necessary for the stated purpose when:

(A) Making disclosures to public officials that are permitted under §164.512, if the public official represents that the information requested is the minimum necessary for the stated purpose(s);

(B) The information is requested by another covered entity;

(C) The information is requested by a professional who is a member of its workforce or is a business associate of the covered entity for the purpose of providing professional services to the covered entity, if the professional represents that the information requested is the minimum necessary for the stated purpose(s); or

(D) Documentation or representations that comply with the applicable requirements of §164.512(i) have been provided by a person requesting the information for research purposes.

(4) Implementation specifications: Minimum necessary requests for protected health information. (i) A covered entity must limit any request for protected health information to that which is reasonably necessary to accomplish the purpose for which the request is made, when requesting such information from other covered entities.

(ii) For a request that is made on a routine and recurring basis, a covered entity must implement policies and procedures (which may be standard protocols) that limit the protected health information requested to the amount reasonably necessary to accomplish the purpose for which the request is made.

(iii) For all other requests, a covered entity must review the request on an individual basis to determine that the protected health information sought is limited to the information reasonably necessary to accomplish the purpose for which the request is made.

(5) Implementation specification: Other content requirement. For all uses, disclosures, or requests to which the requirements in paragraph (d) of this section apply, a covered entity may not use, discloses or request an entire medical record, except when the entire medical record is specifically justified as the amount reasonably necessary to accomplish the purpose of the use, disclosure, or request.
and how the product or service relates to the health of the individual.  
(iii) The covered entity must make reasonable efforts to ensure that 
individuals who decide to opt out of receiving future marketing 
communications, under paragraph (e)(3)(i)(C) of this section, are not sent 
such communications.  

(f)(1) Standard: Uses and disclosures for fundraising. A covered entity may 
use, or disclose to a business associate or to an institutionally related 
foundations, the following protected 
health information for the purpose of 
raising funds for its own benefit, 
without an authorization meeting the 
requirements of § 164.508:  
(i) Demographic information relating to an individual; and  
(ii) Dates of health care provided to an individual.  

(2) Implementation specifications: Fundraising requirements. (i) The 
covered entity may not use or disclose 
protected health information for 
fundraising purposes as otherwise 
permitted by paragraph (f)(1) of this 
section unless a statement required by 
§ 164.520(b)(1)(ii)(B) is included in the 
covered entity’s notice;  
(ii) The covered entity must include in 
young fundraising materials it sends to 
an individual under this paragraph a 
description of how the individual may 
opt out of receiving any further 
fundraising communications.  
(iii) The covered entity must make 
reasonable efforts to ensure that 
individuals who decide to opt out of 
receiving future fundraising 
communications are not sent such 
communications.  

(g) Standard: Uses and disclosures for underwriting and related purposes. If a 
health plan receives protected health information for the purpose of 
underwriting, premium rating, or other 
activities relating to the creation, 
renewal, or replacement of a contract of 
health insurance or health benefits, and 
if such health insurance or health 
benefits are not placed with the health plan, such health plan may not use or 
disclose such protected health 
information for any other purpose, 
except as may be required by law.  

(h)(1) Standard: Verification requirements. Prior to any disclosure 
permitted by this subpart, a covered 
entity must:  
(i) Except with respect to disclosures 
under § 164.510, verify the identity of a 
person requesting protected health 
information and the authority of any 
such person to have access to protected 
health information under this subpart, if 
the identity or any such authority of 
such person is not known to the covered 
entity; and  
(ii) Obtain any documentation, 
statements, or representations, whether 
oral or written, from the person 
requesting the protected health 
information when such documentation, 
statement, or representation is a 
condition of the disclosure under this 
subpart.  

(2) Implementation specifications: Verification. (i) Conditions on 
disclosures. If a disclosure is 
conditioned by this subpart on 
particular documentation, statements, or 
representations from the person 
requesting the protected health 
information, a covered entity may rely, 
if such reliance is reasonable under the 
circumstances, on documentation, 
statements, or representations that, on 
their face, meet the applicable 
requirements.  
(A) The conditions in 
§ 164.512(f)(1)(i)(C) may be satisfied by the 
administrative subpoena or similar 
process or by a separate written 
statement that, on its face, demonstrates 
that the applicable requirements have 
been met.  
(B) The documentation required by 
§ 164.512(f)(2) may be satisfied by one 
or more written statements, provided 
that each is appropriately dated and 
signed in accordance with 
§ 164.512(f)(2)(i) and (v).  
(ii) Identity of public officials. A 
covered entity may rely, if such reliance 
is reasonable under the circumstances, 
on any of the following to verify identity 
when the disclosure of protected health 
information is to a public official or a person acting on behalf of the public 
official or a person acting on 
behalf of the public official:  
(A) A written statement of the legal 
authority under which the information 
is requested, or, if a written statement 
would be impracticable, an oral 
statement of such legal authority;  
(B) If a request is made pursuant to 
legal process, warrant, subpoena, order, 
or other legal process issued by a grand 
jury or a judicial or administrative 
tribunal is presumed to constitute legal 
authority.  

(iv) Exercise of professional judgment. 
The verification requirements of this 
paragraph are met if the covered entity 
relies on the exercise of professional 
judgment in making a use or disclosure 
in accordance with § 164.510 or acts on 
a good faith belief in making a 
disclosure in accordance with 
§ 164.512(j).  

§ 164.520 Notice of privacy practices for 
protected health information.  

(a) Standard: notice of privacy 
practices. (1) Right to notice. Except as 
provided by paragraph (a)(2) or (3) of 
this section, an individual has a right to 
adequate notice of the uses and 
disclosures of protected health 
information that may be made by the 
covered entity, of the individual’s 
rights and the covered entity’s legal 
duties with respect to protected health 
information.  

(ii) From the group health plan, if, 
and to the extent that, such an 
individual does not receive health 
benefits under the group health plan 
through an insurance contract with a 
health insurance issuer or HMO; or  

(B) From the health insurance 
issuer or HMO with respect to the group health 
plan through which such individuals 
receive their health benefits under the 
group health plan.  

(ii) A group health plan that provides 
health benefits solely through an 
insurance contract with a health 
insurance issuer or HMO, and that 
creates or receives protected health 
information in addition to summary 
health information as defined in 
§ 164.504(a) or information on whether 
the individual is participating in the 
group health plan, or is enrolled in or 
has disenrolled from a health insurance 
issuer or HMO offered by the plan, 
must:  
(A) Maintain a notice under this 
section; and  
(B) Provide such notice upon request 
to any person. The provisions of 
paragraph (c)(1) of this section do not 
apply to such group health plan.
(iii) A group health plan that provides health benefits solely through an insurance contract with a health insurance issuer or HMO, and does not create or receive protected health information other than summary health information as defined in § 164.504(a) or information on whether an individual is participating in the group health plan, or is enrolled in or has disenrolled from a health insurance issuer or HMO offered by the plan, is not required to maintain or provide a notice under this section.

(3) Exception for inpatients. An inpatient does not have a right to notice under this section, and the requirements of this section do not apply to a correctional institution that is a covered entity.

(b) Implementation specifications: content of notice.

(1) Required elements. The covered entity must provide a notice that is written in plain language and that contains the elements required by this paragraph.

(i) Header. The notice must contain the following statement as a header or otherwise prominently displayed: “THIS NOTICE DESCRIBES HOW MEDICAL INFORMATION ABOUT YOU MAY BE USED AND DISCLOSED AND HOW YOU CAN GET ACCESS TO THIS INFORMATION. PLEASE REVIEW IT CAREFULLY.”

(ii) Uses and disclosures. The notice must contain:

(A) A description, including at least one example, of the types of uses and disclosures that the covered entity is permitted by this subpart to make for each of the following purposes: treatment, payment, and health care operations.

(B) A description of each of the other purposes for which the covered entity is permitted or required by this subpart to use or disclose protected health information without the individual’s written consent or authorization.

(C) If a use or disclosure for any purpose described in paragraphs (b)(1)(ii)(A) or (B) of this section is prohibited or materially limited by other applicable law, the description of such use or disclosure must reflect the more stringent law as defined in § 160.202 of this subchapter.

(D) For each purpose described in paragraph (b)(1)(ii)(A) or (B) of this section, the description must include sufficient detail to place the individual on notice of the uses and disclosures that are permitted or required by this subpart and other applicable law.

(E) A statement that other uses and disclosures will be made only with the individual’s written authorization and that the individual may revoke such authorization as provided by § 164.508(b)(5).

(iii) Separate statements for certain uses or disclosures. If the covered entity intends to engage in any of the following activities, the description required by paragraph (b)(1)(ii)(A) of this section must include a separate statement, as applicable, that:

(A) The covered entity may contact the individual to provide appointment reminders or information about treatment alternatives or other health-related benefits and services that may be of interest to the individual;

(B) The covered entity may contact the individual to raise funds for the covered entity; or

(C) A group health plan, or a health insurance issuer or HMO with respect to a group health plan, may disclose protected health information to the sponsor of the plan.

(iv) Individual rights. The notice must contain a statement of the individual’s rights with respect to protected health information and a brief description of how the individual may exercise these rights, as follows:

(A) The right to request restrictions on certain uses and disclosures of protected health information as provided by § 164.522(a), including a statement that the covered entity is not required to agree to a requested restriction;

(B) The right to receive confidential communications of protected health information as provided by § 164.522(b), as applicable;

(C) The right to inspect and copy protected health information as provided by § 164.524;

(D) The right to amend protected health information as provided by § 164.526;

(E) The right to receive an accounting of disclosures of protected health information as provided by § 164.528; and

(F) The right of an individual, including an individual who has agreed to receive the notice electronically in accordance with paragraph (c)(3) of this section, to obtain a paper copy of the notice from the covered entity upon request.

(v) Covered entity’s duties. The notice must contain:

(A) A statement that the covered entity is required by law to maintain the privacy of protected health information and to provide individuals with notice of its legal duties and privacy practices with respect to protected health information;

(B) A statement that the covered entity is required to abide by the terms of the notice currently in effect; and

(C) For the covered entity to apply a change in a privacy practice that is described in the notice to protected health information that the covered entity created or received prior to issuing a revised notice, in accordance with § 164.530(i)(2)(ii), a statement that it reserves the right to change the terms of its notice and to make the new notice provisions effective for all protected health information that it maintains.

The statement must also describe how it will provide individuals with a revised notice.

(vi) Complaints. The notice must contain a statement that individuals may complain to the covered entity and to the Secretary if they believe their privacy rights have been violated, a brief description of how the individual may file a complaint with the covered entity, and a statement that the individual will not be retaliated against for filing a complaint.

(vii) Contact. The notice must contain the name, or title, and telephone number of a person or office to contact for further information as required by § 164.530(a)(1)(ii).

(viii) Effective date. The notice must contain the date on which the notice is first in effect, which may not be earlier than the date on which the notice is printed or otherwise published.

(2) Optional elements. (i) In addition to the information required by paragraph (b)(1) of this section, if a covered entity elects to limit the uses or disclosures that it is permitted to make under this subpart, the covered entity may describe its more limited uses or disclosures in its notice, provided that the covered entity may not include in its notice a limitation affecting its right to make a use or disclosure that is required by law or permitted by § 164.512(j)(1)(i). (ii) For the covered entity to apply a change in its more limited uses and disclosures to protected health information created or received prior to issuing a revised notice, in accordance with § 164.530(i)(2)(ii), the notice must include the statements required by paragraph (b)(1)(iv)(C) of this section.

(3) Revisions to the notice. The covered entity must promptly revise and distribute its notice whenever there is a material change to the uses or disclosures, the individual’s rights, the covered entity’s legal duties, or other privacy practices stated in the notice. Except when required by law, a material change to any term of the notice may not be implemented prior to the effective date of the notice in which such material change is reflected.

(E) Implementation specifications: Provision of notice. A covered entity must make the notice required by this
section available on request to any person and to individuals as specified in paragraphs (c)(1) through (c)(4) of this section, as applicable.

(1) Specific requirements for health plans. (i) A health plan must provide notice:

(A) No later than the compliance date for the health plan, to individuals then covered by the plan;

(B) Thereafter, at the time of enrollment, to individuals who are new enrollees; and

(C) Within 60 days of a material revision to the notice, to individuals then covered by the plan.

(ii) No less frequently than once every three years, the health plan must notify individuals then covered by the plan of the availability of the notice and how to obtain the notice.

(iii) The health plan satisfies the requirements of paragraph (c)(1) of this section if notice is provided to the named insured of a policy under which coverage is provided to the named insured and one or more dependents.

(iv) If a health plan has more than one notice, it satisfies the requirements of paragraph (c)(1) of this section by providing the notice that is relevant to the individual or other person requesting the notice.

(2) Specific requirements for certain covered health care providers. (i) A covered health care provider that has a direct treatment relationship with an individual must:

(A) Provide the notice no later than the date of the first service delivery, including service delivered electronically, to such individual after the compliance date for the covered health care provider;

(B) If the covered health care provider maintains a physical service delivery site:

(1) Have the notice available at the service delivery site for individuals to request to take with them; and

(2) Post the notice in a clear and prominent location where it is reasonable to expect individuals seeking service from the covered health care provider to be able to read the notice; and

(C) Whenever the notice is revised, make the notice available upon request on or after the effective date of the revision and promptly comply with the requirements of paragraph (c)(2)(ii) of this section, if applicable.

(3) Specific requirements for electronic notice. (i) A covered entity that maintains a web site that provides information about the covered entity’s customer services or benefits must prominently post its notice on the web site and make the notice available electronically through the web site.

(ii) A covered entity may provide the notice required by this section to an individual by e-mail, if the individual agrees to electronic notice and such agreement has not been withdrawn. If the covered entity knows that the e-mail transmission has failed, a paper copy of the notice must be provided to the individual. Provision of electronic notice by the covered entity will satisfy the provision requirements of paragraph (c) of this section when timely made in accordance with paragraph (c)(1) or (2) of this section.

(iii) For purposes of paragraph (c)(2)(i) of this section, if the first service delivery to an individual is delivered electronically, the covered health care provider must provide electronic notice automatically and contemporaneously in response to the individual’s first request for service.

(iv) The individual who is the recipient of electronic notice retains the right to obtain a paper copy of the notice from a covered entity upon request.

(d) Implementation specifications: Joint notice by separate covered entities. Covered entities that participate in organized health care arrangements may comply with this section by a joint notice, provided that:

(1) The covered entities participating in the organized health care arrangement agree to abide by the terms of the notice with respect to protected health information created or received by the covered entity as part of its participation in the organized health care arrangement;

(2) The joint notice meets the implementation specifications in paragraph (b) of this section, except that the statements required by this section may be altered to reflect the fact that the notice covers more than one covered entity; and

(i) Describes with reasonable specificity the covered entities, or class of entities, to which the joint notice applies;

(ii) Describes with reasonable specificity the service delivery sites, or classes of service delivery sites, to which the joint notice applies; and

(iii) If applicable, states that the covered entities participating in the organized health care arrangement will share protected health information with each other, as necessary to carry out treatment, payment, or health care operations relating to the organized health care arrangement.

(3) The covered entities included in the joint notice must provide the notice to individuals in accordance with the applicable implementation specifications of paragraph (c) of this section. Provision of the joint notice to an individual by any one of the covered entities included in the joint notice will satisfy the provision requirement of paragraph (c) of this section with respect to all others covered by the joint notice.

(e) Implementation specifications: Documentation. A covered entity must document compliance with the notice requirements by retaining copies of the notices issued by the covered entity as required by § 164.530(j).

§ 164.522 Rights to request privacy protection for protected health information.

(a)(1) Standard: Right of an individual to request restriction of uses and disclosures. (i) A covered entity must permit an individual to request that the covered entity restrict:

(A) Uses or disclosures of protected health information about the individual to carry out treatment, payment, or health care operations; and

(B) Disclosures permitted under § 164.510(b).

(ii) A covered entity is not required to agree to a restriction.

(iii) A covered entity that agrees to a restriction under paragraph (a)(1)(i) of this section may not use or disclose protected health information in violation of such restriction, except that, if the individual who requested the restriction is in need of emergency treatment and the restricted protected health information is needed to provide the emergency treatment, the covered entity may use the restricted protected health information, or may disclose such information to a health care provider, to provide such treatment to the individual.

(iv) If restricted protected health information is disclosed to a health care provider for emergency treatment under paragraph (a)(1)(i) of this section, the covered entity must request that such health care provider not further use or disclose the information.

(v) A restriction agreed to by a covered entity under paragraph (a) of this section, is not effective under this subpart to prevent uses or disclosures permitted or required under §§ 164.502(a)(2)(i), 164.510(a) or 164.512.

(2) Implementation specifications: Terminating a restriction. A covered entity may terminate its agreement to a restriction, if:

(i) The individual agrees to or requests the termination in writing;

(ii) The individual orally agrees to the termination and the oral agreement is documented; or

(iii) The covered entity informs the individual that it is terminating its
agreement to a restriction, except that such termination is only effective with respect to protected health information created or received after it has so informed the individual.

(3) Implementation specification: Documentation. A covered entity that agrees to a restriction must document the restriction in accordance with §164.530(i).

(b)(1) Standard: Confidential communications requirements. (i) A covered health care provider must permit individuals to request and must accommodate reasonable requests by individuals to receive communications of protected health information from the covered health care provider by alternative means or at alternative locations.

(ii) A health plan must permit individuals to request and must accommodate reasonable requests by individuals to receive communications of protected health information from the health plan by alternative means or at alternative locations, if the individual clearly states that the disclosure of all or part of that information could endanger the individual.

(2) Implementation specifications: Conditions on providing confidential communications.

(i) A covered entity may require the individual to make a request for a confidential communication described in paragraph (b)(1) of this section in writing.

(ii) A covered entity may condition the provision of a reasonable accommodation on:

(A) When appropriate, information as to how payment, if any, will be handled; and

(B) Specification of an alternative address or other method of contact.

(iii) A covered health care provider may not require an explanation from the individual as to the basis for the request as a condition of providing communications on a confidential basis.

(iv) A health plan may require that a request contain a statement that disclosure of all or part of the information to which the request pertains could endanger the individual.

§164.524 Access of individuals to protected health information.

(a) Standard: Access to protected health information. (1) Right of access. Except as otherwise provided in paragraph (a)(2) or (a)(3) of this section, an individual has a right of access to inspect and obtain a copy of protected health information about the individual in a designated record set, for as long as the protected health information is maintained in the designated record set, except for:

(i) Psychotherapy notes;

(ii) Information compiled in reasonable anticipation of, or for use in, a civil, criminal, or administrative action or proceeding; and

(iii) Protected health information maintained by a covered entity that is:

(A) Subject to the Clinical Laboratory Improvements Amendments of 1988, 42 U.S.C. 263a, to the extent the provision of access to the individual would be prohibited by law; or

(B) Exempt from the Clinical Laboratory Improvements Amendments of 1988, pursuant to 42 CFR 493.3(a)(2).

(2) Unreviewable grounds for denial. A covered entity may deny an individual access without providing the individual an opportunity for review, in the following circumstances:

(i) The protected health information is excepted from the right of access by paragraph (a)(1) of this section.

(ii) A covered entity that is a correctional institution or a covered health care provider acting under the direction of the correctional institution may deny, in whole or in part, an inmate’s request to obtain a copy of protected health information, if obtaining such copy would jeopardize the health, safety, security, custody, or rehabilitation of the individual or of other inmates, or the safety of any officer, employee, or other person at the correctional institution or responsible for the transporting of the inmate.

(iii) An individual’s access to protected health information created or obtained by a covered health care provider in the course of research that includes treatment may be temporarily suspended for as long as the research is in progress, provided that the individual has agreed to the denial of access when consenting to participate in the research that includes treatment, and the covered health care provider has informed the individual that the right of access will be reinstated upon completion of the research.

(iv) An individual’s access to protected health information that is contained in records that are subject to the Privacy Act, 5 U.S.C. 552a, may be denied, if the denial of access under the Privacy Act would meet the requirements of that law.

(v) An individual’s access may be denied if the protected health information was obtained from someone other than a health care provider under a promise of confidentiality and the access requested would be reasonably likely to reveal the source of the information.

(3) Reviewable grounds for denial. A covered entity may deny an individual access, provided that the individual is given a right to have such denials reviewed, as required by paragraph (a)(4) of this section, in the following circumstances:

(i) A licensed health care professional has determined, in the exercise of professional judgment, that the access requested is reasonably likely to endanger the life or physical safety of the individual or another person;

(ii) The protected health information makes reference to another person (unless such other person is a health care provider) and a licensed health care professional has determined, in the exercise of professional judgment, that the access requested is reasonably likely to cause substantial harm to such other person; or

(iii) The request for access is made by the individual’s personal representative and a licensed health care professional who is designated by the covered entity to act as a reviewing official and who did not participate in the original decision to deny. The covered entity must provide or deny access in accordance with the determination of the reviewing official under paragraph (d)(4) of this section.

(b) Implementation specifications: requests for access and timely action. (1) Individual’s request for access. The covered entity must permit an individual to request access to inspect or to obtain a copy of the protected health information about the individual that is maintained in a designated record set. The covered entity may require individuals to make requests for access in writing, provided that it informs individuals of such a requirement.

(2) Timely action by the covered entity. (i) Except as provided in paragraph (b)(2)(ii) of this section, the covered entity must act on a request for access no later than 30 days after receipt of the request as follows:

(A) If the covered entity grants the request, in whole or in part, it must inform the individual of the acceptance of the request and provide the access requested, in accordance with paragraph (c) of this section.
(B) If the covered entity denies the request, in whole or in part, it must provide the individual with a written denial, in accordance with paragraph (d) of this section.

(ii) If the request for access is for protected health information that is not maintained or accessible to the covered entity on-site, the covered entity must take an action required by paragraph (b)(2)(i) of this section by no later than 60 days from the receipt of such a request.

(iii) If the covered entity is unable to take an action required by paragraph (b)(2)(i) or (B) of this section within the time required by paragraph (b)(2)(i) or (ii) of this section, as applicable, the covered entity may extend the time for such actions by no more than 30 days, provided that:

(A) The covered entity, within the time limit set by paragraph (b)(2)(i) or (ii) of this section, as applicable, provides the individual with a written statement of the reasons for the delay and the date by which the covered entity will complete its action on the request; and

(B) The covered entity may have only one such extension of time for action on a request for access.

(c) Implementation specifications: Provision of access. If the covered entity provides an individual with access, in whole or in part, to protected health information, the covered entity must comply with the following requirements.

(1) Providing the access requested.

The covered entity must provide the access requested by individuals, including inspection or obtaining a copy, or both, of the protected health information about them in designated record sets. If the same protected health information that is the subject of a request for access is maintained in more than one designated record set or at more than one location, the covered entity need only produce the protected health information once in response to a request for access.

(2) Form of access requested. (i) The covered entity must provide the individual with access to the protected health information in the form or format requested by the individual, if it is readily producible in such form or format; or, if not, in a readable hard copy form or such other form or format as agreed to by the covered entity and the individual.

(ii) The covered entity may provide the individual with a summary of the protected health information requested, in lieu of providing access to the protected health information or may provide an explanation of the protected health information to which access has been provided, if:

(A) The individual agrees in advance to such a summary or explanation; and

(B) The individual agrees in advance to the fees imposed, if any, by the covered entity for such summary or explanation.

(3) Time and manner of access. The covered entity must provide the access as requested by the individual in a timely manner as required by paragraph (b)(2) of this section, including arranging with the individual for a convenient time and place to inspect or obtain a copy of the protected health information, or mailing the copy of the protected health information at the individual’s request. The covered entity may discuss the scope, format, and other aspects of the request for access with the individual as necessary to facilitate the timely provision of access.

(4) Fees. If the individual requests a copy of the protected health information or agrees to a summary or explanation of such information, the covered entity may impose a reasonable, cost-based fee, provided that the fee includes only the cost of:

(i) Copying, including the cost of supplies for and labor of copying, the protected health information requested by the individual;

(ii) Postage, when the individual has requested the copy, or the summary or explanation, be mailed; and

(iii) Preparing an explanation or summary of the protected health information, if agreed to by the individual as required by paragraph (c)(2)(ii) of this section.

(d) Implementation specifications: Denial of access. If the covered entity denies access, in whole or in part, to protected health information, the covered entity must comply with the following requirements.

(1) Making other information accessible. The covered entity must, to the extent possible, give the individual access to any other protected health information or a record set for as long as the protected health information or a record set is maintained, the covered entity knows where the requested information is maintained, the covered entity does not maintain the protected health information, or mailing the copy of the protected health information at the individual’s request, and

(ii) If applicable, a statement of the individual’s review rights under paragraph (a)(4) of this section, including a description of how the individual may exercise such review rights; and

(iii) A description of how the individual may complain to the covered entity pursuant to the complaint procedures in § 164.530(d) or to the Secretary pursuant to the procedures in § 160.306. The description must include the name, or title, and telephone number of the contact person or office designated in § 164.530(a)(1)(ii).

(3) Other responsibility. If the covered entity does not maintain the protected health information that is the subject of the individual’s request for access, and the covered entity knows where the requested information is maintained, the covered entity must inform the individual where to direct the request for access.

(4) Review of denial requested. If the individual has requested a review of a denial under paragraph (a)(4) of this section, the covered entity must designate a licensed health care professional, who was not directly involved in the denial to review the decision to deny access. The covered entity must promptly refer a request for review to such designated reviewing official. The designated reviewing official must determine, within a reasonable period of time, whether or not to deny the access requested based on the standards in paragraph (a)(3) of this section. The covered entity must promptly provide written notice to the individual of the determination of the designated reviewing official and take other action as required by this section to carry out the designated reviewing official’s determination.

(e) Implementation specification: Documentation. A covered entity must document the following and retain the documentation as required by § 164.530(j):

(1) The designated record sets that are subject to access by individuals; and

(2) The titles of the persons or offices responsible for receiving and processing requests for access by individuals.

82824 Federal Register / Vol. 65, No. 250 / Thursday, December 28, 2000 / Rules and Regulations
originator of protected health information is no longer available to act on the requested amendment;
(iii) Would not be available for inspection under § 164.524; or
(iv) Is accurate and complete.
(b) Implementation specifications: requests for amendment and timely action. (1) Individual’s request for amendment. The covered entity must permit an individual to request that the covered entity amend the protected health information maintained in the designated record set. The covered entity may require individuals to make requests for amendment in writing and to provide a reason to support a requested amendment, provided that it informs individuals in advance of such requirements.
(2) Timely action by the covered entity. (i) The covered entity must act on the individual’s request for an amendment no later than 60 days after receipt of such a request, as follows. (A) If the covered entity grants the requested amendment, in whole or in part, it must take the actions required by paragraphs (c)(1) and (2) of this section.
(B) If the covered entity denies the requested amendment, in whole or in part, it must provide the individual with a written denial, in accordance with paragraph (d)(1) of this section.
(ii) If the covered entity is unable to act on the amendment within the time required by paragraph (b)(2)(i) of this section, the covered entity may extend the time for such action by no more than 30 days, provided that:
(A) The covered entity, within the time limit set by paragraph (b)(2)(i) of this section, provides the individual with a written statement of the reasons for the delay and the date by which the covered entity will complete its action on the request; and
(B) The covered entity may have only one such extension of time for action on a request for an amendment.
(c) Implementation specifications: Accepting the amendment. If the covered entity accepts the requested amendment, in whole or in part, the covered entity must comply with the following requirements.
(1) Making the amendment. The covered entity must make the appropriate amendment to the protected health information or record that is the subject of the request for amendment by, at a minimum, identifying the records in the designated record set that are affected by the amendment and appending or otherwise providing a link to the location of the amendment.
(2) Informing the individual. In accordance with paragraph (b) of this section, the covered entity must timely inform the individual that the amendment is accepted and obtain the individual’s identification of and agreement to have the covered entity notify the relevant persons with which the amendment needs to be shared in accordance with paragraph (c)(3) of this section.
(3) Informing others. The covered entity must make reasonable efforts to inform and provide the amendment within a reasonable time to:
(i) Persons identified by the individual as having received protected health information about the individual and needing the amendment; and
(ii) Persons, including business associates, that the covered entity knows have the protected health information that is the subject of the amendment and that may have relied, or could foreseeably rely, on such information to the detriment of the individual.
(d) Implementation specifications: Denying the amendment. If the covered entity denies the requested amendment, in whole or in part, the covered entity must comply with the following requirements.
(1) Denial. The covered entity must provide the individual with a timely, written denial, in accordance with paragraph (b)(2) of this section. The denial must use plain language and contain:
(i) The basis for the denial, in accordance with paragraph (a)(2) of this section;
(ii) The individual’s right to submit a written statement disagreeing with the denial and how the individual may file such a statement;
(iii) A statement that, if the individual does not submit a statement of disagreement, the individual may request that the covered entity provide the individual’s request for amendment and the denial with any future disclosures of the protected health information that is the subject of the amendment; and
(iv) A description of how the individual may complain to the covered entity pursuant to the complaint procedures established in § 164.530(d) or to the Secretary pursuant to the procedures established in § 160.306. The description must include the name, or title, and telephone number of the contact person or office designated in § 164.530(a)(1)(ii).
(2) Statement of disagreement. The covered entity must permit the individual to submit to the covered entity a written statement disagreeing with the denial of all or part of a requested amendment and the basis of such disagreement. The covered entity may reasonably limit the length of a statement of disagreement.
(3) Rebuttal statement. The covered entity may prepare a written rebuttal to the individual’s statement of disagreement. Whenever such a rebuttal is prepared, the covered entity must provide a copy to the individual who submitted the statement of disagreement.
(e) Implementation specification: Documentation. A covered entity must document the titles of the persons or
§ 164.528 Accounting of disclosures of protected health information.

(a) Standard: Right to an accounting of disclosures of protected health information. (1) An individual has a right to receive an accounting of disclosures of protected health information made by a covered entity in the six years prior to the date on which the accounting is requested, except for disclosures:

(i) To carry out treatment, payment and health care operations as provided in § 164.502;

(ii) To individuals of protected health information about them as provided in § 164.502;

(iii) For the facility’s directory or to persons involved in the individual’s care or other notification purposes as provided in § 164.510;

(iv) For national security or intelligence purposes as provided in § 164.512(k)(2);

(v) To correctional institutions or law enforcement officials as provided in § 164.512(k)(5); or

(vi) That occurred prior to the compliance date for the covered entity.

(2) The covered entity must tempoarily suspend an individual’s right to receive an accounting of disclosures to a health oversight agency or law enforcement official, as provided in § 164.512(d) or (f), respectively, for the time specified by such agency or official, if such agency or official provides the covered entity with a written statement that such an accounting to the individual would be reasonably likely to impede the agency’s activities and specifying the time for which such a suspension is required.

(ii) The written accounting that is made orally, the covered entity must:

(A) Document the statement, including the identity of the agency or official making the statement;

(B) Temporarily suspend the individual’s right to an accounting of disclosures subject to the statement; and

(C) Limit the temporary suspension to no longer than 30 days from the date of the oral statement, unless a written statement pursuant to paragraph (a)(2)(i) of this section is submitted during that time.

(3) An individual may request an accounting of disclosures for a period of time less than six years from the date of the request.

(b) Implementation specifications: Content of the accounting. The covered entity must provide the individual with a written accounting that meets the following requirements.

(1) Except as otherwise provided by paragraph (a) of this section, the accounting must include disclosures of protected health information that occurred during the six years or such shorter time period at the request of the individual as provided in paragraph (a)(3) of this section prior to the date of the request for an accounting, including disclosures to or by business associates of the covered entity.

(2) The accounting must include for each disclosure:

(i) The date of the disclosure;

(ii) The name of the entity or person who received the protected health information; and,

(iii) A brief description of the protected health information disclosed; and

(iv) A brief statement of the purpose of the disclosure that reasonably informs the individual of the basis for the disclosure; or, in lieu of such statement:

(A) A copy of the individual’s written authorization pursuant to § 164.508; or

(B) A copy of a written request for a disclosure under §§ 164.502(a)(2)(ii) or 164.512, if any;

(3) If, during the period covered by the accounting, the covered entity has made multiple disclosures of protected health information to the same person or entity for a single purpose under §§ 164.502(a)(2)(ii) or 164.512, or pursuant to a single authorization under § 164.508, the accounting may, with respect to such multiple disclosures, provide:

(i) The information required by paragraph (b)(2) of this section for the first disclosure during the accounting period;

(ii) The frequency, periodicity, or number of the disclosures made during the accounting period; and

(iii) The date of the last such disclosure during the accounting period.

(c) Implementation specifications: Provision of the accounting. (1) The covered entity must act on the individual’s request for an accounting, no later than 60 days after receipt of such a request, as follows.

(i) The covered entity must provide the individual with the accounting requested; or

(ii) If the covered entity is unable to provide the accounting within the time required by paragraph (c)(1) of this section, the covered entity may extend the time to provide the accounting by no more than 30 days, provided that:

(A) The covered entity, within the time limit set by paragraph (c)(1) of this section, provides the individual with a written statement of the reasons for the delay and the date by which the covered entity will provide the accounting; and

(B) The covered entity may have only one such extension of time for action on a request for an accounting.

(2) The covered entity must provide the first accounting to an individual in any 12 month period without charge. The covered entity may impose a reasonable, cost-based fee for each subsequent request for an accounting by the same individual within the 12 month period, provided that the covered entity informs the individual in advance of the fee and provides the individual with an opportunity to withdraw or modify the request for a subsequent accounting in order to avoid or reduce the fee.

(d) Implementation specification: Documentation. A covered entity must document the following and retain the documentation as required by § 164.530(j):

(1) The information required to be included in an accounting under paragraph (b) of this section for disclosures of protected health information that are subject to an accounting under paragraph (a) of this section;

(2) The written accounting that is provided to the individual under this section; and

(3) The titles of the persons or offices responsible for receiving and processing requests for an accounting by individuals.

§ 164.530 Administrative requirements.

(a)(1) Standard: Personnel designations. (i) A covered entity must designate a privacy official who is responsible for the development and implementation of the policies and procedures of the entity.

(ii) A covered entity must designate a contact person or office who is responsible for receiving complaints under this section and who is able to provide further information about matters covered by the notice required by § 164.520.

(b)(1) Standard: Training. A covered entity must train all members of its workforce on the policies and procedures with respect to protected health information required by this subpart, as necessary and appropriate for the members of the workforce to
carry out their function within the covered entity.

(2) Implementation specifications: Training. (i) A covered entity must provide training that meets the requirements of paragraph (b)(1) of this section, as follows:
(A) To each member of the covered entity’s workforce by no later than the compliance date for the covered entity;
(B) Thereafter, to each new member of the workforce within a reasonable period of time after the person joins the covered entity’s workforce;
(C) To each member of the covered entity’s workforce whose functions are affected by a material change in the policies or procedures required by this subpart, within a reasonable period of time after the material change becomes effective in accordance with paragraph (i) of this section.
(ii) A covered entity must document that the training as described in paragraph (b)(2)(i) of this section has been provided, as required by paragraph (j) of this section.

(c)(1) Standard: Safeguards. A covered entity must have in place appropriate administrative, technical, and physical safeguards to protect the privacy of protected health information.

(2) Implementation specification: Safeguards. A covered entity must reasonably safeguard protected health information from any intentional or unintentional use or disclosure that is in violation of the standards, implementation specifications or other requirements of this subpart.

(d)(1) Complaints to the covered entity. A covered entity must provide a process for individuals to make complaints concerning the covered entity’s policies and procedures required by this subpart or its compliance with such policies and procedures or the requirements of this subpart.

(2) Implementation specification: Documentation of complaints. As required by paragraph (j) of this section, a covered entity must document all complaints received, and their disposition, if any.

(e)(1) Standard: Sanctions. A covered entity must have and apply appropriate sanctions against members of its workforce who fail to comply with the privacy policies and procedures of the covered entity or the requirements of this subpart. This standard does not apply to a member of the covered entity’s workforce with respect to actions that are covered by and that meet the conditions of § 164.502(l) or paragraph (g)(2) of this section.

(2) Implementation specification: Documentation. As required by paragraph (j) of this section, a covered entity must document the sanctions that are applied, if any.

(f) Standard: Mitigation. A covered entity must mitigate, to the extent practicable, any harmful effect that is known to the covered entity of a use or disclosure of protected health information in violation of its policies and procedures or the requirements of this subpart by the covered entity or its business associate.

(g) Standard: Refraining from intimidating or retaliatory acts. A covered entity may not intimidate, threaten, coerce, discriminate against, or take other retaliatory action against:
(1) Individuals. Any individual for the exercise by the individual of any right under, or for participation by the individual in any process established by this subpart, including the filing of a complaint under this section;
(2) Individuals and others. Any individual or other person for:
(i) Filing of a complaint with the Secretary by the covered entity’s workforce; and
(ii) Testifying, assisting, or participating in an investigation, compliance review, proceeding, or hearing under Part C of Title XI; or
(iii) Opposing any act or practice made unlawful by this subpart, provided the individual or person has a good faith belief that the practice opposed is unlawful, and the manner of the opposition is reasonable and does not involve a disclosure of protected health information in violation of this subpart.

(h) Standard: Waiver of rights. A covered entity may not require individuals to waive their rights under § 160.306 of this subchapter or this subpart as a condition of the provision of treatment, payment, enrollment in a health plan, or eligibility for benefits.

(i)(1) Standard: Policies and procedures. A covered entity must implement policies and procedures with respect to protected health information that are designed to comply with the standards, implementation specifications, or other requirements of this subpart. The policies and procedures must be reasonably designed, taking into account the size of and the type of activities that relate to protected health information undertaken by the covered entity, to ensure such compliance. This standard is not to be construed to permit or excuse an action that violates any other standard, implementation specification, or other requirement of this subpart.

(ii) Changes to policies or procedures. (i) A covered entity must change its policies and procedures as necessary and appropriate to comply with changes in the law, including the standards, requirements, and implementation specifications of this subpart;
(ii) When a covered entity changes a privacy practice that is stated in the notice described in § 164.520, and makes corresponding changes to its policies and procedures, it may make the changes effective for protected health information that it created or received prior to the effective date of the notice revision, if the covered entity has, in accordance with § 164.520(b)(1)(v)(C), included in the notice a statement reserving its right to make such a change in its privacy practices; or
(iii) A covered entity may make any other changes to policies and procedures at any time, provided that the changes are documented and implemented in accordance with paragraph (ii)(5) of this section.

(3) Implementation specification: Changes in law. Whenever there is a change in law that necessitates a change to the covered entity’s policies or procedures, the covered entity must promptly document and implement the revised policy or procedure. If the change in law materially affects the content of the notice required by § 164.520, the covered entity must promptly make the appropriate revisions to the notice in accordance with § 164.520(b)(3). Nothing in this paragraph may be used by a covered entity to excuse a failure to comply with the law.

(4) Implementation specifications: Changes to privacy practices stated in the notice. (i) To implement a change as provided by paragraph (ii)(2)(iii) of this section, a covered entity must:
(A) Ensure that the policy or procedure, as revised to reflect a change in the covered entity’s privacy practice as stated in its notice, complies with the standards, requirements, and implementation specifications of this subpart;
(B) Document the policy or procedure, as revised, as required by paragraph (j) of this section; and
(C) Revise the notice as required by § 164.520(b)(3) to state the changed practice and make the revised notice available as required by § 164.520(c). The covered entity may not implement a change to a policy or procedure prior to the effective date of the revised notice.
(ii) If a covered entity has not reserved its right under § 164.520(b)(1)(v)(C) to change a privacy practice that is stated in the notice, the covered entity is bound by the privacy practices as stated
in the notice with respect to protected health information created or received while such notice is in effect. A covered entity may change a privacy practice that is stated in the notice, and the related policies and procedures, without having reserved the right to do so, provided that:

(A) Such change meets the implementation the requirements in paragraphs (i)(4)(i)(A)–(C) of this section; and

(B) Such change is effective only with respect to protected health information created or received after the effective date of the notice.

(5) Implementation specification: Changes to other policies or procedures. A covered entity may change, at any time, a policy or procedure that does not materially affect the content of the notice required by §164.520, provided that:

(i) The policy or procedure, as revised, complies with the standards, requirements, and implementation specifications of this subpart; and

(ii) Prior to the effective date of the change, the policy or procedure, as revised, is documented as required by paragraph (j) of this section.

(j)(1) Standard: Documentation. A covered entity must maintain the policies and procedures provided for in paragraph (i) of this section in written or electronic form:

(ii) If a communication is required by this subpart to be in writing, maintain such writing, or an electronic copy, as documentation; and

(iii) If an action, activity, or designation is required by this subpart to be documented, maintain a written or electronic record of such action, activity, or designation.

(2) Implementation specification: Retention period. A covered entity must retain the documentation required by paragraph (j)(1) of this section for six years from the date of its creation or the date when it last was in effect, whichever is later.

(k) Standard: Group health plans. (1) A group health plan is not subject to the standards or implementation specifications in paragraphs (a) through (f) and (i) of this section, to the extent that:

(i) The group health plan provides health benefits solely through an insurance contract with a health insurance issuer or an HMO; and

(ii) The group health plan does not create or receive protected health information except for:

(A) Summary health information as defined in §164.504(a); or

(B) Information on whether the individual is participating in the group health plan, or is enrolled in or has disenrolled from a health insurance issuer or HMO offered by the plan.

(2) A group health plan described in paragraph (k)(1) of this section is subject to the standard and implementation specification in paragraph (j) of this section only with respect to health information that it created or received before the applicable compliance date of this subpart and to which the consent, authorization, or other express legal permission obtained from an individual applies.

§164.532 Transition provisions.

(a) Standard: Effect of prior consents and authorizations. Notwithstanding other sections of this subpart, the following provisions apply to use or disclosure by a covered entity of protected health information pursuant to a consent, authorization, or other express legal permission obtained from an individual permitting the use or disclosure of protected health information that does not comply with §§164.506 or 164.508 of this subpart consistent with paragraph (b) of this section.

(b) Implementation specification: Requirements for retaining effectiveness of prior consents and authorizations. Notwithstanding other sections of this subpart, the following provisions apply to use or disclosure by a covered entity of protected health information pursuant to a consent, authorization, or other express legal permission obtained from an individual permitting the use or disclosure of protected health information, if the consent, authorization, or other express legal permission was obtained from an individual before the applicable compliance date of this subpart and does not comply with §§164.506 or 164.508 of this subpart.

(1) If the consent, authorization, or other express legal permission obtained from an individual permits a use or disclosure for purposes of the project, the covered entity may, with respect to protected health information, if that created or received either before or after the applicable compliance date of this subpart and to which the consent or authorization applies, make such use or disclosure for purposes of that project, provided that the covered entity complies with all limitations placed by the consent or authorization, or other express legal permission obtained from an individual.

(2) If the consent, authorization, or other express legal permission obtained from an individual specifically permits a use or disclosure for a purpose other than to carry out treatment, payment, or health care operations, the covered entity may, with respect to protected health information that it created or received before the applicable compliance date of this subpart and to which the consent, authorization, or other express legal permission obtained from an individual applies, make such use or disclosure, provided that:

(i) The covered entity does not make any use or disclosure that is expressly excluded from the consent, authorization, or other express legal permission obtained from an individual; and

(ii) The covered entity complies with all limitations placed by the consent, authorization, or other express legal permission obtained from an individual.

(3) In the case of a consent, authorization, or other express legal permission obtained from an individual that identifies a specific research project that includes treatment of individuals:

(i) If the consent, authorization, or other express legal permission obtained from an individual specifically permits a use or disclosure for purposes of the project, the covered entity may, with respect to protected health information that it created or received either before or after the applicable compliance date of this subpart and to which the consent or authorization applies, make such use or disclosure for purposes of that project, provided that the covered entity complies with all limitations placed by the consent, authorization, or other express legal permission obtained from an individual.

(ii) If the consent, authorization, or other express legal permission obtained from an individual is a general consent to participate in the research, such covered entity may, with respect to protected health information that it created or received as part of the project, provided that the covered entity complies with all limitations placed by the consent, authorization, or other express legal permission obtained from an individual.

(4) If, after the applicable compliance date of this subpart, the covered entity agrees to a restriction requested by an individual under §164.522(a), a subsequent use or disclosure of
protected health information that is subject to the restriction based on a consent, authorization, or other express legal permission obtained from an individual as given effect by paragraph (b) of this section, must comply with such restriction.

§ 164.534 Compliance dates for initial implementation of the privacy standards. (a) Health care providers. A covered health care provider must comply with the applicable requirements of this subpart no later than February 26, 2003.

(b) Health plans. A health plan must comply with the applicable requirements of this subpart no later than the following date, as applicable:

(1) Health plans other than small health plans—February 26, 2003.


(c) Health care clearinghouses. A health care clearinghouse must comply with the applicable requirements of this subpart no later than February 26, 2003.

[FR Doc. 00–32678 Filed 12–20–00; 11:21 am]

BILLING CODE 4150–04–P
Thursday,
December 28, 2000

Part III

Department of Agriculture

Agricultural Marketing Service

7 CFR Part 1000, et al.
Milk in the Northeast and Other Marketing Areas; Interim Amendment of Orders; Interim Rule
### DEPARTMENT OF AGRICULTURE

**Agricultural Marketing Service**

**7 CFR Parts 1000, 1001, 1005, 1006, 1007, 1030, 1032, 1033, 1124, 1126, 1131, and 1135**

[Docket No. AO–14–A69, et al.; DA–00–03]

**Milk in the Northeast and Other Marketing Areas; Interim Amendment of Orders**

<table>
<thead>
<tr>
<th>7 CFR part</th>
<th>Marketing area</th>
<th>AO Nos.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1001</td>
<td>Northeast</td>
<td>AO–14–A69, AO–388–A11</td>
</tr>
<tr>
<td>1005</td>
<td>Appalachian</td>
<td>AO–356–A34</td>
</tr>
<tr>
<td>1006</td>
<td>Florida</td>
<td>AO–366–A40, AO–361–A34</td>
</tr>
<tr>
<td>1007</td>
<td>Southeast</td>
<td>AO–313–A43</td>
</tr>
<tr>
<td>1030</td>
<td>Upper Midwest</td>
<td>AO–166–A67, AO–368–A27</td>
</tr>
<tr>
<td>1032</td>
<td>Central</td>
<td>AO–231–A65</td>
</tr>
<tr>
<td>1033</td>
<td>Mideast</td>
<td>AO–271–A35</td>
</tr>
<tr>
<td>1124</td>
<td>Pacific Northwest</td>
<td>AO–380–A17</td>
</tr>
<tr>
<td>1126</td>
<td>Southwest</td>
<td>AO–231–A65</td>
</tr>
<tr>
<td>1131</td>
<td>Arizona-Las Vegas</td>
<td>AO–271–A35</td>
</tr>
<tr>
<td>1135</td>
<td>Western</td>
<td>AO–380–A17</td>
</tr>
</tbody>
</table>

**AGENCY:** Agricultural Marketing Service, USDA.

**ACTION:** Interim amendment of rules.

**SUMMARY:** This interim rule amends, on an emergency basis, the Class III and Class IV pricing formulas used in Federal milk orders, effective for milk marketed on or after January 1, 2001. The rule thereby conforms to the requirements of the Consolidated Appropriations Act, 2000, which mandated reconsideration of the Class III and Class IV pricing formulas included in the final rule for the consolidation and reform of Federal milk orders, with amendments to be effective January 1, 2001.

This rule reduces the cheese make allowance used in the Class III component price calculations, increases the make allowances used in the Class IV component price calculations, provides for separate Class III and Class IV butterfat prices, and removes the butterfat adjustment factor from the protein price formula.

More than the required number of producers in each of the aforesaid marketing areas have approved the issuance of the interim amendments.

**EFFECTIVE DATE:** January 1, 2001.

---

**FOR FURTHER INFORMATION CONTACT:** Constance M. Brenner, Marketing Specialist, USDA/AMS/Dairy Programs, Order Formulation Branch, Room 2971, South Building, P. O. Box 94565, Washington, DC 20090–4565, (202) 720–2357, e-mail address connie.brenner@usda.gov.

**SUPPLEMENTARY INFORMATION:** This administrative rule is governed by the provisions of Sections 556 and 557 of Title 5 of the United States Code and, therefore, is excluded from the requirements of Executive Order 12866.

This interim final rule has been reviewed under Executive Order 12988, Civil Justice Reform. This rule is not intended to have retroactive effect. This rule will not preempt any state or local laws, regulations, or policies, unless they present an irreconcilable conflict with the rule.

The Agricultural Marketing Agreement Act of 1937, as amended (7 U.S.C. 601–674), provides that administrative proceedings must be exhausted before parties may file suit in court. Under section 608c(15)(A) of the Act, any handler subject to an order may request modification or exemption from such order by filing with the Secretary a petition stating that the order, any provision of the order, or any obligation imposed in connection with the order is not in accordance with the law. A handler is afforded the opportunity for a hearing on the petition. After a hearing, the Secretary would rule on the petition. The Act provides that the District Court of the United States in any district in which the handler is an inhabitant, or has its principal place of business, has jurisdiction in equity to review the Secretary’s ruling on the petition. A bill in equity is filed not later than 20 days after the date of the entry of the ruling.

### Small Business Consideration

Pursuant to the requirements set forth in the Regulatory Flexibility Act (5 U.S.C. 601 et seq.), the Agricultural Marketing Service (AMS) considered the economic impact of the changes to the Federal milk marketing order program implemented by this interim final rule on small entities and prepared a regulatory flexibility analysis that was included in the tentative decision (65 FR 76832). The analysis indicates that the Department minimized the significant economic impacts of the regulations on small entities to the fullest extent reasonably possible while adhering to the stated objectives. The Department reviewed the regulatory and financial burdens resulting from the regulations and determined, to the fullest extent possible, the impact on small businesses’ abilities to compete in the market place. The Department reviewed the regulations from both the small producer and small processor perspectives, attempting to maintain a balance between these competing interests. Neither small producers nor small handlers should experience any particular disadvantage as a result of the interim amendments.

No additional information collection or reporting requirements will be necessitated by the amendments.

An analysis of the economic effects of the alternatives selected was done and summarized in the tentative final decision. A complete economic analysis is available upon request from Howard McDowell, Senior Economist, USDA/AMS/Dairy Programs, Office of the Chief Economist, Room 2753, South Building, U.S. Department of Agriculture, Washington, DC 20250, (202) 720–7091, e-mail address howard.mcdowell@usda.gov

### Civil Rights Impact Statement

Pursuant to Departmental Regulation (DR) 4300–4, a comprehensive Civil Rights Impact Analysis (CRIA) was conducted and published with the final decision on Federal milk order consolidation and reform. The conclusion of that analysis disclosed no potential for affecting dairy farmers in protected groups differently than the general population of dairy farmers. This issue was reconsidered in the tentative decision (65 FR 76832) with regard to the interim amendments, and the conclusion has not changed.

Copies of the Civil Rights Impact Analysis done for the final decision on Federal milk order consolidation and reform can be obtained from AMS Dairy Programs at (202) 720–4392; any Milk Market Administrator office; or via the Internet at: www.ams.usda.gov/dairy/ Prior documents in this proceeding: Notice of Hearing; Issued April 6, 2000; published April 14, 2000 (65 FR 76894).

### Tentative Final Decision: Issued November 29, 2000; published December 7, 2000 (65 FR 76832).

### Findings and Determinations

The findings and determinations hereinafter set forth supplement those that were made when the aforesaid orders were first issued and when they were amended. The previous findings and determinations are hereby ratified and confirmed, except where they may conflict with those set forth herein.

The following findings and determinations are hereby made with respect to each of the aforesaid orders:
(a) Findings upon the basis of the hearing record. Pursuant to the provisions of the Agricultural Marketing Agreement Act of 1937, as amended (7 U.S.C. 601–674), and the applicable rules of practice and procedure governing the formulation of marketing agreements and marketing orders (7 CFR Part 900), a public hearing was held upon certain proposed amendments to the tentative marketing agreements and to the orders regulating the handling of milk in the Northeast and other marketing areas. Upon the basis of the evidence introduced at such hearing and the record thereof it is found that:

(1) The said orders, as hereby amended on an interim basis, and all of the terms and conditions thereof, will tend to effectuate the declared policy of the Act;

(2) The parity prices of milk, as determined pursuant to section 2 of the Act, are not reasonable in view of the price of feeds, available supplies of feeds, and other economic conditions which affect market supply and demand for milk in the marketing areas, and the minimum prices specified in the orders, as hereby amended, are such prices as will reflect the aforesaid factors, insure a sufficient quantity of pure and wholesome milk, and be in the public interest; and

(3) The said orders, as hereby amended on an interim basis, regulate the handling of milk in the same manner as, and are applicable only to persons in the respective classes of industrial and commercial activity specified in, marketing agreements upon which a hearing has been held.

(b) Additional Findings. It is necessary in the public interest to make these interim amendments to the Northeast and other orders effective January 1, 2001, to meet the requirements of the Consolidated Appropriations Act, 2000 (P.L. 106–113, 115 Stat. 1501). Any delay beyond that date would tend to disrupt the orderly marketing of milk in the aforesaid marketing areas.

The interim amendments to these orders are known to handlers. In view of the foregoing, it is hereby determined that:

(1) The refusal or failure of handlers (excluding cooperative associations specified in Sec. 8c(9) of the Act) of more than 50 percent of the milk, which is marketed within the specified marketing areas, to sign proposed marketing agreements, tends to prevent the effectuation of the declared policy of the Act;

(2) The issuance of this interim order amending the Northeast and other orders is the only practical means pursuant to the declared policy of the Act of advancing the interests of producers as defined in the orders as hereby amended;

(3) The issuance of the interim order amending the Northeast and other orders is favored by at least two-thirds of the producers who were engaged in the production of milk for sale in the respective marketing areas.

List of Subjects in 7 CFR Parts 1000, 1001, 1005, 1006, 1007, 1030, 1032, 1124, 1126, 1131, and 1135

Milk marketing orders.

Order Relative to Handling

It is therefore ordered, that on and after the effective date hereof, the handling of milk in the Northeast and other marketing areas shall be in conformity to and in compliance with the terms and conditions of the orders, as amended, and as hereby further amended on an interim basis, as follows:

The authority citation for 7 CFR Parts 1000, 1001, 1005, 1006, 1007, 1030, 1032, 1033, 1124, 1126, 1131, and 1135 continues to read as follows:


PART 1000—GENERAL PROVISIONS OF FEDERAL MILK MARKETING ORDERS

1. Section 1000.40 is amended by removing and revising paragraph (c)(1)(ii) and revising paragraph (d)(1)(i) to read as follows:

§ 1000.40 Classes of utilization.

* * * * *

(c) * * *

(1) * * *

(ii) [Reserved]

* * * * *

(d) * * *

(1) * * *

(i) Butter, plastic cream, anhydrous milkfat, and butteroil; and

* * * * *

2. Section 1000.50 is amended by revising the last sentence of the introductory text and paragraphs (a), (b), (c), (g), (h), (j), (l), (m), (o), (p)(1), and (q)(3) and adding paragraph (q)(4) to read as follows:

§ 1000.50 Class prices, component prices, and advanced pricing factors.

* * * * *

The price described in paragraph (d) of this section shall be derived from the Class II skim milk price announced on or before the 23rd day of the month preceding the month to which it applies and the Class IV butterfat price announced on or before the 5th day of the month following the month to which it applies.

(a) Class I price. The Class I price per hundredweight shall be the adjusted Class I differential specified in § 1000.52 plus the higher of the advanced Class III or advanced Class IV prices calculated in paragraph (q)(4) of this section.

(b) Class I skim milk price. The Class I skim milk price per hundredweight shall be the adjusted Class I differential in § 1000.52 plus the advanced Class III or advanced Class IV skim milk price used in the calculation of the higher of the advanced Class III or advanced Class IV prices calculated in paragraph (q)(4) of this section.

(c) Class I butterfat price. The Class I butterfat price per pound shall be the adjusted Class I differential specified in § 1000.52 divided by 100, plus the advanced Class III or advanced Class IV butterfat price used in the calculation of the higher of the advanced Class III or advanced Class IV prices calculated in paragraph (q)(4) of this section.

* * * * *

(g) Class II butterfat price. The Class II butterfat price per pound shall be the Class IV butterfat price plus $.007.

(h) Class III price. The Class III price per hundredweight, rounded to the nearest cent, shall be .965 times the Class III skim milk price plus 3.5 times the Class III butterfat price.

* * * * *

(j) Class IV price. The Class IV price per hundredweight, rounded to the nearest cent, shall be .965 times the Class IV skim milk price plus 3.5 times the Class IV butterfat price.

* * * * *

(l) Class III and Class IV butterfat prices. (1) The Class III butterfat price per pound, rounded to the nearest one-hundredth cent, shall be computed as follows:

(i) Compute a weighted average of the following prices:

* * * * *
Of this section and multiply the result by the Department for the month plus 3 cents;
(ii) Subtract 16.5 cents from the price computed pursuant to paragraph (i)(1)(ii) of this section and multiply the result by 1.582;
(2) The Class IV butterfat price per pound, rounded to the nearest one-hundredth cent, shall be the U.S. average NASS AA butter survey price reported by the Department for the month less 11.5 cents, with the result divided by 0.82.

(m) Nonfat solids price. The nonfat solids price per pound, rounded to the nearest one-hundredth cent, shall be the U.S. average NASS nonfat dry milk survey price reported by the Department for the month minus 14 cents.

(n) Protein price. The protein price per pound, rounded to the nearest one-hundredth cent, shall be computed by subtracting 16.5 cents from the price computed pursuant to paragraph (i)(1)(i) of this section and multiplying the result by 1.405;
(o) Other solids price. The other solids price per pound, rounded to the nearest one-hundredth cent, shall be the U.S. average NASS dry whey survey price reported by the Department for the month minus 14 cents, with the result divided by 0.968. The other solids price shall not be less than zero.
(p) * * * * *
(1) Multiply .0005 by the weighted average price computed pursuant to paragraph (i)(1)(i) of this section and round to the 5th decimal place; * * * * * * * * *
(q) * * *
(3) Calculate the advanced Class III and advanced Class IV butterfat prices as follows:
(i) The advanced Class III butterfat price shall be the sum of the value calculated pursuant to paragraph (q)(1) of this section multiplied by .965 plus the value calculated pursuant to paragraph (q)(3)(i) of this section multiplied by 3.5, rounded to the nearest cent.
(ii) The advanced Class IV price shall be the sum of the value calculated pursuant to paragraph (q)(2) of this section multiplied by .965 plus the value calculated pursuant to paragraph (q)(3)(ii) of this section multiplied by 3.5, rounded to the nearest cent.

PART 1001—MILK IN THE NORTHEAST MARKETING AREA

1. Section 1001.60 is amended by revising paragraphs (c)(3), (d)(2), and (h) to read as follows:

§ 1001.60 Handler’s value of milk.
* * * * *
(c) * * *
(3) Add an amount obtained by multiplying the pounds of butterfat in Class III by the Class III butterfat price.
(d) * * *
(2) Add an amount obtained by multiplying the pounds of butterfat in Class IV by the Class IV butterfat price.
* * * * * * *
(h) Multiply the Class I skim milk and Class I butterfat prices applicable at the location of the nearest unregulated supply plants from which an equivalent volume was received by the pounds of skim milk and butterfat in receipts of concentrated fluid milk products assigned to Class I pursuant to §1000.44(d) and the corresponding step of §1000.44(b) and the pounds of skim milk and butterfat subtracted from Class I pursuant to §1000.44(a)(6) and the corresponding step of §1000.44(b), excluding such skim milk and butterfat in receipts of fluid milk products from an unregulated supply plant to the extent that an equivalent amount of milk or butterfat disposed of to such plant by handlers fully regulated under any Federal milk order is classified as Class I milk and is not used as an offset for any other payment obligation under any order. * * * * * * *

2. Section 1001.61 is revised to read as follows:

§ 1001.61 Computation of producer butterfat price and producer price differential.

For each month, the market administrator shall compute a producer butterfat price per pound of butterfat and a producer price differential per hundredweight for producer milk receipts. The report of any handler who has not made payments required pursuant to §1001.71 for the preceding month shall not be included in the computation of these prices, and such handler’s report shall not be included in the computation for succeeding months until the handler has made full payment of outstanding monthly obligations. Subject to the aforementioned conditions, the market administrator shall compute the producer butterfat price and the producer price differential in the following manner:

(a) Producer butterfat price. The producer butterfat price per pound, rounded to the nearest one-hundredth cent, shall be computed by:
(1) Multiplying the pounds of butterfat in producer milk allocated to Class I pursuant to §1000.44(b) by the respective class butterfat prices;
(2) Adding the butterfat value calculated in §1001.60(h) for other source milk allocated to Class I pursuant to §1000.43(d) and the steps of §1000.44(b) that correspond to §1000.44(a)(3)(i) and §1000.44(a)(8) by the Class I price; and
(3) Dividing the sum of paragraphs (a)(1) and (a)(2) of this section by the sum of the pounds of butterfat in producer milk and other source milk used to calculate the values in paragraphs (a)(1) and (a)(2) of this section.

(b) Producer price differential. (1) Combine into one total the values computed pursuant to §1001.60 for all handlers required to file reports prescribed in §1001.30;
(2) Subtract the total of the values obtained:
(i) By multiplying the total pounds of protein, other solids, and butterfat contained in each handler’s producer milk for which an obligation was computed pursuant to §1001.60(a) through (g) and §1001.60(i) by the protein price, other solids price, and producer butterfat price, respectively;
(ii) By multiplying each handler’s pounds of skim milk and butterfat for which a value is computed pursuant to §1001.60(h) by the Class III skim milk and the producer butterfat price, respectively;
(3) Add an amount equal to the minus location adjustments and subtract an amount equal to the plus location adjustments computed pursuant to §1001.75;
(4) Add an amount equal to not less than one-half of the unobligated balance in the producer-settlement fund; 
(5) Divide the resulting amount by the sum of the following for all handlers included in these computations:
(i) The total hundredweight of producer milk; and
(ii) The total hundredweight for which a value is computed pursuant to §1001.60(h); and
(6) Subtract not less than 4 cents nor more than 5 cents from the price computed pursuant to paragraph (b)(5) of this section. The result shall be known as the producer price differential for the month.

3. Section 1001.62 is amended by revising paragraphs (e) and (g) to read as follows:

§ 1001.62 Announcement of producer prices.

*e * * * *

(e) The producer butterfat price:
** * * * * * (g) The statistical uniform price computed by adding the following values:

(1) The Class III skim milk price computed in §1000.50(i) multiplied by .965;
(2) The producer butterfat price computed in §1001.61(a) multiplied by 3.5; and
(3) The producer price differential computed in §1001.61(b).

4. Section 1001.71 is amended by revising paragraphs (b)(2) and (3) to read as follows:

§ 1001.71 Payments to the producer-settlement fund.

*b * * * * (b) * * *

(2) An amount obtained by multiplying the total pounds of protein, other solids, and butterfat contained in producer milk by the protein, other solids, and producer butterfat prices respectively; and
(3) An amount obtained by multiplying the hundredweight, the pounds of skim milk, and the pounds of butterfat for which a value was computed pursuant to §1001.60(h) by the producer price differential, the Class III skim milk price, and the producer butterfat price, respectively, as adjusted pursuant to §1001.75 applicable at the location of the plant from which received.

5. Section 1001.73 is amended by revising paragraphs (a)(2)(ii) and (b)(3)(vi) to read as follows:

§ 1001.73 Payments to producers and to cooperative associations.

*a * * * * (a) * * *

(2) * * *
(ii) Multiply the pounds of butterfat received by the producer butterfat price for the month:
* * * * * * (b) * * *

(3) ** * * * * * (vi) Multiply the pounds of butterfat in Class III and Class IV milk by the respective butterfat prices for the month:
* * * * * *

PART 1005—MILK IN THE APPALACHIAN MARKETING AREA

1. Section 1005.60 is amended by revising paragraph (e) to read as follows:

§ 1005.60 Handler’s value of milk.

*e * * * * *(e) Multiply the Class I skim milk and Class I butterfat prices applicable at the location of the nearest unregulated supply plants from which an equivalent volume was received by the pounds of skim milk and butterfat in receipts of concentrated fluid milk products assigned to Class I pursuant to §1000.43(d) and §1000.44(a)(3)(i) and the corresponding step of §1000.44(b) and the pounds of skim milk and butterfat subtracted from Class I pursuant to §1000.44(a)(8) and the corresponding step of §1000.44(b), excluding such skim milk and butterfat in receipts of fluid milk products from an unregulated supply plant to the extent that an equivalent amount of skim milk or butterfat disposed of to such plant by handlers fully regulated under any Federal milk order is classified and priced as Class I milk and is not used as an offset for any other payment obligation under any order.
* * * * * *

2. Section 1005.61 is amended by revising paragraphs (a) and (b)(4) to read as follows:

§ 1005.61 Computation of uniform prices.

*a * * * * *(a) Uniform butterfat price. The uniform butterfat price per pound, rounded to the nearest one-hundredth cent, shall be computed by:
(1) Multiplying the pounds of butterfat in producer milk allocated to each class pursuant to §1000.44(b) by the respective class butterfat prices;
(2) Adding the butterfat value calculated in §1005.60(e) for other source milk allocated to Class I pursuant to §1000.43(d) and the steps of §1000.44(b) that correspond to §1000.44(a)(3)(i) and §1000.44(a)(8) by the Class I price; and
(3) Dividing the sum of paragraphs (a)(1) and (a)(2) of this section by the sum of the pounds of butterfat in

(b) * * *

(4) Subtract the value of the total pounds of butterfat for all handlers. The butterfat value shall be computed by multiplying the sum of the pounds of butterfat in producer milk and other source milk used to calculate the values in paragraphs (a)(1) and (a)(2) of this section by the butterfat price computed in paragraph (a) of this section:
* * * * * *

PART 1006—MILK IN THE FLORIDA MARKETING AREA

1. Section 1006.60 is amended by revising paragraph (e) to read as follows:

§ 1006.60 Handler’s value of milk.

*e * * * * *(e) Multiply the Class I skim milk and Class I butterfat prices applicable at the location of the nearest unregulated supply plants from which an equivalent volume was received by the pounds of skim milk and butterfat in receipts of concentrated fluid milk products assigned to Class I pursuant to §1000.43(d) and §1000.44(a)(3)(i) and the corresponding step of §1000.44(b) and the pounds of skim milk and butterfat subtracted from Class I pursuant to §1000.44(a)(8) and the corresponding step of §1000.44(b), excluding such skim milk and butterfat in receipts of fluid milk products from an unregulated supply plant to the extent that an equivalent amount of skim milk or butterfat disposed of to such plant by handlers fully regulated under any Federal milk order is classified and priced as Class I milk and is not used as an offset for any other payment obligation under any order; and
* * * * * *

2. Section 1006.61 is amended by revising paragraphs (a) and (b)(4) to read as follows:

§ 1006.61 Computation of uniform prices.

*a * * * * *(a) Uniform butterfat price. The uniform butterfat price per pound, rounded to the nearest one-hundredth cent, shall be computed by:
(1) Multiplying the pounds of butterfat in producer milk allocated to each class pursuant to §1000.44(b) by the respective class butterfat prices;
(2) Adding the butterfat value calculated in §1006.60(e) for other source milk allocated to Class I pursuant to §1000.43(d) and the steps of §1000.44(b) that correspond to §1000.44(a)(3)(i) and §1000.44(a)(8) by the Class I price; and
(3) Dividing the sum of paragraphs (a)(1) and (a)(2) of this section by the sum of the pounds of butterfat in
producer milk and other source milk used to calculate the values in paragraphs (a)(1) and (a)(2) of this section.

(b) * * *

(4) Subtract the value of the total pounds of butterfat for all handlers. The butterfat value shall be computed by multiplying the sum of the pounds of butterfat in producer milk and other source milk used to calculate the values in paragraphs (a)(1) and (a)(2) of this section by the butterfat price computed in paragraph (a) of this section;

PART 1007—MILK IN THE SOUTHEAST MARKETING AREA

1. Section 1007.60 is amended by revising paragraph (e) to read as follows:

§ 1007.60 Handler’s value of milk.

(e) Multiply the Class I skim milk and Class I butterfat prices applicable at the location of the nearest unregulated supply plants from which an equivalent volume was received by the pounds of skim milk and butterfat in receipts of concentrated fluid milk products assigned to Class I pursuant to § 1000.43(d) and § 1000.44(a)(3)(i) and the corresponding step of § 1000.44(b) and the pounds of skim milk and butterfat subtracted from Class I pursuant to § 1000.44(a)(6) and the corresponding step of § 1000.44(b), excluding such skim milk and butterfat in receipts of fluid milk products from an unregulated supply plant to the extent that an equivalent amount of skim milk or butterfat disposed of to such plant by handlers fully regulated under any Federal milk order is classified and priced as Class I milk and is not used as an offset for any other payment obligation under any order; and

* * * * *

2. Section 1007.61 is amended by revising paragraphs (a) and (b)(4) to read as follows:

§ 1007.61 Computation of uniform prices.

(a) Uniform butterfat price. The uniform butterfat price per pound, rounded to the nearest one-hundredth cent, shall be computed by:

(1) Multiplying the pounds of butterfat in producer milk allocated to each class pursuant to § 1000.44(b) by the respective class butterfat prices;

(2) Adding the butterfat value calculated in § 1007.60(e) for other source milk allocated to Class I pursuant to § 1000.43(d) and the steps of § 1000.44(b) that correspond to §§ 1000.43(d) and § 1000.44(a)(8) by the Class I price; and

(3) Dividing the sum of paragraphs (a)(1) and (a)(2) of this section by the sum of the pounds of butterfat in producer milk and other source milk used to calculate the values in paragraphs (a)(1) and (a)(2) of this section.

(b) * * *

(4) Subtract the value of the total pounds of butterfat for all handlers. The butterfat value shall be computed by multiplying the sum of the pounds of butterfat in producer milk and other source milk used to calculate the values in paragraphs (a)(1) and (a)(2) of this section by the butterfat price computed in paragraph (a) of this section;

* * * * *

PART 1030—MILK IN THE UPPER MIDWEST MARKETING AREA

1. Section 1030.60 is amended by revising paragraphs (c),(d),(2), and (i) to read as follows:

§ 1030.60 Handler’s value of milk.

(c) * * *

(3) Add an amount obtained by multiplying the pounds of butterfat in Class III by the Class III butterfat price.

(d) * * *

(2) Add an amount obtained by multiplying the pounds of butterfat in Class IV by the Class IV butterfat price.

(i) Multiply the Class I skim milk and Class I butterfat prices applicable at the location of the nearest unregulated supply plants from which an equivalent volume was received by the pounds of skim milk and butterfat in receipts of concentrated fluid milk products assigned to Class I pursuant to § 1000.43(d) and § 1000.44(a)(3)(i) and the corresponding step of § 1000.44(b) and the pounds of skim milk and butterfat subtracted from Class I pursuant to § 1000.44(a)(6) and the corresponding step of § 1000.44(b), excluding such skim milk and butterfat in receipts of fluid milk products from an unregulated supply plant to the extent that an equivalent amount of skim milk or butterfat disposed of to such plant by handlers fully regulated under any Federal milk order is classified and priced as Class I milk and is not used as an offset for any other payment obligation under any order; and

* * * * *

2. Section 1030.61 is amended by revising paragraphs (a)(3)(i) and § 1000.44(a)(8) by the Class I price; and

(3) Dividing the sum of paragraphs (a)(1) and (a)(2) of this section by the sum of the pounds of butterfat in producer milk and other source milk used to calculate the values in paragraphs (a)(1) and (a)(2) of this section.

* * * * *

§ 1030.61 Computation of producer butterfat price and producer price differential.

For each month the marketing administrator shall compute a producer butterfat price per pound of butterfat and a producer price differential per hundredweight for producer milk receipts. The report of any handler who has not made payments required pursuant to § 1030.71 for the preceding month shall not be included in the computation of these prices, and such handler’s report shall not be included in the computation for succeeding months until the handler has made full payment of outstanding monthly obligations. Subject to the conditions of this paragraph, the market administrator shall compute the producer butterfat price and the producer price differential in the following manner:

(a) Producer butterfat price. The producer butterfat price per pound, rounded to the nearest one-hundredth cent, shall be computed by:

(1) Multiplying the pounds of butterfat in producer milk allocated to each class pursuant to § 1000.44(b) by the respective class butterfat prices;

(2) Adding the butterfat value calculated in § 1030.60(i) for other source milk allocated to Class I pursuant to § 1000.44(d) and the steps of § 1000.44(b) that correspond to § 1000.44(a)(3)(i) and § 1000.44(a)(8) by the Class I price; and

(3) Dividing the sum of paragraphs (a)(1) and (a)(2) of this section by the sum of the pounds of butterfat in producer milk and other source milk used to calculate the values in paragraphs (a)(1) and (a)(2) of this section.

(b) Producer price differential. (1) Combine into one total the values computed pursuant to § 1030.60 for all handlers required to file reports prescribed in § 1030.30;

(2) Subtract the total of the values obtained:

(i) By multiplying the total pounds of protein, other solids, and butterfat contained in each handler’s producer milk for which an obligation was computed pursuant to § 1030.60(a) through (h) and § 1030.60(j) by the protein price, other solids price, and producer butterfat price, respectively, and the total value of the somatic cell adjustment pursuant to § 1030.30(a)(1) and (c)(1):

(ii) By multiplying each handler’s pounds of skim milk and butterfat for which a value is computed pursuant to § 1030.60(i) by the Class III skim milk price and the producer butterfat price, respectively;
(3) Add an amount equal to the minus location adjustments and subtract an amount equal to the plus location adjustments computed pursuant to §1030.75;

(4) Add an amount equal to not less than one-half of the unobligated balance in the producer-settlement fund;

(5) Divide the resulting amount by the sum of the following for all handlers included in these computations:

(i) The total hundredweight of producer milk; and

(ii) The total hundredweight for which a value is computed pursuant to §1030.60(i); and

(6) Subtract not less than 4 cents nor more than 5 cents from the price computed pursuant to paragraph (b)(5) of this section. The result shall be known as the producer price differential for the month.

3. Section 1030.62 is amended by revising paragraphs (e) and (h) to read as follows:

§1030.62 Announcement of producer prices.

* * * * *

(e) The producer butterfat price;

* * * * *

(h) The statistical uniform price computed by adding the following values:

(1) The Class III skim milk price computed in §1000.50(i) multiplied by .965;

(2) The producer butterfat price computed in §1030.61(a) multiplied by 3.5; and

(3) The producer price differential computed in §1030.61(b).

4. Section 1030.71 is amended by revising paragraphs (b)(2) and (b)(4) to read as follows:

§1030.71 Payments to the producer-settlement fund.

* * * * *

(b) * * *

(2) An amount obtained by multiplying the total pounds of protein, other solids, and butterfat contained in producer milk by the protein, other solids, and producer butterfat prices respectively;

* * * * *

(4) An amount obtained by multiplying the hundredweight, the pounds of skim milk, and the pounds of butterfat for which a value was computed pursuant to §1030.60(i) by the producer price differential, the Class III skim milk price, and the producer butterfat price, respectively, as adjusted pursuant to §1030.75 applicable at the location of the plant from which received.

5. Section 1030.73 is amended by revising paragraphs (a)(2)(ii), (c)(2)(v), and (c)(3)(ii) to read as follows:

§1030.73 Payments to producers and to cooperative associations.

(a) * * *

(2) * * *

(ii) The pounds of butterfat received times the producer butterfat price for the month;

* * * * *

(c) * * *

(2) * * *

(v) The pounds of butterfat in Class III and Class IV milk by the respective butterfat prices for the month;

* * * * *

(3) * * *

(ii) The pounds of butterfat received times the producer butterfat price for the month;

PART 1032—MILK IN THE CENTRAL MARKETING AREA

1. Section 1032.60 is amended by revising paragraphs (c)(3), (d)(2), and (i) to read as follows:

§1032.60 Handler’s value of milk.

* * * * *

(c) * * *

(3) Add an amount obtained by multiplying the pounds of butterfat in Class III by the Class III butterfat price.

(d) * * *

(2) Add an amount obtained by multiplying the pounds of butterfat in Class IV by the Class IV butterfat price.

* * * * *

(i) Multiply the Class I skim milk and Class I butterfat prices applicable at the location of the nearest unregulated supply plants from which an equivalent volume was received by the pounds of skim milk and butterfat in receipts of concentrated fluid milk products assigned to Class I pursuant to §1000.43(d) and §1000.44(a)(3)(i) and the corresponding step of §1000.44(b) and the pounds of skim milk and butterfat subtracted from Class I pursuant to §1000.44(a)(6) and the corresponding step of §1000.44(b), excluding such skim milk and butterfat in receipts of fluid milk products from an unregulated supply plant to the extent that an equivalent amount of skim milk or butterfat disposed of to such plant by handlers fully regulated under any Federal milk order is classified and priced as Class I milk and is not used as an offset for any other payment obligation under any order.

* * * * *

2. Section 1032.61 is revised to read as follows:

§1032.61 Computation of producer butterfat price and producer price differential.

For each month the market administrator shall compute a producer butterfat price per pound of butterfat and a producer price differential per hundredweight for producer milk receipts. The report of any handler who has not made payments required pursuant to §1032.71 for the preceding month shall not be included in the computation of these prices, and such handler’s report shall not be included in the computation for succeeding months until the handler has made full payment of outstanding monthly obligations. Subject to the conditions of this paragraph, the market administrator shall compute the producer butterfat price and the producer price differential in the following manner:

(a) Producer butterfat price. The producer butterfat price per pound, rounded to the nearest one-hundredth cent, shall be computed by:

(1) Multiplying the pounds of butterfat in producer milk allocated to each class pursuant to §1000.44(b) by the respective class butterfat prices;

(2) Adding the butterfat value calculated in §1032.60(i) for other source milk allocated to Class I pursuant to §1000.43(d) and the steps of §1000.44(b) that correspond to §1000.44(a)(3)(i) and §1000.44(a)(8) by the Class I price; and

(3) Dividing the sum of paragraphs (a)(1) and (a)(2) of this section by the sum of the pounds of butterfat in producer milk and other source milk used to calculate the values in paragraphs (a)(1) and (a)(2) of this section.

(b) Producer price differential. (1) Combine into one total the values computed pursuant to §1032.60 for all handlers required to file reports prescribed in §1032.30;

(2) Subtract the total of the values obtained:

(i) By multiplying the total pounds of protein, other solids, and butterfat contained in each handler’s producer milk for which an obligation was computed pursuant to §1032.60 through (h) and §1032.60(j) by the protein price, other solids price, and producer butterfat price, respectively, and the total value of the somatic cell adjustment pursuant to §1032.30(a)(1) and (c)(1);

(ii) By multiplying each handler’s pounds of skim milk and butterfat for which a value is computed pursuant to §1032.60(i) by the Class III skim milk price and the producer butterfat price, respectively;
(3) Add an amount equal to the minus location adjustments and subtract an amount equal to the plus location adjustments computed pursuant to §1032.75:
(4) Add an amount equal to not less than one-half of the unobligated balance in the producer-settlement fund;
(5) Divide the resulting amount by the sum of the following for all handlers included in these computations:
  (i) The total hundredweight of producer milk; and
  (ii) The total hundredweight for which a value is computed pursuant to §1032.60(i); and
(6) Subtract not less than 4 cents nor more than 5 cents from the price computed pursuant to paragraph (b)(5) of this section. The result shall be known as the producer price differential for the month.
3. Section 1032.62 is amended by revising paragraphs (e) and (h) to read as follows:

§ 1032.62 Announcement of producer prices.
* * * *
(e) The producer butterfat price; * * * *

(h) The statistical uniform price computed by adding the following values:
  (1) The Class III skim milk price computed in §1000.50(i) multiplied by .965;
  (2) The producer butterfat price computed in §1032.61(a) multiplied by 3.5; and
  (3) The producer price differential computed in §1032.61(b).
4. Section 1032.71 is amended by revising paragraphs (b)(2) and (4) to read as follows:

§ 1032.71 Payments to the producer-settlement fund.
* * * *
(b) * * *

(2) An amount obtained by multiplying the total pounds of protein, other solids, and butterfat contained in producer milk by the protein, other solids, and producer butterfat prices respectively:
* * * *

(4) An amount obtained by multiplying the hundredweight, the pounds of skim milk, and the pounds of butterfat for which a value was computed pursuant to §1032.60(i) by the producer price differential, the Class III skim milk price, and the producer butterfat price, respectively, as adjusted pursuant to §1032.75 applicable at the location of the plant from which received.

5. Section 1032.73 is amended by revising paragraphs (a)(2)(ii), (c)(2)(v), and (c)(3)(ii) to read as follows:

§ 1032.73 Payments to producers and to cooperative associations.
(a) * * *

(2) * * *

(ii) The pounds of butterfat received times the producer butterfat price for the month;
* * *

(c) * * *

(2) * * *

(v) The pounds of butterfat in Class III and Class IV milk by the respective butterfat prices for the month;
* * *

(3) * * *

(ii) The pounds of butterfat received times the producer butterfat price for the month;
* * *

§ 1033—MILK IN THE MIDEAST MARKETING AREA
1. Section 1033.60 is amended by revising paragraphs (c)(3), (d)(2), and (i) to read as follows:

§ 1033.60 Handler’s value of milk.
* * *

(c) * * *

(3) Add an amount obtained by multiplying the pounds of butterfat in Class III by the Class III butterfat price.
(d) * * *

(2) Add an amount obtained by multiplying the pounds of butterfat in Class IV by the Class IV butterfat price.
* * *

(i) Multiply the Class I skim milk and Class I butterfat prices applicable at the location of the nearest unregulated supply plants from which an equivalent volume was received by the pounds of skim milk and butterfat in receipts of concentrated fluid milk products assigned to Class I pursuant to §1000.43(d) and §1000.44(a)(3)(i) and the corresponding step of §1000.44(b) and the pounds of skim milk and butterfat subtracted from Class I pursuant to §1000.44(a)(8) and the corresponding step of §1000.44(b), excluding such skim milk and butterfat in receipts of fluid milk products from an unregulated supply plant to the extent that an equivalent amount of skim milk or butterfat disposed of to such plant by handlers fully regulated under any Federal milk order is classified and priced as Class I milk and is not used as an offset for any other payment obligation under any order.
* * *

2. Section 1033.61 is revised to read as follows:

§ 1033.61 Computation of producer butterfat price and producer price differential.

For each month the market administrator shall compute a producer butterfat price per pound of butterfat and a producer price differential per hundredweight for producer milk receipts. The report of any handler who has not made payments required pursuant to §1033.71 for the preceding month shall not be included in the computation of these prices, and such handler’s report shall not be included in the computation for succeeding months until the handler has made full payment of outstanding monthly obligations. Subject to the conditions of this paragraph, the market administrator shall compute the producer butterfat price and the producer price differential in the following manner:

(a) *Producer butterfat price.* The producer butterfat price per pound, rounded to the nearest one-hundredth cent, shall be computed by:

(1) Multiplying the pounds of butterfat in producer milk allocated to each class pursuant to §1000.44(b) by the respective class butterfat prices;

(2) Adding the butterfat value calculated in §1033.60(i) for other source milk allocated to Class I pursuant to §1000.43(d) and the steps of §1000.44(b) that correspond to §1000.44(a)(3)(i) and §1000.44(a)(8) by the Class I price; and

(3) Dividing the sum of paragraphs (a)(1) and (a)(2) of this section by the sum of the pounds of butterfat in producer milk and other source milk used to calculate the values in paragraphs (a)(1) and (a)(2) of this section.

(b) *Producer price differential.* (1) Combine into one total the values computed pursuant to §1033.60 for all handlers required to file reports prescribed in §1033.30;

(2) Subtract the total of the values obtained:

(i) By multiplying the total pounds of protein, other solids, and butterfat contained in each handler’s producer milk for which an obligation was computed pursuant to §1033.60(a) through (h) and §1033.60(j) by the protein price, other solids price, and producer butterfat price, respectively, and the total value of the somatic cell adjustment pursuant to §1033.30(a)(1) and (c)(1);

(ii) By multiplying each handler’s pounds of skim milk and butterfat for which a value is computed pursuant to §1033.60(i) by the Class III skim milk price and the producer butterfat price, respectively;
§ 1033.62 Announcement of producer prices.

* * * * *

(e) The producer butterfat price;

* * * * *

(h) The statistical uniform price computed by adding the following values:

(1) The Class III skim milk price computed in § 1000.44(a)(8) and the location of the nearest unregulated supply plant to the plant by handlers fully regulated under any Federal milk order is classified and priced as Class I milk and is not used as an offset for any other payment obligation under any order.

* * * * *

§ 1033.71 Payments to the producer-settlement fund.

* * * * *

(b) * * *

(2) An amount obtained by multiplying the total pounds of protein, other solids, and butterfat contained in producer milk for which an obligation was computed pursuant to § 1000.44(b) that correspond to § 1000.44(a)(3)(i) and § 1000.44(a)(8) by the corresponding step of § 1000.44(b) that correspond to § 1000.44(a)(3)(i) and § 1000.44(a)(8) by the Class I price; and

(3) Dividing the sum of paragraphs (a)(1) and (a)(2) of this section by the sum of the pounds of butterfat in producer milk and other source milk used to calculate the values in paragraphs (a)(1) and (a)(2) of this section.

(b) Producer price differential.

(1) Combine into one total the values computed pursuant to § 1124.60 for all handlers required to file reports prescribed in § 1124.30;

(2) Subtract the total of the values obtained:

(i) By multiplying the total pounds of protein, other solids, and butterfat contained in each handler’s producer milk for which an obligation was computed pursuant to § 1124.60(a) through (g) and § 1124.60(i) by the protein price, other solids price, and butterfat price, respectively;

(ii) By multiplying each handler’s pounds of skim milk and butterfat for which a value is computed pursuant to § 1124.60(h) by the Class III skim milk price and the producer butterfat price, respectively.

(3) Add an amount equal to the minus location adjustments and subtract an amount equal to the plus location adjustments computed pursuant to § 1124.75;

(4) Add an amount equal to not less than one-half of the unobligated balance in the producer-settlement fund;
§ 1124.73 Payments to producers and to cooperative associations.

For each month, the market administrator shall compute a producer butterfat price per pound of butterfat and a producer price differential per pound of butterfat. The report of any handler who has not made payments required pursuant to §1126.71 for the preceding month shall not be included in these computations, and such handler’s report shall not be included in the computation for succeeding months until the handler has made full payment of outstanding monthly obligations. Subject to the aforementioned conditions, the market administrator shall compute the producer butterfat price and the producer price differential in the following manner:

(a) **Producer butterfat price.** The producer butterfat price per pound, rounded to the nearest one-hundredth cent, shall be computed by:

1. Multiplying the pounds of butterfat in producer milk allocated to each class pursuant to §1000.44(b) by the respective class butterfat prices;

2. Adding the butterfat value calculated in §1126.60(i) for other source milk allocated to Class I pursuant to §1000.43(d) and the steps of §1000.44(b) that correspond to §1000.44(a)(3)(i) and §1000.44(a)(8) by the Class I price;

3. Dividing the sum of paragraphs (a)(1) and (a)(2) of this section by the sum of the pounds of butterfat in producer milk and other source milk used to calculate the values in paragraphs (a)(1) and (a)(2) of this section.

(b) **Producer price differential.**

(1) Combine into one total the values computed pursuant to §1126.60 for all handlers required to file reports prescribed in §1126.30;

(2) Subtract the total of the values obtained:

(i) By multiplying the total pounds of protein, other solids, and butterfat contained in each handler’s producer milk for which an obligation was computed pursuant to §1126.60(a) through (h) and §1126.60(j) by the protein price, other solids price, and producer butterfat price, respectively, and the total value of the somatic cell adjustment pursuant to §1126.30(a)(1) and (c)(1);

(ii) By multiplying each handler’s pounds of skim milk and butterfat for which a value is computed pursuant to §1126.60(i) by the Class III skim milk price and the producer butterfat price, respectively;

3. Add an amount equal to the minus location adjustments and subtract an amount equal to the plus location adjustments computed pursuant to §1126.75;

4. Add an amount equal to not less than one-half of the unobligated balance in the producer-settlement fund;
(5) Divide the resulting amount by the sum of the following for all handlers included in these computations:
(i) The total hundredweight of producer milk; and
(ii) The total hundredweight for which a value is computed pursuant to §1126.60(i); and
(6) Subtract not less than 4 cents nor more than 5 cents from the price computed pursuant to paragraph (b)(5) of this section. The result shall be known as the producer price differential for the month.

3. Section 1126.62 is amended by revising paragraphs (e) and (h) to read as follows:

§1126.62 Announcement of producer prices.
* * * * *
(e) The producer butterfat price;
* * * * *
(h) The statistical uniform price computed by adding the following values:
(1) The Class III skim milk price computed in §1000.50(i) multiplied by .965;
(2) The producer butterfat price computed in §1126.61(a) multiplied by 3.5; and
(3) The producer price differential computed in §1126.61(b).

4. Section 1126.71 is amended by revising paragraphs (b)(2) and (4) to read as follows:

§1126.71 Payments to the producer-settlement fund.
* * * * *
(b) * * *
(2) An amount obtained by multiplying the total pounds of protein, other solids, and butterfat contained in producer milk by the protein, other solids, and producer butterfat prices respectively;
* * * * *
(4) An amount obtained by multiplying the hundredweight, the pounds of skim milk, and the pounds of butterfat for which a value was computed pursuant to §1126.60(i) by the producer price differential, the Class III skim milk price, and the producer butterfat price, respectively, as adjusted pursuant to §1126.75 applicable at the location of the plant from which received.

5. Section 1126.73 is amended by revising paragraphs (a)(2)(ii) and (b)(3)(v) to read as follows:

§1126.73 Payments to producers and to cooperative associations.
(a) * * *
(2) * * *
(ii) Multiply the pounds of butterfat received times the producer butterfat price for the month;
* * * * *
(b) * * *
(3) * * *
(v) The pounds of butterfat in Class III and Class IV milk by the respective butterfat prices for the month;
* * * * *

PART 1131—MILK IN THE ARIZONA-LAS VEGAS MARKETING AREA

1. Section 1131.60 is amended by revising paragraph (e) to read as follows:

§1131.60 Handler's value of milk.
* * * * *
(e) Multiply the Class I skim milk and Class I butterfat prices applicable at the location of the nearest unregulated supply plants from which an equivalent volume was received by the pounds of skim milk and butterfat in receipts of concentrated fluid milk products assigned to Class I pursuant to §1000.43(d) and §1000.44(a)(3)(i) and the corresponding step of §1000.44(b) and the pounds of skim milk and butterfat subtracted from Class I pursuant to §1000.44(a)(6) and the corresponding step of §1000.44(b), excluding such skim milk and butterfat in receipts of fluid milk products from an unregulated supply plant to the extent that an equivalent amount of skim milk or butterfat disposed of to such plant by handlers fully regulated under any Federal milk order is classified and priced as Class I milk and is not used as an offset for any other payment obligation under any order.
* * * * *

2. Section 1131.61 is amended by revising paragraphs (a) and (b)(4) to read as follows:

§1131.61 Computation of uniform prices.
* * * * *
(a) Uniform butterfat price. The uniform butterfat price per pound, rounded to the nearest one-hundredth cent, shall be computed by:
(1) Multiplying the pounds of butterfat in producer milk allocated to each class pursuant to §1000.44(b) by the respective class butterfat prices;
(2) Adding the butterfat value calculated in §1131.60(e) for other source milk allocated to Class I pursuant to §1000.44(d) and the steps of §1000.44(b) that correspond to §1000.44(a)(3)(i) and §1000.44(a)(8) by the Class I price; and
(3) Dividing the sum of the values:
* * * * *
used to calculate the values in paragraphs (a)(1) and (a)(2) of this section.
(b) * * *
(4) Subtract the value of the total pounds of butterfat for all handlers. The butterfat value shall be computed by multiplying the sum of the pounds of butterfat in producer milk and other source milk used to calculate the values in paragraphs (a)(1) and (a)(2) of this section by the butterfat price computed in paragraph (a) of this section;
* * * * *

PART 1135—MILK IN THE WESTERN MARKETING AREA

1. Section 1135.60 is amended by revising paragraphs (c)(3), (d)(2) and (h) to read as follows:

§1135.60 Handler's value of milk.
* * * * *
(c) * * *
(3) Add an amount obtained by multiplying the pounds of butterfat in Class III by the Class III butterfat price.
(d) * * *
(2) Add an amount obtained by multiplying the pounds of butterfat in Class IV by the Class IV butterfat price.
* * * * *
(h) Multiply the Class I skim milk and Class I butterfat prices applicable at the location of the nearest unregulated supply plants from which an equivalent volume was received by the pounds of skim milk and butterfat in receipts of concentrated fluid milk products assigned to Class I pursuant to §1000.43(d) and §1000.44(a)(3)(i) and the corresponding step of §1000.44(b) and the pounds of skim milk and butterfat subtracted from Class I pursuant to §1000.44(a)(8) and the corresponding step of §1000.44(b), excluding such skim milk and butterfat in receipts of fluid milk products from an unregulated supply plant to the extent that an equivalent amount of skim milk or butterfat disposed of to such plant by handlers fully regulated under any Federal milk order is classified and priced as Class I milk and is not used as an offset for any other payment obligation under any order.
* * * * *

2. Section 1135.61 is revised to read as follows:

§1135.61 Computation of producer butterfat price and producer price differential.

For each month, the market administrator shall compute the producer butterfat price per pound of butterfat and a producer price differential per hundredweight. The report of any
handler who has not made payments required pursuant to §1135.71 for the preceding month shall not be included in these computations, and such handler's report shall not be included in the computation for succeeding months until the handler has made full payment of outstanding monthly obligations.

Subject to the conditions of this paragraph, the market administrator shall compute the producer butterfat price and the producer price differential in the following manner:

(a) **Producer butterfat price.** The producer butterfat price per pound, rounded to the nearest one-hundredth cent, shall be computed by:

(1) Multiplying the pounds of butterfat in producer milk allocated to each class pursuant to §1000.44(b) by the respective class butterfat prices;

(2) Adding the butterfat value calculated in §1135.60(h) for other source milk allocated to Class I pursuant to §1000.43(d) and the steps of §1000.44(b) that correspond to §1000.44(a)(3)(i) and §1000.44(a)(8) by the Class I price; and

(3) Dividing the sum of paragraphs (a)(1) and (a)(2) of this section by the sum of the pounds of butterfat in producer milk and other source milk used to calculate the values in paragraphs (a)(1) and (a)(2) of this section.

(b) **Producer price differential.** (1) Combine into one total the values computed pursuant to §1135.60 for all handlers required to file reports prescribed in §1135.30;

(2) Subtract the total of the values obtained;

(i) By multiplying the total pounds of protein, other solids, and butterfat contained in each handler's producer milk for which an obligation was computed pursuant to §1135.60(a) through (g) and §1135.60(i) by the protein price, other solids price, and producer butterfat price, respectively;

(ii) By multiplying each handler's pounds of skim milk and butterfat for which a value is computed pursuant to §1135.60(h) by the Class III skim milk price and the producer butterfat price, respectively;

(3) Add an amount equal to the minus location adjustments and subtract an amount equal to the plus location adjustments computed pursuant to §1135.75;

(4) Add an amount equal to not less than one-half of the unobligated balance in the producer-settlement fund;

(5) Divide the resulting amount by the sum of the following for all handlers included in these computations:

(i) The total hundredweight of producer milk; and

(ii) The total hundredweight for which a value is computed pursuant to §1135.60(h); and

(6) Subtract not less than 4 cents nor more than 5 cents from the price computed pursuant to paragraph (b)(5) of this section. The result shall be known as the **producer price differential** for the month.

3. Section 1135.62 is amended by revising paragraphs (e) and (g) to read as follows:

§ 1135.62 Announcement of producer prices.

* * * * *

(e) The producer butterfat price;

* * * * *

(g) The statistical uniform price computed by adding the following values:

(i) The Class III skim milk price computed in §1000.50(i) multiplied by .965;

(ii) The pounds of butterfat received times the producer butterfat price for the month;

* * * * *

(b) * * *

(v) The pounds of butterfat in Class III and Class IV milk times the respective butterfat prices for the month;


Enrique E. Figueroa,
Deputy Under Secretary, Marketing and Regulatory Programs.

[FR Doc. 00–32930 Filed 12–27–00; 8:45 am]

BILLING CODE 3410–02–P
Part IV

Social Security Administration

20 CFR Part 411
The Ticket to Work and Self-Sufficiency Program; Proposed Rule
The Ticket to Work and Self-Sufficiency Program

AGENCY: Social Security Administration.

ACTION: Notice of proposed rulemaking.

SUMMARY: We are proposing rules to implement the new “Ticket to Work and Self-Sufficiency Program” (Ticket to Work program) authorized by the Ticket to Work and Work Incentives Improvement Act of 1999. The Ticket to Work program will provide disabled beneficiaries with expanded access to employment services, vocational rehabilitation services, or other support services. We will pay the providers of those services after the beneficiaries achieve certain levels of work.

DATES: To be sure that your comments are considered, we must receive them no later than February 26, 2001.

ADDRESSES: Comments should be submitted:

• In writing, to the Commissioner of Social Security, P.O. Box 17703, Baltimore, MD 21235–7703;
• By telefax to (410) 966–2830;
• By E-mail to regulations@ssa.gov; or
• Delivered to the Office of Process and Innovation Management, Social Security Administration, 2109 West Low Rise Building, Baltimore, Maryland 21235–6401, between 8 a.m. and 4:30 p.m. on regular business days. You may also inspect comments during these same hours by making arrangements with the contact person shown below.

FOR FURTHER INFORMATION CONTACT: Geoffrey Funk, Team Leader, Legislative Implementation Team, Office of Employment Support Programs, Social Security Administration, 6401 Security Boulevard, Baltimore, Maryland 21235–6401. Call (410) 965–9010 or TTY 1–(800) 988–5906 for information about these proposed rules. For information on eligibility or filing for benefits, call our national toll-free number, 1–(800) 772–1213 or TTY 1–(800) 325–0778. You may also contact SSA Online at www.ssa.gov.

SUPPLEMENTARY INFORMATION:

Background

The National Organization on Disability/Harris Survey of 1998 found that only 29 percent of individuals with disabilities were working full- or part-time. From 1986 to 1999, the number of individuals receiving disability benefits rose 80 percent, with about half receiving Social Security disability benefits and half Supplemental Security Income (SSI) benefits. Among the factors contributing to this increase were expanded eligibility for benefits, SSA’s outreach efforts, the recession of the late 1980’s and early 1990’s, greater demand for benefits due to the lack of adequate, affordable health care insurance, and the aging of the work force. The Federal government spent $51.3 billion on Social Security disability benefits in 1999, and $22.9 billion in SSI. Many States use State funds to supplement the benefits of SSI beneficiaries.

According to the U.S. General Accounting Office, less than 1 percent of Social Security disability and SSI beneficiaries leave the Social Security and SSI rolls each year as a result of paid employment. Of those who leave, about one-third return within 3 years. If just one-half of one percent of the current Social Security disability and SSI recipients were to cease receiving benefits as a result of engaging in self-supporting employment, savings in cash assistance would total $3.5 billion over the work-life of those individuals. These proposed rules are intended to expand the options available for Social Security disability beneficiaries and disabled or blind SSI beneficiaries to access vocational rehabilitation services, employment services, and other support services that are necessary for such beneficiaries to obtain, regain or maintain employment that reduces their dependency on cash assistance. We expect that the expansion of these options and the creation of new work incentives in the Ticket to Work and Work Incentives Improvement Act of 1999 (TWWIIA) will remove some of the disincentives that many beneficiaries with disabilities face when they attempt to work or, if already working, continue working or increase their work effort. If more beneficiaries with disabilities engage in self-supporting employment, the net result will be a reduction in the Social Security and SSI disability rolls and savings to the Social Security Trust Fund and general revenues.

Ticket to Work and Work Incentives Improvement Act of 1999

On December 17, 1999, President Clinton signed into law the Ticket to Work and Work Incentives Improvement Act of 1999 (Public Law 106–170). In section 2(b) of TWWIIA, the Congress states that TWWIIA has four basic purposes. In general, these are:

—To provide health care and employment preparation and placement services to individuals with disabilities that will enable those individuals to reduce their dependence on cash benefit programs.
—To encourage States to adopt the option of allowing individuals with disabilities to purchase Medicaid coverage that is necessary to enable such individuals to maintain employment.
—To provide individuals with disabilities the option of maintaining Medicare coverage while working.
—To establish a “Ticket to Work and Self-Sufficiency Program” that allows Social Security disability and disabled or blind SSI recipients to seek the employment services, vocational rehabilitation services, and other support services needed to obtain, regain, or maintain employment and reduce their dependence on cash benefit programs.

Section 101(a) of TWWIIA amends part A of title XI of the Social Security Act (the Act) by adding a new section 1148, The Ticket to Work and Self-Sufficiency Program (Ticket to Work program). The purpose of the Ticket to Work program is to expand the universe of service providers available to beneficiaries with disabilities who are seeking employment services, vocational rehabilitation services, and other support services to assist them in obtaining, regaining and maintaining self-supporting employment.

The Social Security Administration is required to develop the regulations necessary to implement TWWIIA and to provide details regarding the Ticket to Work program. Section 1148(l) of the Act requires the Commissioner to prescribe such regulations as are necessary to carry out the provisions of section 1148 of the Act. In addition, section 101(e) of TWWIIA requires the Commissioner of Social Security to prescribe such regulations as are necessary to implement the amendments made by section 101. We are proposing these regulations to address a number of areas where specific policy decisions were left to the discretion of the Commissioner.

Under the Ticket to Work program, the Commissioner may issue tickets to Social Security disability beneficiaries and disabled and blind SSI beneficiaries. Each beneficiary will have the option of using his or her ticket to obtain services from a provider known as an employment network (EN). The beneficiary will choose the EN, and the EN will provide employment services, vocational rehabilitation services, and other support services to assist the beneficiary in obtaining, regaining and maintaining self-supporting...
employment. ENs will also be able to choose who they serve.

The Commissioner’s intent in developing the proposed rules for the Ticket to Work program is to allow service providers that have traditionally provided employment services, vocational rehabilitation services and other support services, as well as other types of entities, to qualify as ENs and serve beneficiaries with disabilities under the program. The expansion of options available to obtain these services will provide beneficiaries with real choices in getting the services they need to obtain, regain, or maintain employment.

**Public Education Forums and Conferences**

Immediately following passage of TWWIIA, we began working with the U.S. Departments of Health and Human Services, Education, and Labor, as well as the Presidential Task Force on the Employment of Adults with Disabilities, the President’s Committee on Employment of People with Disabilities, and the National Council on Disability. These Federal partners joined together to plan and conduct a series of public education forums. The purpose of the forums was to increase the awareness of public disability programs among individuals with disabilities, their families and representatives, and service providers. The forums focused on Federal and State employment-related policies and programs for people with disabilities.

Forums were scheduled in eleven major cities across the country. Those cities were Baltimore, MD (December 12, 1999); Kansas City, MO (February 2, 2000); Durham, NC (March 9, 2000); Phoenix, AZ (March 30, 2000); New York, NY (April 6, 2000); Austin, TX (May 17, 2000); Seattle, WA (June 13, 2000); Rochester, MA (June 26, 2000); Chicago, IL (August 1, 2000); Harrisburg, PA (August 15, 2000); and Denver, CO (September 13–14, 2000).

Representatives from many national and community-based organizations (e.g., the SSI Coalition, Virginia Commonwealth University, Disability Rights Education and Defense Fund, the National Brain Injury Association, Consortium for Citizens with Disabilities, Robert Wood Johnson Foundation, National Council on Independent Living, Capstone Group, and State representatives from the Developmental Disabilities Councils, the State Independent Living Councils, and the Governors’ Committees on Employment of People with Disabilities) participated in these forums.

The forums provided participants with both information and an opportunity for discussion. Topics included: SSA customer services and work incentives; State health care systems and models; and employment initiatives of the Departments of Education, Labor, and Health and Human Services.

The forums were also used as an opportunity to share information about TWWIIA and conduct exploratory discussions about policy issues relating to the implementation of the provisions in TWWIIA that were left to the Commissioner to interpret. New models where State and local systems are working together to serve their common customers with disabilities were highlighted.

SSA representatives have also been involved in meetings and conferences on the national, regional, State, and local levels. These included SSA-sponsored forums in Chicago, San Francisco, Dallas, Denver, and Philadelphia conducted in January and February 2000, which focused on the Ticket to Work program. At these meetings and conferences, SSA representatives made presentations on TWWIIA, facilitating discussion and obtaining recommendations that were considered in developing the provisions of the Ticket to Work program that are being addressed in these proposed rules.

**SSA’s Programs for Rehabilitation Services Prior to Implementation of the Ticket to Work Program**

In titles II and XVI of the Social Security Act, Congress provided that we promptly refer individuals applying for or determined eligible for Social Security disability benefits or SSI benefits based on disability or blindness to State vocational rehabilitation (VR) agencies for necessary rehabilitation services. Under the statute and by regulations, if a State VR agency does not serve a beneficiary whom we referred, we may use other public or private agencies, organizations, institutions or individuals to provide services. Under our regulations, these other providers of services are known as alternate participants. We are authorized under the Act to pay State VR agencies and alternate participants for the reasonable and necessary costs of services provided to Social Security disability beneficiaries and disabled and blind SSI beneficiaries under specific circumstances. The most frequent circumstance permitting payment under the Act is when the services provided result in the beneficiary performing substantial gainful activity (SGA) for a period of at least 9 continuous months.

These programs for referral and reimbursement for VR services are provided for in sections 222(a) and (d), and sections 1615(a), (d), and (e) of the Act.

Section 101(b) of TWWIIA makes a number of conforming amendments to the Act, which require amendments to existing regulations that implement these statutory provisions. As we gradually implement the Ticket to Work program in States selected by the Commissioner, the provisions of the Act for referring beneficiaries to State VR agencies will cease to be in effect in those States as provided in sections 101(b), (c) and (d) of TWWIIA. Additionally, the use of alternate participants under the title II and title XVI vocational rehabilitation reimbursement programs will be phased out in the States as the Ticket to Work program is implemented, as authorized under section 101(d)(5) of TWWIIA.

Under sections 222 and 1615 of the Act, the Commissioner is authorized to impose sanctions (i.e., make deductions from Social Security disability benefits or suspend SSI benefits) with respect to any beneficiary who refused, without good cause, to accept rehabilitation services made available by a State VR agency or an alternate participant.

The proposed rules to implement these statutory changes will be published in the Federal Register at a later date.

Section 101(b) of TWWIIA also amends sections 225(b)(1) and 631(a)(6)(A) of the Act by striking “a program of vocational rehabilitation services” and inserting “a program consisting of the Ticket to Work and Self-Sufficiency Program under section 1148 or another program of vocational rehabilitation services, employment services, or other support services”.

Under existing law, SSA continues to pay disability benefits to individuals who recover medically while participating in an approved program of vocational rehabilitation services if the Commissioner determines that continuation in or completion of the program will increase the likelihood that the individual will be permanently removed from the disability rolls. The proposed rules to implement the expanded definition discussed above will be published in the Federal Register at a later date.

We will also publish at a later date in the Federal Register the rule on implementation of section 112 of the TWWIIA, Expedited Reinstatement of Disability Benefits.
General Goals of the Ticket to Work Program

The Ticket to Work program will enhance the range of choices available to Social Security disability and disabled and blind SSI beneficiaries when they are seeking employment services, VR services and other support services to obtain, regain or maintain self-supporting employment. The coordinated and interrelated public policy embodied in various provisions of TWWIIA will remove several disincentives to employment faced by beneficiaries with disabilities. The Ticket to Work program will increase beneficiaries’ access to public and private providers to obtain employment services, VR services, and other support services. As a result, the Ticket to Work program, together with other provisions of TWWIIA, should substantially increase the number of beneficiaries who increase their work effort and leave the Social Security or SSI disability rolls due to income from employment.

In addition to providing the increased opportunity for these beneficiaries to obtain services when they seek employment, TWWIIA may result in substantial savings for the Federal government and State governments. Not only should there be an increase in the number of beneficiaries leaving the Social Security and SSI disability rolls due to work or earnings, some individuals will secure work with employers who offer group health coverage, thereby reducing Medicaid and Medicare expenses. Earned income should also yield tax receipts while reducing expenses in Social Security disability and disabled and blind SSI benefits, food stamps, HUD rent subsidies, and veterans benefits.

Improved employment rates of individuals with disabilities should increase the independence of such individuals and strengthen our communities and workforce.

Ticket to Work Program

Section 1148 of the Act, which was added by section 101(a) of TWWIIA, directs the Commissioner of Social Security (the Commissioner) to establish a Ticket to Work and Self-Sufficiency Program. Section 1148(b) of the Act authorizes the Commissioner to issue tickets to disabled beneficiaries. Beneficiaries may choose among public or private service providers that have been approved by SSA to function as ENs under the program to obtain employment services, vocational rehabilitation services, or other support services to assist them in obtaining, regaining or maintaining employment that will reduce their dependence on cash benefits. Beneficiaries will also have the option of choosing to obtain services from their State VR agency. The overall purpose of the Ticket to Work program is to expand the universe of options available to beneficiaries with disabilities for obtaining such services.

Section 1148(d)(1) of the Act authorizes the Commissioner to conduct a competitive bidding process and enter into an agreement with one or more organizations to serve as a Program Manager (PM) to assist SSA in administering the Ticket to Work program.

The PM will recruit and recommend for selection by the Commissioner ENs for service under the program; monitor all ENs serving in the geographic areas covered under the PM’s agreement to ensure that adequate choices of services are made available to beneficiaries; assure that payment by the Commissioner to ENs is warranted; facilitate access by beneficiaries to ENs; ensure the availability of adequate services; and ensure that sufficient ENs are available and that each beneficiary receiving services under the program has reasonable access to employment services, vocational rehabilitation services, and other support services. Section 1148(d)(4) of the Act directs the Commissioner to select and enter into agreements with service providers that are willing to function as ENs and assume responsibility for the coordination and delivery of employment services, vocational rehabilitation services, and other support services to beneficiaries with disabilities under the Ticket to Work program. A beneficiary with a ticket may assign his or her ticket to any provider that is serving as an EN under the Ticket to Work program and is willing to take the assignment.

Section 1148(l) of the Act requires the Commissioner to prescribe such regulations as are necessary to carry out the provisions of section 1148. In addition, section 101(e) of TWWIIA requires the Commissioner to prescribe such regulations as are necessary to implement the amendments made by section 101 of TWWIIA. The regulations proposed in this notice address those areas which must be regulated in order to begin implementing the Ticket to Work program. Additional regulations necessary for the ongoing implementation of the program will be issued in the Federal Register at a later date. For example, proposed performance measures to be used in conducting site visits as necessary to provide for effective quality assurance in the provision of services by ENs will need to be developed and published in the Federal Register for comment. Refer to the section near the end of this Supplementary Information, titled “Additional Matters for Comment,” for more information on provisions that will be addressed in future regulations.

Proposed Regulations

We are proposing to add a new part 411 to chapter III of title 20 of the Code of Federal Regulations to provide the rules for the Ticket to Work program. The new part 411 is divided into the following subparts.

Subpart A—Introduction

Subpart A of these proposed rules provides an introduction to the rules in the new part 411. Proposed § 411.100 provides an overview of the proposed rules in part 411. Proposed § 411.105 describes the purpose of the Ticket to Work program. Proposed § 411.110 explains that the Ticket to Work program will be implemented in graduated phases in sites around the country as required by section 101(d) of TWWIIA. Proposed § 411.115 provides definitions of terms used in part 411.

Subpart B—Tickets Under the Ticket to Work Program

Subpart B of these proposed rules describes what a ticket is and explains who is eligible to receive a ticket.

Proposed § 411.120 explains that a ticket is a document that provides evidence of the Commissioner’s agreement to pay an EN milestone or outcome payments for services to beneficiaries under the Ticket to Work program. Proposed § 411.125 states the following requirements, among others, for eligibility to receive a ticket: a title II beneficiary must be age 18 to 64, and a title XVI beneficiary must be age 18 to 64 and be eligible for disability payments under the disability standard for adults; a beneficiary must be in current pay status for monthly cash benefits based on disability under title II of the Act or monthly Federal cash benefits based on disability or blindness under title XVI of the Act; and a beneficiary must either: (1) Have a permanent impairment or a nonpermanent impairment (i.e., an impairment for which medical improvement is possible but cannot be predicted), or (2) have an impairment that is expected to improve and have undergone at least one continuing disability review.

In developing requirements for ticket eligibility under the proposed rules, we considered, but decided not to propose,
extending eligibility for a ticket to two additional groups of individuals.

The first group consists of beneficiaries who have impairments that are expected to improve and for whom we have not yet conducted at least one continuing disability review. Because these beneficiaries have conditions that are expected to medically improve in a relatively short period of time, they could be expected to return to work without the need for services under the Ticket to Work program. Continuing disability reviews for this category of beneficiaries are scheduled for six to eighteen months after the initial disability determination. Under the proposed rules, if we determine in the first continuing disability review that the beneficiary remains disabled, we would then issue a ticket, provided that the beneficiary met the other ticket eligibility criteria. This approach would ensure that beneficiaries whose conditions do not improve as anticipated have the opportunity to benefit from services under the Ticket to Work program within a relatively short period of time after the initial determination.

The second group consists of those who received title XVI payments prior to attaining age 18 (i.e., under the disability standard for children) and have since attained age 18, but for whom we have not yet conducted a redetermination of their eligibility under the disability standard for adults. Because ongoing eligibility has not yet been determined for these beneficiaries, we believe that it is premature to issue a ticket to them immediately. Under the proposed rules, if we establish in the redetermination that a beneficiary in this group is eligible for disability payments under the disability standard for adults, we would then issue a ticket, provided that the beneficiary met the other ticket eligibility criteria. We plan to review periodically our policy regarding ticket eligibility, including whether it would be prudent to extend eligibility to the groups discussed above.

Proposed § 411.130 explains that SSA will distribute tickets in graduated phases. Proposed § 411.135 explains that participation in the Ticket to Work program is voluntary. This proposed section explains that if beneficiaries want to participate in the program they can take their tickets to any entity serving under the program. Proposed § 411.140 explains that a beneficiary may assign his or her ticket to any EN or State VR agency that is willing to provide services, that the beneficiary may discuss his or her rehabilitation and employment plans with as many entities as he or she wishes. This proposed section explains that the beneficiary can obtain a list of the approved ENs in his or her area. This section also explains certain requirements a beneficiary must meet in order to assign a ticket. This section provides that beneficiaries and ENs must agree to and sign an individual work plan (IWP) (or, in the case of a State VR agency, an individualized plan for employment (IPE)) before a ticket can be assigned. This provision requires that a copy of the plan be submitted to the PM to facilitate the assignment of the ticket. Proposed § 411.145 describes the conditions under which a beneficiary may take a ticket back after it has been assigned to an EN or State VR agency. It also describes other conditions under which a ticket that is assigned can be taken out of assignment. Proposed § 411.150 explains the beneficiary’s right to reassign a ticket, if the beneficiary chooses.

Proposed § 411.155 explains when a beneficiary’s ticket terminates and eligibility for participation in the Ticket to Work program ends. Once a ticket terminates, a beneficiary may not assign or reassign it to an EN or State VR agency. Under the proposed rules, a ticket will terminate when entitlement to Social Security disability benefits ends or eligibility for SSI benefits based on disability or blindness terminates (whichever is later) for reasons other than the individual’s work activity or earnings; when a Social Security disabled widow(er) beneficiary attains age 65; when a disabled or blind SSI beneficiary reaches age 65 and may qualify for SSI benefits based on age; or after the 60th month for which an outcome payment is made based on that ticket.

Subpart C—Suspension of Continuing Disability Reviews for Beneficiaries Who Are Using a Ticket

Under section 221(i) of the Act and under the authority granted by sections 1631 and 1633 of the Act, we conduct periodic reviews to ensure that beneficiaries continue to meet the definition of disability under sections 223(d) and 1614(a)(3) of the Act. These reviews are called continuing disability reviews. TWWIA amends the Act to add section 1148(i), which states that SSA may not initiate a continuing disability review during any period in which a beneficiary is using a ticket.

The statute states:

“During any period for which an individual is using, as defined by the Commissioner, a ticket to work and self-sufficiency issued under this section, the Commissioner (and any applicable State agency) may not initiate a continuing disability review or other review under section 221 of whether the individual is or is not under a disability or a review under title XVI similar to any such review under section 221.”

The definition of using a ticket is to be determined by the Commissioner of Social Security. Subpart C outlines our proposed definition of using a ticket.

In developing our proposed definition of using a ticket, we considered two key factors. First, the intent of the Ticket to Work program is to allow beneficiaries with disabilities to seek the services they need to work and to reduce or eliminate dependence on Social Security disability and SSI benefits. However, anecdotal evidence suggests that some beneficiaries are afraid that working, or even receiving vocational rehabilitation services, may increase the likelihood that their benefits will be terminated in a continuing disability review. Therefore, using a ticket should be defined in a way that minimizes this employment disincentive for beneficiaries participating in the Ticket to Work program. However, in order to maintain the integrity of the disability programs, it is also important that beneficiaries who have medically improved and who no longer meet the definition of disability under sections 223(d) and 1614(a)(3) of the Act do not continue to receive disability benefits for an undue length of time.

Our proposed definition seeks to balance these concerns by ensuring that continuing disability reviews are suspended only during the period in which beneficiaries are making meaningful progress toward reducing or eliminating dependence on Social Security disability or SSI benefits, while at the same time recognizing that such progress may not always be rapid or continuous.

Under our proposed definition of using a ticket, a beneficiary would be considered to be using a ticket during the period in which he or she was making progress toward the goal of reducing or eliminating dependence on disability benefits within reasonable timeframes. Under this approach, beneficiaries would be allowed a limited period to prepare for work. At the end of this period, they would need to show that they were progressing toward self-sufficiency by demonstrating increasing levels of employment.

An important advantage of this definition of using a ticket is that it increases employment incentives by “rewards” beneficiaries for work and progress toward self-sufficiency with continued deferral of continuing
disability reviews. However, requiring beneficiaries to demonstrate increasing levels of employment within a defined timeframe results in a fairly complex regulation. The complexity arises from our attempt to balance the concerns discussed above and, to the extent possible, to accommodate the diverse employment needs of a wide range of beneficiaries. While some level of complexity is unavoidable, we have attempted wherever possible to simplify the regulation and to make it straightforward to implement.

The following analysis discusses the major provisions of subpart C.

Proposed §§ 411.170 and 411.171 describe when the period of using a ticket begins and ends. We propose that the period of using a ticket begin when the ticket is first assigned to an EN or State VR agency. The primary purpose of the suspension of continuing disability reviews is to ensure that Ticket to Work program participants are not inhibited in their attempts to work or pursue an employment plan by the fear that such activities will increase the likelihood that their benefits will be terminated in a medical review. Prior to the assignment of the ticket, a beneficiary is not participating in these activities under the Ticket to Work program.

Under our proposed definition, the period of using a ticket ends with the earliest of the following:

(1) The completion of the 60-month outcome payment period;
(2) When the beneficiary is no longer making timely progress toward self-supporting employment according to our guidelines (see §§ 411.180 through 411.225);
(3) Three months after the ticket is no longer assigned, if the beneficiary fails to reassign the ticket during this 3-month period; or
(4) When the beneficiary’s entitlement to or eligibility for disability benefits terminates.

Proposed §§ 411.180, 411.185, and 411.220 describe our guidelines for timely progress toward self-supporting employment. We propose that after assigning a ticket, beneficiaries be allowed up to two years to prepare for employment. Under the current VR system, the average time to attain employment with substantial earnings is approximately 2 years.

After 2 years, beneficiaries would be required to meet progressively higher levels of employment to continue to be considered to be using a ticket in order to receive the protection in 1148(f) of the Act permitting non-initiation of continuing disability reviews. Such a progression would allow beneficiaries time to improve their employment capacities. Under our proposed definition, in the third year of Ticket to Work program participation, beneficiaries would be required to work at least 3 months at the SGA level. In the fourth year of the program, they would be required to work at least 6 months at the SGA level. In the fifth and succeeding years, in order to be considered to be using a ticket they would be required to work at least 6 months in each year and have earnings in each such month that were sufficient to eliminate the payment of Social Security disability benefits and Federal SSI benefits.

In developing these guidelines, we recognized that progress toward self-sufficiency is not always continuous and that for some, full self-sufficiency may not be attained. Many beneficiaries have disabilities with cycles of relapse and remission. In addition, some beneficiaries may need to try more than one job before finding a situation that suits their abilities and needs. The requirement that beneficiaries need only work 3 months out of 12 in the third year and 6 months out of 12 in succeeding years recognizes that some beneficiaries may not be able to work on a continuous basis.

In addition, since beneficiaries would be required to work for only 3 months in the third year of their participation in the program, beneficiaries would actually have a total of 2 years and 9 months to prepare for employment. This should allow beneficiaries sufficient preparation time even if they are incapacitated for some portion of that time due to the disabling impairment.

Beneficiaries would also have the option of placing their ticket in inactive status during the initial 24-month period following assignment of a ticket if they expected to be unable to participate in their employment plan for a significant period of time due to a relapse, or if they simply chose to stop participating in the plan temporarily. Any period in which the ticket was inactive would not count toward the time limitations under the timely progress guidelines. However, since the ticket would not be in use during this period, the beneficiary would be subject to a continuing disability review should one become due.

In § 411.185, we propose levels of earnings that an individual must have in order to be considered to be using a ticket. Under the proposed definition, the required earnings level would increase over time. In the third and fourth years of the social Security disability beneficiaries and disabled and blind SSI beneficiaries would be required to work at the SGA level applicable to non-blind beneficiaries for the specified number of months. This level is set by regulation under 20 CFR 404.1574 and is currently $700 a month for non-blind beneficiaries. SSI disability and blindness beneficiaries, Social Security disability beneficiaries who are in a trial work period, and Social Security disability beneficiaries who are statutorily blind would be deemed to have met the requirement to work at the SGA level applicable to non-blind beneficiaries if their gross earnings from employment, before any exclusions, were at or above the dollar amount of the non-blind SGA level, or if their net earnings from self-employment, before any exclusions, were at the SGA level applicable to non-blind beneficiaries.

Earnings at the SGA level applicable to non-blind beneficiaries may not be sufficient to eliminate the payment of all disability benefits, since the amount of earnings needed to eliminate the payment of disability benefits depends on a variety of factors, including whether the beneficiary receives Social Security or SSI benefits, or both, whether the beneficiary is blind, and whether the beneficiary has impairment related work expenses or is eligible for other income exclusions. We are proposing that the earnings requirement for the third and fourth years be at the SGA level for non-blind beneficiaries to establish an initial earnings level that:

(1) Is consistent across different categories of beneficiaries, increasing simplicity; and
(2) Allows beneficiaries time to work toward the higher levels of earnings that may be required to eliminate the payment of disability benefits for the required months.

In the fifth and subsequent years, both Social Security and SSI beneficiaries would be required to work for at least 6 months with earnings in each such month that were sufficient to eliminate payment of Social Security disability and Federal SSI cash benefits in a month. The requirement that individuals using a ticket eventually attain this level of earnings is consistent with the payment structure of the Ticket to Work program, in which ENs receive outcome payments only when Federal disability benefit payments are eliminated. It also reflects that one of the purposes of the Ticket to Work program is to produce savings in benefit payments. Since the suspension of continuing disability reviews for individuals using a ticket means that it is possible that some beneficiaries who no longer meet the definition of disability will continue to be eligible for...
benefits, it is important that the suspension of continuing disability reviews not continue for an undue length of time without a significant reduction in benefit payments due to earnings.

In proposed § 411.210, we discuss beneficiaries who do not meet the timely progress guidelines. Beneficiaries who do not make timely progress toward employment in order to be considered using a ticket would be eligible for any payments that became due. However, these beneficiaries would no longer be considered to be using a ticket as defined by the Commissioner, and therefore would once again be subject to continuing disability reviews.

We also propose that beneficiaries who fail to meet the timely progress guidelines to be considered to be using a ticket have the opportunity to be considered to be using a ticket later. In order to be considered to be using a ticket later, a beneficiary would need to work for a specified number of months. The number of months, and earnings level required, would vary depending on how far the beneficiary had progressed when he or she failed to meet the guidelines.

We propose this method of allowing a beneficiary to once again be considered to be using a ticket because we recognize, as mentioned above, that due to the nature of disability, progress toward increased self-sufficiency is not always direct. Beneficiaries may make unsuccessful attempts before eventually reaching their employment goals, and these unsuccessful attempts should not deprive them of the supports that they need to make renewed efforts.

In proposed §§ 411.190, 411.195, 411.200, and 411.205, we discuss how it will be determined if a beneficiary is meeting the timely progress guidelines. We are proposing that the PM conduct periodic reviews to ensure that beneficiaries are meeting the timely progress guidelines. The first review would be a progress review 24 months after the assignment of the ticket. This would be followed by annual work reviews. After each successful review, the beneficiary would be considered to be meeting the timely progress guidelines until the next review was completed. If a beneficiary disagreed with the PM’s decision in any review, the beneficiary would have the right to ask SSA to review the PM’s decision.

The criteria for the 24-month progress review and annual work reviews are designed to be as clear cut as possible. This feature, combined with the PM’s responsibility for conducting the reviews should allow for rapid processing of reviews and decrease the administrative burden on both the beneficiary and SSA.

Subpart D—Use of One or More Program Managers To Assist in the Administration of the Ticket to Work Program

Section 1148(d)(1) of the Act requires the Commissioner to enter into an agreement with one or more organizations to serve as a PM to assist the Commissioner in administering the Ticket to Work program. Section 101(e)(2)(E) of TWWIIA identifies specific regulations that SSA must promulgate regarding the terms of the agreements to be entered into with a PM. Three items are specifically required:

1. The terms by which a PM would be precluded from direct participation in the delivery of services;
2. Standards which must be met by quality assurance measures and methods of recruitment of ENs; and
3. The format under which dispute resolution will operate under section 1148(d)(7) of the Act.

Among other things, section 1148(d)(7) requires the Commissioner to provide a mechanism for resolving disputes between PMs and ENs, and between PMs and providers of services.

Subpart D of these proposed rules explains that SSA will contract with one or more organizations to serve as a PM and assist SSA in administering the Ticket to Work program. Proposed § 411.230 explains that SSA will conduct a competitive bidding process to select one or more private organizations to perform the PM’s functions. Proposed § 411.235 describes the minimum qualifications required of a PM. Proposed § 411.240 describes certain limitations that are placed on a PM regarding the provision of services under the Ticket to Work program. Proposed § 411.245 identifies key responsibilities that a PM must assume to assist SSA in administering the program and proposed § 411.250 explains how SSA will evaluate a PM.

Subpart E—Employment Networks

Section 1148(d)(4)(A) of the Act requires the Commissioner to select and enter into agreements with ENs to provide services as outlined under the Ticket to Work program. Section 1148(f)(1) states that each EN serving under the Ticket to Work program shall consist of an agency or instrumentality of a State (or a political subdivision thereof) or a private entity that assumes responsibility for the coordination and delivery of services under the program to beneficiaries assigning tickets to it.

These ENs are in addition to State agencies administering or supervising the administration of the State plan approved under title I of the Rehabilitation Act of 1973, as amended (29 U.S.C. 720 et seq.), known as State VR agencies, that will also be serving beneficiaries with disabilities under the Ticket to Work program. State VR agencies will have the option of serving beneficiaries with tickets either as an EN (that is, to be paid under one of the EN payment systems described in subpart H of the proposed rules) or under the existing cost reimbursement payment system authorized in sections 222(d) and 1615(d) of the Act. The Commissioner is also directed to enter into an agreement with any alternate participant operating under the authority of section 222(d)(2) of the Act in any State where the Ticket to Work program is being implemented if the alternate participant chooses to serve as an EN. An EN may consist of a one-stop delivery system established under subtitle B of title I of the Workforce Investment Act of 1998 (29 U.S.C. 2811 et seq.).

Section 1148(f) of the Act requires that entities seeking to participate in the Ticket to Work program as ENs meet certain qualifications. The Commissioner has discretion in determining the qualifications that an entity must meet to be approved to serve as an EN. We are proposing requirements for ENs that are not unduly burdensome and that are intended to permit both traditional as well as other types of entities to qualify. The Commissioner’s intent is to ensure that non-traditional service providers are not prohibited from being approved as ENs, while still requiring evidence that all ENs meet certain minimum qualifications such as licensure, accreditation, academic qualifications, or experience. This inclusive approach is critically important to ensure that beneficiaries with disabilities have a real choice in services necessary to obtain, regain and maintain employment.

Section 1148(f) of the Act also addresses requirements for ENs under the Ticket to Work program. It requires each EN to serve a prescribed service area and ensure that employment services, VR services, and other support services are provided under appropriate IWPs.

Proposed §§ 411.300 and 411.305 explain what an EN is and what entities may apply to be approved as ENs.

Proposed § 411.310 explains how public or private entities will apply to be
approved as ENs and how we will determine whether an entity qualifies to be an EN. Proposed § 411.315 describes the minimum qualifications for an EN under the Ticket to Work program.

Proposed § 411.320 describes the major responsibilities of an entity serving as an EN. Proposed § 411.321 explains the conditions under which we will terminate an EN for inadequate performance. Proposed § 411.325 lists the reporting requirements placed on an entity serving as an EN and proposed § 411.330 explains how we will evaluate an EN’s performance.

**Subpart F—State Vocational Rehabilitation Agencies’ Participation**

Section 1148(c) of the Act addresses participation by State VR agencies in the Ticket to Work program. Among other things, this section gives each State VR agency the opportunity to determine, on a case-by-case basis, whether it will participate in the Ticket to Work program as an EN or under the cost reimbursement payment system authorized under sections 222(d) and 1615(d) of the Act (see 20 CFR 404.2101 et seq. and 416.2201 et seq.). The State VR agency must elect either the outcome payment system or the outcome-milestone payment system to be used when it chooses to function as an EN when serving a beneficiary with a ticket. The Commissioner is directed to provide for periodic opportunities to exercise this election. When the State VR agency serves as an EN under the Ticket to Work program, it means that the State VR agency has chosen, with respect to a particular beneficiary, the option of being paid under the EN payment system it has elected for this purpose. Generally under the Ticket to Work program, however, State VR agencies will continue to operate as they do today. For example, when a State VR agency functions as an EN, it will provide services in accordance with the requirements of the State plan approved under title I of the Rehabilitation Act of 1973, as amended, and a client will complete an individualized plan for employment (IPE) with the State VR agency. If a State VR agency has a dispute over a payment under the cost reimbursement payment system, the State VR agency will use the dispute resolution procedures already in place under 20 CFR 404.2127 and 416.2227. The new responsibilities for State VR agencies under the Ticket to Work program include checking if State VR agency clients have a ticket ready for assignment, routing EN payment disputes questions through the PM, and providing reports regarding the outcomes achieved by its clients who have a ticket.

Subpart F of the proposed rules establishes that the cost reimbursement payment system is a payment option under the Ticket to Work program for State VR agencies. Proposed § 411.360 explains what a State VR agency must do to function as an EN under the Ticket to Work program with respect to a beneficiary and explains that a State VR agency may choose, on a case-by-case basis, to seek payment from SSA under the cost reimbursement payment system or its elected EN payment system.

Proposed § 411.365 describes how a State VR agency will select an EN payment system for use when functioning as an EN. Proposed § 411.370 explains that a State VR agency may choose to serve all beneficiaries with tickets under the cost reimbursement payment system. Proposed § 411.375 explains that State VR agencies must continue to provide services to beneficiaries with tickets under the requirements of the State plan approved under title I of the Rehabilitation Act of 1973, as amended (29 U.S.C. 720 et seq.).

Proposed § 411.380 describes how a State VR agency will determine if a person seeking services is a disabled beneficiary with a ticket. Proposed § 411.385 explains what the State VR agency must do when it determines that a person is a beneficiary with a ticket available for assignment and how it will work with the PM to facilitate the assignment of a beneficiary’s ticket to the State VR agency that the beneficiaries chooses to make such assignment. It also explains how the State VR agency will notify the PM regarding the method of payment it is selecting for a particular beneficiary.

Proposed § 411.390 describes what a State VR agency should do when it determines that a beneficiary already receiving services under an approved IPE is a beneficiary with a ticket available for assignment. Proposed § 411.395 explains that each State VR agency will be required to provide periodic reports to SSA on the specific outcomes achieved with respect to the services provided to beneficiaries under the Ticket to Work program.

Section 1148(c)(3) of the Act requires State VR agencies and ENs to enter into agreements regarding the conditions under which services will be provided when an EN has been assigned the beneficiary’s ticket refers the beneficiary to a State VR agency for services.

Proposed § 411.400 explains that an EN may refer a ticket under the Ticket to Work program to a State VR agency for services only if such an agreement is in place prior to the EN making the referral. Proposed § 411.410 explains that these agreements are broad-based and apply to all beneficiaries who may be referred by an EN to a particular State VR agency.

Proposed § 411.415 explains that the PM will verify the establishment of such agreements based on the EN’s submission of a copy of the agreement to the PM. Proposed § 411.420 provides guidance on what should be included in these agreements and proposed § 411.425 explains what a State VR agency should do if an EN attempts to refer a beneficiary being served under the Ticket to Work program to the State VR agency without having established such an agreement. Proposed § 411.430 explains what the PM should do when notified that a referral has been attempted in the absence of an agreement. Proposed § 411.435 establishes procedures for resolving disputes arising under these agreements.

Subpart G—Requirements for Individual Work Plans

Section 1148(g) of the Act requires each EN to ensure that employment services, vocational rehabilitation services, and other support services provided under the Ticket to Work program are provided under IWP. The minimum requirements for an IWP are spelled out in this section.

Subpart G of these proposed rules establishes the requirements for the IWP that must be developed when an EN and a beneficiary with a ticket come to a mutual understanding to work in partnership under the Ticket to Work program to assist the beneficiary in achieving employment that is self-supporting and that reduces dependence on cash assistance. Beneficiaries who are clients of the State VR agencies will continue to use the individualized plan for employment rather than an IWP. Proposed § 411.455 explains the purpose of the IWP and explains that the EN must develop and implement the plan in a manner that gives the beneficiary the opportunity to exercise informed choice in selecting an employment goal. Proposed § 411.460 explains that the beneficiary and the EN share the responsibility for determining the content of the IWP.

Proposed § 411.465 describes the specific information that must be included in each IWP and proposed § 411.470 explains that an IWP becomes effective on the date it was signed by a beneficiary, or the beneficiary’s representative, and by the EN, provided that the program verifies that a beneficiary has a ticket eligible for assignment and records the assignment.
Subpart H—Employment Network Payment Systems

Section 1148(h) of the Act provides that the Ticket to Work program shall provide for payments authorized by the Commissioner to ENs. These payments shall occur under either an outcome-payment system or an outcome-milestone payment system. The two systems are defined in § 411.500. This section also defines two other terms we use related to the payment systems.

The amount we can pay to an EN (including a State VR agency choosing to be paid as an EN) under either payment system is based upon the prior calendar year’s national average disability benefits payable under title II or title XVI, not upon the specific benefit payable to a beneficiary with a ticket. The amount payable to an EN will depend upon whether the individual who assigned his or her ticket to the EN is entitled to benefits under title II or is eligible for benefits under title XVI. If the beneficiary is concurrently entitled under title II and eligible under title XVI, we will use the title II payment calculation base.

Payments to ENs are for specific milestones or outcomes achieved by a beneficiary who assigns a ticket to the EN. Such payments are not based upon the costs of specific services provided by the EN.

The outcome payments under either payment system are payable for a maximum of 60 months. These months do not have to be consecutive. Section 1148(h)(3)(C) of the Act provides that the schedule of payments to the EN under the outcome-milestone payment system shall be designed so that the total of the payments is less than, on a net present value basis, the total payments the EN would be limited to if the EN were paid under the outcome-payment system.

Section 1148(c) of the Act permits each State VR agency to participate in the program as an EN with respect to a disabled beneficiary. When the State VR agency elects to participate in the Ticket to Work program as an EN with respect to a disabled beneficiary, the State VR agency shall be paid in accordance with its elected EN payment system. If the State VR agency chooses not to participate as an EN with respect to a disabled beneficiary, the State VR agency shall be paid for services provided to the beneficiary in accordance with the cost reimbursement payment system under sections 222(d) and 1615(d) and (e) of the Act. Our regulations concerning this cost reimbursement payment system are at 20 CFR §§ 404.2101 through 404.2127 and §§ 416.2201 through 416.2227.

Payments to State VR agencies are discussed in § 411.510.

Each EN will elect the EN payment system it will be paid under when it agrees to become an EN. We periodically will offer each EN (including a State VR agency) the opportunity to change its elected payment system. If the EN does change its elected payment system, the change will apply only to tickets assigned to the EN after the change in the elected payment system is made known to SSA. These provisions, including the frequency of opportunity for an EN to change its payment system, are discussed in §§ 411.505 through 411.520.

Sections 411.525 through 411.565 provide our proposed rules for computing payments to ENs under the two EN payment systems and for allocating payments to multiple ENs to whom the ticket was assigned at different times.

Section 1148(b)(2) of the Act provides that the outcome payment system shall provide for a schedule of payments to an EN, in connection with a beneficiary who assigns a ticket to the EN, for each month, during the individual’s outcome payment period, for which Social Security disability benefits and Federal SSI benefits based on disability or blindness are not payable to the individual because of work or earnings. There can be a maximum of sixty outcome payment months and, therefore, a maximum of sixty monthly outcome payments. In proposed § 411.525, we propose that monthly outcome payments are for specific milestones or outcomes achieved by a beneficiary who assigns a ticket to the EN. The proposed rules also provide criteria for determining whether a month occurring after the month in which a beneficiary’s entitlement to Social Security disability benefits ends or eligibility for SSI benefits based on disability or blindness terminates due to work activity or earnings will be considered to be an outcome payment month. Under the proposed rules, we will consider any month after the month in which such entitlement ends or eligibility terminates because of work or earnings to be an outcome payment month if the individual has gross earnings from employment (or net earnings from self-employment) in that month that are at or above the SGA dollar amount in 20 CFR 404.1574(b)(2) (for an individual who is not statutorily blind) or in 20 CFR 404.1584(d) (for an individual who is statutorily blind), and the individual is not entitled to any monthly benefits under title II or eligible for any benefits under title XVI for that month.

In § 411.525, we propose that monthly payments under the outcome payment system will be 40 percent of the payment calculation base, which is defined in § 411.500. This percentage is the maximum the law allows at the beginning of the program. Under the outcome payment system, each monthly outcome payment is the same during a calendar year. At the end of each calendar year, the payment calculation base will be refigured for the next year.

For example, at the end of calendar year 2000 the national average disability benefit payable per month for 2000 will be calculated for title II and for title XVI. Forty percent will be multiplied by each of these two amounts to determine the monthly outcome payment amounts for calendar year 2001 under the outcome payment system. At the end of 2001, the computation will be repeated using the 2001 national average disability benefits payable per month to determine the monthly payment under the outcome payment system for 2002.

To illustrate with sample data, if outcome payment months occurred in calendar year 2, the following maximum outcome payments would be based upon the calendar year 1 payment calculation base as follows—

For title II and concurrent title II/XVI beneficiaries:

Average national disability benefit for year 1 = $693 per month
$693 × 40% = $277

$277 is the monthly payment amount to the EN for an outcome payment month in calendar year 2

For title XVI recipients:

Average national disability benefit for year 1 = $440 per month
$440 × 40% = $176

$176 is the monthly payment amount to the EN for an outcome payment month in calendar year 2

As the national average disability benefit payable tends to rise every year due, in part, to cost-of-living adjustments, the annual computation of the payment calculation base should increase the monthly outcome payment amount for each succeeding year.

The outcome-milestone payment system provides payments to the EN when the beneficiary achieves milestones directed toward the goal of permanent employment. Payments for the milestones achieved come before, and are in addition to, payments made during the outcome payment period.

Proposed § 411.525 explains that we will pay an EN to whom a ticket has
been assigned only for milestones or outcomes that are achieved prior to the month in which an individual’s ticket terminates. We will not pay milestone or outcome payments based on an individual’s work activity or earnings in or after the month a ticket terminates.

Section 411.535 describes the two milestones we are proposing. Both milestones occur after work begins and are based upon an earnings level and duration of work. Both milestones can be attained even if there are interruptions in the work pattern. The amount of the second milestone payment is more than the first, but the beneficiary must work longer in order for the EN to receive the second milestone payment. Both milestones are based upon the dollar amount we use when we evaluate monthly earnings to determine if work activity is SGA. For calendar year 2000, these dollar amounts are $700 per month for beneficiaries who are not statutorily blind and $1,170 per month for beneficiaries who are statutorily blind. Section 411.535 proposes the milestone requirements. Section 411.540 proposes how we will calculate the payment for each milestone. For milestone one, we propose using a percentage of the payment calculation base defined in §411.500 that approximately equals two outcome payment months under the outcome-milestone payment system. For milestone two, we propose to double the percentage used for milestone one.

Section 411.545 proposes how, under the outcome-milestone payment system, we will calculate the amount payable for outcome payments made with respect to a ticket. Monthly outcome payments during the first 12 outcome payment period months (months 1–12) will be the lowest and also will be reduced each month by an amount equal to 1/12 of the total outcome payments made with respect to a ticket. Monthly outcome payments during the fifth interval of 12 outcome payment period months (months 49–60) will pay the highest payment per month. The outcome month occurs. Under the outcome-milestone payment system we propose to use, the total potential payment will be about 85 percent of the total potential payment that could be made under the outcome payment system. As stated previously, the outcome payment months do not have to be consecutive months under either EN payment system.

Section 411.555 proposes that an EN may generally keep its milestone and outcome payments received under the elected payment system, even if the beneficiary does not sustain work for 60 outcome payment period months. This section also states that retroactive adjustments to payments already received by ENs may occur for reasons related to our modifying our previous determination about a beneficiary’s right to benefits, or due to allocating a prior payment with another EN.

Sections 411.560 and 411.565 explain that it is possible to pay more than one EN for the same milestone or outcome payment month. In this situation, the payment would be allocated among the ENs that qualify for payment. Section 1148(e)(3) of the Act provides that the PM will determine the allocation based on the services provided by each EN. We propose it also will be possible to pay more than one EN for different milestones or outcome payment months on the same ticket. When more than one EN is eligible for payment with respect to a ticket, we propose paying each EN in accordance with its elected payment system at the time the ticket was assigned to each EN.

Section 411.570 provides that the Act prohibits an EN from requesting or accepting compensation from a beneficiary for the EN’s services. Proposed §411.575 describes how an EN will request payment for either a milestone payment, or an outcome payment month. The EN will make a written request to the PM for payment for each milestone. The request will be accompanied by evidence showing that the milestone was achieved. We do not have to stop a beneficiary’s monthly cash payment in order to pay a milestone payment to an EN.

For outcome payments under either EN payment system, an EN must submit a written request for payment to the PM. The request and evidence of work or earnings that is sufficient to reduce monthly Federal cash benefits to zero are required in order to begin outcome payments to the EN. We will make the determination that the work or earnings are sufficient to stop the beneficiary’s monthly cash payment by using the same criteria we already use to make this determination. For outcome payments for months after a beneficiary’s entitlement to Social Security disability benefits ends or eligibility for SSI benefits based on disability or blindness terminates due to work activity or earnings, an EN must submit evidence that the individual has monthly gross earnings from employment or net earnings from self-employment that are at or above the applicable SGA dollar amount. In order to continue receiving monthly outcome payments, the EN must provide ongoing evidence of work and earnings to demonstrate that it is entitled to each monthly outcome payment.

Proposed §411.580 explains that an EN must first have had the ticket assigned to it before it can be eligible to receive milestone or outcome payments.

As a beneficiary is free to choose where to assign a ticket, proposed §411.585 explains that a State VR agency and an EN can both be eligible for payment on a ticket if the State VR agency elects to be paid as an EN. Therefore, each entity can be paid as an EN under its respective EN payment system. However, if the State VR agency chooses to serve a beneficiary with a ticket and to be paid under the cost reimbursement payment system, then we will pay either the State VR agency under the cost reimbursement payment system or we will pay an EN under its elected payment system. We propose that, for each ticket, a payment either under the cost reimbursement payment system or under an elected EN payment system will exclude any payment under the other payment system. We propose this restriction to comply with the payment limitations that exist in the Act for the cost reimbursement payment system and for the EN payment systems. Absent this restriction, it would be possible to pay separately under both the cost reimbursement payment system and under the EN payment systems such amounts as, when combined, would exceed the statutory limitation of one or both of these payment systems for serving the same beneficiary under the same ticket.

Following is a chart showing an example of payments under each of the two EN payment systems. This chart illustrates how we propose to calculate payments under the outcome payment system and under the outcome-milestone payment system. The payment calculation base was determined as discussed above in the preamble. Actual data, based upon calendar year 2000, should be available at the end of the calendar year for implementing the EN payment systems in calendar year 2001.
# Outcome Payment System

## Title II and Title XIX

<table>
<thead>
<tr>
<th>Milestone</th>
<th>Months 1-12</th>
<th>Months 13-24</th>
<th>Months 25-36</th>
<th>Months 37-48</th>
<th>Months 49-60</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monthly payments ($)</td>
<td>277</td>
<td>277</td>
<td>277</td>
<td>277</td>
<td>277</td>
<td>$16,620</td>
</tr>
<tr>
<td>Yearly payments ($)</td>
<td>3,324</td>
<td>3,324</td>
<td>3,324</td>
<td>3,324</td>
<td>3,324</td>
<td></td>
</tr>
</tbody>
</table>

## Title XIX only

<table>
<thead>
<tr>
<th>Milestone</th>
<th>Months 1-12</th>
<th>Months 13-24</th>
<th>Months 25-36</th>
<th>Months 37-48</th>
<th>Months 49-60</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monthly payments ($)</td>
<td>176</td>
<td>176</td>
<td>176</td>
<td>176</td>
<td>176</td>
<td>$10,560</td>
</tr>
<tr>
<td>Yearly payments ($)</td>
<td>2,112</td>
<td>2,112</td>
<td>2,112</td>
<td>2,112</td>
<td>2,112</td>
<td></td>
</tr>
</tbody>
</table>

## Outcome-Milestone Payment System

## Title II and Title XIX

<table>
<thead>
<tr>
<th>Milestone</th>
<th>Months 1-12</th>
<th>Months 13-24</th>
<th>Months 25-36</th>
<th>Months 37-48</th>
<th>Months 49-60</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Milestone 1 (68% of PCB)</td>
<td>$470</td>
<td>$940</td>
<td>$1,410</td>
<td>$90</td>
<td>$222</td>
<td>$235</td>
</tr>
<tr>
<td>Milestone 2 (136% of PCB)</td>
<td>$940</td>
<td>$1,410</td>
<td>$2,825</td>
<td>$1,901</td>
<td>$2,006</td>
<td>$8,976</td>
</tr>
</tbody>
</table>

## Title XIX only

<table>
<thead>
<tr>
<th>Milestone</th>
<th>Months 1-12</th>
<th>Months 13-24</th>
<th>Months 25-36</th>
<th>Months 37-48</th>
<th>Months 49-60</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Milestone 1 (68% of PCB)</td>
<td>$300</td>
<td>$600</td>
<td>$900</td>
<td>$57</td>
<td>$141</td>
<td>$150</td>
</tr>
</tbody>
</table>

* Excludes year-to-year increase from the average monthly benefit recomputation
** Monthly outcome payment after deducting 12 equal amounts for prior milestone payments

Note: The 60 potential outcome payment months do not have to be consecutive.
Proposed § 411.590 describes what an EN or State VR agency can do if either disagrees with our decision on a payment request which is submitted. This section also explains that an EN cannot appeal our determination about a beneficiary’s right to benefits even when that determination affects the payment to an EN.

Proposed § 411.595 identifies various methods we will use to monitor the EN payment systems for financial integrity. Section 411.597 proposes that we periodically review the conditions affecting payment under the two EN payment systems to determine if these payment systems are providing adequate incentives and appropriate economies for ENs to assist beneficiaries to enter the workforce.

Subpart I—Ticket to Work Program Dispute Resolution

Program managers and employment networks may have disputes with us under the Ticket to Work program. In addition, section 1148(d)(7) of the Act requires us to provide for a mechanism for resolving disputes between beneficiaries and ENs, between ENs and PMs, and between PMs and service providers. As part of this process, SSA is required to provide a party to a dispute a reasonable opportunity for a full and fair review of the matter in dispute. Finally, beneficiaries and State VR agencies may have disputes. The various dispute resolution mechanisms are discussed below.

PM and EN Disputes With SSA

Since PMs will operate under contracts with SSA and since ENs, other than State VR agencies functioning as ENs, will operate under agreements with SSA, disputes between SSA and PMs and between SSA and ENs will be subject to the dispute resolution procedures contained in the contracts and agreements with SSA.

Disputes Between Beneficiaries and ENs

There is a three-step process for resolving disputes between beneficiaries and ENs. This three-step process will ensure that both beneficiaries and ENs have the opportunity to resolve disputes using informal means.

As a first step in the dispute resolution process, each EN is required to have an internal grievance procedure whereby beneficiaries have the opportunity to work with representatives of the EN to try to resolve any disputes arising during the implementation or amending of an IWP. If the dispute is not resolved using the EN’s internal grievance procedures, both the beneficiary and the EN will have the option of contacting the PM for assistance in resolving the dispute. Upon request, the PM will conduct a full review of the matter in dispute and make a recommendation to the beneficiary and the EN as to how the dispute might be resolved (see proposed § 411.615). This second step is intended to provide the parties to the dispute the opportunity to present their case before an impartial third party, the PM. The third step involves bringing the dispute to SSA.

Proposed § 411.605 explains the EN’s responsibilities regarding this dispute resolution process, including informing beneficiaries of the availability of assistance from the State Protection and Advocacy (P&A) system at every step in the dispute resolution process. Proposed § 411.610 identifies specific points in the rehabilitation process when beneficiaries must be informed about the procedures for resolving disputes.

Proposed § 411.615 describes how a disputed issue will be referred to the PM, including what information should be submitted. Proposed § 411.620 tells how long the PM has to provide a written recommendation on how to resolve the dispute. Proposed § 411.625 explains that if the parties to the dispute do not agree with the PM’s recommendation and the dispute continues to be unresolved, either the beneficiary or the EN has the option of bringing the dispute to the attention of a Dispute Resolution Board that will be created within SSA to resolve such disputes and issue administrative decisions.

The Dispute Resolution Board will consist of five members. The members will be SSA staff from the Office of Employment Support Programs who are knowledgeable regarding the Ticket to Work program. As appropriate, the membership will be supplemented with SSA staff with specialized knowledge in other areas.

Proposed § 411.625 also describes the information that must be submitted to SSA to facilitate the Dispute Resolution Board’s review of the dispute. Proposed § 411.630 explains that SSA’s decision is final.

Proposed § 411.635 explains that a beneficiary has the right to be represented in the dispute resolution process under the Ticket to Work program and that the State P&A system is available to provide assistance and advocacy services to beneficiaries regardless of whether the services are being provided under one of the EN payment systems or under the cost...

Disputes Between ENs and PMs

Proposed § 411.650 explains that a dispute between an EN and the PM, that does not involve an EN’s payment request, will be resolved using the procedures for resolving disputes developed by the PM. If the matter cannot be resolved using these procedures, it will be forwarded to SSA for resolution. Proposed § 411.655 explains how a PM will refer disputes to us. Proposed § 411.660 explains that SSA’s decision on a dispute between an EN and a PM is final.

A dispute over a payment request submitted by an EN, including a State VR agency serving as an EN, will be resolved using the dispute resolution procedures contained in § 411.590.

Disputes Between Service Providers and PMs

We are required to provide a mechanism for resolving disputes between service providers and program managers. Most service providers approved to serve beneficiaries under the Ticket to Work program will be serving as ENs. Disputes between PMs and ENs over payments are discussed in subpart H. Other disputes between ENs and PMs are discussed above, and in §§ 411.650, 411.655, and 411.660. State VR agencies that choose not to serve beneficiaries with tickets as ENs will be the only other service providers having a relationship with a PM under the Ticket to Work program. Disputes between a State VR agency that is not functioning as an EN and a PM, that involve issues related to ticket assignment and do not involve a request for payment or other reimbursement issue, will be handled in accordance with the PM’s dispute resolution procedures. A dispute over a payment request submitted by a State VR agency which is serving a beneficiary with a ticket under the vocational rehabilitation cost reimbursement system (see sections 222(d) and 1615(d) of the Act) will be resolved under existing regulations governing the resolution of disputes regarding a payment request (see 20 CFR 404.2127(a) and 416.2227(a)).

Disputes Between Beneficiaries and State VR Agencies

Proposed § 411.640 explains that the dispute resolution procedures in the Rehabilitation Act of 1973, as amended (29 U.S.C. 720 et seq.) apply to any dispute arising between a disabled beneficiary and a State VR agency, regardless of whether the services are being provided under one of the EN payment systems or under the cost...
reimbursement payment system authorized under sections 222(d) and 1615(d) of the Act.

Subpart J—The Ticket to Work Program and Alternate Participants Under the Programs for Payments for Vocational Rehabilitation Services

Section 101(d) of TWWIIA requires graduated implementation of the Ticket to Work program. The program will be phased in nationally over a three-year period, with the first tickets being issued early in 2001. SSA will announce the States selected for participation in the Ticket to Work program in the Federal Register, until the program has been implemented nationwide. By January 1, 2004, the program will be operating in all States and U.S. Territories.

Section 1148(d)(4)(B) of the Act requires the Commissioner, in any State where the Ticket to Work program is implemented, to enter into agreements with any alternate participant that is operating under the authority of section 222(d)(2) of the Act in the State as of the date of enactment of TWWIIA if the alternate participant chooses to serve as an EN under the program.

Subpart J of these proposed rules describes how implementation of the Ticket to Work program affects the current alternate participant payment programs under 20 CFR 404.2101 et seq. and 416.2201 et seq. Proposed § 411.700 explains what an alternate participant is. Proposed § 411.705 and § 411.710 explain that an approved alternate participant has the option of becoming an EN when the Ticket to Work program is implemented in a State and tells an alternate participant what it must do to become an EN. Sections 411.715 through 411.730 describe how the transition process will occur for alternate participants who choose to become ENs. These sections explain how SSA will handle payments related to beneficiaries who were being served by alternate participants under existing employment plans prior to the Ticket to Work program being implemented in the State, and the alternate participant becoming an EN. These sections also provide that SSA will not provide reimbursement for any services provided to a beneficiary under the alternate participant payment system after December 31, 2003.

Clarity of These Proposed Rules

Executive Order 12866 and the President’s memorandum of June 1, 1996 (60 FR 31885) require each agency to write in plain language. In addition to your substantive comments on these proposed rules, we invite your comments on how to make these proposed rules easier to understand. For example:

• Have we organized the material to suit your needs?
• Are the requirements in the rules clearly stated?
• Do the rules contain technical language or jargon that isn’t clear?
• Would a different format (grouping and order of sections, use of headings, paragraphing) make the rules easier to understand?
• Would more (but shorter) sections be better?
• Could we improve clarity by adding tables, lists, or diagrams?
• What else could we do to make the rules easier to understand?

Additional Matters for Comment

While we are proposing rules to implement the new Ticket to Work program authorized in section 101 of TWWIIA, we will at a future time address the following matters:

1. Section 1148(f)(4) of the Social Security Act, as added by section 101 of TWWIIA, requires that “Each employment network shall prepare periodic reports, on at least an annual basis, itemizing for the covered period specific outcomes achieved with respect to specific services provided by the employment network. Such reports shall conform to a national model prescribed under this section.” We invite public comments on what this national model for periodic reports should include.

2. Section 1148(d)(6) of the Social Security Act, as added by section 101 of TWWIIA, requires that “The Commissioner shall provide for such periodic reviews as are necessary to provide for effective quality assurance in the provision of services by employment networks. The Commissioner shall solicit and consider the views of consumers and the program manager under which the employment networks serve and shall consult with providers of services to develop performance measurements.” We invite comments from consumers, service providers, and other members of the public on the performance standards we should use to provide for effective quality assurance of the Ticket to Work program.

Eligibility for a Ticket for SSI Childhood Disability Beneficiaries Age 16 and Older

Proposed 411.125 states that an individual will be eligible to receive a ticket in a month in which he or she is age 18 or older and has not attained age 65, provided the individual has qualified for title II benefits based on disability or qualified for title XVI benefits based on disability under the adult standard or based on blindness. As we gain experience with the Ticket to Work program, we plan, at a later time, to explore the possibility of expanding the age criteria for receiving a ticket to include those SSI beneficiaries age 16 and older who are eligible for disability benefit payments based on the childhood disability standard. We plan to seek comments on this possible age expansion at a later time, but if you wish to comment on the issue of providing tickets to this group of beneficiaries now, please do so. We will consider carefully any comments we receive.

Electronic Version

The electronic version of this document is available on the Internet at http://www.access.gpo.gov/su_docs/aces/aces140.html. It is also available on the Internet site for SSA at http://www.ssa.gov.

Regulatory Procedures

Executive Order 12866

We have consulted with the Office of Management and Budget (OMB) and determined that these proposed rules meet the criteria for a significant regulatory action under Executive Order 12866. Thus, they will be subject to OMB review. For the five-year period from fiscal year 2001 through 2005, the effects on the Old Age, Survivors and Disability benefit payments range from minimal in fiscal year 2001 to savings of $10 million in fiscal year 2005. For the same period, the effects on Federal Supplemental Security Income payments range from minimal in fiscal year 2001 to savings of $22 million in fiscal year 2005. As the costs and savings from fiscal year 2001 through 2005 are not expected to exceed $100 million in any one year, these proposed rules are not “major” under the provisions of 5 U.S.C. 801 et seq.

Regulatory Flexibility Act

We certify that these proposed rules would not have a significant economic impact on a substantial number of small entities because they would primarily affect only individuals, and those entities that voluntarily enter into a contractual agreement with us. Thus, an initial regulatory flexibility analysis as provided in the Regulatory Flexibility Act, as amended, is not required.

Paperwork Reduction Act

The proposed regulations contain new reporting, recordkeeping and disclosure requirements in the sections listed...
As required by the Paperwork Reduction Act of 1995, we have submitted the information requirements to OMB for its review. Organizations and individuals desiring to submit comments on these requirements should direct them to the Office of Information and Regulatory Affairs, OMB, ATTN: OMB Desk Officer for SSA, New Executive Office Building, Room 10235, Washington, D.C. 20503; and to the Social Security Administration, ATTN: Reports Clearance Officer, 1–A–21 Operations Building, Baltimore, MD 21235–0401. OMB is required to make a decision concerning the collections of information contained in these proposed regulations between 30 and 60 days after publication of this document in the Federal Register. Therefore, a comment to OMB will be most useful if received by OMB within 30 days of publication.

The public burden includes the time it will take to understand what is needed, gather the necessary facts and provide the information or maintain the specified records.

SSA is soliciting comments in order to:

- Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the Agency including whether the information will have practical utility;
- Evaluate the accuracy of the Agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;
- Enhance the quality, utility, and clarity of the information to be collected; and
- Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques, or other forms of information technology (e.g., permitting electronic submission of responses).

Below is a brief description of each requirement subject to OMB clearance under the Paperwork Reduction Act. We have used the following abbreviations in the description:

- EN—Employment Network
- IWP—Individual Work Plan (between a beneficiary and an EN)
- IPE—Individualized Plan for Employment (between a beneficiary and a State VR agency)
- PM—Program Manager
- SSA—Social Security Administration
- SVRA—State Vocational Rehabilitation Agency

<table>
<thead>
<tr>
<th>CFR section</th>
<th>Reporting, recordkeeping or disclosure requirement</th>
</tr>
</thead>
<tbody>
<tr>
<td>§ 411.140(c)</td>
<td>Information collected from beneficiary to prepare an IWP/IPE. General reporting and disclosure from EN</td>
</tr>
<tr>
<td>§ 411.325(e)–(f)</td>
<td>Beneficiary/EN/SVRA/PM reporting beneficiaries’ non-participation.</td>
</tr>
<tr>
<td>§ 411.190(a)</td>
<td>Reporting—Beneficiary requests inactive status from PM.</td>
</tr>
<tr>
<td>§ 411.220(b)(1)</td>
<td>Reporting—Beneficiary requests reactivation of ticket from PM.</td>
</tr>
<tr>
<td>§ 411.245(b)(1)</td>
<td>Beneficiary requests/receives current EN roster from PM.</td>
</tr>
<tr>
<td>§ 411.325(d)</td>
<td>EN reports referral agreement with SVRA.</td>
</tr>
<tr>
<td>§ 411.365</td>
<td>SVRA reporting payment option to PM.</td>
</tr>
<tr>
<td>§ 411.575</td>
<td>ENS and SVRAs request payment under EN payment election and provides wage/earnings evidence.</td>
</tr>
<tr>
<td>§ 411.605(b)</td>
<td>Disclosure—Provide internal grievance procedures from EN to beneficiary.</td>
</tr>
<tr>
<td>§ 411.435(c)</td>
<td>Reporting—Request to PM from EN or SVRA on dispute resolution.</td>
</tr>
<tr>
<td>§ 411.615</td>
<td>Reporting—beneficiary or EN request to PM to review disputed issue.</td>
</tr>
<tr>
<td>§ 411.625</td>
<td>Reporting—beneficiary or EN request for SSA review of PM’s recommendation on resolution of dispute.</td>
</tr>
</tbody>
</table>

(List of Subjects in 20 CFR Part 411)

Administrative practice and procedure, Blind, Disability benefits,
Old-age, survivors, and Disability Insurance, Reporting and recordkeeping requirements, Social Security, Supplemental Security Income, Public assistance programs, Vocational rehabilitation.


Kenneth S. Apfel,
Commissioner of Social Security.

For the reasons set forth in the preamble, we propose to add a new part 411 to chapter III of title 20 of the Code of Federal Regulations to read as follows:

PART 411—THE TICKET TO WORK AND SELF-SUFFICIENCY PROGRAM

Sec.

411.100 Scope.

411.105 What is the purpose of the Ticket to Work program?

411.110 How is the Ticket to Work program implemented?

411.115 Definitions of terms used in this part.

Subpart A—Introduction

411.120 What is a ticket under the Ticket to Work program?

411.125 Who is eligible to receive a ticket under the Ticket to Work program?

411.130 How will SSA distribute tickets under the Ticket to Work program?

411.135 What do I do when I receive a ticket?

411.140 When can I assign my ticket and how?

411.145 Once my ticket has been assigned to an EN or State VR agency, can it be taken out of assignment?

411.150 Can I reassign my ticket to a different EN or the State VR agency?

411.155 When does my ticket terminate?

Subpart B—Tickets Under the Ticket to Work Program

411.200 How does the period of using a ticket end?

411.205 When does the period of using a ticket begin?

411.210 What happens if I do not make timely progress toward self-supporting employment?

411.215 How will the PM conduct my annual work review?

411.220 How will the PM conduct my 24-month progress review?

411.225 What if I disagree with the PM’s decision about whether I am making timely progress toward self-supporting employment?

411.230 What is a PM?

411.235 What qualifications are required of a PM?

411.240 What limitations are placed on a PM?

411.245 What are a PM’s responsibilities under the Ticket to Work program?

Evaluation of Program Manager Performance

411.250 How will SSA evaluate a PM?

411.255 What if my PM, the State VR agency, or SSA about its choice of a payment manager?

Subpart C—Suspension of Continuing Disability Reviews for Beneficiaries Who Are Using a Ticket

Introduction

411.300 What is an EN?

411.305 Who is eligible to be an EN?

411.310 How does an EN determine whether a person seeking assistance is working?

411.315 What is the minimum qualification necessary to be an EN?

411.320 What are an EN’s responsibilities as a participant in the Ticket to Work program?

411.321 Under what conditions will SSA terminate an agreement with an EN due to inadequate performance?

411.325 What reporting requirements are placed on an EN as a participant in the Ticket to Work program?

411.330 How will SSA evaluate an EN’s performance?

Subpart D—Employment Networks

411.350 Must a State VR agency participate in the Ticket to Work program?

411.355 What payment options does a State VR agency have under the Ticket to Work program?

411.360 How does a State VR agency become an EN?

411.365 How does a State VR agency notify SSA about its choice of a payment system for use when functioning as an EN?

411.370 Does a State VR agency ever have to function as an EN?
411.515 Can the EN change its elected payment system?
411.520 How are beneficiaries whose ticket is assigned to an EN affected by an EN’s change in elected payment system?
411.525 How are the EN payments calculated under each of the two EN payment systems?
411.530 How will the outcome period payments be reduced when paid under the outcome-milestone payment system?
411.535 What are the milestones for which an EN can be paid?
411.540 What are the payment amounts for each of the milestones?
411.545 What are the payment amounts for outcome payment months under the outcome-milestone payment system?
411.550 What are the payment amounts for outcome payment months under the outcome-game payment system?
411.555 Can the EN keep the milestone and outcome payments even if the beneficiary does not achieve all 60 outcome months?
411.560 Is it possible to pay a milestone or outcome payment to more than one EN?
411.565 What happens if two or more ENs qualify for payment on the same ticket but have elected a different EN payment system?
411.570 Can an EN request payment from the beneficiary who assigned a ticket to the EN?
411.575 How does the EN request payment for milestones or outcome payment months achieved by a beneficiary who assigned a ticket to the EN?
411.580 Can an EN receive payments for milestones or outcome payment months that occur before the beneficiary assigns a ticket to the EN?
411.585 Can a State VR agency and an EN both receive payment for serving the same beneficiary?
411.590 What can an EN do if the EN disagrees with our decision on a payment request?
411.595 What oversight procedures are planned for the EN payment systems?
411.597 Will SSA periodically review the outcome payment system and the outcome-milestone payment system for possible modifications?

Subpart I—Ticket to Work Program Dispute Resolution

Disputes Between Beneficiaries and Employment Networks

411.600 Is there a process for resolving disputes between beneficiaries and ENs?
411.605 What are the responsibilities of the EN regarding the dispute resolution process?
411.610 When should a beneficiary receive information on the procedures for resolving disputes?
411.615 How will a disputed issue be referred to the PM?
411.620 How long does the PM have to recommend a resolution to the dispute?
411.625 Can the beneficiary or the EN request a review of the PM’s recommendation?
411.630 Is SSA’s decision final?

411.635 Can a beneficiary be represented in the dispute resolution process under the Ticket to Work program?

Disputes Between Beneficiaries and State VR Agencies

411.610 Do the dispute resolution procedures of the Rehabilitation Act of 1973, as amended, apply to beneficiaries seeking services from the State VR agency?

Disputes Between Employment Networks and Program Managers

411.650 Is there a process for resolving disputes between ENs and PMs, other than disputes on a payment request?
411.655 How will the PM refer the dispute to us?
411.660 Is SSA’s decision final?

Subpart J—The Ticket to Work Program and Alternate Participants Under the Programs of Payments for Vocational Rehabilitation Services

411.700 What is an alternate participant?
411.705 Can an alternate participant become an EN?
411.710 How will an alternate participant choose to participate as an EN in the Ticket to Work program?
411.715 If an alternate participant becomes an EN, will beneficiaries for whom an employment plan was signed prior to implementation be covered under the Ticket to Work program payment provisions?
411.720 If an alternate participant chooses not to become an EN, can it continue to function under the programs for payments for VR services?
411.725 If an alternate participant becomes an EN and it has signed employment plans, both as an alternate participant and an EN, how will SSA pay for services provided under each employment plan?
411.730 What happens if an alternate participant signed an employment plan with a beneficiary before Ticket to Work program implementation in the State and the required period of substantial gainful activity is not completed by January 1, 2004?


Subpart A—Introduction

§ 411.100 Scope.

The regulations in this part 411 relate to the provisions of section 1148 of the Social Security Act which establishes the Ticket to Work and Self-Sufficiency Program (hereafter referred to as the “Ticket to Work program”). The regulations in this part are divided into ten subparts:

(a) Subpart A explains the scope of this part, explains the purpose and manner of implementation of the Ticket to Work program, and provides definitions of terms used in this part.

(b) Subpart B contains provisions relating to the ticket under the Ticket to Work program.

(c) Subpart C contains provisions relating to the suspension of continuing disability reviews for disabled beneficiaries who are considered to be using a ticket.

(d) Subpart D contains provisions relating to the use of one or more program managers to assist us in the administration of the Ticket to Work program.

(e) Subpart E contains provisions relating to employment networks in the Ticket to Work program.

(f) Subpart F contains provisions relating to State vocational rehabilitation agencies’ participation in the Ticket to Work program.

(g) Subpart G contains provisions relating to individual work plans in the Ticket to Work program.

(h) Subpart H contains provisions establishing employment network payment systems.

(i) Subpart I contains provisions that establish a procedure for resolving disputes under the Ticket to Work program.

(j) Subpart J contains provisions explaining how the implementation of the Ticket to Work program affects alternate participants under the programs for payments for vocational rehabilitation services under subpart V of part 404 and subpart V of part 416 of this chapter.

§ 411.105 What is the purpose of the Ticket to Work program?

The purpose of the Ticket to Work program is to expand the universe of service providers available to individuals who are entitled to Social Security benefits based on disability or eligible for Supplemental Security Income (SSI) benefits based on disability or blindness in obtaining the services necessary to find, enter and retain employment. Expanded employment opportunities for these individuals also will increase the likelihood that these individuals will reduce their dependency on Social Security and SSI cash benefits.

§ 411.110 How is the Ticket to Work program implemented?

We are implementing the Ticket to Work program in graduated phases at phase-in sites around the country. We are implementing the program at sites on a wide enough scale to allow for a thorough evaluation and ensure full implementation of the program on a timely basis.
§ 411.115 Definitions of terms used in this part.

As used in this part:

(a) The Act means the Social Security Act, as amended.

(b) Commissioner means the Commissioner of Social Security.

(c) I, my, you, or your means the disabled beneficiary.

(d) We or us means the Social Security Administration.

(e) Ticket to Work program or program means the Ticket to Work and Self-Sufficiency Program under section 1148 of the Act.

(f) Disabled beneficiary means a title II disability beneficiary or a title XVI disability beneficiary.

(1) Title II disability beneficiary means an individual entitled to disability insurance benefits under section 223 or to monthly insurance benefits under section 202 of the Act based on such individual’s disability as defined in section 223(d) of the Act. (See § 404.1505 of this chapter.) An individual is a title II disability beneficiary for each month for which such individual is entitled to such benefits.

(2) Title XVI disability beneficiary means an individual eligible for Supplemental Security Income benefits under title XVI on the basis of blindness (within the meaning of section 1614(a)(2) of the Act) (§ 416.981 and 416.982 of this chapter) or disability (within the meaning of section 1614(a)(3) of the Act) (§ 416.905 of this chapter). An individual is a title XVI disability beneficiary for each month for which such individual is eligible for such benefits.

(3) Supplemental Security Income benefit under title XVI means a cash benefit under section 1611 or 1619(a) of the Act, and does not include a State supplementary payment, administered Federally or otherwise.

(g) Social Security disability benefits means the benefits described in paragraph (f)(1) of this section.

(h) Federal SSI cash benefits means a Supplemental Security Income benefit under title XVI based on blindness or disability as described in paragraphs (f)(2) and (f)(3) of this section.

(i) State vocational rehabilitation agency or State VR agency means a State agency administering or supervising the administration of the State plan approved under title I of the Rehabilitation Act of 1973, as amended.

(j) Cost reimbursement payment system means the provisions for payment for vocational rehabilitation services under subpart V of part 404 and subpart V of part 416 of this chapter.

(k) Employment plan means an individual work plan under which an employment network (other than a State VR agency) provides services to a disabled beneficiary under the Ticket to Work program or an individualized plan for employment under which a State VR agency provides services. When used in subpart J of this part, “employment plan” also means a “similar document” referred to in § 404.2114(a)(2) and 416.2214(a)(2) of this chapter under which an alternate participant under the programs for payments for vocational rehabilitation services (described in subpart V of part 404 and subpart V of part 416 of this chapter) provides services to a disabled beneficiary under those programs.

Subpart B—Tickets Under the Ticket to Work Program

§ 411.120 What is a ticket under the Ticket to Work program?

A ticket under the Ticket to Work program is a document which provides evidence of the Commissioner’s agreement to pay, under the rules in subpart H of this part, an employment network (EN) or a State VR agency to which a disabled beneficiary’s ticket is assigned, for providing employment services, vocational rehabilitation services, and other support services to the beneficiary.

§ 411.125 Who is eligible to receive a ticket under the Ticket to Work program?

(a) You will be eligible to receive a Ticket to Work in a month in which—

(1) You are age 18 or older and have not attained age 65;

(2)(i)(A) You are a title II disability beneficiary (other than a beneficiary receiving benefit payments under § 404.316(c), § 404.337(c), § 404.352(d), or § 404.1597a of this chapter); and

(B) You are in current pay status for monthly title II cash benefits based on disability (see subpart E of part 404 of this chapter for our rules on nonpayment of title II benefits); or

(ii)(A) You are a title XVI disability beneficiary (other than a beneficiary receiving disability or blindness benefit payments under § 416.996 or § 416.1338 of this chapter);

(B) If you are an individual described in § 416.987(b)(1) of this chapter, you are eligible for benefits under title XVI based on disability under the standard for evaluating disability for adults following a redetermination of your eligibility under § 416.987 of this chapter; and

(C) Your monthly Federal cash benefits based on disability or blindness under title XVI are not suspended (see subpart M of part 416 of this chapter for our rules on suspension of title XVI benefit payments); and

(3) Our records show that—

(i) Your case is not designated as a medical improvement expected diary review case (see §§ 404.1590 and 416.990 of this chapter for what we mean by a medical improvement expected diary review); or

(ii) Your case is designated as a medical improvement expected diary review case, and we have conducted at least one continuing disability review in your case and made a final determination or decision that your disability continues (see subpart J of part 404 or subpart N of part 416 of this chapter for when a determination or decision becomes final).

(b) You will not be eligible to receive more than one ticket during any period during which you are either—

(1) Entitled to title II benefits based on disability (see §§ 404.316(b), 404.337(b) and 404.352(b) of this chapter for when entitlement to title II disability benefits ends); or

(2) Eligible for title XVI benefits based on disability or blindness and your eligibility has not terminated (see subpart M of part 416 of this chapter for our rules on when eligibility for title XVI benefits terminates).

§ 411.130 How will SSA distribute tickets under the Ticket to Work program?

(a) We will distribute tickets in graduated phases at phase-in sites selected by the Commissioner, beginning in 2001, to permit a thorough evaluation of the Ticket to Work program and ensure that the most effective methods are in place for full implementation of the program. (See § 411.110.)

(b) We will distribute a ticket to you when we distribute tickets in your State, if you are eligible to receive a ticket under § 411.125.

§ 411.135 What do I do when I receive a ticket?

Your participation in the Ticket to Work program is voluntary. When you receive your ticket, you are free to choose when and whether to assign it (see § 411.140 for information on assigning your ticket). If you want to participate in the program, you can take your ticket to any EN you choose or to your State VR agency.

§ 411.140 When can I assign my ticket and how?

(a) You may assign your ticket only during a month in which you meet the requirements of § 411.125(a)(1) and (a)(2). You may assign your ticket to any EN which is serving under the program.
and is willing to provide you with services, or you may assign your ticket to a State VR agency that is willing to provide you with services. You may not assign your ticket to more than one provider of services (i.e., an EN or a State VR agency) at a time. However, if you have assigned your ticket to an EN or State VR agency and you are dissatisfied with the services being provided, you may retrieve your ticket under the rules in § 411.145. Also, you may reassign your ticket under the rules in § 411.150.

(b) (1) In determining which EN you want to work with, you may discuss your rehabilitation and employment plans with as many ENs in your area as you wish. You also may discuss your rehabilitation and employment plans with the State VR agency.

(2) You can obtain a list of the approved ENs in your area from the program manager (PM) we have enlisted to assist in the administration of the Ticket to Work program.

(c) Both you and the EN of your choice need to agree upon an individual work plan (IWP). If you are working with a State VR agency, both you and the State VR agency need to agree upon an individualized plan for employment (IPE). The IWP or IPE outlines the services necessary to assist you in achieving your chosen employment goal.

(d) In order to assign your ticket, you and the EN must agree to and sign an IWP, or you and the State VR agency must agree to and sign an IPE. In addition, you must be eligible to assign your ticket under the rules in paragraph (a) of this section. If these requirements are met, we will consider your ticket assigned to the EN or State VR agency. The effective date of the assignment of your ticket will be the date on which you and the EN or State VR agency sign your employment plan. See subpart H of this part.

(2) of this section are met, we will consider your ticket reassigned to the EN or State VR agency. The reassignment of your ticket is effective on the first day of the month following the month in which the EN goes out of business or is no longer approved to participate in the Ticket to Work program. You will be sent a notice informing you that your ticket is no longer assigned to that EN or State VR agency. In addition, if your EN or the State VR agency (in accordance with title I of the Rehabilitation Act of 1973, as amended) is no longer willing or able to provide services to you, the EN or State VR agency may ask the PM to take your ticket out of assignment with that EN or State VR agency. The ticket will be no longer assigned to that EN or State VR agency effective on the first day of the month following the month in which the EN or State VR agency makes a request to the PM that the ticket be taken out of assignment. You will be sent a notice informing you that your ticket is no longer assigned to that EN or State VR agency.

(c) For information about how taking a ticket out of assignment may affect medical reviews that we conduct to determine if you are still disabled under our rules, see §§ 411.171(d) and 411.225.

§ 411.150 Can I reassign my ticket to a different EN or the State VR agency?

(a) Yes. If you previously assigned your ticket and your ticket is no longer assigned (see § 411.145) or you wish to change the assignment, you may reassign your ticket. If you previously assigned your ticket to an EN, you may reassign your ticket to a different EN which is serving under the program and is willing to provide you with services, or you may reassign your ticket to the State VR agency. If you previously assigned your ticket to the State VR agency, you may reassign your ticket to an EN which is serving under the program and is willing to provide you with services.

(b) In order for you to reassign your ticket—

(1) you and the new EN must agree to and sign a new IWP or, if you wish to reassign your ticket to a State VR agency, you and the State VR agency must agree to and sign an IPE;

(2) you must meet the requirements of § 411.125(a)(1) and (a)(2) in the month you and the new EN or State VR agency sign your employment plan; and

(3) you must tell the PM that you want to reassign your ticket.

(c) If the requirements in paragraph (b) of this section are met, we will consider your ticket reassigned to the new EN or State VR agency. The reassignment of your ticket is effective on the first day of the month following the month in which you and the new EN or State VR agency sign your employment plan.

(d) The new EN will submit a copy of your new IWP to the PM to facilitate the reassignment of your ticket to that EN. If you wish to reassign your ticket to the State VR agency, your VR counselor will submit a form to the PM to facilitate the reassignment of your ticket to that agency.

§ 411.155 When does my ticket terminate?

Your ticket will terminate if and when you are no longer eligible to participate in the Ticket to Work program. If your ticket terminates, you may not assign or reassign it to an EN or State VR agency. We will not pay an EN (including a State VR agency) for milestones or outcomes achieved in or after the month in which your ticket terminates (see § 411.525(c)). Your eligibility to participate in the Ticket to Work program will end, and your ticket will terminate, in the earliest of the following months:

(a) The month in which your entitlement to Social Security disability benefits ends, or the month in which your eligibility for benefits under title XVI based on disability or blindness terminates, whichever is later, for reasons other than your work activity or earnings;

(b) If you are entitled to widow’s or widower’s insurance benefits based on disability (see §§ 404.335 and 404.336 of this chapter), the month in which you attain age 65;

(c) If you are eligible for benefits under title XVI based on disability or blindness, the month following the month in which you attain age 65; or

(d) The month following the 60th month for which an outcome payment is made to an EN (including a State VR agency) based on that ticket under subpart H of this part.
Subpart C—Suspension of Continuing Disability Reviews for Beneficiaries Who are Using a Ticket

Introduction

§411.160 What does this subpart do?

(a) This subpart explains our rules about continuing disability reviews for disability beneficiaries who are participating in the Ticket to Work program.

(b) Continuing disability reviews are reviews that we conduct to determine if you are still disabled under our rules (see §§404.1594 and 416.994 of this chapter). For the purposes of this subpart, continuing disability reviews do not include any review to determine if your disability has ended under §404.1594(d)(5) of this chapter because you have demonstrated your ability to engage in substantial gainful activity (SGA), as defined in §§404.1571—404.1576 of this chapter.

§411.165 How does being in the Ticket to Work program affect my continuing disability reviews?

We periodically review your case to determine if you are still disabled under our rules. (See §§404.1594 and 416.994 of this chapter.) However, if you are in the Ticket to Work program, we will not begin a continuing disability review during the period in which you are using a ticket. You must meet certain requirements for us to consider you to be using a ticket.

Definition of Using a Ticket

§411.170 When does the period of using a ticket begin?

The period of using a ticket begins on the effective date of the assignment of your ticket to an employment network (EN) or State VR agency under §411.140.

Exception: If you have previously failed to meet the timely progress guidelines under §§411.180 through 411.190, the period of using a ticket will not begin until you complete the requirements for reentering in-use status. (See §411.210.)

§411.171 When does the period of using a ticket end?

The period of using a ticket ends with the earliest of the following—

(a) The 60th month for which an outcome payment is made to your EN (including a State VR agency) under subpart H of this part;

(b) If you have assigned your ticket to a State VR agency which selects the cost reimbursement payment system, the 60th month for which an outcome payment would have been made had the State VR agency chosen to participate in the Ticket to Work program as an EN;

(c) The day before the effective date of a decision under §411.192, §411.195, §411.200, or §411.205 that you are no longer making timely progress toward self-supporting employment;

(d) The close of the 3-month period which begins with the first month in which your ticket is no longer assigned to an EN or State VR agency (see §411.154), unless you reassign your ticket within this 3-month period (see §411.225 for an explanation of the 3-month extension period which begins when your ticket is no longer assigned); or

(e) The month with which your entitlement to Social Security disability benefits ends or your eligibility for Federal SSI cash benefits terminates. If you are a concurrent title II and title XVI beneficiary, the period of using a ticket will end with the month with which your entitlement to Social Security disability benefits ends or your eligibility for Federal SSI cash benefits terminates, whichever is later. (See §§404.316(b), 404.337(b), 404.352(b) and 416.1331—416.1335 of this chapter.) Although you will no longer be considered to be using a ticket after this month, your EN may still be eligible for payments under the Ticket to Work program if your entitlement to or eligibility for disability benefits terminated due to your work activity or earnings.

§411.175 What if I assign my ticket after a continuing disability review has begun?

(a) If we begin a continuing disability review before the date on which you assign a ticket, you may still assign the ticket and receive services under the Ticket to Work program. However, we will complete the continuing disability review. If in this review we determine that you are no longer disabled, in most cases you will no longer be eligible to receive benefits. However, if you assigned your ticket before we determined that you are no longer disabled, in certain circumstances you may continue to receive benefits (see §§404.316(c), 404.337(c), 404.352(d), and 416.1338 of this chapter). If you appeal the decision that you are no longer disabled, you may also choose to have your benefits continued pending reconsideration and/or a hearing before an administrative law judge on the cessation determination (see §§404.1597a and 416.996 of this chapter).

(b) The date on which we begin the continuing disability review is the date on the notice we send you that tells you that we are beginning to review your disability case.

Guidelines for Timely Progress Toward Self-Supporting Employment

§411.180 What is timely progress toward self-supporting employment?

(a) General. The purpose of the Ticket to Work program is to provide you with the services and supports you need to work and reduce or eliminate your dependence on Social Security disability benefits and SSI benefits based on disability or blindness. We consider you to be making timely progress toward self-supporting employment when you show an increasing ability to work at levels which will reduce or eliminate your dependence on these benefits.

(b) Guidelines. We will determine whether you are making timely progress toward self-supporting employment by using the following guidelines:

(1) During the initial 24-month period after you assign your ticket, you must be actively participating in your employment plan. “Actively participating in your employment plan” means that you are engaging in activities outlined in your employment plan on a regular basis and in the approximate time frames specified in the employment plan.

(2) During your first 12-month work review period, you must work (as defined in §411.185) for at least 3 of these 12 months. The 3 months do not need to be consecutive.

(3) During your second 12-month work review period, and in later 12-month work review periods, you must work (as defined in §411.185) for at least 6 of these 12 months. The 6 months do not need to be consecutive.

(c) Definitions. As used in this subpart—

(1) The initial 24-month period means the 24-month period which begins with the month following the month in which you first assigned your ticket. When we count the 24 months, we will not include any month during which your ticket is not assigned to an EN or State VR agency, as described in §411.145, or any month in which your ticket is in inactive status, as defined in §411.220.

(2) The 12-month work review period means the 12-month period that begins either following the end of the initial 24-month period or following the previous 12-month work review period. When we count the 12 months, we will not include any month during which your ticket is not assigned to an EN or State VR agency, as described in §411.145.
§411.185 How much do I need to earn to be considered to be working?

For the purpose of determining if you are meeting the timely progress requirements for continued ticket use, we will consider you to be working in each month in which you have earnings at the following levels:

(a) For title II disability beneficiaries:

(1) During your first and second 12-month work review periods, we will consider you to be working in a month in which you have earnings from employment or self-employment at the SGA level for non-blind beneficiaries, as defined in §§404.1572 through 404.1576 of this chapter. For a month in which you are in a trial work period (see §404.1592 of this chapter), or if you are statutorily blind as defined in §404.1581 of this chapter, we will consider the following as fulfilling this requirement—

(i) Gross earnings from employment, before any deductions for impairment related work expenses under §404.1576 of this chapter, that are at or above the dollar amount of the SGA level for non-blind beneficiaries in §404.1574 of this chapter; or

(ii) Net earnings from self-employment (as defined in §416.1110(b) of this chapter), before any deductions for impairment related work expenses under §404.1576 of this chapter, that are at or above the dollar amount of the SGA level for non-blind beneficiaries in §404.1574 of this chapter.

(2) During your third 12-month work review period, and during any later 12-month work review periods, we will consider you to be working in a month in which you have earnings from employment or self-employment that are sufficient to preclude the payment of Federal SSI cash benefits for a month.

(c) For concurrent title II and title XVI beneficiaries:

(1) During your first and second 12-month work review periods, we will consider you to be working in a month in which you have earnings from employment or self-employment at the SGA level for non-blind beneficiaries as defined in §404.1572 through 404.1576 of this chapter. For a month in which you are in a trial work period (see §404.1592 of this chapter), or if you are statutorily blind as defined in §404.1581 of this chapter, we will consider the following as fulfilling this requirement—

(i) Gross earnings from employment, before any SSI income exclusions or deductions for impairment related work expenses under §404.1576 of this chapter, that are at or above the dollar amount of the SGA level for non-blind beneficiaries as defined in §416.1180 through 416.1182 of this chapter, you would still be considered to be working in that month.

(2) During your third 12-month work review period, and during any later 12-month work review periods, we will consider you to be working in a month in which you have earnings from employment or self-employment that are sufficient to preclude the payment of Social Security disability benefits and Federal SSI cash benefits for a month.

§411.190 How is it determined if I am meeting the timely progress guidelines?

(a) During the initial 24-month period of using a ticket, you must be actively participating in your employment plan, as defined in §411.180(b)(1). Active participation in your employment plan will be presumed unless you or your EN or State VR agency tell the program manager (PM) that you are not actively participating. If you or your EN or State VR agency tell the PM that you are not actively participating in your employment plan, the PM will follow the procedures outlined in §411.192.

(b) After the initial 24-month period, the PM will conduct reviews to determine if you are meeting the timely progress guidelines for continuing to be considered to be using a ticket.

(1) The PM will conduct a 24-month progress review at the end of the initial 24-month period. (See §411.195.)

(2) If you successfully complete your 24-month progress review, the PM will conduct annual work reviews at the end of each 12-month work review period. (See §411.200.)

§411.191 Table summarizing the guidelines for timely progress toward self-supporting employment.

You may use the following table to determine what you need to do to meet the guidelines for timely progress toward self-supporting employment. For more detail, refer to §§411.180 through 411.190.

<table>
<thead>
<tr>
<th>If you</th>
<th>You are in this period—</th>
<th>You must work—</th>
<th>With this level of earnings—</th>
<th>At the end of the period we will conduct your—</th>
</tr>
</thead>
<tbody>
<tr>
<td>First assigned your ticket less than 24 months ago (not counting any months in which your ticket was unassigned or inactive).</td>
<td>Initial 24-month period</td>
<td>No work requirement. Must be actively participating in employment plan.</td>
<td>Not applicable .............</td>
<td>24-month progress review.</td>
</tr>
<tr>
<td>First assigned your ticket 25 to 36 months ago (not counting any months in which your ticket was unassigned or inactive).</td>
<td>First 12-month work review period.</td>
<td>3 months out of 12 ...</td>
<td>SGA level for non-blind beneficiaries*.</td>
<td>First work review.</td>
</tr>
<tr>
<td>First assigned your ticket 37 to 48 months ago (not counting any months in which your ticket was unassigned or inactive).</td>
<td>Second 12-month work review period.</td>
<td>6 months out of 12 ...</td>
<td>SGA level for non-blind beneficiaries*.</td>
<td>Second work review.</td>
</tr>
<tr>
<td>If you—</td>
<td>You are in this period—</td>
<td>You must work—</td>
<td>With this level of earnings—</td>
<td>At the end of the period we will conduct your—</td>
</tr>
<tr>
<td>------------------------------------------</td>
<td>-------------------------</td>
<td>----------------</td>
<td>-----------------------------</td>
<td>----------------------------------</td>
</tr>
<tr>
<td>First assigned your ticket 49 to 60 months ago (not counting any months in which your ticket was unassigned or inactive).</td>
<td>Third 12-month work review period.</td>
<td>6 months out of 12 ...</td>
<td>Earnings sufficient to preclude Social Security disability and Federal SSI cash benefits for a month.</td>
<td>Third work review.</td>
</tr>
</tbody>
</table>

In later 12-month work review periods, the work and earnings requirements are the same as in the third 12-month work review period.

*For an explanation of how we determine if you meet this requirement if you are in a trial work period, you are blind, or you are a title XVI disability beneficiary, see §411.185.

§411.192 What if my EN, the State VR agency, or I report that I am not actively participating in my employment plan?

(a) If you or your EN or State VR agency report to the PM that you are not actively participating in your employment plan during the initial 24-month period after you assign your ticket, the PM will give you the choice of resuming participation in your employment plan or placing your ticket in inactive status.

(b) If you choose to place the ticket in inactive status, your ticket will be placed in inactive status beginning with the first day of the month following the month in which you make your request. You are not considered to be using a ticket during months in which your ticket is in inactive status, and months in which your ticket is in inactive status do not count toward the time limitations for making timely progress toward self-supporting employment. For more information about inactive status, see §411.220.

(c) If you choose to resume active participation in your employment plan, you will be allowed 3 months to demonstrate this active participation to the PM. During this period, you will be considered to be making timely progress toward self-supporting employment. The PM will contact your EN or State VR agency after the 3 months to determine whether you have been actively participating in your employment plan during these 3 months. If the EN or State VR agency report that you have not been actively participating in your employment plan during these 3 months, the PM will find that you are no longer making timely progress toward self-supporting employment. The PM will send a written notice of this decision to you at your last known address. The notice will explain the reasons for the decision and inform you of the right to ask us to review the decision. The PM will send a written notice of the decision to you at your last known address. The notice will explain the reasons for the decision and inform you of the right to ask us to review the decision. The decision will be effective 30 days after the date on which the PM sends the notice of the decision to you, unless you request that we review the decision under §411.205.

§411.195 How will the PM conduct my 24-month progress review?

(a) In this review the PM will consider the following:

(1) Are you actively participating in your employment plan? By “actively participating in your employment plan,” we mean that you are engaging in activities outlined in your employment plan on a regular basis and in the approximate time frames specified in the plan.

(2) Does your employment plan have a goal of at least 3 months of work (as defined in §411.185) during your next 12-month work review period?

(3) Given your current progress in your employment plan, can you reasonably be expected to reach this goal of at least 3 months of work (as defined in §411.185) during your next 12-month work review period?

(b) If the answer to all three of these questions is yes, the PM will find that you are making timely progress toward self-supporting employment. We will consider you to be making timely progress toward self-supporting employment until your first annual work review.

(c) If the answer to any of these questions is no, the PM will find that you are not making timely progress toward self-supporting employment. The PM will send a written notice of the decision to you at your last known address. The notice will explain the reasons for the decision and inform you of the right to ask us to review the decision. The decision will be effective 30 days after the date on which the PM sends the notice of the decision to you, unless you request that we review the decision under §411.205.

§411.200 How will the PM conduct my annual work review?

(a) The annual work review is a two step process:

1. Step one—Retrospective Review. Did you complete the work requirements (as specified in §411.180 and §411.185) in the last 12-month work review period?

   (i) If you have not completed the work requirements, the PM will find that you are not making timely progress toward self-supporting employment.

   (ii) If you have completed the work requirements, the PM will go to step two.

2. Step two—Anticipated Work Level. Do both you and your EN or State VR agency expect that you will work at the level required during the next 12-month work review period?

   (i) If not, the PM will find that you are not making timely progress toward self-supporting employment.

   (ii) If so, the PM will find that you are making timely progress toward self-supporting employment. We will consider you to be making timely progress toward self-supporting employment until your next annual work review.

§411.205 What if I disagree with the PM’s decision about whether I am making timely progress toward self-supporting employment?

If you disagree with the PM’s decision, you may request that we review the decision. You must make the request before the 30th day after the date on which the PM sends the notice of its decision to you. We will consider you to be making timely progress toward self-supporting employment until we make a decision. We will send a written notice of our decision to you at your last known address. If we decide that you are no longer making timely progress toward self-supporting employment, our decision will be
§411.210 What happens if I do not make timely progress toward self-supporting employment?

(a) General. If it is determined that you are not making timely progress toward self-supporting employment, we shall find that you are no longer using a ticket. If this happens, you will once again be subject to continuing disability reviews. However, you may continue participating in the Ticket to Work program. Your EN also may receive any outcome payments for which it is eligible under §411.500 et seq.

(b) Reentering In-Use Status. If you failed to meet the timely progress guidelines for continuing to use a ticket, you may reenter in-use status. The requirements for reentering in-use status depend on how far you progressed before you failed to meet the timely progress guidelines.

(1) If you failed to meet the timely progress guidelines during the initial 24-month period, in your 24-month progress review, or in your first annual work review.
   (a) If you retrieved your ticket because you were dissatisfied with the services being provided (see §411.145(a)); or
   (b) Your ticket will be reactivated if your ticket is no longer assigned, you are eligible for an extension period if your ticket is no longer assigned because—
      (1) You retrieved your ticket because you were dissatisfied with the services being provided (see §411.145(a)); or
      (2) You were dissatisfied with the services being provided (see §411.145(a)); or
      (3) Your ticket is not considered to be in use during periods in which it is in inactive status. Therefore you will once again be subject to continuing disability reviews.
   (c) Your ticket is not considered to be in use during periods in which it is in inactive status. Therefore you will once again be subject to continuing disability reviews.
   (d) How to reactivate your ticket. (1) If your ticket is still assigned to an EN or State VR agency, you may reactivate your ticket and return to in-use status at any time by submitting a written request to the PM.
   (2) Your ticket will be reactivated beginning with the first day of the month following the month in which the PM receives your request.
   (3) If the PM is told that you are not actively participating in your employment plan. If the PM is told that you are not actively participating in your employment plan, the PM will give you the choice of resuming active participation in your employment plan or placing your ticket in inactive status. See §411.192.

§411.225 What if my ticket is no longer assigned to an EN or State VR agency?

(a) If your ticket was once assigned to an EN or State VR agency and is no longer assigned, you are eligible for an extension period of up to 3 months to reassign your ticket. You are eligible for an extension period if your ticket is no longer assigned because—
   (1) You retrieved your ticket because you were dissatisfied with the services being provided (see §411.145(a)); or
   (2) You removed your ticket from your name or your EN or State VR agency is no longer approved to participate as an EN in the Ticket to Work program, or your EN or State VR agency is no longer willing or able to provide you with services for any other reason (see §411.145(b)).
   (b) During the extension period, the ticket will be considered to be in use. This means that you will not be subject to continuing disability reviews during this period.
   (c) Time spent in the extension period will not count toward the time limitations for making timely progress toward self-supporting employment.

§411.220 What if I am temporarily unable to participate in my employment plan?

(a) General. (1) If you are temporarily unable to participate in your employment plan during the initial 24-month period of using a ticket, you may choose to place your ticket in inactive status.
   (2) If you are temporarily unable to participate in your employment plan during the initial 24-month period of using a ticket, you may choose to place your ticket in inactive status.
   (3) If you are temporarily unable to participate in your employment plan during the initial 24-month period of using a ticket, you may choose to place your ticket in inactive status.

§411.230 What if I no longer wish to participate in the Ticket to Work program?

(a) General. (1) If you no longer wish to participate in the Ticket to Work program, you may request to place your ticket in inactive status.
   (2) When you have requested to place your ticket in inactive status, you may no longer use your ticket for employment purposes.

§411.240 What if I wish to reactivate my ticket?

(a) General. (1) If you wish to reactivate your ticket, you may request to reactivate your ticket.
   (2) When you have requested to reactivate your ticket, you may no longer use your ticket for employment purposes.

§411.250 What if I am no longer able to participate in the Ticket to Work program?

(a) General. (1) If you are no longer able to participate in the Ticket to Work program, you may request to place your ticket in inactive status.
   (2) When you have requested to place your ticket in inactive status, you may no longer use your ticket for employment purposes.
(d) The extension period—
(1) begins on the first day on which the ticket is no longer assigned (see § 411.145); and
(2) ends 3 months after it begins or when you assign your ticket to a new EN or State VR agency, whichever is sooner.
(c) If you do not assign your ticket by the end of the extension period, the ticket will no longer be in use and you will once again be subject to continuing disability reviews.

Subpart D—Use of One or More Program Managers to Assist in Administration of the Ticket to Work Program

§ 411.230 What is a PM?
A program manager (PM) is an organization in the private or public sector that has entered into an agreement to assist us in administering the Ticket to Work program. We will use a competitive bidding process to select one or more PMs.

§ 411.235 What qualifications are required of a PM?
A PM must have expertise and experience in the field of vocational rehabilitation or employment services.

§ 411.240 What limitations are placed on a PM?
A PM is prohibited from directly participating in the delivery of employment services, vocational rehabilitation services, or other support services to beneficiaries with tickets in the PM’s designated service delivery area. A PM is also prohibited from holding a financial interest in an employment network (EN) or service provider that provides services under the Ticket to Work program in the PM’s designated service delivery area.

§ 411.245 What are a PM’s responsibilities under the Ticket to Work program?
A PM will assist us in administering the Ticket to Work program by conducting the following activities:
(a) Recruiting, recommending, and monitoring ENs. A PM must recruit and recommend for selection by us public and private entities to function as ENs under the program. A PM is also responsible for monitoring the ENs operating in its service delivery area. Such monitoring must be done to the extent necessary and appropriate to ensure that adequate choices of services are made available to beneficiaries with tickets. A PM may not limit the number of public or private entities being recommended to function as ENs.
(b) Facilitating access by beneficiaries to ENs. A PM must assist beneficiaries with tickets in accessing ENs.
(c) These performance evaluations shall make a determination of the ENs available to beneficiaries with tickets in its service delivery area and make these lists generally available to the public.
(d) A PM must ensure that all service providers that provide services under the Ticket to Work program has reasonable access to employment services, vocational rehabilitation services, and other support services. The PM shall ensure that services such as the following are available in each service area, including rural areas: case management, work incentives planning, supported employment, career planning, career plan development, vocational assessment, job training, placement, follow-up services, and other services that we may require in an agreement with a PM.
(e) A PM must maintain documentation and provide regular assurances to us that payments to an EN are warranted. The PM shall ensure that an EN is complying with the terms of its agreement and applicable regulations.
(f) Upon the request of an EN, the PM shall make a determination of the allocation of the outcome or outcome-milestone payments due to an EN based on the services provided by the EN.
(g) Administrative requirements. A PM will perform such administrative tasks as are required to assist us in administering and implementing the Ticket to Work program. Administrative tasks required for the implementation of the Program may include, but are not limited to:
(1) Reviewing individual work plans (IWPs) submitted by ENs for ticket assignment. These reviews will be conducted to ensure that the IWPs meet the requirements of § 411.465.

Evaluation of Program Manager Performance

§ 411.250 How will SSA evaluate a PM?
(a) We will periodically conduct a formal evaluation of the PM. The evaluation will include, but not be limited to, an examination of the following:
(1) Quality of services;
(2) Cost control;
(3) Timeliness of performance;
(4) Business relations; and
(5) Customer satisfaction.
(b) Our Project Officer will perform the evaluation. The PM will have an opportunity to comment on the evaluation, and then the Contracting Officer will determine the PM’s final rating.
(c) These performance evaluations will be made part of our database on contractor past performance to which any Federal agency may have access.
(d) Failure to comply with the standards used in the evaluation may result in early termination of our agreement with the PM.

Subpart E—Employment Networks

§ 411.300 What is an EN?
An employment network (EN) is any qualified entity that has entered into an agreement with us to function as an EN under the Ticket to Work program and assume responsibility for the coordination and delivery of employment services, vocational rehabilitation services, and other support services to beneficiaries who have assigned their tickets to that EN.

§ 411.305 Who is eligible to be an EN?
An employment network (EN) is any qualified entity that has entered into an agreement with us to function as an EN under the Ticket to Work program and assume responsibility for the coordination and delivery of employment services, vocational rehabilitation services, and other support services to beneficiaries who have assigned their tickets to that EN.
directly or by entering into an agreement with other organizations or individuals to provide the appropriate services or other assistance that a beneficiary with a ticket may need to find and maintain employment that reduces dependency on disability benefits. ENs may include, but are not limited to:

(a) Any public or private entity that can provide directly, or arrange for other organizations or entities to provide, employment services, vocational rehabilitation services, or other support services.

(b) State agencies administering or supervising the administration of the State plan approved under title I of the Rehabilitation Act of 1973, as amended (29 U.S.C. 720 et seq.) may choose, on a case-by-case basis, to be paid as an EN under the payment systems described in subpart H of this part. For the rules on State VR agencies’ participation in the Ticket to Work program, see subpart F of this part.

(c) One-stop delivery systems established under subtitle B of title I of the Workforce Investment Act of 1998 (29 U.S.C. 2841 et seq.).

(d) Alternate participants currently operating under the authority of section 222(d)(2) of the Social Security Act.

(e) Organizations administering Vocational Rehabilitation Services Projects for American Indians with Disabilities authorized under section 121 of part C of title I of the Rehabilitation Act of 1973, as amended (29 U.S.C. 750 et seq.).

(f) Public or private schools that provide VR or employment services, conduct job training programs, or make services on programs available that can assist students with disabilities in acquiring specific job skills that lead to employment. This includes transition programs that can help students acquire work skills.

(g) Employers that offer job training or other support services or assistance to help individuals with disabilities obtain and retain employment or arrange for individuals with disabilities to receive relevant services or assistance.

§ 411.310 How does an entity apply to be an EN and who will determine whether an entity qualifies as an EN?

(a) An entity applies by responding to our Request for Proposal (RFP), which will be published in the Commerce Business Daily or online through the Federal government’s electronic posting system. Since recruitment of ENs will be an ongoing process, the RFP will be open and continuous. The entity must respond in a format prescribed in the RFP announcement. In its response, the entity must assure SSA that it is qualified to provide employment services, vocational rehabilitation services, and other support services to disabled beneficiaries, either directly or through arrangements with other entities. For example, the entity must assure that it is licensed, certified, accredited, or registered to provide these services or is able to arrange for other entities to provide these services.

(b) The PM will solicit service providers and other qualified entities to respond to the RFP on an ongoing basis. The PM will conduct a preliminary review of responses to the RFP from applicants located in the PM’s service delivery area and make recommendations to the Commissioner regarding selection. The Commissioner will decide which applicants will be approved to serve as ENs under the program.

§ 411.315 What are the minimum qualifications necessary to be an EN?

To serve as an EN under the Ticket to Work program, an entity must meet and maintain compliance with both general selection criteria and specific selection criteria.

(a) The general criteria include:

(1) Having systems in place to protect the confidentiality of personal information about beneficiaries seeking or receiving services;

(2) Being accessible, both physically and programmatically, to beneficiaries seeking or receiving services;

(3) Not discriminating in the provision of services based on a beneficiary’s age, gender, race, color, creed, or national origin;

(4) Having adequate resources to perform the activities required under the agreement with us or the ability to obtain them;

(5) Complying with the terms and conditions in the agreement with us, including delivering or coordinating the delivery of employment services, vocational rehabilitation services, and other support services; and

(6) Implementing accounting procedures and control operations necessary to carry out the Ticket to Work program.

(b) The specific criteria that an entity must meet to qualify as an EN include:

(i) Using staff who are qualified under applicable certification, licensing, or registration standards that apply to their profession; or

(ii) Using staff that are otherwise qualified based on education or experience, such as by using staff with a college degree in a related field such as vocational counseling, human relations, teaching, or psychology; and

(2) Providing medical and related health services under the formal supervision of persons licensed to prescribe or supervise the provision of these services in the State in which the services are performed.

(c) An entity must have applicable certificates, licenses, or other credentials if such documentation is required by State law to provide VR services, employment services or other support services in the State.

(d) We will not use the following as an EN:

(1) Any entity that has had its license, accreditation, certification, or registration suspended or revoked for reasons concerning professional competence or conduct or financial integrity;

(2) Any entity that has surrendered a license, accreditation, certification, or registration with a disciplinary proceeding pending; or

(3) Any entity that is precluded from Federal procurement or non-procurement programs.

§ 411.320 What are an EN’s responsibilities as a participant in the Ticket to Work program?

An EN must—

(a) Enter into an agreement with us.

(b) Serve a prescribed service area.

The EN must designate the geographic area in which it will provide services. This will be designated in the EN’s agreement with us.

(c) Provide services directly, or enter into agreements with other entities to provide employment services, vocational rehabilitation services, or other support services to beneficiaries with tickets.

(d) Ensure that employment services, vocational rehabilitation services, and other support services provided under the Ticket to Work program are provided under appropriate individual work plans (IWP).

(e) Elect a payment system at the time of signing an agreement with us (see § 411.505).

(f) Develop and implement each IWP in partnership with each beneficiary receiving services in a manner that affords the beneficiary the opportunity to exercise informed choice in selecting an employment goal and specific services needed to achieve that employment goal. Each IWP must meet the requirements described in § 411.465.

§ 411.321 Under what conditions will SSA terminate an agreement with an EN due to inadequate performance?

We will terminate our agreement with an EN if it does not comply with the requirements under §§ 411.320 and
411.325 and the conditions in the agreement between SSA and the EN, including minimum performance standards relating to beneficiaries achieving self-supporting employment and leaving the benefit rolls.

§ 411.325 What reporting requirements are placed on an EN as a participant in the Ticket to Work program?

An EN must:
(a) Report to the PM each time it accepts a ticket for assignment.
(b) Submit a copy of each signed IWP to the PM.
(c) Submit to the PM copies of amendments to a beneficiary’s IWP.
(d) Submit to the PM a copy of any agreement the EN has established with a State VR agency regarding the conditions under which the State VR agency will provide services to beneficiaries who are referred by the EN under the Ticket to Work program.
(e) Report to the PM the specific outcomes achieved with respect to specific services the EN provided or secured on behalf of beneficiaries whose tickets it accepted for assignment. Such reports shall conform to a national model prescribed by us and shall be submitted to the PM at least annually.
(f) Provide a copy of its most recent annual report on outcomes to each beneficiary attempting to assign a ticket to it and assure that a copy of its most recent report is available to the public while ensuring that personal information on beneficiaries is kept confidential.
(g) Meet our financial reporting requirements. These requirements will be described in the agreements between ENs and the Commissioner, and will include, among other things, submitting to the program manager, on an annual basis, a financial report that shows the percentage of the employment network’s budget that was spent on serving beneficiaries with tickets, including the amount that was spent on beneficiaries who return to work and those who do not return to work.
(h) Collect and record such data as we shall require, in a form prescribed by us.
(i) Adhere to all requirements specified in the agreement with the Commissioner and all regulatory requirements in part 411 of chapter III of 20 CFR.

§ 411.330 How will SSA evaluate an EN’s performance?

(a) We will periodically review the results of the work of each EN to ensure effective quality assurance in the provision of services by ENs.
(b) In conducting such a review, we will solicit and consider the views of the consumers the EN serves and the PM which monitors the EN.
(c) ENs must make the results of these periodic reviews available to disabled beneficiaries to assist them in choosing among available ENs.

Subpart F—State Vocational Rehabilitation Agencies’ Participation in the Ticket to Work Program

§ 411.350 Must a State VR agency participate in the Ticket to Work program?

Yes. Each State agency administering or supervising the administration of the State plan approved under title I of the Rehabilitation Act of 1973, as amended (29 U.S.C. 720 et seq.), must participate in the Ticket to Work program if it wishes to receive payments from SSA for serving disabled beneficiaries.

§ 411.355 What payment options does a State VR agency have under the Ticket to Work program?

(a) The Ticket to Work program provides different payment options that are available to a State VR agency for providing services to disabled beneficiaries. A State VR agency participates in the program in one of two ways when providing services to a particular disabled beneficiary under the program. On a case-by-case basis, the State VR agency may participate either—
   (1) As an employment network (EN); or
   (2) Under the cost reimbursement payment system (see subpart V of part 404 and subpart V of part 416 of this chapter).
(b) When the State VR agency serves a beneficiary with a ticket as an EN, the State VR agency will be paid according to the payment system it has elected for this purpose, either the outcome payment system or the outcome-milestone payment system (described in § 411.500).
(c) The State VR agency must use its elected EN payment system whenever it functions as an EN. The State VR agency will have periodic opportunities to change the payment system it uses when serving as an EN. When serving a beneficiary who was not issued a ticket, the State VR agency may seek payment only under the cost reimbursement payment system.
(d) The State VR agency may not change the payment system selected for a specific beneficiary once the ticket has been assigned and the payment system has been chosen, even if the State VR agency elects a new EN payment system at a later date.

§ 411.360 How does a State VR agency become an EN?

(a) As the Ticket to Work program is implemented in States, we will notify the State VR agency in writing about payment systems available under the program. The letter will ask the State VR agency to choose a payment system to use when it chooses to function as an EN.
(b) When serving beneficiaries holding tickets, the State VR agency may choose, on a case-by-case basis, to seek payment under its elected EN payment system or under the cost reimbursement payment system.

§ 411.365 How does a State VR agency notify SSA about its choice of a payment system for use when functioning as an EN?

(a) The State VR agency must respond in writing to our letter regarding implementation of the Ticket to Work program and tell us which EN payment system it will use when it chooses to function as an EN for any beneficiary who has a ticket.
(b) The Governor or the Governor’s designated representative must sign the letter. The letter must reach SSA by the deadline in our letter.

§ 411.370 Does a State VR agency ever have to function as an EN?

No. A State VR agency may choose on a case-by-case basis whether it will function as an EN when serving a beneficiary with a ticket. It may continue to serve all beneficiaries with tickets under the cost reimbursement payment system. However, even if the State VR agency is not serving as an EN, it still must tell the program manager (PM) whenever a beneficiary with a ticket is accepted for services to ensure that the beneficiary’s ticket is assigned to that agency.

§ 411.375 Does a State VR agency continue to provide services under the requirements of the State plan approved under title I of the Rehabilitation Act of 1973, as amended, when functioning as an EN?

Yes. The State VR agency must continue to provide services under the requirements of the State plan approved under title I of the Rehabilitation Act of 1973, as amended, even when functioning as an EN.

Ticket Status

§ 411.380 How does a State VR agency determine whether a person seeking services has a ticket?

Once the State VR agency determines that a person seeking VR services is a disabled beneficiary, the State VR agency must contact the PM to verify the beneficiary’s ticket status to see if—
§ 411.385 What does a State VR agency do if a beneficiary who is applying for services has a ticket that is available for assignment?

(a) Once the State VR agency determines that a beneficiary who is applying for services has a ticket that is available for assignment (see § 411.140) and the State VR agency and the beneficiary have agreed to and signed the individualized plan for employment (IPE) required under section 102(b) of the Rehabilitation Act of 1973, as amended, the beneficiary’s ticket is considered to be assigned. (See § 411.165 et seq. for a description of how assigning a ticket may affect continuing disability reviews.) The State VR agency must submit the following information to the PM to ensure the assignment of the beneficiary’s ticket to the State VR agency and the recording of the payment system selected for that beneficiary:

(1) A statement that the beneficiary has decided to assign his ticket to the State VR agency and that an IPE has been agreed to and signed by both the beneficiary and a representative of the State VR agency;

(2) A statement of the vocational goal outlined in the beneficiary’s IPE; and

(3) A statement of the State VR agency’s selection of the system (either cost reimbursement or the previously elected EN payment system) under which the State VR agency will seek payment for providing services to the beneficiary.

(b) The information must be submitted to the PM in a format prescribed by us and must include the signatures of both the beneficiary, or a representative of the beneficiary, and the State VR agency representative working with the beneficiary.

§ 411.390 What does a State VR agency do if a beneficiary to whom it is already providing services has a ticket that is available for assignment?

If, upon implementation of the Ticket to Work program in a State, a beneficiary who is receiving services from the State VR agency under an existing IPE has a ticket available for assignment and decides to assign the ticket to the State VR agency, the State VR agency must submit the information required in § 411.385 to the PM to ensure the assignment of that ticket to the State VR agency. Since the services for that beneficiary were initiated under an IPE prior to implementation of the Ticket to Work program, the State VR agency may only seek payment under the cost reimbursement payment system (see subpart V of part 404 and subpart V of part 416 of this chapter).

§ 411.395 Is a State VR agency required to provide periodic reports?

(a) A State VR agency will be required to prepare periodic reports on the specific outcomes achieved with respect to the specific services the State VR agency provided to or secured for disabled beneficiaries whose tickets it accepted for assignment. These reports must be submitted to the PM at least annually.

(b) The State VR agency must also submit information to assist the PM conducting the reviews necessary to assess a beneficiary’s timely progress towards self-supporting employment to determine if a beneficiary is using a ticket for purposes of suspending continuing disability reviews (see § 411.165–411.200).

§ 411.400 Can an EN to which a beneficiary’s ticket is assigned refer the beneficiary to a State VR agency for services?

Yes. An EN may refer a beneficiary it is serving under the Ticket to Work program to a State VR agency for services. However, a referral can be made only if the State VR agency and the EN have an agreement that specifies the conditions under which services will be provided by the State VR agency. This agreement must be in writing and signed by the State VR agency and the EN prior to the EN referring any beneficiary to the State VR agency for services.

§ 411.405 When does an agreement between an EN and the State VR agency have to be in place?

Each EN must have an agreement with the State VR agency prior to referring a beneficiary it is serving under the Ticket to Work program to the State VR agency for specific services.

§ 411.410 Does each referral from an EN to a State VR agency require its own agreement?

No. The agreements between ENs and State VR agencies should be broad-based and apply to all beneficiaries who may be referred by the EN to the State VR agency for services.

§ 411.415 Who will verify the establishment of agreements between ENs and State VR agencies?

The PM will verify the establishment of these agreements. Each EN is required to submit a copy of the agreement it has established with the State VR agency to the PM.

§ 411.420 What information should be included in an agreement between an EN and a State VR agency?

The agreement between an EN and a State VR agency should state the conditions under which the State VR agency will provide services to a beneficiary when the beneficiary is referred by the EN to the State VR agency for services. Examples of this information include:

(a) Procedures for making referrals and sharing information that will assist in providing services;

(b) A description of the financial responsibilities of each party to the agreement;

(c) The terms and procedures under which the EN will pay the State VR agency for providing services; and

(d) Procedures for resolving disputes under the agreement.

§ 411.425 What should a State VR agency do if it gets an attempted referral from an EN and no agreement has been established between the EN and the State VR agency?

The State VR agency should contact the EN to discuss the need to establish an agreement. If the State VR agency and the EN are not able to negotiate acceptable terms for an agreement, the State VR agency should notify the PM that an attempted referral has been made without an agreement.

§ 411.430 What should the PM do when it is informed that an EN has attempted to make a referral to a State VR agency without an agreement being in place?

The PM will contact the EN to explain that a referral cannot be made to the State VR agency unless an agreement has been established that sets out the conditions under which services will be provided when a beneficiary’s ticket is assigned to the EN and the EN is referring the beneficiary to the State VR agency for specific services.

§ 411.435 How will disputes arising under agreements between ENs and State VR agencies be resolved?

Disputes arising under agreements between ENs and State VR agencies should be resolved using the following steps:

(a) When procedures for resolving disputes are spelled out in the
agreement between the EN and the State VR agency, those procedures should be used.

(b) If procedures for resolving disputes are not included in the agreement between the EN and the State VR agency and procedures for resolving disputes under contracts and interagency agreements are provided for in State law or administrative procedures, the State procedures should be used to resolve disputes under agreements between ENs and State VR agencies.

(c) If procedures for resolving disputes are not spelled out in the agreement or in State law or administrative procedures, the EN or the State VR agency may request that the PM recommend a resolution to the dispute.

(1) The request must be in writing and include—
   (i) A copy of the agreement;
   (ii) Information on the issue(s) in dispute; and
   (iii) Information on the position of both the EN and the State VR agency regarding the dispute.

(2) The PM has 20 calendar days after receiving a written request to recommend a resolution to the dispute. If either the EN or the State VR agency does not agree with the PM’s recommended resolution to the dispute, the EN or the State VR agency has 30 calendar days after receiving the PM’s recommendation to request a decision by us on the matter in dispute.

Subpart G—Requirements for Individual Work Plans

§ 411.450 What is an IWP?

An IWP is a required written document signed by an EN and a beneficiary, or a representative of a beneficiary, with a ticket. It is developed and implemented in partnership when a beneficiary and an EN have come to a mutual understanding to work together to pursue the beneficiary’s employment goal under the Ticket to Work program.

§ 411.455 What is the purpose of an IWP?

The purpose of an IWP is to outline the specific employment services, vocational rehabilitation services and other support services that the EN and beneficiary have determined are necessary to achieve the beneficiary’s stated employment goal. An IWP provides written documentation for both the EN and beneficiary. Both parties should develop and implement the IWP in partnership. The EN will develop and implement the plan in a manner that gives the beneficiary the opportunity to exercise informed choice in selecting an employment goal.

Specific services needed to achieve the designated employment goal are discussed and agreed to by both parties.

§ 411.460 Who is responsible for determining what information is contained in the IWP?

The beneficiary and the EN share the responsibility for determining the employment goal and the specific services needed to achieve that employment goal. The EN will present information and options in a way that affords the beneficiary the opportunity to exercise informed choice in selecting an employment goal and specific services needed to achieve that employment goal.

§ 411.465 What are the minimum requirements for an IWP?

(a) An IWP must include at least—
   (1) A statement of the vocational goal developed with the beneficiary, including, as appropriate, goals for earnings and job advancement;
   (2) A statement of the services and supports necessary for the beneficiary to accomplish that goal;
   (3) A statement of any terms and conditions related to the provision of these services and supports;
   (4) A statement that the EN may not request or receive any compensation for the costs of services and supports from the beneficiary;
   (5) A statement of the conditions under which an EN may amend the IWP or terminate the relationship;
   (6) A statement of the beneficiary’s rights under the Ticket to Work program, including the right to retrieve the ticket at any time if the beneficiary is dissatisfied with the services being provided by the EN;
   (7) A statement of the remedies available to the beneficiary, including information on the availability of advocacy services and assistance in resolving disputes through the State P&A System;
   (8) A statement of the beneficiary’s rights to privacy and confidentiality regarding personal information, including information about the beneficiary’s disability;
   (9) A statement of the beneficiary’s right to seek to amend the IWP (the IWP can be amended if both the beneficiary and the EN agree to the change); and
   (10) A statement of the beneficiary’s right to have a copy of the IWP made available to the beneficiary, including in an accessible format chosen by the beneficiary.

(b) The EN will be responsible for ensuring that each IWP contains this information.

§ 411.470 When does an IWP become effective?

(a) An IWP becomes effective if the following conditions are met—
   (1) It has been signed by the beneficiary or the beneficiary’s representative, and by a representative of the EN; and
   (2) The PM verifies that the beneficiary has a ticket that is eligible for assignment and records the beneficiary’s decision to assign his or her ticket.

(b) If the conditions in paragraph (a) of this section are met, the IWP becomes effective on the date it was signed by both parties.

Subpart H—Employment Network Payment Systems

§ 411.500 Definitions of terms used in this part.

(a) Payment Calculation Base means for any calendar year—
   (1) In connection with a title II disability beneficiary (including a concurrent title II/tile XVI disability beneficiary), the average monthly disability insurance benefit payable under section 223 of the Act for months during the preceding calendar year to all beneficiaries who are in current pay status for the month for which the benefit is payable; and
   (2) In connection with a title XVI disability beneficiary (who is not concurrently a title II disability beneficiary), the average monthly payment of Supplemental Security Income (SSI) benefits based on disability payable under title XVI (excluding State supplementation) for months during the preceding calendar year to all beneficiaries who—
      (i) Have attained age 18 but have not attained age 65;
      (ii) Are not concurrent title II/tile XVI beneficiaries; and
      (iii) Are in current pay status for the month for which the payment is made.

(b) Outcome Payment Period means a period of 60 months, not necessarily consecutive, for which Social Security disability benefits and Federal SSI cash benefits are not payable to the individual because of the performance of substantial gainful activity (SGA) or by reason of earnings from work. This period begins with the first month, ending after the date on which the ticket was first assigned, for which such benefits are not payable due to SGA or earnings. This period ends with the 60th month, consecutive or otherwise, ending after such date, for which such benefits are not payable due to SGA or earnings.

(c) Outcome Payment System is a system providing a schedule of
payments to an employment network (EN) for each month, up to a total of 60 months, during the outcome payment period. The maximum number of outcome payment months for each ticket is sixty.

(d) Outcome-Milestone Payment System is a system providing a schedule of payments to an EN that includes, in addition to payments during the outcome payment period, payment for completion by a beneficiary of up to two milestones directed toward the goal of permanent employment. Milestones occur prior to the beginning of the outcome payment period. Milestone payments consist of payments in addition to any payments made during the outcome payment period. The total payments under the outcome-milestone payment system, with respect to each beneficiary who assigns a ticket to the EN, must be less than, on a net present value basis, the total payments that would be payable to the EN under the outcome payment system.

§ 411.505 How is an EN paid by SSA?

An EN can elect either of two payment systems. These systems are the outcome payment system and the outcome-milestone payment system. The EN will elect a payment system at the time the EN enters into an agreement with SSA. (For State VR agencies, see § 411.365). The EN may periodically change its elected payment system as described in § 411.515.

§ 411.510 How is the State VR agency paid under the Ticket to Work program?

(a) The State VR agency’s payment choices are described in § 411.355.

(b) The State VR agency’s decision to serve the beneficiary must be communicated to the program manager (PM). At the same time, the State VR agency must notify the PM of its selected payment system for that beneficiary.

(c) For each beneficiary who is already a client of the State VR agency prior to receiving a ticket, the State VR agency will notify the PM of the payment system election for each such beneficiary at the time the ticket is assigned to the State VR agency.

§ 411.515 Can the EN change its elected payment system?

(a) Yes. Any change in the elected EN payment system will apply to beneficiaries who assign their ticket to the EN after the EN’s change in election becomes effective. A change in the EN’s election will become effective with the month following the month in which the EN notifies us of the change. For beneficiaries who already assigned their ticket to the EN under the EN’s earlier elected payment system, the EN’s earlier elected payment system will continue to apply.

(b) During the 12 months following the month the EN first elects a payment system, the EN can choose to make one change in its elected payment system at any time.

(c) After an EN (or a State VR agency) first elects a payment system, as part of signing the EN agreement with us (for State VR agencies, see § 411.365), the EN (or State VR agency) will have the opportunity to change from its existing elected payment system during times announced by us. We will offer the opportunity for ENs (and State VR agencies) to make a change in their elected payment system at least every 18 months following January 2001.

§ 411.520 How are beneficiaries whose ticket is assigned to an EN affected by an EN’s change in elected payment system?

A change in an EN’s elected payment system has no effect upon the beneficiaries who have assigned their ticket to an EN.

§ 411.525 How are the EN payments calculated under each of the two EN payment systems?

(a) For payments for outcome payment months, both EN payment systems use the payment calculation base as defined in § 411.500(a)(1) or (a)(2), as appropriate. This base uses the preceding calendar year’s national average disability benefit payment information to compute the values for payments made to ENs for outcome payment months during the next calendar year.

(1)(i) Under the outcome payment system, we can pay up to 120 monthly payments to the EN. For each month for which Social Security disability benefits and Federal SSI cash benefits are not payable to the individual because of work or earnings, the EN is eligible for a monthly outcome payment. Payment for an outcome payment month under the outcome payment system is equal to a fixed percentage of the payment calculation base for the calendar year in which such month occurs. This percentage is 40 percent.

(ii) If a disabled beneficiary’s entitlement to Social Security disability benefits ends (see § § 404.316(b), 404.337(b) and 404.352(b) of this chapter) or eligibility for SSI benefits based on disability or blindness terminates (see § 416.1335 of this chapter) because of the performance of SGA or by reason of earnings from work activity, we will consider any month after the month in which such entitlement ends or eligibility terminates to be a month for which Social Security disability benefits and Federal SSI cash benefits are not payable to the individual because of work or earnings if—

(A) The individual has gross earnings from employment (or net earnings from self-employment as defined in § 416.1110(b) of this chapter) in that month that are at or above the SGA dollar amount in § 404.1574(b)(2) of this chapter (or in § 404.1584(d) of this chapter for an individual who is statutorily blind); and

(B) The individual is not entitled to any monthly benefits under title II or eligible for any benefits under title XVI for that month.

(2) Under the outcome-milestone payment system, we can pay the EN for up to two milestones achieved by a beneficiary who has assigned his or her ticket to the EN. In addition to the milestone payments, monthly outcome payments can be paid to the EN during the outcome payment period.

(b) Under the outcome-milestone payment system, the EN’s total payments for a beneficiary will be less than, on a net present value basis, the total payments if the EN were paid under the outcome payment system. Under the outcome-milestone payment system, the EN’s total potential payment amount is about 85 percent of the total that would have been potentially payable under the outcome payment system for the same beneficiary.

(c) We will pay an EN to whom the individual has assigned a ticket only for milestones or outcomes achieved in months prior to the month in which the ticket terminates (see § 411.155). We will not pay a milestone or outcome payment to an EN based on an individual’s work activity or earnings in or after the month in which the ticket terminates.

§ 411.530 How will the outcome period payments be reduced when paid under the outcome-milestone payment system?

Under the outcome-milestone payment system, the outcome payment for each of the first 12 outcome payment months is reduced by an amount equal to 1/12th of the milestone payments already made based on a ticket.

§ 411.535 What are the milestones for which an EN can be paid?

(a) Under the outcome-milestone payment system, there are two milestones for which the EN can be paid. Both milestones occur after the earnings levels for both milestones are the dollar amounts we use when we consider if
§ 411.545 What are the payment amounts for outcome payment months under the outcome-milestone payment system?

The amount of each monthly outcome payment under the outcome-milestone payment system is as follows—

(a) Beginning with the 1st outcome payment month and ending with the 12th outcome payment month, the payment for an outcome payment month is equal to 30 percent of the payment calculation base for the calendar year in which the month occurs, reduced by an amount equal to \( \frac{1}{12} \) of the total of the milestone payments made with respect to a ticket.

(b) Beginning with the 13th outcome payment month and ending with the 24th outcome payment month, the payment for an outcome payment month is equal to 32 percent of the payment calculation base for the calendar year in which the month occurs.

(c) Beginning with the 25th outcome payment month and ending with the 36th outcome payment month, the payment for an outcome payment month is equal to 34 percent of the payment calculation base for the calendar year in which the month occurs.

(d) Beginning with the 37th outcome payment month and ending with the 48th outcome payment month, the payment for an outcome payment month is equal to 36 percent of the payment calculation base for the calendar year in which the month occurs.

(e) Beginning with the 49th outcome payment month and ending with the 60th outcome payment month, the payment for an outcome payment month is equal to 38 percent of the payment calculation base for the calendar year in which the month occurs.

§ 411.550 What are the payment amounts for outcome payment months under the outcome payment system?

Under the outcome payment system, the payment for an outcome payment month is equal to 40 percent of the payment calculation base for the calendar year in which the month occurs.

§ 411.555 Can the EN keep the milestone and outcome payments even if the beneficiary does not achieve all 60 outcome months?

Yes. The EN can keep each milestone and outcome payment for which the EN is eligible, subject to adjustment under § 411.560.

§ 411.560 Is it possible to pay a milestone or outcome payment to more than one EN?

Yes. It is possible for more than one EN to receive payment based on the same milestone or outcome. If the beneficiary has assigned the ticket to more than one EN at different times, and more than one EN requests payment for the same milestone or outcome payment under its elected payment system, the PM will make a determination of the allocation of payment to each EN. The PM will make this determination based upon the services provided by each EN.

§ 411.565 What happens if two or more ENs qualify for payment on the same ticket but have elected a different EN payment system?

We will pay each EN according to its elected EN payment system in effect at the time the beneficiary assigned the ticket to the EN.

§ 411.570 Can an EN request payment from the beneficiary who assigned a ticket to the EN?

No. Section 1148(b)(4) of the Act prohibits an EN from requesting or receiving compensation from the beneficiary for the services of the EN.

§ 411.575 How does the EN request payment for milestones or outcome payment months achieved by a beneficiary who assigned a ticket to the EN?

The EN will send its request for payment, evidence of the beneficiary’s work or earnings and other information to the PM.

(a) Milestone payments. (1) We will pay the EN for milestones only if the outcome-milestone payment system is the elected EN payment system at the time the beneficiary assigned a ticket to the EN.

(2) The EN must request payment for each milestone achieved by a beneficiary who has assigned a ticket to the EN. The request must include evidence that the milestone was achieved, and other information as we may require, to evaluate the EN’s request. We do not have to stop monthly benefit payments to the beneficiary before we can pay the EN for milestones achieved by the beneficiary.

(b) Outcome payments. (1) We will pay an EN an outcome payment for a month if—

(ii)(A) Social Security disability benefits and Federal SSI cash benefits are not payable to the individual for that month due to work or earnings; or

(B) The requirements of § 411.525(a)(1)(ii) are met in a case where the beneficiary’s entitlement to Social Security disability benefits has ended or eligibility for SSI benefits based on disability or blindness has ended or eligibility for SSI benefits has ended or eligibility for SSI benefits based on disability or blindness has ended or eligibility for SSI benefits based on disability or blindness has
terminated because of work activity or earnings; and

(ii) We have not already paid for 60 other months on the same ticket.

(2) The EN must submit a request for payment for an outcome payment month in order to begin receiving outcome payments for a ticket assigned to the EN by a beneficiary. The request for payment must include proof of the beneficiary’s work or earnings that is sufficient for us to determine that we can stop the beneficiary’s monthly Federal cash benefit payments due to work or earnings. For a payment for a month after the month in which the beneficiary’s entitlement to Social Security disability benefits ends or benefit for SSI benefits based on disability or blindness terminates due to work activity or earnings, the EN must submit proof that the individual has gross earnings from employment or net earnings from self-employment in that month that are at or above the applicable SGA dollar amount as described in §411.525(a)(1)(ii). For an individual who is self-employed, evidence of his or her work activity or earnings should be obtained from the individual. For an individual who is an employee, evidence of his or her work activity or earnings is best obtained from the employer or the employer’s designated payroll preparer.

(3) Before we stop a beneficiary’s monthly benefit(s) payment because of work or earnings, we review his or her work effort. A request accompanied by a Work Activity Report (form SSA—821) can expedite processing the payment request. The Work Activity Report is a form that the beneficiary completes.

(4) While an EN does not need to submit separate requests to continue payments for each outcome month, an EN must continue to submit evidence that the beneficiary’s level of work or earnings is sufficient to preclude payment of monthly Social Security disability and Federal SSI cash benefits. For cases described in §411.525(a)(1)(ii), the EN must continue to submit proof of the individual’s gross earnings from employment or net earnings from self-employment (see paragraph (b)(2) of this section). An EN cannot receive an outcome payment for any month for which a Social Security disability benefit or a Federal SSI cash benefit is payable to the beneficiary.

(5) ENs can submit the evidence of work or earnings to the PM on a monthly basis or an EN can submit 2 months worth of evidence every other month.

§411.580 Can an EN receive payments for milestones or outcome payment months that occur before the beneficiary assigns a ticket to the EN?

No. An EN may be paid only for milestones or outcome payment months that are achieved after the ticket is assigned to the EN.

§411.585 Can a State VR agency and an EN both receive payment for serving the same beneficiary?

Yes. It is possible if the State VR agency serves the beneficiary as an EN. In this case, both the EN and the State VR agency may be eligible for payment based on the same ticket.

(a) If a State VR agency is paid by us under the cost reimbursement payment system with respect to a ticket, such payment precludes any subsequent payment by us based on the same ticket to an EN or to a State VR agency serving as an EN under either the outcome payment system or the outcome-milestone payment system.

(b) If an EN or a State VR agency serving a beneficiary as an EN is paid by us under one of the EN payment systems with respect to a ticket, such payment precludes subsequent payment to a State VR agency under the cost reimbursement payment system based on the same ticket.

§411.590 What can an EN do if the EN disagrees with our decision on a payment request?

(a) If an EN other than a State VR agency has a payment dispute with us, the dispute shall be resolved under the dispute resolution procedures contained in the EN’s agreement with us.

(b) If a State VR agency serving a beneficiary as an EN has a dispute with us regarding payment under an EN payment system, the State VR agency may, within 60 days of receiving notice of our decision, request reconsideration in writing. The State VR agency should send the request for reconsideration to the PM. The PM will forward to us the request for reconsideration and a recommendation. We will notify the State VR agency of our reconsidered decision in writing.

(c) An EN cannot appeal determinations we make which affect a beneficiary’s right to benefits. Only the beneficiary or his or her representative can appeal these determinations. (See §§404.900 through 404.999 and 416.1400 through 416.1499 of this chapter.)

(d) If an appeal by a beneficiary regarding entitlement or eligibility for disability benefits results in a revised determination, our revised determination could affect the EN’s payment or result in an adjustment to payments already made to the EN. While the EN cannot appeal our determination about a beneficiary’s right to benefits, the EN may furnish any evidence the EN has which may support a change in our determination on the beneficiary’s appeal.

§411.595 What oversight procedures are planned for the EN payment systems?

We use audits, reviews, studies and observation of daily activities to identify areas for improvement. Internal reviews of our systems security controls are regularly performed. These reviews provide an overall assurance that our business processes are functioning as intended. The reviews also ensure that our management controls and financial management systems comply with the standards established by the Federal Managers’ Financial Integrity Act and the Federal Financial Management Improvement Act. These reviews operate in accordance with the Office of Management and Budget Circulars A–123, A–127 and Appendix III to A–130. Additionally, our Executive Internal Control Committee meets periodically and provides further oversight of program and management control issues.

§411.597 Will SSA periodically review the outcome payment system and the outcome-milestone payment system for possible modifications?

(a) Yes. We will periodically review the system of payments and their programmatic results to determine if they provide an adequate incentive for ENs to assist beneficiaries to enter the work force, while providing for appropriate economies.

(b) We will specifically review the limitation on monthly outcome payments as a percentage of the payment calculation base, the difference in total payments between the outcome-milestone payment system and the outcome payment system, the length of the outcome payment period, and the number and amount of milestone payments, as well as the benefit savings and numbers of beneficiaries going to work. We will consider altering the payment system conditions based upon the information gathered and our determination that an alteration would better provide for the incentives and economies described above.
Subpart I—Ticket to Work Program Dispute Resolution

Disputes Between Beneficiaries and Employment Networks

§ 411.600 Is there a process for resolving disputes between beneficiaries and ENs?

Yes. After an IWP is signed, a process is available which will assure each party a full, fair and timely review of a disputed matter. This process has three steps.

(a) The beneficiary can seek a solution through the EN’s internal grievance procedures.

(b) If the EN’s internal grievance procedures do not result in an agreeable solution, either the beneficiary or the EN may seek a resolution from the PM.

(c) If either the beneficiary or the EN is dissatisfied with the resolution proposed by the PM, either party may request a decision from us.

§ 411.605 What are the responsibilities of the EN regarding the dispute resolution process?

The EN must:

(a) Have grievance procedures that a beneficiary can use to seek a resolution to a dispute under the Ticket to Work program;

(b) Give each beneficiary seeking services a copy of its internal grievance procedures;

(c) Inform each beneficiary seeking services of the right to refer a dispute first to the PM for review, and then to us for a decision; and

(d) Inform each beneficiary of the availability of assistance from the State P&A system.

§ 411.610 When should a beneficiary receive information on the procedures for resolving disputes?

Each EN must inform each beneficiary seeking services under the Ticket to Work program of the procedures for resolving disputes when—

(a) The EN and the beneficiary complete and sign the IWP;

(b) Services in the beneficiary’s IWP are reduced, suspended or terminated; and

(c) A dispute arises related to the services spelled out in the beneficiary’s IWP or to the beneficiary’s participation in the program.

§ 411.615 How will a disputed issue be referred to the PM?

The beneficiary or the EN may ask the PM to review a disputed issue. The PM will contact the EN to submit all relevant information within 10 working days. The information should include:

(a) A description of the disputed issue(s);

(b) A summary of the beneficiary’s position, prepared by the beneficiary or a representative of the beneficiary, related to each disputed issue;

(c) A summary of the EN’s position related to each disputed issue; and

(d) A description of any solutions proposed by the EN when the beneficiary sought resolution through the EN’s grievance procedures, including the reasons the beneficiary rejected each proposed solution.

§ 411.620 How long does the PM have to recommend a resolution to the dispute?

The PM has 20 working days to provide a written recommendation. The recommendation should explain the reasoning for the proposed resolution.

§ 411.625 Can the beneficiary or the EN request a review of the PM’s recommendation?

(a) Yes. After receiving the PM’s recommendation, either the beneficiary or the EN may request a review by us. The request must be in writing and received by the PM within 15 working days of the receipt of the PM’s recommendation for resolving the dispute.

(b) The PM has 10 working days to refer the request for a review to us. The request for a review must include:

(1) A copy of the beneficiary’s IWP;

(2) Information on the disputed issue(s);

(3) Any relevant evidence; and

(4) The PM’s conclusion(s) and recommendation(s).

§ 411.630 Is SSA’s decision final?

Yes. Our decision is final. If either the beneficiary or the EN is unwilling to accept our decision, either has the right to terminate its relationship with the other.

§ 411.635 Can a beneficiary be represented in the dispute resolution process under the Ticket to Work program?

Yes. Both the beneficiary and the EN may use an attorney or other individual of their choice to represent them at any step in the dispute resolution process. The P&A system in each State and U.S. Territory is available to provide assistance and advocacy services to beneficiaries seeking or receiving services under the Ticket to Work program, including assistance in resolving issues at any stage in the dispute resolution process.

§ 411.640 Do the dispute resolution procedures of the Rehabilitation Act of 1973, as amended, apply to beneficiaries seeking services from the State VR agency?

Yes. The procedures in the Rehabilitation Act of 1973, as amended, apply to any beneficiary who has assigned a ticket to a State VR agency. The Rehabilitation Act requires the State VR agency to provide each person seeking or receiving services with a description of the services available through the Client Assistance Program authorized under section 112 of the Rehabilitation Act of 1973, as amended. It also provides the opportunity to resolve disputes using formal mediation services or the impartial hearing process in section 102(c) of the Rehabilitation Act of 1973, as amended.

Disputes Between Employment Networks and Program Managers

§ 411.650 Is there a process for resolving disputes between ENs and PMs, other than disputes on a payment request?

Yes. Under the agreement to assist us in administering the Ticket to Work program, a PM is required to have procedures to resolve disputes with ENs that do not involve an EN’s payment request. (See § 411.590 for the process for resolving disputes on EN payment requests.) This process must ensure that:

(a) The EN can seek a solution through the PM’s internal grievance procedures.

(b) If the PM’s internal grievance procedures do not result in a mutually agreeable solution, the PM shall refer the dispute to us for a decision.

§ 411.655 How will the PM refer the dispute to us?

The PM has 20 working days from the failure to come to a mutually agreeable solution with an EN to refer the dispute to us with all relevant information. The information should include:

(a) A description of the disputed issue(s);

(b) A summary of the EN’s and PM’s position related to each disputed issue; and

(c) A description of any solutions proposed by the EN and PM when the EN sought resolution through the PM’s grievance procedures, including the reasons each party rejected each proposed solution.

§ 411.660 Is SSA’s decision final?

Yes. Our decision is final.
Subpart J—The Ticket to Work Program and Alternate Participants Under the Programs for Payments for Vocational Rehabilitation Services

§ 411.700 What is an alternate participant?

An alternate participant is any public or private agency (other than a participating State VR agency described in §§404.2104 and 416.2204 of this chapter), organization, institution, or individual with whom the Commissioner has entered into an agreement or contract to provide VR services to disabled beneficiaries under the programs described in subpart V of part 404 and subpart V of part 416 of this chapter. In this subpart J, we refer to these programs as the programs for payments for VR services.

§ 411.705 Can an alternate participant become an EN?

In any State where the Ticket to Work program is implemented, each alternate participant whose service area is in that State will be asked to choose if it wants to participate in the program as an EN.

§ 411.710 How will an alternate participant choose to participate as an EN in the Ticket to Work program?

(a) When the Ticket to Work program is implemented in a State, each alternate participant whose service area is in that State will be notified of its right to choose to participate as an EN in the program in that State. The notification to the alternate participant will provide instructions on how to become an EN and the requirements that an EN must meet to participate in the Ticket to Work program.

(b) An alternate participant who chooses to become an EN must meet the requirements to be an EN, including—

1. Enter into an agreement with SSA to participate as an EN under the Ticket to Work program (see §411.320);
2. Agree to serve a prescribed service area (see §411.320);
3. Agree to the EN reporting requirements (see §411.325); and
4. Elect a payment option under one of the two EN payment systems (see §411.505).

§ 411.715 If an alternate participant becomes an EN, will beneficiaries for whom an employment plan was signed prior to implementation be covered under the Ticket to Work program payment provisions?

No. When an alternate participant becomes an EN in a State in which the Ticket to Work program is implemented, those beneficiaries for whom an employment plan was signed prior to the date of implementation of the program in the State, will continue to be covered for a limited time under the programs for payments for VR services (see §411.730).

§ 411.720 If an alternate participant chooses not to become an EN, can it continue to function under the programs for payments for VR services?

Once the Ticket to Work program has been implemented in a State, the alternate participant programs for payments for VR services begin to be phased-out in that State. We will not pay any alternate participant under these programs for any services that are provided under an employment plan that is signed on or after the date of implementation of the Ticket to Work program in that State. If an employment plan was signed before that date, we will pay the alternate participant, under the programs for payments for VR services, for services provided prior to January 1, 2004 if all other requirements for payment under these programs are met. We will not pay an alternate participant under these programs for any services provided on or after January 1, 2004.

§ 411.725 If an alternate participant becomes an EN and it has signed employment plans, both as an alternate participant and an EN, how will SSA pay for services provided under each employment plan?

We will continue to abide by the programs for payments for VR services in cases where services are provided to a beneficiary under an employment plan signed prior to the date of implementation of the Ticket to Work program in the State. However, we will not pay an alternate participant under these programs for services provided on or after January 1, 2004. For those employment plans signed by a beneficiary and the EN after implementation of the program in the State, the EN’s elected EN payment system under the Ticket to Work program applies.

§ 411.730 What happens if an alternate participant signed an employment plan with a beneficiary before Ticket to Work program implementation in the State and the required period of substantial gainful activity is not completed by January 1, 2004?

The beneficiary does not have to complete the 9-month continuous period of substantial gainful activity (SGA) prior to January 1, 2004, in order for the costs of the services to be payable under the programs for payments for VR services. The 9-month SGA period can be completed after January 1, 2004. However, SSA will not pay an alternate participant under these programs for the costs of any services provided after December 31, 2003.
Thursday,
December 28, 2000

Part V

Department of Defense
General Services Administration

National Aeronautics and Space Administration

48 CFR Part 31
Federal Acquisition Regulation; Signing and Retention of High-Technology Workers; Proposed Rule
is driven by the need to maximize the use of technology to improve the efficiency and effectiveness of Government performance. Due to the tight labor market, companies doing business with the Government often must provide recruitment and retention bonuses to compete with predominantly non-Government firms to attract personnel with critical technical skills. This practice is analogous to the practice in the public sector of permitting signing bonuses for difficult-to-fill positions and retention allowances for essential Government employees.

The proposed rule revises FAR 31.205–34, Recruitment costs, to explicitly allow signing bonuses to recruit, as well as retention bonuses to retain, employees with critical skills (such as scientists and engineers in the software and systems integration fields). The Councils view this revision as a clarification since the FAR currently does not disallow these types of expenses. In addition, the rule moves the current limitations on help-wanted advertising costs from FAR 31.205–34(b) to the paragraph that addresses these costs (currently FAR 31.205–34(a)(1)), and makes several related editorial changes.

This is not a significant regulatory action and, therefore, was not subject to review under Section 6(b) of Executive Order 12866, Regulatory Planning and Review, dated September 30, 1993. This rule is not a major rule under 5 U.S.C. 804.

B. Regulatory Flexibility Act

The Councils do not expect this proposed rule to have a significant economic impact on a substantial number of small entities within the meaning of the Regulatory Flexibility Act, 5 U.S.C. 601, et seq., because most contracts awarded to small entities use simplified acquisition procedures or are awarded on a competitive, fixed-price basis, and do not require application of the cost principle contained in this rule. An Initial Regulatory Flexibility Analysis has, therefore, not been performed. We invite comments from small businesses and other interested parties. The Councils will consider comments from small entities concerning the affected FAR Part in accordance with 5 U.S.C. 610. Interested parties must submit such comments separately and should cite 5 U.S.C. 610, et seq. (FAR case 2000–014), in correspondence.

C. Paperwork Reduction Act

The Paperwork Reduction Act does not apply because the proposed changes to the FAR do not impose information collection requirements that require the approval of the Office of Management and Budget under 44 U.S.C. 3501, et seq.

List of Subjects in 48 CFR Part 31

Government procurement.


Al Matera, Acting Director, Federal Acquisition Policy Division.

Therefore, DoD, GSA, and NASA propose that 48 CFR part 31 be amended as set forth below:

PART 31—CONTRACT COST

PRINCIPLES AND PROCEDURES

1. The authority citation for 48 CFR part 31 continues to read as follows:

Authority: 40 U.S.C. 486(c); 10 U.S.C. chapter 137; and 42 U.S.C. 2473(c).

2. Revise section 31.205–34 to read as follows:

31.205–34 Recruitment and retention costs.

The following costs are allowable:

(a) Costs of help-wanted advertising. However, these costs are unallowable if the advertising—

(1) Does not describe specific positions or classes of positions; or

(2) Includes material that is not relevant for recruitment purposes, such as extensive illustrations or descriptions of the company’s products or capabilities.

(b) Costs of operating an employment office needed to secure and maintain an adequate labor force.

(c) Costs of operating an aptitude and educational testing program.

(d) Travel costs of employees engaged in recruiting personnel.

(e) Travel costs of applicants for interviews.

(f) Costs for employment agencies, not in excess of standard commercial rates.

(g) Signing bonuses needed to recruit employees with critical skills (such as scientists and engineers in fields like software and systems integration), if comparable to the signing bonuses being offered by firms engaged in predominantly non-Government work to attract similar job skills.

(h) Periodic retention bonuses needed to retain employees with critical skills (such as scientists and engineers in fields like software and systems integration), if comparable to the periodic retention bonuses being paid by firms engaged in predominantly non-Government work to retain similar job skills.

[FR Doc. 00–33047 Filed 12–27–00; 8:45 am]
BILLING CODE 6820–EP–U
Thursday,
December 28, 2000

Part VI

Environmental Protection Agency

Proposed CERCLA Prospective Purchaser Agreement for the Old Roosevelt Field Contaminated Groundwater Area Superfund Site, Garden City, Nassau County, NY; Notice
ENVIRONMENTAL PROTECTION AGENCY

[FRL-6925-3]

Proposed CERCLA Prospective Purchaser Agreement for the Old Roosevelt Field Contaminated Groundwater Area Superfund Site, Garden City, Nassau County, NY

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice; request for public comment.

SUMMARY: Consistent with EPA’s May 24, 1995 “Guidance on Agreements with Prospective Purchasers of Contaminated Property,” notice is hereby given of a proposed prospective purchaser agreement (“Agreement”) with Treeline Garden City Plaza, LLC (“Treeline”) concerning real property within the Old Roosevelt Field Contaminated Groundwater Area Superfund Site, Garden City, Nassau County, New York (the “Property”). Under the Agreement, Treeline will make a payment of $400,000 to the Hazardous Substances Superfund and provide other consideration to EPA in exchange for a covenant not to sue pursuant to sections 106 and 107(a) of CERCLA, 42 U.S.C. 9606 and 9607(a). By publication of this Notice, a fifteen (15) day period has been established in which the United States will accept written comments relating to the Agreement. The United States will consider all comments received and may modify or withdraw its consent to the Agreement if comments received disclose facts or considerations which indicate that the Agreement is inappropriate, improper, or inadequate. The United States’ response to any comments received will be available for public inspection at the U.S. Environmental Protection Agency, Region II, Superfund Records Center, 290 Broadway, 18th Floor, New York, NY 10007–1866. A copy of the proposed Agreement may also be obtained from the individual listed below. Comments should reference the Old Roosevelt Field Contaminated Groundwater Area Superfund Site, Garden City, Nassau County, New York and EPA Index No. CERCLA–02–2001–2010, and should be addressed to the individual listed below.

FOR FURTHER INFORMATION CONTACT:
Elizabeth Leilani Davis, Assistant Regional Counsel, New York/Caribbean Superfund Branch, Office of Regional Counsel, U.S. Environmental Protection Agency, Region II, 290 Broadway, 17th Floor, New York, NY 10007–1866, Telephone: (212) 637–3249.


William J. Muszynski,
Acting Regional Administrator, Region II.

[FR Doc. 00–33269 Filed 12–26–00; 12:17 pm]

BILLING CODE 6560–50–P
### Reader Aids

**Federal Register**

Vol. 65, No. 250

Thursday, December 28, 2000

---

### CUSTOMER SERVICE AND INFORMATION

**Federal Register/Code of Federal Regulations**

General Information, indexes and other finding aids

202–523–5227

**Laws**

523–5227

**Presidential Documents**

Executive orders and proclamations

523–5227

The United States Government Manual

523–5227

**Other Services**

Electronic and on-line services (voice)

523–4534

Privacy Act Compilation

523–3187

Public Laws Update Service (numbers, dates, etc.)

523–6641

TTY for the deaf-and-hard-of-hearing

523–5229

---

### ELECTRONIC RESEARCH

**World Wide Web**

Full text of the daily Federal Register, CFR and other publications:

http://www.access.gpo.gov/nara

Federal Register information and research tools, including Public Inspection List, indexes, and links to GPO Access:

http://www.nara.gov/fedreg

**E-mail**

PENS (Public Law Electronic Notification Service) is an E-mail service for notification of recently enacted Public Laws. To subscribe, send E-mail to

listserv@www.gsa.gov

with the text message:

subscribe PUBLAWS-L your name

Use listserv@gpo.gov only to subscribe or unsubscribe to PENS. We cannot respond to specific inquiries.

**Reference questions.** Send questions and comments about the Federal Register system to:

info@fedreg.nara.gov

The Federal Register staff cannot interpret specific documents or regulations.

---

### FEDERAL REGISTER PAGES AND DATE, DECEMBER

<table>
<thead>
<tr>
<th>Page Range</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>75153–75580</td>
<td>1</td>
</tr>
<tr>
<td>75581–75852</td>
<td>4</td>
</tr>
<tr>
<td>75853–76114</td>
<td>5</td>
</tr>
<tr>
<td>76115–76560</td>
<td>6</td>
</tr>
<tr>
<td>76561–76914</td>
<td>7</td>
</tr>
<tr>
<td>76915–77244</td>
<td>8</td>
</tr>
<tr>
<td>77245–77494</td>
<td>11</td>
</tr>
<tr>
<td>77495–77754</td>
<td>12</td>
</tr>
<tr>
<td>77755–78074</td>
<td>13</td>
</tr>
<tr>
<td>78075–78402</td>
<td>14</td>
</tr>
<tr>
<td>78403–78994</td>
<td>15</td>
</tr>
<tr>
<td>78985–79304</td>
<td>18</td>
</tr>
<tr>
<td>79305–79710</td>
<td>19</td>
</tr>
<tr>
<td>79711–80278</td>
<td>20</td>
</tr>
<tr>
<td>80279–80732</td>
<td>21</td>
</tr>
<tr>
<td>80733–81320</td>
<td>22</td>
</tr>
<tr>
<td>81321–81726</td>
<td>26</td>
</tr>
<tr>
<td>81727–82238</td>
<td>27</td>
</tr>
<tr>
<td>82239–82878</td>
<td>28</td>
</tr>
</tbody>
</table>

---

### CFR PARTS AFFECTED DURING DECEMBER

At the end of each month, the Office of the Federal Register publishes separately a List of CFR Sections Affected (LSA), which lists parts and sections affected by documents published since the revision date of each title.

<table>
<thead>
<tr>
<th>CFR</th>
<th>LSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 CFR</td>
<td>77486–82195</td>
</tr>
<tr>
<td>Proclamations:</td>
<td>77486–82195</td>
</tr>
<tr>
<td>5030 (See EO 13178)</td>
<td>76913</td>
</tr>
<tr>
<td>5928 (See EO 13178)</td>
<td>76913</td>
</tr>
<tr>
<td>6425 (See Proc. 7383)</td>
<td>76551</td>
</tr>
<tr>
<td>7219 (See EO 13178)</td>
<td>76913</td>
</tr>
<tr>
<td>7350 (See Proc. 7388)</td>
<td>80723</td>
</tr>
<tr>
<td>7351 (See Proc. 7388)</td>
<td>80723</td>
</tr>
<tr>
<td>7382</td>
<td>76581, 76348</td>
</tr>
<tr>
<td>7383</td>
<td>76551</td>
</tr>
<tr>
<td>7384</td>
<td>76903</td>
</tr>
<tr>
<td>7385</td>
<td>77495</td>
</tr>
<tr>
<td>7386</td>
<td>78075</td>
</tr>
<tr>
<td>7387</td>
<td>80271</td>
</tr>
<tr>
<td>7388</td>
<td>80273</td>
</tr>
<tr>
<td>Executive Orders:</td>
<td>80273</td>
</tr>
<tr>
<td>April 17, 1926</td>
<td>77486–82195</td>
</tr>
<tr>
<td>(Revoked in part by PLO 7470)</td>
<td>76663</td>
</tr>
<tr>
<td>11888 (See Proc. 7383)</td>
<td>76551</td>
</tr>
<tr>
<td>13089 (See EO 13178)</td>
<td>76913</td>
</tr>
<tr>
<td>13158 (See EO 13178)</td>
<td>76913</td>
</tr>
<tr>
<td>13177</td>
<td>76558</td>
</tr>
<tr>
<td>13178</td>
<td>76913</td>
</tr>
<tr>
<td>13179</td>
<td>77487</td>
</tr>
<tr>
<td>13180</td>
<td>77493</td>
</tr>
<tr>
<td>13181</td>
<td>81321</td>
</tr>
<tr>
<td>Administrative Orders:</td>
<td>81321</td>
</tr>
<tr>
<td>Presidential Determinations:</td>
<td>81321</td>
</tr>
<tr>
<td>No. 2001–04</td>
<td>78895</td>
</tr>
<tr>
<td>4 CFR</td>
<td>80279</td>
</tr>
<tr>
<td>28</td>
<td>80279</td>
</tr>
<tr>
<td>5 CFR</td>
<td>80277</td>
</tr>
<tr>
<td>213</td>
<td>78077</td>
</tr>
<tr>
<td>315</td>
<td>78077</td>
</tr>
<tr>
<td>531</td>
<td>75153</td>
</tr>
<tr>
<td>532</td>
<td>79305, 79306</td>
</tr>
<tr>
<td>731</td>
<td>82239</td>
</tr>
<tr>
<td>1315</td>
<td>78403</td>
</tr>
<tr>
<td>1800</td>
<td>81325</td>
</tr>
<tr>
<td>1820</td>
<td>81325</td>
</tr>
<tr>
<td>1830</td>
<td>81325</td>
</tr>
<tr>
<td>1850</td>
<td>81325</td>
</tr>
<tr>
<td>Proposed Rules:</td>
<td>81325</td>
</tr>
<tr>
<td>532</td>
<td>79320</td>
</tr>
<tr>
<td>7 CFR</td>
<td>77555</td>
</tr>
<tr>
<td>2</td>
<td>75464</td>
</tr>
<tr>
<td>59</td>
<td>80548</td>
</tr>
<tr>
<td>205</td>
<td>82246</td>
</tr>
<tr>
<td>225</td>
<td>82246</td>
</tr>
<tr>
<td>8 CFR</td>
<td>81334</td>
</tr>
<tr>
<td>3</td>
<td>82254</td>
</tr>
<tr>
<td>103</td>
<td>82254</td>
</tr>
<tr>
<td>208</td>
<td>82254</td>
</tr>
<tr>
<td>210</td>
<td>82254</td>
</tr>
<tr>
<td>212</td>
<td>82254</td>
</tr>
<tr>
<td>235</td>
<td>82254</td>
</tr>
<tr>
<td>236</td>
<td>82254</td>
</tr>
<tr>
<td>240</td>
<td>82254</td>
</tr>
<tr>
<td>241</td>
<td>82254</td>
</tr>
<tr>
<td>244</td>
<td>82254</td>
</tr>
<tr>
<td>245a</td>
<td>82254</td>
</tr>
<tr>
<td>Proposed Rules:</td>
<td>82254</td>
</tr>
<tr>
<td>208</td>
<td>76121, 76588</td>
</tr>
<tr>
<td>214</td>
<td>79320</td>
</tr>
<tr>
<td>9 CFR</td>
<td>75581</td>
</tr>
<tr>
<td>78</td>
<td>75581</td>
</tr>
<tr>
<td>93</td>
<td>7697, 81727</td>
</tr>
</tbody>
</table>
REMINDEERS
The items in this list were editorially compiled as an aid to Federal Register users. Inclusion or exclusion from this list has no legal significance.

RULES GOING INTO EFFECT DECEMBER 28, 2000

AGRICULTURE DEPARTMENT
Food and Nutrition Service
Child nutrition programs:
  Summer food service program—
    Legislative reforms implementation; published 12-28-00

COMMODITY FUTURES TRADING COMMISSION
Practice and procedure:
  Investment of customer funds; published 12-28-00

ENVIRONMENTAL PROTECTION AGENCY
Pesticides; tolerances in food, animal feeds, and raw agricultural commodities:
  Cyprodinil; published 12-28-00

DEPARTMENT OF COMMERCE
Desmedipham; published 12-28-00

NATIONAL AERONAUTICS AND SPACE ADMINISTRATION
Acquisition regulations:
  Miscellaneous administrative revisions; published 12-28-00

TRANSPORTATION DEPARTMENT
Federal Aviation Administration
Air traffic operating and flight rules, etc.:
  Grand Canyon National Park, AZ; special flight rules in vicinity—
    Special flight rules area and flight free zones; modification of dimensions; published 11-20-00
  Special flight rules area and flight free zones; modification of dimensions; correction; published 11-27-00
  Airworthiness directives:
    Bell; published 12-13-00
    Empresa Brasileira de Aeronautica S.A.; published 12-13-00

AGENCIES REVIEWED

AGENCY FOR INTERNATIONAL DEVELOPMENT
Nondiscrimination on basis of race, color, national origin, handicap, and age in federally assisted programs or activities; comments due by 1-5-01; published 12-6-00

AGRICULTURE DEPARTMENT
Agricultural Marketing Service
Tomatoes grown in—
  Florida; comments due by 1-5-01; published 11-6-00

AGRICULTURE DEPARTMENT
Animal and Plant Health Inspection Service
Exportation and importation of animals and animal products:
  Rinderpest and foot-and-mouth disease—
    KwaZulu-Natal, South Africa; comments due by 1-2-01; published 11-2-00
  Plant-related quarantine, domestic:
    Fire ant, imported; comments due by 1-5-01; published 11-6-00

AGRICULTURE DEPARTMENT
Farm Service Agency
Program regulations:
  Off-farm migrant farmworker projects; operating assistance; comments due by 1-2-01; published 11-2-00

AGRICULTURE DEPARTMENT
Grain Inspection, Packers and Stockyards Administration
Grain inspection:
  Commodities and rice; fees increase; comments due by 1-2-01; published 11-3-00

AGRICULTURE DEPARTMENT
Rural Business-Cooperative Service
Program regulations:
  Off-farm migrant farmworker projects; operating assistance; comments due by 1-2-01; published 11-2-00

AGRICULTURE DEPARTMENT
Rural Housing Service
Program regulations:
  Off-farm migrant farmworker projects; operating assistance; comments due by 1-2-01; published 11-2-00

AGRICULTURE DEPARTMENT
Rural Utilities Service
Program regulations:
  Off-farm migrant farmworker projects; operating assistance; comments due by 1-2-01; published 11-2-00

AGRICULTURE DEPARTMENT
Nondiscrimination on basis of race, color, national origin, handicap, and age in federally assisted programs or activities; comments due by 1-5-01; published 12-6-00

DEFENSE DEPARTMENT
Acquisition regulations:
  Electronic signatures; comments due by 1-2-01; published 11-1-00

EDUCATION DEPARTMENT
Grants:
  Direct grant programs and disability and rehabilitation research projects and centers program; comments due by 1-2-01; published 11-3-00

ENERGY DEPARTMENT
Acquisition regulations:
  Greening the Government Through Waste Prevention, Recycling, and Federal Acquisition; comments due by 1-2-01; published 11-30-00

  Nondiscrimination on basis of race, color, national origin, handicap, and age in federally assisted programs or activities; comments due by 1-5-01; published 12-6-00

ENERGY DEPARTMENT
Federal Energy Regulatory Commission
Practice and procedure:
  Off-the-record communications; comments due by 1-2-01; published 11-30-00

ENVIRONMENTAL PROTECTION AGENCY
Air programs; approval and promulgation; State plans for designated facilities and pollutants:
  New York; comments due by 1-5-01; published 12-6-00

  Air quality implementation plans; approval and promulgation; various States:
    New Jersey; comments due by 1-2-01; published 11-30-00

  New Jersey; correction; comments due by 1-2-01; published 12-12-00

  Nondiscrimination on basis of race, color, national origin, handicap, and age in federally assisted programs or activities; comments due by 1-5-01; published 12-6-00

  Toxic substances:
    Significant new uses—
      Perfluorooctyl sulfonates; comments due by 1-1-01; published 11-21-00
VETERANS AFFAIRS DEPARTMENT

Medical benefits:
Veterans’ medical care or services; reasonable charges; comments due by 1-2-01; published 11-2-00

Nondiscrimination on basis of race, color, national origin, handicap, and age in federally assisted programs or activities; comments due by 1-5-01; published 12-6-00

LIST OF PUBLIC LAWS

This is a continuing list of public bills from the current session of Congress which have become Federal laws. It may be used in conjunction with “P.L.U.S.” (Public Laws Update Service) on 202-523-6641. This list is also available online at http://www.nara.gov/fedreg.


H.R. 1653/P.L. 106–562
To complete the orderly withdrawal of the NOAA from the civil administration of the Pribilof Islands, Alaska, and to assist in the conservation of coral reefs, and for other purposes. (Dec. 23, 2000; 114 Stat. 2794)

H.R. 2570/P.L. 106–563

H.R. 3756/P.L. 106–564
To establish a standard time zone for Guam and the Commonwealth of the Northern Mariana Islands, and for other purposes. (Dec. 23, 2000; 114 Stat. 2811)

H.R. 4907/P.L. 106–565

S. 1694/P.L. 106–566
To direct the Secretary of the Interior to conduct a study on the reclamation and reuse of water and wastewater in the State of Hawaii, and for other purposes. (Dec. 23, 2000; 114 Stat. 2818)

Last List December 27, 2000

---

Public Laws Electronic Notification Service (PENS)

PENS is a free electronic mail notification service of newly enacted public laws. To subscribe, go to http://hydra.gsa.gov/archives/publaws-l.html or send E-mail to listserv@listserv.gsa.gov with the following text message:

SUBSCRIBE PUBLAWS-L Your Name.

Note: This service is strictly for E-mail notification of new laws. The text of laws is not available through this service.

PENS cannot respond to specific inquiries sent to this address.